SE|00000000||tx|1|text|As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY
SE|00000000||tx|1|entity|C0802604|Medications:Presence or Identity:Duration of the study:^Patient:Nominal|clna|||medications||||861|27|37
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|40|47
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|76|82
SE|00000000||tx|1|entity|C1515187|Take|hlca|||taking||||872|90|95
SE|00000000||tx|1|entity|C1170019|Abilify|orch,phsu|||ABILIFY||||872|97|103


SE|00000000||tx|1|text|Therefore, concurrent use of aspirin and ketoprofen is not recommended.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|12|21
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|23|25
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|30|36
SE|00000000||tx|1|entity|C0022635|Ketoprofen|orch,phsu|||ketoprofen||||1000|42|51
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|56|58


SE|00000000||tx|1|text|In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|9|16
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|41|47
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||888|64|71
SE|00000000||tx|1|entity|C0597421|saluretic|phsu|||natriuretic||||888|74|84
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|108|114
SE|00000000||tx|1|entity|C0445022|Loop|spco|||loop||||1000|119|122
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||694|125|133
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|148|165
SE|00000000||tx|1|relation|3|1|C0700798|Indocin|orch,phsu|orch|||INDOCIN||||1000|41|47|VERB|INHIBITS||53|58|5|1|C0597421|saluretic|phsu|phsu|||natriuretic||||888|74|84


SE|00000000||tx|1|text|Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||Warfarin||||1000|1|8
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|15|21
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|26|33
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|39|44
SE|00000000||tx|1|entity|C0017181|Gastrointestinal Hemorrhage|patf|||GI bleeding||||1000|49|59
SE|00000000||tx|1|entity|C2986495|Synergistic|qlco|||synergistic||||1000|65|75
SE|00000000||tx|1|entity|C1706077|user - individual|humn|||users||||1000|88|92
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|102|106
SE|00000000||tx|1|entity|C1883357|Together|qlco|||together||||888|108|115
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|124|127
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||901|132|138
SE|00000000||tx|1|entity|C0017181|Gastrointestinal Hemorrhage|patf|||GI bleeding||||901|140|150
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||966|152|157
SE|00000000||tx|1|entity|C1706077|user - individual|humn|||users||||1000|172|176
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||861|188|191
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|193|197
SE|00000000||tx|1|relation|5|4|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||861|188|191|NOM|PREDISPOSES||124|127|5|1|C0017181|Gastrointestinal Hemorrhage|patf|patf|||GI bleeding||||901|140|150


SE|00000000||tx|1|text|Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||Rifampin||||1000|1|8
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||Rifampin||||1000|11|18
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|34|43
SE|00000000||tx|1|entity|C0015011|Ethinyl Estradiol|horm,phsu,strd|||ethinyl estradiol||||1000|48|64
SE|00000000||tx|1|entity|C0033306|Progestins|horm,phsu,strd|||progestins||||1000|75|84
SE|00000000||tx|1|entity|C0028356|Norethindrone|horm,phsu,strd|||norethindrone||||1000|87|99
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||decreased||||851|115|123
SE|00000000||tx|1|entity|C2364326|Contraceptive|ftcn|||contraceptive||||851|125|137
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effectiveness||||851|139|151
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||901|157|165
SE|00000000||tx|1|entity|C0156404|Irregular periods|patf|||menstrual irregularities||||901|167|190
SE|00000000||tx|1|relation|0|0|C0028356|Norethindrone|horm,phsu,strd|horm|||norethindrone||||1000|87|99|SPEC|ISA||75|99|0|0|C0033306|Progestins|horm,phsu,strd|horm|||progestins||||1000|75|84
SE|00000000||tx|1|relation|2|1|C0035608|Rifampin|antb,orch|antb|||Rifampin||||1000|11|18|VERB|STIMULATES||20|28|6|2|C0015011|Ethinyl Estradiol|horm,phsu,strd|horm|||ethinyl estradiol||||1000|48|64


SE|00000000||tx|1|text|Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.
SE|00000000||tx|1|entity|C0683949|Animal Study|anim|||animal studies||||1000|7|20
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|39|44
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|49|60
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|82|88
SE|00000000||tx|1|entity|C0008287|Chlorpropamide|orch,phsu|||chlorpropamide||||1000|95|108
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|111|122
SE|00000000||tx|1|relation|4|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||1000|82|88|PREP|USES||90|93|3|1|C0008287|Chlorpropamide|orch,phsu|phsu|||chlorpropamide||||1000|95|108


SE|00000000||tx|1|text|Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .
SE|00000000||tx|1|entity|C0013084|Doxapram|orch,phsu|||doxapram||||1000|19|26
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|31|38
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetic||||1000|58|72
SE|00000000||tx|1|entity|C0026454|Monoamine Oxidase|aapp,enzy|||monoamine oxidase||||861|77|93
SE|00000000||tx|1|entity|C0021469|Metabolic Inhibition|moft|||inhibiting||||861|95|104
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||861|106|110
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||851|129|136
SE|00000000||tx|1|entity|C0237795|Pressors|phsu|||pressor||||851|138|144
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||851|146|151
SE|00000000||tx|1|relation|5|1|C0013084|Doxapram|orch,phsu|orch|||doxapram||||1000|19|26|NOM|ADMINISTERED_TO||1|14|5|2|C0030705|Patients|podg,humn|humn|||patients||||1000|31|38
SE|00000000||tx|1|relation|3|1|C0039052|Sympathomimetics|phsu|phsu|||sympathomimetic||||1000|58|72|VERB|ADMINISTERED_TO||48|56|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|31|38
SE|00000000||tx|1|relation|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||861|106|110|VERB|ADMINISTERED_TO||48|56|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|31|38


SE|00000000||tx|1|text|Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine.
SE|00000000||tx|1|entity|C0010968|Dangerousness|idcn|||danger||||900|16|21
SE|00000000||tx|1|entity|C1302234|Fatal|qlco|||fatal||||660|40|44
SE|00000000||tx|1|entity|C0489625|QTC interval|clna|||QTc interval||||1000|66|77
SE|00000000||tx|1|entity|C0120726|halofantrine|orch,phsu|||halofantrine||||1000|80|91
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|98|100
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneously||||1000|111|124
SE|00000000||tx|1|entity|C0025153|Mefloquine|orch,phsu|||Mefloquine||||1000|148|157


SE|00000000||tx|1|text|It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.
SE|00000000||tx|1|entity|C0236281|Serum lithium measurement|lbpr|||serum lithium levels||||988|24|43
SE|00000000||tx|1|entity|C0332183|Frequent|tmco|||frequently||||1000|58|67
SE|00000000||tx|1|entity|C0701176|Prinivil|aapp,phsu|||PRINIVIL||||1000|72|79
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|116|122
SE|00000000||tx|1|relation|2|2|C0236281|Serum lithium measurement|lbpr|lbpr|||serum lithium levels||||988|24|43|PREP|USES||111|114|1|1|C0023870|Lithium|elii,phsu|elii|||lithium||||1000|116|122


SE|00000000||tx|1|text|Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||Methotrexate||||916|1|12
SE|00000000||tx|1|entity|C0597373|renal tubular transport|ortf|||Renal tubular transport||||916|14|36
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|41|52
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|74|84
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|104|116
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||790|142|150
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|152|157
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|169|180


SE|00000000||tx|1|text|Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.
SE|00000000||tx|1|entity|C0037513|Heparin sodium|carb,phsu|||heparin sodium||||1000|17|30
SE|00000000||tx|1|entity|C0005640|Dicumarol|orch,phsu|||dicumarol||||1000|46|54
SE|00000000||tx|1|entity|C0376218|Warfarin Sodium|hops,orch,phsu|||warfarin sodium||||1000|59|73
SE|00000000||tx|1|entity|C0439531|per period (qualifier value)|tmco|||period||||1000|78|83
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|91|95
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||785|99|103
SE|00000000||tx|1|entity|C1517741|Last|qlco|||last||||851|115|118
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||851|120|130
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||851|132|135
SE|00000000||tx|1|entity|C1442770|24 Hours|tmco|||24 hours||||1000|140|147
SE|00000000||tx|1|entity|C1517741|Last|qlco|||last||||851|159|162
SE|00000000||tx|1|entity|C0443315|subcutaneous|spco|||subcutaneous||||851|164|175
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||851|177|180
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||1000|203|207
SE|00000000||tx|1|entity|C2349099|Valid|qlco|||valid||||901|223|227
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||901|229|244
SE|00000000||tx|1|relation|10|1|C0005640|Dicumarol|orch,phsu|orch|||dicumarol||||1000|46|54|VERB|COEXISTS_WITH||35|39|1|1|C0037513|Heparin sodium|carb,phsu|carb|||heparin sodium||||1000|17|30


SE|00000000||tx|1|text|Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||Non-||||875|1|4
SE|00000000||tx|1|entity|C0028621|Nucleosides|nnon|||nucleoside||||875|5|14
SE|00000000||tx|1|entity|C0282519|Reverse Transcriptase Inhibitors|phsu|||reverse transcriptase inhibitors||||875|16|47
SE|00000000||tx|1|entity|C0132326|Nevirapine|nnon,phsu|||Nevirapine||||1000|59|68
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|83|88
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||851|100|110
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||851|112|119
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||851|121|134


SE|00000000||tx|1|text|When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, the risk of hyperkalemia may be increased.
SE|00000000||tx|1|entity|C0546849|Amiloride Hydrochloride|orch,phsu|||amiloride HCl||||1000|6|18
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||angiotensin-converting enzyme inhibitor||||1000|58|96
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|103|106
SE|00000000||tx|1|entity|C0020461|Hyperkalemia|fndg|||hyperkalemia||||1000|111|122


SE|00000000||tx|1|text|Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|15|26
SE|00000000||tx|1|entity|C0700473|Fluvoxamine Maleate|orch,phsu|||fluvoxamine maleate||||1000|52|70
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|77|80
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|103|105
SE|00000000||tx|1|entity|C0205437|Third|qnco|||third||||888|107|111
SE|00000000||tx|1|entity|C0024501|Maintenance|acty|||maintenance||||824|132|142
SE|00000000||tx|1|entity|C2348070|Daily Dose|qnco|||daily maintenance dose||||824|126|147
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|153|173
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|178|189
SE|00000000||tx|1|entity|C0030695|Patient Monitoring|hlca|||monitored||||966|201|209


SE|00000000||tx|1|text|MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO Inhibitors||||1000|1|14
SE|00000000||tx|1|entity|C0591423|Duragesic|orch,phsu|||DURAGESIC||||1000|17|25
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|31|33
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|58|65
SE|00000000||tx|1|entity|C1514756|Receive|qlco|||received||||888|76|83
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAOI||||888|85|88
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|100|103
SE|00000000||tx|1|entity|C0279023|chemosensitization/potentiation|topp|||potentiation||||861|138|149
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|154|167
SE|00000000||tx|1|entity|C0002772|Analgesics, Opioid|orch,phsu|||opioid analgesics||||1000|192|208
SE|00000000||tx|1|relation|3|2|C0591423|Duragesic|orch,phsu|phsu|||DURAGESIC||||1000|17|25|PREP|TREATS||55|56|7|1|C0030705|Patients|podg,humn|podg|||patients||||1000|58|65
SE|00000000||tx|1|relation|9|2|C0279023|chemosensitization/potentiation|topp|topp|||potentiation||||861|138|149|PREP|USES||187|190|1|1|C0002772|Analgesics, Opioid|orch,phsu|phsu|||opioid analgesics||||1000|192|208


SE|00000000||tx|1|text|Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).
SE|00000000||tx|1|entity|C0033978|Psychotropic Drugs|phsu|||Psychoactive Drugs||||1000|1|18
SE|00000000||tx|1|entity|C0018524|Hallucinations|mobd|||Hallucinations||||1000|21|34
SE|00000000||tx|1|entity|C0146226|Toradol|orch,phsu|||TORADOL||||1000|60|66
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|80|87
SE|00000000||tx|1|entity|C0033978|Psychotropic Drugs|phsu|||psychoactive drugs||||1000|96|113
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|116|125
SE|00000000||tx|1|entity|C0039955|Thiothixene|orch,phsu|||thiothixene||||1000|128|138
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|141|150
SE|00000000||tx|1|relation|0|0|C0016365|Fluoxetine|orch,phsu|orch|||fluoxetine||||1000|116|125|SPEC|ISA||96|125|0|0|C0033978|Psychotropic Drugs|phsu|phsu|||psychoactive drugs||||1000|96|113
SE|00000000||tx|1|relation|3|2|C0018524|Hallucinations|mobd|mobd|||Hallucinations||||1000|21|34|PREP|PROCESS_OF||77|78|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|80|87
SE|00000000||tx|1|relation|4|1|C0033978|Psychotropic Drugs|phsu|phsu|||psychoactive drugs||||1000|96|113|VERB|ADMINISTERED_TO||89|94|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|80|87
SE|00000000||tx|1|relation|0|0|C0016365|Fluoxetine|orch,phsu|orch|||fluoxetine||||1000|116|125|INFER|ADMINISTERED_TO(SPEC)||96|125|0|0|C0030705|Patients|podg,humn|humn|||patients||||1000|80|87


SE|00000000||tx|1|text|Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered.
SE|00000000||tx|1|entity|C0009279|Colestipol|orch,phsu|||Colestipol||||1000|1|10
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||Plasma concentrations||||983|13|33
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||1000|38|49
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|61|73
SE|00000000||tx|1|entity|C0009279|Colestipol|orch,phsu|||colestipol||||1000|84|93
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||1000|99|110


SE|00000000||tx|1|text|In patients receiving coumarin-type anticoagulants, the addition of Nalfon to therapy could prolong the prothrombin time.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|4|11
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin-type anticoagulants||||896|23|50
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|57|64
SE|00000000||tx|1|entity|C0700739|Nalfon|orch,phsu|||Nalfon||||1000|69|74
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|79|85
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|105|120
SE|00000000||tx|1|relation|5|1|C0010206|coumarin|orch,phsu|orch|||coumarin-type anticoagulants||||896|23|50|VERB|ADMINISTERED_TO||13|21|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|4|11


SE|00000000||tx|1|text|Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.
SE|00000000||tx|1|entity|C0554831|Digitalization done|topp|||digitalized||||851|29|39
SE|00000000||tx|1|entity|C0020676|Hypothyroidism|dsyn|||hypothyroid||||851|42|52
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||851|54|60
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|79|82
SE|00000000||tx|1|entity|C1514873|Requirement|ftcn|||requirement||||888|84|94
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|99|105


SE|00000000||tx|1|text|Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.
SE|00000000||tx|1|entity|C0041983|Uricosuric Agents|phsu|||Uricosuric Agents||||1000|1|17
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||Aspirin||||1000|20|26
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|45|51
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|56|65
SE|00000000||tx|1|entity|C0038742|Sulfinpyrazone|orch,phsu|||sulfinpyrazone||||1000|68|81
SE|00000000||tx|1|entity|C0031463|Phenylbutazone|orch,phsu|||phenylbutazone||||1000|88|101
SE|00000000||tx|1|relation|2|1|C0004057|Aspirin|orch,phsu|orch|||Aspirin||||1000|20|26|NOM|INTERACTS_WITH||45|51|3|1|C0033209|Probenecid|orch,phsu|orch|||probenecid||||1000|56|65
SE|00000000||tx|1|relation|2|1|C0004057|Aspirin|orch,phsu|orch|||Aspirin||||1000|20|26|NOM|INTERACTS_WITH||45|51|3|1|C0031463|Phenylbutazone|orch,phsu|orch|||phenylbutazone||||1000|88|101
SE|00000000||tx|1|relation|2|1|C0004057|Aspirin|orch,phsu|orch|||Aspirin||||1000|20|26|NOM|INTERACTS_WITH||45|51|3|1|C0038742|Sulfinpyrazone|orch,phsu|orch|||sulfinpyrazone||||1000|68|81


SE|00000000||tx|1|text|Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).
SE|00000000||tx|1|entity|C0017066|Ganciclovir|nnon,phsu|||Ganciclovir||||1000|1|11
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||VIDEX||||802|32|36
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||802|40|44
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||1000|58|67
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|74|77
SE|00000000||tx|1|entity|C0017066|Ganciclovir|nnon,phsu|||ganciclovir||||888|79|89
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|124|131
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||901|140|151
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||901|153|155
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||1000|160|169


SE|00000000||tx|1|text|However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.
SE|00000000||tx|1|entity|C0565930|per second|qnco|||second||||888|17|22
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||888|24|28
SE|00000000||tx|1|entity|C1292430|12 hours|tmco|||12 g cholestyramine 1 hour||||813|49|74
SE|00000000||tx|1|entity|C0585040|Evening meal|tmco|||evening meal||||1000|87|98
SE|00000000||tx|1|entity|C0724549|Cerivastatin sodium|orch,phsu|||cerivastatin sodium||||730|111|129
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||730|131|143
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||730|147|151
SE|00000000||tx|1|entity|C0445247|Same|qlco|||same||||901|163|166
SE|00000000||tx|1|entity|C0585040|Evening meal|tmco|||evening meal||||901|168|179
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|195|202
SE|00000000||tx|1|entity|C0528023|cerivastatin|orch,phsu|||cerivastatin||||888|211|222
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|224|226
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||1000|231|234
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|251|258
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|263|266
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dosing||||890|298|303
SE|00000000||tx|1|entity|C0724549|Cerivastatin sodium|orch,phsu|||cerivastatin sodium||||890|305|323
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|325|329


SE|00000000||tx|1|text|TRACRIUM should not be administered until a patient has recovered from succinylcholine-induced neuromuscular block.
SE|00000000||tx|1|entity|C0592193|Tracrium|orch,phsu|||TRACRIUM||||1000|1|8
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|17|19
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|45|51
SE|00000000||tx|1|entity|C0038627|Succinylcholine|orch,phsu|||succinylcholine||||861|72|86
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induced||||861|88|94
SE|00000000||tx|1|entity|C0235062|Induction of neuromuscular blockade|topp|||neuromuscular block||||861|96|114


SE|00000000||tx|1|text|Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.
SE|00000000||tx|1|entity|C0209738|Lamivudine|nnon,phsu|||Lamivudine||||1000|1|10
SE|00000000||tx|1|entity|C1513475|Mononuclear|clna|||mononuclear||||905|50|60
SE|00000000||tx|1|entity|C0005773|Blood Cells|cell|||peripheral blood mononuclear cells||||905|33|66
SE|00000000||tx|1|entity|C1823394|TMEM132D gene|gngm|121256|TMEM132D|Molt||||802|78|81
SE|00000000||tx|1|entity|C0007634|Cells|cell|||cells||||802|85|89
SE|00000000||tx|1|entity|C0209738|Lamivudine|nnon,phsu|||lamivudine||||861|105|114
SE|00000000||tx|1|entity|C0012132|Zalcitabine|nnon,phsu|||zalcitabine||||888|140|150
SE|00000000||tx|1|entity|C0031715|Phosphorylation|moft|||phosphorylation||||888|152|166
SE|00000000||tx|1|entity|C1512045|Dose-dependent|qnco|||dose dependent||||734|173|186
SE|00000000||tx|1|relation|6|1|C0209738|Lamivudine|nnon,phsu|phsu|||lamivudine||||861|105|114|VERB|DISRUPTS||130|138|2|1|C0031715|Phosphorylation|moft|moft|||phosphorylation||||888|152|166


SE|00000000||tx|1|text|The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.
SE|00000000||tx|1|entity|C0021826|Intestinal Absorption|ortf|||gastrointestinal absorption||||1000|5|31
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|36|45
SE|00000000||tx|1|entity|C0034665|Ranitidine|orch,phsu|||ranitidine||||1000|51|60
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|111|119


SE|00000000||tx|1|text|however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|15|19
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||773|27|32
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||773|34|41
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|44|53
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|73|79
SE|00000000||tx|1|entity|C0022635|Ketoprofen|orch,phsu|||ketoprofen||||901|91|100
SE|00000000||tx|1|entity|C0033618|Protein Binding|moft|||protein binding||||901|102|116
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||833|122|130
SE|00000000||tx|1|entity|C0022635|Ketoprofen|orch,phsu|||ketoprofen||||833|132|141
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||833|143|148
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||833|150|158
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|185|191
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|213|219


SE|00000000||tx|1|text|At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine.
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|4|8
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||785|13|16
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuation||||1000|40|54
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitor||||1000|61|73
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|79|88
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|93|101
SE|00000000||tx|1|entity|C0011786|Dexfenfluramine|orch,phsu|||dexfenfluramine||||1000|108|122
SE|00000000||tx|1|relation|5|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||1000|93|101|PREP|USES||103|106|1|1|C0011786|Dexfenfluramine|orch,phsu|phsu|||dexfenfluramine||||1000|108|122


SE|00000000||tx|1|text|The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.
SE|00000000||tx|1|entity|C1533691|in vitro|qlco|||in vitro||||901|5|12
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||901|14|24
SE|00000000||tx|1|entity|C0132326|Nevirapine|nnon,phsu|||nevirapine||||1000|34|43
SE|00000000||tx|1|entity|C1704311|Antithrombotic Agents|phsu|||antithrombotic agent||||890|53|72
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||890|74|81
SE|00000000||tx|1|entity|C0439855|Complex|qlco|||complex||||1000|86|92


SE|00000000||tx|1|text|Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||Interactions||||966|1|12
SE|00000000||tx|1|entity|||gngm|7076|TIMP1|EPA||||827|32|34
SE|00000000||tx|1|entity|C2348609|Supplement|ftcn|||supplements||||827|36|46
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|52|58
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||non-steroidal anti-inflammatory drugs||||991|70|106
SE|00000000||tx|1|entity|C0019240|Herb|plnt|||herbs||||1000|112|116
SE|00000000||tx|1|entity|C0993630|Garlic|food|||garlic||||1000|126|131
SE|00000000||tx|1|entity|C0017102|Allium sativum|plnt|||Allium sativum||||1000|134|147
SE|00000000||tx|1|entity|C0330206|Ginkgo biloba|plnt|||ginkgo||||1000|154|159
SE|00000000||tx|1|entity|C0330206|Ginkgo biloba|plnt|||Ginkgo biloba||||1000|162|174


SE|00000000||tx|1|text|In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|4|11
SE|00000000||tx|1|entity|C0012091|Diclofenac|orch,phsu|||diclofenac||||1000|20|29
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||861|35|41
SE|00000000||tx|1|entity|C0238242|LITHIUM TOXICITY|inpo|||lithium toxicity||||1000|58|73
SE|00000000||tx|1|relation|3|1|C0012091|Diclofenac|orch,phsu|orch|||diclofenac||||1000|20|29|VERB|ADMINISTERED_TO||13|18|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|4|11


SE|00000000||tx|1|text|There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.
SE|00000000||tx|1|entity|C1704243|Greater|qnco|||greater||||1000|17|23
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two-||||888|30|33
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||888|34|37
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||812|70|75
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|87|111
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|118|127
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|154|164
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|177|182


SE|00000000||tx|1|text|Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||Monoamine Oxidase Inhibitors||||1000|1|28
SE|00000000||tx|1|entity|C0066673|Moclobemide|orch,phsu|||moclobemide||||1000|51|61
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|81|88
SE|00000000||tx|1|entity|C0914729|almotriptan|orch,phsu|||almotriptan||||888|93|103
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|105|113
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|122|129
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|134|137
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|142|154
SE|00000000||tx|1|relation|3|1|C0066673|Moclobemide|orch,phsu|orch|||moclobemide||||1000|51|61|NOM|INHIBITS||81|88|3|1|C0914729|almotriptan|orch,phsu|orch|||almotriptan||||888|93|103


SE|00000000||tx|1|text|Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||Agents||||966|1|6
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|20|25
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|32|44
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|62|69
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||888|74|85
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|87|95
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||827|107|111
SE|00000000||tx|1|relation|5|4|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|20|25|PREP|COEXISTS_WITH||71|72|2|1|C0299792|aripiprazole|orch,phsu|orch|||aripiprazole||||888|74|85


SE|00000000||tx|1|text|Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.
SE|00000000||tx|1|entity|C0025853|Metoclopramide|orch,phsu|||Metoclopramide||||1000|1|14
SE|00000000||tx|1|entity|C0939386|Monurol|orch,phsu|||MONUROL||||1000|42|48
SE|00000000||tx|1|entity|C0025853|Metoclopramide|orch,phsu|||metoclopramide||||1000|51|64
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||1000|69|72
SE|00000000||tx|1|entity|C0017184|Gastrointestinal Motility|ortf|||gastrointestinal motility||||1000|90|114
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentration||||1000|128|146
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||urinary||||888|152|158
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|160|168
SE|00000000||tx|1|entity|C0016610|Fosfomycin|antb,opco|||fosfomycin||||1000|173|182
SE|00000000||tx|1|relation|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||1000|69|72|VERB|AUGMENTS||80|88|4|1|C0017184|Gastrointestinal Motility|ortf|ortf|||gastrointestinal motility||||1000|90|114


SE|00000000||tx|1|text|Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs.
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||Furosemide||||1000|1|10
SE|00000000||tx|1|entity|C1527144|Therapeutic Effect|hlca|||therapeutic effect||||1000|41|58
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensive drugs||||1000|69|90


SE|00000000||tx|1|text|Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;
SE|00000000||tx|1|entity|C2826232|Dose Adjustment|hlca|||Dose adjustment||||1000|1|15
SE|00000000||tx|1|entity|C1435704|Sensipar|orch,phsu|||Sensipar||||1000|20|27
SE|00000000||tx|1|entity|C1970431|PITT-HOPKINS SYNDROME|dsyn|||PTH||||966|49|51
SE|00000000||tx|1|entity|C0006675|Calcium|bacs,elii,phsu|||calcium||||890|63|69
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum calcium concentrations||||890|57|84
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|119|125
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|153|159
SE|00000000||tx|1|entity|C0442821|Strong|qlco|||strong||||802|168|173
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||802|175|180
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||802|182|190
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|199|210
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|213|224
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|227|238
SE|00000000||tx|1|relation|7|4|C0006675|Calcium|bacs,elii,phsu|bacs|||calcium||||890|63|69|NOM|INHIBITS||182|190|7|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||802|175|180


SE|00000000||tx|1|text|Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics, including both sensory and motor blockade.
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||861|10|18
SE|00000000||tx|1|entity|C2926735|Duration|phsu|||duration||||1000|36|43
SE|00000000||tx|1|entity|C0728866|Drug effect|ftcn|||pharmacologic effects||||1000|48|68
SE|00000000||tx|1|entity|C0002934|Local Anesthetics|phsu|||local anesthetics||||901|82|98
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blockade||||861|134|141


SE|00000000||tx|1|text|Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||Cyclosporine||||1000|1|12
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||Increased||||888|15|23
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||888|25|32
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|42|53
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|59|73
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||1000|94|96


SE|00000000||tx|1|text|Cimetidine has been shown to increase the bioavailability of labetalol HCl.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|43|57
SE|00000000||tx|1|entity|C0699440|Labetalol hydrochloride|orch,phsu|||labetalol HCl||||1000|62|74
SE|00000000||tx|1|relation|1|1|C0008783|Cimetidine|orch,phsu|orch|||Cimetidine||||1000|1|10|VERB|STIMULATES||30|37|2|2|C0699440|Labetalol hydrochloride|orch,phsu|orch|||labetalol HCl||||1000|62|74


SE|00000000||tx|1|text|Response to sympathomimetic agents may be enhanced by colchicine.
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetic agents||||1000|13|34
SE|00000000||tx|1|entity|C0009262|Colchicine|orch,phsu|||colchicine||||1000|55|64
SE|00000000||tx|1|relation|1|1|C0009262|Colchicine|orch,phsu|orch|||colchicine||||1000|55|64|VERB|STIMULATES||43|50|2|1|C0039052|Sympathomimetics|phsu|phsu|||sympathomimetic agents||||1000|13|34


SE|00000000||tx|1|text|Antihypertensives: bumetanide may potentiate The effect of various antihypertensive drugs, necessitating a reduction In The dosage of these drugs.
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||Antihypertensives||||1000|1|17
SE|00000000||tx|1|entity|C0006376|Bumetanide|orch,phsu|||bumetanide||||1000|20|29
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|50|55
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensive drugs||||901|68|89
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|108|116
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||1000|125|130
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|141|145


SE|00000000||tx|1|text|Cytadren accelerates the metabolism of dexamethasone;
SE|00000000||tx|1|entity|C0591920|Cytadren|orch,phsu|||Cytadren||||1000|1|8
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|26|35
SE|00000000||tx|1|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||1000|40|52
SE|00000000||tx|1|relation|1|1|C0591920|Cytadren|orch,phsu|orch|||Cytadren||||1000|1|8|VERB|STIMULATES||10|20|2|2|C0011777|Dexamethasone|phsu,strd|phsu|||dexamethasone||||1000|40|52


SE|00000000||tx|1|text|Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
SE|00000000||tx|1|entity|C0428321|Measurement of liver enzyme|lbpr|||Hepatic Enzyme||||734|1|14
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||Inhibitors||||1000|26|35
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|53|57
SE|00000000||tx|1|entity|C1142644|Cytochrome P450 3A4|aapp,enzy|||cytochrome P450 3A4||||893|72|90
SE|00000000||tx|1|entity|C0243102|enzyme activity|moft|||enzyme activity||||893|102|116
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|125|136
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|139|147
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|150|162
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|165|172
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|191|200
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|205|219
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||1000|242|247
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroid||||1000|256|269
SE|00000000||tx|1|relation|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|53|57|VERB|AUGMENTS||65|70|9|1|C0243102|enzyme activity|moft|moft|||enzyme activity||||893|102|116
SE|00000000||tx|1|relation|9|6|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|53|57|VERB|STIMULATES||179|185|4|2|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroids||||1000|205|219


SE|00000000||tx|1|text|Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.
SE|00000000||tx|1|entity|C0031463|Phenylbutazone|orch,phsu|||Phenylbutazone||||1000|1|14
SE|00000000||tx|1|entity|C0031463|Phenylbutazone|orch,phsu|||Phenylbutazone||||1000|17|30
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|39|46
SE|00000000||tx|1|entity|C1880497|Empty (qualifier)|qlco|||free||||861|70|73
SE|00000000||tx|1|entity|C0059865|Etodolac|orch,phsu|||etodolac||||1000|87|94


SE|00000000||tx|1|text|Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||Methotrexate||||1000|1|12
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|18|26
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|28|31
SE|00000000||tx|1|entity|C0019158|Hepatitis|dsyn|||hepatitis||||1000|36|44
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combined||||888|79|86
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|88|90
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|95|106
SE|00000000||tx|1|entity|C0015137|Etretinate|orch,phsu|||etretinate||||1000|112|121
SE|00000000||tx|1|relation|4|4|C0015137|Etretinate|orch,phsu|orch|||etretinate||||1000|112|121|NOM|PREDISPOSES||28|31|4|1|C0019158|Hepatitis|dsyn|dsyn|||hepatitis||||1000|36|44
SE|00000000||tx|1|relation|4|4|C0025677|Methotrexate|orch,phsu|orch|||methotrexate||||1000|95|106|NOM|PREDISPOSES||28|31|4|1|C0019158|Hepatitis|dsyn|dsyn|||hepatitis||||1000|36|44


SE|00000000||tx|1|text|ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.
SE|00000000||tx|1|entity|C0701454|Isuprel|orch,phsu|||ISUPREL||||1000|1|7
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||856|54|59
SE|00000000||tx|1|entity|C0242903|Anesthetics, Inhalation|phsu|||inhalational anesthetics||||856|61|84
SE|00000000||tx|1|entity|C0018549|Halothane|orch,phsu|||halothane||||1000|94|102
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||861|128|136
SE|00000000||tx|1|entity|C0027061|Myocardium|tisu|||myocardium||||1000|155|164
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|169|175
SE|00000000||tx|1|entity|C0002509|Amines, Sympathomimetic|phsu|||sympathomimetic amines||||1000|180|201
SE|00000000||tx|1|relation|0|0|C0018549|Halothane|orch,phsu|orch|||halothane||||1000|94|102|SPEC|ISA||61|102|0|0|C0242903|Anesthetics, Inhalation|phsu|phsu|||inhalational anesthetics||||856|61|84
SE|00000000||tx|1|relation|4|1|C0018549|Halothane|orch,phsu|orch|||halothane||||1000|94|102|VERB|AUGMENTS||141|149|3|1|C0027061|Myocardium|tisu|tisu|||myocardium||||1000|155|164
SE|00000000||tx|1|relation|5|3|C0242903|Anesthetics, Inhalation|phsu|phsu|||inhalational anesthetics||||856|61|84|NOM|INTERACTS_WITH||169|175|1|1|C0002509|Amines, Sympathomimetic|phsu|phsu|||sympathomimetic amines||||1000|180|201
SE|00000000||tx|1|relation|0|0|C0018549|Halothane|orch,phsu|orch|||halothane||||1000|94|102|INFER|INTERACTS_WITH(SPEC)||61|102|0|0|C0002509|Amines, Sympathomimetic|phsu|phsu|||sympathomimetic amines||||1000|180|201


SE|00000000||tx|1|text|Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.
SE|00000000||tx|1|entity|C0065864|medroxyprogesterone acetate|horm,phsu,strd|||Medroxyprogesterone Acetate||||824|1|27
SE|00000000||tx|1|entity|C0019602|Histidine|aapp,bacs,phsu|||histidine||||824|33|41
SE|00000000||tx|1|entity|C0040284|Tissue culture|lbpr|||tissue culture||||1000|71|84
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|91|96
SE|00000000||tx|1|entity|C0065864|medroxyprogesterone acetate|horm,phsu,strd|||medroxyprogesterone acetate||||1000|101|127
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reducing||||1000|132|139
SE|00000000||tx|1|entity|C0237753|Numbers|qnco|||number||||1000|145|150
SE|00000000||tx|1|entity|C1512505|Breast Cancer Cell|cell|||human breast cancer cells||||983|155|179
SE|00000000||tx|1|entity|C0205390|Phase|tmco|||phase||||861|200|204


SE|00000000||tx|1|text|Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|12|14
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|19|32
SE|00000000||tx|1|entity|C0003123|Anorexia|dsyn|||anorectic||||888|53|61
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|63|68
SE|00000000||tx|1|entity|C0012201|Diethylpropion|orch,phsu|||diethylpropion||||1000|73|86
SE|00000000||tx|1|relation|1|1|C0012201|Diethylpropion|orch,phsu|orch|||diethylpropion||||1000|73|86|NOM|AFFECTS||63|68|2|0|C0003123|Anorexia|dsyn|dsyn|||anorectic||||888|53|61


SE|00000000||tx|1|text|The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
SE|00000000||tx|1|entity|C0020616|Hypoglycemic Agents|phsu|||hypoglycemic||||888|5|16
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||888|18|23
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||888|63|69
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|71|75
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory agents||||1000|87|123
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|135|139
SE|00000000||tx|1|entity|C0205250|High|qlco|||highly||||888|150|155
SE|00000000||tx|1|entity|C0033684|Proteins|aapp,bacs|||protein||||888|157|163
SE|00000000||tx|1|entity|C0036077|Salicylates|orch,phsu|||salicylates||||1000|172|182
SE|00000000||tx|1|entity|C0038760|Sulfonamides|orch,phsu|||sulfonamides||||1000|185|196
SE|00000000||tx|1|entity|C0008168|Chloramphenicol|antb,orch|||chloramphenicol||||1000|199|213
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|216|225
SE|00000000||tx|1|entity|C0010207|Coumarins|orch,phsu|||coumarins||||1000|228|236
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|239|266
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta adrenergic blocking agents||||1000|273|303
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory agents||||1000|87|123|SPEC|ISA||87|139|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|135|139
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory agents||||1000|87|123|SPEC|ISA||87|139|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|71|75
SE|00000000||tx|1|relation|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta adrenergic blocking agents||||1000|273|303|SPEC|ISA||87|139|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|135|139
SE|00000000||tx|1|relation|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta adrenergic blocking agents||||1000|273|303|SPEC|ISA||87|139|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|71|75
SE|00000000||tx|1|relation|0|0|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein||||888|157|163|SPEC|ISA||135|163|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|135|139
SE|00000000||tx|1|relation|0|0|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein||||888|157|163|SPEC|ISA||135|163|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|71|75


SE|00000000||tx|1|text|Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0066447|methylxanthine|orch,phsu|||methylxanthines||||1000|28|42
SE|00000000||tx|1|entity|C0002575|Aminophylline|orch,phsu|||aminophylline||||1000|45|57
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|60|71
SE|00000000||tx|1|entity|C0038317|Steroids|strd|||steroids||||1000|75|82
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|88|96
SE|00000000||tx|1|entity|C0020621|Hypokalemia|fndg|||hypokalemic||||853|117|127
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||853|129|134
SE|00000000||tx|1|entity|C0001648|Adrenergic Agonists|phsu|||adrenergic agonists||||1000|139|157
SE|00000000||tx|1|relation|0|0|C0002575|Aminophylline|orch,phsu|orch|||aminophylline||||1000|45|57|SPEC|ISA||28|57|0|0|C0066447|methylxanthine|orch,phsu|orch|||methylxanthines||||1000|28|42
SE|00000000||tx|1|relation|6|2|C0038317|Steroids|strd|strd|||steroids||||1000|75|82|NOM|INTERACTS_WITH||129|134|1|1|C0001648|Adrenergic Agonists|phsu|phsu|||adrenergic agonists||||1000|139|157
SE|00000000||tx|1|relation|6|2|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|88|96|NOM|INTERACTS_WITH||129|134|1|1|C0001648|Adrenergic Agonists|phsu|phsu|||adrenergic agonists||||1000|139|157


SE|00000000||tx|1|text|Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.
SE|00000000||tx|1|entity|C0290883|anastrozole|orch,phsu|||anastrozole||||1000|22|32
SE|00000000||tx|1|entity|C0039286|Tamoxifen|orch,phsu|||tamoxifen||||1000|38|46
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|62|70
SE|00000000||tx|1|entity|C0290883|anastrozole|orch,phsu|||anastrozole||||790|75|85
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|87|92
SE|00000000||tx|1|entity|C0290883|anastrozole|orch,phsu|||anastrozole||||1000|142|152
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|154|158
SE|00000000||tx|1|relation|5|3|C0039286|Tamoxifen|orch,phsu|orch|||tamoxifen||||1000|38|46|VERB|compared_with||108|115|2|1|C0290883|anastrozole|orch,phsu|orch|||anastrozole||||1000|142|152


SE|00000000||tx|1|text|Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||790|12|22
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||790|24|30
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|60|84
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|115|124


SE|00000000||tx|1|text|Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|17|25
SE|00000000||tx|1|entity|C0012772|Disulfiram|orch,phsu|||disulfiram||||1000|32|41
SE|00000000||tx|1|entity|C0700364|Appearance|qlco|||appearance||||1000|79|88
SE|00000000||tx|1|entity|C0231686|Gait, Unsteady|fndg|||unsteady gait||||1000|93|105
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||marked||||888|110|115
SE|00000000||tx|1|entity|C0392747|Changing|ftcn|||changes||||888|117|123
SE|00000000||tx|1|entity|C0278060|Mental state (observable entity)|fndg|||mental status||||1000|128|140
SE|00000000||tx|1|relation|6|1|C0022209|isoniazid|orch,phsu|orch|||isoniazid||||1000|17|25|VERB|ADMINISTERED_TO||10|15|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8
SE|00000000||tx|1|relation|6|4|C0012772|Disulfiram|orch,phsu|phsu|||disulfiram||||1000|32|41|PREP|TREATS||125|126|1|1|C0278060|Mental state (observable entity)|fndg|fndg|||mental status||||1000|128|140


SE|00000000||tx|1|text|Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|entity|C0038633|Sucralfate|carb,phsu|||sucralfate||||861|13|22
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|76|85
SE|00000000||tx|1|entity|C0205251|low|qlco|||low||||623|101|103
SE|00000000||tx|1|entity|C0042036|Urine|bdsu|||urine||||623|105|109


SE|00000000||tx|1|text|Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||Warfarin||||1000|1|8
SE|00000000||tx|1|entity|C1148561|anticoagulant activity|moft|||Anticoagulant activity||||1000|11|32
SE|00000000||tx|1|entity|C1279901|Firstly|qlco|||first||||802|75|79
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||802|85|88
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiating||||966|96|105
SE|00000000||tx|1|entity|C0392747|Changing|ftcn|||changing||||851|110|117
SE|00000000||tx|1|entity|C0876768|Vioxx|orch,phsu|||VIOXX||||851|119|123
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|136|143
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|155|162
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||872|167|173
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||872|175|180
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|195|202
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|214|222
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|224|227
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||888|232|239
SE|00000000||tx|1|entity|C0009566|Complication|patf|||complications||||888|241|253
SE|00000000||tx|1|relation|5|5|C0043031|Warfarin|hops,orch,phsu|phsu|||Warfarin||||1000|1|8|PREP|TREATS||133|134|6|1|C0030705|Patients|podg,humn|podg|||patients||||1000|136|143
SE|00000000||tx|1|relation|5|1|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||1000|155|162|VERB|ADMINISTERED_TO||145|153|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|136|143
SE|00000000||tx|1|relation|9|2|C1254351|Pharmacologic Substance|phsu|phsu|||agents||||872|175|180|NOM|PREDISPOSES||224|227|1|1|C0009566|Complication|patf|patf|||complications||||888|241|253


SE|00000000||tx|1|text|Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||Oral Anticoagulants||||1000|1|19
SE|00000000||tx|1|entity|C0205307|Normal|qlco|||normal||||888|30|35
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|37|46
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|53|63
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|83|92
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|98|105
SE|00000000||tx|1|entity|C0000956|Acenocoumarol|orch,phsu|||acenocoumarol||||1000|108|120
SE|00000000||tx|1|entity|C0031444|Phenprocoumon|orch,phsu|||phenprocoumon||||1000|126|138
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|168|183
SE|00000000||tx|1|relation|1|1|C0354604|Anticoagulants, Oral|orch,phsu|phsu|||Oral Anticoagulants||||1000|1|19|PREP|TREATS||22|23|8|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|37|46


SE|00000000||tx|1|text|Methotrexate (e.g., Mexate) use of Methotrexate with sulfapyridine may increase The chance of side effects affecting The liver and/or The side effects of Methotrexate
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||Methotrexate||||1000|1|12
SE|00000000||tx|1|entity|C0205839|Mexate|orch,phsu|||Mexate||||1000|21|26
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||Methotrexate||||1000|36|47
SE|00000000||tx|1|entity|C0038710|Sulfapyridine|orch,phsu|||sulfapyridine||||1000|54|66
SE|00000000||tx|1|entity|C0237506|Chance|qlco|||chance||||1000|85|90
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||1000|95|106
SE|00000000||tx|1|entity|C0023884|Liver|bpoc|||liver||||1000|122|126
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||1000|139|150
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||Methotrexate||||1000|155|166
SE|00000000||tx|1|relation|6|3|C0038710|Sulfapyridine|orch,phsu|orch|||sulfapyridine||||1000|54|66|VERB|AFFECTS||108|116|3|1|C0023884|Liver|bpoc|bpoc|||liver||||1000|122|126


SE|00000000||tx|1|text|Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.
SE|00000000||tx|1|entity|C0358591|Proton Pump Inhibitors|phsu|||proton pump inhibitors||||1000|12|33
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||890|54|58
SE|00000000||tx|1|entity|C0456693|per 30 minutes|tmco|||30 minutes||||890|60|69
SE|00000000||tx|1|entity|C0038633|Sucralfate|carb,phsu|||sucralfate||||1000|80|89


SE|00000000||tx|1|text|Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0027409|Narcotic Analgesics|phsu|||narcotic analgesics||||1000|26|44
SE|00000000||tx|1|entity|C0017302|General anesthetic drugs|phsu|||general anesthetics||||1000|47|65
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|68|81
SE|00000000||tx|1|entity|C0040614|Tranquilizing Agents|phsu|||tranquilizers||||1000|84|96
SE|00000000||tx|1|entity|C0020592|Hypnotics and Sedatives|phsu|||sedative-hypnotics||||1000|99|116
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|119|143
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||1000|154|168
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|181|187
SE|00000000||tx|1|entity|C0728755|Dilaudid|orch,phsu|||DILAUDID||||1000|209|216
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||901|233|240
SE|00000000||tx|1|entity|C0151559|Central nervous system depression (disorder)|dsyn|||CNS depression||||901|242|255
SE|00000000||tx|1|relation|0|0|C0031436|Phenothiazines|orch,phsu|orch|||phenothiazines||||1000|68|81|SPEC|ISA||68|96|0|0|C0040614|Tranquilizing Agents|phsu|phsu|||tranquilizers||||1000|84|96
SE|00000000||tx|1|relation|0|0|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|119|143|SPEC|ISA||119|168|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|154|168
SE|00000000||tx|1|relation|10|1|C0027409|Narcotic Analgesics|phsu|phsu|||narcotic analgesics||||1000|26|44|VERB|ADMINISTERED_TO||10|18|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8


SE|00000000||tx|1|text|Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.
SE|00000000||tx|1|entity|C0023866|Literature|inpr|||Literature||||888|1|10
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|54|65
SE|00000000||tx|1|entity|C0597421|saluretic|phsu|||natriuretic||||1000|82|92
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|115|121
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|126|135
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|145|152
SE|00000000||tx|1|entity|C0021469|Metabolic Inhibition|moft|||inhibiting||||901|157|166
SE|00000000||tx|1|entity|C1157324|prostaglandin biosynthetic process|moft|||prostaglandin synthesis||||901|168|190
SE|00000000||tx|1|relation|3|1|C0021246|Indomethacin|orch,phsu|orch|||indomethacin||||1000|54|65|VERB|INHIBITS||71|76|5|1|C0597421|saluretic|phsu|phsu|||natriuretic||||1000|82|92
SE|00000000||tx|1|relation|6|1|C0016860|Furosemide|orch,phsu|phsu|||furosemide||||1000|126|135|PREP|TREATS||137|138|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|145|152


SE|00000000||tx|1|text|TCAs decrease the hypotensive effect of guanfacine.
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||TCAs||||966|1|4
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|19|29
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|31|36
SE|00000000||tx|1|entity|C0079466|Guanfacine|orch,phsu|||guanfacine||||1000|41|50
SE|00000000||tx|1|relation|1|1|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||TCAs||||966|1|4|NOM|INTERACTS_WITH||31|36|1|1|C0079466|Guanfacine|orch,phsu|orch|||guanfacine||||1000|41|50


SE|00000000||tx|1|text|However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.
SE|00000000||tx|1|entity|C1621583|Administer|ftcn|||administering||||872|38|50
SE|00000000||tx|1|entity|C0719198|Celebrex|orch,phsu|||CELEBREX||||872|52|59
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|66|73
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|87|94
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|103|111
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|113|116
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||888|121|128
SE|00000000||tx|1|entity|C0009566|Complication|patf|||complications||||888|130|142
SE|00000000||tx|1|relation|4|2|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||1000|66|73|NOM|PREDISPOSES||113|116|1|1|C0009566|Complication|patf|patf|||complications||||888|130|142


SE|00000000||tx|1|text|In patients who have received muscle relaxants, doxapram may temporarily mask the residual effects of muscle relaxant drugs.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|4|11
SE|00000000||tx|1|entity|C1514756|Receive|qlco|||received||||901|22|29
SE|00000000||tx|1|entity|C0358430|Muscle relaxants|phsu|||muscle relaxants||||901|31|46
SE|00000000||tx|1|entity|C0013084|Doxapram|orch,phsu|||doxapram||||1000|49|56
SE|00000000||tx|1|entity|C1609982|Residual|qlco|||residual||||888|83|90
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|92|98
SE|00000000||tx|1|entity|C0358430|Muscle relaxants|phsu|||muscle relaxant||||901|103|117
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||901|119|123
SE|00000000||tx|1|relation|0|0|C0358430|Muscle relaxants|phsu|phsu|||muscle relaxant||||901|103|117|MOD/HEAD|ISA||103|123|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||901|119|123
SE|00000000||tx|1|relation|3|2|C0358430|Muscle relaxants|phsu|phsu|||muscle relaxants||||901|31|46|NOM|INTERACTS_WITH||92|98|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||901|119|123
SE|00000000||tx|1|relation|0|0|C0358430|Muscle relaxants|phsu|phsu|||muscle relaxants||||901|31|46|INFER|INTERACTS_WITH(SPEC)||103|123|0|0|C0358430|Muscle relaxants|phsu|phsu|||muscle relaxant||||901|103|117


SE|00000000||tx|1|text|Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).
SE|00000000||tx|1|entity|C0038633|Sucralfate|carb,phsu|||Sucralfate||||1000|1|10
SE|00000000||tx|1|entity|C1292425|2 Hours|tmco|||2 hours||||1000|25|31
SE|00000000||tx|1|entity|C0065162|lomefloxacin|orch,phsu|||lomefloxacin||||1000|40|51
SE|00000000||tx|1|entity|C0439834|Slow|qlco|||slower||||661|67|72
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||C max||||901|91|95
SE|00000000||tx|1|entity|C2348796|Tmax|qnco|||T max||||901|123|127
SE|00000000||tx|1|entity|C1442450|1 Hour|tmco|||1 hour||||1000|142|147
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||lesser||||888|156|161
SE|00000000||tx|1|entity|C0439792|Extent|spco|||extent||||888|163|168
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||861|190|192
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|207|219


SE|00000000||tx|1|text|It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.
SE|00000000||tx|1|entity|C0282090|Laxatives|phsu|||laxative||||888|27|34
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|36|38
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|47|53
SE|00000000||tx|1|entity|C0701188|Camptosar|orch,phsu|||CAMPTOSAR||||1000|60|68
SE|00000000||tx|1|entity|C0021149|Incidence|qnco|||incidence||||1000|87|95
SE|00000000||tx|1|entity|C0439793|Severities|qlco|||severity||||1000|100|107
SE|00000000||tx|1|entity|C0011991|Diarrhea|sosy|||diarrhea||||1000|112|119
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|135|137
SE|00000000||tx|1|relation|2|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||1000|47|53|PREP|USES||55|58|4|1|C0701188|Camptosar|orch,phsu|phsu|||CAMPTOSAR||||1000|60|68


SE|00000000||tx|1|text|In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||901|4|6
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||clinical studies||||901|8|23
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|26|37
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||794|40|42
SE|00000000||tx|1|entity|C0439272|ug/g|qnco|||mg/kg||||794|46|50
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||794|52|55
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||794|60|62
SE|00000000||tx|1|entity|C0439272|ug/g|qnco|||mg/kg||||794|66|70
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||794|72|76
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|93|95
SE|00000000||tx|1|entity|C0537894|Caspofungin|aapp,phsu|||caspofungin||||1000|100|110
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|115|127


SE|00000000||tx|1|text|Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C1522668|Recombinant Tumor Necrosis Factor Family Protein|aapp,imft|7124|TNF|TNF||||694|32|34
SE|00000000||tx|1|entity|C1700021|Orencia|aapp,imft,phsu|||ORENCIA||||1000|52|58
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|88|96
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|98|101
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||888|106|112
SE|00000000||tx|1|entity|C0021311|Infection|dsyn|||infections||||888|114|123
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||766|132|142
SE|00000000||tx|1|entity|C1524062|Additional|ftcn|||additional||||766|144|153
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||766|155|162
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||766|169|171
SE|00000000||tx|1|entity|C1522668|Recombinant Tumor Necrosis Factor Family Protein|aapp,imft|7124|TNF|TNF||||888|180|182
SE|00000000||tx|1|entity|C0243076|antagonists|chvf|||antagonists||||888|184|194
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|196|200
SE|00000000||tx|1|relation|3|1|C1700021|Orencia|aapp,gngm,imft,phsu|aapp|||ORENCIA||||1000|52|58|NOM|PREDISPOSES||98|101|4|1|C0021311|Infection|dsyn|dsyn|||infections||||888|114|123


SE|00000000||tx|1|text|Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.
SE|00000000||tx|1|entity|C0008168|Chloramphenicol|antb,orch|||Chloramphenicol||||1000|1|15
SE|00000000||tx|1|entity|C0243076|antagonists|chvf|||antagonistic||||928|38|49
SE|00000000||tx|1|entity|C0026458|Monobactams|antb,orch|||beta-lactam antibiotics||||966|54|76
SE|00000000||tx|1|entity|C0007559|Ceftazidime|antb,orch|||ceftazidime||||1000|89|99
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||840|132|135
SE|00000000||tx|1|entity|C0681205|Sacrifice|idcn|||kill||||840|137|140
SE|00000000||tx|1|entity|C0205134|Curved|spco|||curves||||840|142|147
SE|00000000||tx|1|entity|C1304890|Enteral|spco|||enteric||||905|154|160
SE|00000000||tx|1|entity|C0314752|Gram-negative bacillus|bact|||gram-negative bacilli||||905|162|182


SE|00000000||tx|1|text|therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.
SE|00000000||tx|1|entity|C0587267|Closed|ftcn|||close||||694|12|16
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|32|47
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulant||||901|87|99
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||901|101|104
SE|00000000||tx|1|entity|C0592157|Tagamet|orch,phsu|||Tagamet||||1000|128|134


SE|00000000||tx|1|text|Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.
SE|00000000||tx|1|entity|C0232804|Renal function|ortf|||Renal function||||1000|1|14
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high doses||||983|49|58
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycosides||||1000|63|77
SE|00000000||tx|1|entity|C0284915|Maxipime|antb,orch|||MAXIPIME||||1000|107|114
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|131|139
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||888|141|149
SE|00000000||tx|1|entity|C0599918|nephrotoxicity|inpo|||nephrotoxicity||||1000|154|167
SE|00000000||tx|1|entity|C0235280|Ototoxicity|inpo|||ototoxicity||||1000|173|183
SE|00000000||tx|1|entity|C0003233|Antibiotics, Aminoglycoside|antb,carb|||aminoglycoside antibiotics||||1000|188|213


SE|00000000||tx|1|text|In vitro, buspirone may displace less firmly bound drugs like digoxin.
SE|00000000||tx|1|entity|C0006462|Buspirone|orch,phsu|||buspirone||||1000|11|19
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||852|34|37
SE|00000000||tx|1|entity|C1880776|Firmly|qlco|||firmly||||852|39|44
SE|00000000||tx|1|entity|C0678751|protein-bound drug fraction|qnco|||bound drugs||||852|46|56
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|63|69


SE|00000000||tx|1|text|Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||Beta-adrenergic Blocking Agents||||1000|1|31
SE|00000000||tx|1|entity|C0596545|Experience|menp|||Experience||||1000|34|43
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||827|58|65
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||non-||||824|72|75
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||clinical trial||||824|88|101
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|118|128
SE|00000000||tx|1|entity|C0028066|Nifedipine|orch,phsu|||nifedipine||||1000|148|157
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blocking agents||||983|163|182
SE|00000000||tx|1|entity|C3146287|Well|mnob|||well||||827|195|198
SE|00000000||tx|1|entity|C0521114|Infrequent|tmco|||occasional||||851|231|240
SE|00000000||tx|1|entity|C0034036|Publications|inpr,mnob|||literature||||851|242|251
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|281|291
SE|00000000||tx|1|entity|C0033204|Probability|qnco|||likelihood||||1000|310|319
SE|00000000||tx|1|entity|C0018802|Congestive heart failure|dsyn|||congestive heart failure||||1000|324|347
SE|00000000||tx|1|entity|C2678378|Hypotension, severe|fndg|||severe hypotension||||1000|350|367
SE|00000000||tx|1|relation|2|2|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||Beta-adrenergic Blocking Agents||||1000|1|31|PREP|TREATS||45|46|13|1|C0030705|Patients|podg,humn|podg|||patients||||827|58|65
SE|00000000||tx|1|relation|2|2|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blocking agents||||983|163|182|PREP|TREATS||45|46|13|1|C0030705|Patients|podg,humn|podg|||patients||||827|58|65


SE|00000000||tx|1|text|Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||Dose||||888|23|26
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||Reduction||||888|28|36
SE|00000000||tx|1|entity|C0525004|Viracept|orch,phsu|||VIRACEPT||||901|62|69
SE|00000000||tx|1|entity|C0360390|Antimycobacterial agent|phsu|||Antimycobacterial agents||||901|71|94
SE|00000000||tx|1|entity|C0140575|Rifabutin|antb,orch|||rifabutin||||1000|97|105


SE|00000000||tx|1|text|Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.
SE|00000000||tx|1|entity|C0164662|Stavudine|nnon,phsu|||Stavudine||||1000|1|9
SE|00000000||tx|1|entity|C0043474|Zidovudine|nnon,phsu|||Zidovudine||||888|15|24
SE|00000000||tx|1|entity|C0035525|Ribavirin|nnon,phsu|||Ribavirin||||888|26|34
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||827|74|81
SE|00000000||tx|1|entity|C0164662|Stavudine|nnon,phsu|||stavudine||||1000|86|94
SE|00000000||tx|1|entity|C0043474|Zidovudine|nnon,phsu|||zidovudine||||1000|100|109
SE|00000000||tx|1|entity|C0019682|HIV|virs|||HIV||||1000|119|121


SE|00000000||tx|1|text|Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;
SE|00000000||tx|1|entity|C0242896|Anticholinergic Agents|phsu|||Anticholinergic agents||||1000|1|22
SE|00000000||tx|1|entity|C0021826|Intestinal Absorption|ortf|||gastrointestinal absorption||||1000|35|61
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||861|74|78
SE|00000000||tx|1|entity|C0439834|Slow|qlco|||slowly||||1000|89|94
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||1000|107|112
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|123|129
SE|00000000||tx|1|relation|1|1|C0242896|Anticholinergic Agents|phsu|phsu|||Anticholinergic agents||||1000|1|22|VERB|AFFECTS||28|33|4|1|C0021826|Intestinal Absorption|ortf|ortf|||gastrointestinal absorption||||1000|35|61


SE|00000000||tx|1|text|Concomitant administration of probenecid doubled the AUC for cefprozil.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|31|40
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|54|56
SE|00000000||tx|1|entity|C0053882|cefprozil|antb,orch|||cefprozil||||1000|62|70


SE|00000000||tx|1|text|Alternatives to rifampin should be considered during the course of PCP treatment with MEPRON.
SE|00000000||tx|1|entity|C1523987|Alternative|cnce|||Alternatives||||966|1|12
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|17|24
SE|00000000||tx|1|entity|C0750729|Course|tmco|||course||||1000|58|63
SE|00000000||tx|1|entity|||gngm|649,5547,54858|BMP1,PRCP,PGPEP1|PCP||||861|68|70
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||861|72|80
SE|00000000||tx|1|entity|C0378468|Mepron|orch,phsu|||MEPRON||||1000|87|92
SE|00000000||tx|1|relation|4|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||861|72|80|PREP|USES||82|85|1|1|C0378468|Mepron|orch,phsu|phsu|||MEPRON||||1000|87|92


SE|00000000||tx|1|text|In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives
SE|00000000||tx|1|entity|C0332464|Widening|spco|||broad-||||851|22|27
SE|00000000||tx|1|entity|C2827424|Spectrum|cnce|||spectrum||||851|28|35
SE|00000000||tx|1|entity|C0003232|Antibiotics|antb|||antibiotics||||851|37|47
SE|00000000||tx|1|entity|C1171094|Augmentin XR|antb,orch|||AUGMENTIN XR||||1000|50|61
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|78|85
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives||||1000|90|108
SE|00000000||tx|1|relation|2|1|C1171094|Augmentin XR|antb,orch|antb|||AUGMENTIN XR||||1000|50|61|VERB|INHIBITS||67|72|2|2|C0009905|Contraceptives, Oral|phsu|phsu|||oral contraceptives||||1000|90|108


SE|00000000||tx|1|text|Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||1000|1|12
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||Potential||||888|15|23
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||888|25|35
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||1000|40|51
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||Isoniazid||||1000|57|65


SE|00000000||tx|1|text|However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|21|25
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|30|47
SE|00000000||tx|1|entity|C0031327|Drug Kinetics|phsf|||pharmacokinetics||||1000|54|69
SE|00000000||tx|1|entity|C0006491|Butorphanol|orch,phsu|||butorphanol||||1000|74|84
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|118|125
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|130|132
SE|00000000||tx|1|entity|C0450361|38|inpr|||38%||||888|138|140
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||888|142|149
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|154|157
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||750|172|175
SE|00000000||tx|1|entity|C0038119|Stadol|orch,phsu|||STADOL NS||||1000|180|188
SE|00000000||tx|1|entity|C0470296|1 Minute|qnco|||1 minute||||1000|207|214
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||790|230|233
SE|00000000||tx|1|entity|C1253507|Sumatriptan Nasal Spray|clnd|||sumatriptan nasal spray||||1000|238|260


SE|00000000||tx|1|text|Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.
SE|00000000||tx|1|entity|C0017628|Glyburide|orch,phsu|||Glibenclamide||||1000|1|13
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|21|25
SE|00000000||tx|1|entity|C1706429|Male, Self-Reported|orga|||male||||813|40|43
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy male volunteers||||813|32|54
SE|00000000||tx|1|entity|C0050559|Acitretin|orch,phsu|||acitretin||||888|57|65
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||861|93|97
SE|00000000||tx|1|entity|C0441994|Lower - spatial qualifier|spco|||lowering||||861|107|114
SE|00000000||tx|1|entity|C1158774|negative regulation of transcription by glucose|genf|||glucose lowering effect||||861|99|121
SE|00000000||tx|1|entity|C0017628|Glyburide|orch,phsu|||glibenclamide||||1000|126|138
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||1000|156|162
SE|00000000||tx|1|entity|C0008287|Chlorpropamide|orch,phsu|||chlorpropamide||||1000|167|180
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||827|197|204
SE|00000000||tx|1|relation|4|4|C0017628|Glyburide|orch,phsu|orch|||Glibenclamide||||1000|1|13|VERB|AUGMENTS||77|87|6|1|C1158774|negative regulation of transcription by glucose|genf|genf|||glucose lowering effect||||861|99|121


SE|00000000||tx|1|text|Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|15|19
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||884|26|43
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|57|67
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|69|76
SE|00000000||tx|1|entity|C0028066|Nifedipine|orch,phsu|||nifedipine||||852|86|95
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||852|97|102
SE|00000000||tx|1|entity|C0444505|Peak level|qnco|||peak nifedipine plasma levels||||852|81|109
SE|00000000||tx|1|entity|C0205146|Area|spco|||area||||1000|121|124
SE|00000000||tx|1|entity|C0205134|Curved|spco|||curve||||1000|136|140
SE|00000000||tx|1|entity|C0439230|week|tmco|||week||||750|158|161
SE|00000000||tx|1|entity|C0750729|Course|tmco|||course||||750|163|168
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|173|182
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||1000|199|201
SE|00000000||tx|1|entity|C0028066|Nifedipine|orch,phsu|||nifedipine||||1000|207|216
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||1000|231|233


SE|00000000||tx|1|text|Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.
SE|00000000||tx|1|entity|C0014892|Estazolam|orch,phsu|||estazolam||||1000|15|23
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|46|53
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|65|76
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|82|93
SE|00000000||tx|1|entity|C0442824|Very|qlco|||very||||818|106|109
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||818|111|116
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||818|118|127
SE|00000000||tx|1|entity|||gngm|1574|CYP3A|CYP3A||||1000|132|136
SE|00000000||tx|1|relation|1|1|C0014892|Estazolam|orch,phsu|phsu|||estazolam||||1000|15|23|PREP|TREATS||43|44|5|1|C0030705|Patients|podg,humn|podg|||patients||||1000|46|53
SE|00000000||tx|1|relation|4|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|65|76|VERB|ADMINISTERED_TO||55|63|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|46|53
SE|00000000||tx|1|relation|4|1|C0064113|Itraconazole|orch,phsu|orch|||itraconazole||||1000|82|93|VERB|ADMINISTERED_TO||55|63|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|46|53


SE|00000000||tx|1|text|Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.
SE|00000000||tx|1|entity|C0001637|Adrenergic Agents|phsu|||Adrenergic Agents||||1000|1|17
SE|00000000||tx|1|entity|C0237401|Individual|humn|||individuals||||966|24|34
SE|00000000||tx|1|entity|C0876226|Zyvox|orch,phsu|||ZYVOX||||1000|46|50
SE|00000000||tx|1|entity|C0205343|Reversible|ftcn|||reversible||||888|69|78
SE|00000000||tx|1|entity|C2349975|Enhance (action)|acty|||enhancement||||888|80|90
SE|00000000||tx|1|entity|C0237795|Pressors|phsu|||pressor||||694|99|105
SE|00000000||tx|1|entity|C0439852|Indirect|qlco|||indirect||||1000|119|126
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetic agents||||1000|135|156
SE|00000000||tx|1|entity|C0042397|Vasoconstrictor Agents|phsu|||vasopressor||||1000|159|169
SE|00000000||tx|1|entity|C0013036|Dopaminergic Agents|phsu|||dopaminergic agents||||1000|174|192
SE|00000000||tx|1|relation|7|1|C0876226|Zyvox|orch,phsu|orch|||ZYVOX||||1000|46|50|VERB|ADMINISTERED_TO||36|44|2|1|C0237401|Individual|grup,humn|humn|||individuals||||966|24|34


SE|00000000||tx|1|text|In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|6|10
SE|00000000||tx|1|entity|C0009011|Clonazepam|orch,phsu|||clonazepam||||833|30|39
SE|00000000||tx|1|entity|C0442027|Oral|spco|||orally||||833|41|46
SE|00000000||tx|1|entity|C0033447|Propantheline|orch,phsu|||propantheline||||1000|104|116
SE|00000000||tx|1|entity|C0242896|Anticholinergic Agents|phsu|||anticholinergic agent||||1000|122|142
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multiple||||888|149|156
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|158|164
SE|00000000||tx|1|entity|C0017189|Gastrointestinal tract structure|bdsy|||GI tract||||1000|173|180
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|186|203
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|210|212
SE|00000000||tx|1|entity|C0009011|Clonazepam|orch,phsu|||clonazepam||||1000|217|226
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|250|253
SE|00000000||tx|1|entity|C0009011|Clonazepam|orch,phsu|||clonazepam||||1000|258|267
SE|00000000||tx|1|entity|C0442027|Oral|spco|||orally||||1000|292|297
SE|00000000||tx|1|entity|C0033447|Propantheline|orch,phsu|||propantheline||||1000|336|348
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|380|384
SE|00000000||tx|1|relation|2|1|C0033447|Propantheline|orch,phsu|orch|||propantheline||||1000|336|348|VERB|COEXISTS_WITH||325|329|15|3|C0009011|Clonazepam|orch,phsu|orch|||clonazepam||||1000|258|267


SE|00000000||tx|1|text|This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|6|16
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|29|31
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||higher doses||||966|57|68
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|73|83
SE|00000000||tx|1|entity|C0205172|More|ftcn|||more||||1000|93|96
SE|00000000||tx|1|entity|C2348070|Daily Dose|qnco|||daily dose||||824|121|130
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|171|181
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||non-||||851|192|195
SE|00000000||tx|1|entity|C0205132|Linear|spco|||linear||||851|196|201
SE|00000000||tx|1|entity|C0031328|Pharmacokinetic aspects|ftcn|||pharmacokinetics||||851|203|218
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||762|229|234
SE|00000000||tx|1|entity|C1514721|Range|qnco|||range||||762|236|240

SE|00000000||tx|2|text|If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.
SE|00000000||tx|2|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||888|4|13
SE|00000000||tx|2|entity|C0085228|Fluvoxamine|orch,phsu|||Fluvoxamine||||888|39|49
SE|00000000||tx|2|entity|C0039225|Tablet Dosage Form|bodm|||Tablets||||888|51|57
SE|00000000||tx|2|entity|C0205265|Initially|tmco|||initial||||851|64|70
SE|00000000||tx|2|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||851|72|81
SE|00000000||tx|2|entity|C0178602|Dosage|qnco|||dosage||||851|83|88
SE|00000000||tx|2|entity|C0547044|Smaller|qlco|||least||||966|103|107
SE|00000000||tx|2|entity|C1280519|Effectiveness|qlco|||effective||||890|144|152
SE|00000000||tx|2|entity|C0445550|Low dose|qnco|||lowest effective dose||||890|137|157


SE|00000000||tx|1|text|It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|25|32
SE|00000000||tx|1|entity|C0282151|Dopamine Hydrochloride|nsba,orch,phsu|||dopamine HCl||||1000|44|55
SE|00000000||tx|1|entity|C1523987|Alternative|cnce|||alternatives||||966|58|69
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|74|82
SE|00000000||tx|1|entity|C0521306|Anticonvulsant therapy|topp|||anticonvulsant therapy||||901|102|123
SE|00000000||tx|1|relation|4|1|C0282151|Dopamine Hydrochloride|nsba,orch,phsu|nsba|||dopamine HCl||||1000|44|55|VERB|ADMINISTERED_TO||34|42|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|25|32


SE|00000000||tx|1|text|Caution should be used when alosetron and ketoconazole are administered concomitantly.
SE|00000000||tx|1|entity|C0291772|alosetron|orch,phsu|||alosetron||||1000|29|37
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|43|54


SE|00000000||tx|1|text|Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||Cyclosporine||||1000|1|12
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||Combination||||851|15|25
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||851|27|34
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||851|36|49
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|67|76
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|81|92
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||890|106|114
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|116|136
SE|00000000||tx|1|relation|2|1|C0009871|Contraceptive Agents|phsu|phsu|||contraceptives||||851|36|49|VERB|INHIBITS||55|61|3|2|C0010592|Cyclosporine|aapp,gngm,phsu|gngm|||cyclosporine||||1000|81|92


SE|00000000||tx|1|text|The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|5|8
SE|00000000||tx|1|entity|C0020615|Hypoglycemia|dsyn|||hypoglycemia||||1000|13|24
SE|00000000||tx|1|entity|C0205436|second (number)|qnco|||secondary||||1000|26|34
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||888|74|84
SE|00000000||tx|1|entity|C0008287|Chlorpropamide|orch,phsu|||chlorpropamide||||1000|90|103
SE|00000000||tx|1|entity|C1565489|Renal Insufficiency|dsyn|||renal insufficiency||||1000|148|166
SE|00000000||tx|1|relation|7|4|C0002144|Allopurinol|orch,phsu|orch|||allopurinol||||888|74|84|NOM|PREDISPOSES||5|8|7|1|C0020615|Hypoglycemia|dsyn|dsyn|||hypoglycemia||||1000|13|24


SE|00000000||tx|1|text|Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||Calcium Channel Blockers||||1000|1|24
SE|00000000||tx|1|entity|C1853237|Isolated cases|fndg|||Isolated cases||||1000|27|40
SE|00000000||tx|1|entity|C0232219|Abnormal cardiac conduction|patf|||conduction disturbance||||1000|45|66
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||rarely||||1000|69|74
SE|00000000||tx|1|entity|C0019010|Hemodynamics|ortf|||hemodynamic||||888|81|91
SE|00000000||tx|1|entity|C2945640|compromise|fndg|||compromise||||888|93|102
SE|00000000||tx|1|entity|C0719509|Coreg|orch,phsu|||COREG||||1000|129|133
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|159|167


SE|00000000||tx|1|text|Oral contraceptives and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine, since nevirapinemay lower the plasma levels of thesemedications.
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||Oral contraceptives||||1000|1|19
SE|00000000||tx|1|entity|C0700589|Contraceptive methods|topp|||birth control||||1000|50|62
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|71|73
SE|00000000||tx|1|entity|C0700589|Contraceptive methods|topp|||contraception||||694|104|116
SE|00000000||tx|1|entity|C0132326|Nevirapine|nnon,phsu|||nevirapine||||1000|133|142
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|175|180


SE|00000000||tx|1|text|Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.
SE|00000000||tx|1|entity|C0013089|Doxorubicin|antb,orch|||Doxorubicin||||1000|1|11
SE|00000000||tx|1|entity|C0013089|Doxorubicin|antb,orch|||Doxorubicin||||1000|14|24
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|35|42
SE|00000000||tx|1|entity|C0012132|Zalcitabine|nnon,phsu|||zalcitabine||||888|47|57
SE|00000000||tx|1|entity|C0031715|Phosphorylation|moft|||phosphorylation||||888|59|73
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||861|81|90
SE|00000000||tx|1|entity|C0439175|% of total|qnco|||total||||867|95|99
SE|00000000||tx|1|entity|C1156977|phosphagen biosynthetic process|moft|||phosphate formation||||867|101|119
SE|00000000||tx|1|entity|C1823394|TMEM132D gene|gngm|121256|TMEM132D|Molt||||824|130|133
SE|00000000||tx|1|entity|C0600531|U937 Cells|cell|||U937/Molt 4 cells||||824|125|141
SE|00000000||tx|1|relation|3|2|C0013089|Doxorubicin|antb,orch|antb|||Doxorubicin||||1000|14|24|NOM|INTERACTS_WITH||59|73|3|0|C0012132|Zalcitabine|nnon,phsu|nnon|||zalcitabine||||888|47|57
SE|00000000||tx|1|relation|1|1|C0600531|U937 Cells|cell|cell|||U937/Molt 4 cells||||824|125|141|PREP|LOCATION_OF||122|123|6|6|C0013089|Doxorubicin|antb,orch|orch|||Doxorubicin||||1000|1|11


SE|00000000||tx|1|text|In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine.
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|4|11
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||966|14|19
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||877|35|46
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentrations||||877|48|67
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|72|96
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|122|128
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|146|153
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|170|179
SE|00000000||tx|1|relation|5|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||1000|122|128|PREP|TREATS||143|144|2|1|C0030705|Patients|podg,humn|podg|||patients||||861|146|153
SE|00000000||tx|1|relation|1|1|C0008783|Cimetidine|orch,phsu|orch|||cimetidine||||1000|170|179|VERB|ADMINISTERED_TO||163|168|6|1|C0030705|Patients|podg,humn|humn|||patients||||861|146|153


SE|00000000||tx|1|text|Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|13|23
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|33|46
SE|00000000||tx|1|entity|C1450007|Levo-Dromoran|orch,phsu|||Levo-Dromoran||||1000|52|64
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|91|93
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|120|133


SE|00000000||tx|1|text|A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.
SE|00000000||tx|1|entity|C0015127|Etiology aspects|ftcn|||causal||||754|10|15
SE|00000000||tx|1|entity|C0439849|Relationships|qlco|||relationship||||754|17|28
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|34|36
SE|00000000||tx|1|entity|C0031831|Physicians|prog|||physicians||||1000|60|69
SE|00000000||tx|1|entity|C0012091|Diclofenac|orch,phsu|||diclofenac||||1000|108|117
SE|00000000||tx|1|entity|C0241863|DIABETIC|fndg|||diabetic||||583|131|138
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||583|140|146
SE|00000000||tx|1|entity|C0021641|Insulin|aapp,horm,phsu|||insulin||||1000|162|168
SE|00000000||tx|1|entity|C0359086|Oral hypoglycemic|phsu|||oral hypoglycemic agents||||1000|173|196


SE|00000000||tx|1|text|Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.
SE|00000000||tx|1|entity|C0003062|Animals|anim|||Animal||||888|1|6
SE|00000000||tx|1|entity|C0596545|Experience|menp|||experience||||888|8|17
SE|00000000||tx|1|entity|C0009033|Clorazepate Dipotassium|orch,phsu|||clorazepate dipotassium||||1000|34|56
SE|00000000||tx|1|entity|C0424522|Asleep|fndg|||sleeping||||888|71|78
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||888|80|83
SE|00000000||tx|1|entity|C0019469|Hexobarbital|orch,phsu|||hexobarbital||||1000|91|102
SE|00000000||tx|1|entity|C0001962|Ethanol|orch|||ethyl alcohol||||1000|113|125
SE|00000000||tx|1|entity|C0021469|Metabolic Inhibition|moft|||inhibitory||||888|142|151
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|153|159
SE|00000000||tx|1|entity|C0008286|Chlorpromazine|orch,phsu|||chlorpromazine||||1000|164|177
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|189|191
SE|00000000||tx|1|entity|C0026454|Monoamine Oxidase|aapp,enzy|||monoamine oxidase||||901|201|217
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||901|219|228
SE|00000000||tx|1|relation|5|1|C0001962|Ethanol|orch|orch|||ethyl alcohol||||1000|113|125|NOM|INTERACTS_WITH||153|159|2|1|C0008286|Chlorpromazine|orch,phsu|orch|||chlorpromazine||||1000|164|177
SE|00000000||tx|1|relation|5|1|C0019469|Hexobarbital|orch,phsu|orch|||hexobarbital||||1000|91|102|NOM|INTERACTS_WITH||153|159|2|1|C0008286|Chlorpromazine|orch,phsu|orch|||chlorpromazine||||1000|164|177
SE|00000000||tx|1|relation|7|6|C0009033|Clorazepate Dipotassium|orch,phsu|orch|||clorazepate dipotassium||||1000|34|56|NOM|INHIBITS|negation|219|228|7|0|C0026454|Monoamine Oxidase|aapp,gngm,enzy|gngm|||monoamine oxidase||||901|201|217


SE|00000000||tx|1|text|Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
SE|00000000||tx|1|entity|C0040374|Tolbutamide|orch,phsu|||Tolbutamide||||1000|1|11
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|14|23
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|50|52
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|63|68
SE|00000000||tx|1|entity|C0439228|day|tmco|||Days||||861|73|76
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|101|103
SE|00000000||tx|1|entity|C0040374|Tolbutamide|orch,phsu|||tolbutamide||||1000|108|118
SE|00000000||tx|1|entity|||gngm|1559|CYP2C9|CYP2C9||||1000|123|128
SE|00000000||tx|1|entity|C0450348|23|qnco|||23%||||1000|144|146
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|151|153
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|165|167
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|183|185
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|198|203
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|205|208
SE|00000000||tx|1|entity|C0990856|Tolbutamide 500 MG|clnd|||tolbutamide 500 mg||||1000|213|230
SE|00000000||tx|1|entity|C0442027|Oral|spco|||orally||||694|250|255
SE|00000000||tx|1|entity|C1442459|3 Days|tmco|||3-day||||890|292|296
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||regimen||||890|298|304
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|309|318
SE|00000000||tx|1|entity|C0439228|day|tmco|||Days||||861|327|330
SE|00000000||tx|1|relation|6|5|C1176306|aprepitant|orch,phsu|orch|||Aprepitant||||1000|14|23|NOM|INTERACTS_WITH||130|138|6|0|||gngm,aapp|gngm|1559|CYP2C9|CYP2C9||||1000|123|128


SE|00000000||tx|1|text|Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.
SE|00000000||tx|1|entity|C0229960|Entire body as a whole|ffas|||Total body||||901|1|10
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||901|12|20
SE|00000000||tx|1|entity|C0723325|Simulect|imft,orch,phsu|||Simulect||||1000|25|32
SE|00000000||tx|1|entity|C1510992|Average|qnco|||average||||861|52|58
SE|00000000||tx|1|entity|C0004482|Azathioprine|orch,phsu|||azathioprine||||1000|77|88
SE|00000000||tx|1|entity|C0209368|mycophenolate mofetil|orch,phsu|||mycophenolate mofetil||||1000|94|114
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||regimen||||1000|147|153
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|169|180
SE|00000000||tx|1|entity|C1706444|United States Pharmacopeia|hcro|||USP||||1000|183|185
SE|00000000||tx|1|entity|C0392747|Changing|ftcn|||MODIFIED||||1000|188|195
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|202|216


SE|00000000||tx|1|text|Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.
SE|00000000||tx|1|entity|C0008286|Chlorpromazine|orch,phsu|||Chlorpromazine||||1000|1|14
SE|00000000||tx|1|entity|C0008286|Chlorpromazine|orch,phsu|||Chlorpromazine||||1000|17|30
SE|00000000||tx|1|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine||||1000|39|46
SE|00000000||tx|1|entity|C1659436|norepinephrine uptake|celf|||norepinephrine reuptake||||1000|52|74
SE|00000000||tx|1|entity|C0002763|Central Nervous System Stimulants|phsu|||central stimulant||||901|97|113
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||901|115|121
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||amphetamines||||1000|126|137
SE|00000000||tx|1|entity|C0274692|Poisoning by amphetamine|inpo|||amphetamine poisoning||||1000|165|185
SE|00000000||tx|1|relation|2|1|C0008286|Chlorpromazine|orch,phsu|orch|||Chlorpromazine||||1000|17|30|VERB|INHIBITS||32|37|5|1|C0013030|Dopamine|nsba,orch,phsu|nsba|||dopamine||||1000|39|46
SE|00000000||tx|1|relation|4|4|C0008286|Chlorpromazine|orch,phsu|orch|||Chlorpromazine||||1000|1|14|NOM|INTERACTS_WITH||115|121|4|0|C0002763|Central Nervous System Stimulants|phsu|phsu|||central stimulant||||901|97|113
SE|00000000||tx|1|relation|6|1|C0002667|Amphetamines|nsba,orch,phsu|phsu|||amphetamines||||1000|126|137|VERB|TREATS||159|163|1|1|C0274692|Poisoning by amphetamine|inpo|inpo|||amphetamine poisoning||||1000|165|185


SE|00000000||tx|1|text|Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|9|16
SE|00000000||tx|1|entity|C0242896|Anticholinergic Agents|phsu|||anticholinergic agents||||1000|55|76
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneous||||888|79|90
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|92|94
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|105|109


SE|00000000||tx|1|text|Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0428321|Measurement of liver enzyme|lbpr|||hepatic enzymes||||983|19|33
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|43|55
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|58|66
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|72|79
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|98|106
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|111|125
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||1000|143|151
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroid||||790|156|169
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||790|171|174
SE|00000000||tx|1|entity|C0871633|desires|menp|||desired||||661|191|197
SE|00000000||tx|1|relation|5|1|C0035608|Rifampin|antb,orch|antb|||rifampin||||1000|72|79|VERB|STIMULATES||85|92|5|2|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroids||||1000|111|125
SE|00000000||tx|1|relation|5|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|58|66|VERB|STIMULATES||85|92|5|2|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroids||||1000|111|125
SE|00000000||tx|1|relation|5|1|C0031412|Phenobarbital|orch,phsu|orch|||phenobarbital||||1000|43|55|VERB|STIMULATES||85|92|5|2|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroids||||1000|111|125
SE|00000000||tx|1|relation|7|7|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|NOM|STIMULATES||143|151|2|1|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroid||||790|156|169


SE|00000000||tx|1|text|Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.
SE|00000000||tx|1|entity|C0040125|Antithyroid Agents|horm,phsu|||Antithyroid agents||||1000|1|18
SE|00000000||tx|1|entity|C0243144|Uptake|phsf|||uptake||||861|43|48
SE|00000000||tx|1|entity|C0304982|Sodium iodide I131|inch,irda|||sodium iodide I131||||1000|53|70
SE|00000000||tx|1|entity|C0243144|Uptake|phsf|||uptake||||1000|86|91
SE|00000000||tx|1|entity|C1442466|5 Days|tmco|||5 days||||1000|109|114
SE|00000000||tx|1|entity|C2349954|Withdraw (activity)|acty|||withdrawal||||861|129|138
SE|00000000||tx|1|entity|C0006983|Carbimazole|orch,phsu|||Carbimazole||||1000|143|153
SE|00000000||tx|1|relation|4|3|C0243144|Uptake|phsf|phsf|||uptake||||861|43|48|PREP|COEXISTS_WITH||83|84|4|1|C0243144|Uptake|phsf|phsf|||uptake||||1000|86|91


SE|00000000||tx|1|text|Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0717758|Etanercept|aapp,imft,phsu|||etanercept||||1000|30|39
SE|00000000||tx|1|entity|C1522668|Recombinant Tumor Necrosis Factor Family Protein|aapp,imft|7124|TNF|TNF||||851|50|52
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blocking||||851|55|62
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agent||||851|64|68
SE|00000000||tx|1|entity|C0245109|anakinra|aapp,phsu|||anakinra||||1000|75|82
SE|00000000||tx|1|entity|C0021755|Interleukin-1|aapp,imft|||interleukin-1||||734|88|100
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|142|150
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|152|155
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||888|160|166
SE|00000000||tx|1|entity|C0021311|Infection|dsyn|||infections||||888|168|177
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|184|192
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|194|197
SE|00000000||tx|1|entity|C0027947|Neutropenia|dsyn|||neutropenia||||1000|202|212
SE|00000000||tx|1|entity|C1524062|Additional|ftcn|||additional||||888|221|230
SE|00000000||tx|1|entity|C0814225|Benefits|qnco|||benefit||||888|232|238
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medicinal products||||1000|258|275
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|277|281
SE|00000000||tx|1|relation|10|7|C0245109|anakinra|aapp,gngm,phsu|aapp|||anakinra||||1000|75|82|VERB|compared_with||240|247|2|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medicinal products||||1000|258|275
SE|00000000||tx|1|relation|6|3|C0027947|Neutropenia|dsyn|dsyn|||neutropenia||||1000|202|212|NOM|PREDISPOSES||152|155|6|1|C0021311|Infection|dsyn|dsyn|||infections||||888|168|177


SE|00000000||tx|1|text|Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||Urinary||||901|1|7
SE|00000000||tx|1|entity|C0304463|Alkalinizing agent|phsu|||alkalinizing agents||||901|9|27
SE|00000000||tx|1|entity|C0000981|Acetazolamide|orch,phsu|||acetazolamide||||1000|30|42
SE|00000000||tx|1|entity|C0541746|Thiazides|orch,phsu|||thiazides||||1000|50|58
SE|00000000||tx|1|entity|C1979910|Ionized|qlco|||ionized||||877|99|105
SE|00000000||tx|1|entity|C0205370|Unspecified|qlco|||non-ionized species||||877|95|113
SE|00000000||tx|1|entity|C0002658|Amphetamine|nsba,orch,phsu|||amphetamine||||888|122|132
SE|00000000||tx|1|entity|C0567416|Molecule|sbst|||molecule||||888|134|141
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||urinary||||888|163|169
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|171|179


SE|00000000||tx|1|text|The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|17|19
SE|00000000||tx|1|entity|C0028156|Nitrofurantoin|orch,phsu|||nitrofurantoin||||1000|24|37
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|42|44
SE|00000000||tx|1|entity|C0028156|Nitrofurantoin|orch,phsu|||nitrofurantoin||||1000|64|77
SE|00000000||tx|1|entity|C0279516|Anti-Bacterial Agents|antb|||antibacterial||||888|98|110
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|112|117
SE|00000000||tx|1|entity|C0028365|Norfloxacin|orch,phsu|||Norfloxacin||||1000|122|132
SE|00000000||tx|1|entity|C0042027|Urinary tract|bpoc|||urinary tract||||1000|141|153
SE|00000000||tx|1|relation|3|2|C0028156|Nitrofurantoin|orch,phsu|orch|||nitrofurantoin||||1000|24|37|NOM|INTERACTS_WITH||112|117|3|0|C0279516|Anti-Bacterial Agents|antb|antb|||antibacterial||||888|98|110


SE|00000000||tx|1|text|Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|6|13
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulants||||1000|25|43
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||Fluvoxamine||||888|49|59
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||Tablets||||888|61|67
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|87|102
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulant||||901|124|136
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||901|138|141
SE|00000000||tx|1|relation|4|1|C0354604|Anticoagulants, Oral|orch,phsu|orch|||oral anticoagulants||||1000|25|43|VERB|ADMINISTERED_TO||15|23|1|1|C0030705|Patients|podg,humn|humn|||patients||||861|6|13


SE|00000000||tx|1|text|Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||Increases||||1000|1|9
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|14|29
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|50|57
SE|00000000||tx|1|entity|C0443252|Long-term|tmco|||long- term||||861|69|78
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||861|80|87
SE|00000000||tx|1|entity|C0016384|Flutamide|orch,phsu|||flutamide||||1000|103|111


SE|00000000||tx|1|text|Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0019134|Heparin|bacs,carb,phsu|||Heparin||||888|18|24
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||Effect||||888|26|31
SE|00000000||tx|1|entity|C0039651|Tetracyclines|orch|||tetracyclines||||1000|45|57
SE|00000000||tx|1|entity|C0028040|Nicotine|hops,orch,phsu|||nicotine||||1000|60|67
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|73|86
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulant||||901|117|129
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||901|131|136
SE|00000000||tx|1|entity|C0037513|Heparin sodium|carb,phsu|||heparin sodium||||1000|141|154
SE|00000000||tx|1|relation|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|NOM|INTERACTS_WITH||26|31|1|0|C0019134|Heparin|bacs,carb,phsu|bacs|||Heparin||||888|18|24


SE|00000000||tx|1|text|Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
SE|00000000||tx|1|entity|C0003308|Antifungal Agents|phsu|||Antifungals||||1000|1|11
SE|00000000||tx|1|entity|C1511726|Data|idcn|||data||||861|38|41
SE|00000000||tx|1|entity|C0016277|Fluconazole|orch,phsu|||fluconazole||||1000|57|67
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|70|81
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||851|88|91
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||851|93|104
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||markedly||||851|106|113
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|127|136
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|141|149
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|175|182
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||623|187|192
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||623|194|202
SE|00000000||tx|1|entity|C0429028|QT interval feature (observable entity)|clna|||QT interval||||1000|235|245
SE|00000000||tx|1|entity|C0013798|Electrocardiogram|fndg|||ECG||||966|254|256
SE|00000000||tx|1|relation|6|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||851|93|104|VERB|INHIBITS||115|121|7|2|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|141|149
SE|00000000||tx|1|relation|6|1|C0064113|Itraconazole|orch,phsu|orch|||itraconazole||||1000|70|81|VERB|INHIBITS||115|121|7|2|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|141|149
SE|00000000||tx|1|relation|6|1|C0016277|Fluconazole|orch,phsu|orch|||fluconazole||||1000|57|67|VERB|INHIBITS||115|121|7|2|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|141|149
SE|00000000||tx|1|relation|8|8|C0003308|Antifungal Agents|phsu|phsu|||Antifungals||||1000|1|11|NOM|STIMULATES||175|182|4|1|C0072916|Cisapride|orch,phsu|orch|||cisapride||||623|194|202


SE|00000000||tx|1|text|In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.
SE|00000000||tx|1|entity|C1706408|Placebo Control|resa|||placebo-controlled||||901|6|23
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||trial||||901|25|29
SE|00000000||tx|1|entity|C0205307|Normal|qlco|||normal||||888|34|39
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|41|50
SE|00000000||tx|1|entity|C0087136|Unmarried|fndg|||single||||775|77|82
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||775|89|92
SE|00000000||tx|1|entity|C0114873|Doxazosin|orch,phsu|||doxazosin||||1000|97|105
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||861|110|112
SE|00000000||tx|1|entity|C0205450|Four|qnco|||four||||851|121|124
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||851|126|128
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||regimen||||851|130|136
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|141|144
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||888|146|155
SE|00000000||tx|1|entity|C0585361|Twice a day|tmco|||twice daily||||824|165|175
SE|00000000||tx|1|entity|C0052080|antineoplaston A10|orch,phsu|||a 10||||901|190|193
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||901|196|203
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||861|213|215
SE|00000000||tx|1|entity|C0114873|Doxazosin|orch,phsu|||doxazosin||||1000|220|228
SE|00000000||tx|1|entity|C2945599|Mild (qualifier value)|qlco|||slight||||1000|247|252
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|258|260
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||statistically significant||||861|262|286
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|288|295
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||861|305|308
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||901|319|327
SE|00000000||tx|1|entity|C0114873|Doxazosin|orch,phsu|||doxazosin||||1000|332|340


SE|00000000||tx|1|text|Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor.
SE|00000000||tx|1|entity|C0439834|Slow|qlco|||slower||||661|14|19
SE|00000000||tx|1|entity|C0038119|Stadol|orch,phsu|||STADOL NS||||901|49|57
SE|00000000||tx|1|entity|C0205548|Stat (do immediately)|tmco|||immediately||||1000|98|108
SE|00000000||tx|1|entity|C0028429|Nose|bpoc|||nasal||||694|123|127


SE|00000000||tx|1|text|Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||Acetaminophen||||1000|1|13
SE|00000000||tx|1|entity|C0237963|Poisoning by acetaminophen|inpo|||acetaminophen toxicity||||901|35|56
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||840|76|82
SE|00000000||tx|1|entity|C1514756|Receive|qlco|||receiving||||840|84|92
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||Isoniazid||||840|94|102
SE|00000000||tx|1|relation|3|3|C0000970|Acetaminophen|orch,phsu|orch|||Acetaminophen||||1000|1|13|PREP|COEXISTS_WITH||71|72|1|1|C0022209|isoniazid|orch,phsu|orch|||Isoniazid||||840|94|102


SE|00000000||tx|1|text|In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death.
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|6|11
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||888|13|17
SE|00000000||tx|1|entity|C0034693|Rattus norvegicus|mamm|||rats||||1000|20|23
SE|00000000||tx|1|entity|C0442120|Intraperitoneal|spco|||intraperitoneal||||890|36|50
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high intraperitoneal doses||||890|31|56
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitor||||824|64|76
SE|00000000||tx|1|entity|C0012772|Disulfiram|orch,phsu|||disulfiram||||824|83|92
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||861|113|120
SE|00000000||tx|1|entity|C0009951|Convulsions|sosy|||convulsions||||1000|133|143
SE|00000000||tx|1|entity|C0011065|Cessation of life|orgf|||death||||1000|149|153


SE|00000000||tx|1|text|Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||Discontinuation||||1000|1|15
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||766|20|29
SE|00000000||tx|1|entity|C0205170|Good|qlco|||well||||766|34|37
SE|00000000||tx|1|entity|C2587213|Control function|ftcn|||controlled||||766|39|48
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||766|50|57
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|69|93
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|99|108
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|127|132
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|145|152
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants||||1000|161|175
SE|00000000||tx|1|relation|5|1|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|69|93|VERB|ADMINISTERED_TO||59|67|2|1|C0030705|Patients|podg,humn|humn|||patients||||766|50|57


SE|00000000||tx|1|text|Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||1000|22|33
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|59|66
SE|00000000||tx|1|entity|C1120110|aliskiren|orch,phsu|||aliskiren||||888|71|79
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||888|81|84
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|90|92
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multiple||||694|100|107


SE|00000000||tx|1|text|Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||Epinephrine||||1000|1|11
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|20|22
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetic drugs||||1000|65|85
SE|00000000||tx|1|entity|C0022245|Isoproterenol|orch,phsu|||isoproterenol||||1000|96|108
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||851|122|129
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||851|131|138
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||851|140|146
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||888|152|160
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||888|162|169


SE|00000000||tx|1|text|1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.
SE|00000000||tx|1|entity|C0443172|Changed status|qnco|||change||||861|22|27
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||1000|32|35
SE|00000000||tx|1|entity|C0030755|Pediatric discipline|bmod|||Pediatrics||||768|49|58
SE|00000000||tx|1|entity|C1883310|One Thousand|qnco|||10% 2- Pediatrics 3||||768|42|60
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||768|68|75
SE|00000000||tx|1|entity|C0001675|Adult|aggp|||adults||||1000|80|85
SE|00000000||tx|1|entity|C0876196|Trileptal|orch,phsu|||Trileptal||||890|95|103
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high Trileptal doses||||890|90|109
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|124|129
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|141|149
SE|00000000||tx|1|entity|C0439509|/40|tmco|||40%||||1000|170|172
SE|00000000||tx|1|entity|C0876196|Trileptal|orch,phsu|||Trileptal||||1000|180|188
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||1000|203|207
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|220|225


SE|00000000||tx|1|text|Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.
SE|00000000||tx|1|entity|C0007412|Catecholamines|nsba,orch,phsu|||Catecholamine||||829|1|13
SE|00000000||tx|1|entity|C0333668|Depletion|ftcn|||depleting||||829|15|23
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||Agents||||829|25|30
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|33|40
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|54|59
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blocking||||851|68|75
SE|00000000||tx|1|entity|C1292721|Has property|ftcn|||properties||||851|77|86
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||1000|94|97
SE|00000000||tx|1|entity|C0007412|Catecholamines|nsba,orch,phsu|||catecholamines||||1000|116|129
SE|00000000||tx|1|entity|C0035179|Reserpine|orch,phsu|||reserpine||||1000|138|146
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|152|179
SE|00000000||tx|1|entity|C0311392|Physical findings|fndg|||signs||||1000|213|217
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||1000|222|232
SE|00000000||tx|1|entity|C0428977|Bradycardia|patf|||bradycardia||||861|248|258
SE|00000000||tx|1|relation|8|3|C0007412|Catecholamines|nsba,orch,phsu|phsu|||catecholamines||||1000|116|129|PREP|TREATS||209|211|3|1|C0311392|Physical findings|fndg|fndg|||signs||||1000|213|217


SE|00000000||tx|1|text|When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|6|18
SE|00000000||tx|1|entity|C0009429|Combined Modality Therapy|topp|||combination therapy||||1000|42|60
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||888|63|74
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|76|79
SE|00000000||tx|1|entity|C1883708|Then|tmco|||then||||1000|88|91


SE|00000000||tx|1|text|Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.
SE|00000000||tx|1|entity|C0002555|Aminoglutethimide|orch,phsu|||Aminoglutethimide||||1000|1|17
SE|00000000||tx|1|entity|C0002555|Aminoglutethimide|orch,phsu|||Aminoglutethimide||||1000|20|36
SE|00000000||tx|1|entity|C0271738|Secondary hypocortisolism|dsyn|||adrenal suppression||||1000|51|69
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|74|88


SE|00000000||tx|1|text|MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|1|14
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAOI||||888|17|20
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants||||888|22|36
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||1000|52|61
SE|00000000||tx|1|entity|C0016855|Furazolidone|antb,orch|||furazolidone||||1000|66|77
SE|00000000||tx|1|entity|C0439834|Slow|qlco|||slow||||851|80|83
SE|00000000||tx|1|entity|C0002658|Amphetamine|nsba,orch,phsu|||amphetamine||||851|85|95
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||851|97|106
SE|00000000||tx|1|relation|0|0|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||MAOI||||888|17|20|MOD/HEAD|ISA||17|36|0|0|C0003289|Antidepressive Agents|phsu|phsu|||antidepressants||||888|22|36


SE|00000000||tx|1|text|Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.
SE|00000000||tx|1|entity|C1442459|3 Days|tmco|||3-day||||890|12|16
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||regimen||||890|18|24
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|29|38
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives||||1000|65|83
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|89|91
SE|00000000||tx|1|entity|C1523987|Alternative|cnce|||alternative||||1000|107|117
SE|00000000||tx|1|entity|C0004600|Back|blor|||back-||||851|122|126
SE|00000000||tx|1|entity|C0449851|Techniques|ftcn|||methods||||851|130|136
SE|00000000||tx|1|entity|C0700589|Contraceptive methods|topp|||contraception||||1000|141|153
SE|00000000||tx|1|relation|4|1|C0009905|Contraceptives, Oral|phsu|phsu|||oral contraceptives||||1000|65|83|VERB|COEXISTS_WITH||40|44|2|1|C1176306|aprepitant|orch,phsu|orch|||Aprepitant||||1000|29|38
SE|00000000||tx|1|relation|4|4|C0040808|Treatment Protocols|topp|topp|||regimen||||890|18|24|NOM|METHOD_OF||130|136|1|1|C0700589|Contraceptive methods|topp|topp|||contraception||||1000|141|153


SE|00000000||tx|1|text|Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents.
SE|00000000||tx|1|entity|C0007412|Catecholamines|nsba,orch,phsu|||Catecholamine||||840|1|13
SE|00000000||tx|1|entity|C0333668|Depletion|ftcn|||depleting||||840|15|23
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||840|25|29
SE|00000000||tx|1|entity|C0035179|Reserpine|orch,phsu|||reserpine||||1000|36|44
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|59|66
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|68|73
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blocking agents||||983|91|110
SE|00000000||tx|1|relation|1|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blocking agents||||983|91|110|VERB|COEXISTS_WITH||80|84|4|4|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||840|25|29


SE|00000000||tx|1|text|Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||Digoxin||||1000|1|7
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||888|13|21
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|23|25
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||rarely||||1000|34|39
SE|00000000||tx|1|entity|C0042510|Ventricular Fibrillation|dsyn|||ventricular fibrillation||||1000|57|80
SE|00000000||tx|1|entity|C0813510|Adenocard|bacs,nnon|||Adenocard||||1000|101|109
SE|00000000||tx|1|relation|2|2|C0012265|Digoxin|carb,phsu,strd|carb|||Digoxin||||1000|1|7|VERB|ASSOCIATED_WITH||41|50|2|1|C0042510|Ventricular Fibrillation|dsyn|dsyn|||ventricular fibrillation||||1000|57|80


SE|00000000||tx|1|text|The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||888|24|34
SE|00000000||tx|1|entity|C0750492|Probably|idcn|||probably||||888|36|43
SE|00000000||tx|1|entity|C0001674|Adsorption|lbpr|||adsorption||||1000|48|57
SE|00000000||tx|1|entity|C0028156|Nitrofurantoin|orch,phsu|||nitrofurantoin||||1000|62|75
SE|00000000||tx|1|entity|C0205148|Surface|spco|||surface||||1000|86|92
SE|00000000||tx|1|entity|C0065533|magnesium trisilicate|inch,phsu|||magnesium trisilicate||||1000|97|117


SE|00000000||tx|1|text|Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||888|16|24
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|26|29
SE|00000000||tx|1|entity|C1292429|8 Hours|tmco|||8 hours||||1000|48|54
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|61|63
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||851|84|92
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||851|94|102
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||851|104|113
SE|00000000||tx|1|entity|C0674428|efavirenz|orch,phsu|||efavirenz||||1000|122|130


SE|00000000||tx|1|text|Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||Erythromycin||||1000|1|12
SE|00000000||tx|1|entity|C0055856|Clarithromycin|antb,orch|||clarithromycin||||1000|18|31
SE|00000000||tx|1|entity|C2362652|Possible diagnosis|qlco|||possibly||||1000|38|45
SE|00000000||tx|1|entity|C0003240|Macrolide Antibiotics|antb,orch|||macrolide antibiotics||||1000|53|73
SE|00000000||tx|1|entity|C0039644|Tetracycline|antb,orch|||tetracycline||||1000|80|91
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||694|106|112
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|128|135
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|152|158
SE|00000000||tx|1|entity|C0521009|Bacterial|qlco|||bacterial||||888|163|171
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|173|182
SE|00000000||tx|1|entity|C0021853|Intestines|bpoc|||intestine||||861|197|205
SE|00000000||tx|1|entity|C0151595|DIGITALIS INTOXICATION|inpo|||digitalis intoxication||||1000|216|237
SE|00000000||tx|1|relation|5|2|C0039644|Tetracycline|antb,orch|antb|||tetracycline||||1000|80|91|PREP|TREATS||125|126|6|1|C0030705|Patients|podg,humn|podg|||patients||||1000|128|135
SE|00000000||tx|1|relation|5|2|C0003240|Macrolide Antibiotics|antb,orch|antb|||macrolide antibiotics||||1000|53|73|PREP|TREATS||125|126|6|1|C0030705|Patients|podg,humn|podg|||patients||||1000|128|135
SE|00000000||tx|1|relation|6|3|C0039644|Tetracycline|antb,orch|antb|||tetracycline||||1000|80|91|VERB|INHIBITS||141|150|5|1|C0012265|Digoxin|carb,phsu,strd|carb|||digoxin||||1000|152|158
SE|00000000||tx|1|relation|6|3|C0003240|Macrolide Antibiotics|antb,orch|antb|||macrolide antibiotics||||1000|53|73|VERB|INHIBITS||141|150|5|1|C0012265|Digoxin|carb,phsu,strd|carb|||digoxin||||1000|152|158
SE|00000000||tx|1|relation|3|1|C0021853|Intestines|bpoc|bpoc|||intestine||||861|197|205|PREP|LOCATION_OF||184|185|8|2|C0012265|Digoxin|carb,phsu,strd|carb|||digoxin||||1000|152|158


SE|00000000||tx|1|text|In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|4|11
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||923|36|63
SE|00000000||tx|1|entity|C0700467|selegiline hydrochloride|orch,phsu|||selegiline hydrochloride||||1000|80|103
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|109|119
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||827|141|146
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|155|164
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|167|177
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||paroxetine||||1000|180|189
SE|00000000||tx|1|entity|C0074393|Sertraline|orch,phsu|||sertraline||||1000|192|201
SE|00000000||tx|1|entity|C0078569|venlafaxine|orch,phsu|||venlafaxine||||1000|204|214
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|234|240
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||825|245|251
SE|00000000||tx|1|entity|C1998882|Sometimes|tmco|||sometimes||||825|254|262
SE|00000000||tx|1|entity|C1705232|Death Related to Adverse Event|fndg|||fatal||||825|264|268
SE|00000000||tx|1|entity|C1114821|Reaction:Finding:Point in time:^Patient:Nominal|clna|||reactions||||825|271|279
SE|00000000||tx|1|relation|11|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||monoamine oxidase inhibitors||||923|36|63|VERB|ADMINISTERED_TO||13|21|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|4|11


SE|00000000||tx|1|text|However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone.
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||827|16|24
SE|00000000||tx|1|entity|C1704243|Greater|qnco|||greater||||1000|30|36
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||1000|43|54
SE|00000000||tx|1|entity|C0009279|Colestipol|orch,phsu|||colestipol||||1000|60|69
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||861|108|111
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|123|127


SE|00000000||tx|1|text|Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
SE|00000000||tx|1|entity|C0027396|Naproxen|orch,phsu|||Naproxen||||1000|1|8
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|20|25
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|59|64
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||1000|69|79
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blockers||||1000|91|103
SE|00000000||tx|1|relation|0|0|C0027396|Naproxen|orch,phsu|orch|||Naproxen||||1000|1|8|SPEC|ISA||1|25|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|20|25
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|20|25|SPEC|ISA||1|25|0|0|C0027396|Naproxen|orch,phsu|phsu|||Naproxen||||1000|1|8
SE|00000000||tx|1|relation|0|0|C0033497|Propranolol|orch,phsu|orch|||propranolol||||1000|69|79|SPEC|ISA||69|103|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blockers||||1000|91|103
SE|00000000||tx|1|relation|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blockers||||1000|91|103|SPEC|ISA||69|103|0|0|C0033497|Propranolol|orch,phsu|phsu|||propranolol||||1000|69|79
SE|00000000||tx|1|relation|2|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|20|25|NOM|INTERACTS_WITH||59|64|2|1|C0033497|Propranolol|orch,phsu|orch|||propranolol||||1000|69|79
SE|00000000||tx|1|relation|2|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|20|25|NOM|INTERACTS_WITH||59|64|2|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blockers||||1000|91|103
SE|00000000||tx|1|relation|2|1|C0027396|Naproxen|orch,phsu|phsu|||Naproxen||||1000|1|8|NOM|INTERACTS_WITH||59|64|2|1|C0033497|Propranolol|orch,phsu|orch|||propranolol||||1000|69|79
SE|00000000||tx|1|relation|2|2|C0027396|Naproxen|orch,phsu|phsu|||Naproxen||||1000|1|8|NOM|INTERACTS_WITH||59|64|2|2|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blockers||||1000|91|103
SE|00000000||tx|1|relation|0|0|C0027396|Naproxen|orch,phsu|orch|||Naproxen||||1000|1|8|INFER|INTERACTS_WITH(SPEC)||1|25|0|0|C0033497|Propranolol|orch,phsu|orch|||propranolol||||1000|69|79
SE|00000000||tx|1|relation|0|0|C0027396|Naproxen|orch,phsu|orch|||Naproxen||||1000|1|8|INFER|INTERACTS_WITH(SPEC)||1|25|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blockers||||1000|91|103
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|20|25|INFER|INTERACTS_WITH(SPEC)||1|25|0|0|C0033497|Propranolol|orch,phsu|orch|||propranolol||||1000|69|79
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|20|25|INFER|INTERACTS_WITH(SPEC)||1|25|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blockers||||1000|91|103
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|20|25|INFER|INTERACTS_WITH(SPEC)||69|103|0|0|C0033497|Propranolol|orch,phsu|orch|||propranolol||||1000|69|79
SE|00000000||tx|1|relation|0|0|C0027396|Naproxen|orch,phsu|phsu|||Naproxen||||1000|1|8|INFER|INTERACTS_WITH(SPEC)||69|103|0|0|C0033497|Propranolol|orch,phsu|orch|||propranolol||||1000|69|79
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|20|25|INFER|INTERACTS_WITH(SPEC)||69|103|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blockers||||1000|91|103
SE|00000000||tx|1|relation|0|0|C0027396|Naproxen|orch,phsu|phsu|||Naproxen||||1000|1|8|INFER|INTERACTS_WITH(SPEC)||69|103|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blockers||||1000|91|103


SE|00000000||tx|1|text|When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|6|16
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|36|47
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||1000|54|65
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||888|75|86
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|88|91
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|114|116
SE|00000000||tx|1|entity|C2825407|Half|qnco|||half||||888|118|121
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||888|130|135
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|137|140


SE|00000000||tx|1|text|Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.
SE|00000000||tx|1|entity|C0236281|Serum lithium measurement|lbpr|||Serum lithium levels||||988|1|20
SE|00000000||tx|1|entity|C0332183|Frequent|tmco|||frequently||||1000|42|51
SE|00000000||tx|1|entity|C1144054|Inspra|phsu,strd|||INSPRA||||1000|56|61
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|98|104
SE|00000000||tx|1|relation|2|2|C0236281|Serum lithium measurement|lbpr|lbpr|||Serum lithium levels||||988|1|20|PREP|USES||93|96|1|1|C0023870|Lithium|elii,phsu|elii|||lithium||||1000|98|104


SE|00000000||tx|1|text|The concomitant administration of griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000||tx|1|entity|C0018242|Griseofulvin|orch,phsu|||griseofulvin||||1000|35|46
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|80|87
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives||||1000|92|110
SE|00000000||tx|1|entity|C0021149|Incidence|qnco|||incidence||||1000|132|140
SE|00000000||tx|1|entity|C0025874|Metrorrhagia|patf|||breakthrough bleeding||||1000|145|165
SE|00000000||tx|1|relation|2|1|C0018242|Griseofulvin|orch,phsu|orch|||griseofulvin||||1000|35|46|VERB|INHIBITS||69|74|4|2|C0009905|Contraceptives, Oral|phsu|phsu|||oral contraceptives||||1000|92|110


SE|00000000||tx|1|text|Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.
SE|00000000||tx|1|entity|C0021968|Iodine|elii,phsu|||Iodine||||1000|1|6
SE|00000000||tx|1|entity|C0021968|Iodine|elii,phsu|||iodine||||888|11|16
SE|00000000||tx|1|entity|C1979886|Excess|qlco|||excess||||888|18|23
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|42|47
SE|00000000||tx|1|entity|C0006983|Carbimazole|orch,phsu|||Carbimazole||||1000|52|62
SE|00000000||tx|1|entity|C0021968|Iodine|elii,phsu|||iodine||||888|72|77
SE|00000000||tx|1|entity|C0162429|Malnutrition|dsyn|||deficiency||||888|79|88
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|107|112
SE|00000000||tx|1|entity|C0006983|Carbimazole|orch,phsu|||Carbimazole||||1000|117|127
SE|00000000||tx|1|relation|2|2|C0021968|Iodine|elii,phsu|elii|||Iodine||||1000|1|6|NOM|INTERACTS_WITH||42|47|4|1|C0006983|Carbimazole|orch,phsu|orch|||Carbimazole||||1000|52|62
SE|00000000||tx|1|relation|5|1|C0021968|Iodine|elii,phsu|elii|||iodine||||888|72|77|NOM|INTERACTS_WITH||107|112|1|1|C0006983|Carbimazole|orch,phsu|orch|||Carbimazole||||1000|117|127


SE|00000000||tx|1|text|Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
SE|00000000||tx|1|entity|C0041405|Turks and Caicos Islands|geoa|||TCAs||||966|64|67
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRIs||||1000|85|89
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|118|120
SE|00000000||tx|1|entity|C0456387|Class|inpr|||class||||888|122|126


SE|00000000||tx|1|text|Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.
SE|00000000||tx|1|entity|C0024312|Lymphopenia|dsyn|||Lymphocytopenia||||1000|1|15
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|38|45
SE|00000000||tx|1|entity|C0701188|Camptosar|orch,phsu|||CAMPTOSAR||||1000|57|65
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||1000|78|85
SE|00000000||tx|1|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||1000|114|126
SE|00000000||tx|1|entity|C0003297|Antiemetics|phsu|||antiemetic||||901|131|140
SE|00000000||tx|1|entity|C0033107|prevention & control|inpr|||prophylaxis||||901|142|152
SE|00000000||tx|1|entity|C0033204|Probability|qnco|||likelihood||||1000|176|185
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|195|200
SE|00000000||tx|1|relation|1|1|C0024312|Lymphopenia|dsyn|dsyn|||Lymphocytopenia||||1000|1|15|PREP|PROCESS_OF||35|36|8|1|C0030705|Patients|podg,humn|humn|||patients||||1000|38|45
SE|00000000||tx|1|relation|7|1|C0701188|Camptosar|orch,phsu|orch|||CAMPTOSAR||||1000|57|65|VERB|ADMINISTERED_TO||47|55|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|38|45


SE|00000000||tx|1|text|Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.
SE|00000000||tx|1|entity|C1511726|Data|idcn|||data||||1000|7|10
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||872|15|22
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interactions||||872|24|35
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||1000|45|53
SE|00000000||tx|1|entity|C0700534|Disopyramide Phosphate|orch,phsu|||disopyramide phosphate||||1000|59|80
SE|00000000||tx|1|entity|C0012702|Disopyramide|orch,phsu|||disopyramide||||1000|96|107
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|116|118
SE|00000000||tx|1|entity|C1442464|48 Hours|tmco|||48 hours||||1000|143|150
SE|00000000||tx|1|entity|C1442770|24 Hours|tmco|||24 hours||||1000|162|169
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||888|177|185
SE|00000000||tx|1|relation|6|3|C0012702|Disopyramide|orch,phsu|orch|||disopyramide||||1000|96|107|NOM|INTERACTS_WITH||24|35|6|1|C0042523|Verapamil|orch,phsu|orch|||verapamil||||1000|45|53
SE|00000000||tx|1|relation|6|3|C0012702|Disopyramide|orch,phsu|orch|||disopyramide||||1000|96|107|NOM|INTERACTS_WITH||24|35|6|1|C0700534|Disopyramide Phosphate|orch,phsu|orch|||disopyramide phosphate||||1000|59|80


SE|00000000||tx|1|text|Patients who are treated with ZYVOX and concomitant serotonergic agents should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0876226|Zyvox|orch,phsu|||ZYVOX||||1000|31|35
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||901|41|51
SE|00000000||tx|1|entity|C0242701|Serotonin Agents|nsba,phsu|||serotonergic agents||||901|53|71
SE|00000000||tx|1|entity|C0311392|Physical findings|fndg|||signs||||1000|104|108
SE|00000000||tx|1|entity|C1457887|Symptoms|sosy|||symptoms||||1000|114|121
SE|00000000||tx|1|entity|C0699828|Serotonin Syndrome|inpo|||serotonin syndrome||||1000|126|143
SE|00000000||tx|1|entity|C0338656|Impaired cognition|mobd|||cognitive dysfunction||||1000|152|172
SE|00000000||tx|1|entity|C0392676|Hyperpyrexia|patf|||hyperpyrexia||||1000|175|186
SE|00000000||tx|1|entity|C0151889|Hyperreflexia|fndg|||hyperreflexia||||1000|189|201
SE|00000000||tx|1|entity|C0520966|Abnormal coordination|sosy|||incoordination||||1000|204|217
SE|00000000||tx|1|relation|9|1|C0876226|Zyvox|orch,phsu|phsu|||ZYVOX||||1000|31|35|VERB|TREATS||18|24|1|1|C0030705|Patients|podg,humn|podg|||Patients||||1000|1|8
SE|00000000||tx|1|relation|9|1|C0242701|Serotonin Agents|nsba,phsu|phsu|||serotonergic agents||||901|53|71|VERB|TREATS||18|24|1|1|C0030705|Patients|podg,humn|podg|||Patients||||1000|1|8


SE|00000000||tx|1|text|In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|6|10
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|21|28
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||694|35|40
SE|00000000||tx|1|entity|C0439230|week|tmco|||weeks||||861|71|75
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|82|91
SE|00000000||tx|1|entity|C1170364|Kineret|orch,phsu|||Kineret||||888|93|99
SE|00000000||tx|1|entity|C0717758|Etanercept|aapp,imft,phsu|||etanercept||||888|105|114
SE|00000000||tx|1|entity|C1521828|Rate|qnco|||rate||||861|130|133
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||888|138|144
SE|00000000||tx|1|entity|C0021311|Infection|dsyn|||infections||||888|146|155
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||966|181|186
SE|00000000||tx|1|entity|C0717758|Etanercept|aapp,imft,phsu|||etanercept||||1000|212|221
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|223|227
SE|00000000||tx|1|relation|2|1|C0717758|Etanercept|aapp,gngm,imft,phsu|aapp|||etanercept||||1000|212|221|PREP|PART_OF||207|210|9|8|C0030705|Patients|podg,humn|humn|||patients||||1000|21|28


SE|00000000||tx|1|text|Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
SE|00000000||tx|1|entity|C0006525|Butyrophenones|orch,phsu|||Butyrophenones||||1000|1|14
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||haloperidol||||1000|25|35
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|42|55
SE|00000000||tx|1|entity|C0282151|Dopamine Hydrochloride|nsba,orch,phsu|||dopaminergic||||888|74|85
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|87|91
SE|00000000||tx|1|entity|C0025474|Mesentery|blor|||mesenteric||||888|97|106
SE|00000000||tx|1|entity|C0042401|Vasodilation|phsf|||vasodilation||||888|108|119
SE|00000000||tx|1|entity|C0445550|Low dose|qnco|||low dose||||861|134|141
SE|00000000||tx|1|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine||||861|143|150
SE|00000000||tx|1|entity|C0574032|Infusion procedures|topp|||infusion||||861|152|159
SE|00000000||tx|1|relation|3|1|C0031436|Phenothiazines|orch,phsu|orch|||phenothiazines||||1000|42|55|VERB|DISRUPTS||61|68|3|1|C0022646|Kidney|bpoc|bpoc|||renal||||888|87|91
SE|00000000||tx|1|relation|3|1|C0018546|Haloperidol|orch,phsu|orch|||haloperidol||||1000|25|35|VERB|DISRUPTS||61|68|3|1|C0022646|Kidney|bpoc|bpoc|||renal||||888|87|91
SE|00000000||tx|1|relation|1|1|C0013030|Dopamine|nsba,orch,phsu|orch|||dopamine||||861|143|150|VERB|CAUSES||121|127|5|1|C0042401|Vasodilation|phsf|phsf|||vasodilation||||888|108|119


SE|00000000||tx|1|text|Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
SE|00000000||tx|1|entity|C0871935|Theory|idcn|||theoretical||||888|20|30
SE|00000000||tx|1|entity|C1874451|Basis|phsu|||basis||||888|32|36
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|49|55
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|64|71
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|74|76
SE|00000000||tx|1|entity|C0014710|Ergotamine|orch,phsu|||ergotamine||||1000|81|90
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||827|117|127
SE|00000000||tx|1|entity|C0012291|Dihydroergotamine|orch,phsu|||dihydroergotamine||||1000|135|151
SE|00000000||tx|1|entity|C0025842|Methysergide|orch,phsu|||methysergide||||1000|156|167
SE|00000000||tx|1|entity|C0540623|naratriptan|orch,phsu|||naratriptan||||1000|174|184
SE|00000000||tx|1|entity|C1442770|24 Hours|tmco|||24 hours||||1000|193|200


SE|00000000||tx|1|text|Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
SE|00000000||tx|1|entity|C0003286|Anticonvulsants|phsu|||Anticonvulsants||||1000|1|15
SE|00000000||tx|1|entity|C0201734|Pharmacokinetic study|resa|||pharmacokinetic study||||1000|23|43
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximum||||890|46|52
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|54|74
SE|00000000||tx|1|entity|C0015772|Felodipine|orch,phsu|||felodipine||||1000|79|88
SE|00000000||tx|1|entity|C0014544|Epilepsy|dsyn|||epileptic||||888|117|125
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|127|134
SE|00000000||tx|1|entity|C0443252|Long-term|tmco|||long-term||||888|139|147
SE|00000000||tx|1|entity|C0521306|Anticonvulsant therapy|topp|||anticonvulsant therapy||||888|149|170
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|177|185
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|188|200
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|206|218
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|229|246
SE|00000000||tx|1|relation|0|0|C0014544|Epilepsy|dsyn|dsyn|||epileptic||||888|117|125|MOD/HEAD|PROCESS_OF||117|134|0|0|C0030705|Patients|podg,humn|humn|||patients||||888|127|134
SE|00000000||tx|1|relation|5|2|C0015772|Felodipine|orch,phsu|phsu|||felodipine||||1000|79|88|PREP|TREATS||114|115|7|1|C0030705|Patients|podg,humn|podg|||patients||||888|127|134
SE|00000000||tx|1|relation|0|0|C0015772|Felodipine|orch,phsu|phsu|||felodipine||||1000|79|88|INFER|TREATS(INFER)||114|115|0|0|C0014544|Epilepsy|dsyn|dsyn|||epileptic||||888|117|125


SE|00000000||tx|1|text|Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;
SE|00000000||tx|1|entity|C0010582|Cyclopentolate|orch,phsu|||Cyclopentolate||||1000|1|14
SE|00000000||tx|1|entity|C0017601|Glaucoma|dsyn|||glaucoma||||790|44|51
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||790|53|58
SE|00000000||tx|1|entity|C0006945|Carbachol|orch,phsu|||carbachol||||1000|63|71
SE|00000000||tx|1|entity|C0031923|Pilocarpine|orch,phsu|||pilocarpine||||1000|76|86


SE|00000000||tx|1|text|Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||Caffeine||||851|1|8
SE|00000000||tx|1|entity|C0039763|Theobromine|orch,phsu|||Theobromine||||851|10|20
SE|00000000||tx|1|entity|C0287721|grepafloxacin|orch,phsu|||Grepafloxacin||||851|22|34
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|48|57
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|76|85
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|90|97
SE|00000000||tx|1|entity|C0039763|Theobromine|orch,phsu|||theobromine||||1000|103|113
SE|00000000||tx|1|relation|0|0|C0287721|grepafloxacin|orch,phsu|orch|||Grepafloxacin||||851|22|34|SPEC|ISA||22|57|0|0|C0034428|Quinolones|orch|orch|||quinolones||||1000|48|57
SE|00000000||tx|1|relation|2|1|C0034428|Quinolones|orch|orch|||quinolones||||1000|48|57|VERB|INHIBITS||64|70|3|2|C0006644|Caffeine|orch,phsu|orch|||caffeine||||1000|90|97
SE|00000000||tx|1|relation|2|1|C0034428|Quinolones|orch|orch|||quinolones||||1000|48|57|VERB|INHIBITS||64|70|3|2|C0039763|Theobromine|orch,phsu|orch|||theobromine||||1000|103|113
SE|00000000||tx|1|relation|0|0|C0287721|grepafloxacin|orch,phsu|orch|||Grepafloxacin||||851|22|34|INFER|INHIBITS(SPEC)||22|57|0|0|C0006644|Caffeine|orch,phsu|orch|||caffeine||||1000|90|97
SE|00000000||tx|1|relation|0|0|C0287721|grepafloxacin|orch,phsu|orch|||Grepafloxacin||||851|22|34|INFER|INHIBITS(SPEC)||22|57|0|0|C0039763|Theobromine|orch,phsu|orch|||theobromine||||1000|103|113


SE|00000000||tx|1|text|If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||851|4|14
SE|00000000||tx|1|entity|C0075632|Sumatriptan|orch,phsu|||sumatriptan||||1000|31|41
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRI||||1000|50|53
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|62|71
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|74|84
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||paroxetine||||1000|87|96
SE|00000000||tx|1|entity|C0074393|Sertraline|orch,phsu|||sertraline||||1000|99|108
SE|00000000||tx|1|entity|C0008845|Citalopram|orch,phsu|||citalopram||||1000|111|120
SE|00000000||tx|1|entity|C1099456|Escitalopram|orch,phsu|||escitalopram||||1000|123|134
SE|00000000||tx|1|entity|C1548787|Appropriate|qlco|||appropriate||||888|162|172
SE|00000000||tx|1|entity|C1964257|Observation - diagnostic procedure|diap|||observation||||888|174|184
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|193|199


SE|00000000||tx|1|text|Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.
SE|00000000||tx|1|entity|C0427743|Glucose concentration, test strip measurement|lbpr|||glucose concentrations||||983|20|41
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||694|48|57
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||888|92|97
SE|00000000||tx|1|entity|C2827666|Variability|cnce|||variability||||888|99|109
SE|00000000||tx|1|entity|C0027361|Persons|popg|||individual||||890|115|124
SE|00000000||tx|1|entity|C0427743|Glucose concentration, test strip measurement|lbpr|||glucose concentrations||||890|126|147
SE|00000000||tx|1|entity|C1282910|Upper|spco|||above||||1000|154|158
SE|00000000||tx|1|entity|C1706276|Near|qlco|||near||||824|163|166
SE|00000000||tx|1|entity|C0439269|mg/dL|qnco|||mg/dL||||824|171|175
SE|00000000||tx|1|entity|C2826232|Dose Adjustment|hlca|||dose adjustment||||1000|178|192
SE|00000000||tx|1|entity|C0017628|Glyburide|orch,phsu|||glyburide||||1000|198|206
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||773|227|229
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||694|237|246
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|285|287


SE|00000000||tx|1|text|The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|5|14
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|16|18
SE|00000000||tx|1|entity|C0592075|Robinul|orch,phsu|||Robinul||||888|23|29
SE|00000000||tx|1|entity|C1533685|Injection procedure|topp|||Injection||||888|31|39
SE|00000000||tx|1|entity|C0242896|Anticholinergic Agents|phsu|||anticholinergics||||1000|52|67
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||1000|72|82
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||861|105|112
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|123|136
SE|00000000||tx|1|entity|C0003405|Antiparkinson Agents|phsu|||antiparkinson drugs||||1000|139|157
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|163|187
SE|00000000||tx|1|entity|C0003385|Muscarinic Antagonists|phsu|||antimuscarinic||||888|208|221
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|223|229
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|252|259
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||901|280|291
SE|00000000||tx|1|relation|0|0|C1533685|Injection procedure|topp|topp|||Injection||||888|31|39|MOD/HEAD|USES||23|39|0|0|C0592075|Robinul|orch,phsu|phsu|||Robinul||||888|23|29
SE|00000000||tx|1|relation|2|1|C1533685|Injection procedure|topp|topp|||Injection||||888|31|39|PREP|USES||41|44|9|1|C0242896|Anticholinergic Agents|phsu|phsu|||anticholinergics||||1000|52|67
SE|00000000||tx|1|relation|2|1|C1533685|Injection procedure|topp|topp|||Injection||||888|31|39|PREP|USES||41|44|9|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||1000|72|82
SE|00000000||tx|1|relation|8|1|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|163|187|NOM|INTERACTS_WITH||223|229|8|0|C0003385|Muscarinic Antagonists|phsu|phsu|||antimuscarinic||||888|208|221
SE|00000000||tx|1|relation|8|1|C0003405|Antiparkinson Agents|phsu|phsu|||antiparkinson drugs||||1000|139|157|NOM|INTERACTS_WITH||223|229|8|0|C0003385|Muscarinic Antagonists|phsu|phsu|||antimuscarinic||||888|208|221
SE|00000000||tx|1|relation|8|1|C0031436|Phenothiazines|orch,phsu|phsu|||phenothiazines||||1000|123|136|NOM|INTERACTS_WITH||223|229|8|0|C0003385|Muscarinic Antagonists|phsu|phsu|||antimuscarinic||||888|208|221


SE|00000000||tx|1|text|(Thiazides may decrease arterial responsiveness to norepinephrine.
SE|00000000||tx|1|entity|C0541746|Thiazides|orch,phsu|||Thiazides||||1000|2|10
SE|00000000||tx|1|entity|C0221464|Arterial|spco|||arterial||||853|25|32
SE|00000000||tx|1|entity|C0205342|Responsive|ftcn|||responsiveness||||853|34|47
SE|00000000||tx|1|entity|C0028351|Norepinephrine|nsba,orch,phsu|||norepinephrine||||1000|52|65


SE|00000000||tx|1|text|Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.
SE|00000000||tx|1|entity|C0055877|clidinium|orch,phsu|||Clidinium||||1000|1|9
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|28|33
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|38|51
SE|00000000||tx|1|entity|C0023570|Levodopa|aapp,nsba,phsu|||levodopa||||1000|54|61
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|68|79
SE|00000000||tx|1|relation|1|1|C0055877|clidinium|orch,phsu|orch|||Clidinium||||1000|1|9|NOM|INTERACTS_WITH||28|33|3|1|C0031436|Phenothiazines|orch,phsu|orch|||phenothiazines||||1000|38|51
SE|00000000||tx|1|relation|1|1|C0055877|clidinium|orch,phsu|orch|||Clidinium||||1000|1|9|NOM|INTERACTS_WITH||28|33|3|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|68|79
SE|00000000||tx|1|relation|1|1|C0055877|clidinium|orch,phsu|orch|||Clidinium||||1000|1|9|NOM|INTERACTS_WITH||28|33|3|1|C0023570|Levodopa|aapp,gngm,nsba,phsu|aapp|||levodopa||||1000|54|61


SE|00000000||tx|1|text|Cimetidine: Cimetidine has been demonstrated to interfere with the elimination of other quinolones.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|13|22
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|89|98


SE|00000000||tx|1|text|Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||Additive||||901|1|8
SE|00000000||tx|1|entity|C0879626|Adverse effects|patf|||adverse effects||||901|10|24
SE|00000000||tx|1|entity|C0599668|cholinergic|ftcn|||cholinergic||||888|41|51
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blockade||||888|53|60
SE|00000000||tx|1|entity|C0721347|Levsin|orch,phsu|||LEVSIN||||1000|77|82
SE|00000000||tx|1|entity|C0003385|Muscarinic Antagonists|phsu|||antimuscarinics||||1000|125|139
SE|00000000||tx|1|entity|C0002403|Amantadine|orch,phsu|||amantadine||||1000|142|151
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||haloperidol||||1000|154|164
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|167|180
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase (MAO) inhibitors||||1000|183|216
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|219|243
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|253|266


SE|00000000||tx|1|text|It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|7|9
SE|00000000||tx|1|entity|C0279023|chemosensitization/potentiation|topp|||potentiation||||1000|30|41
SE|00000000||tx|1|entity|C0002680|Ampicillin|antb,orch|||ampicillin||||888|46|55
SE|00000000||tx|1|entity|C0015230|Exanthema|dsyn|||rashes||||888|57|62
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|74|84
SE|00000000||tx|1|entity|C0740394|Hyperuricemia|dsyn|||hyperuricemia||||888|93|105
SE|00000000||tx|1|entity|C0150312|Present|qnco|||present||||888|107|113
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|124|131
SE|00000000||tx|1|relation|3|1|C0002144|Allopurinol|orch,phsu|orch|||allopurinol||||1000|74|84|PREP|CAUSES||67|72|2|1|C0015230|Exanthema|dsyn|dsyn|||rashes||||888|57|62
SE|00000000||tx|1|relation|4|4|C0279023|chemosensitization/potentiation|topp|topp|||potentiation||||1000|30|41|PREP|TREATS||115|116|1|1|C0030705|Patients|podg,humn|podg|||patients||||1000|124|131


SE|00000000||tx|1|text|Warfarin-Vitamin K can antagonize the effect of warfarin
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||Warfarin||||901|1|8
SE|00000000||tx|1|entity|C0042878|Vitamin K|lipd,phsu,vita|||Vitamin K||||901|10|18
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|39|44
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|49|56


SE|00000000||tx|1|text|The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.
SE|00000000||tx|1|entity|C0879626|Adverse effects|patf|||adverse effects||||1000|5|19
SE|00000000||tx|1|entity|C0701188|Camptosar|orch,phsu|||CAMPTOSAR||||1000|24|32
SE|00000000||tx|1|entity|C0854467|Myelosuppression|dsyn|||myelosuppression||||1000|43|58
SE|00000000||tx|1|entity|C0011991|Diarrhea|sosy|||diarrhea||||1000|64|71
SE|00000000||tx|1|entity|C0003392|Antineoplastic Agents|orch,phsu|||antineoplastic agents||||1000|119|139
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||901|148|154
SE|00000000||tx|1|entity|C0879626|Adverse effects|patf|||adverse effects||||901|156|170
SE|00000000||tx|1|relation|2|1|C0003392|Antineoplastic Agents|orch,phsu|orch|||antineoplastic agents||||1000|119|139|VERB|AFFECTS||98|108|4|1|C0011991|Diarrhea|sosy|sosy|||diarrhea||||1000|64|71
SE|00000000||tx|1|relation|2|1|C0003392|Antineoplastic Agents|orch,phsu|orch|||antineoplastic agents||||1000|119|139|VERB|AFFECTS||98|108|4|1|C0854467|Myelosuppression|dsyn|dsyn|||myelosuppression||||1000|43|58


SE|00000000||tx|1|text|Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||Digoxin||||1000|1|7
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|10|20
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|40|51
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|57|63
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||905|96|103
SE|00000000||tx|1|entity|C1306421|Serum digoxin measurement|lbpr|||digoxin serum levels||||905|105|124


SE|00000000||tx|1|text|Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.
SE|00000000||tx|1|entity|C1514468|product|enty|||Products||||1000|1|8
SE|00000000||tx|1|entity|C0006675|Calcium|bacs,elii,phsu|||calcium||||1000|21|27
SE|00000000||tx|1|entity|C0007447|Cations|chvs|||cations||||790|51|57
SE|00000000||tx|1|entity|C0332148|Probable diagnosis|qlco|||likely||||790|59|64
SE|00000000||tx|1|entity|C0102118|Alendronate|opco,phsu|||alendronate||||1000|100|110


SE|00000000||tx|1|text|Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||Methotrexate||||1000|1|12
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||888|41|50
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|87|98


SE|00000000||tx|1|text|BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
SE|00000000||tx|1|entity|C1815278|Brovana|orch,phsu|||BROVANA||||1000|1|7
SE|00000000||tx|1|entity|C1417683|NEUROD1 gene|gngm|4760|NEUROD1|beta2||||888|24|28
SE|00000000||tx|1|entity|C0243192|agonists|phsu|||agonists||||888|30|37
SE|00000000||tx|1|entity|C0205403|Extreme|qlco|||extreme||||694|68|74
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|87|94
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|115|142
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|145|169
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|175|179
SE|00000000||tx|1|entity|C0489625|QTC interval|clna|||QTc interval||||1000|202|213
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|227|232
SE|00000000||tx|1|entity|C0001648|Adrenergic Agonists|phsu|||adrenergic agonists||||1000|237|255
SE|00000000||tx|1|entity|C0007226|Cardiovascular system|bdsy|||cardiovascular system||||1000|264|284
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|314|319
SE|00000000||tx|1|relation|0|0|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||monoamine oxidase inhibitors||||1000|115|142|SPEC|ISA||115|169|0|0|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|145|169
SE|00000000||tx|1|relation|8|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|phsu|||monoamine oxidase inhibitors||||1000|115|142|VERB|TREATS||102|108|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|87|94


SE|00000000||tx|1|text|Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);
SE|00000000||tx|1|entity|C0012132|Zalcitabine|nnon,phsu|||Zalcitabine||||1000|1|11
SE|00000000||tx|1|entity|C0209738|Lamivudine|nnon,phsu|||lamivudine||||888|23|32
SE|00000000||tx|1|entity|C0031715|Phosphorylation|moft|||phosphorylation||||888|34|48
SE|00000000||tx|1|entity|C0205250|High|qlco|||high||||802|53|56
SE|00000000||tx|1|entity|C0456603|Ratio|qnco|||ratios||||802|72|77
SE|00000000||tx|1|relation|1|1|C0012132|Zalcitabine|nnon,phsu|phsu|||Zalcitabine||||1000|1|11|VERB|DISRUPTS||13|21|2|1|C0031715|Phosphorylation|moft|moft|||phosphorylation||||888|34|48


SE|00000000||tx|1|text|Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|13|23
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|26|35
SE|00000000||tx|1|entity|C0699034|Xanax|orch,phsu|||Xanax||||851|47|51
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||851|53|56
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||851|58|66


SE|00000000||tx|1|text|Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0237753|Numbers|qnco|||number||||1000|23|28
SE|00000000||tx|1|entity|C0005821|Blood Platelets|cell|||blood platelets||||1000|33|47
SE|00000000||tx|1|entity|C0678227|Causing|ftcn|||causing||||916|52|58
SE|00000000||tx|1|entity|C0151773|Bone marrow depression|dsyn|||bone marrow depression||||916|60|81
SE|00000000||tx|1|entity|C0003392|Antineoplastic Agents|orch,phsu|||antineoplastic agents||||1000|92|112
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|118|122
SE|00000000||tx|1|entity|C1254881|Platelet function|celf|||platelet function||||1000|138|154
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|161|167
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||non-steroidal anti-inflammatory drugs||||991|179|215
SE|00000000||tx|1|entity|C0012582|Dipyridamole|orch,phsu|||dipyridamole||||1000|218|229
SE|00000000||tx|1|entity|C0009002|Clofibrate|orch,phsu|||clofibrate||||1000|250|259
SE|00000000||tx|1|entity|C0086140|Dextran|carb,phsu|||dextran||||1000|262|268
SE|00000000||tx|1|entity|C1458140|Bleeding tendency|patf|||bleeding tendency||||1000|288|304
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|318|331
SE|00000000||tx|1|entity|C0392747|Changing|ftcn|||altering||||850|341|348
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||850|350|365
SE|00000000||tx|1|entity|C0680730|Adjudication|gora|||determinations||||850|367|380
SE|00000000||tx|1|relation|0|0|C0004057|Aspirin|orch,phsu|orch|||aspirin||||1000|161|167|SPEC|ISA||161|215|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||non-steroidal anti-inflammatory drugs||||991|179|215
SE|00000000||tx|1|relation|0|0|C0004057|Aspirin|orch,phsu|orch|||aspirin||||1000|161|167|SPEC|ISA||161|215|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|118|122
SE|00000000||tx|1|relation|6|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|118|122|VERB|DISRUPTS||130|136|11|1|C1254881|Platelet function|celf|celf|||platelet function||||1000|138|154
SE|00000000||tx|1|relation|6|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|VERB|DISRUPTS||130|136|11|1|C1254881|Platelet function|celf|celf|||platelet function||||1000|138|154
SE|00000000||tx|1|relation|14|9|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|118|122|VERB|AUGMENTS||275|282|3|1|C1458140|Bleeding tendency|patf|patf|||bleeding tendency||||1000|288|304
SE|00000000||tx|1|relation|14|9|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|VERB|AUGMENTS||275|282|3|1|C1458140|Bleeding tendency|patf|patf|||bleeding tendency||||1000|288|304
SE|00000000||tx|1|relation|2|1|C0003280|Anticoagulants|phsu|phsu|||anticoagulants||||1000|318|331|VERB|CAUSES||306|313|15|1|C1458140|Bleeding tendency|patf|patf|||bleeding tendency||||1000|288|304
SE|00000000||tx|1|relation|0|0|C0004057|Aspirin|orch,phsu|orch|||aspirin||||1000|161|167|INFER|DISRUPTS(SPEC)||161|215|0|0|C1254881|Platelet function|celf|celf|||platelet function||||1000|138|154
SE|00000000||tx|1|relation|0|0|C0004057|Aspirin|orch,phsu|orch|||aspirin||||1000|161|167|INFER|AUGMENTS(SPEC)||161|215|0|0|C1458140|Bleeding tendency|patf|patf|||bleeding tendency||||1000|288|304


SE|00000000||tx|1|text|Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.
SE|00000000||tx|1|entity|C0140575|Rifabutin|antb,orch|||Rifabutin||||1000|1|9
SE|00000000||tx|1|entity|C0140575|Rifabutin|antb,orch|||rifabutin||||1000|32|40
SE|00000000||tx|1|entity|C0525004|Viracept|orch,phsu|||VIRACEPT||||1000|46|53
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|73|80
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||nelfinavir||||851|85|94
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||851|96|101
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||851|103|105
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|118|125
SE|00000000||tx|1|entity|C0140575|Rifabutin|antb,orch|||rifabutin||||583|130|138
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||583|140|145


SE|00000000||tx|1|text|DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.
SE|00000000||tx|1|entity|C0591362|Diamox|orch,phsu|||DIAMOX||||1000|1|6
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||888|17|25
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|27|36
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||790|43|51
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||790|53|57
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|69|77
SE|00000000||tx|1|relation|1|1|C0591362|Diamox|orch,phsu|orch|||DIAMOX||||1000|1|6|VERB|INTERACTS_WITH||8|15|3|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||888|17|25


SE|00000000||tx|1|text|Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.
SE|00000000||tx|1|entity|C0015846|Fentanyl|orch,phsu|||Fentanyl||||888|1|8
SE|00000000||tx|1|entity|C0278134|Absence of sensation|sosy|||Anesthesia||||888|10|19
SE|00000000||tx|1|entity|C2678378|Hypotension, severe|fndg|||Severe hypotension||||1000|22|39
SE|00000000||tx|1|entity|C0015846|Fentanyl|orch,phsu|||fentanyl||||888|66|73
SE|00000000||tx|1|entity|C0278134|Absence of sensation|sosy|||anesthesia||||888|75|84
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|91|101
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|103|105
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta blocker||||901|112|123
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium channel blocker||||1000|131|153


SE|00000000||tx|1|text|Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||Agents||||966|1|6
SE|00000000||tx|1|entity|||gngm|9360|PPIG|CYP||||1000|17|19
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|81|86
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||1000|116|124
SE|00000000||tx|1|entity|C0008838|Cisplatin|inch,phsu|||Cisplatin||||1000|127|135
SE|00000000||tx|1|entity|C0546861|Doxorubicin Hydrochloride|antb,orch|||doxorubicin HCL||||1000|138|152
SE|00000000||tx|1|entity|C0060135|felbamate|orch,phsu|||felbamate||||1000|155|163
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|166|173
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|176|188
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||1000|191|199
SE|00000000||tx|1|entity|C0033148|Primidone|orch,phsu|||primidone||||1000|205|213
SE|00000000||tx|1|entity|C0109002|methsuximide|orch,phsu|||methsuximide||||1000|216|227
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||861|234|245
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|258|264
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||861|296|301
SE|00000000||tx|1|entity|C1883708|Then|tmco|||then||||1000|321|324
SE|00000000||tx|1|entity|C0750729|Course|tmco|||course||||1000|335|340
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|345|353
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||1000|360|362
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|373|378
SE|00000000||tx|1|entity|C0392360|Indication of (contextual qualifier)|idcn|||reasonable||||789|396|405
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|424|427
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|429|436
SE|00000000||tx|1|relation|20|7|C0039771|Theophylline|bacs,orch,phsu|bacs|||theophylline||||861|234|245|NOM|STIMULATES||380|387|20|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|373|378
SE|00000000||tx|1|relation|20|7|C0109002|methsuximide|orch,phsu|orch|||methsuximide||||1000|216|227|NOM|STIMULATES||380|387|20|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|373|378
SE|00000000||tx|1|relation|20|7|C0033148|Primidone|orch,phsu|orch|||primidone||||1000|205|213|NOM|STIMULATES||380|387|20|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|373|378


SE|00000000||tx|1|text|Absorption of tetracycline is impaired by bismuth subsalicylate.
SE|00000000||tx|1|entity|C0039644|Tetracycline|antb,orch|||tetracycline||||1000|15|26
SE|00000000||tx|1|entity|C0053792|bismuth subsalicylate|orch,phsu|||bismuth subsalicylate||||1000|43|63


SE|00000000||tx|1|text|Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
SE|00000000||tx|1|entity|C0205210|Clinical|qlco|||clinical||||790|9|16
SE|00000000||tx|1|entity|C0596545|Experience|menp|||experience||||790|18|27
SE|00000000||tx|1|entity|C1514873|Requirement|ftcn|||requirements||||966|44|55
SE|00000000||tx|1|entity|C0373746|Assay of volatiles|lbpr|||volatile||||901|61|68
SE|00000000||tx|1|entity|C0242903|Anesthetics, Inhalation|phsu|||inhalation anesthetics||||901|70|91
SE|00000000||tx|1|entity|C1279901|Firstly|qlco|||first||||694|126|130
SE|00000000||tx|1|entity|C0700321|Small|qnco|||minutes||||1000|143|149
SE|00000000||tx|1|entity|C0002025|Alfenta|orch,phsu|||ALFENTA||||888|161|167
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induction||||888|169|177
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|183|193
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|195|197
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|202|213
SE|00000000||tx|1|entity|C0002025|Alfenta|orch,phsu|||ALFENTA||||1000|220|226
SE|00000000||tx|1|entity|C0002025|Alfenta|orch,phsu|||ALFENTA||||888|254|260
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|262|270
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|293|296
SE|00000000||tx|1|entity|C0439590|Prolonged|tmco|||prolonged||||1000|301|309
SE|00000000||tx|1|entity|C0205421|Deferred|tmco|||delayed||||901|314|320
SE|00000000||tx|1|entity|C0235063|Respiratory Depression|patf|||respiratory depression||||901|322|343
SE|00000000||tx|1|relation|7|2|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|202|213|NOM|STIMULATES||169|177|5|0|C0002025|Alfenta|orch,phsu|orch|||ALFENTA||||888|161|167
SE|00000000||tx|1|relation|9|1|C0002025|Alfenta|orch,phsu|orch|||ALFENTA||||1000|220|226|VERB|INHIBITS||246|252|4|1|C0002025|Alfenta|orch,phsu|orch|||ALFENTA||||888|254|260


SE|00000000||tx|1|text|Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|6|12
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|34|44
SE|00000000||tx|1|entity|C0541746|Thiazides|orch,phsu|||thiazides||||1000|64|72
SE|00000000||tx|1|entity|C0042866|Vitamin D|orch,phsu,vita|||vitamin D||||1000|79|87
SE|00000000||tx|1|entity|C0020437|Hypercalcemia|dsyn|||hypercalcemia||||1000|96|108
SE|00000000||tx|1|relation|4|1|C0042866|Vitamin D|orch,phsu,vita|orch|||vitamin D||||1000|79|87|VERB|CAUSES||89|94|1|1|C0020437|Hypercalcemia|dsyn|dsyn|||hypercalcemia||||1000|96|108


SE|00000000||tx|1|text|In combination with other central nervous system depressants, heroin may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased.
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|4|14
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||central nervous system depressants||||1000|27|60
SE|00000000||tx|1|entity|C0011892|Heroin|hops,orch,phsu|||heroin||||1000|63|68
SE|00000000||tx|1|entity|C0596545|Experience|menp|||experienced||||754|90|100
SE|00000000||tx|1|entity|C1706077|user - individual|humn|||users||||754|102|106
SE|00000000||tx|1|entity|C1704410|Tolerance|qlco|||tolerance||||1000|131|139
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||1000|148|151
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||861|196|199


SE|00000000||tx|1|text|In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|4|11
SE|00000000||tx|1|entity|C0443302|Several|qnco|||several||||872|14|20
SE|00000000||tx|1|entity|C0180309|Automated External Defibrillators|medd|||AED s||||872|22|26
SE|00000000||tx|1|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P450||||734|37|51
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|75|95
SE|00000000||tx|1|entity|C0069751|oxcarbazepine|orch,phsu|||oxcarbazepine||||1000|100|112


SE|00000000||tx|1|text|Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
SE|00000000||tx|1|entity|C0939393|Myobloc|orch,phsu|||MYOBLOC||||1000|22|28
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycosides||||1000|34|48
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|59|64
SE|00000000||tx|1|entity|C0260043|Neuromuscular transmission|ortf|||neuromuscular transmission||||1000|83|108
SE|00000000||tx|1|entity|C0010463|Curare|hops,orch,phsu|||curare||||1000|117|122
SE|00000000||tx|1|entity|C0205198|Compound|qlco|||compounds||||966|129|137
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||only||||1000|147|150
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|185|190
SE|00000000||tx|1|entity|C0040549|Toxin|bacs,hops|||toxin||||1000|199|203
SE|00000000||tx|1|relation|0|0|C0002556|Aminoglycosides|carb,phsu|carb|||aminoglycosides||||1000|34|48|SPEC|ISA||34|64|0|0|C0450442|Agent|chvf|chvf|||agents||||966|59|64
SE|00000000||tx|1|relation|0|0|C0939393|Myobloc|orch,phsu|orch|||MYOBLOC||||1000|22|28|SPEC|ISA||34|64|0|0|C0450442|Agent|chvf|chvf|||agents||||966|59|64
SE|00000000||tx|1|relation|4|2|C0002556|Aminoglycosides|carb,phsu|phsu|||aminoglycosides||||1000|34|48|VERB|DISRUPTS||66|76|6|1|C0260043|Neuromuscular transmission|ortf|ortf|||neuromuscular transmission||||1000|83|108
SE|00000000||tx|1|relation|4|2|C0939393|Myobloc|orch,phsu|phsu|||MYOBLOC||||1000|22|28|VERB|DISRUPTS||66|76|6|1|C0260043|Neuromuscular transmission|ortf|ortf|||neuromuscular transmission||||1000|83|108
SE|00000000||tx|1|relation|8|3|C0010463|Curare|hops,orch,phsu|hops|||curare||||1000|117|122|NOM|INTERACTS_WITH||185|190|1|1|C0040549|Toxin|bacs,hops|bacs|||toxin||||1000|199|203


SE|00000000||tx|1|text|DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.
SE|00000000||tx|1|entity|C0012772|Disulfiram|orch,phsu|||DISULFIRAM||||1000|1|10
SE|00000000||tx|1|entity|C0030705|Patients|podg|||PATIENTS||||802|49|56
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||PHENYTOIN||||802|68|76
SE|00000000||tx|1|entity|C0678518|congener|chvs|||CONGENERS||||1000|86|94
SE|00000000||tx|1|relation|2|2|C0012772|Disulfiram|orch,phsu|orch|||DISULFIRAM||||1000|1|10|PREP|COEXISTS_WITH||40|41|2|1|C0031507|Phenytoin|orch,phsu|orch|||PHENYTOIN||||802|68|76


SE|00000000||tx|1|text|The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
SE|00000000||tx|1|entity|C0009214|Codeine|orch,phsu|||codeine||||1000|12|18
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||861|34|41
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressant||||861|43|56
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|58|64
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|91|97
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|100|113
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|139|143
SE|00000000||tx|1|entity|C0151559|Central nervous system depression (disorder)|dsyn|||CNS depression||||1000|158|171
SE|00000000||tx|1|relation|2|1|C0009214|Codeine|orch,phsu|orch|||codeine||||1000|12|18|NOM|INTERACTS_WITH||58|64|2|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressant||||861|43|56
SE|00000000||tx|1|relation|7|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|139|143|VERB|CAUSES||150|156|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|158|171
SE|00000000||tx|1|relation|7|1|C0003360|Antihistamines|orch,phsu|phsu|||antihistamines||||1000|100|113|VERB|CAUSES||150|156|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|158|171
SE|00000000||tx|1|relation|7|1|C0001975|Alcohols|orch,phsu|phsu|||alcohol||||1000|91|97|VERB|CAUSES||150|156|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|158|171


SE|00000000||tx|1|text|Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||Erythromycin||||1000|1|12
SE|00000000||tx|1|entity|C0018684|Health|idcn|||healthy||||836|18|24
SE|00000000||tx|1|entity|C0027361|Persons|popg|||individuals||||836|26|36
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|39|59
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||1000|64|75
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||888|87|99
SE|00000000||tx|1|entity|C0439509|/40|tmco|||40%||||888|101|103
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||1000|130|141
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|147|158
SE|00000000||tx|1|entity|C0205309|Known|qlco|||known||||888|163|167
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||888|169|177
SE|00000000||tx|1|entity|C1142644|Cytochrome P450 3A4|aapp,enzy|||cytochrome P450 3A4||||1000|182|200
SE|00000000||tx|1|relation|7|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|147|158|NOM|INHIBITS||169|177|1|1|C1142644|Cytochrome P450 3A4|aapp,gngm,enzy|gngm|||cytochrome P450 3A4||||1000|182|200
SE|00000000||tx|1|relation|7|1|C0014806|Erythromycin|antb,orch|antb|||Erythromycin||||1000|1|12|NOM|INHIBITS||169|177|1|1|C1142644|Cytochrome P450 3A4|aapp,gngm,enzy|gngm|||cytochrome P450 3A4||||1000|182|200


SE|00000000||tx|1|text|Thioridazine: Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
SE|00000000||tx|1|entity|C0039943|Thioridazine|orch,phsu|||Thioridazine||||1000|1|12
SE|00000000||tx|1|entity|C0087136|Unmarried|fndg|||single||||888|35|40
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|42|46
SE|00000000||tx|1|entity|C0876170|Sonata|orch,phsu|||Sonata||||802|51|56
SE|00000000||tx|1|entity|C1123679|Thioridazine 50 MG|clnd|||thioridazine 50 mg||||1000|68|85
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|96|103
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|105|111
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decreased||||888|116|124
SE|00000000||tx|1|entity|C1443086|Alertness|menp|||alertness||||888|126|134
SE|00000000||tx|1|entity|C1562249|Impaired psychomotor performance|fndg|||impaired psychomotor performance||||1000|140|171
SE|00000000||tx|1|entity|C1292426|4 Hours|tmco|||4 hours||||1000|182|188
SE|00000000||tx|1|relation|6|6|C0039943|Thioridazine|orch,phsu|phsu|||Thioridazine||||1000|1|12|ADJ|INHIBITS||116|124|3|1|C1562249|Impaired psychomotor performance|fndg|fndg|||impaired psychomotor performance||||1000|140|171


SE|00000000||tx|1|text|When a diuretic is added to the therapy of a patient receiving PRINIVIL, an additional antihypertensive effect is usually observed.
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|8|15
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|33|39
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||840|46|52
SE|00000000||tx|1|entity|C1514756|Receive|qlco|||receiving||||840|54|62
SE|00000000||tx|1|entity|C0701176|Prinivil|aapp,phsu|||PRINIVIL||||840|64|71
SE|00000000||tx|1|entity|C1524062|Additional|ftcn|||additional||||802|77|86
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||802|105|110


SE|00000000||tx|1|text|Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.
SE|00000000||tx|1|entity|C1441405|Lithium.serum|elii,phsu|||Lithium serum||||901|1|13
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||901|15|28
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiating||||966|63|72
SE|00000000||tx|1|entity|C0443172|Changed status|qnco|||changing||||888|77|84
SE|00000000||tx|1|entity|C1101725|Bextra|orch,phsu|||BEXTRA||||1000|99|104
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|109|116
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|128|134
SE|00000000||tx|1|relation|4|1|C1101725|Bextra|orch,phsu|phsu|||BEXTRA||||1000|99|104|PREP|TREATS||106|107|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|109|116
SE|00000000||tx|1|relation|1|1|C0023870|Lithium|elii,phsu|elii|||lithium||||1000|128|134|VERB|ADMINISTERED_TO||118|126|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|109|116


SE|00000000||tx|1|text|However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high doses||||983|10|19
SE|00000000||tx|1|entity|C0023413|Leucovorin|orch,phsu,vita|||leucovorin||||1000|24|33
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|50|57
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||827|89|100
SE|00000000||tx|1|relation|2|1|C0023413|Leucovorin|orch,phsu,vita|orch|||leucovorin||||1000|24|33|VERB|INHIBITS||39|44|2|2|C0025677|Methotrexate|orch,phsu|orch|||methotrexate||||827|89|100


SE|00000000||tx|1|text|Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0010798|Cytochromes|aapp,bacs|||cytochrome||||694|20|29
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|49|57
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|80|100
SE|00000000||tx|1|entity|C0016229|Flecainide|orch,phsu|||flecainide||||1000|105|114
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|119|126
SE|00000000||tx|1|entity|C0205191|chronic|tmco|||chronic||||851|140|146
SE|00000000||tx|1|entity|C0016229|Flecainide|orch,phsu|||flecainide||||851|148|157
SE|00000000||tx|1|relation|3|1|C0034414|Quinidine|orch,phsu|orch|||quinidine||||1000|49|57|VERB|STIMULATES||67|74|4|2|C0016229|Flecainide|orch,phsu|orch|||flecainide||||1000|105|114
SE|00000000||tx|1|relation|5|1|C0016229|Flecainide|orch,phsu|phsu|||flecainide||||1000|105|114|PREP|TREATS||116|117|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|119|126


SE|00000000||tx|1|text|Phenobarbital: Decreases aspirin effectiveness by enzyme induction.
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||Phenobarbital||||1000|1|13
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||888|26|32
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effectiveness||||888|34|46
SE|00000000||tx|1|entity|C0014431|Enzyme Induction|genf|||enzyme induction||||1000|51|66


SE|00000000||tx|1|text|Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||890|14|18
SE|00000000||tx|1|entity|C0039773|Theophylline Assay|lbpr|||Theophylline serum levels||||890|1|25
SE|00000000||tx|1|entity|C1548787|Appropriate|qlco|||appropriate||||884|51|61
SE|00000000||tx|1|entity|C2826232|Dose Adjustment|hlca|||dose adjustments||||884|63|78
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|95|102
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|115|126
SE|00000000||tx|1|entity|C1176430|Pegasys|imft,orch,phsu|||PEGASYS||||1000|132|138
SE|00000000||tx|1|relation|2|1|C2826232|Dose Adjustment|hlca|hlca|||dose adjustments||||884|63|78|PREP|TREATS||91|93|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|95|102
SE|00000000||tx|1|relation|2|1|C0039771|Theophylline|bacs,orch,phsu|bacs|||theophylline||||1000|115|126|VERB|ADMINISTERED_TO||104|108|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|95|102
SE|00000000||tx|1|relation|2|1|C1176430|Pegasys|imft,orch,phsu|imft|||PEGASYS||||1000|132|138|VERB|ADMINISTERED_TO||104|108|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|95|102


SE|00000000||tx|1|text|Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor.
SE|00000000||tx|1|entity|C0238242|LITHIUM TOXICITY|inpo|||Lithium toxicity||||1000|1|16
SE|00000000||tx|1|entity|C0205343|Reversible|ftcn|||reversible||||861|30|39
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuation||||1000|46|60
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|65|71
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitor||||1000|81|93


SE|00000000||tx|1|text|Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.
SE|00000000||tx|1|entity|C0016278|Flucytosine|nnon,phsu|||Flucytosine||||1000|1|11
SE|00000000||tx|1|entity|C2986495|Synergistic|qlco|||synergistic||||888|22|32
SE|00000000||tx|1|entity|C0439849|Relationships|qlco|||relationship||||888|34|45
SE|00000000||tx|1|entity|C0002679|Amphotericin B|antb,orch|||amphotericin B||||1000|52|65
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|86|96
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|98|100
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|119|126
SE|00000000||tx|1|entity|C0016278|Flucytosine|nnon,phsu|||flucytosine||||1000|131|141
SE|00000000||tx|1|entity|C2362652|Possible diagnosis|qlco|||possibly||||1000|146|153
SE|00000000||tx|1|entity|C0178539|Cellular|ftcn|||cellular||||888|170|177
SE|00000000||tx|1|entity|C0347980|% uptake|qnco|||uptake||||888|179|184
SE|00000000||tx|1|entity|C0221099|Impaired|ftcn|||impairing||||1000|193|201
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|207|211
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|213|221
SE|00000000||tx|1|relation|4|2|C0002679|Amphotericin B|antb,orch|antb|||amphotericin B||||1000|52|65|VERB|AUGMENTS||106|113|5|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||1000|119|126


SE|00000000||tx|1|text|H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
SE|00000000||tx|1|entity|C0019593|Histamine H2 Antagonists|phsu|||H2 Blockers||||893|1|11
SE|00000000||tx|1|entity|C0358591|Proton Pump Inhibitors|phsu|||Proton Pump Inhibitors||||893|13|34
SE|00000000||tx|1|entity|C0443252|Long-term|tmco|||Long-term||||901|37|45
SE|00000000||tx|1|entity|C0439181|% suppression|qnco|||suppression||||901|47|57
SE|00000000||tx|1|entity|C0232552|Gastric acid secretion|ortf|||gastric acid secretion||||1000|62|83
SE|00000000||tx|1|entity|C0019593|Histamine H2 Antagonists|phsu|||H2 blockers||||1000|88|98
SE|00000000||tx|1|entity|C0358591|Proton Pump Inhibitors|phsu|||proton pump inhibitors||||1000|103|124
SE|00000000||tx|1|entity|C0015620|Famotidine|orch,phsu|||famotidine||||1000|131|140
SE|00000000||tx|1|entity|C0028978|Omeprazole|orch,phsu|||omeprazole||||1000|146|155
SE|00000000||tx|1|entity|C0332148|Probable diagnosis|qlco|||likely||||861|161|166
SE|00000000||tx|1|entity|C1455147|dasatinib|orch,phsu|||dasatinib||||694|178|186
SE|00000000||tx|1|relation|7|2|C0019593|Histamine H2 Antagonists|phsu|phsu|||H2 blockers||||1000|88|98|NOM|INHIBITS||47|57|7|1|C0232552|Gastric acid secretion|ortf|ortf|||gastric acid secretion||||1000|62|83
SE|00000000||tx|1|relation|8|4|C0358591|Proton Pump Inhibitors|phsu|phsu|||proton pump inhibitors||||1000|103|124|VERB|INHIBITS||171|176|1|1|C1455147|dasatinib|orch,phsu|orch|||dasatinib||||694|178|186
SE|00000000||tx|1|relation|8|4|C0358591|Proton Pump Inhibitors|phsu|phsu|||Proton Pump Inhibitors||||893|13|34|VERB|INHIBITS||171|176|1|1|C1455147|dasatinib|orch,phsu|orch|||dasatinib||||694|178|186


SE|00000000||tx|1|text|Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||Rifampin||||1000|1|8
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||775|18|23
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||775|32|35
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|40|49
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||790|84|86
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||regimen||||790|88|94
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|103|108
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|113|120
SE|00000000||tx|1|entity|C0442821|Strong|qlco|||strong||||660|125|130
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||660|132|137
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|152|154
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||aprepitant||||1000|159|168
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||802|180|192
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||802|197|200
SE|00000000||tx|1|entity|C2827968|Terminal Half Life|tmco|||terminal half-life||||923|215|232
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||802|244|256
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||802|260|263
SE|00000000||tx|1|relation|7|1|C0035608|Rifampin|antb,orch|antb|||rifampin||||1000|113|120|NOM|STIMULATES||139|145|7|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||660|132|137


SE|00000000||tx|1|text|Sildenafil citrate - Theoretically, L-arginine supplements taken concomitantly with sildenafil citrate, may potentiate the effects of the drug.
SE|00000000||tx|1|entity|C0724693|Sildenafil citrate|orch,phsu|||Sildenafil citrate||||901|1|18
SE|00000000||tx|1|entity|C0003765|Arginine|aapp,bacs,phsu|||L-arginine||||890|37|46
SE|00000000||tx|1|entity|C2348609|Supplement|ftcn|||supplements||||890|48|58
SE|00000000||tx|1|entity|C0724693|Sildenafil citrate|orch,phsu|||sildenafil citrate||||1000|85|102
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|124|130
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||1000|139|142
SE|00000000||tx|1|relation|2|1|C0724693|Sildenafil citrate|orch,phsu|orch|||sildenafil citrate||||1000|85|102|NOM|INTERACTS_WITH||124|130|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||1000|139|142


SE|00000000||tx|1|text|It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|28|37
SE|00000000||tx|1|entity|C0014964|Ethambutol|orch,phsu|||ethambutol||||1000|57|66
SE|00000000||tx|1|entity|C1874163|ALUMINUM CONTAINING ANTACIDS|phsu|||aluminum hydroxide containing antacids||||923|73|110
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|119|123
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||785|127|131
SE|00000000||tx|1|entity|C0014964|Ethambutol|orch,phsu|||ethambutol||||888|143|152


SE|00000000||tx|1|text|In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||clinical trials||||1000|4|18
SE|00000000||tx|1|entity|C0376357|Flolan|eico,phsu|||FLOLAN||||1000|21|26
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|42|48
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|51|59
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|62|75
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|78|81
SE|00000000||tx|1|entity|C0042402|Vasodilator Agents|phsu|||vasodilators||||888|83|94
SE|00000000||tx|1|entity|C2348609|Supplement|ftcn|||supplemental||||888|101|112
SE|00000000||tx|1|entity|C0030054|Oxygen|elii,phsu|||oxygen||||888|114|119
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|154|161
SE|00000000||tx|1|entity|C0018802|Congestive heart failure|dsyn|||congestive heart failure||||864|168|191
SE|00000000||tx|1|entity|C1514756|Receive|qlco|||receiving||||864|193|201
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||864|203|212
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|217|223
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|233|239
SE|00000000||tx|1|entity|C0376357|Flolan|eico,phsu|||FLOLAN||||1000|246|251
SE|00000000||tx|1|entity|C0750489|apparent|idcn|||apparent||||833|268|275
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||833|277|280
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||833|282|290
SE|00000000||tx|1|entity|C0042295|Values|qlco|||values||||833|292|297
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|303|312
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|327|333
SE|00000000||tx|1|entity|C0632490|N 30|orch,phsu|||n = 30||||1000|336|341
SE|00000000||tx|1|entity|C0457385|seconds|tmco|||second||||888|396|401
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||888|403|405
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|410|416
SE|00000000||tx|1|entity|C1442488|Baseline|qnco|||baseline||||888|438|445
SE|00000000||tx|1|entity|C0042295|Values|qlco|||values||||888|447|452
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||861|457|459
SE|00000000||tx|1|relation|8|2|C0030054|Oxygen|elii,phsu|phsu|||oxygen||||888|114|119|PREP|TREATS||151|152|11|1|C0030705|Patients|podg,humn|podg|||patients||||1000|154|161
SE|00000000||tx|1|relation|8|2|C0042402|Vasodilator Agents|phsu|phsu|||vasodilators||||888|83|94|PREP|TREATS||151|152|11|1|C0030705|Patients|podg,humn|podg|||patients||||1000|154|161
SE|00000000||tx|1|relation|8|2|C0003280|Anticoagulants|phsu|phsu|||anticoagulants||||1000|62|75|PREP|TREATS||151|152|11|1|C0030705|Patients|podg,humn|podg|||patients||||1000|154|161
SE|00000000||tx|1|relation|8|2|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|51|59|PREP|TREATS||151|152|11|1|C0030705|Patients|podg,humn|podg|||patients||||1000|154|161
SE|00000000||tx|1|relation|8|2|C0012265|Digoxin|carb,phsu,strd|phsu|||digoxin||||1000|42|48|PREP|TREATS||151|152|11|1|C0030705|Patients|podg,humn|podg|||patients||||1000|154|161
SE|00000000||tx|1|relation|7|1|C0376357|Flolan|eico,phsu|eico|||FLOLAN||||1000|246|251|PREP|PART_OF||241|244|12|4|C0030705|Patients|podg,humn|humn|||patients||||1000|154|161
SE|00000000||tx|1|relation|0|0|C0376357|Flolan|eico,phsu|eico|||FLOLAN||||1000|246|251|INFER|INTERACTS_WITH(INFER)||151|152|0|0|C0030054|Oxygen|elii,phsu|phsu|||oxygen||||888|114|119
SE|00000000||tx|1|relation|0|0|C0376357|Flolan|eico,phsu|eico|||FLOLAN||||1000|246|251|INFER|INTERACTS_WITH(INFER)||151|152|0|0|C0042402|Vasodilator Agents|phsu|phsu|||vasodilators||||888|83|94
SE|00000000||tx|1|relation|0|0|C0376357|Flolan|eico,phsu|eico|||FLOLAN||||1000|246|251|INFER|INTERACTS_WITH(INFER)||151|152|0|0|C0003280|Anticoagulants|phsu|phsu|||anticoagulants||||1000|62|75
SE|00000000||tx|1|relation|0|0|C0376357|Flolan|eico,phsu|eico|||FLOLAN||||1000|246|251|INFER|INTERACTS_WITH(INFER)||151|152|0|0|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|51|59
SE|00000000||tx|1|relation|0|0|C0376357|Flolan|eico,phsu|eico|||FLOLAN||||1000|246|251|INFER|INTERACTS_WITH(INFER)||151|152|0|0|C0012265|Digoxin|carb,phsu,strd|phsu|||digoxin||||1000|42|48


SE|00000000||tx|1|text|When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|6|13
SE|00000000||tx|1|entity|C0132326|Nevirapine|nnon,phsu|||nevirapine||||1000|39|48
SE|00000000||tx|1|entity|C2917212|Negative Regulation of Coagulation|phsf|||anticoagulation||||694|51|65
SE|00000000||tx|1|entity|C0332183|Frequent|tmco|||frequently||||1000|94|103


SE|00000000||tx|1|text|As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|16|21
SE|00000000||tx|1|entity|C0001443|Adenosine|nnon,nsba,phsu|||adenosine||||1000|26|34
SE|00000000||tx|1|entity|C0004247|Structure of atrioventricular node|bpoc|||A-V node||||1000|74|81
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||872|84|89
SE|00000000||tx|1|entity|C0449286|Degree or extent|qnco|||degrees||||872|91|97
SE|00000000||tx|1|entity|C0018794|Heart Block|dsyn|||heart block||||1000|102|112
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|149|161
SE|00000000||tx|1|relation|6|5|C0001443|Adenosine|nnon,nsba,phsu|nsba|||adenosine||||1000|26|34|NOM|COEXISTS_WITH||137|144|1|1|C0006949|Carbamazepine|orch,phsu|orch|||carbamazepine||||1000|149|161


SE|00000000||tx|1|text|Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.
SE|00000000||tx|1|entity|||gngm|7124|TNF|TNFa||||773|7|10
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blocking||||773|12|19
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||773|21|26
SE|00000000||tx|1|entity|C0723012|Remicade|aapp,imft,phsu|||REMICADE||||1000|39|46
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|57|67
SE|00000000||tx|1|entity|C0245109|anakinra|aapp,phsu|||anakinra||||1000|74|81
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||888|102|108
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicities||||888|110|119
SE|00000000||tx|1|relation|4|1|C0245109|anakinra|aapp,gngm,phsu|aapp|||anakinra||||1000|74|81|VERB|CAUSES||92|97|1|1|C0600688|Toxic effect|inpo|inpo|||toxicities||||888|110|119


SE|00000000||tx|1|text|Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic drugs.
SE|00000000||tx|1|entity|C0557988|Close supervision|topp|||Close supervision||||1000|1|17
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||1000|45|50
SE|00000000||tx|1|entity|C0002752|Anafranil|orch,phsu|||Anafranil||||1000|70|78
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetic drugs||||1000|120|140


SE|00000000||tx|1|text|Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.
SE|00000000||tx|1|entity|C0011816|Dextromethorphan|orch,phsu|||dextromethorphan||||890|9|24
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|26|46
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high doses||||983|67|76
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||1000|81|90
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||827|106|109
SE|00000000||tx|1|entity|C1332830|CYP2D6 gene|gngm|1565|CYP2D6|CYP 2D6||||824|136|142
SE|00000000||tx|1|entity|C0032854|Poverty|grpa|||poor||||824|144|147
SE|00000000||tx|1|entity|C2826232|Dose Adjustment|hlca|||dose adjustment||||1000|178|192
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||694|197|199
SE|00000000||tx|1|relation|1|1|C0011816|Dextromethorphan|orch,phsu|orch|||dextromethorphan||||890|9|24|NOM|COEXISTS_WITH||55|62|7|2|C0913246|valdecoxib|orch,phsu|orch|||valdecoxib||||1000|81|90


SE|00000000||tx|1|text|Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.
SE|00000000||tx|1|entity|C1511726|Data|idcn|||data||||861|17|20
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|33|40
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|57|64
SE|00000000||tx|1|entity|C0144576|Paclitaxel|orch,phsu|||paclitaxel||||888|69|78
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|80|88
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||888|93|105
SE|00000000||tx|1|entity|C0450358|33|inpr|||33%||||888|107|109
SE|00000000||tx|1|entity|C0678133|Taxol|orch,phsu|||TAXOL||||1000|116|120
SE|00000000||tx|1|entity|C0008838|Cisplatin|inch,phsu|||cisplatin||||1000|149|157


SE|00000000||tx|1|text|Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|entity|C0717874|Kaolin / pectin|orch,phsu|||kaolin-pectin||||1000|11|23
SE|00000000||tx|1|entity|C0036078|Sulfasalazine|orch,phsu|||sulfasalazine||||1000|26|38
SE|00000000||tx|1|entity|C0027603|Neomycin|antb,carb|||neomycin||||1000|41|48
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||802|67|73
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||802|86|90
SE|00000000||tx|1|entity|C0025853|Metoclopramide|orch,phsu|||metoclopramide||||1000|97|110
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||901|142|148
SE|00000000||tx|1|entity|C0021826|Intestinal Absorption|ortf|||intestinal digoxin absorption||||901|131|159
SE|00000000||tx|1|entity|C0205251|low|qlco|||low||||813|188|190
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentrations||||813|192|211
SE|00000000||tx|1|relation|0|0|C0717874|Kaolin / pectin|orch,phsu|orch|||kaolin-pectin||||1000|11|23|SPEC|ISA||1|23|0|0|C0003138|Antacids|phsu|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|relation|7|1|C0025853|Metoclopramide|orch,phsu|phsu|||metoclopramide||||1000|97|110|VERB|DISRUPTS||116|124|2|1|C0021826|Intestinal Absorption|ortf|ortf|||intestinal digoxin absorption||||901|131|159
SE|00000000||tx|1|relation|7|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||802|86|90|VERB|DISRUPTS||116|124|2|1|C0021826|Intestinal Absorption|ortf|ortf|||intestinal digoxin absorption||||901|131|159


SE|00000000||tx|1|text|The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|17|19
SE|00000000||tx|1|entity|C0019593|Histamine H2 Antagonists|phsu|||H2 blockers||||1000|24|34
SE|00000000||tx|1|entity|C0358591|Proton Pump Inhibitors|phsu|||proton pump inhibitors||||1000|39|60
SE|00000000||tx|1|entity|C1723829|Sprycel|orch,phsu|||SPRYCEL||||1000|67|73
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|78|80


SE|00000000||tx|1|text|Methotrexate: Ketoprofen, like other NSAIDs, may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||Methotrexate||||1000|1|12
SE|00000000||tx|1|entity|C0022635|Ketoprofen|orch,phsu|||Ketoprofen||||1000|15|24
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|38|43
SE|00000000||tx|1|entity|C0443172|Changed status|qnco|||changes||||1000|56|62
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|86|97
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||790|110|117
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||790|119|123
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||1000|139|142
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|148|156
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||888|158|165
SE|00000000||tx|1|relation|0|0|C0022635|Ketoprofen|orch,phsu|orch|||Ketoprofen||||1000|15|24|SPEC|ISA||15|43|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|38|43


SE|00000000||tx|1|text|Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||1000|27|46
SE|00000000||tx|1|entity|C0935987|Gleevec|orch,phsu|||Gleevec||||694|59|65
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||cmax||||861|94|97
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|103|105
SE|00000000||tx|1|entity|C0074554|Simvastatin|orch,phsu|||simvastatin||||1000|110|120
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|123|128
SE|00000000||tx|1|entity|C0442758|3/5|qnco|||3.5||||901|148|150
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||901|152|155
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|186|195
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|204|209
SE|00000000||tx|1|entity|C0935987|Gleevec|orch,phsu|||Gleevec||||1000|214|220
SE|00000000||tx|1|relation|6|6|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|NOM|INTERACTS_WITH||130|138|6|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|123|128
SE|00000000||tx|1|relation|2|2|C0935987|Gleevec|orch,phsu|orch|||Gleevec||||1000|214|220|NOM|INHIBITS||186|195|2|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|204|209


SE|00000000||tx|1|text|When you are using idoxuridine, it is especially important that your health care professional know if you are using the following: Eye product containing boric acid.
SE|00000000||tx|1|entity|C0020811|Idoxuridine|nnon,phsu|||idoxuridine||||1000|20|30
SE|00000000||tx|1|entity|C0018724|Health Personnel|prog|||health care professional||||1000|70|93
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||1000|121|129
SE|00000000||tx|1|entity|C3205668|Ophthalmic Products|phsu|||Eye product||||955|132|142
SE|00000000||tx|1|entity|C0006020|boric acid|inch,phsu|||boric acid||||1000|155|164


SE|00000000||tx|1|text|Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide.
SE|00000000||tx|1|entity|C0242896|Anticholinergic Agents|phsu|||Anticholinergic drugs||||1000|1|21
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|42|48
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|57|61
SE|00000000||tx|1|entity|C0017184|Gastrointestinal Motility|ortf|||gastrointestinal motility||||1000|74|98
SE|00000000||tx|1|entity|C0025853|Metoclopramide|orch,phsu|||metoclopramide||||1000|109|122
SE|00000000||tx|1|relation|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|57|61|VERB|AFFECTS||68|72|2|1|C0017184|Gastrointestinal Motility|ortf|ortf|||gastrointestinal motility||||1000|74|98


SE|00000000||tx|1|text|RAPTIVA should not be used with other immunosuppressive drugs.
SE|00000000||tx|1|entity|C1320125|Raptiva|aapp,imft,phsu|||RAPTIVA||||1000|1|7
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|16|18
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||861|57|61


SE|00000000||tx|1|text|Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||Methotrexate||||861|1|12
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||1000|25|27
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|41|52
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||888|71|78
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effectiveness||||888|80|92
SE|00000000||tx|1|entity|C2348609|Supplement|ftcn|||supplemental||||802|97|108
SE|00000000||tx|1|entity|C0017797|Glutamine|aapp,bacs,phsu|||glutamine||||802|112|120
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induced||||851|139|145
SE|00000000||tx|1|entity|C0333355|Mucositis|patf|||mucositis||||851|147|155
SE|00000000||tx|1|relation|4|1|C0017797|Glutamine|aapp,gngm,bacs,phsu|phsu|||glutamine||||802|112|120|PREP|TREATS||122|124|1|1|C0333355|Mucositis|patf|patf|||mucositis||||851|147|155


SE|00000000||tx|1|text|Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
SE|00000000||tx|1|entity|C0015052|Ethoxzolamide|orch,phsu|||Ethoxzolamide||||1000|1|13
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|32|37
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclics||||1000|42|51
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||amphetamines||||1000|54|65
SE|00000000||tx|1|entity|C0033216|Procainamide|orch,phsu|||procainamide||||1000|68|79
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|86|94


SE|00000000||tx|1|text|Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||Nonsteroidal anti-inflammatory drugs||||1000|1|36
SE|00000000||tx|1|entity|C0232819|Tubular secretion|ortf|||tubular secretion||||1000|73|89
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|94|105
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|129|136
SE|00000000||tx|1|relation|1|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||Nonsteroidal anti-inflammatory drugs||||1000|1|36|VERB|INHIBITS||60|67|3|1|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|73|89
SE|00000000||tx|1|relation|3|1|C0025677|Methotrexate|orch,phsu|orch|||methotrexate||||1000|94|105|VERB|AUGMENTS||114|123|1|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||1000|129|136


SE|00000000||tx|1|text|The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|17|19
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic blocking agents||||1000|24|54
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium antagonists||||966|75|93
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|104|111
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|113|119
SE|00000000||tx|1|entity|C0439590|Prolonged|tmco|||prolonging||||775|124|133
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||775|163|166


SE|00000000||tx|1|text|Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory drugs||||1000|7|42
SE|00000000||tx|1|entity|C1157324|prostaglandin biosynthetic process|moft|||prostaglandin synthesis||||1000|57|79
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|115|132
SE|00000000||tx|1|entity|C0304490|Potassium Sparing Diuretics|phsu|||potassium-sparing diuretics||||1000|159|185
SE|00000000||tx|1|relation|1|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory drugs||||1000|7|42|VERB|DISRUPTS||49|55|3|1|C1157324|prostaglandin biosynthetic process|moft|moft|||prostaglandin synthesis||||1000|57|79


SE|00000000||tx|1|text|Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
SE|00000000||tx|1|entity|C0085795|Amphotericin|antb,carb|||Amphotericin||||1000|1|12
SE|00000000||tx|1|entity|C0070895|Foscarnet|opco,phsu|||Foscarnet||||1000|15|23
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||Aminoglycosides||||1000|30|44
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|47|51
SE|00000000||tx|1|entity|C0085795|Amphotericin|antb,carb|||amphotericin||||1000|61|72
SE|00000000||tx|1|entity|C0070895|Foscarnet|opco,phsu|||foscarnet||||1000|75|83
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycosides||||1000|90|104
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|123|126
SE|00000000||tx|1|entity|C0031117|Peripheral Neuropathy|dsyn|||peripheral neuropathy||||901|142|162
SE|00000000||tx|1|entity|C0678123|Hivid|nnon,phsu|||HIVID||||824|173|177
SE|00000000||tx|1|entity|C0877248|Adverse event|fndg|||adverse events||||824|190|203
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|229|233
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|235|243
SE|00000000||tx|1|entity|C0012132|Zalcitabine|nnon,phsu|||zalcitabine||||1000|248|258
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||694|277|284
SE|00000000||tx|1|relation|0|0|C0085795|Amphotericin|antb,carb|antb|||amphotericin||||1000|61|72|SPEC|ISA||47|72|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|47|51
SE|00000000||tx|1|relation|7|1|C0002556|Aminoglycosides|carb,phsu|carb|||aminoglycosides||||1000|90|104|NOM|PREDISPOSES||123|126|5|1|C0031117|Peripheral Neuropathy|dsyn|dsyn|||peripheral neuropathy||||901|142|162
SE|00000000||tx|1|relation|7|1|C0070895|Foscarnet|opco,phsu|opco|||Foscarnet||||1000|15|23|NOM|PREDISPOSES||123|126|5|1|C0031117|Peripheral Neuropathy|dsyn|dsyn|||peripheral neuropathy||||901|142|162
SE|00000000||tx|1|relation|7|1|C0085795|Amphotericin|antb,carb|carb|||Amphotericin||||1000|1|12|NOM|PREDISPOSES||123|126|5|1|C0031117|Peripheral Neuropathy|dsyn|dsyn|||peripheral neuropathy||||901|142|162
SE|00000000||tx|1|relation|7|1|C0002556|Aminoglycosides|carb,phsu|carb|||Aminoglycosides||||1000|30|44|NOM|PREDISPOSES||123|126|5|1|C0031117|Peripheral Neuropathy|dsyn|dsyn|||peripheral neuropathy||||901|142|162
SE|00000000||tx|1|relation|10|5|C0070895|Foscarnet|opco,phsu|opco|||foscarnet||||1000|75|83|VERB|DISRUPTS||208|218|3|1|C0022646|Kidney|bpoc|bpoc|||renal||||888|229|233


SE|00000000||tx|1|text|When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
SE|00000000||tx|1|entity|C0935984|Cancidas|aapp,phsu|||CANCIDAS||||1000|6|13
SE|00000000||tx|1|entity|C0683151|drug clearance|phsf|||drug clearance||||1000|51|64
SE|00000000||tx|1|entity|C0674428|efavirenz|orch,phsu|||efavirenz||||1000|75|83
SE|00000000||tx|1|entity|C0132326|Nevirapine|nnon,phsu|||nevirapine||||1000|86|95
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|98|106
SE|00000000||tx|1|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||1000|109|121
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|127|139
SE|00000000||tx|1|entity|C2348070|Daily Dose|qnco|||daily dose||||1000|151|160
SE|00000000||tx|1|entity|C0935984|Cancidas|aapp,phsu|||CANCIDAS||||1000|174|181


SE|00000000||tx|1|text|Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.
SE|00000000||tx|1|entity|C1287351|Finding of liver enzyme levels|lbtr|||liver enzymes||||1000|15|27
SE|00000000||tx|1|entity|C0674427|Sustiva|orch,phsu|||SUSTIVA||||1000|49|55
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|68|78
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|85|93


SE|00000000||tx|1|text|It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.
SE|00000000||tx|1|entity|C0700444|buspirone hydrochloride|orch,phsu|||buspirone hydrochloride||||1000|24|46
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|48|50
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|79|92
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|106|112
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|117|127
SE|00000000||tx|1|entity|C0700444|buspirone hydrochloride|orch,phsu|||buspirone HCl||||1000|147|159
SE|00000000||tx|1|entity|C0033978|Psychotropic Drugs|phsu|||psychotropic drugs||||1000|177|194
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|201|203
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|223|233
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|235|237
SE|00000000||tx|1|entity|C0700444|buspirone hydrochloride|orch,phsu|||buspirone HCl||||1000|242|254
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||901|271|276
SE|00000000||tx|1|entity|C0007680|Central Nervous System Agents|phsu|||CNS-active drugs||||901|267|282
SE|00000000||tx|1|relation|0|0|C0700444|buspirone hydrochloride|orch,phsu|orch|||buspirone HCl||||1000|147|159|SPEC|ISA||147|194|0|0|C0033978|Psychotropic Drugs|phsu|phsu|||psychotropic drugs||||1000|177|194


SE|00000000||tx|1|text|Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interactions||||966|14|25
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|56|58
SE|00000000||tx|1|entity|C0205164|Major|qlco|||major||||623|76|80
SE|00000000||tx|1|entity|C0205210|Clinical|qlco|||clinical||||623|82|89
SE|00000000||tx|1|entity|C0591189|Brevibloc|orch,phsu|||BREVIBLOC||||1000|103|111
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|148|155
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|189|195
SE|00000000||tx|1|entity|C0026549|Morphine|orch,phsu|||morphine||||1000|198|205
SE|00000000||tx|1|entity|C0038627|Succinylcholine|orch,phsu|||succinylcholine||||1000|208|222
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|227|234
SE|00000000||tx|1|relation|5|2|C0591189|Brevibloc|orch,phsu|phsu|||BREVIBLOC||||1000|103|111|PREP|TREATS||145|146|5|1|C0030705|Patients|podg,humn|podg|||patients||||1000|148|155


SE|00000000||tx|1|text|This allows bitolterol to open air passages, increasing the effectiveness of the steroid.
SE|00000000||tx|1|entity|C0053817|bitolterol|orch,phsu|||bitolterol||||861|13|22
SE|00000000||tx|1|entity|C0001861|Air|sbst|||air||||872|32|34
SE|00000000||tx|1|entity|C0439799|Channel|spco|||passages||||872|36|43
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effectiveness||||1000|61|73
SE|00000000||tx|1|entity|C0038317|Steroids|strd|||steroid||||1000|82|88


SE|00000000||tx|1|text|However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.
SE|00000000||tx|1|entity|C0205476|Medical|ftcn|||medical||||790|18|24
SE|00000000||tx|1|entity|C3245512|practice|inpr|||practice||||790|26|33
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|66|81
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|90|97
SE|00000000||tx|1|entity|C0052796|Azithromycin|antb,orch|||azithromycin||||1000|112|123
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||861|129|136
SE|00000000||tx|1|relation|2|1|C0052796|Azithromycin|antb,orch|antb|||azithromycin||||1000|112|123|VERB|TREATS||99|105|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|90|97
SE|00000000||tx|1|relation|2|1|C0043031|Warfarin|hops,orch,phsu|phsu|||warfarin||||861|129|136|VERB|TREATS||99|105|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|90|97


SE|00000000||tx|1|text|In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.
SE|00000000||tx|1|entity|C0028125|Nitrates|chvs|||Nitrates||||1000|18|25
SE|00000000||tx|1|entity|C1272641|Systemic arterial pressure|fndg|||blood pressure||||861|32|45
SE|00000000||tx|1|entity|C0441994|Lower - spatial qualifier|spco|||lowering||||861|47|54
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|56|62
SE|00000000||tx|1|entity|C0028125|Nitrates|chvs|||nitrates||||861|78|85
SE|00000000||tx|1|entity|C1292426|4 Hours|tmco|||4 hours||||1000|108|114
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||vardenafil||||1000|122|131
SE|00000000||tx|1|entity|C0018810|heart rate|orga|||heart rate||||1000|150|159
SE|00000000||tx|1|entity|C1412113|SLC33A1 gene|gngm|9197|SLC33A1|at 1||||1000|172|175
SE|00000000||tx|1|entity|C1292429|8 Hours|tmco|||8 hours||||1000|184|190
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||790|220|223
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||Vardenafil||||1000|228|237
SE|00000000||tx|1|entity|C0205847|Middle Aged|aggp|||middle-aged||||888|250|260
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy middle-aged subjects||||888|242|269
SE|00000000||tx|1|relation|10|2|C1412113|SLC33A1 gene|gngm,aapp|gngm|9197|SLC33A1|at 1||||1000|172|175|VERB|STIMULATES||197|207|3|2|C0971579|vardenafil|orch,phsu|orch|||Vardenafil||||1000|228|237


SE|00000000||tx|1|text|Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||861|12|16
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|27|36
SE|00000000||tx|1|entity|C0038742|Sulfinpyrazone|orch,phsu|||sulfinpyrazone||||1000|42|55
SE|00000000||tx|1|entity|C0678876|renal tubular secretion|ortf|||renal tubular secretion||||1000|70|92
SE|00000000||tx|1|entity|C0028156|Nitrofurantoin|orch,phsu|||nitrofurantoin||||1000|97|110
SE|00000000||tx|1|relation|3|1|C0038742|Sulfinpyrazone|orch,phsu|orch|||sulfinpyrazone||||1000|42|55|VERB|INHIBITS||62|68|2|1|C0678876|renal tubular secretion|ortf|ortf|||renal tubular secretion||||1000|70|92
SE|00000000||tx|1|relation|3|1|C0033209|Probenecid|orch,phsu|orch|||probenecid||||1000|27|36|VERB|INHIBITS||62|68|2|1|C0678876|renal tubular secretion|ortf|ortf|||renal tubular secretion||||1000|70|92
SE|00000000||tx|1|relation|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||861|12|16|VERB|INHIBITS||62|68|2|1|C0678876|renal tubular secretion|ortf|ortf|||renal tubular secretion||||1000|70|92


SE|00000000||tx|1|text|Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||Dose||||888|1|4
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||888|6|14
SE|00000000||tx|1|entity|C0701105|Crixivan|orch,phsu|||CRIXIVAN||||1000|19|26
SE|00000000||tx|1|entity|C1292429|8 Hours|tmco|||8 hours||||1000|44|50
SE|00000000||tx|1|entity|C1621583|Administer|ftcn|||administering||||773|72|84
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||773|86|97


SE|00000000||tx|1|text|Serious toxicity may result if dextromethorphan is coadministered with monoamine oxidase inhibitors (MAOIs).
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||Serious||||888|1|7
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||888|9|16
SE|00000000||tx|1|entity|C0011816|Dextromethorphan|orch,phsu|||dextromethorphan||||888|32|47
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|72|99


SE|00000000||tx|1|text|Drug Interactions with Beta-Blockers: Concomitant use of fenoldopam with beta-blockers should be avoided.
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||Drug Interactions||||1000|1|17
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||Beta-Blockers||||1000|24|36
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|39|49
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|51|53
SE|00000000||tx|1|entity|C0060180|Fenoldopam|orch,phsu|||fenoldopam||||1000|58|67
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blockers||||1000|74|86


SE|00000000||tx|1|text|It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||1000|17|24
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|31|41
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|43|45
SE|00000000||tx|1|entity|C0205309|Known|qlco|||known||||901|56|60
SE|00000000||tx|1|entity|C0162713|Photosensitizing Agents|phsu|||photosensitizing agents||||901|62|84
SE|00000000||tx|1|entity|C0018242|Griseofulvin|orch,phsu|||griseofulvin||||1000|94|105
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|108|125
SE|00000000||tx|1|entity|C0038766|Sulfonylurea Compounds|orch,phsu|||sulfonylureas||||1000|128|140
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|143|156
SE|00000000||tx|1|entity|C0038760|Sulfonamides|orch,phsu|||sulfonamides||||1000|159|170
SE|00000000||tx|1|entity|C0039651|Tetracyclines|orch|||tetracyclines||||1000|176|188
SE|00000000||tx|1|entity|C0162830|Dermatitis, Phototoxic|dsyn|||photosensitivity reaction||||1000|209|233
SE|00000000||tx|1|entity|C0022602|Actinic keratosis|neop|||actinic keratoses||||1000|238|254
SE|00000000||tx|1|entity|C0876066|Levulan Kerastick|orch,phsu|||LEVULAN KERASTICK||||1000|273|289
SE|00000000||tx|1|entity|C0991555|Topical Solution|bodm|||Topical Solution||||1000|295|310
SE|00000000||tx|1|relation|9|1|C0039651|Tetracyclines|orch|orch|||tetracyclines||||1000|176|188|VERB|AUGMENTS||196|203|4|1|C0162830|Dermatitis, Phototoxic|dsyn|dsyn|||photosensitivity reaction||||1000|209|233
SE|00000000||tx|1|relation|9|1|C0038760|Sulfonamides|orch,phsu|orch|||sulfonamides||||1000|159|170|VERB|AUGMENTS||196|203|4|1|C0162830|Dermatitis, Phototoxic|dsyn|dsyn|||photosensitivity reaction||||1000|209|233
SE|00000000||tx|1|relation|9|1|C0031436|Phenothiazines|orch,phsu|orch|||phenothiazines||||1000|143|156|VERB|AUGMENTS||196|203|4|1|C0162830|Dermatitis, Phototoxic|dsyn|dsyn|||photosensitivity reaction||||1000|209|233
SE|00000000||tx|1|relation|9|1|C0038766|Sulfonylurea Compounds|orch,phsu|orch|||sulfonylureas||||1000|128|140|VERB|AUGMENTS||196|203|4|1|C0162830|Dermatitis, Phototoxic|dsyn|dsyn|||photosensitivity reaction||||1000|209|233
SE|00000000||tx|1|relation|9|1|C0012802|Thiazide Diuretics|orch,phsu|orch|||thiazide diuretics||||1000|108|125|VERB|AUGMENTS||196|203|4|1|C0162830|Dermatitis, Phototoxic|dsyn|dsyn|||photosensitivity reaction||||1000|209|233
SE|00000000||tx|1|relation|9|1|C0018242|Griseofulvin|orch,phsu|orch|||griseofulvin||||1000|94|105|VERB|AUGMENTS||196|203|4|1|C0162830|Dermatitis, Phototoxic|dsyn|dsyn|||photosensitivity reaction||||1000|209|233
SE|00000000||tx|1|relation|2|1|C0876066|Levulan Kerastick|orch,phsu|phsu|||LEVULAN KERASTICK||||1000|273|289|VERB|TREATS||256|262|11|1|C0022602|Actinic keratosis|neop|neop|||actinic keratoses||||1000|238|254


SE|00000000||tx|1|text|Adrenergic blockers Adrenergic blockers are inhibited by amphetamines.
SE|00000000||tx|1|entity|C0242889|Adrenergic Antagonists|phsu|||Adrenergic blockers||||694|1|19
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||amphetamines||||1000|58|69


SE|00000000||tx|1|text|Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||Tricyclic antidepressants||||1000|1|25
SE|00000000||tx|1|entity|C0002600|Amitriptyline|orch,phsu|||amitriptyline||||1000|28|40
SE|00000000||tx|1|entity|C0020934|Imipramine|orch,phsu|||imipramine||||1000|43|52
SE|00000000||tx|1|entity|C0028420|Nortriptyline|orch,phsu|||nortriptyline||||1000|55|67
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||Metabolism||||1000|71|80
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||851|102|112
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||851|114|121
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||851|123|136
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|150|155
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressant||||1000|167|180
SE|00000000||tx|1|relation|0|0|C0002600|Amitriptyline|orch,phsu|orch|||amitriptyline||||1000|28|40|SPEC|ISA||1|40|0|0|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||Tricyclic antidepressants||||1000|1|25
SE|00000000||tx|1|relation|3|1|C0009871|Contraceptive Agents|phsu|phsu|||contraceptives||||851|123|136|VERB|INHIBITS||89|97|5|5|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||Tricyclic antidepressants||||1000|1|25
SE|00000000||tx|1|relation|0|0|C0009871|Contraceptive Agents|phsu|phsu|||contraceptives||||851|123|136|INFER|INHIBITS(SPEC)||1|40|0|0|C0002600|Amitriptyline|orch,phsu|orch|||amitriptyline||||1000|28|40


SE|00000000||tx|1|text|Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
SE|00000000||tx|1|entity|C0002600|Amitriptyline|orch,phsu|||Amitriptyline||||1000|1|13
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|16|25
SE|00000000||tx|1|entity|C1337242|cinacalcet|orch,phsu|||cinacalcet||||790|61|70
SE|00000000||tx|1|entity|C0002600|Amitriptyline|orch,phsu|||amitriptyline||||790|83|95
SE|00000000||tx|1|entity|C0002600|Amitriptyline|orch,phsu|||amitriptyline||||694|107|119
SE|00000000||tx|1|entity|C0028420|Nortriptyline|orch,phsu|||nortriptyline||||1000|134|146
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||888|149|154
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||888|156|165
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|180|192
SE|00000000||tx|1|entity|C1332830|CYP2D6 gene|gngm|1565|CYP2D6|CYP2D6||||635|201|206
SE|00000000||tx|1|entity|C0205231|Extensive|qlco|||extensive||||635|208|216
SE|00000000||tx|1|relation|5|1|C0002600|Amitriptyline|orch,phsu|orch|||amitriptyline||||790|83|95|VERB|STIMULATES||97|105|5|1|C0002600|Amitriptyline|orch,phsu|orch|||amitriptyline||||694|107|119
SE|00000000||tx|1|relation|5|1|C0002600|Amitriptyline|orch,phsu|orch|||amitriptyline||||790|83|95|VERB|STIMULATES||97|105|5|1|C0028420|Nortriptyline|orch,phsu|orch|||nortriptyline||||1000|134|146


SE|00000000||tx|1|text|Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||Diminished||||851|1|10
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||urinary||||851|12|18
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||851|20|28
SE|00000000||tx|1|entity|C0028365|Norfloxacin|orch,phsu|||norfloxacin||||1000|33|43
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|74|84
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|104|113
SE|00000000||tx|1|entity|C0028365|Norfloxacin|orch,phsu|||norfloxacin||||1000|119|129


SE|00000000||tx|1|text|Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||1000|15|19
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||773|31|33
SE|00000000||tx|1|entity|C0013231|Drugs, Non-Prescription|phsu|||OTC||||888|36|38
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|40|43
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|64|71
SE|00000000||tx|1|entity|C0114771|dofetilide|orch,phsu|||dofetilide||||790|76|85
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|87|92
SE|00000000||tx|1|entity|C0439211|microgram|qnco|||mcg||||861|106|108
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|110|115
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|117|120


SE|00000000||tx|1|text|Simultaneous administration of SPRYCEL with antacids should be avoided.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Simultaneous||||888|1|12
SE|00000000||tx|1|entity|C1723829|Sprycel|orch,phsu|||SPRYCEL||||1000|32|38
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|45|52


SE|00000000||tx|1|text|Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
SE|00000000||tx|1|entity|C0291772|alosetron|orch,phsu|||alosetron||||1000|21|29
SE|00000000||tx|1|entity|C0442821|Strong|qlco|||strong||||802|35|40
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||802|42|47
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||802|49|58
SE|00000000||tx|1|entity|C0055856|Clarithromycin|antb,orch|||clarithromycin||||1000|69|82
SE|00000000||tx|1|entity|C0907410|telithromycin|antb,orch|||telithromycin||||1000|85|97
SE|00000000||tx|1|entity|C0033607|Protease Inhibitor|bacs,phsu|||protease inhibitors||||1000|100|118
SE|00000000||tx|1|entity|C0393080|voriconazole|orch,phsu|||voriconazole||||1000|121|132
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|139|150
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|156|158
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||861|224|230
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||861|232|240
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interactions||||861|242|258
SE|00000000||tx|1|relation|2|1|C0291772|alosetron|orch,phsu|orch|||alosetron||||1000|21|29|NOM|INHIBITS||49|58|2|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||802|42|47
SE|00000000||tx|1|relation|2|1|C0064113|Itraconazole|orch,phsu|orch|||itraconazole||||1000|139|150|NOM|INHIBITS||49|58|2|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||802|42|47
SE|00000000||tx|1|relation|2|1|C0393080|voriconazole|orch,phsu|orch|||voriconazole||||1000|121|132|NOM|INHIBITS||49|58|2|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||802|42|47
SE|00000000||tx|1|relation|2|1|C0033607|Protease Inhibitor|bacs,phsu|bacs|||protease inhibitors||||1000|100|118|NOM|INHIBITS||49|58|2|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||802|42|47
SE|00000000||tx|1|relation|2|1|C0907410|telithromycin|antb,orch|orch|||telithromycin||||1000|85|97|NOM|INHIBITS||49|58|2|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||802|42|47
SE|00000000||tx|1|relation|2|1|C0055856|Clarithromycin|antb,orch|orch|||clarithromycin||||1000|69|82|NOM|INHIBITS||49|58|2|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||802|42|47


SE|00000000||tx|1|text|Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0439861|Substance|sbst|||substances||||1000|17|26
SE|00000000||tx|1|entity|||gngm|9360|PPIG|CYP||||827|47|49
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||827|54|63
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||clinical studies||||1000|81|96
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|108|122
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||827|149|158
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|201|210
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|221|235
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|290|299
SE|00000000||tx|1|entity|C0470187|Availability of|ftcn|||Available||||888|303|311
SE|00000000||tx|1|entity|C1511726|Data|idcn|||data||||888|313|316
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||clinical studies||||1000|323|338
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|343|357
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|370|379
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||901|391|398
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interaction||||901|400|415
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|422|431
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||1000|441|449
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|452|460
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|463|471
SE|00000000||tx|1|entity|C0003240|Macrolide Antibiotics|antb,orch|||macrolide antibiotics||||1000|474|494
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|504|515
SE|00000000||tx|1|entity|C0055856|Clarithromycin|antb,orch|||clarithromycin||||1000|521|534
SE|00000000||tx|1|entity|C0452456|Grapefruit juice|food|||grapefruit juice||||1000|541|556
SE|00000000||tx|1|relation|0|0|C0002333|Alprazolam|orch,phsu|orch|||alprazolam||||1000|201|210|SPEC|ISA||201|235|0|0|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|221|235
SE|00000000||tx|1|relation|0|0|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|504|515|SPEC|ISA||474|515|0|0|C0003240|Macrolide Antibiotics|antb,orch|antb|||macrolide antibiotics||||1000|474|494
SE|00000000||tx|1|relation|0|0|C0055856|Clarithromycin|antb,orch|antb|||clarithromycin||||1000|521|534|SPEC|ISA||474|515|0|0|C0003240|Macrolide Antibiotics|antb,orch|antb|||macrolide antibiotics||||1000|474|494
SE|00000000||tx|1|relation|4|4|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|VERB|INTERACTS_WITH||98|106|21|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|108|122
SE|00000000||tx|1|relation|5|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|108|122|VERB|INTERACTS_WITH||124|134|20|1|C0002333|Alprazolam|orch,phsu|orch|||alprazolam||||827|149|158


SE|00000000||tx|1|text|Patients on rifampin should receive 70 mg of CANCIDAS daily.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|13|20
SE|00000000||tx|1|entity|C0935984|Cancidas|aapp,phsu|||CANCIDAS||||888|46|53
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||888|55|59


SE|00000000||tx|1|text|In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.
SE|00000000||tx|1|entity|C0205455|Nine|qnco|||nine||||888|20|23
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|25|32
SE|00000000||tx|1|entity|C0006142|Malignant neoplasm of breast|neop|||breast cancer||||1000|39|51
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||decreased||||888|75|83
SE|00000000||tx|1|entity|C1457887|Symptoms|sosy|||symptoms||||888|85|92
SE|00000000||tx|1|entity|C0439849|Relationships|qlco|||related||||901|110|116
SE|00000000||tx|1|entity|C0568062|Methotrexate poisoning|inpo|||methotrexate-related toxicity||||901|97|125
SE|00000000||tx|1|entity|C1442162|GIVEN|cnce|||given||||775|132|136
SE|00000000||tx|1|entity|C2348609|Supplement|ftcn|||supplemental||||775|138|149
SE|00000000||tx|1|entity|C0017797|Glutamine|aapp,bacs,phsu|||glutamine||||775|153|161
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|168|171
SE|00000000||tx|1|entity|C0444499|0/5|qnco|||0.5||||893|176|178
SE|00000000||tx|1|entity|C1532536|g/kg/day|qnco|||gram/kilogram/day||||893|180|196
SE|00000000||tx|1|relation|6|1|C0006142|Malignant neoplasm of breast|neop|neop|||breast cancer||||1000|39|51|PREP|PROCESS_OF||34|37|2|1|C0030705|Patients|podg,humn|humn|||patients||||888|25|32
SE|00000000||tx|1|relation|5|1|C1457887|Symptoms|sosy|sosy|||symptoms||||888|85|92|AUX|PROCESS_OF||70|73|3|2|C0030705|Patients|podg,humn|humn|||patients||||888|25|32


SE|00000000||tx|1|text|Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|16|24
SE|00000000||tx|1|entity|C0718644|Arava|orch,phsu|||ARAVA||||660|30|34
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multiple||||694|72|79
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|115|122
SE|00000000||tx|1|entity|C0718644|Arava|orch,phsu|||ARAVA||||1000|149|153
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|159|166
SE|00000000||tx|1|relation|2|1|C0718644|Arava|orch,phsu|orch|||ARAVA||||1000|149|153|VERB|ADMINISTERED_TO||134|142|5|1|C0030705|Patients|podg,humn|humn|||patients||||888|115|122
SE|00000000||tx|1|relation|2|1|C0035608|Rifampin|antb,orch|orch|||rifampin||||1000|159|166|VERB|ADMINISTERED_TO||134|142|5|1|C0030705|Patients|podg,humn|humn|||patients||||888|115|122


SE|00000000||tx|1|text|If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampicin||||851|4|13
SE|00000000||tx|1|entity|C0071304|Isradipine|orch,phsu|||isradipine||||888|36|45
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|47|60
SE|00000000||tx|1|entity|C1527144|Therapeutic Effect|hlca|||therapeutic effects||||983|66|84
SE|00000000||tx|1|entity|C0332148|Probable diagnosis|qlco|||likely||||861|90|95
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||markedly||||1000|103|110
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|153|161
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|163|172
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||872|178|183
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||872|185|193
SE|00000000||tx|1|entity|C0071304|Isradipine|orch,phsu|||isradipine||||1000|198|207


SE|00000000||tx|1|text|Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.
SE|00000000||tx|1|entity|C0332185|Recent|tmco|||recent||||888|18|23
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||888|25|29
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|75|83
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|89|100
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||790|112|119
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|121|126
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|138|149
SE|00000000||tx|1|entity|C1550608|Instance|idcn|||instances||||966|164|172
SE|00000000||tx|1|entity|C2945599|Mild (qualifier value)|qlco|||slight||||888|176|181
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||888|183|190
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|214|222


SE|00000000||tx|1|text|Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||Agents||||966|1|6
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||Increased||||694|13|21
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||Carbamazepine||||1000|49|61
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|88|93
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||872|109|117
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||872|119|124
SE|00000000||tx|1|entity|C0009010|Clomipramine|orch,phsu|||Clomipramine||||694|127|138
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||1000|145|153
SE|00000000||tx|1|entity|C0033148|Primidone|orch,phsu|||primidone||||861|163|171
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|184|190
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||861|222|227
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||1000|232|234
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|243|248
SE|00000000||tx|1|entity|C0683312|Categories|inpr|||category||||1000|258|265
SE|00000000||tx|1|entity|C1883708|Then|tmco|||then||||1000|272|275
SE|00000000||tx|1|entity|C0750729|Course|tmco|||course||||1000|286|291
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|300|308
SE|00000000||tx|1|entity|C0392360|Indication of (contextual qualifier)|idcn|||reasonable||||789|332|341
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|360|363
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||888|365|372
SE|00000000||tx|1|entity|C2347852|Concomitant Agent|idcn|||concomitant agent||||1000|382|398
SE|00000000||tx|1|relation|18|6|C0031507|Phenytoin|orch,phsu|orch|||Phenytoin||||1000|145|153|NOM|COEXISTS_WITH||37|44|18|1|C0006949|Carbamazepine|orch,phsu|orch|||Carbamazepine||||1000|49|61
SE|00000000||tx|1|relation|18|6|C0033148|Primidone|orch,phsu|orch|||primidone||||861|163|171|NOM|COEXISTS_WITH||37|44|18|1|C0006949|Carbamazepine|orch,phsu|orch|||Carbamazepine||||1000|49|61


SE|00000000||tx|1|text|Digoxin: Enoxacin may raise serum digoxin levels in some individuals.
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||Digoxin||||1000|1|7
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||Enoxacin||||1000|10|17
SE|00000000||tx|1|entity|C1306421|Serum digoxin measurement|lbpr|||serum digoxin levels||||983|29|48
SE|00000000||tx|1|entity|C0237401|Individual|humn|||individuals||||966|58|68
SE|00000000||tx|1|relation|3|2|C0014310|Enoxacin|orch,phsu|phsu|||Enoxacin||||1000|10|17|PREP|TREATS||50|51|1|1|C0237401|Individual|grup,humn|humn|||individuals||||966|58|68


SE|00000000||tx|1|text|Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.
SE|00000000||tx|1|entity|C0025638|Methenamine|orch,phsu|||Methenamine||||888|1|11
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||Urinary||||888|22|28
SE|00000000||tx|1|entity|C0504085|Body Excretions|bdsu|||excretion||||888|30|38
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||amphetamines||||1000|43|54
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|74|81
SE|00000000||tx|1|entity|C0304461|Acidifying preparation|phsu|||acidifying agents||||1000|98|114
SE|00000000||tx|1|entity|C0025638|Methenamine|orch,phsu|||methenamine||||888|124|134


SE|00000000||tx|1|text|In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|4|6
SE|00000000||tx|1|entity|C0038951|Surveys|inpr|||survey||||888|8|13
SE|00000000||tx|1|entity|C1519042|Phase II/III Trial|resa|||2.3%||||1000|16|19
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|24|31
SE|00000000||tx|1|entity|C0699440|Labetalol hydrochloride|orch,phsu|||labetalol HCl||||1000|40|52
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|57|67
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|74|98
SE|00000000||tx|1|entity|C0040822|Tremor|sosy|||tremor||||1000|112|117
SE|00000000||tx|1|entity|C0699440|Labetalol hydrochloride|orch,phsu|||labetalol HCl||||1000|163|175
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|177|181
SE|00000000||tx|1|relation|6|2|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|74|98|VERB|compared_with||123|130|2|1|C0699440|Labetalol hydrochloride|orch,phsu|orch|||labetalol HCl||||1000|163|175
SE|00000000||tx|1|relation|6|1|C0699440|Labetalol hydrochloride|orch,phsu|orch|||labetalol HCl||||1000|40|52|VERB|ADMINISTERED_TO||33|38|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|24|31


SE|00000000||tx|1|text|Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||Indinavir||||861|1|9
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||861|11|22
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||861|24|27
SE|00000000||tx|1|entity|C2827771|Cmin|qnco|||Cmin||||1000|39|42
SE|00000000||tx|1|entity|C0450361|38|inpr|||38%||||1000|67|69
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|98|108
SE|00000000||tx|1|entity|C0754188|Amprenavir|orch,phsu|||amprenavir||||888|110|119


SE|00000000||tx|1|text|A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day.
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|3|7
SE|00000000||tx|1|entity|C0205454|Eight|qnco|||eight||||890|12|16
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||890|18|35
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|53|60
SE|00000000||tx|1|entity|C0028094|Nimodipine|orch,phsu|||nimodipine||||790|75|84
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|86|91
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||peak nimodipine plasma concentrations||||790|70|106
SE|00000000||tx|1|entity|C0439083|>90|qnco|||90%||||888|114|116
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|118|125
SE|00000000||tx|1|entity|C0205146|Area|spco|||area||||861|135|138
SE|00000000||tx|1|entity|C0205134|Curved|spco|||curve||||1000|150|154
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||851|165|167
SE|00000000||tx|1|entity|C0439230|week|tmco|||week||||851|169|172
SE|00000000||tx|1|entity|C0750729|Course|tmco|||course||||851|174|179
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||660|184|193
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|204|209
SE|00000000||tx|1|entity|C0028094|Nimodipine|orch,phsu|||nimodipine||||1000|215|224
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|232|237


SE|00000000||tx|1|text|Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|10|20
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|22|24
SE|00000000||tx|1|entity|C0009079|Clozapine|orch,phsu|||Clozapine||||1000|29|37
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|43|55
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|60|62
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuation||||1000|101|115
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||851|120|130
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||851|132|144
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|178|185
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||890|200|205
SE|00000000||tx|1|entity|C0524086|Clozapine measurement|lbpr|||Clozapine plasma levels||||890|190|212


SE|00000000||tx|1|text|Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|12|18
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|43|58
SE|00000000||tx|1|entity|C0302350|Therapeutic|ftcn|||therapeutic||||888|71|81
SE|00000000||tx|1|entity|C1514721|Range|qnco|||range||||888|83|87
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|92|99
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|108|117
SE|00000000||tx|1|entity|C0023556|Levamisole|orch,phsu|||levamisole||||888|119|128
SE|00000000||tx|1|entity|C0376218|Warfarin Sodium|hops,orch,phsu|||warfarin sodium||||1000|134|148
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|176|191
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||1000|225|228
SE|00000000||tx|1|entity|C0376218|Warfarin Sodium|hops,orch,phsu|||warfarin sodium||||1000|233|247
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin||||1000|258|265
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|272|276
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|313|320
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|334|338
SE|00000000||tx|1|relation|0|0|C0376218|Warfarin Sodium|hops,orch,phsu|hops|||warfarin sodium||||1000|233|247|SPEC|ISA||233|265|0|0|C0010206|coumarin|orch,phsu|orch|||coumarin||||1000|258|265
SE|00000000||tx|1|relation|0|0|C0010206|coumarin|orch,phsu|orch|||coumarin||||1000|258|265|SPEC|ISA||233|265|0|0|C0376218|Warfarin Sodium|hops,orch,phsu|orch|||warfarin sodium||||1000|233|247
SE|00000000||tx|1|relation|9|1|C0023556|Levamisole|orch,phsu|orch|||levamisole||||888|119|128|VERB|ADMINISTERED_TO||101|106|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|92|99
SE|00000000||tx|1|relation|9|1|C0376218|Warfarin Sodium|hops,orch,phsu|orch|||warfarin sodium||||1000|134|148|VERB|ADMINISTERED_TO||101|106|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|92|99
SE|00000000||tx|1|relation|12|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|272|276|PREP|TREATS||310|311|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|313|320
SE|00000000||tx|1|relation|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|334|338|VERB|ADMINISTERED_TO||322|327|13|1|C0030705|Patients|podg,humn|humn|||patients||||1000|313|320


SE|00000000||tx|1|text|Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||Valproate||||1000|1|9
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|16|23
SE|00000000||tx|1|entity|C0068897|tiagabine|orch,phsu|||tiagabine||||1000|28|36
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|41|48
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||valproate||||861|57|65
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|86|91
SE|00000000||tx|1|entity|C0068897|tiagabine|orch,phsu|||tiagabine||||888|96|104
SE|00000000||tx|1|entity|C0031328|Pharmacokinetic aspects|ftcn|||pharmacokinetics||||888|106|121
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||valproate||||574|128|136
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decreased||||574|152|160
SE|00000000||tx|1|entity|C0068897|tiagabine|orch,phsu|||tiagabine||||574|162|170
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|230|237
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||888|242|254
SE|00000000||tx|1|entity|C0439509|/40|tmco|||40%||||888|256|258
SE|00000000||tx|1|entity|C1880497|Empty (qualifier)|qlco|||free||||623|267|270
SE|00000000||tx|1|entity|C0068897|tiagabine|orch,phsu|||tiagabine||||623|272|280
SE|00000000||tx|1|relation|7|1|C0080356|Valproate|lipd,phsu|lipd|||valproate||||861|57|65|VERB|ADMINISTERED_TO||50|55|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|41|48
SE|00000000||tx|1|relation|5|3|C0068897|tiagabine|orch,phsu|orch|||tiagabine||||1000|28|36|NOM|INTERACTS_WITH|negation|86|91|5|1|C0068897|tiagabine|orch,phsu|orch|||tiagabine||||888|96|104
SE|00000000||tx|1|relation|7|7|C0080356|Valproate|lipd,phsu|lipd|||Valproate||||1000|1|9|NOM|INTERACTS_WITH||172|178|7|0|C0068897|tiagabine|orch,phsu|orch|||tiagabine||||574|162|170


SE|00000000||tx|1|text|Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
SE|00000000||tx|1|entity|C0033607|Protease Inhibitor|bacs,phsu|||Protease inhibitors||||1000|1|19
SE|00000000||tx|1|entity|C0754188|Amprenavir|orch,phsu|||Amprenavir||||1000|22|31
SE|00000000||tx|1|entity|C0674432|lopinavir|orch,phsu|||lopinavir||||1000|34|42
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||nelfinavir||||1000|45|54
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|61|69
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|99|104
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||851|116|126
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||851|128|135
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||851|137|150


SE|00000000||tx|1|text|In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||888|4|9
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|11|20
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|32|43
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|68|77
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|93|97
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|99|107
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|141|146
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|158|169
SE|00000000||tx|1|relation|6|1|C0021246|Indomethacin|orch,phsu|orch|||indomethacin||||1000|32|43|VERB|ADMINISTERED_TO||22|30|1|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|11|20


SE|00000000||tx|1|text|Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
SE|00000000||tx|1|entity|C0876768|Vioxx|orch,phsu|||VIOXX||||1000|12|16
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|22|28
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||966|61|68
SE|00000000||tx|1|entity|C0311392|Physical findings|fndg|||signs||||1000|103|107
SE|00000000||tx|1|entity|C0238242|LITHIUM TOXICITY|inpo|||lithium toxicity||||1000|112|127
SE|00000000||tx|1|relation|3|2|C0023870|Lithium|elii,phsu|phsu|||lithium||||1000|22|28|PREP|TREATS||99|101|2|1|C0311392|Physical findings|fndg|fndg|||signs||||1000|103|107
SE|00000000||tx|1|relation|3|2|C0876768|Vioxx|orch,phsu|phsu|||VIOXX||||1000|12|16|PREP|TREATS||99|101|2|1|C0311392|Physical findings|fndg|fndg|||signs||||1000|103|107


SE|00000000||tx|1|text|Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.
SE|00000000||tx|1|entity|C0025598|Metformin|orch,phsu|||Metformin||||1000|1|9
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy subjects||||1000|15|30
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||775|38|43
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||775|52|56
SE|00000000||tx|1|entity|C0007716|Cephalexin|antb,orch|||cephalexin||||1000|61|70
SE|00000000||tx|1|entity|C0025598|Metformin|orch,phsu|||metformin||||1000|76|84
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||775|87|92
SE|00000000||tx|1|entity|C0025598|Metformin|orch,phsu|||metformin||||775|94|102
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||cmax||||775|109|112
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|118|120
SE|00000000||tx|1|entity|C1510992|Average|qnco|||average||||1000|138|144
SE|00000000||tx|1|entity|C0025598|Metformin|orch,phsu|||metformin||||775|180|188
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||775|195|199
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||775|201|209


SE|00000000||tx|1|text|Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||861|4|14
SE|00000000||tx|1|entity|||gngm|9360|PPIG|CYP||||1000|28|30
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampicin||||1000|43|52
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|55|63
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|66|78
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|81|93
SE|00000000||tx|1|entity|C0936242|Hypericum perforatum|plnt|||St. John s wort||||923|99|113
SE|00000000||tx|1|entity|C0851344|exemestane|phsu,strd|||exemestane||||1000|155|164


SE|00000000||tx|1|text|Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.
SE|00000000||tx|1|entity|C0032950|prednisolone|phsu,strd|||Prednisolone||||1000|1|12
SE|00000000||tx|1|entity|C0015011|Ethinyl Estradiol|horm,phsu,strd|||Ethinyl estradiol||||1000|15|31
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|49|58
SE|00000000||tx|1|entity|C0032950|prednisolone|phsu,strd|||prednisolone||||1000|63|74
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||890|88|96
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|98|118
SE|00000000||tx|1|relation|2|1|C0015011|Ethinyl Estradiol|horm,phsu,strd|horm|||Ethinyl estradiol||||1000|15|31|VERB|INHIBITS||37|43|3|2|C0032950|prednisolone|phsu,strd|phsu|||prednisolone||||1000|63|74


SE|00000000||tx|1|text|The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|5|8
SE|00000000||tx|1|entity|C0546852|2-Bromoergocryptine Mesylate|orch,phsu|||bromocriptine mesylate||||1000|19|40
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|45|55
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|68|72
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|78|80
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|117|123
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||1000|144|155
SE|00000000||tx|1|entity|C0546852|2-Bromoergocryptine Mesylate|orch,phsu|||bromocriptine mesylate||||1000|160|181
SE|00000000||tx|1|relation|0|0|C0546852|2-Bromoergocryptine Mesylate|orch,phsu|orch|||bromocriptine mesylate||||1000|19|40|SPEC|ISA||19|72|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|68|72


SE|00000000||tx|1|text|Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
SE|00000000||tx|1|entity|C0007412|Catecholamines|nsba,orch,phsu|||Catecholamine||||840|1|13
SE|00000000||tx|1|entity|C0333668|Depletion|ftcn|||depleting||||840|15|23
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||840|25|29
SE|00000000||tx|1|entity|C0035179|Reserpine|orch,phsu|||reserpine||||1000|38|46
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|61|68
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|70|75
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blocking agents||||983|93|112
SE|00000000||tx|1|relation|1|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blocking agents||||983|93|112|VERB|COEXISTS_WITH||82|86|3|3|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||840|25|29


SE|00000000||tx|1|text|In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.
SE|00000000||tx|1|entity|C0009951|Convulsions|sosy|||convulsions||||861|16|26
SE|00000000||tx|1|entity|C0015021|Ethionamide|orch,phsu|||ethionamide||||1000|52|62
SE|00000000||tx|1|entity|C0010590|Cycloserine|aapp,antb|||cycloserine||||1000|85|95
SE|00000000||tx|1|entity|C0205555|Special|qlco|||special||||694|101|107
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||treatment regimen||||1000|139|155
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|180|184


SE|00000000||tx|1|text|This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|6|13
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|29|38
SE|00000000||tx|1|entity|C0538927|celecoxib|orch,phsu|||celecoxib||||888|43|51
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|53|62
SE|00000000||tx|1|entity|||gngm|1555|CYP2B6|P450||||694|68|71
SE|00000000||tx|1|entity|C0016277|Fluconazole|orch,phsu|||fluconazole||||1000|80|90
SE|00000000||tx|1|entity|C0031332|Clinical pharmacology discipline|bmod|||CLINICAL PHARMACOLOGY||||901|97|117
SE|00000000||tx|1|entity|C0031328|Pharmacokinetic aspects|ftcn|||Pharmacokinetics||||901|121|136
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||Metabolism||||1000|139|148
SE|00000000||tx|1|relation|5|3|C0016277|Fluconazole|orch,phsu|orch|||fluconazole||||1000|80|90|NOM|INHIBITS||29|38|5|1|C0538927|celecoxib|orch,phsu|orch|||celecoxib||||888|43|51


SE|00000000||tx|1|text|Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|1|10
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|15|24
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|27|37
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|57|66
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|71|80
SE|00000000||tx|1|entity|C0012132|Zalcitabine|nnon,phsu|||zalcitabine||||1000|111|121
SE|00000000||tx|1|entity|C0332148|Probable diagnosis|qlco|||likely||||1000|129|134
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|139|148
SE|00000000||tx|1|entity|C0678876|renal tubular secretion|ortf|||renal tubular secretion||||1000|153|175
SE|00000000||tx|1|entity|C0012132|Zalcitabine|nnon,phsu|||zalcitabine||||1000|180|190
SE|00000000||tx|1|relation|2|2|C0012132|Zalcitabine|nnon,phsu|phsu|||zalcitabine||||1000|180|190|NOM|INHIBITS||139|148|2|1|C0678876|renal tubular secretion|ortf|ortf|||renal tubular secretion||||1000|153|175


SE|00000000||tx|1|text|In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|6|10
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|21|28
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||694|35|40
SE|00000000||tx|1|entity|C0439230|week|tmco|||weeks||||861|71|75
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|82|91
SE|00000000||tx|1|entity|C0720193|Enbrel|aapp,phsu|||ENBREL||||888|93|98
SE|00000000||tx|1|entity|C0245109|anakinra|aapp,phsu|||anakinra||||888|105|112
SE|00000000||tx|1|entity|C1521828|Rate|qnco|||rate||||861|128|131
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||888|136|142
SE|00000000||tx|1|entity|C0021311|Infection|dsyn|||infections||||888|144|153
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||966|179|184
SE|00000000||tx|1|entity|C0720193|Enbrel|aapp,phsu|||ENBREL||||1000|210|215
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|218|222
SE|00000000||tx|1|relation|7|1|C0720193|Enbrel|aapp,gngm,phsu|aapp|||ENBREL||||888|93|98|PREP|PART_OF||77|80|4|3|C0030705|Patients|podg,humn|humn|||patients||||1000|21|28
SE|00000000||tx|1|relation|7|1|C0245109|anakinra|aapp,gngm,phsu|aapp|||anakinra||||888|105|112|PREP|PART_OF||77|80|4|3|C0030705|Patients|podg,humn|humn|||patients||||1000|21|28
SE|00000000||tx|1|relation|2|1|C0720193|Enbrel|aapp,gngm,phsu|aapp|||ENBREL||||1000|210|215|PREP|PART_OF||205|208|9|8|C0030705|Patients|podg,humn|humn|||patients||||1000|21|28


SE|00000000||tx|1|text|The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|35|44
SE|00000000||tx|1|entity|C0028365|Norfloxacin|orch,phsu|||norfloxacin||||1000|56|66
SE|00000000||tx|1|entity|C0017628|Glyburide|orch,phsu|||glyburide||||1000|73|81
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agent||||861|99|103
SE|00000000||tx|1|entity|C0521114|Infrequent|tmco|||rare||||847|114|117
SE|00000000||tx|1|entity|C0521114|Infrequent|tmco|||occasions||||847|119|127
SE|00000000||tx|1|entity|C0020615|Hypoglycemia|dsyn|||hypoglycemia||||861|149|160
SE|00000000||tx|1|relation|6|3|C0017628|Glyburide|orch,phsu|orch|||glyburide||||1000|73|81|VERB|CAUSES||130|137|1|1|C0020615|Hypoglycemia|dsyn|dsyn|||hypoglycemia||||861|149|160


SE|00000000||tx|1|text|Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.
SE|00000000||tx|1|entity|C0171023|olanzapine|orch,phsu|||Olanzapine||||1000|1|10
SE|00000000||tx|1|entity|C1577190|Eszopiclone 3 MG|clnd|||eszopiclone 3 mg||||1000|33|48
SE|00000000||tx|1|entity|C0988260|olanzapine 10 MG|clnd|||olanzapine 10 mg||||1000|54|69
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|82|89
SE|00000000||tx|1|entity|C0814254|Digit Symbol Substitution Test|inpr|||DSST||||888|94|97
SE|00000000||tx|1|entity|C0449820|Score|qnco|||scores||||888|99|104


SE|00000000||tx|1|text|Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|6|15
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|28|40
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|86|95
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|100|107
SE|00000000||tx|1|relation|2|1|C0008809|Ciprofloxacin|orch,phsu|orch|||ciprofloxacin||||1000|28|40|VERB|DISRUPTS||67|75|2|1|C0025519|Metabolism|orgf|orgf|||metabolism||||1000|86|95


SE|00000000||tx|1|text|In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|6|10
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy subjects||||1000|22|37
SE|00000000||tx|1|entity|C0592158|Tambocor|orch,phsu|||TAMBOCOR||||1000|49|56
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||861|62|72
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||623|88|93
SE|00000000||tx|1|entity|C0016229|Flecainide|orch,phsu|||flecainide||||623|95|104
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||694|142|152
SE|00000000||tx|1|entity|C0042295|Values|qlco|||values||||802|206|211


SE|00000000||tx|1|text|This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.
SE|00000000||tx|1|entity|C1441672|Observed|ftcn|||observed||||888|6|13
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|15|22
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|31|45
SE|00000000||tx|1|entity|C0296800|fexofenadine|orch,phsu|||fexofenadine||||1000|50|61
SE|00000000||tx|1|entity|C0163712|Relate - vinyl resin|orch|||related||||790|87|93
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||790|95|101
SE|00000000||tx|1|entity|C0242643|P-Glycoprotein|aapp,bacs|||p-glycoprotein||||1000|112|125
SE|00000000||tx|1|entity|C0683949|Animal Study|anim|||animal studies||||861|136|149
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|206|217
SE|00000000||tx|1|entity|C0296800|fexofenadine|orch,phsu|||fexofenadine||||851|229|240
SE|00000000||tx|1|entity|C2707256|Gastrointestinal:-:Point in time:^Patient:-|clna|||gastrointestinal||||851|242|257
SE|00000000||tx|1|entity|C0036537|Bodily secretions|bdsu|||secretion||||851|259|267
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|276|287
SE|00000000||tx|1|entity|C0521378|Biliary|ftcn|||biliary||||888|307|313
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|315|323
SE|00000000||tx|1|relation|3|1|C0296800|fexofenadine|orch,phsu|orch|||fexofenadine||||1000|50|61|NOM|INTERACTS_WITH||95|101|3|0|C0163712|Relate - vinyl resin|orch|orch|||related||||790|87|93


SE|00000000||tx|1|text|Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|20|30
SE|00000000||tx|1|entity|C0024027|Lovastatin|orch,phsu|||lovastatin||||888|32|41
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|47|58
SE|00000000||tx|1|relation|2|1|C0024027|Lovastatin|orch,phsu|orch|||lovastatin||||888|32|41|VERB|ADMINISTERED_TO||10|18|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8


SE|00000000||tx|1|text|Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin;
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|42|52
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||1000|72|83
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|89|97
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|113|122
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|127|135
SE|00000000||tx|1|relation|4|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|89|97|VERB|INTERACTS_WITH||103|107|2|2|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|127|135


SE|00000000||tx|1|text|Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.
SE|00000000||tx|1|entity|C1548787|Appropriate|qlco|||Appropriate||||901|1|11
SE|00000000||tx|1|entity|C0022885|Laboratory Procedures|lbpr|||laboratory testing||||901|13|30
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiating||||890|62|71
SE|00000000||tx|1|entity|C0009429|Combined Modality Therapy|topp|||combination therapy||||890|73|91
SE|00000000||tx|1|entity|C0754188|Amprenavir|orch,phsu|||Amprenavir||||1000|98|107
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|113|121
SE|00000000||tx|1|entity|C0332182|Periodic|tmco|||periodic||||888|130|137
SE|00000000||tx|1|entity|C1272706|Interval|tmco|||intervals||||888|139|147
SE|00000000||tx|1|entity|C0205210|Clinical|qlco|||clinical||||888|159|166
SE|00000000||tx|1|entity|C0311392|Physical findings|fndg|||signs||||888|168|172
SE|00000000||tx|1|entity|C1457887|Symptoms|sosy|||symptoms||||1000|177|184
SE|00000000||tx|1|entity|C0020473|Hyperlipidemia|dsyn|||hyperlipidemia||||1000|189|202
SE|00000000||tx|1|entity|C0877359|Elevated liver function tests|fndg|||elevated liver function tests||||1000|207|235
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|250|256
SE|00000000||tx|1|relation|2|1|C0009429|Combined Modality Therapy|topp|topp|||combination therapy||||890|73|91|PREP|USES||93|96|9|1|C0754188|Amprenavir|orch,phsu|phsu|||Amprenavir||||1000|98|107


SE|00000000||tx|1|text|There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||1000|10|12
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|41|51
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|53|55
SE|00000000||tx|1|entity|C0282369|Trazodone Hydrochloride|orch,phsu|||trazodone hydrochloride||||1000|60|82
SE|00000000||tx|1|entity|C0701914|Desyrel|orch,phsu|||Desyrel||||1000|85|91
SE|00000000||tx|1|entity|C0700444|buspirone hydrochloride|orch,phsu|||buspirone HCl||||1000|98|110
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||790|136|139
SE|00000000||tx|1|entity|C0702240|Elevation|spco|||elevations||||790|141|150
SE|00000000||tx|1|entity|C0001899|Alanine Transaminase|aapp,enzy|||ALT||||966|161|163
SE|00000000||tx|1|entity|C0205388|Few|qnco|||few||||888|171|173
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|175|182
SE|00000000||tx|1|relation|0|0|C0701914|Desyrel|orch,phsu|orch|||Desyrel||||1000|85|91|SPEC|ISA||60|91|0|0|C0282369|Trazodone Hydrochloride|orch,phsu|orch|||trazodone hydrochloride||||1000|60|82
SE|00000000||tx|1|relation|8|4|C0700444|buspirone hydrochloride|orch,phsu|phsu|||buspirone HCl||||1000|98|110|PREP|TREATS||166|167|1|1|C0030705|Patients|podg,humn|podg|||patients||||888|175|182
SE|00000000||tx|1|relation|8|4|C0701914|Desyrel|orch,phsu|phsu|||Desyrel||||1000|85|91|PREP|TREATS||166|167|1|1|C0030705|Patients|podg,humn|podg|||patients||||888|175|182


SE|00000000||tx|1|text|Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||Tricyclic antidepressants||||1000|1|25
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|59|69
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|71|76
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||888|81|88
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||888|90|98
SE|00000000||tx|1|relation|2|2|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||Tricyclic antidepressants||||1000|1|25|NOM|INTERACTS_WITH||71|76|1|1|C0009014|Clonidine|orch,phsu|orch|||clonidine||||888|90|98


SE|00000000||tx|1|text|Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||Interactions||||966|1|12
SE|00000000||tx|1|entity|C0682770|agonists and antagonists|phsu|||Agonist/Antagonist||||826|25|42
SE|00000000||tx|1|entity|C0002772|Analgesics, Opioid|orch,phsu|||Opioid Analgesics||||826|44|60
SE|00000000||tx|1|entity|C0682770|agonists and antagonists|phsu|||Agonist/antagonist||||901|63|80
SE|00000000||tx|1|entity|C0002771|Analgesics|phsu|||analgesics||||901|82|91
SE|00000000||tx|1|entity|C0030873|Pentazocine|orch,phsu|||pentazocine||||1000|98|108
SE|00000000||tx|1|entity|C0027348|Nalbuphine|orch,phsu|||nalbuphine||||1000|111|120
SE|00000000||tx|1|entity|C0006491|Butorphanol|orch,phsu|||butorphanol||||1000|123|133
SE|00000000||tx|1|entity|C0057626|dezocine|orch,phsu|||dezocine||||1000|136|143
SE|00000000||tx|1|entity|C0006405|Buprenorphine|orch,phsu|||buprenorphine||||1000|149|161
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||NOT||||1000|171|173
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|196|202
SE|00000000||tx|1|entity|C0750729|Course|tmco|||course||||1000|239|244
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|249|255
SE|00000000||tx|1|entity|C2247561|5-(carboxyamino)imidazole ribonucleotide mutase activity|moft|||pure||||861|264|267
SE|00000000||tx|1|entity|C2987634|Agonist|phsu|||agonist||||861|269|275
SE|00000000||tx|1|entity|C0002772|Analgesics, Opioid|orch,phsu|||opioid analgesic||||861|277|292
SE|00000000||tx|1|entity|C1450007|Levo-Dromoran|orch,phsu|||Levo-Dromoran||||1000|302|314
SE|00000000||tx|1|relation|0|0|C1450007|Levo-Dromoran|orch,phsu|orch|||Levo-Dromoran||||1000|302|314|SPEC|ISA||277|314|0|0|C0002772|Analgesics, Opioid|orch,phsu|orch|||opioid analgesic||||861|277|292
SE|00000000||tx|1|relation|9|7|C0002771|Analgesics|phsu|phsu|||analgesics||||901|82|91|VERB|ADMINISTERED_TO||178|189|5|1|C0030705|Patients|podg,humn|humn|||patient||||1000|196|202
SE|00000000||tx|1|relation|12|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||1000|249|255|PREP|USES||257|260|2|1|C0002772|Analgesics, Opioid|orch,phsu|phsu|||opioid analgesic||||861|277|292
SE|00000000||tx|1|relation|0|0|C0087111|Therapeutic procedure|topp|topp|||therapy||||1000|249|255|INFER|USES(SPEC)||277|314|0|0|C1450007|Levo-Dromoran|orch,phsu|orch|||Levo-Dromoran||||1000|302|314


SE|00000000||tx|1|text|Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;
SE|00000000||tx|1|entity|C0003968|Ascorbic Acid|orch,phsu,vita|||Ascorbic acid||||1000|1|13
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||Doses||||1000|16|20
SE|00000000||tx|1|entity|C0003968|Ascorbic Acid|orch,phsu,vita|||ascorbic acid||||1000|25|37
SE|00000000||tx|1|entity|C0003968|Ascorbic Acid|orch,phsu,vita|||vitamin C||||1000|40|48
SE|00000000||tx|1|entity|C1442449|1 Day|tmco|||1 g/day||||901|51|57
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||1000|90|109
SE|00000000||tx|1|entity|C0014941|Estrogens, Synthetic|orch,phsu|||synthetic estrogens||||1000|114|132
SE|00000000||tx|1|entity|C2362652|Possible diagnosis|qlco|||possibly||||1000|143|150
SE|00000000||tx|1|entity|C0021469|Metabolic Inhibition|moft|||inhibiting||||888|155|164
SE|00000000||tx|1|entity|C1160466|conjugation|celf|||conjugation||||888|166|176
SE|00000000||tx|1|relation|5|3|C0003968|Ascorbic Acid|orch,phsu,vita|orch|||ascorbic acid||||1000|25|37|VERB|STIMULATES||81|88|3|2|C0014941|Estrogens, Synthetic|orch,phsu|orch|||synthetic estrogens||||1000|114|132


SE|00000000||tx|1|text|Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||Multiple-||||851|1|9
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||851|10|13
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||741|37|42
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||741|44|49
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||741|59|66
SE|00000000||tx|1|entity|C1442770|24 Hours|tmco|||24 hours||||1000|82|89
SE|00000000||tx|1|entity|C1275548|Every twenty four hours|tmco|||q24h||||1000|92|95
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|105|108
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduced||||851|121|127
SE|00000000||tx|1|entity|C0251504|zaleplon|orch,phsu|||zaleplon||||851|129|136
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||851|138|141
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|147|149
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|154|166


SE|00000000||tx|1|text|Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0445550|Low dose|qnco|||low-dose||||888|30|37
SE|00000000||tx|1|entity|C0282151|Dopamine Hydrochloride|nsba,orch,phsu|||dopamine HCl||||888|39|50
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||872|56|63
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||872|65|70
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||1000|87|94
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|112|117
SE|00000000||tx|1|entity|C0042036|Urine|bdsu|||urine||||888|122|126
SE|00000000||tx|1|entity|C0806140|Flow|npop|||flow||||888|128|131
SE|00000000||tx|1|relation|0|0|C0012798|Diuretics|phsu|phsu|||diuretic||||872|56|63|MOD/HEAD|ISA||56|70|0|0|C1254351|Pharmacologic Substance|phsu|phsu|||agents||||872|65|70


SE|00000000||tx|1|text|Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|1|10
SE|00000000||tx|1|entity|C0026458|Monobactams|antb,orch|||lactam antibiotics||||901|29|46
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|49|58
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|73|77
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|79|87
SE|00000000||tx|1|entity|C0060405|cefdinir|antb,orch|||cefdinir||||1000|92|99
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximate||||888|118|128
SE|00000000||tx|1|entity|C0205173|Duplicate|ftcn|||doubling||||888|130|137
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|153|160
SE|00000000||tx|1|entity|C0060405|cefdinir|antb,orch|||cefdinir||||852|170|177
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||852|179|184
SE|00000000||tx|1|entity|C0444505|Peak level|qnco|||peak cefdinir plasma levels||||852|165|191
SE|00000000||tx|1|entity|C0750489|apparent|idcn|||apparent||||916|224|231
SE|00000000||tx|1|entity|C2348397|Elimination Half Life|qnco|||elimination half-life||||916|233|253
SE|00000000||tx|1|relation|3|1|C0033209|Probenecid|orch,phsu|orch|||probenecid||||1000|49|58|VERB|DISRUPTS||60|67|8|1|C0221102|Excretory function|phsf|phsf|||excretion||||888|79|87


SE|00000000||tx|1|text|Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||Aspirin||||1000|1|7
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|10|20
SE|00000000||tx|1|entity|C2608320|Low-Dose Aspirin|orch,phsu|||low-dose aspirin||||1000|40|55
SE|00000000||tx|1|entity|C0876768|Vioxx|orch,phsu|||VIOXX||||1000|62|66
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|85|93
SE|00000000||tx|1|entity|C1521828|Rate|qnco|||rate||||888|95|98
SE|00000000||tx|1|entity|C0041582|Ulcer|patf|||ulceration||||861|106|115
SE|00000000||tx|1|entity|C0009566|Complication|patf|||complications||||1000|126|138
SE|00000000||tx|1|entity|C0876768|Vioxx|orch,phsu|||VIOXX||||1000|160|164
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|166|170


SE|00000000||tx|1|text|therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||nelfinavir||||1000|12|21
SE|00000000||tx|1|entity|C0016452|Food|food|||food||||1000|52|55
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|58|60
SE|00000000||tx|1|entity|C0564385|/hour|qnco|||hour||||888|62|65
SE|00000000||tx|1|entity|C0205172|More|ftcn|||more||||1000|76|79
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||888|86|88
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||888|90|94
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||1000|103|112


SE|00000000||tx|1|text|MAO inhibitors prolong and intensify the effects of antihistamines.
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|1|14
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|42|48
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|53|66


SE|00000000||tx|1|text|Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||Clearance||||1000|1|9
SE|00000000||tx|1|entity|C0671572|hydrodolasetron|orch|||hydrodolasetron||||1000|14|28
SE|00000000||tx|1|entity|C0065818|dolasetron mesylate|orch,phsu|||dolasetron mesylate||||1000|58|76
SE|00000000||tx|1|entity|C0004147|Atenolol|orch,phsu|||atenolol||||1000|128|135


SE|00000000||tx|1|text|Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic blocking agents||||1000|20|50
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||861|70|73
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||884|78|88
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium antagonists||||884|90|108
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||916|134|141
SE|00000000||tx|1|entity|C1834655|Atrioventricular conduction disturbances|fndg|||atrioventricular conduction disturbances||||916|143|182
SE|00000000||tx|1|entity|C0023212|Left-Sided Heart Failure|dsyn|||left ventricular failure||||1000|185|208
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||1000|214|224
SE|00000000||tx|1|relation|6|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-adrenergic blocking agents||||1000|20|50|VERB|ADMINISTERED_TO||10|18|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8
SE|00000000||tx|1|relation|4|1|C0006684|Calcium Channel Blockers|phsu|phsu|||calcium antagonists||||884|90|108|PREP|TREATS||130|132|3|1|C1834655|Atrioventricular conduction disturbances|fndg|fndg|||atrioventricular conduction disturbances||||916|143|182
SE|00000000||tx|1|relation|4|1|C0006684|Calcium Channel Blockers|phsu|phsu|||calcium antagonists||||884|90|108|PREP|TREATS||130|132|3|1|C0020649|Hypotension|fndg|fndg|||hypotension||||1000|214|224
SE|00000000||tx|1|relation|4|1|C0006684|Calcium Channel Blockers|phsu|phsu|||calcium antagonists||||884|90|108|PREP|TREATS||130|132|3|1|C0023212|Left-Sided Heart Failure|dsyn|dsyn|||left ventricular failure||||1000|185|208


SE|00000000||tx|1|text|Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.
SE|00000000||tx|1|entity|C0042845|Vitamin B 12|orch,phsu,vita|||vitamin B12||||916|34|44
SE|00000000||tx|1|entity|C0242295|Dietary Supplements|food|||supplement||||916|46|55
SE|00000000||tx|1|entity|C0030125|aminosalicylic acid|orch,phsu|||aminosalicylic acid||||1000|70|88


SE|00000000||tx|1|text|In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||757|6|11
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subject||||757|13|19
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||757|27|29
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||757|31|34
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||802|39|51
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||802|55|59
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||1000|69|72
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||851|77|86
SE|00000000||tx|1|entity|C0032042|Placebos|topp|||placebo||||851|88|94
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||851|96|102
SE|00000000||tx|1|entity|C1704243|Greater|qnco|||greater||||1000|107|113
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||861|124|132
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|141|143
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|148|160


SE|00000000||tx|1|text|It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|7|9
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|24|30
SE|00000000||tx|1|entity|C0006491|Butorphanol|orch,phsu|||butorphanol||||1000|35|45
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|62|72
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||888|74|84
SE|00000000||tx|1|entity|C0205054|Hepatic|blor|||hepatic||||888|98|104
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|106|115
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|120|124
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|127|138
SE|00000000||tx|1|entity|C1548556|etc.|idcn|||etc||||1000|141|143
SE|00000000||tx|1|entity|C0031831|Physicians|prog|||physicians||||1000|152|161
SE|00000000||tx|1|entity|C0239110|Consciousness clear|fndg|||alert||||1000|173|177
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||smaller||||851|205|211
SE|00000000||tx|1|entity|C1279901|Firstly|qlco|||initial||||851|213|219
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||851|221|224
SE|00000000||tx|1|entity|C0205166|Long|qlco|||longer||||872|230|235
SE|00000000||tx|1|entity|C1272706|Interval|tmco|||intervals||||872|237|245
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||1000|255|259
SE|00000000||tx|1|relation|0|0|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|127|138|SPEC|ISA||120|138|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|120|124
SE|00000000||tx|1|relation|12|5|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|127|138|NOM|INTERACTS_WITH||24|30|12|1|C0006491|Butorphanol|orch,phsu|orch|||butorphanol||||1000|35|45
SE|00000000||tx|1|relation|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||888|74|84|VERB|INTERACTS_WITH||91|96|10|2|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|120|124
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||888|74|84|INFER|INTERACTS_WITH(SPEC)||120|138|0|0|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|127|138


SE|00000000||tx|1|text|Gentamicin - Methionine may protect against the ototoxic effects of gentamicin.
SE|00000000||tx|1|entity|C0017436|Gentamicins|antb,carb|||Gentamicin||||888|1|10
SE|00000000||tx|1|entity|C0025646|Methionine|aapp,bacs,phsu|||Methionine||||888|14|23
SE|00000000||tx|1|entity|C0235280|Ototoxicity|inpo|||ototoxic||||853|49|56
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||853|58|64
SE|00000000||tx|1|entity|C0017436|Gentamicins|antb,carb|||gentamicin||||1000|69|78
SE|00000000||tx|1|relation|1|1|C0025646|Methionine|aapp,gngm,bacs,phsu|aapp|||Methionine||||888|14|23|NOM|INTERACTS_WITH||58|64|1|1|C0017436|Gentamicins|antb,carb|antb|||gentamicin||||1000|69|78


SE|00000000||tx|1|text|Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||adrenaline||||1000|58|67
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|72|79
SE|00000000||tx|1|entity|C0701981|Fluothane|orch,phsu|||FLUOTHANE||||1000|100|108
SE|00000000||tx|1|entity|C0003811|Cardiac Arrhythmia|patf|||arrhythmias||||1000|113|123
SE|00000000||tx|1|relation|4|1|C0014563|Epinephrine|horm,nsba,orch,phsu|horm|||adrenaline||||1000|58|67|NOM|ADMINISTERED_TO||40|53|4|2|C0030705|Patients|podg,humn|humn|||patients||||1000|72|79


SE|00000000||tx|1|text|However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|10|16
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|31|36
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|72|77
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitors||||1000|82|95


SE|00000000||tx|1|text|d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
SE|00000000||tx|1|entity|C0011812|Dextroamphetamine|orch,phsu|||d-amphetamine||||1000|1|13
SE|00000000||tx|1|entity|C0011685|Desipramine|orch,phsu|||desipramine||||1000|20|30
SE|00000000||tx|1|entity|C0033743|Protriptyline|orch,phsu|||protriptyline||||1000|35|47
SE|00000000||tx|1|entity|C2362652|Possible diagnosis|qlco|||possibly||||1000|53|60
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclics||||1000|68|77
SE|00000000||tx|1|entity|C0443318|Sustained|ftcn|||sustained||||888|98|106
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||888|108|116
SE|00000000||tx|1|entity|C0011812|Dextroamphetamine|orch,phsu|||d-amphetamine||||1000|142|154
SE|00000000||tx|1|entity|C0006104|Brain|bpoc|||brain||||1000|163|167
SE|00000000||tx|1|relation|3|2|C0011812|Dextroamphetamine|orch,phsu|orch|||d-amphetamine||||1000|142|154|NOM|AUGMENTS||108|116|3|3|C0006104|Brain|bpoc|bpoc|||brain||||1000|163|167


SE|00000000||tx|1|text|Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.
SE|00000000||tx|1|entity|C1997138|Blunted|qlco|||Blunting||||966|1|8
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|34|39
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenoceptor blocking agents||||988|44|76
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||non-steroidal antiinflammatory drugs||||991|81|116
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|128|134
SE|00000000||tx|1|relation|3|2|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||non-steroidal antiinflammatory drugs||||991|81|116|NOM|INTERACTS_WITH||34|39|3|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-adrenoceptor blocking agents||||988|44|76


SE|00000000||tx|1|text|Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||694|14|20
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|35|40
SE|00000000||tx|1|entity|C0700323|Observation of Neuromuscular Block|dsyn|||neuromuscular blockade||||1000|67|88
SE|00000000||tx|1|entity|C0010464|Neuromuscular Nondepolarizing Agents|phsu|||non-depolarizing muscle relaxants||||1000|113|145
SE|00000000||tx|1|entity|C0031955|Piperacillin|antb,orch|||piperacillin||||1000|185|196
SE|00000000||tx|1|relation|4|1|C0010464|Neuromuscular Nondepolarizing Agents|phsu|phsu|||non-depolarizing muscle relaxants||||1000|113|145|NOM|COEXISTS_WITH||173|180|1|1|C0031955|Piperacillin|antb,orch|antb|||piperacillin||||1000|185|196


SE|00000000||tx|1|text|The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.
SE|00000000||tx|1|entity|C0360528|Oral form dexamethasone|clnd|||oral dexamethasone||||901|5|22
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||901|24|28
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|51|63
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|94|103
SE|00000000||tx|1|entity|C0728853|Accident due to exposure to weather conditions|phpr|||exposures||||1000|117|125
SE|00000000||tx|1|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||1000|130|142
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||1000|144|150
SE|00000000||tx|1|entity|C1301820|Obtain|ftcn|||obtained||||1000|161|168
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|195|204


SE|00000000||tx|1|text|Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||Beta blockers||||1000|1|13
SE|00000000||tx|1|entity|C0520540|Rebound hypertension|dsyn|||rebound hypertension||||1000|34|53
SE|00000000||tx|1|entity|C2349954|Withdraw (activity)|acty|||withdrawal||||1000|76|85
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||1000|90|98
SE|00000000||tx|1|relation|1|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||Beta blockers||||1000|1|13|VERB|AFFECTS||19|28|3|1|C0520540|Rebound hypertension|dsyn|dsyn|||rebound hypertension||||1000|34|53


SE|00000000||tx|1|text|Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.
SE|00000000||tx|1|entity|C0132326|Nevirapine|nnon,phsu|||Nevirapine||||1000|1|10
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|16|27
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||645|36|38
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||694|89|100
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|138|145
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||1000|154|157
SE|00000000||tx|1|relation|4|3|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|16|27|VERB|INHIBITS||127|132|2|2|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||1000|154|157
SE|00000000||tx|1|relation|4|3|C0132326|Nevirapine|nnon,phsu|phsu|||Nevirapine||||1000|1|10|VERB|INHIBITS||127|132|2|2|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||1000|154|157


SE|00000000||tx|1|text|FLEXERIL may have life-threatening interactions with MAO inhibitors.
SE|00000000||tx|1|entity|C0728797|Flexeril|orch,phsu|||FLEXERIL||||1000|1|8
SE|00000000||tx|1|entity|C2826244|Life Threatening|fndg|||life-threatening||||884|19|34
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interactions||||884|36|47
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|54|67


SE|00000000||tx|1|text|Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||Nonsteroidal Anti-inflammatory Drugs||||1000|1|36
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|52|62
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti inflammatory drug||||1000|84|118
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolone||||1000|127|135
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risks||||1000|154|158
SE|00000000||tx|1|entity|C0151560|Central nervous system stimulation (procedure)|topp|||CNS stimulation||||1000|163|177
SE|00000000||tx|1|entity|C0009951|Convulsions|sosy|||convulsions||||1000|183|193


SE|00000000||tx|1|text|Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.
SE|00000000||tx|1|entity|C0000981|Acetazolamide|orch,phsu|||Acetazolamide||||1000|1|13
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||urinary||||888|25|31
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|33|41
SE|00000000||tx|1|entity|C0002658|Amphetamine|nsba,orch,phsu|||amphetamine||||1000|46|56
SE|00000000||tx|1|entity|C1704240|Magnitude|qnco|||magnitude||||1000|78|86
SE|00000000||tx|1|entity|C2926735|Duration|phsu|||duration||||1000|92|99
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|110|115


SE|00000000||tx|1|text|Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||Ritonavir||||1000|1|9
SE|00000000||tx|1|entity|C0439423|Milligram per 24 Hours|qnco|||mg b.i.d.||||790|16|24
SE|00000000||tx|1|entity|C1176941|vardenafil 5 MG|clnd|||Vardenafil 5 mg||||1000|48|62
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||790|81|84
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||790|86|93
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||vardenafil||||888|98|107
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|109|111
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||790|122|125
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||790|127|134
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||vardenafil||||888|139|148
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||888|150|153


SE|00000000||tx|1|text|If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.
SE|00000000||tx|1|entity|C0028066|Nifedipine|orch,phsu|||nifedipine||||851|4|13
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||888|41|47
SE|00000000||tx|1|entity|C0521116|Current (present time)|tmco|||currently||||888|49|57
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|69|78
SE|00000000||tx|1|relation|2|1|C0008783|Cimetidine|orch,phsu|orch|||cimetidine||||1000|69|78|VERB|ADMINISTERED_TO||59|67|2|1|C0030705|Patients|podg,humn|humn|||patient||||888|41|47


SE|00000000||tx|1|text|Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.
SE|00000000||tx|1|entity|C0020261|Hydrochlorothiazide|orch,phsu|||Hydrochlorothiazide||||1000|1|19
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||888|25|30
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|32|41
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|44|54
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|74|83
SE|00000000||tx|1|entity|C0020261|Hydrochlorothiazide|orch,phsu|||hydrochlorothiazide||||1000|89|107
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||750|135|143
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||750|145|150
SE|00000000||tx|1|entity|C0020261|Hydrochlorothiazide|orch,phsu|||hydrochlorothiazide||||1000|162|180
SE|00000000||tx|1|relation|1|1|C0020261|Hydrochlorothiazide|orch,phsu|phsu|||Hydrochlorothiazide||||1000|1|19|PREP|TREATS||22|23|6|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|32|41
SE|00000000||tx|1|relation|1|1|C0020261|Hydrochlorothiazide|orch,phsu|phsu|||hydrochlorothiazide||||1000|89|107|PREP|TREATS||22|23|6|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|32|41


SE|00000000||tx|1|text|Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||Central Nervous System Depressants||||1000|1|34
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|41|51
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|53|55
SE|00000000||tx|1|entity|C0591423|Duragesic|orch,phsu|||DURAGESIC||||1000|60|68
SE|00000000||tx|1|entity|C0015846|Fentanyl|orch,phsu|||fentanyl||||851|72|79
SE|00000000||tx|1|entity|C0694643|transdermal|spco|||transdermal||||851|81|91
SE|00000000||tx|1|entity|C0449913|System|ftcn|||system||||851|93|98
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||central nervous system depressants||||1000|112|145
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|162|164
SE|00000000||tx|1|entity|C0242402|Opioids|hops,orch,phsu|||opioids||||1000|183|189
SE|00000000||tx|1|entity|C0036557|Sedatives|phsu|||sedatives||||1000|192|200
SE|00000000||tx|1|entity|C0020591|Hypnotics|phsu|||hypnotics||||1000|203|211
SE|00000000||tx|1|entity|C0040614|Tranquilizing Agents|phsu|||tranquilizers||||1000|214|226
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|235|249
SE|00000000||tx|1|entity|C0017302|General anesthetic drugs|phsu|||general anesthetics||||1000|253|271
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|274|287
SE|00000000||tx|1|entity|C0037250|Skeletal Muscle Relaxants|phsu|||skeletal muscle relaxants||||1000|290|314
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|321|327
SE|00000000||tx|1|entity|C0235063|Respiratory Depression|patf|||respiratory depression||||1000|340|361
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||1000|364|374
SE|00000000||tx|1|entity|C0439808|Profound|qlco|||profound||||888|381|388
SE|00000000||tx|1|entity|C0600097|Sedation|sosy|||sedation||||888|390|397
SE|00000000||tx|1|entity|C0009421|Comatose|dsyn|||coma||||1000|425|428
SE|00000000||tx|1|entity|C0011065|Cessation of life|orgf|||death||||1000|433|437
SE|00000000||tx|1|relation|14|1|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|321|327|VERB|CAUSES||334|338|5|1|C0235063|Respiratory Depression|patf|patf|||respiratory depression||||1000|340|361
SE|00000000||tx|1|relation|17|1|C0600097|Sedation|sosy|sosy|||sedation||||888|390|397|VERB|CAUSES||415|420|2|1|C0009421|Comatose|dsyn|dsyn|||coma||||1000|425|428
SE|00000000||tx|1|relation|17|1|C0600097|Sedation|sosy|sosy|||sedation||||888|390|397|VERB|CAUSES||415|420|2|1|C0011065|Cessation of life|orgf|orgf|||death||||1000|433|437


SE|00000000||tx|1|text|This may occur because diflunisal competitively displaces coumarins from protein binding sites.
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||861|24|33
SE|00000000||tx|1|entity|C0010207|Coumarins|orch,phsu|||coumarins||||1000|59|67
SE|00000000||tx|1|entity|C0033684|Proteins|aapp,bacs|||protein||||901|74|80
SE|00000000||tx|1|entity|C0005456|Binding Sites|rcpt|||binding sites||||901|82|94


SE|00000000||tx|1|text|Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly.
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|57|62
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|74|86


SE|00000000||tx|1|text|Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||Tablets||||1000|1|7
SE|00000000||tx|1|entity|C1533685|Injection procedure|topp|||Injection||||1000|10|18
SE|00000000||tx|1|entity|C0991536|Oral Solution|bodm|||Oral Solution||||861|25|37
SE|00000000||tx|1|entity|C0205447|One|qnco|||One||||861|39|41
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||861|43|47
SE|00000000||tx|1|entity|C0205452|Six|qnco|||six||||872|52|54
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||872|56|63
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|87|97
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|102|111
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||acetylsalicylic acid||||822|117|136
SE|00000000||tx|1|entity|C1856356|Reduced creatinine clearance|fndg|||reduced creatinine clearance||||822|150|177
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|182|189
SE|00000000||tx|1|entity|C0022661|Kidney Failure, Chronic|dsyn|||chronic renal insufficiency||||1000|196|222
SE|00000000||tx|1|relation|7|1|C1856356|Reduced creatinine clearance|fndg|fndg|||reduced creatinine clearance||||822|150|177|PREP|PROCESS_OF||179|180|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|182|189
SE|00000000||tx|1|relation|1|1|C0022661|Kidney Failure, Chronic|dsyn|dsyn|||chronic renal insufficiency||||1000|196|222|PREP|PROCESS_OF||191|194|8|1|C0030705|Patients|podg,humn|humn|||patients||||1000|182|189


SE|00000000||tx|1|text|The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
SE|00000000||tx|1|entity|C0439792|Extent|spco|||extent||||1000|5|10
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRI-TCA||||840|21|28
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||SSRI-TCA||||840|21|28
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interactions||||840|30|41
SE|00000000||tx|1|entity|C0205210|Clinical|qlco|||clinical||||694|52|59
SE|00000000||tx|1|entity|C0441889|Levels (qualifier value)|qlco|||degree||||1000|89|94
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|99|108
SE|00000000||tx|1|entity|C0031327|Drug Kinetics|phsf|||pharmacokinetics||||1000|118|133
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRI||||1000|142|145


SE|00000000||tx|1|text|Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||Oral anticoagulants||||1000|1|19
SE|00000000||tx|1|entity|C0020616|Hypoglycemic Agents|phsu|||hypoglycemic||||888|40|51
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||888|53|58
SE|00000000||tx|1|entity|C0020616|Hypoglycemic Agents|phsu|||hypoglycemic agents||||1000|63|81
SE|00000000||tx|1|entity|C0040374|Tolbutamide|orch,phsu|||tolbutamide||||1000|88|98
SE|00000000||tx|1|entity|C0008287|Chlorpropamide|orch,phsu|||chlorpropamide||||1000|104|117
SE|00000000||tx|1|entity|C0021469|Metabolic Inhibition|moft|||inhibiting||||1000|123|132
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|140|149
SE|00000000||tx|1|entity|C0023884|Liver|bpoc|||liver||||1000|158|162
SE|00000000||tx|1|relation|1|1|C0023884|Liver|bpoc|bpoc|||liver||||1000|158|162|PREP|LOCATION_OF||151|152|8|3|C0008287|Chlorpropamide|orch,phsu|orch|||chlorpropamide||||1000|104|117
SE|00000000||tx|1|relation|1|1|C0023884|Liver|bpoc|bpoc|||liver||||1000|158|162|PREP|LOCATION_OF||151|152|8|3|C0040374|Tolbutamide|orch,phsu|orch|||tolbutamide||||1000|88|98


SE|00000000||tx|1|text|Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|1|10
SE|00000000||tx|1|entity|C0678876|renal tubular secretion|ortf|||renal tubular secretion||||1000|25|47
SE|00000000||tx|1|entity|C2266959|Cephalosporin Antibacterial [EPC]|antb,orch|||cephalosporins||||1000|52|65
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||1000|104|112
SE|00000000||tx|1|entity|C0205172|More|ftcn|||more||||740|118|121
SE|00000000||tx|1|entity|C0439590|Prolonged|tmco|||prolonged||||740|123|131
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||740|147|151
SE|00000000||tx|1|relation|1|1|C0033209|Probenecid|orch,phsu|orch|||Probenecid||||1000|1|10|VERB|INHIBITS||16|23|4|1|C0678876|renal tubular secretion|ortf|ortf|||renal tubular secretion||||1000|25|47


SE|00000000||tx|1|text|Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of doxepin (75 mg/day).
SE|00000000||tx|1|entity|C0040372|Tolazamide|orch,phsu|||Tolazamide||||1000|1|10
SE|00000000||tx|1|entity|C0020615|Hypoglycemia|dsyn|||hypoglycemia||||861|30|41
SE|00000000||tx|1|entity|C0441730|Type 2|clas|||type II||||861|66|72
SE|00000000||tx|1|entity|C0241863|DIABETIC|fndg|||diabetic||||861|74|81
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||861|83|89
SE|00000000||tx|1|entity|C0040372|Tolazamide|orch,phsu|||tolazamide||||1000|105|114
SE|00000000||tx|1|entity|C1442449|1 Day|tmco|||1 gm/day||||913|117|124
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|130|133
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|145|152
SE|00000000||tx|1|entity|C0013085|Doxepin|orch,phsu|||doxepin||||1000|157|163
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|169|174
SE|00000000||tx|1|relation|0|0|C0241863|DIABETIC|fndg|fndg|||diabetic||||861|74|81|MOD/HEAD|PROCESS_OF||74|89|0|0|C0030705|Patients|podg,humn|humn|||patient||||861|83|89
SE|00000000||tx|1|relation|3|1|C0020615|Hypoglycemia|dsyn|dsyn|||hypoglycemia||||861|30|41|PREP|PROCESS_OF||61|62|7|1|C0030705|Patients|podg,humn|humn|||patient||||861|83|89


SE|00000000||tx|1|text|Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.
SE|00000000||tx|1|entity|C0439272|ug/g|qnco|||mg/kg||||861|23|27
SE|00000000||tx|1|entity|C0530102|Nimbex|orch,phsu|||NIMBEX||||1000|40|45
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||861|94|97
SE|00000000||tx|1|entity|C0038627|Succinylcholine|orch,phsu|||succinylcholine||||1000|102|116
SE|00000000||tx|1|entity|C0439272|ug/g|qnco|||mg/kg||||901|121|125
SE|00000000||tx|1|entity|C0235062|Induction of neuromuscular blockade|topp|||neuromuscular block||||901|142|160


SE|00000000||tx|1|text|Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.
SE|00000000||tx|1|entity|C0011065|Cessation of life|orgf|||Death||||1000|1|5
SE|00000000||tx|1|entity|C0030305|Pancreatitis|dsyn|||pancreatitis||||790|24|35
SE|00000000||tx|1|entity|C2362652|Possible diagnosis|qlco|||possibly||||790|37|44
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||888|57|67
SE|00000000||tx|1|entity|C0030863|Pentamidine|orch,phsu|||pentamidine||||888|69|79
SE|00000000||tx|1|entity|C0678123|Hivid|nnon,phsu|||HIVID||||1000|85|89
SE|00000000||tx|1|relation|3|1|C0030305|Pancreatitis|dsyn|dsyn|||pancreatitis||||790|24|35|PREP|CAUSES||7|12|1|1|C0011065|Cessation of life|orgf|orgf|||Death||||1000|1|5


SE|00000000||tx|1|text|However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin.
SE|00000000||tx|1|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||HMG-CoA reductase inhibitor||||1000|18|44
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||1000|74|77
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||888|84|86
SE|00000000||tx|1|entity|C0565930|per second|qnco|||second||||888|88|93
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|107|122
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|127|144
SE|00000000||tx|1|entity|C0445550|Low dose|qnco|||low doses||||983|156|164
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|169|176


SE|00000000||tx|1|text|Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||non-steroidal anti-inflammatory drugs||||939|19|55
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|76|87
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|117|124
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||851|129|140
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induced||||851|142|148
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||851|150|157
SE|00000000||tx|1|entity|C2362652|Possible diagnosis|qlco|||possibly||||1000|160|167
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decreased||||888|176|184
SE|00000000||tx|1|entity|C0220781|Anabolism|biof|||synthesis||||888|186|194
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|199|203
SE|00000000||tx|1|entity|C0033567|Epoprostenol|bacs,eico,phsu|||prostacyclin||||888|205|216
SE|00000000||tx|1|relation|3|3|C0033567|Epoprostenol|bacs,eico,phsu|bacs|||prostacyclin||||888|205|216|NOM|AUGMENTS||117|124|3|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||851|150|157
SE|00000000||tx|1|relation|0|0|C0033567|Epoprostenol|bacs,eico,phsu|bacs|||prostacyclin||||888|205|216|MOD/HEAD|PART_OF||199|216|0|0|C0022646|Kidney|bpoc|bpoc|||renal||||888|199|203


SE|00000000||tx|1|text|Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.
SE|00000000||tx|1|entity|C1511726|Data|idcn|||data||||861|9|12
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|17|24
SE|00000000||tx|1|entity|C0205309|Known|qlco|||known||||623|36|40
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzyme||||623|42|47
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|60|68
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|71|83
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|86|98
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||only||||1000|111|114
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|122|129
SE|00000000||tx|1|entity|C1521828|Rate|qnco|||rate||||1000|138|141
SE|00000000||tx|1|entity|C0016229|Flecainide|orch,phsu|||flecainide||||888|146|155


SE|00000000||tx|1|text|Vasoconstrictors: D.H.E.
SE|00000000||tx|1|entity|C0042397|Vasoconstrictor Agents|phsu|||Vasoconstrictors||||1000|1|16

SE|00000000||tx|2|text|45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.
SE|00000000||tx|2|entity|C0700532|Dihydroergotamine Mesylate|orch,phsu|||dihydroergotamine mesylate||||1000|6|31
SE|00000000||tx|2|entity|C1533685|Injection procedure|topp|||Injection||||1000|34|42
SE|00000000||tx|2|entity|C1706444|United States Pharmacopeia|hcro|||USP||||1000|45|47
SE|00000000||tx|2|entity|C1518422|Negation|ftcn|||not||||1000|56|58
SE|00000000||tx|2|entity|C0205100|Peripheral|spco|||peripheral||||888|73|82
SE|00000000||tx|2|entity|C0042397|Vasoconstrictor Agents|phsu|||vasoconstrictors||||888|84|99
SE|00000000||tx|2|entity|C0205195|Combined|qlco|||combination||||1000|113|123
SE|00000000||tx|2|entity|C2986495|Synergistic|qlco|||synergistic||||888|135|145
SE|00000000||tx|2|entity|C0702240|Elevation|spco|||elevation||||888|147|155
SE|00000000||tx|2|entity|C0005823|Blood Pressure|orgf|||blood pressure||||1000|160|173
SE|00000000||tx|2|relation|3|2|C1533685|Injection procedure|topp|topp|||Injection||||1000|34|42|PREP|USES||68|71|4|1|C0042397|Vasoconstrictor Agents|phsu|phsu|||vasoconstrictors||||888|84|99


SE|00000000||tx|1|text|If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.
SE|00000000||tx|1|entity|C1299987|Replaced by|ftcn|||replacing||||888|4|12
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||888|14|22
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blocker||||901|27|38
SE|00000000||tx|1|entity|C1293116|Introduction procedure|hlca|||introduction||||1000|53|64
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta blockers||||1000|69|81
SE|00000000||tx|1|entity|C0443302|Several|qnco|||several||||888|105|111
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||888|113|116
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||888|124|132


SE|00000000||tx|1|text|Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.
SE|00000000||tx|1|entity|C1619629|deferasirox|orch,phsu|||deferasirox||||1000|10|20
SE|00000000||tx|1|entity|C0002367|Aluminum|elii|||aluminum||||1000|47|54
SE|00000000||tx|1|entity|C0302583|Iron|bacs,elii,phsu|||iron||||1000|65|68
SE|00000000||tx|1|entity|C1609706|Exjade|orch,phsu|||Exjade||||1000|71|76
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|85|87
SE|00000000||tx|1|entity|C1874163|ALUMINUM CONTAINING ANTACIDS|phsu|||aluminum-containing antacid||||900|103|129
SE|00000000||tx|1|entity|C1521827|Preparation|ftcn|||preparations||||900|131|142
SE|00000000||tx|1|relation|4|3|C1609706|Exjade|orch,phsu|orch|||Exjade||||1000|71|76|NOM|INTERACTS_WITH||34|41|4|1|C0002367|Aluminum|elii|elii|||aluminum||||1000|47|54


SE|00000000||tx|1|text|INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|1|7
SE|00000000||tx|1|entity|C0232819|Tubular secretion|ortf|||tubular secretion||||1000|43|59
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|64|75
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|99|106
SE|00000000||tx|1|relation|1|1|C0700798|Indocin|orch,phsu|orch|||INDOCIN||||1000|1|7|VERB|INHIBITS||30|37|3|1|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|43|59
SE|00000000||tx|1|relation|3|1|C0025677|Methotrexate|orch,phsu|orch|||methotrexate||||1000|64|75|VERB|AUGMENTS||84|93|1|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||1000|99|106


SE|00000000||tx|1|text|Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.
SE|00000000||tx|1|entity|C0060135|felbamate|orch,phsu|||Felbamate||||888|1|9
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|39|46
SE|00000000||tx|1|entity|C0061246|Gestodene|phsu,strd|||gestodene||||750|55|63
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||750|65|67
SE|00000000||tx|1|entity|C2347946|Relevance|qlco|||relevant||||790|93|100
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||790|102|107
SE|00000000||tx|1|entity|C0449381|Observation parameter|fndg|||parameters||||861|145|154
SE|00000000||tx|1|entity|C0015011|Ethinyl Estradiol|horm,phsu,strd|||ethinyl estradiol||||1000|159|175


SE|00000000||tx|1|text|SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||CONCOMITANT||||888|11|21
SE|00000000||tx|1|entity|C0205448|Two|qnco|||TWO||||888|47|49
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||DRUGS||||888|51|55
SE|00000000||tx|1|entity|C0274630|Poisoning by phenytoin|inpo|||PHENYTOIN INTOXICATION||||1000|69|90
SE|00000000||tx|1|entity|C1621583|Administer|ftcn|||ADMINISTERING||||872|102|114
SE|00000000||tx|1|entity|C0012772|Disulfiram|orch,phsu|||DISULFIRAM||||872|116|125
SE|00000000||tx|1|entity|C0030705|Patients|podg|||PATIENT||||1000|132|138
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||PHENYTOIN||||888|143|151
SE|00000000||tx|1|entity|C1442488|Baseline|qnco|||BASELINE||||833|164|171
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||PHENYTOIN||||833|173|181
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||SERUM||||833|183|187
SE|00000000||tx|1|entity|C2946261|Level|phsu|||LEVEL||||833|189|193


SE|00000000||tx|1|text|Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||1000|1|9
SE|00000000||tx|1|entity|C1514228|Population Analysis|resa|||Population pharmacokinetic analyses||||896|12|46
SE|00000000||tx|1|entity|C0068897|tiagabine|orch,phsu|||tiagabine||||888|62|70
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|72|80
SE|00000000||tx|1|entity|C1704243|Greater|qnco|||greater||||861|89|95
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|100|107
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|116|124
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzyme||||851|148|153
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||inducing||||851|156|163
SE|00000000||tx|1|entity|C0180309|Automated External Defibrillators|medd|||AEDs||||851|165|168
SE|00000000||tx|1|relation|4|2|C0068897|tiagabine|orch,phsu|phsu|||tiagabine||||888|62|70|PREP|TREATS||97|98|3|1|C0030705|Patients|podg,humn|podg|||patients||||1000|100|107
SE|00000000||tx|1|relation|2|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|116|124|VERB|ADMINISTERED_TO||109|114|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|100|107


SE|00000000||tx|1|text|Concomitant administration of gemfibrozil with Targretin capsules is not recommended.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0017245|Gemfibrozil|lipd,phsu|||gemfibrozil||||1000|31|41
SE|00000000||tx|1|entity|C0813158|Targretin|orch,phsu|||Targretin||||888|48|56
SE|00000000||tx|1|entity|C0006935|capsule (pharmacologic)|bodm|||capsules||||888|58|65
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|70|72


SE|00000000||tx|1|text|Use with Angiotensln Converting Enzyme Inhibitors: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.
SE|00000000||tx|1|entity|C0014432|Enzyme Inhibitors|phsu|||Enzyme Inhibitors||||861|33|49
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||angiotensin converting enzyme inhibitors||||937|63|102
SE|00000000||tx|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||1000|115|126
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|131|138
SE|00000000||tx|1|entity|C0004482|Azathioprine|orch,phsu|||azathioprine||||1000|143|154
SE|00000000||tx|1|entity|C0023530|Leukopenia|dsyn|||leukopenia||||861|191|200
SE|00000000||tx|1|relation|4|1|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|phsu|||angiotensin converting enzyme inhibitors||||937|63|102|VERB|TREATS||107|113|4|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||1000|115|126
SE|00000000||tx|1|relation|5|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||1000|115|126|PREP|PROCESS_OF||128|129|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|131|138
SE|00000000||tx|1|relation|7|1|C0004482|Azathioprine|orch,phsu|orch|||azathioprine||||1000|143|154|VERB|CAUSES||177|182|1|1|C0023530|Leukopenia|dsyn|dsyn|||leukopenia||||861|191|200


SE|00000000||tx|1|text|Meperidine: Amphetamines potentiate the analgesic effect of meperidine.
SE|00000000||tx|1|entity|C0025376|Meperidine|orch,phsu|||Meperidine||||1000|1|10
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||Amphetamines||||1000|13|24
SE|00000000||tx|1|entity|C0948482|analgesic effect|fndg|||analgesic effect||||1000|41|56
SE|00000000||tx|1|entity|C0025376|Meperidine|orch,phsu|||meperidine||||1000|61|70
SE|00000000||tx|1|relation|2|1|C0002667|Amphetamines|nsba,orch,phsu|orch|||Amphetamines||||1000|13|24|VERB|AUGMENTS||26|35|2|1|C0948482|analgesic effect|fndg|fndg|||analgesic effect||||1000|41|56


SE|00000000||tx|1|text|CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||Active||||861|5|10
SE|00000000||tx|1|entity|C0007680|Central Nervous System Agents|phsu|||CNS-Active Drugs||||861|1|16
SE|00000000||tx|1|entity|C0001962|Ethanol|orch|||Ethanol||||861|18|24
SE|00000000||tx|1|entity|C0876170|Sonata|orch,phsu|||Sonata||||802|27|32
SE|00000000||tx|1|entity|C0221099|Impaired|ftcn|||impairing||||790|60|68
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||790|70|76
SE|00000000||tx|1|entity|C0001962|Ethanol|orch|||ethanol||||812|81|87
SE|00000000||tx|1|entity|C1300563|Gram per Kilogram|qnco|||g/kg||||812|94|97
SE|00000000||tx|1|entity|C0205415|Balanced - adjective|ftcn|||balance||||888|102|108
SE|00000000||tx|1|entity|C0392366|Tests (qualifier value)|inpr|||testing||||888|110|116
SE|00000000||tx|1|entity|C0034746|Reaction Time|tmco|||reaction time||||1000|122|134
SE|00000000||tx|1|entity|C1442450|1 Hour|tmco|||1 hour||||1000|140|145
SE|00000000||tx|1|entity|C0001962|Ethanol|orch|||ethanol||||888|153|159
SE|00000000||tx|1|entity|C0814254|Digit Symbol Substitution Test|inpr|||digit symbol substitution test||||1000|187|216
SE|00000000||tx|1|entity|C0679214|symbol|idcn|||symbol||||802|226|231
SE|00000000||tx|1|entity|C0392366|Tests (qualifier value)|inpr|||test||||802|241|244
SE|00000000||tx|1|entity|C2827666|Variability|cnce|||variability||||694|255|265
SE|00000000||tx|1|entity|C0589101|Divided attention|menp|||divided attention||||901|284|300
SE|00000000||tx|1|entity|C0392366|Tests (qualifier value)|inpr|||test||||901|302|305
SE|00000000||tx|1|entity|C1442453|2.5 Hours|tmco|||2.5 hours||||1000|311|319
SE|00000000||tx|1|entity|C0001962|Ethanol|orch|||ethanol||||888|327|333
SE|00000000||tx|1|relation|0|0|C0001962|Ethanol|orch|orch|||Ethanol||||861|18|24|MOD/HEAD|ISA||1|24|0|0|C0007680|Central Nervous System Agents|phsu|phsu|||CNS-Active Drugs||||861|1|16

SE|00000000||tx|2|text|Indinavir has been shown to increase plasma levels of combination hormonal contraceptives.
SE|00000000||tx|2|entity|C0376637|Indinavir|orch,phsu|||Indinavir||||1000|1|9
SE|00000000||tx|2|entity|C0032105|Plasma|bdsu|||plasma||||861|38|43
SE|00000000||tx|2|entity|C0205195|Combined|qlco|||combination||||851|55|65
SE|00000000||tx|2|entity|C0458083|Hormonal|qlco|||hormonal||||851|67|74
SE|00000000||tx|2|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||851|76|89


SE|00000000||tx|1|text|Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
SE|00000000||tx|1|entity|C0036825|Serum Proteins|aapp,bacs|||Serum Proteins||||1000|12|25
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||872|32|40
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||872|42|47
SE|00000000||tx|1|entity|C0079691|Levothyroxine Sodium|aapp,horm,phsu|||levothyroxine sodium||||734|68|87
SE|00000000||tx|1|entity|C0036825|Serum Proteins|aapp,bacs|||serum proteins||||1000|100|113
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||1000|128|141
SE|00000000||tx|1|entity|C0036825|Serum Proteins|aapp,bacs|||serum binding proteins||||913|146|167
SE|00000000||tx|1|entity|C0002844|Androgens|horm,phsu|||androgens||||1000|170|178
SE|00000000||tx|1|entity|C0163712|Relate - vinyl resin|orch|||related||||802|184|190
SE|00000000||tx|1|entity|C0019932|Hormones|horm|||hormones||||802|201|208
SE|00000000||tx|1|entity|C0003993|ASPARAGINASE|aapp,enzy,phsu|||asparaginase||||1000|211|222
SE|00000000||tx|1|entity|C0009002|Clofibrate|orch,phsu|||clofibrate||||1000|225|234
SE|00000000||tx|1|entity|C0014939|Estrogens|horm,phsu,strd|||estrogens||||1000|237|245
SE|00000000||tx|1|entity|C2700400|Contain (action)|acty|||containing||||877|260|269
SE|00000000||tx|1|entity|C0014939|Estrogens|horm,phsu,strd|||estrogen-containing compounds||||877|251|279
SE|00000000||tx|1|entity|C0016360|Fluorouracil|nnon,phsu|||5-fluorouracil||||1000|282|295
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|298|307
SE|00000000||tx|1|entity|C0017710|Glucocorticoids|horm,strd|||glucocorticoids||||1000|310|324
SE|00000000||tx|1|entity|C0025042|Meclofenamic Acid|orch,phsu|||meclofenamic acid||||1000|327|343
SE|00000000||tx|1|entity|C0025152|Mefenamic Acid|orch,phsu|||mefenamic acid||||1000|346|359
SE|00000000||tx|1|entity|C0025605|Methadone|orch,phsu|||methadone||||1000|362|370
SE|00000000||tx|1|entity|C0031184|Perphenazine|orch,phsu|||perphenazine||||1000|373|384
SE|00000000||tx|1|entity|C0031463|Phenylbutazone|orch,phsu|||phenylbutazone||||1000|387|400
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|403|411
SE|00000000||tx|1|entity|C0036077|Salicylates|orch,phsu|||salicylates||||1000|414|424
SE|00000000||tx|1|entity|C0039286|Tamoxifen|orch,phsu|||tamoxifen||||1000|427|435
SE|00000000||tx|1|relation|23|9|C0003993|ASPARAGINASE|aapp,gngm,enzy,phsu|aapp|||asparaginase||||1000|211|222|NOM|INTERACTS_WITH||1|7|23|1|C0036825|Serum Proteins|aapp,gngm,bacs|aapp|||Serum Proteins||||1000|12|25
SE|00000000||tx|1|relation|23|9|C0014939|Estrogens|horm,phsu,strd|horm|||estrogen-containing compounds||||877|251|279|NOM|INTERACTS_WITH||1|7|23|1|C0036825|Serum Proteins|aapp,gngm,bacs|aapp|||Serum Proteins||||1000|12|25
SE|00000000||tx|1|relation|23|9|C0002844|Androgens|horm,phsu|horm|||androgens||||1000|170|178|NOM|INTERACTS_WITH||1|7|23|1|C0036825|Serum Proteins|aapp,gngm,bacs|aapp|||Serum Proteins||||1000|12|25
SE|00000000||tx|1|relation|23|9|C0014939|Estrogens|horm,phsu,strd|horm|||estrogens||||1000|237|245|NOM|INTERACTS_WITH||1|7|23|1|C0036825|Serum Proteins|aapp,gngm,bacs|aapp|||Serum Proteins||||1000|12|25
SE|00000000||tx|1|relation|23|9|C0009002|Clofibrate|orch,phsu|orch|||clofibrate||||1000|225|234|NOM|INTERACTS_WITH||1|7|23|1|C0036825|Serum Proteins|aapp,gngm,bacs|aapp|||Serum Proteins||||1000|12|25
SE|00000000||tx|1|relation|23|9|C0019932|Hormones|horm|horm|||hormones||||802|201|208|NOM|INTERACTS_WITH||1|7|23|1|C0036825|Serum Proteins|aapp,gngm,bacs|aapp|||Serum Proteins||||1000|12|25
SE|00000000||tx|1|relation|3|0|C0079691|Levothyroxine Sodium|aapp,gngm,horm,phsu|aapp|||levothyroxine sodium||||734|68|87|NOM|INTERACTS_WITH||89|95|20|1|C0036825|Serum Proteins|aapp,gngm,bacs|aapp|||serum proteins||||1000|100|113
SE|00000000||tx|1|relation|5|3|C1254351|Pharmacologic Substance|phsu|phsu|||agents||||872|42|47|VERB|INTERACTS_WITH||118|122|19|2|C0036825|Serum Proteins|aapp,gngm,bacs|aapp|||serum binding proteins||||913|146|167


SE|00000000||tx|1|text|When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||888|6|16
SE|00000000||tx|1|entity|C0026549|Morphine|orch,phsu|||morphine||||888|18|25
SE|00000000||tx|1|entity|C0591189|Brevibloc|orch,phsu|||BREVIBLOC||||1000|31|39
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||872|76|81
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||872|83|90
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|96|101
SE|00000000||tx|1|entity|C0026549|Morphine|orch,phsu|||morphine||||790|106|113
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||790|115|119
SE|00000000||tx|1|entity|C0591189|Brevibloc|orch,phsu|||BREVIBLOC||||833|142|150
SE|00000000||tx|1|entity|C0205361|Steady|qlco|||steady-||||833|152|158
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||833|165|169
SE|00000000||tx|1|entity|C0683927|state wide area|spco|||state blood levels||||833|159|176
SE|00000000||tx|1|entity|C0026549|Morphine|orch,phsu|||morphine||||1000|219|226
SE|00000000||tx|1|relation|6|5|C0591189|Brevibloc|orch,phsu|orch|||BREVIBLOC||||1000|31|39|NOM|COEXISTS_WITH||207|214|1|1|C0026549|Morphine|orch,phsu|orch|||morphine||||1000|219|226
SE|00000000||tx|1|relation|6|5|C0026549|Morphine|orch,phsu|orch|||morphine||||888|18|25|NOM|COEXISTS_WITH||207|214|1|1|C0026549|Morphine|orch,phsu|orch|||morphine||||1000|219|226


SE|00000000||tx|1|text|Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of propranolol but not atenolol.
SE|00000000||tx|1|entity|C0016377|Flurbiprofen|orch,phsu|||Flurbiprofen||||888|1|12
SE|00000000||tx|1|entity|C1550147|Pretreatment|sbst|||pretreatment||||888|14|25
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|42|52
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|54|59
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|66|71
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|73|76
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||1000|81|91
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||888|97|99
SE|00000000||tx|1|entity|C0004147|Atenolol|orch,phsu|||atenolol||||888|101|108
SE|00000000||tx|1|relation|3|2|C0033497|Propranolol|orch,phsu|orch|||propranolol||||1000|81|91|NOM|AFFECTS||54|59|1|0|C0857353|Hypotensive|patf|patf|||hypotensive||||888|42|52
SE|00000000||tx|1|relation|3|2|C0004147|Atenolol|orch,phsu|orch|||atenolol||||888|101|108|NOM|AFFECTS||54|59|1|0|C0857353|Hypotensive|patf|patf|||hypotensive||||888|42|52


SE|00000000||tx|1|text|Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.
SE|00000000||tx|1|entity|C0085149|Tacrolimus|orch,phsu|||tacrolimus||||1000|22|31
SE|00000000||tx|1|entity|C0252643|bosentan|orch,phsu|||bosentan||||1000|37|44
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||markedly||||852|58|65
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||852|67|75
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||852|77|97
SE|00000000||tx|1|entity|C0252643|bosentan|orch,phsu|||bosentan||||1000|102|109
SE|00000000||tx|1|entity|C0003062|Animals|anim|||animals||||1000|114|120
SE|00000000||tx|1|relation|1|1|C0003062|Animals|anim|anim|||animals||||1000|114|120|PREP|LOCATION_OF||111|112|5|1|C0252643|bosentan|orch,phsu|orch|||bosentan||||1000|102|109


SE|00000000||tx|1|text|The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.
SE|00000000||tx|1|entity|C0439792|Extent|spco|||extent||||1000|5|10
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRI-TCA||||840|21|28
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||SSRI-TCA||||840|21|28
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interactions||||840|30|41
SE|00000000||tx|1|entity|C0205210|Clinical|qlco|||clinical||||694|52|59
SE|00000000||tx|1|entity|C0441889|Levels (qualifier value)|qlco|||degree||||1000|89|94
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|99|108
SE|00000000||tx|1|entity|C0031327|Drug Kinetics|phsf|||pharmacokinetics||||1000|119|134
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRI||||1000|143|146


SE|00000000||tx|1|text|In addition, other quinolones have been reported to decrease the CYP3A4-mediated metabolism of cyclosporine.
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|4|11
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|20|29
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||790|66|71
SE|00000000||tx|1|entity|C0127400|Mediator brand of benfluorex hydrochloride|orch,phsu|||mediated||||790|73|80
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||790|82|91
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|96|107
SE|00000000||tx|1|relation|2|1|C0034428|Quinolones|orch|orch|||quinolones||||1000|20|29|VERB|INHIBITS||53|60|2|1|C0127400|Mediator brand of benfluorex hydrochloride|orch,phsu|orch|||mediated||||790|73|80


SE|00000000||tx|1|text|Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||Risk||||1000|1|4
SE|00000000||tx|1|entity|C0002792|anaphylaxis|patf|||Anaphylactic Reaction||||1000|9|29
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|58|65
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blockers||||1000|70|82
SE|00000000||tx|1|entity|C0205269|Unresponsive to Treatment|ftcn|||refractory||||1000|91|100
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||epinephrine||||1000|105|115
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|124|132
SE|00000000||tx|1|entity|C0002792|anaphylaxis|patf|||anaphylactic shock||||1000|137|154
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blockers||||1000|157|169
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|179|186
SE|00000000||tx|1|entity|C0443264|Modulated|spco|||modulation||||1000|208|217
SE|00000000||tx|1|entity|C1527304|Allergic Reaction|patf|||allergic reaction||||1000|222|238
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|255|263
SE|00000000||tx|1|entity|C0439793|Severities|qlco|||severity||||888|265|272
SE|00000000||tx|1|entity|C0439603|Frequencies (time pattern)|tmco|||frequency||||1000|281|289
SE|00000000||tx|1|entity|C1304680|Observation of attack|fndg|||attacks||||1000|294|300
SE|00000000||tx|1|relation|14|8|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blockers||||1000|157|169|NOM|PREDISPOSES||1|4|14|1|C0002792|anaphylaxis|patf|patf|||Anaphylactic Reaction||||1000|9|29
SE|00000000||tx|1|relation|6|1|C0014563|Epinephrine|horm,nsba,orch,phsu|phsu|||epinephrine||||1000|105|115|NOM|TREATS||124|132|8|1|C0002792|anaphylaxis|patf|patf|||anaphylactic shock||||1000|137|154


SE|00000000||tx|1|text|However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.
SE|00000000||tx|1|entity|C1511726|Data|idcn|||data||||861|36|39
SE|00000000||tx|1|entity|C1332830|CYP2D6 gene|gngm|1565|CYP2D6|CYP2D6||||784|61|66
SE|00000000||tx|1|entity|C0021469|Metabolic Inhibition|moft|||inhibitory||||784|68|77
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||784|79|84
SE|00000000||tx|1|entity|C1099456|Escitalopram|orch,phsu|||escitalopram||||1000|90|101
SE|00000000||tx|1|entity|C1099456|Escitalopram|orch,phsu|||escitalopram||||1000|130|141
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|147|152
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|161|164
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressant||||901|176|199
SE|00000000||tx|1|entity|C0011685|Desipramine|orch,phsu|||desipramine||||901|201|211
SE|00000000||tx|1|entity|C0087136|Unmarried|fndg|||single||||888|214|219
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|221|224
SE|00000000||tx|1|entity|C1332830|CYP2D6 gene|gngm|1565|CYP2D6|CYP2D6||||1000|253|258
SE|00000000||tx|1|entity|C0439509|/40|tmco|||40%||||888|275|277
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|279|286
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|291|294
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|307|314
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|319|321
SE|00000000||tx|1|entity|C0011685|Desipramine|orch,phsu|||desipramine||||1000|326|336
SE|00000000||tx|1|relation|0|0|C0011685|Desipramine|orch,phsu|orch|||desipramine||||901|201|211|MOD/HEAD|ISA||176|211|0|0|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressant||||901|176|199
SE|00000000||tx|1|relation|16|4|C1099456|Escitalopram|orch,phsu|phsu|||escitalopram||||1000|130|141|NOM|AFFECTS||79|84|1|0|C0021469|Metabolic Inhibition|moft|moft|||inhibitory||||784|68|77
SE|00000000||tx|1|relation|11|3|C0011685|Desipramine|orch,phsu|orch|||desipramine||||901|201|211|NOM|INTERACTS_WITH||239|247|6|1|C1332830|CYP2D6 gene|gngm,aapp|gngm|1565|CYP2D6|CYP2D6||||1000|253|258


SE|00000000||tx|1|text|Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||Warfarin||||1000|1|8
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||Quinolones||||1000|11|20
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|56|62
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulant||||901|71|88
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||901|90|97
SE|00000000||tx|1|entity|C0243072|derivatives|chvs|||derivatives||||1000|106|116
SE|00000000||tx|1|relation|0|0|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||901|90|97|MOD/HEAD|ISA||71|97|0|0|C0354604|Anticoagulants, Oral|orch,phsu|orch|||oral anticoagulant||||901|71|88
SE|00000000||tx|1|relation|2|1|C0034428|Quinolones|orch|orch|||Quinolones||||1000|11|20|NOM|INTERACTS_WITH||56|62|2|1|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||901|90|97
SE|00000000||tx|1|relation|2|1|C0034428|Quinolones|orch|orch|||Quinolones||||1000|11|20|NOM|INTERACTS_WITH||56|62|2|1|C0243072|derivatives|chvs|chvs|||derivatives||||1000|106|116


SE|00000000||tx|1|text|These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin.
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||1000|7|15
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptive||||1000|56|73
SE|00000000||tx|1|entity|C0043210|Woman|popg|||woman||||840|81|85
SE|00000000||tx|1|entity|C1515187|Take|hlca|||taking||||840|87|92
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||840|94|105


SE|00000000||tx|1|text|Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other s metabolism.
SE|00000000||tx|1|entity|C0031434|phenothiazine|orch,phsu|||Phenothiazine||||901|1|13
SE|00000000||tx|1|entity|C0600686|related compounds|chvs|||related compounds||||901|15|31
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic blocking agents||||1000|37|67
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||802|78|85
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||802|99|105
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|118|127
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|145|154


SE|00000000||tx|1|text|While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|11|17
SE|00000000||tx|1|entity|C0205191|chronic|tmco|||chronic||||888|22|28
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||888|30|38
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||888|43|55
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|72|77
SE|00000000||tx|1|entity|C0530102|Nimbex|orch,phsu|||NIMBEX||||1000|82|87
SE|00000000||tx|1|entity|C0439673|Unknown|qlco|||unknown||||844|93|99
SE|00000000||tx|1|entity|C0750482|Slightly|idcn|||slightly||||844|102|109
SE|00000000||tx|1|entity|C0439593|Short duration|qlco|||shorter durations||||844|111|127
SE|00000000||tx|1|entity|C0234119|Neuromuscular inhibition|dsyn|||neuromuscular block||||1000|132|150
SE|00000000||tx|1|entity|C2964135|Infusion Rate|tmco|||infusion rate||||890|175|187
SE|00000000||tx|1|entity|C1514873|Requirement|ftcn|||requirements||||890|189|200
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||966|209|214
SE|00000000||tx|1|relation|8|4|C0530102|Nimbex|orch,phsu|orch|||NIMBEX||||1000|82|87|NOM|INTERACTS_WITH||11|17|8|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||888|30|38
SE|00000000||tx|1|relation|8|4|C0530102|Nimbex|orch,phsu|orch|||NIMBEX||||1000|82|87|NOM|INTERACTS_WITH||11|17|8|1|C0006949|Carbamazepine|orch,phsu|orch|||carbamazepine||||888|43|55


SE|00000000||tx|1|text|Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
SE|00000000||tx|1|entity|C0020934|Imipramine|orch,phsu|||Imipramine||||1000|1|10
SE|00000000||tx|1|entity|C0087136|Unmarried|fndg|||single||||888|33|38
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|40|44
SE|00000000||tx|1|entity|C0876170|Sonata|orch,phsu|||Sonata||||802|49|54
SE|00000000||tx|1|entity|C0020934|Imipramine|orch,phsu|||imipramine||||802|66|75
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|92|99
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|101|107
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decreased||||888|112|120
SE|00000000||tx|1|entity|C1443086|Alertness|menp|||alertness||||888|122|130
SE|00000000||tx|1|entity|C1562249|Impaired psychomotor performance|fndg|||impaired psychomotor performance||||1000|136|167
SE|00000000||tx|1|entity|C1292426|4 Hours|tmco|||4 hours||||1000|178|184
SE|00000000||tx|1|relation|6|6|C0020934|Imipramine|orch,phsu|phsu|||Imipramine||||1000|1|10|ADJ|INHIBITS||112|120|3|1|C1562249|Impaired psychomotor performance|fndg|fndg|||impaired psychomotor performance||||1000|136|167


SE|00000000||tx|1|text|Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
SE|00000000||tx|1|entity|C0039651|Tetracyclines|orch|||tetracyclines||||1000|9|21
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||901|50|55
SE|00000000||tx|1|entity|C0200396|Clotting factor II assay|lbpr|||prothrombin activity||||901|57|76
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|79|86
SE|00000000||tx|1|entity|C0150457|Anticoagulant therapy|topp|||anticoagulant therapy||||1000|99|119
SE|00000000||tx|1|entity|C0205104|Downward|spco|||downward||||694|133|140
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulant||||901|162|174
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||901|176|181


SE|00000000||tx|1|text|When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents: may enhance the potential for renal toxicity, bronchospasm and hypotension.
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||888|37|45
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|47|51
SE|00000000||tx|1|entity|C0002679|Amphotericin B|antb,orch|||amphotericin B||||1000|71|84
SE|00000000||tx|1|entity|C0003392|Antineoplastic Agents|orch,phsu|||Antineoplastic agents||||1000|87|107
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|126|134
SE|00000000||tx|1|entity|C0595916|Toxic nephropathy|dsyn|||renal toxicity||||1000|140|153
SE|00000000||tx|1|entity|C0006266|Bronchial Spasm|dsyn|||bronchospasm||||1000|156|167
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||1000|173|183
SE|00000000||tx|1|relation|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|47|51|VERB|INTERACTS_WITH||57|64|6|1|C0002679|Amphotericin B|antb,orch|antb|||amphotericin B||||1000|71|84
SE|00000000||tx|1|relation|4|2|C0003392|Antineoplastic Agents|orch,phsu|phsu|||Antineoplastic agents||||1000|87|107|PREP|TREATS||136|138|3|1|C0595916|Toxic nephropathy|dsyn|dsyn|||renal toxicity||||1000|140|153
SE|00000000||tx|1|relation|4|2|C0003392|Antineoplastic Agents|orch,phsu|phsu|||Antineoplastic agents||||1000|87|107|PREP|TREATS||136|138|3|1|C0020649|Hypotension|fndg|fndg|||hypotension||||1000|173|183
SE|00000000||tx|1|relation|4|2|C0003392|Antineoplastic Agents|orch,phsu|phsu|||Antineoplastic agents||||1000|87|107|PREP|TREATS||136|138|3|1|C0006266|Bronchial Spasm|dsyn|dsyn|||bronchospasm||||1000|156|167


SE|00000000||tx|1|text|Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.
SE|00000000||tx|1|entity|C0025605|Methadone|orch,phsu|||Methadone||||1000|1|9
SE|00000000||tx|1|entity|C0754188|Amprenavir|orch,phsu|||amprenavir||||1000|32|41
SE|00000000||tx|1|entity|C0025605|Methadone|orch,phsu|||methadone||||1000|47|55
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|70|75
SE|00000000||tx|1|entity|C0025605|Methadone|orch,phsu|||methadone||||1000|87|95


SE|00000000||tx|1|text|Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
SE|00000000||tx|1|entity|C0008947|Clindamycin|antb,carb|||Clindamycin||||1000|1|11
SE|00000000||tx|1|entity|C0234119|Neuromuscular inhibition|dsyn|||neuromuscular blocking||||890|36|57
SE|00000000||tx|1|entity|C1292721|Has property|ftcn|||properties||||890|59|68
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|91|96
SE|00000000||tx|1|entity|C0027866|Neuromuscular Blocking Agents|phsu|||neuromuscular blocking agents||||1000|107|135


SE|00000000||tx|1|text|Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|21|29
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|45|47
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||midazolam||||1000|52|60
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||triazolam||||1000|66|74
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||901|83|86
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|96|99
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||888|106|109
SE|00000000||tx|1|entity|C1696465|placebo|bodm|||placebo||||1000|124|130


SE|00000000||tx|1|text|Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.
SE|00000000||tx|1|entity|C0011777|Dexamethasone|phsu,strd|||Dexamethasone||||1000|1|13
SE|00000000||tx|1|entity|C0678587|steady state|npop|||Steady-state||||861|16|27
SE|00000000||tx|1|entity|C0444506|Trough|qnco|||trough||||861|29|34
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||861|36|49
SE|00000000||tx|1|entity|C0051091|albendazole sulfoxide|orch,phsu|||albendazole sulfoxide||||1000|54|74
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||793|91|96
SE|00000000||tx|1|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||790|108|120
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|151|154
SE|00000000||tx|1|entity|C0001911|Albendazole|orch,phsu|||albendazole||||1000|159|169
SE|00000000||tx|1|entity|C0439400|mg/day/kg|qnco|||mg/kg/day||||923|175|183
SE|00000000||tx|1|entity|C0205454|Eight|qnco|||eight||||851|189|193
SE|00000000||tx|1|entity|C0338437|Neurocysticercosis|dsyn|||neurocysticercosis||||851|195|212
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||851|214|221
SE|00000000||tx|1|relation|0|0|C0338437|Neurocysticercosis|dsyn|dsyn|||neurocysticercosis||||851|195|212|MOD/HEAD|PROCESS_OF||195|221|0|0|C0030705|Patients|podg,humn|humn|||patients||||851|214|221
SE|00000000||tx|1|relation|8|2|C0001911|Albendazole|orch,phsu|phsu|||albendazole||||1000|159|169|PREP|TREATS||186|187|1|1|C0030705|Patients|podg,humn|podg|||patients||||851|214|221
SE|00000000||tx|1|relation|0|0|C0001911|Albendazole|orch,phsu|phsu|||albendazole||||1000|159|169|INFER|TREATS(INFER)||186|187|0|0|C0338437|Neurocysticercosis|dsyn|dsyn|||neurocysticercosis||||851|195|212


SE|00000000||tx|1|text|Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.
SE|00000000||tx|1|entity|C0068333|nabilone|orch,phsu|||Nabilone||||1000|1|8
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||861|36|43
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressant||||861|45|58
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|60|65
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||861|90|97
SE|00000000||tx|1|entity|C0037473|Sodium|bacs,elii|||sodium||||861|114|119
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|122|128
SE|00000000||tx|1|entity|C0009214|Codeine|orch,phsu|||codeine||||1000|133|139
SE|00000000||tx|1|relation|1|1|C0068333|nabilone|orch,phsu|orch|||Nabilone||||1000|1|8|NOM|INTERACTS_WITH||60|65|1|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressant||||861|45|58


SE|00000000||tx|1|text|Cimetidine: Cimetidine increases nicardipine HCl plasma levels.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|13|22
SE|00000000||tx|1|entity|C0028005|Nicardipine|orch,phsu|||nicardipine||||763|34|44
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||763|50|55


SE|00000000||tx|1|text|Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.
SE|00000000||tx|1|entity|C0747055|Organic|qlco|||Organic||||775|1|7
SE|00000000||tx|1|entity|C0028125|Nitrates|chvs|||nitrates||||775|9|16
SE|00000000||tx|1|entity|C0003765|Arginine|aapp,bacs,phsu|||arginine||||775|22|29
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|76|82
SE|00000000||tx|1|entity|C0747055|Organic|qlco|||organic||||888|87|93
SE|00000000||tx|1|entity|C0028125|Nitrates|chvs|||nitrates||||888|95|102


SE|00000000||tx|1|text|Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||901|10|17
SE|00000000||tx|1|entity|C3179159|Sedative Effect|phsf|||sedative effects||||901|19|34
SE|00000000||tx|1|entity|C0009676|Confusion|mobd|||confusional states||||901|40|57
SE|00000000||tx|1|entity|C0008290|Chlorprothixene|orch,phsu|||chlorprothixene||||1000|73|87
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|103|117
SE|00000000||tx|1|relation|2|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|103|117|VERB|COEXISTS_WITH||92|96|3|1|C0008290|Chlorprothixene|orch,phsu|orch|||chlorprothixene||||1000|73|87


SE|00000000||tx|1|text|Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects
SE|00000000||tx|1|entity|C0042839|Vitamin A|orch,phsu,vita|||Vitamin A||||1000|1|9
SE|00000000||tx|1|entity|C0439849|Relationships|qlco|||relationship||||1000|27|38
SE|00000000||tx|1|entity|C0699581|Accutane|orch,phsu|||Accutane||||1000|43|50
SE|00000000||tx|1|entity|C0042839|Vitamin A|orch,phsu,vita|||vitamin A||||1000|55|63
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|66|73
SE|00000000||tx|1|entity|C1515187|Take|hlca|||taking||||879|101|106
SE|00000000||tx|1|entity|C0681579|vitamin supplement|food|||vitamin supplements||||879|108|126
SE|00000000||tx|1|entity|C0042839|Vitamin A|orch,phsu,vita|||vitamin A||||901|139|147
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||884|158|165
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxic effects||||884|167|179


SE|00000000||tx|1|text|In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|4|11
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|18|28
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|48|54
SE|00000000||tx|1|entity|C0114771|dofetilide|orch,phsu|||dofetilide||||1000|61|70
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||872|94|99
SE|00000000||tx|1|entity|C2745955|Occurrence|tmco|||occurrence||||872|101|110
SE|00000000||tx|1|entity|C0040479|Torsades de Pointes|dsyn|||torsade de pointes||||1000|115|132
SE|00000000||tx|1|relation|4|2|C0012265|Digoxin|carb,phsu,strd|carb|||digoxin||||1000|48|54|VERB|ASSOCIATED_WITH||76|85|2|2|C0040479|Torsades de Pointes|dsyn|dsyn|||torsade de pointes||||1000|115|132


SE|00000000||tx|1|text|This decrease in bioavailability was about 5% when gabapentin was administered 2 hours after Maalox.
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|6|13
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|18|32
SE|00000000||tx|1|entity|C0060926|gabapentin|orch,phsu|||gabapentin||||1000|52|61
SE|00000000||tx|1|entity|C1292425|2 Hours|tmco|||2 hours||||1000|80|86
SE|00000000||tx|1|entity|C0065461|Maalox|inch,phsu|||Maalox||||1000|94|99


SE|00000000||tx|1|text|Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.
SE|00000000||tx|1|entity|C0205341|Repeat|ftcn|||Repeated||||888|1|8
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|10|14
SE|00000000||tx|1|entity|C0354648|Colestipol Hydrochloride|orch,phsu|||colestipol hydrochloride||||1000|19|42
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|61|66
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|68|71
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||1000|76|86
SE|00000000||tx|1|entity|C0086418|Homo sapiens|humn|||human||||872|91|95
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||trials||||872|97|102
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||694|135|145


SE|00000000||tx|1|text|Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.
SE|00000000||tx|1|entity|C0442821|Strong|qlco|||strong||||791|7|12
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||791|24|29
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||791|31|40
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|50|61
SE|00000000||tx|1|entity|C0251504|zaleplon|orch,phsu|||zaleplon||||1000|112|119
SE|00000000||tx|1|relation|2|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|50|61|VERB|STIMULATES||87|94|2|2|C0251504|zaleplon|orch,phsu|orch|||zaleplon||||1000|112|119


SE|00000000||tx|1|text|Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
SE|00000000||tx|1|entity|C0234119|Neuromuscular inhibition|dsyn|||neuromuscular blocking||||890|19|40
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||890|42|47
SE|00000000||tx|1|entity|C0027866|Neuromuscular Blocking Agents|phsu|||neuromuscular blocking agents||||923|68|96
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||791|123|130
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||791|157|165
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|170|182
SE|00000000||tx|1|relation|3|1|C0027866|Neuromuscular Blocking Agents|phsu|phsu|||neuromuscular blocking agents||||923|68|96|PREP|COEXISTS_WITH||120|121|2|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||791|157|165
SE|00000000||tx|1|relation|3|1|C0027866|Neuromuscular Blocking Agents|phsu|phsu|||neuromuscular blocking agents||||923|68|96|PREP|COEXISTS_WITH||120|121|2|1|C0006949|Carbamazepine|orch,phsu|orch|||carbamazepine||||1000|170|182


SE|00000000||tx|1|text|Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||Effects||||1000|1|7
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||861|31|35
SE|00000000||tx|1|entity|C0720560|Gabitril|orch,phsu|||GABITRIL||||1000|47|54
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||Carbamazepine||||1000|58|70
SE|00000000||tx|1|entity|C1514228|Population Analysis|resa|||Population pharmacokinetic analyses||||896|73|107
SE|00000000||tx|1|entity|C0068897|tiagabine|orch,phsu|||tiagabine||||888|123|131
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|133|141
SE|00000000||tx|1|entity|C1704243|Greater|qnco|||greater||||861|150|156
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|161|168
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|177|189
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzyme||||775|213|218
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||inducing||||775|221|228
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||AEDs||||775|230|233
SE|00000000||tx|1|relation|9|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||861|31|35|NOM|INTERACTS_WITH||1|7|9|2|C0720560|Gabitril|orch,phsu|orch|||GABITRIL||||1000|47|54
SE|00000000||tx|1|relation|9|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||AEDs||||775|230|233|NOM|INTERACTS_WITH||1|7|9|2|C0720560|Gabitril|orch,phsu|orch|||GABITRIL||||1000|47|54
SE|00000000||tx|1|relation|7|2|C0068897|tiagabine|orch,phsu|phsu|||tiagabine||||888|123|131|PREP|TREATS||158|159|3|1|C0030705|Patients|podg,humn|podg|||patients||||1000|161|168
SE|00000000||tx|1|relation|2|1|C0006949|Carbamazepine|orch,phsu|orch|||carbamazepine||||1000|177|189|VERB|ADMINISTERED_TO||170|175|8|1|C0030705|Patients|podg,humn|humn|||patients||||1000|161|168


SE|00000000||tx|1|text|Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||Rifampin||||1000|1|8
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|31|38
SE|00000000||tx|1|entity|C0525004|Viracept|orch,phsu|||VIRACEPT||||1000|44|51
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|72|79
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||nelfinavir||||583|84|93
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||583|95|100


SE|00000000||tx|1|text|Diflunisal decreased the hyperuricemic effect of furosemide.
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||Diflunisal||||1000|1|10
SE|00000000||tx|1|entity|C0740394|Hyperuricemia|dsyn|||hyperuricemic||||888|26|38
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|40|45
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|50|59
SE|00000000||tx|1|relation|1|1|C0012228|Diflunisal|orch,phsu|orch|||Diflunisal||||1000|1|10|NOM|INTERACTS_WITH||40|45|1|1|C0016860|Furosemide|orch,phsu|orch|||furosemide||||1000|50|59


SE|00000000||tx|1|text|Acetazolamide may increase the effects of other folic acid antagonists.
SE|00000000||tx|1|entity|C0000981|Acetazolamide|orch,phsu|||Acetazolamide||||1000|1|13
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|32|38
SE|00000000||tx|1|entity|C0016411|Folic Acid Antagonists|phsu|||folic acid antagonists||||1000|49|70
SE|00000000||tx|1|relation|1|1|C0000981|Acetazolamide|orch,phsu|orch|||Acetazolamide||||1000|1|13|NOM|INTERACTS_WITH||32|38|1|1|C0016411|Folic Acid Antagonists|phsu|phsu|||folic acid antagonists||||1000|49|70


SE|00000000||tx|1|text|Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.
SE|00000000||tx|1|entity|C0439175|% of total|qnco|||total||||851|10|14
SE|00000000||tx|1|entity|C1120106|ertapenem|antb,orch|||ertapenem||||851|16|24
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||851|26|39
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|42|51
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|67|69
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||1000|94|99
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||872|105|109
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearances||||872|111|120


SE|00000000||tx|1|text|CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.
SE|00000000||tx|1|entity|C0719198|Celebrex|orch,phsu|||CELEBREX||||1000|1|8
SE|00000000||tx|1|entity|C0034866|Recommendation|idcn|||recommended||||890|45|55
SE|00000000||tx|1|entity|C0445550|Low dose|qnco|||lowest recommended dose||||890|38|60
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|65|72
SE|00000000||tx|1|entity|C0016277|Fluconazole|orch,phsu|||fluconazole||||1000|84|94
SE|00000000||tx|1|relation|2|2|C0719198|Celebrex|orch,phsu|phsu|||CELEBREX||||1000|1|8|PREP|TREATS||62|63|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|65|72
SE|00000000||tx|1|relation|1|1|C0016277|Fluconazole|orch,phsu|orch|||fluconazole||||1000|84|94|VERB|ADMINISTERED_TO||74|82|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|65|72


SE|00000000||tx|1|text|Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.
SE|00000000||tx|1|entity|C0041405|Turks and Caicos Islands|geoa|||TCAs||||966|63|66
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRIs||||1000|84|88
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|117|119
SE|00000000||tx|1|entity|C0456387|Class|inpr|||class||||888|121|125


SE|00000000||tx|1|text|Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.
SE|00000000||tx|1|entity|C0701977|Phospholine Iodide|opco,phsu|||Phospholine Iodide||||1000|1|18
SE|00000000||tx|1|entity|C0008425|Cholinesterase Inhibitors|orch,phsu|||cholinesterase inhibitors||||1000|38|62
SE|00000000||tx|1|entity|C0038627|Succinylcholine|orch,phsu|||succinylcholine||||1000|72|86
SE|00000000||tx|1|entity|C0031701|Phosphoric Acid Esters|opco|||organophosphate||||1000|91|105
SE|00000000||tx|1|entity|C0021578|Carbamate insecticide|hops|||carbamate insecticides||||983|111|132
SE|00000000||tx|1|relation|0|0|C0701977|Phospholine Iodide|opco,phsu|opco|||Phospholine Iodide||||1000|1|18|SPEC|ISA||1|62|0|0|C0008425|Cholinesterase Inhibitors|orch,phsu|orch|||cholinesterase inhibitors||||1000|38|62
SE|00000000||tx|1|relation|1|1|C0701977|Phospholine Iodide|opco,phsu|opco|||Phospholine Iodide||||1000|1|18|VERB|STIMULATES||20|30|4|1|C0008425|Cholinesterase Inhibitors|orch,phsu|orch|||cholinesterase inhibitors||||1000|38|62
SE|00000000||tx|1|relation|0|0|C0701977|Phospholine Iodide|opco,phsu|opco|||Phospholine Iodide||||1000|1|18|INFER|STIMULATES(SPEC)||1|62|0|0|C0701977|Phospholine Iodide|opco,phsu|opco|||Phospholine Iodide||||1000|1|18


SE|00000000||tx|1|text|Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||epinephrine||||1000|19|29
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|34|41
SE|00000000||tx|1|entity|C0010587|cyclopropane|orch,phsu|||cyclopropane||||1000|53|64
SE|00000000||tx|1|entity|C0020250|Hydrocarbons, Halogenated|orch|||halogenated hydrocarbon||||888|69|91
SE|00000000||tx|1|entity|C0017302|General anesthetic drugs|phsu|||general anesthetics||||888|93|111
SE|00000000||tx|1|entity|C0018549|Halothane|orch,phsu|||halothane||||1000|121|129
SE|00000000||tx|1|entity|C0027061|Myocardium|tisu|||myocardium||||1000|151|160
SE|00000000||tx|1|entity|C0003811|Cardiac Arrhythmia|patf|||cardiac arrhythmia||||1000|174|191
SE|00000000||tx|1|relation|0|0|C0018549|Halothane|orch,phsu|orch|||halothane||||1000|121|129|SPEC|ISA||93|129|0|0|C0017302|General anesthetic drugs|phsu|phsu|||general anesthetics||||888|93|111
SE|00000000||tx|1|relation|7|1|C0014563|Epinephrine|horm,nsba,orch,phsu|horm|||epinephrine||||1000|19|29|NOM|ADMINISTERED_TO||1|14|7|2|C0030705|Patients|podg,humn|humn|||patients||||1000|34|41
SE|00000000||tx|1|relation|5|1|C0010587|cyclopropane|orch,phsu|orch|||cyclopropane||||1000|53|64|VERB|ADMINISTERED_TO||43|51|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|34|41
SE|00000000||tx|1|relation|5|1|C0017302|General anesthetic drugs|phsu|phsu|||general anesthetics||||888|93|111|VERB|ADMINISTERED_TO||43|51|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|34|41
SE|00000000||tx|1|relation|6|1|C0018549|Halothane|orch,phsu|orch|||halothane||||1000|121|129|VERB|AUGMENTS||137|145|2|1|C0027061|Myocardium|tisu|tisu|||myocardium||||1000|151|160
SE|00000000||tx|1|relation|7|2|C0018549|Halothane|orch,phsu|orch|||halothane||||1000|121|129|VERB|CAUSES||167|172|1|1|C0003811|Cardiac Arrhythmia|patf|patf|||cardiac arrhythmia||||1000|174|191
SE|00000000||tx|1|relation|0|0|C0018549|Halothane|orch,phsu|orch|||halothane||||1000|121|129|INFER|ADMINISTERED_TO(SPEC)||93|129|0|0|C0030705|Patients|podg,humn|humn|||patients||||1000|34|41


SE|00000000||tx|1|text|Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||1000|1|12
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||1000|15|26
SE|00000000||tx|1|entity|C1883254|Synthesis|acty|||synthetic||||1000|45|53
SE|00000000||tx|1|entity|C0311402|catabolic|ftcn|||catabolic||||888|59|67
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzymes||||888|69|75
SE|00000000||tx|1|entity|C0042866|Vitamin D|orch,phsu,vita|||vitamin D||||1000|80|88


SE|00000000||tx|1|text|The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
SE|00000000||tx|1|entity|C0025815|Methylprednisolone|horm,phsu,strd|||methylprednisolone||||790|8|25
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||790|27|30
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|53|65
SE|00000000||tx|1|entity|C0360556|Oral form methylprednisolone|clnd|||oral methylprednisolone||||901|80|102
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||901|104|107
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|130|142
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||861|173|182
SE|00000000||tx|1|entity|C0274281|Injury due to exposure to external cause|inpo|||exposures||||1000|195|203
SE|00000000||tx|1|entity|C0025815|Methylprednisolone|horm,phsu,strd|||methylprednisolone||||1000|208|225
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||1000|227|233
SE|00000000||tx|1|entity|C1301820|Obtain|ftcn|||obtained||||1000|244|251
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|278|287


SE|00000000||tx|1|text|Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.
SE|00000000||tx|1|entity|C0015043|Ethosuximide|orch,phsu|||Ethosuximide||||1000|1|12
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||Amphetamines||||1000|15|26
SE|00000000||tx|1|entity|C0021826|Intestinal Absorption|ortf|||intestinal absorption||||1000|38|58
SE|00000000||tx|1|entity|C0015043|Ethosuximide|orch,phsu|||ethosuximide||||1000|63|74
SE|00000000||tx|1|relation|2|1|C0002667|Amphetamines|nsba,orch,phsu|nsba|||Amphetamines||||1000|15|26|VERB|AFFECTS||32|36|2|1|C0021826|Intestinal Absorption|ortf|ortf|||intestinal absorption||||1000|38|58


SE|00000000||tx|1|text|Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole) can not be ruled out.
SE|00000000||tx|1|entity|C0020615|Hypoglycemia|dsyn|||hypoglycemia||||861|16|27
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|50|57
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|83|86
SE|00000000||tx|1|entity|C0025942|Miconazole|orch,phsu|||miconazole||||888|88|97
SE|00000000||tx|1|entity|C0020923|Imidazole|orch,phsu|||imidazole||||1000|103|111
SE|00000000||tx|1|entity|C0359086|Oral hypoglycemic|phsu|||oral hypoglycemic agents||||1000|118|141
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||888|151|159
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||888|161|171
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||827|194|199
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||888|230|241
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||888|243|249
SE|00000000||tx|1|entity|C0020923|Imidazole|orch,phsu|||imidazole||||1000|255|263
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|270|272
SE|00000000||tx|1|entity|C0849355|Removed|qlco|||out||||1000|283|285
SE|00000000||tx|1|relation|1|1|C0020615|Hypoglycemia|dsyn|dsyn|||hypoglycemia||||861|16|27|PREP|PROCESS_OF||47|48|8|1|C0030705|Patients|podg,humn|humn|||patients||||861|50|57
SE|00000000||tx|1|relation|7|1|C0025942|Miconazole|orch,phsu|orch|||miconazole||||888|88|97|VERB|ADMINISTERED_TO||73|81|2|1|C0030705|Patients|podg,humn|humn|||patients||||861|50|57


SE|00000000||tx|1|text|Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|1|10
SE|00000000||tx|1|entity|C0027396|Naproxen|orch,phsu|||naproxen||||775|41|48
SE|00000000||tx|1|entity|C0003075|Anions|elii|||anion||||775|50|54
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||775|56|61
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||824|86|91
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||824|93|101


SE|00000000||tx|1|text|In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy subjects||||1000|4|19
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|31|40
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||635|48|52
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|59|61
SE|00000000||tx|1|entity|C0439230|week|tmco|||week||||888|63|66
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||623|69|74
SE|00000000||tx|1|entity|C0016229|Flecainide|orch,phsu|||flecainide||||623|76|85
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||1000|121|129


SE|00000000||tx|1|text|Tricyclic antidepressants may antagonize the hypotensive effects of clonidine.
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||Tricyclic antidepressants||||1000|1|25
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|46|56
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|58|64
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||1000|69|77


SE|00000000||tx|1|text|Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||1000|21|30
SE|00000000||tx|1|entity|C0722329|Ortho-Novum 1/35|horm,phsu,strd|||Ortho-Novum 1/35||||1000|36|51
SE|00000000||tx|1|entity|C0028356|Norethindrone|horm,phsu,strd|||norethindrone||||1000|80|92
SE|00000000||tx|1|entity|C0015011|Ethinyl Estradiol|horm,phsu,strd|||ethinyl estradiol||||1000|98|114
SE|00000000||tx|1|relation|2|0|C0722329|Ortho-Novum 1/35|horm,phsu,strd|horm|||Ortho-Novum 1/35||||1000|36|51|VERB|STIMULATES||54|62|3|2|C0028356|Norethindrone|horm,phsu,strd|horm|||norethindrone||||1000|80|92
SE|00000000||tx|1|relation|2|0|C0722329|Ortho-Novum 1/35|horm,phsu,strd|horm|||Ortho-Novum 1/35||||1000|36|51|VERB|STIMULATES||54|62|3|2|C0015011|Ethinyl Estradiol|horm,phsu,strd|horm|||ethinyl estradiol||||1000|98|114


SE|00000000||tx|1|text|Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||Phenobarbital||||1000|1|13
SE|00000000||tx|1|entity|C0060135|felbamate|orch,phsu|||felbamate||||1000|36|44
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|51|63
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|75|82
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||890|87|99
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|101|121
SE|00000000||tx|1|entity|C1706429|Male, Self-Reported|orga|||male||||774|148|151
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy male volunteers||||774|140|162
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|174|186
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||901|193|204
SE|00000000||tx|1|entity|C0444506|Trough|qnco|||trough||||901|206|211
SE|00000000||tx|1|entity|C2827771|Cmin|qnco|||Cmin||||1000|214|217
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||694|220|232
SE|00000000||tx|1|entity|C0439268|Microgram per Milliliter|qnco|||micrograms/mL||||844|257|269
SE|00000000||tx|1|relation|7|6|C0031412|Phenobarbital|orch,phsu|orch|||phenobarbital||||694|220|232|NOM|STIMULATES||75|82|7|1|C0031412|Phenobarbital|orch,phsu|orch|||phenobarbital||||890|87|99


SE|00000000||tx|1|text|Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.
SE|00000000||tx|1|entity|C0085672|Microbiology procedure|lbpr|||Micro||||844|1|5
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosed||||844|7|11
SE|00000000||tx|1|entity|C0033308|Progesterone|horm,phsu,strd|||Progesterone Preparations||||844|13|37
SE|00000000||tx|1|entity|C0085672|Microbiology procedure|lbpr|||Micro||||844|40|44
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosed||||844|46|50
SE|00000000||tx|1|entity|C0033308|Progesterone|horm,phsu,strd|||progesterone preparations||||844|52|76
SE|00000000||tx|1|entity|C0850358|minipill|topp|||minipills||||1000|79|87
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|97|99
SE|00000000||tx|1|entity|C0014939|Estrogens|horm,phsu,strd|||estrogen||||1000|112|119
SE|00000000||tx|1|entity|C0700589|Contraceptive methods|topp|||contraception||||1000|153|165
SE|00000000||tx|1|entity|C0699581|Accutane|orch,phsu|||Accutane||||888|174|181
SE|00000000||tx|1|relation|4|2|C0850358|minipill|topp|topp|||minipills||||1000|79|87|NOM|METHOD_OF||143|148|2|1|C0700589|Contraceptive methods|topp|topp|||contraception||||1000|153|165


SE|00000000||tx|1|text|Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|12|14
SE|00000000||tx|1|entity|C0006491|Butorphanol|orch,phsu|||butorphanol||||1000|19|29
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||central nervous system depressants||||1000|36|69
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|78|84
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|87|98
SE|00000000||tx|1|entity|C0040614|Tranquilizing Agents|phsu|||tranquilizers||||1000|101|113
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|120|133
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||central nervous system depressant||||892|160|192
SE|00000000||tx|1|entity|C0595938|EFFECT INCREASED|patf|||increased central nervous system depressant effects||||892|150|200
SE|00000000||tx|1|relation|7|5|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressants||||1000|36|69|VERB|CAUSES||140|145|1|1|C0595938|EFFECT INCREASED|patf|patf|||increased central nervous system depressant effects||||892|150|200


SE|00000000||tx|1|text|Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0004482|Azathioprine|orch,phsu|||azathioprine||||1000|20|31
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||861|37|47
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|77|80
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||888|82|90
SE|00000000||tx|1|entity|C0004482|Azathioprine|orch,phsu|||azathioprine||||1000|95|106
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||750|112|124
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||861|147|150
SE|00000000||tx|1|relation|5|1|C0004482|Azathioprine|orch,phsu|orch|||azathioprine||||1000|20|31|VERB|ADMINISTERED_TO||10|18|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8


SE|00000000||tx|1|text|Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|11|21
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|40|51
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||1000|57|67
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|72|74
SE|00000000||tx|1|entity|C0058445|dirithromycin|antb,orch|||dirithromycin||||1000|89|101


SE|00000000||tx|1|text|Agents Causing Renin Release Captopril's effect will be augmented by antihypertensive agents that cause renin release.
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||Agents||||966|1|6
SE|00000000||tx|1|entity|C0035100|Chymosin|aapp,enzy,phsu|||Renin||||833|16|20
SE|00000000||tx|1|entity|C0391871|Released (action)|ftcn|||Release||||833|22|28
SE|00000000||tx|1|entity|C0006938|Captopril|aapp,phsu|||Captopril's||||833|30|40
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||833|42|47
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensive agents||||1000|70|92
SE|00000000||tx|1|entity|C0035100|Chymosin|aapp,enzy,phsu|||renin||||888|105|109
SE|00000000||tx|1|entity|C0391871|Released (action)|ftcn|||release||||888|111|117


SE|00000000||tx|1|text|ROMAZICON blocks the central effects of benzodiazepines by competitive interaction at the receptor level.
SE|00000000||tx|1|entity|C0591091|Romazicon|orch,phsu|||ROMAZICON||||1000|1|9
SE|00000000||tx|1|entity|C1879652|Central Minus|lbpr|||central||||888|22|28
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|30|36
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|41|55
SE|00000000||tx|1|entity|C0679932|competition|socb|||competitive||||888|60|70
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||888|72|82
SE|00000000||tx|1|entity|C0597357|receptor|aapp,rcpt|||receptor||||888|91|98
SE|00000000||tx|1|entity|C2946261|Level|phsu|||level||||888|100|104


SE|00000000||tx|1|text|Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0016377|Flurbiprofen|orch,phsu|||flurbiprofen||||1000|22|33
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blocker||||901|41|52
SE|00000000||tx|1|entity|C1547307|Satisfactory|inpr|||satisfactory||||851|91|102
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||851|104|114
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||851|116|121
SE|00000000||tx|1|relation|3|1|C0016377|Flurbiprofen|orch,phsu|orch|||flurbiprofen||||1000|22|33|VERB|ADMINISTERED_TO||10|15|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8
SE|00000000||tx|1|relation|3|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blocker||||901|41|52|VERB|ADMINISTERED_TO||10|15|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8


SE|00000000||tx|1|text|Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
SE|00000000||tx|1|entity|C0581528|Close observation|topp|||Close observation||||1000|1|17
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|26|32
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blocker||||901|56|67
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|88|95
SE|00000000||tx|1|entity|C0007412|Catecholamines|nsba,orch,phsu|||catecholamine||||840|107|119
SE|00000000||tx|1|entity|C0333668|Depletion|ftcn|||depleting||||840|121|129
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||840|131|135
SE|00000000||tx|1|entity|C0035179|Reserpine|orch,phsu|||reserpine||||1000|145|153
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||851|167|174
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||851|176|183
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||851|185|191
SE|00000000||tx|1|entity|C0033268|production|ocac|||production||||1000|201|210
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||1000|215|225
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||marked||||888|234|239
SE|00000000||tx|1|entity|C0428977|Bradycardia|patf|||bradycardia||||888|241|251
SE|00000000||tx|1|entity|C0042571|Vertigo|sosy|||vertigo||||1000|272|278
SE|00000000||tx|1|entity|C0039070|Syncope|sosy|||syncope||||1000|281|287
SE|00000000||tx|1|entity|C0020651|Hypotension, Orthostatic|fndg|||postural hypotension||||1000|293|312
SE|00000000||tx|1|relation|0|0|C0035179|Reserpine|orch,phsu|orch|||reserpine||||1000|145|153|SPEC|ISA||131|153|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||840|131|135
SE|00000000||tx|1|relation|3|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blocker||||901|56|67|VERB|ADMINISTERED_TO||72|83|10|1|C0030705|Patients|podg,humn|humn|||patients||||1000|88|95
SE|00000000||tx|1|relation|9|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||840|131|135|VERB|ADMINISTERED_TO||97|105|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|88|95
SE|00000000||tx|1|relation|10|5|C0035179|Reserpine|orch,phsu|orch|||reserpine||||1000|145|153|VERB|CAUSES||264|270|3|1|C0042571|Vertigo|sosy|sosy|||vertigo||||1000|272|278
SE|00000000||tx|1|relation|0|0|C0035179|Reserpine|orch,phsu|orch|||reserpine||||1000|145|153|INFER|ADMINISTERED_TO(SPEC)||131|153|0|0|C0030705|Patients|podg,humn|humn|||patients||||1000|88|95


SE|00000000||tx|1|text|If a diuretic is also used, the risk of lithium toxicity may be increased.
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|6|13
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|33|36
SE|00000000||tx|1|entity|C0238242|LITHIUM TOXICITY|inpo|||lithium toxicity||||1000|41|56
SE|00000000||tx|1|relation|2|1|C0012798|Diuretics|phsu|phsu|||diuretic||||1000|6|13|NOM|PREDISPOSES||33|36|1|1|C0238242|LITHIUM TOXICITY|inpo|inpo|||lithium toxicity||||1000|41|56


SE|00000000||tx|1|text|Cimetidine treatment should be stopped during treatment with ELLENCE.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||888|1|10
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|47|55
SE|00000000||tx|1|entity|C0701345|Ellence|orch,phsu|||ELLENCE||||1000|62|68
SE|00000000||tx|1|relation|2|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||1000|47|55|PREP|USES||57|60|1|1|C0701345|Ellence|orch,phsu|phsu|||ELLENCE||||1000|62|68


SE|00000000||tx|1|text|The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.
SE|00000000||tx|1|entity|C1272641|Systemic arterial pressure|fndg|||blood pressure||||901|5|18
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||901|20|25
SE|00000000||tx|1|entity|C0723503|Sular|orch,phsu|||SULAR||||1000|30|34
SE|00000000||tx|1|entity|C1704243|Greater|qnco|||greater||||1000|49|55
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|60|67
SE|00000000||tx|1|entity|C0004147|Atenolol|orch,phsu|||atenolol||||1000|72|79
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|89|96
SE|00000000||tx|1|entity|C0585941|Antihypertensive therapy|topp|||antihypertensive therapy||||1000|110|133
SE|00000000||tx|1|relation|6|1|C0723503|Sular|orch,phsu|phsu|||SULAR||||1000|30|34|NOM|AFFECTS||20|25|0|0|C1272641|Systemic arterial pressure|fndg|fndg|||blood pressure||||901|5|18
SE|00000000||tx|1|relation|5|1|C0004147|Atenolol|orch,phsu|phsu|||atenolol||||1000|72|79|PREP|TREATS||86|87|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|89|96


SE|00000000||tx|1|text|Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||Rifampin||||1000|1|8
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||901|29|35
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum digoxin concentration||||901|23|49
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|66|73
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|80|84
SE|00000000||tx|1|entity|C0442808|Increasing|ftcn|||increasing||||1000|102|111
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||non-||||851|117|120
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||851|121|125
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||851|127|135
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|140|146
SE|00000000||tx|1|relation|1|1|C0035608|Rifampin|antb,orch|antb|||Rifampin||||1000|1|8|VERB|INHIBITS||14|21|6|1|C0012265|Digoxin|carb,phsu,strd|carb|||digoxin||||901|29|35


SE|00000000||tx|1|text|Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||1000|1|12
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|35|46
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|53|58
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|67|70
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|86|91
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|93|96
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||1000|101|112
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|128|130
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||1000|135|146
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||888|156|161
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||888|163|172


SE|00000000||tx|1|text|In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|6|10
SE|00000000||tx|1|entity|C0241863|DIABETIC|fndg|||diabetics||||1000|15|23
SE|00000000||tx|1|entity|C0730345|Microalbuminuria|dsyn|||microalbuminuria||||775|30|45
SE|00000000||tx|1|entity|C1144054|Inspra|phsu,strd|||INSPRA||||775|47|52
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitor||||794|79|91
SE|00000000||tx|1|entity|C0014025|Enalapril|aapp,phsu|||enalapril||||794|93|101
SE|00000000||tx|1|entity|C0439603|Frequencies (time pattern)|tmco|||frequency||||1000|123|131
SE|00000000||tx|1|entity|C0020461|Hyperkalemia|fndg|||hyperkalemia||||1000|136|147
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||774|150|154
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||774|156|164
SE|00000000||tx|1|entity|C0439375|mEq/L|qnco|||mEq/L)||||774|171|176
SE|00000000||tx|1|entity|C0014025|Enalapril|aapp,phsu|||enalapril||||1000|190|198
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|200|204
SE|00000000||tx|1|entity|C0450361|38|inpr|||38%||||1000|209|211


SE|00000000||tx|1|text|If it is necessary to continue the diuretic, initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|36|43
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|55|61
SE|00000000||tx|1|entity|C0701176|Prinivil|aapp,phsu|||PRINIVIL||||1000|68|75
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|82|85
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||851|95|99
SE|00000000||tx|1|entity|C0205476|Medical|ftcn|||medical||||901|120|126
SE|00000000||tx|1|entity|C0557988|Close supervision|topp|||close medical supervision||||901|114|138
SE|00000000||tx|1|entity|C0205265|Initially|tmco|||initial||||888|150|156
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|158|161
SE|00000000||tx|1|entity|C0005823|Blood Pressure|orgf|||blood pressure||||1000|169|182
SE|00000000||tx|1|relation|2|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||1000|55|61|PREP|USES||63|66|6|1|C0701176|Prinivil|aapp,gngm,phsu|phsu|||PRINIVIL||||1000|68|75


SE|00000000||tx|1|text|Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.
SE|00000000||tx|1|entity|C0678587|steady state|npop|||Steady-state||||877|1|12
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentrations||||877|14|33
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|38|62
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|109|118
SE|00000000||tx|1|entity|C1524062|Additional|ftcn|||added||||861|130|134
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||888|156|159
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||regimen||||888|161|167
SE|00000000||tx|1|relation|0|0|C0040808|Treatment Protocols|topp|topp|||regimen||||888|161|167|MOD/HEAD|USES||156|167|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||888|156|159


SE|00000000||tx|1|text|Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|13|22
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|40|49
SE|00000000||tx|1|entity|C0008269|Chloroquine|orch,phsu|||chloroquine||||1000|54|64
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||888|82|87
SE|00000000||tx|1|entity|C2946261|Level|phsu|||level||||888|89|93
SE|00000000||tx|1|relation|2|1|C0008783|Cimetidine|orch,phsu|orch|||Cimetidine||||1000|13|22|VERB|INHIBITS||28|34|3|2|C0008269|Chloroquine|orch,phsu|orch|||chloroquine||||1000|54|64


SE|00000000||tx|1|text|Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.
SE|00000000||tx|1|entity|C0030125|aminosalicylic acid|orch,phsu|||Aminosalicylic acid||||1000|1|19
SE|00000000||tx|1|entity|C0042845|Vitamin B 12|orch,phsu,vita|||vitamin B12||||1000|57|67
SE|00000000||tx|1|entity|C0011155|Deficiency|ftcn|||deficiency||||1000|90|99


SE|00000000||tx|1|text|Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied
SE|00000000||tx|1|entity|C1882911|Reciprocal|qlco|||Reciprocal||||872|1|10
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interactions||||872|12|23
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|40|50
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|52|54
SE|00000000||tx|1|entity|C0604279|Antizol|orch,phsu|||Antizol||||1000|59|65
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|71|75
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|82|89
SE|00000000||tx|1|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P450||||916|106|120
SE|00000000||tx|1|entity|C0449913|System|ftcn|||system||||916|122|127
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|136|144
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|147|159
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|162|171
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|174|185
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|205|207
SE|00000000||tx|1|relation|5|2|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|71|75|VERB|INHIBITS||94|100|5|1|C0010762|Cytochrome P450|aapp,gngm,enzy|gngm|||cytochrome P450||||916|106|120
SE|00000000||tx|1|relation|5|2|C0604279|Antizol|orch,phsu|phsu|||Antizol||||1000|59|65|VERB|INHIBITS||94|100|5|1|C0010762|Cytochrome P450|aapp,gngm,enzy|gngm|||cytochrome P450||||916|106|120


SE|00000000||tx|1|text|A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||901|3|10
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interaction||||901|12|27
SE|00000000||tx|1|entity|C0730991|Foscavir|opco,phsu|||FOSCAVIR||||1000|32|39
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||888|45|55
SE|00000000||tx|1|entity|C0030863|Pentamidine|orch,phsu|||pentamidine||||888|57|67


SE|00000000||tx|1|text|Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||694|12|20
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|36|42
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiating||||966|64|73
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuing||||872|90|102
SE|00000000||tx|1|entity|C0719509|Coreg|orch,phsu|||COREG||||872|104|108


SE|00000000||tx|1|text|Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high doses||||983|20|29
SE|00000000||tx|1|entity|C0036077|Salicylates|orch,phsu|||salicylates||||861|34|44
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|65|74
SE|00000000||tx|1|entity|C0035435|Rheumatism|dsyn|||rheumatic disease||||1000|83|99
SE|00000000||tx|1|entity|C0161544|Poisoning by salicylate|inpo|||salicylate toxicity||||1000|117|135
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||861|146|150
SE|00000000||tx|1|entity|C0679932|competition|socb|||competitive||||775|163|173
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||775|175|179
SE|00000000||tx|1|entity|C0205145|Site|spco|||sites||||775|191|195
SE|00000000||tx|1|relation|4|1|C0016860|Furosemide|orch,phsu|phsu|||furosemide||||1000|65|74|PREP|TREATS||80|81|4|1|C0035435|Rheumatism|dsyn|dsyn|||rheumatic disease||||1000|83|99
SE|00000000||tx|1|relation|3|1|C0161544|Poisoning by salicylate|inpo|inpo|||salicylate toxicity||||1000|117|135|VERB|PROCESS_OF||106|115|5|5|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8


SE|00000000||tx|1|text|If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||851|4|14
SE|00000000||tx|1|entity|C0540623|naratriptan|orch,phsu|||naratriptan||||1000|31|41
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRI||||1000|50|53
SE|00000000||tx|1|entity|C1548787|Appropriate|qlco|||appropriate||||888|80|90
SE|00000000||tx|1|entity|C1964257|Observation - diagnostic procedure|diap|||observation||||888|92|102
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|111|117


SE|00000000||tx|1|text|Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||Magnesium||||1000|1|9
SE|00000000||tx|1|entity|C1874163|ALUMINUM CONTAINING ANTACIDS|phsu|||aluminum-containing antacids||||1000|19|46
SE|00000000||tx|1|entity|C1514468|product|enty|||products||||1000|49|56
SE|00000000||tx|1|entity|C0060282|ferrous sulfate|inch,phsu|||ferrous sulfate||||1000|69|83
SE|00000000||tx|1|entity|C0302583|Iron|bacs,elii,phsu|||iron||||1000|86|89
SE|00000000||tx|1|entity|C0301532|Multivitamin preparation|orch,phsu,vita|||multivitamin preparations||||1000|93|117
SE|00000000||tx|1|entity|C0043481|Zinc|bacs,elii,phsu|||zinc||||1000|130|133
SE|00000000||tx|1|entity|C0025552|Metals|inch|||metal||||888|144|148
SE|00000000||tx|1|entity|C0007447|Cations|chvs|||cations||||888|150|156
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||Videx||||1000|162|166
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||1000|169|178
SE|00000000||tx|1|entity|C0006353|Buffers|irda,phsu|||buffered||||901|190|197
SE|00000000||tx|1|entity|C0304290|Chewable Tablet|bodm|||chewable/buffered tablets||||901|181|205
SE|00000000||tx|1|entity|C1521725|Pediatric|qlco|||pediatric||||694|214|222
SE|00000000||tx|1|entity|C0991536|Oral Solution|bodm|||oral solution||||1000|235|247
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|256|258
SE|00000000||tx|1|entity|C1442460|3 Hours|tmco|||3 hours||||1000|276|282
SE|00000000||tx|1|entity|C1292425|2 Hours|tmco|||2 hours||||1000|294|300
SE|00000000||tx|1|entity|C1320102|Factive|antb,orch|||FACTIVE||||1000|308|314
SE|00000000||tx|1|relation|0|0|C0060282|ferrous sulfate|inch,phsu|inch|||ferrous sulfate||||1000|69|83|SPEC|ISA||69|89|0|0|C0302583|Iron|bacs,elii,phsu|bacs|||iron||||1000|86|89
SE|00000000||tx|1|relation|0|0|C0592249|Videx|nnon,phsu|nnon|||Videx||||1000|162|166|SPEC|ISA||162|178|0|0|C0012133|Didanosine|nnon,phsu|nnon|||didanosine||||1000|169|178


SE|00000000||tx|1|text|Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|9|19
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|33|41
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|51|58
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||888|68|73
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||888|75|84
SE|00000000||tx|1|entity|C0011279|Nordazepam|orch,phsu|||desmethyldiazepam||||861|89|105
SE|00000000||tx|1|entity|C0442821|Strong|qlco|||strong||||888|119|124
SE|00000000||tx|1|entity|C0033204|Probability|qnco|||likelihood||||888|126|135
SE|00000000||tx|1|entity|C1705920|Species|cnce|||species||||1000|173|179
SE|00000000||tx|1|entity|C0205191|chronic|tmco|||chronic||||802|188|194
SE|00000000||tx|1|relation|1|1|C0085228|Fluvoxamine|orch,phsu|orch|||fluvoxamine||||1000|9|19|VERB|INHIBITS||21|27|8|2|C0012010|Diazepam|orch,phsu|orch|||diazepam||||1000|51|58


SE|00000000||tx|1|text|Avoid the concomitant use of chlorprothixene and tramadol (Ultram).
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|11|21
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|23|25
SE|00000000||tx|1|entity|C0008290|Chlorprothixene|orch,phsu|||chlorprothixene||||1000|30|44
SE|00000000||tx|1|entity|C0040610|Tramadol|orch,phsu|||tramadol||||1000|50|57
SE|00000000||tx|1|entity|C0724054|Ultram|orch,phsu|||Ultram||||1000|60|65
SE|00000000||tx|1|relation|0|0|C0724054|Ultram|orch,phsu|orch|||Ultram||||1000|60|65|SPEC|ISA||50|65|0|0|C0040610|Tramadol|orch,phsu|orch|||tramadol||||1000|50|57


SE|00000000||tx|1|text|However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|25|27
SE|00000000||tx|1|entity|C0151872|Prothrombin time increased|fndg|||prolonged prothrombin time||||1000|39|64
SE|00000000||tx|1|entity|C0006462|Buspirone|orch,phsu|||buspirone||||1000|71|79
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||regimen||||1000|98|104
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|111|117
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|132|139
SE|00000000||tx|1|relation|1|1|C0043031|Warfarin|hops,orch,phsu|phsu|||warfarin||||1000|132|139|VERB|TREATS||119|125|5|1|C0030705|Patients|podg,humn|podg|||patient||||1000|111|117


SE|00000000||tx|1|text|Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|12|17
SE|00000000||tx|1|entity|C0333164|Narrow|qnco|||narrow||||901|46|51
SE|00000000||tx|1|entity|C0678793|Therapeutic Index|qnco|||therapeutic index||||901|53|69
SE|00000000||tx|1|entity|C0002026|Alfentanil|orch,phsu|||alfentanil||||1000|79|88
SE|00000000||tx|1|entity|C0085170|Astemizole|orch,phsu|||astemizole||||1000|91|100
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||1000|103|113
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|116|124
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|127|138
SE|00000000||tx|1|entity|C0015846|Fentanyl|orch,phsu|||fentanyl||||1000|141|148
SE|00000000||tx|1|entity|C0031935|Pimozide|orch,phsu|||pimozide||||1000|151|158
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|161|169
SE|00000000||tx|1|entity|C0072980|Sirolimus|antb,orch|||sirolimus||||1000|172|180
SE|00000000||tx|1|entity|C0085149|Tacrolimus|orch,phsu|||tacrolimus||||1000|183|192
SE|00000000||tx|1|entity|C0014707|Ergot Alkaloids|bacs,orch,phsu|||ergot alkaloids||||1000|198|212
SE|00000000||tx|1|entity|C0014710|Ergotamine|orch,phsu|||ergotamine||||1000|215|224
SE|00000000||tx|1|entity|C0012291|Dihydroergotamine|orch,phsu|||dihydroergotamine||||1000|227|243
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|285|292
SE|00000000||tx|1|entity|C1723829|Sprycel|orch,phsu|||SPRYCEL||||1000|304|310
SE|00000000||tx|1|relation|0|0|C0014710|Ergotamine|orch,phsu|orch|||ergotamine||||1000|215|224|SPEC|ISA||198|224|0|0|C0014707|Ergot Alkaloids|bacs,orch,phsu|bacs|||ergot alkaloids||||1000|198|212
SE|00000000||tx|1|relation|16|4|C0014707|Ergot Alkaloids|bacs,orch,phsu|phsu|||ergot alkaloids||||1000|198|212|PREP|TREATS||282|283|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|285|292
SE|00000000||tx|1|relation|1|1|C1723829|Sprycel|orch,phsu|orch|||SPRYCEL||||1000|304|310|VERB|ADMINISTERED_TO||294|302|17|1|C0030705|Patients|podg,humn|humn|||patients||||1000|285|292
SE|00000000||tx|1|relation|0|0|C0014710|Ergotamine|orch,phsu|orch|||ergotamine||||1000|215|224|INFER|TREATS(SPEC)||198|224|0|0|C0030705|Patients|podg,humn|podg|||patients||||1000|285|292


SE|00000000||tx|1|text|Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
SE|00000000||tx|1|entity|C0252643|bosentan|orch,phsu|||Bosentan||||1000|1|8
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|37|57
SE|00000000||tx|1|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||statins||||1000|68|74
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|86|96
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|98|107
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|112|117
SE|00000000||tx|1|entity|C0024027|Lovastatin|orch,phsu|||lovastatin||||1000|128|137
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||1000|143|154
SE|00000000||tx|1|relation|1|1|C0252643|bosentan|orch,phsu|orch|||Bosentan||||1000|1|8|VERB|INHIBITS||30|35|6|2|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|orch|||statins||||1000|68|74


SE|00000000||tx|1|text|Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||Aspirin||||1000|1|7
SE|00000000||tx|1|entity|C0700001|Lodine|orch,phsu|||Lodine||||1000|15|20
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|43|49
SE|00000000||tx|1|entity|C0033618|Protein Binding|moft|||protein binding||||1000|56|70
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|97|105
SE|00000000||tx|1|entity|C1880497|Empty (qualifier)|qlco|||free||||888|110|113
SE|00000000||tx|1|entity|C0059865|Etodolac|orch,phsu|||etodolac||||888|115|122
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|127|129


SE|00000000||tx|1|text|Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.
SE|00000000||tx|1|entity|C0017628|Glyburide|orch,phsu|||Glyburide||||1000|1|9
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|16|26
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|46|58
SE|00000000||tx|1|entity|C0017628|Glyburide|orch,phsu|||glyburide||||861|82|90
SE|00000000||tx|1|entity|C0521114|Infrequent|tmco|||rare||||847|100|103
SE|00000000||tx|1|entity|C0521114|Infrequent|tmco|||occasions||||847|105|113
SE|00000000||tx|1|entity|C0020615|Hypoglycemia|dsyn|||hypoglycemia||||861|135|146
SE|00000000||tx|1|relation|5|2|C0017628|Glyburide|orch,phsu|orch|||glyburide||||861|82|90|VERB|CAUSES||116|123|1|1|C0020615|Hypoglycemia|dsyn|dsyn|||hypoglycemia||||861|135|146


SE|00000000||tx|1|text|Lethargy and somnolence have been reported following doses of REVIA and thioridazine.
SE|00000000||tx|1|entity|C0023380|Lethargy|sosy|||Lethargy||||1000|1|8
SE|00000000||tx|1|entity|C2830004|Somnolence|fndg|||somnolence||||1000|14|23
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||1000|54|58
SE|00000000||tx|1|entity|C0591842|ReVia|orch,phsu|||REVIA||||1000|63|67
SE|00000000||tx|1|entity|C0039943|Thioridazine|orch,phsu|||thioridazine||||1000|73|84


SE|00000000||tx|1|text|Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.
SE|00000000||tx|1|entity|C0449976|Initial presentation|ftcn|||initial presentation||||1000|21|40
SE|00000000||tx|1|entity|C0237753|Numbers|qnco|||number||||1000|47|52
SE|00000000||tx|1|entity|C1290884|Inflammatory disorder|dsyn|||inflammatory disorders||||983|72|93
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|123|132
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|134|136
SE|00000000||tx|1|entity|C0002199|Interferon-alpha|aapp,imft,phsu|||interferon-alfa||||1000|141|155
SE|00000000||tx|1|entity|C0701339|Proleukin|orch,phsu|||PROLEUKIN||||1000|161|169
SE|00000000||tx|1|entity|C0444628|Crescents|spco|||crescentic||||865|182|191
SE|00000000||tx|1|entity|C0017661|IGA Glomerulonephritis|dsyn|||IgA glomerulonephritis||||865|193|214
SE|00000000||tx|1|entity|C1947952|anatomical bulb|anst|||bulbar||||824|223|228
SE|00000000||tx|1|entity|C0026896|Myasthenia Gravis|dsyn|||myasthenia gravis||||824|230|246
SE|00000000||tx|1|entity|C0003864|Arthritis|dsyn|||inflammatory arthritis||||1000|249|270
SE|00000000||tx|1|entity|C0040147|Thyroiditis|dsyn|||thyroiditis||||1000|273|283
SE|00000000||tx|1|entity|C0030805|Bullous pemphigoid|dsyn|||bullous pemphigoid||||1000|286|303
SE|00000000||tx|1|entity|C0038325|Stevens-Johnson Syndrome|dsyn|||Stevens-Johnson syndrome||||1000|310|333


SE|00000000||tx|1|text|NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|1|6
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|39|46
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|55|66
SE|00000000||tx|1|entity|C0232804|Renal function|ortf|||renal function||||1000|73|86
SE|00000000||tx|1|relation|2|2|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|1|6|PREP|TREATS||36|37|3|1|C0030705|Patients|podg,humn|podg|||patients||||1000|39|46
SE|00000000||tx|1|relation|2|1|C0010592|Cyclosporine|aapp,gngm,phsu|phsu|||cyclosporine||||1000|55|66|VERB|ADMINISTERED_TO||48|53|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|39|46


SE|00000000||tx|1|text|A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||rare||||1000|3|6
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||694|13|19
SE|00000000||tx|1|entity|C1457887|Symptoms|sosy|||symptoms||||1000|39|46
SE|00000000||tx|1|entity|C0699828|Serotonin Syndrome|inpo|||serotonin syndrome||||901|56|73
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|103|113
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|115|117
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||selective serotonin reuptake inhibitors||||1000|122|160
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|174|179
SE|00000000||tx|1|entity|C0149931|Migraine Disorders|dsyn|||migraine||||888|185|192
SE|00000000||tx|1|entity|C0721044|Imitrex|orch,phsu|||Imitrex||||1000|211|217
SE|00000000||tx|1|entity|C0206599|Sumatriptan Succinate|orch,phsu|||sumatriptan succinate||||1000|220|240
SE|00000000||tx|1|entity|C0012291|Dihydroergotamine|orch,phsu|||dihydroergotamine||||1000|247|263
SE|00000000||tx|1|relation|0|0|C0721044|Imitrex|orch,phsu|orch|||Imitrex||||1000|211|217|SPEC|ISA||211|240|0|0|C0206599|Sumatriptan Succinate|orch,phsu|orch|||sumatriptan succinate||||1000|220|240
SE|00000000||tx|1|relation|7|2|C0360105|Selective serotonin re-uptake inhibitor|phsu|phsu|||selective serotonin reuptake inhibitors||||1000|122|160|NOM|TREATS||194|200|7|0|C0149931|Migraine Disorders|dsyn|dsyn|||migraine||||888|185|192


SE|00000000||tx|1|text|Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|12|19
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||888|27|38
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||901|95|107
SE|00000000||tx|1|entity|C1707479|Concomitant Therapy|topp|||concomitant ciprofloxacin therapy||||901|83|115
SE|00000000||tx|1|relation|0|0|C1707479|Concomitant Therapy|topp|topp|||concomitant ciprofloxacin therapy||||901|83|115|MOD/HEAD|USES||95|115|0|0|C0008809|Ciprofloxacin|orch,phsu|phsu|||ciprofloxacin||||901|95|107


SE|00000000||tx|1|text|If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.
SE|00000000||tx|1|entity|C0071304|Isradipine|orch,phsu|||isradipine||||851|4|13
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||888|41|47
SE|00000000||tx|1|entity|C0521116|Current (present time)|tmco|||currently||||888|49|57
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||660|69|78
SE|00000000||tx|1|entity|C0559546|Adverse reactions|fndg|||adverse reactions||||1000|103|119
SE|00000000||tx|1|entity|C0205104|Downward|spco|||downward||||901|136|143
SE|00000000||tx|1|entity|C2826232|Dose Adjustment|hlca|||dose adjustment||||901|145|159


SE|00000000||tx|1|text|There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.
SE|00000000||tx|1|entity|C0205412|Inadequate (qualifier)|qlco|||insufficient||||790|10|21
SE|00000000||tx|1|entity|C0596545|Experience|menp|||experience||||790|23|32
SE|00000000||tx|1|entity|C0036043|Safety|hcpp|||safety||||1000|48|53
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|59|66
SE|00000000||tx|1|entity|C1700021|Orencia|aapp,imft,phsu|||ORENCIA||||1000|71|77
SE|00000000||tx|1|entity|C0245109|anakinra|aapp,phsu|||anakinra||||1000|110|117
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|146|148


SE|00000000||tx|1|text|The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.
SE|00000000||tx|1|entity|C2936720|Hypoglycemic Effect|phsf|||hypoglycemic effect||||1000|5|23
SE|00000000||tx|1|entity|C0040374|Tolbutamide|orch,phsu|||tolbutamide||||1000|28|38
SE|00000000||tx|1|entity|C0591129|Atromid|orch,phsu|||Atromid-S||||1000|75|83


SE|00000000||tx|1|text|Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||Cisapride||||1000|1|9
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|18|20
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|55|59
SE|00000000||tx|1|entity|C0429028|QT interval feature (observable entity)|clna|||QT interval||||1000|82|92
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||888|95|101
SE|00000000||tx|1|entity|C0003195|Anti-Arrhythmia Agents|phsu|||antiarrhythmics||||888|103|117
SE|00000000||tx|1|entity|C0456387|Class|inpr|||Class||||694|139|143
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|157|165
SE|00000000||tx|1|entity|C0033216|Procainamide|orch,phsu|||procainamide||||1000|171|182
SE|00000000||tx|1|entity|C0441887|Class 3|inpr|||Class III||||1000|189|197
SE|00000000||tx|1|entity|C0037707|Sotalol|orch,phsu|||sotalol||||1000|208|214


SE|00000000||tx|1|text|Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||Diuretic||||872|1|8
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||872|10|15
SE|00000000||tx|1|entity|C1801960|Vascular|qlco|||vascular||||694|30|37
SE|00000000||tx|1|entity|C0237795|Pressors|phsu|||pressor||||888|51|57
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|59|63
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||epinephrine||||1000|73|83
SE|00000000||tx|1|relation|0|0|C0012798|Diuretics|phsu|phsu|||Diuretic||||872|1|8|MOD/HEAD|ISA||1|15|0|0|C1254351|Pharmacologic Substance|phsu|phsu|||agents||||872|10|15
SE|00000000||tx|1|relation|0|0|C0014563|Epinephrine|horm,nsba,orch,phsu|horm|||epinephrine||||1000|73|83|SPEC|ISA||59|83|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|59|63


SE|00000000||tx|1|text|With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneous||||694|6|17
SE|00000000||tx|1|entity|C1176940|vardenafil 20 MG|clnd|||Vardenafil 20 mg||||1000|29|44
SE|00000000||tx|1|entity|C1123697|Terazosin 10 MG|clnd|||terazosin 10 mg||||1000|50|64
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||827|74|81
SE|00000000||tx|1|entity|C0488055|Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative|clna|||systolic blood pressure||||923|106|128
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||1000|133|136
SE|00000000||tx|1|entity|C0439475|mmHg|qnco|||mm Hg||||901|146|150


SE|00000000||tx|1|text|Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.
SE|00000000||tx|1|entity|C1274040|Result|ftcn|||Results||||1000|1|7
SE|00000000||tx|1|entity|C0439611|Preliminary|tmco|||preliminary||||888|12|22
SE|00000000||tx|1|entity|C0947630|Scientific Study|lbpr|||studies||||888|24|30
SE|00000000||tx|1|entity|C0086418|Homo sapiens|humn|||humans||||1000|35|40
SE|00000000||tx|1|entity|C0034693|Rattus norvegicus|mamm|||rats||||1000|46|49
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||861|78|85
SE|00000000||tx|1|entity|C0022957|Lactulose|carb,phsu|||lactulose||||1000|111|119
SE|00000000||tx|1|entity|C0871633|desires|menp|||desired||||825|137|143
SE|00000000||tx|1|entity|C0022957|Lactulose|carb,phsu|||lactulose||||825|145|153
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induced||||825|155|161
SE|00000000||tx|1|entity|C1705648|Dropping|acty|||drop||||825|163|166
SE|00000000||tx|1|entity|C0009368|Colon structure (body structure)|bpoc|||colonic||||888|171|177
SE|00000000||tx|1|relation|3|1|C0022957|Lactulose|carb,phsu|carb|||lactulose||||1000|111|119|VERB|COEXISTS_WITH||87|91|5|1|C0003138|Antacids|phsu|phsu|||antacids||||861|78|85


SE|00000000||tx|1|text|Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.
SE|00000000||tx|1|entity|C0288171|irbesartan|orch,phsu|||irbesartan||||1000|22|31
SE|00000000||tx|1|entity|C1120110|aliskiren|orch,phsu|||aliskiren||||888|41|49
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||888|51|54
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multiple||||694|72|79


SE|00000000||tx|1|text|Microdosed minipill progestin preparations are not recommended for use with Soriatane.
SE|00000000||tx|1|entity|C0850358|minipill|topp|||minipill||||824|12|19
SE|00000000||tx|1|entity|C0033306|Progestins|horm,phsu,strd|||progestin preparations||||824|21|42
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|48|50
SE|00000000||tx|1|entity|C0678135|Soriatane|orch,phsu|||Soriatane||||1000|77|85


SE|00000000||tx|1|text|Concurrent use of tetracycline may render oral contraceptives less effective.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|12|14
SE|00000000||tx|1|entity|C0039644|Tetracycline|antb,orch|||tetracycline||||1000|19|30
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives||||1000|43|61
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||888|63|66
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effective||||888|68|76


SE|00000000||tx|1|text|Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||Monoamine oxidase (MAO) inhibitors||||1000|1|34
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|78|84
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|89|102


SE|00000000||tx|1|text|Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|1|10
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|13|22
SE|00000000||tx|1|entity|C0678876|renal tubular secretion|ortf|||renal tubular secretion||||1000|40|62
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|67|79
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|97|104
SE|00000000||tx|1|entity|C2946261|Level|phsu|||level||||1000|113|117
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|122|134
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||1000|139|143
SE|00000000||tx|1|relation|2|1|C0033209|Probenecid|orch,phsu|phsu|||Probenecid||||1000|13|22|VERB|DISRUPTS||24|33|6|1|C0678876|renal tubular secretion|ortf|ortf|||renal tubular secretion||||1000|40|62
SE|00000000||tx|1|relation|3|2|C0008809|Ciprofloxacin|orch,phsu|orch|||ciprofloxacin||||1000|122|134|NOM|STIMULATES||97|104|3|1|C2946261|Level|phsu|phsu|||level||||1000|113|117


SE|00000000||tx|1|text|Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||Nelfinavir||||861|1|10
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||861|12|23
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||861|25|28
SE|00000000||tx|1|entity|C2827771|Cmin|qnco|||Cmin||||1000|40|43
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|99|109
SE|00000000||tx|1|entity|C0754188|Amprenavir|orch,phsu|||amprenavir||||888|111|120


SE|00000000||tx|1|text|Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitors||||1000|14|27
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|32|42
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|49|57
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|77|80
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitor||||1000|89|101
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|142|149
SE|00000000||tx|1|relation|1|1|C0012798|Diuretics|phsu|phsu|||diuretic||||1000|142|149|VERB|COEXISTS_WITH||129|133|6|1|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|phsu|||ACE inhibitor||||1000|89|101


SE|00000000||tx|1|text|Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||Lithium||||1000|1|7
SE|00000000||tx|1|entity|C0012091|Diclofenac|orch,phsu|||Diclofenac||||1000|10|19
SE|00000000||tx|1|entity|C0369615|Lithium renal clearance|clna|||lithium renal clearance||||1000|31|53
SE|00000000||tx|1|entity|C1440916|Lithium.plasma|elii,phsu|||lithium plasma||||901|69|82


SE|00000000||tx|1|text|Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|entity|C0065533|magnesium trisilicate|inch,phsu|||magnesium trisilicate||||1000|21|41
SE|00000000||tx|1|entity|C0028156|Nitrofurantoin|orch,phsu|||nitrofurantoin||||1000|81|94
SE|00000000||tx|1|entity|C1521828|Rate|qnco|||rate||||1000|113|116
SE|00000000||tx|1|entity|C0439792|Extent|spco|||extent||||1000|122|127


SE|00000000||tx|1|text|In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|4|11
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|14|18
SE|00000000||tx|1|entity|C0449444|Route|spco|||route||||1000|56|60
SE|00000000||tx|1|entity|C0040869|Triamterene|orch,phsu|||triamterene||||1000|69|79
SE|00000000||tx|1|entity|C0025598|Metformin|orch,phsu|||metformin||||1000|82|90
SE|00000000||tx|1|entity|C0002502|Amiloride|orch,phsu|||amiloride||||1000|96|104
SE|00000000||tx|1|entity|C0114771|dofetilide|orch,phsu|||dofetilide||||694|166|175
SE|00000000||tx|1|relation|7|6|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|14|18|VERB|STIMULATES||157|164|1|1|C0114771|dofetilide|orch,phsu|orch|||dofetilide||||694|166|175


SE|00000000||tx|1|text|Therefore, diflunisal and INDOCIN should not be used concomitantly.
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|12|21
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|27|33
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|42|44


SE|00000000||tx|1|text|Aminoglutethimide: May increase CYP metabolism of progestins leading to possible decrease in contraceptive effectiveness.
SE|00000000||tx|1|entity|C0002555|Aminoglutethimide|orch,phsu|||Aminoglutethimide||||1000|1|17
SE|00000000||tx|1|entity|||gngm|9360|PPIG|CYP||||861|33|35
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||861|37|46
SE|00000000||tx|1|entity|C0033306|Progestins|horm,phsu,strd|||progestins||||1000|51|60
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||888|73|80
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||888|82|89
SE|00000000||tx|1|entity|C2364326|Contraceptive|ftcn|||contraceptive||||888|94|106
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effectiveness||||888|108|120
SE|00000000||tx|1|relation|2|2|C0002555|Aminoglutethimide|orch,phsu|orch|||Aminoglutethimide||||1000|1|17|VERB|STIMULATES||24|31|4|1|||gngm,aapp|gngm|9360|PPIG|CYP||||861|33|35


SE|00000000||tx|1|text|Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.
SE|00000000||tx|1|entity|C0015042|profenamine|orch,phsu|||Ethopropazine||||1000|1|13
SE|00000000||tx|1|entity|C0008286|Chlorpromazine|orch,phsu|||chlorpromazine||||1000|33|46
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|64|73
SE|00000000||tx|1|entity|C0008286|Chlorpromazine|orch,phsu|||chlorpromazine||||1000|78|91
SE|00000000||tx|1|relation|1|1|C0015042|profenamine|orch,phsu|orch|||Ethopropazine||||1000|1|13|VERB|INTERACTS_WITH||19|26|3|1|C0008286|Chlorpromazine|orch,phsu|orch|||chlorpromazine||||1000|33|46
SE|00000000||tx|1|relation|2|1|C0008286|Chlorpromazine|orch,phsu|orch|||chlorpromazine||||1000|33|46|VERB|STIMULATES||49|58|2|2|C0008286|Chlorpromazine|orch,phsu|orch|||chlorpromazine||||1000|78|91


SE|00000000||tx|1|text|It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||1000|35|40
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulants||||1000|45|63
SE|00000000||tx|1|entity|C0439659|Beginning|tmco|||beginning||||1000|70|78
SE|00000000||tx|1|entity|C0723457|Stop brand of fluoride|inch,phsu|||stopping||||888|83|90
SE|00000000||tx|1|entity|C0012772|Disulfiram|orch,phsu|||disulfiram||||888|92|101
SE|00000000||tx|1|entity|C0012772|Disulfiram|orch,phsu|||disulfiram||||1000|110|119
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|133|148


SE|00000000||tx|1|text|EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.
SE|00000000||tx|1|entity|C0591434|Edecrin|orch,phsu|||EDECRIN||||1000|1|7
SE|00000000||tx|1|entity|C0235280|Ototoxicity|inpo|||ototoxic||||853|26|33
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||853|35|43
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|54|58
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycoside||||1000|68|81
SE|00000000||tx|1|entity|C2266959|Cephalosporin Antibacterial [EPC]|antb,orch|||cephalosporin antibiotics||||1000|92|116
SE|00000000||tx|1|relation|0|0|C0002556|Aminoglycosides|carb,phsu|carb|||aminoglycoside||||1000|68|81|SPEC|ISA||54|81|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|54|58
SE|00000000||tx|1|relation|0|0|C2266959|Cephalosporin Antibacterial [EPC]|antb,orch|antb|||cephalosporin antibiotics||||1000|92|116|SPEC|ISA||54|81|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|54|58


SE|00000000||tx|1|text|Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
SE|00000000||tx|1|entity|C0008402|Cholestyramine Resin|orch,phsu|||Cholestyramine resin||||1000|1|20
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||901|60|70
SE|00000000||tx|1|entity|C0175795|Oral medication|topp|||oral medication||||901|72|86
SE|00000000||tx|1|entity|C0031463|Phenylbutazone|orch,phsu|||phenylbutazone||||1000|96|109
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|112|119
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|122|139
SE|00000000||tx|1|entity|C0001128|Acids|chem|||acidic||||1000|142|147
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||1000|153|163
SE|00000000||tx|1|entity|C1527178|Basis - conceptual entity|ftcn|||basic||||1000|166|170
SE|00000000||tx|1|entity|C0039644|Tetracycline|antb,orch|||tetracycline||||901|185|196
SE|00000000||tx|1|entity|C0030827|Penicillin G|antb,orch|||penicillin G||||901|198|209
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|212|224
SE|00000000||tx|1|entity|C0040165|Thyroxine|aapp,horm,phsu|||thyroxine preparations||||983|239|260
SE|00000000||tx|1|entity|C0014939|Estrogens|horm,phsu,strd|||estrogens||||1000|263|271
SE|00000000||tx|1|entity|C0033306|Progestins|horm,phsu,strd|||progestins||||1000|277|286


SE|00000000||tx|1|text|Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.
SE|00000000||tx|1|entity|C0008425|Cholinesterase Inhibitors|orch,phsu|||Cholinesterase Inhibitors||||1000|1|25
SE|00000000||tx|1|entity|C0012582|Dipyridamole|orch,phsu|||Dipyridamole||||1000|28|39
SE|00000000||tx|1|entity|C0008425|Cholinesterase Inhibitors|orch,phsu|||anticholinesterase||||888|60|77
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|79|84
SE|00000000||tx|1|entity|C0008425|Cholinesterase Inhibitors|orch,phsu|||cholinesterase inhibitors||||1000|89|113
SE|00000000||tx|1|entity|C0026896|Myasthenia Gravis|dsyn|||myasthenia gravis||||1000|148|164
SE|00000000||tx|1|relation|2|0|C0008425|Cholinesterase Inhibitors|orch,phsu|orch|||anticholinesterase||||888|60|77|NOM|INTERACTS_WITH||79|84|2|1|C0008425|Cholinesterase Inhibitors|orch,phsu|orch|||cholinesterase inhibitors||||1000|89|113
SE|00000000||tx|1|relation|4|3|C0012582|Dipyridamole|orch,phsu|phsu|||Dipyridamole||||1000|28|39|VERB|COMPLICATES||136|146|1|1|C0026896|Myasthenia Gravis|dsyn|dsyn|||myasthenia gravis||||1000|148|164


SE|00000000||tx|1|text|Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
SE|00000000||tx|1|entity|C0009079|Clozapine|orch,phsu|||clozapine||||1000|33|41
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|54|58
SE|00000000||tx|1|entity|C0022173|Isoenzymes|aapp,enzy|||isozyme||||1000|89|95
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants||||1000|108|122
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|125|138
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|141|153
SE|00000000||tx|1|entity|||gngm|6445|SGCG|Type||||827|160|163
SE|00000000||tx|1|entity|C0003195|Anti-Arrhythmia Agents|phsu|||antiarrhythmics||||827|168|182
SE|00000000||tx|1|entity|C0033429|Propafenone|orch,phsu|||propafenone||||1000|191|201
SE|00000000||tx|1|entity|C0016229|Flecainide|orch,phsu|||flecainide||||1000|204|213
SE|00000000||tx|1|entity|C0085251|Encainide|orch,phsu|||encainide||||1000|219|227
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzyme||||1000|252|257
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|266|274
SE|00000000||tx|1|relation|11|1|C0022173|Isoenzymes|aapp,gngm,enzy|aapp|||isozyme||||1000|89|95|VERB|INTERACTS_WITH||69|79|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|54|58
SE|00000000||tx|1|relation|11|4|C0003195|Anti-Arrhythmia Agents|phsu|phsu|||antiarrhythmics||||827|168|182|VERB|INHIBITS||239|245|3|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme||||1000|252|257
SE|00000000||tx|1|relation|11|4|C0006949|Carbamazepine|orch,phsu|phsu|||carbamazepine||||1000|141|153|VERB|INHIBITS||239|245|3|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme||||1000|252|257
SE|00000000||tx|1|relation|11|4|C0031436|Phenothiazines|orch,phsu|phsu|||phenothiazines||||1000|125|138|VERB|INHIBITS||239|245|3|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme||||1000|252|257
SE|00000000||tx|1|relation|11|4|C0003289|Antidepressive Agents|phsu|phsu|||antidepressants||||1000|108|122|VERB|INHIBITS||239|245|3|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme||||1000|252|257


SE|00000000||tx|1|text|Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.
SE|00000000||tx|1|entity|C0308131|Bupropion Oral Tablet [Wellbutrin]|clnd|||WELLBUTRIN Tablets||||1000|19|36
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|41|48
SE|00000000||tx|1|entity|C0023570|Levodopa|aapp,nsba,phsu|||levodopa||||861|67|74
SE|00000000||tx|1|entity|C0002403|Amantadine|orch,phsu|||amantadine||||861|79|88
SE|00000000||tx|1|entity|C0700321|Small|qnco|||small||||851|144|148
SE|00000000||tx|1|entity|C0205265|Initially|tmco|||initial||||851|150|156
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||851|158|162
SE|00000000||tx|1|entity|C0700321|Small|qnco|||small||||833|168|172
SE|00000000||tx|1|entity|C0439833|Gradual|qlco|||gradual||||833|174|180
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||833|182|185
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||833|187|195
SE|00000000||tx|1|relation|5|1|C0023570|Levodopa|aapp,gngm,nsba,phsu|nsba|||levodopa||||861|67|74|VERB|ADMINISTERED_TO||50|58|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|41|48


SE|00000000||tx|1|text|Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|21|30
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|43|47
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|58|62
SE|00000000||tx|1|entity|||gngm|1559|CYP2C9|CYP2C9||||1000|100|105
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|116|124
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||884|147|167
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|178|182
SE|00000000||tx|1|relation|4|1|||gngm,aapp|gngm|1559|CYP2C9|CYP2C9||||1000|100|105|VERB|INTERACTS_WITH||85|95|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|58|62
SE|00000000||tx|1|relation|4|1|||gngm,aapp|gngm|1559|CYP2C9|CYP2C9||||1000|100|105|VERB|INTERACTS_WITH||85|95|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|43|47


SE|00000000||tx|1|text|Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||Inhibitors||||1000|14|23
SE|00000000||tx|1|entity|C0205054|Hepatic|blor|||Hepatic||||888|28|34
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||Metabolism||||888|36|45
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||Rifampin||||1000|48|55
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|65|85
SE|00000000||tx|1|entity|C0054836|carvedilol|orch,phsu|||carvedilol||||1000|90|99
SE|00000000||tx|1|relation|4|1|C0035608|Rifampin|antb,orch|antb|||Rifampin||||1000|48|55|VERB|INHIBITS||57|63|2|2|C0054836|carvedilol|orch,phsu|orch|||carvedilol||||1000|90|99


SE|00000000||tx|1|text|Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.
SE|00000000||tx|1|entity|C0007412|Catecholamines|nsba,orch,phsu|||Catecholamine||||840|1|13
SE|00000000||tx|1|entity|C0333668|Depletion|ftcn|||depleting||||840|15|23
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||840|25|29
SE|00000000||tx|1|entity|C0035179|Reserpine|orch,phsu|||reserpine||||1000|40|48
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|63|70
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|72|77
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blocking agents||||983|95|114
SE|00000000||tx|1|relation|0|0|C0035179|Reserpine|orch,phsu|orch|||reserpine||||1000|40|48|SPEC|ISA||25|48|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||840|25|29
SE|00000000||tx|1|relation|1|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blocking agents||||983|95|114|VERB|COEXISTS_WITH||84|88|3|2|C0035179|Reserpine|orch,phsu|orch|||reserpine||||1000|40|48


SE|00000000||tx|1|text|Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.
SE|00000000||tx|1|entity|C0001641|Adrenergic alpha-Antagonists|phsu|||Alpha-blockers||||1000|1|14
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||Vardenafil||||861|22|31
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||813|58|75
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneously||||813|84|97
SE|00000000||tx|1|entity|C1292428|6 Hours|tmco|||6 hours||||1000|102|108
SE|00000000||tx|1|entity|C0052080|antineoplaston A10|orch,phsu|||a 10||||861|116|119
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||861|124|127
SE|00000000||tx|1|entity|C0076107|Terazosin|orch,phsu|||terazosin||||1000|132|140
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|143|153
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||888|155|165
SE|00000000||tx|1|entity|C0237753|Numbers|qnco|||number||||861|194|199
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||966|204|211


SE|00000000||tx|1|text|The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers.
SE|00000000||tx|1|entity|C0344315|Depressed mood|fndg|||depression||||1000|5|14
SE|00000000||tx|1|entity|C0027045|Myocardial Contraction|ortf|||cardiac contractility||||950|19|39
SE|00000000||tx|1|entity|C0205554|Automated (qualifier value)|ftcn|||automaticity||||928|60|71
SE|00000000||tx|1|entity|C0595862|Vasodilation disorder|patf|||vascular dilation||||1000|88|104
SE|00000000||tx|1|entity|C0002932|Anesthetics|phsu|||anesthetics||||1000|122|132
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium channel blockers||||1000|156|179
SE|00000000||tx|1|relation|2|1|C0002932|Anesthetics|phsu|phsu|||anesthetics||||1000|122|132|VERB|AFFECTS||106|115|5|1|C0595862|Vasodilation disorder|patf|patf|||vascular dilation||||1000|88|104
SE|00000000||tx|1|relation|1|1|C0006684|Calcium Channel Blockers|phsu|phsu|||calcium channel blockers||||1000|156|179|VERB|AUGMENTS||141|151|6|5|C0027045|Myocardial Contraction|ortf|ortf|||cardiac contractility||||950|19|39


SE|00000000||tx|1|text|Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.
SE|00000000||tx|1|entity|C0011786|Dexfenfluramine|orch,phsu|||dexfenfluramine||||1000|9|23
SE|00000000||tx|1|entity|C0036751|Serotonin|nsba,orch|||serotonin||||694|30|38
SE|00000000||tx|1|entity|C1579360|Reuptake Inhibitors|phsu|||reuptake inhibitor||||983|53|70
SE|00000000||tx|1|entity|C0011786|Dexfenfluramine|orch,phsu|||dexfenfluramine||||1000|73|87
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|96|98
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitor||||1000|129|141


SE|00000000||tx|1|text|Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||Warfarin||||1000|1|8
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||Digoxin||||1000|11|17
SE|00000000||tx|1|entity|C0036075|salicylate|orch,phsu|||Salicylate||||1000|20|29
SE|00000000||tx|1|entity|C0019134|Heparin|bacs,carb,phsu|||Heparin||||1000|36|42
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|68|75
SE|00000000||tx|1|entity|C0032120|Plasma Proteins|aapp,bacs|||plasma proteins||||1000|80|94
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||only||||888|99|102
SE|00000000||tx|1|entity|C0750482|Slightly|idcn|||slightly||||888|104|111
SE|00000000||tx|1|entity|C0064326|Ketorolac Tromethamine|orch,phsu|||ketorolac tromethamine||||1000|124|145
SE|00000000||tx|1|entity|C0073631|Ketorolac|orch,phsu|||ketorolac||||890|177|185
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|187|207
SE|00000000||tx|1|entity|C1300565|Kilogram per Liter|qnco|||g/mL||||812|224|227
SE|00000000||tx|1|relation|6|1|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||1000|68|75|NOM|INTERACTS_WITH||57|63|6|2|C0032120|Plasma Proteins|aapp,gngm,bacs|aapp|||plasma proteins||||1000|80|94
SE|00000000||tx|1|relation|4|1|C0064326|Ketorolac Tromethamine|orch,phsu|orch|||ketorolac tromethamine||||1000|124|145|VERB|INHIBITS||113|119|7|4|C0019134|Heparin|bacs,carb,phsu|bacs|||Heparin||||1000|36|42
SE|00000000||tx|1|relation|4|1|C0064326|Ketorolac Tromethamine|orch,phsu|orch|||ketorolac tromethamine||||1000|124|145|VERB|INHIBITS||113|119|7|4|C0036075|salicylate|orch,phsu|orch|||Salicylate||||1000|20|29
SE|00000000||tx|1|relation|4|1|C0064326|Ketorolac Tromethamine|orch,phsu|orch|||ketorolac tromethamine||||1000|124|145|VERB|INHIBITS||113|119|7|4|C0012265|Digoxin|carb,phsu,strd|carb|||Digoxin||||1000|11|17
SE|00000000||tx|1|relation|4|1|C0064326|Ketorolac Tromethamine|orch,phsu|orch|||ketorolac tromethamine||||1000|124|145|VERB|INHIBITS||113|119|7|4|C0043031|Warfarin|hops,orch,phsu|hops|||Warfarin||||1000|1|8


SE|00000000||tx|1|text|Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|12|19
SE|00000000||tx|1|entity|C0542341|Function|ftcn|||functioning||||901|31|41
SE|00000000||tx|1|entity|C0040132|Thyroid Gland|bpoc|||thyroid gland||||901|43|55
SE|00000000||tx|1|entity|C0279033|Replacement therapy|topp|||replacement therapy||||901|76|94
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||861|131|134
SE|00000000||tx|1|entity|C0014939|Estrogens|horm,phsu,strd|||estrogens||||1000|139|147
SE|00000000||tx|1|entity|C0014939|Estrogens|horm,phsu,strd|||estrogen||||1000|152|159
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives||||1000|172|190


SE|00000000||tx|1|text|Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl.
SE|00000000||tx|1|entity|C0205374|Transitory|tmco|||Transient||||888|1|9
SE|00000000||tx|1|entity|C0011206|Delirium|mobd|||delirium||||888|11|18
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|41|48
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|72|74
SE|00000000||tx|1|entity|C0439208|gram|qnco|||gram||||888|76|79
SE|00000000||tx|1|entity|C0014987|Ethchlorvynol|orch,phsu|||ethchlorvynol||||1000|84|96
SE|00000000||tx|1|entity|C0700523|Amitriptyline Hydrochloride|orch,phsu|||amitriptyline HCl||||1000|117|133
SE|00000000||tx|1|relation|1|1|C0011206|Delirium|mobd|mobd|||delirium||||888|11|18|PREP|PROCESS_OF||38|39|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|41|48


SE|00000000||tx|1|text|Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.
SE|00000000||tx|1|entity|C0000981|Acetazolamide|orch,phsu|||Acetazolamide||||1000|1|13
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||urinary||||888|23|29
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|31|39
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|44|52
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|74|79
SE|00000000||tx|1|relation|1|1|C0000981|Acetazolamide|orch,phsu|orch|||Acetazolamide||||1000|1|13|VERB|DISRUPTS||15|21|3|1|C0221102|Excretory function|phsf|phsf|||excretion||||888|31|39


SE|00000000||tx|1|text|Furosemide may decrease arterial responsiveness to norepinephrine.
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||Furosemide||||1000|1|10
SE|00000000||tx|1|entity|C0221464|Arterial|spco|||arterial||||853|25|32
SE|00000000||tx|1|entity|C0205342|Responsive|ftcn|||responsiveness||||853|34|47
SE|00000000||tx|1|entity|C0028351|Norepinephrine|nsba,orch,phsu|||norepinephrine||||1000|52|65


SE|00000000||tx|1|text|This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decreased||||775|20|28
SE|00000000||tx|1|entity|C0036075|salicylate|orch,phsu|||salicylate||||775|30|39
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||775|41|45
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|70|73
SE|00000000||tx|1|entity|C0161544|Poisoning by salicylate|inpo|||salicylate toxicity||||1000|78|96
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroid||||1000|103|116


SE|00000000||tx|1|text|Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||Increased||||888|1|9
SE|00000000||tx|1|entity|C0599918|nephrotoxicity|inpo|||nephrotoxicity||||888|11|24
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|54|64
SE|00000000||tx|1|entity|C2266959|Cephalosporin Antibacterial [EPC]|antb,orch|||cephalosporins||||1000|84|97
SE|00000000||tx|1|entity|C0003233|Antibiotics, Aminoglycoside|antb,carb|||aminoglycoside antibiotics||||1000|103|128


SE|00000000||tx|1|text|Lithium: generally should not be given with diuretics.
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||Lithium||||1000|1|7
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|27|29
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|45|53
SE|00000000||tx|1|relation|1|1|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|45|53|VERB|COEXISTS_WITH||34|38|1|1|C0023870|Lithium|elii,phsu|elii|||Lithium||||1000|1|7


SE|00000000||tx|1|text|ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||ERYTHROMYCIN||||1000|1|12
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|39|46
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||861|49|60
SE|00000000||tx|1|entity|C0528023|cerivastatin|orch,phsu|||cerivastatin||||861|62|73
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||861|75|77
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|83|86
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|98|110
SE|00000000||tx|1|entity|C1547061|10 days|tmco|||10 days||||1000|143|149
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|177|188
SE|00000000||tx|1|entity|C0205309|Known|qlco|||known||||888|193|197
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||888|199|207
SE|00000000||tx|1|entity|C1142644|Cytochrome P450 3A4|aapp,enzy|||cytochrome P450 3A4||||1000|212|230
SE|00000000||tx|1|relation|1|1|C0014806|Erythromycin|antb,orch|antb|||ERYTHROMYCIN||||1000|1|12|PREP|TREATS||15|16|8|1|C0030705|Patients|podg,humn|podg|||patients||||861|39|46
SE|00000000||tx|1|relation|7|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|177|188|NOM|INHIBITS||199|207|1|1|C1142644|Cytochrome P450 3A4|aapp,gngm,enzy|gngm|||cytochrome P450 3A4||||1000|212|230


SE|00000000||tx|1|text|Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.
SE|00000000||tx|1|entity|C0205198|Compound|qlco|||Compounds||||966|1|9
SE|00000000||tx|1|entity|C0683312|Categories|inpr|||categories||||1000|20|29
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||decreased||||888|43|51
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||888|53|60
SE|00000000||tx|1|entity|C0546852|2-Bromoergocryptine Mesylate|orch,phsu|||bromocriptine mesylate||||1000|65|86
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|89|102
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||haloperidol||||1000|105|115
SE|00000000||tx|1|entity|C0025853|Metoclopramide|orch,phsu|||metoclopramide||||1000|118|131
SE|00000000||tx|1|entity|C0031935|Pimozide|orch,phsu|||pimozide||||1000|134|141


SE|00000000||tx|1|text|Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||Antihistamines||||1000|1|14
SE|00000000||tx|1|entity|C0520996|Anticoagulant effect|ortf|||anticoagulation effects||||947|45|67
SE|00000000||tx|1|entity|C0019134|Heparin|bacs,carb,phsu|||heparin||||1000|72|78
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|83|90
SE|00000000||tx|1|relation|1|1|C0003360|Antihistamines|orch,phsu|orch|||Antihistamines||||1000|1|14|VERB|INHIBITS||30|39|3|1|C0520996|Anticoagulant effect|ortf|ortf|||anticoagulation effects||||947|45|67


SE|00000000||tx|1|text|Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|16|24
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interaction||||1000|39|54
SE|00000000||tx|1|entity|C0085934|Wellbutrin|orch,phsu|||WELLBUTRIN||||1000|64|73
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|79|83
SE|00000000||tx|1|entity|||gngm|1555|CYP2B6|CYP2B6||||861|101|106
SE|00000000||tx|1|entity|C0022173|Isoenzymes|aapp,enzy|||isoenzyme||||861|108|116
SE|00000000||tx|1|entity|C0029309|Orphenadrine|orch,phsu|||orphenadrine||||1000|125|136
SE|00000000||tx|1|entity|C0010583|Cyclophosphamide|opco,phsu|||cyclophosphamide||||1000|142|157
SE|00000000||tx|1|relation|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|79|83|VERB|INTERACTS_WITH||90|95|3|1|||gngm,aapp|gngm|1555|CYP2B6|CYP2B6||||861|101|106
SE|00000000||tx|1|relation|4|1|C0085934|Wellbutrin|orch,phsu|phsu|||WELLBUTRIN||||1000|64|73|VERB|INTERACTS_WITH||90|95|3|1|||gngm,aapp|gngm|1555|CYP2B6|CYP2B6||||861|101|106


SE|00000000||tx|1|text|Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.
SE|00000000||tx|1|entity|C0581528|Close observation|topp|||Close observation||||1000|1|17
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|26|32
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blocker||||901|56|67
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|88|95
SE|00000000||tx|1|entity|C0007412|Catecholamines|nsba,orch,phsu|||catecholamine||||840|107|119
SE|00000000||tx|1|entity|C0333668|Depletion|ftcn|||depleting||||840|121|129
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||840|131|135
SE|00000000||tx|1|entity|C0035179|Reserpine|orch,phsu|||reserpine||||1000|145|153
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||851|167|174
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||851|176|183
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||851|185|191
SE|00000000||tx|1|entity|C0033268|production|ocac|||production||||1000|201|210
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||1000|215|225
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||marked||||888|234|239
SE|00000000||tx|1|entity|C0428977|Bradycardia|patf|||bradycardia||||888|241|251
SE|00000000||tx|1|entity|C0042571|Vertigo|sosy|||vertigo||||1000|272|278
SE|00000000||tx|1|entity|C0039070|Syncope|sosy|||syncope||||1000|281|287
SE|00000000||tx|1|entity|C0020651|Hypotension, Orthostatic|fndg|||postural hypotension||||1000|292|311
SE|00000000||tx|1|relation|0|0|C0035179|Reserpine|orch,phsu|orch|||reserpine||||1000|145|153|SPEC|ISA||131|153|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||840|131|135
SE|00000000||tx|1|relation|3|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blocker||||901|56|67|VERB|ADMINISTERED_TO||72|83|10|1|C0030705|Patients|podg,humn|humn|||patients||||1000|88|95
SE|00000000||tx|1|relation|9|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||840|131|135|VERB|ADMINISTERED_TO||97|105|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|88|95
SE|00000000||tx|1|relation|10|5|C0035179|Reserpine|orch,phsu|orch|||reserpine||||1000|145|153|VERB|CAUSES||264|270|3|1|C0042571|Vertigo|sosy|sosy|||vertigo||||1000|272|278
SE|00000000||tx|1|relation|0|0|C0035179|Reserpine|orch,phsu|orch|||reserpine||||1000|145|153|INFER|ADMINISTERED_TO(SPEC)||131|153|0|0|C0030705|Patients|podg,humn|humn|||patients||||1000|88|95


SE|00000000||tx|1|text|Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|38|48
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|50|52
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|65|75
SE|00000000||tx|1|entity|C0076110|terbinafine|orch,phsu|||terbinafine||||861|89|99
SE|00000000||tx|1|entity|C0085170|Astemizole|orch,phsu|||astemizole||||1000|102|111
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|117|125


SE|00000000||tx|1|text|The physician should be cautious when administering flurbiprofen to patients taking anticoagulants.
SE|00000000||tx|1|entity|C0804815|Physician:Identifier:Point in time:^Patient:Nominal|clna|||physician||||1000|5|13
SE|00000000||tx|1|entity|C1621583|Administer|ftcn|||administering||||872|39|51
SE|00000000||tx|1|entity|C0016377|Flurbiprofen|orch,phsu|||flurbiprofen||||872|53|64
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|69|76
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|85|98
SE|00000000||tx|1|relation|1|1|C0003280|Anticoagulants|phsu|phsu|||anticoagulants||||1000|85|98|VERB|ADMINISTERED_TO||78|83|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|69|76


SE|00000000||tx|1|text|It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|25|32
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||827|83|93
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|103|111
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|117|129
SE|00000000||tx|1|entity|C1853126|MOLECULAR BASIS|idcn|||molecular basis||||1000|137|151
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|162|172


SE|00000000||tx|1|text|The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|5|11
SE|00000000||tx|1|entity|C0243192|agonists|phsu|||agonists||||861|34|41
SE|00000000||tx|1|entity|C0205923|Benzodiazepine Receptor|aapp,rcpt|||benzodiazepine receptors||||1000|46|69
SE|00000000||tx|1|entity|C0078847|zopiclone|orch,phsu|||zopiclone||||1000|80|88
SE|00000000||tx|1|entity|C1955473|Others|fndg|||others||||1000|115|120
SE|00000000||tx|1|entity|C0591091|Romazicon|orch,phsu|||ROMAZICON||||1000|143|151
SE|00000000||tx|1|relation|1|1|C0591091|Romazicon|orch,phsu|phsu|||ROMAZICON||||1000|143|151|VERB|INHIBITS||132|138|6|1|C1955473|Others|fndg|fndg|||others||||1000|115|120
SE|00000000||tx|1|relation|1|1|C0591091|Romazicon|orch,phsu|phsu|||ROMAZICON||||1000|143|151|VERB|INHIBITS||132|138|6|1|C0078847|zopiclone|orch,phsu|orch|||zopiclone||||1000|80|88
SE|00000000||tx|1|relation|1|1|C0591091|Romazicon|orch,phsu|phsu|||ROMAZICON||||1000|143|151|VERB|INHIBITS||132|138|6|1|C0205923|Benzodiazepine Receptor|aapp,gngm,rcpt|gngm|||benzodiazepine receptors||||1000|46|69


SE|00000000||tx|1|text|This may indicate that ibuprofen could enhance the toxicity of methotrexate.
SE|00000000||tx|1|entity|C0020740|Ibuprofen|orch,phsu|||ibuprofen||||1000|24|32
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|52|59
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|64|75
SE|00000000||tx|1|relation|1|1|C0020740|Ibuprofen|orch,phsu|orch|||ibuprofen||||1000|24|32|VERB|AUGMENTS||40|46|2|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||1000|52|59


SE|00000000||tx|1|text|Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C2946261|Level|phsu|||Level||||1000|47|51
SE|00000000||tx|1|entity|C0001128|Acids|chem|||Acidity||||1000|56|62
SE|00000000||tx|1|entity|C0038351|Stomach|bpoc|||Stomach||||1000|71|77
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|80|84
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|94|105
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|111|122
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|150|154
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||785|158|162
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||VIDEX||||1000|185|189
SE|00000000||tx|1|relation|0|0|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|94|105|SPEC|ISA||80|105|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|80|84
SE|00000000||tx|1|relation|9|1|C2946261|Level|phsu|phsu|||Level||||1000|47|51|VERB|INTERACTS_WITH||31|38|2|2|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5


SE|00000000||tx|1|text|Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0008845|Citalopram|orch,phsu|||Citalopram||||660|41|50
SE|00000000||tx|1|entity|C1099456|Escitalopram|orch,phsu|||escitalopram||||1000|71|82
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||888|91|96
SE|00000000||tx|1|entity|C0022203|Isomerism|npop|||isomer||||888|98|103
SE|00000000||tx|1|entity|C0008845|Citalopram|orch,phsu|||citalopram||||861|116|125
SE|00000000||tx|1|entity|C0719199|Celexa|orch,phsu|||Celexa||||1000|128|133
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||872|141|143
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||872|145|150
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|159|161
SE|00000000||tx|1|relation|0|0|C1099456|Escitalopram|orch,phsu|orch|||escitalopram||||1000|71|82|SPEC|ISA||71|125|0|0|C0008845|Citalopram|orch,phsu|orch|||citalopram||||861|116|125
SE|00000000||tx|1|relation|0|0|C0719199|Celexa|orch,phsu|orch|||Celexa||||1000|128|133|SPEC|ISA||116|133|0|0|C0008845|Citalopram|orch,phsu|orch|||citalopram||||861|116|125


SE|00000000||tx|1|text|Potassium-depleting diuretics are a major contributing factor to digitalis toxicity.
SE|00000000||tx|1|entity|C1563712|Potassium Depleting Diuretics|phsu|||Potassium-depleting diuretics||||1000|1|29
SE|00000000||tx|1|entity|C0205164|Major|qlco|||major||||851|37|41
SE|00000000||tx|1|entity|C1880177|Contribution|acty|||contributing||||851|43|54
SE|00000000||tx|1|entity|C1521761|Factor|ftcn|||factor||||851|56|61
SE|00000000||tx|1|entity|C0012254|Digitalis Toxicity|inpo|||digitalis toxicity||||1000|66|83


SE|00000000||tx|1|text|At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).
SE|00000000||tx|1|entity|C1442770|24 Hours|tmco|||24 hours||||1000|4|11
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||888|25|31
SE|00000000||tx|1|entity|C1709707|Proportion|qnco|||proportion||||888|33|42
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|47|54
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|69|80
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|82|86
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|124|135
SE|00000000||tx|1|entity|C0762662|rofecoxib|orch,phsu|||rofecoxib||||1000|167|175
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||890|187|198
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|200|220
SE|00000000||tx|1|entity|C1513040|Measurable|ftcn|||measurable||||888|232|241
SE|00000000||tx|1|entity|C0439801|Limited (extensiveness)|ftcn|||limit||||888|243|247
SE|00000000||tx|1|entity|C0439275|Microgram per Liter|qnco|||ng/mL||||901|252|256
SE|00000000||tx|1|relation|8|1|C0025677|Methotrexate|orch,phsu|phsu|||methotrexate||||1000|69|80|VERB|TREATS||56|62|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|47|54


SE|00000000||tx|1|text|Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||Fluvoxamine||||888|35|45
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||Tablets||||888|47|53
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|55|57
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|70|80
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAOIs||||966|87|91
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|107|110
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuing||||872|115|127
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAOI||||1000|146|149
SE|00000000||tx|1|relation|4|2|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|phsu|||MAOIs||||966|87|91|NOM|TREATS||129|137|4|0|C1444662|Discontinued|fndg|fndg|||discontinuing||||872|115|127


SE|00000000||tx|1|text|The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|5|11
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|16|26
SE|00000000||tx|1|entity|C0592158|Tambocor|orch,phsu|||TAMBOCOR||||1000|46|53
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||1000|59|69
SE|00000000||tx|1|entity|C0429087|Electrocardiogram: P-R interval|fndg|||PR interval||||1000|78|88
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||1000|95|98
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||1000|105|112


SE|00000000||tx|1|text|At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||966|4|9
SE|00000000||tx|1|entity|C0034866|Recommendation|idcn|||recommended||||888|16|26
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|28|32
SE|00000000||tx|1|entity|C0876768|Vioxx|orch,phsu|||VIOXX||||802|35|39
SE|00000000||tx|1|entity|C0556983|Once daily|tmco|||once daily||||1000|60|69
SE|00000000||tx|1|entity|C1547061|10 days|tmco|||10 days||||1000|75|81
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|93|113
SE|00000000||tx|1|entity|C0450348|23|qnco|||23%||||1000|118|120
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|150|157
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||827|169|180
SE|00000000||tx|1|entity|C0439230|week|tmco|||week||||790|195|198
SE|00000000||tx|1|entity|C0003873|Rheumatoid Arthritis|dsyn|||rheumatoid arthritis||||1000|204|223


SE|00000000||tx|1|text|Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E.
SE|00000000||tx|1|entity|C0003240|Macrolide Antibiotics|antb,orch|||Macrolide Antibiotics||||1000|1|21
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||790|30|41
SE|00000000||tx|1|entity|C0041165|Troleandomycin|antb,orch|||troleandomycin||||1000|47|60
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||Agents||||966|64|69
SE|00000000||tx|1|entity|C0014707|Ergot Alkaloids|bacs,orch,phsu|||ergot alkaloid||||901|78|91
SE|00000000||tx|1|entity|C0456387|Class|inpr|||class||||901|93|97
SE|00000000||tx|1|relation|0|0|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||790|30|41|SPEC|ISA||1|41|0|0|C0003240|Macrolide Antibiotics|antb,orch|antb|||Macrolide Antibiotics||||1000|1|21
SE|00000000||tx|1|relation|0|0|C0041165|Troleandomycin|antb,orch|antb|||troleandomycin||||1000|47|60|SPEC|ISA||1|41|0|0|C0003240|Macrolide Antibiotics|antb,orch|antb|||Macrolide Antibiotics||||1000|1|21

SE|00000000||tx|2|text|45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
SE|00000000||tx|2|entity|C0700532|Dihydroergotamine Mesylate|orch,phsu|||dihydroergotamine mesylate||||1000|6|31
SE|00000000||tx|2|entity|C1533685|Injection procedure|topp|||Injection||||1000|34|42
SE|00000000||tx|2|entity|C1706444|United States Pharmacopeia|hcro|||USP||||1000|45|47
SE|00000000||tx|2|entity|C0680022|member|popg|||member||||1000|54|59
SE|00000000||tx|2|entity|C0003232|Antibiotics|antb|||antibiotics||||1000|95|105
SE|00000000||tx|2|entity|C0282563|Macrolides|orch,phsu|||macrolide||||888|114|122
SE|00000000||tx|2|entity|C0456387|Class|inpr|||class||||888|124|128
SE|00000000||tx|2|entity|C0205217|Increased|qnco|||increased||||790|144|152
SE|00000000||tx|2|entity|C0032105|Plasma|bdsu|||plasma||||790|154|159
SE|00000000||tx|2|entity|C2346711|About The Same|qlco|||unchanged||||888|171|179
SE|00000000||tx|2|entity|C0002062|Alkaloids|orch,phsu|||alkaloids||||888|181|189
SE|00000000||tx|2|entity|C0205100|Peripheral|spco|||peripheral||||888|195|204
SE|00000000||tx|2|entity|C0042396|Vascular constriction (function)|ortf|||vasoconstriction||||888|206|221
SE|00000000||tx|2|relation|4|3|C1533685|Injection procedure|topp|topp|||Injection||||1000|34|42|PREP|USES||90|93|5|1|C0003232|Antibiotics|antb|antb|||antibiotics||||1000|95|105


SE|00000000||tx|1|text|The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.
SE|00000000||tx|1|entity|C0205100|Peripheral|spco|||peripheral||||888|5|14
SE|00000000||tx|1|entity|C0042396|Vascular constriction (function)|ortf|||vasoconstriction||||888|16|31
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high doses||||983|43|52
SE|00000000||tx|1|entity|C0282151|Dopamine Hydrochloride|nsba,orch,phsu|||dopamine HCl||||1000|57|68
SE|00000000||tx|1|entity|C0001641|Adrenergic alpha-Antagonists|phsu|||alpha-adrenergic blocking agents||||1000|88|119
SE|00000000||tx|1|relation|1|1|C0001641|Adrenergic alpha-Antagonists|phsu|phsu|||alpha-adrenergic blocking agents||||1000|88|119|VERB|DISRUPTS||73|83|3|3|C0042396|Vascular constriction (function)|ortf|ortf|||vasoconstriction||||888|16|31


SE|00000000||tx|1|text|Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|13|15
SE|00000000||tx|1|entity|C0033551|Prostaglandin-Endoperoxide Synthase|aapp,enzy|||prostaglandin synthase||||861|20|41
SE|00000000||tx|1|entity|C0021469|Metabolic Inhibition|moft|||inhibiting||||861|43|52
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||861|54|58
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|65|76
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|96|106
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|108|114
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta blockers||||1000|119|131


SE|00000000||tx|1|text|Chirocaine   should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.
SE|00000000||tx|1|entity|C0875986|Chirocaine|orch,phsu|||Chirocaine||||1000|1|10
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|45|52
SE|00000000||tx|1|entity|C0002934|Local Anesthetics|phsu|||local anesthetics||||1000|70|86
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||827|91|96
SE|00000000||tx|1|entity|C0360090|Amide type local anesthetic|orch,phsu|||amide-type local anesthetics||||988|122|149
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxic effects||||966|161|173
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|184|188
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||1000|199|206
SE|00000000||tx|1|relation|2|2|C0875986|Chirocaine|orch,phsu|phsu|||Chirocaine||||1000|1|10|PREP|TREATS||42|43|7|1|C0030705|Patients|podg,humn|podg|||patients||||1000|45|52
SE|00000000||tx|1|relation|6|1|C0002934|Local Anesthetics|phsu|phsu|||local anesthetics||||1000|70|86|VERB|ADMINISTERED_TO||54|62|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|45|52


SE|00000000||tx|1|text|The prior administration of succinylcholine does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by TRACRIUM.
SE|00000000||tx|1|entity|C0332152|Before|tmco|||prior||||888|5|9
SE|00000000||tx|1|entity|C0038627|Succinylcholine|orch,phsu|||succinylcholine||||1000|29|43
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|50|52
SE|00000000||tx|1|entity|C2926735|Duration|phsu|||duration||||1000|66|73
SE|00000000||tx|1|entity|C0205125|Depth|spco|||depth||||1000|120|124
SE|00000000||tx|1|entity|C0235062|Induction of neuromuscular blockade|topp|||neuromuscular block||||1000|130|148
SE|00000000||tx|1|entity|C0592193|Tracrium|orch,phsu|||TRACRIUM||||1000|161|168
SE|00000000||tx|1|relation|2|1|C0038627|Succinylcholine|orch,phsu|orch|||succinylcholine||||1000|29|43|VERB|STIMULATES|negation|54|60|5|1|C2926735|Duration|phsu|phsu|||duration||||1000|66|73


SE|00000000||tx|1|text|Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||Quinolones||||1000|1|10
SE|00000000||tx|1|entity|C0027353|Nalidixic Acid|antb,orch|||nalidixic acid||||1000|23|36
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|55|61
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulant||||901|70|87
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||901|89|96
SE|00000000||tx|1|entity|C0243072|derivatives|chvs|||derivatives||||1000|105|115
SE|00000000||tx|1|relation|0|0|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||901|89|96|MOD/HEAD|ISA||70|96|0|0|C0354604|Anticoagulants, Oral|orch,phsu|orch|||oral anticoagulant||||901|70|87
SE|00000000||tx|1|relation|2|1|C0027353|Nalidixic Acid|antb,orch|antb|||nalidixic acid||||1000|23|36|NOM|INTERACTS_WITH||55|61|2|1|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||901|89|96
SE|00000000||tx|1|relation|2|1|C0027353|Nalidixic Acid|antb,orch|antb|||nalidixic acid||||1000|23|36|NOM|INTERACTS_WITH||55|61|2|1|C0243072|derivatives|chvs|chvs|||derivatives||||1000|105|115


SE|00000000||tx|1|text|In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|4|11
SE|00000000||tx|1|entity|C1306577|Death (finding)|fndg|||deaths||||1000|14|19
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||rarely||||1000|40|45
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|52|62
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||1000|82|92
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|98|109


SE|00000000||tx|1|text|In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.
SE|00000000||tx|1|entity|C1279901|Firstly|qlco|||first||||888|8|12
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||888|14|18
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|21|31
SE|00000000||tx|1|entity|C0724549|Cerivastatin sodium|orch,phsu|||cerivastatin sodium||||785|58|76
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decreases||||1000|114|122
SE|00000000||tx|1|entity|C0205172|More|ftcn|||more||||1000|127|130
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|145|147
SE|00000000||tx|1|entity|C0439509|/40|tmco|||40%||||1000|153|155
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|161|164
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dosing||||890|183|188
SE|00000000||tx|1|entity|C0724549|Cerivastatin sodium|orch,phsu|||cerivastatin sodium||||890|190|208
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|210|214
SE|00000000||tx|1|relation|7|5|C0724549|Cerivastatin sodium|orch,phsu|orch|||cerivastatin sodium||||785|58|76|VERB|compared_with||171|178|2|1|C0724549|Cerivastatin sodium|orch,phsu|orch|||cerivastatin sodium||||890|190|208


SE|00000000||tx|1|text|Colchicine may increase sensitivity to the CNS depressants.
SE|00000000||tx|1|entity|C0009262|Colchicine|orch,phsu|||Colchicine||||1000|1|10
SE|00000000||tx|1|entity|C0427965|Antimicrobial susceptibility|fndg|||sensitivity||||1000|25|35
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||1000|44|58
SE|00000000||tx|1|relation|1|1|C0009262|Colchicine|orch,phsu|orch|||Colchicine||||1000|1|10|VERB|AUGMENTS||16|23|2|1|C0427965|Antimicrobial susceptibility|fndg|fndg|||sensitivity||||1000|25|35


SE|00000000||tx|1|text|Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||1000|1|9
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|25|33
SE|00000000||tx|1|entity|C0006463|Busulfan|hops,orch,phsu|||busulfan||||1000|38|45
SE|00000000||tx|1|entity|C0205172|More|ftcn|||more||||1000|57|60
SE|00000000||tx|1|entity|C2362652|Possible diagnosis|qlco|||possibly||||1000|63|70
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induction||||1000|83|91
SE|00000000||tx|1|entity|C0017837|Glutathione S-Transferase|aapp,enzy|||glutathione-S-transferase||||1000|96|120
SE|00000000||tx|1|relation|1|1|C0031507|Phenytoin|orch,phsu|orch|||Phenytoin||||1000|1|9|VERB|STIMULATES||11|19|4|2|C0006463|Busulfan|hops,orch,phsu|hops|||busulfan||||1000|38|45


SE|00000000||tx|1|text|Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0358591|Proton Pump Inhibitors|phsu|||proton pump inhibitors||||1000|23|44
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||861|50|57
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||1000|102|110
SE|00000000||tx|1|entity|C0525032|International Normalized Ratio|lbpr|||INR||||1000|115|117
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|123|138
SE|00000000||tx|1|relation|5|1|C0358591|Proton Pump Inhibitors|phsu|phsu|||proton pump inhibitors||||1000|23|44|VERB|TREATS||10|16|1|1|C0030705|Patients|podg,humn|podg|||Patients||||1000|1|8


SE|00000000||tx|1|text|Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.
SE|00000000||tx|1|entity|C0937846|Esomeprazole|orch,phsu|||esomeprazole||||802|21|32
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|44|51
SE|00000000||tx|1|entity|C1332828|CYP2C19 gene|gngm|1557|CYP2C19|CYP2C19||||694|56|62
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|93|100
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|105|113
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|118|125
SE|00000000||tx|1|relation|3|1|C0012010|Diazepam|orch,phsu|orch|||diazepam||||1000|44|51|NOM|INTERACTS_WITH||64|72|3|0|C1332828|CYP2C19 gene|gngm,aapp|gngm|1557|CYP2C19|CYP2C19||||694|56|62


SE|00000000||tx|1|text|Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.
SE|00000000||tx|1|entity|C0733402|Trecator|orch,phsu|||Trecator||||1000|1|8
SE|00000000||tx|1|entity|C0879626|Adverse effects|patf|||adverse effects||||1000|29|43
SE|00000000||tx|1|entity|C0003448|Antitubercular Agents|phsu|||antituberculous drugs||||1000|54|74
SE|00000000||tx|1|relation|1|1|C0733402|Trecator|orch,phsu|orch|||Trecator||||1000|1|8|VERB|AUGMENTS||14|23|2|1|C0879626|Adverse effects|patf|patf|||adverse effects||||1000|29|43


SE|00000000||tx|1|text|Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||Carbamazepine||||1000|1|13
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|36|48
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||773|58|60
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||560|66|71
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||560|73|78
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||1000|94|105
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximate||||802|133|143
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||802|149|156
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|161|164
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|170|172
SE|00000000||tx|1|entity|C0042295|Values|qlco|||values||||888|174|179
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||1000|189|200
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||888|210|215
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||888|217|226
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||861|237|248
SE|00000000||tx|1|relation|4|1|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|orch|||BID||||773|58|60|NOM|STIMULATES||80|86|4|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||560|73|78


SE|00000000||tx|1|text|Acetazolamide may prevent the urinary antiseptic effect of methenamine.
SE|00000000||tx|1|entity|C0000981|Acetazolamide|orch,phsu|||Acetazolamide||||1000|1|13
SE|00000000||tx|1|entity|C0003426|Antiseptics, Urinary|phsu|||urinary antiseptic||||890|31|48
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||890|50|55
SE|00000000||tx|1|entity|C0025638|Methenamine|orch,phsu|||methenamine||||1000|60|70
SE|00000000||tx|1|relation|1|0|C0003426|Antiseptics, Urinary|phsu|phsu|||urinary antiseptic||||890|31|48|NOM|INTERACTS_WITH||50|55|1|1|C0025638|Methenamine|orch,phsu|orch|||methenamine||||1000|60|70


SE|00000000||tx|1|text|Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||790|16|21
SE|00000000||tx|1|entity|C1524026|Metabolic Process, Cellular|celf|||metabolized||||790|23|33
SE|00000000||tx|1|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||statins||||790|35|41
SE|00000000||tx|1|entity|C0201950|Cholesterol measurement test|lbpr|||cholesterol levels||||1000|55|72
SE|00000000||tx|1|entity|C1101331|Tracleer|orch,phsu|||TRACLEER||||1000|90|97
SE|00000000||tx|1|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||statin||||888|131|136
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|138|141
SE|00000000||tx|1|relation|5|1|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|orch|||statins||||790|35|41|VERB|ADMINISTERED_TO||10|14|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8


SE|00000000||tx|1|text|The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|5|7
SE|00000000||tx|1|entity|C1436328|Eszopiclone|orch,phsu|||eszopiclone||||1000|12|22
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||802|42|45
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|70|81
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||838|86|91
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||838|93|101
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|106|111
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||790|121|125
SE|00000000||tx|1|entity|C1442466|5 Days|tmco|||5 days||||1000|131|136
SE|00000000||tx|1|relation|5|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|70|81|NOM|INHIBITS||93|101|3|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|106|111


SE|00000000||tx|1|text|Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||Phenothiazines||||1000|1|14
SE|00000000||tx|1|entity|C0031957|piperazine|orch,phsu|||piperazine||||1000|25|34
SE|00000000||tx|1|entity|C0031434|phenothiazine|orch,phsu|||phenothiazine||||888|42|54
SE|00000000||tx|1|entity|C1883357|Together|qlco|||together||||888|56|63
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|82|85
SE|00000000||tx|1|entity|C0009951|Convulsions|sosy|||convulsions||||1000|90|100
SE|00000000||tx|1|entity|C0036572|Seizures|sosy|||seizures||||1000|103|110
SE|00000000||tx|1|relation|0|0|C0009951|Convulsions|sosy|sosy|||convulsions||||1000|90|100|SPEC|ISA||90|110|0|0|C0036572|Seizures|sosy|sosy|||seizures||||1000|103|110
SE|00000000||tx|1|relation|3|1|C0031434|phenothiazine|orch,phsu|orch|||phenothiazine||||888|42|54|NOM|PREDISPOSES||82|85|2|1|C0009951|Convulsions|sosy|sosy|||convulsions||||1000|90|100


SE|00000000||tx|1|text|Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.
SE|00000000||tx|1|entity|C0008286|Chlorpromazine|orch,phsu|||Chlorpromazine||||1000|1|14
SE|00000000||tx|1|entity|C0008286|Chlorpromazine|orch,phsu|||Chlorpromazine||||1000|17|30
SE|00000000||tx|1|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine||||1000|39|46
SE|00000000||tx|1|entity|C0068979|Norepinephrine Receptors|aapp,rcpt|||norepinephrine receptors||||1000|52|75
SE|00000000||tx|1|entity|C0002763|Central Nervous System Stimulants|phsu|||central stimulant||||901|98|114
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||901|116|122
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||amphetamines||||1000|127|138
SE|00000000||tx|1|entity|C0274692|Poisoning by amphetamine|inpo|||amphetamine poisoning||||1000|165|185
SE|00000000||tx|1|relation|2|1|C0008286|Chlorpromazine|orch,phsu|orch|||Chlorpromazine||||1000|17|30|VERB|INHIBITS||32|37|5|1|C0013030|Dopamine|nsba,orch,phsu|nsba|||dopamine||||1000|39|46
SE|00000000||tx|1|relation|4|1|C0068979|Norepinephrine Receptors|aapp,gngm,rcpt|aapp|||norepinephrine receptors||||1000|52|75|NOM|INTERACTS_WITH||116|122|4|0|C0002763|Central Nervous System Stimulants|phsu|phsu|||central stimulant||||901|98|114
SE|00000000||tx|1|relation|6|1|C0002667|Amphetamines|nsba,orch,phsu|phsu|||amphetamines||||1000|127|138|VERB|TREATS||159|163|1|1|C0274692|Poisoning by amphetamine|inpo|inpo|||amphetamine poisoning||||1000|165|185


SE|00000000||tx|1|text|Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|31|38
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||888|45|56
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||888|58|64
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||861|78|82


SE|00000000||tx|1|text|Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|49|57
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|62|76


SE|00000000||tx|1|text|In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||888|16|24
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|26|29
SE|00000000||tx|1|entity|C0011175|Dehydration|dsyn|||dehydration||||1000|34|44
SE|00000000||tx|1|entity|C0205436|second (number)|qnco|||secondary||||1000|46|54
SE|00000000||tx|1|entity|C0042963|Vomiting|sosy|||vomiting||||1000|59|66
SE|00000000||tx|1|entity|C0011991|Diarrhea|sosy|||diarrhea||||1000|75|82
SE|00000000||tx|1|entity|C0701188|Camptosar|orch,phsu|||CAMPTOSAR||||1000|95|103
SE|00000000||tx|1|entity|C0804815|Physician:Identifier:Point in time:^Patient:Nominal|clna|||physician||||1000|110|118
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|141|149
SE|00000000||tx|1|entity|C0701188|Camptosar|orch,phsu|||CAMPTOSAR||||1000|170|178
SE|00000000||tx|1|entity|C0439531|per period (qualifier value)|tmco|||periods||||966|203|209
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||888|214|219
SE|00000000||tx|1|entity|C0042963|Vomiting|sosy|||vomiting||||888|221|228
SE|00000000||tx|1|entity|C0011991|Diarrhea|sosy|||diarrhea||||1000|233|240
SE|00000000||tx|1|relation|12|6|C0804815|Physician:Identifier:Point in time:^Patient:Nominal|clna|clna|||physician||||1000|110|118|NOM|PREDISPOSES||26|29|12|1|C0011175|Dehydration|dsyn|dsyn|||dehydration||||1000|34|44
SE|00000000||tx|1|relation|8|1|C0701188|Camptosar|orch,phsu|orch|||CAMPTOSAR||||1000|95|103|VERB|CAUSES||84|90|5|1|C0011991|Diarrhea|sosy|sosy|||diarrhea||||1000|75|82
SE|00000000||tx|1|relation|8|1|C0701188|Camptosar|orch,phsu|orch|||CAMPTOSAR||||1000|95|103|VERB|CAUSES||84|90|5|1|C0042963|Vomiting|sosy|sosy|||vomiting||||1000|59|66


SE|00000000||tx|1|text|Leucovorin may enhance the toxicity of 5-fluorouracil.
SE|00000000||tx|1|entity|C0023413|Leucovorin|orch,phsu,vita|||Leucovorin||||1000|1|10
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|28|35
SE|00000000||tx|1|entity|C0016360|Fluorouracil|nnon,phsu|||5-fluorouracil||||1000|40|53
SE|00000000||tx|1|relation|1|1|C0023413|Leucovorin|orch,phsu,vita|orch|||Leucovorin||||1000|1|10|VERB|AUGMENTS||16|22|2|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||1000|28|35


SE|00000000||tx|1|text|Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).
SE|00000000||tx|1|entity|C0025859|Metoprolol|orch,phsu|||Metoprolol||||888|1|10
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||824|35|40
SE|00000000||tx|1|entity|C1170371|Lexapro|orch,phsu|||LEXAPRO||||824|42|48
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|57|60
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|65|82
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|102|109
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|114|117
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|127|134
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|139|141
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic blocker||||916|150|172
SE|00000000||tx|1|entity|C0025859|Metoprolol|orch,phsu|||metoprolol||||916|174|183
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|197|202
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|204|207
SE|00000000||tx|1|relation|0|0|C0025859|Metoprolol|orch,phsu|orch|||metoprolol||||916|174|183|MOD/HEAD|ISA||150|183|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-adrenergic blocker||||916|150|172


SE|00000000||tx|1|text|Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
SE|00000000||tx|1|entity|C0003232|Antibiotics|antb|||Antibiotics||||1000|1|11
SE|00000000||tx|1|entity|C1511726|Data|idcn|||data||||861|38|41
SE|00000000||tx|1|entity|C0055856|Clarithromycin|antb,orch|||clarithromycin||||1000|53|66
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|69|80
SE|00000000||tx|1|entity|C0041165|Troleandomycin|antb,orch|||troleandomycin||||888|87|100
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||markedly||||888|102|109
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|123|132
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|137|145
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|171|178
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||623|183|188
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||623|190|198
SE|00000000||tx|1|entity|C0429028|QT interval feature (observable entity)|clna|||QT interval||||1000|231|241
SE|00000000||tx|1|entity|C0013798|Electrocardiogram|fndg|||ECG||||966|250|252
SE|00000000||tx|1|relation|6|1|C0041165|Troleandomycin|antb,orch|antb|||troleandomycin||||888|87|100|VERB|INHIBITS||111|117|7|2|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|137|145
SE|00000000||tx|1|relation|6|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|69|80|VERB|INHIBITS||111|117|7|2|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|137|145
SE|00000000||tx|1|relation|6|1|C0055856|Clarithromycin|antb,orch|antb|||clarithromycin||||1000|53|66|VERB|INHIBITS||111|117|7|2|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|137|145
SE|00000000||tx|1|relation|8|8|C0003232|Antibiotics|antb|antb|||Antibiotics||||1000|1|11|NOM|STIMULATES||171|178|4|1|C0072916|Cisapride|orch,phsu|orch|||cisapride||||623|190|198


SE|00000000||tx|1|text|Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||Drug Interactions||||861|29|45
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||Benzodiazepines||||1000|48|62
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||Benzodiazepines||||1000|65|79
SE|00000000||tx|1|entity|C0205054|Hepatic|blor|||hepatic||||888|96|102
SE|00000000||tx|1|entity|C0030011|Oxidation|moft|||oxidation||||888|104|112
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|121|130
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||midazolam||||1000|133|141
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||triazolam||||888|144|152
SE|00000000||tx|1|entity|C0539791|Small Inducible Cytokine A19|aapp,imft|6363|CCL19|elc||||888|154|156
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|200|208
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|219|223
SE|00000000||tx|1|entity|C0332148|Probable diagnosis|qlco|||likely||||861|228|233
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|252|262
SE|00000000||tx|1|relation|0|0|C0085228|Fluvoxamine|orch,phsu|orch|||fluvoxamine||||1000|252|262|SPEC|ISA||219|262|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|219|223
SE|00000000||tx|1|relation|1|1|C0085228|Fluvoxamine|orch,phsu|orch|||fluvoxamine||||1000|252|262|VERB|INHIBITS||241|247|10|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|219|223
SE|00000000||tx|1|relation|0|0|C0085228|Fluvoxamine|orch,phsu|orch|||fluvoxamine||||1000|252|262|INFER|INHIBITS(SPEC)||219|262|0|0|C0085228|Fluvoxamine|orch,phsu|orch|||fluvoxamine||||1000|252|262


SE|00000000||tx|1|text|Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride.
SE|00000000||tx|1|entity|C0010583|Cyclophosphamide|opco,phsu|||Cyclophosphamide||||888|1|16
SE|00000000||tx|1|entity|C1706089|Marked|qlco|||marked||||1000|44|49
SE|00000000||tx|1|entity|C0205322|Persistent|tmco|||persistent||||888|55|64
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||888|66|75
SE|00000000||tx|1|entity|C1149831|cholinesterase activity|moft|||cholinesterase activity||||1000|80|102
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|121|126
SE|00000000||tx|1|entity|C0012792|Suxamethonium Chloride|orch,phsu|||succinylcholine chloride||||1000|131|154


SE|00000000||tx|1|text|There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|17|23
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||861|28|39
SE|00000000||tx|1|entity|C0163712|Relate - vinyl resin|orch|||related||||861|41|47
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||861|49|60
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|65|72
SE|00000000||tx|1|entity|C1707479|Concomitant Therapy|topp|||concomitant therapy||||1000|77|95
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|102|111
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|117|128


SE|00000000||tx|1|text|If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||888|4|11
SE|00000000||tx|1|entity|C0285868|Omnicef|antb,orch|||OMNICEF||||888|33|39
SE|00000000||tx|1|entity|C0285868|Omnicef|antb,orch|||OMNICEF||||1000|50|56
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|77|81
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||785|85|89
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacid||||1000|111|117


SE|00000000||tx|1|text|Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.
SE|00000000||tx|1|entity|C2348402|Spontaneous Report|inpr|||Spontaneous reports||||983|1|19
SE|00000000||tx|1|entity|C0699828|Serotonin Syndrome|inpo|||serotonin syndrome||||1000|24|41
SE|00000000||tx|1|entity|C0876226|Zyvox|orch,phsu|||ZYVOX||||1000|80|84
SE|00000000||tx|1|entity|C0242701|Serotonin Agents|nsba,phsu|||serotonergic agents||||1000|90|108
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants||||1000|121|135
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||selective serotonin reuptake inhibitors||||1000|145|183
SE|00000000||tx|1|relation|0|0|C0360105|Selective serotonin re-uptake inhibitor|phsu|phsu|||selective serotonin reuptake inhibitors||||1000|145|183|SPEC|ISA||121|183|0|0|C0003289|Antidepressive Agents|phsu|phsu|||antidepressants||||1000|121|135


SE|00000000||tx|1|text|The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|19|22
SE|00000000||tx|1|entity|C0533545|gemifloxacin|antb,orch|||gemifloxacin||||888|24|35
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|69|79
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacid||||851|102|108
SE|00000000||tx|1|entity|C2700400|Contain (action)|acty|||containing||||851|110|119
SE|00000000||tx|1|entity|C0002367|Aluminum|elii|||aluminum||||851|121|128
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||magnesium||||1000|134|142


SE|00000000||tx|1|text|When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.
SE|00000000||tx|1|entity|C0442027|Oral|spco|||orally||||1000|12|17
SE|00000000||tx|1|entity|C0020923|Imidazole|orch,phsu|||imidazole||||872|21|29
SE|00000000||tx|1|entity|C0205198|Compound|qlco|||compounds||||872|31|39
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|46|57
SE|00000000||tx|1|entity|C0520996|Anticoagulant effect|ortf|||anticoagulant effect||||1000|75|94
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin||||1000|99|106
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|113|117
SE|00000000||tx|1|relation|2|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|46|57|VERB|AUGMENTS||63|69|3|1|C0520996|Anticoagulant effect|ortf|ortf|||anticoagulant effect||||1000|75|94


SE|00000000||tx|1|text|In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|6|10
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||888|15|20
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|22|31
SE|00000000||tx|1|entity|C0205191|chronic|tmco|||chronic||||851|52|58
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||851|60|69
SE|00000000||tx|1|entity|C0442759|3/6|fndg|||3.6||||901|89|91
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|98|104
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||1000|110|112
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||740|124|135
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||740|137|141
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||740|150|162


SE|00000000||tx|1|text|Fluvoxamine has also been shown to inhibit P450 1A2, an isoform also involved in TCAmetabolism.
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||Fluvoxamine||||1000|1|11
SE|00000000||tx|1|entity|||gngm|1555|CYP2B6|P450||||694|44|47
SE|00000000||tx|1|entity|C0597298|Protein Isoforms|aapp|||isoform||||861|57|63


SE|00000000||tx|1|text|Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|19|28
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|35|42
SE|00000000||tx|1|entity|C0002367|Aluminum|elii|||aluminum||||1000|55|62
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||magnesium||||1000|65|73
SE|00000000||tx|1|entity|C0006675|Calcium|bacs,elii,phsu|||calcium||||1000|79|85
SE|00000000||tx|1|entity|C0038633|Sucralfate|carb,phsu|||sucralfate||||1000|93|102
SE|00000000||tx|1|entity|C0025552|Metals|inch|||metal||||888|110|114
SE|00000000||tx|1|entity|C0007447|Cations|chvs|||cations||||888|116|122
SE|00000000||tx|1|entity|C0302583|Iron|bacs,elii,phsu|||iron||||1000|132|135
SE|00000000||tx|1|entity|C0301532|Multivitamin preparation|orch,phsu,vita|||multivitamins||||1000|146|158
SE|00000000||tx|1|entity|C0302583|Iron|bacs,elii,phsu|||iron||||1000|171|174
SE|00000000||tx|1|entity|C0043481|Zinc|bacs,elii,phsu|||zinc||||1000|179|182
SE|00000000||tx|1|entity|C0007447|Cations|chvs|||cations||||861|240|246
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||VIDEX||||1000|256|260
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||1000|263|272
SE|00000000||tx|1|entity|C0006353|Buffers|irda,phsu|||buffered||||901|284|291
SE|00000000||tx|1|entity|C0304290|Chewable Tablet|bodm|||chewable/buffered tablets||||901|275|299
SE|00000000||tx|1|entity|C1521725|Pediatric|qlco|||pediatric||||694|308|316
SE|00000000||tx|1|entity|C0991536|Oral Solution|bodm|||oral solution||||1000|329|341
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|395|404
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||888|420|427
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|429|442
SE|00000000||tx|1|relation|0|0|C0592249|Videx|nnon,phsu|nnon|||VIDEX||||1000|256|260|SPEC|ISA||256|272|0|0|C0012133|Didanosine|nnon,phsu|nnon|||didanosine||||1000|263|272


SE|00000000||tx|1|text|phenytoin (e.g., Dilantin) use of phenytoin with sulfapyridine may increase The chance of side effects affecting The liver and/or The side effects of phenytoin
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|1|9
SE|00000000||tx|1|entity|C0699512|Dilantin|orch,phsu|||Dilantin||||1000|18|25
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|35|43
SE|00000000||tx|1|entity|C0038710|Sulfapyridine|orch,phsu|||sulfapyridine||||1000|50|62
SE|00000000||tx|1|entity|C0237506|Chance|qlco|||chance||||1000|81|86
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||1000|91|102
SE|00000000||tx|1|entity|C0023884|Liver|bpoc|||liver||||1000|118|122
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||1000|135|146
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|151|159
SE|00000000||tx|1|relation|6|3|C0038710|Sulfapyridine|orch,phsu|orch|||sulfapyridine||||1000|50|62|VERB|AFFECTS||104|112|3|1|C0023884|Liver|bpoc|bpoc|||liver||||1000|118|122


SE|00000000||tx|1|text|Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.
SE|00000000||tx|1|entity|C0702073|Peganone|orch,phsu|||PEGANONE||||888|45|52
SE|00000000||tx|1|entity|C0702064|Phenurone|orch,phsu|||Phenurone||||1000|88|96
SE|00000000||tx|1|entity|C0070525|phenacemide|orch,phsu|||phenacemide||||1000|99|109
SE|00000000||tx|1|entity|C1457887|Symptoms|sosy|||symptoms||||861|127|134
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|162|168
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|180|190
SE|00000000||tx|1|relation|0|0|C0702064|Phenurone|orch,phsu|orch|||Phenurone||||1000|88|96|SPEC|ISA||88|109|0|0|C0070525|phenacemide|orch,phsu|orch|||phenacemide||||1000|99|109


SE|00000000||tx|1|text|Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.
SE|00000000||tx|1|entity|C0599739|synergism|moft|||Synergism||||1000|1|9
SE|00000000||tx|1|entity|C0354772|Xanthine bronchodilators|nnon,phsu|||xanthine bronchodilators||||1000|19|42
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|51|62
SE|00000000||tx|1|entity|C0014479|Ephedrine|orch,phsu|||ephedrine||||1000|66|74
SE|00000000||tx|1|entity|C1579392|Bronchodilators, Sympathomimetic|phsu|||sympathomimetic bronchodilators||||1000|87|117
SE|00000000||tx|1|relation|0|0|C0014479|Ephedrine|orch,phsu|orch|||ephedrine||||1000|66|74|SPEC|ISA||66|117|0|0|C1579392|Bronchodilators, Sympathomimetic|phsu|phsu|||sympathomimetic bronchodilators||||1000|87|117


SE|00000000||tx|1|text|In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.
SE|00000000||tx|1|entity|C1515187|Take|hlca|||taking||||872|26|31
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||872|33|39
SE|00000000||tx|1|entity|C0030125|aminosalicylic acid|orch,phsu|||aminosalicylic acid||||1000|54|72
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||higher doses||||966|75|86
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|91|97


SE|00000000||tx|1|text|MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|1|14
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|58|64
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|69|82


SE|00000000||tx|1|text|Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.
SE|00000000||tx|1|entity|C1621583|Administer|ftcn|||administering||||872|34|46
SE|00000000||tx|1|entity|C0068334|nabumetone|orch,phsu|||nabumetone||||872|48|57
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|64|71
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interactions||||966|79|90
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|118|123


SE|00000000||tx|1|text|These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage.
SE|00000000||tx|1|entity|C0003232|Antibiotics|antb|||antibiotics||||1000|7|17
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||804|52|58
SE|00000000||tx|1|entity|C1883708|Then|tmco|||then||||660|97|100
SE|00000000||tx|1|entity|C2825951|Adjunctive Orthodontic Procedure|topp|||adjunctive||||851|139|148
SE|00000000||tx|1|entity|C0008425|Cholinesterase Inhibitors|orch,phsu|||anticholinesterase||||851|150|167
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||851|169|174
SE|00000000||tx|1|relation|1|1|C0003232|Antibiotics|antb|antb|||antibiotics||||1000|7|17|PREP|TREATS||34|35|3|1|C0030705|Patients|podg,humn|podg|||patient||||804|52|58


SE|00000000||tx|1|text|However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.
SE|00000000||tx|1|entity|C0771752|Fexofenadine hydrochloride|orch,phsu|||fexofenadine hydrochloride||||1000|32|57
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||861|71|82
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|87|98
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||890|107|115
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|117|137
SE|00000000||tx|1|entity|C0296800|fexofenadine|orch,phsu|||fexofenadine||||1000|142|153


SE|00000000||tx|1|text|Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.
SE|00000000||tx|1|entity|C0591189|Brevibloc|orch,phsu|||BREVIBLOC||||1000|15|23
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|32|34
SE|00000000||tx|1|entity|C0039240|Supraventricular tachycardia|dsyn|||supraventricular tachycardia||||1000|55|82
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|103|108
SE|00000000||tx|1|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine||||1000|159|166
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||epinephrine||||1000|169|179
SE|00000000||tx|1|entity|C0028351|Norepinephrine|nsba,orch,phsu|||norepinephrine||||1000|186|199
SE|00000000||tx|1|entity|C0010968|Dangerousness|idcn|||danger||||900|216|221
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blocking||||867|226|233
SE|00000000||tx|1|entity|C0027045|Myocardial Contraction|ortf|||cardiac contractility||||867|235|255
SE|00000000||tx|1|entity|C1258192|Total Peripheral Resistance|phsf|||systemic vascular resistance||||1000|262|289
SE|00000000||tx|1|entity|C0205250|High|qlco|||high||||1000|294|297
SE|00000000||tx|1|relation|1|1|C0591189|Brevibloc|orch,phsu|phsu|||BREVIBLOC||||1000|15|23|VERB|TREATS||47|53|12|1|C0039240|Supraventricular tachycardia|dsyn|dsyn|||supraventricular tachycardia||||1000|55|82


SE|00000000||tx|1|text|Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.
SE|00000000||tx|1|entity|C0663241|linezolid|orch,phsu|||linezolid||||1000|12|20
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|30|38
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|44|54
SE|00000000||tx|1|entity|C0599756|adrenergic|ftcn|||adrenergic||||1000|61|70
SE|00000000||tx|1|entity|C0242701|Serotonin Agents|nsba,phsu|||serotonergic agents||||1000|76|94


SE|00000000||tx|1|text|drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|1|5
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||890|32|40
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma phenytoin concentrations||||890|25|55
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|66|78
SE|00000000||tx|1|entity|C0001973|Alcoholic Intoxication, Chronic|mobd|||chronic alcohol abuse||||1000|81|101
SE|00000000||tx|1|entity|C0035179|Reserpine|orch,phsu|||reserpine||||1000|104|112
SE|00000000||tx|1|relation|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|1|5|VERB|INHIBITS||16|23|4|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||890|32|40


SE|00000000||tx|1|text|The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|5|11
SE|00000000||tx|1|entity|C0700758|Ergomar|orch,phsu|||ERGOMAR||||1000|16|22
SE|00000000||tx|1|entity|C0041165|Troleandomycin|antb,orch|||triacetyloleandomycin||||1000|46|66
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|87|96
SE|00000000||tx|1|entity|C0014710|Ergotamine|orch,phsu|||ergotamine||||1000|101|110
SE|00000000||tx|1|relation|3|1|C0041165|Troleandomycin|antb,orch|antb|||triacetyloleandomycin||||1000|46|66|VERB|STIMULATES||31|41|2|1|C0700758|Ergomar|orch,phsu|orch|||ERGOMAR||||1000|16|22
SE|00000000||tx|1|relation|3|1|C0041165|Troleandomycin|antb,orch|antb|||triacetyloleandomycin||||1000|46|66|VERB|INHIBITS||74|81|2|2|C0014710|Ergotamine|orch,phsu|orch|||ergotamine||||1000|101|110


SE|00000000||tx|1|text|Some quinolones have also been shown to interfere with the metabolism of caffeine.
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|6|15
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|60|69
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|74|81
SE|00000000||tx|1|relation|1|1|C0034428|Quinolones|orch|orch|||quinolones||||1000|6|15|VERB|DISRUPTS||41|49|2|1|C0025519|Metabolism|orgf|orgf|||metabolism||||1000|60|69


SE|00000000||tx|1|text|Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0592075|Robinul|orch,phsu|||Robinul||||888|31|37
SE|00000000||tx|1|entity|C1533685|Injection procedure|topp|||Injection||||888|39|47
SE|00000000||tx|1|entity|C0032825|Potassium Chloride|inch,phsu|||potassium chloride||||1000|53|70
SE|00000000||tx|1|entity|C0043076|Waxes|bacs,bodm,lipd|||wax||||694|77|79
SE|00000000||tx|1|entity|C0439793|Severities|qlco|||severity||||1000|105|112
SE|00000000||tx|1|entity|C0032825|Potassium Chloride|inch,phsu|||potassium chloride||||840|117|134
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induced||||840|136|142
SE|00000000||tx|1|entity|C0521362|gastrointestinal|spco|||gastrointestinal||||840|144|159
SE|00000000||tx|1|entity|C0221198|Lesion|fndg|||lesions||||840|161|167
SE|00000000||tx|1|entity|C1274040|Result|ftcn|||result||||1000|174|179
SE|00000000||tx|1|entity|C0439834|Slow|qlco|||slower||||900|186|191
SE|00000000||tx|1|entity|C0232484|Gastrointestinal transit time|ortf|||gastrointestinal transit time||||900|193|221
SE|00000000||tx|1|relation|0|0|C1533685|Injection procedure|topp|topp|||Injection||||888|39|47|MOD/HEAD|USES||31|47|0|0|C0592075|Robinul|orch,phsu|phsu|||Robinul||||888|31|37
SE|00000000||tx|1|relation|4|2|C0032825|Potassium Chloride|inch,phsu|inch|||potassium chloride||||1000|53|70|VERB|AUGMENTS||92|99|4|2|C0221198|Lesion|fndg|fndg|||lesions||||840|161|167


SE|00000000||tx|1|text|Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||Caffeine||||1000|1|8
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||Enoxacin||||1000|11|18
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||838|25|30
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||838|32|40
SE|00000000||tx|1|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P-450||||916|49|64
SE|00000000||tx|1|entity|C0022173|Isoenzymes|aapp,enzy|||isozymes||||916|66|73
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|95|104
SE|00000000||tx|1|entity|C0066447|methylxanthine|orch,phsu|||methylxanthines||||1000|109|123
SE|00000000||tx|1|relation|2|1|C0014310|Enoxacin|orch,phsu|orch|||Enoxacin||||1000|11|18|NOM|INHIBITS||32|40|4|1|C0010762|Cytochrome P450|aapp,gngm,enzy|gngm|||cytochrome P-450||||916|49|64
SE|00000000||tx|1|relation|4|4|C0006644|Caffeine|orch,phsu|orch|||Caffeine||||1000|1|8|ADJ|AFFECTS||75|85|2|1|C0025519|Metabolism|orgf|orgf|||metabolism||||1000|95|104


SE|00000000||tx|1|text|Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||Anticoagulants||||1000|1|14
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|33|39
SE|00000000||tx|1|entity|C0151502|INCREASED ANTICOAGULANT EFFECT|fndg|||increased anticoagulant effects||||966|44|74
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|81|92
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulants||||1000|98|116


SE|00000000||tx|1|text|Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||Certain||||888|1|7
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|9|13
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory agents||||1000|26|62
SE|00000000||tx|1|entity|C0036077|Salicylates|orch,phsu|||salicylates||||1000|74|84
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|87|114
SE|00000000||tx|1|entity|C0304515|Non-selective beta-blocking agent|phsu|||non-selective beta-adrenergic-blocking agents||||988|121|165
SE|00000000||tx|1|entity|C0020616|Hypoglycemic Agents|phsu|||hypoglycemic||||888|186|197
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||888|199|204
SE|00000000||tx|1|entity|C1323198|Starlix|orch,phsu|||Starlix||||1000|209|215
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||901|227|230
SE|00000000||tx|1|entity|C0935929|Antidiabetics|phsu|||antidiabetic drugs||||901|232|249
SE|00000000||tx|1|relation|0|0|C0036077|Salicylates|orch,phsu|orch|||salicylates||||1000|74|84|SPEC|ISA||26|84|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory agents||||1000|26|62
SE|00000000||tx|1|relation|0|0|C1323198|Starlix|orch,phsu|orch|||Starlix||||1000|209|215|SPEC|ISA||209|249|0|0|C0935929|Antidiabetics|phsu|phsu|||antidiabetic drugs||||901|232|249
SE|00000000||tx|1|relation|0|0|C1323198|Starlix|orch,phsu|orch|||Starlix||||1000|209|215|SPEC|ISA||209|249|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|9|13


SE|00000000||tx|1|text|When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.
SE|00000000||tx|1|entity|C0038119|Stadol|orch,phsu|||STADOL NS||||1000|10|18
SE|00000000||tx|1|entity|C1442458|30 Minutes|tmco|||30 minutes||||1000|37|46
SE|00000000||tx|1|entity|C1253507|Sumatriptan Nasal Spray|clnd|||sumatriptan nasal spray||||1000|58|80
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|87|89
SE|00000000||tx|1|entity|C0006491|Butorphanol|orch,phsu|||butorphanol||||1000|94|104
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|124|127


SE|00000000||tx|1|text|Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.
SE|00000000||tx|1|entity|C0006935|capsule (pharmacologic)|bodm|||Capsules||||789|1|8
SE|00000000||tx|1|entity|C0986692|Indomethacin 50 MG|clnd|||INDOCIN 50 mg||||789|10|22
SE|00000000||tx|1|entity|C2347946|Relevance|qlco|||relevant||||790|53|60
SE|00000000||tx|1|entity|C0702240|Elevation|spco|||elevation||||790|62|70
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||888|75|80
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||888|82|88
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|94|102
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||851|107|111
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||851|113|119
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||851|121|129
SE|00000000||tx|1|entity|C0748064|Psychiatric inpatient|podg|||psychiatric patients||||1000|134|153
SE|00000000||tx|1|entity|C0205307|Normal|qlco|||normal||||872|159|164
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||872|166|173
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady state||||849|180|191
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||849|200|206
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma lithium concentrations||||849|193|221
SE|00000000||tx|1|relation|4|4|C0023870|Lithium|elii,phsu|elii|||lithium||||849|200|206|NOM|INHIBITS||94|102|4|1|C0023870|Lithium|elii,phsu|elii|||lithium||||851|113|119
SE|00000000||tx|1|relation|0|0|C0023870|Lithium|elii,phsu|elii|||lithium||||851|113|119|MOD/HEAD|PART_OF||107|119|0|0|C0022646|Kidney|bpoc|bpoc|||renal||||851|107|111


SE|00000000||tx|1|text|Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|37|50
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||1000|59|61
SE|00000000||tx|1|entity|C0205449|Three|qnco|||three||||888|66|70
SE|00000000||tx|1|entity|C0439230|week|tmco|||weeks||||888|72|76
SE|00000000||tx|1|entity|C0282151|Dopamine Hydrochloride|nsba,orch,phsu|||dopamine HCl||||1000|109|120
SE|00000000||tx|1|entity|C1279901|Firstly|qlco|||initial||||888|137|143
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|145|149
SE|00000000||tx|1|entity|C0282151|Dopamine Hydrochloride|nsba,orch,phsu|||dopamine HCl||||1000|154|165
SE|00000000||tx|1|entity|C1704243|Greater|qnco|||greater||||1000|170|176
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|183|185
SE|00000000||tx|1|entity|C0205444|Tenth|qnco|||tenth||||888|187|191
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||861|213|216
SE|00000000||tx|1|relation|9|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|phsu|||MAO inhibitors||||1000|37|50|VERB|TREATS||24|30|1|1|C0030705|Patients|podg,humn|podg|||Patients||||1000|1|8


SE|00000000||tx|1|text|Potassium Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.
SE|00000000||tx|1|entity|C0304475|Potassium supplement|inch,phsu|||Potassium Supplements||||983|1|21
SE|00000000||tx|1|entity|C0304490|Potassium Sparing Diuretics|phsu|||Potassium-Sparing Diuretics||||1000|27|53
SE|00000000||tx|1|entity|C0733440|Fosinopril Sodium|opco,phsu|||Fosinopril sodium||||1000|56|72
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||888|88|96
SE|00000000||tx|1|entity|C1517945|Loss|qnco|||loss||||888|98|101
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|113|130
SE|00000000||tx|1|relation|3|1|C0733440|Fosinopril Sodium|opco,phsu|opco|||Fosinopril sodium||||1000|56|72|VERB|INHIBITS||78|86|2|1|C0032821|Potassium|elii|elii|||potassium||||888|88|96


SE|00000000||tx|1|text|Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||Alcohol||||1000|1|7
SE|00000000||tx|1|entity|C0687676|Post|tmco|||post-||||851|13|17
SE|00000000||tx|1|entity|C0024826|Marketing|ocac|||marketing||||851|18|26
SE|00000000||tx|1|entity|C0596545|Experience|menp|||experience||||851|28|37
SE|00000000||tx|1|entity|C0521114|Infrequent|tmco|||rare||||888|56|59
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||888|61|67
SE|00000000||tx|1|entity|C1705413|Adverse Event Domain|idcn|||adverse neuropsychiatric events||||913|72|102
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduced||||851|107|113
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||851|115|121
SE|00000000||tx|1|entity|C1704410|Tolerance|qlco|||tolerance||||851|123|131
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|136|143
SE|00000000||tx|1|entity|C0001948|Alcohol consumption|inbe|||drinking alcohol||||1000|154|169
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|178|186
SE|00000000||tx|1|entity|C0085934|Wellbutrin|orch,phsu|||WELLBUTRIN||||1000|193|202
SE|00000000||tx|1|relation|4|4|C0001975|Alcohols|orch,phsu|orch|||Alcohol||||1000|1|7|ADJ|INHIBITS||107|113|4|4|C0085934|Wellbutrin|orch,phsu|orch|||WELLBUTRIN||||1000|193|202


SE|00000000||tx|1|text|For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.
SE|00000000||tx|1|entity|C0392360|Indication of (contextual qualifier)|idcn|||reasons||||1000|11|17
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||966|45|52
SE|00000000||tx|1|entity|C0439856|Unsatisfactory|qlco|||unsatisfactory||||623|70|83
SE|00000000||tx|1|entity|C0023779|Lipids|lipd|||lipid||||623|85|89
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||861|110|113
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|115|119
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||888|126|133
SE|00000000||tx|1|entity|C0814225|Benefits|qnco|||benefits||||888|135|142
SE|00000000||tx|1|entity|C0033972|Psychotherapy, Multiple|topp|||combined therapy||||1000|147|162
SE|00000000||tx|1|entity|C0024027|Lovastatin|orch,phsu|||lovastatin||||1000|169|178
SE|00000000||tx|1|entity|C1449704|Fibrates|orch,phsu|||fibrate||||966|186|192
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|197|199
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risks||||1000|214|218
SE|00000000||tx|1|entity|C0026848|Myopathy|dsyn|||myopathy||||861|230|237
SE|00000000||tx|1|entity|C0035410|Rhabdomyolysis|patf|||rhabdomyolysis||||1000|240|253
SE|00000000||tx|1|entity|C0022660|Kidney Failure, Acute|dsyn|||acute renal failure||||1000|260|278
SE|00000000||tx|1|relation|7|1|C0033972|Psychotherapy, Multiple|topp|topp|||combined therapy||||1000|147|162|PREP|USES||164|167|6|1|C0024027|Lovastatin|orch,phsu|phsu|||lovastatin||||1000|169|178
SE|00000000||tx|1|relation|7|1|C0033972|Psychotherapy, Multiple|topp|topp|||combined therapy||||1000|147|162|PREP|USES||164|167|6|1|C1449704|Fibrates|orch,phsu|phsu|||fibrate||||966|186|192
SE|00000000||tx|1|relation|9|6|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||861|110|113|NOM|PREDISPOSES|negation|214|218|3|1|C0026848|Myopathy|dsyn|dsyn|||myopathy||||861|230|237
SE|00000000||tx|1|relation|9|6|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||861|110|113|NOM|PREDISPOSES|negation|214|218|3|1|C0022660|Kidney Failure, Acute|dsyn|dsyn|||acute renal failure||||1000|260|278
SE|00000000||tx|1|relation|9|6|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||861|110|113|NOM|PREDISPOSES|negation|214|218|3|1|C0035410|Rhabdomyolysis|patf|patf|||rhabdomyolysis||||1000|240|253


SE|00000000||tx|1|text|The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||888|5|13
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|15|21
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||890|26|34
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|36|56
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||midazolam||||1000|61|69
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|80|94
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|112|117
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|120|129
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||triazolam||||1000|132|140
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|191|196
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|203|212
SE|00000000||tx|1|relation|0|0|C0026056|Midazolam|orch,phsu|orch|||midazolam||||1000|61|69|SPEC|ISA||61|94|0|0|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|80|94
SE|00000000||tx|1|relation|0|0|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|80|94|SPEC|ISA||61|94|0|0|C0026056|Midazolam|orch,phsu|orch|||midazolam||||1000|61|69
SE|00000000||tx|1|relation|4|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|80|94|VERB|INTERACTS_WITH||96|106|5|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|112|117
SE|00000000||tx|1|relation|4|1|C0026056|Midazolam|orch,phsu|orch|||midazolam||||1000|61|69|VERB|INTERACTS_WITH||96|106|5|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|112|117
SE|00000000||tx|1|relation|0|0|C0026056|Midazolam|orch,phsu|orch|||midazolam||||1000|61|69|INFER|INTERACTS_WITH(SPEC)||61|94|0|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|112|117
SE|00000000||tx|1|relation|0|0|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|80|94|INFER|INTERACTS_WITH(SPEC)||61|94|0|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|112|117


SE|00000000||tx|1|text|Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||Vardenafil||||888|1|10
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|12|15
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|24|26
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximum||||1000|37|43
SE|00000000||tx|1|entity|C0450346|2/5|qnco|||2.5||||901|48|50
SE|00000000||tx|1|entity|C0439584|24 hour time frame|tmco|||24-hour||||890|60|66
SE|00000000||tx|1|entity|C0439531|per period (qualifier value)|tmco|||period||||890|68|73
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|78|85
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||901|109|117
SE|00000000||tx|1|entity|C1707479|Concomitant Therapy|topp|||concomitant indinavir therapy||||901|97|125
SE|00000000||tx|1|relation|4|4|C0971579|vardenafil|orch,phsu|phsu|||Vardenafil||||888|1|10|PREP|TREATS||75|76|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|78|85
SE|00000000||tx|1|relation|1|1|C1707479|Concomitant Therapy|topp|topp|||concomitant indinavir therapy||||901|97|125|VERB|ADMINISTERED_TO||87|95|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|78|85
SE|00000000||tx|1|relation|0|0|C1707479|Concomitant Therapy|topp|topp|||concomitant indinavir therapy||||901|97|125|MOD/HEAD|USES||109|125|0|0|C0376637|Indinavir|orch,phsu|phsu|||indinavir||||901|109|117


SE|00000000||tx|1|text|Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.
SE|00000000||tx|1|entity|C0030125|aminosalicylic acid|orch,phsu|||Aminosalicylic acid||||1000|1|19
SE|00000000||tx|1|entity|C1265611|Quantity|qnco|||amount||||1000|38|43
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|48|54
SE|00000000||tx|1|entity|C0699988|Lanoxin|carb,phsu,strd|||Lanoxin||||1000|57|63
SE|00000000||tx|1|entity|C0701372|Lanoxicaps|carb,phsu,strd|||Lanoxicaps||||1000|66|75
SE|00000000||tx|1|relation|0|0|C0699988|Lanoxin|carb,phsu,strd|carb|||Lanoxin||||1000|57|63|SPEC|ISA||48|63|0|0|C0012265|Digoxin|carb,phsu,strd|carb|||digoxin||||1000|48|54
SE|00000000||tx|1|relation|1|1|C0030125|aminosalicylic acid|orch,phsu|orch|||Aminosalicylic acid||||1000|1|19|VERB|INHIBITS||25|32|6|2|C0012265|Digoxin|carb,phsu,strd|carb|||digoxin||||1000|48|54
SE|00000000||tx|1|relation|0|0|C0030125|aminosalicylic acid|orch,phsu|orch|||Aminosalicylic acid||||1000|1|19|INFER|INHIBITS(SPEC)||48|63|0|0|C0699988|Lanoxin|carb,phsu,strd|carb|||Lanoxin||||1000|57|63


SE|00000000||tx|1|text|It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.
SE|00000000||tx|1|entity|C0591237|Casodex|orch,phsu|||CASODEX||||1000|27|33
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|49|56
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin anticoagulants||||983|76|98
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin times||||1000|101|117
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulant||||901|169|181
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||901|183|186
SE|00000000||tx|1|relation|1|1|C0591237|Casodex|orch,phsu|phsu|||CASODEX||||1000|27|33|PREP|TREATS||46|47|6|1|C0030705|Patients|podg,humn|podg|||patients||||861|49|56
SE|00000000||tx|1|relation|5|1|C0010206|coumarin|orch,phsu|orch|||coumarin anticoagulants||||983|76|98|VERB|ADMINISTERED_TO||66|74|2|1|C0030705|Patients|podg,humn|humn|||patients||||861|49|56


SE|00000000||tx|1|text|Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.
SE|00000000||tx|1|entity|C0701063|Cerubidine|orch,phsu|||Cerubidine||||1000|1|10
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|19|21
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|34|41
SE|00000000||tx|1|entity|C0034866|Recommendation|idcn|||recommended||||850|76|86
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximum||||850|88|94
SE|00000000||tx|1|entity|C2986497|Cumulative Dose|cnce|||cumulative doses||||850|96|111
SE|00000000||tx|1|entity|C0013089|Doxorubicin|antb,orch|||doxorubicin||||1000|116|126
SE|00000000||tx|1|entity|C0701063|Cerubidine|orch,phsu|||Cerubidine||||1000|131|140
SE|00000000||tx|1|relation|1|1|C0701063|Cerubidine|orch,phsu|phsu|||Cerubidine||||1000|1|10|PREP|TREATS||31|32|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|34|41
SE|00000000||tx|1|relation|1|1|C0701063|Cerubidine|orch,phsu|phsu|||Cerubidine||||1000|131|140|PREP|TREATS||31|32|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|34|41


SE|00000000||tx|1|text|Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
SE|00000000||tx|1|entity|C0242896|Anticholinergic Agents|phsu|||Anticholinergics||||1000|1|16
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|19|28
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||785|48|54
SE|00000000||tx|1|entity|C0205198|Compound|qlco|||compounds||||785|72|80
SE|00000000||tx|1|entity|C0004954|Belladonna Alkaloids|bacs,orch,phsu|||belladonna alkaloids||||1000|91|110
SE|00000000||tx|1|entity|C0012125|Dicyclomine|orch,phsu|||dicyclomine||||1000|116|126
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|176|182
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|187|195
SE|00000000||tx|1|relation|5|1|C0012125|Dicyclomine|orch,phsu|orch|||dicyclomine||||1000|116|126|NOM|INTERACTS_WITH||176|182|1|1|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|187|195
SE|00000000||tx|1|relation|5|1|C0004954|Belladonna Alkaloids|bacs,orch,phsu|orch|||belladonna alkaloids||||1000|91|110|NOM|INTERACTS_WITH||176|182|1|1|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|187|195


SE|00000000||tx|1|text|There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|17|23
SE|00000000||tx|1|entity|C0151502|INCREASED ANTICOAGULANT EFFECT|fndg|||increased anticoagulant effects||||966|28|58
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|65|76
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulants||||1000|82|100


SE|00000000||tx|1|text|Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||Theophylline||||1000|1|12
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|34|43
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|46|55
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|75|87
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|94|105
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||890|119|126
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentrations||||890|128|147
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|152|163
SE|00000000||tx|1|entity|C2348397|Elimination Half Life|qnco|||elimination half-life||||1000|189|209


SE|00000000||tx|1|text|Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||Midazolam||||1000|1|9
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|12|21
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|37|39
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||midazolam||||1000|44|52
SE|00000000||tx|1|entity|C0332324|Sensitive|ftcn|||sensitive||||660|57|65
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||660|67|72
SE|00000000||tx|1|entity|C1519042|Phase II/III Trial|resa|||2.3||||901|88|90
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||901|92|95
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|100|102
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||827|114|117
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|122|124
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||851|136|141
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||851|143|146
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||851|148|151
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||midazolam||||802|156|164
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|193|195
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|203|205
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||regimen||||1000|214|220
SE|00000000||tx|1|entity|C1331019|aprepitant 125 MG|clnd|||Aprepitant 125 mg||||1000|225|241
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|246|248
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|259|264
SE|00000000||tx|1|entity|C0439228|day|tmco|||Days||||861|269|272
SE|00000000||tx|1|relation|4|1|C0026056|Midazolam|orch,phsu|orch|||midazolam||||1000|44|52|NOM|INTERACTS_WITH||74|82|4|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||660|67|72


SE|00000000||tx|1|text|This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.
SE|00000000||tx|1|entity|C0700321|Small|qnco|||small||||888|6|10
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||888|12|19
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||1000|24|32
SE|00000000||tx|1|entity|C0060926|gabapentin|orch,phsu|||gabapentin||||1000|37|46
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|51|60
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|65|67
SE|00000000||tx|1|entity|C0205210|Clinical|qlco|||clinical||||694|87|94


SE|00000000||tx|1|text|Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).
SE|00000000||tx|1|entity|C0037250|Skeletal Muscle Relaxants|phsu|||Skeletal muscle relaxants||||1000|1|25
SE|00000000||tx|1|entity|C0002679|Amphotericin B|antb,orch|||amphotericin B||||861|28|41
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induced||||861|43|49
SE|00000000||tx|1|entity|C0020621|Hypokalemia|fndg|||hypokalemia||||861|51|61
SE|00000000||tx|1|entity|C0010463|Curare|hops,orch,phsu|||curariform||||853|79|88
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||853|90|95
SE|00000000||tx|1|entity|C0037250|Skeletal Muscle Relaxants|phsu|||skeletal muscle relaxants||||1000|100|124
SE|00000000||tx|1|entity|C0041345|Tubocurarine|orch,phsu|||tubocurarine||||1000|133|144
SE|00000000||tx|1|relation|2|0|C0010463|Curare|hops,orch,phsu|hops|||curariform||||853|79|88|NOM|INTERACTS_WITH||90|95|2|1|C0037250|Skeletal Muscle Relaxants|phsu|phsu|||skeletal muscle relaxants||||1000|100|124


SE|00000000||tx|1|text|Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||Clinical studies||||1000|1|16
SE|00000000||tx|1|entity|C0538927|celecoxib|orch,phsu|||celecoxib||||1000|23|31
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||773|61|71
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interactions||||773|73|84
SE|00000000||tx|1|entity|C0016277|Fluconazole|orch,phsu|||fluconazole||||1000|91|101
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|107|113


SE|00000000||tx|1|text|Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||851|21|26
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||851|29|32
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||851|34|38
SE|00000000||tx|1|entity|C0251504|zaleplon|orch,phsu|||zaleplon||||1000|43|50
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|57|68
SE|00000000||tx|1|entity|C0442821|Strong|qlco|||strong||||791|106|111
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||791|124|129
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||791|131|139
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|156|163
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximal||||813|178|184
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||813|186|206
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|218|225
SE|00000000||tx|1|entity|C0205146|Area|spco|||area||||1000|234|237
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration-||||861|249|269
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||861|270|273
SE|00000000||tx|1|entity|C0205134|Curved|spco|||curve||||861|275|279
SE|00000000||tx|1|relation|6|3|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|57|68|NOM|INHIBITS||131|139|6|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||791|124|129


SE|00000000||tx|1|text|Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.
SE|00000000||tx|1|entity|C0876188|Tikosyn|orch,phsu|||TIKOSYN||||1000|22|28
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||1000|35|43
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||1000|57|65
SE|00000000||tx|1|entity|C0114771|dofetilide|orch,phsu|||dofetilide||||852|70|79
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||852|86|91
SE|00000000||tx|1|entity|C0444505|Peak level|qnco|||peak plasma levels||||852|81|98
SE|00000000||tx|1|entity|C1561607|Overall|qlco|||overall||||694|117|123
SE|00000000||tx|1|entity|C0114771|dofetilide|orch,phsu|||dofetilide||||1000|137|146
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|152|154


SE|00000000||tx|1|text|Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||Aripiprazole||||888|1|12
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|14|17
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|40|42
SE|00000000||tx|1|entity|C2825407|Half|qnco|||half||||888|44|47
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||888|56|61
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|63|66
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|73|83
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|103|111
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||1000|118|129


SE|00000000||tx|1|text|Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||Paroxetine||||1000|1|10
SE|00000000||tx|1|entity|C2348070|Daily Dose|qnco|||daily doses||||966|38|48
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||aprepitant||||1000|53|62
SE|00000000||tx|1|entity|C1706433|Capsule Dosing Unit|qnco|||capsule||||694|126|132
SE|00000000||tx|1|entity|C0993445|Paroxetine 20 MG|clnd|||paroxetine 20 mg||||1000|152|167
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||1000|174|178
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|195|202
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|207|209
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|214|226
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|236|239
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|245|257
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||aprepitant||||1000|271|280
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||paroxetine||||1000|286|295


SE|00000000||tx|1|text|Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|19|27
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|32|39
SE|00000000||tx|1|entity|C0282151|Dopamine Hydrochloride|nsba,orch,phsu|||dopamine HCl||||1000|51|62
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||1000|93|103
SE|00000000||tx|1|entity|C0428977|Bradycardia|patf|||bradycardia||||1000|109|119
SE|00000000||tx|1|relation|5|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|19|27|NOM|ADMINISTERED_TO||1|14|5|2|C0030705|Patients|podg,humn|humn|||patients||||1000|32|39
SE|00000000||tx|1|relation|3|1|C0282151|Dopamine Hydrochloride|nsba,orch,phsu|nsba|||dopamine HCl||||1000|51|62|VERB|ADMINISTERED_TO||41|49|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|32|39


SE|00000000||tx|1|text|Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.
SE|00000000||tx|1|entity|C0540413|ibuprofen arginine|orch,phsu|||Ibuprofen - L-arginine||||913|1|22
SE|00000000||tx|1|entity|C0020740|Ibuprofen|orch,phsu|||ibuprofen||||1000|55|63


SE|00000000||tx|1|text|Careful observation is required when amantadine is administered concurrently with central nervous system stimulants.
SE|00000000||tx|1|entity|C1964257|Observation - diagnostic procedure|diap|||observation||||861|9|19
SE|00000000||tx|1|entity|C0002403|Amantadine|orch,phsu|||amantadine||||1000|38|47
SE|00000000||tx|1|entity|C0002763|Central Nervous System Stimulants|phsu|||central nervous system stimulants||||1000|83|115
SE|00000000||tx|1|relation|2|2|C1964257|Observation - diagnostic procedure|diap|diap|||observation||||861|9|19|PREP|USES||78|81|1|1|C0002763|Central Nervous System Stimulants|phsu|phsu|||central nervous system stimulants||||1000|83|115


SE|00000000||tx|1|text|Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.
SE|00000000||tx|1|entity|C0036079|Salicylic Acid|orch,phsu|||Salicylic acid||||1000|1|14
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||Combination||||851|17|27
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||851|29|36
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||851|38|51
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|70|78
SE|00000000||tx|1|entity|C0036079|Salicylic Acid|orch,phsu|||salicylic acid||||1000|83|96
SE|00000000||tx|1|relation|2|1|C0009871|Contraceptive Agents|phsu|phsu|||contraceptives||||851|38|51|VERB|STIMULATES||57|64|2|2|C0036079|Salicylic Acid|orch,phsu|orch|||salicylic acid||||1000|83|96


SE|00000000||tx|1|text|Concomitant administration of alosetron and fluvoxamine is contraindicated.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0291772|alosetron|orch,phsu|||alosetron||||1000|31|39
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|45|55


SE|00000000||tx|1|text|Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.
SE|00000000||tx|1|entity|C0286738|Saquinavir|orch,phsu|||Saquinavir||||1000|1|10
SE|00000000||tx|1|entity|C0286738|Saquinavir|orch,phsu|||saquinavir||||1000|33|42
SE|00000000||tx|1|entity|C1517586|Investigational|qlco|||experimental||||604|54|65
SE|00000000||tx|1|entity|C0205358|Soft|qlco|||soft-||||604|67|71
SE|00000000||tx|1|entity|C0017237|Gelatin|aapp,bodm,phsu|||gelatin||||604|72|78
SE|00000000||tx|1|entity|C1706433|Capsule Dosing Unit|qnco|||capsule||||604|80|86
SE|00000000||tx|1|entity|C0286738|Saquinavir|orch,phsu|||saquinavir||||694|103|112
SE|00000000||tx|1|entity|C0525004|Viracept|orch,phsu|||VIRACEPT||||1000|127|134
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|155|162
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||nelfinavir||||851|167|176
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||851|178|183
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||851|185|187
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||851|197|200
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||851|202|209
SE|00000000||tx|1|entity|C0286738|Saquinavir|orch,phsu|||saquinavir||||583|214|223
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||583|225|230


SE|00000000||tx|1|text|Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.
SE|00000000||tx|1|entity|C0025638|Methenamine|orch,phsu|||Methenamine||||833|1|11
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||Urinary||||833|21|27
SE|00000000||tx|1|entity|C0504085|Body Excretions|bdsu|||excretion||||833|29|37
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||amphetamines||||1000|42|53
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|73|80
SE|00000000||tx|1|entity|C0304461|Acidifying preparation|phsu|||acidifying agents||||1000|96|112
SE|00000000||tx|1|entity|C0025638|Methenamine|orch,phsu|||methenamine||||888|122|132
SE|00000000||tx|1|relation|2|1|C0304461|Acidifying preparation|phsu|phsu|||acidifying agents||||1000|96|112|VERB|INHIBITS||85|91|3|2|C0002667|Amphetamines|nsba,orch,phsu|nsba|||amphetamines||||1000|42|53


SE|00000000||tx|1|text|Beta-adrenergic blocking agents may also interact with sympathomimetics.
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||Beta-adrenergic blocking agents||||1000|1|31
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetics||||1000|56|71
SE|00000000||tx|1|relation|1|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||Beta-adrenergic blocking agents||||1000|1|31|VERB|INTERACTS_WITH||42|49|1|1|C0039052|Sympathomimetics|phsu|phsu|||sympathomimetics||||1000|56|71


SE|00000000||tx|1|text|Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||Theophylline||||1000|1|12
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||Enoxacin||||1000|15|22
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||838|29|34
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||838|36|44
SE|00000000||tx|1|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P-450||||916|53|68
SE|00000000||tx|1|entity|C0022173|Isoenzymes|aapp,enzy|||isozymes||||916|70|77
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|99|108
SE|00000000||tx|1|entity|C0066447|methylxanthine|orch,phsu|||methylxanthines||||1000|113|127
SE|00000000||tx|1|relation|2|1|C0014310|Enoxacin|orch,phsu|orch|||Enoxacin||||1000|15|22|NOM|INHIBITS||36|44|4|1|C0010762|Cytochrome P450|aapp,gngm,enzy|gngm|||cytochrome P-450||||916|53|68
SE|00000000||tx|1|relation|4|4|C0039771|Theophylline|bacs,orch,phsu|bacs|||Theophylline||||1000|1|12|ADJ|AFFECTS||79|89|2|1|C0025519|Metabolism|orgf|orgf|||metabolism||||1000|99|108


SE|00000000||tx|1|text|Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||Alcohol||||1000|1|7
SE|00000000||tx|1|entity|C0001948|Alcohol consumption|inbe|||alcohol ingestion||||1000|42|58
SE|00000000||tx|1|entity|C0010968|Dangerousness|idcn|||danger||||900|77|82
SE|00000000||tx|1|entity|C1283828|intent|qlco|||intentional||||1000|100|110
SE|00000000||tx|1|entity|C1283932|Unintentional|ftcn|||unintentional||||623|115|127
SE|00000000||tx|1|entity|C0728757|Sinequan|orch,phsu|||SINEQUAN||||623|129|136


SE|00000000||tx|1|text|poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
SE|00000000||tx|1|entity|C0032854|Poverty|grpa|||poor||||861|1|4
SE|00000000||tx|1|entity|C0011082|Debrisoquin|orch,phsu|||debrisoquin||||1000|22|32
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||Interactions||||966|35|46
SE|00000000||tx|1|entity|C0054836|carvedilol|orch,phsu|||carvedilol||||1000|51|60
SE|00000000||tx|1|entity|C0442821|Strong|qlco|||strong||||888|67|72
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||888|74|83
SE|00000000||tx|1|entity|C1332830|CYP2D6 gene|gngm|1565|CYP2D6|CYP2D6||||1000|88|93
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|104|112
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|115|124
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||paroxetine||||1000|127|136
SE|00000000||tx|1|entity|C0033429|Propafenone|orch,phsu|||propafenone||||1000|143|153
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|161|163
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|189|193
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||861|225|229
SE|00000000||tx|1|entity|C0599473|enantiomer|chvs|||enantiomer||||1000|250|259
SE|00000000||tx|1|entity|C0054836|carvedilol|orch,phsu|||carvedilol||||1000|264|273
SE|00000000||tx|1|relation|12|3|C1332830|CYP2D6 gene|gngm,aapp|gngm|1565|CYP2D6|CYP2D6||||1000|88|93|NOM|INTERACTS_WITH||35|46|12|1|C0054836|carvedilol|orch,phsu|orch|||carvedilol||||1000|51|60


SE|00000000||tx|1|text|Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased half-life by 29%.
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives||||1000|21|39
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximum||||901|55|61
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||901|63|82
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|87|96
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||decreased||||888|106|114
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|116|124
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||901|138|146
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||901|148|156
SE|00000000||tx|1|relation|2|1|C0009905|Contraceptives, Oral|phsu|phsu|||oral contraceptives||||1000|21|39|VERB|STIMULATES||41|49|4|2|C0002333|Alprazolam|orch,phsu|orch|||alprazolam||||1000|87|96


SE|00000000||tx|1|text|Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.
SE|00000000||tx|1|entity|C0332464|Widening|spco|||wide||||802|8|11
SE|00000000||tx|1|entity|C2827666|Variability|cnce|||variability||||802|29|39
SE|00000000||tx|1|entity|C2826232|Dose Adjustment|hlca|||dose adjustment||||1000|48|62
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||888|97|108
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|110|123
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|152|161
SE|00000000||tx|1|entity|C0054836|carvedilol|orch,phsu|||carvedilol||||888|166|175
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|198|201
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|206|217
SE|00000000||tx|1|entity|C1548787|Appropriate|qlco|||appropriate||||1000|234|244


SE|00000000||tx|1|text|Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.
SE|00000000||tx|1|entity|C0014939|Estrogens|horm,phsu,strd|||Estrogens||||1000|1|9
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives||||1000|22|40
SE|00000000||tx|1|entity|C0014939|Estrogens|horm,phsu,strd|||Estrogens||||1000|43|51
SE|00000000||tx|1|entity|C0205054|Hepatic|blor|||hepatic||||888|70|76
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||888|78|87
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||888|92|98
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||888|100|114
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|142|147
SE|00000000||tx|1|relation|3|1|C0014939|Estrogens|horm,phsu,strd|horm|||Estrogens||||1000|43|51|VERB|INHIBITS||57|64|3|2|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroids||||888|100|114


SE|00000000||tx|1|text|Thus, probenecid should not be administered concurrently with bumetanide.
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|7|16
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|25|27
SE|00000000||tx|1|entity|C0006376|Bumetanide|orch,phsu|||bumetanide||||1000|63|72


SE|00000000||tx|1|text|Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||Hormonal||||775|1|8
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||775|10|23
SE|00000000||tx|1|entity|C0876196|Trileptal|orch,phsu|||Trileptal||||1000|46|54
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptive||||1000|64|81
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|115|135
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||851|144|146
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||851|148|155
SE|00000000||tx|1|entity|C0449432|Component object|mnob|||components||||851|157|166
SE|00000000||tx|1|entity|C0015011|Ethinyl Estradiol|horm,phsu,strd|||ethinylestradiol||||1000|169|184
SE|00000000||tx|1|entity|C0023566|Levonorgestrel|horm,phsu,strd|||levonorgestrel||||1000|195|208


SE|00000000||tx|1|text|Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a  stimulating  effect in some depressed patients.
SE|00000000||tx|1|entity|C0035179|Reserpine|orch,phsu|||reserpine||||1000|19|27
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|36|42
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressant||||1000|51|74
SE|00000000||tx|1|entity|C1948023|Stimulation (motivation)|npop|||stimulating||||888|105|115
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|118|123
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|143|150
SE|00000000||tx|1|relation|3|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||1000|36|42|PREP|USES||44|47|3|1|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressant||||1000|51|74
SE|00000000||tx|1|relation|4|3|C0035179|Reserpine|orch,phsu|orch|||reserpine||||1000|19|27|NOM|AFFECTS||118|123|4|0|C1948023|Stimulation (motivation)|npop|npop|||stimulating||||888|105|115


SE|00000000||tx|1|text|Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|27|33
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||694|42|49
SE|00000000||tx|1|entity|C0540623|naratriptan|orch,phsu|||naratriptan||||1000|72|82
SE|00000000||tx|1|entity|C0439084|>5|qnco|||5-HT1||||851|94|98
SE|00000000||tx|1|entity|C0450565|HT1|blor|||5-HT1||||851|94|98
SE|00000000||tx|1|entity|C0243192|agonists|phsu|||agonists||||851|100|107
SE|00000000||tx|1|entity|C1442770|24 Hours|tmco|||24 hours||||1000|116|123
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|142|144


SE|00000000||tx|1|text|Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.
SE|00000000||tx|1|entity|C0042210|Vaccines|imft,phsu|||Vaccines||||1000|1|8
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|11|18
SE|00000000||tx|1|entity|C0149783|Steroid therapy|topp|||corticosteroid therapy||||1000|23|44
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||diminished||||694|60|69
SE|00000000||tx|1|entity|C0040555|Toxoids|imft,phsu|||toxoids||||1000|83|89
SE|00000000||tx|1|entity|C1548795|Live|qlco|||live||||1000|95|98
SE|00000000||tx|1|entity|C0042212|Vaccines, Inactivated|imft,phsu|||inactivated vaccines||||1000|103|122
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|131|140
SE|00000000||tx|1|entity|C0003261|Antibody Formation|biof|||antibody response||||1000|145|161
SE|00000000||tx|1|relation|7|1|C0042212|Vaccines, Inactivated|imft,phsu|phsu|||inactivated vaccines||||1000|103|122|NOM|DISRUPTS||131|140|1|1|C0003261|Antibody Formation|biof|biof|||antibody response||||1000|145|161
SE|00000000||tx|1|relation|7|1|C0042210|Vaccines|imft,phsu|phsu|||Vaccines||||1000|1|8|NOM|DISRUPTS||131|140|1|1|C0003261|Antibody Formation|biof|biof|||antibody response||||1000|145|161


SE|00000000||tx|1|text|Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||Diuretics||||1000|1|9
SE|00000000||tx|1|entity|C0205307|Normal|qlco|||normal||||888|23|28
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|30|39
SE|00000000||tx|1|entity|C0016377|Flurbiprofen|orch,phsu|||flurbiprofen||||1000|57|68
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory drugs||||1000|81|116
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|142|148
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|153|162
SE|00000000||tx|1|relation|2|2|C0012798|Diuretics|phsu|phsu|||Diuretics||||1000|1|9|PREP|TREATS||20|21|5|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|30|39
SE|00000000||tx|1|relation|5|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory drugs||||1000|81|116|NOM|INTERACTS_WITH||142|148|1|1|C0016860|Furosemide|orch,phsu|orch|||furosemide||||1000|153|162


SE|00000000||tx|1|text|Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided.
SE|00000000||tx|1|entity|C0017710|Glucocorticoids|horm,strd|||glucocorticoids||||1000|10|24
SE|00000000||tx|1|entity|C0701339|Proleukin|orch,phsu|||PROLEUKIN||||861|52|60
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induced||||861|62|68
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||861|70|81
SE|00000000||tx|1|entity|C0015967|Fever|fndg|||fever||||1000|93|97
SE|00000000||tx|1|entity|C1565489|Renal Insufficiency|dsyn|||renal insufficiency||||1000|100|118
SE|00000000||tx|1|entity|C0311468|Increased bilirubin level (finding)|fndg|||hyperbilirubinemia||||1000|121|138
SE|00000000||tx|1|entity|C0009676|Confusion|mobd|||confusion||||1000|141|149
SE|00000000||tx|1|entity|C0013404|Dyspnea|sosy|||dyspnea||||1000|156|162
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|165|175
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|201|206
SE|00000000||tx|1|entity|C0701339|Proleukin|orch,phsu|||PROLEUKIN||||1000|213|221
SE|00000000||tx|1|entity|C2986475|Antitumor|qlco|||antitumor||||888|238|246
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effectiveness||||888|248|260
SE|00000000||tx|1|entity|C0701339|Proleukin|orch,phsu|||PROLEUKIN||||1000|265|273

SE|00000000||tx|2|text|12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
SE|00000000||tx|2|entity|C0001645|Adrenergic beta-Antagonists|phsu|||Beta-blockers||||901|4|16
SE|00000000||tx|2|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensives||||1000|28|44
SE|00000000||tx|2|entity|C0020649|Hypotension|fndg|||hypotension||||1000|65|75
SE|00000000||tx|2|entity|C0701339|Proleukin|orch,phsu|||PROLEUKIN||||1000|87|95
SE|00000000||tx|2|relation|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||Beta-blockers||||901|4|16|SPEC|ISA||4|44|0|0|C0003364|Antihypertensive Agents|phsu|phsu|||antihypertensives||||1000|28|44
SE|00000000||tx|2|relation|0|0|C0003364|Antihypertensive Agents|phsu|phsu|||antihypertensives||||1000|28|44|SPEC|ISA||4|44|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||Beta-blockers||||901|4|16
SE|00000000||tx|2|relation|2|1|C0003364|Antihypertensive Agents|phsu|phsu|||antihypertensives||||1000|28|44|VERB|AUGMENTS||50|59|2|1|C0020649|Hypotension|fndg|fndg|||hypotension||||1000|65|75
SE|00000000||tx|2|relation|2|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||Beta-blockers||||901|4|16|VERB|AUGMENTS||50|59|2|1|C0020649|Hypotension|fndg|fndg|||hypotension||||1000|65|75
SE|00000000||tx|2|relation|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||Beta-blockers||||901|4|16|INFER|AUGMENTS(SPEC)||4|44|0|0|C0020649|Hypotension|fndg|fndg|||hypotension||||1000|65|75
SE|00000000||tx|2|relation|0|0|C0003364|Antihypertensive Agents|phsu|phsu|||antihypertensives||||1000|28|44|INFER|AUGMENTS(SPEC)||4|44|0|0|C0020649|Hypotension|fndg|fndg|||hypotension||||1000|65|75


SE|00000000||tx|1|text|An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.
SE|00000000||tx|1|entity|C0085584|Encephalopathies|dsyn|||encephalopathic||||853|4|18
SE|00000000||tx|1|entity|C0039082|Syndrome|dsyn|||syndrome||||853|20|27
SE|00000000||tx|1|entity|C1883552|Weakness|sosy|||weakness||||1000|47|54
SE|00000000||tx|1|entity|C0023380|Lethargy|sosy|||lethargy||||1000|57|64
SE|00000000||tx|1|entity|C0015967|Fever|fndg|||fever||||1000|67|71
SE|00000000||tx|1|entity|C0542247|Tremulousness|fndg|||tremulousness||||1000|74|86
SE|00000000||tx|1|entity|C0009676|Confusion|mobd|||confusion||||1000|92|100
SE|00000000||tx|1|entity|C0234133|Extrapyramidal sign|sosy|||extrapyramidal symptoms||||1000|103|125
SE|00000000||tx|1|entity|C0750426|White blood cell count increased (lab result)|fndg|||leukocytosis||||1000|128|139
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||901|151|155
SE|00000000||tx|1|entity|C0743534|enzymes elevated|fndg|||elevated serum enzymes||||901|142|163
SE|00000000||tx|1|entity|||gngm|26269,64319|FBXO8,FBRS|FBS||||1000|175|177
SE|00000000||tx|1|entity|C0270611|Brain Injuries|inpo|||brain damage||||901|205|216
SE|00000000||tx|1|entity|C0205388|Few|qnco|||few||||888|236|238
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|240|247
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||802|262|268
SE|00000000||tx|1|entity|C0591585|Haldol|orch,phsu|||HALDOL||||802|275|280
SE|00000000||tx|1|relation|12|1|C0270611|Brain Injuries|inpo|inpo|||brain damage||||901|205|216|VERB|OCCURS_IN||222|229|2|1|C0030705|Patients|podg,humn|podg|||patients||||888|240|247
SE|00000000||tx|1|relation|1|1|C0591585|Haldol|orch,phsu|phsu|||HALDOL||||802|275|280|VERB|TREATS||249|255|13|1|C0030705|Patients|podg,humn|podg|||patients||||888|240|247


SE|00000000||tx|1|text|If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|10|15
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||888|54|65
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|67|80
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||888|119|127


SE|00000000||tx|1|text|Dexfenfluramine should not be administered with other serotoninergic agents.
SE|00000000||tx|1|entity|C0011786|Dexfenfluramine|orch,phsu|||Dexfenfluramine||||1000|1|15
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|24|26
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||827|70|75


SE|00000000||tx|1|text|In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride;
SE|00000000||tx|1|entity|C1511726|Data|idcn|||data||||861|10|13
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||802|28|39
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||markedly||||802|46|53
SE|00000000||tx|1|entity|C0220798|biotransformational|ftcn|||biotransformation||||888|68|84
SE|00000000||tx|1|entity|C0449913|System|ftcn|||system||||888|86|91
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|120|129
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|134|142
SE|00000000||tx|1|relation|2|1|C0064113|Itraconazole|orch,phsu|orch|||itraconazole||||802|28|39|ADJ|AFFECTS||100|110|2|1|C0025519|Metabolism|orgf|orgf|||metabolism||||1000|120|129


SE|00000000||tx|1|text|Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.
SE|00000000||tx|1|entity|C0242889|Adrenergic Antagonists|phsu|||Adrenergic blockers||||1000|1|19
SE|00000000||tx|1|entity|C0242889|Adrenergic Antagonists|phsu|||Adrenergic blockers||||1000|22|40
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||amphetamines||||1000|59|70
SE|00000000||tx|1|relation|1|1|C0002667|Amphetamines|nsba,orch,phsu|nsba|||amphetamines||||1000|59|70|VERB|INHIBITS||46|54|2|1|C0242889|Adrenergic Antagonists|phsu|phsu|||Adrenergic blockers||||1000|22|40


SE|00000000||tx|1|text|When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|6|18
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||888|32|43
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||888|54|65
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|67|70


SE|00000000||tx|1|text|The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium.
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|20|30
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|32|38
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|85|92
SE|00000000||tx|1|entity|C0442808|Increasing|ftcn|||increasing||||901|97|106
SE|00000000||tx|1|entity|C0489767|salt intake|orga|||salt intake||||901|108|118
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|129|138
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|143|151
SE|00000000||tx|1|entity|C0733440|Fosinopril Sodium|opco,phsu|||fosinopril sodium||||1000|158|174
SE|00000000||tx|1|relation|3|1|C0012798|Diuretics|phsu|phsu|||diuretic||||1000|85|92|ADJ|STIMULATES||97|106|3|3|C0733440|Fosinopril Sodium|opco,phsu|opco|||fosinopril sodium||||1000|158|174


SE|00000000||tx|1|text|Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.
SE|00000000||tx|1|entity|C0012254|Digitalis Toxicity|inpo|||Digitalis toxicity||||1000|1|18
SE|00000000||tx|1|entity|C0205265|Initially|tmco|||initial||||888|45|51
SE|00000000||tx|1|entity|C0391871|Released (action)|ftcn|||release||||888|53|59
SE|00000000||tx|1|entity|C0028351|Norepinephrine|nsba,orch,phsu|||norepinephrine||||1000|64|77
SE|00000000||tx|1|entity|C0006168|Bretylium Tosylate|orch,phsu|||Bretylium Tosylate||||901|89|106
SE|00000000||tx|1|entity|C1533685|Injection procedure|topp|||Injection||||901|108|116
SE|00000000||tx|1|relation|0|0|C1533685|Injection procedure|topp|topp|||Injection||||901|108|116|MOD/HEAD|USES||89|116|0|0|C0006168|Bretylium Tosylate|orch,phsu|phsu|||Bretylium Tosylate||||901|89|106


SE|00000000||tx|1|text|It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|31|38
SE|00000000||tx|1|entity|C0040869|Triamterene|orch,phsu|||triamterene||||1000|43|53
SE|00000000||tx|1|entity|C0024501|Maintenance|acty|||maintenance||||694|60|70
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|84|90
SE|00000000||tx|1|entity|C0205178|acute|tmco|||acute||||916|115|119
SE|00000000||tx|1|entity|C1843276|Renal failure, reversible|fndg|||reversible acute renal failure||||916|104|133
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||1000|138|140
SE|00000000||tx|1|entity|C0205450|Four|qnco|||four||||890|145|148
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||890|150|167
SE|00000000||tx|1|relation|4|1|C0700798|Indocin|orch,phsu|orch|||INDOCIN||||1000|84|90|VERB|CAUSES||92|99|3|1|C1843276|Renal failure, reversible|fndg|fndg|||reversible acute renal failure||||916|104|133


SE|00000000||tx|1|text|Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Medications||||1000|1|11
SE|00000000||tx|1|entity|C0178638|Folate|orch,phsu,vita|||folate||||694|32|37
SE|00000000||tx|1|entity|C0003286|Anticonvulsants|phsu|||anticonvulsant||||888|63|76
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||888|78|88
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|99|107
SE|00000000||tx|1|entity|C0033148|Primidone|orch,phsu|||primidone||||1000|114|122
SE|00000000||tx|1|entity|C0025598|Metformin|orch,phsu|||metformin||||1000|125|133
SE|00000000||tx|1|entity|C1998882|Sometimes|tmco|||sometimes||||1000|136|144
SE|00000000||tx|1|entity|C0005802|Blood Glucose|carb|||blood sugar||||1000|168|178
SE|00000000||tx|1|entity|C0011860|Diabetes Mellitus, Non-Insulin-Dependent|dsyn|||type 2 diabetes||||1000|183|197
SE|00000000||tx|1|entity|C0036078|Sulfasalazine|orch,phsu|||sulfasalazine||||1000|200|212
SE|00000000||tx|1|entity|C0021368|Inflammation|patf|||inflammation||||1000|231|242
SE|00000000||tx|1|entity|C0010346|Crohn Disease|dsyn|||Crohns disease||||1000|260|273
SE|00000000||tx|1|entity|C0009324|Ulcerative Colitis|dsyn|||ulcerative colitis||||1000|279|296
SE|00000000||tx|1|entity|C0040869|Triamterene|orch,phsu|||triamterene||||1000|299|309
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|314|321
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||Methotrexate||||861|324|335
SE|00000000||tx|1|entity|C2699424|Concern|idcn|||concern||||1000|352|358
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|370|380
SE|00000000||tx|1|entity|C0042845|Vitamin B 12|orch,phsu,vita|||vitamin B12||||1000|390|400
SE|00000000||tx|1|entity|C0016410|Folic Acid|orch,phsu,vita|||folic acid||||1000|406|415
SE|00000000||tx|1|relation|0|0|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsant||||888|63|76|MOD/HEAD|ISA||63|88|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||888|78|88
SE|00000000||tx|1|relation|7|1|C0005802|Blood Glucose|carb|carb|||blood sugar||||1000|168|178|PREP|ASSOCIATED_WITH||180|181|12|1|C0011860|Diabetes Mellitus, Non-Insulin-Dependent|dsyn|dsyn|||type 2 diabetes||||1000|183|197
SE|00000000||tx|1|relation|9|1|C0010346|Crohn Disease|dsyn|dsyn|||Crohns disease||||1000|260|273|VERB|COEXISTS_WITH||244|253|10|1|C0021368|Inflammation|patf|patf|||inflammation||||1000|231|242
SE|00000000||tx|1|relation|16|2|C0025677|Methotrexate|orch,phsu|orch|||Methotrexate||||861|324|335|NOM|INTERACTS_WITH||370|380|2|1|C0042845|Vitamin B 12|orch,phsu,vita|orch|||vitamin B12||||1000|390|400
SE|00000000||tx|1|relation|16|2|C0025677|Methotrexate|orch,phsu|orch|||Methotrexate||||861|324|335|NOM|INTERACTS_WITH||370|380|2|1|C0016410|Folic Acid|orch,phsu,vita|orch|||folic acid||||1000|406|415


SE|00000000||tx|1|text|The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effectiveness||||1000|5|17
SE|00000000||tx|1|entity|C0033306|Progestins|horm,phsu,strd|||progestin||||802|22|30
SE|00000000||tx|1|entity|C0994475|Pills|bodm|||pills||||802|37|41
SE|00000000||tx|1|entity|C0428321|Measurement of liver enzyme|lbpr|||hepatic enzyme||||861|57|70
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||inducing||||861|72|79
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||861|81|85
SE|00000000||tx|1|entity|C0003286|Anticonvulsants|phsu|||anticonvulsants||||888|99|113
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||888|115|123
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|126|138
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|145|156
SE|00000000||tx|1|entity|C0003448|Antitubercular Agents|phsu|||antituberculosis||||851|167|182
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||851|184|187
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||851|189|196
SE|00000000||tx|1|relation|0|0|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||888|115|123|MOD/HEAD|ISA||99|123|0|0|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsants||||888|99|113
SE|00000000||tx|1|relation|0|0|C0035608|Rifampin|antb,orch|antb|||rifampin||||851|189|196|MOD/HEAD|ISA||184|196|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||851|184|187
SE|00000000||tx|1|relation|0|0|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||888|115|123|SPEC|ISA||81|123|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||861|81|85
SE|00000000||tx|1|relation|0|0|C0035608|Rifampin|antb,orch|orch|||rifampin||||851|189|196|SPEC|ISA||81|123|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||861|81|85
SE|00000000||tx|1|relation|0|0|C0006949|Carbamazepine|orch,phsu|orch|||carbamazepine||||1000|126|138|SPEC|ISA||81|123|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||861|81|85
SE|00000000||tx|1|relation|0|0|C0004745|Barbiturates|orch,phsu|orch|||barbiturates||||1000|145|156|SPEC|ISA||81|123|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||861|81|85


SE|00000000||tx|1|text|Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|13|15
SE|00000000||tx|1|entity|C0022154|Isocarboxazid|orch,phsu|||Isocarboxazid||||1000|20|32
SE|00000000||tx|1|entity|C0033978|Psychotropic Drugs|phsu|||psychotropic agents||||1000|44|62
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|77|79
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||802|104|111
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||802|126|132
SE|00000000||tx|1|relation|0|0|C0022154|Isocarboxazid|orch,phsu|orch|||Isocarboxazid||||1000|20|32|SPEC|ISA||20|62|0|0|C0033978|Psychotropic Drugs|phsu|phsu|||psychotropic agents||||1000|44|62
SE|00000000||tx|1|relation|0|0|C0033978|Psychotropic Drugs|phsu|phsu|||psychotropic agents||||1000|44|62|SPEC|ISA||20|62|0|0|C0022154|Isocarboxazid|orch,phsu|phsu|||Isocarboxazid||||1000|20|32


SE|00000000||tx|1|text|When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.
SE|00000000||tx|1|entity|C0004259|Atropine|orch,phsu|||atropine||||1000|6|13
SE|00000000||tx|1|entity|C0071808|pralidoxime|orch,phsu|||pralidoxime||||1000|19|29
SE|00000000||tx|1|entity|C1883357|Together|qlco|||together||||1000|40|47
SE|00000000||tx|1|entity|C0311392|Physical findings|fndg|||signs||||1000|54|58
SE|00000000||tx|1|entity|C1444620|Atropine penalization therapy|topp|||atropinization||||1000|63|76
SE|00000000||tx|1|entity|C0016382|Flushing|sosy|||flushing||||1000|79|86
SE|00000000||tx|1|entity|C0026961|Mydriasis|sosy|||mydriasis||||1000|89|97
SE|00000000||tx|1|entity|C0039231|Tachycardia|fndg|||tachycardia||||1000|100|110
SE|00000000||tx|1|entity|C0230028|Oral region|blor|||mouth||||1000|128|132
SE|00000000||tx|1|entity|C0028429|Nose|bpoc|||nose||||1000|138|141
SE|00000000||tx|1|entity|C1279919|Early|tmco|||earlier||||966|154|160
SE|00000000||tx|1|entity|C0004259|Atropine|orch,phsu|||atropine||||1000|195|202
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|212|216
SE|00000000||tx|1|entity|C0071808|pralidoxime|orch,phsu|||pralidoxime||||1000|226|236
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|257|262
SE|00000000||tx|1|entity|C0004259|Atropine|orch,phsu|||atropine||||1000|267|274
SE|00000000||tx|1|entity||<<earliness>>||||earlier|||||154|160
SE|00000000||tx|1|relation|11|8|C1444620|Atropine penalization therapy|topp|topp|||atropinization||||1000|63|76|PREP|compared_with||162|165|6|2|C0004259|Atropine|orch,phsu|orch|||atropine||||1000|195|202
SE|00000000||tx|1|relation|11|8|C1444620|Atropine penalization therapy|topp|topp|||atropinization||||1000|63|76|PREP|higher_than||162|165|6|2|C0004259|Atropine|orch,phsu|orch|||atropine||||1000|195|202
SE|00000000||tx|1|relation|14|3|C0004259|Atropine|orch,phsu|orch|||atropine||||1000|195|202|NOM|INTERACTS_WITH||257|262|1|1|C0004259|Atropine|orch,phsu|orch|||atropine||||1000|267|274


SE|00000000||tx|1|text|ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.
SE|00000000||tx|1|entity|C0720260|Ergamisol|orch,phsu|||ERGAMISOL||||1000|1|9
SE|00000000||tx|1|entity|C0733383|Levamisole Hydrochloride|orch,phsu|||levamisole hydrochloride||||1000|13|36
SE|00000000||tx|1|entity|C0591096|Antabuse|orch,phsu|||ANTABUSE||||1000|68|75
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||1000|82|93
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|125|131
SE|00000000||tx|1|relation|0|0|C0720260|Ergamisol|orch,phsu|orch|||ERGAMISOL||||1000|1|9|SPEC|ISA||1|36|0|0|C0733383|Levamisole Hydrochloride|orch,phsu|orch|||levamisole hydrochloride||||1000|13|36
SE|00000000||tx|1|relation|1|1|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|125|131|VERB|COEXISTS_WITH||100|104|4|2|C0591096|Antabuse|orch,phsu|orch|||ANTABUSE||||1000|68|75


SE|00000000||tx|1|text|Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.
SE|00000000||tx|1|entity|C0000981|Acetazolamide|orch,phsu|||Acetazolamide||||1000|1|13
SE|00000000||tx|1|entity|C0074722|Sodium Bicarbonate|orch,phsu|||sodium bicarbonate||||1000|19|36
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|70|73
SE|00000000||tx|1|entity|C0022650|Kidney Calculi|patf|||renal calculus||||901|78|91
SE|00000000||tx|1|entity|C0439634|Formations|spco|||formation||||901|93|101
SE|00000000||tx|1|relation|2|1|C0074722|Sodium Bicarbonate|orch,phsu|orch|||sodium bicarbonate||||1000|19|36|NOM|PREDISPOSES||70|73|1|1|C0022650|Kidney Calculi|patf|patf|||renal calculus||||901|78|91
SE|00000000||tx|1|relation|2|1|C0000981|Acetazolamide|orch,phsu|orch|||Acetazolamide||||1000|1|13|NOM|PREDISPOSES||70|73|1|1|C0022650|Kidney Calculi|patf|patf|||renal calculus||||901|78|91


SE|00000000||tx|1|text|Amphetamines may decrease the hypotensive effect of antihypertensives.
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||Amphetamines||||1000|1|12
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|31|41
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|43|48
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensives||||1000|53|69
SE|00000000||tx|1|relation|1|1|C0002667|Amphetamines|nsba,orch,phsu|nsba|||Amphetamines||||1000|1|12|NOM|INTERACTS_WITH||43|48|1|1|C0003364|Antihypertensive Agents|phsu|phsu|||antihypertensives||||1000|53|69


SE|00000000||tx|1|text|In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|4|11
SE|00000000||tx|1|entity|C0868928|Case (situation)|ftcn|||cases||||1000|30|34
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|54|64
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|66|68
SE|00000000||tx|1|entity|C0002679|Amphotericin B|antb,orch|||amphotericin B||||1000|73|86
SE|00000000||tx|1|entity|C0020268|Hydrocortisone|horm,phsu,strd|||hydrocortisone||||1000|92|105
SE|00000000||tx|1|entity|C0018800|Cardiomegaly|fndg|||cardiac enlargement||||1000|123|141
SE|00000000||tx|1|entity|C0018802|Congestive heart failure|dsyn|||congestive heart failure||||1000|147|170


SE|00000000||tx|1|text|Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||890|1|12
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|14|34
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||1000|61|72
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|78|86


SE|00000000||tx|1|text|Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulant||||734|43|60
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||decreased||||574|76|84
SE|00000000||tx|1|entity|C1879840|Bin|qnco|||bin||||574|95|97
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||574|99|102
SE|00000000||tx|1|entity|C0024554|Male gender|fndg|||man||||861|117|119
SE|00000000||tx|1|entity|C2986474|Adrenocortical|qlco|||adrenocortical||||888|144|157
SE|00000000||tx|1|entity|C0038317|Steroids|strd|||steroids||||888|159|166
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|168|174
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|177|184
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|186|199
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|201|212
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|214|226
SE|00000000||tx|1|entity|C0008161|Chloral Hydrate|orch,phsu|||chloral hydrate||||1000|228|242
SE|00000000||tx|1|entity|C0008188|Chlordiazepoxide|orch,phsu|||chlordiazepoxide||||1000|245|260
SE|00000000||tx|1|entity|C0012155|Diet|food|||diet||||1000|277|280
SE|00000000||tx|1|entity|C0205250|High|qlco|||high||||1000|282|285
SE|00000000||tx|1|entity|C0042878|Vitamin K|lipd,phsu,vita|||vitamin K||||1000|290|298
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|300|308
SE|00000000||tx|1|entity|C0014987|Ethchlorvynol|orch,phsu|||ethchlorvynol||||1000|311|323
SE|00000000||tx|1|entity|C0017845|Glutethimide|orch,phsu|||glutethimide||||1000|325|336
SE|00000000||tx|1|entity|C0018242|Griseofulvin|orch,phsu|||griseofulvin||||1000|338|349
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||haloperidol||||1000|351|361
SE|00000000||tx|1|entity|C0025386|Meprobamate|orch,phsu|||meprobamate||||1000|363|373
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives||||1000|375|393
SE|00000000||tx|1|entity|C0030438|Paraldehyde|orch,phsu|||paraldehyde||||1000|395|405
SE|00000000||tx|1|entity|C0033148|Primidone|orch,phsu|||primidone||||1000|407|415
SE|00000000||tx|1|entity|C0034665|Ranitidine|orch,phsu|||ranitidine||||1000|417|426
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|429|436
SE|00000000||tx|1|entity|C0749770|unreliable|idcn|||unreliable||||861|438|447
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||861|449|464
SE|00000000||tx|1|entity|C0680730|Adjudication|gora|||determinations||||861|466|479
SE|00000000||tx|1|entity|C0003968|Ascorbic Acid|orch,phsu,vita|||vitamin C||||1000|481|489
SE|00000000||tx|1|entity|C0376218|Warfarin Sodium|hops,orch,phsu|||warfarin sodium||||824|491|505
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||824|513|518
SE|00000000||tx|1|relation|3|3|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|ADJ|INHIBITS||76|84|27|1|C0024554|Male gender|fndg|fndg|||man||||861|117|119
SE|00000000||tx|1|relation|16|4|C0008188|Chlordiazepoxide|orch,phsu|orch|||chlordiazepoxide||||1000|245|260|PREP|COEXISTS_WITH||287|288|15|1|C0042878|Vitamin K|lipd,phsu,vita|lipd|||vitamin K||||1000|290|298


SE|00000000||tx|1|text|MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||861|1|14
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAOI||||861|16|19
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants||||861|21|35
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||1000|51|60
SE|00000000||tx|1|entity|C0016855|Furazolidone|antb,orch|||furazolidone||||1000|65|76
SE|00000000||tx|1|entity|C0439834|Slow|qlco|||slow||||851|79|82
SE|00000000||tx|1|entity|C0002658|Amphetamine|nsba,orch,phsu|||amphetamine||||851|84|94
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||851|96|105
SE|00000000||tx|1|relation|0|0|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||MAOI||||861|16|19|MOD/HEAD|ISA||16|35|0|0|C0003289|Antidepressive Agents|phsu|phsu|||antidepressants||||861|21|35


SE|00000000||tx|1|text|Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious initiation of therapy with SINEQUAN.
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|12|25
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||840|53|57
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||840|59|61
SE|00000000||tx|1|entity|C0439230|week|tmco|||weeks||||840|63|67
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||861|91|100
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|105|111
SE|00000000||tx|1|entity|C0728757|Sinequan|orch,phsu|||SINEQUAN||||1000|118|125
SE|00000000||tx|1|relation|4|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||1000|105|111|PREP|USES||113|116|1|1|C0728757|Sinequan|orch,phsu|phsu|||SINEQUAN||||1000|118|125


SE|00000000||tx|1|text|Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).
SE|00000000||tx|1|entity|C0379199|Ibandronate|orch,phsu|||Ibandronate||||1000|1|11
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|32|36
SE|00000000||tx|1|entity|C0700321|Small|qnco|||minutes||||785|41|47
SE|00000000||tx|1|entity|C0175795|Oral medication|topp|||oral medications||||983|60|75
SE|00000000||tx|1|entity|C0007447|Cations|chvs|||cations||||861|100|106
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|119|126
SE|00000000||tx|1|entity|C2348609|Supplement|ftcn|||supplements||||966|129|139
SE|00000000||tx|1|entity|C0042890|Vitamins|orch,phsu,vita|||vitamins||||1000|144|151


SE|00000000||tx|1|text|Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.
SE|00000000||tx|1|entity|C1274040|Result|ftcn|||results||||1000|35|41
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|57|62
SE|00000000||tx|1|entity|C0337449|Digoxin measurement|lbpr|||digoxin levels||||1000|67|80
SE|00000000||tx|1|entity|C0337449|Digoxin measurement|lbpr|||digoxin levels||||1000|106|119
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiating||||966|139|148
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuing||||787|166|178
SE|00000000||tx|1|entity|C0700579|Diltiazem Hydrochloride|orch,phsu|||diltiazem hydrochloride||||787|180|202
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||861|221|228
SE|00000000||tx|1|entity|C2919279|Administration of digitalis|hlca|||digitalization||||1000|245|258


SE|00000000||tx|1|text|Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.
SE|00000000||tx|1|entity|C0700579|Diltiazem Hydrochloride|orch,phsu|||diltiazem hydrochloride||||901|19|41
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||1000|62|72
SE|00000000||tx|1|entity|C0205451|Five|qnco|||five||||851|77|80
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||851|82|87
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||851|89|98
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||623|112|120
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||623|122|132
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|161|175
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||1000|180|190
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|206|218
SE|00000000||tx|1|relation|3|1|C0033497|Propranolol|orch,phsu|phsu|||propranolol||||1000|62|72|PREP|TREATS||74|75|4|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||851|89|98
SE|00000000||tx|1|relation|4|3|C0700579|Diltiazem Hydrochloride|orch,phsu|orch|||diltiazem hydrochloride||||901|19|41|PREP|COEXISTS_WITH||109|110|3|1|C0033497|Propranolol|orch,phsu|orch|||propranolol||||623|122|132


SE|00000000||tx|1|text|In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||888|6|12
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||888|14|18
SE|00000000||tx|1|entity|C0257343|tamsulosin|orch,phsu|||tamsulosin||||1000|25|34
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|39|56
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||827|67|74
SE|00000000||tx|1|entity|C1176940|vardenafil 20 MG|clnd|||Vardenafil 20 mg||||1000|87|102
SE|00000000||tx|1|entity|C0257343|tamsulosin|orch,phsu|||tamsulosin||||791|108|117
SE|00000000||tx|1|entity|C1292428|6 Hours|tmco|||6 hours||||1000|139|145
SE|00000000||tx|1|entity|C0488055|Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative|clna|||systolic blood pressure||||923|170|192
SE|00000000||tx|1|entity|C0439475|mmHg|qnco|||mm Hg||||901|203|207


SE|00000000||tx|1|text|If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
SE|00000000||tx|1|entity|C0700529|Desipramine Hydrochloride|orch,phsu|||desipramine hydrochloride||||901|4|28
SE|00000000||tx|1|entity|C0033978|Psychotropic Drugs|phsu|||psychotropic agents||||1000|59|77
SE|00000000||tx|1|entity|C0040614|Tranquilizing Agents|phsu|||tranquilizers||||1000|87|99
SE|00000000||tx|1|entity|C0020592|Hypnotics and Sedatives|phsu|||sedative/hypnotics||||1000|104|121
SE|00000000||tx|1|entity|C0518609|consideration|fndg|||consideration||||861|132|144
SE|00000000||tx|1|entity|C0031330|Pharmacology|bmod|||pharmacology||||1000|169|180
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|189|194
SE|00000000||tx|1|entity|C3179159|Sedative Effect|phsf|||sedative effects||||1000|215|230
SE|00000000||tx|1|entity|C0011685|Desipramine|orch,phsu|||desipramine||||1000|235|245
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|251|265
SE|00000000||tx|1|entity|C0008188|Chlordiazepoxide|orch,phsu|||chlordiazepoxide||||1000|274|289
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|294|301
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||1000|308|315
SE|00000000||tx|1|relation|0|0|C0700529|Desipramine Hydrochloride|orch,phsu|orch|||desipramine hydrochloride||||901|4|28|SPEC|ISA||4|77|0|0|C0033978|Psychotropic Drugs|phsu|phsu|||psychotropic agents||||1000|59|77
SE|00000000||tx|1|relation|0|0|C0040614|Tranquilizing Agents|phsu|phsu|||tranquilizers||||1000|87|99|SPEC|ISA||59|99|0|0|C0033978|Psychotropic Drugs|phsu|phsu|||psychotropic agents||||1000|59|77
SE|00000000||tx|1|relation|12|1|C0033978|Psychotropic Drugs|phsu|phsu|||psychotropic agents||||1000|59|77|VERB|COEXISTS_WITH||39|46|1|1|C0700529|Desipramine Hydrochloride|orch,phsu|orch|||desipramine hydrochloride||||901|4|28
SE|00000000||tx|1|relation|0|0|C0700529|Desipramine Hydrochloride|orch,phsu|orch|||desipramine hydrochloride||||901|4|28|INFER|COEXISTS_WITH(SPEC)||4|77|0|0|C0700529|Desipramine Hydrochloride|orch,phsu|orch|||desipramine hydrochloride||||901|4|28
SE|00000000||tx|1|relation|0|0|C0040614|Tranquilizing Agents|phsu|phsu|||tranquilizers||||1000|87|99|INFER|COEXISTS_WITH(SPEC)||59|99|0|0|C0700529|Desipramine Hydrochloride|orch,phsu|orch|||desipramine hydrochloride||||901|4|28


SE|00000000||tx|1|text|Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.
SE|00000000||tx|1|entity|C0002680|Ampicillin|antb,orch|||Ampicillin||||1000|1|10
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|18|22
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|27|44
SE|00000000||tx|1|entity|C0008269|Chloroquine|orch,phsu|||chloroquine||||861|47|57
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|85|99
SE|00000000||tx|1|entity|C0002680|Ampicillin|antb,orch|||ampicillin||||1000|104|113
SE|00000000||tx|1|relation|4|1|C0008269|Chloroquine|orch,phsu|orch|||chloroquine||||861|47|57|VERB|INHIBITS||73|79|2|2|C0002680|Ampicillin|antb,orch|antb|||ampicillin||||1000|104|113


SE|00000000||tx|1|text|A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||888|3|11
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||888|13|23
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|33|36
SE|00000000||tx|1|entity|C0025942|Miconazole|orch,phsu|||miconazole||||888|38|47
SE|00000000||tx|1|entity|C0359086|Oral hypoglycemic|phsu|||oral hypoglycemic agents||||1000|53|76
SE|00000000||tx|1|entity|C0020615|Hypoglycemia|dsyn|||hypoglycemia||||861|96|107
SE|00000000||tx|1|relation|3|1|C0359086|Oral hypoglycemic|phsu|phsu|||oral hypoglycemic agents||||1000|53|76|VERB|CAUSES||78|84|1|1|C0020615|Hypoglycemia|dsyn|dsyn|||hypoglycemia||||861|96|107
SE|00000000||tx|1|relation|3|1|C0025942|Miconazole|orch,phsu|phsu|||miconazole||||888|38|47|VERB|CAUSES||78|84|1|1|C0020615|Hypoglycemia|dsyn|dsyn|||hypoglycemia||||861|96|107


SE|00000000||tx|1|text|Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.
SE|00000000||tx|1|entity|C0026156|Mineral Oil|lipd,phsu|||Mineral oil||||1000|1|11
SE|00000000||tx|1|entity|C0259753|Fat soluble vitamin product|orch,vita|||fat-soluble vitamins||||1000|47|66
SE|00000000||tx|1|entity|C0042866|Vitamin D|orch,phsu,vita|||vitamin D preparations||||1000|79|100


SE|00000000||tx|1|text|Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.
SE|00000000||tx|1|entity|C0444506|Trough|qnco|||Trough||||608|1|6
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||608|8|13
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||enoxacin||||608|15|22
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||793|45|50
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|57|64
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||enoxacin||||1000|70|77


SE|00000000||tx|1|text|Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|1|10
SE|00000000||tx|1|entity|C0026458|Monobactams|antb,orch|||lactam antibiotics||||901|29|46
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|70|79
SE|00000000||tx|1|entity|C0245519|cefditoren pivoxil|antb,orch|||cefditoren pivoxil||||1000|86|103
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|120|127
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||694|136|141
SE|00000000||tx|1|entity|C0287573|cefditoren|orch,phsu|||cefditoren||||1000|155|164
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|178|185
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||861|195|198
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|208|215
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||861|225|227
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|240|247
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||1000|252|260


SE|00000000||tx|1|text|Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||Magnesium||||1000|1|9
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||Magnesium||||840|12|20
SE|00000000||tx|1|entity|C2700400|Contain (action)|acty|||containing||||840|22|31
SE|00000000||tx|1|entity|C1521827|Preparation|ftcn|||preparations||||840|33|44
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|51|58
SE|00000000||tx|1|entity|C0151714|Hypermagnesemia|dsyn|||hypermagnesemia||||1000|71|85
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|108|110
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|128|134
SE|00000000||tx|1|entity|C0042866|Vitamin D|orch,phsu,vita|||vitamin D||||1000|141|149
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|154|161
SE|00000000||tx|1|entity|C0205191|chronic|tmco|||chronic||||901|166|172
SE|00000000||tx|1|entity|C0019004|Hemodialysis|topp|||renal dialysis||||901|174|187
SE|00000000||tx|1|relation|4|4|C0024467|Magnesium|elii|elii|||Magnesium||||1000|1|9|VERB|CAUSES||65|69|5|1|C0151714|Hypermagnesemia|dsyn|dsyn|||hypermagnesemia||||1000|71|85
SE|00000000||tx|1|relation|6|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||1000|128|134|PREP|USES||136|139|3|1|C0042866|Vitamin D|orch,phsu,vita|phsu|||vitamin D||||1000|141|149


SE|00000000||tx|1|text|Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.
SE|00000000||tx|1|entity|C0028040|Nicotine|hops,orch,phsu|||Nicotine||||1000|1|8
SE|00000000||tx|1|entity|C0028040|Nicotine|hops,orch,phsu|||Nicotine||||1000|11|18
SE|00000000||tx|1|entity|C0042396|Vascular constriction (function)|ortf|||vasoconstriction||||1000|32|47
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|57|64
SE|00000000||tx|1|entity|C0443228|Largest|qnco|||greater||||623|85|91
SE|00000000||tx|1|entity|C0475224|Ischemic|ftcn|||ischemic||||623|93|100
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||861|120|126
SE|00000000||tx|1|relation|3|1|C0042396|Vascular constriction (function)|ortf|ortf|||vasoconstriction||||1000|32|47|PREP|PROCESS_OF||49|50|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|57|64


SE|00000000||tx|1|text|Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.
SE|00000000||tx|1|entity|C0005642|Bismuth|inch,phsu|||Bismuth||||1000|1|7
SE|00000000||tx|1|entity|C0053792|bismuth subsalicylate|orch,phsu|||Bismuth subsalicylate||||1000|10|30
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||enoxacin||||1000|58|65
SE|00000000||tx|1|entity|C0700321|Small|qnco|||minutes||||861|73|79
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||enoxacin||||888|91|98
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||decreased||||851|116|124
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||enoxacin||||851|126|133
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||851|135|149
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|154|166
SE|00000000||tx|1|relation|4|1|C0014310|Enoxacin|orch,phsu|orch|||enoxacin||||1000|58|65|VERB|COEXISTS_WITH||33|37|2|1|C0053792|bismuth subsalicylate|orch,phsu|orch|||Bismuth subsalicylate||||1000|10|30


SE|00000000||tx|1|text|If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.
SE|00000000||tx|1|entity|C0311392|Physical findings|fndg|||signs||||888|4|8
SE|00000000||tx|1|entity|C1457887|Symptoms|sosy|||symptoms||||1000|14|21
SE|00000000||tx|1|entity|C0274727|Poisoning by digoxin|inpo|||digoxin toxicity||||1000|37|52
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||enoxacin||||1000|65|72
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|78|84
SE|00000000||tx|1|entity|C0031831|Physicians|prog|||physicians||||1000|111|120
SE|00000000||tx|1|entity|C1306421|Serum digoxin measurement|lbpr|||serum digoxin levels||||983|144|163
SE|00000000||tx|1|entity|C0366448|Digoxin:Mass:Point in time:Dose med or substance:Quantitative|clna|||digoxin doses||||901|176|188


SE|00000000||tx|1|text|drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|1|5
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|23|30
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||852|35|42
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||852|51|59
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma phenytoin concentrations||||852|44|74
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|85|97
SE|00000000||tx|1|entity|C0001128|Acids|chem|||acid||||861|109|112
SE|00000000||tx|1|entity|C0037567|Sodium Valproate|lipd,phsu|||sodium valproate||||1000|119|134


SE|00000000||tx|1|text|Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0007412|Catecholamines|nsba,orch,phsu|||catecholamine||||840|20|32
SE|00000000||tx|1|entity|C0333668|Depletion|ftcn|||depleting||||840|34|42
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||840|44|48
SE|00000000||tx|1|entity|C0035179|Reserpine|orch,phsu|||reserpine||||1000|59|67
SE|00000000||tx|1|entity|C0018318|Guanethidine|orch,phsu|||guanethidine||||1000|72|83
SE|00000000||tx|1|entity|C1524062|Additional|ftcn|||added||||794|127|131
SE|00000000||tx|1|entity|C0599515|adrenergic block|topp|||adrenergic blocking||||794|138|156
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||794|158|163
SE|00000000||tx|1|entity|C0724461|Zebeta|orch,phsu|||ZEBETA||||1000|168|173
SE|00000000||tx|1|entity|C0442802|Excessive|qlco|||excessive||||888|187|195
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||888|197|205
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||861|222|229
SE|00000000||tx|1|relation|0|0|C0035179|Reserpine|orch,phsu|orch|||reserpine||||1000|59|67|SPEC|ISA||44|67|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||840|44|48
SE|00000000||tx|1|relation|7|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||840|44|48|VERB|ADMINISTERED_TO||10|18|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8
SE|00000000||tx|1|relation|0|0|C0035179|Reserpine|orch,phsu|orch|||reserpine||||1000|59|67|INFER|ADMINISTERED_TO(SPEC)||44|67|0|0|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8


SE|00000000||tx|1|text|Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|entity|C1521828|Rate|qnco|||rate||||1000|23|26
SE|00000000||tx|1|entity|C0033798|Pseudoephedrine|orch,phsu|||pseudoephedrine||||1000|45|59
SE|00000000||tx|1|entity|C0022499|Kaolin|inch,phsu|||kaolin||||1000|68|73


SE|00000000||tx|1|text|Doxylamine may enhance the effects of epinephrine.
SE|00000000||tx|1|entity|C0013092|Doxylamine|orch,phsu|||Doxylamine||||1000|1|10
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|28|34
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||epinephrine||||1000|39|49


SE|00000000||tx|1|text|WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.
SE|00000000||tx|1|entity|C0939530|Welchol|orch,phsu|||WelChol||||1000|1|7
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|24|27
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|33|35
SE|00000000||tx|1|entity|C0443318|Sustained|ftcn|||sustained-||||851|40|49
SE|00000000||tx|1|entity|C0391871|Released (action)|ftcn|||release||||851|50|56
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||851|58|66
SE|00000000||tx|1|entity|C0700935|Calan|orch,phsu|||Calan||||1000|69|73
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||888|83|95
SE|00000000||tx|1|entity|C0450355|31|inpr|||31%||||888|97|99
SE|00000000||tx|1|relation|0|0|C0700935|Calan|orch,phsu|orch|||Calan||||1000|69|73|SPEC|ISA||58|73|0|0|C0042523|Verapamil|orch,phsu|orch|||verapamil||||851|58|66


SE|00000000||tx|1|text|PROSTIN E2 may augment the activity of other oxytocic drugs.
SE|00000000||tx|1|entity|C0699579|Prostin E2|eico,horm,phsu|||PROSTIN E2||||1000|1|10
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||1000|28|35
SE|00000000||tx|1|entity|C0030094|Oxytocics|phsu|||oxytocic drugs||||1000|46|59
SE|00000000||tx|1|relation|1|1|C0699579|Prostin E2|eico,horm,phsu|eico|||PROSTIN E2||||1000|1|10|VERB|STIMULATES||16|22|2|2|C0030094|Oxytocics|phsu|phsu|||oxytocic drugs||||1000|46|59


SE|00000000||tx|1|text|Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||1000|1|9
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||Amphetamines||||1000|12|23
SE|00000000||tx|1|entity|C0021826|Intestinal Absorption|ortf|||intestinal absorption||||1000|35|55
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|60|68
SE|00000000||tx|1|relation|2|1|C0002667|Amphetamines|nsba,orch,phsu|nsba|||Amphetamines||||1000|12|23|VERB|AFFECTS||29|33|2|1|C0021826|Intestinal Absorption|ortf|ortf|||intestinal absorption||||1000|35|55


SE|00000000||tx|1|text|Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||Tricyclic antidepressants||||1000|1|25
SE|00000000||tx|1|entity|C0036572|Seizures|sosy|||seizure||||888|43|49
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|51|54
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|59|66
SE|00000000||tx|1|entity|C0040610|Tramadol|orch,phsu|||tramadol||||1000|75|82
SE|00000000||tx|1|relation|2|2|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||Tricyclic antidepressants||||1000|1|25|PREP|TREATS||56|57|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|59|66
SE|00000000||tx|1|relation|1|1|C0040610|Tramadol|orch,phsu|orch|||tramadol||||1000|75|82|VERB|ADMINISTERED_TO||68|73|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|59|66


SE|00000000||tx|1|text|Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.
SE|00000000||tx|1|entity|C0723503|Sular|orch,phsu|||SULAR||||1000|21|25
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|32|40
SE|00000000||tx|1|entity|C0205309|Known|qlco|||known||||660|49|53
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||660|55|60
SE|00000000||tx|1|entity|C0002346|Alternative Medicine|bmod|||alternative antihypertensive therapy||||913|92|127


SE|00000000||tx|1|text|If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|6|12
SE|00000000||tx|1|entity|C0876188|Tikosyn|orch,phsu|||TIKOSYN||||1000|23|29
SE|00000000||tx|1|entity|C0041582|Ulcer|patf|||ulcer||||790|40|44
SE|00000000||tx|1|entity|C0028978|Omeprazole|orch,phsu|||omeprazole||||1000|76|85
SE|00000000||tx|1|entity|C0034665|Ranitidine|orch,phsu|||ranitidine||||1000|88|97
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|103|110
SE|00000000||tx|1|entity|C0002367|Aluminum|elii|||aluminum||||1000|113|120
SE|00000000||tx|1|entity|C0024476|Magnesium Hydroxide|inch,phsu|||magnesium hydroxides||||983|126|145
SE|00000000||tx|1|entity|C1523987|Alternative|cnce|||alternatives||||966|159|170
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|175|184
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|196|201
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|211|216
SE|00000000||tx|1|entity|C2003903|Profiling (action)|ftcn|||profile||||861|241|247
SE|00000000||tx|1|entity|C0876188|Tikosyn|orch,phsu|||TIKOSYN||||1000|252|258
SE|00000000||tx|1|relation|3|1|C0876188|Tikosyn|orch,phsu|phsu|||TIKOSYN||||1000|23|29|NOM|TREATS||46|52|3|0|C0041582|Ulcer|patf|patf|||ulcer||||790|40|44


SE|00000000||tx|1|text|There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||861|31|37
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interactions||||1000|42|58
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|65|76
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|101|109
SE|00000000||tx|1|entity|C0003811|Cardiac Arrhythmia|patf|||cardiac arrythmias||||1000|142|159
SE|00000000||tx|1|entity|C0042514|Tachycardia, Ventricular|patf|||ventricular tachycardia||||1000|162|184
SE|00000000||tx|1|entity|C1522565|Ventricular|spco|||ventricular||||694|187|197
SE|00000000||tx|1|entity|C0040479|Torsades de Pointes|dsyn|||torsades de pointes||||1000|216|234
SE|00000000||tx|1|entity|C0205393|Most|qnco|||most||||1000|237|240
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|254|263
SE|00000000||tx|1|entity|C0205054|Hepatic|blor|||hepatic||||888|268|274
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|276|285
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|290|298
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|303|314
SE|00000000||tx|1|relation|3|3|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|303|314|NOM|INHIBITS||254|263|3|2|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|290|298


SE|00000000||tx|1|text|Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.
SE|00000000||tx|1|entity|C0021641|Insulin|aapp,horm,phsu|||Insulin||||1000|1|7
SE|00000000||tx|1|entity|C0359086|Oral hypoglycemic|phsu|||Oral Hypoglycemics||||1000|12|29
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||Agents||||966|32|37
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blocking||||851|46|53
SE|00000000||tx|1|entity|C1292721|Has property|ftcn|||properties||||851|55|64
SE|00000000||tx|1|entity|C0005802|Blood Glucose|carb|||blood-sugar||||861|82|92
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reducing||||861|94|101
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|103|108
SE|00000000||tx|1|entity|C0021641|Insulin|aapp,horm,phsu|||insulin||||1000|113|119
SE|00000000||tx|1|entity|C0359086|Oral hypoglycemic|phsu|||oral hypoglycemics||||1000|125|142


SE|00000000||tx|1|text|Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents.
SE|00000000||tx|1|entity|C0007412|Catecholamines|nsba,orch,phsu|||Catecholamine||||840|1|13
SE|00000000||tx|1|entity|C0333668|Depletion|ftcn|||depleting||||840|15|23
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||840|25|29
SE|00000000||tx|1|entity|C0035179|Reserpine|orch,phsu|||reserpine||||1000|38|46
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|61|68
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|70|75
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta blocking agents||||983|93|112
SE|00000000||tx|1|relation|1|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta blocking agents||||983|93|112|VERB|COEXISTS_WITH||82|86|3|2|C0035179|Reserpine|orch,phsu|orch|||reserpine||||1000|38|46


SE|00000000||tx|1|text|Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||Plasma concentrations||||983|1|21
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||645|24|26
SE|00000000||tx|1|entity|||gngm|1822,3035,6430,9146|ATN1,HARS,SRSF5,HGS|hrs||||645|33|35
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|41|52
SE|00000000||tx|1|entity|C0065180|Loratadine|orch,phsu|||loratadine||||1000|93|102
SE|00000000||tx|1|entity|C0205345|Relative|qlco|||relative||||1000|104|111
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|135|146
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|148|152


SE|00000000||tx|1|text|Caution should be exercised when administering ETOPOPHOS with drugs that are known to inhibit phosphatase activities (e.g., levamisole hydrochloride).
SE|00000000||tx|1|entity|C1621583|Administer|ftcn|||administering||||872|34|46
SE|00000000||tx|1|entity|C0904036|Etopofos|orch,phsu|||ETOPOPHOS||||872|48|56
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|63|67
SE|00000000||tx|1|entity|C1149880|phosphoric monoester hydrolase activity|moft|||phosphatase activities||||983|95|116
SE|00000000||tx|1|entity|C0733383|Levamisole Hydrochloride|orch,phsu|||levamisole hydrochloride||||1000|125|148
SE|00000000||tx|1|relation|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|63|67|VERB|DISRUPTS||87|93|2|1|C1149880|phosphoric monoester hydrolase activity|moft|moft|||phosphatase activities||||983|95|116


SE|00000000||tx|1|text|This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.
SE|00000000||tx|1|entity|C0243076|antagonists|chvf|||antagonistic||||853|6|17
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||853|19|24
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|29|38
SE|00000000||tx|1|entity|C0006376|Bumetanide|orch,phsu|||bumetanide||||888|43|52
SE|00000000||tx|1|entity|C0027477|Natriuresis|ortf|||natriuresis||||888|54|64
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|69|71
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||861|89|94
SE|00000000||tx|1|entity|C0037473|Sodium|bacs,elii|||sodium||||888|99|104
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|106|114
SE|00000000||tx|1|entity|C0750492|Probably|idcn|||probably||||888|123|130
SE|00000000||tx|1|entity|C0205436|second (number)|qnco|||secondary||||888|132|140
SE|00000000||tx|1|entity|C0021469|Metabolic Inhibition|moft|||inhibitory||||888|149|158
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|160|165
SE|00000000||tx|1|entity|C0678876|renal tubular secretion|ortf|||renal tubular secretion||||1000|170|192
SE|00000000||tx|1|entity|C0006376|Bumetanide|orch,phsu|||bumetanide||||1000|197|206
SE|00000000||tx|1|relation|0|0|C0027477|Natriuresis|ortf|ortf|||natriuresis||||888|54|64|SPEC|ISA||54|114|0|0|C0221102|Excretory function|phsf|phsf|||excretion||||888|106|114
SE|00000000||tx|1|relation|0|0|C0678876|renal tubular secretion|ortf|ortf|||renal tubular secretion||||1000|170|192|SPEC|ISA||106|192|0|0|C0221102|Excretory function|phsf|phsf|||excretion||||888|106|114
SE|00000000||tx|1|relation|8|1|C0033209|Probenecid|orch,phsu|orch|||probenecid||||1000|29|38|NOM|AFFECTS||19|24|8|2|C0027477|Natriuresis|ortf|ortf|||natriuresis||||888|54|64
SE|00000000||tx|1|relation|2|2|C0006376|Bumetanide|orch,phsu|orch|||bumetanide||||1000|197|206|NOM|AFFECTS||160|165|2|1|C0678876|renal tubular secretion|ortf|ortf|||renal tubular secretion||||1000|170|192


SE|00000000||tx|1|text|Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.
SE|00000000||tx|1|entity|C0039651|Tetracyclines|orch|||Tetracyclines||||1000|1|13
SE|00000000||tx|1|entity|C0050559|Acitretin|orch,phsu|||acitretin||||1000|27|35
SE|00000000||tx|1|entity|C0039651|Tetracyclines|orch|||tetracyclines||||1000|41|53
SE|00000000||tx|1|entity|C0151740|Intracranial Hypertension|dsyn|||increased intracranial pressure||||1000|65|95
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combined||||888|104|111
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|113|115
SE|00000000||tx|1|relation|3|1|C0039651|Tetracyclines|orch|orch|||tetracyclines||||1000|41|53|VERB|CAUSES||59|63|2|1|C0151740|Intracranial Hypertension|dsyn|dsyn|||increased intracranial pressure||||1000|65|95
SE|00000000||tx|1|relation|3|1|C0039651|Tetracyclines|orch|orch|||Tetracyclines||||1000|1|13|VERB|CAUSES||59|63|2|1|C0151740|Intracranial Hypertension|dsyn|dsyn|||increased intracranial pressure||||1000|65|95


SE|00000000||tx|1|text|Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants, should be checked before departure.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|19|25
SE|00000000||tx|1|entity|C0025153|Mefloquine|orch,phsu|||Mefloquine||||1000|30|39
SE|00000000||tx|1|entity|C0687759|traveler|popg|||travelers||||1000|44|52
SE|00000000||tx|1|entity|C0241863|DIABETIC|fndg|||diabetics||||861|91|99
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|104|111
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|119|132
SE|00000000||tx|1|relation|7|5|C0030705|Patients|podg,humn|podg|||patients||||1000|104|111|NOM|INTERACTS_WITH||19|25|7|2|C0687759|traveler|popg,humn|popg|||travelers||||1000|44|52
SE|00000000||tx|1|relation|2|1|C0003280|Anticoagulants|phsu|phsu|||anticoagulants||||1000|119|132|VERB|ADMINISTERED_TO||113|117|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|104|111


SE|00000000||tx|1|text|The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|17|19
SE|00000000||tx|1|entity|C0694643|transdermal|spco|||transdermal||||888|24|34
SE|00000000||tx|1|entity|C0015846|Fentanyl|orch,phsu|||fentanyl||||888|36|43
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|50|58
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||752|69|74
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||752|80|89
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|99|110
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|113|124
SE|00000000||tx|1|entity|C0041165|Troleandomycin|antb,orch|||troleandomycin||||1000|127|140
SE|00000000||tx|1|entity|C0055856|Clarithromycin|antb,orch|||clarithromycin||||1000|143|156
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||nelfinavir||||1000|159|168
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|203|210
SE|00000000||tx|1|entity|C0015846|Fentanyl|orch,phsu|||fentanyl||||890|215|222
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|224|244
SE|00000000||tx|1|relation|10|2|C0525005|Nelfinavir|orch,phsu|orch|||nelfinavir||||1000|159|168|NOM|STIMULATES||203|210|1|1|C0015846|Fentanyl|orch,phsu|orch|||fentanyl||||890|215|222


SE|00000000||tx|1|text|Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents.
SE|00000000||tx|1|entity|C0020615|Hypoglycemia|dsyn|||hypoglycemia||||861|8|19
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|42|49
SE|00000000||tx|1|entity|C0004504|Azoles|orch|||azole||||901|75|79
SE|00000000||tx|1|entity|C0003308|Antifungal Agents|phsu|||antifungal agents||||901|81|97
SE|00000000||tx|1|entity|C0359086|Oral hypoglycemic|phsu|||oral hypoglycemic agents||||1000|103|126
SE|00000000||tx|1|relation|1|1|C0020615|Hypoglycemia|dsyn|dsyn|||hypoglycemia||||861|8|19|PREP|PROCESS_OF||39|40|3|1|C0030705|Patients|podg,humn|humn|||patients||||861|42|49
SE|00000000||tx|1|relation|2|1|C0003308|Antifungal Agents|phsu|phsu|||antifungal agents||||901|81|97|VERB|ADMINISTERED_TO||65|73|2|1|C0030705|Patients|podg,humn|humn|||patients||||861|42|49
SE|00000000||tx|1|relation|2|1|C0359086|Oral hypoglycemic|phsu|phsu|||oral hypoglycemic agents||||1000|103|126|VERB|ADMINISTERED_TO||65|73|2|1|C0030705|Patients|podg,humn|humn|||patients||||861|42|49


SE|00000000||tx|1|text|Acetazolamide may elevate cyclosporine levels.
SE|00000000||tx|1|entity|C0000981|Acetazolamide|orch,phsu|||Acetazolamide||||1000|1|13
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||694|27|38


SE|00000000||tx|1|text|There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|12|22
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|24|31
SE|00000000||tx|1|entity|C0935989|imatinib|orch,phsu|||imatinib||||1000|48|55
SE|00000000||tx|1|entity|C0935987|Gleevec|orch,phsu|||Gleevec||||1000|62|68
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|93|104
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||861|107|112
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||861|114|122
SE|00000000||tx|1|relation|5|2|C0935987|Gleevec|orch,phsu|orch|||Gleevec||||1000|62|68|NOM|INHIBITS||114|122|5|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||861|107|112


SE|00000000||tx|1|text|It is recommended that gabapentin be taken at least 2 hours following Maalox administration.
SE|00000000||tx|1|entity|C0060926|gabapentin|orch,phsu|||gabapentin||||1000|24|33
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|47|51
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||785|55|59
SE|00000000||tx|1|entity|C0065461|Maalox|inch,phsu|||Maalox||||888|71|76


SE|00000000||tx|1|text|The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)
SE|00000000||tx|1|entity|C0220811|Consumption-archaic term for TB|dsyn|||consumption||||1000|5|15
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|20|26
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|35|43
SE|00000000||tx|1|entity|C0085934|Wellbutrin|orch,phsu|||WELLBUTRIN||||1000|50|59
SE|00000000||tx|1|relation|3|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||1000|35|43|PREP|USES||45|48|3|1|C0085934|Wellbutrin|orch,phsu|phsu|||WELLBUTRIN||||1000|50|59


SE|00000000||tx|1|text|When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur.
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetic drugs||||1000|6|26
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|41|48
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|60|87
SE|00000000||tx|1|entity|C0443286|Reaction|ftcn|||reactions||||827|103|111
SE|00000000||tx|1|entity|C0020546|Hypertensive crisis|dsyn|||hypertensive crises||||966|124|142
SE|00000000||tx|1|relation|1|1|C0039052|Sympathomimetics|phsu|phsu|||sympathomimetic drugs||||1000|6|26|VERB|ADMINISTERED_TO||32|36|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|41|48
SE|00000000||tx|1|relation|3|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||monoamine oxidase inhibitors||||1000|60|87|VERB|ADMINISTERED_TO||50|58|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|41|48


SE|00000000||tx|1|text|Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|17|23
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|29|35
SE|00000000||tx|1|entity|C1306421|Serum digoxin measurement|lbpr|||serum digoxin levels||||983|61|80


SE|00000000||tx|1|text|Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
SE|00000000||tx|1|entity|C0072664|pyrazolone|orch,phsu|||Pyrazolone||||888|1|10
SE|00000000||tx|1|entity|C0243072|derivatives|chvs|||Derivatives||||888|12|22
SE|00000000||tx|1|entity|C0031463|Phenylbutazone|orch,phsu|||phenylbutazone||||1000|25|38
SE|00000000||tx|1|entity|C0030078|Oxyphenbutazone|orch,phsu|||oxyphenbutazone||||1000|41|55
SE|00000000||tx|1|entity|C2362652|Possible diagnosis|qlco|||possibly||||888|62|69
SE|00000000||tx|1|entity|C0012586|Dipyrone|orch,phsu|||dipyrone||||888|71|78
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|82|92
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|114|120
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|139|142
SE|00000000||tx|1|entity|C2707256|Gastrointestinal:-:Point in time:^Patient:-|clna|||gastrointestinal||||888|147|162
SE|00000000||tx|1|entity|C0041582|Ulcer|patf|||ulceration||||888|164|173
SE|00000000||tx|1|relation|6|1|C0004057|Aspirin|orch,phsu|orch|||aspirin||||1000|114|120|NOM|PREDISPOSES||139|142|1|1|C0041582|Ulcer|patf|patf|||ulceration||||888|164|173


SE|00000000||tx|1|text|therefore concomitant administration of Itraconazole with cisapride is contraindicated.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||790|11|21
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||1000|41|52
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|59|67


SE|00000000||tx|1|text|There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|17|23
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interactions||||966|28|39
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|44|55
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|62|74
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|77|88
SE|00000000||tx|1|entity|C0085149|Tacrolimus|orch,phsu|||tacrolimus||||1000|91|100
SE|00000000||tx|1|entity|C0019469|Hexobarbital|orch,phsu|||hexobarbital||||1000|103|114
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|117|125
SE|00000000||tx|1|entity|C0002026|Alfentanil|orch,phsu|||alfentanil||||1000|128|137
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|140|148
SE|00000000||tx|1|entity|C0012702|Disopyramide|orch,phsu|||disopyramide||||1000|151|162
SE|00000000||tx|1|entity|C0024027|Lovastatin|orch,phsu|||lovastatin||||1000|165|174
SE|00000000||tx|1|entity|C0006230|Bromocriptine|orch,phsu|||bromocriptine||||1000|177|189
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||valproate||||1000|192|200
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||1000|203|213
SE|00000000||tx|1|entity|C0085170|Astemizole|orch,phsu|||astemizole||||1000|220|229
SE|00000000||tx|1|relation|14|2|C0006949|Carbamazepine|orch,phsu|orch|||carbamazepine||||1000|62|74|NOM|INTERACTS_WITH||28|39|14|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|44|55
SE|00000000||tx|1|relation|14|2|C0085170|Astemizole|orch,phsu|orch|||astemizole||||1000|220|229|NOM|INTERACTS_WITH||28|39|14|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|44|55
SE|00000000||tx|1|relation|14|2|C0085173|Terfenadine|orch,phsu|orch|||terfenadine||||1000|203|213|NOM|INTERACTS_WITH||28|39|14|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|44|55
SE|00000000||tx|1|relation|14|2|C0080356|Valproate|lipd,phsu|lipd|||valproate||||1000|192|200|NOM|INTERACTS_WITH||28|39|14|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|44|55
SE|00000000||tx|1|relation|14|2|C0006230|Bromocriptine|orch,phsu|orch|||bromocriptine||||1000|177|189|NOM|INTERACTS_WITH||28|39|14|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|44|55
SE|00000000||tx|1|relation|14|2|C0024027|Lovastatin|orch,phsu|orch|||lovastatin||||1000|165|174|NOM|INTERACTS_WITH||28|39|14|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|44|55
SE|00000000||tx|1|relation|14|2|C0012702|Disopyramide|orch,phsu|orch|||disopyramide||||1000|151|162|NOM|INTERACTS_WITH||28|39|14|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|44|55
SE|00000000||tx|1|relation|14|2|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|140|148|NOM|INTERACTS_WITH||28|39|14|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|44|55
SE|00000000||tx|1|relation|14|2|C0002026|Alfentanil|orch,phsu|orch|||alfentanil||||1000|128|137|NOM|INTERACTS_WITH||28|39|14|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|44|55
SE|00000000||tx|1|relation|14|2|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|117|125|NOM|INTERACTS_WITH||28|39|14|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|44|55
SE|00000000||tx|1|relation|14|2|C0019469|Hexobarbital|orch,phsu|orch|||hexobarbital||||1000|103|114|NOM|INTERACTS_WITH||28|39|14|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|44|55
SE|00000000||tx|1|relation|14|2|C0085149|Tacrolimus|orch,phsu|orch|||tacrolimus||||1000|91|100|NOM|INTERACTS_WITH||28|39|14|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|44|55
SE|00000000||tx|1|relation|14|2|C0010592|Cyclosporine|aapp,gngm,phsu|aapp|||cyclosporine||||1000|77|88|NOM|INTERACTS_WITH||28|39|14|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|44|55


SE|00000000||tx|1|text|Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||Systemic||||694|1|8
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|22|34
SE|00000000||tx|1|entity|C0935987|Gleevec|orch,phsu|||Gleevec||||1000|89|95


SE|00000000||tx|1|text|Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|13|20
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|27|38
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|53|58
SE|00000000||tx|1|entity|C0009079|Clozapine|orch,phsu|||Clozapine||||1000|70|78
SE|00000000||tx|1|entity|C0879626|Adverse effects|patf|||adverse effects||||1000|106|120
SE|00000000||tx|1|relation|5|1|C0009079|Clozapine|orch,phsu|orch|||Clozapine||||1000|70|78|VERB|CAUSES||93|101|1|1|C0879626|Adverse effects|patf|patf|||adverse effects||||1000|106|120


SE|00000000||tx|1|text|Concurrent therapy with ORENCIA and TNF antagonists is not recommended.
SE|00000000||tx|1|entity|C0009429|Combined Modality Therapy|topp|||Concurrent therapy||||1000|1|18
SE|00000000||tx|1|entity|C1700021|Orencia|aapp,imft,phsu|||ORENCIA||||1000|25|31
SE|00000000||tx|1|entity|C1522668|Recombinant Tumor Necrosis Factor Family Protein|aapp,imft|7124|TNF|TNF||||888|37|39
SE|00000000||tx|1|entity|C0243076|antagonists|chvf|||antagonists||||888|41|51
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|56|58
SE|00000000||tx|1|relation|1|1|C0009429|Combined Modality Therapy|topp|topp|||Concurrent therapy||||1000|1|18|PREP|USES||20|23|2|1|C1700021|Orencia|aapp,gngm,imft,phsu|phsu|||ORENCIA||||1000|25|31


SE|00000000||tx|1|text|Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.
SE|00000000||tx|1|entity|C0274643|Poisoning by phenobarbital|inpo|||Phenobarbital toxicity||||1000|1|22
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|64|70
SE|00000000||tx|1|entity|C0205191|chronic|tmco|||chronic||||901|75|81
SE|00000000||tx|1|entity|C0747568|phenobarbital treatment|topp|||phenobarbital treatment||||901|83|105
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|121|130
SE|00000000||tx|1|entity|C0012091|Diclofenac|orch,phsu|||diclofenac||||888|135|144
SE|00000000||tx|1|relation|1|1|C0274643|Poisoning by phenobarbital|inpo|inpo|||Phenobarbital toxicity||||1000|1|22|VERB|OCCURS_IN||50|57|4|1|C0030705|Patients|podg,humn|podg|||patient||||1000|64|70


SE|00000000||tx|1|text|Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.
SE|00000000||tx|1|entity|C1096779|Clinical Trial, Phase II|inpr|||Phase II clinical trial||||928|1|23
SE|00000000||tx|1|entity|C3245479|data|medd|||data||||928|25|28
SE|00000000||tx|1|entity|C0919281|Iressa|orch,phsu|||IRESSA||||861|37|42
SE|00000000||tx|1|entity|C0078257|vinorelbine|orch,phsu|||vinorelbine||||1000|48|58
SE|00000000||tx|1|entity|C0919281|Iressa|orch,phsu|||IRESSA||||1000|104|109
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|142|147
SE|00000000||tx|1|entity|C0078257|vinorelbine|orch,phsu|||vinorelbine||||1000|152|162
SE|00000000||tx|1|relation|4|2|C0078257|vinorelbine|orch,phsu|orch|||vinorelbine||||1000|48|58|NOM|INTERACTS_WITH||142|147|1|1|C0078257|vinorelbine|orch,phsu|orch|||vinorelbine||||1000|152|162
SE|00000000||tx|1|relation|4|2|C0919281|Iressa|orch,phsu|orch|||IRESSA||||861|37|42|NOM|INTERACTS_WITH||142|147|1|1|C0078257|vinorelbine|orch,phsu|orch|||vinorelbine||||1000|152|162


SE|00000000||tx|1|text|Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0935989|imatinib|orch,phsu|||imatinib||||852|22|29
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||852|31|36
SE|00000000||tx|1|entity|C0678756|drug concentration|qnco|||concentrations Drugs||||852|38|57
SE|00000000||tx|1|entity|C0935989|imatinib|orch,phsu|||imatinib||||890|77|84
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|86|106
SE|00000000||tx|1|entity|C1621583|Administer|ftcn|||administering||||872|137|149
SE|00000000||tx|1|entity|C0935987|Gleevec|orch,phsu|||Gleevec||||872|151|157
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||1000|164|173
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||861|182|187
SE|00000000||tx|1|entity|C0015576|Family|famg|||family||||861|189|194
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|203|214
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|217|228
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|231|242
SE|00000000||tx|1|entity|C0055856|Clarithromycin|antb,orch|||clarithromycin||||1000|245|258
SE|00000000||tx|1|relation|2|2|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|VERB|STIMULATES||68|75|9|1|C0935989|imatinib|orch,phsu|orch|||imatinib||||890|77|84
SE|00000000||tx|1|relation|2|2|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|VERB|STIMULATES||68|75|9|1|C0935987|Gleevec|orch,phsu|orch|||Gleevec||||872|151|157


SE|00000000||tx|1|text|The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|5|14
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|16|18
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||1000|23|25
SE|00000000||tx|1|entity|C0205172|More|ftcn|||more||||888|30|33
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|35|39
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||861|62|69
SE|00000000||tx|1|entity|C0040615|Antipsychotic Agents|phsu|||antipsychotic drug||||1000|83|100
SE|00000000||tx|1|entity|C0008286|Chlorpromazine|orch,phsu|||chlorpromazine||||1000|107|120
SE|00000000||tx|1|entity|C0003405|Antiparkinson Agents|phsu|||antiparkinsonian drug||||983|127|147
SE|00000000||tx|1|entity|C0041009|Trihexyphenidyl|orch,phsu|||trihexyphenidyl||||1000|154|168
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressant||||1000|181|204
SE|00000000||tx|1|entity|C0002600|Amitriptyline|orch,phsu|||amitriptyline||||1000|211|223
SE|00000000||tx|1|entity|C0442802|Excessive|qlco|||excessive||||802|247|255
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||802|273|279
SE|00000000||tx|1|entity|C0043352|Xerostomia|dsyn|||dry mouth||||1000|292|300
SE|00000000||tx|1|entity|C0226984|Dental|qlco|||dental||||790|317|322
SE|00000000||tx|1|entity|C0009566|Complication|patf|||complications||||790|324|336
SE|00000000||tx|1|entity|C0344232|Blurred vision|sosy|||blurred vision||||1000|339|352
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|363|370
SE|00000000||tx|1|entity|C0015967|Fever|fndg|||high temperature||||1000|383|398
SE|00000000||tx|1|entity|C0020167|Humidity|npop|||humidity||||1000|404|411
SE|00000000||tx|1|entity|C0392676|Hyperpyrexia|patf|||hyperpyrexia||||1000|414|425
SE|00000000||tx|1|relation|17|1|C0344232|Blurred vision|sosy|sosy|||blurred vision||||1000|339|352|PREP|PROCESS_OF||360|361|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|363|370


SE|00000000||tx|1|text|Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
SE|00000000||tx|1|entity|C0245561|duloxetine|orch,phsu|||Duloxetine||||1000|33|42
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|55|59
SE|00000000||tx|1|entity|C0022173|Isoenzymes|aapp,enzy|||isozyme||||1000|102|108
SE|00000000||tx|1|entity|C0333164|Narrow|qnco|||narrow||||901|127|132
SE|00000000||tx|1|entity|C0678793|Therapeutic Index|qnco|||therapeutic index||||901|134|150
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||888|163|169
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants||||888|171|185
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|188|212
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||TCAs||||966|215|218
SE|00000000||tx|1|entity|C0028420|Nortriptyline|orch,phsu|||nortriptyline||||1000|230|242
SE|00000000||tx|1|entity|C0002600|Amitriptyline|orch,phsu|||amitriptyline||||1000|245|257
SE|00000000||tx|1|entity|C0020934|Imipramine|orch,phsu|||imipramine||||1000|264|273
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|277|290
SE|00000000||tx|1|entity|||gngm|6445|SGCG|Type||||827|296|299
SE|00000000||tx|1|entity|C0003195|Anti-Arrhythmia Agents|phsu|||antiarrhythmics||||827|304|318
SE|00000000||tx|1|entity|C0033429|Propafenone|orch,phsu|||propafenone||||1000|327|337
SE|00000000||tx|1|entity|C0016229|Flecainide|orch,phsu|||flecainide||||1000|340|349
SE|00000000||tx|1|relation|0|0|C0022173|Isoenzymes|aapp,gngm,enzy|aapp|||isozyme||||1000|102|108|SPEC|ISA||55|108|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|55|59
SE|00000000||tx|1|relation|0|0|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|188|212|SPEC|ISA||171|212|0|0|C0003289|Antidepressive Agents|phsu|phsu|||antidepressants||||888|171|185
SE|00000000||tx|1|relation|13|1|C0022173|Isoenzymes|aapp,gngm,enzy|aapp|||isozyme||||1000|102|108|VERB|INTERACTS_WITH||82|92|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|55|59
SE|00000000||tx|1|relation|0|0|C0022173|Isoenzymes|aapp,gngm,enzy|aapp|||isozyme||||1000|102|108|INFER|INTERACTS_WITH(SPEC)||55|108|0|0|C0022173|Isoenzymes|aapp,gngm,enzy|aapp|||isozyme||||1000|102|108


SE|00000000||tx|1|text|Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||Warfarin||||1000|1|8
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||Quinolones||||1000|11|20
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||enoxacin||||1000|33|40
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|56|64
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||888|71|78
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||851|85|88
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||851|90|95
SE|00000000||tx|1|entity|C0022203|Isomerism|npop|||isomer||||851|97|102
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||861|115|122
SE|00000000||tx|1|relation|3|1|C0014310|Enoxacin|orch,phsu|orch|||enoxacin||||1000|33|40|VERB|INHIBITS||43|50|4|2|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||888|71|78


SE|00000000||tx|1|text|In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued.
SE|00000000||tx|1|entity|C0205170|Good|qlco|||well||||833|4|7
SE|00000000||tx|1|entity|C2587213|Control function|ftcn|||controlled||||833|9|18
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||833|20|27
SE|00000000||tx|1|entity|C0009429|Combined Modality Therapy|topp|||concurrent therapy||||1000|40|57
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|64|73
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|78|85
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||877|94|105
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentrations||||877|107|126
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|131|155
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||827|184|190
SE|00000000||tx|1|relation|6|1|C0009429|Combined Modality Therapy|topp|topp|||concurrent therapy||||1000|40|57|VERB|TREATS||29|38|1|1|C0030705|Patients|podg,humn|podg|||patients||||833|20|27
SE|00000000||tx|1|relation|2|1|C0009429|Combined Modality Therapy|topp|topp|||concurrent therapy||||1000|40|57|PREP|USES||59|62|5|1|C0008783|Cimetidine|orch,phsu|phsu|||cimetidine||||1000|64|73


SE|00000000||tx|1|text|Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption .
SE|00000000||tx|1|entity|C0033228|Fenofibrate|orch,phsu|||fenofibrate||||1000|12|22
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|43|47
SE|00000000||tx|1|entity|C0564385|/hour|qnco|||hour||||785|51|54
SE|00000000||tx|1|entity|C1292426|4 Hours|tmco|||4-6 hours||||913|66|74
SE|00000000||tx|1|entity|C2266924|Bile-acid Binding Resin [EPC]|phsu|||bile acid binding resin||||937|84|106


SE|00000000||tx|1|text|Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
SE|00000000||tx|1|entity|C0003286|Anticonvulsants|phsu|||Anticonvulsants||||1000|1|15
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|18|30
SE|00000000||tx|1|entity|C0060135|felbamate|orch,phsu|||felbamate||||1000|33|41
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|44|56
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|59|67
SE|00000000||tx|1|entity|C0076829|topiramate|orch,phsu|||topiramate||||1000|70|79
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|96|105
SE|00000000||tx|1|entity|C0015011|Ethinyl Estradiol|horm,phsu,strd|||ethinyl estradiol||||1000|110|126
SE|00000000||tx|1|entity|C0033306|Progestins|horm,phsu,strd|||progestins||||1000|140|149
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||888|163|170
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||888|172|179
SE|00000000||tx|1|entity|C2364326|Contraceptive|ftcn|||contraceptive||||888|184|196
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effectiveness||||888|198|210
SE|00000000||tx|1|relation|0|0|C0006949|Carbamazepine|orch,phsu|orch|||carbamazepine||||1000|18|30|SPEC|ISA||1|30|0|0|C0003286|Anticonvulsants|phsu|phsu|||Anticonvulsants||||1000|1|15
SE|00000000||tx|1|relation|6|6|C0003286|Anticonvulsants|phsu|phsu|||Anticonvulsants||||1000|1|15|VERB|STIMULATES||83|90|5|2|C0015011|Ethinyl Estradiol|horm,phsu,strd|horm|||ethinyl estradiol||||1000|110|126
SE|00000000||tx|1|relation|0|0|C0006949|Carbamazepine|orch,phsu|orch|||carbamazepine||||1000|18|30|INFER|STIMULATES(SPEC)||1|30|0|0|C0015011|Ethinyl Estradiol|horm,phsu,strd|horm|||ethinyl estradiol||||1000|110|126


SE|00000000||tx|1|text|Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|32|38
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|43|50
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||901|57|64
SE|00000000||tx|1|entity|C0337449|Digoxin measurement|lbpr|||digoxin levels||||901|66|79
SE|00000000||tx|1|entity|C0337449|Digoxin measurement|lbpr|||digoxin levels||||1000|105|118
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiating||||966|138|147
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuing||||773|165|177
SE|00000000||tx|1|entity|C0028066|Nifedipine|orch,phsu|||nifedipine||||773|179|188
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||861|199|206
SE|00000000||tx|1|entity|C2919279|Administration of digitalis|hlca|||digitalization||||1000|223|236


SE|00000000||tx|1|text|Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.
SE|00000000||tx|1|entity|C2700400|Contain (action)|acty|||containing||||901|10|19
SE|00000000||tx|1|entity|C0279494|estrogen therapy|topp|||Estrogen-containing therapies||||901|1|29
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|38|40
SE|00000000||tx|1|entity|C0878174|Arimidex|orch,phsu|||ARIMIDEX||||1000|55|62
SE|00000000||tx|1|entity|C0243146|pharmacologic action|ftcn|||pharmacologic action||||1000|89|108
SE|00000000||tx|1|relation|1|1|C0279494|estrogen therapy|topp|topp|||Estrogen-containing therapies||||901|1|29|PREP|USES||50|53|2|1|C0878174|Arimidex|orch,phsu|phsu|||ARIMIDEX||||1000|55|62


SE|00000000||tx|1|text|Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines.
SE|00000000||tx|1|entity|C2986414|Anecdotal Report|inpr|||anecdotal reports||||983|10|26
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|45|55
SE|00000000||tx|1|entity|C0006405|Buprenorphine|orch,phsu|||buprenorphine||||1000|65|77
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|83|97


SE|00000000||tx|1|text|Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||861|1|8
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||1000|32|41
SE|00000000||tx|1|entity|C1517945|Loss|qnco|||loss||||1000|75|78
SE|00000000||tx|1|entity|C1457887|Symptoms|sosy|||symptom||||861|83|89
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||694|104|112
SE|00000000||tx|1|relation|3|2|C0913246|valdecoxib|orch,phsu|phsu|||valdecoxib||||1000|32|41|NOM|TREATS||91|97|3|0|C1457887|Symptoms|sosy|sosy|||symptom||||861|83|89


SE|00000000||tx|1|text|In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|4|11
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|29|35
SE|00000000||tx|1|entity|C0023570|Levodopa|aapp,nsba,phsu|||levodopa||||1000|40|47
SE|00000000||tx|1|entity|C0030567|Parkinson Disease|dsyn|||Parkinsons disease||||1000|52|69
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|108|116
SE|00000000||tx|1|entity|C0030350|Papaverine|orch,phsu|||papaverine||||1000|122|131
SE|00000000||tx|1|relation|4|4|C0030350|Papaverine|orch,phsu|orch|||papaverine||||1000|122|131|NOM|INTERACTS_WITH||29|35|4|1|C0023570|Levodopa|aapp,gngm,nsba,phsu|aapp|||levodopa||||1000|40|47
SE|00000000||tx|1|relation|4|4|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|108|116|NOM|INTERACTS_WITH||29|35|4|1|C0023570|Levodopa|aapp,gngm,nsba,phsu|aapp|||levodopa||||1000|40|47
SE|00000000||tx|1|relation|3|1|C0023570|Levodopa|aapp,gngm,nsba,phsu|aapp|||levodopa||||1000|40|47|PREP|ASSOCIATED_WITH||49|50|3|1|C0030567|Parkinson Disease|dsyn|dsyn|||Parkinsons disease||||1000|52|69


SE|00000000||tx|1|text|Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.
SE|00000000||tx|1|entity|C1176316|tadalafil|orch,phsu|||Tadalafil||||888|1|9
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|11|14
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|23|25
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximum||||1000|36|42
SE|00000000||tx|1|entity|C1292423|72 Hours|tmco|||72- hour||||901|58|65
SE|00000000||tx|1|entity|C0439531|per period (qualifier value)|tmco|||period||||901|67|72
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|77|84
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||901|108|116
SE|00000000||tx|1|entity|C1707479|Concomitant Therapy|topp|||concomitant indinavir therapy||||901|96|124
SE|00000000||tx|1|relation|4|4|C1176316|tadalafil|orch,phsu|phsu|||Tadalafil||||888|1|9|PREP|TREATS||74|75|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|77|84
SE|00000000||tx|1|relation|1|1|C1707479|Concomitant Therapy|topp|topp|||concomitant indinavir therapy||||901|96|124|VERB|ADMINISTERED_TO||86|94|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|77|84
SE|00000000||tx|1|relation|0|0|C1707479|Concomitant Therapy|topp|topp|||concomitant indinavir therapy||||901|96|124|MOD/HEAD|USES||108|124|0|0|C0376637|Indinavir|orch,phsu|phsu|||indinavir||||901|108|116


SE|00000000||tx|1|text|When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.
SE|00000000||tx|1|entity|C1120106|ertapenem|antb,orch|||ertapenem||||1000|6|14
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|40|49
SE|00000000||tx|1|entity|C1292428|6 Hours|tmco|||6 hours||||1000|70|76
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|80|89
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||901|104|109
SE|00000000||tx|1|entity|C0232819|Tubular secretion|ortf|||tubular secretion||||901|111|127
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|145|149
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|151|159
SE|00000000||tx|1|entity|C1120106|ertapenem|antb,orch|||ertapenem||||1000|164|172
SE|00000000||tx|1|relation|6|2|C0033209|Probenecid|orch,phsu|orch|||probenecid||||1000|80|89|VERB|INHIBITS||133|139|2|2|C1120106|ertapenem|antb,orch|antb|||ertapenem||||1000|164|172


SE|00000000||tx|1|text|Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis.
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||Increased||||791|1|9
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||791|29|36
SE|00000000||tx|1|entity|C0033798|Pseudoephedrine|orch,phsu|||pseudoephedrine||||1000|53|67


SE|00000000||tx|1|text|Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||Lithium||||1000|1|7
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||Increased||||908|10|18
SE|00000000||tx|1|entity|C0236281|Serum lithium measurement|lbpr|||serum lithium levels||||908|20|39
SE|00000000||tx|1|entity|C1457887|Symptoms|sosy|||symptoms||||1000|45|52
SE|00000000||tx|1|entity|C0238242|LITHIUM TOXICITY|inpo|||lithium toxicity||||1000|57|72
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|96|103
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitors||||1000|115|128
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|137|143
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|150|156
SE|00000000||tx|1|relation|4|1|C0238242|LITHIUM TOXICITY|inpo|inpo|||lithium toxicity||||1000|57|72|PREP|PROCESS_OF||93|94|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|96|103
SE|00000000||tx|1|relation|3|1|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|phsu|||ACE inhibitors||||1000|115|128|VERB|ADMINISTERED_TO||105|113|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|96|103
SE|00000000||tx|1|relation|7|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||1000|137|143|PREP|USES||145|148|1|1|C0023870|Lithium|elii,phsu|phsu|||lithium||||1000|150|156


SE|00000000||tx|1|text|Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.
SE|00000000||tx|1|entity|C0599918|nephrotoxicity|inpo|||Nephrotoxicity||||1000|1|14
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|44|54
SE|00000000||tx|1|entity|C2266959|Cephalosporin Antibacterial [EPC]|antb,orch|||cephalosporins||||1000|80|93
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||838|100|105
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||838|107|115
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|125|134
SE|00000000||tx|1|relation|0|0|C0016860|Furosemide|orch,phsu|orch|||furosemide||||1000|125|134|SPEC|ISA||107|134|0|0|C0012798|Diuretics|phsu|phsu|||diuretics||||838|107|115


SE|00000000||tx|1|text|concomitant use of tricyclic antidepressants may reduce The efficacy of lofexidine.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|1|11
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|13|15
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|20|44
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|61|68
SE|00000000||tx|1|entity|C0065152|lofexidine|orch,phsu|||lofexidine||||1000|73|82
SE|00000000||tx|1|relation|2|1|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|20|44|VERB|INHIBITS||50|55|2|2|C0065152|lofexidine|orch,phsu|orch|||lofexidine||||1000|73|82


SE|00000000||tx|1|text|Sucralfate should not be taken within 2 hours of FACTIVE.
SE|00000000||tx|1|entity|C0038633|Sucralfate|carb,phsu|||Sucralfate||||1000|1|10
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|19|21
SE|00000000||tx|1|entity|C1292425|2 Hours|tmco|||2 hours||||1000|39|45
SE|00000000||tx|1|entity|C1320102|Factive|antb,orch|||FACTIVE||||1000|50|56


SE|00000000||tx|1|text|Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
SE|00000000||tx|1|entity|C0039651|Tetracyclines|orch|||tetracyclines||||1000|13|25
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||901|54|59
SE|00000000||tx|1|entity|C0200396|Clotting factor II assay|lbpr|||prothrombin activity||||901|61|80
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|83|90
SE|00000000||tx|1|entity|C0150457|Anticoagulant therapy|topp|||anticoagulant therapy||||1000|103|123
SE|00000000||tx|1|entity|C0205104|Downward|spco|||downward||||694|137|144
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulant||||901|166|178
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||901|180|185


SE|00000000||tx|1|text|Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
SE|00000000||tx|1|entity|C0033493|Propoxyphene|orch,phsu|||Propoxyphene||||1000|1|12
SE|00000000||tx|1|entity|C0868928|Case (situation)|ftcn|||cases||||1000|18|22
SE|00000000||tx|1|entity|C0033493|Propoxyphene|orch,phsu|||propoxyphene||||694|27|38
SE|00000000||tx|1|entity|C0002658|Amphetamine|nsba,orch,phsu|||amphetamine||||901|52|62
SE|00000000||tx|1|entity|C0151560|Central nervous system stimulation (procedure)|topp|||CNS stimulation||||901|64|78
SE|00000000||tx|1|entity|C1705232|Death Related to Adverse Event|fndg|||fatal||||888|99|103
SE|00000000||tx|1|entity|C0009951|Convulsions|sosy|||convulsions||||888|105|115
SE|00000000||tx|1|relation|0|0|C0151560|Central nervous system stimulation (procedure)|topp|topp|||CNS stimulation||||901|64|78|MOD/HEAD|USES||52|78|0|0|C0002658|Amphetamine|nsba,orch,phsu|phsu|||amphetamine||||901|52|62


SE|00000000||tx|1|text|The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
SE|00000000||tx|1|entity|C0855329|Electrocardiographic changes|fndg|||ECG changes||||983|5|15
SE|00000000||tx|1|entity|C0020621|Hypokalemia|fndg|||hypokalemia||||1000|24|34
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||non||||916|79|81
SE|00000000||tx|1|entity|C0304490|Potassium Sparing Diuretics|phsu|||potassium sparing diuretics||||916|83|109
SE|00000000||tx|1|entity|C0445022|Loop|spco|||loop||||1000|120|123
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|128|145
SE|00000000||tx|1|entity|C0243192|agonists|phsu|||agonists||||861|180|187
SE|00000000||tx|1|entity|C0034866|Recommendation|idcn|||recommended||||888|210|220
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|222|225
SE|00000000||tx|1|entity|C2987634|Agonist|phsu|||agonist||||861|239|245


SE|00000000||tx|1|text|Tablet If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the effect of clonidine may be reduced, thus necessitating an increase in dosage.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||850|13|19
SE|00000000||tx|1|entity|C1514756|Receive|qlco|||receiving||||850|21|29
SE|00000000||tx|1|entity|C0546860|Clonidine Hydrochloride|orch,phsu|||clonidine hydrochloride||||850|31|53
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|70|94
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|101|106
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||1000|111|119
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|159|166
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||1000|171|176
SE|00000000||tx|1|relation|3|1|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|70|94|NOM|INTERACTS_WITH||101|106|3|1|C0009014|Clonidine|orch,phsu|orch|||clonidine||||1000|111|119


SE|00000000||tx|1|text|In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|6|10
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||888|15|20
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|22|31
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|34|44
SE|00000000||tx|1|entity|C0700444|buspirone hydrochloride|orch,phsu|||buspirone HCl||||1000|64|76
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||haloperidol||||1000|82|92
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||852|106|114
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||haloperidol||||852|122|132
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum haloperidol concentrations||||852|116|147
SE|00000000||tx|1|relation|5|1|C0018546|Haloperidol|orch,phsu|orch|||haloperidol||||1000|82|92|PREP|COEXISTS_WITH||103|104|1|1|C0018546|Haloperidol|orch,phsu|orch|||haloperidol||||852|122|132
SE|00000000||tx|1|relation|5|1|C0700444|buspirone hydrochloride|orch,phsu|orch|||buspirone HCl||||1000|64|76|PREP|COEXISTS_WITH||103|104|1|1|C0018546|Haloperidol|orch,phsu|orch|||haloperidol||||852|122|132


SE|00000000||tx|1|text|Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||802|28|33
SE|00000000||tx|1|entity|C0007680|Central Nervous System Agents|phsu|||centrally acting drugs||||1000|94|115
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|121|127


SE|00000000||tx|1|text|Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.
SE|00000000||tx|1|entity|C1144054|Inspra|phsu,strd|||INSPRA||||1000|17|22
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|28|33
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|59|66
SE|00000000||tx|1|entity|C0871633|desires|menp|||desired||||872|112|118
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||872|120|125
SE|00000000||tx|1|entity|C0005823|Blood Pressure|orgf|||blood pressure||||1000|130|143
SE|00000000||tx|1|relation|3|2|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|28|33|NOM|AFFECTS||120|125|1|1|C0005823|Blood Pressure|orgf|orgf|||blood pressure||||1000|130|143
SE|00000000||tx|1|relation|3|2|C1144054|Inspra|phsu,strd|phsu|||INSPRA||||1000|17|22|NOM|AFFECTS||120|125|1|1|C0005823|Blood Pressure|orgf|orgf|||blood pressure||||1000|130|143


SE|00000000||tx|1|text|Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E.
SE|00000000||tx|1|entity|C0075632|Sumatriptan|orch,phsu|||Sumatriptan||||1000|1|11
SE|00000000||tx|1|entity|C0075632|Sumatriptan|orch,phsu|||Sumatriptan||||1000|14|24
SE|00000000||tx|1|entity|C0010073|Coronary Artery Vasospasm|dsyn|||coronary artery vasospasm||||1000|53|77
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|88|93
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||1000|104|111
SE|00000000||tx|1|relation|2|1|C0075632|Sumatriptan|orch,phsu|orch|||Sumatriptan||||1000|14|24|VERB|CAUSES||47|51|4|1|C0010073|Coronary Artery Vasospasm|dsyn|dsyn|||coronary artery vasospasm||||1000|53|77

SE|00000000||tx|2|text|45  (dihydroergotamine mesylate) Injection, USP.
SE|00000000||tx|2|entity|C0700532|Dihydroergotamine Mesylate|orch,phsu|||dihydroergotamine mesylate||||1000|6|31
SE|00000000||tx|2|entity|C1533685|Injection procedure|topp|||Injection||||1000|34|42
SE|00000000||tx|2|entity|C1706444|United States Pharmacopeia|hcro|||USP||||1000|45|47


SE|00000000||tx|1|text|However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
SE|00000000||tx|1|entity|C0678812|systemic administration|topp|||systemic administration||||1000|14|36
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|46|55
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|83|103
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|108|119
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|141|150
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|155|162
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|181|187
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulant||||901|196|213
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||901|215|222
SE|00000000||tx|1|entity|C0243072|derivatives|chvs|||derivatives||||1000|232|242
SE|00000000||tx|1|entity|C0205374|Transitory|tmco|||transient||||888|274|282
SE|00000000||tx|1|entity|C0702240|Elevation|spco|||elevations||||888|284|293
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||888|298|302
SE|00000000||tx|1|entity|C0010294|Creatinine|bacs,orch|||creatinine||||888|304|313
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|318|325
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||790|337|344
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||790|346|357
SE|00000000||tx|1|relation|0|0|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||901|215|222|MOD/HEAD|ISA||196|222|0|0|C0354604|Anticoagulants, Oral|orch,phsu|orch|||oral anticoagulant||||901|196|213
SE|00000000||tx|1|relation|4|1|C0039771|Theophylline|bacs,orch,phsu|bacs|||theophylline||||1000|108|119|VERB|DISRUPTS||122|130|9|1|C0025519|Metabolism|orgf|orgf|||metabolism||||1000|141|150
SE|00000000||tx|1|relation|6|6|C0010592|Cyclosporine|aapp,gngm,phsu|aapp|||cyclosporine||||790|346|357|NOM|INTERACTS_WITH||181|187|6|1|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||901|215|222


SE|00000000||tx|1|text|Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
SE|00000000||tx|1|entity|C0591434|Edecrin|orch,phsu|||EDECRIN||||1000|17|23
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||non- steroidal anti- inflammatory agents||||1000|29|68
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|98|104
SE|00000000||tx|1|entity|C0871633|desires|menp|||desired||||872|153|159
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||872|161|166
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|175|182
SE|00000000||tx|1|relation|4|3|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||non- steroidal anti- inflammatory agents||||1000|29|68|NOM|INTERACTS_WITH||161|166|1|1|C0012798|Diuretics|phsu|phsu|||diuretic||||1000|175|182
SE|00000000||tx|1|relation|4|3|C0591434|Edecrin|orch,phsu|phsu|||EDECRIN||||1000|17|23|NOM|INTERACTS_WITH||161|166|1|1|C0012798|Diuretics|phsu|phsu|||diuretic||||1000|175|182


SE|00000000||tx|1|text|Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||Epinephrine||||1000|1|11
SE|00000000||tx|1|entity|C0027882|Neurons|cell|||neuron||||888|32|37
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blockade||||888|39|46
SE|00000000||tx|1|entity|C0018318|Guanethidine|orch,phsu|||guanethidine||||1000|60|71
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decreased||||802|86|94
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||802|113|118
SE|00000000||tx|1|entity|C1514873|Requirement|ftcn|||requiring||||840|124|132
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||840|134|142
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||840|144|149


SE|00000000||tx|1|text|The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|20|30
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|32|38
SE|00000000||tx|1|entity|C0006938|Captopril|aapp,phsu|||captopril||||1000|45|53
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|100|107
SE|00000000||tx|1|entity|C0442808|Increasing|ftcn|||increasing||||1000|112|121
SE|00000000||tx|1|entity|C0489767|salt intake|orga|||salt intake||||840|127|137
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||840|139|151
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||840|153|155
SE|00000000||tx|1|entity|C0439230|week|tmco|||week||||840|157|160
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|171|180
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|185|193
SE|00000000||tx|1|entity|C0006938|Captopril|aapp,phsu|||captopril||||1000|200|208
SE|00000000||tx|1|entity|C0006938|Captopril|aapp,phsu|||captopril||||888|211|219
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||888|221|227
SE|00000000||tx|1|entity|C1706444|United States Pharmacopeia|hcro|||USP||||1000|230|232
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiating||||872|238|247
SE|00000000||tx|1|entity|C0700321|Small|qnco|||small||||888|262|266
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|268|272
SE|00000000||tx|1|relation|8|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||1000|185|193|PREP|USES||195|198|6|1|C0006938|Captopril|aapp,gngm,phsu|phsu|||captopril||||1000|200|208


SE|00000000||tx|1|text|Both digoxin and COREG slow AV conduction.
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|6|12
SE|00000000||tx|1|entity|C0719509|Coreg|orch,phsu|||COREG||||583|18|22
SE|00000000||tx|1|entity|C0439834|Slow|qlco|||slow||||583|24|27


SE|00000000||tx|1|text|If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.
SE|00000000||tx|1|entity|C1096697|antacid therapy|topp|||antacid therapy||||901|4|18
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacid||||888|35|41
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|43|46
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|74|78
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||785|82|86
SE|00000000||tx|1|entity|C1292425|2 Hours|tmco|||2 hours||||1000|100|106
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||1000|118|121
SE|00000000||tx|1|entity|C1723829|Sprycel|orch,phsu|||SPRYCEL||||1000|126|132


SE|00000000||tx|1|text|Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||Lithium||||1000|1|7
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|10|15
SE|00000000||tx|1|entity|C0702240|Elevation|spco|||elevation||||1000|34|42
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||623|47|52
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||623|54|60
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|75|83
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||851|88|92
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||851|94|100
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||851|102|110
SE|00000000||tx|1|relation|4|3|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|10|15|NOM|INHIBITS||75|83|1|1|C0023870|Lithium|elii,phsu|elii|||lithium||||851|94|100
SE|00000000||tx|1|relation|0|0|C0023870|Lithium|elii,phsu|elii|||lithium||||851|94|100|MOD/HEAD|PART_OF||88|100|0|0|C0022646|Kidney|bpoc|bpoc|||renal||||851|88|92


SE|00000000||tx|1|text|Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
SE|00000000||tx|1|entity|C0033618|Protein Binding|moft|||Protein Binding||||1000|1|15
SE|00000000||tx|1|entity|C0012091|Diclofenac|orch,phsu|||diclofenac||||1000|27|36
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|62|64
SE|00000000||tx|1|entity|C0033618|Protein Binding|moft|||protein binding||||1000|82|96
SE|00000000||tx|1|entity|C0036079|Salicylic Acid|orch,phsu|||salicylic acid||||1000|101|114
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|121|128
SE|00000000||tx|1|entity|C0040374|Tolbutamide|orch,phsu|||tolbutamide||||1000|143|153
SE|00000000||tx|1|entity|C0032950|prednisolone|phsu,strd|||prednisolone||||1000|156|167
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|174|181
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|199|206


SE|00000000||tx|1|text|Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||Vardenafil||||1000|33|42
SE|00000000||tx|1|entity|C0556984|Three times daily|tmco|||TID||||775|56|58
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||775|60|68
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|75|78
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|84|86
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|91|99
SE|00000000||tx|1|entity|C0439509|/40|tmco|||40%||||1000|117|119


SE|00000000||tx|1|text|For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.
SE|00000000||tx|1|entity|C1707959|Example|cnce|||example||||1000|5|11
SE|00000000||tx|1|entity|C0042878|Vitamin K|lipd,phsu,vita|||vitamin K||||901|19|27
SE|00000000||tx|1|entity|C0243076|antagonists|chvf|||antagonists||||901|29|39
SE|00000000||tx|1|entity|C0068771|nilutamide|orch,phsu|||nilutamide||||1000|77|86
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|89|104
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||1000|158|163
SE|00000000||tx|1|entity|C0042878|Vitamin K|lipd,phsu,vita|||vitamin K||||901|168|176
SE|00000000||tx|1|entity|C0243076|antagonists|chvf|||antagonists||||901|178|188
SE|00000000||tx|1|relation|7|5|C0068771|nilutamide|orch,phsu|orch|||nilutamide||||1000|77|86|NOM|INHIBITS||178|188|7|0|C0042878|Vitamin K|lipd,phsu,vita|lipd|||vitamin K||||901|168|176


SE|00000000||tx|1|text|Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||Dosage||||694|1|6
SE|00000000||tx|1|entity|C1176420|Strattera|orch,phsu|||STRATTERA||||1000|22|30
SE|00000000||tx|1|entity|C1332830|CYP2D6 gene|gngm|1565|CYP2D6|CYP2D6||||901|74|79
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||901|81|90
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||paroxetine||||1000|99|108
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|111|120
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|127|135
SE|00000000||tx|1|relation|3|2|C1176420|Strattera|orch,phsu|orch|||STRATTERA||||1000|22|30|NOM|INHIBITS||81|90|3|0|C1332830|CYP2D6 gene|gngm,aapp|gngm|1565|CYP2D6|CYP2D6||||901|74|79


SE|00000000||tx|1|text|Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
SE|00000000||tx|1|entity|C0002600|Amitriptyline|orch,phsu|||Amitriptyline||||1000|1|13
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|18|28
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||1000|35|43
SE|00000000||tx|1|entity|C0205319|Manifest|ftcn|||manifestation||||1000|58|70
SE|00000000||tx|1|entity|C0151571|Corneal lesion|patf|||corneal lesions||||966|75|89
SE|00000000||tx|1|entity|C0034693|Rattus norvegicus|mamm|||rats||||861|94|97
SE|00000000||tx|1|entity|C0021486|Peridural Injection|ftcn|||Epidural Injection||||861|99|116
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||Clonidine||||861|118|126
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||827|162|167
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|172|178
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|181|192
SE|00000000||tx|1|entity|C0235195|Sedated state|fndg|||sedating||||888|203|210
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|212|216
SE|00000000||tx|1|relation|0|0|C0004745|Barbiturates|orch,phsu|orch|||barbiturates||||1000|181|192|SPEC|ISA||181|216|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|212|216
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|212|216|SPEC|ISA||181|216|0|0|C0004745|Barbiturates|orch,phsu|phsu|||barbiturates||||1000|181|192
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|212|216|SPEC|ISA||181|216|0|0|C0001975|Alcohols|orch,phsu|phsu|||alcohol||||1000|172|178
SE|00000000||tx|1|relation|0|0|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|172|178|SPEC|ISA||181|216|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|212|216
SE|00000000||tx|1|relation|5|3|C0009014|Clonidine|orch,phsu|orch|||clonidine||||1000|35|43|PREP|COEXISTS_WITH||91|92|5|1|C0009014|Clonidine|orch,phsu|orch|||Clonidine||||861|118|126


SE|00000000||tx|1|text|Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.
SE|00000000||tx|1|entity|C0034036|Publications|inpr,mnob|||Literature||||888|1|10
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||884|33|36
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium antagonists||||884|38|56
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|73|83
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic blocking agents||||1000|90|120
SE|00000000||tx|1|entity|C0232164|Cardiac function|ortf|||heart function||||1000|127|140
SE|00000000||tx|1|entity|C0205307|Normal|qlco|||normal||||1000|145|150
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|178|185
SE|00000000||tx|1|entity|C0241826|CARDIAC FUNCTION, IMPAIRED|dsyn|||impaired cardiac function||||1000|192|216
SE|00000000||tx|1|relation|6|2|C0232164|Cardiac function|ortf|ortf|||heart function||||1000|127|140|PREP|PROCESS_OF||175|176|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|178|185
SE|00000000||tx|1|relation|1|1|C0241826|CARDIAC FUNCTION, IMPAIRED|dsyn|dsyn|||impaired cardiac function||||1000|192|216|PREP|PROCESS_OF||187|190|7|1|C0030705|Patients|podg,humn|humn|||patients||||1000|178|185


SE|00000000||tx|1|text|Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.
SE|00000000||tx|1|entity|C0074554|Simvastatin|orch,phsu|||Simvastatin||||1000|1|11
SE|00000000||tx|1|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||Statins||||1000|23|29
SE|00000000||tx|1|entity|C0252643|bosentan|orch,phsu|||bosentan||||1000|53|60
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|76|96
SE|00000000||tx|1|entity|C0074554|Simvastatin|orch,phsu|||simvastatin||||1000|101|111
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|116|121
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||851|143|148
SE|00000000||tx|1|entity|C0020317|Hydroxy Acids|orch|||hydroxy acid||||851|152|163
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||851|165|174
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|180|192
SE|00000000||tx|1|relation|0|0|C0074554|Simvastatin|orch,phsu|orch|||Simvastatin||||1000|1|11|SPEC|ISA||1|29|0|0|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|orch|||Statins||||1000|23|29
SE|00000000||tx|1|relation|0|0|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|orch|||Statins||||1000|23|29|SPEC|ISA||1|29|0|0|C0074554|Simvastatin|orch,phsu|orch|||Simvastatin||||1000|1|11
SE|00000000||tx|1|relation|4|1|C0252643|bosentan|orch,phsu|orch|||bosentan||||1000|53|60|VERB|INHIBITS||62|70|4|2|C0074554|Simvastatin|orch,phsu|orch|||simvastatin||||1000|101|111
SE|00000000||tx|1|relation|4|1|C0252643|bosentan|orch,phsu|orch|||bosentan||||1000|53|60|VERB|INHIBITS||62|70|4|2|C0020317|Hydroxy Acids|orch|orch|||hydroxy acid||||851|152|163


SE|00000000||tx|1|text|Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||790|16|26
SE|00000000||tx|1|entity|C1512806|Intake|ftcn|||intake||||790|28|33
SE|00000000||tx|1|entity|C0042878|Vitamin K|lipd,phsu,vita|||vitamin K||||1000|57|65
SE|00000000||tx|1|entity|C0042878|Vitamin K|lipd,phsu,vita|||vitamin K||||1000|96|104


SE|00000000||tx|1|text|Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||Treatment||||1000|1|9
SE|00000000||tx|1|entity|C1176430|Pegasys|imft,orch,phsu|||PEGASYS||||1000|16|22
SE|00000000||tx|1|entity|C0558293|Once a week|tmco|||once weekly||||1000|24|34
SE|00000000||tx|1|entity|C1442465|4 Weeks|tmco|||4 weeks||||1000|40|46
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy subjects||||1000|51|66
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|91|100
SE|00000000||tx|1|entity|||gngm|1555|CYP2B6|P450||||694|105|108
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|124|131
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||888|136|147
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|149|151
SE|00000000||tx|1|relation|1|1|C0087111|Therapeutic procedure|topp|topp|||Treatment||||1000|1|9|PREP|USES||11|14|8|1|C1176430|Pegasys|imft,orch,phsu|phsu|||PEGASYS||||1000|16|22


SE|00000000||tx|1|text|Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||Certain||||888|1|7
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|9|13
SE|00000000||tx|1|entity|C0541746|Thiazides|orch,phsu|||thiazides||||1000|25|33
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|36|50
SE|00000000||tx|1|entity|C1514468|product|enty|||products||||861|61|68
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetics||||1000|75|90
SE|00000000||tx|1|entity|C0020616|Hypoglycemic Agents|phsu|||hypoglycemic||||888|107|118
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||888|120|125
SE|00000000||tx|1|entity|C1323198|Starlix|orch,phsu|||Starlix||||1000|130|136
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||901|148|151
SE|00000000||tx|1|entity|C0935929|Antidiabetics|phsu|||antidiabetic drugs||||901|153|170
SE|00000000||tx|1|relation|0|0|C1323198|Starlix|orch,phsu|orch|||Starlix||||1000|130|136|SPEC|ISA||130|170|0|0|C0935929|Antidiabetics|phsu|phsu|||antidiabetic drugs||||901|153|170
SE|00000000||tx|1|relation|0|0|C1323198|Starlix|orch,phsu|orch|||Starlix||||1000|130|136|SPEC|ISA||130|170|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|9|13


SE|00000000||tx|1|text|Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||Allopurinol||||1000|1|11
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|18|20
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||1000|25|34
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||888|58|61
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|68|78
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|87|92
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||775|120|125
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||775|134|137
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||VIDEX||||1000|142|146
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||888|151|153
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|155|162
SE|00000000||tx|1|entity|C0341697|Renal impairment|dsyn|||renal impairment||||1000|169|184
SE|00000000||tx|1|entity|C1413808|CTRC gene|gngm|11330|CTRC|CLcr||||1000|187|190
SE|00000000||tx|1|entity|C0439445|mL/min|qnco|||mL/min||||901|202|207
SE|00000000||tx|1|relation|3|1|C0341697|Renal impairment|dsyn|dsyn|||renal impairment||||1000|169|184|PREP|PROCESS_OF||164|167|9|1|C0030705|Patients|podg,humn|humn|||patients||||888|155|162


SE|00000000||tx|1|text|The effect of corticosteroids on oral anticoagulants is variable.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|5|10
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|15|29
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulants||||1000|34|52
SE|00000000||tx|1|relation|3|1|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroids||||1000|15|29|NOM|INTERACTS_WITH||5|10|3|2|C0354604|Anticoagulants, Oral|orch,phsu|orch|||oral anticoagulants||||1000|34|52


SE|00000000||tx|1|text|Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.
SE|00000000||tx|1|entity|C0015052|Ethoxzolamide|orch,phsu|||ethoxzolamide||||1000|21|33
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|46|54
SE|00000000||tx|1|entity|C0002679|Amphotericin B|antb,orch|||amphotericin B||||1000|57|70
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|77|91
SE|00000000||tx|1|entity|C0020621|Hypokalemia|fndg|||hypokalemia||||1000|103|113
SE|00000000||tx|1|relation|5|1|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroids||||1000|77|91|VERB|CAUSES||97|101|1|1|C0020621|Hypokalemia|fndg|fndg|||hypokalemia||||1000|103|113
SE|00000000||tx|1|relation|5|1|C0002679|Amphotericin B|antb,orch|antb|||amphotericin B||||1000|57|70|VERB|CAUSES||97|101|1|1|C0020621|Hypokalemia|fndg|fndg|||hypokalemia||||1000|103|113
SE|00000000||tx|1|relation|5|1|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|46|54|VERB|CAUSES||97|101|1|1|C0020621|Hypokalemia|fndg|fndg|||hypokalemia||||1000|103|113


SE|00000000||tx|1|text|Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.
SE|00000000||tx|1|entity|C0001962|Ethanol|orch|||Ethanol||||1000|1|7
SE|00000000||tx|1|entity|C0205210|Clinical|qlco|||Clinical||||694|9|16
SE|00000000||tx|1|entity|C0015137|Etretinate|orch,phsu|||etretinate||||1000|42|51
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|72|81
SE|00000000||tx|1|entity|C0232478|Ingestion|biof|||ingestion||||888|83|91
SE|00000000||tx|1|entity|C0050559|Acitretin|orch,phsu|||acitretin||||1000|96|104
SE|00000000||tx|1|entity|C0001962|Ethanol|orch|||ethanol||||1000|110|116


SE|00000000||tx|1|text|Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
SE|00000000||tx|1|entity|C0014710|Ergotamine|orch,phsu|||Ergotamine||||1000|1|10
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|13|22
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|24|26
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|31|42
SE|00000000||tx|1|entity|C0014710|Ergotamine|orch,phsu|||ergotamine||||1000|48|57
SE|00000000||tx|1|entity|C0012291|Dihydroergotamine|orch,phsu|||dihydroergotamine||||1000|62|78
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|108|115
SE|00000000||tx|1|entity|C0205178|acute|tmco|||acute||||802|122|126
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||802|134|141
SE|00000000||tx|1|entity|C0205100|Peripheral|spco|||peripheral||||790|167|176
SE|00000000||tx|1|entity|C0042396|Vascular constriction (function)|ortf|||vasospasm||||790|178|186
SE|00000000||tx|1|entity|C0392699|Dysesthesia|sosy|||dysesthesia||||1000|192|202
SE|00000000||tx|1|relation|5|1|C0012291|Dihydroergotamine|orch,phsu|phsu|||dihydroergotamine||||1000|62|78|PREP|TREATS||100|101|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|108|115
SE|00000000||tx|1|relation|5|1|C0014710|Ergotamine|orch,phsu|phsu|||ergotamine||||1000|48|57|PREP|TREATS||100|101|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|108|115
SE|00000000||tx|1|relation|3|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||802|134|141|PREP|PROCESS_OF||117|120|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|108|115
SE|00000000||tx|1|relation|0|0|C0012291|Dihydroergotamine|orch,phsu|phsu|||dihydroergotamine||||1000|62|78|INFER|TREATS(INFER)||100|101|0|0|C0600688|Toxic effect|inpo|inpo|||toxicity||||802|134|141
SE|00000000||tx|1|relation|0|0|C0014710|Ergotamine|orch,phsu|phsu|||ergotamine||||1000|48|57|INFER|TREATS(INFER)||100|101|0|0|C0600688|Toxic effect|inpo|inpo|||toxicity||||802|134|141


SE|00000000||tx|1|text|Although there was a slight reduction in blood sugar concentrations during concomitant administration of flurbiprofen and hypoglycemic agents, there were no signs or symptoms of hypoglycemia.
SE|00000000||tx|1|entity|C2945599|Mild (qualifier value)|qlco|||slight||||888|22|27
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||888|29|37
SE|00000000||tx|1|entity|C0005802|Blood Glucose|carb|||blood sugar||||901|42|52
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||901|54|67
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|76|86
SE|00000000||tx|1|entity|C0016377|Flurbiprofen|orch,phsu|||flurbiprofen||||1000|106|117
SE|00000000||tx|1|entity|C0020616|Hypoglycemic Agents|phsu|||hypoglycemic agents||||1000|123|141
SE|00000000||tx|1|entity|C0311392|Physical findings|fndg|||signs||||1000|158|162
SE|00000000||tx|1|entity|C1457887|Symptoms|sosy|||symptoms||||1000|167|174
SE|00000000||tx|1|entity|C0020615|Hypoglycemia|dsyn|||hypoglycemia||||1000|179|190
SE|00000000||tx|1|relation|7|3|C0016377|Flurbiprofen|orch,phsu|orch|||flurbiprofen||||1000|106|117|NOM|INHIBITS||29|37|7|1|C0005802|Blood Glucose|carb|carb|||blood sugar||||901|42|52


SE|00000000||tx|1|text|As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.
SE|00000000||tx|1|entity|C0027866|Neuromuscular Blocking Agents|phsu|||neuromuscular blocking agents||||923|36|64
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||1000|71|74
SE|00000000||tx|1|entity|C0234119|Neuromuscular inhibition|dsyn|||neuromuscular block||||1000|88|106
SE|00000000||tx|1|entity|C0133255|Nuromax|orch,phsu|||NUROMAX||||1000|119|125
SE|00000000||tx|1|entity|C2926735|Duration|phsu|||duration||||1000|149|156
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||block||||1000|161|165
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|183|190
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|202|210
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|215|227
SE|00000000||tx|1|relation|6|1|C0133255|Nuromax|orch,phsu|orch|||NUROMAX||||1000|119|125|VERB|CAUSES||108|114|4|1|C0234119|Neuromuscular inhibition|dsyn|dsyn|||neuromuscular block||||1000|88|106
SE|00000000||tx|1|relation|7|2|C2926735|Duration|phsu|phsu|||duration||||1000|149|156|PREP|TREATS||180|181|3|1|C0030705|Patients|podg,humn|podg|||patients||||1000|183|190
SE|00000000||tx|1|relation|2|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|202|210|VERB|ADMINISTERED_TO||192|200|8|1|C0030705|Patients|podg,humn|humn|||patients||||1000|183|190
SE|00000000||tx|1|relation|2|1|C0006949|Carbamazepine|orch,phsu|orch|||carbamazepine||||1000|215|227|VERB|ADMINISTERED_TO||192|200|8|1|C0030705|Patients|podg,humn|humn|||patients||||1000|183|190


SE|00000000||tx|1|text|The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.
SE|00000000||tx|1|entity|C0079466|Guanfacine|orch,phsu|||guanfacine||||861|23|32
SE|00000000||tx|1|entity|C0205309|Known|qlco|||known||||647|53|57
SE|00000000||tx|1|entity|C0815014|microsomal enzymes|aapp,enzy|||microsomal enzyme||||647|59|75
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|86|98
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|103|111
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||888|117|119
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|121|128
SE|00000000||tx|1|entity|C0341697|Renal impairment|dsyn|||renal impairment||||901|135|150
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|175|185
SE|00000000||tx|1|entity|C0301630|Reduction (chemical)|npop|||reductions||||888|187|196
SE|00000000||tx|1|entity|C2348397|Elimination Half Life|qnco|||elimination half-life||||1000|201|221
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||1000|227|246
SE|00000000||tx|1|relation|2|1|C0079466|Guanfacine|orch,phsu|orch|||guanfacine||||861|23|32|NOM|STIMULATES||77|83|2|0|C0815014|microsomal enzymes|aapp,gngm,enzy|gngm|||microsomal enzyme||||647|59|75
SE|00000000||tx|1|relation|4|1|C0341697|Renal impairment|dsyn|dsyn|||renal impairment||||901|135|150|PREP|PROCESS_OF||130|133|6|1|C0030705|Patients|podg,humn|humn|||patients||||888|121|128


SE|00000000||tx|1|text|Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||Interactions||||966|1|12
SE|00000000||tx|1|entity|C1520059|Vitamin D Analog|vita|||vitamin D analogues||||983|18|36
SE|00000000||tx|1|entity|C0014695|Ergocalciferol|orch,phsu,vita|||Vitamin D2||||1000|39|48
SE|00000000||tx|1|entity|C3265062|vitamin D3|phsu|||Vitamin D3||||1000|51|60
SE|00000000||tx|1|entity|C0006674|Calcitriol|horm,phsu,strd,vita|||Calcitriol||||1000|63|72
SE|00000000||tx|1|entity|C0006657|Calcifediol|phsu,strd,vita|||Calcidiol||||1000|79|87
SE|00000000||tx|1|entity|C0021826|Intestinal Absorption|ortf|||intestinal absorption||||1000|150|170
SE|00000000||tx|1|entity|C0259753|Fat soluble vitamin product|orch,vita|||fat soluble vitamins||||1000|175|194
SE|00000000||tx|1|relation|8|7|C1520059|Vitamin D Analog|vita|vita|||vitamin D analogues||||983|18|36|VERB|DISRUPTS||143|148|2|1|C0021826|Intestinal Absorption|ortf|ortf|||intestinal absorption||||1000|150|170


SE|00000000||tx|1|text|Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||Quinidine||||1000|1|9
SE|00000000||tx|1|entity|C0052080|antineoplaston A10|orch,phsu|||a 10||||901|32|35
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|40|45
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|47|50
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||1000|55|66
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|73|81
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|88|93
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|102|105
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||838|111|116
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||838|118|126
SE|00000000||tx|1|entity|C1332830|CYP2D6 gene|gngm|1565|CYP2D6|CYP2D6||||1000|131|136
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|153|155
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||1000|160|171
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|199|201
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||888|210|215
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||888|217|226
SE|00000000||tx|1|entity|C1872486|dehydroaripiprazole|orch|||dehydroaripiprazole||||1000|229|247
SE|00000000||tx|1|relation|8|3|C0034414|Quinidine|orch,phsu|orch|||quinidine||||1000|73|81|NOM|INHIBITS||118|126|6|1|C1332830|CYP2D6 gene|gngm,aapp|gngm|1565|CYP2D6|CYP2D6||||1000|131|136


SE|00000000||tx|1|text|The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|5|10
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|15|25
SE|00000000||tx|1|entity|C0016277|Fluconazole|orch,phsu|||fluconazole||||1000|45|55
SE|00000000||tx|1|entity|C0017642|Glipizide|orch,phsu|||glipizide||||1000|61|69
SE|00000000||tx|1|entity|C0599724|placebo-controlled study|inpr,resa|||placebo-controlled crossover study||||923|98|131
SE|00000000||tx|1|entity|C0205307|Normal|qlco|||normal||||888|136|141
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|143|152
SE|00000000||tx|1|relation|5|2|C0017642|Glipizide|orch,phsu|phsu|||glipizide||||1000|61|69|PREP|TREATS||133|134|1|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|143|152
SE|00000000||tx|1|relation|5|2|C0016277|Fluconazole|orch,phsu|phsu|||fluconazole||||1000|45|55|PREP|TREATS||133|134|1|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|143|152


SE|00000000||tx|1|text|Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||861|22|26
SE|00000000||tx|1|entity|C0004635|Bactericide, NOS|antb|||bactericidal||||853|51|62
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||853|64|69
SE|00000000||tx|1|entity|C0220892|Penicillin|antb,orch|||penicillin||||1000|74|83
SE|00000000||tx|1|entity|C0039651|Tetracyclines|orch|||tetracyclines||||1000|118|130
SE|00000000||tx|1|entity|C0220892|Penicillin|antb,orch|||penicillin||||1000|152|161


SE|00000000||tx|1|text|Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.
SE|00000000||tx|1|entity|C0008287|Chlorpropamide|orch,phsu|||Chlorpropamide||||1000|1|14
SE|00000000||tx|1|entity|C0008287|Chlorpropamide|orch,phsu|||Chlorpropamides||||850|17|31
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||850|33|38
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||850|40|48
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|70|80
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|89|99
SE|00000000||tx|1|entity|C0008287|Chlorpropamide|orch,phsu|||chlorpropamide||||1000|105|118
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||1000|136|144
SE|00000000||tx|1|entity|C1283878|Entire renal tubule|bpoc|||renal tubule||||1000|153|164
SE|00000000||tx|1|relation|1|1|C1283878|Entire renal tubule|bpoc|bpoc|||renal tubule||||1000|153|164|PREP|LOCATION_OF||146|147|6|2|C0008287|Chlorpropamide|orch,phsu|orch|||chlorpropamide||||1000|105|118


SE|00000000||tx|1|text|ZEBETA should not be combined with other beta-blocking agents.
SE|00000000||tx|1|entity|C0724461|Zebeta|orch,phsu|||ZEBETA||||1000|1|6
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|15|17
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blocking agents||||983|42|61
SE|00000000||tx|1|relation|1|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blocking agents||||983|42|61|VERB|COEXISTS_WITH||22|29|1|1|C0724461|Zebeta|orch,phsu|orch|||ZEBETA||||1000|1|6


SE|00000000||tx|1|text|The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|17|19
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||861|30|35
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||861|37|46
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|56|64
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|70|81
SE|00000000||tx|1|entity|C0694643|transdermal|spco|||transdermal||||888|88|98
SE|00000000||tx|1|entity|C0015846|Fentanyl|orch,phsu|||fentanyl||||888|100|107
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|131|138
SE|00000000||tx|1|entity|C0015846|Fentanyl|orch,phsu|||fentanyl||||890|143|150
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|152|172
SE|00000000||tx|1|entity|C0041755|Adverse reaction to drug|inpo|||adverse drug effects||||1000|207|226
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||901|242|248
SE|00000000||tx|1|entity|C0235063|Respiratory Depression|patf|||respiratory depression||||901|250|271
SE|00000000||tx|1|relation|5|1|C0015846|Fentanyl|orch,phsu|orch|||fentanyl||||888|100|107|NOM|STIMULATES||131|138|3|1|C0015846|Fentanyl|orch,phsu|orch|||fentanyl||||890|143|150
SE|00000000||tx|1|relation|7|4|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|70|81|VERB|AFFECTS||199|205|2|1|C0041755|Adverse reaction to drug|inpo|inpo|||adverse drug effects||||1000|207|226
SE|00000000||tx|1|relation|7|4|C0012373|Diltiazem|orch,phsu|orch|||diltiazem||||1000|56|64|VERB|AFFECTS||199|205|2|1|C0041755|Adverse reaction to drug|inpo|inpo|||adverse drug effects||||1000|207|226


SE|00000000||tx|1|text|Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.
SE|00000000||tx|1|entity|C0442027|Oral|spco|||Oral||||901|1|4
SE|00000000||tx|1|entity|C0027607|Neomycin Sulfate|antb,carb|||neomycin sulfate||||901|6|21
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|39|44
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin||||1000|49|56
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|61|74
SE|00000000||tx|1|entity|C1142530|Decreased vitamin K|fndg|||decreasing vitamin K||||740|79|98
SE|00000000||tx|1|relation|3|1|C0010206|coumarin|orch,phsu|orch|||coumarin||||1000|49|56|NOM|INTERACTS_WITH||39|44|3|2|C0003280|Anticoagulants|phsu|phsu|||anticoagulants||||1000|61|74


SE|00000000||tx|1|text|Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||Oral Contraceptives||||1000|1|19
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||1000|42|53
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptive||||857|62|79
SE|00000000||tx|1|entity|C1708492|Increased Drug AUC|fndg|||increased AUC||||857|81|93
SE|00000000||tx|1|entity|C0042295|Values|qlco|||values||||857|95|100
SE|00000000||tx|1|entity|C0028356|Norethindrone|horm,phsu,strd|||norethindrone||||1000|106|118
SE|00000000||tx|1|entity|C0015011|Ethinyl Estradiol|horm,phsu,strd|||ethinyl estradiol||||1000|124|140
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|145|157


SE|00000000||tx|1|text|Bile acid binding resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone.
SE|00000000||tx|1|entity|C2266924|Bile-acid Binding Resin [EPC]|phsu|||Bile acid binding resins||||988|1|24
SE|00000000||tx|1|entity|C0031701|Phosphoric Acid Esters|opco|||phosphate||||901|73|81
SE|00000000||tx|1|entity|C0351437|Oral supplement|phsu|||oral phosphate supplements||||901|68|93
SE|00000000||tx|1|entity|C0020268|Hydrocortisone|horm,phsu,strd|||hydrocortisone||||1000|99|112


SE|00000000||tx|1|text|The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|12|17
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|22|29
SE|00000000||tx|1|entity|C1514756|Receive|qlco|||receiving||||884|39|47
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitors||||884|49|62
SE|00000000||tx|1|entity|C0022658|Kidney Diseases|dsyn|||renal disease||||901|79|91
SE|00000000||tx|1|entity|C1301808|Geographic state|geoa|||states||||901|93|98
SE|00000000||tx|1|relation|2|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|12|17|PREP|TREATS||19|20|3|1|C0030705|Patients|podg,humn|podg|||patients||||1000|22|29


SE|00000000||tx|1|text|Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.
SE|00000000||tx|1|entity|C0205250|High|qlco|||Elevated||||790|1|8
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||790|10|14
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|26|37
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|67|77
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|79|81
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|91|100
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|106|117


SE|00000000||tx|1|text|Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines.
SE|00000000||tx|1|entity|C0304463|Alkalinizing agent|phsu|||Alkalinizing agents||||1000|1|19
SE|00000000||tx|1|entity|C0017173|Gastrointestinal Agents|phsu|||Gastrointestinal alkalinizing agents||||913|22|57
SE|00000000||tx|1|entity|C0074722|Sodium Bicarbonate|orch,phsu|||sodium bicarbonate||||1000|60|77
SE|00000000||tx|1|entity|C1548556|etc.|idcn|||etc||||1000|80|82
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||amphetamines||||1000|109|120
SE|00000000||tx|1|relation|0|0|C0074722|Sodium Bicarbonate|orch,phsu|orch|||sodium bicarbonate||||1000|60|77|SPEC|ISA||22|77|0|0|C0017173|Gastrointestinal Agents|phsu|phsu|||Gastrointestinal alkalinizing agents||||913|22|57


SE|00000000||tx|1|text|Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||Monoamine Oxidase Inhibitors||||1000|1|28
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||Tricyclic Antidepressants||||1000|34|58
SE|00000000||tx|1|entity|C0592533|Foradil|orch,phsu|||FORADIL||||1000|61|67
SE|00000000||tx|1|entity|C0205403|Extreme|qlco|||extreme||||694|97|103
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|116|123
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|144|171
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|176|200
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|214|219
SE|00000000||tx|1|entity|C0060657|formoterol|orch,phsu|||formoterol||||1000|224|233
SE|00000000||tx|1|entity|C0007226|Cardiovascular system|bdsy|||cardiovascular system||||1000|242|262
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|292|297
SE|00000000||tx|1|relation|4|2|C0592533|Foradil|orch,phsu|phsu|||FORADIL||||1000|61|67|PREP|TREATS||113|114|7|1|C0030705|Patients|podg,humn|podg|||patients||||1000|116|123


SE|00000000||tx|1|text|Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.
SE|00000000||tx|1|entity|C1548795|Live|qlco|||live||||861|12|15
SE|00000000||tx|1|entity|C0042211|Vaccines, Attenuated|imft,phsu|||attenuated vaccines||||1000|26|44
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|53|55
SE|00000000||tx|1|entity|C1320125|Raptiva|aapp,imft,phsu|||RAPTIVA||||888|80|86


SE|00000000||tx|1|text|Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.
SE|00000000||tx|1|entity|C0085217|Lithium Carbonate|inch,phsu|||Lithium carbonate||||1000|1|17
SE|00000000||tx|1|entity|C0003123|Anorexia|dsyn|||anorectic||||1000|24|32
SE|00000000||tx|1|entity|C0175727|Stimulator|medd|||stimulatory||||853|38|48
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||853|50|56
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||amphetamines||||1000|61|72
SE|00000000||tx|1|entity|C0085217|Lithium Carbonate|inch,phsu|||lithium carbonate||||1000|94|110
SE|00000000||tx|1|relation|1|1|C0085217|Lithium Carbonate|inch,phsu|inch|||lithium carbonate||||1000|94|110|VERB|INHIBITS||81|89|4|1|C0002667|Amphetamines|nsba,orch,phsu|nsba|||amphetamines||||1000|61|72


SE|00000000||tx|1|text|Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.
SE|00000000||tx|1|entity|C0205250|High|qlco|||Elevated||||775|1|8
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||775|10|21
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||775|23|27
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|64|74
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|76|78
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|83|92
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|98|109


SE|00000000||tx|1|text|In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|9|16
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combined||||888|19|26
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|28|30
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|35|41
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|47|56
SE|00000000||tx|1|entity|C1302234|Fatal|qlco|||fatal||||901|83|87
SE|00000000||tx|1|entity|C0017181|Gastrointestinal Hemorrhage|patf|||gastrointestinal hemorrhage||||901|89|115
SE|00000000||tx|1|relation|1|1|C0017181|Gastrointestinal Hemorrhage|patf|patf|||gastrointestinal hemorrhage||||901|89|115|VERB|AFFECTS||67|76|4|4|C0030705|Patients|podg,humn|humn|||patients||||1000|9|16


SE|00000000||tx|1|text|Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||1000|21|32
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|39|42
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||midazolam||||888|44|52
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||triazolam||||1000|57|65
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||890|83|90
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|92|112
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||790|128|130
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||790|132|136


SE|00000000||tx|1|text|Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|22|33
SE|00000000||tx|1|entity|C0442821|Strong|qlco|||strong||||888|38|43
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||888|45|53
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|58|63
SE|00000000||tx|1|entity|C1337242|cinacalcet|orch,phsu|||cinacalcet||||694|76|85
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||833|108|113
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||833|121|124
SE|00000000||tx|1|entity|C1435704|Sensipar|orch,phsu|||Sensipar||||1000|129|136
SE|00000000||tx|1|entity|C1519042|Phase II/III Trial|resa|||2.3||||901|141|143
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||901|145|148
SE|00000000||tx|1|relation|2|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|22|33|NOM|INHIBITS||45|53|5|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|58|63
SE|00000000||tx|1|relation|4|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|58|63|VERB|STIMULATES||66|74|4|1|C1337242|cinacalcet|orch,phsu|orch|||cinacalcet||||694|76|85


SE|00000000||tx|1|text|Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||1000|1|12
SE|00000000||tx|1|entity|C0585361|Twice a day|tmco|||twice-daily||||798|43|53
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||798|55|66
SE|00000000||tx|1|entity|C1120110|aliskiren|orch,phsu|||aliskiren||||1000|73|81
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximate||||802|98|108
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||802|114|121
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|126|131
SE|00000000||tx|1|entity|C1120110|aliskiren|orch,phsu|||aliskiren||||1000|143|151


SE|00000000||tx|1|text|When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|6|12
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|26|33
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|45|54
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|61|66
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|78|89
SE|00000000||tx|1|entity|C0332148|Probable diagnosis|qlco|||likely||||861|95|100
SE|00000000||tx|1|relation|1|1|C0700798|Indocin|orch,phsu|orch|||INDOCIN||||1000|6|12|VERB|ADMINISTERED_TO||17|21|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|26|33
SE|00000000||tx|1|relation|3|1|C0033209|Probenecid|orch,phsu|orch|||probenecid||||1000|45|54|VERB|ADMINISTERED_TO||35|43|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|26|33


SE|00000000||tx|1|text|The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|17|19
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|24|30
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|43|48
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|53|55
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||694|80|88
SE|00000000||tx|1|entity|C1142499|gastrointestinal toxicity|fndg|||gastrointestinal toxicity||||1000|105|129
SE|00000000||tx|1|entity|C0700321|Small|qnco|||little||||1000|137|142
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|150|157
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|162|169


SE|00000000||tx|1|text|The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|5|14
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|34|44
SE|00000000||tx|1|entity|C0002680|Ampicillin|antb,orch|||ampicillin||||1000|50|59
SE|00000000||tx|1|entity|C0021149|Incidence|qnco|||incidence||||1000|89|97
SE|00000000||tx|1|entity|C0015230|Exanthema|dsyn|||rashes||||1000|102|107
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|112|119
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|136|140
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|157|164
SE|00000000||tx|1|entity|C0002680|Ampicillin|antb,orch|||ampicillin||||1000|176|185
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|187|191
SE|00000000||tx|1|relation|3|1|C0002680|Ampicillin|antb,orch|antb|||ampicillin||||1000|50|59|VERB|AUGMENTS||61|69|7|2|C0015230|Exanthema|dsyn|dsyn|||rashes||||1000|102|107
SE|00000000||tx|1|relation|3|1|C0002144|Allopurinol|orch,phsu|orch|||allopurinol||||1000|34|44|VERB|AUGMENTS||61|69|7|2|C0015230|Exanthema|dsyn|dsyn|||rashes||||1000|102|107
SE|00000000||tx|1|relation|5|1|C0015230|Exanthema|dsyn|dsyn|||rashes||||1000|102|107|PREP|PROCESS_OF||109|110|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|112|119
SE|00000000||tx|1|relation|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|136|140|VERB|ADMINISTERED_TO||121|129|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|112|119
SE|00000000||tx|1|relation|2|1|C0002680|Ampicillin|antb,orch|antb|||ampicillin||||1000|176|185|VERB|ADMINISTERED_TO||166|174|8|1|C0030705|Patients|podg,humn|humn|||patients||||1000|157|164


SE|00000000||tx|1|text|Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||Videx||||1000|1|5
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||Didanosine||||1000|8|17
SE|00000000||tx|1|entity|C0006353|Buffers|irda,phsu|||buffered||||901|29|36
SE|00000000||tx|1|entity|C0304290|Chewable Tablet|bodm|||chewable/buffered tablets||||901|20|44
SE|00000000||tx|1|entity|C1521725|Pediatric|qlco|||pediatric||||694|53|61
SE|00000000||tx|1|entity|C0991536|Oral Solution|bodm|||oral solution||||1000|74|86
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|95|97
SE|00000000||tx|1|entity|C1292425|2 Hours|tmco|||2 hours||||1000|145|151
SE|00000000||tx|1|entity|C0028365|Norfloxacin|orch,phsu|||norfloxacin||||1000|179|189
SE|00000000||tx|1|entity|C1514468|product|enty|||products||||1000|206|213
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||861|264|268
SE|00000000||tx|1|entity|C0042036|Urine|bdsu|||urine||||694|274|278
SE|00000000||tx|1|entity|C0028365|Norfloxacin|orch,phsu|||norfloxacin||||1000|290|300
SE|00000000||tx|1|relation|0|0|C0592249|Videx|nnon,phsu|nnon|||Videx||||1000|1|5|SPEC|ISA||1|17|0|0|C0012133|Didanosine|nnon,phsu|nnon|||Didanosine||||1000|8|17


SE|00000000||tx|1|text|Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||Furosemide||||1000|1|10
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||Clinical studies||||1000|13|28
SE|00000000||tx|1|entity|C0687676|Post|tmco|||post-||||851|42|46
SE|00000000||tx|1|entity|C0024826|Marketing|ocac|||marketing||||851|47|55
SE|00000000||tx|1|entity|C0700325|Patient observation|hlca|||observations||||851|57|68
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|87|92
SE|00000000||tx|1|entity|C3179308|Natriuretic Effect|phsf|||natriuretic effect||||1000|109|126
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|131|140
SE|00000000||tx|1|entity|C0541746|Thiazides|orch,phsu|||thiazides||||1000|146|154
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|164|171
SE|00000000||tx|1|relation|4|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|87|92|VERB|DISRUPTS||98|103|4|1|C3179308|Natriuretic Effect|phsf|phsf|||natriuretic effect||||1000|109|126
SE|00000000||tx|1|relation|7|3|C3179308|Natriuretic Effect|phsf|phsf|||natriuretic effect||||1000|109|126|PREP|PROCESS_OF||156|157|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|164|171


SE|00000000||tx|1|text|Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||861|20|25
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||861|27|34
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|41|53
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|56|63
SE|00000000||tx|1|entity|C0140575|Rifabutin|antb,orch|||rifabutin||||1000|66|74
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|111|119
SE|00000000||tx|1|entity|C0674428|efavirenz|orch,phsu|||efavirenz||||1000|124|132
SE|00000000||tx|1|entity|C0441994|Lower - spatial qualifier|spco|||lowered||||890|147|153
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|155|175
SE|00000000||tx|1|relation|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|VERB|STIMULATES||13|18|8|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||861|20|25
SE|00000000||tx|1|relation|6|6|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|VERB|STIMULATES||98|105|3|2|C0674428|efavirenz|orch,phsu|orch|||efavirenz||||1000|124|132


SE|00000000||tx|1|text|Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.
SE|00000000||tx|1|entity|C2826293|Clinical Significance|fndg|||clinical significance||||1000|14|34
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|39|41
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|56|58
SE|00000000||tx|1|entity|C0245519|cefditoren pivoxil|antb,orch|||cefditoren pivoxil||||1000|77|94
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|124|131


SE|00000000||tx|1|text|Corticosteroids: Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||Corticosteroids||||1000|1|15
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|18|28
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|50|56
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|75|78
SE|00000000||tx|1|entity|C2707256|Gastrointestinal:-:Point in time:^Patient:-|clna|||gastrointestinal||||888|83|98
SE|00000000||tx|1|entity|C0041582|Ulcer|patf|||ulceration||||888|100|109
SE|00000000||tx|1|entity|C0555145|Serum salicylate measurement|lbpr|||serum salicylate levels||||988|126|148
SE|00000000||tx|1|relation|3|1|C0004057|Aspirin|orch,phsu|orch|||aspirin||||1000|50|56|NOM|PREDISPOSES||75|78|2|1|C0041582|Ulcer|patf|patf|||ulceration||||888|100|109


SE|00000000||tx|1|text|Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.
SE|00000000||tx|1|entity|C0205411|Adequate|qlco|||Adequate||||694|1|8
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||890|24|35
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|37|57
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|85|91
SE|00000000||tx|1|entity|C0876768|Vioxx|orch,phsu|||VIOXX||||1000|98|102
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|131|138
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|150|161
SE|00000000||tx|1|relation|3|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||1000|85|91|PREP|USES||93|96|3|1|C0876768|Vioxx|orch,phsu|phsu|||VIOXX||||1000|98|102
SE|00000000||tx|1|relation|4|3|C0039771|Theophylline|bacs,orch,phsu|phsu|||theophylline||||890|24|35|PREP|TREATS||128|129|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|131|138
SE|00000000||tx|1|relation|1|1|C0039771|Theophylline|bacs,orch,phsu|bacs|||theophylline||||1000|150|161|VERB|ADMINISTERED_TO||140|148|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|131|138


SE|00000000||tx|1|text|Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||Cyclosporine||||1000|1|12
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||Digoxin||||1000|15|21
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||Methotrexate||||888|24|35
SE|00000000||tx|1|entity|C0700001|Lodine|orch,phsu|||Lodine||||888|37|42
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|56|61
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|72|78
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|83|87
SE|00000000||tx|1|entity|C0033554|Prostaglandins|bacs,eico,phsu|||prostaglandins||||888|89|102
SE|00000000||tx|1|entity|C0443172|Changed status|qnco|||changes||||1000|115|121
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|151|155
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||790|168|175
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||790|177|181
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|193|204
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|207|213
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|216|227
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|234|242
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||888|244|251
SE|00000000||tx|1|relation|0|0|C0700001|Lodine|orch,phsu|orch|||Lodine||||888|37|42|SPEC|ISA||37|61|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|56|61
SE|00000000||tx|1|relation|9|7|C0012265|Digoxin|carb,phsu,strd|carb|||digoxin||||1000|207|213|NOM|INTERACTS_WITH||72|78|9|1|C0033554|Prostaglandins|bacs,eico,phsu|bacs|||prostaglandins||||888|89|102
SE|00000000||tx|1|relation|9|7|C0025677|Methotrexate|orch,phsu|orch|||methotrexate||||1000|216|227|NOM|INTERACTS_WITH||72|78|9|1|C0033554|Prostaglandins|bacs,eico,phsu|bacs|||prostaglandins||||888|89|102
SE|00000000||tx|1|relation|9|7|C0010592|Cyclosporine|aapp,gngm,phsu|aapp|||cyclosporine||||1000|193|204|NOM|INTERACTS_WITH||72|78|9|1|C0033554|Prostaglandins|bacs,eico,phsu|bacs|||prostaglandins||||888|89|102
SE|00000000||tx|1|relation|0|0|C0033554|Prostaglandins|bacs,eico,phsu|bacs|||prostaglandins||||888|89|102|MOD/HEAD|PART_OF||83|102|0|0|C0022646|Kidney|bpoc|bpoc|||renal||||888|83|87


SE|00000000||tx|1|text|Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|6|15
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|28|40
SE|00000000||tx|1|entity|C0205374|Transitory|tmco|||transient||||888|69|77
SE|00000000||tx|1|entity|C0702240|Elevation|spco|||elevations||||888|79|88
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||888|93|97
SE|00000000||tx|1|entity|C0010294|Creatinine|bacs,orch|||creatinine||||888|99|108
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|113|120
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||861|132|143
SE|00000000||tx|1|relation|2|1|C0008809|Ciprofloxacin|orch,phsu|orch|||ciprofloxacin||||1000|28|40|NOM|STIMULATES||79|88|3|1|C0010294|Creatinine|bacs,orch|bacs|||creatinine||||888|99|108
SE|00000000||tx|1|relation|1|1|C0010592|Cyclosporine|aapp,gngm,phsu|phsu|||cyclosporine||||861|132|143|VERB|ADMINISTERED_TO||122|130|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|113|120


SE|00000000||tx|1|text|therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.
SE|00000000||tx|1|entity|C0525004|Viracept|orch,phsu|||VIRACEPT||||1000|12|19
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|28|30
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||1000|66|76
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|93|101
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||1000|107|113
SE|00000000||tx|1|entity|C2826244|Life Threatening|fndg|||life-threatening||||888|122|137
SE|00000000||tx|1|entity|C0003811|Cardiac Arrhythmia|patf|||cardiac arrhythmias||||888|139|157


SE|00000000||tx|1|text|With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||851|6|9
SE|00000000||tx|1|entity|C0010980|Dapsone|orch,phsu|||dapsone||||851|11|17
SE|00000000||tx|1|entity|C0016411|Folic Acid Antagonists|phsu|||folic acid antagonists||||1000|30|51
SE|00000000||tx|1|entity|C0034283|Pyrimethamine|orch,phsu|||pyrimethamine||||1000|61|73
SE|00000000||tx|1|entity|C2362652|Possible diagnosis|qlco|||possibly||||888|94|101
SE|00000000||tx|1|entity|C0033204|Probability|qnco|||likelihood||||1000|116|125
SE|00000000||tx|1|entity|C0205488|Hematologic|ftcn|||hematologic||||872|130|140
SE|00000000||tx|1|entity|C1114821|Reaction:Finding:Point in time:^Patient:Nominal|clna|||reactions||||872|142|150
SE|00000000||tx|1|relation|0|0|C0034283|Pyrimethamine|orch,phsu|orch|||pyrimethamine||||1000|61|73|SPEC|ISA||30|73|0|0|C0016411|Folic Acid Antagonists|phsu|phsu|||folic acid antagonists||||1000|30|51


SE|00000000||tx|1|text|Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||Reports||||1000|1|7
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|22|27
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|63|68
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitors||||1000|73|86
SE|00000000||tx|1|entity|C0065374|Lisinopril|aapp,phsu|||lisinopril||||1000|99|108


SE|00000000||tx|1|text|Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
SE|00000000||tx|1|entity|C0851347|Pharmacodynamics|biof|||Pharmacodynamic||||872|1|15
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||Interactions||||872|17|28
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS-depressant||||901|35|48
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||901|50|55
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepine||||888|64|77
SE|00000000||tx|1|entity|C0456387|Class|inpr|||class||||888|79|83
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|88|92
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|116|122
SE|00000000||tx|1|entity|C0027415|Narcotics|hops,phsu|||narcotics||||1000|125|133
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|136|147
SE|00000000||tx|1|entity|C0020591|Hypnotics|phsu|||hypnotics||||861|165|173
SE|00000000||tx|1|entity|C0040616|Anti-Anxiety Agents|phsu|||antianxiety agents||||1000|176|193
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|200|213
SE|00000000||tx|1|entity|C0039961|Thioxanthenes|orch,phsu|||thioxanthene||||1000|216|227
SE|00000000||tx|1|entity|C0006525|Butyrophenones|orch,phsu|||butyrophenone||||888|233|245
SE|00000000||tx|1|entity|C0456387|Class|inpr|||classes||||888|247|253
SE|00000000||tx|1|entity|C0040615|Antipsychotic Agents|phsu|||antipsychotic agents||||1000|258|277
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|280|307
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|317|341
SE|00000000||tx|1|entity|C0003286|Anticonvulsants|phsu|||anticonvulsant drugs||||1000|357|376
SE|00000000||tx|1|relation|12|1|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|116|122|VERB|STIMULATES||101|111|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|88|92
SE|00000000||tx|1|relation|12|1|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|116|122|VERB|STIMULATES||101|111|4|1|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsant drugs||||1000|357|376
SE|00000000||tx|1|relation|12|1|C0039961|Thioxanthenes|orch,phsu|orch|||thioxanthene||||1000|216|227|VERB|STIMULATES||101|111|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|88|92
SE|00000000||tx|1|relation|12|7|C0039961|Thioxanthenes|orch,phsu|orch|||thioxanthene||||1000|216|227|VERB|STIMULATES||101|111|12|12|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsant drugs||||1000|357|376
SE|00000000||tx|1|relation|12|6|C0031436|Phenothiazines|orch,phsu|orch|||phenothiazines||||1000|200|213|VERB|STIMULATES||101|111|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|88|92
SE|00000000||tx|1|relation|12|6|C0031436|Phenothiazines|orch,phsu|orch|||phenothiazines||||1000|200|213|VERB|STIMULATES||101|111|4|1|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsant drugs||||1000|357|376
SE|00000000||tx|1|relation|12|6|C0040616|Anti-Anxiety Agents|phsu|phsu|||antianxiety agents||||1000|176|193|VERB|STIMULATES||101|111|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|88|92
SE|00000000||tx|1|relation|12|5|C0040616|Anti-Anxiety Agents|phsu|phsu|||antianxiety agents||||1000|176|193|VERB|STIMULATES||101|111|12|12|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsant drugs||||1000|357|376
SE|00000000||tx|1|relation|12|4|C0020591|Hypnotics|phsu|phsu|||hypnotics||||861|165|173|VERB|STIMULATES||101|111|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|88|92
SE|00000000||tx|1|relation|12|4|C0020591|Hypnotics|phsu|phsu|||hypnotics||||861|165|173|VERB|STIMULATES||101|111|4|1|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsant drugs||||1000|357|376
SE|00000000||tx|1|relation|12|4|C0004745|Barbiturates|orch,phsu|orch|||barbiturates||||1000|136|147|VERB|STIMULATES||101|111|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|88|92
SE|00000000||tx|1|relation|12|3|C0004745|Barbiturates|orch,phsu|orch|||barbiturates||||1000|136|147|VERB|STIMULATES||101|111|12|12|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsant drugs||||1000|357|376
SE|00000000||tx|1|relation|12|2|C0027415|Narcotics|hops,phsu|hops|||narcotics||||1000|125|133|VERB|STIMULATES||101|111|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|88|92
SE|00000000||tx|1|relation|12|2|C0027415|Narcotics|hops,phsu|hops|||narcotics||||1000|125|133|VERB|STIMULATES||101|111|4|1|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsant drugs||||1000|357|376


SE|00000000||tx|1|text|Diuretic: Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||Diuretic||||1000|1|8
SE|00000000||tx|1|entity|C0020261|Hydrochlorothiazide|orch,phsu|||Hydrochlorothiazide||||1000|11|29
SE|00000000||tx|1|entity|C0022635|Ketoprofen|orch,phsu|||ketoprofen||||1000|57|66
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|80|88
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||urinary||||888|93|99
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||888|101|109
SE|00000000||tx|1|entity|C0008203|Chlorides|inch|||chloride||||888|115|122
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|124|132
SE|00000000||tx|1|entity|C0020261|Hydrochlorothiazide|orch,phsu|||hydrochlorothiazide||||888|146|164
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|166|170
SE|00000000||tx|1|relation|6|1|C0022635|Ketoprofen|orch,phsu|orch|||ketoprofen||||1000|57|66|VERB|COEXISTS_WITH||32|36|2|1|C0020261|Hydrochlorothiazide|orch,phsu|orch|||Hydrochlorothiazide||||1000|11|29
SE|00000000||tx|1|relation|3|3|C0012798|Diuretics|phsu|phsu|||Diuretic||||1000|1|8|NOM|INHIBITS||80|88|4|1|C0032821|Potassium|elii|elii|||potassium||||888|101|109


SE|00000000||tx|1|text|In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of coumarin by fondaparinux (200 m m M i.e., 350 mg/L) was 17-28%.
SE|00000000||tx|1|entity|C1533691|in vitro|qlco|||in vitro||||901|7|14
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||901|16|20
SE|00000000||tx|1|entity|C0086418|Homo sapiens|humn|||human||||901|25|29
SE|00000000||tx|1|entity|C0026030|Microsomes, Liver|celc|||liver microsomes||||901|31|46
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|49|58
SE|00000000||tx|1|entity|||gngm|1548|CYP2A6|CYP2A6||||861|63|68
SE|00000000||tx|1|entity|C0020365|Hydroxylation|npop|||hydroxylation||||861|70|82
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin||||1000|87|94
SE|00000000||tx|1|entity|C1098510|fondaparinux|carb,phsu|||fondaparinux||||1000|99|110
SE|00000000||tx|1|entity|C0439268|Microgram per Milliliter|qnco|||mg/L)||||901|133|137
SE|00000000||tx|1|relation|0|0|C0026030|Microsomes, Liver|celc|celc|||liver microsomes||||901|31|46|MOD/HEAD|PART_OF||25|46|0|0|C0086418|Homo sapiens|grup,humn|humn|||human||||901|25|29
SE|00000000||tx|1|relation|5|2|C0010206|coumarin|orch,phsu|orch|||coumarin||||1000|87|94|NOM|INHIBITS||49|58|5|1|||gngm,aapp|gngm|1548|CYP2A6|CYP2A6||||861|63|68


SE|00000000||tx|1|text|In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|4|11
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|14|25
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|27|31
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||adrenal corticosteroid||||901|45|66
SE|00000000||tx|1|entity|C0220781|Anabolism|biof|||synthesis||||901|68|76
SE|00000000||tx|1|entity|C0001623|Adrenal gland hypofunction|dsyn|||adrenal insufficiency||||1000|92|112
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroid||||888|121|134
SE|00000000||tx|1|entity|C2349954|Withdraw (activity)|acty|||withdrawal||||888|136|145
SE|00000000||tx|1|relation|3|2|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|14|25|VERB|INHIBITS||37|43|3|1|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||adrenal corticosteroid||||901|45|66


SE|00000000||tx|1|text|Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||Blood||||861|1|5
SE|00000000||tx|1|entity|C0671572|hydrodolasetron|orch|||hydrodolasetron||||1000|17|31
SE|00000000||tx|1|entity|C0209210|Dolasetron|orch,phsu|||dolasetron||||1000|52|61
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|87|96
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||861|112|120
SE|00000000||tx|1|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P-450)||||1000|125|141
SE|00000000||tx|1|entity|C1547085|7 days|tmco|||7 days||||1000|147|152
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|198|205
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||594|208|213
SE|00000000||tx|1|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P-450)||||1000|226|242
SE|00000000||tx|1|entity|C1547085|7 days|tmco|||7 days||||1000|248|253
SE|00000000||tx|1|relation|4|2|C0209210|Dolasetron|orch,phsu|orch|||dolasetron||||1000|52|61|NOM|INHIBITS||112|120|7|1|C0010762|Cytochrome P450|aapp,gngm,enzy|gngm|||cytochrome P-450)||||1000|125|141
SE|00000000||tx|1|relation|9|4|C0010762|Cytochrome P450|aapp,gngm,enzy|aapp|||cytochrome P-450)||||1000|125|141|NOM|STIMULATES||215|221|2|1|C0010762|Cytochrome P450|aapp,gngm,enzy|gngm|||cytochrome P-450)||||1000|226|242


SE|00000000||tx|1|text|Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|19|24
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||Rifampicin||||1000|27|36
SE|00000000||tx|1|entity|C0078847|zopiclone|orch,phsu|||zopiclone||||660|47|55
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||802|87|97
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampicin||||802|105|114
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||594|119|124
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|137|142
SE|00000000||tx|1|relation|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|VERB|STIMULATES||12|17|6|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|19|24
SE|00000000||tx|1|relation|5|1|C0035608|Rifampin|antb,orch|antb|||rifampicin||||802|105|114|NOM|STIMULATES||126|132|1|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|137|142


SE|00000000||tx|1|text|Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||888|1|9
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||Phenobarbital||||888|11|23
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|50|58
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|63|75
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|82|84
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|93|113
SE|00000000||tx|1|entity|C0042866|Vitamin D|orch,phsu,vita|||vitamin D||||1000|118|126
SE|00000000||tx|1|entity|C0205227|Endogenous|ftcn|||endogenous||||790|144|153
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|155|160
SE|00000000||tx|1|entity|C0006674|Calcitriol|horm,phsu,strd,vita|||calcitriol||||694|172|181
SE|00000000||tx|1|entity|C0521110|Accelerated|ftcn|||accelerating||||872|201|212
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||872|214|223
SE|00000000||tx|1|relation|4|1|C0031412|Phenobarbital|orch,phsu|orch|||phenobarbital||||1000|63|75|VERB|INTERACTS_WITH|negation|86|91|5|2|C0042866|Vitamin D|orch,phsu,vita|orch|||vitamin D||||1000|118|126
SE|00000000||tx|1|relation|4|1|C0031412|Phenobarbital|orch,phsu|orch|||Phenobarbital||||888|11|23|VERB|INTERACTS_WITH|negation|86|91|5|2|C0042866|Vitamin D|orch,phsu,vita|orch|||vitamin D||||1000|118|126


SE|00000000||tx|1|text|The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|5|12
SE|00000000||tx|1|entity|C0439400|mg/day/kg|qnco|||mg/kg/day||||923|21|29
SE|00000000||tx|1|entity|C0012694|Cromolyn Sodium|orch,phsu|||cromolyn sodium||||1000|34|48
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||802|51|63
SE|00000000||tx|1|entity|C0040223|Time|tmco|||times||||802|69|73
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximum||||1000|79|85
SE|00000000||tx|1|entity|C0004048|Inspiration function|orgf|||inhalation||||901|105|114
SE|00000000||tx|1|entity|C2348070|Daily Dose|qnco|||daily inhalation dose||||901|99|119
SE|00000000||tx|1|entity|C0001675|Adult|aggp|||adults||||1000|124|129
SE|00000000||tx|1|entity|C1319266|mg/sq.m|qnco|||mg/m2||||901|136|140
SE|00000000||tx|1|entity|C1874451|Basis|phsu|||basis||||901|142|146
SE|00000000||tx|1|entity|C0439400|mg/day/kg|qnco|||mg/kg/day||||850|156|164
SE|00000000||tx|1|entity|C0022245|Isoproterenol|orch,phsu|||isoproterenol||||1000|169|181
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||802|184|196
SE|00000000||tx|1|entity|C0040223|Time|tmco|||times||||802|200|204
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximum||||1000|210|216
SE|00000000||tx|1|entity|C0004048|Inspiration function|orgf|||inhalation||||901|236|245
SE|00000000||tx|1|entity|C2348070|Daily Dose|qnco|||daily inhalation dose||||901|230|250
SE|00000000||tx|1|entity|C0001675|Adult|aggp|||adults||||1000|255|260
SE|00000000||tx|1|entity|C1319266|mg/sq.m|qnco|||mg/m2||||901|267|271
SE|00000000||tx|1|entity|C1874451|Basis|phsu|||basis||||901|273|277
SE|00000000||tx|1|entity|C0021149|Incidence|qnco|||incidence||||1000|310|318
SE|00000000||tx|1|entity|C2985494|Resorption|orgf|||resorptions||||966|328|338
SE|00000000||tx|1|entity|C0000768|Congenital Abnormality|cgab|||malformations||||1000|344|356
SE|00000000||tx|1|relation|15|6|C0022245|Isoproterenol|orch,phsu|orch|||isoproterenol||||1000|169|181|VERB|AUGMENTS||296|304|3|2|C2985494|Resorption|orgf|orgf|||resorptions||||966|328|338
SE|00000000||tx|1|relation|15|6|C0022245|Isoproterenol|orch,phsu|orch|||isoproterenol||||1000|169|181|VERB|AUGMENTS||296|304|3|2|C0000768|Congenital Abnormality|cgab|cgab|||malformations||||1000|344|356


SE|00000000||tx|1|text|The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||901|5|13
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interactions||||901|15|31
SE|00000000||tx|1|entity|C1242799|Ketoconazole Oral Tablet [Nizoral]|clnd|||NIZORAL Tablets||||1000|64|78
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|90|94
SE|00000000||tx|1|entity|C0010762|Cytochrome P450|aapp,enzy|1555|CYP2B6|cytochrome P450 3A4 enzyme system||||924|115|147
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||888|150|161
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||888|163|169
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|183|192
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||1000|197|207
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||901|226|234
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||901|236|255
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||1000|260|270
SE|00000000||tx|1|entity|C0205421|Deferred|tmco|||delay||||1000|278|282
SE|00000000||tx|1|entity|C0001128|Acids|chem|||acid||||888|310|313
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||888|315|324
SE|00000000||tx|1|relation|9|1|C0010762|Cytochrome P450|aapp,gngm,enzy|aapp|1555|CYP2B6|cytochrome P450 3A4 enzyme system||||924|115|147|VERB|INTERACTS_WITH||96|106|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|90|94


SE|00000000||tx|1|text|Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|12|19
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|31|40
SE|00000000||tx|1|entity|C0205251|low|qlco|||low||||790|64|66
SE|00000000||tx|1|entity|C0206088|Renal Plasma Flow, Effective|ortf|||ERPF||||790|68|71
SE|00000000||tx|1|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAH||||773|80|82
SE|00000000||tx|1|entity|C0042295|Values|qlco|||values||||773|84|89
SE|00000000||tx|1|relation|3|1|C0033209|Probenecid|orch,phsu|orch|||probenecid||||1000|31|40|VERB|ADMINISTERED_TO||21|29|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|12|19


SE|00000000||tx|1|text|These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.
SE|00000000||tx|1|entity|C1533691|in vitro|qlco|||in vitro||||901|7|14
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|37|47
SE|00000000||tx|1|entity|C0012132|Zalcitabine|nnon,phsu|||zalcitabine||||1000|67|77
SE|00000000||tx|1|entity|C0209738|Lamivudine|nnon,phsu|||lamivudine||||1000|83|92
SE|00000000||tx|1|entity|C0086418|Homo sapiens|humn|||humans||||1000|97|102
SE|00000000||tx|1|entity|C1264637|Substance amount|qnco|||sub-||||851|118|121
SE|00000000||tx|1|entity|C0302350|Therapeutic|ftcn|||therapeutic||||851|122|132
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||851|134|147
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||802|152|157
SE|00000000||tx|1|entity|C0012132|Zalcitabine|nnon,phsu|||zalcitabine||||802|174|184
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decreased||||802|207|215
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||802|232|237
SE|00000000||tx|1|entity|C0012132|Zalcitabine|nnon,phsu|||zalcitabine||||1000|242|252
SE|00000000||tx|1|relation|4|1|C0209738|Lamivudine|nnon,phsu|phsu|||lamivudine||||1000|83|92|PREP|TREATS||94|95|5|1|C0086418|Homo sapiens|grup,humn|humn|||humans||||1000|97|102
SE|00000000||tx|1|relation|4|1|C0012132|Zalcitabine|nnon,phsu|phsu|||zalcitabine||||1000|67|77|PREP|TREATS||94|95|5|1|C0086418|Homo sapiens|grup,humn|humn|||humans||||1000|97|102
SE|00000000||tx|1|relation|7|1|C0012132|Zalcitabine|nnon,phsu|nnon|||zalcitabine||||802|174|184|NOM|INTERACTS_WITH||232|237|1|1|C0012132|Zalcitabine|nnon,phsu|nnon|||zalcitabine||||1000|242|252


SE|00000000||tx|1|text|Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.
SE|00000000||tx|1|entity|C0871935|Theory|idcn|||theoretical||||888|20|30
SE|00000000||tx|1|entity|C1874451|Basis|phsu|||basis||||888|32|36
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|49|55
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|64|71
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|74|76
SE|00000000||tx|1|entity|C0014710|Ergotamine|orch,phsu|||ergotamine||||1000|81|90
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||827|117|127
SE|00000000||tx|1|entity|C0012291|Dihydroergotamine|orch,phsu|||dihydroergotamine||||1000|135|151
SE|00000000||tx|1|entity|C0025842|Methysergide|orch,phsu|||methysergide||||1000|156|167
SE|00000000||tx|1|entity|C0939679|Axert|orch,phsu|||AXERT||||1000|174|178
SE|00000000||tx|1|entity|C1442770|24 Hours|tmco|||24 hours||||1000|187|194


SE|00000000||tx|1|text|Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||Inhibitors||||1000|1|10
SE|00000000||tx|1|entity|C0205227|Endogenous|ftcn|||Endogenous||||901|15|24
SE|00000000||tx|1|entity|C1157324|prostaglandin biosynthetic process|moft|||Prostaglandin Synthesis||||901|26|48
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|76|87
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|121|126
SE|00000000||tx|1|entity|C0006938|Captopril|aapp,phsu|||captopril||||1000|131|139
SE|00000000||tx|1|entity|C0868928|Case (situation)|ftcn|||cases||||1000|156|160
SE|00000000||tx|1|entity|C0597849|low renin hypertension|patf|||low renin hypertension||||1000|165|186
SE|00000000||tx|1|relation|3|1|C0021246|Indomethacin|orch,phsu|orch|||indomethacin||||1000|76|87|NOM|INTERACTS_WITH||121|126|3|1|C0006938|Captopril|aapp,gngm,phsu|aapp|||captopril||||1000|131|139


SE|00000000||tx|1|text|Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||Methotrexate||||1000|1|12
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|15|25
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|45|56
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|67|72
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|106|114
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|119|130
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|147|154
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|159|170
SE|00000000||tx|1|relation|4|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|67|72|VERB|INHIBITS||95|100|4|2|C0025677|Methotrexate|orch,phsu|orch|||methotrexate||||1000|119|130
SE|00000000||tx|1|relation|4|1|C0025677|Methotrexate|orch,phsu|phsu|||methotrexate||||1000|45|56|VERB|INHIBITS||95|100|4|2|C0025677|Methotrexate|orch,phsu|orch|||methotrexate||||1000|119|130
SE|00000000||tx|1|relation|6|1|C0025677|Methotrexate|orch,phsu|orch|||methotrexate||||1000|119|130|VERB|AUGMENTS||133|141|2|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||1000|147|154


SE|00000000||tx|1|text|Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.
SE|00000000||tx|1|entity|C1579410|Nucleoside Analogs|nnon,phsu|||Nucleoside Analogues||||794|1|20
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||Didanosine||||794|22|31
SE|00000000||tx|1|entity|C1170183|Copegus|orch,phsu|||COPEGUS||||1000|54|60
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||1000|66|75
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|80|82


SE|00000000||tx|1|text|Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|16|19
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||890|24|30
SE|00000000||tx|1|entity|C0085612|Ventricular arrhythmia|patf|||ventricular arrhythmias||||890|32|54
SE|00000000||tx|1|entity|C0011071|Sudden death|patf|||sudden death||||901|60|71
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||790|101|108
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|110|115
SE|00000000||tx|1|entity|C0039943|Thioridazine|orch,phsu|||thioridazine||||1000|127|138
SE|00000000||tx|1|entity|C0245561|duloxetine|orch,phsu|||Duloxetine||||1000|141|150
SE|00000000||tx|1|entity|C0039943|Thioridazine|orch,phsu|||thioridazine||||1000|156|167
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|176|178
SE|00000000||tx|1|relation|6|5|C0245561|duloxetine|orch,phsu|orch|||Duloxetine||||1000|141|150|NOM|PREDISPOSES||16|19|6|1|C0085612|Ventricular arrhythmia|patf|patf|||ventricular arrhythmias||||890|32|54
SE|00000000||tx|1|relation|6|5|C0245561|duloxetine|orch,phsu|orch|||Duloxetine||||1000|141|150|NOM|PREDISPOSES||16|19|6|1|C0011071|Sudden death|patf|patf|||sudden death||||901|60|71


SE|00000000||tx|1|text|The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|17|19
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||888|24|33
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||888|35|41
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|53|58
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|63|65
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||694|90|98
SE|00000000||tx|1|entity|C1142499|gastrointestinal toxicity|fndg|||gastrointestinal toxicity||||1000|115|139
SE|00000000||tx|1|entity|C0700321|Small|qnco|||little||||1000|147|152
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|160|167
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|172|179


SE|00000000||tx|1|text|Quinolones have been shown to interfere with the metabolism of caffeine.
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||Quinolones||||1000|1|10
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|50|59
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|64|71
SE|00000000||tx|1|relation|1|1|C0034428|Quinolones|orch|orch|||Quinolones||||1000|1|10|VERB|DISRUPTS||31|39|2|1|C0025519|Metabolism|orgf|orgf|||metabolism||||1000|50|59


SE|00000000||tx|1|text|Warfarin: Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||Warfarin||||1000|1|8
SE|00000000||tx|1|entity|C0853225|INR raised|fndg|||Increased INR||||1000|11|23
SE|00000000||tx|1|entity|C0525032|International Normalized Ratio|lbpr|||International Normalized Ratio||||1000|26|55
SE|00000000||tx|1|entity|C0718644|Arava|orch,phsu|||ARAVA||||1000|63|67
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|73|80
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||rarely||||1000|112|117


SE|00000000||tx|1|text|Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|19|34
SE|00000000||tx|1|entity|C0441509|Coagulation procedure|topp|||coagulation||||790|54|64
SE|00000000||tx|1|entity|C0022885|Laboratory Procedures|lbpr|||test||||790|66|69
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|96|103
SE|00000000||tx|1|entity|C0243072|derivatives|chvs|||derivatives||||1000|112|122
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||enoxacin||||1000|128|135
SE|00000000||tx|1|relation|0|0|C0033707|Prothrombin time assay|lbpr|lbpr|||prothrombin time||||1000|19|34|SPEC|ISA||19|69|0|0|C0022885|Laboratory Procedures|lbpr|lbpr|||test||||790|66|69
SE|00000000||tx|1|relation|0|0|C0022885|Laboratory Procedures|lbpr|lbpr|||test||||790|66|69|SPEC|ISA||19|69|0|0|C0033707|Prothrombin time assay|lbpr|lbpr|||prothrombin time||||1000|19|34


SE|00000000||tx|1|text|Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|11|21
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|41|48
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||magnesium||||1000|61|69
SE|00000000||tx|1|entity|C0002367|Aluminum|elii|||aluminum||||1000|74|81
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||VIDEX||||786|88|92
SE|00000000||tx|1|entity|C0006353|Buffers|irda,phsu|||Buffered||||786|115|122
SE|00000000||tx|1|entity|C1273630|Tablet For Suspension Dosage Form|bodm|||Dispersible Buffered Tablets||||786|103|130
SE|00000000||tx|1|entity|C1521725|Pediatric|qlco|||Pediatric||||694|135|143
SE|00000000||tx|1|entity|C0991536|Oral Solution|bodm|||Oral Solution||||1000|156|168
SE|00000000||tx|1|entity|C0877248|Adverse event|fndg|||adverse events||||1000|185|198
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacid||||888|220|226
SE|00000000||tx|1|entity|C0449432|Component object|mnob|||components||||888|228|237
SE|00000000||tx|1|relation|8|4|C0002367|Aluminum|elii|elii|||aluminum||||1000|74|81|VERB|AUGMENTS||174|183|2|1|C0877248|Adverse event|fndg|fndg|||adverse events||||1000|185|198


SE|00000000||tx|1|text|Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||Cyclosporine||||1000|1|12
SE|00000000||tx|1|entity|C0205250|High|qlco|||Elevated||||790|15|22
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||790|24|28
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|40|51
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|77|87
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|89|91
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|96|107
SE|00000000||tx|1|entity|C0680022|member|popg|||members||||1000|120|126
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolone||||888|135|143
SE|00000000||tx|1|entity|C0456387|Class|inpr|||class||||888|145|149


SE|00000000||tx|1|text|Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|13|15
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|20|33
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|40|46
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|49|73
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|76|87
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||central nervous system depressants||||1000|99|132
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|146|153
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|155|160
SE|00000000||tx|1|relation|0|0|C0004745|Barbiturates|orch,phsu|orch|||barbiturates||||1000|76|87|SPEC|ISA||76|132|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressants||||1000|99|132
SE|00000000||tx|1|relation|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressants||||1000|99|132|SPEC|ISA||76|132|0|0|C0004745|Barbiturates|orch,phsu|phsu|||barbiturates||||1000|76|87
SE|00000000||tx|1|relation|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressants||||1000|99|132|SPEC|ISA||76|132|0|0|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|49|73
SE|00000000||tx|1|relation|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressants||||1000|99|132|SPEC|ISA||76|132|0|0|C0001975|Alcohols|orch,phsu|phsu|||alcohol||||1000|40|46
SE|00000000||tx|1|relation|0|0|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|49|73|SPEC|ISA||76|132|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressants||||1000|99|132
SE|00000000||tx|1|relation|0|0|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|40|46|SPEC|ISA||76|132|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressants||||1000|99|132


SE|00000000||tx|1|text|Probenecid depresses tubular secretion of certain weak acids such as PAH.
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|1|10
SE|00000000||tx|1|entity|C0232819|Tubular secretion|ortf|||tubular secretion||||1000|22|38
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||851|43|49
SE|00000000||tx|1|entity|C1762617|Weak|qlco|||weak||||851|51|54
SE|00000000||tx|1|entity|C0001128|Acids|chem|||acids||||851|56|60
SE|00000000||tx|1|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAH||||966|70|72
SE|00000000||tx|1|relation|1|1|C0033209|Probenecid|orch,phsu|orch|||Probenecid||||1000|1|10|VERB|AFFECTS||12|20|3|1|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|22|38


SE|00000000||tx|1|text|The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|5|10
SE|00000000||tx|1|entity|C0205309|Known|qlco|||known||||790|43|47
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||790|49|58
SE|00000000||tx|1|entity|C0205054|Hepatic|blor|||hepatic||||916|63|69
SE|00000000||tx|1|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P-450||||916|71|86
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzyme||||888|93|98
SE|00000000||tx|1|entity|C0449913|System|ftcn|||system||||888|100|105
SE|00000000||tx|1|entity|C0444693|First pass|tmco|||first-pass||||901|127|136
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||901|138|147
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|152|160
SE|00000000||tx|1|relation|5|5|C0012373|Diltiazem|orch,phsu|orch|||diltiazem||||1000|152|160|NOM|INHIBITS||49|58|5|1|C0010762|Cytochrome P450|aapp,gngm,enzy|gngm|||cytochrome P-450||||916|71|86
SE|00000000||tx|1|relation|0|0|C0010762|Cytochrome P450|aapp,gngm,enzy|gngm|||cytochrome P-450||||916|71|86|MOD/HEAD|PART_OF||63|86|0|0|C0205054|Hepatic|blor|blor|||hepatic||||916|63|69


SE|00000000||tx|1|text|Paroxetine produced only minor changes in the levels of clozapine and its metabolites.
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||Paroxetine||||1000|1|10
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||only||||802|21|24
SE|00000000||tx|1|entity|C0443172|Changed status|qnco|||changes||||802|32|38
SE|00000000||tx|1|entity|C0009079|Clozapine|orch,phsu|||clozapine||||1000|57|65
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolites||||1000|75|85


SE|00000000||tx|1|text|Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving clonazepam.
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||clinical studies||||1000|10|25
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|32|34
SE|00000000||tx|1|entity|C0059563|cytochrome P450 3A|aapp,enzy|||cytochrome P-450 3A||||916|84|102
SE|00000000||tx|1|entity|C1301584|Last Name|inpr|||family||||916|104|109
SE|00000000||tx|1|entity|C0009011|Clonazepam|orch,phsu|||clonazepam||||888|114|123
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|125|134
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||1000|137|146
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzyme||||888|156|161
SE|00000000||tx|1|entity|C0449913|System|ftcn|||system||||888|163|168
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||824|179|182
SE|00000000||tx|1|entity|C0003308|Antifungal Agents|phsu|||antifungal agents||||824|184|200
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|232|239
SE|00000000||tx|1|entity|C0009011|Clonazepam|orch,phsu|||clonazepam||||1000|251|260
SE|00000000||tx|1|relation|7|5|C0003308|Antifungal Agents|phsu|phsu|||antifungal agents||||824|184|200|NOM|INTERACTS_WITH||65|75|7|2|C0009011|Clonazepam|orch,phsu|orch|||clonazepam||||888|114|123
SE|00000000||tx|1|relation|1|1|C0009011|Clonazepam|orch,phsu|orch|||clonazepam||||1000|251|260|VERB|ADMINISTERED_TO||241|249|8|1|C0030705|Patients|podg,humn|humn|||patients||||1000|232|239


SE|00000000||tx|1|text|Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||1000|1|9
SE|00000000||tx|1|entity|C0028040|Nicotine|hops,orch,phsu|||nicotine||||1000|12|19
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|26|33
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||890|58|63
SE|00000000||tx|1|entity|C0524086|Clozapine measurement|lbpr|||Clozapine plasma levels||||890|48|70
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|88|95
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effectiveness||||1000|100|112
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effective||||824|130|138
SE|00000000||tx|1|entity|C1148292|Clozapine:Mass:Point in time:Dose med or substance:Quantitative|clna|||Clozapine dose||||824|140|153


SE|00000000||tx|1|text|It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|19|21
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||775|35|40
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||775|47|50
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||Vardenafil||||1000|55|64
SE|00000000||tx|1|entity|C0439584|24 hour time frame|tmco|||24-hour||||890|71|77
SE|00000000||tx|1|entity|C0439531|per period (qualifier value)|tmco|||period||||890|79|84
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|99|109
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|116|127


SE|00000000||tx|1|text|plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|1|6
SE|00000000||tx|1|entity|C0443302|Several|qnco|||several||||861|18|24
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|42|66
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|110|120
SE|00000000||tx|1|entity|C0025810|Methylphenidate|orch,phsu|||methylphenidate||||1000|140|154
SE|00000000||tx|1|entity|C0205054|Hepatic|blor|||hepatic||||901|159|165
SE|00000000||tx|1|entity|C0014432|Enzyme Inhibitors|phsu|||enzyme inhibitors||||901|167|183
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|192|201
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|204|213
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|237|247
SE|00000000||tx|1|entity|C0428321|Measurement of liver enzyme|lbpr|||hepatic enzyme||||734|267|280
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|298|309
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|312|320
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|336|341
SE|00000000||tx|1|entity|C3146287|Well|mnob|||well||||1000|374|377


SE|00000000||tx|1|text|The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
SE|00000000||tx|1|entity|C0002934|Local Anesthetics|phsu|||local anesthetic||||901|23|38
SE|00000000||tx|1|entity|C0037633|Solutions|sbst|||solutions||||901|40|48
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||epinephrine||||1000|61|71
SE|00000000||tx|1|entity|C0028351|Norepinephrine|nsba,orch,phsu|||norepinephrine||||1000|76|89
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|94|101
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|113|140
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|143|167
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|172|185
SE|00000000||tx|1|entity|C0439590|Prolonged|tmco|||prolonged||||901|207|215
SE|00000000||tx|1|entity|C2678378|Hypotension, severe|fndg|||severe, prolonged hypotension||||901|199|227
SE|00000000||tx|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||1000|232|243
SE|00000000||tx|1|relation|5|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||monoamine oxidase inhibitors||||1000|113|140|VERB|ADMINISTERED_TO||103|111|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|94|101
SE|00000000||tx|1|relation|8|1|C0031436|Phenothiazines|orch,phsu|orch|||phenothiazines||||1000|172|185|VERB|CAUSES||191|197|2|1|C2678378|Hypotension, severe|fndg|fndg|||severe, prolonged hypotension||||901|199|227
SE|00000000||tx|1|relation|8|1|C0031436|Phenothiazines|orch,phsu|orch|||phenothiazines||||1000|172|185|VERB|CAUSES||191|197|2|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||1000|232|243


SE|00000000||tx|1|text|In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN.
SE|00000000||tx|1|entity|C0687676|Post|tmco|||post-||||851|4|8
SE|00000000||tx|1|entity|C0024826|Marketing|ocac|||marketing||||851|9|17
SE|00000000||tx|1|entity|C0596545|Experience|menp|||experience||||851|19|28
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|61|68
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|73|83
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|100|113
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|119|125


SE|00000000||tx|1|text|Orlistat-Orlistat may decrease the absorption of vitamin K.
SE|00000000||tx|1|entity|C0076275|orlistat|orch,phsu|||Orlistat||||694|1|8
SE|00000000||tx|1|entity|C0042878|Vitamin K|lipd,phsu,vita|||vitamin K||||1000|50|58


SE|00000000||tx|1|text|Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||Antidepressants||||1000|1|15
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic||||966|18|26
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||Amphetamines||||1000|29|40
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||1000|58|65
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic||||966|70|78
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetic agents||||1000|83|104
SE|00000000||tx|1|relation|3|1|C0002667|Amphetamines|nsba,orch,phsu|nsba|||Amphetamines||||1000|29|40|VERB|STIMULATES||46|52|3|2|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic||||966|70|78
SE|00000000||tx|1|relation|3|1|C0002667|Amphetamines|nsba,orch,phsu|nsba|||Amphetamines||||1000|29|40|VERB|STIMULATES||46|52|3|2|C0039052|Sympathomimetics|phsu|phsu|||sympathomimetic agents||||1000|83|104


SE|00000000||tx|1|text|Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||Lithium||||861|1|7
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|26|28
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|44|52
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||790|83|87
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||790|89|97
SE|00000000||tx|1|entity|C0205250|High|qlco|||high||||888|109|112
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|114|117
SE|00000000||tx|1|entity|C0238242|LITHIUM TOXICITY|inpo|||lithium toxicity||||1000|122|137
SE|00000000||tx|1|relation|4|1|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|44|52|VERB|COEXISTS_WITH||33|37|1|1|C0023870|Lithium|elii,phsu|elii|||Lithium||||861|1|7


SE|00000000||tx|1|text|If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.
SE|00000000||tx|1|entity|C1135136|Tarceva|orch,phsu|||TARCEVA||||888|8|14
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|16|19
SE|00000000||tx|1|entity|C1282911|Upward|spco|||upward||||1000|33|38
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|45|48
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuation||||1000|79|93
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampicin||||1000|98|107
SE|00000000||tx|1|relation|4|3|C1135136|Tarceva|orch,phsu|phsu|||TARCEVA||||888|8|14|VERB|INHIBITS||66|72|3|1|C1444662|Discontinued|fndg|fndg|||discontinuation||||1000|79|93


SE|00000000||tx|1|text|Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..
SE|00000000||tx|1|entity|C0681876|Population Study (research activity)|resa|||Population pharmacokinetic studies||||913|1|34
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||872|43|48
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||872|50|63
SE|00000000||tx|1|entity|C0055729|cilostazol|orch,phsu|||cilostazol||||1000|68|77
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|85|92
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|120|128
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||1000|134|142
SE|00000000||tx|1|relation|3|1|C0012373|Diltiazem|orch,phsu|phsu|||diltiazem||||1000|120|128|VERB|TREATS||107|113|4|1|C0030705|Patients|podg,humn|podg|||patients||||861|85|92


SE|00000000||tx|1|text|In vitro, propranolol appears to be displaced from its binding sites by diltiazem.
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||1000|11|21
SE|00000000||tx|1|entity|C0005456|Binding Sites|rcpt|||binding sites||||1000|56|68
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|73|81


SE|00000000||tx|1|text|Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||Indinavir||||1000|1|9
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||694|15|24
SE|00000000||tx|1|entity|C0006353|Buffers|irda,phsu|||buffer||||1000|50|55
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||764|83|87
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||764|89|91
SE|00000000||tx|1|entity|C0564385|/hour|qnco|||hour||||764|93|96
SE|00000000||tx|1|entity|C0038351|Stomach|bpoc|||stomach||||861|116|122
SE|00000000||tx|1|relation|1|1|C0038351|Stomach|bpoc|bpoc|||stomach||||861|116|122|PREP|LOCATION_OF||104|105|4|4|C0376637|Indinavir|orch,phsu|orch|||Indinavir||||1000|1|9


SE|00000000||tx|1|text|1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.
SE|00000000||tx|1|entity|C0242889|Adrenergic Antagonists|phsu|||adrenergic receptor antagonism||||883|4|33
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||1000|36|47
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||861|57|65
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|82|87
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||901|92|98
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensive agents||||901|100|122
SE|00000000||tx|1|relation|2|1|C0299792|aripiprazole|orch,phsu|orch|||aripiprazole||||1000|36|47|NOM|INTERACTS_WITH||82|87|1|1|C0003364|Antihypertensive Agents|phsu|phsu|||antihypertensive agents||||901|100|122


SE|00000000||tx|1|text|Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||Lithium||||861|1|7
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|26|28
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|44|52
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|78|82
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|84|92
SE|00000000||tx|1|entity|C0205250|High|qlco|||high||||888|104|107
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|109|112
SE|00000000||tx|1|entity|C0238242|LITHIUM TOXICITY|inpo|||lithium toxicity||||1000|117|132
SE|00000000||tx|1|relation|4|1|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|44|52|VERB|COEXISTS_WITH||33|37|1|1|C0023870|Lithium|elii,phsu|elii|||Lithium||||861|1|7


SE|00000000||tx|1|text|Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|27|37
SE|00000000||tx|1|entity|C0015837|Fenoprofen|orch,phsu|||fenoprofen||||1000|47|56
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|62|68
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|73|75
SE|00000000||tx|1|entity|C0014431|Enzyme Induction|genf|||enzyme induction||||1000|92|107
SE|00000000||tx|1|entity|C2347509|Physical Shift|phpr|||displacement||||1000|113|124
SE|00000000||tx|1|entity|C0015837|Fenoprofen|orch,phsu|||fenoprofen||||1000|129|138
SE|00000000||tx|1|entity|C1260311|Plasma Albumin|aapp,bacs|||plasma albumin||||888|145|158
SE|00000000||tx|1|entity|C0005456|Binding Sites|rcpt|||binding sites||||888|160|172


SE|00000000||tx|1|text|Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|33|57
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|70|74
SE|00000000||tx|1|entity|C0022173|Isoenzymes|aapp,enzy|||isoenzyme||||1000|105|113
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants||||1000|132|146
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|149|162
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|165|177
SE|00000000||tx|1|entity|||gngm|6445|SGCG|Type||||827|184|187
SE|00000000||tx|1|entity|C0003195|Anti-Arrhythmia Agents|phsu|||antiarrhythmics||||827|192|206
SE|00000000||tx|1|entity|C0033429|Propafenone|orch,phsu|||propafenone||||1000|213|223
SE|00000000||tx|1|entity|C0016229|Flecainide|orch,phsu|||flecainide||||1000|226|235
SE|00000000||tx|1|entity|C0085251|Encainide|orch,phsu|||encainide||||1000|242|250
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzyme||||1000|275|280
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|287|295
SE|00000000||tx|1|relation|13|1|C0022173|Isoenzymes|aapp,gngm,enzy|aapp|||isoenzyme||||1000|105|113|VERB|INTERACTS_WITH||85|95|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|70|74
SE|00000000||tx|1|relation|12|5|C0003195|Anti-Arrhythmia Agents|phsu|phsu|||antiarrhythmics||||827|192|206|VERB|INHIBITS||262|268|4|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme||||1000|275|280
SE|00000000||tx|1|relation|12|5|C0006949|Carbamazepine|orch,phsu|phsu|||carbamazepine||||1000|165|177|VERB|INHIBITS||262|268|4|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme||||1000|275|280
SE|00000000||tx|1|relation|12|5|C0031436|Phenothiazines|orch,phsu|phsu|||phenothiazines||||1000|149|162|VERB|INHIBITS||262|268|4|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme||||1000|275|280
SE|00000000||tx|1|relation|12|5|C0003289|Antidepressive Agents|phsu|phsu|||antidepressants||||1000|132|146|VERB|INHIBITS||262|268|4|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme||||1000|275|280


SE|00000000||tx|1|text|After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multiple||||694|7|14
SE|00000000||tx|1|entity|C0254119|Interferon beta-1a|aapp,imft,phsu|||interferon beta-1a||||1000|24|41
SE|00000000||tx|1|entity|C0594372|Avonex|aapp,imft,phsu|||AVONEX||||597|44|49
SE|00000000||tx|1|entity|C0439211|microgram|qnco|||mcg||||597|55|57
SE|00000000||tx|1|entity|C0558293|Once a week|tmco|||once weekly||||1000|62|72
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduced||||851|75|81
SE|00000000||tx|1|entity|C1529600|Tysabri|aapp,imft,phsu|||TYSABRI||||851|83|89
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||851|92|100
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|105|117


SE|00000000||tx|1|text|Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.
SE|00000000||tx|1|entity|C0444506|Trough|qnco|||trough||||775|10|15
SE|00000000||tx|1|entity|C0008845|Citalopram|orch,phsu|||citalopram||||775|17|26
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||775|28|33
SE|00000000||tx|1|entity|C2986417|Unaffected|cnce|||unaffected||||1000|47|56
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzyme||||851|69|74
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||inducing||||851|76|83
SE|00000000||tx|1|entity|C1292721|Has property|ftcn|||properties||||851|85|94
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|99|111
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|135|147
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|168|176
SE|00000000||tx|1|entity|C1099456|Escitalopram|orch,phsu|||escitalopram||||1000|181|192
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||888|222|224
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|226|230
SE|00000000||tx|1|relation|6|1|C0006949|Carbamazepine|orch,phsu|orch|||carbamazepine||||1000|135|147|VERB|STIMULATES||155|162|4|2|C1099456|Escitalopram|orch,phsu|orch|||escitalopram||||1000|181|192


SE|00000000||tx|1|text|The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|9|15
SE|00000000||tx|1|entity|C0054234|butalbital|orch,phsu|||butalbital||||1000|20|29
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase (MAO) inhibitors||||1000|50|83
SE|00000000||tx|1|relation|1|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||monoamine oxidase (MAO) inhibitors||||1000|50|83|VERB|STIMULATES||38|45|2|1|C0054234|butalbital|orch,phsu|orch|||butalbital||||1000|20|29


SE|00000000||tx|1|text|There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||861|16|22
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|27|34
SE|00000000||tx|1|entity|C0151539|Blood urea increased|fndg|||increased BUN||||1000|50|62
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||888|65|69
SE|00000000||tx|1|entity|C0010294|Creatinine|bacs,orch|||creatinine||||888|71|80
SE|00000000||tx|1|entity|C0543465|Serum Potassium result|lbtr|||serum potassium levels||||966|86|107
SE|00000000||tx|1|entity|C0043094|Weight Gain|fndg|||weight gain||||1000|114|124
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|131|140
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|171|176
SE|00000000||tx|1|relation|6|1|C0151539|Blood urea increased|fndg|fndg|||increased BUN||||1000|50|62|VERB|PROCESS_OF||40|48|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|27|34
SE|00000000||tx|1|relation|6|1|C0043094|Weight Gain|fndg|fndg|||weight gain||||1000|114|124|VERB|PROCESS_OF||40|48|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|27|34
SE|00000000||tx|1|relation|1|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|171|176|VERB|ADMINISTERED_TO||146|149|7|6|C0030705|Patients|podg,humn|humn|||patients||||1000|27|34


SE|00000000||tx|1|text|The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||888|5|13
SE|00000000||tx|1|entity|C1882442|Precaution|cnce|||precautions||||888|15|25
SE|00000000||tx|1|entity|C0229992|Psyche structure|menp|||mind||||1000|45|48
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|57|65
SE|00000000||tx|1|entity|C0008425|Cholinesterase Inhibitors|orch,phsu|||anticholinesterase||||888|70|87
SE|00000000||tx|1|entity|C0032343|Poisoning|inpo|||poisoning||||888|89|97
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|116|118
SE|00000000||tx|1|entity|C1947931|Direct (qualifier)|qlco|||directly||||1000|125|132
SE|00000000||tx|1|entity|C0004259|Atropine|orch,phsu|||atropine||||1000|148|155
SE|00000000||tx|1|entity|C0071808|pralidoxime|orch,phsu|||pralidoxime||||1000|161|171


SE|00000000||tx|1|text|Phenytoin: Serum phenytoin levels may be increased by aspirin.
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||1000|1|9
SE|00000000||tx|1|entity|C0236479|Serum phenytoin measurement|lbpr|||Serum phenytoin levels||||988|12|33
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|55|61
SE|00000000||tx|1|relation|1|1|C0004057|Aspirin|orch,phsu|orch|||aspirin||||1000|55|61|VERB|STIMULATES||42|50|2|2|C0031507|Phenytoin|orch,phsu|orch|||Phenytoin||||1000|1|9


SE|00000000||tx|1|text|Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
SE|00000000||tx|1|entity|C0242702|Dopamine Antagonists|nsba,phsu|||Dopamine Antagonists||||1000|1|20
SE|00000000||tx|1|entity|C0003596|Apomorphine|orch,phsu|||apomorphine||||1000|29|39
SE|00000000||tx|1|entity|C0178601|Dopamine Agonists|phsu|||dopamine agonist||||1000|46|61
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||1000|70|77
SE|00000000||tx|1|entity|C0242702|Dopamine Antagonists|nsba,phsu|||dopamine antagonists||||1000|84|103
SE|00000000||tx|1|entity|C0040615|Antipsychotic Agents|phsu|||neuroleptics||||1000|118|129
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|132|145
SE|00000000||tx|1|entity|C0006525|Butyrophenones|orch,phsu|||butyrophenones||||1000|148|161
SE|00000000||tx|1|entity|C0039961|Thioxanthenes|orch,phsu|||thioxanthenes||||1000|164|176
SE|00000000||tx|1|entity|C0025853|Metoclopramide|orch,phsu|||metoclopramide||||1000|182|195
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effectiveness||||1000|215|227
SE|00000000||tx|1|entity|C1589388|Apokyn|orch,phsu|||APOKYN||||1000|232|237
SE|00000000||tx|1|relation|0|0|C0003596|Apomorphine|orch,phsu|orch|||apomorphine||||1000|29|39|SPEC|ISA||29|61|0|0|C0178601|Dopamine Agonists|phsu|phsu|||dopamine agonist||||1000|46|61
SE|00000000||tx|1|relation|0|0|C0031436|Phenothiazines|orch,phsu|orch|||phenothiazines||||1000|132|145|SPEC|ISA||118|145|0|0|C0040615|Antipsychotic Agents|phsu|phsu|||neuroleptics||||1000|118|129
SE|00000000||tx|1|relation|0|0|C0006525|Butyrophenones|orch,phsu|orch|||butyrophenones||||1000|148|161|SPEC|ISA||118|145|0|0|C0040615|Antipsychotic Agents|phsu|phsu|||neuroleptics||||1000|118|129


SE|00000000||tx|1|text|Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.
SE|00000000||tx|1|entity|C0035410|Rhabdomyolysis|patf|||rhabdomyolysis||||861|11|24
SE|00000000||tx|1|entity|C1279919|Early|tmco|||early||||1000|43|47
SE|00000000||tx|1|entity|C0205449|Three|qnco|||three||||888|52|56
SE|00000000||tx|1|entity|C0439230|week|tmco|||weeks||||888|58|62
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|70|79
SE|00000000||tx|1|entity|C0033972|Psychotherapy, Multiple|topp|||combined therapy||||1000|84|99
SE|00000000||tx|1|entity|C1449704|Fibrates|orch,phsu|||fibrate||||966|114|120
SE|00000000||tx|1|entity|C0024027|Lovastatin|orch,phsu|||lovastatin||||1000|126|135
SE|00000000||tx|1|entity|C0443302|Several|qnco|||several||||888|159|165
SE|00000000||tx|1|entity|C0439231|month|tmco|||months||||888|167|172
SE|00000000||tx|1|relation|5|1|C0033972|Psychotherapy, Multiple|topp|topp|||combined therapy||||1000|84|99|PREP|USES||101|104|3|1|C1449704|Fibrates|orch,phsu|phsu|||fibrate||||966|114|120


SE|00000000||tx|1|text|Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||Benzodiazepines||||1000|1|15
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||Combination||||851|18|28
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||851|30|37
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||851|39|52
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|71|79
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|89|103
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|106|115
SE|00000000||tx|1|entity|C0008188|Chlordiazepoxide|orch,phsu|||chlordiazepoxide||||1000|118|133
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|136|143
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|163|171
SE|00000000||tx|1|entity|C1955473|Others|fndg|||others||||1000|176|181
SE|00000000||tx|1|entity|C0024002|Lorazepam|orch,phsu|||lorazepam||||1000|184|192
SE|00000000||tx|1|entity|C0029997|Oxazepam|orch,phsu|||oxazepam||||1000|195|202
SE|00000000||tx|1|entity|C0039468|Temazepam|orch,phsu|||temazepam||||1000|205|213
SE|00000000||tx|1|relation|0|0|C0002333|Alprazolam|orch,phsu|orch|||alprazolam||||1000|106|115|SPEC|ISA||89|115|0|0|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|89|103
SE|00000000||tx|1|relation|2|1|C0009871|Contraceptive Agents|phsu|phsu|||contraceptives||||851|39|52|VERB|INHIBITS||58|65|10|2|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|89|103
SE|00000000||tx|1|relation|7|7|C0005064|Benzodiazepines|orch,phsu|orch|||Benzodiazepines||||1000|1|15|VERB|AUGMENTS||150|157|5|2|C1955473|Others|fndg|fndg|||others||||1000|176|181
SE|00000000||tx|1|relation|0|0|C0009871|Contraceptive Agents|phsu|phsu|||contraceptives||||851|39|52|INFER|INHIBITS(SPEC)||89|115|0|0|C0002333|Alprazolam|orch,phsu|orch|||alprazolam||||1000|106|115


SE|00000000||tx|1|text|In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.
SE|00000000||tx|1|entity|C1882348|Permutation|qlco|||order||||861|4|8
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||694|22|30
SE|00000000||tx|1|entity|C0877248|Adverse event|fndg|||adverse experiences||||983|46|64
SE|00000000||tx|1|entity|C1148284|Felbamate:Mass:Point in time:Dose med or substance:Quantitative|clna|||felbamate dose||||1000|83|96
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|106|111
SE|00000000||tx|1|entity|C0366626|Phenytoin:Mass:Point in time:Dose med or substance:Quantitative|clna|||phenytoin dose||||901|116|129
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||901|131|139
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||888|144|156
SE|00000000||tx|1|entity|C0439509|/40|tmco|||40%||||888|158|160
SE|00000000||tx|1|entity|C0205454|Eight|qnco|||eight||||1000|180|184
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||827|198|205


SE|00000000||tx|1|text|Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.
SE|00000000||tx|1|entity|C0591174|Betagan|orch,phsu|||BETAGAN||||1000|10|16
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|23|27
SE|00000000||tx|1|entity|C0700321|Small|qnco|||little||||1000|33|38
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|46|51
SE|00000000||tx|1|entity|C0034121|Pupil|bpoc|||pupil||||888|56|60
SE|00000000||tx|1|entity|C0456389|size|spco|||size||||888|62|65
SE|00000000||tx|1|entity|C0026961|Mydriasis|sosy|||mydriasis||||1000|68|76
SE|00000000||tx|1|entity|C1707479|Concomitant Therapy|topp|||concomitant therapy||||1000|93|111
SE|00000000||tx|1|entity|C0591174|Betagan|orch,phsu|||BETAGAN||||1000|118|124
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||epinephrine||||1000|130|140
SE|00000000||tx|1|relation|7|1|C1707479|Concomitant Therapy|topp|topp|||concomitant therapy||||1000|93|111|PREP|USES||113|116|2|1|C0591174|Betagan|orch,phsu|phsu|||BETAGAN||||1000|118|124


SE|00000000||tx|1|text|Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||Paroxetine||||1000|1|10
SE|00000000||tx|1|entity|C0245561|duloxetine|orch,phsu|||duloxetine||||1000|54|63
SE|00000000||tx|1|entity|C0443228|Largest|qnco|||greater||||888|94|100
SE|00000000||tx|1|entity|C0449286|Degree or extent|qnco|||degrees||||888|102|108
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|113|122
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||higher doses||||966|142|153
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||paroxetine||||1000|158|167
SE|00000000||tx|1|relation|2|2|C0070122|Paroxetine|orch,phsu|orch|||Paroxetine||||1000|1|10|VERB|STIMULATES||23|31|7|2|C0245561|duloxetine|orch,phsu|orch|||duloxetine||||1000|54|63


SE|00000000||tx|1|text|Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||Alcohol||||1000|1|7
SE|00000000||tx|1|entity|C2986495|Synergistic|qlco|||synergistic||||888|16|26
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|28|33
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|40|46
SE|00000000||tx|1|entity|C0678227|Causing|ftcn|||causing||||901|51|57
SE|00000000||tx|1|entity|C0017181|Gastrointestinal Hemorrhage|patf|||gastrointestinal bleeding||||901|59|83
SE|00000000||tx|1|relation|2|1|C0004057|Aspirin|orch,phsu|orch|||aspirin||||1000|40|46|NOM|AFFECTS||28|33|2|2|C0017181|Gastrointestinal Hemorrhage|patf|patf|||gastrointestinal bleeding||||901|59|83


SE|00000000||tx|1|text|Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving terfenadine concomitantly with other macrolide antibiotics.
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||Serious||||901|1|7
SE|00000000||tx|1|entity|C0003811|Cardiac Arrhythmia|patf|||cardiac dysrhythmias||||901|9|28
SE|00000000||tx|1|entity|C0011065|Cessation of life|orgf|||death||||1000|49|53
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|73|80
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||861|92|102
SE|00000000||tx|1|entity|C0003240|Macrolide Antibiotics|antb,orch|||macrolide antibiotics||||1000|129|149
SE|00000000||tx|1|relation|1|1|C0003811|Cardiac Arrhythmia|patf|patf|||cardiac dysrhythmias||||901|9|28|VERB|CAUSES||36|44|4|1|C0011065|Cessation of life|orgf|orgf|||death||||1000|49|53
SE|00000000||tx|1|relation|2|1|C0085173|Terfenadine|orch,phsu|orch|||terfenadine||||861|92|102|VERB|ADMINISTERED_TO||82|90|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|73|80


SE|00000000||tx|1|text|Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||Interactions||||966|1|12
SE|00000000||tx|1|entity|C0028027|Niacinamide|orch,phsu,vita|||Vitamin B3||||1000|18|27
SE|00000000||tx|1|entity|C0027996|Niacin|orch,phsu,vita|||Niacin||||1000|30|35
SE|00000000||tx|1|entity|C0585941|Antihypertensive therapy|topp|||Antihypertensive Therapy||||1000|39|62
SE|00000000||tx|1|entity|C0027996|Niacin|orch,phsu,vita|||Nicotinic acid||||1000|65|78
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|99|105
SE|00000000||tx|1|entity|C2267059|Autonomic Ganglionic Blockers [EPC]|phsu|||ganglionic blocking agents||||1000|110|135
SE|00000000||tx|1|entity|C1980011|Vasoactive|qlco|||vasoactive||||888|141|150
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|152|156
SE|00000000||tx|1|entity|C0020651|Hypotension, Orthostatic|fndg|||postural hypotension||||1000|171|190
SE|00000000||tx|1|relation|0|0|C0028027|Niacinamide|orch,phsu,vita|orch|||Vitamin B3||||1000|18|27|SPEC|ISA||18|35|0|0|C0027996|Niacin|orch,phsu,vita|orch|||Niacin||||1000|30|35
SE|00000000||tx|1|relation|8|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|152|156|VERB|CAUSES||158|166|1|1|C0020651|Hypotension, Orthostatic|fndg|fndg|||postural hypotension||||1000|171|190


SE|00000000||tx|1|text|Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||Diuretic||||872|1|8
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||872|10|15
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|28|32
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|34|42
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|47|53
SE|00000000||tx|1|entity|C0205250|High|qlco|||high||||888|65|68
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|70|73
SE|00000000||tx|1|entity|C0238242|LITHIUM TOXICITY|inpo|||lithium toxicity||||1000|78|93
SE|00000000||tx|1|relation|0|0|C0012798|Diuretics|phsu|phsu|||Diuretic||||872|1|8|MOD/HEAD|ISA||1|15|0|0|C1254351|Pharmacologic Substance|phsu|phsu|||agents||||872|10|15
SE|00000000||tx|1|relation|1|1|C1254351|Pharmacologic Substance|phsu|phsu|||agents||||872|10|15|VERB|INHIBITS||17|22|4|2|C0023870|Lithium|elii,phsu|elii|||lithium||||1000|47|53
SE|00000000||tx|1|relation|0|0|C0012798|Diuretics|phsu|phsu|||Diuretic||||872|1|8|INFER|INHIBITS(SPEC)||1|15|0|0|C0023870|Lithium|elii,phsu|elii|||lithium||||1000|47|53


SE|00000000||tx|1|text|Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
SE|00000000||tx|1|entity|C0027396|Naproxen|orch,phsu|||Naproxen||||1000|1|8
SE|00000000||tx|1|entity|C0546873|Naproxen sodium|orch,phsu|||naproxen sodium||||1000|11|25
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|37|42
SE|00000000||tx|1|entity|C0232819|Tubular secretion|ortf|||tubular secretion||||1000|77|93
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|98|109
SE|00000000||tx|1|entity|C0599779|Animal Model|anim|||animal model||||1000|117|128
SE|00000000||tx|1|entity|C2362652|Possible diagnosis|qlco|||possibly||||1000|131|138
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|155|162
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|167|178
SE|00000000||tx|1|relation|0|0|C0546873|Naproxen sodium|orch,phsu|orch|||naproxen sodium||||1000|11|25|SPEC|ISA||11|42|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|37|42
SE|00000000||tx|1|relation|0|0|C0546873|Naproxen sodium|orch,phsu|orch|||naproxen sodium||||1000|11|25|SPEC|ISA||11|42|0|0|C0027396|Naproxen|orch,phsu|phsu|||Naproxen||||1000|1|8
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|37|42|SPEC|ISA||11|42|0|0|C0546873|Naproxen sodium|orch,phsu|phsu|||naproxen sodium||||1000|11|25
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|37|42|SPEC|ISA||11|42|0|0|C0027396|Naproxen|orch,phsu|phsu|||Naproxen||||1000|1|8
SE|00000000||tx|1|relation|0|0|C0027396|Naproxen|orch,phsu|orch|||Naproxen||||1000|1|8|SPEC|ISA||11|42|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|37|42
SE|00000000||tx|1|relation|0|0|C0027396|Naproxen|orch,phsu|orch|||Naproxen||||1000|1|8|SPEC|ISA||11|42|0|0|C0546873|Naproxen sodium|orch,phsu|phsu|||naproxen sodium||||1000|11|25
SE|00000000||tx|1|relation|3|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|37|42|VERB|INHIBITS||66|71|5|1|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|77|93
SE|00000000||tx|1|relation|3|1|C0546873|Naproxen sodium|orch,phsu|phsu|||naproxen sodium||||1000|11|25|VERB|INHIBITS||66|71|5|1|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|77|93
SE|00000000||tx|1|relation|3|1|C0027396|Naproxen|orch,phsu|phsu|||Naproxen||||1000|1|8|VERB|INHIBITS||66|71|5|1|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|77|93
SE|00000000||tx|1|relation|5|2|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|77|93|PREP|PROCESS_OF||111|112|3|1|C0599779|Animal Model|anim|anim|||animal model||||1000|117|128
SE|00000000||tx|1|relation|0|0|C0546873|Naproxen sodium|orch,phsu|orch|||naproxen sodium||||1000|11|25|INFER|INHIBITS(SPEC)||11|42|0|0|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|77|93
SE|00000000||tx|1|relation|0|0|C0546873|Naproxen sodium|orch,phsu|orch|||naproxen sodium||||1000|11|25|INFER|INHIBITS(SPEC)||11|42|0|0|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|77|93
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|37|42|INFER|INHIBITS(SPEC)||11|42|0|0|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|77|93
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|37|42|INFER|INHIBITS(SPEC)||11|42|0|0|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|77|93
SE|00000000||tx|1|relation|0|0|C0027396|Naproxen|orch,phsu|orch|||Naproxen||||1000|1|8|INFER|INHIBITS(SPEC)||11|42|0|0|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|77|93
SE|00000000||tx|1|relation|0|0|C0027396|Naproxen|orch,phsu|orch|||Naproxen||||1000|1|8|INFER|INHIBITS(SPEC)||11|42|0|0|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|77|93


SE|00000000||tx|1|text|Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.
SE|00000000||tx|1|entity|C0814472|co-treatment|hlca|||Co-treatment||||1000|1|12
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||742|23|28
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||742|30|35
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||742|37|45
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||742|47|58
SE|00000000||tx|1|entity|C1135135|erlotinib|orch,phsu|||erlotinib||||888|70|78
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|80|82
SE|00000000||tx|1|entity|C1519042|Phase II/III Trial|resa|||2/3||||1000|87|89
SE|00000000||tx|1|relation|1|1|C0814472|co-treatment|hlca|hlca|||Co-treatment||||1000|1|12|PREP|USES||14|17|2|1|C0022625|Ketoconazole|orch,phsu|phsu|||ketoconazole||||742|47|58


SE|00000000||tx|1|text|Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|39|47
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induction||||1000|61|69
SE|00000000||tx|1|entity|C2603361|P prime|clna|||P-450IIE1||||694|74|82
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|91|98
SE|00000000||tx|1|entity|C0023884|Liver|bpoc|||liver||||888|100|104
SE|00000000||tx|1|entity|C0443228|Largest|qnco|||greater||||888|136|142
SE|00000000||tx|1|entity|C1709707|Proportion|qnco|||proportion||||888|144|153
SE|00000000||tx|1|entity|C0232478|Ingestion|biof|||ingested||||888|162|169
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||888|171|183
SE|00000000||tx|1|entity|C1407029|Toxic|qlco|||toxic||||888|208|212
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolites||||888|214|224
SE|00000000||tx|1|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver||||888|100|104|MOD/HEAD|PART_OF||91|104|0|0|C0030705|Patients|podg,humn|humn|||patients||||888|91|98
SE|00000000||tx|1|relation|4|1|C0023884|Liver|bpoc|bpoc|||liver||||888|100|104|PREP|LOCATION_OF||84|85|3|3|C0022209|isoniazid|orch,phsu|orch|||isoniazid||||1000|39|47


SE|00000000||tx|1|text|Caution should be used when NSAIDs are administered concomitantly with methotrexate.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|29|34
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|72|83


SE|00000000||tx|1|text|Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||Cyclosporin||||1000|1|11
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||Reports||||1000|14|20
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||694|36|47
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|80|90
SE|00000000||tx|1|entity|C0278766|Allopurinol Sodium|orch,phsu|||allopurinol sodium||||1000|107|124
SE|00000000||tx|1|entity|C1533685|Injection procedure|topp|||injection||||1000|130|138
SE|00000000||tx|1|relation|1|1|C1533685|Injection procedure|topp|topp|||injection||||1000|130|138|PREP|USES||126|128|5|1|C0278766|Allopurinol Sodium|orch,phsu|phsu|||allopurinol sodium||||1000|107|124


SE|00000000||tx|1|text|However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|13|20
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||916|35|38
SE|00000000||tx|1|entity|C0007036|Carbonic Anhydrase Inhibitors|phsu|||carbonic anhydrase inhibitors||||916|40|68
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||rare||||872|71|74
SE|00000000||tx|1|entity|C1550608|Instance|idcn|||instances||||872|76|84
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interactions||||1000|89|105
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high-dose||||861|126|134
SE|00000000||tx|1|entity|C0036075|salicylate|orch,phsu|||salicylate||||861|136|145
SE|00000000||tx|1|relation|4|1|C0007036|Carbonic Anhydrase Inhibitors|phsu|phsu|||carbonic anhydrase inhibitors||||916|40|68|VERB|TREATS||22|28|1|1|C0030705|Patients|podg,humn|podg|||patients||||1000|13|20


SE|00000000||tx|1|text|Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||valproate||||901|8|16
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||Plasma valproate concentration||||901|1|30
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|57|65
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||valproate||||1000|71|79
SE|00000000||tx|1|entity|C1548787|Appropriate|qlco|||appropriate||||851|106|116
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||851|118|123
SE|00000000||tx|1|entity|C0456081|Adjustment Action|ftcn|||adjustments||||851|125|135
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||valproate||||1000|140|148


SE|00000000||tx|1|text|Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||Quinolones||||1000|1|10
SE|00000000||tx|1|entity|C0008806|Cinoxacin|orch,phsu|||cinoxacin||||1000|23|31
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|50|56
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulants||||1000|61|79
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|90|97
SE|00000000||tx|1|entity|C0243072|derivatives|chvs|||derivatives||||1000|106|116
SE|00000000||tx|1|relation|2|1|C0008806|Cinoxacin|orch,phsu|orch|||cinoxacin||||1000|23|31|NOM|INTERACTS_WITH||50|56|3|1|C0354604|Anticoagulants, Oral|orch,phsu|orch|||oral anticoagulants||||1000|61|79
SE|00000000||tx|1|relation|2|1|C0008806|Cinoxacin|orch,phsu|orch|||cinoxacin||||1000|23|31|NOM|INTERACTS_WITH||50|56|3|1|C0243072|derivatives|chvs|chvs|||derivatives||||1000|106|116
SE|00000000||tx|1|relation|2|1|C0008806|Cinoxacin|orch,phsu|orch|||cinoxacin||||1000|23|31|NOM|INTERACTS_WITH||50|56|3|1|C0043031|Warfarin|hops,orch,phsu|orch|||warfarin||||1000|90|97


SE|00000000||tx|1|text|A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;
SE|00000000||tx|1|entity|C0237753|Numbers|qnco|||number||||1000|3|8
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|13|17
SE|00000000||tx|1|entity|C0014963|Ethacrynic Acid|orch,phsu|||ethacrynic acid||||1000|30|44
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|75|82
SE|00000000||tx|1|entity|C0032120|Plasma Proteins|aapp,bacs|||plasma protein||||1000|89|102


SE|00000000||tx|1|text|In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|4|11
SE|00000000||tx|1|entity|C0020261|Hydrochlorothiazide|orch,phsu|||HCTZ||||833|23|26
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||833|28|32
SE|00000000||tx|1|entity|C0114771|dofetilide|orch,phsu|||dofetilide||||833|35|44
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||833|46|48
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|71|74


SE|00000000||tx|1|text|The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
SE|00000000||tx|1|entity|C2348070|Daily Dose|qnco|||daily dose||||1000|5|14
SE|00000000||tx|1|entity|C1310721|Enablex|orch,phsu|||ENABLEX||||1000|19|25
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|34|36
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||752|77|82
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||752|84|89
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||752|91|100
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|109|120
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|123|134
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|137|145
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||nelfinavir||||1000|148|157
SE|00000000||tx|1|entity|C0055856|Clarithromycin|antb,orch|||clarithromycin||||1000|160|173
SE|00000000||tx|1|relation|3|2|C1310721|Enablex|orch,phsu|orch|||ENABLEX||||1000|19|25|NOM|INHIBITS||91|100|3|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||752|84|89


SE|00000000||tx|1|text|Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0042397|Vasoconstrictor Agents|phsu|||vasopressor||||888|30|40
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|42|46
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|57|65
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||1000|70|80
SE|00000000||tx|1|entity|C0205484|Obstetrical|ftcn|||obstetric||||888|93|101
SE|00000000||tx|1|entity|C0028778|Obstruction|patf|||blocks||||888|103|108
SE|00000000||tx|1|entity|C0030094|Oxytocics|phsu|||oxytocic drugs||||861|126|139
SE|00000000||tx|1|entity|C0205322|Persistent|tmco|||persistent||||790|159|168
SE|00000000||tx|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||790|170|181
SE|00000000||tx|1|entity|C0038454|Cerebrovascular accident|dsyn|||cerebrovascular accidents||||1000|186|210
SE|00000000||tx|1|relation|0|0|C0042397|Vasoconstrictor Agents|phsu|phsu|||vasopressor||||888|30|40|MOD/HEAD|ISA||30|46|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|42|46
SE|00000000||tx|1|relation|2|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|42|46|NOM|TREATS||57|65|5|1|C0020649|Hypotension|fndg|fndg|||hypotension||||1000|70|80
SE|00000000||tx|1|relation|6|1|C0030094|Oxytocics|phsu|phsu|||oxytocic drugs||||861|126|139|VERB|CAUSES||145|149|2|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||790|170|181
SE|00000000||tx|1|relation|6|1|C0030094|Oxytocics|phsu|phsu|||oxytocic drugs||||861|126|139|VERB|CAUSES||145|149|2|1|C0038454|Cerebrovascular accident|dsyn|dsyn|||cerebrovascular accidents||||1000|186|210
SE|00000000||tx|1|relation|0|0|C0042397|Vasoconstrictor Agents|phsu|phsu|||vasopressor||||888|30|40|INFER|TREATS(SPEC)||30|46|0|0|C0020649|Hypotension|fndg|fndg|||hypotension||||1000|70|80


SE|00000000||tx|1|text|Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||Inhibitors||||1000|1|10
SE|00000000||tx|1|entity|C1332830|CYP2D6 gene|gngm|1565|CYP2D6|CYP2D6||||1000|29|34
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|43|51
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||selective serotonin reuptake inhibitors||||1000|54|92
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRIs||||1000|95|99
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||1000|120|139
SE|00000000||tx|1|entity|C0013085|Doxepin|orch,phsu|||doxepin||||1000|144|150
SE|00000000||tx|1|relation|7|5|C1332830|CYP2D6 gene|gngm,aapp|gngm|1565|CYP2D6|CYP2D6||||1000|29|34|VERB|STIMULATES||107|114|2|2|C0013085|Doxepin|orch,phsu|orch|||doxepin||||1000|144|150


SE|00000000||tx|1|text|The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|12|19
SE|00000000||tx|1|entity|C0019593|Histamine H2 Antagonists|phsu|||H2 blockers||||1000|54|64
SE|00000000||tx|1|entity|C0358591|Proton Pump Inhibitors|phsu|||proton pump inhibitors||||1000|69|90
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|95|102
SE|00000000||tx|1|entity|C1723829|Sprycel|orch,phsu|||SPRYCEL||||888|114|120
SE|00000000||tx|1|relation|4|1|C0358591|Proton Pump Inhibitors|phsu|phsu|||proton pump inhibitors||||1000|69|90|PREP|TREATS||92|93|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|95|102


SE|00000000||tx|1|text|Therefore, 4 to 5 hours should elapse between administration of cholestyramine and thyroid hormones.
SE|00000000||tx|1|entity|C1442467|5 Hours|tmco|||5 hours||||1000|17|23
SE|00000000||tx|1|entity|C0040135|Thyroid Hormones|aapp,horm|||thyroid hormones||||1000|84|99


SE|00000000||tx|1|text|Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|23|27
SE|00000000||tx|1|entity|C0205160|Negative|qlco|||negative||||802|34|41
SE|00000000||tx|1|entity|C1292721|Has property|ftcn|||properties||||802|53|62
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|72|78
SE|00000000||tx|1|entity|C0592158|Tambocor|orch,phsu|||TAMBOCOR||||1000|105|112
SE|00000000||tx|1|entity|C0439673|Unknown|qlco|||unknown||||1000|118|124
SE|00000000||tx|1|entity|C0012702|Disopyramide|orch,phsu|||disopyramide||||802|135|146
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||802|152|160
SE|00000000||tx|1|entity|C0592158|Tambocor|orch,phsu|||TAMBOCOR||||1000|203|210
SE|00000000||tx|1|entity|C0022423|Judgment|menp|||judgment||||1000|227|234
SE|00000000||tx|1|entity|C0804815|Physician:Identifier:Point in time:^Patient:Nominal|clna|||physician||||1000|243|251
SE|00000000||tx|1|entity|C0814225|Benefits|qnco|||benefits||||1000|258|265
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|275|285
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risks||||1000|300|304


SE|00000000||tx|1|text|Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0000946|Acebutolol|orch,phsu|||acebutolol||||597|23|32
SE|00000000||tx|1|entity|C0007412|Catecholamines|nsba,orch,phsu|||catecholamine||||597|39|51
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||marked||||888|118|123
SE|00000000||tx|1|entity|C0428977|Bradycardia|patf|||bradycardia||||888|125|135
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||1000|140|150
SE|00000000||tx|1|entity|C0042571|Vertigo|sosy|||vertigo||||1000|173|179
SE|00000000||tx|1|entity|C0039070|Syncope|sosy|||syncope||||888|182|188
SE|00000000||tx|1|entity|C0700200|Presyncope|sosy|||presyncope||||888|190|199
SE|00000000||tx|1|entity|C0231472|Standing position|phsf|||orthostatic||||888|205|215
SE|00000000||tx|1|entity|C0392747|Changing|ftcn|||changes||||888|217|223
SE|00000000||tx|1|entity|C0005823|Blood Pressure|orgf|||blood pressure||||1000|228|241
SE|00000000||tx|1|entity|C0231186|Compensatory|ftcn|||compensatory||||888|251|262
SE|00000000||tx|1|entity|C0039231|Tachycardia|fndg|||tachycardia||||888|264|274
SE|00000000||tx|1|relation|5|1|C0042571|Vertigo|sosy|sosy|||vertigo||||1000|173|179|VERB|MANIFESTATION_OF||162|168|5|2|C0428977|Bradycardia|patf|patf|||bradycardia||||888|125|135
SE|00000000||tx|1|relation|5|1|C0700200|Presyncope|sosy|sosy|||presyncope||||888|190|199|VERB|MANIFESTATION_OF||162|168|5|2|C0428977|Bradycardia|patf|patf|||bradycardia||||888|125|135


SE|00000000||tx|1|text|Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
SE|00000000||tx|1|entity|C0054234|butalbital|orch,phsu|||Butalbital||||1000|1|10
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|13|25
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|31|38
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|56|62
SE|00000000||tx|1|entity|C0027409|Narcotic Analgesics|phsu|||narcotic analgesics||||1000|74|92
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|95|101
SE|00000000||tx|1|entity|C0017302|General anesthetic drugs|phsu|||general anesthetics||||1000|104|122
SE|00000000||tx|1|entity|C0040614|Tranquilizing Agents|phsu|||tranquilizers||||1000|125|137
SE|00000000||tx|1|entity|C0008188|Chlordiazepoxide|orch,phsu|||chlordiazepoxide||||1000|147|162
SE|00000000||tx|1|entity|C0020592|Hypnotics and Sedatives|phsu|||sedative-hypnotics||||1000|165|182
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||1000|194|208
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||901|219|227
SE|00000000||tx|1|entity|C0151559|Central nervous system depression (disorder)|dsyn|||CNS depression||||901|229|242
SE|00000000||tx|1|relation|0|0|C0008188|Chlordiazepoxide|orch,phsu|orch|||chlordiazepoxide||||1000|147|162|SPEC|ISA||125|162|0|0|C0040614|Tranquilizing Agents|phsu|phsu|||tranquilizers||||1000|125|137
SE|00000000||tx|1|relation|0|0|C0008188|Chlordiazepoxide|orch,phsu|orch|||chlordiazepoxide||||1000|147|162|SPEC|ISA||147|182|0|0|C0020592|Hypnotics and Sedatives|phsu|phsu|||sedative-hypnotics||||1000|165|182
SE|00000000||tx|1|relation|0|0|C0020592|Hypnotics and Sedatives|phsu|phsu|||sedative-hypnotics||||1000|165|182|SPEC|ISA||165|208|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|194|208
SE|00000000||tx|1|relation|11|1|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|194|208|VERB|CAUSES||211|217|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||901|229|242
SE|00000000||tx|1|relation|0|0|C0020592|Hypnotics and Sedatives|phsu|phsu|||sedative-hypnotics||||1000|165|182|INFER|CAUSES(SPEC)||165|208|0|0|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||901|229|242


SE|00000000||tx|1|text|The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.
SE|00000000||tx|1|entity|C0306166|Factrel|aapp,horm,phsu|||Factrel||||1000|17|23
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|43|56
SE|00000000||tx|1|entity|C0242702|Dopamine Antagonists|nsba,phsu|||dopamine antagonists||||1000|62|81
SE|00000000||tx|1|entity|C0033371|Prolactin|aapp,horm,phsu|||prolactin||||1000|105|113
SE|00000000||tx|1|relation|5|2|C0242702|Dopamine Antagonists|nsba,phsu|nsba|||dopamine antagonists||||1000|62|81|PREP|COEXISTS_WITH||102|103|1|1|C0033371|Prolactin|aapp,gngm,horm,phsu|aapp|||prolactin||||1000|105|113
SE|00000000||tx|1|relation|5|2|C0031436|Phenothiazines|orch,phsu|orch|||phenothiazines||||1000|43|56|PREP|COEXISTS_WITH||102|103|1|1|C0033371|Prolactin|aapp,gngm,horm,phsu|aapp|||prolactin||||1000|105|113


SE|00000000||tx|1|text|Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.
SE|00000000||tx|1|entity|C0205191|chronic|tmco|||Chronic||||888|1|7
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|27|39
SE|00000000||tx|1|entity|C0205309|Known|qlco|||known||||623|44|48
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzyme||||623|50|55
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|91|98
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||901|107|112
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||901|114|122
SE|00000000||tx|1|entity|C0015837|Fenoprofen|orch,phsu|||fenoprofen||||1000|127|136


SE|00000000||tx|1|text|Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;
SE|00000000||tx|1|entity|C0018242|Griseofulvin|orch,phsu|||Griseofulvin||||1000|1|12
SE|00000000||tx|1|entity|C0018242|Griseofulvin|orch,phsu|||Griseofulvin||||1000|15|26
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|43|52
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||851|57|67
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||851|69|76
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||851|78|91
SE|00000000||tx|1|entity|C0025344|Menstruation|orgf|||menstrual||||888|101|109
SE|00000000||tx|1|entity|C0392747|Changing|ftcn|||changes||||888|111|117
SE|00000000||tx|1|relation|2|1|C0018242|Griseofulvin|orch,phsu|orch|||Griseofulvin||||1000|15|26|VERB|STIMULATES||32|37|3|2|C0009871|Contraceptive Agents|phsu|phsu|||contraceptives||||851|78|91


SE|00000000||tx|1|text|Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin.
SE|00000000||tx|1|entity|C0587267|Closed|ftcn|||close||||694|12|16
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|32|47
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulant||||901|86|98
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||901|100|103
SE|00000000||tx|1|entity|C0306139|Eulexin Capsules|clnd|||EULEXIN Capsules||||1000|127|142
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|180|187
SE|00000000||tx|1|relation|6|5|C0033707|Prothrombin time assay|lbpr|lbpr|||prothrombin time||||1000|32|47|PREP|USES||175|178|1|1|C0043031|Warfarin|hops,orch,phsu|phsu|||warfarin||||1000|180|187


SE|00000000||tx|1|text|Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||Serum concentration||||1000|1|19
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|24|30
SE|00000000||tx|1|entity|C0012258|Digitoxin|carb,phsu,strd|||digitoxin||||1000|36|44
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|64|71
SE|00000000||tx|1|entity|C0040125|Antithyroid Agents|horm,phsu|||antithyroid agents||||1000|78|95
SE|00000000||tx|1|relation|1|1|C0040125|Antithyroid Agents|horm,phsu|horm|||antithyroid agents||||1000|78|95|VERB|ADMINISTERED_TO||73|76|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|64|71


SE|00000000||tx|1|text|Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||Hypotension||||1000|1|11
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|14|21
SE|00000000||tx|1|entity|C0948575|diuretic therapy|topp|||Diuretic Therapy||||1000|26|41
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|44|51
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|56|64
SE|00000000||tx|1|entity|C0948575|diuretic therapy|topp|||diuretic therapy||||1000|95|110
SE|00000000||tx|1|entity|C0332185|Recent|tmco|||recently||||1000|116|123
SE|00000000||tx|1|entity|C0442802|Excessive|qlco|||excessive||||888|168|176
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||888|178|186
SE|00000000||tx|1|entity|C0005823|Blood Pressure|orgf|||blood pressure||||1000|191|204
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|212|221
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|226|232
SE|00000000||tx|1|entity|C0014025|Enalapril|aapp,phsu|||enalapril||||1000|239|247
SE|00000000||tx|1|entity|C0014027|Enalaprilat|aapp,phsu|||enalaprilat||||1000|252|262
SE|00000000||tx|1|relation|5|4|C0014025|Enalapril|aapp,gngm,phsu|aapp|||enalapril||||1000|239|247|NOM|DISRUPTS||178|186|5|1|C0005823|Blood Pressure|orgf|orgf|||blood pressure||||1000|191|204
SE|00000000||tx|1|relation|5|4|C0014027|Enalaprilat|aapp,gngm,phsu|aapp|||enalaprilat||||1000|252|262|NOM|DISRUPTS||178|186|5|1|C0005823|Blood Pressure|orgf|orgf|||blood pressure||||1000|191|204


SE|00000000||tx|1|text|A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.
SE|00000000||tx|1|entity|C0201734|Pharmacokinetic study|resa|||pharmacokinetic study||||1000|3|23
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|60|65
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|67|70
SE|00000000||tx|1|entity|C1144054|Inspra|phsu,strd|||INSPRA||||802|75|80
SE|00000000||tx|1|entity|C0992485|Ketoconazole 200 MG|clnd|||ketoconazole 200 mg||||908|94|112
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||908|114|116
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||838|121|126
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||838|128|136
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|145|150
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||794|174|177
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||794|179|186
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|191|194
SE|00000000||tx|1|entity|C0961485|eplerenone|phsu,strd|||eplerenone||||1000|199|208
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||775|220|223
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||775|225|232
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|237|239
SE|00000000||tx|1|entity|C0961485|eplerenone|phsu,strd|||eplerenone||||1000|244|253
SE|00000000||tx|1|relation|5|1|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|orch|||BID||||908|114|116|NOM|INHIBITS||128|136|7|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|145|150


SE|00000000||tx|1|text|Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||Lithium||||1000|1|7
SE|00000000||tx|1|entity|C0020740|Ibuprofen|orch,phsu|||Ibuprofen||||1000|10|18
SE|00000000||tx|1|entity|C0702240|Elevation|spco|||elevation||||1000|32|40
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||623|45|50
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||623|52|58
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|73|81
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||851|86|90
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||851|92|98
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||851|100|108
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|115|119
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||790|131|136
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||790|138|147
SE|00000000||tx|1|relation|0|0|C0023870|Lithium|elii,phsu|elii|||lithium||||851|92|98|MOD/HEAD|PART_OF||86|98|0|0|C0022646|Kidney|bpoc|bpoc|||renal||||851|86|90
SE|00000000||tx|1|relation|5|2|C0023870|Lithium|elii,phsu|elii|||lithium||||623|52|58|PREP|COEXISTS_WITH||83|84|3|1|C0023870|Lithium|elii,phsu|elii|||lithium||||851|92|98


SE|00000000||tx|1|text|Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|1|10
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|26|28
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||midazolam||||1000|33|41
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|53|55
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|77|79
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||midazolam||||1000|84|92
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||802|104|106
SE|00000000||tx|1|entity|C1547039|*Relative|qnco|||relative||||802|110|117
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|136|145
SE|00000000||tx|1|entity|C0439228|day|tmco|||Days||||861|150|153


SE|00000000||tx|1|text|Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||1000|1|9
SE|00000000||tx|1|entity|C0687676|Post|tmco|||post-||||851|15|19
SE|00000000||tx|1|entity|C0024826|Marketing|ocac|||marketing||||851|20|28
SE|00000000||tx|1|entity|C0596545|Experience|menp|||experience||||851|30|39
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|58|64
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||1000|74|82
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||694|101|109
SE|00000000||tx|1|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||802|123|135
SE|00000000||tx|1|entity|C1515926|Alteration|idcn|||alterations||||966|167|177
SE|00000000||tx|1|entity|C0036572|Seizures|sosy|||seizure||||861|182|188
SE|00000000||tx|1|relation|4|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||694|101|109|VERB|INHIBITS||88|96|4|4|C0031507|Phenytoin|orch,phsu|orch|||Phenytoin||||1000|1|9


SE|00000000||tx|1|text|Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|13|15
SE|00000000||tx|1|entity|C1723829|Sprycel|orch,phsu|||SPRYCEL||||1000|20|26
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|32|36
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|51|56
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|63|74
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|77|88
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|91|102
SE|00000000||tx|1|entity|C0055856|Clarithromycin|antb,orch|||clarithromycin||||1000|105|118
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|121|129
SE|00000000||tx|1|entity|C1145759|Atazanavir|orch,phsu|||atazanavir||||1000|132|141
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|144|152
SE|00000000||tx|1|entity|C0068485|nefazodone|orch,phsu|||nefazodone||||1000|155|164
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||nelfinavir||||1000|167|176
SE|00000000||tx|1|entity|C0286738|Saquinavir|orch,phsu|||saquinavir||||1000|179|188
SE|00000000||tx|1|entity|C0907410|telithromycin|antb,orch|||telithromycin||||1000|191|203
SE|00000000||tx|1|entity|C1455147|dasatinib|orch,phsu|||dasatinib||||1000|231|239
SE|00000000||tx|1|relation|0|0|C0055856|Clarithromycin|antb,orch|antb|||clarithromycin||||1000|105|118|SPEC|ISA||91|118|0|0|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|91|102
SE|00000000||tx|1|relation|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|32|36|VERB|INHIBITS||43|49|15|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|51|56
SE|00000000||tx|1|relation|3|1|C1723829|Sprycel|orch,phsu|phsu|||SPRYCEL||||1000|20|26|VERB|INHIBITS||43|49|15|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|51|56


SE|00000000||tx|1|text|The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||861|5|17
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||861|19|30
SE|00000000||tx|1|entity|C2827771|Cmin|qnco|||Cmin||||861|32|35
SE|00000000||tx|1|entity|C0450355|31|inpr|||31%||||1000|47|49
SE|00000000||tx|1|entity|C0439268|Microgram per Milliliter|qnco|||micrograms/mL||||813|58|70
SE|00000000||tx|1|entity|C0060135|felbamate|orch,phsu|||felbamate||||1000|77|85
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|93|98
SE|00000000||tx|1|entity|C0205449|Three|qnco|||three||||888|114|118
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|120|124


SE|00000000||tx|1|text|Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||Tablets||||1000|1|7
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|14|28
SE|00000000||tx|1|entity|C0024002|Lorazepam|orch,phsu|||lorazepam||||1000|41|49
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS-depressant||||901|60|73
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||901|75|81
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||1000|111|121
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|126|137
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|142|148
SE|00000000||tx|1|relation|3|1|C0024002|Lorazepam|orch,phsu|orch|||lorazepam||||1000|41|49|NOM|INTERACTS_WITH||75|81|3|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS-depressant||||901|60|73


SE|00000000||tx|1|text|Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||Antidepressants||||1000|1|15
SE|00000000||tx|1|entity|C1511726|Data|idcn|||data||||861|27|30
SE|00000000||tx|1|entity|C0068485|nefazodone|orch,phsu|||nefazodone||||1000|46|55
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|70|79
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|84|92
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|118|125
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||623|130|135
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||623|137|145
SE|00000000||tx|1|entity|C0429028|QT interval feature (observable entity)|clna|||QT interval||||1000|178|188
SE|00000000||tx|1|entity|C0013798|Electrocardiogram|fndg|||ECG||||966|197|199
SE|00000000||tx|1|relation|3|1|C0068485|nefazodone|orch,phsu|orch|||nefazodone||||1000|46|55|VERB|INHIBITS||57|64|7|2|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|84|92
SE|00000000||tx|1|relation|5|5|C0003289|Antidepressive Agents|phsu|phsu|||Antidepressants||||1000|1|15|NOM|STIMULATES||118|125|4|1|C0072916|Cisapride|orch,phsu|orch|||cisapride||||623|137|145


SE|00000000||tx|1|text|To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|15|25
SE|00000000||tx|1|entity|C0288165|Delavirdine|orch,phsu|||delavirdine||||1000|28|38
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|43|51
SE|00000000||tx|1|entity|C1442450|1 Hour|tmco|||1 hour||||1000|69|74
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||VIDEX||||1000|97|101


SE|00000000||tx|1|text|Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||Verapamil||||1000|1|9
SE|00000000||tx|1|entity|C0914729|almotriptan|orch,phsu|||almotriptan||||1000|32|42
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||1000|48|56
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|76|83
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|88|108
SE|00000000||tx|1|entity|C0914729|almotriptan|orch,phsu|||almotriptan||||1000|113|123


SE|00000000||tx|1|text|However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||1000|18|25
SE|00000000||tx|1|entity|C0020740|Ibuprofen|orch,phsu|||ibuprofen||||1000|50|58
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory agents||||1000|70|106
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|134|141
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin-type anticoagulants||||896|146|173
SE|00000000||tx|1|entity|C0804815|Physician:Identifier:Point in time:^Patient:Nominal|clna|||physician||||1000|180|188
SE|00000000||tx|1|entity|C1621583|Administer|ftcn|||administering||||872|214|226
SE|00000000||tx|1|entity|C0020740|Ibuprofen|orch,phsu|||ibuprofen||||872|228|236
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|241|248
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|253|266
SE|00000000||tx|1|relation|0|0|C0020740|Ibuprofen|orch,phsu|orch|||ibuprofen||||1000|50|58|SPEC|ISA||50|106|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory agents||||1000|70|106
SE|00000000||tx|1|relation|0|0|C0020740|Ibuprofen|orch,phsu|orch|||ibuprofen||||872|228|236|SPEC|ISA||50|106|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory agents||||1000|70|106
SE|00000000||tx|1|relation|3|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory agents||||1000|70|106|VERB|ADMINISTERED_TO||118|129|7|1|C0030705|Patients|podg,humn|humn|||patients||||1000|134|141
SE|00000000||tx|1|relation|0|0|C0020740|Ibuprofen|orch,phsu|orch|||ibuprofen||||1000|50|58|INFER|ADMINISTERED_TO(SPEC)||50|106|0|0|C0030705|Patients|podg,humn|humn|||patients||||1000|134|141
SE|00000000||tx|1|relation|0|0|C0020740|Ibuprofen|orch,phsu|orch|||ibuprofen||||872|228|236|INFER|ADMINISTERED_TO(SPEC)||50|106|0|0|C0030705|Patients|podg,humn|humn|||patients||||1000|134|141


SE|00000000||tx|1|text|Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
SE|00000000||tx|1|entity|C1515187|Take|hlca|||taking||||872|8|13
SE|00000000||tx|1|entity|C0061323|glimepiride|orch,phsu|||glimepiride||||872|15|25
SE|00000000||tx|1|entity|C0031831|Physicians|prog|||doctor||||1000|38|43
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||888|74|82
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medicines||||888|84|92
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|97|103
SE|00000000||tx|1|entity|C0036075|salicylate|orch,phsu|||salicylate||||1000|116|125
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||magnesium||||901|135|143
SE|00000000||tx|1|entity|C0055573|choline salicylate|orch,phsu|||choline salicylate||||901|145|162
SE|00000000||tx|1|entity|C0878190|Trilisate|orch,phsu|||Trilisate||||1000|165|173
SE|00000000||tx|1|entity|C0073983|Salsalate|orch,phsu|||salsalate||||1000|177|185
SE|00000000||tx|1|entity|C0702072|Disalcid|orch,phsu|||Disalcid||||1000|188|195
SE|00000000||tx|1|entity|C1955473|Others|fndg|||others||||1000|198|203
SE|00000000||tx|1|entity|C0055573|choline salicylate|orch,phsu|||choline salicylate||||1000|207|224
SE|00000000||tx|1|entity|C0718670|Arthropan|orch,phsu|||Arthropan||||1000|227|235
SE|00000000||tx|1|entity|C0126789|Magnesium Salicylate|orch,phsu|||magnesium salicylate||||1000|239|258
SE|00000000||tx|1|entity|C0721519|Magan|orch,phsu|||Magan||||1000|261|265
SE|00000000||tx|1|entity|C0053792|bismuth subsalicylate|orch,phsu|||bismuth subsalicylate||||1000|272|292
SE|00000000||tx|1|entity|C0136074|Pepto-bismol|orch,phsu|||Pepto-Bismol||||1000|295|306
SE|00000000||tx|1|relation|0|0|C0055573|choline salicylate|orch,phsu|orch|||choline salicylate||||901|145|162|SPEC|ISA||116|162|0|0|C0036075|salicylate|orch,phsu|orch|||salicylate||||1000|116|125
SE|00000000||tx|1|relation|0|0|C0878190|Trilisate|orch,phsu|orch|||Trilisate||||1000|165|173|SPEC|ISA||145|173|0|0|C0055573|choline salicylate|orch,phsu|orch|||choline salicylate||||901|145|162
SE|00000000||tx|1|relation|0|0|C0702072|Disalcid|orch,phsu|orch|||Disalcid||||1000|188|195|SPEC|ISA||177|195|0|0|C0073983|Salsalate|orch,phsu|orch|||salsalate||||1000|177|185
SE|00000000||tx|1|relation|0|0|C0718670|Arthropan|orch,phsu|orch|||Arthropan||||1000|227|235|SPEC|ISA||207|235|0|0|C0055573|choline salicylate|orch,phsu|orch|||choline salicylate||||1000|207|224
SE|00000000||tx|1|relation|0|0|C0721519|Magan|orch,phsu|orch|||Magan||||1000|261|265|SPEC|ISA||239|265|0|0|C0126789|Magnesium Salicylate|orch,phsu|orch|||magnesium salicylate||||1000|239|258
SE|00000000||tx|1|relation|0|0|C0136074|Pepto-bismol|orch,phsu|orch|||Pepto-Bismol||||1000|295|306|SPEC|ISA||272|306|0|0|C0053792|bismuth subsalicylate|orch,phsu|orch|||bismuth subsalicylate||||1000|272|292


SE|00000000||tx|1|text|Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|20|30
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|32|34
SE|00000000||tx|1|entity|C0048470|argatroban|aapp,phsu|||Argatroban||||1000|39|48
SE|00000000||tx|1|entity|C0085826|Antiplatelet Agents|phsu|||antiplatelet agents||||1000|55|73
SE|00000000||tx|1|entity|C0016018|Fibrinolytic Agents|phsu|||thrombolytics||||1000|76|88
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|101|114
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|133|136
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||1000|141|148
SE|00000000||tx|1|relation|0|0|C0016018|Fibrinolytic Agents|phsu|phsu|||thrombolytics||||1000|76|88|SPEC|ISA||76|114|0|0|C0003280|Anticoagulants|phsu|phsu|||anticoagulants||||1000|101|114
SE|00000000||tx|1|relation|0|0|C0016018|Fibrinolytic Agents|phsu|phsu|||thrombolytics||||1000|76|88|SPEC|ISA||76|114|0|0|C0085826|Antiplatelet Agents|phsu|phsu|||antiplatelet agents||||1000|55|73
SE|00000000||tx|1|relation|0|0|C0003280|Anticoagulants|phsu|phsu|||anticoagulants||||1000|101|114|SPEC|ISA||76|114|0|0|C0016018|Fibrinolytic Agents|phsu|phsu|||thrombolytics||||1000|76|88
SE|00000000||tx|1|relation|0|0|C0085826|Antiplatelet Agents|phsu|phsu|||antiplatelet agents||||1000|55|73|SPEC|ISA||76|114|0|0|C0016018|Fibrinolytic Agents|phsu|phsu|||thrombolytics||||1000|76|88
SE|00000000||tx|1|relation|6|1|C0003280|Anticoagulants|phsu|phsu|||anticoagulants||||1000|101|114|NOM|PREDISPOSES||133|136|1|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|141|148
SE|00000000||tx|1|relation|6|1|C0016018|Fibrinolytic Agents|phsu|phsu|||thrombolytics||||1000|76|88|NOM|PREDISPOSES||133|136|1|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|141|148
SE|00000000||tx|1|relation|6|1|C0085826|Antiplatelet Agents|phsu|phsu|||antiplatelet agents||||1000|55|73|NOM|PREDISPOSES||133|136|1|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|141|148
SE|00000000||tx|1|relation|0|0|C0016018|Fibrinolytic Agents|phsu|phsu|||thrombolytics||||1000|76|88|INFER|PREDISPOSES(SPEC)||76|114|0|0|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|141|148
SE|00000000||tx|1|relation|0|0|C0016018|Fibrinolytic Agents|phsu|phsu|||thrombolytics||||1000|76|88|INFER|PREDISPOSES(SPEC)||76|114|0|0|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|141|148
SE|00000000||tx|1|relation|0|0|C0003280|Anticoagulants|phsu|phsu|||anticoagulants||||1000|101|114|INFER|PREDISPOSES(SPEC)||76|114|0|0|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|141|148
SE|00000000||tx|1|relation|0|0|C0085826|Antiplatelet Agents|phsu|phsu|||antiplatelet agents||||1000|55|73|INFER|PREDISPOSES(SPEC)||76|114|0|0|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|141|148


SE|00000000||tx|1|text|Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
SE|00000000||tx|1|entity|C1704240|Magnitude|qnco|||magnitude||||1000|10|18
SE|00000000||tx|1|entity|C2926735|Duration|phsu|||duration||||1000|24|31
SE|00000000||tx|1|entity|C0927232|Neuraxis|bdsy|||central nervous system||||1000|36|57
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|78|84
SE|00000000||tx|1|entity|C0002025|Alfenta|orch,phsu|||ALFENTA||||1000|107|113
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|134|144
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||1000|157|171
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|181|192
SE|00000000||tx|1|entity|C0040614|Tranquilizing Agents|phsu|||tranquilizers||||1000|195|207
SE|00000000||tx|1|entity|C0242402|Opioids|hops,orch,phsu|||opioids||||1000|210|216
SE|00000000||tx|1|entity|C0205246|Generalized|spco|||general||||901|233|239
SE|00000000||tx|1|entity|C0242903|Anesthetics, Inhalation|phsu|||inhalation general anesthetics||||901|222|251
SE|00000000||tx|1|relation|0|0|C0004745|Barbiturates|orch,phsu|orch|||barbiturates||||1000|181|192|SPEC|ISA||157|192|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|157|171
SE|00000000||tx|1|relation|0|0|C0242903|Anesthetics, Inhalation|phsu|phsu|||inhalation general anesthetics||||901|222|251|SPEC|ISA||157|192|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|157|171
SE|00000000||tx|1|relation|0|0|C0242402|Opioids|hops,orch,phsu|orch|||opioids||||1000|210|216|SPEC|ISA||157|192|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|157|171
SE|00000000||tx|1|relation|0|0|C0040614|Tranquilizing Agents|phsu|phsu|||tranquilizers||||1000|195|207|SPEC|ISA||157|192|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|157|171


SE|00000000||tx|1|text|A dose adjustment is not needed when zidovudine is administered with VIRACEPT.
SE|00000000||tx|1|entity|C2826232|Dose Adjustment|hlca|||dose adjustment||||1000|3|17
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|22|24
SE|00000000||tx|1|entity|C0043474|Zidovudine|nnon,phsu|||zidovudine||||1000|38|47
SE|00000000||tx|1|entity|C0525004|Viracept|orch,phsu|||VIRACEPT||||1000|70|77
SE|00000000||tx|1|relation|2|2|C2826232|Dose Adjustment|hlca|hlca|||dose adjustment||||1000|3|17|PREP|USES||65|68|1|1|C0525004|Viracept|orch,phsu|phsu|||VIRACEPT||||1000|70|77


SE|00000000||tx|1|text|The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|5|7
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|12|24
SE|00000000||tx|1|entity|C1510992|Average|qnco|||average||||1000|43|49
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||861|57|60
SE|00000000||tx|1|entity|C0018684|Health|idcn|||healthy||||789|68|74
SE|00000000||tx|1|entity|C1442162|GIVEN|cnce|||given||||888|85|89
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||888|91|103
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||775|109|118
SE|00000000||tx|1|entity|C0032042|Placebos|topp|||placebo||||775|120|126
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||775|128|134


SE|00000000||tx|1|text|Antagonism has been demonstrated between clindamycin and erythromycin in vitro.
SE|00000000||tx|1|entity|C0680242|antagonism|socb|||Antagonism||||1000|1|10
SE|00000000||tx|1|entity|C0008947|Clindamycin|antb,carb|||clindamycin||||1000|42|52
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|58|69


SE|00000000||tx|1|text|Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||clinical studies||||1000|13|28
SE|00000000||tx|1|entity|C0332148|Probable diagnosis|qlco|||likely||||1000|57|62
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|73|82
SE|00000000||tx|1|entity|C0873118|Levobupivacaine|orch,phsu|||levobupivacaine||||1000|87|101
SE|00000000||tx|1|entity|C0205309|Known|qlco|||known||||660|126|130
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||660|132|137
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|157|165
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|168|180
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|183|190
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||861|194|199
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||861|201|210
SE|00000000||tx|1|entity|C0004504|Azoles|orch|||azole||||694|213|217
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|238|249
SE|00000000||tx|1|relation|3|1|C0873118|Levobupivacaine|orch,phsu|orch|||levobupivacaine||||1000|87|101|NOM|STIMULATES||139|146|3|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||660|132|137
SE|00000000||tx|1|relation|7|1|C0035608|Rifampin|antb,orch|antb|||rifampin||||1000|183|190|NOM|INHIBITS||201|210|7|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||861|194|199


SE|00000000||tx|1|text|Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||Methotrexate||||1000|1|12
SE|00000000||tx|1|entity|C0020740|Ibuprofen|orch,phsu|||Ibuprofen||||1000|15|23
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory drugs||||1000|43|78
SE|00000000||tx|1|entity|C0750492|Probably|idcn|||probably||||1000|81|88
SE|00000000||tx|1|entity|C0232819|Tubular secretion|ortf|||tubular secretion||||1000|102|118
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|123|134
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||kidney||||773|172|177
SE|00000000||tx|1|entity|C1519355|Slice|sbst|||slices||||773|179|184
SE|00000000||tx|1|relation|0|0|C0020740|Ibuprofen|orch,phsu|orch|||Ibuprofen||||1000|15|23|SPEC|ISA||15|78|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory drugs||||1000|43|78
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory drugs||||1000|43|78|SPEC|ISA||15|78|0|0|C0020740|Ibuprofen|orch,phsu|phsu|||Ibuprofen||||1000|15|23
SE|00000000||tx|1|relation|3|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory drugs||||1000|43|78|VERB|INHIBITS||90|96|4|1|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|102|118
SE|00000000||tx|1|relation|3|1|C0020740|Ibuprofen|orch,phsu|phsu|||Ibuprofen||||1000|15|23|VERB|INHIBITS||90|96|4|1|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|102|118
SE|00000000||tx|1|relation|0|0|C0020740|Ibuprofen|orch,phsu|orch|||Ibuprofen||||1000|15|23|INFER|INHIBITS(SPEC)||15|78|0|0|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|102|118
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory drugs||||1000|43|78|INFER|INHIBITS(SPEC)||15|78|0|0|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|102|118


SE|00000000||tx|1|text|Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).
SE|00000000||tx|1|entity|C1882348|Permutation|qlco|||order||||861|9|13
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||1000|24|31
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduced||||888|34|40
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||888|42|47
SE|00000000||tx|1|entity|C0019134|Heparin|bacs,carb,phsu|||heparin||||1000|52|58
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|82|90
SE|00000000||tx|1|entity|C0003438|Antithrombin III|aapp,phsu|||antithrombin III||||1000|97|112
SE|00000000||tx|1|entity|C0086418|Homo sapiens|humn|||human||||1000|115|119
SE|00000000||tx|1|relation|5|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||1000|82|90|PREP|USES||92|95|2|1|C0003438|Antithrombin III|aapp,gngm,phsu|phsu|||antithrombin III||||1000|97|112


SE|00000000||tx|1|text|Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycoside||||1000|14|27
SE|00000000||tx|1|entity|C1144789|Penicillinum, Homeopathic preparation|antb|||penicillin-type drug||||913|35|54
SE|00000000||tx|1|entity|C1705242|Different|qlco|||different||||888|87|95
SE|00000000||tx|1|entity|C0449444|Route|spco|||routes||||888|97|102
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|107|115
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycoside||||861|120|133
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||861|135|139
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||861|141|149
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||861|154|158
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|188|195
SE|00000000||tx|1|entity|C0341697|Renal impairment|dsyn|||impaired renal function||||1000|202|224
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|238|245
SE|00000000||tx|1|entity|C0232805|Normal renal function|fndg|||normal renal function||||1000|252|272
SE|00000000||tx|1|relation|6|5|C1144789|Penicillinum, Homeopathic preparation|antb|antb|||penicillin-type drug||||913|35|54|PREP|TREATS||185|186|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|188|195
SE|00000000||tx|1|relation|6|5|C1144789|Penicillinum, Homeopathic preparation|antb|antb|||penicillin-type drug||||913|35|54|PREP|TREATS||185|186|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|238|245
SE|00000000||tx|1|relation|6|5|C0002556|Aminoglycosides|carb,phsu|phsu|||aminoglycoside||||1000|14|27|PREP|TREATS||185|186|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|188|195
SE|00000000||tx|1|relation|6|6|C0002556|Aminoglycosides|carb,phsu|phsu|||aminoglycoside||||1000|14|27|PREP|TREATS||185|186|4|3|C0030705|Patients|podg,humn|podg|||patients||||1000|238|245
SE|00000000||tx|1|relation|3|1|C0341697|Renal impairment|dsyn|dsyn|||impaired renal function||||1000|202|224|PREP|PROCESS_OF||197|200|7|1|C0030705|Patients|podg,humn|humn|||patients||||1000|188|195
SE|00000000||tx|1|relation|3|1|C0341697|Renal impairment|dsyn|dsyn|||impaired renal function||||1000|202|224|PREP|PROCESS_OF||197|200|7|1|C0030705|Patients|podg,humn|humn|||patients||||1000|238|245
SE|00000000||tx|1|relation|0|0|C1144789|Penicillinum, Homeopathic preparation|antb|antb|||penicillin-type drug||||913|35|54|INFER|TREATS(INFER)||185|186|0|0|C0341697|Renal impairment|dsyn|dsyn|||impaired renal function||||1000|202|224
SE|00000000||tx|1|relation|0|0|C1144789|Penicillinum, Homeopathic preparation|antb|antb|||penicillin-type drug||||913|35|54|INFER|TREATS(INFER)||185|186|0|0|C0341697|Renal impairment|dsyn|dsyn|||impaired renal function||||1000|202|224
SE|00000000||tx|1|relation|0|0|C0002556|Aminoglycosides|carb,phsu|phsu|||aminoglycoside||||1000|14|27|INFER|TREATS(INFER)||185|186|0|0|C0341697|Renal impairment|dsyn|dsyn|||impaired renal function||||1000|202|224
SE|00000000||tx|1|relation|0|0|C0002556|Aminoglycosides|carb,phsu|phsu|||aminoglycoside||||1000|14|27|INFER|TREATS(INFER)||185|186|0|0|C0341697|Renal impairment|dsyn|dsyn|||impaired renal function||||1000|202|224


SE|00000000||tx|1|text|Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||Anticoagulants||||1000|1|14
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||1000|17|20
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|44|58
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||861|64|71
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|92|101
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|118|125
SE|00000000||tx|1|entity|C0009671|Conflict (Psychology)|inbe|||conflicting||||888|158|168


SE|00000000||tx|1|text|Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|28|34
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|37|48
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAOIs||||966|55|59
SE|00000000||tx|1|entity|C0151559|Central nervous system depression (disorder)|dsyn|||CNS depression||||1000|73|86
SE|00000000||tx|1|entity|C0014987|Ethchlorvynol|orch,phsu|||ethchlorvynol||||1000|111|123
SE|00000000||tx|1|relation|4|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||MAOIs||||966|55|59|VERB|AUGMENTS||65|71|2|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|73|86
SE|00000000||tx|1|relation|4|1|C0004745|Barbiturates|orch,phsu|orch|||barbiturates||||1000|37|48|VERB|AUGMENTS||65|71|2|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|73|86
SE|00000000||tx|1|relation|4|1|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|28|34|VERB|AUGMENTS||65|71|2|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|73|86


SE|00000000||tx|1|text|Methadone levels may be decreased;
SE|00000000||tx|1|entity|C0025605|Methadone|orch,phsu|||Methadone||||694|1|9

SE|00000000||tx|2|text|increased dosages may be required to prevent symptoms of opiate withdrawal.
SE|00000000||tx|2|entity|C0442805|Increase|ftcn|||increased||||888|1|9
SE|00000000||tx|2|entity|C0178602|Dosage|qnco|||dosages||||888|11|17
SE|00000000||tx|2|entity|C1457887|Symptoms|sosy|||symptoms||||1000|46|53
SE|00000000||tx|2|entity|C0376196|Opiates|hops,phsu|||opiate||||888|58|63
SE|00000000||tx|2|entity|C2349954|Withdraw (activity)|acty|||withdrawal||||888|65|74

SE|00000000||tx|3|text|Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.
SE|00000000||tx|3|entity|C0025605|Methadone|orch,phsu|||Methadone||||851|1|9
SE|00000000||tx|3|entity|C1314677|Maintaining (action)|ftcn|||maintained||||851|11|20
SE|00000000||tx|3|entity|C0030705|Patients|podg|||patients||||851|22|29
SE|00000000||tx|3|entity|C0132326|Nevirapine|nnon,phsu|||nevirapine||||888|41|50
SE|00000000||tx|3|entity|C2349954|Withdraw (activity)|acty|||withdrawal||||1000|95|104
SE|00000000||tx|3|entity|C0366544|Methadone:Mass:Point in time:Dose med or substance:Quantitative|clna|||methadone dose||||1000|110|123


SE|00000000||tx|1|text|However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|23|32
SE|00000000||tx|1|entity|C0520996|Anticoagulant effect|ortf|||anticoagulant effects||||966|68|88
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|93|100
SE|00000000||tx|1|entity|C0243072|derivatives|chvs|||derivatives||||1000|109|119
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|124|131
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|138|153
SE|00000000||tx|1|entity|C0441509|Coagulation procedure|topp|||coagulation||||790|173|183
SE|00000000||tx|1|entity|C0022885|Laboratory Procedures|lbpr|||test||||790|185|188
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolone||||1000|223|231
SE|00000000||tx|1|entity|C1136254|Microbicides|phsu|||antimicrobial||||1000|233|245
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|282|289
SE|00000000||tx|1|entity|C0243072|derivatives|chvs|||derivatives||||1000|298|308
SE|00000000||tx|1|relation|0|0|C0033707|Prothrombin time assay|lbpr|lbpr|||prothrombin time||||1000|138|153|SPEC|ISA||138|188|0|0|C0022885|Laboratory Procedures|lbpr|lbpr|||test||||790|185|188
SE|00000000||tx|1|relation|1|1|C0034428|Quinolones|orch|orch|||quinolones||||1000|23|32|VERB|AUGMENTS||56|62|11|1|C0520996|Anticoagulant effect|ortf|ortf|||anticoagulant effects||||966|68|88
SE|00000000||tx|1|relation|4|3|C0520996|Anticoagulant effect|ortf|ortf|||anticoagulant effects||||966|68|88|PREP|PROCESS_OF||121|122|8|1|C0030705|Patients|podg,humn|humn|||patients||||1000|124|131
SE|00000000||tx|1|relation|10|4|C0022885|Laboratory Procedures|lbpr|lbpr|||test||||790|185|188|PREP|USES||277|280|2|1|C0043031|Warfarin|hops,orch,phsu|phsu|||warfarin||||1000|282|289
SE|00000000||tx|1|relation|0|0|C0033707|Prothrombin time assay|lbpr|lbpr|||prothrombin time||||1000|138|153|INFER|USES(SPEC)||138|188|0|0|C0043031|Warfarin|hops,orch,phsu|phsu|||warfarin||||1000|282|289


SE|00000000||tx|1|text|Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0027409|Narcotic Analgesics|phsu|||narcotic analgesics||||1000|26|44
SE|00000000||tx|1|entity|C0040615|Antipsychotic Agents|phsu|||antipsychotics||||1000|47|60
SE|00000000||tx|1|entity|C0040616|Anti-Anxiety Agents|phsu|||antianxiety agents||||1000|63|80
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||1000|92|106
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|119|125
SE|00000000||tx|1|entity|C0020264|Hydrocodone|orch,phsu|||hydrocodone||||1000|147|157
SE|00000000||tx|1|entity|C1243075|Acetaminophen Oral Tablet [Tylenol]|clnd|||acetaminophen tablets||||972|163|183
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||901|200|207
SE|00000000||tx|1|entity|C0151559|Central nervous system depression (disorder)|dsyn|||CNS depression||||901|209|222
SE|00000000||tx|1|relation|0|0|C0040616|Anti-Anxiety Agents|phsu|phsu|||antianxiety agents||||1000|63|80|SPEC|ISA||63|106|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|92|106
SE|00000000||tx|1|relation|8|1|C0027409|Narcotic Analgesics|phsu|phsu|||narcotic analgesics||||1000|26|44|VERB|ADMINISTERED_TO||10|18|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8


SE|00000000||tx|1|text|Hydrocodone increases gabapentin AUC values by 14%.
SE|00000000||tx|1|entity|C0020264|Hydrocodone|orch,phsu|||Hydrocodone||||1000|1|11
SE|00000000||tx|1|entity|C0060926|gabapentin|orch,phsu|||gabapentin||||851|23|32
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||851|34|36
SE|00000000||tx|1|entity|C0042295|Values|qlco|||values||||851|38|43


SE|00000000||tx|1|text|Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.
SE|00000000||tx|1|entity|C1707478|Conclusion|idcn|||conclusion||||1000|25|34
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|76|86
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|92|99
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|119|123
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|134|151
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|164|169
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|174|184
SE|00000000||tx|1|entity|C0087136|Unmarried|fndg|||single||||851|206|211
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||851|213|216
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||851|218|221
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|235|242


SE|00000000||tx|1|text|Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||Acetaminophen||||1000|1|13
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||888|19|24
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|26|35
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|38|48
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|68|77
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|83|95
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximate||||802|112|122
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||802|128|135
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|140|145
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|157|169
SE|00000000||tx|1|relation|1|1|C0000970|Acetaminophen|orch,phsu|phsu|||Acetaminophen||||1000|1|13|PREP|TREATS||16|17|7|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|26|35
SE|00000000||tx|1|relation|1|1|C0000970|Acetaminophen|orch,phsu|phsu|||acetaminophen||||1000|83|95|PREP|TREATS||16|17|7|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|26|35


SE|00000000||tx|1|text|Conversely, the coumarin anticoagulants have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin anticoagulants||||983|17|39
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||861|76|80
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||901|105|109
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||901|111|119
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|124|132
SE|00000000||tx|1|entity|C0021469|Metabolic Inhibition|moft|||inhibiting||||1000|137|146
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|152|161


SE|00000000||tx|1|text|Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||Diflunisal||||1000|1|10
SE|00000000||tx|1|entity|C0740394|Hyperuricemia|dsyn|||hyperuricemic||||888|26|38
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|40|45
SE|00000000||tx|1|entity|C0020261|Hydrochlorothiazide|orch,phsu|||hydrochlorothiazide||||1000|50|68
SE|00000000||tx|1|relation|1|1|C0012228|Diflunisal|orch,phsu|orch|||Diflunisal||||1000|1|10|NOM|INTERACTS_WITH||40|45|1|1|C0020261|Hydrochlorothiazide|orch,phsu|orch|||hydrochlorothiazide||||1000|50|68


SE|00000000||tx|1|text|therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.
SE|00000000||tx|1|entity|C0017887|Nitroglycerin|orch,phsu|||nitroglycerin||||1000|12|24
SE|00000000||tx|1|entity|C0028125|Nitrates|chvs|||nitrates||||1000|35|42
SE|00000000||tx|1|entity|C0001554|Administration occupational activities|ocac|||management||||1000|57|66
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|88|92
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||861|113|120
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||1000|133|140
SE|00000000||tx|1|entity|C0439659|Beginning|tmco|||starting||||872|166|173
SE|00000000||tx|1|entity|C0006938|Captopril|aapp,phsu|||captopril||||872|175|183


SE|00000000||tx|1|text|Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.
SE|00000000||tx|1|entity|C1511726|Data|idcn|||data||||861|17|20
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|36|39
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||888|41|52
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|67|76
SE|00000000||tx|1|entity|C0085170|Astemizole|orch,phsu|||astemizole||||1000|81|90
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||790|106|113
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|115|120
SE|00000000||tx|1|entity|C0085170|Astemizole|orch,phsu|||astemizole||||1000|132|141
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||851|151|156
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||851|158|167
SE|00000000||tx|1|entity|C0525890|desmethylastemizole|orch|||desmethylastemizole||||851|169|187
SE|00000000||tx|1|entity|C0429028|QT interval feature (observable entity)|clna|||QT intervals||||966|207|218
SE|00000000||tx|1|relation|2|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||888|41|52|VERB|INHIBITS||54|61|6|2|C0085170|Astemizole|orch,phsu|orch|||astemizole||||1000|81|90


SE|00000000||tx|1|text|Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.
SE|00000000||tx|1|entity|C0028351|Norepinephrine|nsba,orch,phsu|||Norepinephrine||||1000|1|14
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||Amphetamines||||1000|17|28
SE|00000000||tx|1|entity|C3179174|Adrenergic Effect|phsf|||adrenergic effect||||1000|42|58
SE|00000000||tx|1|entity|C0028351|Norepinephrine|nsba,orch,phsu|||norepinephrine||||1000|63|76
SE|00000000||tx|1|relation|2|1|C0002667|Amphetamines|nsba,orch,phsu|orch|||Amphetamines||||1000|17|28|VERB|AUGMENTS||30|36|2|1|C3179174|Adrenergic Effect|phsf|phsf|||adrenergic effect||||1000|42|58


SE|00000000||tx|1|text|Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||Effect||||1000|1|6
SE|00000000||tx|1|entity|C0180309|Automated External Defibrillators|medd|||AEDs||||1000|11|14
SE|00000000||tx|1|entity|C1521725|Pediatric|qlco|||Pediatric||||790|19|27
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||790|29|36
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|60|67
SE|00000000||tx|1|entity|C0750489|apparent|idcn|||apparent||||861|72|79
SE|00000000||tx|1|entity|C0229960|Entire body as a whole|ffas|||total body||||861|81|90
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||861|92|100
SE|00000000||tx|1|entity|C0377265|Levetiracetam|orch,phsu|||levetiracetam||||1000|105|117
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzyme||||851|152|157
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||inducing||||851|159|166
SE|00000000||tx|1|entity|C0180309|Automated External Defibrillators|medd|||AEDs||||851|168|171
SE|00000000||tx|1|relation|2|1|C0180309|Automated External Defibrillators|medd|medd|||AEDs||||1000|11|14|PREP|TREATS||16|17|5|1|C0030705|Patients|podg,humn|podg|||Patients||||790|29|36
SE|00000000||tx|1|relation|3|2|C0377265|Levetiracetam|orch,phsu|orch|||levetiracetam||||1000|105|117|NOM|AUGMENTS||60|67|3|1|C0229960|Entire body as a whole|ffas|ffas|||total body||||861|81|90


SE|00000000||tx|1|text|for adult-onset diabetics, dosage adjustment of hypoglycemic medications may be necessary during and after thiazide diuretic therapy;
SE|00000000||tx|1|entity|C1836537|Adult onset|fndg|||adult-onset||||901|5|15
SE|00000000||tx|1|entity|C0241863|DIABETIC|fndg|||diabetics||||901|17|25
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||694|28|33
SE|00000000||tx|1|entity|C0020616|Hypoglycemic Agents|phsu|||hypoglycemic||||888|49|60
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||888|62|72
SE|00000000||tx|1|entity|C0541746|Thiazides|orch,phsu|||thiazide||||901|108|115
SE|00000000||tx|1|entity|C0948575|diuretic therapy|topp|||diuretic therapy||||901|117|132
SE|00000000||tx|1|relation|0|0|C0020616|Hypoglycemic Agents|phsu|phsu|||hypoglycemic||||888|49|60|MOD/HEAD|ISA||49|72|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||888|62|72
SE|00000000||tx|1|relation|0|0|C0948575|diuretic therapy|topp|topp|||diuretic therapy||||901|117|132|MOD/HEAD|USES||108|132|0|0|C0541746|Thiazides|orch,phsu|phsu|||thiazide||||901|108|115


SE|00000000||tx|1|text|In Europe, Nimotop  was observed to occasionally intensify the effect of antihypertensive compounds taken concomitantly by patients suffering from hypertension;
SE|00000000||tx|1|entity|C0015176|Europe|geoa|||Europe||||1000|4|9
SE|00000000||tx|1|entity|C0678207|Nimotop|orch,phsu|||Nimotop||||1000|12|18
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|64|69
SE|00000000||tx|1|entity|C0205198|Compound|qlco|||compounds||||827|91|99
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|124|131
SE|00000000||tx|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||1000|148|159
SE|00000000||tx|1|relation|4|3|C0678207|Nimotop|orch,phsu|orch|||Nimotop||||1000|12|18|VERB|ADMINISTERED_TO||101|105|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|124|131
SE|00000000||tx|1|relation|1|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||1000|148|159|VERB|PROCESS_OF||133|141|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|124|131


SE|00000000||tx|1|text|When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|6|18
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|50|58
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||694|61|66
SE|00000000||tx|1|entity|C0700739|Nalfon|orch,phsu|||Nalfon||||1000|82|87


SE|00000000||tx|1|text|In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single-||||833|6|12
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||833|13|16
SE|00000000||tx|1|entity|C0150097|Cross-Over Studies|resa|||crossover study||||833|18|32
SE|00000000||tx|1|entity|C0332128|Examined|fndg|||examining||||833|34|42
SE|00000000||tx|1|entity|C1145828|lansoprazole 30 MG|clnd|||lansoprazole 30 mg||||833|44|61
SE|00000000||tx|1|entity|C0988268|Omeprazole 20 MG|clnd|||omeprazole 20 mg||||1000|67|82
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|102|106
SE|00000000||tx|1|entity|C0038633|Sucralfate|carb,phsu|||sucralfate||||802|131|140
SE|00000000||tx|1|entity|C0439208|gram|qnco|||gram||||802|144|147
SE|00000000||tx|1|entity|C0358591|Proton Pump Inhibitors|phsu|||proton pump inhibitors||||1000|168|189
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|213|227
SE|00000000||tx|1|entity|C0038633|Sucralfate|carb,phsu|||sucralfate||||1000|308|317


SE|00000000||tx|1|text|Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.
SE|00000000||tx|1|entity|C0043474|Zidovudine|nnon,phsu|||Zidovudine||||1000|1|10
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|99|108
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||1000|117|119
SE|00000000||tx|1|entity|C0286078|Vistide|nnon,phsu|||VISTIDE||||888|124|130
SE|00000000||tx|1|entity|C0574032|Infusion procedures|topp|||infusion||||888|132|139


SE|00000000||tx|1|text|Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||Antihistamines||||1000|1|14
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|32|38
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|43|67
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|70|81
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|84|90
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||1000|103|117
SE|00000000||tx|1|relation|0|0|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|84|90|SPEC|ISA||84|117|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|103|117
SE|00000000||tx|1|relation|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|103|117|SPEC|ISA||84|117|0|0|C0001975|Alcohols|orch,phsu|phsu|||alcohol||||1000|84|90
SE|00000000||tx|1|relation|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|103|117|SPEC|ISA||84|117|0|0|C0004745|Barbiturates|orch,phsu|phsu|||barbiturates||||1000|70|81
SE|00000000||tx|1|relation|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|103|117|SPEC|ISA||84|117|0|0|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|43|67
SE|00000000||tx|1|relation|0|0|C0004745|Barbiturates|orch,phsu|orch|||barbiturates||||1000|70|81|SPEC|ISA||84|117|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|103|117
SE|00000000||tx|1|relation|0|0|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|43|67|SPEC|ISA||84|117|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|103|117


SE|00000000||tx|1|text|Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.
SE|00000000||tx|1|entity|C0574032|Infusion procedures|topp|||Infusion||||872|1|8
SE|00000000||tx|1|entity|C1514873|Requirement|ftcn|||requirements||||872|10|21
SE|00000000||tx|1|entity|C0530102|Nimbex|orch,phsu|||NIMBEX||||1000|26|31
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|36|43
SE|00000000||tx|1|entity|C0038627|Succinylcholine|orch,phsu|||succinylcholine||||1000|58|72
SE|00000000||tx|1|entity|C0574032|Infusion procedures|topp|||infusions||||1000|83|91
SE|00000000||tx|1|entity|C0530102|Nimbex|orch,phsu|||NIMBEX||||1000|96|101
SE|00000000||tx|1|entity|C0750482|Slightly|idcn|||slightly||||888|125|132
SE|00000000||tx|1|entity|C0443228|Largest|qnco|||greater||||888|134|140
SE|00000000||tx|1|entity|C0038627|Succinylcholine|orch,phsu|||succinylcholine||||1000|152|166
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|172|174
SE|00000000||tx|1|entity||<<greatness>>||||greater|||||134|140
SE|00000000||tx|1|relation|8|3|C0530102|Nimbex|orch,phsu|orch|||NIMBEX||||1000|96|101|PREP|compared_with||142|145|2|2|C0038627|Succinylcholine|orch,phsu|orch|||succinylcholine||||1000|152|166
SE|00000000||tx|1|relation|8|3|C0530102|Nimbex|orch,phsu|orch|||NIMBEX||||1000|96|101|PREP|higher_than||142|145|2|2|C0038627|Succinylcholine|orch,phsu|orch|||succinylcholine||||1000|152|166
SE|00000000||tx|1|relation|2|1|C0530102|Nimbex|orch,phsu|phsu|||NIMBEX||||1000|26|31|PREP|TREATS||33|34|7|1|C0030705|Patients|podg,humn|podg|||patients||||1000|36|43
SE|00000000||tx|1|relation|6|1|C0038627|Succinylcholine|orch,phsu|orch|||succinylcholine||||1000|58|72|VERB|ADMINISTERED_TO||45|56|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|36|43


SE|00000000||tx|1|text|Apraclonidine should not be used in patients receiving MAO inhibitors..
SE|00000000||tx|1|entity|C0048038|apraclonidine|orch,phsu|||Apraclonidine||||1000|1|13
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|22|24
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|37|44
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|56|69
SE|00000000||tx|1|relation|1|1|C0048038|apraclonidine|orch,phsu|phsu|||Apraclonidine||||1000|1|13|PREP|TREATS||34|35|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|37|44
SE|00000000||tx|1|relation|1|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||MAO inhibitors||||1000|56|69|VERB|ADMINISTERED_TO||46|54|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|37|44


SE|00000000||tx|1|text|Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
SE|00000000||tx|1|entity|C0721124|Iron Supplement|phsu|||Iron Supplements||||983|1|16
SE|00000000||tx|1|entity|C0016452|Food|food|||Foods||||1000|22|26
SE|00000000||tx|1|entity|C0302583|Iron|bacs,elii,phsu|||Iron||||851|43|46
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||851|48|58
SE|00000000||tx|1|entity|C0060405|cefdinir|antb,orch|||cefdinir||||1000|78|85
SE|00000000||tx|1|entity|C0302350|Therapeutic|ftcn|||therapeutic||||901|94|104
SE|00000000||tx|1|entity|C0721124|Iron Supplement|phsu|||iron supplement||||901|106|120
SE|00000000||tx|1|entity|C0876023|elemental iron|inch,phsu|||elemental iron||||1000|142|155
SE|00000000||tx|1|entity|C0042890|Vitamins|orch,phsu,vita|||vitamins||||1000|171|178
SE|00000000||tx|1|entity|C0876023|elemental iron|inch,phsu|||elemental iron||||1000|207|220
SE|00000000||tx|1|entity|C0439792|Extent|spco|||extent||||1000|230|235
SE|00000000||tx|1|entity|C0450355|31|inpr|||31%||||1000|262|264


SE|00000000||tx|1|text|Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|12|23
SE|00000000||tx|1|entity|C0907850|ciclesonide|bacs,phsu,strd|||ciclesonide||||861|77|87


SE|00000000||tx|1|text|Warfarin: Meclofenamate sodium enhances the effect of warfarin.
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||Warfarin||||1000|1|8
SE|00000000||tx|1|entity|C0025041|Sodium Meclofenamate|orch,phsu|||Meclofenamate sodium||||1000|11|30
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|45|50
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|55|62


SE|00000000||tx|1|text|Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||Selective serotonin reuptake inhibitors||||1000|1|39
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|56|65
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|68|78
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||paroxetine||||1000|81|90
SE|00000000||tx|1|entity|C0074393|Sertraline|orch,phsu|||sertraline||||1000|93|102
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||rarely||||1000|125|130
SE|00000000||tx|1|entity|C1883552|Weakness|sosy|||weakness||||1000|142|149
SE|00000000||tx|1|entity|C0151889|Hyperreflexia|fndg|||hyperreflexia||||1000|152|164
SE|00000000||tx|1|entity|C0520966|Abnormal coordination|sosy|||incoordination||||1000|171|184
SE|00000000||tx|1|entity|C0439084|>5|qnco|||5-HT1||||851|211|215
SE|00000000||tx|1|entity|C0450565|HT1|blor|||5-HT1||||851|211|215
SE|00000000||tx|1|entity|C0243192|agonists|phsu|||agonists||||851|217|224
SE|00000000||tx|1|relation|5|5|C0360105|Selective serotonin re-uptake inhibitor|phsu|phsu|||Selective serotonin reuptake inhibitors||||1000|1|39|VERB|CAUSES||136|140|4|1|C1883552|Weakness|sosy|sosy|||weakness||||1000|142|149


SE|00000000||tx|1|text|Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|13|21
SE|00000000||tx|1|entity|C0175727|Stimulator|medd|||stimulator||||1000|33|42
SE|00000000||tx|1|entity|C1157065|coumarin metabolic process|moft|||coumarin metabolism||||1000|47|65
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||decreased||||790|98|106
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||790|108|112
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin anticoagulants||||983|128|150
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||833|156|164
SE|00000000||tx|1|entity|C0033706|Prothrombin|aapp,bacs,phsu|||prothrombin||||833|166|176
SE|00000000||tx|1|entity|C0015502|Blood Coagulation Factor VII|aapp,bacs,phsu|||proconvertin||||833|178|189
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||833|191|204
SE|00000000||tx|1|relation|3|3|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|13|21|ADJ|INHIBITS||98|106|2|1|C0010206|coumarin|orch,phsu|orch|||coumarin anticoagulants||||983|128|150
SE|00000000||tx|1|relation|3|3|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|13|21|ADJ|INHIBITS||98|106|2|1|C0015502|Blood Coagulation Factor VII|aapp,gngm,bacs,phsu|gngm|||proconvertin||||833|178|189


SE|00000000||tx|1|text|Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|13|15
SE|00000000||tx|1|entity|C0701345|Ellence|orch,phsu|||ELLENCE||||1000|20|26
SE|00000000||tx|1|entity|C0205198|Compound|qlco|||compounds||||827|52|60
SE|00000000||tx|1|entity|C0018801|Heart failure|dsyn|||heart failure||||1000|79|91
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium channel blockers||||1000|100|123
SE|00000000||tx|1|entity|C0587267|Closed|ftcn|||close||||694|136|140
SE|00000000||tx|1|entity|C0232164|Cardiac function|ortf|||cardiac function||||1000|156|171
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|184|192
SE|00000000||tx|1|relation|3|2|C0701345|Ellence|orch,phsu|orch|||ELLENCE||||1000|20|26|VERB|CAUSES||73|77|5|1|C0018801|Heart failure|dsyn|dsyn|||heart failure||||1000|79|91


SE|00000000||tx|1|text|Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interaction||||824|19|34
SE|00000000||tx|1|entity|C0947630|Scientific Study|lbpr|||studies||||824|36|42
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|49|51
SE|00000000||tx|1|entity|C1170041|Alphagan-P|orch,phsu|||ALPHAGAN P||||1000|73|82
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||1000|107|114
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|132|137
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||1000|144|158
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|161|167
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|170|181
SE|00000000||tx|1|entity|C0376196|Opiates|hops,phsu|||opiates||||1000|184|190
SE|00000000||tx|1|entity|C0036557|Sedatives|phsu|||sedatives||||1000|193|201
SE|00000000||tx|1|entity|C0002932|Anesthetics|phsu|||anesthetics||||1000|207|217
SE|00000000||tx|1|relation|0|0|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|161|167|SPEC|ISA||144|167|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|144|158
SE|00000000||tx|1|relation|1|1|C0947630|Scientific Study|lbpr|lbpr|||studies||||824|36|42|PREP|USES||68|71|10|1|C1170041|Alphagan-P|orch,phsu|phsu|||ALPHAGAN P||||1000|73|82


SE|00000000||tx|1|text|The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||888|5|13
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|15|21
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|26|32
SE|00000000||tx|1|entity|C0304490|Potassium Sparing Diuretics|phsu|||potassium-sparing diuretics||||1000|38|64
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||888|69|77
SE|00000000||tx|1|entity|C0022702|Kinetics|npop|||kinetics||||888|79|86
SE|00000000||tx|1|entity|C0232804|Renal function|ortf|||renal function||||1000|92|105
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|139|144


SE|00000000||tx|1|text|Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0030078|Oxyphenbutazone|orch,phsu|||oxyphenbutazone||||1000|30|44
SE|00000000||tx|1|entity|C0002844|Androgens|horm,phsu|||androgens||||1000|50|58
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||790|74|81
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||790|83|87
SE|00000000||tx|1|entity|C0030078|Oxyphenbutazone|orch,phsu|||oxyphenbutazone||||1000|99|113


SE|00000000||tx|1|text|Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.):
SE|00000000||tx|1|entity|C0020924|Imidazoles|orch,phsu|||Imidazoles||||1000|1|10
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|20|31
SE|00000000||tx|1|entity|C0025942|Miconazole|orch,phsu|||miconazole||||1000|34|43
SE|00000000||tx|1|entity|C0009074|Clotrimazole|orch,phsu|||clotrimazole||||1000|46|57
SE|00000000||tx|1|entity|C0016277|Fluconazole|orch,phsu|||fluconazole||||1000|60|70
SE|00000000||tx|1|entity|C1548556|etc.|idcn|||etc||||1000|73|75

SE|00000000||tx|2|text|in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
SE|00000000||tx|2|entity|C0683949|Animal Study|anim|||animal studies||||1000|14|27
SE|00000000||tx|2|entity|C0205195|Combined|qlco|||combination||||1000|38|48
SE|00000000||tx|2|entity|C0002679|Amphotericin B|antb,orch|||amphotericin B||||1000|53|66
SE|00000000||tx|2|entity|C0020924|Imidazoles|orch,phsu|||imidazoles||||1000|72|81
SE|00000000||tx|2|entity|C0020924|Imidazoles|orch,phsu|||imidazoles||||1000|96|105
SE|00000000||tx|2|entity|C0521033|Fungal|ftcn|||fungal||||694|118|123
SE|00000000||tx|2|entity|C0002679|Amphotericin B|antb,orch|||amphotericin B||||1000|139|152


SE|00000000||tx|1|text|In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|9|16
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combined||||888|22|29
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|31|33
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|38|49
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|55|64
SE|00000000||tx|1|entity|C1302234|Fatal|qlco|||fatal||||901|91|95
SE|00000000||tx|1|entity|C0017181|Gastrointestinal Hemorrhage|patf|||gastrointestinal hemorrhage||||901|97|123
SE|00000000||tx|1|relation|1|1|C0017181|Gastrointestinal Hemorrhage|patf|patf|||gastrointestinal hemorrhage||||901|97|123|VERB|AFFECTS||75|84|4|4|C0030705|Patients|podg,humn|humn|||patients||||1000|9|16


SE|00000000||tx|1|text|Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.
SE|00000000||tx|1|entity|C0205547|Routine|qlco|||Routine||||888|1|7
SE|00000000||tx|1|entity|C0042210|Vaccines|imft,phsu|||vaccines||||1000|27|34
SE|00000000||tx|1|entity|C0040555|Toxoids|imft,phsu|||toxoids||||1000|39|45
SE|00000000||tx|1|entity|C0149783|Steroid therapy|topp|||corticosteroid therapy||||1000|72|93
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||1000|114|121


SE|00000000||tx|1|text|CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.
SE|00000000||tx|1|entity|C0701105|Crixivan|orch,phsu|||CRIXIVAN||||1000|1|8
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|14|16
SE|00000000||tx|1|entity|C1704419|Effective|qlco|||effective||||1000|21|29
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decreased||||851|38|46
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||851|48|56
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||851|58|71
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|76|83
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||827|98|103
SE|00000000||tx|1|relation|0|0|C0701105|Crixivan|orch,phsu|orch|||CRIXIVAN||||1000|1|8|SPEC|ISA||1|56|0|0|C0376637|Indinavir|orch,phsu|orch|||indinavir||||851|48|56
SE|00000000||tx|1|relation|3|1|C0376637|Indinavir|orch,phsu|phsu|||indinavir||||851|48|56|PREP|TREATS||73|74|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|76|83
SE|00000000||tx|1|relation|0|0|C0701105|Crixivan|orch,phsu|orch|||CRIXIVAN||||1000|1|8|INFER|TREATS(SPEC)||1|56|0|0|C0030705|Patients|podg,humn|podg|||patients||||1000|76|83


SE|00000000||tx|1|text|Chlorthalidone may add to or potentiate the action of other antihypertensive drugs.
SE|00000000||tx|1|entity|C0008294|Chlorthalidone|orch,phsu|||Chlorthalidone||||1000|1|14
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|45|50
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensive drugs||||1000|61|82


SE|00000000||tx|1|text|A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||756|18|20
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||756|22|28
SE|00000000||tx|1|entity|C1515187|Take|hlca|||taking||||756|30|35
SE|00000000||tx|1|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||756|37|46
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||766|59|67
SE|00000000||tx|1|entity|C0205449|Three|qnco|||three||||766|76|80
SE|00000000||tx|1|entity|C0040223|Time|tmco|||times||||766|82|86
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||1000|90|92
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||1000|106|114
SE|00000000||tx|1|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||888|119|128
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|130|143
SE|00000000||tx|1|entity|C0439268|Microgram per Milliliter|qnco|||mg/L||||861|154|157
SE|00000000||tx|1|entity|C0439268|Microgram per Milliliter|qnco|||mg/L||||824|166|169


SE|00000000||tx|1|text|Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|17|19
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|55|65
SE|00000000||tx|1|entity|C0009079|Clozapine|orch,phsu|||Clozapine||||1000|75|83
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|89|103
SE|00000000||tx|1|entity|C0009079|Clozapine|orch,phsu|||clozapine||||1000|153|161
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|179|186
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepine||||1000|197|210
SE|00000000||tx|1|entity|C0033978|Psychotropic Drugs|phsu|||psychotropic drug||||1000|225|241
SE|00000000||tx|1|relation|8|7|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepine||||1000|197|210|NOM|INTERACTS_WITH||55|65|8|1|C0009079|Clozapine|orch,phsu|orch|||Clozapine||||1000|75|83
SE|00000000||tx|1|relation|8|7|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepine||||1000|197|210|NOM|INTERACTS_WITH||55|65|8|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|89|103
SE|00000000||tx|1|relation|8|7|C0033978|Psychotropic Drugs|phsu|phsu|||psychotropic drug||||1000|225|241|NOM|INTERACTS_WITH||55|65|8|1|C0009079|Clozapine|orch,phsu|orch|||Clozapine||||1000|75|83
SE|00000000||tx|1|relation|8|8|C0033978|Psychotropic Drugs|phsu|phsu|||psychotropic drug||||1000|225|241|NOM|INTERACTS_WITH||55|65|8|2|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|89|103
SE|00000000||tx|1|relation|6|1|C0009079|Clozapine|orch,phsu|phsu|||clozapine||||1000|153|161|PREP|TREATS||176|177|3|1|C0030705|Patients|podg,humn|podg|||patients||||1000|179|186
SE|00000000||tx|1|relation|6|1|C0009079|Clozapine|orch,phsu|phsu|||Clozapine||||1000|75|83|PREP|TREATS||176|177|3|1|C0030705|Patients|podg,humn|podg|||patients||||1000|179|186


SE|00000000||tx|1|text|Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||Digoxin||||1000|1|7
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multiple||||888|15|22
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|24|28
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||1000|33|44
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|50|56
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||849|79|90
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||849|99|105
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma digoxin concentrations||||849|92|120
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|135|147


SE|00000000||tx|1|text|Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||1000|1|12
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||1000|24|28
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximum||||1000|35|41
SE|00000000||tx|1|entity|C0033080|Prescription procedure|hlca|||prescription||||888|52|63
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|65|68
SE|00000000||tx|1|entity|C0876188|Tikosyn|orch,phsu|||TIKOSYN||||1000|92|98
SE|00000000||tx|1|entity|C0439211|microgram|qnco|||mcg||||773|105|107
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||773|109|111
SE|00000000||tx|1|entity|C1547085|7 days|tmco|||7 days||||1000|118|123
SE|00000000||tx|1|entity|C0114771|dofetilide|orch,phsu|||dofetilide||||888|152|161
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||888|163|166
SE|00000000||tx|1|entity|C0086582|Males|popg|||males||||1000|178|182
SE|00000000||tx|1|entity|C0439073|97|inpr|||97%||||1000|188|190
SE|00000000||tx|1|entity|C0086287|Females|popg|||females||||1000|195|201
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|208|210
SE|00000000||tx|1|entity|C0086582|Males|popg|||males||||1000|222|226
SE|00000000||tx|1|entity|C0450388|69|inpr|||69%||||1000|232|234
SE|00000000||tx|1|entity|C0086287|Females|popg|||females||||1000|239|245
SE|00000000||tx|1|relation|9|4|C0876188|Tikosyn|orch,phsu|phsu|||TIKOSYN||||1000|92|98|PREP|TREATS||175|176|5|1|C0086582|Males|popg,humn|popg|||males||||1000|178|182
SE|00000000||tx|1|relation|10|10|C0022625|Ketoconazole|orch,phsu|phsu|||Ketoconazole||||1000|1|12|PREP|TREATS||192|193|4|1|C0086287|Females|popg,humn|popg|||females||||1000|195|201


SE|00000000||tx|1|text|Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||Selective Serotonin Reuptake Inhibitors||||1000|1|39
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRIs||||1000|50|54
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|63|72
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|75|85
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||paroxetine||||1000|88|97
SE|00000000||tx|1|entity|C0074393|Sertraline|orch,phsu|||sertraline||||1000|100|109
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||rarely||||1000|122|127
SE|00000000||tx|1|entity|C1883552|Weakness|sosy|||weakness||||1000|147|154
SE|00000000||tx|1|entity|C0151889|Hyperreflexia|fndg|||hyperreflexia||||1000|157|169
SE|00000000||tx|1|entity|C0520966|Abnormal coordination|sosy|||incoordination||||1000|176|189
SE|00000000||tx|1|entity|C0439084|>5|qnco|||5-HT1||||851|216|220
SE|00000000||tx|1|entity|C0450565|HT1|blor|||5-HT1||||851|216|220
SE|00000000||tx|1|entity|C0243192|agonists|phsu|||agonists||||851|222|229
SE|00000000||tx|1|relation|6|5|C0360105|Selective serotonin re-uptake inhibitor|phsu|phsu|||SSRIs||||1000|50|54|VERB|CAUSES||141|145|4|1|C1883552|Weakness|sosy|sosy|||weakness||||1000|147|154


SE|00000000||tx|1|text|Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|1|10
SE|00000000||tx|1|entity|C0022914|Lactams|antb,orch|||lactams||||888|29|35
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|42|46
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|48|56
SE|00000000||tx|1|entity|C0007716|Cephalexin|antb,orch|||cephalexin||||1000|61|70
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|88|97
SE|00000000||tx|1|relation|1|1|C0033209|Probenecid|orch,phsu|orch|||probenecid||||1000|88|97|VERB|INHIBITS||75|83|4|1|C0007716|Cephalexin|antb,orch|antb|||cephalexin||||1000|61|70


SE|00000000||tx|1|text|The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.
SE|00000000||tx|1|entity|C1521828|Rate|qnco|||rate||||1000|5|8
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|13|22
SE|00000000||tx|1|entity|C0023530|Leukopenia|dsyn|||leukopenic||||853|32|41
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||853|43|50
SE|00000000||tx|1|entity|C0010583|Cyclophosphamide|opco,phsu|||cyclophosphamide||||861|55|70
SE|00000000||tx|1|entity|C0205191|chronic|tmco|||chronic||||888|100|106
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high doses||||983|126|135
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|140|152


SE|00000000||tx|1|text|Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.
SE|00000000||tx|1|entity|C0075632|Sumatriptan|orch,phsu|||Sumatriptan||||861|1|11
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||rare||||694|31|34
SE|00000000||tx|1|entity|C1552738|described|idcn|||describing||||872|58|67
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||872|69|76
SE|00000000||tx|1|entity|C1883552|Weakness|sosy|||weakness||||1000|83|90
SE|00000000||tx|1|entity|C0151889|Hyperreflexia|fndg|||hyperreflexia||||1000|93|105
SE|00000000||tx|1|entity|C0520966|Abnormal coordination|sosy|||incoordination||||1000|112|125
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||selective serotonin reuptake inhibitor||||1000|150|187
SE|00000000||tx|1|entity|C0075632|Sumatriptan|orch,phsu|||sumatriptan||||1000|200|210
SE|00000000||tx|1|relation|6|1|C1883552|Weakness|sosy|sosy|||weakness||||1000|83|90|PREP|PROCESS_OF||78|81|2|1|C0030705|Patients|podg,humn|humn|||patients||||872|69|76


SE|00000000||tx|1|text|If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.
SE|00000000||tx|1|entity|C0007553|Cefotan|antb,orch|||CEFOTAN||||888|4|10
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycoside||||1000|19|32
SE|00000000||tx|1|entity|C0232804|Renal function|ortf|||renal function||||1000|58|71
SE|00000000||tx|1|entity|C0599918|nephrotoxicity|inpo|||nephrotoxicity||||1000|112|125


SE|00000000||tx|1|text|Cocaine sometimes proves to be fatal when used in combination with heroin.
SE|00000000||tx|1|entity|C0009170|Cocaine|hops,orch,phsu|||Cocaine||||888|1|7
SE|00000000||tx|1|entity|C1998882|Sometimes|tmco|||sometimes||||888|9|17
SE|00000000||tx|1|entity|C1302234|Fatal|qlco|||fatal||||1000|32|36
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|51|61
SE|00000000||tx|1|entity|C0011892|Heroin|hops,orch,phsu|||heroin||||1000|68|73


SE|00000000||tx|1|text|Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.
SE|00000000||tx|1|entity|C0205250|High|qlco|||Elevated||||790|1|8
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||790|10|14
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|26|37
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|63|73
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|75|77
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|82|93
SE|00000000||tx|1|entity|C0028365|Norfloxacin|orch,phsu|||norfloxacin||||1000|100|110


SE|00000000||tx|1|text|Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.
SE|00000000||tx|1|entity|C0022180|Isoflurane|orch,phsu|||Isoflurane||||1000|1|10
SE|00000000||tx|1|entity|C0358430|Muscle relaxants|phsu|||muscle relaxant||||901|28|42
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||901|44|49
SE|00000000||tx|1|entity|C0358430|Muscle relaxants|phsu|||muscle relaxants||||1000|58|73
SE|00000000||tx|1|entity|C0205393|Most|qnco|||most||||812|76|79
SE|00000000||tx|1|entity|C0358430|Muscle relaxants|phsu|||muscle relaxants||||812|105|120
SE|00000000||tx|1|entity|C0599662|magnetic cell separation system|lbpr|||MAC (||||852|127|131
SE|00000000||tx|1|entity|C1440080|Alveolar|bpoc|||alveolar||||852|140|147
SE|00000000||tx|1|entity|C2827771|Cmin|qnco|||minimum alveolar concentration||||852|132|161
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|178|188
SE|00000000||tx|1|relation|5|2|C0358430|Muscle relaxants|phsu|phsu|||muscle relaxants||||812|105|120|NOM|INTERACTS_WITH||44|49|5|1|C0358430|Muscle relaxants|phsu|phsu|||muscle relaxants||||1000|58|73


SE|00000000||tx|1|text|Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.
SE|00000000||tx|1|entity|C0232478|Ingestion|biof|||Ingestion||||1000|1|9
SE|00000000||tx|1|entity|C0012091|Diclofenac|orch,phsu|||diclofenac||||1000|14|23
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentrations||||983|38|57
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|62|68
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|74|85
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||775|91|98
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||775|100|111
SE|00000000||tx|1|entity|C0599918|nephrotoxicity|inpo|||nephrotoxicity||||775|115|128
SE|00000000||tx|1|relation|2|1|C0012091|Diclofenac|orch,phsu|orch|||diclofenac||||1000|14|23|VERB|STIMULATES||29|36|4|2|C0012265|Digoxin|carb,phsu,strd|carb|||digoxin||||1000|62|68
SE|00000000||tx|1|relation|2|1|C0012091|Diclofenac|orch,phsu|orch|||diclofenac||||1000|14|23|VERB|STIMULATES||29|36|4|2|C0025677|Methotrexate|orch,phsu|orch|||methotrexate||||1000|74|85


SE|00000000||tx|1|text|Lofexidine may enhance The CNS depressive effects of alcohol, barbiturates and other sedatives
SE|00000000||tx|1|entity|C0065152|lofexidine|orch,phsu|||Lofexidine||||1000|1|10
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||827|43|49
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|54|60
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|63|74
SE|00000000||tx|1|entity|C0036557|Sedatives|phsu|||sedatives||||1000|86|94


SE|00000000||tx|1|text|Human growth hormone - Concomitant use of L-glutamine and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.
SE|00000000||tx|1|entity|C0169964|Somatropin|aapp,horm,phsu|||Human growth hormone||||875|1|20
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||875|24|34
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||875|36|38
SE|00000000||tx|1|entity|C0017797|Glutamine|aapp,bacs,phsu|||L-glutamine||||1000|43|53
SE|00000000||tx|1|entity|C0169964|Somatropin|aapp,horm,phsu|||human growth hormone||||1000|59|78
SE|00000000||tx|1|entity|C1961155|Absorption of nutrients|phsf|||nutrient absorption||||1000|92|110
SE|00000000||tx|1|entity|C0332287|In addition to|qlco|||with||||850|121|124
SE|00000000||tx|1|entity|C0036992|Short Bowel Syndrome|dsyn|||short bowel syndrome||||850|133|152
SE|00000000||tx|1|relation|3|1|C0169964|Somatropin|aapp,gngm,horm,phsu|aapp|||human growth hormone||||1000|59|78|VERB|AUGMENTS||84|90|2|1|C1961155|Absorption of nutrients|phsf|phsf|||nutrient absorption||||1000|92|110
SE|00000000||tx|1|relation|3|1|C0017797|Glutamine|aapp,gngm,bacs,phsu|aapp|||L-glutamine||||1000|43|53|VERB|AUGMENTS||84|90|2|1|C1961155|Absorption of nutrients|phsf|phsf|||nutrient absorption||||1000|92|110


SE|00000000||tx|1|text|Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.
SE|00000000||tx|1|entity|C0599918|nephrotoxicity|inpo|||Nephrotoxicity||||1000|1|14
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|44|54
SE|00000000||tx|1|entity|C2266959|Cephalosporin Antibacterial [EPC]|antb,orch|||cephalosporins||||1000|74|87
SE|00000000||tx|1|entity|C0003233|Antibiotics, Aminoglycoside|antb,carb|||aminoglycoside antibiotics||||1000|94|119
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||838|124|129
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||838|131|139
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|149|158
SE|00000000||tx|1|relation|0|0|C0016860|Furosemide|orch,phsu|orch|||furosemide||||1000|149|158|SPEC|ISA||131|158|0|0|C0012798|Diuretics|phsu|phsu|||diuretics||||838|131|139


SE|00000000||tx|1|text|These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.
SE|00000000||tx|1|entity|C1274040|Result|ftcn|||results||||1000|7|13
SE|00000000||tx|1|entity|C0205210|Clinical|qlco|||clinical||||888|49|56
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|58|60
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|65|76
SE|00000000||tx|1|entity|C0699262|Elspar|aapp,enzy,phsu|||ELSPAR||||1000|83|88
SE|00000000||tx|1|entity|C0439531|per period (qualifier value)|tmco|||period||||1000|105|110
SE|00000000||tx|1|entity|C0699262|Elspar|aapp,enzy,phsu|||ELSPAR||||888|122|127
SE|00000000||tx|1|entity|C1271686|Plasma asparagine measurement|lbpr|||plasma asparagine levels||||988|142|165
SE|00000000||tx|1|entity|C0205307|Normal|qlco|||normal||||1000|177|182


SE|00000000||tx|1|text|Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||888|16|24
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|26|29
SE|00000000||tx|1|entity|C1292429|8 Hours|tmco|||8 hours||||1000|48|54
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|61|63
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||851|84|92
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||851|94|102
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||851|104|113
SE|00000000||tx|1|entity|C0674427|Sustiva|orch,phsu|||SUSTIVA||||1000|122|128


SE|00000000||tx|1|text|Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0205164|Major|qlco|||major||||901|15|19
SE|00000000||tx|1|entity|C0033975|Psychotic Disorders|mobd|||psychotic disorders||||901|21|39
SE|00000000||tx|1|entity|C0040615|Antipsychotic Agents|phsu|||neuroleptics||||1000|55|66
SE|00000000||tx|1|entity|C0178601|Dopamine Agonists|phsu|||dopamine agonists||||901|92|108
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||888|122|130
SE|00000000||tx|1|entity|C0814225|Benefits|qnco|||benefits||||888|132|139
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risks||||1000|154|158
SE|00000000||tx|1|relation|5|1|C0033975|Psychotic Disorders|mobd|mobd|||psychotic disorders||||901|21|39|PREP|PROCESS_OF||10|13|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8
SE|00000000||tx|1|relation|4|1|C0040615|Antipsychotic Agents|phsu|phsu|||neuroleptics||||1000|55|66|VERB|TREATS||42|48|2|1|C0033975|Psychotic Disorders|mobd|mobd|||psychotic disorders||||901|21|39
SE|00000000||tx|1|relation|3|1|C0178601|Dopamine Agonists|phsu|phsu|||dopamine agonists||||901|92|108|VERB|TREATS||79|85|3|3|C0030705|Patients|podg,humn|podg|||Patients||||1000|1|8
SE|00000000||tx|1|relation|0|0|C0178601|Dopamine Agonists|phsu|phsu|||dopamine agonists||||901|92|108|INFER|TREATS(INFER)||79|85|0|0|C0033975|Psychotic Disorders|mobd|mobd|||psychotic disorders||||901|21|39


SE|00000000||tx|1|text|Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
SE|00000000||tx|1|entity|C0009214|Codeine|orch,phsu|||Codeine||||1000|1|7
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|12|22
SE|00000000||tx|1|entity|C0027409|Narcotic Analgesics|phsu|||narcotic analgesics||||1000|35|53
SE|00000000||tx|1|entity|C0017302|General anesthetic drugs|phsu|||general anesthetics||||1000|56|74
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|77|90
SE|00000000||tx|1|entity|C0040614|Tranquilizing Agents|phsu|||tranquilizers||||1000|93|105
SE|00000000||tx|1|entity|C0020592|Hypnotics and Sedatives|phsu|||sedative-hypnotics||||1000|108|125
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||1000|137|151
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|164|170
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||802|177|184
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||802|197|203
SE|00000000||tx|1|relation|0|0|C0009214|Codeine|orch,phsu|orch|||Codeine||||1000|1|7|SPEC|ISA||1|53|0|0|C0027409|Narcotic Analgesics|phsu|phsu|||narcotic analgesics||||1000|35|53
SE|00000000||tx|1|relation|0|0|C0009214|Codeine|orch,phsu|orch|||Codeine||||1000|1|7|SPEC|ISA||1|53|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|137|151
SE|00000000||tx|1|relation|0|0|C0009214|Codeine|orch,phsu|orch|||Codeine||||1000|1|7|SPEC|ISA||1|53|0|0|C0020592|Hypnotics and Sedatives|phsu|phsu|||sedative-hypnotics||||1000|108|125
SE|00000000||tx|1|relation|0|0|C0020592|Hypnotics and Sedatives|phsu|phsu|||sedative-hypnotics||||1000|108|125|SPEC|ISA||108|151|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|137|151
SE|00000000||tx|1|relation|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|137|151|SPEC|ISA||108|151|0|0|C0020592|Hypnotics and Sedatives|phsu|phsu|||sedative-hypnotics||||1000|108|125
SE|00000000||tx|1|relation|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|137|151|SPEC|ISA||108|151|0|0|C0040614|Tranquilizing Agents|phsu|phsu|||tranquilizers||||1000|93|105
SE|00000000||tx|1|relation|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|137|151|SPEC|ISA||108|151|0|0|C0031436|Phenothiazines|orch,phsu|phsu|||phenothiazines||||1000|77|90
SE|00000000||tx|1|relation|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|137|151|SPEC|ISA||108|151|0|0|C0017302|General anesthetic drugs|phsu|phsu|||general anesthetics||||1000|56|74
SE|00000000||tx|1|relation|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|137|151|SPEC|ISA||108|151|0|0|C0027409|Narcotic Analgesics|phsu|phsu|||narcotic analgesics||||1000|35|53
SE|00000000||tx|1|relation|0|0|C0040614|Tranquilizing Agents|phsu|phsu|||tranquilizers||||1000|93|105|SPEC|ISA||108|151|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|137|151
SE|00000000||tx|1|relation|0|0|C0040614|Tranquilizing Agents|phsu|phsu|||tranquilizers||||1000|93|105|SPEC|ISA||108|151|0|0|C0031436|Phenothiazines|orch,phsu|phsu|||phenothiazines||||1000|77|90
SE|00000000||tx|1|relation|0|0|C0031436|Phenothiazines|orch,phsu|phsu|||phenothiazines||||1000|77|90|SPEC|ISA||108|151|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|137|151
SE|00000000||tx|1|relation|0|0|C0031436|Phenothiazines|orch,phsu|phsu|||phenothiazines||||1000|77|90|SPEC|ISA||108|151|0|0|C0040614|Tranquilizing Agents|phsu|phsu|||tranquilizers||||1000|93|105
SE|00000000||tx|1|relation|0|0|C0017302|General anesthetic drugs|phsu|phsu|||general anesthetics||||1000|56|74|SPEC|ISA||108|151|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|137|151
SE|00000000||tx|1|relation|0|0|C0027409|Narcotic Analgesics|phsu|phsu|||narcotic analgesics||||1000|35|53|SPEC|ISA||108|151|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|137|151


SE|00000000||tx|1|text|Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||966|17|24
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|46|49
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||794|57|62
SE|00000000||tx|1|entity|C0008845|Citalopram|orch,phsu|||citalopram||||794|72|81
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combined||||888|84|91
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||824|115|120
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||824|122|131
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|139|142
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|159|166
SE|00000000||tx|1|entity|C0008845|Citalopram|orch,phsu|||citalopram||||888|171|180
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|182|184
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|190|193


SE|00000000||tx|1|text|Therefore, hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered.
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||888|12|19
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||888|21|34
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||851|47|50
SE|00000000||tx|1|entity|C1272883|Injection product|bodm|||injectable||||851|53|62
SE|00000000||tx|1|entity|C0694643|transdermal|spco|||transdermal||||851|65|75
SE|00000000||tx|1|entity|C0021102|Implants|medd|||implantable||||888|82|92
SE|00000000||tx|1|entity|C0348078|Qualitative form|qlco|||forms||||888|94|98
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|105|107
SE|00000000||tx|1|entity|C1101331|Tracleer|orch,phsu|||TRACLEER||||1000|126|133


SE|00000000||tx|1|text|Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.
SE|00000000||tx|1|entity|C0991507|Extended Release Tablet|bodm|||Extended Release Tablets||||1000|1|24
SE|00000000||tx|1|entity|C0028066|Nifedipine|orch,phsu|||nifedipine||||1000|45|54
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|61|67
SE|00000000||tx|1|entity|C0337449|Digoxin measurement|lbpr|||digoxin levels||||1000|79|92
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||790|105|110
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||790|112|121


SE|00000000||tx|1|text|Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||clinical studies||||1000|15|30
SE|00000000||tx|1|entity|C0700325|Patient observation|hlca|||observations||||861|58|69
SE|00000000||tx|1|entity|C0700001|Lodine|orch,phsu|||Lodine||||1000|87|92
SE|00000000||tx|1|entity|C3179308|Natriuretic Effect|phsf|||natriuretic effect||||1000|109|126
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|131|140
SE|00000000||tx|1|entity|C0541746|Thiazides|orch,phsu|||thiazides||||1000|146|154
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|164|171
SE|00000000||tx|1|relation|3|1|C0700001|Lodine|orch,phsu|orch|||Lodine||||1000|87|92|VERB|DISRUPTS||98|103|4|1|C3179308|Natriuretic Effect|phsf|phsf|||natriuretic effect||||1000|109|126
SE|00000000||tx|1|relation|6|3|C3179308|Natriuretic Effect|phsf|phsf|||natriuretic effect||||1000|109|126|PREP|PROCESS_OF||156|157|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|164|171


SE|00000000||tx|1|text|The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.
SE|00000000||tx|1|entity|C0237795|Pressors|phsu|||pressor||||888|5|11
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|13|19
SE|00000000||tx|1|entity|C0700758|Ergomar|orch,phsu|||ERGOMAR||||1000|24|30
SE|00000000||tx|1|entity|C0042397|Vasoconstrictor Agents|phsu|||vasoconstrictor drugs||||1000|42|62
SE|00000000||tx|1|entity|C0010968|Dangerousness|idcn|||dangerous||||853|85|93
SE|00000000||tx|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||853|95|106
SE|00000000||tx|1|relation|0|0|C0700758|Ergomar|orch,phsu|orch|||ERGOMAR||||1000|24|30|SPEC|ISA||24|62|0|0|C0042397|Vasoconstrictor Agents|phsu|phsu|||vasoconstrictor drugs||||1000|42|62
SE|00000000||tx|1|relation|0|0|C0042397|Vasoconstrictor Agents|phsu|phsu|||vasoconstrictor drugs||||1000|42|62|SPEC|ISA||24|62|0|0|C0700758|Ergomar|orch,phsu|phsu|||ERGOMAR||||1000|24|30
SE|00000000||tx|1|relation|3|1|C0042397|Vasoconstrictor Agents|phsu|phsu|||vasoconstrictor drugs||||1000|42|62|VERB|CAUSES||79|83|1|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||853|95|106
SE|00000000||tx|1|relation|3|1|C0700758|Ergomar|orch,phsu|phsu|||ERGOMAR||||1000|24|30|VERB|CAUSES||79|83|1|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||853|95|106
SE|00000000||tx|1|relation|0|0|C0700758|Ergomar|orch,phsu|orch|||ERGOMAR||||1000|24|30|INFER|CAUSES(SPEC)||24|62|0|0|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||853|95|106
SE|00000000||tx|1|relation|0|0|C0042397|Vasoconstrictor Agents|phsu|phsu|||vasoconstrictor drugs||||1000|42|62|INFER|CAUSES(SPEC)||24|62|0|0|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||853|95|106


SE|00000000||tx|1|text|Antacids may interfere with the absorption of LEVSIN.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|entity|C0721347|Levsin|orch,phsu|||LEVSIN||||1000|47|52


SE|00000000||tx|1|text|Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.
SE|00000000||tx|1|entity|C0031935|Pimozide|orch,phsu|||Pimozide||||1000|1|8
SE|00000000||tx|1|entity|C0719199|Celexa|orch,phsu|||Celexa||||1000|14|19
SE|00000000||tx|1|entity|C0681867|Controlled Study|resa|||controlled study||||1000|28|43
SE|00000000||tx|1|entity|C0087136|Unmarried|fndg|||single||||888|48|53
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|55|58
SE|00000000||tx|1|entity|C0988890|Pimozide 2 MG|clnd|||pimozide 2 mg||||1000|63|75
SE|00000000||tx|1|entity|C1124670|Citalopram 40 MG|clnd|||citalopram 40 mg||||923|106|121
SE|00000000||tx|1|entity|C0556983|Once daily|tmco|||once daily||||1000|129|138
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|147|150
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|179|186
SE|00000000||tx|1|entity|C0042295|Values|qlco|||values||||861|195|200
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||802|205|217
SE|00000000||tx|1|entity|C0439223|millisecond|tmco|||msec||||802|222|225
SE|00000000||tx|1|entity|C0031935|Pimozide|orch,phsu|||pimozide||||775|239|246
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||775|254|258


SE|00000000||tx|1|text|ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE-inhibitors||||1000|1|14
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|37|42
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|78|83
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE-inhibitors||||1000|88|101


SE|00000000||tx|1|text|Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
SE|00000000||tx|1|entity|C1514118|Nephrotoxic|qlco|||Nephrotoxic||||872|1|11
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||872|13|18
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|22|32
SE|00000000||tx|1|entity|C0286078|Vistide|nnon,phsu|||VISTIDE||||1000|52|58
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|64|69
SE|00000000||tx|1|entity|C1514118|Nephrotoxic|qlco|||nephrotoxic||||888|76|86
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||888|88|96
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||888|105|115
SE|00000000||tx|1|entity|C0003233|Antibiotics, Aminoglycoside|antb,carb|||aminoglycosides||||888|117|131
SE|00000000||tx|1|entity|C0040341|Tobramycin|antb,carb|||tobramycin||||1000|140|149
SE|00000000||tx|1|entity|C0017436|Gentamicins|antb,carb|||gentamicin||||1000|152|161
SE|00000000||tx|1|entity|C0002499|Amikacin|antb,carb|||amikacin||||1000|168|175
SE|00000000||tx|1|entity|C0002679|Amphotericin B|antb,orch|||amphotericin B||||1000|179|192
SE|00000000||tx|1|entity|C0070895|Foscarnet|opco,phsu|||foscarnet||||1000|195|203
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||888|206|216
SE|00000000||tx|1|entity|C0030863|Pentamidine|orch,phsu|||pentamidine||||888|218|228
SE|00000000||tx|1|entity|C0042313|Vancomycin|aapp,antb|||vancomycin||||1000|231|240
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||non-steroidal anti-inflammatory agents||||1000|247|284


SE|00000000||tx|1|text|Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.
SE|00000000||tx|1|entity|C0025853|Metoclopramide|orch,phsu|||metoclopramide||||1000|10|23
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|42|56
SE|00000000||tx|1|entity|C0023570|Levodopa|aapp,nsba,phsu|||levodopa||||1000|61|68
SE|00000000||tx|1|entity|C0442808|Increasing|ftcn|||increasing||||901|73|82
SE|00000000||tx|1|entity|C0017127|Gastric Emptying|ortf|||gastric emptying||||901|84|99
SE|00000000||tx|1|entity|C0025853|Metoclopramide|orch,phsu|||metoclopramide||||1000|102|115
SE|00000000||tx|1|entity|C0920467|disorder control (procedure)|topp|||disease control||||1000|143|157
SE|00000000||tx|1|entity|C0242702|Dopamine Antagonists|nsba,phsu|||dopamine receptor antagonistic||||892|166|195
SE|00000000||tx|1|entity|C1292721|Has property|ftcn|||properties||||892|197|206
SE|00000000||tx|1|relation|1|1|C0025853|Metoclopramide|orch,phsu|orch|||metoclopramide||||1000|10|23|VERB|STIMULATES||29|36|6|2|C0023570|Levodopa|aapp,gngm,nsba,phsu|gngm|||levodopa||||1000|61|68


SE|00000000||tx|1|text|Wait 2 weeks after stopping an MAO inhibitor before starting escitalopram.
SE|00000000||tx|1|entity|C1610166|wait|ftcn|||Wait||||802|1|4
SE|00000000||tx|1|entity|C0439230|week|tmco|||weeks||||802|8|12
SE|00000000||tx|1|entity|C0723457|Stop brand of fluoride|inch,phsu|||stopping||||1000|20|27
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitor||||1000|32|44
SE|00000000||tx|1|entity|C0439659|Beginning|tmco|||starting||||872|53|60
SE|00000000||tx|1|entity|C1099456|Escitalopram|orch,phsu|||escitalopram||||872|62|73


SE|00000000||tx|1|text|Adenosine effects are potentiated by dipyridamole.
SE|00000000||tx|1|entity|C0001443|Adenosine|nnon,nsba,phsu|||Adenosine||||888|1|9
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|11|17
SE|00000000||tx|1|entity|C0012582|Dipyridamole|orch,phsu|||dipyridamole||||1000|38|49


SE|00000000||tx|1|text|Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.
SE|00000000||tx|1|entity|C0599918|nephrotoxicity|inpo|||Nephrotoxicity||||1000|1|14
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|44|54
SE|00000000||tx|1|entity|C0003233|Antibiotics, Aminoglycoside|antb,carb|||aminoglycoside antibiotics||||1000|74|99
SE|00000000||tx|1|entity|C2266959|Cephalosporin Antibacterial [EPC]|antb,orch|||cephalosporin antibiotics||||1000|105|129


SE|00000000||tx|1|text|Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4.
SE|00000000||tx|1|entity|C0252643|bosentan|orch,phsu|||Bosentan||||1000|1|8
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|37|57
SE|00000000||tx|1|entity|C0359086|Oral hypoglycemic|phsu|||oral hypoglycemic agents||||1000|68|91
SE|00000000||tx|1|entity|||gngm|1559|CYP2C9|CYP2C9||||1000|131|136
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|141|146
SE|00000000||tx|1|relation|1|1|C0252643|bosentan|orch,phsu|orch|||Bosentan||||1000|1|8|VERB|INHIBITS||30|35|4|2|C0359086|Oral hypoglycemic|phsu|phsu|||oral hypoglycemic agents||||1000|68|91
SE|00000000||tx|1|relation|2|1|||gngm,aapp|gngm|1559|CYP2C9|CYP2C9||||1000|131|136|VERB|INTERACTS_WITH||116|126|3|1|C0359086|Oral hypoglycemic|phsu|phsu|||oral hypoglycemic agents||||1000|68|91
SE|00000000||tx|1|relation|2|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|141|146|VERB|INTERACTS_WITH||116|126|3|1|C0359086|Oral hypoglycemic|phsu|phsu|||oral hypoglycemic agents||||1000|68|91


SE|00000000||tx|1|text|Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|7|16
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||marked||||888|48|53
SE|00000000||tx|1|entity|C2346501|Interference|acty|||interference||||888|55|66
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|77|86
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|91|98
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduced||||888|116|122
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|124|132
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||901|153|158
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||901|160|168
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|178|185
SE|00000000||tx|1|entity|C1457887|Symptoms|sosy|||symptoms||||1000|190|197
SE|00000000||tx|1|entity|C0205250|High|qlco|||high||||694|214|217
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|229|236
SE|00000000||tx|1|relation|4|1|C0006644|Caffeine|orch,phsu|orch|||caffeine||||1000|91|98|ADJ|INHIBITS||116|122|6|6|C0006644|Caffeine|orch,phsu|orch|||caffeine||||1000|229|236


SE|00000000||tx|1|text|Vasospastic reactions have been reported with therapeutic doses of ergotamine-containing drugs when co-administered with these antibiotics.
SE|00000000||tx|1|entity|C0443286|Reaction|ftcn|||reactions||||827|13|21
SE|00000000||tx|1|entity|C0302350|Therapeutic|ftcn|||therapeutic||||888|47|57
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|59|63
SE|00000000||tx|1|entity|C0014710|Ergotamine|orch,phsu|||ergotamine||||851|68|77
SE|00000000||tx|1|entity|C2700400|Contain (action)|acty|||containing||||851|79|88
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||851|90|94
SE|00000000||tx|1|entity|C0003232|Antibiotics|antb|||antibiotics||||1000|128|138


SE|00000000||tx|1|text|In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.
SE|00000000||tx|1|entity|C0591237|Casodex|orch,phsu|||CASODEX||||1000|29|35
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin anticoagulants||||983|50|72
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|83|90
SE|00000000||tx|1|entity|C0033684|Proteins|aapp,bacs|||protein-||||901|104|111
SE|00000000||tx|1|entity|C0005456|Binding Sites|rcpt|||binding sites||||901|112|124
SE|00000000||tx|1|relation|0|0|C0005456|Binding Sites|rcpt|rcpt|||binding sites||||901|112|124|MOD/HEAD|ISA||104|124|0|0|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein-||||901|104|111
SE|00000000||tx|1|relation|0|0|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||1000|83|90|SPEC|ISA||50|90|0|0|C0010206|coumarin|orch,phsu|orch|||coumarin anticoagulants||||983|50|72


SE|00000000||tx|1|text|Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.
SE|00000000||tx|1|entity|C0453882|Combinations|mnob|||Combinations||||1000|1|12
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|23|27
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|34|36
SE|00000000||tx|1|entity|C0701105|Crixivan|orch,phsu|||CRIXIVAN||||1000|75|82
SE|00000000||tx|1|entity|C1145759|Atazanavir|orch,phsu|||atazanavir||||1000|88|97
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|102|104
SE|00000000||tx|1|relation|4|4|C1145759|Atazanavir|orch,phsu|orch|||atazanavir||||1000|88|97|NOM|COEXISTS_WITH||1|12|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|23|27


SE|00000000||tx|1|text|Cimetidine reduces the clearance of ALFENTA.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|24|32
SE|00000000||tx|1|entity|C0002025|Alfenta|orch,phsu|||ALFENTA||||1000|37|43
SE|00000000||tx|1|relation|1|1|C0008783|Cimetidine|orch,phsu|orch|||Cimetidine||||1000|1|10|VERB|INHIBITS||12|18|2|2|C0002025|Alfenta|orch,phsu|orch|||ALFENTA||||1000|37|43


SE|00000000||tx|1|text|Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||Tricyclic antidepressants||||1000|1|25
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|59|69
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|71|76
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||888|81|88
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||888|90|98
SE|00000000||tx|1|relation|2|2|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||Tricyclic antidepressants||||1000|1|25|NOM|INTERACTS_WITH||71|76|1|1|C0009014|Clonidine|orch,phsu|orch|||clonidine||||888|90|98

SE|00000000||tx|2|text|It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.
SE|00000000||tx|2|entity|C1518422|Negation|ftcn|||not||||1000|7|9
SE|00000000||tx|2|entity|C0205420|Concurrent|tmco|||concurrent||||888|29|38
SE|00000000||tx|2|entity|C0042153|utilization qualifier|ftcn|||use||||888|40|42
SE|00000000||tx|2|entity|C0450442|Agent|chvf|||agents||||966|53|58
SE|00000000||tx|2|entity|C1170041|Alphagan-P|orch,phsu|||ALPHAGAN P||||1000|65|74
SE|00000000||tx|2|entity|C0086418|Homo sapiens|humn|||humans||||1000|79|84
SE|00000000||tx|2|entity|C0678226|Due to|ftcn|||resulting||||888|98|106
SE|00000000||tx|2|entity|C2346501|Interference|acty|||interference||||888|108|119
SE|00000000||tx|2|entity|C0441994|Lower - spatial qualifier|spco|||lowering||||790|134|141
SE|00000000||tx|2|entity|C1280500|Effect|qlco|||effect||||790|143|148
SE|00000000||tx|2|relation|3|1|C1170041|Alphagan-P|orch,phsu|phsu|||ALPHAGAN P||||1000|65|74|PREP|TREATS||76|77|3|1|C0086418|Homo sapiens|grup,humn|humn|||humans||||1000|79|84


SE|00000000||tx|1|text|Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||Antihypertensives||||1000|1|17
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||Amphetamines||||1000|20|31
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|52|62
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|64|70
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensives||||1000|75|91


SE|00000000||tx|1|text|A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||888|3|10
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||888|12|22
SE|00000000||tx|1|entity|C0017628|Glyburide|orch,phsu|||glyburide||||1000|32|40
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|46|58
SE|00000000||tx|1|entity|C0949665|Fluoroquinolones|orch,phsu|||fluoroquinolone||||888|63|77
SE|00000000||tx|1|entity|C0003232|Antibiotics|antb|||antibiotic||||888|79|88
SE|00000000||tx|1|entity|C0279023|chemosensitization/potentiation|topp|||potentiation||||1000|125|136
SE|00000000||tx|1|entity|C0020616|Hypoglycemic Agents|phsu|||hypoglycemic||||888|145|156
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||888|158|163
SE|00000000||tx|1|entity|C0017628|Glyburide|orch,phsu|||glyburide||||1000|168|176
SE|00000000||tx|1|relation|0|0|C0008809|Ciprofloxacin|orch,phsu|orch|||ciprofloxacin||||1000|46|58|SPEC|ISA||46|88|0|0|C0003232|Antibiotics|antb|antb|||antibiotic||||888|79|88
SE|00000000||tx|1|relation|0|0|C0017628|Glyburide|orch,phsu|orch|||glyburide||||1000|32|40|SPEC|ISA||46|88|0|0|C0003232|Antibiotics|antb|antb|||antibiotic||||888|79|88
SE|00000000||tx|1|relation|6|3|C0003232|Antibiotics|antb|antb|||antibiotic||||888|79|88|NOM|INTERACTS_WITH||12|22|6|1|C0017628|Glyburide|orch,phsu|orch|||glyburide||||1000|32|40
SE|00000000||tx|1|relation|6|3|C0003232|Antibiotics|antb|antb|||antibiotic||||888|79|88|NOM|INTERACTS_WITH||12|22|6|1|C0008809|Ciprofloxacin|orch,phsu|orch|||ciprofloxacin||||1000|46|58
SE|00000000||tx|1|relation|0|0|C0008809|Ciprofloxacin|orch,phsu|orch|||ciprofloxacin||||1000|46|58|INFER|INTERACTS_WITH(SPEC)||46|88|0|0|C0017628|Glyburide|orch,phsu|orch|||glyburide||||1000|32|40
SE|00000000||tx|1|relation|0|0|C0008809|Ciprofloxacin|orch,phsu|orch|||ciprofloxacin||||1000|46|58|INFER|INTERACTS_WITH(SPEC)||46|88|0|0|C0008809|Ciprofloxacin|orch,phsu|orch|||ciprofloxacin||||1000|46|58
SE|00000000||tx|1|relation|0|0|C0017628|Glyburide|orch,phsu|orch|||glyburide||||1000|32|40|INFER|INTERACTS_WITH(SPEC)||46|88|0|0|C0017628|Glyburide|orch,phsu|orch|||glyburide||||1000|32|40
SE|00000000||tx|1|relation|0|0|C0017628|Glyburide|orch,phsu|orch|||glyburide||||1000|32|40|INFER|INTERACTS_WITH(SPEC)||46|88|0|0|C0008809|Ciprofloxacin|orch,phsu|orch|||ciprofloxacin||||1000|46|58


SE|00000000||tx|1|text|Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0033228|Fenofibrate|orch,phsu|||fenofibrate||||1000|31|41
SE|00000000||tx|1|entity|C0205163|Equal|qlco|||equivalent||||1000|44|53
SE|00000000||tx|1|entity|C0723893|Tricor|orch,phsu|||TRICOR||||790|65|70
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||1000|78|89
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||1000|104|108
SE|00000000||tx|1|entity|C1547061|10 days|tmco|||10 days||||1000|114|120
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||802|134|146
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||802|152|159
SE|00000000||tx|1|entity|C1514721|Range|qnco|||range||||1000|162|166
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|177|184
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|193|200
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||851|206|217
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||851|219|221
SE|00000000||tx|1|entity|C0042295|Values|qlco|||values||||851|223|228
SE|00000000||tx|1|entity|C0018684|Health|idcn|||healthy||||754|236|242
SE|00000000||tx|1|entity|C0024554|Male gender|fndg|||males||||754|244|248
SE|00000000||tx|1|relation|12|8|C0286651|atorvastatin|orch,phsu|phsu|||atorvastatin||||1000|78|89|PREP|TREATS||230|231|1|1|C0024554|Male gender|fndg|fndg|||males||||754|244|248


SE|00000000||tx|1|text|Therefore, concomitant use of TORADOL and probenecid is contraindicated.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|12|22
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|24|26
SE|00000000||tx|1|entity|C0146226|Toradol|orch,phsu|||TORADOL||||1000|31|37
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|43|52


SE|00000000||tx|1|text|Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|7|18
SE|00000000||tx|1|entity|C0304490|Potassium Sparing Diuretics|phsu|||potassium-sparing diuretics||||1000|24|50
SE|00000000||tx|1|entity|C0026054|Midamor|orch,phsu|||MIDAMOR||||1000|63|69
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||905|110|114
SE|00000000||tx|1|entity|C0553704|Potassium, increased level|fndg|||increased serum potassium levels||||905|100|131
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||888|138|146
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|148|154
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||888|159|167
SE|00000000||tx|1|entity|C0220865|kinetic characteristics|ftcn|||kinetics||||888|169|176
SE|00000000||tx|1|entity|C0232804|Renal function|ortf|||renal function||||1000|182|195
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|229|234


SE|00000000||tx|1|text|Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||Aspirin||||1000|1|7
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|10|19
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|39|45
SE|00000000||tx|1|entity|C0016377|Flurbiprofen|orch,phsu|||flurbiprofen||||1000|51|62
SE|00000000||tx|1|entity|C0016377|Flurbiprofen|orch,phsu|||flurbiprofen||||774|92|103
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum flurbiprofen concentrations||||774|86|118
SE|00000000||tx|1|relation|4|1|C0016377|Flurbiprofen|orch,phsu|orch|||flurbiprofen||||1000|51|62|PREP|COEXISTS_WITH||73|74|1|1|C0016377|Flurbiprofen|orch,phsu|orch|||flurbiprofen||||774|92|103
SE|00000000||tx|1|relation|4|1|C0004057|Aspirin|orch,phsu|orch|||aspirin||||1000|39|45|PREP|COEXISTS_WITH||73|74|1|1|C0016377|Flurbiprofen|orch,phsu|orch|||flurbiprofen||||774|92|103


SE|00000000||tx|1|text|Using calcium acetate with digitalis glycosides (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.
SE|00000000||tx|1|entity|C0717537|calcium acetate|irda,orch,phsu|||calcium acetate||||1000|7|21
SE|00000000||tx|1|entity|C0012253|Digitalis Glycosides|carb,phsu|||digitalis glycosides||||1000|28|47
SE|00000000||tx|1|entity|C0018787|Heart|bpoc|||heart||||888|50|54
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medicine||||888|56|63
SE|00000000||tx|1|entity|C0020437|Hypercalcemia|dsyn|||hypercalcemia||||1000|76|88
SE|00000000||tx|1|entity|C0006675|Calcium|bacs,elii,phsu|||calcium||||1000|100|106
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||1000|115|119
SE|00000000||tx|1|entity|C0237506|Chance|qlco|||chance||||1000|148|153
SE|00000000||tx|1|entity|C0237314|Irregular heart beat|fndg|||irregular heartbeat||||1000|172|190
SE|00000000||tx|1|relation|0|0|C0012253|Digitalis Glycosides|carb,phsu|carb|||digitalis glycosides||||1000|28|47|SPEC|ISA||28|63|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medicine||||888|56|63
SE|00000000||tx|1|relation|3|2|C0012253|Digitalis Glycosides|carb,phsu|carb|||digitalis glycosides||||1000|28|47|VERB|CAUSES||70|74|6|1|C0020437|Hypercalcemia|dsyn|dsyn|||hypercalcemia||||1000|76|88
SE|00000000||tx|1|relation|4|1|C0005767|Blood|tisu|tisu|||blood||||1000|115|119|PREP|LOCATION_OF||108|109|5|1|C0006675|Calcium|bacs,elii,phsu|elii|||calcium||||1000|100|106


SE|00000000||tx|1|text|Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.
SE|00000000||tx|1|entity|C0026162|Minerals|inch|||Mineral||||861|1|7
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||861|13|23
SE|00000000||tx|1|entity|C0556200|Oil intake|fndg|||Oil-Concomitant intake||||861|9|30
SE|00000000||tx|1|entity|C0026156|Mineral Oil|lipd,phsu|||mineral oil||||1000|35|45
SE|00000000||tx|1|entity|C0042878|Vitamin K|lipd,phsu,vita|||vitamin K||||1000|51|59
SE|00000000||tx|1|entity|C0042878|Vitamin K|lipd,phsu,vita|||vitamin K||||1000|90|98


SE|00000000||tx|1|text|Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.
SE|00000000||tx|1|entity|C0242896|Anticholinergic Agents|phsu|||Anticholinergic agents||||1000|1|22
SE|00000000||tx|1|entity|C0700580|Ipratropium Bromide|orch,phsu|||ipratropium bromide||||1000|34|52
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||888|85|92
SE|00000000||tx|1|entity|C1516559|Circulatory Process|orgf|||circulation||||888|94|104
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|121|129
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|138|145
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||888|147|157
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||861|199|209


SE|00000000||tx|1|text|Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.
SE|00000000||tx|1|entity|C0439659|Beginning|tmco|||beginning||||1000|25|33
SE|00000000||tx|1|entity|C0392747|Changing|ftcn|||changing||||1000|54|61
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|67|70
SE|00000000||tx|1|entity|C0591362|Diamox|orch,phsu|||DIAMOX||||1000|75|80
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|85|92
SE|00000000||tx|1|entity|C0033148|Primidone|orch,phsu|||primidone||||1000|104|112
SE|00000000||tx|1|relation|5|1|C0591362|Diamox|orch,phsu|phsu|||DIAMOX||||1000|75|80|PREP|TREATS||82|83|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|85|92
SE|00000000||tx|1|relation|1|1|C0033148|Primidone|orch,phsu|orch|||primidone||||1000|104|112|VERB|ADMINISTERED_TO||94|102|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|85|92


SE|00000000||tx|1|text|In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|4|11
SE|00000000||tx|1|entity|C0000618|mercaptopurine|nnon,phsu|||mercaptopurine||||1000|23|36
SE|00000000||tx|1|entity|C0722911|Purinethol|nnon,phsu|||Purinethol||||1000|39|48
SE|00000000||tx|1|entity|C0004482|Azathioprine|orch,phsu|||azathioprine||||1000|54|65
SE|00000000||tx|1|entity|C0699279|Imuran|orch,phsu|||Imuran||||1000|68|73
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|81|91
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|125|135
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||1000|141|143
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|160|168
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||1000|173|176
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||851|181|193
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||851|195|197
SE|00000000||tx|1|entity|C0205437|Third|qnco|||third||||851|199|203
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|208|210
SE|00000000||tx|1|entity|C0205438|Fourth|qnco|||fourth||||888|212|217
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||861|232|235
SE|00000000||tx|1|entity|C0000618|mercaptopurine|nnon,phsu|||mercaptopurine||||1000|240|253
SE|00000000||tx|1|entity|C0004482|Azathioprine|orch,phsu|||azathioprine||||1000|258|269
SE|00000000||tx|1|relation|0|0|C0722911|Purinethol|nnon,phsu|nnon|||Purinethol||||1000|39|48|SPEC|ISA||23|48|0|0|C0000618|mercaptopurine|nnon,phsu|nnon|||mercaptopurine||||1000|23|36
SE|00000000||tx|1|relation|0|0|C0699279|Imuran|orch,phsu|orch|||Imuran||||1000|68|73|SPEC|ISA||54|73|0|0|C0004482|Azathioprine|orch,phsu|orch|||azathioprine||||1000|54|65
SE|00000000||tx|1|relation|0|0|C0699279|Imuran|orch,phsu|orch|||Imuran||||1000|68|73|SPEC|ISA||54|73|0|0|C0004482|Azathioprine|orch,phsu|orch|||azathioprine||||1000|258|269
SE|00000000||tx|1|relation|14|1|C0000618|mercaptopurine|nnon,phsu|phsu|||mercaptopurine||||1000|23|36|VERB|ADMINISTERED_TO||13|21|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|4|11
SE|00000000||tx|1|relation|0|0|C0722911|Purinethol|nnon,phsu|nnon|||Purinethol||||1000|39|48|INFER|ADMINISTERED_TO(SPEC)||23|48|0|0|C0030705|Patients|podg,humn|humn|||patients||||1000|4|11


SE|00000000||tx|1|text|Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
SE|00000000||tx|1|entity|C0007680|Central Nervous System Agents|phsu|||CNS depressant drugs||||913|7|26
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||790|34|45
SE|00000000||tx|1|entity|C0040614|Tranquilizing Agents|phsu|||tranquilizers||||1000|48|60
SE|00000000||tx|1|entity|C0242402|Opioids|hops,orch,phsu|||opioids||||1000|63|69
SE|00000000||tx|1|entity|C0017302|General anesthetic drugs|phsu|||general anesthetics||||1000|75|93
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||1000|101|108
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|126|132
SE|00000000||tx|1|entity|C0699335|Inapsine|orch,phsu|||INAPSINE||||1000|139|146
SE|00000000||tx|1|relation|0|0|C0004745|Barbiturates|orch,phsu|orch|||barbiturates||||790|34|45|SPEC|ISA||7|45|0|0|C0007680|Central Nervous System Agents|phsu|phsu|||CNS depressant drugs||||913|7|26
SE|00000000||tx|1|relation|0|0|C0017302|General anesthetic drugs|phsu|phsu|||general anesthetics||||1000|75|93|SPEC|ISA||7|45|0|0|C0007680|Central Nervous System Agents|phsu|phsu|||CNS depressant drugs||||913|7|26
SE|00000000||tx|1|relation|0|0|C0242402|Opioids|hops,orch,phsu|orch|||opioids||||1000|63|69|SPEC|ISA||7|45|0|0|C0007680|Central Nervous System Agents|phsu|phsu|||CNS depressant drugs||||913|7|26
SE|00000000||tx|1|relation|0|0|C0040614|Tranquilizing Agents|phsu|phsu|||tranquilizers||||1000|48|60|SPEC|ISA||7|45|0|0|C0007680|Central Nervous System Agents|phsu|phsu|||CNS depressant drugs||||913|7|26


SE|00000000||tx|1|text|This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|6|16
SE|00000000||tx|1|entity|C0518609|consideration|fndg|||consideration||||1000|34|46
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|51|58
SE|00000000||tx|1|entity|C0876768|Vioxx|orch,phsu|||VIOXX||||861|67|71
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitors||||1000|92|105
SE|00000000||tx|1|relation|2|1|C0518609|consideration|fndg|fndg|||consideration||||1000|34|46|PREP|PROCESS_OF||48|49|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|51|58
SE|00000000||tx|1|relation|2|1|C0876768|Vioxx|orch,phsu|orch|||VIOXX||||861|67|71|VERB|ADMINISTERED_TO||60|65|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|51|58


SE|00000000||tx|1|text|Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|31|42
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|48|54
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||905|87|94
SE|00000000||tx|1|entity|C1306421|Serum digoxin measurement|lbpr|||digoxin serum levels||||905|96|115


SE|00000000||tx|1|text|The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.
SE|00000000||tx|1|entity|C2826293|Clinical Significance|fndg|||clinical significance||||1000|5|25
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|35|43
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|48|50
SE|00000000||tx|1|entity|C0012132|Zalcitabine|nnon,phsu|||zalcitabine||||861|65|75
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|80|82
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneously||||1000|111|124
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||magnesium||||916|131|139
SE|00000000||tx|1|entity|C1874163|ALUMINUM CONTAINING ANTACIDS|phsu|||aluminum-containing antacids||||916|141|168


SE|00000000||tx|1|text|FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.
SE|00000000||tx|1|entity|C0728797|Flexeril|orch,phsu|||FLEXERIL||||1000|1|8
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|26|32
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|37|43
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|46|57
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||1000|70|84
SE|00000000||tx|1|relation|0|0|C0004745|Barbiturates|orch,phsu|orch|||barbiturates||||1000|46|57|SPEC|ISA||46|84|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|70|84
SE|00000000||tx|1|relation|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|70|84|SPEC|ISA||46|84|0|0|C0004745|Barbiturates|orch,phsu|phsu|||barbiturates||||1000|46|57
SE|00000000||tx|1|relation|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|70|84|SPEC|ISA||46|84|0|0|C0001975|Alcohols|orch,phsu|phsu|||alcohol||||1000|37|43
SE|00000000||tx|1|relation|0|0|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|37|43|SPEC|ISA||46|84|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|70|84


SE|00000000||tx|1|text|Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.
SE|00000000||tx|1|entity|C0439611|Preliminary|tmco|||Preliminary||||888|1|11
SE|00000000||tx|1|entity|C0947630|Scientific Study|lbpr|||studies||||888|13|19
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|39|49
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|51|53
SE|00000000||tx|1|entity|C0012963|Dobutamine|orch,phsu|||dobutamine||||1000|58|67
SE|00000000||tx|1|entity|C0028193|Nitroprusside|inch,phsu|||nitroprusside||||1000|73|85
SE|00000000||tx|1|entity|C0085128|Cardiac Output, High|fndg|||higher cardiac output||||983|100|120
SE|00000000||tx|1|entity|C0034094|Pulmonary Wedge Pressure|clna|||pulmonary wedge pressure||||923|144|167
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||861|186|189
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|199|203
SE|00000000||tx|1|relation|4|1|C0028193|Nitroprusside|inch,phsu|inch|||nitroprusside||||1000|73|85|VERB|CAUSES||87|93|4|1|C0085128|Cardiac Output, High|fndg|fndg|||higher cardiac output||||983|100|120
SE|00000000||tx|1|relation|4|1|C0012963|Dobutamine|orch,phsu|orch|||dobutamine||||1000|58|67|VERB|CAUSES||87|93|4|1|C0085128|Cardiac Output, High|fndg|fndg|||higher cardiac output||||983|100|120


SE|00000000||tx|1|text|An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||851|4|11
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||851|13|23
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||851|25|30
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|59|69
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||888|74|81
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||888|83|91
SE|00000000||tx|1|entity|C1281543|Neuroleptic therapy|topp|||neuroleptic therapy||||1000|97|115
SE|00000000||tx|1|relation|3|3|C1281543|Neuroleptic therapy|topp|topp|||neuroleptic therapy||||1000|97|115|NOM|AFFECTS||25|30|0|0|C0857353|Hypotensive|patf|patf|||hypotensive||||851|13|23
SE|00000000||tx|1|relation|3|3|C0009014|Clonidine|orch,phsu|orch|||clonidine||||888|83|91|NOM|AFFECTS||25|30|0|0|C0857353|Hypotensive|patf|patf|||hypotensive||||851|13|23


SE|00000000||tx|1|text|Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.
SE|00000000||tx|1|entity|C0007158|Cardiac Glycosides|carb,phsu|||Cardiac glycosides||||1000|1|18
SE|00000000||tx|1|entity|C0344315|Depressed mood|fndg|||depression||||1000|41|50
SE|00000000||tx|1|entity|C0004247|Structure of atrioventricular node|bpoc|||AV nodal||||698|55|62
SE|00000000||tx|1|entity|C0770909|Bepridil hydrochloride|orch,phsu|||bepridil hydrochloride||||1000|89|110


SE|00000000||tx|1|text|Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0701129|Norpace|orch,phsu|||Norpace||||1000|31|37
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|43|51
SE|00000000||tx|1|entity|C2945599|Mild (qualifier value)|qlco|||slight||||888|65|70
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||888|72|80
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||623|85|90
SE|00000000||tx|1|entity|C0012702|Disopyramide|orch,phsu|||disopyramide||||623|92|103
SE|00000000||tx|1|entity|C2945599|Mild (qualifier value)|qlco|||slight||||888|116|121
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decreases||||888|123|131
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||623|136|141
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||623|143|151
SE|00000000||tx|1|relation|3|1|C0034414|Quinidine|orch,phsu|orch|||quinidine||||1000|43|51|NOM|STIMULATES||72|80|3|1|C0012702|Disopyramide|orch,phsu|orch|||disopyramide||||623|92|103
SE|00000000||tx|1|relation|3|1|C0701129|Norpace|orch,phsu|orch|||Norpace||||1000|31|37|NOM|STIMULATES||72|80|3|1|C0012702|Disopyramide|orch,phsu|orch|||disopyramide||||623|92|103


SE|00000000||tx|1|text|Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E.
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||Beta Blockers||||1000|1|13
SE|00000000||tx|1|entity|C1274040|Result|ftcn|||results||||1000|29|35
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||clinical study||||1000|42|55
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|61|63

SE|00000000||tx|2|text|45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
SE|00000000||tx|2|entity|C0700532|Dihydroergotamine Mesylate|orch,phsu|||dihydroergotamine mesylate||||1000|6|31
SE|00000000||tx|2|entity|C1533685|Injection procedure|topp|||Injection||||1000|34|42
SE|00000000||tx|2|entity|C1706444|United States Pharmacopeia|hcro|||USP||||1000|45|47
SE|00000000||tx|2|entity|C1550501|Subject -direct target|idcn|||subjects||||827|52|59
SE|00000000||tx|2|entity|C0033497|Propranolol|orch,phsu|||propranolol||||1000|79|89
SE|00000000||tx|2|entity|C0033497|Propranolol|orch,phsu|||propranolol||||1000|121|131
SE|00000000||tx|2|entity|C3266814|Action|acty|||action||||861|169|174
SE|00000000||tx|2|entity|C0014710|Ergotamine|orch,phsu|||ergotamine||||1000|179|188
SE|00000000||tx|2|entity|C0332206|Blocking|ftcn|||blocking||||1000|193|200
SE|00000000||tx|2|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||epinephrine||||1000|231|241


SE|00000000||tx|1|text|In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|6|10
SE|00000000||tx|1|entity|C1706429|Male, Self-Reported|orga|||male||||773|18|21
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||773|23|30
SE|00000000||tx|1|entity|C0001779|Age|orga|||ages||||827|33|36
SE|00000000||tx|1|entity|C0439234|year|tmco|||years||||861|47|51
SE|00000000||tx|1|entity|C0205231|Extensive|qlco|||extensive||||694|63|71
SE|00000000||tx|1|entity|C1332830|CYP2D6 gene|gngm|1565|CYP2D6|CYP2D6||||901|93|98
SE|00000000||tx|1|entity|C0022173|Isoenzymes|aapp,enzy|||isoenzyme||||901|100|108
SE|00000000||tx|1|entity|C2348070|Daily Dose|qnco|||daily doses||||966|111|121
SE|00000000||tx|1|entity|C0085208|Bupropion|orch,phsu|||bupropion||||1000|126|134
SE|00000000||tx|1|entity|C0585361|Twice a day|tmco|||twice daily||||824|152|162
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|178|183
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|185|188
SE|00000000||tx|1|entity|C0011685|Desipramine|orch,phsu|||desipramine||||790|199|209
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|225|228
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|231|233
SE|00000000||tx|1|entity|C0011685|Desipramine|orch,phsu|||desipramine||||1000|248|258
SE|00000000||tx|1|entity|C1510992|Average|qnco|||average||||1000|266|272
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|277|289
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||888|304|307


SE|00000000||tx|1|text|Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||Non-steroidal anti-inflammatory agents||||1000|1|38
SE|00000000||tx|1|entity|C0036572|Seizures|sosy|||Seizures||||1000|41|48
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|72|79
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||enoxacin||||861|88|95
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory drug||||928|120|154
SE|00000000||tx|1|entity|C0060156|fenbufen|orch,phsu|||fenbufen||||928|156|163
SE|00000000||tx|1|relation|0|0|C0060156|fenbufen|orch,phsu|orch|||fenbufen||||928|156|163|MOD/HEAD|ISA||120|163|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory drug||||928|120|154
SE|00000000||tx|1|relation|2|1|C0036572|Seizures|sosy|sosy|||Seizures||||1000|41|48|PREP|PROCESS_OF||69|70|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|72|79
SE|00000000||tx|1|relation|2|1|C0014310|Enoxacin|orch,phsu|orch|||enoxacin||||861|88|95|VERB|ADMINISTERED_TO||81|86|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|72|79


SE|00000000||tx|1|text|Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||Interactions||||966|1|12
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||861|40|44
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||Significant||||888|47|57
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decreases||||888|59|67
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|76|78
SE|00000000||tx|1|entity|C0288165|Delavirdine|orch,phsu|||delavirdine||||1000|83|93
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|105|113
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneous||||888|140|151
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|177|182
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||VIDEX||||1000|189|193


SE|00000000||tx|1|text|It is possible that the cardiovascular action of other calcium channel blockers could be enhanced by the addition of Nimotop .
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||1000|7|14
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||861|40|45
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium channel blockers||||1000|56|79
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|106|113
SE|00000000||tx|1|entity|C0678207|Nimotop|orch,phsu|||Nimotop||||1000|118|124
SE|00000000||tx|1|relation|3|1|C0006684|Calcium Channel Blockers|phsu|phsu|||calcium channel blockers||||1000|56|79|VERB|STIMULATES||90|97|2|2|C0678207|Nimotop|orch,phsu|orch|||Nimotop||||1000|118|124


SE|00000000||tx|1|text|INDOCIN and triamterene should not be administered together.
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|1|7
SE|00000000||tx|1|entity|C0040869|Triamterene|orch,phsu|||triamterene||||1000|13|23
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|32|34
SE|00000000||tx|1|entity|C1883357|Together|qlco|||together||||1000|52|59


SE|00000000||tx|1|text|Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine therapy is initiated.
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||Serious||||802|1|7
SE|00000000||tx|1|entity|C1457887|Symptoms|sosy|||symptoms||||802|25|32
SE|00000000||tx|1|entity|C0043352|Xerostomia|dsyn|||dry mouth||||901|48|56
SE|00000000||tx|1|entity|C0080274|Urinary Retention|fndg|||urinary retention||||1000|59|75
SE|00000000||tx|1|entity|C0344232|Blurred vision|sosy|||blurred vision||||1000|81|94
SE|00000000||tx|1|entity|C0702240|Elevation|spco|||elevations||||1000|123|132
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||861|141|145
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressant||||1000|157|180
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||888|187|196


SE|00000000||tx|1|text|Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.
SE|00000000||tx|1|entity|C0042397|Vasoconstrictor Agents|phsu|||Vasopressors||||1000|1|12
SE|00000000||tx|1|entity|C0040165|Thyroxine|aapp,horm,phsu|||Thyroxine||||1000|15|23
SE|00000000||tx|1|entity|C3179174|Adrenergic Effect|phsf|||adrenergic effect||||1000|39|55
SE|00000000||tx|1|entity|C0007412|Catecholamines|nsba,orch,phsu|||catecholamines||||1000|60|73
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||epinephrine||||1000|83|93
SE|00000000||tx|1|entity|C0028351|Norepinephrine|nsba,orch,phsu|||norepinephrine||||1000|99|112
SE|00000000||tx|1|relation|0|0|C0014563|Epinephrine|horm,nsba,orch,phsu|horm|||epinephrine||||1000|83|93|SPEC|ISA||60|93|0|0|C0007412|Catecholamines|nsba,orch,phsu|nsba|||catecholamines||||1000|60|73
SE|00000000||tx|1|relation|0|0|C0028351|Norepinephrine|nsba,orch,phsu|nsba|||norepinephrine||||1000|99|112|SPEC|ISA||60|93|0|0|C0007412|Catecholamines|nsba,orch,phsu|nsba|||catecholamines||||1000|60|73
SE|00000000||tx|1|relation|2|1|C0040165|Thyroxine|aapp,gngm,horm,phsu|aapp|||Thyroxine||||1000|15|23|VERB|AUGMENTS||25|33|4|1|C3179174|Adrenergic Effect|phsf|phsf|||adrenergic effect||||1000|39|55


SE|00000000||tx|1|text|In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|9|16
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||non- steroidal antiinflammatory agent||||1000|43|79
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||888|96|103
SE|00000000||tx|1|entity|C0597421|saluretic|phsu|||natriuretic||||888|106|116
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|140|146
SE|00000000||tx|1|entity|C0445022|Loop|spco|||loop||||1000|151|154
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||694|157|165
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|180|197
SE|00000000||tx|1|relation|3|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||non- steroidal antiinflammatory agent||||1000|43|79|VERB|INHIBITS||85|90|5|1|C0597421|saluretic|phsu|phsu|||natriuretic||||888|106|116


SE|00000000||tx|1|text|MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO Inhibitors||||1000|1|14
SE|00000000||tx|1|entity|C0003062|Animals|anim|||animals||||1000|28|34
SE|00000000||tx|1|entity|C0205178|acute|tmco|||acute||||888|57|61
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||888|63|70
SE|00000000||tx|1|entity|C0085208|Bupropion|orch,phsu|||bupropion||||1000|75|83
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitor||||901|104|116
SE|00000000||tx|1|entity|C0031392|Phenelzine|orch,phsu|||phenelzine||||901|118|127
SE|00000000||tx|1|relation|0|0|C0031392|Phenelzine|orch,phsu|orch|||phenelzine||||901|118|127|MOD/HEAD|ISA||104|127|0|0|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||MAO inhibitor||||901|104|116
SE|00000000||tx|1|relation|4|1|C0003062|Animals|anim|anim|||animals||||1000|28|34|PREP|LOCATION_OF||25|26|2|2|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||MAO Inhibitors||||1000|1|14
SE|00000000||tx|1|relation|1|1|C0031392|Phenelzine|orch,phsu|orch|||phenelzine||||901|118|127|VERB|STIMULATES||88|95|5|1|C0085208|Bupropion|orch,phsu|orch|||bupropion||||1000|75|83


SE|00000000||tx|1|text|Sumatriptan and D.H.E.
SE|00000000||tx|1|entity|C0075632|Sumatriptan|orch,phsu|||Sumatriptan||||1000|1|11

SE|00000000||tx|2|text|45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..
SE|00000000||tx|2|entity|C0700532|Dihydroergotamine Mesylate|orch,phsu|||dihydroergotamine mesylate||||1000|6|31
SE|00000000||tx|2|entity|C1533685|Injection procedure|topp|||Injection||||1000|34|42
SE|00000000||tx|2|entity|C1706444|United States Pharmacopeia|hcro|||USP||||1000|45|47
SE|00000000||tx|2|entity|C1518422|Negation|ftcn|||not||||1000|56|58
SE|00000000||tx|2|entity|C1442770|24 Hours|tmco|||24 hours||||1000|76|83


SE|00000000||tx|1|text|Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||Carbamazepine||||1000|1|13
SE|00000000||tx|1|entity|C0728742|Felbatol|orch,phsu|||Felbatol||||1000|16|23
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|35|42
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||849|51|62
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||849|64|76
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||849|78|98
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|107|114
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||851|123|134
SE|00000000||tx|1|entity|C0054640|carbamazepine epoxide|orch,phsu|||carbamazepine epoxide||||851|136|156
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||851|158|177
SE|00000000||tx|1|relation|3|2|C0728742|Felbatol|orch,phsu|orch|||Felbatol||||1000|16|23|PREP|COEXISTS_WITH||44|45|3|1|C0006949|Carbamazepine|orch,phsu|orch|||carbamazepine||||849|64|76
SE|00000000||tx|1|relation|5|5|C0006949|Carbamazepine|orch,phsu|orch|||Carbamazepine||||1000|1|13|PREP|COEXISTS_WITH||116|117|1|1|C0054640|carbamazepine epoxide|orch,phsu|orch|||carbamazepine epoxide||||851|136|156


SE|00000000||tx|1|text|Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.
SE|00000000||tx|1|entity|C0009003|Clofibric Acid|orch,phsu|||Clofibric acid||||1000|1|14
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||Combination||||851|17|27
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||851|29|36
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||851|38|51
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|70|78
SE|00000000||tx|1|entity|C0009003|Clofibric Acid|orch,phsu|||clofibric acid||||1000|83|96
SE|00000000||tx|1|relation|2|1|C0009871|Contraceptive Agents|phsu|phsu|||contraceptives||||851|38|51|VERB|STIMULATES||57|64|2|2|C0009003|Clofibric Acid|orch,phsu|orch|||clofibric acid||||1000|83|96


SE|00000000||tx|1|text|Since iloprost inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants.
SE|00000000||tx|1|entity|C0079594|Iloprost|eico,phsu|||iloprost||||1000|7|14
SE|00000000||tx|1|entity|C1254881|Platelet function|celf|||platelet function||||1000|25|41
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|55|63
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|69|77
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|79|82
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||1000|87|94
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|113|120
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|136|149
SE|00000000||tx|1|relation|1|1|C0079594|Iloprost|eico,phsu|eico|||iloprost||||1000|7|14|VERB|DISRUPTS||16|23|6|1|C1254881|Platelet function|celf|celf|||platelet function||||1000|25|41
SE|00000000||tx|1|relation|5|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|87|94|PREP|PROCESS_OF||110|111|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|113|120


SE|00000000||tx|1|text|Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacid||||1000|1|7
SE|00000000||tx|1|entity|C0065461|Maalox|inch,phsu|||Maalox||||1000|10|15
SE|00000000||tx|1|entity|C0065461|Maalox|inch,phsu|||Maalox||||1000|20|25
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|39|53
SE|00000000||tx|1|entity|C0060926|gabapentin|orch,phsu|||gabapentin||||1000|58|67
SE|00000000||tx|1|relation|0|0|C0065461|Maalox|inch,phsu|inch|||Maalox||||1000|10|15|SPEC|ISA||1|15|0|0|C0003138|Antacids|phsu|phsu|||Antacid||||1000|1|7
SE|00000000||tx|1|relation|3|1|C0065461|Maalox|inch,phsu|inch|||Maalox||||1000|20|25|VERB|INHIBITS||27|33|2|2|C0060926|gabapentin|orch,phsu|orch|||gabapentin||||1000|58|67


SE|00000000||tx|1|text|Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||Hypotension||||1000|1|11
SE|00000000||tx|1|entity|C0232219|Abnormal cardiac conduction|patf|||conduction disturbances||||884|17|39
SE|00000000||tx|1|entity|C0023212|Left-Sided Heart Failure|dsyn|||left ventricular failure||||1000|46|69
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|98|105
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic blocking agents||||1000|117|147
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||901|157|160
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium antagonist||||901|162|179
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||treatment regimen||||1000|198|214
SE|00000000||tx|1|relation|3|1|C0023212|Left-Sided Heart Failure|dsyn|dsyn|||left ventricular failure||||1000|46|69|PREP|PROCESS_OF||90|91|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|98|105
SE|00000000||tx|1|relation|3|1|C0232219|Abnormal cardiac conduction|patf|patf|||conduction disturbances||||884|17|39|PREP|PROCESS_OF||90|91|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|98|105
SE|00000000||tx|1|relation|3|1|C0020649|Hypotension|fndg|fndg|||Hypotension||||1000|1|11|PREP|PROCESS_OF||90|91|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|98|105
SE|00000000||tx|1|relation|3|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-adrenergic blocking agents||||1000|117|147|VERB|ADMINISTERED_TO||107|115|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|98|105


SE|00000000||tx|1|text|Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.
SE|00000000||tx|1|entity|C0144576|Paclitaxel|orch,phsu|||Paclitaxel||||1000|1|10
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|17|19
SE|00000000||tx|1|entity|C0017797|Glutamine|aapp,bacs,phsu|||L-glutamine||||1000|29|39
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|46|49
SE|00000000||tx|1|entity|C0470534|10 grams|qnco|||10 grams||||893|54|61
SE|00000000||tx|1|entity|C0556984|Three times daily|tmco|||three times daily||||893|63|79
SE|00000000||tx|1|entity|C1442770|24 Hours|tmco|||24 hours||||1000|88|95
SE|00000000||tx|1|entity|C1514756|Receive|qlco|||receiving||||872|103|111
SE|00000000||tx|1|entity|C0144576|Paclitaxel|orch,phsu|||paclitaxel||||872|113|122
SE|00000000||tx|1|entity|C1527148|Development|ftcn|||development||||1000|149|159
SE|00000000||tx|1|entity|C0231528|Myalgia|sosy|||myalgia||||1000|164|170
SE|00000000||tx|1|entity|C0003862|Arthralgia|sosy|||arthralgia||||1000|176|185
SE|00000000||tx|1|entity|C0559546|Adverse reactions|fndg|||adverse reactions||||1000|188|204
SE|00000000||tx|1|entity|C0144576|Paclitaxel|orch,phsu|||paclitaxel||||1000|209|218
SE|00000000||tx|1|relation|6|1|C0144576|Paclitaxel|orch,phsu|phsu|||paclitaxel||||872|113|122|VERB|PREVENTS||137|143|5|2|C0231528|Myalgia|sosy|sosy|||myalgia||||1000|164|170
SE|00000000||tx|1|relation|6|1|C0144576|Paclitaxel|orch,phsu|phsu|||paclitaxel||||872|113|122|VERB|PREVENTS||137|143|5|2|C0003862|Arthralgia|sosy|sosy|||arthralgia||||1000|176|185


SE|00000000||tx|1|text|In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|4|11
SE|00000000||tx|1|entity|C0442804|Very high|fndg|||very high||||901|19|27
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||901|29|33
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||888|48|54
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||888|56|60
SE|00000000||tx|1|entity|C0555145|Serum salicylate measurement|lbpr|||serum salicylate levels||||988|76|98
SE|00000000||tx|1|entity|C0085154|Nizatidine|orch,phsu|||nizatidine||||1000|115|124
SE|00000000||tx|1|entity|C0439423|Milligram per 24 Hours|qnco|||mg b.i.d.||||790|131|139


SE|00000000||tx|1|text|Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.
SE|00000000||tx|1|entity|C0051809|anagrelide|orch,phsu|||Anagrelide||||1000|1|10
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|12|16
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|25|30
SE|00000000||tx|1|entity|C0032176|Platelet aggregation|celf|||platelet aggregation||||1000|35|54
SE|00000000||tx|1|entity|C0750482|Slightly|idcn|||slightly||||1000|65|72
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|86|95
SE|00000000||tx|1|entity|C0032176|Platelet aggregation|celf|||platelet aggregation||||1000|100|119
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|124|130
SE|00000000||tx|1|relation|2|2|C0051809|anagrelide|orch,phsu|orch|||Anagrelide||||1000|1|10|NOM|AFFECTS|negation|25|30|4|1|C0032176|Platelet aggregation|celf|celf|||platelet aggregation||||1000|35|54
SE|00000000||tx|1|relation|2|2|C0004057|Aspirin|orch,phsu|orch|||aspirin||||1000|124|130|NOM|DISRUPTS||86|95|2|1|C0032176|Platelet aggregation|celf|celf|||platelet aggregation||||1000|100|119


SE|00000000||tx|1|text|The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000||tx|1|entity|C0041983|Uricosuric Agents|phsu|||uricosuric agents||||1000|35|51
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|57|67
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|96|103
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||1000|112|120
SE|00000000||tx|1|entity|C0597159|oxypurine|orch|||oxypurines||||1000|125|134
SE|00000000||tx|1|entity|C0020684|Hypoxanthine|bacs,orch|||hypoxanthine||||1000|137|148
SE|00000000||tx|1|entity|C0043314|xanthine|bacs,nnon|||xanthine||||1000|154|161
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|171|178
SE|00000000||tx|1|entity|C0428286|Urine urate measurement|lbpr|||urinary uric acid||||873|183|199
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||873|201|209
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|244|254
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|256|260
SE|00000000||tx|1|relation|10|3|C0043314|xanthine|bacs,nnon|bacs|||xanthine||||1000|154|161|VERB|compared_with||211|218|2|1|C0002144|Allopurinol|orch,phsu|orch|||allopurinol||||1000|244|254
SE|00000000||tx|1|relation|0|0|C0020684|Hypoxanthine|bacs,orch|bacs|||hypoxanthine||||1000|137|148|SPEC|ISA||125|148|0|0|C0597159|oxypurine|orch|orch|||oxypurines||||1000|125|134
SE|00000000||tx|1|relation|0|0|C0043314|xanthine|bacs,nnon|bacs|||xanthine||||1000|154|161|SPEC|ISA||125|148|0|0|C0597159|oxypurine|orch|orch|||oxypurines||||1000|125|134
SE|00000000||tx|1|relation|9|5|C0221102|Excretory function|phsf|phsf|||excretion||||1000|112|120|PREP|COEXISTS_WITH||180|181|3|1|C0221102|Excretory function|phsf|phsf|||excretion||||873|201|209


SE|00000000||tx|1|text|Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|25|34
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|41|46
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|51|61
SE|00000000||tx|1|entity|C0205172|More|ftcn|||more||||1000|75|78
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||higher doses||||966|118|129
SE|00000000||tx|1|relation|1|1|C0002333|Alprazolam|orch,phsu|orch|||alprazolam||||1000|25|34|NOM|INTERACTS_WITH||41|46|2|1|C0085228|Fluvoxamine|orch,phsu|orch|||fluvoxamine||||1000|51|61


SE|00000000||tx|1|text|Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|15|25
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|45|54
SE|00000000||tx|1|entity|C0442821|Strong|qlco|||strong||||802|61|66
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||802|68|73
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||802|75|84
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|93|104
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|107|118
SE|00000000||tx|1|entity|C0068485|nefazodone|orch,phsu|||nefazodone||||1000|121|130
SE|00000000||tx|1|entity|C0041165|Troleandomycin|antb,orch|||troleandomycin||||1000|133|146
SE|00000000||tx|1|entity|C0055856|Clarithromycin|antb,orch|||clarithromycin||||1000|149|162
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|165|173
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||nelfinavir||||1000|176|185
SE|00000000||tx|1|relation|2|1|C1176306|aprepitant|orch,phsu|orch|||Aprepitant||||1000|45|54|NOM|INHIBITS||75|84|2|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||802|68|73


SE|00000000||tx|1|text|Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|1|10
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|13|23
SE|00000000||tx|1|entity|C0146226|Toradol|orch,phsu|||TORADOL||||1000|43|49
SE|00000000||tx|1|entity|C0442027|Oral|spco|||ORAL||||1000|51|54
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|60|69
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||decreased||||888|83|91
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|93|101
SE|00000000||tx|1|entity|C0073631|Ketorolac|orch,phsu|||ketorolac||||1000|106|114
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|120|130
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||888|132|140
SE|00000000||tx|1|entity|C0073631|Ketorolac|orch,phsu|||ketorolac||||790|145|153
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|155|160
SE|00000000||tx|1|entity|C0439175|% of total|qnco|||total||||888|170|174
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|176|178
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||694|190|202
SE|00000000||tx|1|entity|C1300565|Kilogram per Liter|qnco|||g/h/mL||||839|233|238
SE|00000000||tx|1|entity|C2827968|Terminal Half Life|tmco|||terminal half-life||||1000|245|262
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||694|274|286
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||827|313|317
SE|00000000||tx|1|relation|5|1|C0033209|Probenecid|orch,phsu|orch|||probenecid||||1000|60|69|ADJ|INHIBITS||83|91|9|1|C0073631|Ketorolac|orch,phsu|orch|||ketorolac||||1000|106|114
SE|00000000||tx|1|relation|5|1|C0033209|Probenecid|orch,phsu|orch|||Probenecid||||1000|1|10|ADJ|INHIBITS||83|91|9|1|C0073631|Ketorolac|orch,phsu|orch|||ketorolac||||1000|106|114


SE|00000000||tx|1|text|In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multiple-||||851|6|14
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||851|15|18
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||851|20|24
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||enoxacin||||1000|27|34
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose-||||851|45|49
SE|00000000||tx|1|entity|C0163712|Relate - vinyl resin|orch|||related||||851|50|56
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||851|58|65
SE|00000000||tx|1|entity|C2348397|Elimination Half Life|qnco|||elimination half-life||||923|79|99
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|104|111
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|137|145
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|150|157
SE|00000000||tx|1|entity|C0205451|Five|qnco|||five-||||851|189|193
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||851|194|197
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||851|199|206
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|215|217
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||1000|227|235
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|240|247
SE|00000000||tx|1|relation|8|2|C0006644|Caffeine|orch,phsu|orch|||caffeine||||1000|104|111|NOM|STIMULATES||58|65|2|0|C0163712|Relate - vinyl resin|orch|orch|||related||||851|50|56
SE|00000000||tx|1|relation|5|4|C0014310|Enoxacin|orch,phsu|orch|||enoxacin||||1000|27|34|VERB|INHIBITS||122|131|6|2|C0006644|Caffeine|orch,phsu|orch|||caffeine||||1000|150|157


SE|00000000||tx|1|text|Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
SE|00000000||tx|1|entity|C0042839|Vitamin A|orch,phsu,vita|||Vitamin A||||1000|1|9
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|15|18
SE|00000000||tx|1|entity|C0035339|Retinoids|bacs,orch,phsu|||retinoids||||888|20|28
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|31|41
SE|00000000||tx|1|entity|C0042839|Vitamin A|orch,phsu,vita|||vitamin A||||1000|61|69
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|84|87
SE|00000000||tx|1|entity|C0035339|Retinoids|bacs,orch,phsu|||retinoids||||888|89|97
SE|00000000||tx|1|entity|C0050559|Acitretin|orch,phsu|||acitretin||||1000|104|112
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|145|148
SE|00000000||tx|1|entity|C0020579|Hypervitaminosis A|dsyn|||hypervitaminosis A||||1000|153|170
SE|00000000||tx|1|relation|0|0|C0042839|Vitamin A|orch,phsu,vita|orch|||vitamin A||||1000|61|69|SPEC|ISA||61|97|0|0|C0035339|Retinoids|bacs,orch,phsu|bacs|||retinoids||||888|89|97
SE|00000000||tx|1|relation|0|0|C0042839|Vitamin A|orch,phsu,vita|orch|||vitamin A||||1000|61|69|SPEC|ISA||61|97|0|0|C0035339|Retinoids|bacs,orch,phsu|bacs|||retinoids||||888|20|28
SE|00000000||tx|1|relation|6|1|C0050559|Acitretin|orch,phsu|orch|||acitretin||||1000|104|112|NOM|PREDISPOSES||145|148|1|1|C0020579|Hypervitaminosis A|dsyn|dsyn|||hypervitaminosis A||||1000|153|170


SE|00000000||tx|1|text|Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulant||||734|36|53
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||623|69|77
SE|00000000||tx|1|entity|C0033706|Prothrombin|aapp,bacs,phsu|||prothrombin||||623|79|89
SE|00000000||tx|1|entity|C0024554|Male gender|fndg|||man||||1000|104|106
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|116|122
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|125|135
SE|00000000||tx|1|entity|C0030125|aminosalicylic acid|orch,phsu|||aminosalicylic acid||||1000|137|155
SE|00000000||tx|1|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||1000|157|166
SE|00000000||tx|1|entity|C0002744|Anabolic steroids|phsu,strd|||anabolic steroids||||1000|168|184
SE|00000000||tx|1|entity|C0003232|Antibiotics|antb|||antibiotics||||1000|186|196
SE|00000000||tx|1|entity|C0006217|Bromelains|aapp,enzy,phsu|||bromelains||||1000|198|207
SE|00000000||tx|1|entity|C0008161|Chloral Hydrate|orch,phsu|||chloral hydrate||||1000|209|223
SE|00000000||tx|1|entity|C0008287|Chlorpropamide|orch,phsu|||chlorpropamide||||1000|226|239
SE|00000000||tx|1|entity|C0008742|CHYMOTRYPSIN|aapp,enzy,phsu|||chymotrypsin||||1000|241|252
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|254|263
SE|00000000||tx|1|entity|C0008793|cinchophen|orch,phsu|||cinchophen||||1000|265|274
SE|00000000||tx|1|entity|C0009002|Clofibrate|orch,phsu|||clofibrate||||1000|276|285
SE|00000000||tx|1|entity|C0086140|Dextran|carb,phsu|||dextran||||1000|287|293
SE|00000000||tx|1|entity|C0011824|Dextrothyroxine|aapp,horm,phsu|||dextrothyroxine||||1000|295|309
SE|00000000||tx|1|entity|C0012022|Diazoxide|orch,phsu|||diazoxide||||1000|311|319
SE|00000000||tx|1|entity|C0162429|Malnutrition|dsyn|||dietary deficiencies||||983|321|340
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|342|351
SE|00000000||tx|1|entity|C0012772|Disulfiram|orch,phsu|||disulfiram||||1000|353|362
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|364|368
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||888|380|384
SE|00000000||tx|1|entity|C0013879|Elements|elii|||elements||||888|386|393
SE|00000000||tx|1|entity|C0014963|Ethacrynic Acid|orch,phsu|||ethacrynic acid||||1000|395|409
SE|00000000||tx|1|entity|C0015837|Fenoprofen|orch,phsu|||fenoprofen||||1000|411|420
SE|00000000||tx|1|entity|C0017687|Glucagon|aapp,horm,nsba,phsu|||glucagon||||1000|422|429
SE|00000000||tx|1|entity|C0235378|Hepatotoxicity|inpo|||hepatotoxic||||853|431|441
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||853|443|447
SE|00000000||tx|1|entity|C0020740|Ibuprofen|orch,phsu|||ibuprofen||||1000|449|457
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|459|470
SE|00000000||tx|1|entity|C0021403|Influenza virus vaccine|imft,phsu|||influenza virus vaccine||||1000|472|494
SE|00000000||tx|1|entity|C0242903|Anesthetics, Inhalation|phsu|||inhalation anesthetics||||1000|496|517
SE|00000000||tx|1|entity|C0025152|Mefenamic Acid|orch,phsu|||mefenamic acid||||1000|519|532
SE|00000000||tx|1|entity|C0025741|Methyldopa|nsba,phsu|||methyldopa||||1000|534|543
SE|00000000||tx|1|entity|C0025810|Methylphenidate|orch,phsu|||methylphenidate||||1000|545|559
SE|00000000||tx|1|entity|C0025872|Metronidazole|orch,phsu|||metronidazole||||1000|561|573
SE|00000000||tx|1|entity|C0025942|Miconazole|orch,phsu|||miconazole||||1000|575|584
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|586|613
SE|00000000||tx|1|entity|C0027353|Nalidixic Acid|antb,orch|||nalidixic acid||||1000|615|628
SE|00000000||tx|1|entity|C0027396|Naproxen|orch,phsu|||naproxen||||1000|630|637
SE|00000000||tx|1|entity|C0030031|Oxolinic Acid|antb,orch|||oxolinic acid||||1000|639|651
SE|00000000||tx|1|entity|C0030078|Oxyphenbutazone|orch,phsu|||oxyphenbutazone||||1000|653|667
SE|00000000||tx|1|entity|C0030899|Pentoxifylline|orch,phsu|||pentoxifylline||||1000|669|682
SE|00000000||tx|1|entity|C0031463|Phenylbutazone|orch,phsu|||phenylbutazone||||1000|684|697
SE|00000000||tx|1|entity|C1510448|phenyramidol|orch,phsu|||phenyramidol||||1000|699|710
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|712|720
SE|00000000||tx|1|entity|C0439590|Prolonged|tmco|||prolonged||||901|722|730
SE|00000000||tx|1|entity|C0337004|Hot weather|npop|||hot weather||||901|732|742
SE|00000000||tx|1|entity|C0439590|Prolonged|tmco|||prolonged||||888|744|752
SE|00000000||tx|1|entity|C0027415|Narcotics|hops,phsu|||narcotics||||888|754|762
SE|00000000||tx|1|entity|C1449668|Pyrazolones|orch|||pyrazolones||||1000|764|774
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|776|784
SE|00000000||tx|1|entity|C0034417|Quinine|orch,phsu|||quinine||||1000|786|792
SE|00000000||tx|1|entity|C0034665|Ranitidine|orch,phsu|||ranitidine||||1000|794|803
SE|00000000||tx|1|entity|C0036077|Salicylates|orch,phsu|||salicylates||||1000|806|816
SE|00000000||tx|1|entity|C0038742|Sulfinpyrazone|orch,phsu|||sulfinpyrazone||||1000|818|831
SE|00000000||tx|1|entity|C0038760|Sulfonamides|orch,phsu|||sulfonamides||||1000|833|844
SE|00000000||tx|1|entity|C0205166|Long|qlco|||long||||861|847|850
SE|00000000||tx|1|entity|C0038792|Sulindac|orch,phsu|||sulindac||||1000|859|866
SE|00000000||tx|1|entity|C0279175|Thyroid preparation|aapp,horm,phsu|||thyroid drugs||||983|868|880
SE|00000000||tx|1|entity|C0040374|Tolbutamide|orch,phsu|||tolbutamide||||1000|882|892
SE|00000000||tx|1|entity|C0355022|Triclofos sodium|opco,phsu|||triclofos sodium||||1000|894|909
SE|00000000||tx|1|entity|C0041044|Trimethoprim-Sulfamethoxazole Combination|orch,phsu|||trimethoprim/sulfamethoxazole||||1000|911|939
SE|00000000||tx|1|entity|C0749770|unreliable|idcn|||unreliable||||861|941|950
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||861|952|967
SE|00000000||tx|1|entity|C0680730|Adjudication|gora|||determinations||||861|969|982
SE|00000000||tx|1|entity|C0037473|Sodium|bacs,elii|||sodium||||901|993|998
SE|00000000||tx|1|entity|C0573797|Warfarin overdosage|inpo|||warfarin sodium overdosage||||901|984|1009
SE|00000000||tx|1|relation|4|4|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|PREP|TREATS||101|102|61|1|C0024554|Male gender|fndg|fndg|||man||||1000|104|106
SE|00000000||tx|1|relation|25|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|364|368|VERB|AFFECTS||370|378|40|1|C0005767|Blood|tisu|tisu|||blood||||888|380|384


SE|00000000||tx|1|text|Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.
SE|00000000||tx|1|entity|C0085170|Astemizole|orch,phsu|||astemizole||||1000|21|30
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||888|37|48
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||888|50|56


SE|00000000||tx|1|text|Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||773|22|24
SE|00000000||tx|1|entity|C0033080|Prescription procedure|hlca|||prescription||||790|37|48
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||790|50|53
SE|00000000||tx|1|entity|C0876188|Tikosyn|orch,phsu|||TIKOSYN||||1000|77|83
SE|00000000||tx|1|entity|C0439211|microgram|qnco|||mcg||||773|90|92
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||773|94|96
SE|00000000||tx|1|entity|C1547085|7 days|tmco|||7 days||||1000|103|108
SE|00000000||tx|1|entity|C0114771|dofetilide|orch,phsu|||dofetilide||||790|137|146
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|148|153


SE|00000000||tx|1|text|Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||Ritonavir||||1000|1|9
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|15|23
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|31|41
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||Vardenafil||||1000|69|78
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||764|92|94
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||764|96|104
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|111|114
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|120|122
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|127|135
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|153|165


SE|00000000||tx|1|text|Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|26|31
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|47|71
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuation||||1000|97|111
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|116|125
SE|00000000||tx|1|entity|C1517945|Loss|qnco|||loss||||1000|151|154
SE|00000000||tx|1|entity|C2348767|Therapeutic Efficacy|qlco|||therapeutic efficacy||||1000|163|182
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressant||||901|191|214


SE|00000000||tx|1|text|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|7|11
SE|00000000||tx|1|entity|C0234119|Neuromuscular inhibition|dsyn|||neuromuscular blocking||||890|35|56
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||890|58|63
SE|00000000||tx|1|entity|C0304435|Nondepolarizing agent|phsu|||nondepolarizing agents||||983|68|89
SE|00000000||tx|1|entity|C0133255|Nuromax|orch,phsu|||NUROMAX||||1000|99|105
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||888|115|121
SE|00000000||tx|1|entity|C0003232|Antibiotics|antb|||antibiotics||||888|123|133
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycosides||||1000|143|157
SE|00000000||tx|1|entity|C0039651|Tetracyclines|orch|||tetracyclines||||1000|160|172
SE|00000000||tx|1|entity|C0004599|Bacitracin|aapp,antb|||bacitracin||||1000|175|184
SE|00000000||tx|1|entity|C0032539|Polymyxins|aapp,antb|||polymyxins||||1000|187|196
SE|00000000||tx|1|entity|C0023726|Lincomycin|antb,carb|||lincomycin||||1000|199|208
SE|00000000||tx|1|entity|C0008947|Clindamycin|antb,carb|||clindamycin||||1000|211|221
SE|00000000||tx|1|entity|C0009316|Colistin|aapp,antb|||colistin||||1000|224|231
SE|00000000||tx|1|entity|C0037473|Sodium|bacs,elii|||sodium||||888|238|243
SE|00000000||tx|1|entity|C0009315|colistimethate|aapp,antb|||colistimethate||||888|245|258
SE|00000000||tx|1|entity|C0302211|Magnesium salt|inch,phsu|||magnesium salts||||1000|262|276
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|279|285
SE|00000000||tx|1|entity|C0002934|Local Anesthetics|phsu|||local anesthetics||||1000|288|304
SE|00000000||tx|1|entity|C0033216|Procainamide|orch,phsu|||procainamide||||1000|307|318
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|325|333
SE|00000000||tx|1|relation|0|0|C0133255|Nuromax|orch,phsu|orch|||NUROMAX||||1000|99|105|SPEC|ISA||68|105|0|0|C0304435|Nondepolarizing agent|phsu|phsu|||nondepolarizing agents||||983|68|89


SE|00000000||tx|1|text|Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..
SE|00000000||tx|1|entity|C1314792|Etiology|ftcn|||causal||||623|12|17
SE|00000000||tx|1|entity|C0015127|Etiology aspects|ftcn|||cause||||1000|35|39
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|45|50
SE|00000000||tx|1|entity|C0439849|Relationships|qlco|||relationship||||888|52|63
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|70|72
SE|00000000||tx|1|entity|C0232804|Renal function|ortf|||renal function||||1000|123|136
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|161|168
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|173|190
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||861|196|206
SE|00000000||tx|1|entity|C0332197|Absent|qnco|||absence||||1000|220|226
SE|00000000||tx|1|entity|C0035078|Kidney Failure|dsyn|||renal failure||||1000|231|243
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||694|250|255
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|317|324
SE|00000000||tx|1|entity|C0033972|Psychotherapy, Multiple|topp|||combined therapy||||1000|334|349
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||diminished||||901|354|363
SE|00000000||tx|1|entity|C0232804|Renal function|ortf|||renal function||||901|365|378
SE|00000000||tx|1|relation|5|1|C0232804|Renal function|ortf|ortf|||renal function||||1000|123|136|PREP|PROCESS_OF||158|159|9|1|C0030705|Patients|podg,humn|humn|||patients||||1000|161|168
SE|00000000||tx|1|relation|5|1|C0232804|Renal function|ortf|ortf|||renal function||||901|365|378|PREP|PROCESS_OF||158|159|9|1|C0030705|Patients|podg,humn|humn|||patients||||1000|161|168
SE|00000000||tx|1|relation|11|2|C0035078|Kidney Failure|dsyn|dsyn|||renal failure||||1000|231|243|PREP|PROCESS_OF||308|309|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|317|324


SE|00000000||tx|1|text|Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.
SE|00000000||tx|1|entity|C0031330|Pharmacology|bmod|||Pharmacological||||840|1|15
SE|00000000||tx|1|entity|C0851347|Pharmacodynamics|biof|||Pharmacodynamic||||840|17|31
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||Interactions||||840|33|44
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||Carbamazepine||||851|51|63
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||851|65|75
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|95|107
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|113|119
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|138|141
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||901|157|168


SE|00000000||tx|1|text|Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.
SE|00000000||tx|1|entity|C0699335|Inapsine|orch,phsu|||INAPSINE||||1000|33|40
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|47|50
SE|00000000||tx|1|entity|C0007680|Central Nervous System Agents|phsu|||CNS depressant drugs||||913|61|80
SE|00000000||tx|1|relation|0|0|C0699335|Inapsine|orch,phsu|orch|||INAPSINE||||1000|33|40|SPEC|ISA||33|80|0|0|C0007680|Central Nervous System Agents|phsu|phsu|||CNS depressant drugs||||913|61|80


SE|00000000||tx|1|text|The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||814|29|37
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensives||||814|47|63
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|70|75
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|123|128
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|138|145
SE|00000000||tx|1|entity|C1274040|Result|ftcn|||result||||1000|151|156
SE|00000000||tx|1|entity|C0020461|Hyperkalemia|fndg|||hyperkalemia||||861|168|179
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|184|191
SE|00000000||tx|1|entity|C0341697|Renal impairment|dsyn|||impaired renal function||||1000|198|220
SE|00000000||tx|1|relation|5|5|C0341697|Renal impairment|dsyn|dsyn|||impaired renal function||||1000|198|220|NOM|AFFECTS||123|128|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|138|145


SE|00000000||tx|1|text|therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|16|23
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives||||1000|28|46
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|73|82


SE|00000000||tx|1|text|Two percent of patients treated concurrently with ENBREL  and anakinra developed neutropenia (ANC   1 x 109/L).
SE|00000000||tx|1|entity|C0205448|Two|qnco|||Two||||694|1|3
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|16|23
SE|00000000||tx|1|entity|C0720193|Enbrel|aapp,phsu|||ENBREL||||1000|51|56
SE|00000000||tx|1|entity|C0245109|anakinra|aapp,phsu|||anakinra||||1000|63|70
SE|00000000||tx|1|entity|C0027947|Neutropenia|dsyn|||neutropenia||||1000|82|92
SE|00000000||tx|1|entity|C0254908|ANC 1|orch,phsu|||ANC   1||||673|95|101
SE|00000000||tx|1|relation|4|1|C0720193|Enbrel|aapp,gngm,phsu|phsu|||ENBREL||||1000|51|56|VERB|TREATS||25|31|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|16|23


SE|00000000||tx|1|text|Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.
SE|00000000||tx|1|entity|C1997138|Blunted|qlco|||Blunting||||966|1|8
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|34|39
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenoceptor blocking agents||||988|44|76
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory drugs||||1000|81|116
SE|00000000||tx|1|relation|2|2|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory drugs||||1000|81|116|NOM|INTERACTS_WITH||34|39|2|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-adrenoceptor blocking agents||||988|44|76


SE|00000000||tx|1|text|Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||Antihistamines||||1000|1|14
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|25|32
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|34|40
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|47|53
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||1000|65|79
SE|00000000||tx|1|entity|C0020591|Hypnotics|phsu|||hypnotics||||1000|88|96
SE|00000000||tx|1|entity|C0036557|Sedatives|phsu|||sedatives||||1000|99|107
SE|00000000||tx|1|entity|C0040614|Tranquilizing Agents|phsu|||tranquilizers||||1000|110|122
SE|00000000||tx|1|entity|C0040616|Anti-Anxiety Agents|phsu|||antianxiety agents||||1000|125|142
SE|00000000||tx|1|relation|0|0|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|47|53|SPEC|ISA||47|79|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|65|79
SE|00000000||tx|1|relation|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|65|79|SPEC|ISA||47|79|0|0|C0001975|Alcohols|orch,phsu|phsu|||alcohol||||1000|47|53


SE|00000000||tx|1|text|Chlorthalidone and related drugs may increase the responsiveness to tubocurarine.
SE|00000000||tx|1|entity|C0008294|Chlorthalidone|orch,phsu|||Chlorthalidone||||1000|1|14
SE|00000000||tx|1|entity|C0163712|Relate - vinyl resin|orch|||related||||888|20|26
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|28|32
SE|00000000||tx|1|entity|C0205342|Responsive|ftcn|||responsiveness||||928|51|64
SE|00000000||tx|1|entity|C0041345|Tubocurarine|orch,phsu|||tubocurarine||||1000|69|80


SE|00000000||tx|1|text|In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||clinical trials||||1000|4|18
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|23|30
SE|00000000||tx|1|entity|C0002997|Angioplasty, Balloon, Coronary|topp|||PTCA||||694|43|46
SE|00000000||tx|1|entity|||gngm|5104|SERPINA5|PCI||||694|48|50
SE|00000000||tx|1|entity|C0939677|Angiomax|aapp,phsu|||Angiomax||||1000|74|81
SE|00000000||tx|1|entity|C0019134|Heparin|bacs,carb,phsu|||heparin||||1000|88|94
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|97|104
SE|00000000||tx|1|entity|C0016018|Fibrinolytic Agents|phsu|||thrombolytics||||1000|107|119
SE|00000000||tx|1|entity|C0016011|Platelet Glycoprotein GPIIb-IIIa Complex|aapp,imft,rcpt|||glycoprotein IIb/IIIa||||916|124|144
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||916|146|155
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|177|185
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risks||||888|187|191
SE|00000000||tx|1|entity|C0205164|Major|qlco|||major||||851|196|200
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||851|202|209
SE|00000000||tx|1|entity|C0441471|Event|evnt|||events||||851|211|216
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|230|237
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|239|241
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|259|269
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||888|271|281
SE|00000000||tx|1|relation|8|1|C0019134|Heparin|bacs,carb,phsu|bacs|||heparin||||1000|88|94|PREP|PART_OF||83|86|5|4|C0030705|Patients|podg,humn|humn|||patients||||1000|23|30
SE|00000000||tx|1|relation|8|2|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||1000|97|104|NOM|INHIBITS||146|155|8|0|C0016011|Platelet Glycoprotein GPIIb-IIIa Complex|aapp,gngm,imft,rcpt|gngm|||glycoprotein IIb/IIIa||||916|124|144
SE|00000000||tx|1|relation|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||888|271|281|VERB|ADMINISTERED_TO|negation|243|251|12|1|C0030705|Patients|podg,humn|humn|||patients||||1000|230|237


SE|00000000||tx|1|text|The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|5|14
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|16|18
SE|00000000||tx|1|entity|C0039644|Tetracycline|antb,orch|||tetracycline||||1000|23|34
SE|00000000||tx|1|entity|C0728777|Penthrane|orch,phsu|||Penthrane||||1000|40|48
SE|00000000||tx|1|entity|C0025688|Methoxyflurane|orch,phsu|||methoxyflurane||||1000|51|64
SE|00000000||tx|1|entity|C1302234|Fatal|qlco|||fatal||||901|98|102
SE|00000000||tx|1|entity|C0595916|Toxic nephropathy|dsyn|||renal toxicity||||901|104|117
SE|00000000||tx|1|relation|0|0|C0728777|Penthrane|orch,phsu|orch|||Penthrane||||1000|40|48|SPEC|ISA||40|64|0|0|C0025688|Methoxyflurane|orch,phsu|orch|||methoxyflurane||||1000|51|64
SE|00000000||tx|1|relation|4|2|C0728777|Penthrane|orch,phsu|orch|||Penthrane||||1000|40|48|VERB|CAUSES||88|93|1|1|C0595916|Toxic nephropathy|dsyn|dsyn|||renal toxicity||||901|104|117
SE|00000000||tx|1|relation|4|2|C0039644|Tetracycline|antb,orch|orch|||tetracycline||||1000|23|34|VERB|CAUSES||88|93|1|1|C0595916|Toxic nephropathy|dsyn|dsyn|||renal toxicity||||901|104|117


SE|00000000||tx|1|text|If a diuretic is also used, it may increase the risk of lithium toxicity.
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|6|13
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|49|52
SE|00000000||tx|1|entity|C0238242|LITHIUM TOXICITY|inpo|||lithium toxicity||||1000|57|72
SE|00000000||tx|1|relation|2|1|C0012798|Diuretics|phsu|phsu|||diuretic||||1000|6|13|NOM|PREDISPOSES||49|52|1|1|C0238242|LITHIUM TOXICITY|inpo|inpo|||lithium toxicity||||1000|57|72


SE|00000000||tx|1|text|Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||Carbamazepine||||1000|1|13
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||Carbamazepine||||1000|16|28
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximate||||802|40|50
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||802|56|63
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|72|80
SE|00000000||tx|1|entity|C0728742|Felbatol|orch,phsu|||Felbatol||||1000|85|92
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady state||||1000|98|109
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|131|138
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|143|155
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximate||||851|171|181
SE|00000000||tx|1|entity|C0439509|/40|tmco|||40%||||851|183|185
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decrease||||851|187|194
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||861|203|214
SE|00000000||tx|1|entity|C0444506|Trough|qnco|||trough||||861|216|221
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||861|223|236
SE|00000000||tx|1|entity|C0728742|Felbatol|orch,phsu|||Felbatol||||1000|241|248
SE|00000000||tx|1|entity|C0445247|Same|qlco|||same||||888|270|273
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|275|278
SE|00000000||tx|1|entity|C0728742|Felbatol|orch,phsu|||Felbatol||||1000|283|290


SE|00000000||tx|1|text|SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.
SE|00000000||tx|1|entity|C0674427|Sustiva|orch,phsu|||SUSTIVA||||1000|1|7
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||861|17|25
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|39|59
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|64|75
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|81|92
SE|00000000||tx|1|relation|1|1|C0674427|Sustiva|orch,phsu|orch|||SUSTIVA||||1000|1|7|VERB|INHIBITS||30|37|3|2|C0064113|Itraconazole|orch,phsu|orch|||itraconazole||||1000|64|75
SE|00000000||tx|1|relation|1|1|C0674427|Sustiva|orch,phsu|orch|||SUSTIVA||||1000|1|7|VERB|INHIBITS||30|37|3|2|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|81|92


SE|00000000||tx|1|text|Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).
SE|00000000||tx|1|entity|C0003286|Anticonvulsants|phsu|||Anticonvulsants||||1000|1|15
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||1000|18|26
SE|00000000||tx|1|entity|C0678587|steady state|npop|||Steady state||||658|30|41
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||658|43|48
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|60|62
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||1000|68|77
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||840|86|88
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|97|100
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multiple||||888|150|157
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|159|163
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|183|186
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|192|200
SE|00000000||tx|1|entity|||gngm|9360|PPIG|CYP||||1000|205|207
SE|00000000||tx|1|relation|0|0|C0031507|Phenytoin|orch,phsu|orch|||Phenytoin||||1000|18|26|SPEC|ISA||1|26|0|0|C0003286|Anticonvulsants|phsu|phsu|||Anticonvulsants||||1000|1|15


SE|00000000||tx|1|text|Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
SE|00000000||tx|1|entity|C0004320|Auranofin|orch,phsu|||Auranofin||||1000|1|9
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|18|20
SE|00000000||tx|1|entity|C0030817|Penicillamine|aapp,phsu|||penicillamine||||1000|44|56
SE|00000000||tx|1|entity|C0719754|Depen|aapp,phsu|||Depen||||1000|59|63
SE|00000000||tx|1|entity|C0699483|Cuprimine|aapp,phsu|||Cuprimine||||1000|66|74
SE|00000000||tx|1|entity|C0003864|Arthritis|dsyn|||arthritis||||888|86|94
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medication||||888|96|105
SE|00000000||tx|1|relation|0|0|C0719754|Depen|aapp,gngm,phsu|aapp|||Depen||||1000|59|63|SPEC|ISA||44|63|0|0|C0030817|Penicillamine|aapp,gngm,phsu|aapp|||penicillamine||||1000|44|56


SE|00000000||tx|1|text|This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||only||||775|24|27
SE|00000000||tx|1|entity|C2347946|Relevance|qlco|||relevant||||775|40|47
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||775|49|59
SE|00000000||tx|1|entity|C0332307|Type - attribute|qlco|||kind||||1000|69|72
SE|00000000||tx|1|entity|C0025153|Mefloquine|orch,phsu|||Mefloquine||||1000|79|88
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|141|145
SE|00000000||tx|1|entity|C0232217|Cardiac conduction|ortf|||cardiac conduction||||1000|162|179
SE|00000000||tx|1|entity|C0003195|Anti-Arrhythmia Agents|phsu|||anti-arrhythmic||||1000|186|200
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic blocking agents||||1000|205|235
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium channel blockers||||1000|238|261
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|264|277
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blocking||||773|285|292
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||773|294|299
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|302|326
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|332|345
SE|00000000||tx|1|entity|C0489625|QTC interval|clna|||QTc interval||||1000|395|406
SE|00000000||tx|1|relation|5|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|141|145|VERB|AFFECTS||156|160|11|1|C0232217|Cardiac conduction|ortf|ortf|||cardiac conduction||||1000|162|179


SE|00000000||tx|1|text|Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||Urinary||||901|1|7
SE|00000000||tx|1|entity|C0304461|Acidifying preparation|phsu|||acidifying agents||||901|9|25
SE|00000000||tx|1|entity|C0002615|Ammonium Chloride|inch,phsu|||ammonium chloride||||1000|28|44
SE|00000000||tx|1|entity|C0770578|Sodium Phosphate, Monobasic|inch,phsu|||sodium acid phosphate||||1000|47|67
SE|00000000||tx|1|entity|C1548556|etc.|idcn|||etc||||1000|70|72
SE|00000000||tx|1|entity|C1979910|Ionized|qlco|||ionized||||888|110|116
SE|00000000||tx|1|entity|C1705920|Species|cnce|||species||||888|118|124
SE|00000000||tx|1|entity|C0002658|Amphetamine|nsba,orch,phsu|||amphetamine||||888|133|143
SE|00000000||tx|1|entity|C0567416|Molecule|sbst|||molecule||||888|145|152
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||urinary||||888|174|180
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|182|190
SE|00000000||tx|1|relation|0|0|C0002615|Ammonium Chloride|inch,phsu|inch|||ammonium chloride||||1000|28|44|SPEC|ISA||9|44|0|0|C0304461|Acidifying preparation|phsu|phsu|||acidifying agents||||901|9|25
SE|00000000||tx|1|relation|7|1|C0002658|Amphetamine|nsba,orch,phsu|orch|||amphetamine||||888|133|143|VERB|AUGMENTS||163|172|1|1|C0221102|Excretory function|phsf|phsf|||excretion||||888|182|190


SE|00000000||tx|1|text|Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.
SE|00000000||tx|1|entity|C0033447|Propantheline|orch,phsu|||Propantheline||||1000|1|13
SE|00000000||tx|1|entity|C0012525|Diphenoxylate|orch,phsu|||diphenoxylate||||1000|19|31
SE|00000000||tx|1|entity|C0442797|Decreasing|qlco|||decreasing||||851|37|46
SE|00000000||tx|1|entity|C0017189|Gastrointestinal tract structure|bdsy|||gut||||851|48|50
SE|00000000||tx|1|entity|C1510470|Motility|orgf|||motility||||851|52|59
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||694|75|81


SE|00000000||tx|1|text|If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||851|4|14
SE|00000000||tx|1|entity|C0030863|Pentamidine|orch,phsu|||pentamidine||||851|16|26
SE|00000000||tx|1|entity|C0032305|Pneumonia, Pneumocystis carinii|dsyn|||Pneumocystis carinii pneumonia||||1000|49|78
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|81|89
SE|00000000||tx|1|entity|C0678123|Hivid|nnon,phsu|||HIVID||||1000|96|100
SE|00000000||tx|1|relation|1|1|C0030863|Pentamidine|orch,phsu|phsu|||pentamidine||||851|16|26|VERB|TREATS||43|47|3|1|C0032305|Pneumonia, Pneumocystis carinii|dsyn|dsyn|||Pneumocystis carinii pneumonia||||1000|49|78
SE|00000000||tx|1|relation|3|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||1000|81|89|PREP|USES||91|94|1|1|C0678123|Hivid|nnon,phsu|phsu|||HIVID||||1000|96|100


SE|00000000||tx|1|text|Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulant||||734|43|60
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decreased||||574|76|84
SE|00000000||tx|1|entity|C1879840|Bin|qnco|||bin||||574|95|97
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||574|99|102
SE|00000000||tx|1|entity|C0024554|Male gender|fndg|||man||||861|117|119
SE|00000000||tx|1|entity|C2986474|Adrenocortical|qlco|||adrenocortical||||888|144|157
SE|00000000||tx|1|entity|C0038317|Steroids|strd|||steroids||||888|159|166
SE|00000000||tx|1|relation|3|3|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|ADJ|INHIBITS||76|84|2|1|C0024554|Male gender|fndg|fndg|||man||||861|117|119


SE|00000000||tx|1|text|therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|12|32
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|37|45
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||1000|107|118
SE|00000000||tx|1|relation|1|1|C0064113|Itraconazole|orch,phsu|orch|||Itraconazole||||1000|107|118|VERB|COEXISTS_WITH||83|87|2|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|37|45


SE|00000000||tx|1|text|Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.
SE|00000000||tx|1|entity|C0722229|Ocupress|orch,phsu|||Ocupress||||1000|1|8
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|41|48
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic blocking agent||||876|70|99
SE|00000000||tx|1|entity|C0442027|Oral|spco|||orally||||876|101|106
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|123|131
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|137|144
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|146|152
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||802|157|164
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blockade||||802|171|178
SE|00000000||tx|1|relation|2|2|C0722229|Ocupress|orch,phsu|phsu|||Ocupress||||1000|1|8|PREP|TREATS||38|39|5|1|C0030705|Patients|podg,humn|podg|||patients||||1000|41|48
SE|00000000||tx|1|relation|4|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-adrenergic blocking agent||||876|70|99|VERB|ADMINISTERED_TO||58|66|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|41|48


SE|00000000||tx|1|text|Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||Valproate||||1000|1|9
SE|00000000||tx|1|entity|C0332185|Recent|tmco|||recent||||901|14|19
SE|00000000||tx|1|entity|C0085973|Case Study|inpr|||case study||||901|21|30
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||888|44|51
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|53|60
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||888|69|74
SE|00000000||tx|1|entity|C2946261|Level|phsu|||level||||888|76|80
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||valproate||||1000|85|93
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|121|129


SE|00000000||tx|1|text|Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|33|35
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||753|49|54
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||Vardenafil||||753|63|72
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||753|74|77
SE|00000000||tx|1|entity|C1292423|72 Hours|tmco|||72-hour||||901|84|90
SE|00000000||tx|1|entity|C0439531|per period (qualifier value)|tmco|||period||||901|92|97
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|112|122
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|129|137


SE|00000000||tx|1|text|When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.
SE|00000000||tx|1|entity|C0002932|Anesthetics|phsu|||anesthetics||||1000|26|36
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium channel blockers||||1000|42|65


SE|00000000||tx|1|text|It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.
SE|00000000||tx|1|entity|C1274040|Result|ftcn|||results||||1000|27|33
SE|00000000||tx|1|entity|C0003062|Animals|anim|||animals||||1000|49|55
SE|00000000||tx|1|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine||||852|71|78
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induced||||852|80|86
SE|00000000||tx|1|entity|C0085612|Ventricular arrhythmia|patf|||ventricular arrhythmias||||852|88|110
SE|00000000||tx|1|entity|C0278134|Absence of sensation|sosy|||anesthesia||||1000|119|128
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||1000|149|159
SE|00000000||tx|1|relation|1|1|C0033497|Propranolol|orch,phsu|phsu|||propranolol||||1000|149|159|VERB|TREATS||137|144|5|1|C0278134|Absence of sensation|sosy|sosy|||anesthesia||||1000|119|128


SE|00000000||tx|1|text|However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|16|22
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|25|30
SE|00000000||tx|1|entity|C0012544|Diphosphonates|opco,phsu|||bisphosphonates||||1000|37|51
SE|00000000||tx|1|entity|C2697368|Gastrointestinal irritation|dsyn|||gastrointestinal irritation||||1000|77|103
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|141|151
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|153|155
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|160|166
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|171|176
SE|00000000||tx|1|entity|C0379199|Ibandronate|orch,phsu|||Ibandronate||||1000|183|193
SE|00000000||tx|1|relation|0|0|C0004057|Aspirin|orch,phsu|orch|||aspirin||||1000|16|22|SPEC|ISA||16|30|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|25|30


SE|00000000||tx|1|text|Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.
SE|00000000||tx|1|entity|C0035410|Rhabdomyolysis|patf|||Rhabdomyolysis||||1000|1|14
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|37|44
SE|00000000||tx|1|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||HMG-CoA reductase inhibitors||||1000|56|83
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|98|102
SE|00000000||tx|1|entity|C0034866|Recommendation|idcn|||recommended||||888|108|118
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosages||||888|120|126
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||861|169|173
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|185|196
SE|00000000||tx|1|relation|1|1|C0035410|Rhabdomyolysis|patf|patf|||Rhabdomyolysis||||1000|1|14|PREP|PROCESS_OF||34|35|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|37|44
SE|00000000||tx|1|relation|5|1|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|orch|||HMG-CoA reductase inhibitors||||1000|56|83|VERB|ADMINISTERED_TO||46|54|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|37|44


SE|00000000||tx|1|text|Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.
SE|00000000||tx|1|entity|C0023413|Leucovorin|orch,phsu,vita|||Leucovorin||||1000|1|10
SE|00000000||tx|1|entity|C0016360|Fluorouracil|nnon,phsu|||5-fluorouracil||||1000|34|47
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|70|77
SE|00000000||tx|1|entity|C0023413|Leucovorin|orch,phsu,vita|||leucovorin||||1000|98|107
SE|00000000||tx|1|relation|1|1|C0023413|Leucovorin|orch,phsu,vita|orch|||leucovorin||||1000|98|107|VERB|STIMULATES||86|93|4|2|C0016360|Fluorouracil|nnon,phsu|phsu|||5-fluorouracil||||1000|34|47


SE|00000000||tx|1|text|In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.
SE|00000000||tx|1|entity|C0205166|Long|qlco|||long||||901|4|7
SE|00000000||tx|1|entity|C0543467|Operative Surgical Procedures|diap,topp|||surgical procedures||||901|9|27
SE|00000000||tx|1|entity|C0014277|Enflurane|orch,phsu|||enflurane||||1000|36|44
SE|00000000||tx|1|entity|C0022180|Isoflurane|orch,phsu|||isoflurane||||888|49|58
SE|00000000||tx|1|entity|C0278134|Absence of sensation|sosy|||anesthesia||||888|60|69
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||608|72|75
SE|00000000||tx|1|entity|C0332183|Frequent|tmco|||frequent||||608|77|84
SE|00000000||tx|1|entity|C0024501|Maintenance|acty|||maintenance||||608|86|96
SE|00000000||tx|1|entity|C0024501|Maintenance|acty|||maintenance||||888|112|122
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|124|128
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduced||||890|134|140
SE|00000000||tx|1|entity|C2964135|Infusion Rate|tmco|||infusion rates||||890|142|155
SE|00000000||tx|1|entity|C0530102|Nimbex|orch,phsu|||NIMBEX||||1000|160|165
SE|00000000||tx|1|relation|5|4|C0014277|Enflurane|orch,phsu|orch|||enflurane||||1000|36|44|ADJ|INHIBITS||134|140|2|1|C0530102|Nimbex|orch,phsu|orch|||NIMBEX||||1000|160|165


SE|00000000||tx|1|text|Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
SE|00000000||tx|1|entity|C0301532|Multivitamin preparation|orch,phsu,vita|||Multivitamins||||1000|1|13
SE|00000000||tx|1|entity|C1514468|product|enty|||products||||1000|25|32
SE|00000000||tx|1|entity|C0302583|Iron|bacs,elii,phsu|||iron||||1000|45|48
SE|00000000||tx|1|entity|C0043481|Zinc|bacs,elii,phsu|||zinc||||1000|53|56
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|59|66
SE|00000000||tx|1|entity|C0038633|Sucralfate|carb,phsu|||sucralfate||||1000|71|80
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|89|91
SE|00000000||tx|1|entity|C1292425|2 Hours|tmco|||2 hours||||1000|139|145
SE|00000000||tx|1|entity|C0028365|Norfloxacin|orch,phsu|||norfloxacin||||1000|173|183
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||861|248|252
SE|00000000||tx|1|entity|C0042036|Urine|bdsu|||urine||||694|258|262
SE|00000000||tx|1|entity|C0028365|Norfloxacin|orch,phsu|||norfloxacin||||1000|274|284


SE|00000000||tx|1|text|In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|4|11
SE|00000000||tx|1|entity|C0162758|Serotonin Uptake Inhibitors|phsu|||serotonin reuptake inhibitor||||916|31|58
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||916|60|63
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|68|78
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|85|112
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|138|144
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||825|149|155
SE|00000000||tx|1|entity|C1998882|Sometimes|tmco|||sometimes||||825|158|166
SE|00000000||tx|1|entity|C1705232|Death Related to Adverse Event|fndg|||fatal||||825|168|172
SE|00000000||tx|1|entity|C0443286|Reaction|ftcn|||reactions||||825|175|183
SE|00000000||tx|1|entity|C1704628|Hyperthermia|fndg|||hyperthermia||||1000|195|206
SE|00000000||tx|1|entity|C0027066|Myoclonus|sosy|||myoclonus||||1000|219|227
SE|00000000||tx|1|entity|C0262385|AUTONOMIC INSTABILITY|dsyn|||autonomic instability||||1000|230|250
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||851|257|264
SE|00000000||tx|1|entity|C0439831|Rapid|qlco|||rapid||||851|266|270
SE|00000000||tx|1|entity|C0231239|Fluctuation|sosy|||fluctuations||||851|272|283
SE|00000000||tx|1|entity|C0518766|Vital signs|clna|||vital signs||||1000|288|298
SE|00000000||tx|1|entity|C0856054|Change in mental status NOS|sosy|||mental status changes||||1000|305|325
SE|00000000||tx|1|entity|C0205403|Extreme|qlco|||extreme||||851|340|346
SE|00000000||tx|1|entity|C0085631|Agitation|sosy|||agitation||||851|348|356
SE|00000000||tx|1|entity|C0205329|Progressive|ftcn|||progressing||||851|358|368
SE|00000000||tx|1|entity|C0011206|Delirium|mobd|||delirium||||1000|373|380
SE|00000000||tx|1|entity|C0009421|Comatose|dsyn|||coma||||1000|386|389
SE|00000000||tx|1|relation|0|0|C0162758|Serotonin Uptake Inhibitors|phsu|phsu|||serotonin reuptake inhibitor||||916|31|58|MOD/HEAD|ISA||31|63|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||916|60|63
SE|00000000||tx|1|relation|15|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||916|60|63|VERB|ADMINISTERED_TO||13|21|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|4|11
SE|00000000||tx|1|relation|0|0|C0162758|Serotonin Uptake Inhibitors|phsu|phsu|||serotonin reuptake inhibitor||||916|31|58|INFER|ADMINISTERED_TO(SPEC)||31|63|0|0|C0030705|Patients|podg,humn|humn|||patients||||1000|4|11


SE|00000000||tx|1|text|If additional adrenergic drugs are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of BROVANA may be potentiated.
SE|00000000||tx|1|entity|C1524062|Additional|ftcn|||additional||||861|4|13
SE|00000000||tx|1|entity|C0001637|Adrenergic Agents|phsu|||adrenergic drugs||||861|15|30
SE|00000000||tx|1|entity|C0449444|Route|spco|||route||||1000|62|66
SE|00000000||tx|1|entity|C2371925|Predictability|menp|||predictable||||728|132|142
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||728|156|162
SE|00000000||tx|1|entity|C1815278|Brovana|orch,phsu|||BROVANA||||1000|167|173
SE|00000000||tx|1|relation|3|3|C0001637|Adrenergic Agents|phsu|phsu|||adrenergic drugs||||861|15|30|NOM|INTERACTS_WITH||156|162|1|1|C1815278|Brovana|orch,phsu|orch|||BROVANA||||1000|167|173


SE|00000000||tx|1|text|Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0012091|Diclofenac|orch,phsu|||diclofenac||||1000|27|36
SE|00000000||tx|1|entity|C0012091|Diclofenac|orch,phsu|||diclofenac||||888|60|69
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|71|74
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAID||||1000|89|93
SE|00000000||tx|1|entity|C1515187|Take|hlca|||taking||||872|101|106
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||872|108|114
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|117|128
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|134|145
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||888|159|166
SE|00000000||tx|1|entity|C1521970|Characteristics|qlco|||characteristics||||888|168|182
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|194|198
SE|00000000||tx|1|relation|8|1|C0012091|Diclofenac|orch,phsu|orch|||diclofenac||||1000|27|36|VERB|ADMINISTERED_TO||20|25|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8
SE|00000000||tx|1|relation|2|1|C0012091|Diclofenac|orch,phsu|orch|||diclofenac||||1000|27|36|VERB|STIMULATES||45|52|7|1|C0012091|Diclofenac|orch,phsu|orch|||diclofenac||||888|60|69
SE|00000000||tx|1|relation|2|1|C0012091|Diclofenac|orch,phsu|orch|||diclofenac||||1000|27|36|VERB|STIMULATES||45|52|7|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAID||||1000|89|93


SE|00000000||tx|1|text|Concomitant use of L-phenylalanine and non-selective MAO inhibitors may cause hypertension.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|13|15
SE|00000000||tx|1|entity|C0031453|Phenylalanine|aapp,bacs,phsu|||L-phenylalanine||||1000|20|34
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||non-||||824|40|43
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||824|54|67
SE|00000000||tx|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||1000|79|90
SE|00000000||tx|1|relation|3|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||MAO inhibitors||||824|54|67|VERB|CAUSES||73|77|1|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||1000|79|90
SE|00000000||tx|1|relation|3|1|C0031453|Phenylalanine|aapp,gngm,bacs,phsu|aapp|||L-phenylalanine||||1000|20|34|VERB|CAUSES||73|77|1|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||1000|79|90


SE|00000000||tx|1|text|Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||Lithium||||851|1|7
SE|00000000||tx|1|entity|C0205343|Reversible|ftcn|||Reversible||||851|9|18
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||851|20|28
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||890|39|45
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum lithium concentrations||||890|33|60
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|66|73
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|101|111
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|131|137
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitors||||1000|144|157
SE|00000000||tx|1|entity|C0521942|Angiotensin II receptor antagonist|phsu|||angiotensin II receptor antagonists||||1000|174|208


SE|00000000||tx|1|text|Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||838|34|42
SE|00000000||tx|1|entity|C0010968|Dangerousness|idcn|||danger||||838|44|49
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||901|58|68
SE|00000000||tx|1|entity|C0036589|Self Administration|topp|||self-administration||||901|70|88
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|93|107
SE|00000000||tx|1|entity|C0542339|Inferior|spco|||under||||888|115|119
SE|00000000||tx|1|entity|C1170625|Suboxone|orch,phsu|||SUBOXONE||||1000|136|143
SE|00000000||tx|1|entity|C0006404|Subutex|orch,phsu|||SUBUTEX||||1000|148|154
SE|00000000||tx|1|relation|5|3|C0036589|Self Administration|topp|topp|||self-administration||||901|70|88|PREP|USES||131|134|2|1|C1170625|Suboxone|orch,phsu|phsu|||SUBOXONE||||1000|136|143
SE|00000000||tx|1|relation|5|3|C0036589|Self Administration|topp|topp|||self-administration||||901|70|88|PREP|USES||131|134|2|1|C0006404|Subutex|orch,phsu|phsu|||SUBUTEX||||1000|148|154


SE|00000000||tx|1|text|Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.
SE|00000000||tx|1|entity|C2709094|pre treatment|tmco|||Pre-treatment||||1000|1|13
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||827|24|29
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampicin||||827|39|48
SE|00000000||tx|1|entity|C1135135|erlotinib|orch,phsu|||erlotinib||||888|60|68
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|70|72


SE|00000000||tx|1|text|Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||851|16|23
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||851|25|32
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||851|34|40
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|45|49
SE|00000000||tx|1|entity|C1269560|Entire nervous system|bdsy|||nervous system||||1000|72|85
SE|00000000||tx|1|entity|C0001962|Ethanol|orch|||ethanol||||1000|88|94
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||triazolam||||1000|99|107
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|138|148
SE|00000000||tx|1|entity|C0068897|tiagabine|orch,phsu|||tiagabine||||1000|155|163


SE|00000000||tx|1|text|In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|4|11
SE|00000000||tx|1|entity|C1299392|Mild to moderate|qlco|||mild to moderate||||916|18|33
SE|00000000||tx|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||916|35|46
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||790|73|77
SE|00000000||tx|1|entity|C0876768|Vioxx|orch,phsu|||VIOXX||||1000|82|86
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitor||||901|97|109
SE|00000000||tx|1|entity|C0053091|benazepril|orch,phsu|||benazepril||||901|111|120
SE|00000000||tx|1|entity|C1442465|4 Weeks|tmco|||4 weeks||||1000|139|145
SE|00000000||tx|1|entity|C1510992|Average|qnco|||average||||888|171|177
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|179|186
SE|00000000||tx|1|entity|C0428886|Mean blood pressure|fndg|||mean arterial pressure||||1000|191|212
SE|00000000||tx|1|entity|C0439475|mmHg|qnco|||mm Hg||||861|225|229
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitor||||1000|243|255
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|257|261
SE|00000000||tx|1|relation|11|6|C0053091|benazepril|orch,phsu|orch|||benazepril||||901|111|120|VERB|compared_with||231|238|2|1|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|phsu|||ACE inhibitor||||1000|243|255
SE|00000000||tx|1|relation|0|0|C0053091|benazepril|orch,phsu|orch|||benazepril||||901|111|120|MOD/HEAD|ISA||97|120|0|0|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|phsu|||ACE inhibitor||||901|97|109
SE|00000000||tx|1|relation|12|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||916|35|46|PREP|PROCESS_OF||13|16|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|4|11
SE|00000000||tx|1|relation|8|3|C0053091|benazepril|orch,phsu|orch|||benazepril||||901|111|120|NOM|AUGMENTS||179|186|4|1|C0428886|Mean blood pressure|fndg|fndg|||mean arterial pressure||||1000|191|212
SE|00000000||tx|1|relation|8|3|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|phsu|||ACE inhibitor||||1000|243|255|NOM|AUGMENTS||179|186|4|1|C0428886|Mean blood pressure|fndg|fndg|||mean arterial pressure||||1000|191|212


SE|00000000||tx|1|text|Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.
SE|00000000||tx|1|entity|C0004320|Auranofin|orch,phsu|||Auranofin||||1000|1|9
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|32|39
SE|00000000||tx|1|entity|C0019665|Historical aspects qualifier|inpr|||history||||1000|48|54
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||888|59|65
SE|00000000||tx|1|entity|C0443286|Reaction|ftcn|||reaction||||888|67|74
SE|00000000||tx|1|entity|C0018026|Gold|elii,phsu|||gold||||888|83|86
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medication||||888|88|97
SE|00000000||tx|1|entity|C0728786|Solganal|orch,phsu|||Solganal||||1000|110|117
SE|00000000||tx|1|entity|C0700008|Myochrysine|orch,phsu|||Myochrysine||||1000|123|133
SE|00000000||tx|1|relation|0|0|C0018026|Gold|elii,phsu|elii|||gold||||888|83|86|MOD/HEAD|ISA||83|97|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medication||||888|88|97


SE|00000000||tx|1|text|HEMABATE may augment the activity of other oxytocic agents.
SE|00000000||tx|1|entity|C0121295|Hemabate|orch,phsu|||HEMABATE||||1000|1|8
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||1000|26|33
SE|00000000||tx|1|entity|C0030094|Oxytocics|phsu|||oxytocic agents||||1000|44|58
SE|00000000||tx|1|relation|1|1|C0121295|Hemabate|orch,phsu|orch|||HEMABATE||||1000|1|8|VERB|STIMULATES||14|20|2|2|C0030094|Oxytocics|phsu|phsu|||oxytocic agents||||1000|44|58


SE|00000000||tx|1|text|Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.
SE|00000000||tx|1|entity|C0700739|Nalfon|orch,phsu|||Nalfon||||1000|9|14
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|20|22
SE|00000000||tx|1|entity|C1524062|Additional|ftcn|||additional||||888|50|59
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|61|66
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|94|100
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|102|106
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|120|126
SE|00000000||tx|1|entity|C1521828|Rate|qnco|||rate||||1000|142|145
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||1000|150|158
SE|00000000||tx|1|entity|C0700739|Nalfon|orch,phsu|||Nalfon||||1000|163|168
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|175|185
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|187|189
SE|00000000||tx|1|entity|C0700739|Nalfon|orch,phsu|||Nalfon||||1000|194|199
SE|00000000||tx|1|entity|C0036077|Salicylates|orch,phsu|||salicylates||||1000|205|215
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|220|222
SE|00000000||tx|1|relation|5|1|C0004057|Aspirin|orch,phsu|orch|||aspirin||||1000|120|126|VERB|AUGMENTS||128|136|6|2|C0221102|Excretory function|phsf|phsf|||excretion||||1000|150|158
SE|00000000||tx|1|relation|5|1|C0004057|Aspirin|orch,phsu|orch|||aspirin||||1000|94|100|VERB|AUGMENTS||128|136|6|2|C0221102|Excretory function|phsf|phsf|||excretion||||1000|150|158


SE|00000000||tx|1|text|Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||Phenobarbital||||1000|1|13
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||Amphetamines||||1000|16|27
SE|00000000||tx|1|entity|C0021826|Intestinal Absorption|ortf|||intestinal absorption||||1000|39|59
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|64|76
SE|00000000||tx|1|relation|2|1|C0002667|Amphetamines|nsba,orch,phsu|nsba|||Amphetamines||||1000|16|27|VERB|AFFECTS||33|37|2|1|C0021826|Intestinal Absorption|ortf|ortf|||intestinal absorption||||1000|39|59


SE|00000000||tx|1|text|Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.
SE|00000000||tx|1|entity|C0034235|Pyrantel|orch,phsu|||Pyrantel||||1000|1|8
SE|00000000||tx|1|entity|C0701073|Antiminth|orch,phsu|||Antiminth||||1000|17|25
SE|00000000||tx|1|entity|C1883727|Taken|cnce|||Taking||||872|30|35
SE|00000000||tx|1|entity|C0031957|piperazine|orch,phsu|||piperazine||||872|37|46
SE|00000000||tx|1|entity|C0034235|Pyrantel|orch,phsu|||pyrantel||||888|52|59
SE|00000000||tx|1|entity|C1883357|Together|qlco|||together||||888|61|68
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|87|93
SE|00000000||tx|1|entity|C0031957|piperazine|orch,phsu|||piperazine||||1000|98|107
SE|00000000||tx|1|relation|4|1|C0034235|Pyrantel|orch,phsu|orch|||pyrantel||||888|52|59|NOM|INTERACTS_WITH||87|93|1|1|C0031957|piperazine|orch,phsu|orch|||piperazine||||1000|98|107
SE|00000000||tx|1|relation|4|1|C0034235|Pyrantel|orch,phsu|orch|||Pyrantel||||1000|1|8|NOM|INTERACTS_WITH||87|93|1|1|C0031957|piperazine|orch,phsu|orch|||piperazine||||1000|98|107


SE|00000000||tx|1|text|In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||1000|4|6
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||clinical study||||1000|19|32
SE|00000000||tx|1|entity|C0031955|Piperacillin|antb,orch|||piperacillin||||1000|68|79
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|111|116
SE|00000000||tx|1|entity|C0242531|Vecuronium|phsu,strd|||vecuronium||||1000|121|130


SE|00000000||tx|1|text|Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.
SE|00000000||tx|1|entity|C0016277|Fluconazole|orch,phsu|||Fluconazole||||1000|1|11
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||1000|17|25
SE|00000000||tx|1|entity|||gngm|1555|CYP2B6|P450||||694|30|33
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||623|50|55
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||623|57|66
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||623|86|94
SE|00000000||tx|1|entity|C0126174|Losartan|orch,phsu|||losartan||||623|96|103


SE|00000000||tx|1|text|Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
SE|00000000||tx|1|entity|C0442027|Oral|spco|||Oral||||888|1|4
SE|00000000||tx|1|entity|C0027603|Neomycin|antb,carb|||neomycin||||888|6|13
SE|00000000||tx|1|entity|C0021826|Intestinal Absorption|ortf|||gastrointestinal absorption||||1000|28|54
SE|00000000||tx|1|entity|C0030840|Penicillin V|antb,orch|||penicillin V||||1000|59|70
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||916|73|76
SE|00000000||tx|1|entity|C0042845|Vitamin B 12|orch,phsu,vita|||vitamin B-12||||916|78|89
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|92|103
SE|00000000||tx|1|entity|C0016360|Fluorouracil|nnon,phsu|||5-fluorouracil||||1000|109|122
SE|00000000||tx|1|relation|1|1|C0027603|Neomycin|antb,carb|antb|||neomycin||||888|6|13|VERB|DISRUPTS||15|22|5|1|C0021826|Intestinal Absorption|ortf|ortf|||gastrointestinal absorption||||1000|28|54


SE|00000000||tx|1|text|Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.
SE|00000000||tx|1|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||888|16|25
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||888|27|34
SE|00000000||tx|1|entity|C0031082|Periodicals|inpr,mnob|||serial||||888|40|45
SE|00000000||tx|1|entity|C0242485|Measurement|ftcn|||measurement||||888|47|57
SE|00000000||tx|1|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||901|62|71
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentration||||901|73|91
SE|00000000||tx|1|entity|C0033607|Protease Inhibitor|bacs,phsu|||protease inhibitor||||888|112|129
SE|00000000||tx|1|entity|C1707479|Concomitant Therapy|topp|||concomitant protease inhibitor therapy||||888|100|137
SE|00000000||tx|1|relation|0|0|C1707479|Concomitant Therapy|topp|topp|||concomitant protease inhibitor therapy||||888|100|137|MOD/HEAD|USES||112|137|0|0|C0033607|Protease Inhibitor|bacs,phsu|phsu|||protease inhibitor||||888|112|129


SE|00000000||tx|1|text|In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.
SE|00000000||tx|1|entity|C0205430|Mixed (qualifier value)|ftcn|||mixing||||861|10|15
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycoside||||1000|23|36
SE|00000000||tx|1|entity|C0003232|Antibiotics|antb|||antibiotics||||827|59|69
SE|00000000||tx|1|entity|C0030842|Penicillins|antb,orch|||penicillins||||1000|72|82
SE|00000000||tx|1|entity|C2266959|Cephalosporin Antibacterial [EPC]|antb,orch|||cephalosporins||||1000|87|100
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||851|119|129
SE|00000000||tx|1|entity|C1709100|Mutual|qlco|||mutual||||851|131|136
SE|00000000||tx|1|entity|C0544461|Inactivation|comd|||inactivation||||851|138|149
SE|00000000||tx|1|relation|0|0|C0030842|Penicillins|antb,orch|antb|||penicillins||||1000|72|82|SPEC|ISA||59|82|0|0|C0003232|Antibiotics|antb|antb|||antibiotics||||827|59|69
SE|00000000||tx|1|relation|0|0|C2266959|Cephalosporin Antibacterial [EPC]|antb,orch|antb|||cephalosporins||||1000|87|100|SPEC|ISA||59|82|0|0|C0003232|Antibiotics|antb|antb|||antibiotics||||827|59|69
SE|00000000||tx|1|relation|5|3|C0003232|Antibiotics|antb|antb|||antibiotics||||827|59|69|VERB|CAUSES||107|112|1|1|C0544461|Inactivation|comd|comd|||inactivation||||851|138|149
SE|00000000||tx|1|relation|0|0|C0030842|Penicillins|antb,orch|antb|||penicillins||||1000|72|82|INFER|CAUSES(SPEC)||59|82|0|0|C0544461|Inactivation|comd|comd|||inactivation||||851|138|149
SE|00000000||tx|1|relation|0|0|C2266959|Cephalosporin Antibacterial [EPC]|antb,orch|antb|||cephalosporins||||1000|87|100|INFER|CAUSES(SPEC)||59|82|0|0|C0544461|Inactivation|comd|comd|||inactivation||||851|138|149


SE|00000000||tx|1|text|Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
SE|00000000||tx|1|entity|C1511726|Data|idcn|||Data||||1000|1|4
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|39|42
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||888|44|55
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|61|69
SE|00000000||tx|1|entity|C0429028|QT interval feature (observable entity)|clna|||QT interval||||1000|105|115
SE|00000000||tx|1|entity|C0013798|Electrocardiogram|fndg|||ECG||||966|124|126


SE|00000000||tx|1|text|The mean clearances of dofetilide were 16% and 15% lower in patients on thiazide diuretics and inhibitors of tubular organic cation transport, respectively.
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearances||||827|10|19
SE|00000000||tx|1|entity|C0114771|dofetilide|orch,phsu|||dofetilide||||1000|24|33
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|61|68
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|73|90
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||1000|96|105
SE|00000000||tx|1|entity|C0151747|Renal tubular disorder|dsyn|||tubular||||916|110|116
SE|00000000||tx|1|entity|C1159692|organic cation transport|celf|||organic cation transport||||916|118|141
SE|00000000||tx|1|relation|3|2|C0114771|dofetilide|orch,phsu|phsu|||dofetilide||||1000|24|33|PREP|TREATS||58|59|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|61|68


SE|00000000||tx|1|text|Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||Urinary||||901|1|7
SE|00000000||tx|1|entity|C0304461|Acidifying preparation|phsu|||acidifying agents||||901|9|25
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|33|38
SE|00000000||tx|1|entity|C0002615|Ammonium Chloride|inch,phsu|||ammonium chloride||||1000|41|57
SE|00000000||tx|1|entity|C0770578|Sodium Phosphate, Monobasic|inch,phsu|||sodium acid phosphate||||1000|60|80
SE|00000000||tx|1|entity|C1548556|etc.|idcn|||etc||||1000|83|85
SE|00000000||tx|1|entity|C1979910|Ionized|qlco|||ionized||||888|123|129
SE|00000000||tx|1|entity|C1705920|Species|cnce|||species||||888|131|137
SE|00000000||tx|1|entity|C0002658|Amphetamine|nsba,orch,phsu|||amphetamine||||888|146|156
SE|00000000||tx|1|entity|C0567416|Molecule|sbst|||molecule||||888|158|165
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||urinary||||888|187|193
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|195|203
SE|00000000||tx|1|relation|0|0|C0002615|Ammonium Chloride|inch,phsu|inch|||ammonium chloride||||1000|41|57|SPEC|ISA||33|57|0|0|C0450442|Agent|chvf|chvf|||agents||||966|33|38
SE|00000000||tx|1|relation|8|1|C0002658|Amphetamine|nsba,orch,phsu|orch|||amphetamine||||888|146|156|VERB|AUGMENTS||176|185|1|1|C0221102|Excretory function|phsf|phsf|||excretion||||888|195|203


SE|00000000||tx|1|text|Morphine: Combination hormonal contraceptives may increase the clearance of morphine.
SE|00000000||tx|1|entity|C0026549|Morphine|orch,phsu|||Morphine||||1000|1|8
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||Combination||||851|11|21
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||851|23|30
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||851|32|45
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|64|72
SE|00000000||tx|1|entity|C0026549|Morphine|orch,phsu|||morphine||||1000|77|84
SE|00000000||tx|1|relation|2|1|C0009871|Contraceptive Agents|phsu|phsu|||contraceptives||||851|32|45|VERB|STIMULATES||51|58|2|2|C0026549|Morphine|orch,phsu|orch|||morphine||||1000|77|84


SE|00000000||tx|1|text|Wait 5 weeks after stopping escitalopram before starting a non-selective MAO inhibitor.
SE|00000000||tx|1|entity|C1610166|wait|ftcn|||Wait||||802|1|4
SE|00000000||tx|1|entity|C0439230|week|tmco|||weeks||||802|8|12
SE|00000000||tx|1|entity|C0723457|Stop brand of fluoride|inch,phsu|||stopping||||888|20|27
SE|00000000||tx|1|entity|C1099456|Escitalopram|orch,phsu|||escitalopram||||888|29|40
SE|00000000||tx|1|entity|C1272689|Started|qlco|||starting||||966|49|56
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||non-||||824|60|63
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitor||||824|74|86


SE|00000000||tx|1|text|Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.
SE|00000000||tx|1|entity|C0596545|Experience|menp|||Experience||||1000|1|10
SE|00000000||tx|1|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||HMG-CoA reductase inhibitors||||1000|38|65
SE|00000000||tx|1|entity|C0015846|Fentanyl|orch,phsu|||Fentanyl||||1000|71|78
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|83|90
SE|00000000||tx|1|entity|C0518609|consideration|fndg|||consideration||||1000|113|125
SE|00000000||tx|1|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||HMG-CoA reductase inhibitors||||1000|176|203
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|208|215
SE|00000000||tx|1|entity|C0015846|Fentanyl|orch,phsu|||Fentanyl||||1000|227|234
SE|00000000||tx|1|relation|4|1|C0015846|Fentanyl|orch,phsu|phsu|||Fentanyl||||1000|71|78|PREP|TREATS||80|81|6|1|C0030705|Patients|podg,humn|podg|||patients||||1000|83|90
SE|00000000||tx|1|relation|4|1|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|phsu|||HMG-CoA reductase inhibitors||||1000|38|65|PREP|TREATS||80|81|6|1|C0030705|Patients|podg,humn|podg|||patients||||1000|83|90
SE|00000000||tx|1|relation|8|3|C0518609|consideration|fndg|fndg|||consideration||||1000|113|125|PREP|PROCESS_OF||205|206|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|208|215
SE|00000000||tx|1|relation|1|1|C0015846|Fentanyl|orch,phsu|orch|||Fentanyl||||1000|227|234|VERB|ADMINISTERED_TO||217|225|9|1|C0030705|Patients|podg,humn|humn|||patients||||1000|208|215


SE|00000000||tx|1|text|Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||901|1|11
SE|00000000||tx|1|entity|C0001563|Administration, Oral|topp|||oral administration||||901|13|31
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|36|47
SE|00000000||tx|1|entity|C0205309|Known|qlco|||known||||888|52|56
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||888|58|66
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||861|71|76
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||861|78|85
SE|00000000||tx|1|entity|C0023884|Liver|bpoc|||liver||||1000|94|98
SE|00000000||tx|1|entity|C0021839|Intestinal Mucosa|tisu|||intestinal mucosa||||1000|111|127
SE|00000000||tx|1|entity|C0205454|Eight|qnco|||eight-||||851|140|145
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||851|146|149
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||851|151|158
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||694|167|174
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|188|191
SE|00000000||tx|1|entity|C0054201|Budesonide|phsu,strd|||budesonide||||888|193|202
SE|00000000||tx|1|relation|5|1|C0023884|Liver|bpoc|bpoc|||liver||||1000|94|98|PREP|LOCATION_OF||87|88|4|1|||gngm,aapp|aapp|1576|CYP3A4|CYP3A4||||861|71|76
SE|00000000||tx|1|relation|5|1|C0021839|Intestinal Mucosa|tisu|tisu|||intestinal mucosa||||1000|111|127|PREP|LOCATION_OF||87|88|4|1|||gngm,aapp|aapp|1576|CYP3A4|CYP3A4||||861|71|76


SE|00000000||tx|1|text|Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||Furosemide||||1000|1|10
SE|00000000||tx|1|entity|C1120110|aliskiren|orch,phsu|||aliskiren||||1000|18|26
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|53|62
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|69|71
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|77|80
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|85|94


SE|00000000||tx|1|text|Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.
SE|00000000||tx|1|entity|C0008425|Cholinesterase Inhibitors|orch,phsu|||Anticholinesterases||||1000|1|19
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|22|32
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|34|36
SE|00000000||tx|1|entity|C0008425|Cholinesterase Inhibitors|orch,phsu|||anticholinesterase agents||||1000|41|65
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|71|85
SE|00000000||tx|1|entity|C1883552|Weakness|sosy|||weakness||||861|106|113
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|118|125
SE|00000000||tx|1|entity|C0026896|Myasthenia Gravis|dsyn|||myasthenia gravis||||1000|132|148
SE|00000000||tx|1|relation|4|1|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroids||||1000|71|85|VERB|CAUSES||91|97|3|1|C1883552|Weakness|sosy|sosy|||weakness||||861|106|113
SE|00000000||tx|1|relation|4|1|C0008425|Cholinesterase Inhibitors|orch,phsu|orch|||anticholinesterase agents||||1000|41|65|VERB|CAUSES||91|97|3|1|C1883552|Weakness|sosy|sosy|||weakness||||861|106|113
SE|00000000||tx|1|relation|5|1|C1883552|Weakness|sosy|sosy|||weakness||||861|106|113|PREP|PROCESS_OF||115|116|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|118|125
SE|00000000||tx|1|relation|1|1|C0026896|Myasthenia Gravis|dsyn|dsyn|||myasthenia gravis||||1000|132|148|PREP|PROCESS_OF||127|130|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|118|125


SE|00000000||tx|1|text|Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.
SE|00000000||tx|1|entity|C0051809|anagrelide|orch,phsu|||Anagrelide||||1000|1|10
SE|00000000||tx|1|entity|C0021469|Metabolic Inhibition|moft|||inhibitory||||790|38|47
SE|00000000||tx|1|entity|C0439167|Percent Activity|qnco|||activity||||790|49|56
SE|00000000||tx|1|entity|C1332826|CYP1A2 gene|gngm|1544|CYP1A2|CYP1A2||||1000|66|71
SE|00000000||tx|1|entity|C0871935|Theory|idcn|||theoretical||||888|93|103
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||888|105|113
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|119|129
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medicinal products||||901|157|174
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||762|189|197
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||762|214|225


SE|00000000||tx|1|text|HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.
SE|00000000||tx|1|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||HMG-CoA reductase inhibitors||||1000|1|28
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combined||||888|35|42
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|44|46
SE|00000000||tx|1|entity|C0723893|Tricor|orch,phsu|||TRICOR||||1000|51|56
SE|00000000||tx|1|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||HMG-CoA reductase inhibitors||||1000|62|89
SE|00000000||tx|1|entity|C0814225|Benefits|qnco|||benefit||||1000|120|126
SE|00000000||tx|1|entity|C1517331|Further|spco|||further||||872|131|137
SE|00000000||tx|1|entity|C1515926|Alteration|idcn|||alterations||||872|139|149
SE|00000000||tx|1|entity|C0023779|Lipids|lipd|||lipid||||861|154|158
SE|00000000||tx|1|entity|C0332148|Probable diagnosis|qlco|||likely||||861|170|175
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||888|193|201
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|203|206
SE|00000000||tx|1|entity|C0013162|Drug Combinations|phsu|||drug combination||||1000|216|231


SE|00000000||tx|1|text|CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||Active||||861|5|10
SE|00000000||tx|1|entity|C0007680|Central Nervous System Agents|phsu|||CNS-Active Drugs||||861|1|16
SE|00000000||tx|1|entity|C0001962|Ethanol|orch|||Ethanol||||861|18|24
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|29|36
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|38|43
SE|00000000||tx|1|entity|C0033923|Psychomotor Performance|menp|||psychomotor performance||||1000|48|70
SE|00000000||tx|1|entity|C1436328|Eszopiclone|orch,phsu|||eszopiclone||||1000|106|116
SE|00000000||tx|1|entity|C1381542|Ethanol 70%|clnd|||ethanol 0.70||||822|122|133
SE|00000000||tx|1|entity|C1300563|Gram per Kilogram|qnco|||g/kg||||822|135|138
SE|00000000||tx|1|entity|C1292426|4 Hours|tmco|||4 hours||||1000|150|156
SE|00000000||tx|1|entity|C0001962|Ethanol|orch|||ethanol||||888|164|170
SE|00000000||tx|1|relation|0|0|C0001962|Ethanol|orch|orch|||Ethanol||||861|18|24|MOD/HEAD|ISA||1|24|0|0|C0007680|Central Nervous System Agents|phsu|phsu|||CNS-Active Drugs||||861|1|16


SE|00000000||tx|1|text|Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
SE|00000000||tx|1|entity|C0053091|benazepril|orch,phsu|||Benazepril||||1000|1|10
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitors||||1000|24|37
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||1000|48|51
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|58|65
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|67|73
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic blockers||||1000|80|103
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|130|134
SE|00000000||tx|1|entity|C0005823|Blood Pressure|orgf|||blood pressure||||1000|142|155
SE|00000000||tx|1|entity|C0021469|Metabolic Inhibition|moft|||inhibiting||||888|160|169
SE|00000000||tx|1|entity|C1709471|Part Dosing Unit|qnco|||parts||||888|171|175
SE|00000000||tx|1|entity|C0035096|Renin-angiotensin system|bdsy|||renin-angiotensin system||||1000|184|207
SE|00000000||tx|1|relation|0|0|C0053091|benazepril|orch,phsu|orch|||Benazepril||||1000|1|10|SPEC|ISA||1|37|0|0|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|phsu|||ACE inhibitors||||1000|24|37
SE|00000000||tx|1|relation|5|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|130|134|VERB|AFFECTS||136|140|3|1|C0005823|Blood Pressure|orgf|orgf|||blood pressure||||1000|142|155


SE|00000000||tx|1|text|Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C1320102|Factive|antb,orch|||FACTIVE||||1000|31|37
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|44|53
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|73|80
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||694|85|92
SE|00000000||tx|1|entity|C0533545|gemifloxacin|antb,orch|||gemifloxacin||||1000|106|117


SE|00000000||tx|1|text|Antidiabetics, oral (diabetes medicine you take by mouth) use of oral Antidiabetics with sulfapyridine may increase The chance of side effects affecting The blood and/or The side effects or oral Antidiabetics
SE|00000000||tx|1|entity|C0935929|Antidiabetics|phsu|||Antidiabetics||||1000|1|13
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||1000|16|19
SE|00000000||tx|1|entity|C0020616|Hypoglycemic Agents|phsu|||diabetes medicine||||983|22|38
SE|00000000||tx|1|entity|C0230028|Oral region|blor|||mouth||||1000|52|56
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||901|66|69
SE|00000000||tx|1|entity|C0935929|Antidiabetics|phsu|||Antidiabetics||||901|71|83
SE|00000000||tx|1|entity|C0038710|Sulfapyridine|orch,phsu|||sulfapyridine||||1000|90|102
SE|00000000||tx|1|entity|C0237506|Chance|qlco|||chance||||1000|121|126
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||1000|131|142
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||1000|158|162
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||1000|175|186
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||901|191|194
SE|00000000||tx|1|entity|C0935929|Antidiabetics|phsu|||Antidiabetics||||901|196|208
SE|00000000||tx|1|relation|8|3|C0038710|Sulfapyridine|orch,phsu|orch|||sulfapyridine||||1000|90|102|VERB|AFFECTS||144|152|3|1|C0005767|Blood|tisu|tisu|||blood||||1000|158|162


SE|00000000||tx|1|text|Aspirin: CELEBREX can be used with low dose aspirin.
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||Aspirin||||1000|1|7
SE|00000000||tx|1|entity|C0719198|Celebrex|orch,phsu|||CELEBREX||||1000|10|17
SE|00000000||tx|1|entity|C2608320|Low-Dose Aspirin|orch,phsu|||low dose aspirin||||1000|36|51


SE|00000000||tx|1|text|Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||Beta-blockers||||1000|1|13
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||1000|16|24
SE|00000000||tx|1|entity|C0302213|Lithium salt|inch,phsu|||lithium salts||||1000|27|39
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|46|52
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood-||||861|90|95
SE|00000000||tx|1|entity|C0441994|Lower - spatial qualifier|spco|||lowering||||861|104|111
SE|00000000||tx|1|entity|C1158774|negative regulation of transcription by glucose|genf|||glucose-lowering effect||||861|96|118
SE|00000000||tx|1|entity|C0021641|Insulin|aapp,horm,phsu|||insulin||||1000|123|129


SE|00000000||tx|1|text|Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|30|34
SE|00000000||tx|1|entity|C1514118|Nephrotoxic|qlco|||nephrotoxic||||1000|47|57
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycosides||||1000|66|80
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|83|94
SE|00000000||tx|1|entity|C0677881|Cytotoxic Chemotherapy|topp|||cytotoxic chemotherapy||||1000|116|137
SE|00000000||tx|1|entity|C0876994|cardiac toxicity|inpo|||cardiotoxic||||928|141|151
SE|00000000||tx|1|entity|C0013089|Doxorubicin|antb,orch|||doxorubicin||||1000|160|170
SE|00000000||tx|1|entity|C0235378|Hepatotoxicity|inpo|||hepatotoxic||||928|176|186
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|195|206
SE|00000000||tx|1|entity|C0003993|ASPARAGINASE|aapp,enzy,phsu|||asparaginase||||1000|209|220
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|223|229
SE|00000000||tx|1|entity|C0701339|Proleukin|orch,phsu|||PROLEUKIN||||1000|236|244
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|259|266
SE|00000000||tx|1|entity|C0460002|body system|bdsy|||organ systems||||1000|277|289
SE|00000000||tx|1|relation|14|1|C0701339|Proleukin|orch,phsu|orch|||PROLEUKIN||||1000|236|244|VERB|AUGMENTS||250|257|2|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||1000|259|266


SE|00000000||tx|1|text|Studies in humans show that the absorption of chlorothiazide as reflected in urinary excretion is markedly decreased even when administered one hour before colestipol hydrochloride.
SE|00000000||tx|1|entity|C0086418|Homo sapiens|humn|||humans||||1000|12|17
SE|00000000||tx|1|entity|C0008273|Chlorothiazide|orch,phsu|||chlorothiazide||||1000|47|60
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||urinary||||888|78|84
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|86|94
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||markedly||||1000|99|106
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||790|141|143
SE|00000000||tx|1|entity|C0564385|/hour|qnco|||hour||||790|145|148
SE|00000000||tx|1|entity|C0354648|Colestipol Hydrochloride|orch,phsu|||colestipol hydrochloride||||1000|157|180
SE|00000000||tx|1|relation|1|1|C0354648|Colestipol Hydrochloride|orch,phsu|orch|||colestipol hydrochloride||||1000|157|180|ADJ|ADMINISTERED_TO||128|139|5|4|C0086418|Homo sapiens|grup,humn|humn|||humans||||1000|12|17


SE|00000000||tx|1|text|Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.
SE|00000000||tx|1|entity|C0022885|Laboratory Procedures|lbpr|||Laboratory Test||||888|6|20
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||Drug/Laboratory Test Interactions||||888|1|33
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||Amphetamines||||1000|36|47
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|61|71
SE|00000000||tx|1|entity|C0702240|Elevation|spco|||elevation||||888|73|81
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||623|86|91
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroid||||623|93|106
SE|00000000||tx|1|relation|3|2|C0002667|Amphetamines|nsba,orch,phsu|nsba|||Amphetamines||||1000|36|47|PREP|COEXISTS_WITH||83|84|1|1|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroid||||623|93|106


SE|00000000||tx|1|text|Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .
SE|00000000||tx|1|entity|C0007955|Charcoal|elii,phsu|||Charcoal||||888|20|27
SE|00000000||tx|1|entity|C0001275|Activated Charcoal|orch,phsu|||activated charcoal||||1000|65|82
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|87|94
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||1000|107|116
SE|00000000||tx|1|entity|C0439831|Rapid|qlco|||rapid||||1000|139|143
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|149|159
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||888|161|168
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||1000|173|178
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||888|188|193
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||888|195|204
SE|00000000||tx|1|entity|C0063041|leflunomide|orch,phsu|||leflunomide||||1000|209|219
SE|00000000||tx|1|relation|4|1|C0001275|Activated Charcoal|orch,phsu|phsu|||activated charcoal||||1000|65|82|PREP|TREATS||84|85|9|1|C0030705|Patients|podg,humn|podg|||patients||||1000|87|94
SE|00000000||tx|1|relation|4|1|C0001275|Activated Charcoal|orch,phsu|phsu|||activated charcoal||||1000|65|82|PREP|TREATS||84|85|9|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||1000|107|116


SE|00000000||tx|1|text|Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||Ritonavir||||861|1|9
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||1000|39|47
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||vardenafil||||1000|52|61
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||861|69|73


SE|00000000||tx|1|text|However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|14|24
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|26|28
SE|00000000||tx|1|entity|C0048470|argatroban|aapp,phsu|||Argatroban||||1000|33|42
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|48|55
SE|00000000||tx|1|entity|C0205265|Initially|tmco|||initial||||775|67|73
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||775|75|78
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||775|80|83
SE|00000000||tx|1|entity|C0450346|2/5|qnco|||2.5||||786|97|99
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||786|103|108
SE|00000000||tx|1|entity|C0442027|Oral|spco|||orally||||786|110|115
SE|00000000||tx|1|entity|C1442469|6 Days|tmco|||6-10 days||||913|121|129
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|163|178
SE|00000000||tx|1|entity|C0525032|International Normalized Ratio|lbpr|||International Normalized Ratio||||1000|189|218


SE|00000000||tx|1|text|Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.
SE|00000000||tx|1|entity|C0201734|Pharmacokinetic study|resa|||Pharmacokinetic studies||||1000|1|23
SE|00000000||tx|1|entity|C0028978|Omeprazole|orch,phsu|||omeprazole||||1000|48|57
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||861|63|74
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||694|104|111
SE|00000000||tx|1|entity|C0055729|cilostazol|orch,phsu|||cilostazol||||1000|125|134
SE|00000000||tx|1|entity|C0205164|Major|qlco|||major||||888|147|151
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolites||||888|153|163
SE|00000000||tx|1|relation|3|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||861|63|74|VERB|STIMULATES||90|98|3|2|C0055729|cilostazol|orch,phsu|orch|||cilostazol||||1000|125|134
SE|00000000||tx|1|relation|3|1|C0028978|Omeprazole|orch,phsu|orch|||omeprazole||||1000|48|57|VERB|STIMULATES||90|98|3|2|C0055729|cilostazol|orch,phsu|orch|||cilostazol||||1000|125|134


SE|00000000||tx|1|text|Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||Antidepressants||||1000|1|15
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic||||872|18|26
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||Amphetamines||||872|28|39
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||1000|57|64
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|69|93
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetic agents||||1000|98|119
SE|00000000||tx|1|relation|2|1|C0002667|Amphetamines|nsba,orch,phsu|nsba|||Amphetamines||||872|28|39|VERB|STIMULATES||45|51|3|2|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|69|93
SE|00000000||tx|1|relation|2|1|C0002667|Amphetamines|nsba,orch,phsu|nsba|||Amphetamines||||872|28|39|VERB|STIMULATES||45|51|3|2|C0039052|Sympathomimetics|phsu|phsu|||sympathomimetic agents||||1000|98|119


SE|00000000||tx|1|text|In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.
SE|00000000||tx|1|entity|C0302350|Therapeutic|ftcn|||therapeutic||||888|36|46
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|48|61
SE|00000000||tx|1|entity|C0036075|salicylate|orch,phsu|||salicylate||||1000|66|75
SE|00000000||tx|1|entity|C1300565|Kilogram per Liter|qnco|||g/mL||||861|84|87
SE|00000000||tx|1|entity|C0073631|Ketorolac|orch,phsu|||ketorolac||||1000|106|114
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||827|133|145
SE|00000000||tx|1|entity|C0439073|97|inpr|||97.5||||861|156|159
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||802|178|186
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||802|196|203
SE|00000000||tx|1|entity|C0073631|Ketorolac|orch,phsu|||ketorolac||||750|216|224
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||750|226|231
SE|00000000||tx|1|relation|4|2|C0036075|salicylate|orch,phsu|orch|||salicylate||||1000|66|75|NOM|INTERACTS_WITH||95|101|3|1|C0073631|Ketorolac|orch,phsu|orch|||ketorolac||||1000|106|114


SE|00000000||tx|1|text|Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.
SE|00000000||tx|1|entity|C0591091|Romazicon|orch,phsu|||ROMAZICON||||1000|44|52
SE|00000000||tx|1|entity|C0868928|Case (situation)|ftcn|||cases||||1000|57|61
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||660|72|75
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxic effects||||966|98|110
SE|00000000||tx|1|entity|C0009951|Convulsions|sosy|||convulsions||||1000|121|131
SE|00000000||tx|1|entity|C0003811|Cardiac Arrhythmia|patf|||cardiac dysrhythmias||||1000|137|156
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|168|172
SE|00000000||tx|1|entity|C0029944|overdose|inpo|||overdose||||1000|183|190
SE|00000000||tx|1|entity|C0439596|Cyclical|tmco|||cyclic||||790|204|209
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants||||790|211|225
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepine||||888|264|277
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|279|284
SE|00000000||tx|1|entity|C0016293|Flumazenil|orch,phsu|||flumazenil||||1000|289|298
SE|00000000||tx|1|relation|9|4|C0600688|Toxic effect|inpo|inpo|||toxic effects||||966|98|110|PREP|COEXISTS_WITH||180|181|5|1|C0029944|overdose|inpo|inpo|||overdose||||1000|183|190
SE|00000000||tx|1|relation|12|2|C0003289|Antidepressive Agents|phsu|phsu|||antidepressants||||790|211|225|NOM|INTERACTS_WITH||279|284|12|0|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepine||||888|264|277


SE|00000000||tx|1|text|Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||Alprazolam||||1000|1|10
SE|00000000||tx|1|entity|C0700473|Fluvoxamine Maleate|orch,phsu|||fluvoxamine maleate||||1000|18|36
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|54|63
SE|00000000||tx|1|entity|C0439423|Milligram per 24 Hours|qnco|||mg q.d||||824|68|73
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady state||||901|100|111
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||1000|114|133
SE|00000000||tx|1|entity|C0031327|Drug Kinetics|phsf|||pharmacokinetics||||888|145|160
SE|00000000||tx|1|entity|C0449381|Observation parameter|fndg|||parameters||||888|162|171
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|174|176
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|179|182
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|195|204
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|211|223
SE|00000000||tx|1|entity|C1441672|Observed|ftcn|||observed||||1000|237|244
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|251|260
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|279|283


SE|00000000||tx|1|text|Patients treated with Nalfon may be resistant to the effects of loop diuretics.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0700739|Nalfon|orch,phsu|||Nalfon||||1000|23|28
SE|00000000||tx|1|entity|C2827757|Antimicrobial Resistance Result|lbtr|||resistant||||1000|37|45
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|54|60
SE|00000000||tx|1|entity|C0354100|Loop Diuretics|phsu|||loop diuretics||||1000|65|78
SE|00000000||tx|1|relation|4|1|C0700739|Nalfon|orch,phsu|phsu|||Nalfon||||1000|23|28|VERB|TREATS||10|16|1|1|C0030705|Patients|podg,humn|podg|||Patients||||1000|1|8


SE|00000000||tx|1|text|Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.
SE|00000000||tx|1|entity|C0700579|Diltiazem Hydrochloride|orch,phsu|||diltiazem hydrochloride||||1000|19|41
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|48|54
SE|00000000||tx|1|entity|C0018684|Health|idcn|||healthy||||754|62|68
SE|00000000||tx|1|entity|C1706429|Male, Self-Reported|orga|||male||||754|70|73
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||780|84|92
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||780|101|107
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma digoxin concentrations||||780|94|122
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||780|124|136


SE|00000000||tx|1|text|The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||1000|5|13
SE|00000000||tx|1|entity|C1707959|Example|cnce|||examples||||966|19|26
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|31|35
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|58|67
SE|00000000||tx|1|entity|C0163712|Relate - vinyl resin|orch|||related||||888|78|84
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||888|86|100
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|122|131
SE|00000000||tx|1|entity|||gngm|1574|CYP3A|CYP3A||||1000|136|140
SE|00000000||tx|1|entity|C0068485|nefazodone|orch,phsu|||nefazodone||||1000|143|152
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|155|165
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|168|177
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|180|188
SE|00000000||tx|1|entity|C0003240|Macrolide Antibiotics|antb,orch|||macrolide antibiotics||||1000|212|232
SE|00000000||tx|1|relation|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|31|35|VERB|INHIBITS||46|52|10|2|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||888|86|100
SE|00000000||tx|1|relation|7|3|C0085228|Fluvoxamine|orch,phsu|orch|||fluvoxamine||||1000|155|165|NOM|INHIBITS||122|131|7|1|||gngm,aapp|gngm|1574|CYP3A|CYP3A||||1000|136|140
SE|00000000||tx|1|relation|7|3|C0003240|Macrolide Antibiotics|antb,orch|orch|||macrolide antibiotics||||1000|212|232|NOM|INHIBITS||122|131|7|1|||gngm,aapp|gngm|1574|CYP3A|CYP3A||||1000|136|140
SE|00000000||tx|1|relation|7|3|C0012373|Diltiazem|orch,phsu|orch|||diltiazem||||1000|180|188|NOM|INHIBITS||122|131|7|1|||gngm,aapp|gngm|1574|CYP3A|CYP3A||||1000|136|140
SE|00000000||tx|1|relation|7|3|C0008783|Cimetidine|orch,phsu|orch|||cimetidine||||1000|168|177|NOM|INHIBITS||122|131|7|1|||gngm,aapp|gngm|1574|CYP3A|CYP3A||||1000|136|140
SE|00000000||tx|1|relation|7|3|C0068485|nefazodone|orch,phsu|orch|||nefazodone||||1000|143|152|NOM|INHIBITS||122|131|7|1|||gngm,aapp|gngm|1574|CYP3A|CYP3A||||1000|136|140


SE|00000000||tx|1|text|Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||Theophylline||||861|1|12
SE|00000000||tx|1|entity|C0163712|Relate - vinyl resin|orch|||related||||861|14|20
SE|00000000||tx|1|entity|C0879626|Adverse effects|patf|||adverse effects||||861|22|36
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|55|62
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|69|80
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||enoxacin||||1000|86|93
SE|00000000||tx|1|relation|1|1|C0879626|Adverse effects|patf|patf|||adverse effects||||861|22|36|VERB|OCCURS_IN||43|50|3|1|C0030705|Patients|podg,humn|podg|||patients||||1000|55|62


SE|00000000||tx|1|text|In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|4|11
SE|00000000||tx|1|entity|C0205170|Good|qlco|||well||||888|42|45
SE|00000000||tx|1|entity|C2587213|Control function|ftcn|||controlled||||888|47|56
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|61|85
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||901|108|117
SE|00000000||tx|1|entity|C0009429|Combined Modality Therapy|topp|||concurrent cimetidine therapy||||901|97|125
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuation||||1000|128|142
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|147|156
SE|00000000||tx|1|entity|C0443211|Established|qlco|||established||||822|188|198
SE|00000000||tx|1|entity|C0205361|Steady|qlco|||steady-||||822|200|206
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||822|213|217
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressant||||822|219|242
SE|00000000||tx|1|entity|C0683927|state wide area|spco|||state serum tricyclic antidepressant levels||||822|207|249
SE|00000000||tx|1|entity|C1527144|Therapeutic Effect|hlca|||therapeutic effects||||983|272|290
SE|00000000||tx|1|relation|5|1|C0009429|Combined Modality Therapy|topp|topp|||concurrent cimetidine therapy||||901|97|125|VERB|ADMINISTERED_TO||87|95|3|3|C0030705|Patients|podg,humn|humn|||patients||||1000|4|11
SE|00000000||tx|1|relation|0|0|C0009429|Combined Modality Therapy|topp|topp|||concurrent cimetidine therapy||||901|97|125|MOD/HEAD|USES||108|125|0|0|C0008783|Cimetidine|orch,phsu|phsu|||cimetidine||||901|108|117


SE|00000000||tx|1|text|Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulants.
SE|00000000||tx|1|entity|C1621583|Administer|ftcn|||administering||||872|35|47
SE|00000000||tx|1|entity|C0702073|Peganone|orch,phsu|||PEGANONE||||872|49|56
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|61|68
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin anticoagulants||||983|80|102
SE|00000000||tx|1|relation|1|1|C0010206|coumarin|orch,phsu|orch|||coumarin anticoagulants||||983|80|102|VERB|ADMINISTERED_TO||70|78|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|61|68


SE|00000000||tx|1|text|Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.
SE|00000000||tx|1|entity|C0006463|Busulfan|hops,orch,phsu|||busulfan||||1000|9|16
SE|00000000||tx|1|entity|C1160466|conjugation|celf|||conjugation||||1000|50|60
SE|00000000||tx|1|entity|C0017817|Glutathione|aapp,bacs|||glutathione||||1000|67|77
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|87|99
SE|00000000||tx|1|entity|C1292423|72 Hours|tmco|||72 hours||||1000|112|119
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||1000|125|134
SE|00000000||tx|1|entity|C0939273|Busulfex|orch,phsu|||BUSULFEX||||1000|141|148
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduced||||851|164|170
SE|00000000||tx|1|entity|C0006463|Busulfan|hops,orch,phsu|||busulfan||||851|172|179
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||851|181|189
SE|00000000||tx|1|entity|C0205309|Known|qlco|||known||||694|206|210
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||861|224|236
SE|00000000||tx|1|entity|C0017817|Glutathione|aapp,bacs|||glutathione||||861|250|260
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||1000|276|280
SE|00000000||tx|1|entity|C0040300|Body tissue|tisu|||tissues||||1000|286|292
SE|00000000||tx|1|relation|9|1|C0939273|Busulfex|orch,phsu|orch|||BUSULFEX||||1000|141|148|ADJ|INHIBITS||164|170|5|2|C0000970|Acetaminophen|orch,phsu|orch|||acetaminophen||||861|224|236
SE|00000000||tx|1|relation|2|1|C0005767|Blood|tisu|tisu|||blood||||1000|276|280|PREP|LOCATION_OF||269|270|13|8|C0000970|Acetaminophen|orch,phsu|orch|||acetaminophen||||1000|87|99
SE|00000000||tx|1|relation|2|1|C0040300|Body tissue|tisu|tisu|||tissues||||1000|286|292|PREP|LOCATION_OF||269|270|13|8|C0000970|Acetaminophen|orch,phsu|orch|||acetaminophen||||1000|87|99


SE|00000000||tx|1|text|However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|23|32
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|68|74
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|79|86
SE|00000000||tx|1|entity|C0243072|derivatives|chvs|||derivatives||||1000|95|105
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|108|123
SE|00000000||tx|1|entity|C2917212|Negative Regulation of Coagulation|phsf|||anticoagulation||||802|143|157
SE|00000000||tx|1|entity|C0022885|Laboratory Procedures|lbpr|||test||||802|159|162
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolone||||1000|197|205
SE|00000000||tx|1|entity|C1136254|Microbicides|phsu|||antimicrobial||||1000|207|219
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|242|249
SE|00000000||tx|1|entity|C0243072|derivatives|chvs|||derivatives||||1000|258|268
SE|00000000||tx|1|relation|0|0|C0033707|Prothrombin time assay|lbpr|lbpr|||prothrombin time||||1000|108|123|SPEC|ISA||108|162|0|0|C0022885|Laboratory Procedures|lbpr|lbpr|||test||||802|159|162
SE|00000000||tx|1|relation|8|5|C0034428|Quinolones|orch|orch|||quinolone||||1000|197|205|NOM|INTERACTS_WITH||68|74|8|1|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||1000|79|86


SE|00000000||tx|1|text|Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||Plasma concentrations||||983|1|21
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|26|37
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||1000|86|91
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|117|124
SE|00000000||tx|1|entity|C0028005|Nicardipine|orch,phsu|||nicardipine||||1000|139|149
SE|00000000||tx|1|relation|3|2|C0010592|Cyclosporine|aapp,gngm,phsu|phsu|||cyclosporine||||1000|26|37|PREP|TREATS||114|115|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|117|124
SE|00000000||tx|1|relation|1|1|C0028005|Nicardipine|orch,phsu|phsu|||nicardipine||||1000|139|149|VERB|TREATS||126|132|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|117|124


SE|00000000||tx|1|text|When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|6|16
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|33|38
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blocking||||851|47|54
SE|00000000||tx|1|entity|C1292721|Has property|ftcn|||properties||||851|56|65
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||1000|71|79
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blocking||||851|108|115
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agent||||851|117|121
SE|00000000||tx|1|entity|C1279901|Firstly|qlco|||first||||1000|146|150


SE|00000000||tx|1|text|H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.
SE|00000000||tx|1|entity|C0034815|Histamine H2 Receptors|aapp,rcpt|||H2 Receptor||||901|1|11
SE|00000000||tx|1|entity|C0243076|antagonists|chvf|||Antagonists||||901|13|23
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||694|26|35
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||861|66|74
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|81|86
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||peak plasma concentration||||861|76|100
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|106|108
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|113|121
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|136|141
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||694|146|154
SE|00000000||tx|1|entity|C0034665|Ranitidine|orch,phsu|||ranitidine||||1000|198|207


SE|00000000||tx|1|text|Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||Lithium||||1000|1|7
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|15|19
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy subjects||||1000|34|49
SE|00000000||tx|1|entity|C0205361|Steady|qlco|||steady-||||798|57|63
SE|00000000||tx|1|entity|C1440916|Lithium.plasma|elii,phsu|||lithium plasma||||798|70|83
SE|00000000||tx|1|entity|C0683927|state wide area|spco|||state lithium plasma levels||||798|64|90
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|102|114
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||966|123|130
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||764|142|148
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||764|157|159
SE|00000000||tx|1|entity|C0719198|Celebrex|orch,phsu|||CELEBREX||||764|166|173
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||764|182|184
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||966|201|208
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|220|226
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|228|232


SE|00000000||tx|1|text|Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||Aspirin||||1000|1|7
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|10|20
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||888|22|28
SE|00000000||tx|1|entity|C0311400|Metabolic|ftcn|||metabolic||||888|47|55
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|57|65
SE|00000000||tx|1|entity|C0027996|Niacin|orch,phsu,vita|||nicotinic acid||||1000|70|83
SE|00000000||tx|1|relation|2|1|C0004057|Aspirin|orch,phsu|orch|||aspirin||||888|22|28|VERB|INHIBITS||34|41|2|2|C0027996|Niacin|orch,phsu,vita|orch|||nicotinic acid||||1000|70|83


SE|00000000||tx|1|text|If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.
SE|00000000||tx|1|entity|C0721124|Iron Supplement|phsu|||iron supplements||||890|4|19
SE|00000000||tx|1|entity|C0285868|Omnicef|antb,orch|||OMNICEF||||888|41|47
SE|00000000||tx|1|entity|C0285868|Omnicef|antb,orch|||OMNICEF||||1000|58|64
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|85|89
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||785|93|97
SE|00000000||tx|1|entity|C2348609|Supplement|ftcn|||supplement||||1000|119|128


SE|00000000||tx|1|text|Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.
SE|00000000||tx|1|entity|C0009079|Clozapine|orch,phsu|||Clozapine||||1000|1|9
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|30|40
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|42|48
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensive drugs||||1000|53|74
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|100|106
SE|00000000||tx|1|entity|C0004259|Atropine|orch,phsu|||atropine||||890|111|118
SE|00000000||tx|1|entity|C0457591|Types of drugs|qlco|||type drugs||||890|120|129
SE|00000000||tx|1|relation|3|1|C0003364|Antihypertensive Agents|phsu|phsu|||antihypertensive drugs||||1000|53|74|NOM|AFFECTS||42|48|1|0|C0857353|Hypotensive|patf|patf|||hypotensive||||888|30|40


SE|00000000||tx|1|text|There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.
SE|00000000||tx|1|entity|C0521114|Infrequent|tmco|||rare||||888|11|14
SE|00000000||tx|1|entity|C0024826|Marketing|ocac|||marketing||||888|39|47
SE|00000000||tx|1|entity|C0596545|Experience|menp|||experiences||||888|49|59
SE|00000000||tx|1|entity|C0443172|Changed status|qnco|||changes||||1000|65|71
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|76|82
SE|00000000||tx|1|entity|C0021641|Insulin|aapp,horm,phsu|||insulin||||1000|87|93
SE|00000000||tx|1|entity|C0359086|Oral hypoglycemic|phsu|||oral hypoglycemic agents||||1000|98|121
SE|00000000||tx|1|entity|C0012091|Diclofenac|orch,phsu|||diclofenac||||1000|142|151
SE|00000000||tx|1|entity|C0443172|Changed status|qnco|||changes||||861|171|177
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||1000|186|190
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|200|205
SE|00000000||tx|1|relation|7|4|C0012091|Diclofenac|orch,phsu|orch|||diclofenac||||1000|142|151|NOM|INTERACTS_WITH||76|82|7|1|C0021641|Insulin|aapp,gngm,horm,phsu|aapp|||insulin||||1000|87|93
SE|00000000||tx|1|relation|7|4|C0012091|Diclofenac|orch,phsu|orch|||diclofenac||||1000|142|151|NOM|INTERACTS_WITH||76|82|7|1|C0359086|Oral hypoglycemic|phsu|phsu|||oral hypoglycemic agents||||1000|98|121


SE|00000000||tx|1|text|The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.
SE|00000000||tx|1|entity|C1274040|Result|ftcn|||results||||1000|5|11
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|18|22
SE|00000000||tx|1|entity|C0014964|Ethambutol|orch,phsu|||ethambutol||||1000|47|56
SE|00000000||tx|1|entity|C0439272|ug/g|qnco|||mg/kg||||901|62|66
SE|00000000||tx|1|entity|C2700400|Contain (action)|acty|||containing||||916|96|105
SE|00000000||tx|1|entity|C0002371|Aluminum Hydroxide|inch,phsu|||aluminum hydroxide containing antacid||||916|77|113
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|121|128
SE|00000000||tx|1|entity|C0041296|Tuberculosis|dsyn|||tuberculosis||||1000|135|146
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|157|165
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentrations||||884|175|194
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||urinary||||888|200|206
SE|00000000||tx|1|entity|C0504085|Body Excretions|bdsu|||excretion||||888|208|216
SE|00000000||tx|1|entity|C0014964|Ethambutol|orch,phsu|||ethambutol||||1000|221|230
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|235|247
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||694|296|299
SE|00000000||tx|1|entity|C0014964|Ethambutol|orch,phsu|||ethambutol||||1000|315|324
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacid products||||1000|350|365
SE|00000000||tx|1|relation|14|3|C0014964|Ethambutol|orch,phsu|orch|||ethambutol||||1000|47|56|NOM|CAUSES||5|11|14|7|C0041296|Tuberculosis|dsyn|dsyn|||tuberculosis||||1000|135|146
SE|00000000||tx|1|relation|1|1|C0003138|Antacids|phsu|phsu|||antacid products||||1000|350|365|VERB|INHIBITS||333|339|14|1|C0014964|Ethambutol|orch,phsu|orch|||ethambutol||||1000|315|324


SE|00000000||tx|1|text|Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|1|10
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|14|23
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|55|64
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||901|69|73
SE|00000000||tx|1|entity|C0232819|Tubular secretion|ortf|||tubular excretion||||901|75|91
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|101|105
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|114|126
SE|00000000||tx|1|entity|C0001367|Acyclovir|nnon,phsu|||acyclovir||||1000|129|137
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||angiotensin-converting enzyme inhibitors||||1000|140|179
SE|00000000||tx|1|entity|C0030125|aminosalicylic acid|orch,phsu|||aminosalicylic acid||||1000|182|200
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|203|214
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|217|231
SE|00000000||tx|1|entity|C0006376|Bumetanide|orch,phsu|||bumetanide||||1000|234|243
SE|00000000||tx|1|entity|C0009002|Clofibrate|orch,phsu|||clofibrate||||1000|246|255
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|258|269
SE|00000000||tx|1|entity|C0015620|Famotidine|orch,phsu|||famotidine||||1000|272|281
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|284|293
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory agents||||1000|296|332
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|335|346
SE|00000000||tx|1|entity|C0043474|Zidovudine|nnon,phsu|||zidovudine||||1000|353|362


SE|00000000||tx|1|text|If any signs or symptoms occur physicians should consider discontinuation of either one or both agents (ZYVOX or concomitant serotonergic agents).
SE|00000000||tx|1|entity|C0311392|Physical findings|fndg|||signs||||1000|8|12
SE|00000000||tx|1|entity|C1457887|Symptoms|sosy|||symptoms||||1000|17|24
SE|00000000||tx|1|entity|C0031831|Physicians|prog|||physicians||||1000|32|41
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuation||||1000|59|73
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||861|85|87
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|97|102
SE|00000000||tx|1|entity|C0876226|Zyvox|orch,phsu|||ZYVOX||||1000|105|109
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||901|114|124
SE|00000000||tx|1|entity|C0242701|Serotonin Agents|nsba,phsu|||serotonergic agents||||901|126|144
SE|00000000||tx|1|relation|0|0|C0876226|Zyvox|orch,phsu|orch|||ZYVOX||||1000|105|109|SPEC|ISA||97|109|0|0|C0450442|Agent|chvf|chvf|||agents||||966|97|102


SE|00000000||tx|1|text|ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
SE|00000000||tx|1|entity|C0724461|Zebeta|orch,phsu|||ZEBETA||||1000|1|6
SE|00000000||tx|1|entity|C0027048|Cardiac Depressants|phsu|||myocardial depressants||||1000|38|59
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||1000|64|73
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||884|101|107
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium antagonists||||884|109|127
SE|00000000||tx|1|entity|C0597214|Phenylalkylamine|orch|||phenylalkylamine||||1000|150|165
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||1000|168|176
SE|00000000||tx|1|entity|C1320166|Benzothiazepine|orch|||benzothiazepine||||1000|183|197
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|200|208
SE|00000000||tx|1|entity|C0456387|Class|inpr|||classes||||1000|211|217
SE|00000000||tx|1|entity|C0003195|Anti-Arrhythmia Agents|phsu|||antiarrhythmic agents||||983|224|244
SE|00000000||tx|1|entity|C0012702|Disopyramide|orch,phsu|||disopyramide||||1000|255|266
SE|00000000||tx|1|relation|0|0|C0012702|Disopyramide|orch,phsu|orch|||disopyramide||||1000|255|266|SPEC|ISA||224|266|0|0|C0003195|Anti-Arrhythmia Agents|phsu|phsu|||antiarrhythmic agents||||983|224|244


SE|00000000||tx|1|text|When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
SE|00000000||tx|1|entity|C0302350|Therapeutic|ftcn|||therapeutic||||888|14|24
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|26|30
SE|00000000||tx|1|entity|C0052796|Azithromycin|antb,orch|||azithromycin||||1000|33|44
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|59|64
SE|00000000||tx|1|entity|C0031327|Drug Kinetics|phsf|||pharmacokinetics||||1000|73|88
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||1000|93|104
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|107|119
SE|00000000||tx|1|entity|C0055147|Cetirizine|orch,phsu|||cetirizine||||1000|122|131
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||1000|134|143
SE|00000000||tx|1|entity|C0674428|efavirenz|orch,phsu|||efavirenz||||1000|146|154
SE|00000000||tx|1|entity|C0016277|Fluconazole|orch,phsu|||fluconazole||||1000|157|167
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|170|178
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||midazolam||||1000|181|189
SE|00000000||tx|1|entity|C0140575|Rifabutin|antb,orch|||rifabutin||||1000|192|200
SE|00000000||tx|1|entity|C0529793|sildenafil|orch,phsu|||sildenafil||||1000|203|212
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|215|226
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||1000|229|239
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||1000|245|248
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||triazolam||||1000|252|260
SE|00000000||tx|1|entity|C0041044|Trimethoprim-Sulfamethoxazole Combination|orch,phsu|||trimethoprim/sulfamethoxazole||||1000|263|291
SE|00000000||tx|1|entity|C0043474|Zidovudine|nnon,phsu|||zidovudine||||1000|296|305
SE|00000000||tx|1|relation|17|2|C0286651|atorvastatin|orch,phsu|orch|||atorvastatin||||1000|93|104|NOM|AFFECTS||59|64|17|1|C0031327|Drug Kinetics|phsf|phsf|||pharmacokinetics||||1000|73|88


SE|00000000||tx|1|text|The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
SE|00000000||tx|1|entity|C0350422|Dextromethorphan Hydrobromide|orch,phsu|||dextromethorphan hydrobromide||||1000|12|40
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||861|56|63
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressant||||861|65|78
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|80|86
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|113|119
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|122|135
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|161|165
SE|00000000||tx|1|entity|C0151559|Central nervous system depression (disorder)|dsyn|||CNS depression||||1000|180|193
SE|00000000||tx|1|relation|2|1|C0350422|Dextromethorphan Hydrobromide|orch,phsu|orch|||dextromethorphan hydrobromide||||1000|12|40|NOM|INTERACTS_WITH||80|86|2|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressant||||861|65|78
SE|00000000||tx|1|relation|7|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|161|165|VERB|CAUSES||172|178|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|180|193
SE|00000000||tx|1|relation|7|1|C0003360|Antihistamines|orch,phsu|phsu|||antihistamines||||1000|122|135|VERB|CAUSES||172|178|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|180|193
SE|00000000||tx|1|relation|7|1|C0001975|Alcohols|orch,phsu|phsu|||alcohol||||1000|113|119|VERB|CAUSES||172|178|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|180|193


SE|00000000||tx|1|text|Therefore, indomethacin and diflunisal should not be used concomitantly.
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|12|23
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|29|38
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|47|49


SE|00000000||tx|1|text|Since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions.
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|7|18
SE|00000000||tx|1|entity|C0008425|Cholinesterase Inhibitors|orch,phsu|||anticholinesterases||||1000|43|61
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|102|110
SE|00000000||tx|1|entity|C0009951|Convulsions|sosy|||convulsions||||1000|115|125
SE|00000000||tx|1|relation|3|1|C0008425|Cholinesterase Inhibitors|orch,phsu|orch|||anticholinesterases||||1000|43|61|VERB|STIMULATES||24|34|1|1|C0004745|Barbiturates|orch,phsu|orch|||barbiturates||||1000|7|18


SE|00000000||tx|1|text|(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|10|17
SE|00000000||tx|1|entity|C0038317|Steroids|strd|||steroidal||||892|24|32
SE|00000000||tx|1|entity|C0003209|Anti-Inflammatory Agents|phsu|||anti-inflammatory agent||||892|34|56
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||888|73|80
SE|00000000||tx|1|entity|C0597421|saluretic|phsu|||natriuretic||||888|83|93
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|117|123
SE|00000000||tx|1|entity|C0445022|Loop|spco|||loop||||1000|128|131
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||694|134|142
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|157|174
SE|00000000||tx|1|relation|2|1|C0003209|Anti-Inflammatory Agents|phsu|phsu|||anti-inflammatory agent||||892|34|56|VERB|INHIBITS||62|67|5|1|C0597421|saluretic|phsu|phsu|||natriuretic||||888|83|93


SE|00000000||tx|1|text|When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multi-||||851|19|24
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||851|25|27
SE|00000000||tx|1|entity|C0750729|Course|tmco|||course||||851|29|34
SE|00000000||tx|1|entity|C0287721|grepafloxacin|orch,phsu|||grepafloxacin||||1000|39|51
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|58|64
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|80|91
SE|00000000||tx|1|entity|C0024501|Maintenance|acty|||maintenance||||901|111|121
SE|00000000||tx|1|entity|C0366665|Theophylline:Mass:Point in time:Dose med or substance:Quantitative|clna|||theophylline maintenance dose||||901|98|126
SE|00000000||tx|1|entity|C0439531|per period (qualifier value)|tmco|||period||||1000|153|158
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|163|172
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|174|176
SE|00000000||tx|1|entity|C0287721|grepafloxacin|orch,phsu|||grepafloxacin||||1000|181|193
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||890|219|230
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum theophylline concentrations||||890|213|245
SE|00000000||tx|1|entity|C1517331|Further|spco|||further||||851|281|287
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||851|289|294
SE|00000000||tx|1|entity|C0456081|Adjustment Action|ftcn|||adjustments||||851|296|306
SE|00000000||tx|1|relation|2|1|C0287721|grepafloxacin|orch,phsu|phsu|||grepafloxacin||||1000|39|51|PREP|TREATS||53|54|10|1|C0030705|Patients|podg,humn|podg|||patient||||1000|58|64


SE|00000000||tx|1|text|Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
SE|00000000||tx|1|entity|C0205198|Compound|qlco|||compounds||||966|23|31
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||594|42|47
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|61|66
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|73|85
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|88|96
SE|00000000||tx|1|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||1000|99|111
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|114|126
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||decreased||||790|143|151
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|153|158
SE|00000000||tx|1|entity|C0286738|Saquinavir|orch,phsu|||saquinavir||||1000|170|179
SE|00000000||tx|1|relation|9|6|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|61|66|ADJ|INHIBITS||143|151|1|1|C0286738|Saquinavir|orch,phsu|orch|||saquinavir||||1000|170|179


SE|00000000||tx|1|text|INDOCIN can reduce the antihypertensive effects of captopril and losartan.
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|1|7
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|41|47
SE|00000000||tx|1|entity|C0006938|Captopril|aapp,phsu|||captopril||||1000|52|60
SE|00000000||tx|1|entity|C0126174|Losartan|orch,phsu|||losartan||||1000|66|73
SE|00000000||tx|1|relation|1|1|C0700798|Indocin|orch,phsu|orch|||INDOCIN||||1000|1|7|NOM|INTERACTS_WITH||41|47|2|1|C0006938|Captopril|aapp,gngm,phsu|aapp|||captopril||||1000|52|60
SE|00000000||tx|1|relation|1|1|C0700798|Indocin|orch,phsu|orch|||INDOCIN||||1000|1|7|NOM|INTERACTS_WITH||41|47|2|1|C0126174|Losartan|orch,phsu|orch|||losartan||||1000|66|73


SE|00000000||tx|1|text|In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;
SE|00000000||tx|1|entity|C0205456|Ten|qnco|||ten||||851|6|8
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subject||||851|10|16
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||851|18|22
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|45|53
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||bid||||773|63|65
SE|00000000||tx|1|entity|C0024027|Lovastatin|orch,phsu|||lovastatin||||1000|73|82
SE|00000000||tx|1|entity|C1632851|Times|qnco|||times||||901|102|106
SE|00000000||tx|1|entity|C0024027|Lovastatin|orch,phsu|||lovastatin||||790|125|134
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||790|136|138
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|144|147
SE|00000000||tx|1|entity|C0024027|Lovastatin|orch,phsu|||lovastatin||||1000|153|162
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|164|168


SE|00000000||tx|1|text|The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.
SE|00000000||tx|1|entity|C0024200|Lymecycline|antb,orch|||lymecycline||||1000|19|29
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneous||||888|54|65
SE|00000000||tx|1|entity|C0013395|Dyspepsia|sosy|||indigestion||||694|85|95
SE|00000000||tx|1|entity|C0302583|Iron|bacs,elii,phsu|||iron||||1000|107|110
SE|00000000||tx|1|entity|C1268859|Zinc supplement|inch,phsu|||zinc supplements||||983|115|130


SE|00000000||tx|1|text|Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.
SE|00000000||tx|1|entity|C0032911|Praziquantel|orch,phsu|||Praziquantel||||1000|1|12
SE|00000000||tx|1|entity|C0342895|Fish-Eye Disease|dsyn|||fed||||888|22|24
SE|00000000||tx|1|entity|C1442792|State|ftcn|||state||||888|26|30
SE|00000000||tx|1|entity|C0032911|Praziquantel|orch,phsu|||praziquantel||||1000|33|44
SE|00000000||tx|1|entity|C0439272|ug/g|qnco|||mg/kg||||901|50|54
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||794|57|65
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximum||||794|72|78
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||794|80|99
SE|00000000||tx|1|entity|C0205146|Area|spco|||area||||1000|105|108
SE|00000000||tx|1|entity|C0205134|Curved|spco|||curve||||1000|120|124
SE|00000000||tx|1|entity|C0051091|albendazole sulfoxide|orch,phsu|||albendazole sulfoxide||||1000|129|149
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy subjects||||1000|167|182
SE|00000000||tx|1|entity|C0443299|Separate|spco|||separate||||888|207|214
SE|00000000||tx|1|entity|C0441833|Groups|idcn|||group||||888|216|220
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||966|225|232
SE|00000000||tx|1|entity|C1442162|GIVEN|cnce|||given||||888|240|244
SE|00000000||tx|1|entity|C0001911|Albendazole|orch,phsu|||albendazole||||888|246|256
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|258|262


SE|00000000||tx|1|text|SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.
SE|00000000||tx|1|entity|C0006404|Subutex|orch,phsu|||SUBUTEX||||1000|1|7
SE|00000000||tx|1|entity|C1170625|Suboxone|orch,phsu|||SUBOXONE||||1000|13|20
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|59|66
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|71|85
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|96|100
SE|00000000||tx|1|entity|C0927232|Neuraxis|bdsy|||central nervous system||||1000|118|139
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|170|174
SE|00000000||tx|1|entity|C0150600|Advice|hlca|||advice||||1000|193|198
SE|00000000||tx|1|entity|C0031831|Physicians|prog|||physician||||1000|205|213
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|231|235
SE|00000000||tx|1|entity|C1328247|Abuse|mobd|||abuse||||1000|240|244
SE|00000000||tx|1|relation|0|0|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|71|85|SPEC|ISA||71|100|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|96|100
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|96|100|SPEC|ISA||71|100|0|0|C0005064|Benzodiazepines|orch,phsu|phsu|||benzodiazepines||||1000|71|85
SE|00000000||tx|1|relation|4|1|C0150600|Advice|hlca|hlca|||advice||||1000|193|198|VERB|ADMINISTERED_TO||180|184|8|5|C0030705|Patients|podg,humn|humn|||patients||||1000|59|66
SE|00000000||tx|1|relation|2|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|231|235|VERB|ADMINISTERED_TO||222|226|10|1|C0031831|Physicians|prog,humn|humn|||physician||||1000|205|213


SE|00000000||tx|1|text|Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||851|16|21
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||851|23|26
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||851|28|32
SE|00000000||tx|1|entity|C0232478|Ingestion|biof|||ingestion||||1000|41|49
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacid||||1000|57|63
SE|00000000||tx|1|entity|C0439208|gram|qnco|||gram||||802|80|83
SE|00000000||tx|1|entity|C0024476|Magnesium Hydroxide|inch,phsu|||magnesium hydroxide||||1000|88|106
SE|00000000||tx|1|entity|C0025152|Mefenamic Acid|orch,phsu|||mefenamic acid||||1000|123|136
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|152|155
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|161|163
SE|00000000||tx|1|entity|C0025152|Mefenamic Acid|orch,phsu|||mefenamic acid||||1000|168|181

SE|00000000||tx|2|text|A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.
SE|00000000||tx|2|entity|C0237753|Numbers|qnco|||number||||1000|3|8
SE|00000000||tx|2|entity|C0205198|Compound|qlco|||compounds||||966|13|21
SE|00000000||tx|2|entity|C0243077|inhibitors|chvf|||inhibitors||||1000|27|36
SE|00000000||tx|2|entity|||gngm|1559|CYP2C9|CYP2C9||||1000|41|46
SE|00000000||tx|2|entity|C0016277|Fluconazole|orch,phsu|||fluconazole||||1000|58|68
SE|00000000||tx|2|entity|C0024027|Lovastatin|orch,phsu|||lovastatin||||1000|71|80
SE|00000000||tx|2|entity|C0041041|Trimethoprim|antb,orch|||trimethoprim||||1000|86|97


SE|00000000||tx|1|text|Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||Allopurinol||||1000|10|20
SE|00000000||tx|1|entity|C0205225|Primary|qlco|||principal||||694|27|35
SE|00000000||tx|1|entity|C0025516|Metabolic Detoxication, Drug|orgf|||detoxification||||1000|49|62
SE|00000000||tx|1|entity|C0004482|Azathioprine|orch,phsu|||azathioprine||||1000|67|78
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|96|106
SE|00000000||tx|1|relation|1|1|C0002144|Allopurinol|orch,phsu|orch|||allopurinol||||1000|96|106|VERB|INHIBITS||83|91|5|1|C0004482|Azathioprine|orch,phsu|orch|||azathioprine||||1000|67|78


SE|00000000||tx|1|text|However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.
SE|00000000||tx|1|entity|C0301283|Drug additive|bodm|||additional drug||||950|19|33
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|46|52
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|71|79
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|84|91
SE|00000000||tx|1|entity|C0150457|Anticoagulant therapy|topp|||anticoagulant therapy||||1000|96|116
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|123|130
SE|00000000||tx|1|entity|C1515926|Alteration|idcn|||alterations||||966|155|165
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|174|189
SE|00000000||tx|1|relation|2|1|C0700798|Indocin|orch,phsu|phsu|||INDOCIN||||1000|46|52|NOM|TREATS||71|79|5|1|C0030705|Patients|podg,humn|podg|||patients||||1000|84|91


SE|00000000||tx|1|text|Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|entity|C0597357|receptor|aapp,rcpt|||receptor||||861|17|24
SE|00000000||tx|1|entity|C0243076|antagonists|chvf|||antagonists||||861|26|36
SE|00000000||tx|1|entity|C0058445|dirithromycin|antb,orch|||dirithromycin||||1000|44|56
SE|00000000||tx|1|entity|C0205548|Stat (do immediately)|tmco|||immediately||||1000|74|84
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|96|103
SE|00000000||tx|1|entity|C0597357|receptor|aapp,rcpt|||receptor||||861|113|120
SE|00000000||tx|1|entity|C0243076|antagonists|chvf|||antagonists||||861|122|132
SE|00000000||tx|1|entity|C0058445|dirithromycin|antb,orch|||dirithromycin||||1000|153|165
SE|00000000||tx|1|entity|C0750482|Slightly|idcn|||slightly||||1000|170|177


SE|00000000||tx|1|text|During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
SE|00000000||tx|1|entity|C1707479|Concomitant Therapy|topp|||concomitant therapy||||1000|8|26
SE|00000000||tx|1|entity|C0699209|Ponstel|orch,phsu|||Ponstel||||1000|31|37
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|44|53
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|60|66
SE|00000000||tx|1|entity|C0311392|Physical findings|fndg|||signs||||1000|99|103
SE|00000000||tx|1|entity|C0035078|Kidney Failure|dsyn|||renal failure||||1000|108|120
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||888|144|151
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||888|153|160
SE|00000000||tx|1|relation|2|2|C1707479|Concomitant Therapy|topp|topp|||concomitant therapy||||1000|8|26|PREP|USES||39|42|5|1|C0016860|Furosemide|orch,phsu|phsu|||furosemide||||1000|44|53


SE|00000000||tx|1|text|Indinavir concentrations may be decreased in the presence of nevirapine.
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||Indinavir||||888|1|9
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|11|24
SE|00000000||tx|1|entity|C0132326|Nevirapine|nnon,phsu|||nevirapine||||1000|62|71
SE|00000000||tx|1|relation|1|1|C0376637|Indinavir|orch,phsu|orch|||Indinavir||||888|1|9|NOM|COEXISTS_WITH||50|57|1|1|C0132326|Nevirapine|nnon,phsu|phsu|||nevirapine||||1000|62|71


SE|00000000||tx|1|text|Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.
SE|00000000||tx|1|entity|C0048038|apraclonidine|orch,phsu|||apraclonidine||||1000|7|19
SE|00000000||tx|1|entity|C0005823|Blood Pressure|orgf|||blood pressure||||1000|42|55
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|75|79
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blockers||||1000|89|101
SE|00000000||tx|1|entity|C0015392|Eye|bpoc|||ophthalmic||||944|104|113
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||1000|119|126
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensives||||1000|130|146
SE|00000000||tx|1|entity|C0007158|Cardiac Glycosides|carb,phsu|||cardiac glycosides||||1000|153|170
SE|00000000||tx|1|relation|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blockers||||1000|89|101|SPEC|ISA||75|101|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|75|79


SE|00000000||tx|1|text|Elevated plasma levels of theophylline have been reported with concomitant quinolone use.
SE|00000000||tx|1|entity|C0205250|High|qlco|||Elevated||||790|1|8
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|10|15
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|27|38
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||851|64|74
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolone||||851|76|84
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||851|86|88


SE|00000000||tx|1|text|Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drugs Drug interactions||||966|7|29
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|55|65
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|85|96
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||1000|108|118
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|131|142
SE|00000000||tx|1|entity|C0019469|Hexobarbital|orch,phsu|||hexobarbital||||1000|145|156
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|159|171
SE|00000000||tx|1|entity|C0002026|Alfentanil|orch,phsu|||alfentanil||||1000|174|183
SE|00000000||tx|1|entity|C0012702|Disopyramide|orch,phsu|||disopyramide||||1000|186|197
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|200|208
SE|00000000||tx|1|entity|C0006230|Bromocriptine|orch,phsu|||bromocriptine||||1000|211|223
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||valproate||||1000|226|234
SE|00000000||tx|1|entity|C0085170|Astemizole|orch,phsu|||astemizole||||1000|237|246
SE|00000000||tx|1|entity|C0024027|Lovastatin|orch,phsu|||lovastatin||||1000|253|262
SE|00000000||tx|1|relation|0|0|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|85|96|SPEC|ISA||85|118|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||1000|108|118


SE|00000000||tx|1|text|Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.
SE|00000000||tx|1|entity|C0439808|Profound|qlco|||Profound||||890|1|8
SE|00000000||tx|1|entity|C0520541|Hypotensive episode|dsyn|||hypotensive episodes||||890|10|29
SE|00000000||tx|1|entity|C0012022|Diazoxide|orch,phsu|||diazoxide||||888|46|54
SE|00000000||tx|1|entity|C0021311|Infection|dsyn|||infection||||888|56|64
SE|00000000||tx|1|entity|C0020223|Hydralazine|orch,phsu|||hydralazine||||1000|70|80


SE|00000000||tx|1|text|Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).
SE|00000000||tx|1|entity|C0002598|Amiodarone|orch,phsu|||Amiodarone||||1000|1|10
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||Verapamil||||1000|15|23
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|30|33
SE|00000000||tx|1|entity|C0026848|Myopathy|dsyn|||myopathy||||888|38|45
SE|00000000||tx|1|entity|C0035410|Rhabdomyolysis|patf|||rhabdomyolysis||||888|47|60
SE|00000000||tx|1|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||861|87|96
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||1000|101|109
SE|00000000||tx|1|entity|C0163712|Relate - vinyl resin|orch|||related||||790|148|154
SE|00000000||tx|1|entity|C0680022|member|popg|||member||||790|156|161
SE|00000000||tx|1|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||HMG-CoA reductase inhibitor||||928|170|196
SE|00000000||tx|1|entity|C0456387|Class|inpr|||class||||928|198|202
SE|00000000||tx|1|entity|C0871599|Cautionary Warning|gora|||WARNINGS||||1000|209|216
SE|00000000||tx|1|entity|C0026848|Myopathy|dsyn|||Myopathy||||888|219|226
SE|00000000||tx|1|entity|C0035410|Rhabdomyolysis|patf|||Rhabdomyolysis||||888|228|241
SE|00000000||tx|1|relation|7|2|C0002598|Amiodarone|orch,phsu|orch|||amiodarone||||861|87|96|NOM|PREDISPOSES||30|33|7|1|C0035410|Rhabdomyolysis|patf|patf|||rhabdomyolysis||||888|47|60
SE|00000000||tx|1|relation|6|1|C0042523|Verapamil|orch,phsu|orch|||verapamil||||1000|101|109|VERB|ADMINISTERED_TO||114|117|4|1|C0680022|member|popg,humn|humn|||member||||790|156|161


SE|00000000||tx|1|text|Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||861|6|15
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|39|43
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|45|53
SE|00000000||tx|1|entity|C0060926|gabapentin|orch,phsu|||gabapentin||||1000|63|72
SE|00000000||tx|1|entity|C0010294|Creatinine|bacs,orch|||creatinine||||1000|78|87
SE|00000000||tx|1|entity|C0205227|Endogenous|ftcn|||endogenous||||888|93|102
SE|00000000||tx|1|entity|C0005516|Biological Markers|clna|||marker||||888|104|109
SE|00000000||tx|1|entity|C0232804|Renal function|ortf|||renal function||||1000|114|127
SE|00000000||tx|1|relation|1|1|C0008783|Cimetidine|orch,phsu|orch|||cimetidine||||861|6|15|VERB|AFFECTS||29|33|5|1|C0221102|Excretory function|phsf|phsf|||excretion||||888|45|53


SE|00000000||tx|1|text|It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.
SE|00000000||tx|1|entity|C0236281|Serum lithium measurement|lbpr|||serum lithium levels||||988|24|43
SE|00000000||tx|1|entity|C0332183|Frequent|tmco|||frequently||||1000|58|67
SE|00000000||tx|1|entity|C0014025|Enalapril|aapp,phsu|||enalapril||||1000|72|80
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|117|123
SE|00000000||tx|1|relation|2|2|C0236281|Serum lithium measurement|lbpr|lbpr|||serum lithium levels||||988|24|43|PREP|USES||112|115|1|1|C0023870|Lithium|elii,phsu|elii|||lithium||||1000|117|123


SE|00000000||tx|1|text|Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0051124|Aldehyde oxidase|aapp,enzy|||Aldehyde Oxidase||||1000|25|40
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||861|46|51
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||861|53|62
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|65|74
SE|00000000||tx|1|entity|C0051124|Aldehyde oxidase|aapp,enzy|||aldehyde oxidase||||1000|90|105
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|122|127
SE|00000000||tx|1|entity|C0205436|second (number)|qnco|||secondary||||888|169|177
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzymes||||888|179|185
SE|00000000||tx|1|entity|C0251504|zaleplon|orch,phsu|||zaleplon||||888|218|225
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|227|236
SE|00000000||tx|1|relation|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|VERB|INHIBITS||12|18|12|1|C0051124|Aldehyde oxidase|aapp,gngm,enzy|gngm|||Aldehyde Oxidase||||1000|25|40
SE|00000000||tx|1|relation|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|VERB|INHIBITS||12|18|12|1|C0008783|Cimetidine|orch,phsu|orch|||Cimetidine||||861|53|62
SE|00000000||tx|1|relation|4|1|C0008783|Cimetidine|orch,phsu|orch|||Cimetidine||||1000|65|74|VERB|INHIBITS||76|83|9|1|C0051124|Aldehyde oxidase|aapp,gngm,enzy|gngm|||aldehyde oxidase||||1000|90|105
SE|00000000||tx|1|relation|4|1|C0008783|Cimetidine|orch,phsu|orch|||Cimetidine||||1000|65|74|VERB|INHIBITS||76|83|9|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|122|127


SE|00000000||tx|1|text|Acetazolamide increases lithium excretion and the lithium may be decreased.
SE|00000000||tx|1|entity|C0000981|Acetazolamide|orch,phsu|||Acetazolamide||||1000|1|13
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||888|25|31
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|33|41
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|51|57
SE|00000000||tx|1|relation|1|1|C0000981|Acetazolamide|orch,phsu|orch|||Acetazolamide||||1000|1|13|VERB|AUGMENTS||15|23|2|1|C0221102|Excretory function|phsf|phsf|||excretion||||888|33|41


SE|00000000||tx|1|text|Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||Not||||1000|19|21
SE|00000000||tx|1|entity|C0525004|Viracept|orch,phsu|||VIRACEPT||||888|46|53
SE|00000000||tx|1|entity|C0003195|Anti-Arrhythmia Agents|phsu|||Antiarrhythmics||||888|55|69
SE|00000000||tx|1|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||1000|72|81
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||888|84|92
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||Antihistamines||||888|94|107
SE|00000000||tx|1|entity|C0085170|Astemizole|orch,phsu|||astemizole||||1000|110|119
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||1000|122|132
SE|00000000||tx|1|entity|C0870507|Ergot Derivative [EPC]|orch,phsu|||ergot derivatives||||888|148|164
SE|00000000||tx|1|entity|C0360390|Antimycobacterial agent|phsu|||Antimycobacterial agents||||888|166|189
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||851|192|199
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||Benzodiazepines||||851|201|215
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||midazolam||||851|217|225
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||triazolam||||764|228|236
SE|00000000||tx|1|entity|C1510470|Motility|orgf|||motility||||764|241|248
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||764|250|255
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|258|266
SE|00000000||tx|1|relation|0|0|C0026056|Midazolam|orch,phsu|orch|||midazolam||||851|217|225|MOD/HEAD|ISA||201|225|0|0|C0005064|Benzodiazepines|orch,phsu|orch|||Benzodiazepines||||851|201|215


SE|00000000||tx|1|text|In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||1000|16|23
SE|00000000||tx|1|entity|C0019134|Heparin|bacs,carb,phsu|||heparin||||1000|41|47
SE|00000000||tx|1|entity|C0042878|Vitamin K|lipd,phsu,vita|||vitamin K||||901|53|61
SE|00000000||tx|1|entity|C0243076|antagonists|chvf|||antagonists||||901|63|73
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|76|80
SE|00000000||tx|1|entity|C1254881|Platelet function|celf|||platelet function||||1000|93|109
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||acetylsalicylic acid||||1000|120|139
SE|00000000||tx|1|entity|C0012582|Dipyridamole|orch,phsu|||dipyridamole||||1000|142|153
SE|00000000||tx|1|entity|C0288672|abciximab|aapp,imft,phsu|||Abciximab||||1000|159|167
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|187|190
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||1000|195|202
SE|00000000||tx|1|entity|C0032143|Alteplase|aapp,enzy,phsu|||Activase||||888|247|254
SE|00000000||tx|1|relation|10|1|C0019134|Heparin|bacs,carb,phsu|bacs|||heparin||||1000|41|47|VERB|ASSOCIATED_WITH||25|34|1|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|16|23
SE|00000000||tx|1|relation|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|76|80|VERB|AFFECTS||87|91|7|1|C1254881|Platelet function|celf|celf|||platelet function||||1000|93|109
SE|00000000||tx|1|relation|8|1|C0288672|abciximab|aapp,gngm,imft,phsu|aapp|||Abciximab||||1000|159|167|NOM|PREDISPOSES||187|190|2|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|195|202
SE|00000000||tx|1|relation|8|1|C0012582|Dipyridamole|orch,phsu|orch|||dipyridamole||||1000|142|153|NOM|PREDISPOSES||187|190|2|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|195|202
SE|00000000||tx|1|relation|8|1|C0004057|Aspirin|orch,phsu|orch|||acetylsalicylic acid||||1000|120|139|NOM|PREDISPOSES||187|190|2|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|195|202


SE|00000000||tx|1|text|Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.
SE|00000000||tx|1|entity|C0701215|Invirase|orch,phsu|||INVIRASE||||1000|7|14
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|39|47
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||888|54|62
SE|00000000||tx|1|entity|C2827499|Labeling Activity|gora|||label||||888|64|68
SE|00000000||tx|1|entity|C0301283|Drug additive|bodm|||additional drugs||||950|93|108
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|122|124
SE|00000000||tx|1|relation|2|1|C0292818|Ritonavir|orch,phsu|orch|||ritonavir||||1000|39|47|NOM|INTERACTS_WITH||64|68|2|0|C0292818|Ritonavir|orch,phsu|orch|||ritonavir||||888|54|62


SE|00000000||tx|1|text|Anafranil should not be used with MAO inhibitors.
SE|00000000||tx|1|entity|C0002752|Anafranil|orch,phsu|||Anafranil||||1000|1|9
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|18|20
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|35|48


SE|00000000||tx|1|text|Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0594753|Hexalen|orch,phsu|||HEXALEN||||1000|30|36
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants||||1000|42|56
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitor||||901|65|77
SE|00000000||tx|1|entity|C0456387|Class|inpr|||class||||901|79|83
SE|00000000||tx|1|entity|C0020651|Hypotension, Orthostatic|fndg|||orthostatic hypotension||||901|102|124
SE|00000000||tx|1|relation|4|2|C0003289|Antidepressive Agents|phsu|phsu|||antidepressants||||1000|42|56|VERB|CAUSES||89|93|1|1|C0020651|Hypotension, Orthostatic|fndg|fndg|||orthostatic hypotension||||901|102|124
SE|00000000||tx|1|relation|4|2|C0594753|Hexalen|orch,phsu|phsu|||HEXALEN||||1000|30|36|VERB|CAUSES||89|93|1|1|C0020651|Hypotension, Orthostatic|fndg|fndg|||orthostatic hypotension||||901|102|124

SE|00000000||tx|2|text|Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.
SE|00000000||tx|2|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|2|entity|C1999216|Inhibitor|qlco|||inhibitor||||1000|16|24
SE|00000000||tx|2|entity|C1979928|Microsomal|qlco|||microsomal||||901|29|38
SE|00000000||tx|2|entity|C0683140|Drug Metabolism|moft|||drug metabolism||||901|40|54
SE|00000000||tx|2|entity|C0205217|Increased|qnco|||increased||||824|57|65
SE|00000000||tx|2|entity|C0018517|Half-Life|tmco|||half-life||||824|80|88
SE|00000000||tx|2|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|94|101
SE|00000000||tx|2|entity|C0034693|Rattus norvegicus|mamm|||rat||||888|108|110
SE|00000000||tx|2|entity|C3161035|Model|inpr|||model||||888|112|116
SE|00000000||tx|2|relation|1|1|C0008783|Cimetidine|orch,phsu|phsu|||Cimetidine||||1000|1|10|NOM|DISRUPTS||16|24|4|1|C0683140|Drug Metabolism|moft|moft|||drug metabolism||||901|40|54
SE|00000000||tx|2|relation|1|1|C0008783|Cimetidine|orch,phsu|phsu|||Cimetidine||||1000|1|10|NOM|DISRUPTS||16|24|4|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||1000|94|101


SE|00000000||tx|1|text|Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.
SE|00000000||tx|1|entity|C0914729|almotriptan|orch,phsu|||almotriptan||||1000|21|31
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||742|41|46
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||742|48|53
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||742|55|63
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||742|65|76
SE|00000000||tx|1|entity|C0439423|Milligram per 24 Hours|qnco|||mg q.d||||875|83|88
SE|00000000||tx|1|entity|C1442459|3 Days|tmco|||3 days||||1000|95|100
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||802|118|130
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||802|136|143
SE|00000000||tx|1|entity|C0205146|Area|spco|||area||||1000|152|155
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration-||||861|167|187
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||861|188|191
SE|00000000||tx|1|entity|C0205134|Curved|spco|||curve||||861|193|197
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximal||||890|203|209
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|211|231
SE|00000000||tx|1|entity|C0914729|almotriptan|orch,phsu|||almotriptan||||1000|236|246


SE|00000000||tx|1|text|A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|3|7
SE|00000000||tx|1|entity|C0205452|Six|qnco|||six||||890|12|14
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||890|16|33
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|47|57
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|59|66
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||852|76|84
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||852|86|91
SE|00000000||tx|1|entity|C0444505|Peak level|qnco|||peak diltiazem plasma levels||||852|71|98
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|110|112
SE|00000000||tx|1|entity|C0439230|week|tmco|||week||||750|130|133
SE|00000000||tx|1|entity|C0750729|Course|tmco|||course||||750|135|140
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||824|145|154
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||824|161|166
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|174|179
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|181|184
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||694|189|197


SE|00000000||tx|1|text|Consequently, the combination of methotrexate with acitretin is also contraindicated.
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|19|29
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|34|45
SE|00000000||tx|1|entity|C0050559|Acitretin|orch,phsu|||acitretin||||1000|52|60
SE|00000000||tx|1|relation|2|2|C0050559|Acitretin|orch,phsu|orch|||acitretin||||1000|52|60|NOM|COEXISTS_WITH||19|29|2|1|C0025677|Methotrexate|orch,phsu|orch|||methotrexate||||1000|34|45


SE|00000000||tx|1|text|Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||888|1|8
SE|00000000||tx|1|entity|C0521116|Current (present time)|tmco|||currently||||888|10|18
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||888|30|38
SE|00000000||tx|1|entity|C0443172|Changed status|qnco|||change||||1000|84|89
SE|00000000||tx|1|entity|C0728866|Drug effect|ftcn|||pharmacological effect||||933|94|115
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiating||||966|122|131
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuing||||872|137|149
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|164|173
SE|00000000||tx|1|relation|1|1|C0008783|Cimetidine|orch,phsu|phsu|||cimetidine||||1000|164|173|NOM|TREATS||151|157|5|0|C1444662|Discontinued|fndg|fndg|||discontinuing||||872|137|149


SE|00000000||tx|1|text|Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl.
SE|00000000||tx|1|entity|C0599739|synergism|moft|||Synergism||||1000|1|9
SE|00000000||tx|1|entity|C0018549|Halothane|orch,phsu|||halothane||||888|34|42
SE|00000000||tx|1|entity|C0278134|Absence of sensation|sosy|||anesthesia||||888|44|53
SE|00000000||tx|1|entity|C0699440|Labetalol hydrochloride|orch,phsu|||labetalol HCl||||861|86|98


SE|00000000||tx|1|text|Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
SE|00000000||tx|1|entity|C1882518|Quinolone Antibiotic|antb|||Quinolone Antibiotics||||983|1|21
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||VIDEX||||1000|24|28
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|56|60
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||785|64|68
SE|00000000||tx|1|entity|C1292428|6 Hours|tmco|||6 hours||||1000|79|85
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|106|118
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|128|148
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|153|165
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|204|211
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||magnesium||||1000|224|232
SE|00000000||tx|1|entity|C0006675|Calcium|bacs,elii,phsu|||calcium||||1000|235|241
SE|00000000||tx|1|entity|C0002367|Aluminum|elii|||aluminum||||1000|247|254


SE|00000000||tx|1|text|Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.
SE|00000000||tx|1|entity|C0019593|Histamine H2 Antagonists|phsu|||Histamine H2 antagonists||||1000|1|24
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|27|36
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|47|52
SE|00000000||tx|1|entity|C0455317|Serum amiodarone measurement|lbpr|||serum amiodarone levels||||988|71|93
SE|00000000||tx|1|relation|2|1|C0008783|Cimetidine|orch,phsu|orch|||Cimetidine||||1000|27|36|VERB|INHIBITS||38|45|2|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|47|52


SE|00000000||tx|1|text|Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||Aspirin||||1000|1|7
SE|00000000||tx|1|entity|C0038317|Steroids|strd|||steroids||||861|63|70
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|75|82
SE|00000000||tx|1|relation|2|2|C0004057|Aspirin|orch,phsu|phsu|||Aspirin||||1000|1|7|PREP|TREATS||72|73|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|75|82


SE|00000000||tx|1|text|Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|31|33
SE|00000000||tx|1|entity|C0059865|Etodolac|orch,phsu|||etodolac||||851|55|62
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||851|64|72
SE|00000000||tx|1|entity|C0031463|Phenylbutazone|orch,phsu|||phenylbutazone||||1000|108|121
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|130|132


SE|00000000||tx|1|text|Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||Quinidine||||1000|1|9
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||bid||||773|21|23
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|39|53
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|56|58
SE|00000000||tx|1|entity|C0028116|Nisoldipine|orch,phsu|||nisoldipine||||1000|64|74
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|88|90
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||peak concentration||||1000|96|113


SE|00000000||tx|1|text|Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.
SE|00000000||tx|1|entity|C0304475|Potassium supplement|inch,phsu|||Potassium Supplements||||983|1|21
SE|00000000||tx|1|entity|C0304490|Potassium Sparing Diuretics|phsu|||Potassium-Sparing Diuretics||||916|27|53
SE|00000000||tx|1|entity|C0721436|Lotensin|orch,phsu|||Lotensin||||916|55|62
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||888|78|86
SE|00000000||tx|1|entity|C1517945|Loss|qnco|||loss||||888|88|91
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|103|120
SE|00000000||tx|1|relation|2|1|C0721436|Lotensin|orch,phsu|orch|||Lotensin||||916|55|62|VERB|INHIBITS||68|76|2|1|C0032821|Potassium|elii|elii|||potassium||||888|78|86
SE|00000000||tx|1|relation|2|1|C0304475|Potassium supplement|inch,phsu|inch|||Potassium Supplements||||983|1|21|VERB|INHIBITS||68|76|2|1|C0032821|Potassium|elii|elii|||potassium||||888|78|86


SE|00000000||tx|1|text|Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||Calcium Antagonists||||966|1|19
SE|00000000||tx|1|entity|C0205341|Repeat|ftcn|||repeated||||802|28|35
SE|00000000||tx|1|entity|C0876196|Trileptal|orch,phsu|||Trileptal||||1000|58|66
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|73|75
SE|00000000||tx|1|entity|C0015772|Felodipine|orch,phsu|||felodipine||||1000|80|89
SE|00000000||tx|1|entity|C0439083|>90|qnco|||90%||||694|111|113
SE|00000000||tx|1|entity|C0450358|33|inpr|||20-33||||861|119|123


SE|00000000||tx|1|text|Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|12|14
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|21|30
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||861|41|45
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||916|75|80
SE|00000000||tx|1|entity|C0678876|renal tubular secretion|ortf|||renal tubular secretion||||916|82|104
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||890|120|128
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|130|150
SE|00000000||tx|1|entity|C0164815|penciclovir|nnon,phsu|||penciclovir||||1000|155|165
SE|00000000||tx|1|relation|0|0|C0033209|Probenecid|orch,phsu|orch|||probenecid||||1000|21|30|SPEC|ISA||21|45|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||861|41|45
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||861|41|45|SPEC|ISA||21|45|0|0|C0033209|Probenecid|orch,phsu|phsu|||probenecid||||1000|21|30


SE|00000000||tx|1|text|Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.
SE|00000000||tx|1|entity|C1306577|Death (finding)|fndg|||Deaths||||1000|1|6
SE|00000000||tx|1|entity|C0014356|Enterocolitis|dsyn|||enterocolitis||||861|20|32
SE|00000000||tx|1|entity|C0011991|Diarrhea|sosy|||diarrhea||||1000|35|42
SE|00000000||tx|1|entity|C0011175|Dehydration|dsyn|||dehydration||||1000|49|59
SE|00000000||tx|1|entity|C1999167|Old age|fndg|||elderly||||888|83|89
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|91|98
SE|00000000||tx|1|entity|C0332174|Weekly|tmco|||weekly||||888|110|115
SE|00000000||tx|1|entity|C0023413|Leucovorin|orch,phsu,vita|||leucovorin||||888|117|126
SE|00000000||tx|1|entity|C0016360|Fluorouracil|nnon,phsu|||fluorouracil||||1000|132|143
SE|00000000||tx|1|relation|0|0|C1999167|Old age|fndg|fndg|||elderly||||888|83|89|MOD/HEAD|PROCESS_OF||83|98|0|0|C0030705|Patients|podg,humn|humn|||patients||||888|91|98
SE|00000000||tx|1|relation|4|1|C0011175|Dehydration|dsyn|dsyn|||dehydration||||1000|49|59|PREP|PROCESS_OF||80|81|3|1|C0030705|Patients|podg,humn|humn|||patients||||888|91|98
SE|00000000||tx|1|relation|4|1|C0011991|Diarrhea|sosy|sosy|||diarrhea||||1000|35|42|PREP|PROCESS_OF||80|81|3|1|C0030705|Patients|podg,humn|humn|||patients||||888|91|98
SE|00000000||tx|1|relation|4|1|C0014356|Enterocolitis|dsyn|dsyn|||enterocolitis||||861|20|32|PREP|PROCESS_OF||80|81|3|1|C0030705|Patients|podg,humn|humn|||patients||||888|91|98
SE|00000000||tx|1|relation|2|1|C0023413|Leucovorin|orch,phsu,vita|orch|||leucovorin||||888|117|126|VERB|ADMINISTERED_TO||100|108|5|1|C0030705|Patients|podg,humn|humn|||patients||||888|91|98
SE|00000000||tx|1|relation|2|1|C0016360|Fluorouracil|nnon,phsu|phsu|||fluorouracil||||1000|132|143|VERB|ADMINISTERED_TO||100|108|5|1|C0030705|Patients|podg,humn|humn|||patients||||888|91|98


SE|00000000||tx|1|text|Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|entity|C0002371|Aluminum Hydroxide|inch,phsu|||aluminum hydroxide||||1000|21|38
SE|00000000||tx|1|entity|C0024476|Magnesium Hydroxide|inch,phsu|||magnesium hydroxide||||1000|44|62
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||694|75|78
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||enoxacin||||1000|94|101


SE|00000000||tx|1|text|Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|||gngm|9360|PPIG|CYP||||1000|21|23
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|36|47
SE|00000000||tx|1|entity|C0003240|Macrolide Antibiotics|antb,orch|||macrolide antibiotics||||1000|50|70
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|80|91
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||861|103|111
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||890|126|134
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|136|156
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|161|175
SE|00000000||tx|1|relation|0|0|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|80|91|SPEC|ISA||50|91|0|0|C0003240|Macrolide Antibiotics|antb,orch|antb|||macrolide antibiotics||||1000|50|70


SE|00000000||tx|1|text|Caution should be used if INDOCIN is administered simultaneously with methotrexate.
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||888|27|33
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneously||||1000|51|64
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|71|82


SE|00000000||tx|1|text|Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.
SE|00000000||tx|1|entity|C1323198|Starlix|orch,phsu|||Starlix||||1000|1|7
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||888|14|22
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||888|24|32
SE|00000000||tx|1|entity|||gngm|1559|CYP2C9|CYP2C9||||861|41|46
SE|00000000||tx|1|entity|C0022173|Isoenzymes|aapp,enzy|||isoenzyme||||861|48|56
SE|00000000||tx|1|entity|C0085732|Ability|orga|||ability||||861|86|92
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||861|118|127
SE|00000000||tx|1|entity|C0040374|Tolbutamide|orch,phsu|||tolbutamide||||1000|132|142
SE|00000000||tx|1|relation|1|1|C1323198|Starlix|orch,phsu|orch|||Starlix||||1000|1|7|NOM|INHIBITS||24|32|5|1|||gngm,aapp|gngm|1559|CYP2C9|CYP2C9||||861|41|46


SE|00000000||tx|1|text|Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||Warfarin||||1000|1|8
SE|00000000||tx|1|entity|C0700473|Fluvoxamine Maleate|orch,phsu|||fluvoxamine maleate||||1000|16|34
SE|00000000||tx|1|entity|C0556984|Three times daily|tmco|||tid||||790|43|45
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|84|91
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||888|97|99
SE|00000000||tx|1|entity|C0439230|week|tmco|||weeks||||888|101|105
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||890|108|115
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|117|137
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin times||||1000|160|176


SE|00000000||tx|1|text|If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.
SE|00000000||tx|1|entity|C0699440|Labetalol hydrochloride|orch,phsu|||labetalol HCl||||901|4|16
SE|00000000||tx|1|entity|C0017887|Nitroglycerin|orch,phsu|||nitroglycerin||||1000|31|43
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|48|55
SE|00000000||tx|1|entity|C0002962|Angina Pectoris|sosy|||angina pectoris||||1000|62|76
SE|00000000||tx|1|entity|C1524062|Additional|ftcn|||additional||||802|79|88
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||802|107|113
SE|00000000||tx|1|relation|2|1|C0017887|Nitroglycerin|orch,phsu|phsu|||nitroglycerin||||1000|31|43|PREP|TREATS||45|46|3|1|C0030705|Patients|podg,humn|podg|||patients||||1000|48|55
SE|00000000||tx|1|relation|2|1|C0002962|Angina Pectoris|sosy|sosy|||angina pectoris||||1000|62|76|PREP|PROCESS_OF||57|60|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|48|55
SE|00000000||tx|1|relation|0|0|C0017887|Nitroglycerin|orch,phsu|phsu|||nitroglycerin||||1000|31|43|INFER|TREATS(INFER)||45|46|0|0|C0002962|Angina Pectoris|sosy|sosy|||angina pectoris||||1000|62|76


SE|00000000||tx|1|text|Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
SE|00000000||tx|1|entity|C0032188|Platelet Inhibitors|phsu|||Platelet inhibitors||||1000|1|19
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|22|26
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||acetylsalicylic acid||||1000|36|55
SE|00000000||tx|1|entity|C0086140|Dextran|carb,phsu|||dextran||||1000|58|64
SE|00000000||tx|1|entity|C0031463|Phenylbutazone|orch,phsu|||phenylbutazone||||1000|67|80
SE|00000000||tx|1|entity|C0020740|Ibuprofen|orch,phsu|||ibuprofen||||1000|83|91
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|94|105
SE|00000000||tx|1|entity|C0012582|Dipyridamole|orch,phsu|||dipyridamole||||1000|108|119
SE|00000000||tx|1|entity|C0020336|Hydroxychloroquine|orch,phsu|||hydroxychloroquine||||1000|122|139
SE|00000000||tx|1|entity|C1955473|Others|fndg|||others||||1000|145|150
SE|00000000||tx|1|entity|C0032176|Platelet aggregation|celf|||platelet-aggregation||||884|172|191
SE|00000000||tx|1|entity|C0443286|Reaction|ftcn|||reactions||||884|193|201
SE|00000000||tx|1|entity|C0205225|Primary|qlco|||main||||851|208|211
SE|00000000||tx|1|entity|C0019120|Hemostatic Agents|phsu|||hemostatic||||851|213|222
SE|00000000||tx|1|entity|C1880266|Defense|cnce|||defense||||851|224|230
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|247|254
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||1000|268|275
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|312|319
SE|00000000||tx|1|entity|C0037513|Heparin sodium|carb,phsu|||heparin sodium||||1000|331|344
SE|00000000||tx|1|relation|0|0|C0004057|Aspirin|orch,phsu|orch|||acetylsalicylic acid||||1000|36|55|SPEC|ISA||22|55|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|22|26
SE|00000000||tx|1|relation|0|0|C0020336|Hydroxychloroquine|orch,phsu|orch|||hydroxychloroquine||||1000|122|139|SPEC|ISA||22|55|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|22|26
SE|00000000||tx|1|relation|0|0|C0012582|Dipyridamole|orch,phsu|orch|||dipyridamole||||1000|108|119|SPEC|ISA||22|55|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|22|26
SE|00000000||tx|1|relation|0|0|C0021246|Indomethacin|orch,phsu|orch|||indomethacin||||1000|94|105|SPEC|ISA||22|55|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|22|26
SE|00000000||tx|1|relation|0|0|C0020740|Ibuprofen|orch,phsu|orch|||ibuprofen||||1000|83|91|SPEC|ISA||22|55|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|22|26
SE|00000000||tx|1|relation|0|0|C0031463|Phenylbutazone|orch,phsu|orch|||phenylbutazone||||1000|67|80|SPEC|ISA||22|55|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|22|26
SE|00000000||tx|1|relation|0|0|C0086140|Dextran|carb,phsu|carb|||dextran||||1000|58|64|SPEC|ISA||22|55|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|22|26
SE|00000000||tx|1|relation|10|2|C0020336|Hydroxychloroquine|orch,phsu|orch|||hydroxychloroquine||||1000|122|139|VERB|DISRUPTS||157|165|7|1|C0032176|Platelet aggregation|celf|celf|||platelet-aggregation||||884|172|191
SE|00000000||tx|1|relation|10|2|C0012582|Dipyridamole|orch,phsu|orch|||dipyridamole||||1000|108|119|VERB|DISRUPTS||157|165|7|1|C0032176|Platelet aggregation|celf|celf|||platelet-aggregation||||884|172|191
SE|00000000||tx|1|relation|10|2|C0021246|Indomethacin|orch,phsu|orch|||indomethacin||||1000|94|105|VERB|DISRUPTS||157|165|7|1|C0032176|Platelet aggregation|celf|celf|||platelet-aggregation||||884|172|191
SE|00000000||tx|1|relation|10|2|C0020740|Ibuprofen|orch,phsu|orch|||ibuprofen||||1000|83|91|VERB|DISRUPTS||157|165|7|1|C0032176|Platelet aggregation|celf|celf|||platelet-aggregation||||884|172|191
SE|00000000||tx|1|relation|10|2|C0031463|Phenylbutazone|orch,phsu|orch|||phenylbutazone||||1000|67|80|VERB|DISRUPTS||157|165|7|1|C0032176|Platelet aggregation|celf|celf|||platelet-aggregation||||884|172|191
SE|00000000||tx|1|relation|10|2|C0086140|Dextran|carb,phsu|carb|||dextran||||1000|58|64|VERB|DISRUPTS||157|165|7|1|C0032176|Platelet aggregation|celf|celf|||platelet-aggregation||||884|172|191
SE|00000000||tx|1|relation|10|2|C0004057|Aspirin|orch,phsu|orch|||acetylsalicylic acid||||1000|36|55|VERB|DISRUPTS||157|165|7|1|C0032176|Platelet aggregation|celf|celf|||platelet-aggregation||||884|172|191
SE|00000000||tx|1|relation|13|5|C0020336|Hydroxychloroquine|orch,phsu|orch|||hydroxychloroquine||||1000|122|139|VERB|CAUSES||261|266|4|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|268|275
SE|00000000||tx|1|relation|13|5|C0012582|Dipyridamole|orch,phsu|orch|||dipyridamole||||1000|108|119|VERB|CAUSES||261|266|4|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|268|275
SE|00000000||tx|1|relation|13|5|C0021246|Indomethacin|orch,phsu|orch|||indomethacin||||1000|94|105|VERB|CAUSES||261|266|4|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|268|275
SE|00000000||tx|1|relation|13|5|C0020740|Ibuprofen|orch,phsu|orch|||ibuprofen||||1000|83|91|VERB|CAUSES||261|266|4|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|268|275
SE|00000000||tx|1|relation|13|5|C0031463|Phenylbutazone|orch,phsu|orch|||phenylbutazone||||1000|67|80|VERB|CAUSES||261|266|4|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|268|275
SE|00000000||tx|1|relation|13|5|C0086140|Dextran|carb,phsu|carb|||dextran||||1000|58|64|VERB|CAUSES||261|266|4|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|268|275
SE|00000000||tx|1|relation|13|5|C0004057|Aspirin|orch,phsu|orch|||acetylsalicylic acid||||1000|36|55|VERB|CAUSES||261|266|4|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|268|275
SE|00000000||tx|1|relation|15|7|C0020336|Hydroxychloroquine|orch,phsu|phsu|||hydroxychloroquine||||1000|122|139|PREP|TREATS||309|310|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|312|319
SE|00000000||tx|1|relation|15|7|C0012582|Dipyridamole|orch,phsu|phsu|||dipyridamole||||1000|108|119|PREP|TREATS||309|310|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|312|319
SE|00000000||tx|1|relation|15|7|C0021246|Indomethacin|orch,phsu|phsu|||indomethacin||||1000|94|105|PREP|TREATS||309|310|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|312|319
SE|00000000||tx|1|relation|15|7|C0020740|Ibuprofen|orch,phsu|phsu|||ibuprofen||||1000|83|91|PREP|TREATS||309|310|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|312|319
SE|00000000||tx|1|relation|15|7|C0031463|Phenylbutazone|orch,phsu|phsu|||phenylbutazone||||1000|67|80|PREP|TREATS||309|310|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|312|319
SE|00000000||tx|1|relation|15|7|C0086140|Dextran|carb,phsu|phsu|||dextran||||1000|58|64|PREP|TREATS||309|310|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|312|319
SE|00000000||tx|1|relation|15|7|C0004057|Aspirin|orch,phsu|phsu|||acetylsalicylic acid||||1000|36|55|PREP|TREATS||309|310|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|312|319
SE|00000000||tx|1|relation|1|1|C0037513|Heparin sodium|carb,phsu|carb|||heparin sodium||||1000|331|344|VERB|ADMINISTERED_TO||321|329|16|1|C0030705|Patients|podg,humn|humn|||patients||||1000|312|319


SE|00000000||tx|1|text|Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).
SE|00000000||tx|1|entity|C0003299|Antiepileptic Agents|phsu|||Antiepileptic Drugs||||1000|1|19
SE|00000000||tx|1|entity|C0205422|Sporadic|tmco|||Sporadic||||888|22|29
SE|00000000||tx|1|entity|C0868928|Case (situation)|ftcn|||cases||||888|31|35
SE|00000000||tx|1|entity|C0036572|Seizures|sosy|||seizures||||1000|40|47
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|75|85
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|87|89
SE|00000000||tx|1|entity|C0146226|Toradol|orch,phsu|||TORADOL||||1000|94|100
SE|00000000||tx|1|entity|C0003299|Antiepileptic Agents|phsu|||antiepileptic drugs||||1000|106|124
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|127|135
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|138|150


SE|00000000||tx|1|text|Caution should be used if naproxen is administered concomitantly with methotrexate.
SE|00000000||tx|1|entity|C0027396|Naproxen|orch,phsu|||naproxen||||888|27|34
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|71|82


SE|00000000||tx|1|text|Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
SE|00000000||tx|1|entity|C0020261|Hydrochlorothiazide|orch,phsu|||Hydrochlorothiazide||||1000|17|35
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||non-steroidal anti-inflammatory agents||||1000|41|78
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|108|114
SE|00000000||tx|1|entity|C0871633|desires|menp|||desired||||872|163|169
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||872|171|176
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|185|192
SE|00000000||tx|1|relation|4|3|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||non-steroidal anti-inflammatory agents||||1000|41|78|NOM|INTERACTS_WITH||171|176|1|1|C0012798|Diuretics|phsu|phsu|||diuretic||||1000|185|192
SE|00000000||tx|1|relation|4|3|C0020261|Hydrochlorothiazide|orch,phsu|phsu|||Hydrochlorothiazide||||1000|17|35|NOM|INTERACTS_WITH||171|176|1|1|C0012798|Diuretics|phsu|phsu|||diuretic||||1000|185|192


SE|00000000||tx|1|text|Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
SE|00000000||tx|1|entity|C1621583|Administer|ftcn|||administering||||966|29|41
SE|00000000||tx|1|entity|C1515187|Take|hlca|||taking||||872|46|51
SE|00000000||tx|1|entity|C1135136|Tarceva|orch,phsu|||TARCEVA||||872|53|59
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|66|77
SE|00000000||tx|1|entity|C0442821|Strong|qlco|||strong||||802|89|94
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||802|96|101
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||802|103|112
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|127|129
SE|00000000||tx|1|entity|C1145759|Atazanavir|orch,phsu|||atazanavir||||1000|143|152
SE|00000000||tx|1|entity|C0055856|Clarithromycin|antb,orch|||clarithromycin||||1000|155|168
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|171|179
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|182|193
SE|00000000||tx|1|entity|C0068485|nefazodone|orch,phsu|||nefazodone||||1000|196|205
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||nelfinavir||||1000|208|217
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|220|228
SE|00000000||tx|1|entity|C0286738|Saquinavir|orch,phsu|||saquinavir||||1000|231|240
SE|00000000||tx|1|entity|C0907410|telithromycin|antb,orch|||telithromycin||||1000|243|255
SE|00000000||tx|1|entity|C0041165|Troleandomycin|antb,orch|||troleandomycin||||1000|258|271
SE|00000000||tx|1|entity|C0393080|voriconazole|orch,phsu|||voriconazole||||1000|284|295


SE|00000000||tx|1|text|Colchicine is inhibited by acidifying agents.
SE|00000000||tx|1|entity|C0009262|Colchicine|orch,phsu|||Colchicine||||1000|1|10
SE|00000000||tx|1|entity|C0304461|Acidifying preparation|phsu|||acidifying agents||||1000|28|44
SE|00000000||tx|1|relation|1|1|C0304461|Acidifying preparation|phsu|phsu|||acidifying agents||||1000|28|44|VERB|INHIBITS||15|23|1|1|C0009262|Colchicine|orch,phsu|orch|||Colchicine||||1000|1|10


SE|00000000||tx|1|text|Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.
SE|00000000||tx|1|entity|C0009279|Colestipol|orch,phsu|||Colestipol||||851|1|10
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||851|12|22
SE|00000000||tx|1|entity|C1512806|Intake|ftcn|||intake||||851|24|29
SE|00000000||tx|1|entity|C0009279|Colestipol|orch,phsu|||colestipol||||1000|34|43
SE|00000000||tx|1|entity|C0042878|Vitamin K|lipd,phsu,vita|||vitamin K||||1000|49|57
SE|00000000||tx|1|entity|C0042878|Vitamin K|lipd,phsu,vita|||vitamin K||||1000|88|96


SE|00000000||tx|1|text|Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|13|15
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||861|20|31
SE|00000000||tx|1|entity|C0018242|Griseofulvin|orch,phsu|||griseofulvin||||888|51|62
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||888|64|71
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||1000|105|110


SE|00000000||tx|1|text|Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||Inhibitors||||1000|1|10
SE|00000000||tx|1|entity|C0022173|Isoenzymes|aapp,enzy|||isoenzyme||||1000|20|28
SE|00000000||tx|1|entity|C0003240|Macrolide Antibiotics|antb,orch|||macrolide antibiotics||||1000|37|57
SE|00000000||tx|1|entity|C0004504|Azoles|orch|||azole||||901|60|64
SE|00000000||tx|1|entity|C0003308|Antifungal Agents|phsu|||antifungal agents||||901|66|82
SE|00000000||tx|1|entity|C0033607|Protease Inhibitor|bacs,phsu|||protease inhibitors||||1000|85|103
SE|00000000||tx|1|entity|C0162758|Serotonin Uptake Inhibitors|phsu|||serotonin reuptake inhibitors||||1000|106|134
SE|00000000||tx|1|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||1000|137|146
SE|00000000||tx|1|entity|C0006864|Cannabinoids|orch,phsu|||cannabinoids||||1000|149|160
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|163|171
SE|00000000||tx|1|entity|C0452456|Grapefruit juice|food|||grapefruit juice||||1000|174|189
SE|00000000||tx|1|entity|C0028365|Norfloxacin|orch,phsu|||norfloxacin||||1000|204|214
SE|00000000||tx|1|entity|C0034417|Quinine|orch,phsu|||quinine||||1000|217|223
SE|00000000||tx|1|entity|C0378466|zafirlukast|orch,phsu|||zafirlukast||||1000|226|236
SE|00000000||tx|1|entity|C0876188|Tikosyn|orch,phsu|||TIKOSYN||||1000|280|286
SE|00000000||tx|1|entity|C0114771|dofetilide|orch,phsu|||dofetilide||||694|321|330
SE|00000000||tx|1|relation|15|1|C0876188|Tikosyn|orch,phsu|orch|||TIKOSYN||||1000|280|286|VERB|STIMULATES||312|319|1|1|C0114771|dofetilide|orch,phsu|orch|||dofetilide||||694|321|330


SE|00000000||tx|1|text|Lofexidine may enhance The effects of Anti-hypertensive drug therapy
SE|00000000||tx|1|entity|C0065152|lofexidine|orch,phsu|||Lofexidine||||1000|1|10
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|28|34
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||Anti-hypertensive drug||||916|39|60


SE|00000000||tx|1|text|The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|18|24
SE|00000000||tx|1|entity|C0064079|Isosorbide Mononitrate|orch,phsu|||isosorbide mononitrate||||1000|29|50
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||1000|59|66
SE|00000000||tx|1|entity|C0042402|Vasodilator Agents|phsu|||vasodilators||||1000|88|99
SE|00000000||tx|1|relation|0|0|C0064079|Isosorbide Mononitrate|orch,phsu|orch|||isosorbide mononitrate||||1000|29|50|SPEC|ISA||29|99|0|0|C0042402|Vasodilator Agents|phsu|phsu|||vasodilators||||1000|88|99


SE|00000000||tx|1|text|Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
SE|00000000||tx|1|entity|C0722654|Pletal|orch,phsu|||PLETAL||||1000|7|12
SE|00000000||tx|1|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P-450||||916|44|59
SE|00000000||tx|1|entity|C0022173|Isoenzymes|aapp,enzy|||isoenzymes||||916|61|70
SE|00000000||tx|1|entity|C0722654|Pletal|orch,phsu|||PLETAL||||1000|106|111
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||1000|136|145
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|165|176
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|182|193
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||1000|198|207
SE|00000000||tx|1|entity|C1332828|CYP2C19 gene|gngm|1557|CYP2C19|CYP2C19||||1000|212|218
SE|00000000||tx|1|entity|C0028978|Omeprazole|orch,phsu|||omeprazole||||1000|228|237
SE|00000000||tx|1|relation|10|1|C0010762|Cytochrome P450|aapp,gngm,enzy|aapp|||cytochrome P-450||||916|44|59|VERB|INTERACTS_WITH||29|39|1|1|C0722654|Pletal|orch,phsu|orch|||PLETAL||||1000|7|12
SE|00000000||tx|1|relation|8|5|C0722654|Pletal|orch,phsu|orch|||PLETAL||||1000|106|111|NOM|INHIBITS||198|207|2|1|C1332828|CYP2C19 gene|gngm,aapp|gngm|1557|CYP2C19|CYP2C19||||1000|212|218


SE|00000000||tx|1|text|Methotrexate: Piperacillin sodium may reduce the excretion of methotrexate.
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||Methotrexate||||1000|1|12
SE|00000000||tx|1|entity|C0700463|Piperacillin Sodium|antb,orch|||Piperacillin sodium||||1000|15|33
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||1000|50|58
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|63|74
SE|00000000||tx|1|relation|2|1|C0700463|Piperacillin Sodium|antb,orch|antb|||Piperacillin sodium||||1000|15|33|VERB|DISRUPTS||39|44|2|1|C0221102|Excretory function|phsf|phsf|||excretion||||1000|50|58


SE|00000000||tx|1|text|Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||Methotrexate||||1000|1|12
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|15|20
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||694|66|77
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||kidney||||773|102|107
SE|00000000||tx|1|entity|C1519355|Slice|sbst|||slices||||773|109|114


SE|00000000||tx|1|text|Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interactions||||901|22|38
SE|00000000||tx|1|entity|C0017601|Glaucoma|dsyn|||glaucoma||||790|53|60
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||790|62|66
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||888|71|78
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||888|80|90
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||clinical studies||||1000|111|126
SE|00000000||tx|1|entity|C0361803|apraclonidine 5 MG/ML Ophthalmic Solution [Iopidine]|clnd|||IOPIDINE 0.5% Ophthalmic Solution||||1000|131|163
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||1000|188|195
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|213|218
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||1000|225|239
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|242|248
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|251|262
SE|00000000||tx|1|entity|C0376196|Opiates|hops,phsu|||opiates||||1000|265|271
SE|00000000||tx|1|entity|C0036557|Sedatives|phsu|||sedatives||||1000|274|282
SE|00000000||tx|1|entity|C0002932|Anesthetics|phsu|||anesthetics||||1000|285|295
SE|00000000||tx|1|relation|0|0|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|242|248|SPEC|ISA||225|248|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|225|239


SE|00000000||tx|1|text|The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|20|30
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|32|38
SE|00000000||tx|1|entity|C0721436|Lotensin|orch,phsu|||Lotensin||||1000|45|52
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|99|106
SE|00000000||tx|1|entity|C0442808|Increasing|ftcn|||increasing||||1000|111|120
SE|00000000||tx|1|entity|C0489767|salt intake|orga|||salt intake||||1000|126|136
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|147|156
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|161|169
SE|00000000||tx|1|entity|C0721436|Lotensin|orch,phsu|||Lotensin||||1000|176|183
SE|00000000||tx|1|relation|8|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||1000|161|169|PREP|USES||171|174|1|1|C0721436|Lotensin|orch,phsu|phsu|||Lotensin||||1000|176|183


SE|00000000||tx|1|text|Caution should be exercised when anticoagulants are given in conjunction with Atromid-S.
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|34|47
SE|00000000||tx|1|entity|C0591129|Atromid|orch,phsu|||Atromid-S||||1000|79|87


SE|00000000||tx|1|text|Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug.
SE|00000000||tx|1|entity|C0683949|Animal Study|anim|||Animal studies||||1000|1|14
SE|00000000||tx|1|entity|C0012963|Dobutamine|orch,phsu|||dobutamine||||1000|30|39
SE|00000000||tx|1|entity|C3242229|ineffective|idcn|||ineffective||||1000|48|58
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|67|73
SE|00000000||tx|1|entity|C0332185|Recent|tmco|||recently||||1000|79|86
SE|00000000||tx|1|entity|C2955666|Block drugs|ftcn|||blocking drug||||901|101|113


SE|00000000||tx|1|text|Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.
SE|00000000||tx|1|entity|C0010587|cyclopropane|orch,phsu|||Cyclopropane||||1000|1|12
SE|00000000||tx|1|entity|C0020250|Hydrocarbons, Halogenated|orch|||halogenated hydrocarbon||||901|17|39
SE|00000000||tx|1|entity|C0002932|Anesthetics|phsu|||anesthetics||||901|41|51
SE|00000000||tx|1|entity|C0018787|Heart|bpoc|||cardiac||||802|62|68
SE|00000000||tx|1|entity|C0022107|Irritable Mood|fndg|||irritability||||802|80|91
SE|00000000||tx|1|entity|C0027061|Myocardium|tisu|||myocardium||||1000|115|124
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|133|138
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||791|143|149
SE|00000000||tx|1|entity|C0007412|Catecholamines|nsba,orch,phsu|||catecholamines||||791|178|191
SE|00000000||tx|1|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine||||1000|202|209
SE|00000000||tx|1|relation|0|0|C0013030|Dopamine|nsba,orch,phsu|nsba|||dopamine||||1000|202|209|SPEC|ISA||178|209|0|0|C0007412|Catecholamines|nsba,orch,phsu|nsba|||catecholamines||||791|178|191
SE|00000000||tx|1|relation|2|1|C0002932|Anesthetics|phsu|phsu|||anesthetics||||901|41|51|VERB|AUGMENTS||53|60|5|1|C0022107|Irritable Mood|fndg|fndg|||irritability||||802|80|91
SE|00000000||tx|1|relation|2|1|C0010587|cyclopropane|orch,phsu|phsu|||Cyclopropane||||1000|1|12|VERB|AUGMENTS||53|60|5|1|C0022107|Irritable Mood|fndg|fndg|||irritability||||802|80|91


SE|00000000||tx|1|text|Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||1000|23|32
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||840|41|43
SE|00000000||tx|1|entity|C1547085|7 days|tmco|||7 days||||1000|49|54
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|71|81
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|83|90
SE|00000000||tx|1|entity|C0011816|Dextromethorphan|orch,phsu|||dextromethorphan||||790|95|110
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|112|117
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||1000|152|156
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||1000|159|168
SE|00000000||tx|1|entity|C1762617|Weak|qlco|||weak||||888|175|178
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||888|180|188


SE|00000000||tx|1|text|When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.
SE|00000000||tx|1|entity|C0050940|lansoprazole|orch,phsu|||lansoprazole||||1000|6|17
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|55|66
SE|00000000||tx|1|entity|C1332826|CYP1A2 gene|gngm|1544|CYP1A2|CYP1A2||||1000|69|74
SE|00000000||tx|1|entity|||gngm|1574|CYP3A|CYP3A||||1000|77|81
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|93|100
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|115|123
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|128|139


SE|00000000||tx|1|text|Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||Antihistamines||||1000|1|14
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||Amphetamines||||1000|17|28
SE|00000000||tx|1|entity|C3179159|Sedative Effect|phsf|||sedative effect||||1000|49|63
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|68|81
SE|00000000||tx|1|relation|2|1|C0002667|Amphetamines|nsba,orch,phsu|nsba|||Amphetamines||||1000|17|28|VERB|DISRUPTS||34|43|2|1|C3179159|Sedative Effect|phsf|phsf|||sedative effect||||1000|49|63


SE|00000000||tx|1|text|Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||Digoxin||||1000|1|7
SE|00000000||tx|1|entity|C0681867|Controlled Study|resa|||controlled studies||||983|13|30
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|35|52
SE|00000000||tx|1|entity|C0770909|Bepridil hydrochloride|orch,phsu|||bepridil hydrochloride||||901|55|76
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|92|97
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|100|102
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||888|104|108
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||861|141|149
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||888|163|165
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||849|179|190
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||849|198|204
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum digoxin concentrations||||849|192|219


SE|00000000||tx|1|text|Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||Drug-Drug Interactions||||868|1|22
SE|00000000||tx|1|entity|C0001927|Albuterol|orch,phsu|||Albuterol||||868|24|32
SE|00000000||tx|1|entity|C1176420|Strattera|orch,phsu|||STRATTERA||||868|36|44
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|85|92
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||1000|140|143
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||1000|148|158
SE|00000000||tx|1|entity|C0001927|Albuterol|orch,phsu|||albuterol||||1000|161|169
SE|00000000||tx|1|entity|C1417683|NEUROD1 gene|gngm|4760|NEUROD1|beta2||||888|181|185
SE|00000000||tx|1|entity|C0243192|agonists|phsu|||agonists||||888|187|194
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|209|214
SE|00000000||tx|1|entity|C0001927|Albuterol|orch,phsu|||albuterol||||1000|219|227
SE|00000000||tx|1|entity|C0007226|Cardiovascular system|bdsy|||cardiovascular system||||1000|236|256
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||1000|290|298
SE|00000000||tx|1|entity|C0018810|heart rate|orga|||heart rate||||1000|303|312
SE|00000000||tx|1|entity|C0005823|Blood Pressure|orgf|||blood pressure||||1000|318|331
SE|00000000||tx|1|relation|10|3|C0001927|Albuterol|orch,phsu|orch|||albuterol||||1000|161|169|ADJ|ADMINISTERED_TO||126|137|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|85|92


SE|00000000||tx|1|text|Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulants||||1000|9|27
SE|00000000||tx|1|entity|C0205054|Hepatic|blor|||hepatic||||888|52|58
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|60|69
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|74|82
SE|00000000||tx|1|entity|C1407029|Toxic|qlco|||toxic||||694|85|89
SE|00000000||tx|1|entity|C0003286|Anticonvulsants|phsu|||anticonvulsant||||1000|105|118
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulant||||1000|138|155
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|161|169


SE|00000000||tx|1|text|Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
SE|00000000||tx|1|entity|C0242702|Dopamine Antagonists|nsba,phsu|||Dopamine D2 receptor antagonists||||916|1|32
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|41|54
SE|00000000||tx|1|entity|C0006525|Butyrophenones|orch,phsu|||butyrophenones||||1000|57|70
SE|00000000||tx|1|entity|C0073393|Risperidone|orch,phsu|||risperidone||||1000|73|83
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|90|98
SE|00000000||tx|1|entity|C1527144|Therapeutic Effect|hlca|||therapeutic effects||||983|115|133
SE|00000000||tx|1|entity|C0023570|Levodopa|aapp,nsba,phsu|||levodopa||||1000|138|145


SE|00000000||tx|1|text|Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.
SE|00000000||tx|1|entity|C0085217|Lithium Carbonate|inch,phsu|||Lithium carbonate||||1000|1|17
SE|00000000||tx|1|entity|C0175727|Stimulator|medd|||stimulatory||||853|24|34
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||853|36|42
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||amphetamines||||1000|47|58
SE|00000000||tx|1|entity|C0085217|Lithium Carbonate|inch,phsu|||lithium carbonate||||1000|80|96
SE|00000000||tx|1|relation|1|1|C0085217|Lithium Carbonate|inch,phsu|inch|||lithium carbonate||||1000|80|96|VERB|INHIBITS||67|75|3|1|C0002667|Amphetamines|nsba,orch,phsu|nsba|||amphetamines||||1000|47|58


SE|00000000||tx|1|text|Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin.
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||Cyclosporine||||802|1|12
SE|00000000||tx|1|entity|C0003765|Arginine|aapp,bacs,phsu|||arginine||||802|18|25
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|60|65
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporin||||1000|70|80


SE|00000000||tx|1|text|Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||861|22|26
SE|00000000||tx|1|entity|C0039644|Tetracycline|antb,orch|||tetracycline||||888|41|52
SE|00000000||tx|1|entity|C0456387|Class|inpr|||class||||888|54|58
SE|00000000||tx|1|entity|C0003232|Antibiotics|antb|||antibiotics||||1000|63|73
SE|00000000||tx|1|entity|C0004635|Bactericide, NOS|antb|||bactericidal||||853|99|110
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||853|112|117
SE|00000000||tx|1|entity|C0030842|Penicillins|antb,orch|||penicillins||||1000|122|132
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||827|141|143
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||861|175|179
SE|00000000||tx|1|relation|0|0|C0030842|Penicillins|antb,orch|antb|||penicillins||||1000|122|132|SPEC|ISA||122|179|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||861|175|179


SE|00000000||tx|1|text|Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.
SE|00000000||tx|1|entity|C0205403|Extreme|qlco|||EXTREME||||694|12|18
SE|00000000||tx|1|entity|C1621583|Administer|ftcn|||administering||||890|53|65
SE|00000000||tx|1|entity|C0282151|Dopamine Hydrochloride|nsba,orch,phsu|||dopamine HCl||||890|67|78
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|83|90
SE|00000000||tx|1|entity|C0010587|cyclopropane|orch,phsu|||cyclopropane||||1000|102|113
SE|00000000||tx|1|entity|C0020250|Hydrocarbons, Halogenated|orch|||halogenated hydrocarbon||||901|118|140
SE|00000000||tx|1|entity|C0002932|Anesthetics|phsu|||anesthetics||||901|142|152
SE|00000000||tx|1|relation|2|1|C0010587|cyclopropane|orch,phsu|orch|||cyclopropane||||1000|102|113|VERB|ADMINISTERED_TO||92|100|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|83|90
SE|00000000||tx|1|relation|2|1|C0002932|Anesthetics|phsu|phsu|||anesthetics||||901|142|152|VERB|ADMINISTERED_TO||92|100|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|83|90


SE|00000000||tx|1|text|Quinolones have also been shown to interfere with the metabolism of caffeine.
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||Quinolones||||1000|1|10
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|55|64
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|69|76
SE|00000000||tx|1|relation|1|1|C0034428|Quinolones|orch|orch|||Quinolones||||1000|1|10|VERB|DISRUPTS||36|44|2|1|C0025519|Metabolism|orgf|orgf|||metabolism||||1000|55|64


SE|00000000||tx|1|text|Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.
SE|00000000||tx|1|entity|C0304520|Digitalis preparation|carb,phsu|||digitalis preparations||||1000|44|65
SE|00000000||tx|1|entity|C0009671|Conflict (Psychology)|inbe|||conflicting||||888|83|93
SE|00000000||tx|1|entity|C1274040|Result|ftcn|||results||||888|95|101
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|111|116
SE|00000000||tx|1|entity|C0354648|Colestipol Hydrochloride|orch,phsu|||colestipol hydrochloride||||1000|121|144
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|169|175
SE|00000000||tx|1|entity|C0012258|Digitoxin|carb,phsu,strd|||digitoxin||||1000|181|189
SE|00000000||tx|1|relation|4|3|C0012265|Digoxin|carb,phsu,strd|carb|||digoxin||||1000|169|175|NOM|INTERACTS_WITH||111|116|4|1|C0354648|Colestipol Hydrochloride|orch,phsu|orch|||colestipol hydrochloride||||1000|121|144
SE|00000000||tx|1|relation|4|3|C0012258|Digitoxin|carb,phsu,strd|carb|||digitoxin||||1000|181|189|NOM|INTERACTS_WITH||111|116|4|1|C0354648|Colestipol Hydrochloride|orch,phsu|orch|||colestipol hydrochloride||||1000|121|144


SE|00000000||tx|1|text|ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.
SE|00000000||tx|1|entity|C1110594|Allegra|orch,phsu|||ALLEGRA||||1000|1|7
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|16|18
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||1000|40|43
SE|00000000||tx|1|entity|C0002367|Aluminum|elii|||aluminum||||1000|50|57
SE|00000000||tx|1|entity|C1875461|MAGNESIUM CONTAINING ANTACIDS|phsu|||magnesium containing antacids||||1000|63|91


SE|00000000||tx|1|text|Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|30|39
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|45|69
SE|00000000||tx|1|entity|C0750502|Significant|idcn|||significant||||790|94|104
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||790|106|114
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|123|128
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|144|168


SE|00000000||tx|1|text|Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
SE|00000000||tx|1|entity|C0245109|anakinra|aapp,phsu|||Anakinra||||1000|1|8
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|11|20
SE|00000000||tx|1|entity|C0245109|anakinra|aapp,phsu|||anakinra||||1000|40|47
SE|00000000||tx|1|entity|C0021755|Interleukin-1|aapp,imft|||interleukin-1||||734|53|65
SE|00000000||tx|1|entity|C1522668|Recombinant Tumor Necrosis Factor Family Protein|aapp,imft|7124|TNF|TNF||||851|91|93
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blocking||||851|95|102
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agent||||851|104|108
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|138|146
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|148|151
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||888|156|162
SE|00000000||tx|1|entity|C0021311|Infection|dsyn|||infections||||888|164|173
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|179|187
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|189|192
SE|00000000||tx|1|entity|C0027947|Neutropenia|dsyn|||neutropenia||||1000|197|207
SE|00000000||tx|1|entity|C1524062|Additional|ftcn|||additional||||888|216|225
SE|00000000||tx|1|entity|C0814225|Benefits|qnco|||benefit||||888|227|233
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medicinal products||||1000|253|270
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|272|276
SE|00000000||tx|1|relation|10|6|C1254351|Pharmacologic Substance|phsu|phsu|||agent||||851|104|108|VERB|compared_with||235|242|2|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medicinal products||||1000|253|270
SE|00000000||tx|1|relation|6|3|C0027947|Neutropenia|dsyn|dsyn|||neutropenia||||1000|197|207|NOM|PREDISPOSES||148|151|6|1|C0021311|Infection|dsyn|dsyn|||infections||||888|164|173


SE|00000000||tx|1|text|Antagonism between lincomycin and erythromycin in vitro has been demonstrated.
SE|00000000||tx|1|entity|C0680242|antagonism|socb|||Antagonism||||1000|1|10
SE|00000000||tx|1|entity|C0023726|Lincomycin|antb,carb|||lincomycin||||1000|20|29
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|35|46


SE|00000000||tx|1|text|Diuretics: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||Diuretics||||1000|1|9
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|12|19
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|24|32
SE|00000000||tx|1|entity|C0750310|volume depletion intravascular|fndg|||intravascular volume depletion||||1000|57|86
SE|00000000||tx|1|entity|C0442802|Excessive|qlco|||excessive||||888|120|128
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||888|130|138
SE|00000000||tx|1|entity|C0005823|Blood Pressure|orgf|||blood pressure||||1000|143|156
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|164|173
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|178|184
SE|00000000||tx|1|entity|C0733440|Fosinopril Sodium|opco,phsu|||fosinopril sodium||||1000|191|207
SE|00000000||tx|1|relation|6|1|C0750310|volume depletion intravascular|fndg|fndg|||intravascular volume depletion||||1000|57|86|PREP|PROCESS_OF||52|55|3|2|C0030705|Patients|podg,humn|humn|||Patients||||1000|12|19
SE|00000000||tx|1|relation|4|4|C0733440|Fosinopril Sodium|opco,phsu|opco|||fosinopril sodium||||1000|191|207|NOM|DISRUPTS||130|138|4|1|C0005823|Blood Pressure|orgf|orgf|||blood pressure||||1000|143|156


SE|00000000||tx|1|text|Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||Phenothiazines||||1000|1|14
SE|00000000||tx|1|entity|C0006525|Butyrophenones|orch,phsu|||butyrophenones||||1000|20|33
SE|00000000||tx|1|entity|C0237795|Pressors|phsu|||pressor||||888|61|67
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|69|74
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||epinephrine||||1000|79|89
SE|00000000||tx|1|relation|2|1|C0006525|Butyrophenones|orch,phsu|orch|||butyrophenones||||1000|20|33|NOM|INTERACTS_WITH||69|74|2|0|C0237795|Pressors|phsu|phsu|||pressor||||888|61|67
SE|00000000||tx|1|relation|2|1|C0031436|Phenothiazines|orch,phsu|orch|||Phenothiazines||||1000|1|14|NOM|INTERACTS_WITH||69|74|2|0|C0237795|Pressors|phsu|phsu|||pressor||||888|61|67


SE|00000000||tx|1|text|Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).
SE|00000000||tx|1|entity|C0022154|Isocarboxazid|orch,phsu|||Isocarboxazid||||1000|1|13
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|54|61
SE|00000000||tx|1|entity|C0591096|Antabuse|orch,phsu|||Antabuse||||1000|73|80
SE|00000000||tx|1|entity|C0012772|Disulfiram|orch,phsu|||disulfiram||||1000|83|92
SE|00000000||tx|1|entity|C0331760|Ayerst|hcro|||Ayerst||||901|101|106
SE|00000000||tx|1|entity|C0331933|Wyeth-Ayerst|hcro|||Wyeth-Ayerst Laboratories||||901|95|119
SE|00000000||tx|1|relation|0|0|C0591096|Antabuse|orch,phsu|orch|||Antabuse||||1000|73|80|SPEC|ISA||73|92|0|0|C0012772|Disulfiram|orch,phsu|orch|||disulfiram||||1000|83|92
SE|00000000||tx|1|relation|3|1|C0591096|Antabuse|orch,phsu|orch|||Antabuse||||1000|73|80|VERB|ADMINISTERED_TO||63|71|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|54|61


SE|00000000||tx|1|text|Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|12|21
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|23|25
SE|00000000||tx|1|entity|C0876196|Trileptal|orch,phsu|||Trileptal||||1000|30|38
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||888|45|52
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||888|54|67
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||1000|86|99
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||888|101|104
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effective||||888|106|114


SE|00000000||tx|1|text|The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|5|10
SE|00000000||tx|1|entity|C0146226|Toradol|orch,phsu|||TORADOL||||1000|15|21
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||888|26|31
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||888|33|39
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|45|47
SE|00000000||tx|1|entity|C0868928|Case (situation)|ftcn|||cases||||1000|67|71
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||824|76|84
SE|00000000||tx|1|entity|C1440916|Lithium.plasma|elii,phsu|||lithium plasma||||824|86|99
SE|00000000||tx|1|entity|C0146226|Toradol|orch,phsu|||TORADOL||||888|115|121
SE|00000000||tx|1|relation|5|1|C0146226|Toradol|orch,phsu|orch|||TORADOL||||1000|15|21|NOM|INTERACTS_WITH||5|10|5|2|C0023870|Lithium|elii,phsu|elii|||lithium||||888|33|39


SE|00000000||tx|1|text|Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||Lithium||||1000|1|7
SE|00000000||tx|1|entity|C1321706|valdecoxib 40 MG|clnd|||Valdecoxib 40 mg||||908|10|25
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||908|27|29
SE|00000000||tx|1|entity|C1547085|7 days|tmco|||7 days||||1000|35|40
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|51|61
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decreases||||888|63|71
SE|00000000||tx|1|entity|C1441405|Lithium.serum|elii,phsu|||lithium serum||||901|76|88
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||901|90|98
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|110|114
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|116|124
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||566|143|148
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||566|150|154
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|177|183
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|185|189
SE|00000000||tx|1|relation|7|3|C1441405|Lithium.serum|elii,phsu|elii|||lithium serum||||901|76|88|VERB|compared_with||165|172|2|1|C0023870|Lithium|elii,phsu|elii|||lithium||||1000|177|183
SE|00000000||tx|1|relation|4|3|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|orch|||BID||||908|27|29|PREP|COEXISTS_WITH||73|74|5|1|C1441405|Lithium.serum|elii,phsu|elii|||lithium serum||||901|76|88
SE|00000000||tx|1|relation|4|3|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|orch|||BID||||908|27|29|PREP|COEXISTS_WITH||73|74|5|1|C0023870|Lithium|elii,phsu|elii|||lithium||||1000|177|183
SE|00000000||tx|1|relation|3|1|C0229671|Serum|bdsu|bdsu|||serum||||566|150|154|PREP|PART_OF||132|135|6|1|C0022646|Kidney|bpoc|bpoc|||renal||||888|110|114


SE|00000000||tx|1|text|The potential for increased sedation when guanfacine is given with other CNS-depressant drug should be appreciated.
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|5|13
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|19|27
SE|00000000||tx|1|entity|C0600097|Sedation|sosy|||sedation||||888|29|36
SE|00000000||tx|1|entity|C0079466|Guanfacine|orch,phsu|||guanfacine||||1000|43|52
SE|00000000||tx|1|entity|C0007680|Central Nervous System Agents|phsu|||CNS-depressant drug||||913|74|92
SE|00000000||tx|1|relation|1|1|C0007680|Central Nervous System Agents|phsu|phsu|||CNS-depressant drug||||913|74|92|VERB|COEXISTS_WITH||57|61|3|1|C0079466|Guanfacine|orch,phsu|orch|||guanfacine||||1000|43|52


SE|00000000||tx|1|text|Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).
SE|00000000||tx|1|entity|C1550147|Pretreatment|sbst|||Pretreatment||||1000|1|12
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|17|34
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multiple||||888|41|48
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|50|54
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|59|66
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|82|87
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|89|92
SE|00000000||tx|1|entity|C0935987|Gleevec|orch,phsu|||Gleevec||||1000|97|103
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||822|106|114
SE|00000000||tx|1|entity|C0935987|Gleevec|orch,phsu|||Gleevec||||822|116|122
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||822|124|127
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||822|129|132
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||822|134|142
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||827|151|154
SE|00000000||tx|1|entity|C1707650|Decreased Peak Drug Blood Concentration|fndg|||decreased mean cmax||||913|186|204
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|210|212


SE|00000000||tx|1|text|The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|12|25
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|30|54
SE|00000000||tx|1|entity|C0020264|Hydrocodone|orch,phsu|||hydrocodone||||872|61|71
SE|00000000||tx|1|entity|C1521827|Preparation|ftcn|||preparations||||872|73|84
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|103|108
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressant||||1000|124|137
SE|00000000||tx|1|entity|C0020264|Hydrocodone|orch,phsu|||hydrocodone||||1000|142|152


SE|00000000||tx|1|text|Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||Cyclosporin||||1000|1|11
SE|00000000||tx|1|entity|C1293116|Introduction procedure|hlca|||introduction||||1000|20|31
SE|00000000||tx|1|entity|C0008269|Chloroquine|orch,phsu|||chloroquine||||1000|36|46
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|49|52
SE|00000000||tx|1|entity|C1522492|Formation|ftcn|||form||||888|54|57
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|70|77
SE|00000000||tx|1|entity|C0580936|Serum cyclosporin measurement|lbpr|||serum cyclosporin level||||1000|82|104


SE|00000000||tx|1|text|Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|15|21
SE|00000000||tx|1|entity|C1698656|Vaprisol|orch,phsu|||VAPRISOL||||1000|44|51
SE|00000000||tx|1|entity|C0871685|Clinician|prog|||clinician||||1000|58|66
SE|00000000||tx|1|entity|C0239110|Consciousness clear|fndg|||alert||||1000|78|82
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||1000|106|114
SE|00000000||tx|1|entity|C0337449|Digoxin measurement|lbpr|||digoxin levels||||1000|119|132


SE|00000000||tx|1|text|Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
SE|00000000||tx|1|entity|C0937846|Esomeprazole|orch,phsu|||esomeprazole||||1000|12|23
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||824|62|66
SE|00000000||tx|1|entity|C1168023|Gastric pH|diap|||gastric pH||||824|74|83
SE|00000000||tx|1|entity|C1521761|Factor|ftcn|||determinant||||861|101|111
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|116|130
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|137|148
SE|00000000||tx|1|entity|C0302206|Iron salt|inch|||iron salts||||966|151|160
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|166|172


SE|00000000||tx|1|text|There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;
SE|00000000||tx|1|entity|C0700321|Small|qnco|||small||||888|13|17
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||888|19|26
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|35|43
SE|00000000||tx|1|entity|C0055147|Cetirizine|orch,phsu|||cetirizine||||1000|48|57
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||790|78|81
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|86|97


SE|00000000||tx|1|text|The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.
SE|00000000||tx|1|entity|C0009393|Color|irda,npop|||color||||861|13|17
SE|00000000||tx|1|entity|C1522492|Formation|ftcn|||formation||||1000|33|41
SE|00000000||tx|1|entity|C0439855|Complex|qlco|||complex||||861|62|68
SE|00000000||tx|1|entity|C0060405|cefdinir|antb,orch|||cefdinir||||1000|78|85
SE|00000000||tx|1|entity|C0699900|Catabolism|orgf|||breakdown||||888|94|102
SE|00000000||tx|1|entity|C1514468|product|enty|||products||||888|104|111
SE|00000000||tx|1|entity|C0302583|Iron|bacs,elii,phsu|||iron||||1000|117|120
SE|00000000||tx|1|entity|C1281182|Entire gastrointestinal tract|bdsy|||gastrointestinal tract||||1000|129|150


SE|00000000||tx|1|text|The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.
SE|00000000||tx|1|entity|C2348397|Elimination Half Life|qnco|||elimination half life||||1000|5|25
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||midazolam||||1000|30|38
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||triazolam||||861|44|52
SE|00000000||tx|1|entity|C0450316|1/5|qnco|||1.5||||812|70|72
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||812|78|81
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|113|121


SE|00000000||tx|1|text|Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||Corticosteroids||||1000|1|15
SE|00000000||tx|1|entity|C0439849|Relationships|qlco|||relationship||||1000|20|31
SE|00000000||tx|1|entity|C0205245|Functional|ftcn|||functional||||888|36|45
SE|00000000||tx|1|entity|C0680242|antagonism|socb|||antagonism||||888|47|56
SE|00000000||tx|1|entity|C1520059|Vitamin D Analog|vita|||vitamin D analogues||||983|73|91
SE|00000000||tx|1|entity|C0006675|Calcium|bacs,elii,phsu|||calcium||||694|108|114
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|132|146
SE|00000000||tx|1|entity|C0006675|Calcium|bacs,elii,phsu|||calcium||||694|163|169


SE|00000000||tx|1|text|INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|1|7
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|34|40
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentration||||1000|76|94
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||1000|112|120
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|125|131
SE|00000000||tx|1|relation|4|1|C0012265|Digoxin|carb,phsu,strd|carb|||digoxin||||1000|34|40|VERB|COEXISTS_WITH||9|13|1|1|C0700798|Indocin|orch,phsu|orch|||INDOCIN||||1000|1|7


SE|00000000||tx|1|text|Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).
SE|00000000||tx|1|entity|C1096917|Trisenox|inch,phsu|||TRISENOX||||1000|25|32
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||1000|63|73
SE|00000000||tx|1|entity|C0429028|QT interval feature (observable entity)|clna|||QT interval||||1000|96|106
SE|00000000||tx|1|entity|C0205423|Certain (qualifier value)|qlco|||certain||||751|114|120
SE|00000000||tx|1|entity|C0003195|Anti-Arrhythmia Agents|phsu|||antiarrhythmics||||751|122|136
SE|00000000||tx|1|entity|C0039943|Thioridazine|orch,phsu|||thioridazine||||1000|141|152
SE|00000000||tx|1|entity|C0151613|Electrolytes abnormal|fndg|||electrolyte abnormalities||||983|166|190
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|201|209
SE|00000000||tx|1|entity|C0002679|Amphotericin B|antb,orch|||amphotericin B||||1000|214|227
SE|00000000||tx|1|relation|6|4|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||1000|63|73|VERB|CAUSES||158|161|3|1|C0151613|Electrolytes abnormal|fndg|fndg|||electrolyte abnormalities||||983|166|190


SE|00000000||tx|1|text|Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||802|23|29
SE|00000000||tx|1|entity|C0009079|Clozapine|orch,phsu|||Clozapine||||1000|34|42
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||901|105|110
SE|00000000||tx|1|entity|C0007680|Central Nervous System Agents|phsu|||CNS-active drugs||||901|101|116
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|121|127


SE|00000000||tx|1|text|apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.
SE|00000000||tx|1|entity|C0003596|Apomorphine|orch,phsu|||apomorphine||||851|1|11
SE|00000000||tx|1|entity|C0332152|Before|tmco|||prior||||851|15|19
SE|00000000||tx|1|entity|C0232478|Ingestion|biof|||ingestion||||851|21|29
SE|00000000||tx|1|entity|C0058371|diphenidol|orch,phsu|||diphenidol||||1000|34|43
SE|00000000||tx|1|entity|C0013973|Emetics|phsu|||emetic||||694|62|67
SE|00000000||tx|1|entity|C0003596|Apomorphine|orch,phsu|||apomorphine||||1000|81|91
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|100|108
SE|00000000||tx|1|entity|C0032343|Poisoning|inpo|||poisoning||||1000|113|121
SE|00000000||tx|1|relation|4|1|C0003596|Apomorphine|orch,phsu|phsu|||apomorphine||||1000|81|91|NOM|TREATS||100|108|1|1|C0032343|Poisoning|inpo|inpo|||poisoning||||1000|113|121


SE|00000000||tx|1|text|Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||Plasma||||694|1|6
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|18|20
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||1000|26|35
SE|00000000||tx|1|entity|C0016277|Fluconazole|orch,phsu|||fluconazole||||1000|80|90
SE|00000000||tx|1|entity|C0450361|38|inpr|||38%||||1000|96|98
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|125|136


SE|00000000||tx|1|text|Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||Interactions||||966|1|12
SE|00000000||tx|1|entity|C0007680|Central Nervous System Agents|phsu|||CNS Agents||||1000|25|34
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|37|46
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|48|50
SE|00000000||tx|1|entity|C1450007|Levo-Dromoran|orch,phsu|||Levo-Dromoran||||1000|55|67
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||central nervous system depressants||||1000|78|111
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|118|124
SE|00000000||tx|1|entity|C0036557|Sedatives|phsu|||sedatives||||1000|127|135
SE|00000000||tx|1|entity|C0020591|Hypnotics|phsu|||hypnotics||||1000|138|146
SE|00000000||tx|1|entity|C0242402|Opioids|hops,orch,phsu|||opioids||||1000|155|161
SE|00000000||tx|1|entity|C0017302|General anesthetic drugs|phsu|||general anesthetics||||1000|164|182
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|185|196
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|199|223
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|226|239
SE|00000000||tx|1|entity|C0040614|Tranquilizing Agents|phsu|||tranquilizers||||1000|242|254
SE|00000000||tx|1|entity|C0037250|Skeletal Muscle Relaxants|phsu|||skeletal muscle relaxants||||1000|257|281
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|287|300
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|317|324
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||central nervous system depressant||||888|326|358
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|360|366
SE|00000000||tx|1|relation|17|1|C0003360|Antihistamines|orch,phsu|orch|||antihistamines||||1000|287|300|NOM|INTERACTS_WITH||360|366|17|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressant||||888|326|358
SE|00000000||tx|1|relation|17|1|C0037250|Skeletal Muscle Relaxants|phsu|phsu|||skeletal muscle relaxants||||1000|257|281|NOM|INTERACTS_WITH||360|366|17|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressant||||888|326|358
SE|00000000||tx|1|relation|17|1|C0040614|Tranquilizing Agents|phsu|phsu|||tranquilizers||||1000|242|254|NOM|INTERACTS_WITH||360|366|17|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressant||||888|326|358
SE|00000000||tx|1|relation|17|1|C0031436|Phenothiazines|orch,phsu|orch|||phenothiazines||||1000|226|239|NOM|INTERACTS_WITH||360|366|17|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressant||||888|326|358
SE|00000000||tx|1|relation|17|1|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|199|223|NOM|INTERACTS_WITH||360|366|17|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressant||||888|326|358
SE|00000000||tx|1|relation|17|1|C0004745|Barbiturates|orch,phsu|orch|||barbiturates||||1000|185|196|NOM|INTERACTS_WITH||360|366|17|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressant||||888|326|358
SE|00000000||tx|1|relation|17|1|C0017302|General anesthetic drugs|phsu|phsu|||general anesthetics||||1000|164|182|NOM|INTERACTS_WITH||360|366|17|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressant||||888|326|358
SE|00000000||tx|1|relation|17|1|C0242402|Opioids|hops,orch,phsu|orch|||opioids||||1000|155|161|NOM|INTERACTS_WITH||360|366|17|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressant||||888|326|358
SE|00000000||tx|1|relation|17|1|C0020591|Hypnotics|phsu|phsu|||hypnotics||||1000|138|146|NOM|INTERACTS_WITH||360|366|17|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressant||||888|326|358
SE|00000000||tx|1|relation|17|1|C0036557|Sedatives|phsu|phsu|||sedatives||||1000|127|135|NOM|INTERACTS_WITH||360|366|17|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressant||||888|326|358
SE|00000000||tx|1|relation|17|1|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|118|124|NOM|INTERACTS_WITH||360|366|17|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressant||||888|326|358


SE|00000000||tx|1|text|Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|12|14
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|19|30
SE|00000000||tx|1|entity|C0014710|Ergotamine|orch,phsu|||ergotamine||||1000|36|45
SE|00000000||tx|1|entity|C0012291|Dihydroergotamine|orch,phsu|||dihydroergotamine||||1000|50|66
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|96|103
SE|00000000||tx|1|entity|C0205178|acute|tmco|||acute||||802|110|114
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||802|122|129
SE|00000000||tx|1|entity|C0205100|Peripheral|spco|||peripheral||||790|155|164
SE|00000000||tx|1|entity|C0042396|Vascular constriction (function)|ortf|||vasospasm||||790|166|174
SE|00000000||tx|1|entity|C0392699|Dysesthesia|sosy|||dysesthesia||||1000|180|190
SE|00000000||tx|1|relation|4|1|C0012291|Dihydroergotamine|orch,phsu|phsu|||dihydroergotamine||||1000|50|66|PREP|TREATS||88|89|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|96|103
SE|00000000||tx|1|relation|4|1|C0014710|Ergotamine|orch,phsu|phsu|||ergotamine||||1000|36|45|PREP|TREATS||88|89|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|96|103
SE|00000000||tx|1|relation|3|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||802|122|129|PREP|PROCESS_OF||105|108|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|96|103
SE|00000000||tx|1|relation|0|0|C0012291|Dihydroergotamine|orch,phsu|phsu|||dihydroergotamine||||1000|50|66|INFER|TREATS(INFER)||88|89|0|0|C0600688|Toxic effect|inpo|inpo|||toxicity||||802|122|129
SE|00000000||tx|1|relation|0|0|C0014710|Ergotamine|orch,phsu|phsu|||ergotamine||||1000|36|45|INFER|TREATS(INFER)||88|89|0|0|C0600688|Toxic effect|inpo|inpo|||toxicity||||802|122|129


SE|00000000||tx|1|text|Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||1000|23|27
SE|00000000||tx|1|entity|C0876196|Trileptal|orch,phsu|||Trileptal||||1000|32|40
SE|00000000||tx|1|entity|C1704243|Greater|qnco|||greater||||1000|42|48
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|60|65
SE|00000000||tx|1|entity|C0677850|adjuvant therapy|topp|||adjunctive therapy||||1000|74|91
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|96|103
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|112|115
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|120|128


SE|00000000||tx|1|text|Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
SE|00000000||tx|1|entity|C0439861|Substance|sbst|||Substances||||1000|1|10
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||838|21|26
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||838|28|37
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||861|42|47
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||861|49|56
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|63|74
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|80|91
SE|00000000||tx|1|entity|C1122962|gefitinib|orch,phsu|||gefitinib||||888|103|111
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|113|122
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||852|128|135
SE|00000000||tx|1|entity|C1122962|gefitinib|orch,phsu|||gefitinib||||852|137|145
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||852|147|167
SE|00000000||tx|1|relation|6|4|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||861|42|47|VERB|INHIBITS||94|101|2|1|C1122962|gefitinib|orch,phsu|orch|||gefitinib||||888|103|111
SE|00000000||tx|1|relation|6|4|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||861|42|47|VERB|INHIBITS||94|101|2|1|C1122962|gefitinib|orch,phsu|orch|||gefitinib||||852|137|145


SE|00000000||tx|1|text|Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0205450|Four|qnco|||four||||888|26|29
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|31|38
SE|00000000||tx|1|entity|C0041700|United Kingdom|geoa|||United Kingdom||||1000|47|60
SE|00000000||tx|1|entity|C0730991|Foscavir|opco,phsu|||FOSCAVIR||||1000|67|74
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||888|80|90
SE|00000000||tx|1|entity|C0030863|Pentamidine|orch,phsu|||pentamidine||||888|92|102
SE|00000000||tx|1|entity|C0015127|Etiology aspects|ftcn|||caused||||872|113|118
SE|00000000||tx|1|entity|C0020598|Hypocalcemia|patf|||hypocalcemia||||872|120|131
SE|00000000||tx|1|relation|5|3|C0730991|Foscavir|opco,phsu|phsu|||FOSCAVIR||||1000|67|74|NOM|TREATS||13|21|5|1|C0030705|Patients|podg,humn|podg|||patients||||888|31|38
SE|00000000||tx|1|relation|5|3|C0030863|Pentamidine|orch,phsu|phsu|||pentamidine||||888|92|102|NOM|TREATS||13|21|5|1|C0030705|Patients|podg,humn|podg|||patients||||888|31|38


SE|00000000||tx|1|text|While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|7|9
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||888|35|41
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|43|47
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|64|73
SE|00000000||tx|1|entity|C0085208|Bupropion|orch,phsu|||bupropion||||1000|78|86
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|95|107
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|110|122
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|125|133
SE|00000000||tx|1|relation|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|43|47|VERB|STIMULATES||53|58|5|2|C0085208|Bupropion|orch,phsu|orch|||bupropion||||1000|78|86


SE|00000000||tx|1|text|Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||Cyclosporine||||1000|1|12
SE|00000000||tx|1|entity|C0085149|Tacrolimus|orch,phsu|||tacrolimus||||1000|15|24
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||888|30|36
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|38|51
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|80|89
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||888|94|105
SE|00000000||tx|1|entity|C0332183|Frequent|tmco|||frequently||||861|119|128
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||1000|150|153
SE|00000000||tx|1|entity|C0205449|Three|qnco|||three||||851|164|168
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||851|170|173
SE|00000000||tx|1|entity|C1514468|product|enty|||products||||851|175|182


SE|00000000||tx|1|text|however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.
SE|00000000||tx|1|entity|C0034665|Ranitidine|orch,phsu|||ranitidine||||888|20|29
SE|00000000||tx|1|entity|C0585327|Every twelve hours|tmco|||q12h||||888|31|34
SE|00000000||tx|1|entity|C1442459|3 Days|tmco|||3 days||||1000|40|45
SE|00000000||tx|1|entity|C0055014|ceftibuten|antb,orch|||ceftibuten||||888|61|70
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||C max||||888|72|76
SE|00000000||tx|1|entity|C0450348|23|qnco|||23%||||1000|81|83
SE|00000000||tx|1|entity|C0055014|ceftibuten|antb,orch|||ceftibuten||||888|89|98
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|100|102


SE|00000000||tx|1|text|Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
SE|00000000||tx|1|entity|C0002680|Ampicillin|antb,orch|||Ampicillin||||888|1|10
SE|00000000||tx|1|entity|C0002645|Amoxicillin|antb,orch|||Amoxicillin||||888|12|22
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|28|35
SE|00000000||tx|1|entity|C0439603|Frequencies (time pattern)|tmco|||frequency||||1000|44|52
SE|00000000||tx|1|entity|C0015230|Exanthema|dsyn|||skin rash||||1000|57|65
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|91|98
SE|00000000||tx|1|entity|C0002680|Ampicillin|antb,orch|||ampicillin||||1000|110|119
SE|00000000||tx|1|entity|C0002645|Amoxicillin|antb,orch|||amoxicillin||||861|124|134
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|154|164
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|178|185
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|195|197
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|214|218
SE|00000000||tx|1|relation|4|1|C0015230|Exanthema|dsyn|dsyn|||skin rash||||1000|57|65|PREP|PROCESS_OF||85|89|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|91|98
SE|00000000||tx|1|relation|5|1|C0002680|Ampicillin|antb,orch|antb|||ampicillin||||1000|110|119|VERB|ADMINISTERED_TO||100|108|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|91|98
SE|00000000||tx|1|relation|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|214|218|VERB|ADMINISTERED_TO|negation|199|207|9|1|C0030705|Patients|podg,humn|humn|||patients||||1000|178|185


SE|00000000||tx|1|text|Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||888|13|21
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||888|23|33
SE|00000000||tx|1|entity|C0674428|efavirenz|orch,phsu|||efavirenz||||1000|38|46
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives||||1000|53|71
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|77|79
SE|00000000||tx|1|entity|C0004764|Contraception, Barrier|topp|||barrier contraception||||1000|128|148
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives||||1000|180|198
SE|00000000||tx|1|relation|5|2|C0009905|Contraceptives, Oral|phsu|phsu|||oral contraceptives||||1000|53|71|NOM|INTERACTS_WITH||23|33|5|1|C0674428|efavirenz|orch,phsu|orch|||efavirenz||||1000|38|46
SE|00000000||tx|1|relation|5|1|C0004764|Contraception, Barrier|topp|topp|||barrier contraception||||1000|128|148|VERB|USES||160|163|1|1|C0009905|Contraceptives, Oral|phsu|phsu|||oral contraceptives||||1000|180|198


SE|00000000||tx|1|text|If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine.
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||888|8|10
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|12|16
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta blocker||||1000|42|53
SE|00000000||tx|1|entity|C0443302|Several|qnco|||several||||888|75|81
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||888|83|86
SE|00000000||tx|1|entity|C0439833|Gradual|qlco|||gradual||||888|99|105
SE|00000000||tx|1|entity|C2349954|Withdraw (activity)|acty|||withdrawal||||888|107|116
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||1000|121|129


SE|00000000||tx|1|text|Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.
SE|00000000||tx|1|entity|C0022180|Isoflurane|orch,phsu|||Isoflurane||||1000|1|10
SE|00000000||tx|1|entity|C0014277|Enflurane|orch,phsu|||enflurane||||1000|13|21
SE|00000000||tx|1|entity|C0018549|Halothane|orch,phsu|||halothane||||1000|28|36
SE|00000000||tx|1|entity|C0133255|Nuromax|orch,phsu|||NUROMAX||||1000|59|65


SE|00000000||tx|1|text|The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|5|8
SE|00000000||tx|1|entity|C0028356|Norethindrone|horm,phsu,strd|||norethindrone||||1000|13|25
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||827|35|40
SE|00000000||tx|1|entity|C0060926|gabapentin|orch,phsu|||gabapentin||||1000|74|83


SE|00000000||tx|1|text|Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.
SE|00000000||tx|1|entity|C0036572|Seizures|sosy|||Seizures||||1000|1|8
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|32|39
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolone||||888|56|64
SE|00000000||tx|1|entity|C0456387|Class|inpr|||class||||888|66|70
SE|00000000||tx|1|entity|C1136254|Microbicides|phsu|||antimicrobial||||1000|72|84
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory drug||||876|94|128
SE|00000000||tx|1|entity|C0060156|fenbufen|orch,phsu|||fenbufen||||876|130|137
SE|00000000||tx|1|relation|0|0|C0060156|fenbufen|orch,phsu|orch|||fenbufen||||876|130|137|MOD/HEAD|ISA||94|137|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory drug||||876|94|128
SE|00000000||tx|1|relation|1|1|C0036572|Seizures|sosy|sosy|||Seizures||||1000|1|8|PREP|PROCESS_OF||29|30|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|32|39


SE|00000000||tx|1|text|Iron salts may reduce the bioavailability of carbidopa and levodopa.
SE|00000000||tx|1|entity|C0302206|Iron salt|inch|||Iron salts||||966|1|10
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|27|41
SE|00000000||tx|1|entity|C0006982|Carbidopa|orch,phsu|||carbidopa||||1000|46|54
SE|00000000||tx|1|entity|C0023570|Levodopa|aapp,nsba,phsu|||levodopa||||1000|60|67
SE|00000000||tx|1|relation|1|1|C0302206|Iron salt|inch|inch|||Iron salts||||966|1|10|VERB|INHIBITS||16|21|3|2|C0006982|Carbidopa|orch,phsu|orch|||carbidopa||||1000|46|54
SE|00000000||tx|1|relation|1|1|C0302206|Iron salt|inch|inch|||Iron salts||||966|1|10|VERB|INHIBITS||16|21|3|2|C0023570|Levodopa|aapp,gngm,nsba,phsu|gngm|||levodopa||||1000|60|67


SE|00000000||tx|1|text|At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor.
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|4|8
SE|00000000||tx|1|entity|C0439230|week|tmco|||weeks||||785|12|16
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuation||||1000|40|54
SE|00000000||tx|1|entity|C0011786|Dexfenfluramine|orch,phsu|||dexfenfluramine||||1000|59|73
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|79|88
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|93|101
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitor||||1000|110|122
SE|00000000||tx|1|relation|5|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||1000|93|101|PREP|USES||103|106|1|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|phsu|||MAO inhibitor||||1000|110|122


SE|00000000||tx|1|text|Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0033228|Fenofibrate|orch,phsu|||fenofibrate||||1000|31|41
SE|00000000||tx|1|entity|C0205163|Equal|qlco|||equivalent||||1000|44|53
SE|00000000||tx|1|entity|C0723893|Tricor|orch,phsu|||TRICOR||||861|64|69
SE|00000000||tx|1|entity|C0085542|Pravastatin|orch,phsu|||pravastatin||||1000|77|87
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||1000|102|106
SE|00000000||tx|1|entity|C1547061|10 days|tmco|||10 days||||1000|112|118
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||861|156|159
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|165|167
SE|00000000||tx|1|entity|C0042295|Values|qlco|||values||||888|169|174
SE|00000000||tx|1|entity|C0085542|Pravastatin|orch,phsu|||pravastatin||||1000|180|190
SE|00000000||tx|1|entity|C1514721|Range|qnco|||range||||1000|200|204
SE|00000000||tx|1|entity|C0450388|69|inpr|||69%||||888|211|213
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||888|215|222
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|232|239
SE|00000000||tx|1|entity|C1514721|Range|qnco|||range||||1000|251|255
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|266|273
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|283|290
SE|00000000||tx|1|entity|C0700307|hydroxyl group|inch|||hydroxy||||775|319|325
SE|00000000||tx|1|entity|C1668248|Iso|fish|||iso||||775|327|329
SE|00000000||tx|1|entity|C0085542|Pravastatin|orch,phsu|||pravastatin||||775|331|341
SE|00000000||tx|1|entity|C0450382|55|inpr|||55%||||1000|346|348
SE|00000000||tx|1|entity|C1514721|Range|qnco|||range||||1000|351|355
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|366|373
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|383|390
SE|00000000||tx|1|entity|C1514721|Range|qnco|||range||||1000|402|406
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|417|424
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|434|441
SE|00000000||tx|1|entity|C0686750|Well adult|fndg|||healthy adults||||890|464|477
SE|00000000||tx|1|relation|23|7|C0085542|Pravastatin|orch,phsu|phsu|||pravastatin||||775|331|341|PREP|TREATS||458|459|1|1|C0686750|Well adult|fndg|fndg|||healthy adults||||890|464|477
SE|00000000||tx|1|relation|23|7|C0085542|Pravastatin|orch,phsu|phsu|||pravastatin||||1000|180|190|PREP|TREATS||458|459|1|1|C0686750|Well adult|fndg|fndg|||healthy adults||||890|464|477


SE|00000000||tx|1|text|Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|37|43
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|48|55
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blockers||||1000|67|79
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||861|85|93
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blocker||||1000|113|124
SE|00000000||tx|1|entity|C0439834|Slow|qlco|||slowly||||813|149|154
SE|00000000||tx|1|entity|C0585022|During day|tmco|||over several days||||813|156|172
SE|00000000||tx|1|entity|C0439833|Gradual|qlco|||gradual||||888|185|191
SE|00000000||tx|1|entity|C2349954|Withdraw (activity)|acty|||withdrawal||||888|193|202
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||1000|207|215
SE|00000000||tx|1|relation|1|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||1000|37|43|PREP|TREATS||45|46|7|1|C0030705|Patients|podg,humn|podg|||patients||||1000|48|55
SE|00000000||tx|1|relation|6|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blockers||||1000|67|79|VERB|ADMINISTERED_TO||57|65|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|48|55


SE|00000000||tx|1|text|Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|19|28
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulants||||1000|51|69
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|76|91
SE|00000000||tx|1|entity|C0443302|Several|qnco|||several||||888|136|142
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||888|144|147
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||901|155|165
SE|00000000||tx|1|entity|C0150270|Medication Management|hlca|||drug administration||||901|167|185


SE|00000000||tx|1|text|The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|17|19
SE|00000000||tx|1|entity|C0042397|Vasoconstrictor Agents|phsu|||vasopressors||||1000|24|35
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|55|60
SE|00000000||tx|1|entity|C0014704|Ergonovine|orch,phsu|||ergonovine||||1000|71|80
SE|00000000||tx|1|entity|C0030094|Oxytocics|phsu|||oxytocic drugs||||1000|92|105
SE|00000000||tx|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||861|128|139
SE|00000000||tx|1|relation|5|1|C0030094|Oxytocics|phsu|phsu|||oxytocic drugs||||1000|92|105|VERB|CAUSES||111|116|1|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||861|128|139


SE|00000000||tx|1|text|Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
SE|00000000||tx|1|entity|C0010762|Cytochrome P450|aapp,enzy|||Cytochrome P-450||||756|1|16
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|36|44
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|47|59
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|65|77
SE|00000000||tx|1|entity|C0009011|Clonazepam|orch,phsu|||clonazepam||||888|87|96
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|98|107
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||802|121|133
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||802|139|146
SE|00000000||tx|1|entity|C1271587|Plasma clonazepam level|lbpr|||plasma clonazepam levels||||988|151|174
SE|00000000||tx|1|relation|4|1|C0031412|Phenobarbital|orch,phsu|orch|||phenobarbital||||1000|65|77|VERB|STIMULATES||80|85|3|1|C0009011|Clonazepam|orch,phsu|orch|||clonazepam||||888|87|96
SE|00000000||tx|1|relation|4|1|C0006949|Carbamazepine|orch,phsu|orch|||carbamazepine||||1000|47|59|VERB|STIMULATES||80|85|3|1|C0009011|Clonazepam|orch,phsu|orch|||clonazepam||||888|87|96
SE|00000000||tx|1|relation|4|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|36|44|VERB|STIMULATES||80|85|3|1|C0009011|Clonazepam|orch,phsu|orch|||clonazepam||||888|87|96


SE|00000000||tx|1|text|Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.
SE|00000000||tx|1|entity|C0205448|Two|qnco|||Two||||1000|1|3
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||827|11|18
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneously||||1000|26|39
SE|00000000||tx|1|entity|C1176939|vardenafil 10 MG|clnd|||Vardenafil 10 mg||||1000|46|61
SE|00000000||tx|1|entity|C0257343|tamsulosin|orch,phsu|||tamsulosin||||791|67|76
SE|00000000||tx|1|entity|C0488055|Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative|clna|||systolic blood pressure||||923|108|130
SE|00000000||tx|1|entity|C0439475|mmHg|qnco|||mm Hg||||901|141|145


SE|00000000||tx|1|text|Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|32|41
SE|00000000||tx|1|entity|C0585291|Four times daily|tmco|||QID||||790|53|55
SE|00000000||tx|1|entity|C0750489|apparent|idcn|||apparent||||775|73|80
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||775|82|85
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||775|87|95
SE|00000000||tx|1|entity|C0060926|gabapentin|orch,phsu|||gabapentin||||1000|100|109
SE|00000000||tx|1|entity|C0812399|Creatinine clearance|fndg|||creatinine clearance||||1000|127|146
SE|00000000||tx|1|relation|5|4|C0060926|gabapentin|orch,phsu|orch|||gabapentin||||1000|100|109|NOM|COEXISTS_WITH||20|27|5|1|C0008783|Cimetidine|orch,phsu|orch|||cimetidine||||1000|32|41


SE|00000000||tx|1|text|Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function.
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||Furosemide||||1000|1|10
SE|00000000||tx|1|entity|C0235280|Ototoxicity|inpo|||ototoxic||||853|29|36
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||853|38|46
SE|00000000||tx|1|entity|C0003233|Antibiotics, Aminoglycoside|antb,carb|||aminoglycoside antibiotics||||1000|51|76
SE|00000000||tx|1|entity|C0341697|Renal impairment|dsyn|||impaired renal function||||1000|109|131


SE|00000000||tx|1|text|The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady state||||877|5|16
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||877|18|38
SE|00000000||tx|1|entity|C0020934|Imipramine|orch,phsu|||imipramine||||1000|43|52
SE|00000000||tx|1|entity|C0011685|Desipramine|orch,phsu|||desipramine||||1000|58|68
SE|00000000||tx|1|entity|C1510992|Average|qnco|||average||||1000|108|114
SE|00000000||tx|1|entity|C0450355|31|inpr|||31%||||1000|119|121
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|153|163
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||888|183|192
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||888|194|200
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||1000|205|209
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|219|224


SE|00000000||tx|1|text|Non-steroidal Anti-inflammatory drugs: In some patients, The administration of a Non-steroidal Anti-inflammatory agent can reduce The diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||Non-steroidal Anti-inflammatory drugs||||991|1|37
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|48|55
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||Non-steroidal Anti-inflammatory agent||||1000|82|118
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||888|135|142
SE|00000000||tx|1|entity|C0597421|saluretic|phsu|||natriuretic||||888|145|155
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|179|185
SE|00000000||tx|1|entity|C0445022|Loop|spco|||loop||||1000|190|193
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||694|196|204
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|218|235
SE|00000000||tx|1|relation|1|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||Non-steroidal Anti-inflammatory drugs||||991|1|37|PREP|TREATS||40|41|8|1|C0030705|Patients|podg,humn|podg|||patients||||1000|48|55
SE|00000000||tx|1|relation|4|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||Non-steroidal Anti-inflammatory agent||||1000|82|118|VERB|INHIBITS||124|129|5|1|C0597421|saluretic|phsu|phsu|||natriuretic||||888|145|155


SE|00000000||tx|1|text|Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0235062|Induction of neuromuscular blockade|topp|||neuromuscular blocking||||890|29|50
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||890|52|57
SE|00000000||tx|1|entity|C0592193|Tracrium|orch,phsu|||TRACRIUM||||1000|62|69
SE|00000000||tx|1|entity|C0014277|Enflurane|orch,phsu|||enflurane||||1000|80|88


SE|00000000||tx|1|text|Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.
SE|00000000||tx|1|entity|C0220806|Chemicals|chem|||chemical||||694|14|21
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|38|49
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|55|66
SE|00000000||tx|1|entity|C0085170|Astemizole|orch,phsu|||astemizole||||1000|89|98
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|105|116


SE|00000000||tx|1|text|Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0234119|Neuromuscular inhibition|dsyn|||neuromuscular blocking||||890|29|50
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||890|52|57
SE|00000000||tx|1|entity|C0592193|Tracrium|orch,phsu|||TRACRIUM||||1000|62|69
SE|00000000||tx|1|entity|C0014277|Enflurane|orch,phsu|||enflurane||||1000|80|88
SE|00000000||tx|1|entity|C0022180|Isoflurane|orch,phsu|||isoflurane||||1000|90|99
SE|00000000||tx|1|entity|C0018549|Halothane|orch,phsu|||halothane||||1000|101|109
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||888|111|117
SE|00000000||tx|1|entity|C0003232|Antibiotics|antb|||antibiotics||||888|119|129
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycosides||||1000|147|161
SE|00000000||tx|1|entity|C0032539|Polymyxins|aapp,antb|||polymyxins||||1000|167|176
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|178|184
SE|00000000||tx|1|entity|C0302211|Magnesium salt|inch,phsu|||magnesium salts||||1000|186|200
SE|00000000||tx|1|entity|C0033216|Procainamide|orch,phsu|||procainamide||||1000|202|213
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|219|227


SE|00000000||tx|1|text|Concurrent use of flurbiprofen and aspirin is therefore not recommended.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|12|14
SE|00000000||tx|1|entity|C0016377|Flurbiprofen|orch,phsu|||flurbiprofen||||1000|19|30
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|36|42
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|57|59


SE|00000000||tx|1|text|Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|12|17
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|23|29
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||966|62|69
SE|00000000||tx|1|entity|C0311392|Physical findings|fndg|||signs||||1000|104|108
SE|00000000||tx|1|entity|C0238242|LITHIUM TOXICITY|inpo|||lithium toxicity||||1000|113|128
SE|00000000||tx|1|relation|3|2|C0023870|Lithium|elii,phsu|phsu|||lithium||||1000|23|29|PREP|TREATS||100|102|2|1|C0311392|Physical findings|fndg|fndg|||signs||||1000|104|108
SE|00000000||tx|1|relation|3|2|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|12|17|PREP|TREATS||100|102|2|1|C0311392|Physical findings|fndg|fndg|||signs||||1000|104|108


SE|00000000||tx|1|text|Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.
SE|00000000||tx|1|entity|C0002752|Anafranil|orch,phsu|||Anafranil||||1000|9|17
SE|00000000||tx|1|entity|C0205250|High|qlco|||highly||||1000|22|27
SE|00000000||tx|1|entity|C0036825|Serum Proteins|aapp,bacs|||serum protein||||1000|38|50
SE|00000000||tx|1|entity|C0002752|Anafranil|orch,phsu|||Anafranil||||1000|75|83
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|88|95
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|110|114
SE|00000000||tx|1|entity|C0205250|High|qlco|||highly||||1000|125|130
SE|00000000||tx|1|entity|C0033684|Proteins|aapp,bacs|||protein||||1000|141|147
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|156|163
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|166|172
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|188|195
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|200|220
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|231|235
SE|00000000||tx|1|entity|C0879626|Adverse effects|patf|||adverse effects||||1000|263|277
SE|00000000||tx|1|relation|0|0|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein||||1000|141|147|SPEC|ISA||110|147|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|110|114
SE|00000000||tx|1|relation|10|1|C0002752|Anafranil|orch,phsu|orch|||Anafranil||||1000|75|83|NOM|ADMINISTERED_TO||57|70|10|2|C0030705|Patients|podg,humn|humn|||patients||||1000|88|95
SE|00000000||tx|1|relation|8|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|110|114|VERB|ADMINISTERED_TO||97|102|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|88|95
SE|00000000||tx|1|relation|12|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|231|235|VERB|CAUSES||250|258|1|1|C0879626|Adverse effects|patf|patf|||adverse effects||||1000|263|277
SE|00000000||tx|1|relation|0|0|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein||||1000|141|147|INFER|ADMINISTERED_TO(SPEC)||110|147|0|0|C0030705|Patients|podg,humn|humn|||patients||||1000|88|95


SE|00000000||tx|1|text|Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||Renal||||851|1|5
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||851|7|15
SE|00000000||tx|1|entity|C0242485|Measurement|ftcn|||measurements||||851|17|28
SE|00000000||tx|1|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAH||||966|33|35
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|61|71
SE|00000000||tx|1|entity|C0443131|Accurate (qualifier)|qlco|||accuracy||||888|73|80
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|85|92
SE|00000000||tx|1|entity|C0038760|Sulfonamides|orch,phsu|||sulfonamides||||1000|104|115
SE|00000000||tx|1|entity|C0033218|Procaine|orch,phsu|||procaine||||1000|118|125
SE|00000000||tx|1|relation|3|1|C0038760|Sulfonamides|orch,phsu|orch|||sulfonamides||||1000|104|115|VERB|ADMINISTERED_TO||94|102|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|85|92


SE|00000000||tx|1|text|Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.
SE|00000000||tx|1|entity|C0030695|Patient Monitoring|hlca|||patient monitoring||||901|22|39
SE|00000000||tx|1|entity|C2826232|Dose Adjustment|hlca|||dose adjustment||||1000|45|59
SE|00000000||tx|1|entity|C0025598|Metformin|orch,phsu|||metformin||||1000|64|72
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|92|99
SE|00000000||tx|1|entity|C0007716|Cephalexin|antb,orch|||cephalexin||||1000|122|131
SE|00000000||tx|1|entity|C0025598|Metformin|orch,phsu|||metformin||||1000|137|145
SE|00000000||tx|1|relation|3|1|C0025598|Metformin|orch,phsu|phsu|||metformin||||1000|64|72|PREP|TREATS||89|90|3|1|C0030705|Patients|podg,humn|podg|||patients||||861|92|99
SE|00000000||tx|1|relation|3|1|C0025598|Metformin|orch,phsu|phsu|||metformin||||1000|137|145|PREP|TREATS||89|90|3|1|C0030705|Patients|podg,humn|podg|||patients||||861|92|99
SE|00000000||tx|1|relation|2|1|C0007716|Cephalexin|antb,orch|antb|||cephalexin||||1000|122|131|VERB|ADMINISTERED_TO||115|120|4|1|C0030705|Patients|podg,humn|humn|||patients||||861|92|99


SE|00000000||tx|1|text|Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.
SE|00000000||tx|1|entity|C0282145|Diphenoxylate Hydrochloride|orch,phsu|||Diphenoxylate HCl||||1000|1|17
SE|00000000||tx|1|entity|C0596005|Atropine Sulfate|orch,phsu|||atropine sulfate||||1000|23|38
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|58|71
SE|00000000||tx|1|entity|C1706429|Male, Self-Reported|orga|||male||||888|89|92
SE|00000000||tx|1|entity|C0034693|Rattus norvegicus|mamm|||rats||||888|94|97
SE|00000000||tx|1|entity|C0282145|Diphenoxylate Hydrochloride|orch,phsu|||diphenoxylate hydrochloride||||1000|100|126
SE|00000000||tx|1|entity|C1979928|Microsomal|qlco|||microsomal||||861|161|170
SE|00000000||tx|1|entity|C0428321|Measurement of liver enzyme|lbpr|||hepatic microsomal enzyme||||861|153|177
SE|00000000||tx|1|entity|C0449913|System|ftcn|||system||||861|179|184
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|191|194
SE|00000000||tx|1|entity|C0439400|mg/day/kg|qnco|||mg/kg/day||||916|201|209
SE|00000000||tx|1|relation|2|1|C0596005|Atropine Sulfate|orch,phsu|orch|||atropine sulfate||||1000|23|38|VERB|INTERACTS_WITH||44|51|7|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||MAO inhibitors||||1000|58|71
SE|00000000||tx|1|relation|2|1|C0282145|Diphenoxylate Hydrochloride|orch,phsu|orch|||Diphenoxylate HCl||||1000|1|17|VERB|INTERACTS_WITH||44|51|7|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||MAO inhibitors||||1000|58|71


SE|00000000||tx|1|text|FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.
SE|00000000||tx|1|entity|C0701981|Fluothane|orch,phsu|||FLUOTHANE||||1000|1|9
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|24|29
SE|00000000||tx|1|entity|C0010464|Neuromuscular Nondepolarizing Agents|phsu|||non-depolarising muscle relaxants||||1000|34|66
SE|00000000||tx|1|entity|C0358430|Muscle relaxants|phsu|||muscle relaxant||||901|76|90
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||901|92|98
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycosides||||1000|103|117
SE|00000000||tx|1|relation|3|0|C0358430|Muscle relaxants|phsu|phsu|||muscle relaxant||||901|76|90|NOM|INTERACTS_WITH||92|98|1|1|C0002556|Aminoglycosides|carb,phsu|carb|||aminoglycosides||||1000|103|117


SE|00000000||tx|1|text|Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0025153|Mefloquine|orch,phsu|||Mefloquine||||1000|31|40
SE|00000000||tx|1|entity|C0600686|related compounds|chvs|||related compounds||||1000|52|68
SE|00000000||tx|1|entity|C0034417|Quinine|orch,phsu|||quinine||||1000|75|81
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|84|92
SE|00000000||tx|1|entity|C0008269|Chloroquine|orch,phsu|||chloroquine||||1000|98|108
SE|00000000||tx|1|entity|C0522055|Electrocardiogram abnormal|fndg|||electrocardiographic abnormalities||||1000|123|156
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|175|178
SE|00000000||tx|1|entity|C0009951|Convulsions|sosy|||convulsions||||1000|183|193
SE|00000000||tx|1|relation|7|6|C0025153|Mefloquine|orch,phsu|orch|||Mefloquine||||1000|31|40|VERB|CAUSES||115|121|3|1|C0522055|Electrocardiogram abnormal|fndg|fndg|||electrocardiographic abnormalities||||1000|123|156


SE|00000000||tx|1|text|The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.
SE|00000000||tx|1|entity|C2348070|Daily Dose|qnco|||daily dose||||1000|5|14
SE|00000000||tx|1|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||1000|19|31
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||clinical studies||||1000|49|64
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|71|80
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximate||||802|94|104
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||802|110|118
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|127|130
SE|00000000||tx|1|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||1000|135|147


SE|00000000||tx|1|text|Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.
SE|00000000||tx|1|entity|C0027360|Naltrexone|orch,phsu|||naltrexone||||1000|22|31
SE|00000000||tx|1|entity|C0284941|acamprosate|orch,phsu|||Acamprosate||||1000|38|48
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|65|72
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|77|79
SE|00000000||tx|1|entity|C0450358|33|inpr|||33%||||888|87|89
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|91|98
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|107|110
SE|00000000||tx|1|entity|C0284941|acamprosate|orch,phsu|||acamprosate||||1000|115|125


SE|00000000||tx|1|text|Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.
SE|00000000||tx|1|entity|C0033405|Promethazine|orch,phsu|||Promethazine||||1000|1|12
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|37|42
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|44|47
SE|00000000||tx|1|entity|C0251504|zaleplon|orch,phsu|||zaleplon||||1000|52|59
SE|00000000||tx|1|entity|C0033405|Promethazine|orch,phsu|||promethazine||||1000|65|76
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|125|132
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximal||||890|137|143
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|145|165
SE|00000000||tx|1|entity|C0251504|zaleplon|orch,phsu|||zaleplon||||1000|170|177
SE|00000000||tx|1|entity|C0443172|Changed status|qnco|||change||||1000|187|192
SE|00000000||tx|1|entity|C0205146|Area|spco|||area||||1000|201|204
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration-||||861|216|236
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||861|237|240
SE|00000000||tx|1|entity|C0205134|Curved|spco|||curve||||861|242|246


SE|00000000||tx|1|text|Therefore, use of lamivudine in combination with zalcitabine is not recommended
SE|00000000||tx|1|entity|C0209738|Lamivudine|nnon,phsu|||lamivudine||||1000|19|28
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|33|43
SE|00000000||tx|1|entity|C0012132|Zalcitabine|nnon,phsu|||zalcitabine||||1000|50|60
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|65|67


SE|00000000||tx|1|text|Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C0051091|albendazole sulfoxide|orch,phsu|||Albendazole sulfoxide||||901|13|33
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||901|35|48
SE|00000000||tx|1|entity|C0600608|Cyst Fluid|bdsu|||cystic fluid||||964|62|73
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||827|99|102
SE|00000000||tx|1|entity|C0013502|Echinococcosis|dsyn|||hydatid cyst||||901|108|119
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||901|121|128
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|143|152
SE|00000000||tx|1|entity|C0439400|mg/day/kg|qnco|||mg/kg/day||||923|158|166
SE|00000000||tx|1|entity|C0001911|Albendazole|orch,phsu|||albendazole||||1000|189|199
SE|00000000||tx|1|entity|C0439400|mg/day/kg|qnco|||mg/kg/day||||923|205|213
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|216|220
SE|00000000||tx|1|relation|8|2|C0008783|Cimetidine|orch,phsu|orch|||cimetidine||||1000|143|152|VERB|compared_with||175|182|3|1|C0001911|Albendazole|orch,phsu|orch|||albendazole||||1000|189|199
SE|00000000||tx|1|relation|0|0|C0013502|Echinococcosis|dsyn|dsyn|||hydatid cyst||||901|108|119|MOD/HEAD|PROCESS_OF||108|128|0|0|C0030705|Patients|podg,humn|humn|||patients||||901|121|128
SE|00000000||tx|1|relation|5|4|C0051091|albendazole sulfoxide|orch,phsu|phsu|||Albendazole sulfoxide||||901|13|33|PREP|TREATS||105|106|6|1|C0030705|Patients|podg,humn|podg|||patients||||901|121|128
SE|00000000||tx|1|relation|5|1|C0008783|Cimetidine|orch,phsu|phsu|||cimetidine||||1000|143|152|VERB|TREATS||130|136|6|1|C0030705|Patients|podg,humn|podg|||patients||||901|121|128
SE|00000000||tx|1|relation|5|1|C0001911|Albendazole|orch,phsu|phsu|||albendazole||||1000|189|199|VERB|TREATS||130|136|6|1|C0030705|Patients|podg,humn|podg|||patients||||901|121|128
SE|00000000||tx|1|relation|0|0|C0051091|albendazole sulfoxide|orch,phsu|phsu|||Albendazole sulfoxide||||901|13|33|INFER|TREATS(INFER)||105|106|0|0|C0013502|Echinococcosis|dsyn|dsyn|||hydatid cyst||||901|108|119
SE|00000000||tx|1|relation|0|0|C0008783|Cimetidine|orch,phsu|phsu|||cimetidine||||1000|143|152|INFER|TREATS(INFER)||130|136|0|0|C0013502|Echinococcosis|dsyn|dsyn|||hydatid cyst||||901|108|119
SE|00000000||tx|1|relation|0|0|C0001911|Albendazole|orch,phsu|phsu|||albendazole||||1000|189|199|INFER|TREATS(INFER)||130|136|0|0|C0013502|Echinococcosis|dsyn|dsyn|||hydatid cyst||||901|108|119


SE|00000000||tx|1|text|It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.
SE|00000000||tx|1|entity|C1332826|CYP1A2 gene|gngm|1544|CYP1A2|CYP1A2||||1000|18|23
SE|00000000||tx|1|entity|C0443302|Several|qnco|||several||||901|41|47
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medicinal products||||901|49|66
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|79|89
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medicinal products||||1000|101|118
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|164|172
SE|00000000||tx|1|entity|C0051809|anagrelide|orch,phsu|||anagrelide||||1000|177|186
SE|00000000||tx|1|relation|5|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medicinal products||||901|49|66|VERB|INHIBITS||28|36|1|1|C1332826|CYP1A2 gene|gngm,aapp|gngm|1544|CYP1A2|CYP1A2||||1000|18|23
SE|00000000||tx|1|relation|5|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medicinal products||||1000|101|118|VERB|INHIBITS||28|36|1|1|C1332826|CYP1A2 gene|gngm,aapp|gngm|1544|CYP1A2|CYP1A2||||1000|18|23
SE|00000000||tx|1|relation|4|2|C0085228|Fluvoxamine|orch,phsu|orch|||fluvoxamine||||1000|79|89|VERB|INTERACTS_WITH||150|158|2|2|C0051809|anagrelide|orch,phsu|orch|||anagrelide||||1000|177|186


SE|00000000||tx|1|text|Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.
SE|00000000||tx|1|entity|C0009429|Combined Modality Therapy|topp|||combined treatment||||1000|17|34
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|74|81
SE|00000000||tx|1|entity|C0009079|Clozapine|orch,phsu|||Clozapine||||1000|116|124
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|149|153
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|174|184
SE|00000000||tx|1|relation|2|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|149|153|VERB|COEXISTS_WITH||129|136|4|1|C0009079|Clozapine|orch,phsu|orch|||Clozapine||||1000|116|124


SE|00000000||tx|1|text|Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.
SE|00000000||tx|1|entity|C0163712|Relate - vinyl resin|orch|||related||||901|37|43
SE|00000000||tx|1|entity|C0568062|Methotrexate poisoning|inpo|||methotrexate-related toxicity||||901|24|52
SE|00000000||tx|1|entity|C0876768|Vioxx|orch,phsu|||VIOXX||||888|77|81
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|87|98


SE|00000000||tx|1|text|Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||Warfarin||||1000|1|8
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||Anticoagulants||||1000|14|27
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||Increased||||901|30|38
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||901|40|55
SE|00000000||tx|1|entity|C0205210|Clinical|qlco|||clinical||||888|74|81
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||888|83|90
SE|00000000||tx|1|entity|C0060400|Cefixime|antb,orch|||cefixime||||1000|116|123


SE|00000000||tx|1|text|This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|6|16
SE|00000000||tx|1|entity|C0518609|consideration|fndg|||consideration||||1000|34|46
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|51|58
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||861|67|72
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitors||||1000|93|106
SE|00000000||tx|1|relation|2|1|C0518609|consideration|fndg|fndg|||consideration||||1000|34|46|PREP|PROCESS_OF||48|49|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|51|58
SE|00000000||tx|1|relation|2|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||861|67|72|VERB|ADMINISTERED_TO||60|65|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|51|58


SE|00000000||tx|1|text|There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||901|12|17
SE|00000000||tx|1|entity|C0007320|Case Reports Publication Type|inpr|||case report||||901|19|29
SE|00000000||tx|1|entity|C0038633|Sucralfate|carb,phsu|||sucralfate||||1000|52|61
SE|00000000||tx|1|entity|C0051809|anagrelide|orch,phsu|||anagrelide||||694|82|91


SE|00000000||tx|1|text|Rifampin: Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||Rifampin||||1000|1|8
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|31|38
SE|00000000||tx|1|entity|C0378468|Mepron|orch,phsu|||MEPRON||||888|44|49
SE|00000000||tx|1|entity|C0038960|Suspensions|bodm|||Suspension||||888|51|60
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|75|85
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||888|87|94
SE|00000000||tx|1|entity|C1510992|Average|qnco|||average||||832|99|105
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady- state||||832|107|119
SE|00000000||tx|1|entity|C0165603|Atovaquone|orch,phsu|||atovaquone||||832|128|137
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma atovaquone concentrations||||832|121|152
SE|00000000||tx|1|relation|4|2|C0035608|Rifampin|antb,orch|antb|||rifampin||||1000|31|38|NOM|INHIBITS||87|94|1|1|C0165603|Atovaquone|orch,phsu|orch|||atovaquone||||832|128|137


SE|00000000||tx|1|text|Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||1000|1|12
SE|00000000||tx|1|entity|C0291772|alosetron|orch,phsu|||alosetron||||813|29|37
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||813|39|59
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|62|64
SE|00000000||tx|1|relation|1|1|C0022625|Ketoconazole|orch,phsu|orch|||Ketoconazole||||1000|1|12|VERB|STIMULATES||14|22|2|1|C0291772|alosetron|orch,phsu|orch|||alosetron||||813|29|37


SE|00000000||tx|1|text|As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|15|20
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blocking||||851|29|36
SE|00000000||tx|1|entity|C1292721|Has property|ftcn|||properties||||851|38|47
SE|00000000||tx|1|entity|C0719509|Coreg|orch,phsu|||COREG||||1000|53|57
SE|00000000||tx|1|entity|C0442027|Oral|spco|||orally||||1000|81|86
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium channel blockers||||1000|93|116
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||1000|125|133
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||694|138|146
SE|00000000||tx|1|entity|C0013798|Electrocardiogram|fndg|||ECG||||966|177|179
SE|00000000||tx|1|entity|C0005823|Blood Pressure|orgf|||blood pressure||||1000|185|198


SE|00000000||tx|1|text|The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|17|19
SE|00000000||tx|1|entity|C1310721|Enablex|orch,phsu|||ENABLEX||||1000|24|30
SE|00000000||tx|1|entity|C0242896|Anticholinergic Agents|phsu|||anticholinergic agents||||1000|43|64
SE|00000000||tx|1|entity|C0439603|Frequencies (time pattern)|tmco|||frequency||||1000|83|91
SE|00000000||tx|1|entity|C0439793|Severities|qlco|||severity||||1000|100|107
SE|00000000||tx|1|entity|C0043352|Xerostomia|dsyn|||dry mouth||||1000|112|120
SE|00000000||tx|1|entity|C0009806|Constipation|sosy|||constipation||||1000|123|134
SE|00000000||tx|1|entity|C0344232|Blurred vision|sosy|||blurred vision||||1000|137|150
SE|00000000||tx|1|entity|C0728866|Drug effect|ftcn|||pharmacological effects||||851|178|200


SE|00000000||tx|1|text|Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||1000|21|30
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||840|39|41
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||861|44|46
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||827|65|68
SE|00000000||tx|1|entity|C0017628|Glyburide|orch,phsu|||glyburide||||1000|81|89
SE|00000000||tx|1|entity|C0017628|Glyburide|orch,phsu|||glyburide||||764|98|106
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||764|108|110
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|129|136
SE|00000000||tx|1|entity|C0017628|Glyburide|orch,phsu|||glyburide||||827|141|149
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|169|176
SE|00000000||tx|1|entity|C0017628|Glyburide|orch,phsu|||glyburide||||888|181|189
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||888|191|194
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|213|220
SE|00000000||tx|1|entity|C0017725|Glucose|bacs,carb,phsu|||glucose||||827|225|231


SE|00000000||tx|1|text|Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.
SE|00000000||tx|1|entity|C0001962|Ethanol|orch|||ethanol||||1000|12|18
SE|00000000||tx|1|entity|C1521828|Rate|qnco|||rate||||1000|34|37
SE|00000000||tx|1|entity|C0604279|Antizol|orch,phsu|||Antizol||||1000|57|63
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|69|81
SE|00000000||tx|1|entity|C0445247|Same|qlco|||same||||694|95|98


SE|00000000||tx|1|text|Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.
SE|00000000||tx|1|entity|C1704240|Magnitude|qnco|||magnitude||||1000|14|22
SE|00000000||tx|1|entity|C0443172|Changed status|qnco|||changes||||1000|27|33
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||623|38|45
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||623|47|52
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||1000|88|97
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||790|104|106
SE|00000000||tx|1|entity|C0205410|Sufficient|qlco|||sufficient||||790|108|117
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||888|130|135
SE|00000000||tx|1|entity|C0456081|Adjustment Action|ftcn|||adjustments||||888|137|147
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|150|157
SE|00000000||tx|1|entity|C2349975|Enhance (action)|acty|||enhanced||||861|174|181
SE|00000000||tx|1|entity|C0020592|Hypnotics and Sedatives|phsu|||sedative||||861|183|190
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||861|192|203
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||694|215|223
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|237|244


SE|00000000||tx|1|text|However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.
SE|00000000||tx|1|entity|C0079594|Iloprost|eico,phsu|||iloprost||||1000|10|17
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||861|27|35
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|53|63
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|65|70
SE|00000000||tx|1|entity|C0042402|Vasodilator Agents|phsu|||vasodilators||||1000|75|86
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensive agents||||1000|92|114
SE|00000000||tx|1|relation|1|1|C0079594|Iloprost|eico,phsu|eico|||iloprost||||1000|10|17|NOM|INTERACTS_WITH||65|70|2|1|C0042402|Vasodilator Agents|phsu|phsu|||vasodilators||||1000|75|86
SE|00000000||tx|1|relation|1|1|C0079594|Iloprost|eico,phsu|eico|||iloprost||||1000|10|17|NOM|INTERACTS_WITH||65|70|2|1|C0003364|Antihypertensive Agents|phsu|phsu|||antihypertensive agents||||1000|92|114


SE|00000000||tx|1|text|In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|4|11
SE|00000000||tx|1|entity|C0205191|chronic|tmco|||chronic||||851|16|22
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||851|24|31
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|46|61
SE|00000000||tx|1|entity|C0525032|International Normalized Ratio|lbpr|||INR||||1000|64|66
SE|00000000||tx|1|entity|C1442457|2 Weeks|tmco|||2-week||||890|104|109
SE|00000000||tx|1|entity|C0439531|per period (qualifier value)|tmco|||period||||890|111|116
SE|00000000||tx|1|entity|C1547061|10 days|tmco|||10 days||||1000|140|146
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|159|168
SE|00000000||tx|1|entity|C1442459|3 Days|tmco|||3-day||||890|177|181
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||regimen||||890|183|189
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|194|203
SE|00000000||tx|1|entity|C1302181|Chemotherapy cycle|topp|||chemotherapy cycle||||1000|215|232
SE|00000000||tx|1|relation|0|0|C0525032|International Normalized Ratio|lbpr|lbpr|||INR||||1000|64|66|SPEC|ISA||46|66|0|0|C0033707|Prothrombin time assay|lbpr|lbpr|||prothrombin time||||1000|46|61


SE|00000000||tx|1|text|Potential for reduction in anticonvulsant and/or efavirenz plasma levels;
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||Potential||||1000|1|9
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|15|23
SE|00000000||tx|1|entity|C0003286|Anticonvulsants|phsu|||anticonvulsant||||1000|28|41
SE|00000000||tx|1|entity|C0674428|efavirenz|orch,phsu|||efavirenz||||790|50|58
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|60|65


SE|00000000||tx|1|text|therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||861|32|39
SE|00000000||tx|1|entity|C0050940|lansoprazole|orch,phsu|||lansoprazole||||1000|46|57
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||824|96|100
SE|00000000||tx|1|entity|C1168023|Gastric pH|diap|||gastric pH||||824|108|117
SE|00000000||tx|1|entity|C1521761|Factor|ftcn|||determinant||||861|135|145
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|150|164
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||790|172|183
SE|00000000||tx|1|entity|C0002680|Ampicillin|antb,orch|||ampicillin||||888|186|195
SE|00000000||tx|1|entity|C0014898|Esters|orch|||esters||||888|197|202
SE|00000000||tx|1|entity|C0302206|Iron salt|inch|||iron salts||||966|205|214
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|217|223


SE|00000000||tx|1|text|Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||851|1|12
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||Combined||||851|16|23
SE|00000000||tx|1|entity|C0008845|Citalopram|orch,phsu|||citalopram||||861|51|60
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|74|85
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|110|113
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|119|121
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|126|137
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|177|179
SE|00000000||tx|1|entity|C0031327|Drug Kinetics|phsf|||pharmacokinetics||||1000|206|221
SE|00000000||tx|1|entity|C0008845|Citalopram|orch,phsu|||citalopram||||1000|226|235
SE|00000000||tx|1|relation|8|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|126|137|VERB|INTERACTS_WITH|negation|195|200|2|2|C0008845|Citalopram|orch,phsu|orch|||citalopram||||1000|226|235


SE|00000000||tx|1|text|Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||Digoxin||||1000|1|7
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|30|36
SE|00000000||tx|1|entity|C0017968|Glycoproteins|aapp,carb|||glycoprotein||||645|43|54
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|72|75
SE|00000000||tx|1|entity|C0966107|conivaptan|orch,phsu|||conivaptan||||888|77|86
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|102|110
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|115|123
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|132|139
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||888|144|150
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||888|152|155
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|161|163
SE|00000000||tx|1|entity|C0042295|Values|qlco|||values||||888|165|170
SE|00000000||tx|1|relation|3|1|C0012265|Digoxin|carb,phsu,strd|carb|||digoxin||||1000|30|36|NOM|INTERACTS_WITH||56|64|3|0|C0017968|Glycoproteins|aapp,gngm,carb|aapp|||glycoprotein||||645|43|54


SE|00000000||tx|1|text|Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||Theophylline||||750|1|12
SE|00000000||tx|1|entity|C0876768|Vioxx|orch,phsu|||VIOXX||||750|14|18
SE|00000000||tx|1|entity|C0556983|Once daily|tmco|||once daily||||1000|53|62
SE|00000000||tx|1|entity|C1547085|7 days|tmco|||7 days||||1000|68|73
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||890|92|103
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma theophylline concentrations||||890|85|118
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|121|123
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy subjects||||1000|147|162
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||775|179|184
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||775|193|196
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|201|212


SE|00000000||tx|1|text|The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|20|30
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|32|38
SE|00000000||tx|1|entity|C0701176|Prinivil|aapp,phsu|||PRINIVIL||||1000|45|52
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|99|106
SE|00000000||tx|1|entity|C0442808|Increasing|ftcn|||increasing||||1000|111|120
SE|00000000||tx|1|entity|C0489767|salt intake|orga|||salt intake||||1000|126|136
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|147|156
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|161|169
SE|00000000||tx|1|entity|C0701176|Prinivil|aapp,phsu|||PRINIVIL||||1000|176|183
SE|00000000||tx|1|relation|8|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||1000|161|169|PREP|USES||171|174|1|1|C0701176|Prinivil|aapp,gngm,phsu|phsu|||PRINIVIL||||1000|176|183


SE|00000000||tx|1|text|Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||Nonsteroidal anti-inflammatory agents||||1000|1|37
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|49|59
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|61|63
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|68|74
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal antiinflammatory agents||||1000|86|121
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|128|142
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|158|161
SE|00000000||tx|1|entity|C2707256|Gastrointestinal:-:Point in time:^Patient:-|clna|||gastrointestinal||||901|166|181
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||901|183|194


SE|00000000||tx|1|text|All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.
SE|00000000||tx|1|entity|C0042397|Vasoconstrictor Agents|phsu|||vasopressors||||1000|5|16
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|47|54
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase (MAO) inhibitors||||1000|63|96
SE|00000000||tx|1|relation|1|1|C0042397|Vasoconstrictor Agents|phsu|phsu|||vasopressors||||1000|5|16|PREP|TREATS||44|45|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|47|54
SE|00000000||tx|1|relation|1|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||monoamine oxidase (MAO) inhibitors||||1000|63|96|VERB|ADMINISTERED_TO||56|61|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|47|54


SE|00000000||tx|1|text|Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||Diuretics||||1000|1|9
SE|00000000||tx|1|entity|C0012091|Diclofenac|orch,phsu|||Diclofenac||||1000|12|21
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|33|38
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||1000|56|63
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|68|76
SE|00000000||tx|1|relation|0|0|C0012091|Diclofenac|orch,phsu|orch|||Diclofenac||||1000|12|21|SPEC|ISA||12|38|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|33|38
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|33|38|SPEC|ISA||12|38|0|0|C0012091|Diclofenac|orch,phsu|phsu|||Diclofenac||||1000|12|21
SE|00000000||tx|1|relation|3|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|33|38|VERB|INHIBITS||44|50|2|2|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|68|76
SE|00000000||tx|1|relation|3|1|C0012091|Diclofenac|orch,phsu|phsu|||Diclofenac||||1000|12|21|VERB|INHIBITS||44|50|2|2|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|68|76
SE|00000000||tx|1|relation|0|0|C0012091|Diclofenac|orch,phsu|orch|||Diclofenac||||1000|12|21|INFER|INHIBITS(SPEC)||12|38|0|0|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|68|76
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|33|38|INFER|INHIBITS(SPEC)||12|38|0|0|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|68|76


SE|00000000||tx|1|text|However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy.
SE|00000000||tx|1|entity|C0205388|Few|qnco|||few||||890|64|66
SE|00000000||tx|1|entity|C2348402|Spontaneous Report|inpr|||spontaneous reports||||890|68|86
SE|00000000||tx|1|entity|C0151872|Prothrombin time increased|fndg|||prolonged prothrombin times||||983|91|117
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||1000|136|143
SE|00000000||tx|1|entity|C0059865|Etodolac|orch,phsu|||etodolac||||851|149|156
SE|00000000||tx|1|entity|C1522326|Treating|ftcn|||treated||||851|158|164
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||851|166|173
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||901|197|204
SE|00000000||tx|1|entity|C1707479|Concomitant Therapy|topp|||concomitant warfarin therapy||||901|185|212
SE|00000000||tx|1|relation|4|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|136|143|PREP|PROCESS_OF|negation|146|147|2|1|C0030705|Patients|podg,humn|humn|||patients||||851|166|173
SE|00000000||tx|1|relation|1|1|C1707479|Concomitant Therapy|topp|topp|||concomitant warfarin therapy||||901|185|212|VERB|ADMINISTERED_TO||175|183|5|1|C0030705|Patients|podg,humn|humn|||patients||||851|166|173
SE|00000000||tx|1|relation|0|0|C1707479|Concomitant Therapy|topp|topp|||concomitant warfarin therapy||||901|185|212|MOD/HEAD|USES||197|212|0|0|C0043031|Warfarin|hops,orch,phsu|phsu|||warfarin||||901|197|204


SE|00000000||tx|1|text|Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||890|7|18
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||Serum theophylline concentrations||||890|1|33
SE|00000000||tx|1|entity|C0287721|grepafloxacin|orch,phsu|||grepafloxacin||||1000|49|61
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|81|87
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|103|114
SE|00000000||tx|1|relation|2|1|C0287721|grepafloxacin|orch,phsu|phsu|||grepafloxacin||||1000|49|61|PREP|TREATS||76|77|2|1|C0030705|Patients|podg,humn|podg|||patient||||1000|81|87


SE|00000000||tx|1|text|Additionally, higher than expected tricyclic antidepressant levels have been observed when they are begun in patients already taking cimetidine.
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||966|15|20
SE|00000000||tx|1|entity|C1517001|Expected|idcn|||expected||||658|27|34
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressant||||658|36|59
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|110|117
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|134|143
SE|00000000||tx|1|relation|2|1|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressant||||658|36|59|PREP|TREATS||107|108|2|1|C0030705|Patients|podg,humn|podg|||patients||||861|110|117
SE|00000000||tx|1|relation|1|1|C0008783|Cimetidine|orch,phsu|orch|||cimetidine||||1000|134|143|VERB|ADMINISTERED_TO||127|132|3|1|C0030705|Patients|podg,humn|humn|||patients||||861|110|117


SE|00000000||tx|1|text|When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||Vardenafil||||694|6|15
SE|00000000||tx|1|entity|C1123697|Terazosin 10 MG|clnd|||terazosin 10 mg||||1000|43|57
SE|00000000||tx|1|entity|C1292428|6 Hours|tmco|||6 hours||||1000|62|68
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||827|79|86
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||Vardenafil||||1000|110|119
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|135|142
SE|00000000||tx|1|entity|C0488055|Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative|clna|||systolic blood pressure||||923|156|178
SE|00000000||tx|1|entity|C0439475|mmHg|qnco|||mm Hg||||901|189|193


SE|00000000||tx|1|text|Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs   1500  M min in some patients.
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||1000|1|12
SE|00000000||tx|1|entity|C0006463|Busulfan|hops,orch,phsu|||busulfan||||888|24|31
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|33|41
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUCs||||775|73|76
SE|00000000||tx|1|entity|C0702093|/minute|tmco|||min||||775|88|90
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|100|107
SE|00000000||tx|1|relation|1|1|C0064113|Itraconazole|orch,phsu|orch|||Itraconazole||||1000|1|12|VERB|INHIBITS||14|22|3|1|C0006463|Busulfan|hops,orch,phsu|hops|||busulfan||||888|24|31


SE|00000000||tx|1|text|Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.
SE|00000000||tx|1|entity|C0439611|Preliminary|tmco|||Preliminary||||888|1|11
SE|00000000||tx|1|entity|C3245479|data|medd|||data||||888|13|16
SE|00000000||tx|1|entity|C0010980|Dapsone|orch,phsu|||dapsone||||1000|37|43
SE|00000000||tx|1|entity|C0333348|Inflammatory|ftcn|||inflammatory||||790|66|77
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||790|79|86
SE|00000000||tx|1|entity|C0700047|Lamprene|irda,orch,phsu|||Lamprene||||1000|91|98
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|105|107
SE|00000000||tx|1|relation|2|1|C0010980|Dapsone|orch,phsu|orch|||dapsone||||1000|37|43|VERB|INHIBITS||49|55|2|2|C0700047|Lamprene|irda,orch,phsu|orch|||Lamprene||||1000|91|98


SE|00000000||tx|1|text|Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|9|15
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|46|52
SE|00000000||tx|1|entity|C1099456|Escitalopram|orch,phsu|||escitalopram||||1000|57|68
SE|00000000||tx|1|entity|C1170371|Lexapro|orch,phsu|||LEXAPRO||||1000|104|110
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|116|122
SE|00000000||tx|1|relation|4|3|C1170371|Lexapro|orch,phsu|orch|||LEXAPRO||||1000|104|110|NOM|INTERACTS_WITH||46|52|4|1|C1099456|Escitalopram|orch,phsu|orch|||escitalopram||||1000|57|68


SE|00000000||tx|1|text|Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin.
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||901|23|31
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||901|33|48
SE|00000000||tx|1|entity|C0205388|Few|qnco|||few||||888|74|76
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|78|85
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin anticoagulants||||884|94|116
SE|00000000||tx|1|entity|C0024027|Lovastatin|orch,phsu|||lovastatin||||1000|137|146
SE|00000000||tx|1|relation|2|1|C0010206|coumarin|orch,phsu|orch|||coumarin anticoagulants||||884|94|116|VERB|ADMINISTERED_TO||87|92|2|1|C0030705|Patients|podg,humn|humn|||patients||||888|78|85
SE|00000000||tx|1|relation|3|3|C0033707|Prothrombin time assay|lbpr|lbpr|||prothrombin time||||901|33|48|PREP|USES||132|135|1|1|C0024027|Lovastatin|orch,phsu|phsu|||lovastatin||||1000|137|146


SE|00000000||tx|1|text|Amphetamines may enhance the effects of tricyclic antidepressants.
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||Amphetamines||||1000|1|12
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|30|36
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|41|65


SE|00000000||tx|1|text|Corticosteroids may increase the clearance of chronic high dose aspirin.
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||Corticosteroids||||1000|1|15
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|34|42
SE|00000000||tx|1|entity|C0205191|chronic|tmco|||chronic||||861|47|53
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high dose||||861|55|63
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||861|65|71
SE|00000000||tx|1|relation|1|1|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||Corticosteroids||||1000|1|15|VERB|STIMULATES||21|28|2|2|C0004057|Aspirin|orch,phsu|orch|||aspirin||||861|65|71


SE|00000000||tx|1|text|These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|29|40
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||802|45|56
SE|00000000||tx|1|entity|C0296800|fexofenadine|orch,phsu|||fexofenadine||||901|85|96
SE|00000000||tx|1|entity|C0021826|Intestinal Absorption|ortf|||gastrointestinal absorption||||901|98|124
SE|00000000||tx|1|relation|3|2|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|29|40|VERB|AUGMENTS||76|83|1|1|C0021826|Intestinal Absorption|ortf|ortf|||gastrointestinal absorption||||901|98|124
SE|00000000||tx|1|relation|3|2|C0014806|Erythromycin|antb,orch|orch|||erythromycin||||802|45|56|VERB|AUGMENTS||76|83|1|1|C0021826|Intestinal Absorption|ortf|ortf|||gastrointestinal absorption||||901|98|124


SE|00000000||tx|1|text|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|7|11
SE|00000000||tx|1|entity|C0234119|Neuromuscular inhibition|dsyn|||neuromuscular blocking||||890|35|56
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||890|58|63
SE|00000000||tx|1|entity|C0304435|Nondepolarizing agent|phsu|||nondepolarizing agents||||983|68|89
SE|00000000||tx|1|entity|C0530102|Nimbex|orch,phsu|||NIMBEX||||1000|99|104
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||888|114|120
SE|00000000||tx|1|entity|C0003232|Antibiotics|antb|||antibiotics||||888|122|132
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycosides||||1000|142|156
SE|00000000||tx|1|entity|C0039651|Tetracyclines|orch|||tetracyclines||||1000|159|171
SE|00000000||tx|1|entity|C0004599|Bacitracin|aapp,antb|||bacitracin||||1000|174|183
SE|00000000||tx|1|entity|C0032539|Polymyxins|aapp,antb|||polymyxins||||1000|186|195
SE|00000000||tx|1|entity|C0023726|Lincomycin|antb,carb|||lincomycin||||1000|198|207
SE|00000000||tx|1|entity|C0008947|Clindamycin|antb,carb|||clindamycin||||1000|210|220
SE|00000000||tx|1|entity|C0009316|Colistin|aapp,antb|||colistin||||1000|223|230
SE|00000000||tx|1|entity|C0037473|Sodium|bacs,elii|||sodium||||694|237|242
SE|00000000||tx|1|entity|C0302211|Magnesium salt|inch,phsu|||magnesium salts||||1000|261|275
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|278|284
SE|00000000||tx|1|entity|C0002934|Local Anesthetics|phsu|||local anesthetics||||1000|287|303
SE|00000000||tx|1|entity|C0033216|Procainamide|orch,phsu|||procainamide||||1000|306|317
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|324|332
SE|00000000||tx|1|relation|0|0|C0530102|Nimbex|orch,phsu|orch|||NIMBEX||||1000|99|104|SPEC|ISA||68|104|0|0|C0304435|Nondepolarizing agent|phsu|phsu|||nondepolarizing agents||||983|68|89


SE|00000000||tx|1|text|Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.
SE|00000000||tx|1|entity|C0002509|Amines, Sympathomimetic|phsu|||Sympathomimetic amines||||1000|1|22
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|56|62
SE|00000000||tx|1|entity|C0035179|Reserpine|orch,phsu|||reserpine||||1000|67|75
SE|00000000||tx|1|entity|C0042528|Veratrum Alkaloids|orch,phsu|||veratrum alkaloids||||1000|78|95
SE|00000000||tx|1|entity|C0025741|Methyldopa|nsba,phsu|||methyldopa||||1000|98|107
SE|00000000||tx|1|entity|C0025029|Mecamylamine|orch,phsu|||mecamylamine||||1000|113|124
SE|00000000||tx|1|relation|1|1|C0002509|Amines, Sympathomimetic|phsu|phsu|||Sympathomimetic amines||||1000|1|22|NOM|INTERACTS_WITH||56|62|4|1|C0035179|Reserpine|orch,phsu|orch|||reserpine||||1000|67|75
SE|00000000||tx|1|relation|1|1|C0002509|Amines, Sympathomimetic|phsu|phsu|||Sympathomimetic amines||||1000|1|22|NOM|INTERACTS_WITH||56|62|4|1|C0025029|Mecamylamine|orch,phsu|orch|||mecamylamine||||1000|113|124
SE|00000000||tx|1|relation|1|1|C0002509|Amines, Sympathomimetic|phsu|phsu|||Sympathomimetic amines||||1000|1|22|NOM|INTERACTS_WITH||56|62|4|1|C0025741|Methyldopa|nsba,phsu|nsba|||methyldopa||||1000|98|107
SE|00000000||tx|1|relation|1|1|C0002509|Amines, Sympathomimetic|phsu|phsu|||Sympathomimetic amines||||1000|1|22|NOM|INTERACTS_WITH||56|62|4|1|C0042528|Veratrum Alkaloids|orch,phsu|orch|||veratrum alkaloids||||1000|78|95


SE|00000000||tx|1|text|The clearance of salicylates may be increased with concurrent use of corticosteroids.
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|5|13
SE|00000000||tx|1|entity|C0036077|Salicylates|orch,phsu|||salicylates||||1000|18|28
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|52|61
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|63|65
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|70|84


SE|00000000||tx|1|text|If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||851|4|14
SE|00000000||tx|1|entity|C0754647|frovatriptan|orch,phsu|||frovatriptan||||1000|31|42
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRI||||1000|51|54
SE|00000000||tx|1|entity|C1548787|Appropriate|qlco|||appropriate||||888|81|91
SE|00000000||tx|1|entity|C1964257|Observation - diagnostic procedure|diap|||observation||||888|93|103
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|112|118


SE|00000000||tx|1|text|Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.
SE|00000000||tx|1|entity|C0557988|Close supervision|topp|||Close supervision||||1000|1|17
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||1000|49|54
SE|00000000||tx|1|entity|C0700459|Nortriptyline Hydrochloride|orch,phsu|||nortriptyline hydrochloride||||1000|74|100
SE|00000000||tx|1|entity|C0242896|Anticholinergic Agents|phsu|||anticholinergic drugs||||1000|121|141
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetic drugs||||1000|146|166
SE|00000000||tx|1|relation|4|4|C0557988|Close supervision|topp|topp|||Close supervision||||1000|1|17|PREP|USES||110|113|2|1|C0242896|Anticholinergic Agents|phsu|phsu|||anticholinergic drugs||||1000|121|141
SE|00000000||tx|1|relation|4|4|C0557988|Close supervision|topp|topp|||Close supervision||||1000|1|17|PREP|USES||110|113|2|1|C0039052|Sympathomimetics|phsu|phsu|||sympathomimetic drugs||||1000|146|166


SE|00000000||tx|1|text|Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||Furosemide||||1000|1|10
SE|00000000||tx|1|entity|C0723785|Toradol IV/IM|orch,phsu|||TORADOL IV/IM||||1000|13|25
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||694|39|46
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|60|69
SE|00000000||tx|1|entity|C0232092|Normovolemic|fndg|||normovolemic||||901|74|85
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy subjects||||901|87|102
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|107|119
SE|00000000||tx|1|entity|C0037473|Sodium|bacs,elii|||sodium||||861|131|136
SE|00000000||tx|1|entity|C0232856|Urine volume function|clna|||urinary output||||1000|142|155


SE|00000000||tx|1|text|drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|1|5
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|13|20
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|37|45
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|56|69
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|72|86
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin||||1000|89|96
SE|00000000||tx|1|entity|C0012258|Digitoxin|carb,phsu,strd|||digitoxin||||1000|99|107
SE|00000000||tx|1|entity|C0013090|Doxycycline|antb,orch|||doxycycline||||1000|110|120
SE|00000000||tx|1|entity|C0014939|Estrogens|horm,phsu,strd|||estrogens||||1000|123|131
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|134|143
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives||||1000|146|164
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|167|174
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|177|185
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|188|199
SE|00000000||tx|1|entity|C0042866|Vitamin D|orch,phsu,vita|||vitamin D||||1000|202|210


SE|00000000||tx|1|text|Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||Anticoagulants||||1000|1|14
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||Combination||||851|17|27
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||851|29|36
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||851|38|51
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|82|88
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin||||888|93|100
SE|00000000||tx|1|entity|C0243072|derivatives|chvs|||derivatives||||888|102|112
SE|00000000||tx|1|relation|2|1|C0009871|Contraceptive Agents|phsu|phsu|||contraceptives||||851|38|51|NOM|INTERACTS_WITH||82|88|1|1|C0010206|coumarin|orch,phsu|orch|||coumarin||||888|93|100


SE|00000000||tx|1|text|Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C1527240|Derivative|ftcn|||derivative||||813|26|35
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin-derivative anticoagulants||||813|17|50
SE|00000000||tx|1|entity|C0671970|capecitabine|nnon,phsu|||capecitabine||||1000|71|82
SE|00000000||tx|1|entity|C1515926|Alteration|idcn|||alterations||||966|118|128
SE|00000000||tx|1|entity|C0441509|Coagulation procedure|topp|||coagulation||||888|139|149
SE|00000000||tx|1|entity|C0449381|Observation parameter|fndg|||parameters||||888|151|160
SE|00000000||tx|1|entity|C0525032|International Normalized Ratio|lbpr|||INR||||1000|169|171
SE|00000000||tx|1|relation|6|1|C0010206|coumarin|orch,phsu|orch|||coumarin-derivative anticoagulants||||813|17|50|VERB|ADMINISTERED_TO||10|15|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8
SE|00000000||tx|1|relation|3|1|C0671970|capecitabine|nnon,phsu|phsu|||capecitabine||||1000|71|82|NOM|AFFECTS||118|128|3|1|C0449381|Observation parameter|fndg|fndg|||parameters||||888|151|160


SE|00000000||tx|1|text|However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|10|20
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|40|46
SE|00000000||tx|1|entity|C0719198|Celebrex|orch,phsu|||CELEBREX||||1000|53|60
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|79|87
SE|00000000||tx|1|entity|C1521828|Rate|qnco|||rate||||888|89|92
SE|00000000||tx|1|entity|C0041582|Ulcer|patf|||ulceration||||861|100|109
SE|00000000||tx|1|entity|C0009566|Complication|patf|||complications||||1000|120|132
SE|00000000||tx|1|entity|C0719198|Celebrex|orch,phsu|||CELEBREX||||1000|154|161
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|163|167


SE|00000000||tx|1|text|DIDREX should not be used concomitantly with other CNS stimulants.
SE|00000000||tx|1|entity|C0012139|Didrex|orch,phsu|||DIDREX||||1000|1|6
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|15|17
SE|00000000||tx|1|entity|C0002763|Central Nervous System Stimulants|phsu|||CNS stimulants||||1000|52|65


SE|00000000||tx|1|text|There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|11|17
SE|00000000||tx|1|entity|C2349975|Enhance (action)|acty|||enhanced||||1000|22|29
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||diminished||||888|42|51
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|53|59
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|64|77
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|108|122
SE|00000000||tx|1|relation|1|1|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroids||||1000|108|122|VERB|COEXISTS_WITH||84|88|4|1|C0003280|Anticoagulants|phsu|phsu|||anticoagulants||||1000|64|77


SE|00000000||tx|1|text|Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacid||||1000|1|7
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||1000|15|26
SE|00000000||tx|1|entity|C0353791|Maalox TC Suspension|clnd|||Maalox TC suspension||||1000|32|51
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|74|94
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||1000|99|110
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|122|134


SE|00000000||tx|1|text|Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.
SE|00000000||tx|1|entity|C0093437|cevimeline|orch,phsu|||Cevimeline||||1000|1|10
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|51|58
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta adrenergic antagonists||||988|67|93
SE|00000000||tx|1|entity|C0232219|Abnormal cardiac conduction|patf|||conduction disturbances||||983|126|148
SE|00000000||tx|1|relation|3|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta adrenergic antagonists||||988|67|93|VERB|ADMINISTERED_TO||60|65|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|51|58


SE|00000000||tx|1|text|It has been reported that Itraconazole enhances the anticoagulant effect of coumarin-like drugs.
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||1000|27|38
SE|00000000||tx|1|entity|C0520996|Anticoagulant effect|ortf|||anticoagulant effect||||1000|53|72
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin||||1000|77|84
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|91|95
SE|00000000||tx|1|relation|1|1|C0064113|Itraconazole|orch,phsu|orch|||Itraconazole||||1000|27|38|VERB|AUGMENTS||40|47|3|1|C0520996|Anticoagulant effect|ortf|ortf|||anticoagulant effect||||1000|53|72


SE|00000000||tx|1|text|However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|10|17
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|22|28
SE|00000000||tx|1|entity|C0702240|Elevation|spco|||elevations||||1000|39|48
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||888|53|59
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|61|74
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|82|91
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|96|102
SE|00000000||tx|1|entity|C0376357|Flolan|eico,phsu|||FLOLAN||||1000|109|114
SE|00000000||tx|1|entity|C0750502|Significant|idcn|||significant||||861|141|151
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|156|163
SE|00000000||tx|1|entity|C0274727|Poisoning by digoxin|inpo|||digoxin toxicity||||1000|174|189
SE|00000000||tx|1|relation|5|1|C0376357|Flolan|eico,phsu|eico|||FLOLAN||||1000|109|114|PREP|PART_OF||104|107|6|6|C0030705|Patients|podg,humn|humn|||patients||||1000|10|17


SE|00000000||tx|1|text|Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||Propranolol||||1000|1|11
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirins||||775|27|34
SE|00000000||tx|1|entity|C0333348|Inflammatory|ftcn|||inflammatory||||775|41|52
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||775|54|59
SE|00000000||tx|1|entity|C0445247|Same|qlco|||same||||888|82|85
SE|00000000||tx|1|entity|C0597357|receptor|aapp,rcpt|||receptors||||888|87|95


SE|00000000||tx|1|text|The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||1000|5|24
SE|00000000||tx|1|entity|C0020934|Imipramine|orch,phsu|||imipramine||||1000|29|38
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||1000|62|65
SE|00000000||tx|1|entity|C0205054|Hepatic|blor|||hepatic||||901|95|101
SE|00000000||tx|1|entity|C0014432|Enzyme Inhibitors|phsu|||enzyme inhibitors||||901|103|119
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|128|137
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|140|149
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|156|163
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|168|178
SE|00000000||tx|1|entity|C0428321|Measurement of liver enzyme|lbpr|||hepatic enzyme||||734|198|211
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|229|240
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|243|251
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||1000|277|282
SE|00000000||tx|1|entity|C0020934|Imipramine|orch,phsu|||imipramine||||1000|287|296
SE|00000000||tx|1|relation|12|1|C0014432|Enzyme Inhibitors|phsu|phsu|||enzyme inhibitors||||901|103|119|VERB|COEXISTS_WITH||70|74|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||1000|62|65


SE|00000000||tx|1|text|Cimetidine increased the AUC of epirubicin by 50%.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|26|28
SE|00000000||tx|1|entity|C0014582|Epirubicin|orch,phsu|||epirubicin||||1000|33|42


SE|00000000||tx|1|text|In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|4|11
SE|00000000||tx|1|entity|C0034980|Regression Analysis|inpr|||regression analyses||||1000|27|45
SE|00000000||tx|1|entity|C2707520|Patient data|inpr|||patient pharmacokinetic data||||913|50|77
SE|00000000||tx|1|entity|C0683151|drug clearance|phsf|||drug clearance||||1000|131|144
SE|00000000||tx|1|entity|C0674428|efavirenz|orch,phsu|||efavirenz||||1000|147|155
SE|00000000||tx|1|entity|C0132326|Nevirapine|nnon,phsu|||nevirapine||||1000|158|167
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|170|178
SE|00000000||tx|1|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||1000|181|193
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|199|211
SE|00000000||tx|1|entity|C0935984|Cancidas|aapp,phsu|||CANCIDAS||||1000|219|226
SE|00000000||tx|1|entity|C0876919|Meaning|idcn|||meaningful||||754|253|262
SE|00000000||tx|1|entity|C0301630|Reduction (chemical)|npop|||reductions||||754|264|273
SE|00000000||tx|1|entity|C0537894|Caspofungin|aapp,phsu|||caspofungin||||888|278|288
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|290|303
SE|00000000||tx|1|relation|12|1|C0935984|Cancidas|aapp,gngm,phsu|aapp|||CANCIDAS||||1000|219|226|NOM|INHIBITS||264|273|1|1|C0537894|Caspofungin|aapp,gngm,phsu|gngm|||caspofungin||||888|278|288


SE|00000000||tx|1|text|Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||Aspirin||||1000|1|7
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|10|20
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|40|46
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||1000|53|62
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|81|89
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|91|94
SE|00000000||tx|1|entity|C0041582|Ulcer|patf|||ulceration||||861|102|111
SE|00000000||tx|1|entity|C0009566|Complication|patf|||complications||||1000|117|129
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||888|143|152
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|154|158
SE|00000000||tx|1|relation|4|1|C0913246|valdecoxib|orch,phsu|orch|||valdecoxib||||1000|53|62|NOM|PREDISPOSES||91|94|4|1|C0041582|Ulcer|patf|patf|||ulceration||||861|102|111


SE|00000000||tx|1|text|Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||Dose||||888|1|4
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||888|6|14
SE|00000000||tx|1|entity|C0140575|Rifabutin|antb,orch|||rifabutin||||1000|19|27
SE|00000000||tx|1|entity|C2825407|Half|qnco|||half||||1000|32|35
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||861|50|53
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|61|64
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|66|73
SE|00000000||tx|1|entity|C0701105|Crixivan|orch,phsu|||CRIXIVAN||||1000|78|85
SE|00000000||tx|1|entity|C0205449|Three|qnco|||three||||813|99|103
SE|00000000||tx|1|entity|C2347138|Milligram per Capsule|qnco|||mg capsules||||813|109|119
SE|00000000||tx|1|entity|C1292429|8 Hours|tmco|||8 hours||||1000|128|134
SE|00000000||tx|1|entity|C0140575|Rifabutin|antb,orch|||rifabutin||||1000|157|165
SE|00000000||tx|1|entity|C0701105|Crixivan|orch,phsu|||CRIXIVAN||||1000|171|178


SE|00000000||tx|1|text|The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol;
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||1000|5|24
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|74|84
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||haloperidol||||1000|104|114


SE|00000000||tx|1|text|For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.
SE|00000000||tx|1|entity|C1707959|Example|cnce|||example||||1000|5|11
SE|00000000||tx|1|entity|C0021826|Intestinal Absorption|ortf|||gastrointestinal absorption||||1000|50|76
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulants||||1000|90|108
SE|00000000||tx|1|entity|C0042878|Vitamin K|lipd,phsu,vita|||vitamin K||||1000|114|122
SE|00000000||tx|1|entity|C1423506|SPINK5 gene|gngm|11005|SPINK5|net||||872|129|131
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||872|133|139
SE|00000000||tx|1|relation|5|1|C0042878|Vitamin K|lipd,phsu,vita|lipd|||vitamin K||||1000|114|122|NOM|INTERACTS_WITH||133|139|5|0|C1423506|SPINK5 gene|gngm,aapp|gngm|11005|SPINK5|net||||872|129|131


SE|00000000||tx|1|text|Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
SE|00000000||tx|1|entity|C0033554|Prostaglandins|bacs,eico,phsu|||prostaglandins||||1000|9|22
SE|00000000||tx|1|entity|C0019116|Hemostatic function|ortf|||hemostasis||||1000|50|59
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|66|71
SE|00000000||tx|1|entity|C1254881|Platelet function|celf|||platelet function||||1000|80|96
SE|00000000||tx|1|entity|C0205170|Good|qlco|||well||||901|101|104
SE|00000000||tx|1|entity|C0009429|Combined Modality Therapy|topp|||concurrent therapy||||901|107|124
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|135|140
SE|00000000||tx|1|entity|C0012091|Diclofenac|orch,phsu|||diclofenac||||1000|153|162
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|169|176
SE|00000000||tx|1|entity|C0587267|Closed|ftcn|||close||||694|187|191
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|207|214
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||1000|222|228
SE|00000000||tx|1|entity|C0443172|Changed status|qnco|||change||||1000|238|243
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulant||||901|254|266
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||901|268|273
SE|00000000||tx|1|relation|12|6|C0012091|Diclofenac|orch,phsu|orch|||diclofenac||||1000|153|162|NOM|AFFECTS||42|45|12|1|C0019116|Hemostatic function|ortf|ortf|||hemostasis||||1000|50|59
SE|00000000||tx|1|relation|12|6|C0043031|Warfarin|hops,orch,phsu|orch|||warfarin||||1000|169|176|NOM|AFFECTS||42|45|12|1|C0019116|Hemostatic function|ortf|ortf|||hemostasis||||1000|50|59
SE|00000000||tx|1|relation|6|1|C0009429|Combined Modality Therapy|topp|topp|||concurrent therapy||||901|107|124|PREP|USES||126|129|8|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|135|140


SE|00000000||tx|1|text|Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine.
SE|00000000||tx|1|entity|C0439590|Prolonged|tmco|||Prolonged||||802|1|9
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||802|20|23
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||888|38|49
SE|00000000||tx|1|entity|C0027415|Narcotics|hops,phsu|||narcotics||||1000|58|66
SE|00000000||tx|1|entity|C0022614|Ketamine|orch,phsu|||ketamine||||1000|95|102


SE|00000000||tx|1|text|Cimetidine: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|13|22
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||790|64|74
SE|00000000||tx|1|entity|C0231239|Fluctuation|sosy|||fluctuations||||790|76|87
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||877|92|103
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentrations||||877|105|124
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||901|137|161
SE|00000000||tx|1|relation|2|1|C0008783|Cimetidine|orch,phsu|orch|||Cimetidine||||1000|13|22|VERB|CAUSES||45|51|3|1|C0231239|Fluctuation|sosy|sosy|||fluctuations||||790|76|87


SE|00000000||tx|1|text|Probenecid: Pretreatment with Probenecid reduces both The natriuresis and hyperreninemia produced by bumetanide.
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|1|10
SE|00000000||tx|1|entity|C1550147|Pretreatment|sbst|||Pretreatment||||1000|13|24
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|31|40
SE|00000000||tx|1|entity|C0027477|Natriuresis|ortf|||natriuresis||||1000|59|69
SE|00000000||tx|1|entity|C0006376|Bumetanide|orch,phsu|||bumetanide||||1000|102|111
SE|00000000||tx|1|relation|3|1|C0033209|Probenecid|orch,phsu|orch|||Probenecid||||1000|31|40|VERB|INHIBITS||42|48|3|1|C0027477|Natriuresis|ortf|ortf|||natriuresis||||1000|59|69


SE|00000000||tx|1|text|Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||Tricyclic Antidepressants||||1000|1|25
SE|00000000||tx|1|entity|C1514468|product|enty|||products||||861|43|50
SE|00000000||tx|1|entity|C0020934|Imipramine|orch,phsu|||imipramine||||1000|57|66
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|78|102
SE|00000000||tx|1|entity|C0597362|receptor sensitivity|ftcn|||receptor sensitivity||||1000|117|136
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressant||||840|150|163
SE|00000000||tx|1|entity|C0439167|Percent Activity|qnco|||activity||||840|165|172
SE|00000000||tx|1|entity|C0205374|Transitory|tmco|||transient||||840|174|182
SE|00000000||tx|1|entity|C0003811|Cardiac Arrhythmia|patf|||cardiac arrhythmias||||840|184|202
SE|00000000||tx|1|relation|0|0|C0020934|Imipramine|orch,phsu|orch|||imipramine||||1000|57|66|SPEC|ISA||57|102|0|0|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|78|102
SE|00000000||tx|1|relation|0|0|C0020934|Imipramine|orch,phsu|orch|||imipramine||||1000|57|66|SPEC|ISA||57|102|0|0|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||Tricyclic Antidepressants||||1000|1|25


SE|00000000||tx|1|text|Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.
SE|00000000||tx|1|entity|C0282210|Isoproterenol Hydrochloride|orch,phsu|||Isoproterenol hydrochloride||||901|1|27
SE|00000000||tx|1|entity|C1533685|Injection procedure|topp|||injection||||901|29|37
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||epinephrine||||1000|43|53
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|62|64
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneously||||1000|82|95
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|110|114
SE|00000000||tx|1|entity|C0007209|Cardiotonic Agents|phsu|||cardiac stimulants||||901|127|144
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combined||||888|156|163
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|165|171
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||888|184|190
SE|00000000||tx|1|entity|C0003811|Cardiac Arrhythmia|patf|||arrhythmias||||888|192|202
SE|00000000||tx|1|relation|0|0|C0007209|Cardiotonic Agents|phsu|phsu|||cardiac stimulants||||901|127|144|SPEC|ISA||110|144|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|110|114
SE|00000000||tx|1|relation|0|0|C1533685|Injection procedure|topp|topp|||injection||||901|29|37|MOD/HEAD|USES||1|37|0|0|C0282210|Isoproterenol Hydrochloride|orch,phsu|phsu|||Isoproterenol hydrochloride||||901|1|27
SE|00000000||tx|1|relation|5|2|C0007209|Cardiotonic Agents|phsu|phsu|||cardiac stimulants||||901|127|144|VERB|CAUSES||177|182|1|1|C0003811|Cardiac Arrhythmia|patf|patf|||arrhythmias||||888|192|202


SE|00000000||tx|1|text|Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
SE|00000000||tx|1|entity|C1310721|Enablex|orch,phsu|||ENABLEX||||1000|30|36
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||1000|65|75
SE|00000000||tx|1|entity|C1332830|CYP2D6 gene|gngm|1565|CYP2D6|CYP2D6||||1000|115|120
SE|00000000||tx|1|entity|C0333164|Narrow|qnco|||narrow||||851|139|144
SE|00000000||tx|1|entity|C0302350|Therapeutic|ftcn|||therapeutic||||851|146|156
SE|00000000||tx|1|entity|C1272706|Interval|tmco|||window||||851|158|163
SE|00000000||tx|1|entity|C0016229|Flecainide|orch,phsu|||flecainide||||1000|174|183
SE|00000000||tx|1|entity|C0039943|Thioridazine|orch,phsu|||thioridazine||||1000|186|197
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|203|227
SE|00000000||tx|1|entity|C0031332|Clinical pharmacology discipline|bmod|||CLINICAL PHARMACOLOGY||||1000|234|254
SE|00000000||tx|1|relation|6|1|C1332830|CYP2D6 gene|gngm,aapp|gngm|1565|CYP2D6|CYP2D6||||1000|115|120|VERB|INTERACTS_WITH||100|110|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||1000|65|75


SE|00000000||tx|1|text|Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
SE|00000000||tx|1|entity|C0701176|Prinivil|aapp,phsu|||PRINIVIL||||1000|8|15
SE|00000000||tx|1|entity|C0304490|Potassium Sparing Diuretics|phsu|||potassium-sparing diuretics||||1000|22|48
SE|00000000||tx|1|entity|C0037982|Spironolactone|phsu,strd|||spironolactone||||1000|57|70
SE|00000000||tx|1|entity|C0040869|Triamterene|orch,phsu|||triamterene||||1000|73|83
SE|00000000||tx|1|entity|C0002502|Amiloride|orch,phsu|||amiloride||||1000|89|97
SE|00000000||tx|1|entity|C0304475|Potassium supplement|inch,phsu|||potassium supplements||||983|101|121
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||852|127|135
SE|00000000||tx|1|entity|C2700400|Contain (action)|acty|||containing||||852|137|146
SE|00000000||tx|1|entity|C0784217|Salt Substitute|inch,phsu|||salt substitutes||||852|148|163
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|177|187
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||888|189|197
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||888|202|206
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||888|208|216
SE|00000000||tx|1|relation|8|1|C0784217|Salt Substitute|inch,phsu|inch|||salt substitutes||||852|148|163|NOM|STIMULATES||189|197|1|1|C0032821|Potassium|elii|elii|||potassium||||888|208|216
SE|00000000||tx|1|relation|8|1|C0304475|Potassium supplement|inch,phsu|inch|||potassium supplements||||983|101|121|NOM|STIMULATES||189|197|1|1|C0032821|Potassium|elii|elii|||potassium||||888|208|216


SE|00000000||tx|1|text|Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.
SE|00000000||tx|1|entity|C0041983|Uricosuric Agents|phsu|||Uricosuric Agents||||1000|1|17
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||1000|30|38
SE|00000000||tx|1|entity|C0030086|Oxypurinol|orch,phsu|||oxipurinol||||1000|43|52
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||1000|57|63
SE|00000000||tx|1|entity|C0935936|Urate|bacs,nnon|||urate||||1000|76|80
SE|00000000||tx|1|entity|C0041983|Uricosuric Agents|phsu|||uricosuric agents||||1000|83|99
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||1000|121|129
SE|00000000||tx|1|entity|C0935936|Urate|bacs,nnon|||urate||||1000|134|138
SE|00000000||tx|1|entity|C0332148|Probable diagnosis|qlco|||likely||||827|150|155
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||1000|173|181
SE|00000000||tx|1|entity|C0030086|Oxypurinol|orch,phsu|||oxipurinol||||1000|186|195
SE|00000000||tx|1|entity|C0441889|Levels (qualifier value)|qlco|||degree||||1000|216|221
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|226|235
SE|00000000||tx|1|entity|C0043317|Xanthine Oxidase|aapp,enzy|||xanthine oxidase||||1000|240|255
SE|00000000||tx|1|relation|6|1|C0041983|Uricosuric Agents|phsu|phsu|||uricosuric agents||||1000|83|99|VERB|AUGMENTS||108|115|7|1|C0221102|Excretory function|phsf|phsf|||excretion||||1000|121|129
SE|00000000||tx|1|relation|8|1|C0935936|Urate|bacs,nnon|nnon|||urate||||1000|134|138|VERB|AUGMENTS||160|167|5|1|C0221102|Excretory function|phsf|phsf|||excretion||||1000|173|181
SE|00000000||tx|1|relation|11|2|C0030086|Oxypurinol|orch,phsu|orch|||oxipurinol||||1000|186|195|NOM|INHIBITS||226|235|1|1|C0043317|Xanthine Oxidase|aapp,gngm,enzy|gngm|||xanthine oxidase||||1000|240|255


SE|00000000||tx|1|text|When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.
SE|00000000||tx|1|entity|C0591179|Bezalip|orch,phsu|||Bezalip||||1000|6|12
SE|00000000||tx|1|entity|C0591179|Bezalip|orch,phsu|||Bezalip||||1000|17|23
SE|00000000||tx|1|entity|C0445247|Same|qlco|||same||||888|47|50
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||888|52|55
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medicines||||1000|66|74
SE|00000000||tx|1|entity|C0439861|Substance|sbst|||substances||||1000|79|88
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||872|94|102
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interactions||||872|104|115
SE|00000000||tx|1|entity|C2741673|Account number:Identifier:Point in time:^Patient:Nominal|clna|||account||||1000|136|142
SE|00000000||tx|1|entity|C0591179|Bezalip|orch,phsu|||Bezalip||||1000|147|153
SE|00000000||tx|1|entity|C0591179|Bezalip|orch,phsu|||Bezalip||||1000|159|165
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|190|195
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|200|213
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin||||694|222|229


SE|00000000||tx|1|text|Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.
SE|00000000||tx|1|entity|C0016410|Folic Acid|orch,phsu,vita|||Folic acid||||1000|1|10
SE|00000000||tx|1|entity|C0549177|Large|qnco|||large||||888|15|19
SE|00000000||tx|1|entity|C1265611|Quantity|qnco|||amounts||||888|21|27
SE|00000000||tx|1|entity|C0003299|Antiepileptic Agents|phsu|||antiepileptic||||901|48|60
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||901|62|67
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|72|84
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|87|95
SE|00000000||tx|1|entity|C0033148|Primidone|orch,phsu|||primidone||||1000|101|109
SE|00000000||tx|1|entity|C0439603|Frequencies (time pattern)|tmco|||frequency||||1000|129|137
SE|00000000||tx|1|entity|C0036572|Seizures|sosy|||seizures||||1000|142|149
SE|00000000||tx|1|entity|C0231204|Susceptible|ftcn|||susceptible||||851|154|164
SE|00000000||tx|1|entity|C0030755|Pediatric discipline|bmod|||pediatric||||851|166|174
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||851|176|183
SE|00000000||tx|1|relation|6|2|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|87|95|NOM|INTERACTS_WITH||62|67|6|1|C0031412|Phenobarbital|orch,phsu|orch|||phenobarbital||||1000|72|84
SE|00000000||tx|1|relation|6|1|C0033148|Primidone|orch,phsu|orch|||primidone||||1000|101|109|VERB|AUGMENTS||116|123|3|2|C0036572|Seizures|sosy|sosy|||seizures||||1000|142|149
SE|00000000||tx|1|relation|8|1|C0036572|Seizures|sosy|sosy|||seizures||||1000|142|149|PREP|PROCESS_OF||151|152|1|1|C0030705|Patients|podg,humn|humn|||patients||||851|176|183


SE|00000000||tx|1|text|In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multiple||||851|6|13
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||851|15|18
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||851|20|24
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|29|40
SE|00000000||tx|1|entity|C0556983|Once daily|tmco|||once daily||||1000|50|59
SE|00000000||tx|1|entity|C1442459|3 Days|tmco|||3 days||||1000|65|70
SE|00000000||tx|1|entity|C0055147|Cetirizine|orch,phsu|||cetirizine||||1000|77|86
SE|00000000||tx|1|entity|C0556983|Once daily|tmco|||once daily||||1000|95|104
SE|00000000||tx|1|entity|C1442459|3 Days|tmco|||3 days||||1000|110|115
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|125|132
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|141|149
SE|00000000||tx|1|entity|C0055147|Cetirizine|orch,phsu|||cetirizine||||1000|154|163


SE|00000000||tx|1|text|Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
SE|00000000||tx|1|entity|C0961485|eplerenone|phsu,strd|||eplerenone||||1000|19|28
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||861|41|46
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||861|48|57
SE|00000000||tx|1|entity|C1374596|Erythromycin 500 MG|clnd|||erythromycin 500 mg||||908|66|84
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||908|86|88
SE|00000000||tx|1|entity|C1123819|Verapamil 240 MG|clnd|||verapamil 240 mg||||916|91|106
SE|00000000||tx|1|entity|C0286738|Saquinavir|orch,phsu|||saquinavir||||775|112|121
SE|00000000||tx|1|entity|C0556984|Three times daily|tmco|||TID||||775|131|133
SE|00000000||tx|1|entity|C0986076|Fluconazole 200 MG|clnd|||fluconazole 200 mg||||916|136|153
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||1000|171|179
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|184|187
SE|00000000||tx|1|entity|C0961485|eplerenone|phsu,strd|||eplerenone||||872|192|201
SE|00000000||tx|1|entity|C1514721|Range|qnco|||ranging||||872|203|209
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||802|229|232
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|238|240
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||802|260|263
SE|00000000||tx|1|relation|2|1|C0961485|eplerenone|phsu,strd|phsu|||eplerenone||||1000|19|28|NOM|INHIBITS||48|57|2|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||861|41|46


SE|00000000||tx|1|text|The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|5|11
SE|00000000||tx|1|entity|C0001443|Adenosine|nnon,nsba,phsu|||adenosine||||1000|16|24
SE|00000000||tx|1|entity|C0066447|methylxanthine|orch,phsu|||methylxanthines||||1000|45|59
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|69|76
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|82|93
SE|00000000||tx|1|relation|0|0|C0006644|Caffeine|orch,phsu|orch|||caffeine||||1000|69|76|SPEC|ISA||45|76|0|0|C0066447|methylxanthine|orch,phsu|orch|||methylxanthines||||1000|45|59
SE|00000000||tx|1|relation|0|0|C0039771|Theophylline|bacs,orch,phsu|orch|||theophylline||||1000|82|93|SPEC|ISA||45|76|0|0|C0066447|methylxanthine|orch,phsu|orch|||methylxanthines||||1000|45|59


SE|00000000||tx|1|text|Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered.
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||Coumarin Anticoagulants||||983|1|23
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||rare||||888|42|45
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||901|58|66
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||901|68|83
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|88|95
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin anticoagulants||||983|104|126
SE|00000000||tx|1|entity|C0028066|Nifedipine|orch,phsu|||nifedipine||||1000|136|145
SE|00000000||tx|1|relation|3|3|C0010206|coumarin|orch,phsu|phsu|||Coumarin Anticoagulants||||983|1|23|PREP|TREATS||85|86|3|1|C0030705|Patients|podg,humn|podg|||patients||||1000|88|95
SE|00000000||tx|1|relation|2|1|C0010206|coumarin|orch,phsu|orch|||coumarin anticoagulants||||983|104|126|VERB|ADMINISTERED_TO||97|102|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|88|95


SE|00000000||tx|1|text|Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||central nervous system depressants||||1000|16|49
SE|00000000||tx|1|entity|C0020404|Hydroxyzine|orch,phsu|||hydroxyzine||||1000|87|97
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||1000|105|110


SE|00000000||tx|1|text|Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||Fluvoxamine||||762|1|11
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||762|13|21
SE|00000000||tx|1|entity|C0291772|alosetron|orch,phsu|||alosetron||||762|28|36
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||762|38|58
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|61|63
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||802|66|78
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||802|82|85
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||1000|105|113
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||802|118|130
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||802|134|137


SE|00000000||tx|1|text|However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||840|17|24
SE|00000000||tx|1|entity|C0851347|Pharmacodynamics|biof|||pharmacodynamic||||840|26|40
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interactions||||840|42|53
SE|00000000||tx|1|entity|C0876757|Precedex|orch,phsu|||PRECEDEX||||1000|82|89
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|94|102
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||1000|107|112
SE|00000000||tx|1|entity|C0876757|Precedex|orch,phsu|||PRECEDEX||||1000|117|124
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||851|133|143
SE|00000000||tx|1|entity|C0002932|Anesthetics|phsu|||anesthetic||||851|145|154
SE|00000000||tx|1|entity|C0020592|Hypnotics and Sedatives|phsu|||sedative||||851|157|164
SE|00000000||tx|1|entity|C0020591|Hypnotics|phsu|||hypnotic||||1000|167|174
SE|00000000||tx|1|entity|C0242402|Opioids|hops,orch,phsu|||opioid||||1000|179|184


SE|00000000||tx|1|text|The intake of furosemide and sucralfate should be separated by at least two hours.
SE|00000000||tx|1|entity|C1512806|Intake|ftcn|||intake||||1000|5|10
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|15|24
SE|00000000||tx|1|entity|C0038633|Sucralfate|carb,phsu|||sucralfate||||1000|30|39
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||840|67|71
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||840|73|75
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||840|77|81


SE|00000000||tx|1|text|Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.
SE|00000000||tx|1|entity|C0015011|Ethinyl Estradiol|horm,phsu,strd|||Ethinyl Estradiol||||1000|1|17
SE|00000000||tx|1|entity|C0028356|Norethindrone|horm,phsu,strd|||Norethindrone||||1000|23|35
SE|00000000||tx|1|entity|C0525004|Viracept|orch,phsu|||VIRACEPT||||1000|58|65
SE|00000000||tx|1|entity|C0307169|ovcon 35|clnd|||OVCON-35||||1000|72|79
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|99|106
SE|00000000||tx|1|entity|C0015011|Ethinyl Estradiol|horm,phsu,strd|||ethinyl estradiol||||1000|111|127
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|140|147
SE|00000000||tx|1|entity|C0028356|Norethindrone|horm,phsu,strd|||norethindrone||||890|152|164
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|166|186
SE|00000000||tx|1|relation|4|1|C0525004|Viracept|orch,phsu|orch|||VIRACEPT||||1000|58|65|NOM|INHIBITS||99|106|3|1|C0015011|Ethinyl Estradiol|horm,phsu,strd|horm|||ethinyl estradiol||||1000|111|127


SE|00000000||tx|1|text|If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.
SE|00000000||tx|1|entity|C0008290|Chlorprothixene|orch,phsu|||chlorprothixene||||888|4|18
SE|00000000||tx|1|entity|C0242402|Opioids|hops,orch,phsu|||opioids||||1000|48|54
SE|00000000||tx|1|entity|C0242402|Opioids|hops,orch,phsu|||opioid||||888|61|66
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|68|71
SE|00000000||tx|1|entity|C0008290|Chlorprothixene|orch,phsu|||chlorprothixene||||1000|117|131
SE|00000000||tx|1|entity|C0302350|Therapeutic|ftcn|||therapeutic||||888|147|157
SE|00000000||tx|1|entity|C0441472|Clinical action|ftcn|||actions||||888|159|165
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side-effects||||1000|171|182
SE|00000000||tx|1|entity|C0242402|Opioids|hops,orch,phsu|||opioids||||888|187|193
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||massively||||888|195|203
SE|00000000||tx|1|relation|6|1|C0242402|Opioids|hops,orch,phsu|hops|||opioids||||1000|48|54|VERB|COEXISTS_WITH||23|27|1|1|C0008290|Chlorprothixene|orch,phsu|orch|||chlorprothixene||||888|4|18


SE|00000000||tx|1|text|After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||787|38|41
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||787|43|54
SE|00000000||tx|1|entity|C0585361|Twice a day|tmco|||twice daily||||787|56|66
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||775|72|74
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||775|82|85
SE|00000000||tx|1|entity|C0065180|Loratadine|orch,phsu|||loratadine||||1000|90|99
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||827|107|114
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|121|123
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|129|132
SE|00000000||tx|1|entity|C0065180|Loratadine|orch,phsu|||loratadine||||1000|137|146
SE|00000000||tx|1|entity|C1301820|Obtain|ftcn|||obtained||||1000|220|227
SE|00000000||tx|1|entity|C0814472|co-treatment|hlca|||co-treatment||||1000|235|246
SE|00000000||tx|1|entity|C1696465|placebo|bodm|||placebo||||1000|253|259


SE|00000000||tx|1|text|In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|26|33
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|48|51
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||haloperidol||||888|53|63
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|69|76
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuation||||1000|79|93
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|98|105
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||728|127|130
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||728|132|139
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||haloperidol||||888|144|154
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|156|169
SE|00000000||tx|1|relation|6|1|C0018546|Haloperidol|orch,phsu|phsu|||haloperidol||||888|53|63|VERB|TREATS||35|41|1|1|C0030705|Patients|podg,humn|podg|||patients||||861|26|33
SE|00000000||tx|1|relation|5|3|C0035608|Rifampin|antb,orch|antb|||rifampin||||1000|69|76|NOM|STIMULATES||132|139|1|1|C0018546|Haloperidol|orch,phsu|orch|||haloperidol||||888|144|154


SE|00000000||tx|1|text|Indomethacin: Indomethacin blunts The increases In urine volume and sodium excretion seen during bumetanide treatment and inhibits The bumetanide-induced increase In plasma renin activity.
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||Indomethacin||||1000|1|12
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||Indomethacin||||1000|15|26
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||1000|39|47
SE|00000000||tx|1|entity|C0042036|Urine|bdsu|||urine||||888|52|56
SE|00000000||tx|1|entity|C0449468|Volume|qnco|||volume||||888|58|63
SE|00000000||tx|1|entity|C0037473|Sodium|bacs,elii|||sodium||||888|69|74
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|76|84
SE|00000000||tx|1|entity|C0006376|Bumetanide|orch,phsu|||bumetanide||||888|98|107
SE|00000000||tx|1|entity|C0006376|Bumetanide|orch,phsu|||bumetanide||||851|136|145
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induced||||851|147|153
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||851|155|162
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||901|167|172
SE|00000000||tx|1|entity|C1150120|renin activity|moft|||renin activity||||901|174|187


SE|00000000||tx|1|text|Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR.
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||Oral Anticoagulants||||1000|1|19
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||COUMARIN ANTICOAGULANTS||||983|54|76
SE|00000000||tx|1|entity|C0723893|Tricor|orch,phsu|||TRICOR||||1000|108|113


SE|00000000||tx|1|text|The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|18|24
SE|00000000||tx|1|entity|C0022252|Isosorbide Dinitrate|orch,phsu|||isosorbide dinitrate||||1000|29|48
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||1000|57|64
SE|00000000||tx|1|entity|C0042402|Vasodilator Agents|phsu|||vasodilators||||1000|86|97
SE|00000000||tx|1|relation|0|0|C0022252|Isosorbide Dinitrate|orch,phsu|orch|||isosorbide dinitrate||||1000|29|48|SPEC|ISA||29|97|0|0|C0042402|Vasodilator Agents|phsu|phsu|||vasodilators||||1000|86|97


SE|00000000||tx|1|text|It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|28|38
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||901|43|53
SE|00000000||tx|1|entity|C0010977|Dantrolene Sodium|orch,phsu|||dantrolene sodium||||901|55|71
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium channel blockers||||1000|77|100
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||1000|111|119
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|122|124
SE|00000000||tx|1|entity|C1883357|Together|qlco|||together||||1000|134|141
SE|00000000||tx|1|entity|C0001554|Administration occupational activities|ocac|||management||||1000|154|163
SE|00000000||tx|1|entity|C0024591|Malignant hyperpyrexia due to anesthesia|dsyn|||malignant hyperthermia||||901|168|189
SE|00000000||tx|1|entity|C0231224|Crisis|fndg|||crisis||||901|191|196
SE|00000000||tx|1|entity|C2347946|Relevance|qlco|||relevance||||1000|208|216
SE|00000000||tx|1|entity|C2926606|Procedure findings:Finding:Point in time:^Patient:Narrative|clna|||findings||||1000|227|234
SE|00000000||tx|1|entity|C0086418|Homo sapiens|humn|||humans||||1000|239|244
SE|00000000||tx|1|relation|0|0|C0042523|Verapamil|orch,phsu|orch|||verapamil||||1000|111|119|SPEC|ISA||77|119|0|0|C0006684|Calcium Channel Blockers|phsu|phsu|||calcium channel blockers||||1000|77|100
SE|00000000||tx|1|relation|4|1|C0042523|Verapamil|orch,phsu|phsu|||verapamil||||1000|111|119|NOM|TREATS||154|163|4|1|C0231224|Crisis|fndg|fndg|||crisis||||901|191|196


SE|00000000||tx|1|text|Other CNS depressant drugs should be used with caution in patients taking fenfluramine, since the effects may be additive.
SE|00000000||tx|1|entity|C0007680|Central Nervous System Agents|phsu|||CNS depressant drugs||||913|7|26
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|59|66
SE|00000000||tx|1|entity|C0015827|Fenfluramine|orch,phsu|||fenfluramine||||1000|75|86
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|99|105
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||1000|114|121
SE|00000000||tx|1|relation|2|2|C0007680|Central Nervous System Agents|phsu|phsu|||CNS depressant drugs||||913|7|26|PREP|TREATS||56|57|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|59|66
SE|00000000||tx|1|relation|3|1|C0015827|Fenfluramine|orch,phsu|orch|||fenfluramine||||1000|75|86|VERB|ADMINISTERED_TO||68|73|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|59|66


SE|00000000||tx|1|text|Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).
SE|00000000||tx|1|entity|C0871935|Theory|idcn|||theoretical||||888|10|20
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|22|25
SE|00000000||tx|1|entity|C0851347|Pharmacodynamics|biof|||pharmacodynamic||||888|32|46
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||888|48|58
SE|00000000||tx|1|entity|C0014710|Ergotamine|orch,phsu|||ergotamine||||1000|68|77
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||827|104|114
SE|00000000||tx|1|entity|C0012291|Dihydroergotamine|orch,phsu|||dihydroergotamine||||1000|122|138
SE|00000000||tx|1|entity|C0025842|Methysergide|orch,phsu|||methysergide||||1000|143|154
SE|00000000||tx|1|entity|C1099778|Frova|orch,phsu|||FROVA||||1000|161|165
SE|00000000||tx|1|entity|C1442770|24 Hours|tmco|||24 hours||||1000|174|181
SE|00000000||tx|1|entity|C1099778|Frova|orch,phsu|||frova||||562|229|233


SE|00000000||tx|1|text|Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|10|12
SE|00000000||tx|1|entity|C0291772|alosetron|orch,phsu|||alosetron||||1000|27|35
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|38|47
SE|00000000||tx|1|entity|C1261253|NAT2 protein, human|aapp,enzy|10|NAT2|N-acetyltransferase||||1000|52|70
SE|00000000||tx|1|entity|C2347946|Relevance|qlco|||relevant||||790|92|99
SE|00000000||tx|1|entity|C0686907|Consequence of|ftcn|||consequences||||790|101|112
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|118|122
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|132|140
SE|00000000||tx|1|entity|C0033216|Procainamide|orch,phsu|||procainamide||||1000|143|154
SE|00000000||tx|1|entity|C0020223|Hydralazine|orch,phsu|||hydralazine||||1000|161|171
SE|00000000||tx|1|relation|0|0|C0022209|isoniazid|orch,phsu|orch|||isoniazid||||1000|132|140|SPEC|ISA||118|140|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|118|122
SE|00000000||tx|1|relation|0|0|C0020223|Hydralazine|orch,phsu|orch|||hydralazine||||1000|161|171|SPEC|ISA||118|140|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|118|122
SE|00000000||tx|1|relation|0|0|C0033216|Procainamide|orch,phsu|orch|||procainamide||||1000|143|154|SPEC|ISA||118|140|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|118|122
SE|00000000||tx|1|relation|6|5|C0033216|Procainamide|orch,phsu|orch|||procainamide||||1000|143|154|NOM|INHIBITS||38|47|6|1|C1261253|NAT2 protein, human|aapp,gngm,enzy|gngm|10|NAT2|N-acetyltransferase||||1000|52|70
SE|00000000||tx|1|relation|6|5|C0020223|Hydralazine|orch,phsu|orch|||hydralazine||||1000|161|171|NOM|INHIBITS||38|47|6|1|C1261253|NAT2 protein, human|aapp,gngm,enzy|gngm|10|NAT2|N-acetyltransferase||||1000|52|70
SE|00000000||tx|1|relation|6|5|C0022209|isoniazid|orch,phsu|orch|||isoniazid||||1000|132|140|NOM|INHIBITS||38|47|6|1|C1261253|NAT2 protein, human|aapp,gngm,enzy|gngm|10|NAT2|N-acetyltransferase||||1000|52|70


SE|00000000||tx|1|text|Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|17|19
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|57|67
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||752|74|79
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||752|87|95
SE|00000000||tx|1|entity|C0332148|Probable diagnosis|qlco|||likely||||861|104|109
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||861|140|150
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|155|165
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|172|181
SE|00000000||tx|1|relation|2|2|C0002333|Alprazolam|orch,phsu|orch|||alprazolam||||1000|172|181|NOM|INTERACTS_WITH||140|150|2|1|C0085228|Fluvoxamine|orch,phsu|orch|||fluvoxamine||||1000|155|165


SE|00000000||tx|1|text|Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0027396|Naproxen|orch,phsu|||naproxen||||1000|31|38
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|44|50
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|55|57
SE|00000000||tx|1|entity|C0027396|Naproxen|orch,phsu|||naproxen||||1000|79|86
SE|00000000||tx|1|entity|C0005456|Binding Sites|rcpt|||binding sites||||1000|110|122
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|135|145
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|165|171
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||884|193|213
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||890|224|229
SE|00000000||tx|1|entity|C0444505|Peak level|qnco|||peak plasma levels||||890|219|236


SE|00000000||tx|1|text|Acitretin: Interferes with the contraceptive effect of microdosed progestin-containing minipill preparations.
SE|00000000||tx|1|entity|C0050559|Acitretin|orch,phsu|||Acitretin||||1000|1|9
SE|00000000||tx|1|entity|C3179447|Contraceptive Effect|phsf|||contraceptive effect||||1000|32|51
SE|00000000||tx|1|entity|C0033306|Progestins|horm,phsu,strd|||progestin||||861|67|75
SE|00000000||tx|1|entity|C0850358|minipill|topp|||minipill||||872|88|95
SE|00000000||tx|1|entity|C1521827|Preparation|ftcn|||preparations||||872|97|108


SE|00000000||tx|1|text|The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|25|31
SE|00000000||tx|1|entity|C2986719|Biological Half-Life|phpr|||biologic half-life||||964|47|64
SE|00000000||tx|1|entity|C0015837|Fenoprofen|orch,phsu|||fenoprofen||||1000|69|78
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|94|101
SE|00000000||tx|1|entity|C0311400|Metabolic|ftcn|||metabolic||||888|106|114
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|116|124
SE|00000000||tx|1|entity|C1274040|Result|ftcn|||results||||1000|131|137
SE|00000000||tx|1|entity|C0443228|Largest|qnco|||greater||||888|144|150
SE|00000000||tx|1|entity|C1265611|Quantity|qnco|||amount||||888|152|157
SE|00000000||tx|1|entity|C0015837|Fenoprofen|orch,phsu|||fenoprofen||||861|175|184
SE|00000000||tx|1|entity|C0042036|Urine|bdsu|||urine||||1000|193|197


SE|00000000||tx|1|text|Digitalis glycosides: amphotericin B-induced hypokalemia may potentiate digitalis toxicity.
SE|00000000||tx|1|entity|C0012253|Digitalis Glycosides|carb,phsu|||Digitalis glycosides||||1000|1|20
SE|00000000||tx|1|entity|C0002679|Amphotericin B|antb,orch|||amphotericin B||||861|23|36
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induced||||861|38|44
SE|00000000||tx|1|entity|C0020621|Hypokalemia|fndg|||hypokalemia||||861|46|56
SE|00000000||tx|1|entity|C0012254|Digitalis Toxicity|inpo|||digitalis toxicity||||1000|73|90
SE|00000000||tx|1|relation|2|2|C0012253|Digitalis Glycosides|carb,phsu|carb|||Digitalis glycosides||||1000|1|20|VERB|AUGMENTS||62|71|1|1|C0012254|Digitalis Toxicity|inpo|inpo|||digitalis toxicity||||1000|73|90


SE|00000000||tx|1|text|Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|12|14
SE|00000000||tx|1|entity|C0282563|Macrolides|orch,phsu|||macrolides||||1000|19|28
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|34|41
SE|00000000||tx|1|entity|C0205210|Clinical|qlco|||clinical||||888|46|53
SE|00000000||tx|1|entity|C3245512|practice|inpr|||practice||||888|55|62
SE|00000000||tx|1|entity|C0151502|INCREASED ANTICOAGULANT EFFECT|fndg|||increased anticoagulant effects||||966|89|119


SE|00000000||tx|1|text|Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.
SE|00000000||tx|1|entity|C0020546|Hypertensive crisis|dsyn|||Hypertensive crises||||966|1|19
SE|00000000||tx|1|entity|C0002509|Amines, Sympathomimetic|phsu|||sympathomimetic amines||||1000|40|61
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||827|101|104
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|123|150


SE|00000000||tx|1|text|Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||Cyclosporine||||1000|1|12
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||861|22|30
SE|00000000||tx|1|entity|C0444506|Trough|qnco|||trough||||775|40|45
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||775|47|58
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||775|60|73
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|99|108
SE|00000000||tx|1|entity|C0054836|carvedilol|orch,phsu|||carvedilol||||888|113|122
SE|00000000||tx|1|entity|C0022671|Kidney Transplantation|topp|||renal transplant||||824|140|155
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||824|157|164
SE|00000000||tx|1|entity|C0205191|chronic|tmco|||chronic||||851|181|187
SE|00000000||tx|1|entity|C1801960|Vascular|qlco|||vascular||||851|189|196
SE|00000000||tx|1|entity|C1548437|Rejected|idcn|||rejection||||851|198|206
SE|00000000||tx|1|relation|2|2|C0010592|Cyclosporine|aapp,gngm,phsu|aapp|||Cyclosporine||||1000|1|12|PREP|COEXISTS_WITH||32|33|5|1|C0010592|Cyclosporine|aapp,gngm,phsu|gngm|||cyclosporine||||775|47|58
SE|00000000||tx|1|relation|4|0|C0054836|carvedilol|orch,phsu|phsu|||carvedilol||||888|113|122|NOM|TREATS||124|132|2|1|C0030705|Patients|podg,humn|podg|||patients||||824|157|164


SE|00000000||tx|1|text|Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||Agents||||966|1|6
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||Serum||||888|19|23
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||Potassium||||888|25|33
SE|00000000||tx|1|entity|C0014025|Enalapril|aapp,phsu|||Enalapril||||1000|36|44
SE|00000000||tx|1|entity|C0014025|Enalapril|aapp,phsu|||enalapril||||694|50|58
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||888|73|81
SE|00000000||tx|1|entity|C1517945|Loss|qnco|||loss||||888|83|86
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide-type diuretics||||913|98|120
SE|00000000||tx|1|relation|4|2|C0014025|Enalapril|aapp,gngm,phsu|aapp|||Enalapril||||1000|36|44|VERB|INHIBITS||63|71|2|1|C0032821|Potassium|elii|elii|||potassium||||888|73|81


SE|00000000||tx|1|text|Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||Quinidine||||1000|1|9
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||1000|12|20
SE|00000000||tx|1|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||1000|23|32
SE|00000000||tx|1|entity|C0033429|Propafenone|orch,phsu|||propafenone||||1000|35|45
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|48|59
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|62|73
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|76|85
SE|00000000||tx|1|entity|C0037982|Spironolactone|phsu,strd|||spironolactone||||1000|92|105
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||901|123|129
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum digoxin concentration||||901|117|143
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|154|162
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|167|175
SE|00000000||tx|1|entity|C0449468|Volume|qnco|||volume||||1000|187|192
SE|00000000||tx|1|entity|C1704711|Distribution|ftcn|||distribution||||1000|197|208
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||1000|217|220
SE|00000000||tx|1|entity|C0151595|DIGITALIS INTOXICATION|inpo|||digitalis intoxication||||1000|249|270


SE|00000000||tx|1|text|Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.
SE|00000000||tx|1|entity|C0700321|Small|qnco|||small||||888|16|20
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|22|27
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||1000|32|40
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||861|69|78
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||1000|94|102
SE|00000000||tx|1|entity|C1120106|ertapenem|antb,orch|||ertapenem||||1000|107|115
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|120|122


SE|00000000||tx|1|text|Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||Acetaminophen||||1000|1|13
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||802|19|30
SE|00000000||tx|1|entity|C0025646|Methionine|aapp,bacs,phsu|||methionine||||802|36|45
SE|00000000||tx|1|entity|C0205054|Hepatic|blor|||hepatic||||888|60|66
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||888|68|75
SE|00000000||tx|1|entity|C0332287|In addition to|qlco|||with||||623|86|89
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||623|91|103
SE|00000000||tx|1|entity|C1515187|Take|hlca|||taking||||872|128|133
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||872|135|146
SE|00000000||tx|1|relation|2|1|C0025646|Methionine|aapp,gngm,bacs,phsu|bacs|||methionine||||802|36|45|VERB|PREVENTS||51|58|3|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||888|68|75
SE|00000000||tx|1|relation|0|0|C0205054|Hepatic|blor|blor|||hepatic||||888|60|66|MOD/HEAD|LOCATION_OF||60|75|0|0|C0600688|Toxic effect|inpo|inpo|||toxicity||||888|68|75


SE|00000000||tx|1|text|Clarithromycin exposure was significantly decreased by nevirapine;
SE|00000000||tx|1|entity|C0055856|Clarithromycin|antb,orch|||Clarithromycin||||694|1|14
SE|00000000||tx|1|entity|C0132326|Nevirapine|nnon,phsu|||nevirapine||||1000|56|65
SE|00000000||tx|1|relation|1|1|C0132326|Nevirapine|nnon,phsu|phsu|||nevirapine||||1000|56|65|VERB|INHIBITS||43|51|1|1|C0055856|Clarithromycin|antb,orch|antb|||Clarithromycin||||694|1|14


SE|00000000||tx|1|text|Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0591842|ReVia|orch,phsu|||REVIA||||1000|17|21
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|27|29
SE|00000000||tx|1|entity|C0242402|Opioids|hops,orch,phsu|||opioid||||851|44|49
SE|00000000||tx|1|entity|C2700400|Contain (action)|acty|||containing||||851|51|60
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medicines||||851|62|70
SE|00000000||tx|1|entity|C0010200|Coughing|sosy|||cough||||1000|81|85
SE|00000000||tx|1|entity|C1521827|Preparation|ftcn|||preparations||||827|96|107
SE|00000000||tx|1|entity|C0718565|Anti-Diarrheal|orch,phsu|||antidiarrheal||||872|110|122
SE|00000000||tx|1|entity|C1521827|Preparation|ftcn|||preparations||||872|124|135
SE|00000000||tx|1|entity|C0002772|Analgesics, Opioid|orch,phsu|||opioid analgesics||||1000|142|158
SE|00000000||tx|1|relation|6|1|C0591842|ReVia|orch,phsu|orch|||REVIA||||1000|17|21|VERB|ADMINISTERED_TO||10|15|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8


SE|00000000||tx|1|text|It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||888|40|46
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|48|61
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|66|73
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|85|96
SE|00000000||tx|1|relation|1|1|C0012265|Digoxin|carb,phsu,strd|phsu|||digoxin||||888|40|46|PREP|TREATS||63|64|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|66|73
SE|00000000||tx|1|relation|1|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|85|96|VERB|ADMINISTERED_TO||75|83|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|66|73


SE|00000000||tx|1|text|As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|24|30
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|36|42
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|73|79
SE|00000000||tx|1|entity|C0311392|Physical findings|fndg|||signs||||1000|114|118
SE|00000000||tx|1|entity|C0238242|LITHIUM TOXICITY|inpo|||lithium toxicity||||1000|123|138
SE|00000000||tx|1|relation|4|2|C0023870|Lithium|elii,phsu|phsu|||lithium||||1000|36|42|PREP|TREATS||110|112|2|1|C0311392|Physical findings|fndg|fndg|||signs||||1000|114|118
SE|00000000||tx|1|relation|4|2|C0700798|Indocin|orch,phsu|phsu|||INDOCIN||||1000|24|30|PREP|TREATS||110|112|2|1|C0311392|Physical findings|fndg|fndg|||signs||||1000|114|118


SE|00000000||tx|1|text|Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||Oral contraceptives||||1000|1|19
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|22|31
SE|00000000||tx|1|entity|C0556983|Once daily|tmco|||once daily||||1000|45|54
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|63|66
SE|00000000||tx|1|entity|C2347138|Milligram per Capsule|qnco|||mg capsule||||901|77|86
SE|00000000||tx|1|entity|C0029151|Oral contraception|topp|||oral contraceptive||||1000|96|113
SE|00000000||tx|1|entity|C0439211|microgram|qnco|||mcg||||861|129|131
SE|00000000||tx|1|entity|C0015011|Ethinyl Estradiol|horm,phsu,strd|||ethinyl estradiol||||1000|136|152
SE|00000000||tx|1|entity|C0028356|Norethindrone|horm,phsu,strd|||norethindrone||||1000|166|178
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|195|197
SE|00000000||tx|1|entity|C0015011|Ethinyl Estradiol|horm,phsu,strd|||ethinyl estradiol||||1000|202|218
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|246|248
SE|00000000||tx|1|entity|C0028356|Norethindrone|horm,phsu,strd|||norethindrone||||1000|253|265


SE|00000000||tx|1|text|Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;
SE|00000000||tx|1|entity|C1511726|Data|idcn|||Data||||1000|1|4
SE|00000000||tx|1|entity|C0034656|Randomization|resa|||randomized||||888|13|22
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||trial||||888|24|28
SE|00000000||tx|1|entity|C0594753|Hexalen|orch,phsu|||HEXALEN||||1000|33|39
SE|00000000||tx|1|entity|C0008838|Cisplatin|inch,phsu|||cisplatin||||1000|45|53
SE|00000000||tx|1|entity|C0332288|Without|qlco|||minus||||888|63|67
SE|00000000||tx|1|entity|C0034272|pyridoxine|orch,phsu,vita|||pyridoxine||||888|69|78
SE|00000000||tx|1|entity|C0029925|Ovarian Carcinoma|neop|||ovarian cancer||||1000|83|96
SE|00000000||tx|1|entity|C0034272|pyridoxine|orch,phsu,vita|||pyridoxine||||597|113|122
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduced||||597|138|144
SE|00000000||tx|1|relation|5|1|C0034272|pyridoxine|orch,phsu,vita|vita|||pyridoxine||||888|69|78|PREP|ASSOCIATED_WITH||80|81|2|1|C0029925|Ovarian Carcinoma|neop|neop|||ovarian cancer||||1000|83|96
SE|00000000||tx|1|relation|5|1|C0008838|Cisplatin|inch,phsu|inch|||cisplatin||||1000|45|53|PREP|ASSOCIATED_WITH||80|81|2|1|C0029925|Ovarian Carcinoma|neop|neop|||ovarian cancer||||1000|83|96


SE|00000000||tx|1|text|conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).
SE|00000000||tx|1|entity|C0012201|Diethylpropion|orch,phsu|||diethylpropion||||1000|13|26
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensive drugs||||1000|47|68
SE|00000000||tx|1|entity|C0018318|Guanethidine|orch,phsu|||guanethidine||||1000|77|88
SE|00000000||tx|1|entity|C0025741|Methyldopa|nsba,phsu|||methyldopa||||1000|93|102


SE|00000000||tx|1|text|Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|entity|C0031332|Clinical pharmacology discipline|bmod|||clinical pharmacology||||901|16|36
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||901|38|42
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacid||||1000|68|74
SE|00000000||tx|1|entity|C0002371|Aluminum Hydroxide|inch,phsu|||aluminum hydroxide||||1000|77|94
SE|00000000||tx|1|entity|C0024476|Magnesium Hydroxide|inch,phsu|||magnesium hydroxide||||1000|97|115
SE|00000000||tx|1|entity|C0037138|Simethicone|bodm,orch,phsu|||simethicone||||1000|122|132
SE|00000000||tx|1|entity|C0118168|Fosinopril|opco,phsu|||fosinopril||||1000|140|149
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||861|159|163
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||urinary||||888|176|182
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|184|192
SE|00000000||tx|1|entity|C0075061|fosinoprilic acid|aapp,opco,phsu|||fosinoprilat||||1000|197|208
SE|00000000||tx|1|entity|C0118168|Fosinopril|opco,phsu|||fosinopril||||1000|227|236
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|251|255
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|274|281
SE|00000000||tx|1|entity|C0118168|Fosinopril|opco,phsu|||fosinopril||||1000|308|317
SE|00000000||tx|1|relation|11|1|C0075061|fosinoprilic acid|aapp,gngm,opco,phsu|aapp|||fosinoprilat||||1000|197|208|VERB|compared_with||213|220|5|1|C0118168|Fosinopril|opco,phsu|opco|||fosinopril||||1000|227|236
SE|00000000||tx|1|relation|0|0|C0002371|Aluminum Hydroxide|inch,phsu|inch|||aluminum hydroxide||||1000|77|94|SPEC|ISA||68|94|0|0|C0003138|Antacids|phsu|phsu|||antacid||||1000|68|74
SE|00000000||tx|1|relation|0|0|C0024476|Magnesium Hydroxide|inch,phsu|inch|||magnesium hydroxide||||1000|97|115|SPEC|ISA||68|94|0|0|C0003138|Antacids|phsu|phsu|||antacid||||1000|68|74


SE|00000000||tx|1|text|Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen.
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||Serious||||802|1|7
SE|00000000||tx|1|entity|C1457887|Symptoms|sosy|||symptoms||||802|25|32
SE|00000000||tx|1|entity|C0043352|Xerostomia|dsyn|||dry mouth||||901|42|50
SE|00000000||tx|1|entity|C0080274|Urinary Retention|fndg|||urinary retention||||1000|53|69
SE|00000000||tx|1|entity|C0344232|Blurred vision|sosy|||blurred vision||||1000|72|85
SE|00000000||tx|1|entity|C0702240|Elevation|spco|||elevations||||1000|114|123
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||861|132|136
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|148|172
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|179|188
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||888|206|209
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||regimen||||888|211|217
SE|00000000||tx|1|relation|0|0|C0043352|Xerostomia|dsyn|dsyn|||dry mouth||||901|42|50|SPEC|ISA||25|50|0|0|C1457887|Symptoms|sosy|sosy|||symptoms||||802|25|32
SE|00000000||tx|1|relation|0|0|C0040808|Treatment Protocols|topp|topp|||regimen||||888|211|217|MOD/HEAD|USES||206|217|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||888|206|209


SE|00000000||tx|1|text|Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||Inhibitors||||1000|1|10
SE|00000000||tx|1|entity|C1332826|CYP1A2 gene|gngm|1544|CYP1A2|CYP1A2||||1000|15|20
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|23|33
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|35|37
SE|00000000||tx|1|entity|C0245561|duloxetine|orch,phsu|||duloxetine||||1000|42|51
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|58|68
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||1000|74|82
SE|00000000||tx|1|entity|C1332826|CYP1A2 gene|gngm|1544|CYP1A2|CYP1A2||||1000|87|92
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||1000|106|118
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||790|124|127
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||790|129|136
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|141|143
SE|00000000||tx|1|entity|C0450346|2/5|qnco|||2.5||||861|157|159
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||861|161|164
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|166|173
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|178|181
SE|00000000||tx|1|entity|C0245561|duloxetine|orch,phsu|||duloxetine||||1000|186|195
SE|00000000||tx|1|relation|5|1|C0085228|Fluvoxamine|orch,phsu|orch|||fluvoxamine||||1000|58|68|NOM|INHIBITS||74|82|6|1|C1332826|CYP1A2 gene|gngm,aapp|gngm|1544|CYP1A2|CYP1A2||||1000|87|92


SE|00000000||tx|1|text|Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulant||||734|36|53
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||623|69|77
SE|00000000||tx|1|entity|C0033706|Prothrombin|aapp,bacs,phsu|||prothrombin||||623|79|89
SE|00000000||tx|1|entity|C0024554|Male gender|fndg|||man||||1000|104|106
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|116|122
SE|00000000||tx|1|relation|4|4|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|PREP|TREATS||101|102|2|1|C0024554|Male gender|fndg|fndg|||man||||1000|104|106


SE|00000000||tx|1|text|However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interactions||||966|10|21
SE|00000000||tx|1|entity|C1174734|UroXatral|orch,phsu|||UROXATRAL||||1000|44|52
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||NOT||||1000|61|63
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|76|86
SE|00000000||tx|1|entity|C0001641|Adrenergic alpha-Antagonists|phsu|||alpha-blockers||||1000|99|112


SE|00000000||tx|1|text|Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||824|13|20
SE|00000000||tx|1|entity|C0150457|Anticoagulant therapy|topp|||anticoagulant therapy||||824|27|47
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||694|61|66
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulant||||1000|86|98
SE|00000000||tx|1|entity|C0018242|Griseofulvin|orch,phsu|||griseofulvin||||888|117|128


SE|00000000||tx|1|text|Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||Terfenadine||||1000|1|11
SE|00000000||tx|1|entity|C0085170|Astemizole|orch,phsu|||astemizole||||1000|14|23
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|29|37
SE|00000000||tx|1|entity|C0010798|Cytochromes|aapp,bacs|||cytochrome||||802|66|75
SE|00000000||tx|1|entity|C0022173|Isoenzymes|aapp,enzy|||isozyme||||802|87|93
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|130|141
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||838|146|151
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||838|153|161
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|184|193
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|204|208
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||890|224|232
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|234|254
SE|00000000||tx|1|entity|C0030551|parent|famg|||parent||||888|259|264
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||888|266|269
SE|00000000||tx|1|relation|8|1|C0010798|Cytochromes|aapp,gngm,bacs|aapp|||cytochrome||||802|66|75|VERB|INTERACTS_WITH||47|57|3|1|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|29|37
SE|00000000||tx|1|relation|8|1|C0010798|Cytochromes|aapp,gngm,bacs|aapp|||cytochrome||||802|66|75|VERB|INTERACTS_WITH||47|57|3|1|C0085170|Astemizole|orch,phsu|orch|||astemizole||||1000|14|23
SE|00000000||tx|1|relation|8|1|C0010798|Cytochromes|aapp,gngm,bacs|aapp|||cytochrome||||802|66|75|VERB|INTERACTS_WITH||47|57|3|1|C0085173|Terfenadine|orch,phsu|orch|||Terfenadine||||1000|1|11
SE|00000000||tx|1|relation|7|3|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|130|141|VERB|INHIBITS||173|178|4|2|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|204|208


SE|00000000||tx|1|text|Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.
SE|00000000||tx|1|entity|C0028005|Nicardipine|orch,phsu|||Nicardipine||||660|1|11
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|30|32
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|44|49
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|61|67
SE|00000000||tx|1|entity|C1306421|Serum digoxin measurement|lbpr|||serum digoxin levels||||983|79|98
SE|00000000||tx|1|entity|C1707479|Concomitant Therapy|topp|||concomitant therapy||||1000|126|144
SE|00000000||tx|1|entity|C0028005|Nicardipine|orch,phsu|||nicardipine||||694|151|161


SE|00000000||tx|1|text|Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|15|25
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|31|33
SE|00000000||tx|1|entity|C0008806|Cinoxacin|orch,phsu|||cinoxacin||||1000|54|62
SE|00000000||tx|1|entity|C0008806|Cinoxacin|orch,phsu|||cinoxacin||||1000|98|106
SE|00000000||tx|1|entity|C2700400|Contain (action)|acty|||containing||||901|145|154
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine-containing products||||901|136|163
SE|00000000||tx|1|relation|1|1|C0006644|Caffeine|orch,phsu|orch|||caffeine-containing products||||901|136|163|VERB|COEXISTS_WITH||111|115|4|1|C0008806|Cinoxacin|orch,phsu|orch|||cinoxacin||||1000|98|106


SE|00000000||tx|1|text|therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|32|41
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|48|52
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||861|75|80
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||861|82|89
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|98|105
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|108|120
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|123|131
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||890|156|161
SE|00000000||tx|1|entity|C0424099|Reduced concentration|fndg|||reduced plasma concentrations||||890|148|176
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||aprepitant||||1000|181|190
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||decreased||||888|211|219
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||888|221|228
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|233|242
SE|00000000||tx|1|relation|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|48|52|VERB|STIMULATES||68|73|8|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||861|75|80
SE|00000000||tx|1|relation|7|5|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|48|52|VERB|CAUSES||138|143|4|1|C0424099|Reduced concentration|fndg|fndg|||reduced plasma concentrations||||890|148|176
SE|00000000||tx|1|relation|9|1|C1176306|aprepitant|orch,phsu|orch|||aprepitant||||1000|181|190|ADJ|INHIBITS||211|219|1|1|C1176306|aprepitant|orch,phsu|orch|||Aprepitant||||1000|233|242


SE|00000000||tx|1|text|Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|14|21
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|24|32
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|35|47
SE|00000000||tx|1|entity|C1142644|Cytochrome P450 3A4|aapp,enzy|||cytochrome P450 3A4||||1000|72|90
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|104|112
SE|00000000||tx|1|entity|C0765273|bexarotene|orch,phsu|||bexarotene||||890|124|133
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma bexarotene concentrations||||890|117|148
SE|00000000||tx|1|relation|3|1|C0031412|Phenobarbital|orch,phsu|orch|||phenobarbital||||1000|35|47|NOM|STIMULATES||60|67|3|1|C1142644|Cytochrome P450 3A4|aapp,gngm,enzy|gngm|||cytochrome P450 3A4||||1000|72|90
SE|00000000||tx|1|relation|5|4|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|24|32|NOM|INHIBITS||104|112|1|1|C0765273|bexarotene|orch,phsu|orch|||bexarotene||||890|124|133


SE|00000000||tx|1|text|Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|13|15
SE|00000000||tx|1|entity|C0546852|2-Bromoergocryptine Mesylate|orch,phsu|||bromocriptine mesylate||||1000|20|41
SE|00000000||tx|1|entity|C0014707|Ergot Alkaloids|bacs,orch,phsu|||ergot alkaloids||||1000|54|68
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|73|75


SE|00000000||tx|1|text|Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||TCA||||890|8|10
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||Plasma TCA concentrations||||890|1|25
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|60|63
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||TCA||||1000|72|74
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||TCA||||1000|104|106
SE|00000000||tx|1|entity|C0245561|duloxetine|orch,phsu|||Duloxetine||||1000|132|141


SE|00000000||tx|1|text|Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
SE|00000000||tx|1|entity|C0079691|Levothyroxine Sodium|aapp,horm,phsu|||Levothyroxine Sodium||||734|1|20
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||872|38|46
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||872|48|53
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||694|68|75
SE|00000000||tx|1|entity|C0079691|Levothyroxine Sodium|aapp,horm,phsu|||levothyroxine sodium||||1000|91|110
SE|00000000||tx|1|entity|C1281182|Entire gastrointestinal tract|bdsy|||gastrointestinal tract||||1000|121|142
SE|00000000||tx|1|entity|C0002367|Aluminum|elii|||aluminum||||694|145|152
SE|00000000||tx|1|entity|C0008402|Cholestyramine Resin|orch,phsu|||cholestyramine resin||||1000|164|183
SE|00000000||tx|1|entity|C0354648|Colestipol Hydrochloride|orch,phsu|||colestipol hydrochloride||||1000|186|209
SE|00000000||tx|1|entity|C0060282|ferrous sulfate|inch,phsu|||ferrous sulfate||||1000|212|226
SE|00000000||tx|1|entity|C0142915|Sodium polystyrene sulfonate|orch,phsu|||sodium polystyrene sulfonate||||1000|229|256
SE|00000000||tx|1|entity|C1262902|Glycine max|plnt|||soybean||||901|259|265
SE|00000000||tx|1|entity|C0016260|Flour|food|||flour||||901|267|271
SE|00000000||tx|1|entity|C0150589|Infant formula|food|||infant formula||||1000|280|293
SE|00000000||tx|1|entity|C0038633|Sucralfate|carb,phsu|||sucralfate||||1000|297|306


SE|00000000||tx|1|text|Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||Warfarin||||1000|1|8
SE|00000000||tx|1|entity|C0252643|bosentan|orch,phsu|||bosentan||||768|32|39
SE|00000000||tx|1|entity|C0439423|Milligram per 24 Hours|qnco|||mg b.i.d||||768|45|52
SE|00000000||tx|1|entity|C1442469|6 Days|tmco|||6 days||||1000|59|64
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|80|100
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||888|112|119
SE|00000000||tx|1|entity|||gngm|1559|CYP2C9|CYP2C9||||1000|124|129
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||888|148|155
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|160|165
SE|00000000||tx|1|entity|C0450361|38|inpr|||38%||||1000|188|190
SE|00000000||tx|1|relation|4|4|C0043031|Warfarin|hops,orch,phsu|hops|||Warfarin||||1000|1|8|VERB|INHIBITS||66|74|5|2|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||888|112|119
SE|00000000||tx|1|relation|4|4|C0043031|Warfarin|hops,orch,phsu|hops|||Warfarin||||1000|1|8|VERB|INHIBITS||66|74|5|2|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||888|148|155


SE|00000000||tx|1|text|Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic blockers||||1000|10|33
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium channel blockers||||1000|38|61
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|67|73
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||861|92|102
SE|00000000||tx|1|entity|C0004238|Atrial Fibrillation|patf|||atrial fibrillation||||1000|115|133
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|142|149
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|151|157
SE|00000000||tx|1|entity|C0004247|Structure of atrioventricular node|bpoc|||AV node||||734|162|168
SE|00000000||tx|1|entity|C0151517|Complete atrioventricular block|dsyn|||complete heart block||||1000|207|226
SE|00000000||tx|1|relation|5|3|C0012265|Digoxin|carb,phsu,strd|phsu|||digoxin||||1000|67|73|VERB|TREATS||107|113|5|1|C0004238|Atrial Fibrillation|patf|patf|||atrial fibrillation||||1000|115|133
SE|00000000||tx|1|relation|5|3|C0012265|Digoxin|carb,phsu,strd|phsu|||digoxin||||1000|67|73|VERB|TREATS||107|113|5|1|C0151517|Complete atrioventricular block|dsyn|dsyn|||complete heart block||||1000|207|226
SE|00000000||tx|1|relation|5|3|C0006684|Calcium Channel Blockers|phsu|phsu|||calcium channel blockers||||1000|38|61|VERB|TREATS||107|113|5|1|C0004238|Atrial Fibrillation|patf|patf|||atrial fibrillation||||1000|115|133
SE|00000000||tx|1|relation|5|4|C0006684|Calcium Channel Blockers|phsu|phsu|||calcium channel blockers||||1000|38|61|VERB|TREATS||107|113|5|5|C0151517|Complete atrioventricular block|dsyn|dsyn|||complete heart block||||1000|207|226


SE|00000000||tx|1|text|Haloperidol: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||Haloperidol||||1000|1|11
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||Haloperidol||||1000|14|24
SE|00000000||tx|1|entity|C0034798|Dopamine Receptor|aapp,rcpt|||dopamine receptors||||1000|33|50
SE|00000000||tx|1|entity|C0002763|Central Nervous System Stimulants|phsu|||central stimulant||||901|73|89
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||901|91|97
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||amphetamines||||1000|102|113
SE|00000000||tx|1|relation|2|1|C0018546|Haloperidol|orch,phsu|orch|||Haloperidol||||1000|14|24|VERB|INHIBITS||26|31|3|1|C0034798|Dopamine Receptor|aapp,gngm,rcpt|gngm|||dopamine receptors||||1000|33|50
SE|00000000||tx|1|relation|3|3|C0018546|Haloperidol|orch,phsu|orch|||Haloperidol||||1000|1|11|NOM|INTERACTS_WITH||91|97|3|0|C0002763|Central Nervous System Stimulants|phsu|phsu|||central stimulant||||901|73|89


SE|00000000||tx|1|text|Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||775|34|41
SE|00000000||tx|1|entity|C0205160|Negative|qlco|||negative||||775|43|50
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||775|62|68
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta blockers||||1000|73|85
SE|00000000||tx|1|entity|C0016229|Flecainide|orch,phsu|||flecainide||||1000|91|100


SE|00000000||tx|1|text|Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.
SE|00000000||tx|1|entity|C0002679|Amphotericin B|antb,orch|||Amphotericin B||||901|1|14
SE|00000000||tx|1|entity|C1533685|Injection procedure|topp|||injection||||901|16|24
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||829|30|38
SE|00000000||tx|1|entity|C0333668|Depletion|ftcn|||depleting||||829|40|48
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||829|50|55
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|63|77
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||829|115|123
SE|00000000||tx|1|entity|C0333668|Depletion|ftcn|||depleting||||829|125|133
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||829|135|140
SE|00000000||tx|1|entity|C0002679|Amphotericin B|antb,orch|||amphotericin B||||1000|149|162
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|165|173
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|177|184
SE|00000000||tx|1|entity|C1527148|Development|ftcn|||development||||1000|217|227
SE|00000000||tx|1|entity|C0020621|Hypokalemia|fndg|||hypokalemia||||1000|232|242
SE|00000000||tx|1|relation|0|0|C1533685|Injection procedure|topp|topp|||injection||||901|16|24|MOD/HEAD|USES||1|24|0|0|C0002679|Amphotericin B|antb,orch|antb|||Amphotericin B||||901|1|14
SE|00000000||tx|1|relation|3|3|C1533685|Injection procedure|topp|topp|||injection||||901|16|24|PREP|USES||110|113|6|1|C1254351|Pharmacologic Substance|phsu|phsu|||agents||||829|135|140


SE|00000000||tx|1|text|Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;
SE|00000000||tx|1|entity|C0030095|Oxytocin|aapp,horm,phsu|||Oxytocin||||1000|1|8
SE|00000000||tx|1|entity|C0030094|Oxytocics|phsu|||oxytocics||||1000|19|27
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|30|39
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|41|43
SE|00000000||tx|1|entity|C0012471|Dinoprost|eico,horm,phsu|||dinoprost||||1000|50|58
SE|00000000||tx|1|entity|C0269842|Hypertonic uterine dysfunction|patf|||uterine hypertonus||||1000|74|91
SE|00000000||tx|1|entity|C2362652|Possible diagnosis|qlco|||possibly||||1000|94|101
SE|00000000||tx|1|entity|C0042143|Uterine Rupture|dsyn|||uterine rupture||||1000|111|125
SE|00000000||tx|1|entity|C0007851|Cervical laceration|inpo|||cervical laceration||||1000|130|148
SE|00000000||tx|1|entity|C0332197|Absent|qnco|||absence||||1000|169|175
SE|00000000||tx|1|entity|C0205410|Sufficient|qlco|||adequate||||623|180|187
SE|00000000||tx|1|entity|C0205064|Cervical|spco|||cervical||||623|189|196
SE|00000000||tx|1|relation|0|0|C0030095|Oxytocin|aapp,gngm,horm,phsu|aapp|||Oxytocin||||1000|1|8|SPEC|ISA||1|27|0|0|C0030094|Oxytocics|phsu|phsu|||oxytocics||||1000|19|27
SE|00000000||tx|1|relation|0|0|C0030094|Oxytocics|phsu|phsu|||oxytocics||||1000|19|27|SPEC|ISA||1|27|0|0|C0030095|Oxytocin|aapp,gngm,horm,phsu|phsu|||Oxytocin||||1000|1|8
SE|00000000||tx|1|relation|4|1|C0012471|Dinoprost|eico,horm,phsu|eico|||dinoprost||||1000|50|58|VERB|CAUSES||64|69|5|1|C0269842|Hypertonic uterine dysfunction|patf|patf|||uterine hypertonus||||1000|74|91


SE|00000000||tx|1|text|ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitors||||1000|1|14
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||Reports||||1000|17|23
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|38|43
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|79|84
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitors||||1000|89|102


SE|00000000||tx|1|text|Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|16|26
SE|00000000||tx|1|entity|C0245109|anakinra|aapp,phsu|||anakinra||||1000|31|38
SE|00000000||tx|1|entity|C1522668|Recombinant Tumor Necrosis Factor Family Protein|aapp,imft|7124|TNF|TNF||||840|51|53
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blocking||||840|55|62
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||840|64|69
SE|00000000||tx|1|entity|C1171255|Humira|aapp,imft,phsu|||HUMIRA||||1000|82|87
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||775|110|116
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicities||||775|118|127
SE|00000000||tx|1|relation|4|2|C1254351|Pharmacologic Substance|phsu|phsu|||agents||||840|64|69|NOM|COEXISTS_WITH||16|26|4|1|C0245109|anakinra|aapp,gngm,phsu|aapp|||anakinra||||1000|31|38


SE|00000000||tx|1|text|Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.
SE|00000000||tx|1|entity|C0035191|Resins, Plant|bodm|||Resins||||1000|1|6
SE|00000000||tx|1|entity|C0304522|Bile acid sequestrant antilipemic agent|phsu|||bile acid sequestrants||||1000|15|36
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|53|57
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|79|86
SE|00000000||tx|1|entity|C0723893|Tricor|orch,phsu|||TRICOR||||1000|100|105
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|110|114
SE|00000000||tx|1|entity|C0564385|/hour|qnco|||hour||||785|118|121
SE|00000000||tx|1|entity|C1292426|4 Hours|tmco|||4-6 hours||||913|133|141
SE|00000000||tx|1|entity|C2266924|Bile-acid Binding Resin [EPC]|phsu|||bile acid binding resin||||937|151|173
SE|00000000||tx|1|relation|2|1|C0304522|Bile acid sequestrant antilipemic agent|phsu|phsu|||bile acid sequestrants||||1000|15|36|VERB|INTERACTS_WITH||42|45|8|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|53|57
SE|00000000||tx|1|relation|2|1|C0035191|Resins, Plant|bodm|bodm|||Resins||||1000|1|6|VERB|INTERACTS_WITH||42|45|8|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|53|57
SE|00000000||tx|1|relation|6|1|C0723893|Tricor|orch,phsu|orch|||TRICOR||||1000|100|105|VERB|ADMINISTERED_TO||95|98|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|79|86


SE|00000000||tx|1|text|In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.
SE|00000000||tx|1|entity|C0274770|Poisoning by theophylline|inpo|||theophylline toxicity||||1000|12|32
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||852|41|48
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||852|50|54
SE|00000000||tx|1|entity|C0039773|Theophylline Assay|lbpr|||theophylline levels||||852|56|74
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|81|84
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|89|100
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|130|136
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||901|163|174
SE|00000000||tx|1|entity|C1707479|Concomitant Therapy|topp|||concomitant erythromycin therapy||||901|151|182
SE|00000000||tx|1|relation|1|1|C1707479|Concomitant Therapy|topp|topp|||concomitant erythromycin therapy||||901|151|182|VERB|ADMINISTERED_TO||141|149|5|1|C0030705|Patients|podg,humn|humn|||patient||||1000|130|136
SE|00000000||tx|1|relation|0|0|C1707479|Concomitant Therapy|topp|topp|||concomitant erythromycin therapy||||901|151|182|MOD/HEAD|USES||163|182|0|0|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||901|163|174


SE|00000000||tx|1|text|Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||Rifampin||||1000|1|8
SE|00000000||tx|1|entity|C0683140|Drug Metabolism|moft|||drug metabolism||||1000|25|39
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||1000|56|69
SE|00000000||tx|1|entity|C0126174|Losartan|orch,phsu|||losartan||||1000|74|81
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||888|91|96
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||888|98|107
SE|00000000||tx|1|relation|3|3|C0035608|Rifampin|antb,orch|antb|||Rifampin||||1000|1|8|VERB|INHIBITS||42|50|3|2|C0126174|Losartan|orch,phsu|orch|||losartan||||1000|74|81


SE|00000000||tx|1|text|VIRACEPT and rifampin should not be coadministered.
SE|00000000||tx|1|entity|C0525004|Viracept|orch,phsu|||VIRACEPT||||1000|1|8
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|14|21
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|30|32


SE|00000000||tx|1|text|Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||Alcohol||||1000|1|7
SE|00000000||tx|1|entity|C1170371|Lexapro|orch,phsu|||LEXAPRO||||1000|20|26
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|32|34
SE|00000000||tx|1|entity|C1516691|Cognitive|ftcn|||cognitive||||1000|51|59
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|71|77
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|82|88
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||clinical trial||||1000|95|108
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||861|138|148
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|162|168
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|173|180
SE|00000000||tx|1|entity|C1170371|Lexapro|orch,phsu|||LEXAPRO||||1000|189|195
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|200|202
SE|00000000||tx|1|relation|7|3|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||861|138|148|NOM|INTERACTS_WITH||71|77|7|1|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|82|88
SE|00000000||tx|1|relation|1|1|C1170371|Lexapro|orch,phsu|orch|||LEXAPRO||||1000|189|195|VERB|ADMINISTERED_TO||182|187|10|1|C0030705|Patients|podg,humn|humn|||patients||||1000|173|180


SE|00000000||tx|1|text|There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|17|23
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||861|28|39
SE|00000000||tx|1|entity|C0163712|Relate - vinyl resin|orch|||related||||861|41|47
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side-effects||||861|49|60
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|65|72
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||861|89|100
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolone||||861|102|110
SE|00000000||tx|1|entity|C1707479|Concomitant Therapy|topp|||concomitant theophylline-quinolone therapy||||861|77|118


SE|00000000||tx|1|text|Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||Increases||||1000|1|9
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|14|19
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|31|55
SE|00000000||tx|1|entity|C0439603|Frequencies (time pattern)|tmco|||frequency||||1000|69|77
SE|00000000||tx|1|entity|C0439793|Severities|qlco|||severity||||1000|83|90
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||1000|95|106
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|163|172
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||888|191|194
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||regimen||||888|196|202
SE|00000000||tx|1|relation|0|0|C0040808|Treatment Protocols|topp|topp|||regimen||||888|196|202|MOD/HEAD|USES||191|202|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||888|191|194


SE|00000000||tx|1|text|Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC  1 x 109/L).
SE|00000000||tx|1|entity|C0205448|Two|qnco|||Two||||694|1|3
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|16|23
SE|00000000||tx|1|entity|C1170364|Kineret|orch,phsu|||Kineret||||1000|51|57
SE|00000000||tx|1|entity|C0717758|Etanercept|aapp,imft,phsu|||etanercept||||802|63|72
SE|00000000||tx|1|entity|C0027947|Neutropenia|dsyn|||neutropenia||||802|84|94
SE|00000000||tx|1|entity|C0254908|ANC 1|orch,phsu|||ANC  1||||673|97|102
SE|00000000||tx|1|relation|3|1|C1170364|Kineret|orch,phsu|phsu|||Kineret||||1000|51|57|VERB|TREATS||25|31|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|16|23


SE|00000000||tx|1|text|H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.
SE|00000000||tx|1|entity|C0034815|Histamine H2 Receptors|aapp,rcpt|||H2-Receptor||||901|1|11
SE|00000000||tx|1|entity|C0243076|antagonists|chvf|||Antagonists||||901|13|23
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|49|54
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|56|59
SE|00000000||tx|1|entity|C0015620|Famotidine|orch,phsu|||famotidine||||827|91|100
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||694|122|125
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||775|143|148
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||775|157|160
SE|00000000||tx|1|entity|C0245519|cefditoren pivoxil|antb,orch|||cefditoren pivoxil||||1000|165|182
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|237|244
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||861|254|257
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|269|276
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||861|286|288


SE|00000000||tx|1|text|Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic agents are coadministered.
SE|00000000||tx|1|entity|C2585282|Blood glucose concentration|fndg|||Blood glucose concentrations||||983|1|28
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||1000|65|76
SE|00000000||tx|1|entity|C0359086|Oral hypoglycemic|phsu|||oral hypoglycemic agents||||1000|82|105


SE|00000000||tx|1|text|NSAIDs may decrease the hemodynamic effects of hydralazine;
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|1|6
SE|00000000||tx|1|entity|C0019010|Hemodynamics|ortf|||hemodynamic||||888|25|35
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|37|43
SE|00000000||tx|1|entity|C0020223|Hydralazine|orch,phsu|||hydralazine||||1000|48|58
SE|00000000||tx|1|relation|1|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|1|6|NOM|INTERACTS_WITH||37|43|1|1|C0020223|Hydralazine|orch,phsu|orch|||hydralazine||||1000|48|58


SE|00000000||tx|1|text|Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||888|13|19
SE|00000000||tx|1|entity|C0719198|Celebrex|orch,phsu|||CELEBREX||||1000|64|71


SE|00000000||tx|1|text|Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||Phenobarbital||||1000|1|13
SE|00000000||tx|1|entity|C0033148|Primidone|orch,phsu|||Primidone||||1000|16|24
SE|00000000||tx|1|entity|C1514228|Population Analysis|resa|||Population pharmacokinetic analyses||||896|28|62
SE|00000000||tx|1|entity|C0068897|tiagabine|orch,phsu|||tiagabine||||888|78|86
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|88|96
SE|00000000||tx|1|entity|C1704243|Greater|qnco|||greater||||861|105|111
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|116|123
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|132|144
SE|00000000||tx|1|entity|C0033148|Primidone|orch,phsu|||primidone||||1000|147|155
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzyme||||851|180|185
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||inducing||||851|187|194
SE|00000000||tx|1|entity|C0180309|Automated External Defibrillators|medd|||AEDs||||851|196|199
SE|00000000||tx|1|relation|0|0|C0033148|Primidone|orch,phsu|orch|||Primidone||||1000|16|24|SPEC|ISA||1|24|0|0|C0031412|Phenobarbital|orch,phsu|orch|||Phenobarbital||||1000|1|13
SE|00000000||tx|1|relation|0|0|C0033148|Primidone|orch,phsu|orch|||primidone||||1000|147|155|SPEC|ISA||132|155|0|0|C0031412|Phenobarbital|orch,phsu|orch|||phenobarbital||||1000|132|144
SE|00000000||tx|1|relation|5|2|C0068897|tiagabine|orch,phsu|phsu|||tiagabine||||888|78|86|PREP|TREATS||113|114|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|116|123
SE|00000000||tx|1|relation|3|1|C0031412|Phenobarbital|orch,phsu|orch|||phenobarbital||||1000|132|144|VERB|ADMINISTERED_TO||125|130|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|116|123
SE|00000000||tx|1|relation|0|0|C0033148|Primidone|orch,phsu|orch|||primidone||||1000|147|155|INFER|ADMINISTERED_TO(SPEC)||132|155|0|0|C0030705|Patients|podg,humn|humn|||patients||||1000|116|123


SE|00000000||tx|1|text|Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.
SE|00000000||tx|1|entity|C0132326|Nevirapine|nnon,phsu|||Nevirapine||||1000|1|10
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|16|23
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||645|32|34
SE|00000000||tx|1|entity|C0132326|Nevirapine|nnon,phsu|||nevirapine||||694|85|94
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||802|132|139
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||802|147|150
SE|00000000||tx|1|relation|4|3|C0035608|Rifampin|antb,orch|antb|||rifampin||||1000|16|23|VERB|INHIBITS||121|126|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||802|147|150
SE|00000000||tx|1|relation|4|3|C0132326|Nevirapine|nnon,phsu|phsu|||Nevirapine||||1000|1|10|VERB|INHIBITS||121|126|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||802|147|150


SE|00000000||tx|1|text|The concomitant administration of bosentan and cyclosporine A is contraindicated.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000||tx|1|entity|C0252643|bosentan|orch,phsu|||bosentan||||1000|35|42
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine A||||1000|48|61


SE|00000000||tx|1|text|Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||833|1|11
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||833|13|18
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||833|20|23
SE|00000000||tx|1|entity|C1166366|valdecoxib 20 MG|clnd|||valdecoxib 20 mg||||1000|43|58
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multiple||||888|65|72
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|74|78
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|83|94
SE|00000000||tx|1|entity|C0016277|Fluconazole|orch,phsu|||fluconazole||||1000|100|110
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|123|133
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|135|142
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||1000|159|168


SE|00000000||tx|1|text|The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed
SE|00000000||tx|1|entity|C0814225|Benefits|qnco|||benefits||||1000|5|12
SE|00000000||tx|1|entity|C0723893|Tricor|orch,phsu|||TRICOR||||1000|33|38
SE|00000000||tx|1|entity|C0021081|Immunosuppressive Agents|imft,phsu|||immunosuppressants||||1000|45|62
SE|00000000||tx|1|entity|C1514118|Nephrotoxic|qlco|||nephrotoxic||||773|86|96
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||773|98|103
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effective||||890|152|160
SE|00000000||tx|1|entity|C0445550|Low dose|qnco|||lowest effective dose||||890|145|165
SE|00000000||tx|1|relation|0|0|C0021081|Immunosuppressive Agents|imft,phsu|imft|||immunosuppressants||||1000|45|62|SPEC|ISA||45|103|0|0|C1254351|Pharmacologic Substance|phsu|phsu|||agents||||773|98|103


SE|00000000||tx|1|text|Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||Nonsteroidal Antiinflammatory Agents||||1000|1|36
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||Aspirin||||1000|39|45
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|69|76
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory agents||||1000|104|140
SE|00000000||tx|1|relation|2|1|C0004057|Aspirin|orch,phsu|phsu|||Aspirin||||1000|39|45|PREP|TREATS||66|67|3|1|C0030705|Patients|podg,humn|podg|||patients||||1000|69|76


SE|00000000||tx|1|text|Concomitant use of zalcitabine and lamivudine is not recommended.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|13|15
SE|00000000||tx|1|entity|C0012132|Zalcitabine|nnon,phsu|||zalcitabine||||1000|20|30
SE|00000000||tx|1|entity|C0209738|Lamivudine|nnon,phsu|||lamivudine||||1000|36|45
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|50|52


SE|00000000||tx|1|text|Plasma concentrations of azole antifungal agents are reduced when given concurrently with isoniazid.
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||Plasma concentrations||||983|1|21
SE|00000000||tx|1|entity|C0004504|Azoles|orch|||azole||||901|26|30
SE|00000000||tx|1|entity|C0003308|Antifungal Agents|phsu|||antifungal agents||||901|32|48
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|91|99
SE|00000000||tx|1|relation|1|1|C0022209|isoniazid|orch,phsu|orch|||isoniazid||||1000|91|99|VERB|COEXISTS_WITH||67|71|2|1|C0003308|Antifungal Agents|phsu|phsu|||antifungal agents||||901|32|48


SE|00000000||tx|1|text|Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
SE|00000000||tx|1|entity|C0033607|Protease Inhibitor|bacs,phsu|||Protease Inhibitors||||1000|1|19
SE|00000000||tx|1|entity|C1511726|Data|idcn|||data||||861|31|34
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|50|58
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||888|64|72
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||markedly||||888|74|81
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|95|104
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|109|117
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|142|149
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||623|154|159
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||623|161|169
SE|00000000||tx|1|entity|C0429028|QT interval feature (observable entity)|clna|||QT interval||||1000|202|212
SE|00000000||tx|1|entity|C0013798|Electrocardiogram|fndg|||ECG||||966|221|223
SE|00000000||tx|1|relation|4|1|C0292818|Ritonavir|orch,phsu|orch|||ritonavir||||888|64|72|VERB|INHIBITS||83|89|7|2|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|109|117
SE|00000000||tx|1|relation|4|1|C0376637|Indinavir|orch,phsu|orch|||indinavir||||1000|50|58|VERB|INHIBITS||83|89|7|2|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|109|117
SE|00000000||tx|1|relation|6|6|C0033607|Protease Inhibitor|bacs,phsu|bacs|||Protease Inhibitors||||1000|1|19|NOM|STIMULATES||142|149|4|1|C0072916|Cisapride|orch,phsu|orch|||cisapride||||623|161|169


SE|00000000||tx|1|text|A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug-drug interaction||||916|3|23
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||916|25|29
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|36|43
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|48|65
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|83|90
SE|00000000||tx|1|entity|C0537894|Caspofungin|aapp,phsu|||caspofungin||||851|95|105
SE|00000000||tx|1|entity|C0444506|Trough|qnco|||trough||||851|107|112
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||851|114|127


SE|00000000||tx|1|text|Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.
SE|00000000||tx|1|entity|C0935929|Antidiabetics|phsu|||Antidiabetics||||1000|1|13
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|24|38
SE|00000000||tx|1|entity|C2585282|Blood glucose concentration|fndg|||blood glucose concentrations||||983|53|80
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||888|83|88
SE|00000000||tx|1|entity|C0456081|Adjustment Action|ftcn|||adjustments||||888|90|100
SE|00000000||tx|1|entity|C0935929|Antidiabetics|phsu|||antidiabetic agents||||1000|105|123
SE|00000000||tx|1|relation|2|1|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|phsu|||corticosteroids||||1000|24|38|VERB|AUGMENTS||44|51|3|1|C2585282|Blood glucose concentration|fndg|fndg|||blood glucose concentrations||||983|53|80
SE|00000000||tx|1|relation|2|1|C0935929|Antidiabetics|phsu|phsu|||Antidiabetics||||1000|1|13|VERB|AUGMENTS||44|51|3|1|C2585282|Blood glucose concentration|fndg|fndg|||blood glucose concentrations||||983|53|80


SE|00000000||tx|1|text|In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.
SE|00000000||tx|1|entity|C0087136|Unmarried|fndg|||single||||1000|4|9
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multiple||||851|15|22
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||851|24|27
SE|00000000||tx|1|entity|C0947630|Scientific Study|lbpr|||studies||||851|29|35
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy subjects||||1000|40|55
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|72|79
SE|00000000||tx|1|entity|C0762662|rofecoxib|orch,phsu|||rofecoxib||||1000|85|93
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|96|111
SE|00000000||tx|1|entity|C0525032|International Normalized Ratio|lbpr|||INR||||1000|126|128
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|148|160


SE|00000000||tx|1|text|Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||Ritonavir||||1000|1|9
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|32|40
SE|00000000||tx|1|entity|C0525004|Viracept|orch,phsu|||VIRACEPT||||1000|47|54
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|75|82
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||nelfinavir||||851|87|96
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||851|98|103
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||851|105|107
SE|00000000||tx|1|entity|C0442824|Very|qlco|||very||||851|113|116
SE|00000000||tx|1|entity|C0700321|Small|qnco|||little||||851|118|123
SE|00000000||tx|1|entity|C0392747|Changing|ftcn|||change||||851|125|130
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||583|135|143
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||583|145|150


SE|00000000||tx|1|text|Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|1|10
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||694|41|50
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|60|67
SE|00000000||tx|1|entity|C0040374|Tolbutamide|orch,phsu|||tolbutamide||||1000|73|83
SE|00000000||tx|1|entity|||gngm|1559|CYP2C9|CYP2C9||||1000|116|121
SE|00000000||tx|1|relation|4|1|C0040374|Tolbutamide|orch,phsu|orch|||tolbutamide||||1000|73|83|VERB|INTERACTS_WITH||96|106|1|1|||gngm,aapp|gngm|1559|CYP2C9|CYP2C9||||1000|116|121
SE|00000000||tx|1|relation|4|1|C0043031|Warfarin|hops,orch,phsu|orch|||warfarin||||1000|60|67|VERB|INTERACTS_WITH||96|106|1|1|||gngm,aapp|gngm|1559|CYP2C9|CYP2C9||||1000|116|121


SE|00000000||tx|1|text|Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine.
SE|00000000||tx|1|entity|C0020592|Hypnotics and Sedatives|phsu|||sedative||||1000|10|17
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|39|45
SE|00000000||tx|1|entity|C0040615|Antipsychotic Agents|phsu|||major tranquilizers||||1000|54|72
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||861|83|90
SE|00000000||tx|1|entity|C0011685|Desipramine|orch,phsu|||desipramine||||1000|104|114


SE|00000000||tx|1|text|Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
SE|00000000||tx|1|entity|C0205253|Immediate|tmco|||Immediate||||1000|1|9
SE|00000000||tx|1|entity|C0991507|Extended Release Tablet|bodm|||Extended Release Tablets||||1000|15|38
SE|00000000||tx|1|entity|C0020616|Hypoglycemic Agents|phsu|||hypoglycemic||||888|44|55
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||888|57|62
SE|00000000||tx|1|entity|C0038766|Sulfonylurea Compounds|orch,phsu|||sulfonylureas||||1000|67|79
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||888|103|109
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|111|115
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory agents||||1000|127|163
SE|00000000||tx|1|entity|C0004504|Azoles|orch|||azoles||||1000|171|176
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|188|192
SE|00000000||tx|1|entity|C0205250|High|qlco|||highly||||888|203|208
SE|00000000||tx|1|entity|C0033684|Proteins|aapp,bacs|||protein||||888|210|216
SE|00000000||tx|1|entity|C0036077|Salicylates|orch,phsu|||salicylates||||1000|225|235
SE|00000000||tx|1|entity|C0038760|Sulfonamides|orch,phsu|||sulfonamides||||1000|238|249
SE|00000000||tx|1|entity|C0008168|Chloramphenicol|antb,orch|||chloramphenicol||||1000|252|266
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|269|278
SE|00000000||tx|1|entity|C0010207|Coumarins|orch,phsu|||coumarins||||1000|281|289
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|292|319
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta adrenergic blocking agents||||1000|326|356
SE|00000000||tx|1|relation|0|0|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein||||888|210|216|SPEC|ISA||188|216|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|188|192
SE|00000000||tx|1|relation|0|0|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein||||888|210|216|SPEC|ISA||188|216|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|111|115
SE|00000000||tx|1|relation|12|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|111|115|VERB|STIMULATES||88|98|4|1|C0038766|Sulfonylurea Compounds|orch,phsu|orch|||sulfonylureas||||1000|67|79
SE|00000000||tx|1|relation|12|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|188|192|VERB|STIMULATES||88|98|4|1|C0038766|Sulfonylurea Compounds|orch,phsu|orch|||sulfonylureas||||1000|67|79
SE|00000000||tx|1|relation|0|0|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein||||888|210|216|INFER|STIMULATES(SPEC)||188|216|0|0|C0038766|Sulfonylurea Compounds|orch,phsu|orch|||sulfonylureas||||1000|67|79
SE|00000000||tx|1|relation|0|0|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein||||888|210|216|INFER|STIMULATES(SPEC)||188|216|0|0|C0038766|Sulfonylurea Compounds|orch,phsu|orch|||sulfonylureas||||1000|67|79


SE|00000000||tx|1|text|Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.
SE|00000000||tx|1|entity|C0443303|Short-term|tmco|||Short-term||||888|1|10
SE|00000000||tx|1|entity|C0201734|Pharmacokinetic study|resa|||pharmacokinetic studies||||888|12|34
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|59|69
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|89|96
SE|00000000||tx|1|entity|C0700001|Lodine|orch,phsu|||Lodine||||1000|102|107
SE|00000000||tx|1|entity|C0059865|Etodolac|orch,phsu|||etodolac||||888|111|118
SE|00000000||tx|1|entity|C0006935|capsule (pharmacologic)|bodm|||capsules||||888|120|127
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||1000|133|139
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduced||||901|153|159
SE|00000000||tx|1|entity|C0033618|Protein Binding|moft|||protein binding||||901|161|175
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|180|187
SE|00000000||tx|1|entity|C0443172|Changed status|qnco|||change||||1000|207|212
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|221|229
SE|00000000||tx|1|entity|C1880497|Empty (qualifier)|qlco|||free||||888|234|237
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||888|239|246
SE|00000000||tx|1|relation|6|3|C0700001|Lodine|orch,phsu|orch|||Lodine||||1000|102|107|ADJ|INHIBITS||153|159|4|1|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||1000|180|187
SE|00000000||tx|1|relation|6|3|C0043031|Warfarin|hops,orch,phsu|orch|||warfarin||||1000|89|96|ADJ|INHIBITS||153|159|4|1|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||1000|180|187


SE|00000000||tx|1|text|Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.
SE|00000000||tx|1|entity|C0279023|chemosensitization/potentiation|topp|||Potentiation||||1000|1|12
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|21|31
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|33|39
SE|00000000||tx|1|entity|C0028125|Nitrates|chvs|||nitrates||||1000|44|51
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|57|64
SE|00000000||tx|1|entity|C0010054|Coronary Arteriosclerosis|dsyn|||ischemic heart disease||||1000|71|92
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|98|100
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|122|132
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|134|136
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||Vardenafil||||1000|141|150
SE|00000000||tx|1|relation|3|3|C0279023|chemosensitization/potentiation|topp|topp|||Potentiation||||1000|1|12|PREP|TREATS||53|55|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|57|64
SE|00000000||tx|1|relation|3|1|C0010054|Coronary Arteriosclerosis|dsyn|dsyn|||ischemic heart disease||||1000|71|92|PREP|PROCESS_OF||66|69|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|57|64
SE|00000000||tx|1|relation|0|0|C0279023|chemosensitization/potentiation|topp|topp|||Potentiation||||1000|1|12|INFER|TREATS(INFER)||53|55|0|0|C0010054|Coronary Arteriosclerosis|dsyn|dsyn|||ischemic heart disease||||1000|71|92


SE|00000000||tx|1|text|Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
SE|00000000||tx|1|entity|C0023726|Lincomycin|antb,carb|||Lincomycin||||1000|1|10
SE|00000000||tx|1|entity|C0234119|Neuromuscular inhibition|dsyn|||neuromuscular blocking||||890|35|56
SE|00000000||tx|1|entity|C1292721|Has property|ftcn|||properties||||890|58|67
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|90|95
SE|00000000||tx|1|entity|C0027866|Neuromuscular Blocking Agents|phsu|||neuromuscular blocking agents||||1000|106|134


SE|00000000||tx|1|text|Aspirin: Concurrent administration of aspirin may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||Aspirin||||1000|1|7
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|10|19
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|39|45
SE|00000000||tx|1|entity|C1289957|Meclofenamate|orch,phsu|||meclofenamate||||824|57|69
SE|00000000||tx|1|entity|C0858175|plasma sodium|lbpr|||sodium plasma||||824|71|83
SE|00000000||tx|1|entity|C2362652|Possible diagnosis|qlco|||possibly||||1000|93|100
SE|00000000||tx|1|entity|C0033684|Proteins|aapp,bacs|||protein-||||901|119|126
SE|00000000||tx|1|entity|C0005456|Binding Sites|rcpt|||binding sites||||901|127|139
SE|00000000||tx|1|relation|0|0|C0005456|Binding Sites|rcpt|rcpt|||binding sites||||901|127|139|MOD/HEAD|ISA||119|139|0|0|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein-||||901|119|126


SE|00000000||tx|1|text|Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||Tablets||||851|1|7
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Simultaneous||||851|9|20
SE|00000000||tx|1|entity|C0038633|Sucralfate|carb,phsu|||sucralfate||||1000|40|49
SE|00000000||tx|1|entity|C1246331|Furosemide Oral Tablet|clnd|||furosemide tablets||||1000|55|72
SE|00000000||tx|1|entity|C0597421|saluretic|phsu|||natriuretic||||1000|89|99
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|122|128
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|133|142
SE|00000000||tx|1|relation|3|2|C0038633|Sucralfate|carb,phsu|carb|||sucralfate||||1000|40|49|VERB|INHIBITS||78|83|3|1|C0597421|saluretic|phsu|phsu|||natriuretic||||1000|89|99


SE|00000000||tx|1|text|In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.
SE|00000000||tx|1|entity|C0013956|Emergency Situation|phpr|||emergency situation||||1000|7|25
SE|00000000||tx|1|entity|C0002772|Analgesics, Opioid|orch,phsu|||opioid analgesia||||964|32|47
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||840|75|81
SE|00000000||tx|1|entity|C1514756|Receive|qlco|||receiving||||840|83|91
SE|00000000||tx|1|entity|C0591842|ReVia|orch,phsu|||REVIA||||840|93|97
SE|00000000||tx|1|entity|C1265611|Quantity|qnco|||amount||||1000|104|109
SE|00000000||tx|1|entity|C0242402|Opioids|hops,orch,phsu|||opioid||||1000|114|119
SE|00000000||tx|1|entity|C1704243|Greater|qnco|||greater||||1000|137|143
SE|00000000||tx|1|entity|C0678226|Due to|ftcn|||resulting||||901|165|173
SE|00000000||tx|1|entity|C0235063|Respiratory Depression|patf|||respiratory depression||||901|175|196
SE|00000000||tx|1|entity|C0205125|Depth|spco|||deeper||||966|205|210
SE|00000000||tx|1|entity|C0205172|More|ftcn|||more||||1000|216|219


SE|00000000||tx|1|text|Boric acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.
SE|00000000||tx|1|entity|C0006020|boric acid|inch,phsu|||Boric acid||||1000|1|10
SE|00000000||tx|1|entity|C0020811|Idoxuridine|nnon,phsu|||idoxuridine||||888|34|44
SE|00000000||tx|1|entity|C1521827|Preparation|ftcn|||preparation||||888|46|56
SE|00000000||tx|1|entity|C0440273|Grit (substance)|chvs|||gritty substance||||865|68|83
SE|00000000||tx|1|entity|C0033086|Pharmaceutical Preservatives|bodm|||preservative||||1000|118|129
SE|00000000||tx|1|entity|C0020811|Idoxuridine|nnon,phsu|||idoxuridine||||888|138|148
SE|00000000||tx|1|entity|C1521827|Preparation|ftcn|||preparation||||888|150|160
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxic effect||||1000|172|183
SE|00000000||tx|1|entity|C0015392|Eye|bpoc|||eye||||1000|192|194
SE|00000000||tx|1|relation|1|1|C0006020|boric acid|inch,phsu|inch|||Boric acid||||1000|1|10|VERB|INTERACTS_WITH||16|23|6|1|C0020811|Idoxuridine|nnon,phsu|nnon|||idoxuridine||||888|34|44
SE|00000000||tx|1|relation|3|1|C0440273|Grit (substance)|chvs|chvs|||gritty substance||||865|68|83|VERB|INTERACTS_WITH||100|107|4|1|C0033086|Pharmaceutical Preservatives|bodm|bodm|||preservative||||1000|118|129
SE|00000000||tx|1|relation|5|1|C0020811|Idoxuridine|nnon,phsu|nnon|||idoxuridine||||888|138|148|VERB|CAUSES||162|168|2|1|C0600688|Toxic effect|inpo|inpo|||toxic effect||||1000|172|183
SE|00000000||tx|1|relation|1|1|C0015392|Eye|bpoc|bpoc|||eye||||1000|192|194|PREP|LOCATION_OF||185|186|6|1|C0600688|Toxic effect|inpo|inpo|||toxic effect||||1000|172|183


SE|00000000||tx|1|text|Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
SE|00000000||tx|1|entity|C0885426|Hydrogen, Homeopathic preparation|inch|||hydrogen||||901|13|20
SE|00000000||tx|1|entity|C0070413|perhexiline maleate|orch,phsu|||Perhexiline hydrogen maleate||||901|1|28
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO-inhibitors||||1000|33|46
SE|00000000||tx|1|entity|C0235378|Hepatotoxicity|inpo|||hepatotoxic||||853|54|64
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||853|66|74
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|82|84
SE|00000000||tx|1|entity|C0591179|Bezalip|orch,phsu|||Bezalip||||1000|116|122
SE|00000000||tx|1|entity|C0591179|Bezalip|orch,phsu|||Bezalip||||1000|127|133


SE|00000000||tx|1|text|Chloral hydrate may cause an increased prothrombin response by displacing the anticoagulant from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction, thus leading to inter-patient variation in ultimate prothrombin effect.
SE|00000000||tx|1|entity|C0008161|Chloral Hydrate|orch,phsu|||Chloral hydrate||||1000|1|15
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||623|30|38
SE|00000000||tx|1|entity|C0033706|Prothrombin|aapp,bacs,phsu|||prothrombin||||623|40|50
SE|00000000||tx|1|entity|C0012727|Spatial Displacement|spco|||displacing||||1000|64|73
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulant||||1000|79|91
SE|00000000||tx|1|entity|C0033684|Proteins|aapp,bacs|||protein||||901|98|104
SE|00000000||tx|1|entity|C0005456|Binding Sites|rcpt|||binding sites||||901|106|118
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||diminished||||623|125|134
SE|00000000||tx|1|entity|C0033706|Prothrombin|aapp,bacs,phsu|||prothrombin||||623|136|146
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|165|173
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|175|184
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||861|201|204
SE|00000000||tx|1|entity|C0205054|Hepatic|blor|||hepatic||||901|209|215
SE|00000000||tx|1|entity|C0014431|Enzyme Induction|genf|||enzyme induction||||901|217|232
SE|00000000||tx|1|entity|C1548610|Inter|tmco|||inter-||||833|251|256
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||833|257|263
SE|00000000||tx|1|entity|C0205419|Variant|qlco|||variation||||833|265|273
SE|00000000||tx|1|entity|C0033706|Prothrombin|aapp,bacs,phsu|||prothrombin||||790|287|297
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||790|299|304
SE|00000000||tx|1|relation|10|3|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||861|201|204|NOM|INTERACTS_WITH||299|304|10|0|C0033706|Prothrombin|aapp,gngm,bacs,phsu|aapp|||prothrombin||||790|287|297


SE|00000000||tx|1|text|Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|13|15
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|20|26
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetics||||1000|32|47
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|63|66
SE|00000000||tx|1|entity|C0003811|Cardiac Arrhythmia|patf|||cardiac arrhythmias||||1000|71|89
SE|00000000||tx|1|relation|3|1|C0039052|Sympathomimetics|phsu|phsu|||sympathomimetics||||1000|32|47|NOM|PREDISPOSES||63|66|1|1|C0003811|Cardiac Arrhythmia|patf|patf|||cardiac arrhythmias||||1000|71|89
SE|00000000||tx|1|relation|3|1|C0012265|Digoxin|carb,phsu,strd|phsu|||digoxin||||1000|20|26|NOM|PREDISPOSES||63|66|1|1|C0003811|Cardiac Arrhythmia|patf|patf|||cardiac arrhythmias||||1000|71|89


SE|00000000||tx|1|text|It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|19|21
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||753|35|40
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||Vardenafil||||753|49|58
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||753|60|63
SE|00000000||tx|1|entity|C0439584|24 hour time frame|tmco|||24-hour||||890|70|76
SE|00000000||tx|1|entity|C0439531|per period (qualifier value)|tmco|||period||||890|78|83
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|98|108
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|115|123


SE|00000000||tx|1|text|Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||861|9|12
SE|00000000||tx|1|entity|C0360363|Azole antifungal|orch,phsu|||azole antifungal||||861|14|29
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||861|32|43
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|59|68
SE|00000000||tx|1|entity|C0085170|Astemizole|orch,phsu|||astemizole||||1000|73|82
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||890|98|105
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|107|127
SE|00000000||tx|1|entity|C0085170|Astemizole|orch,phsu|||astemizole||||1000|132|141
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||623|151|156
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||623|158|167
SE|00000000||tx|1|entity|C0429028|QT interval feature (observable entity)|clna|||QT intervals||||966|208|219
SE|00000000||tx|1|relation|1|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||861|32|43|VERB|INHIBITS||46|53|6|2|C0085170|Astemizole|orch,phsu|orch|||astemizole||||1000|73|82


SE|00000000||tx|1|text|Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.
SE|00000000||tx|1|entity|C0286738|Saquinavir|orch,phsu|||Saquinavir||||861|1|10
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||861|12|23
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||861|25|28
SE|00000000||tx|1|entity|C2827771|Cmin|qnco|||Cmin||||1000|40|43
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|116|126
SE|00000000||tx|1|entity|C0754188|Amprenavir|orch,phsu|||amprenavir||||888|128|137


SE|00000000||tx|1|text|There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||623|10|12
SE|00000000||tx|1|entity|C0700287|Reporting|hlca|||reported||||623|14|21
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|33|39
SE|00000000||tx|1|entity|C0011206|Delirium|mobd|||acute delirium||||1000|46|59
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneous||||888|81|92
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|94|96
SE|00000000||tx|1|entity|C0016368|Fluphenazine|orch,phsu|||fluphenazine||||1000|101|112
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|118|121
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||888|123|131
SE|00000000||tx|1|relation|4|1|C0011206|Delirium|mobd|mobd|||acute delirium||||1000|46|59|PREP|PROCESS_OF||41|44|2|1|C0030705|Patients|podg,humn|humn|||patient||||1000|33|39


SE|00000000||tx|1|text|Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||Valdecoxib||||1000|1|10
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||statistically significant||||901|21|45
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||901|47|54
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||888|59|64
SE|00000000||tx|1|entity|C0274281|Injury due to exposure to external cause|inpo|||exposures||||888|66|74
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||597|81|88
SE|00000000||tx|1|entity|C0047247|3-azido-2,7-naphthalene disulfonate|orch|||and S||||597|90|94
SE|00000000||tx|1|entity|C0851347|Pharmacodynamics|biof|||pharmacodynamic||||888|145|159
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|161|167
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|170|185
SE|00000000||tx|1|entity|C0525032|International Normalized Ratio|lbpr|||INR||||1000|200|202
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|208|215


SE|00000000||tx|1|text|HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.
SE|00000000||tx|1|entity|C0162714|HIV Protease Inhibitors|phsu|||HIV Protease Inhibitors||||1000|1|23
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||Indinavir||||1000|26|34
SE|00000000||tx|1|entity|C0439423|Milligram per 24 Hours|qnco|||mg t.i.d.||||790|41|49
SE|00000000||tx|1|entity|C1176939|vardenafil 10 MG|clnd|||Vardenafil 10 mg||||1000|73|88
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||790|107|110
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||790|112|119
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||vardenafil||||888|124|133
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|135|137
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||790|144|147
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||790|149|156
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||vardenafil||||888|161|170
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||888|172|175
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||851|185|188
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||851|190|197
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||vardenafil||||901|202|211
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||901|213|221


SE|00000000||tx|1|text|Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||Effects||||1000|1|7
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetics||||1000|12|27
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|48|61
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta adrenergic blockers||||1000|67|90
SE|00000000||tx|1|relation|3|3|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta adrenergic blockers||||1000|67|90|NOM|INTERACTS_WITH||1|7|3|1|C0039052|Sympathomimetics|phsu|phsu|||sympathomimetics||||1000|12|27
SE|00000000||tx|1|relation|3|3|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|phsu|||MAO inhibitors||||1000|48|61|NOM|INTERACTS_WITH||1|7|3|1|C0039052|Sympathomimetics|phsu|phsu|||sympathomimetics||||1000|12|27


SE|00000000||tx|1|text|If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||888|4|12
SE|00000000||tx|1|entity|C0428321|Measurement of liver enzyme|lbpr|||hepatic enzyme||||734|23|36
SE|00000000||tx|1|entity|C0701129|Norpace|orch,phsu|||Norpace||||1000|75|81
SE|00000000||tx|1|entity|C0722154|Norpace CR|orch,phsu|||Norpace CR||||1000|86|95
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|104|109
SE|00000000||tx|1|entity|C0012702|Disopyramide|orch,phsu|||disopyramide||||1000|121|132


SE|00000000||tx|1|text|Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|entity|C0022499|Kaolin|inch,phsu|||kaolin||||1000|14|19
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|22|29
SE|00000000||tx|1|entity|C0022499|Kaolin|inch,phsu|||kaolin||||1000|35|40
SE|00000000||tx|1|entity|C0008269|Chloroquine|orch,phsu|||chloroquine||||1000|67|77


SE|00000000||tx|1|text|In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|38|47
SE|00000000||tx|1|entity|C0246415|docetaxel|orch,phsu|||docetaxel||||1000|52|60
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|85|95
SE|00000000||tx|1|entity|C0205198|Compound|qlco|||compounds||||966|115|123
SE|00000000||tx|1|entity|C1142644|Cytochrome P450 3A4|aapp,enzy|||cytochrome P450 3A4||||1000|169|187
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|198|209
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||1000|212|222
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|225|236
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|239|250
SE|00000000||tx|1|entity|C0041165|Troleandomycin|antb,orch|||troleandomycin||||1000|257|270
SE|00000000||tx|1|relation|6|1|C1142644|Cytochrome P450 3A4|aapp,gngm,enzy|aapp|||cytochrome P450 3A4||||1000|169|187|VERB|INTERACTS_WITH||154|164|5|3|C0246415|docetaxel|orch,phsu|orch|||docetaxel||||1000|52|60
SE|00000000||tx|1|relation|6|1|C0041165|Troleandomycin|antb,orch|antb|||troleandomycin||||1000|257|270|VERB|INTERACTS_WITH||154|164|5|3|C0246415|docetaxel|orch,phsu|orch|||docetaxel||||1000|52|60
SE|00000000||tx|1|relation|6|1|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|239|250|VERB|INTERACTS_WITH||154|164|5|3|C0246415|docetaxel|orch,phsu|orch|||docetaxel||||1000|52|60
SE|00000000||tx|1|relation|6|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|225|236|VERB|INTERACTS_WITH||154|164|5|3|C0246415|docetaxel|orch,phsu|orch|||docetaxel||||1000|52|60
SE|00000000||tx|1|relation|6|1|C0085173|Terfenadine|orch,phsu|orch|||terfenadine||||1000|212|222|VERB|INTERACTS_WITH||154|164|5|3|C0246415|docetaxel|orch,phsu|orch|||docetaxel||||1000|52|60
SE|00000000||tx|1|relation|6|1|C0010592|Cyclosporine|aapp,gngm,phsu|aapp|||cyclosporine||||1000|198|209|VERB|INTERACTS_WITH||154|164|5|3|C0246415|docetaxel|orch,phsu|orch|||docetaxel||||1000|52|60


SE|00000000||tx|1|text|The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|22|28
SE|00000000||tx|1|entity|C0025741|Methyldopa|nsba,phsu|||methyldopa||||1000|33|42
SE|00000000||tx|1|entity|C0025029|Mecamylamine|orch,phsu|||mecamylamine||||1000|45|56
SE|00000000||tx|1|entity|C0035179|Reserpine|orch,phsu|||reserpine||||1000|59|67
SE|00000000||tx|1|entity|C0042528|Veratrum Alkaloids|orch,phsu|||veratrum alkaloids||||1000|74|91
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetics||||1000|111|126
SE|00000000||tx|1|relation|1|1|C0039052|Sympathomimetics|phsu|phsu|||sympathomimetics||||1000|111|126|VERB|INHIBITS||100|106|5|1|C0042528|Veratrum Alkaloids|orch,phsu|orch|||veratrum alkaloids||||1000|74|91
SE|00000000||tx|1|relation|1|1|C0039052|Sympathomimetics|phsu|phsu|||sympathomimetics||||1000|111|126|VERB|INHIBITS||100|106|5|1|C0035179|Reserpine|orch,phsu|orch|||reserpine||||1000|59|67
SE|00000000||tx|1|relation|1|1|C0039052|Sympathomimetics|phsu|phsu|||sympathomimetics||||1000|111|126|VERB|INHIBITS||100|106|5|1|C0025029|Mecamylamine|orch,phsu|orch|||mecamylamine||||1000|45|56
SE|00000000||tx|1|relation|1|1|C0039052|Sympathomimetics|phsu|phsu|||sympathomimetics||||1000|111|126|VERB|INHIBITS||100|106|5|1|C0025741|Methyldopa|nsba,phsu|nsba|||methyldopa||||1000|33|42


SE|00000000||tx|1|text|Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||Valproate||||1000|1|9
SE|00000000||tx|1|entity|C0068897|tiagabine|orch,phsu|||Tiagabine||||1000|12|20
SE|00000000||tx|1|entity|C2945599|Mild (qualifier value)|qlco|||slight||||888|31|36
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decrease||||888|38|45
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||861|62|73
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||valproate||||861|75|83
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||861|85|98
SE|00000000||tx|1|relation|3|2|C0068897|tiagabine|orch,phsu|orch|||Tiagabine||||1000|12|20|PREP|COEXISTS_WITH||59|60|1|1|C0080356|Valproate|lipd,phsu|lipd|||valproate||||861|75|83


SE|00000000||tx|1|text|Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.
SE|00000000||tx|1|entity|C0746730|myocardial injury|inpo|||Myocardial injury||||1000|1|17
SE|00000000||tx|1|entity|C0027051|Myocardial Infarction|dsyn|||myocardial infarction||||1000|30|50
SE|00000000||tx|1|entity|C0027059|Myocarditis|dsyn|||myocarditis||||1000|53|63
SE|00000000||tx|1|entity|C0919702|ventricular hypokinesia|dsyn|||ventricular hypokinesia||||1000|66|88
SE|00000000||tx|1|entity|C0035410|Rhabdomyolysis|patf|||rhabdomyolysis||||861|102|115
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|143|150
SE|00000000||tx|1|entity|C0701339|Proleukin|orch,phsu|||PROLEUKIN||||1000|162|170
SE|00000000||tx|1|entity|C0002199|Interferon-alpha|aapp,imft,phsu|||interferon-alfa||||901|176|190
SE|00000000||tx|1|relation|5|1|C0035410|Rhabdomyolysis|patf|patf|||rhabdomyolysis||||861|102|115|PREP|PROCESS_OF||140|141|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|143|150
SE|00000000||tx|1|relation|2|1|C0701339|Proleukin|orch,phsu|orch|||PROLEUKIN||||1000|162|170|VERB|ADMINISTERED_TO||152|160|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|143|150
SE|00000000||tx|1|relation|2|1|C0002199|Interferon-alpha|aapp,gngm,imft,phsu|imft|||interferon-alfa||||901|176|190|VERB|ADMINISTERED_TO||152|160|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|143|150


SE|00000000||tx|1|text|The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency.
SE|00000000||tx|1|entity|C0520996|Anticoagulant effect|ortf|||anticoagulant effect||||1000|5|24
SE|00000000||tx|1|entity|C0019134|Heparin|bacs,carb,phsu|||heparin||||1000|29|35
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|52|61
SE|00000000||tx|1|entity|C0003438|Antithrombin III|aapp,phsu|||antithrombin III||||1000|78|93
SE|00000000||tx|1|entity|C0086418|Homo sapiens|humn|||human||||1000|96|100
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|106|113
SE|00000000||tx|1|entity|C2586031|Hereditary antithrombin III deficiency|dsyn|||hereditary antithrombin III deficiency||||1000|120|157
SE|00000000||tx|1|relation|5|5|C0520996|Anticoagulant effect|ortf|ortf|||anticoagulant effect||||1000|5|24|PREP|PROCESS_OF||103|104|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|106|113
SE|00000000||tx|1|relation|1|1|C2586031|Hereditary antithrombin III deficiency|dsyn|dsyn|||hereditary antithrombin III deficiency||||1000|120|157|PREP|PROCESS_OF||115|118|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|106|113


SE|00000000||tx|1|text|Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0813158|Targretin|orch,phsu|||Targretin||||888|31|39
SE|00000000||tx|1|entity|C0006935|capsule (pharmacologic)|bodm|||capsules||||888|41|48
SE|00000000||tx|1|entity|C0017245|Gemfibrozil|lipd,phsu|||gemfibrozil||||1000|54|64
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||861|90|98
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|103|123
SE|00000000||tx|1|entity|C0765273|bexarotene|orch,phsu|||bexarotene||||1000|128|137
SE|00000000||tx|1|entity|C0750492|Probably|idcn|||probably||||1000|140|147
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||827|152|156
SE|00000000||tx|1|entity|C1142644|Cytochrome P450 3A4|aapp,enzy|||cytochrome P450 3A4||||916|179|197
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||916|199|208
SE|00000000||tx|1|entity|C0017245|Gemfibrozil|lipd,phsu|||gemfibrozil||||1000|213|223
SE|00000000||tx|1|relation|6|1|C0765273|bexarotene|orch,phsu|orch|||bexarotene||||1000|128|137|NOM|INHIBITS||199|208|6|0|C1142644|Cytochrome P450 3A4|aapp,gngm,enzy|gngm|||cytochrome P450 3A4||||916|179|197


SE|00000000||tx|1|text|Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|11|21
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|41|48
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|61|66
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|78|87


SE|00000000||tx|1|text|Beta-adrenergic blocking agents should be withdrawn at least 48 hours before conducting an arbutamine-mediated stress test.
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||Beta-adrenergic blocking agents||||1000|1|31
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||890|56|60
SE|00000000||tx|1|entity|C0439586|48 hour time frame|tmco|||48 hours||||890|62|69
SE|00000000||tx|1|entity|C0004927|Behavior|inbe|||conducting||||1000|78|87
SE|00000000||tx|1|entity|C0172021|arbutamine|orch,phsu|||arbutamine||||833|92|101
SE|00000000||tx|1|entity|C0127400|Mediator brand of benfluorex hydrochloride|orch,phsu|||mediated||||833|103|110
SE|00000000||tx|1|entity|C0038435|Stress|fndg|||stress||||833|112|117
SE|00000000||tx|1|entity|C0022885|Laboratory Procedures|lbpr|||test||||833|119|122


SE|00000000||tx|1|text|Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.
SE|00000000||tx|1|entity|C0754188|Amprenavir|orch,phsu|||amprenavir||||1000|21|30
SE|00000000||tx|1|entity|C0025605|Methadone|orch,phsu|||methadone||||1000|36|44
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||non||||824|63|65
SE|00000000||tx|1|entity|C0024908|Matched Groups|grup|||matched historicalcontrol group||||824|67|97
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|131|138
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||851|143|147
SE|00000000||tx|1|entity|C0754188|Amprenavir|orch,phsu|||amprenavir||||851|149|158
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||851|160|162
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|165|168


SE|00000000||tx|1|text|Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.
SE|00000000||tx|1|entity|C0003195|Anti-Arrhythmia Agents|phsu|||Anti-arrhythmics||||1000|1|16
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic anti-depressants||||1000|22|47
SE|00000000||tx|1|entity|C0429028|QT interval feature (observable entity)|clna|||QT interval||||1000|90|100
SE|00000000||tx|1|entity|C0770909|Bepridil hydrochloride|orch,phsu|||bepridil hydrochloride||||1000|116|137


SE|00000000||tx|1|text|Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||Hypotension||||888|1|11
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||888|15|22
SE|00000000||tx|1|entity|C0948575|diuretic therapy|topp|||Diuretic Therapy||||1000|27|42
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|45|52
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|57|65
SE|00000000||tx|1|entity|C0948575|diuretic therapy|topp|||diuretic therapy||||1000|96|111
SE|00000000||tx|1|entity|C0332185|Recent|tmco|||recently||||1000|117|124
SE|00000000||tx|1|entity|C0206136|Sodium Chloride, Dietary|food,inch|||dietary salt||||824|165|176
SE|00000000||tx|1|entity|C0443288|Restricted|ftcn|||restriction||||824|178|188
SE|00000000||tx|1|entity|C0011946|Dialysis procedure|topp|||dialysis||||1000|193|200
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||861|245|253
SE|00000000||tx|1|entity|C0005823|Blood Pressure|orgf|||blood pressure||||901|258|271
SE|00000000||tx|1|entity|C1279901|Firstly|qlco|||first||||888|292|296
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hour||||888|298|301
SE|00000000||tx|1|entity|C0205265|Initially|tmco|||initial||||888|323|329
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|331|334
SE|00000000||tx|1|entity|C0006938|Captopril|aapp,phsu|||captopril||||1000|339|347
SE|00000000||tx|1|relation|0|0|C0020649|Hypotension|fndg|fndg|||Hypotension||||888|1|11|MOD/HEAD|PROCESS_OF||1|22|0|0|C0030705|Patients|podg,humn|humn|||Patients||||888|15|22
SE|00000000||tx|1|relation|7|4|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|57|65|NOM|DISRUPTS||245|253|4|1|C0005823|Blood Pressure|orgf|orgf|||blood pressure||||901|258|271
SE|00000000||tx|1|relation|2|2|C0006938|Captopril|aapp,gngm,phsu|phsu|||captopril||||1000|339|347|VERB|ADMINISTERED_TO||309|317|10|8|C0030705|Patients|podg,humn|humn|||Patients||||1000|45|52


SE|00000000||tx|1|text|Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.
SE|00000000||tx|1|entity|C0546860|Clonidine Hydrochloride|orch,phsu|||Clonidine hydrochloride||||1000|1|23
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||827|56|62
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|67|73
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|76|87
SE|00000000||tx|1|entity|C0036557|Sedatives|phsu|||sedatives||||1000|98|106


SE|00000000||tx|1|text|Methyldopa (e.g., Aldomet) use of Methyldopa with sulfapyridine may increase The chance of side effects affecting The liver and/or The blood
SE|00000000||tx|1|entity|C0025741|Methyldopa|nsba,phsu|||Methyldopa||||1000|1|10
SE|00000000||tx|1|entity|C0591055|Aldomet|aapp,phsu|||Aldomet||||1000|19|25
SE|00000000||tx|1|entity|C0025741|Methyldopa|nsba,phsu|||Methyldopa||||1000|35|44
SE|00000000||tx|1|entity|C0038710|Sulfapyridine|orch,phsu|||sulfapyridine||||1000|51|63
SE|00000000||tx|1|entity|C0237506|Chance|qlco|||chance||||1000|82|87
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||1000|92|103
SE|00000000||tx|1|entity|C0023884|Liver|bpoc|||liver||||1000|119|123
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||1000|136|140
SE|00000000||tx|1|relation|6|3|C0038710|Sulfapyridine|orch,phsu|orch|||sulfapyridine||||1000|51|63|VERB|AFFECTS||105|113|2|1|C0023884|Liver|bpoc|bpoc|||liver||||1000|119|123
SE|00000000||tx|1|relation|6|3|C0038710|Sulfapyridine|orch,phsu|orch|||sulfapyridine||||1000|51|63|VERB|AFFECTS||105|113|2|1|C0005767|Blood|tisu|tisu|||blood||||1000|136|140


SE|00000000||tx|1|text|Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability;
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||1000|16|20
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacid||||1000|25|31
SE|00000000||tx|1|entity|C0065162|lomefloxacin|orch,phsu|||lomefloxacin||||1000|37|48
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|65|72
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|77|91


SE|00000000||tx|1|text|Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||901|13|16
SE|00000000||tx|1|entity|C0935929|Antidiabetics|phsu|||antidiabetic agents||||901|18|36
SE|00000000||tx|1|entity|C1174739|Velcade|orch,phsu|||VELCADE||||888|48|54
SE|00000000||tx|1|entity|C0587267|Closed|ftcn|||close||||694|78|82
SE|00000000||tx|1|entity|C0428554|Finding of blood glucose level|lbtr|||blood glucose levels||||1000|104|123
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|147|150
SE|00000000||tx|1|entity|C0935929|Antidiabetics|phsu|||antidiabetic||||888|161|172
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medication||||888|174|183
SE|00000000||tx|1|relation|0|0|C0935929|Antidiabetics|phsu|phsu|||antidiabetic||||888|161|172|MOD/HEAD|ISA||161|183|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medication||||888|174|183


SE|00000000||tx|1|text|Concomitant administration of other sympathomimetic agents may potentiate the undesirable effects of FORADIL.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetic agents||||1000|37|58
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||undesirable effects||||1000|79|97
SE|00000000||tx|1|entity|C0592533|Foradil|orch,phsu|||FORADIL||||1000|102|108


SE|00000000||tx|1|text|Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|34|40
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|46|59


SE|00000000||tx|1|text|Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blockers||||901|20|32
SE|00000000||tx|1|entity|C0027302|Nadolol|orch,phsu|||nadolol||||1000|35|41
SE|00000000||tx|1|entity|C0040233|Timolol|orch,phsu|||timolol||||1000|55|61
SE|00000000||tx|1|entity|C0520540|Rebound hypertension|dsyn|||rebound hypertension||||1000|79|98
SE|00000000||tx|1|entity|C0079466|Guanfacine|orch,phsu|||guanfacine||||1000|105|114
SE|00000000||tx|1|relation|0|0|C0027302|Nadolol|orch,phsu|orch|||nadolol||||1000|35|41|SPEC|ISA||20|41|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blockers||||901|20|32
SE|00000000||tx|1|relation|4|4|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blockers||||901|20|32|VERB|AFFECTS||68|77|2|1|C0520540|Rebound hypertension|dsyn|dsyn|||rebound hypertension||||1000|79|98
SE|00000000||tx|1|relation|0|0|C0027302|Nadolol|orch,phsu|orch|||nadolol||||1000|35|41|INFER|AFFECTS(SPEC)||20|41|0|0|C0520540|Rebound hypertension|dsyn|dsyn|||rebound hypertension||||1000|79|98


SE|00000000||tx|1|text|Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||Drug Interactions||||1000|1|17
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||888|24|31
SE|00000000||tx|1|entity|C0771752|Fexofenadine hydrochloride|orch,phsu|||fexofenadine hydrochloride||||1000|61|86
SE|00000000||tx|1|entity|C2347138|Milligram per Capsule|qnco|||mg capsule||||812|96|105
SE|00000000||tx|1|entity|C1442447|15 Minutes|tmco|||15 minutes||||1000|115|124
SE|00000000||tx|1|entity|C0002367|Aluminum|elii|||aluminum||||1000|132|139
SE|00000000||tx|1|entity|C1875461|MAGNESIUM CONTAINING ANTACIDS|phsu|||magnesium containing antacid||||988|145|172
SE|00000000||tx|1|entity|C0065461|Maalox|inch,phsu|||Maalox||||1000|175|180
SE|00000000||tx|1|entity|C0296800|fexofenadine|orch,phsu|||fexofenadine||||901|194|205
SE|00000000||tx|1|entity|C1707649|Decreased Drug AUC|fndg|||decreased fexofenadine AUC||||901|184|209
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||cmax||||1000|222|225


SE|00000000||tx|1|text|Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.
SE|00000000||tx|1|entity|C0015042|profenamine|orch,phsu|||Ethopropazine||||1000|1|13
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|33|39
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||1000|50|64
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||901|75|83
SE|00000000||tx|1|entity|C3179159|Sedative Effect|phsf|||sedative effects||||901|85|100
SE|00000000||tx|1|relation|0|0|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|33|39|SPEC|ISA||33|64|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|50|64
SE|00000000||tx|1|relation|1|1|C0015042|profenamine|orch,phsu|orch|||Ethopropazine||||1000|1|13|VERB|INTERACTS_WITH||19|26|3|1|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|33|39
SE|00000000||tx|1|relation|3|1|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|50|64|VERB|CAUSES||67|73|1|1|C3179159|Sedative Effect|phsf|phsf|||sedative effects||||901|85|100
SE|00000000||tx|1|relation|0|0|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|33|39|INFER|CAUSES(SPEC)||33|64|0|0|C3179159|Sedative Effect|phsf|phsf|||sedative effects||||901|85|100


SE|00000000||tx|1|text|Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A.
SE|00000000||tx|1|entity|C0678587|steady state|npop|||Steady-state||||849|1|12
SE|00000000||tx|1|entity|C0252643|bosentan|orch,phsu|||bosentan||||849|14|21
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||849|23|43
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||888|58|61
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||966|63|68
SE|00000000||tx|1|entity|C0332197|Absent|qnco|||absence||||1000|82|88
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine A||||1000|93|106


SE|00000000||tx|1|text|Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
SE|00000000||tx|1|entity|C0008402|Cholestyramine Resin|orch,phsu|||Cholestyramine resin||||1000|1|20
SE|00000000||tx|1|entity|C0031327|Drug Kinetics|phsf|||pharmacokinetics||||1000|45|60
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|65|69
SE|00000000||tx|1|entity|C0014362|Enterohepatic Circulation|ortf|||enterohepatic circulation||||1000|84|108
SE|00000000||tx|1|entity|C0008402|Cholestyramine Resin|orch,phsu|||cholestyramine resin||||1000|133|152
SE|00000000||tx|1|entity|C0598697|Hazard|qlco|||hazard||||1000|167|172
SE|00000000||tx|1|entity|C0018684|Health|idcn|||health||||1000|177|182
SE|00000000||tx|1|entity|C1407029|Toxic|qlco|||toxic||||790|201|205
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||790|207|210
SE|00000000||tx|1|entity|C0024501|Maintenance|acty|||maintenance||||888|254|264
SE|00000000||tx|1|entity|C2946261|Level|phsu|||level||||888|266|270
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|282|288
SE|00000000||tx|1|entity|C1515187|Take|hlca|||taking||||884|294|299
SE|00000000||tx|1|entity|C0008402|Cholestyramine Resin|orch,phsu|||cholestyramine resin||||884|301|320
SE|00000000||tx|1|relation|1|1|C0008402|Cholestyramine Resin|orch,phsu|orch|||Cholestyramine resin||||1000|1|20|VERB|DISRUPTS||26|34|12|1|C0031327|Drug Kinetics|phsf|phsf|||pharmacokinetics||||1000|45|60


SE|00000000||tx|1|text|CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
SE|00000000||tx|1|entity|C0935984|Cancidas|aapp,phsu|||CANCIDAS||||1000|1|8
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||827|22|26
SE|00000000||tx|1|entity|C0085149|Tacrolimus|orch,phsu|||tacrolimus||||1000|39|48
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|53|65
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||901|77|81
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||peak blood concentration||||901|72|95
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|98|101
SE|00000000||tx|1|entity|C1292430|12 hours|tmco|||12-hour||||888|116|122
SE|00000000||tx|1|entity|C0699870|Blood drug concentration|qnco|||blood concentration||||888|124|142
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy subjects||||1000|162|177
SE|00000000||tx|1|entity|C0085149|Tacrolimus|orch,phsu|||tacrolimus||||1000|184|193
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|198|202
SE|00000000||tx|1|entity|C0439272|ug/g|qnco|||mg/kg||||766|211|215
SE|00000000||tx|1|entity|C0456695|/12h|tmco|||12 hours||||766|217|224
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||861|262|264
SE|00000000||tx|1|entity|C0935984|Cancidas|aapp,phsu|||CANCIDAS||||775|269|276
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||775|284|288
SE|00000000||tx|1|entity|C1274040|Result|ftcn|||results||||1000|306|312
SE|00000000||tx|1|entity|C0439531|per period (qualifier value)|tmco|||period||||861|329|334
SE|00000000||tx|1|entity|C0085149|Tacrolimus|orch,phsu|||tacrolimus||||1000|345|354
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|373|377
SE|00000000||tx|1|relation|14|7|C0085149|Tacrolimus|orch,phsu|orch|||tacrolimus||||1000|184|193|PREP|COEXISTS_WITH||336|337|2|1|C0085149|Tacrolimus|orch,phsu|orch|||tacrolimus||||1000|345|354
SE|00000000||tx|1|relation|14|7|C0085149|Tacrolimus|orch,phsu|orch|||tacrolimus||||1000|39|48|PREP|COEXISTS_WITH||336|337|2|1|C0085149|Tacrolimus|orch,phsu|orch|||tacrolimus||||1000|345|354


SE|00000000||tx|1|text|Neuroleptic Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.
SE|00000000||tx|1|entity|C0040615|Antipsychotic Agents|phsu|||Neuroleptic Drugs||||824|1|17
SE|00000000||tx|1|entity|C0031453|Phenylalanine|aapp,bacs,phsu|||phenylalanine||||824|23|35
SE|00000000||tx|1|entity|C0152115|Lingual-Facial-Buccal Dyskinesia|dsyn|||tardive dyskinesia||||850|56|73
SE|00000000||tx|1|entity|C0441987|Side|spco|||side||||850|75|78
SE|00000000||tx|1|entity|C1114821|Reaction:Finding:Point in time:^Patient:Nominal|clna|||reactions||||850|80|88
SE|00000000||tx|1|entity|C0040615|Antipsychotic Agents|phsu|||neuroleptic drugs||||1000|93|109
SE|00000000||tx|1|relation|1|1|C0031453|Phenylalanine|aapp,gngm,bacs,phsu|aapp|||phenylalanine||||824|23|35|VERB|STIMULATES||41|50|2|2|C0040615|Antipsychotic Agents|phsu|phsu|||neuroleptic drugs||||1000|93|109


SE|00000000||tx|1|text|It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium.
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||623|24|29
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||623|31|37
SE|00000000||tx|1|entity|C0022635|Ketoprofen|orch,phsu|||ketoprofen||||1000|64|73
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|98|104


SE|00000000||tx|1|text|A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two-||||802|3|6
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||802|11|21
SE|00000000||tx|1|entity|C0020208|Hydantoin|orch,phsu|||hydantoin||||861|35|43
SE|00000000||tx|1|entity|C0003299|Antiepileptic Agents|phsu|||antiepileptic||||861|45|57
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||861|60|68
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin anticoagulants||||983|79|101


SE|00000000||tx|1|text|Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||Hormonal||||888|1|8
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||Contraceptives||||888|10|23
SE|00000000||tx|1|entity|C0442027|Oral|spco|||Oral||||888|36|39
SE|00000000||tx|1|entity|C1272883|Injection product|bodm|||Injectable||||888|42|51
SE|00000000||tx|1|entity|C0694643|transdermal|spco|||Transdermal||||1000|54|64
SE|00000000||tx|1|entity|C0021102|Implants|medd|||Implantable||||888|71|81
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||Contraceptives||||888|83|96
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||888|102|112
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||888|114|118
SE|00000000||tx|1|entity|C0252643|bosentan|orch,phsu|||bosentan||||1000|159|166
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||857|181|188
SE|00000000||tx|1|entity|C0029151|Oral contraception|topp|||oral hormonal contraceptive||||857|176|202
SE|00000000||tx|1|entity|C0722328|Ortho Novum|phsu,strd|||Ortho-Novum||||857|204|214
SE|00000000||tx|1|entity|C1510992|Average|qnco|||average||||888|225|231
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decreases||||888|233|241
SE|00000000||tx|1|entity|C0028356|Norethindrone|horm,phsu,strd|||norethindrone||||1000|246|258
SE|00000000||tx|1|entity|C0337434|Estradiol measurement|lbpr|||estradiol levels||||867|272|287
SE|00000000||tx|1|entity|C0450355|31|inpr|||31%||||1000|300|302


SE|00000000||tx|1|text|Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|12|14
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|19|26
SE|00000000||tx|1|entity|C2707259|Metabolic:-:Point in time:^Patient:-|clna|||metabolic||||888|42|50
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|52|60
SE|00000000||tx|1|entity|C0724461|Zebeta|orch,phsu|||ZEBETA||||1000|65|70
SE|00000000||tx|1|entity|C1282927|Shortened|qlco|||shortened||||916|88|96
SE|00000000||tx|1|entity|C2348397|Elimination Half Life|qnco|||elimination half-life||||916|98|118
SE|00000000||tx|1|entity|C0724461|Zebeta|orch,phsu|||ZEBETA||||1000|123|128
SE|00000000||tx|1|relation|2|1|C0035608|Rifampin|antb,orch|antb|||rifampin||||1000|19|26|VERB|STIMULATES||28|36|4|2|C0724461|Zebeta|orch,phsu|orch|||ZEBETA||||1000|65|70


SE|00000000||tx|1|text|Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide
SE|00000000||tx|1|entity|C0030174|Package Inserts|mnob|||package insert||||1000|14|27
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||872|33|39
SE|00000000||tx|1|entity|C1521827|Preparation|ftcn|||preparations||||872|41|52
SE|00000000||tx|1|entity|C1521827|Preparation|ftcn|||preparations||||966|73|84
SE|00000000||tx|1|entity|C0008273|Chlorothiazide|orch,phsu|||chlorothiazide||||1000|91|104


SE|00000000||tx|1|text|The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.
SE|00000000||tx|1|entity|C0813510|Adenocard|bacs,nnon|||Adenocard||||1000|12|20
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|25|32
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||rarely||||1000|61|66
SE|00000000||tx|1|entity|C0042510|Ventricular Fibrillation|dsyn|||ventricular fibrillation||||1000|84|107
SE|00000000||tx|1|relation|4|3|C0813510|Adenocard|bacs,nnon|bacs|||Adenocard||||1000|12|20|VERB|ASSOCIATED_WITH||68|77|1|1|C0042510|Ventricular Fibrillation|dsyn|dsyn|||ventricular fibrillation||||1000|84|107


SE|00000000||tx|1|text|Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.
SE|00000000||tx|1|entity|C0009262|Colchicine|orch,phsu|||Colchicine||||916|1|10
SE|00000000||tx|1|entity|C0030125|aminosalicylic acid|orch,phsu|||para-aminosalicylic acid||||916|12|35
SE|00000000||tx|1|entity|C0001948|Alcohol consumption|inbe|||alcohol intake||||901|47|60
SE|00000000||tx|1|entity|C0205166|Long|qlco|||longer||||966|66|71
SE|00000000||tx|1|entity|C1442457|2 Weeks|tmco|||2 weeks||||1000|78|84
SE|00000000||tx|1|entity|C0042845|Vitamin B 12|orch,phsu,vita|||vitamin B12||||1000|115|125


SE|00000000||tx|1|text|The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|20|30
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|32|38
SE|00000000||tx|1|entity|C0014025|Enalapril|aapp,phsu|||enalapril||||1000|45|53
SE|00000000||tx|1|entity|C0014027|Enalaprilat|aapp,phsu|||enalaprilat||||1000|58|68
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|115|122
SE|00000000||tx|1|entity|C0442808|Increasing|ftcn|||increasing||||1000|127|136
SE|00000000||tx|1|entity|C0489767|salt intake|orga|||salt intake||||1000|142|152
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|163|172
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|177|185
SE|00000000||tx|1|entity|C0014025|Enalapril|aapp,phsu|||enalapril||||1000|192|200
SE|00000000||tx|1|entity|C0014027|Enalaprilat|aapp,phsu|||enalaprilat||||1000|205|215
SE|00000000||tx|1|relation|9|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||1000|177|185|PREP|USES||187|190|2|1|C0014025|Enalapril|aapp,gngm,phsu|phsu|||enalapril||||1000|192|200


SE|00000000||tx|1|text|Therefore, the combined use of lovastatin with fibrates should generally be avoided.
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combined||||888|16|23
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|25|27
SE|00000000||tx|1|entity|C0024027|Lovastatin|orch,phsu|||lovastatin||||1000|32|41
SE|00000000||tx|1|entity|C1449704|Fibrates|orch,phsu|||fibrates||||1000|48|55


SE|00000000||tx|1|text|Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.
SE|00000000||tx|1|entity|C0010583|Cyclophosphamide|opco,phsu|||Cyclophosphamide||||1000|1|16
SE|00000000||tx|1|entity|C0701063|Cerubidine|orch,phsu|||Cerubidine||||1000|41|50
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|71|79
SE|00000000||tx|1|entity|C0876994|cardiac toxicity|inpo|||cardiotoxicity||||888|81|94
SE|00000000||tx|1|relation|2|1|C0701063|Cerubidine|orch,phsu|orch|||Cerubidine||||1000|41|50|VERB|CAUSES||61|66|1|1|C0876994|cardiac toxicity|inpo|inpo|||cardiotoxicity||||888|81|94


SE|00000000||tx|1|text|Ketamine: When administered to patients on a thyroid preparation, this parenteral anesthetic may cause hypertension and tachycardia.
SE|00000000||tx|1|entity|C0022614|Ketamine|orch,phsu|||Ketamine||||1000|1|8
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|32|39
SE|00000000||tx|1|entity|C0279175|Thyroid preparation|aapp,horm,phsu|||thyroid preparation||||1000|46|64
SE|00000000||tx|1|entity|C0242904|Anesthetics, Intravenous|phsu|||parenteral anesthetic||||1000|72|92
SE|00000000||tx|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||1000|104|115
SE|00000000||tx|1|entity|C0039231|Tachycardia|fndg|||tachycardia||||1000|121|131
SE|00000000||tx|1|relation|1|1|C0022614|Ketamine|orch,phsu|orch|||Ketamine||||1000|1|8|VERB|ADMINISTERED_TO||16|27|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|32|39
SE|00000000||tx|1|relation|4|1|C0242904|Anesthetics, Intravenous|phsu|phsu|||parenteral anesthetic||||1000|72|92|VERB|CAUSES||98|102|2|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||1000|104|115
SE|00000000||tx|1|relation|4|1|C0242904|Anesthetics, Intravenous|phsu|phsu|||parenteral anesthetic||||1000|72|92|VERB|CAUSES||98|102|2|1|C0039231|Tachycardia|fndg|fndg|||tachycardia||||1000|121|131


SE|00000000||tx|1|text|ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE Inhibitors||||1000|1|14
SE|00000000||tx|1|entity|C0521942|Angiotensin II receptor antagonist|phsu|||Angiotensin II Receptor Antagonists||||1000|20|54
SE|00000000||tx|1|entity|C0020538|Hypertensive disease|dsyn|||Hypertension||||1000|57|68
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||clinical studies||||1000|75|90
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|95|102
SE|00000000||tx|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||1000|109|120
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|127|134
SE|00000000||tx|1|entity|C1144054|Inspra|phsu,strd|||INSPRA||||861|139|144
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitors||||1000|162|175
SE|00000000||tx|1|entity|C0521942|Angiotensin II receptor antagonist|phsu|||angiotensin II receptor antagonists||||1000|181|215
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||775|232|236
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||775|238|246
SE|00000000||tx|1|entity|C0750482|Slightly|idcn|||slightly||||775|248|255
SE|00000000||tx|1|entity|C0439375|mEq/L|qnco|||mEq/L||||818|274|278
SE|00000000||tx|1|relation|7|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||1000|109|120|PREP|PROCESS_OF||104|107|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|95|102
SE|00000000||tx|1|relation|10|1|C0521942|Angiotensin II receptor antagonist|phsu|phsu|||angiotensin II receptor antagonists||||1000|181|215|VERB|STIMULATES||217|225|2|1|C0032821|Potassium|elii|elii|||potassium||||775|238|246
SE|00000000||tx|1|relation|10|1|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|phsu|||ACE Inhibitors||||1000|1|14|VERB|STIMULATES||217|225|2|1|C0032821|Potassium|elii|elii|||potassium||||775|238|246
SE|00000000||tx|1|relation|10|1|C0521942|Angiotensin II receptor antagonist|phsu|phsu|||Angiotensin II Receptor Antagonists||||1000|20|54|VERB|STIMULATES||217|225|2|1|C0032821|Potassium|elii|elii|||potassium||||775|238|246


SE|00000000||tx|1|text|Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||Erythromycin||||1000|1|12
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|59|68
SE|00000000||tx|1|entity|C1136312|Histamine H1 Antagonists, Non-Sedating|phsu|||nonsedating antihistamines||||905|73|98
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||905|100|110
SE|00000000||tx|1|entity|C0085170|Astemizole|orch,phsu|||astemizole||||1000|116|125
SE|00000000||tx|1|relation|0|0|C0085173|Terfenadine|orch,phsu|orch|||terfenadine||||905|100|110|MOD/HEAD|ISA||73|110|0|0|C1136312|Histamine H1 Antagonists, Non-Sedating|phsu|phsu|||nonsedating antihistamines||||905|73|98
SE|00000000||tx|1|relation|1|1|C0014806|Erythromycin|antb,orch|antb|||Erythromycin||||1000|1|12|VERB|INTERACTS_WITH||49|53|3|2|C0085173|Terfenadine|orch,phsu|orch|||terfenadine||||905|100|110


SE|00000000||tx|1|text|Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.
SE|00000000||tx|1|entity|C0036579|Selegiline|orch,phsu|||Selegiline||||1000|1|10
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||Combination||||851|13|23
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||851|25|32
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||851|34|47
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentration||||1000|66|84
SE|00000000||tx|1|entity|C0036579|Selegiline|orch,phsu|||selegiline||||1000|89|98
SE|00000000||tx|1|relation|2|1|C0009871|Contraceptive Agents|phsu|phsu|||contraceptives||||851|34|47|VERB|STIMULATES||53|60|2|2|C0036579|Selegiline|orch,phsu|orch|||selegiline||||1000|89|98


SE|00000000||tx|1|text|Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
SE|00000000||tx|1|entity|C1511726|Data|idcn|||Data||||1000|1|4
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|31|45
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|58|67
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||901|79|86
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interaction||||901|88|103
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||1000|113|121
SE|00000000||tx|1|entity|C0014710|Ergotamine|orch,phsu|||ergotamine||||1000|124|133
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|136|147
SE|00000000||tx|1|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||1000|150|159
SE|00000000||tx|1|entity|C0028005|Nicardipine|orch,phsu|||nicardipine||||1000|162|172
SE|00000000||tx|1|entity|C0028066|Nifedipine|orch,phsu|||nifedipine||||1000|179|188


SE|00000000||tx|1|text|Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||Triazolam||||1000|1|9
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||Erythromycin||||1000|12|23
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|59|67
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||triazolam||||1000|72|80
SE|00000000||tx|1|entity|C0728866|Drug effect|ftcn|||pharmacologic effect||||983|110|129
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||triazolam||||1000|134|142
SE|00000000||tx|1|relation|2|1|C0014806|Erythromycin|antb,orch|antb|||Erythromycin||||1000|12|23|VERB|INHIBITS||46|53|4|2|C0040879|Triazolam|orch,phsu|orch|||triazolam||||1000|72|80


SE|00000000||tx|1|text|The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|17|19
SE|00000000||tx|1|entity|C0037490|Sodium Cephalothin|antb,orch|||sodium cephalothin||||1000|24|41
SE|00000000||tx|1|entity|C0719445|Coly Mycin M|orch,phsu|||Coly-Mycin M||||1000|47|58


SE|00000000||tx|1|text|INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||INH||||944|1|3
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||Isoniazid||||1000|6|14
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||790|44|55
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||790|57|70
SE|00000000||tx|1|relation|2|2|C0022209|isoniazid|orch,phsu|orch|||INH||||944|1|3|VERB|INTERACTS_WITH||37|42|1|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||790|44|55


SE|00000000||tx|1|text|Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|entity|C0038633|Sucralfate|carb,phsu|||sucralfate||||1000|14|23
SE|00000000||tx|1|entity|C0038633|Sucralfate|carb,phsu|||Sucralfate||||1000|26|35
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|41|48
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||magnesium||||1000|61|69
SE|00000000||tx|1|entity|C0002367|Aluminum|elii|||aluminum||||1000|74|81
SE|00000000||tx|1|entity|C0007447|Cations|chvs|||cations||||861|142|148
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||Videx||||1000|158|162
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||1000|166|175
SE|00000000||tx|1|entity|C0006353|Buffers|irda,phsu|||buffered||||901|188|195
SE|00000000||tx|1|entity|C0304290|Chewable Tablet|bodm|||chewable/buffered tablets||||901|179|203
SE|00000000||tx|1|entity|C1521725|Pediatric|qlco|||pediatric||||694|212|220
SE|00000000||tx|1|entity|C0991536|Oral Solution|bodm|||oral solution||||1000|233|245
SE|00000000||tx|1|entity|C1527256|Chelating Activity [MoA]|moft|||chelation||||888|256|264
SE|00000000||tx|1|entity|C1704241|complex (molecular entity)|chvs|||complexes||||888|266|274
SE|00000000||tx|1|entity|C0065162|lomefloxacin|orch,phsu|||lomefloxacin||||1000|281|292
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|317|331
SE|00000000||tx|1|relation|0|0|C0592249|Videx|nnon,phsu|nnon|||Videx||||1000|158|162|SPEC|ISA||158|175|0|0|C0012133|Didanosine|nnon,phsu|nnon|||didanosine||||1000|166|175


SE|00000000||tx|1|text|Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|18|22
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|27|44
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||851|49|51
SE|00000000||tx|1|entity|C0439230|week|tmco|||week||||851|53|56
SE|00000000||tx|1|entity|C0750729|Course|tmco|||course||||851|58|63
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|68|77
SE|00000000||tx|1|entity|C0439423|Milligram per 24 Hours|qnco|||mg b.i.d||||790|86|93
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||775|103|108
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||775|115|118
SE|00000000||tx|1|entity|C0071304|Isradipine|orch,phsu|||isradipine||||1000|123|132
SE|00000000||tx|1|entity|C0205440|Sixth|qnco|||sixth||||888|141|145
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||888|147|149
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|161|168
SE|00000000||tx|1|entity|C0071304|Isradipine|orch,phsu|||isradipine||||801|173|182
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||801|194|214
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|226|236
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|238|245
SE|00000000||tx|1|entity|C0205146|Area|spco|||area||||1000|250|253
SE|00000000||tx|1|entity|C0205134|Curved|spco|||curve||||1000|265|269


SE|00000000||tx|1|text|Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||890|12|19
SE|00000000||tx|1|entity|C0445550|Low dose|qnco|||lowest possible dose||||890|5|24
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||1000|29|40
SE|00000000||tx|1|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||HMG-CoA reductase inhibitors||||1000|79|106
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|117|119
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|146|151
SE|00000000||tx|1|entity|C0085542|Pravastatin|orch,phsu|||pravastatin||||1000|162|172
SE|00000000||tx|1|entity|C0082608|fluvastatin|orch,phsu|||fluvastatin||||1000|175|185
SE|00000000||tx|1|entity|C0965129|rosuvastatin|orch,phsu|||rosuvastatin||||1000|191|202
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|207|217
SE|00000000||tx|1|entity|C0701105|Crixivan|orch,phsu|||CRIXIVAN||||1000|224|231
SE|00000000||tx|1|relation|6|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|146|151|VERB|INTERACTS_WITH|negation|131|141|4|1|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|orch|||HMG-CoA reductase inhibitors||||1000|79|106
SE|00000000||tx|1|relation|6|1|C0965129|rosuvastatin|orch,phsu|orch|||rosuvastatin||||1000|191|202|VERB|INTERACTS_WITH|negation|131|141|4|1|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|orch|||HMG-CoA reductase inhibitors||||1000|79|106
SE|00000000||tx|1|relation|6|1|C0082608|fluvastatin|orch,phsu|orch|||fluvastatin||||1000|175|185|VERB|INTERACTS_WITH|negation|131|141|4|1|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|orch|||HMG-CoA reductase inhibitors||||1000|79|106
SE|00000000||tx|1|relation|6|1|C0085542|Pravastatin|orch,phsu|orch|||pravastatin||||1000|162|172|VERB|INTERACTS_WITH|negation|131|141|4|1|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|orch|||HMG-CoA reductase inhibitors||||1000|79|106


SE|00000000||tx|1|text|Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
SE|00000000||tx|1|entity|C0700702|Botox|hops,orch,phsu|||BOTOX||||1000|22|26
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycosides||||1000|32|46
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|57|62
SE|00000000||tx|1|entity|C0260043|Neuromuscular transmission|ortf|||neuromuscular transmission||||1000|81|106
SE|00000000||tx|1|entity|C0010463|Curare|hops,orch,phsu|||curare||||1000|115|120
SE|00000000||tx|1|entity|C0205198|Compound|qlco|||compounds||||966|127|135
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||only||||1000|145|148
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|183|188
SE|00000000||tx|1|entity|C0040549|Toxin|bacs,hops|||toxin||||1000|197|201
SE|00000000||tx|1|relation|0|0|C0002556|Aminoglycosides|carb,phsu|carb|||aminoglycosides||||1000|32|46|SPEC|ISA||32|62|0|0|C0450442|Agent|chvf|chvf|||agents||||966|57|62
SE|00000000||tx|1|relation|0|0|C0700702|Botox|hops,orch,phsu|hops|||BOTOX||||1000|22|26|SPEC|ISA||32|62|0|0|C0450442|Agent|chvf|chvf|||agents||||966|57|62
SE|00000000||tx|1|relation|4|2|C0002556|Aminoglycosides|carb,phsu|phsu|||aminoglycosides||||1000|32|46|VERB|DISRUPTS||64|74|6|1|C0260043|Neuromuscular transmission|ortf|ortf|||neuromuscular transmission||||1000|81|106
SE|00000000||tx|1|relation|4|2|C0700702|Botox|hops,orch,phsu|phsu|||BOTOX||||1000|22|26|VERB|DISRUPTS||64|74|6|1|C0260043|Neuromuscular transmission|ortf|ortf|||neuromuscular transmission||||1000|81|106
SE|00000000||tx|1|relation|8|3|C0010463|Curare|hops,orch,phsu|hops|||curare||||1000|115|120|NOM|INTERACTS_WITH||183|188|1|1|C0040549|Toxin|bacs,hops|bacs|||toxin||||1000|197|201


SE|00000000||tx|1|text|Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||Clonidine||||1000|1|9
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|12|22
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||1000|42|50
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|57|62
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blocking||||851|71|78
SE|00000000||tx|1|entity|C1292721|Has property|ftcn|||properties||||851|80|89
SE|00000000||tx|1|entity|C0005823|Blood Pressure|orgf|||blood-pressure||||1000|106|119
SE|00000000||tx|1|entity|C0018810|heart rate|orga|||heart-rate||||861|126|135
SE|00000000||tx|1|entity|C0441994|Lower - spatial qualifier|spco|||lowering||||861|137|144
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|146|152
SE|00000000||tx|1|relation|5|3|C0009014|Clonidine|orch,phsu|orch|||clonidine||||1000|42|50|VERB|AUGMENTS||95|104|2|1|C0005823|Blood Pressure|orgf|orgf|||blood-pressure||||1000|106|119


SE|00000000||tx|1|text|Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||Erythromycin||||1000|1|12
SE|00000000||tx|1|entity|C0439423|Milligram per 24 Hours|qnco|||mg t.i.d)||||790|19|27
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||851|42|45
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||851|47|54
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||vardenafil||||888|59|68
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|70|72
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||790|82|85
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||790|87|94
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|99|102
SE|00000000||tx|1|entity|C1176941|vardenafil 5 MG|clnd|||Vardenafil 5 mg||||1000|130|144
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|149|166


SE|00000000||tx|1|text|Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect.
SE|00000000||tx|1|entity|C0699440|Labetalol hydrochloride|orch,phsu|||Labetalol HCl||||1000|1|13
SE|00000000||tx|1|entity|C1328539|Reflex tachycardia|fndg|||reflex tachycardia||||1000|26|43
SE|00000000||tx|1|entity|C0017887|Nitroglycerin|orch,phsu|||nitroglycerin||||1000|57|69
SE|00000000||tx|1|entity|C1292733|Preventing (action)|ftcn|||preventing||||966|79|88
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|94|104
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|106|111
SE|00000000||tx|1|relation|3|1|C0017887|Nitroglycerin|orch,phsu|orch|||nitroglycerin||||1000|57|69|VERB|CAUSES||45|52|2|1|C1328539|Reflex tachycardia|fndg|fndg|||reflex tachycardia||||1000|26|43


SE|00000000||tx|1|text|Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.
SE|00000000||tx|1|entity|C0439611|Preliminary|tmco|||Preliminary||||901|1|11
SE|00000000||tx|1|entity|C1516606|Clinical Data|inpr|||clinical data||||901|13|25
SE|00000000||tx|1|entity|C0021149|Incidence|qnco|||incidence||||1000|44|52
SE|00000000||tx|1|entity|C0392525|Nephrolithiasis|dsyn|||nephrolithiasis||||1000|57|71
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||966|76|81
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|86|93
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|105|113
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|118|128
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|135|143
SE|00000000||tx|1|entity|C1514756|Receive|qlco|||receiving||||749|156|164
SE|00000000||tx|1|entity|C0701105|Crixivan|orch,phsu|||CRIXIVAN||||749|166|173
SE|00000000||tx|1|entity|C0585326|Every eight hours|tmco|||q8h||||749|182|184
SE|00000000||tx|1|relation|4|2|C0392525|Nephrolithiasis|dsyn|dsyn|||nephrolithiasis||||1000|57|71|PREP|PROCESS_OF||83|84|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|86|93
SE|00000000||tx|1|relation|4|1|C0376637|Indinavir|orch,phsu|orch|||indinavir||||1000|105|113|VERB|ADMINISTERED_TO||95|103|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|86|93


SE|00000000||tx|1|text|The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).
SE|00000000||tx|1|entity|C0021149|Incidence|qnco|||incidence||||1000|5|13
SE|00000000||tx|1|entity|C0392156|Akathisia|dsyn|||akathisia||||1000|18|26
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||clinical trials||||1000|31|45
SE|00000000||tx|1|entity|C0332174|Weekly|tmco|||weekly||||623|54|59
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||623|61|66
SE|00000000||tx|1|entity|C1704243|Greater|qnco|||greater||||1000|81|87
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||802|101|108
SE|00000000||tx|1|entity|C0033229|Prochlorperazine|orch,phsu|||prochlorperazine||||1000|116|131
SE|00000000||tx|1|entity|C0445247|Same|qlco|||same||||888|157|160
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||888|162|164
SE|00000000||tx|1|entity|C0701188|Camptosar|orch,phsu|||CAMPTOSAR||||1000|169|177
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|195|199
SE|00000000||tx|1|entity|C0443299|Separate|spco|||separate||||888|215|222
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||888|224|227
SE|00000000||tx|1|entity|C0470206|+1|qnco|||1.3||||861|230|232
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||802|241|248


SE|00000000||tx|1|text|- Although not a true drug interaction, tricyclic antidepressants may precipitate seizures in susceptible patients and Cerebyx dosage may need to be adjusted
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|12|14
SE|00000000||tx|1|entity|C0205238|True|qlco|||true||||901|18|21
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interaction||||901|23|38
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|41|65
SE|00000000||tx|1|entity|C0036572|Seizures|sosy|||seizures||||1000|83|90
SE|00000000||tx|1|entity|C0231204|Susceptible|ftcn|||susceptible||||888|95|105
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|107|114
SE|00000000||tx|1|entity|C0525944|Cerebyx|orch,phsu|||Cerebyx||||888|120|126
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||888|128|133
SE|00000000||tx|1|relation|2|1|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|41|65|VERB|CAUSES||71|81|3|1|C0036572|Seizures|sosy|sosy|||seizures||||1000|83|90
SE|00000000||tx|1|relation|3|1|C0036572|Seizures|sosy|sosy|||seizures||||1000|83|90|PREP|PROCESS_OF||92|93|2|1|C0030705|Patients|podg,humn|humn|||patients||||888|107|114


SE|00000000||tx|1|text|In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||1000|4|8
SE|00000000||tx|1|entity|C0018787|Heart|bpoc|||cardiac||||901|14|20
SE|00000000||tx|1|entity|C0376387|Recipient, Transplant|podg|||transplant recipients||||901|22|42
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|47|55
SE|00000000||tx|1|entity|C0366433|Cyclosporine:Mass:Point in time:Dose med or substance:Quantitative|clna|||cyclosporine dose||||890|60|76
SE|00000000||tx|1|entity|C1514721|Range|qnco|||ranging||||890|78|84
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||851|128|139
SE|00000000||tx|1|entity|C0444506|Trough|qnco|||trough||||851|141|146
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||851|148|161
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||1000|163|169
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|198|205
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|210|218


SE|00000000||tx|1|text|Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||Quinidine||||1000|1|9
SE|00000000||tx|1|entity|C0205253|Immediate|tmco|||Immediate||||851|12|20
SE|00000000||tx|1|entity|C0391871|Released (action)|ftcn|||Release||||851|22|28
SE|00000000||tx|1|entity|C0006935|capsule (pharmacologic)|bodm|||Capsules||||851|30|37
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||rare||||888|56|59
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|75|85
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|95|103
SE|00000000||tx|1|entity|C0028066|Nifedipine|orch,phsu|||nifedipine||||1000|109|118
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||decreased||||851|128|136
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||851|138|143
SE|00000000||tx|1|entity|C2946261|Level|phsu|||level||||851|145|149
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|154|162
SE|00000000||tx|1|relation|4|4|C0034414|Quinidine|orch,phsu|orch|||quinidine||||1000|154|162|NOM|INTERACTS_WITH||75|85|4|1|C0034414|Quinidine|orch,phsu|orch|||quinidine||||1000|95|103
SE|00000000||tx|1|relation|4|4|C0034414|Quinidine|orch,phsu|orch|||quinidine||||1000|154|162|NOM|INTERACTS_WITH||75|85|4|1|C0028066|Nifedipine|orch,phsu|orch|||nifedipine||||1000|109|118


SE|00000000||tx|1|text|MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|1|14
SE|00000000||tx|1|entity|C0011682|Desiccation|npop|||drying||||1000|59|64
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|67|73
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|78|91


SE|00000000||tx|1|text|Probenecid: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|1|10
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||888|13|22
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||888|24|32
SE|00000000||tx|1|entity|C1880497|Empty (qualifier)|qlco|||free||||1000|39|42
SE|00000000||tx|1|entity|C1167622|Binding (Molecular Function)|moft|||bound||||888|48|52
SE|00000000||tx|1|entity|C0022635|Ketoprofen|orch,phsu|||ketoprofen||||888|54|63
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reducing||||1000|68|75
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||888|81|86
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|88|96
SE|00000000||tx|1|entity|C0022635|Ketoprofen|orch,phsu|||ketoprofen||||762|101|110
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||762|121|123
SE|00000000||tx|1|entity|C0205437|Third|qnco|||third||||762|125|129
SE|00000000||tx|1|entity|C0442797|Decreasing|qlco|||decreasing||||1000|143|152
SE|00000000||tx|1|entity|C0033618|Protein Binding|moft|||protein binding||||1000|158|172


SE|00000000||tx|1|text|Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||Diltiazem||||1000|1|9
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|15|22
SE|00000000||tx|1|entity|C1299392|Mild to moderate|qlco|||mild to moderate||||916|29|44
SE|00000000||tx|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||916|46|57
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||aprepitant||||1000|78|87
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||1000|94|98
SE|00000000||tx|1|entity|C1706433|Capsule Dosing Unit|qnco|||capsule||||694|153|159
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||740|179|187
SE|00000000||tx|1|entity|C1632851|Times|qnco|||times||||740|198|202
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||740|204|208
SE|00000000||tx|1|entity|C1442466|5 Days|tmco|||5 days||||1000|214|219
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||851|238|241
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||851|243|250
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||aprepitant||||888|255|264
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|266|268
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneous||||762|276|287
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||762|293|296
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||762|298|305
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||888|310|318
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|320|322
SE|00000000||tx|1|relation|1|1|C0012373|Diltiazem|orch,phsu|phsu|||Diltiazem||||1000|1|9|PREP|TREATS||12|13|14|1|C0030705|Patients|podg,humn|podg|||patients||||1000|15|22
SE|00000000||tx|1|relation|13|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||916|46|57|PREP|PROCESS_OF||24|27|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|15|22
SE|00000000||tx|1|relation|0|0|C0012373|Diltiazem|orch,phsu|phsu|||Diltiazem||||1000|1|9|INFER|TREATS(INFER)||12|13|0|0|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||916|46|57


SE|00000000||tx|1|text|Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||Rifampin||||1000|1|8
SE|00000000||tx|1|entity|C0876768|Vioxx|orch,phsu|||VIOXX||||1000|32|36
SE|00000000||tx|1|entity|C1104996|Rifampin 600 MG|clnd|||rifampin 600 mg||||916|43|57
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||916|59|63
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||594|68|73
SE|00000000||tx|1|entity|C0205054|Hepatic|blor|||hepatic||||888|86|92
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|94|103
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximate||||802|118|128
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||802|134|141
SE|00000000||tx|1|entity|C0762662|rofecoxib|orch,phsu|||rofecoxib||||890|146|154
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|156|176
SE|00000000||tx|1|relation|6|4|C0876768|Vioxx|orch,phsu|orch|||VIOXX||||1000|32|36|NOM|INHIBITS||134|141|1|1|C0762662|rofecoxib|orch,phsu|orch|||rofecoxib||||890|146|154


SE|00000000||tx|1|text|Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||Agents||||966|1|6
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||decreased||||790|54|62
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|64|69
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induction||||1000|114|122
SE|00000000||tx|1|entity|||gngm|9360|PPIG|CYP||||861|127|129
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzymes||||861|131|137
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||1000|147|155
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||Acetaminophen||||1000|158|170
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|173|182
SE|00000000||tx|1|entity|C0002600|Amitriptyline|orch,phsu|||amitriptyline||||1000|185|197
SE|00000000||tx|1|entity|C0085208|Bupropion|orch,phsu|||bupropion||||1000|200|208
SE|00000000||tx|1|entity|C0006462|Buspirone|orch,phsu|||buspirone||||1000|211|219
SE|00000000||tx|1|entity|C0008845|Citalopram|orch,phsu|||citalopram||||1000|222|231
SE|00000000||tx|1|entity|C0055891|clobazam|orch,phsu|||clobazam||||1000|234|241
SE|00000000||tx|1|entity|C0009011|Clonazepam|orch,phsu|||clonazepam||||1000|244|253
SE|00000000||tx|1|entity|C0009079|Clozapine|orch,phsu|||clozapine||||1000|256|264
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporin||||1000|267|277
SE|00000000||tx|1|entity|C0288165|Delavirdine|orch,phsu|||delavirdine||||1000|280|290
SE|00000000||tx|1|entity|C0011685|Desipramine|orch,phsu|||desipramine||||1000|293|303
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|306|313
SE|00000000||tx|1|entity|C0005640|Dicumarol|orch,phsu|||dicumarol||||1000|316|324
SE|00000000||tx|1|entity|C0013090|Doxycycline|antb,orch|||doxycycline||||1000|327|337
SE|00000000||tx|1|entity|C0015043|Ethosuximide|orch,phsu|||ethosuximide||||1000|340|351
SE|00000000||tx|1|entity|C0060135|felbamate|orch,phsu|||felbamate||||1000|354|362
SE|00000000||tx|1|entity|C0015772|Felodipine|orch,phsu|||felodipine||||1000|365|374
SE|00000000||tx|1|entity|C0017710|Glucocorticoids|horm,strd|||glucocorticoids||||1000|377|391
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||haloperidol||||1000|394|404
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|407|418
SE|00000000||tx|1|entity|C0064636|lamotrigine|orch,phsu|||lamotrigine||||1000|421|431
SE|00000000||tx|1|entity|C0040165|Thyroxine|aapp,horm,phsu|||levothyroxine||||1000|434|446
SE|00000000||tx|1|entity|C0024002|Lorazepam|orch,phsu|||lorazepam||||1000|449|457
SE|00000000||tx|1|entity|C0025605|Methadone|orch,phsu|||methadone||||1000|460|468
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||midazolam||||1000|471|479
SE|00000000||tx|1|entity|C0049506|Mirtazapine|orch,phsu|||mirtazapine||||1000|482|492
SE|00000000||tx|1|entity|C0028420|Nortriptyline|orch,phsu|||nortriptyline||||1000|495|507
SE|00000000||tx|1|entity|C0171023|olanzapine|orch,phsu|||olanzapine||||1000|510|519
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives||||1000|522|540
SE|00000000||tx|1|entity|C0069751|oxcarbazepine|orch,phsu|||oxcarbazepine||||1000|546|558
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||1000|561|569
SE|00000000||tx|1|entity|C0032911|Praziquantel|orch,phsu|||praziquantel||||1000|575|586
SE|00000000||tx|1|entity|C0033607|Protease Inhibitor|bacs,phsu|||protease inhibitors||||1000|589|607
SE|00000000||tx|1|entity|C0123091|quetiapine|orch,phsu|||quetiapine||||1000|610|619
SE|00000000||tx|1|entity|C0073393|Risperidone|orch,phsu|||risperidone||||1000|622|632
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|635|646
SE|00000000||tx|1|entity|C0076829|topiramate|orch,phsu|||topiramate||||1000|649|658
SE|00000000||tx|1|entity|C0068897|tiagabine|orch,phsu|||tiagabine||||1000|661|669
SE|00000000||tx|1|entity|C0040610|Tramadol|orch,phsu|||tramadol||||1000|672|679
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||triazolam||||1000|682|690
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||valproate||||1000|693|701
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|704|711
SE|00000000||tx|1|entity|C0380393|ziprasidone|orch,phsu|||ziprasidone||||1000|718|728
SE|00000000||tx|1|entity|C0078844|zonisamide|orch,phsu|||zonisamide||||1000|735|744
SE|00000000||tx|1|relation|47|3|C0000970|Acetaminophen|orch,phsu|orch|||Acetaminophen||||1000|158|170|NOM|STIMULATES||114|122|47|1|||gngm,aapp|gngm|9360|PPIG|CYP||||861|127|129


SE|00000000||tx|1|text|Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|1|10
SE|00000000||tx|1|entity|C0678876|renal tubular secretion|ortf|||renal tubular secretion||||1000|26|48
SE|00000000||tx|1|entity|C0002680|Ampicillin|antb,orch|||ampicillin||||1000|53|62
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||790|77|85
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||790|87|91
SE|00000000||tx|1|entity|C0002680|Ampicillin|antb,orch|||ampicillin||||888|107|116
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||888|118|125
SE|00000000||tx|1|relation|2|2|C0033209|Probenecid|orch,phsu|orch|||Probenecid||||1000|1|10|VERB|INHIBITS||17|24|4|1|C0678876|renal tubular secretion|ortf|ortf|||renal tubular secretion||||1000|26|48


SE|00000000||tx|1|text|Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).
SE|00000000||tx|1|entity|C1621583|Administer|ftcn|||administering||||872|40|52
SE|00000000||tx|1|entity|C0935987|Gleevec|orch,phsu|||Gleevec||||872|54|60
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|67|72
SE|00000000||tx|1|entity|C0205168|Thin (qualifier value)|qlco|||narrow||||851|97|102
SE|00000000||tx|1|entity|C0302350|Therapeutic|ftcn|||therapeutic||||851|104|114
SE|00000000||tx|1|entity|C1272706|Interval|tmco|||window||||851|116|121
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|130|141
SE|00000000||tx|1|entity|C0031935|Pimozide|orch,phsu|||pimozide||||1000|146|153
SE|00000000||tx|1|relation|2|1|C0935987|Gleevec|orch,phsu|orch|||Gleevec||||872|54|60|NOM|INTERACTS_WITH||74|83|2|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|67|72


SE|00000000||tx|1|text|Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||Lithium||||1000|1|7
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||Increased||||908|10|18
SE|00000000||tx|1|entity|C0236281|Serum lithium measurement|lbpr|||serum lithium levels||||908|20|39
SE|00000000||tx|1|entity|C1457887|Symptoms|sosy|||symptoms||||1000|45|52
SE|00000000||tx|1|entity|C0238242|LITHIUM TOXICITY|inpo|||lithium toxicity||||1000|57|72
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|96|103
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|115|125
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||888|127|133
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitor||||901|139|151
SE|00000000||tx|1|relation|4|1|C0238242|LITHIUM TOXICITY|inpo|inpo|||lithium toxicity||||1000|57|72|PREP|PROCESS_OF||93|94|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|96|103
SE|00000000||tx|1|relation|2|1|C0023870|Lithium|elii,phsu|elii|||lithium||||888|127|133|VERB|ADMINISTERED_TO||105|113|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|96|103
SE|00000000||tx|1|relation|2|1|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|phsu|||ACE inhibitor||||901|139|151|VERB|ADMINISTERED_TO||105|113|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|96|103


SE|00000000||tx|1|text|Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C1320102|Factive|antb,orch|||FACTIVE||||1000|31|37
SE|00000000||tx|1|entity|C0006681|Calcium Carbonate|inch,phsu|||calcium carbonate||||1000|43|59
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|62|71
SE|00000000||tx|1|entity|C0028978|Omeprazole|orch,phsu|||omeprazole||||1000|74|83
SE|00000000||tx|1|entity|C0014939|Estrogens|horm,phsu,strd|||estrogen||||767|92|99
SE|00000000||tx|1|entity|C0033308|Progesterone|horm,phsu,strd|||progesterone||||767|101|112
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptive||||767|114|131
SE|00000000||tx|1|entity|C0443172|Changed status|qnco|||changes||||767|148|154
SE|00000000||tx|1|entity|C0031327|Drug Kinetics|phsf|||pharmacokinetics||||1000|163|178
SE|00000000||tx|1|entity|C0533545|gemifloxacin|antb,orch|||gemifloxacin||||1000|183|194
SE|00000000||tx|1|entity|C2826293|Clinical Significance|fndg|||clinical significance||||1000|233|253


SE|00000000||tx|1|text|Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||1000|1|12
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||775|22|27
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||775|36|39
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|44|53
SE|00000000||tx|1|entity|C0052080|antineoplaston A10|orch,phsu|||a 10||||861|83|86
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||861|88|90
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||regimen||||861|92|98
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|107|112
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|117|128
SE|00000000||tx|1|entity|C0442821|Strong|qlco|||strong||||802|133|138
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||802|140|145
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||802|147|155
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|162|164
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||aprepitant||||1000|169|178
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||802|190|202
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||802|206|209
SE|00000000||tx|1|entity|C2827968|Terminal Half Life|tmco|||terminal half-life||||923|224|241
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||aprepitant||||1000|246|255
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||802|267|279
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||802|283|286
SE|00000000||tx|1|relation|7|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|117|128|NOM|INHIBITS||147|155|7|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||802|140|145


SE|00000000||tx|1|text|Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||Single||||888|1|6
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|8|12
SE|00000000||tx|1|entity|C0009279|Colestipol|orch,phsu|||colestipol||||888|42|51
SE|00000000||tx|1|entity|C0035191|Resins, Plant|bodm|||resins||||888|53|58
SE|00000000||tx|1|entity|C0020261|Hydrochlorothiazide|orch,phsu|||hydrochlorothiazide||||1000|69|87
SE|00000000||tx|1|entity|C1281182|Entire gastrointestinal tract|bdsy|||gastrointestinal tract||||1000|124|145
SE|00000000||tx|1|relation|3|1|C0035191|Resins, Plant|bodm|bodm|||resins||||888|53|58|VERB|INTERACTS_WITH||60|63|4|1|C0020261|Hydrochlorothiazide|orch,phsu|orch|||hydrochlorothiazide||||1000|69|87


SE|00000000||tx|1|text|Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||Lithium||||1000|1|7
SE|00000000||tx|1|entity|C0238242|LITHIUM TOXICITY|inpo|||Lithium toxicity||||1000|10|25
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|48|55
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||861|67|73
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|94|98
SE|00000000||tx|1|entity|C0037473|Sodium|bacs,elii|||sodium||||1000|127|132
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitors||||1000|145|158
SE|00000000||tx|1|relation|2|1|C0238242|LITHIUM TOXICITY|inpo|inpo|||Lithium toxicity||||1000|10|25|PREP|PROCESS_OF||45|46|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|48|55
SE|00000000||tx|1|relation|5|1|C0023870|Lithium|elii,phsu|elii|||lithium||||861|67|73|VERB|ADMINISTERED_TO||57|65|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|48|55


SE|00000000||tx|1|text|After stopping Fluvoxamine Tablets, at least 2 weeks should be allowed before starting a MAOI.
SE|00000000||tx|1|entity|C0723457|Stop brand of fluoride|inch,phsu|||stopping||||851|7|14
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||Fluvoxamine||||851|16|26
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||Tablets||||851|28|34
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|40|44
SE|00000000||tx|1|entity|C0439230|week|tmco|||weeks||||785|48|52
SE|00000000||tx|1|entity|C1272689|Started|qlco|||starting||||966|79|86
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAOI||||1000|90|93


SE|00000000||tx|1|text|Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||Haloperidol||||1000|1|11
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||Haloperidol||||1000|14|24
SE|00000000||tx|1|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine||||1000|33|40
SE|00000000||tx|1|entity|C1659436|norepinephrine uptake|celf|||norepinephrine reuptake||||1000|46|68
SE|00000000||tx|1|entity|C0002763|Central Nervous System Stimulants|phsu|||central stimulant||||901|91|107
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||901|109|115
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||amphetamines||||1000|120|131
SE|00000000||tx|1|relation|2|1|C0018546|Haloperidol|orch,phsu|orch|||Haloperidol||||1000|14|24|VERB|INHIBITS||26|31|4|1|C0013030|Dopamine|nsba,orch,phsu|nsba|||dopamine||||1000|33|40
SE|00000000||tx|1|relation|4|4|C0018546|Haloperidol|orch,phsu|orch|||Haloperidol||||1000|1|11|NOM|INTERACTS_WITH||109|115|4|0|C0002763|Central Nervous System Stimulants|phsu|phsu|||central stimulant||||901|91|107


SE|00000000||tx|1|text|Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.
SE|00000000||tx|1|entity|C0030446|Paralytic Ileus|dsyn|||Paralytic ileus||||1000|1|15
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|30|37
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|46|70
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|75|85
SE|00000000||tx|1|entity|C0242896|Anticholinergic Agents|phsu|||anticholinergic-type drugs||||913|92|117
SE|00000000||tx|1|relation|1|1|C0030446|Paralytic Ileus|dsyn|dsyn|||Paralytic ileus||||1000|1|15|VERB|OCCURS_IN||21|25|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|30|37
SE|00000000||tx|1|relation|3|1|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|46|70|VERB|ADMINISTERED_TO||39|44|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|30|37


SE|00000000||tx|1|text|The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin.
SE|00000000||tx|1|entity|C1272706|Interval|tmco|||interval||||763|15|22
SE|00000000||tx|1|entity|C0439223|millisecond|tmco|||msec||||1000|25|28
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||1000|44|54
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|56|60
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||802|75|85
SE|00000000||tx|1|entity|C0058445|dirithromycin|antb,orch|||dirithromycin||||802|92|104


SE|00000000||tx|1|text|Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C0205054|Hepatic|blor|||hepatic||||888|34|40
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|42|51
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||901|56|62
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||901|64|88
SE|00000000||tx|1|entity|C0442808|Increasing|ftcn|||increasing||||861|124|133
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||861|135|146
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||861|148|161
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|172|176
SE|00000000||tx|1|relation|1|1|C0008783|Cimetidine|orch,phsu|orch|||Cimetidine||||1000|1|10|VERB|INHIBITS||27|32|5|2|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||901|64|88


SE|00000000||tx|1|text|Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine.
SE|00000000||tx|1|entity|C0008294|Chlorthalidone|orch,phsu|||Chlorthalidone||||1000|1|14
SE|00000000||tx|1|entity|C0163712|Relate - vinyl resin|orch|||related||||888|20|26
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|28|32
SE|00000000||tx|1|entity|C0221464|Arterial|spco|||arterial||||853|47|54
SE|00000000||tx|1|entity|C0205342|Responsive|ftcn|||responsiveness||||853|56|69
SE|00000000||tx|1|entity|C0028351|Norepinephrine|nsba,orch,phsu|||norepinephrine||||1000|74|87


SE|00000000||tx|1|text|Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.
SE|00000000||tx|1|entity|C0341697|Renal impairment|dsyn|||renal impairment||||1000|41|56
SE|00000000||tx|1|entity|C0730991|Foscavir|opco,phsu|||FOSCAVIR||||1000|70|77
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|100|110
SE|00000000||tx|1|entity|C1514118|Nephrotoxic|qlco|||nephrotoxic||||790|129|139
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||790|141|145
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycosides||||1000|155|169
SE|00000000||tx|1|entity|C0002679|Amphotericin B|antb,orch|||amphotericin B||||1000|172|185
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||888|191|201
SE|00000000||tx|1|entity|C0030863|Pentamidine|orch,phsu|||pentamidine||||888|203|213
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||888|226|234
SE|00000000||tx|1|entity|C0814225|Benefits|qnco|||benefits||||888|236|243
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risks||||1000|258|262
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|271|277
SE|00000000||tx|1|relation|0|0|C0002556|Aminoglycosides|carb,phsu|carb|||aminoglycosides||||1000|155|169|SPEC|ISA||141|169|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||790|141|145


SE|00000000||tx|1|text|Calcium channel blockers may also have an additive effect when given with TENORMIN .
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||Calcium channel blockers||||1000|1|24
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|43|50
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|52|57
SE|00000000||tx|1|entity|C0592168|Tenormin|orch,phsu|||TENORMIN||||1000|75|82
SE|00000000||tx|1|relation|1|1|C0592168|Tenormin|orch,phsu|orch|||TENORMIN||||1000|75|82|VERB|COEXISTS_WITH||64|68|2|2|C0006684|Calcium Channel Blockers|phsu|phsu|||Calcium channel blockers||||1000|1|24


SE|00000000||tx|1|text|In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.
SE|00000000||tx|1|entity|C0700321|Small|qnco|||small||||1000|6|10
SE|00000000||tx|1|entity|C0632490|N 30|orch,phsu|||n=30||||1000|13|16
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||888|19|29
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||888|31|35
SE|00000000||tx|1|entity|C0718644|Arava|orch,phsu|||ARAVA||||1000|40|44
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|51|62
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||790|75|78
SE|00000000||tx|1|entity|C0702240|Elevation|spco|||elevation||||790|80|88
SE|00000000||tx|1|entity|C0443764|Liver enzyme|aapp,enzy|||liver enzymes||||1000|93|105
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|127|134
SE|00000000||tx|1|relation|5|2|C0025677|Methotrexate|orch,phsu|orch|||methotrexate||||1000|51|62|NOM|COEXISTS_WITH||19|29|5|1|C0718644|Arava|orch,phsu|orch|||ARAVA||||1000|40|44
SE|00000000||tx|1|relation|4|3|C0632490|N 30|orch,phsu|orch|||n=30||||1000|13|16|NOM|STIMULATES||80|88|2|1|C0443764|Liver enzyme|aapp,gngm,enzy|gngm|||liver enzymes||||1000|93|105


SE|00000000||tx|1|text|A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||1000|12|19
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||901|28|39
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||901|41|43
SE|00000000||tx|1|entity|C0017066|Ganciclovir|nnon,phsu|||ganciclovir||||1000|48|58
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||VIDEX||||1000|78|82
SE|00000000||tx|1|entity|C1292425|2 Hours|tmco|||2 hours||||1000|101|107
SE|00000000||tx|1|entity|C0017066|Ganciclovir|nnon,phsu|||ganciclovir||||1000|118|128
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|135|137
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||888|148|150
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|152|156
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneously||||1000|176|189


SE|00000000||tx|1|text|FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.
SE|00000000||tx|1|entity|C0701981|Fluothane|orch,phsu|||FLUOTHANE||||1000|1|9
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||1000|27|37
SE|00000000||tx|1|entity|C0017067|Ganglia|bpoc|||ganglionic||||851|53|62
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blocking||||851|64|71
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||851|73|78
SE|00000000||tx|1|entity|C0041345|Tubocurarine|orch,phsu|||tubocurarine||||1000|83|94
SE|00000000||tx|1|relation|1|1|C0701981|Fluothane|orch,phsu|orch|||FLUOTHANE||||1000|1|9|VERB|AUGMENTS||15|21|3|1|C0020649|Hypotension|fndg|fndg|||hypotension||||1000|27|37


SE|00000000||tx|1|text|These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||888|7|15
SE|00000000||tx|1|entity|C0728853|Accident due to exposure to weather conditions|phpr|||exposures||||888|17|25
SE|00000000||tx|1|entity|C0028356|Norethindrone|horm,phsu,strd|||norethindrone||||1000|30|42
SE|00000000||tx|1|entity|C0015011|Ethinyl Estradiol|horm,phsu,strd|||ethinyl estradiol||||1000|48|64
SE|00000000||tx|1|entity|C0029151|Oral contraception|topp|||oral contraceptive||||1000|119|136
SE|00000000||tx|1|entity|C0043210|Woman|popg|||women||||1000|142|146
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||1000|155|164
SE|00000000||tx|1|relation|5|1|C0029151|Oral contraception|topp|topp|||oral contraceptive||||1000|119|136|PREP|TREATS||138|140|2|1|C0043210|Woman|popg,humn|popg|||women||||1000|142|146
SE|00000000||tx|1|relation|1|1|C0913246|valdecoxib|orch,phsu|orch|||valdecoxib||||1000|155|164|VERB|ADMINISTERED_TO||148|153|6|1|C0043210|Woman|popg,humn|humn|||women||||1000|142|146


SE|00000000||tx|1|text|Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||Magnesium||||1000|1|9
SE|00000000||tx|1|entity|C1874163|ALUMINUM CONTAINING ANTACIDS|phsu|||aluminum-containing antacids||||1000|16|43
SE|00000000||tx|1|entity|C0065162|lomefloxacin|orch,phsu|||lomefloxacin||||1000|78|89
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|120|134
SE|00000000||tx|1|entity|C0065162|lomefloxacin|orch,phsu|||lomefloxacin||||1000|145|156


SE|00000000||tx|1|text|Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
SE|00000000||tx|1|entity|C1242799|Ketoconazole Oral Tablet [Nizoral]|clnd|||NIZORAL  Tablets||||1000|21|36
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||midazolam||||1000|43|51
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||triazolam||||1000|56|64
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||890|82|89
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|91|111
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||790|127|129
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||790|131|135


SE|00000000||tx|1|text|Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive.
SE|00000000||tx|1|entity|C0242889|Adrenergic Antagonists|phsu|||adrenergic blocking drugs||||923|6|30
SE|00000000||tx|1|entity|C1517331|Further|spco|||further||||802|41|47
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||802|66|71
SE|00000000||tx|1|entity|C0006938|Captopril|aapp,phsu|||captopril||||1000|76|84
SE|00000000||tx|1|entity|C1561607|Overall|qlco|||overall||||861|95|101
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||1000|115|118
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||1000|125|132


SE|00000000||tx|1|text|In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.
SE|00000000||tx|1|entity|C0066447|methylxanthine|orch,phsu|||methylxanthines||||1000|26|40
SE|00000000||tx|1|entity|C0443228|Largest|qnco|||larger||||888|43|48
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|50|54
SE|00000000||tx|1|entity|C0001443|Adenosine|nnon,nsba,phsu|||adenosine||||1000|59|67
SE|00000000||tx|1|entity|C0001443|Adenosine|nnon,nsba,phsu|||adenosine||||1000|88|96
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|102|104
SE|00000000||tx|1|entity|C1704419|Effective|qlco|||effective||||1000|109|117
SE|00000000||tx|1|relation|5|3|C0001443|Adenosine|nnon,nsba,phsu|nsba|||adenosine||||1000|59|67|NOM|COEXISTS_WITH||8|15|5|1|C0066447|methylxanthine|orch,phsu|orch|||methylxanthines||||1000|26|40


SE|00000000||tx|1|text|Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|14|24
SE|00000000||tx|1|entity|C0914729|almotriptan|orch,phsu|||almotriptan||||1000|34|44
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||752|56|61
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||752|63|68
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||752|70|79
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|88|99
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|102|110
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|117|128
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|135|137
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|153|161
SE|00000000||tx|1|entity|C0274281|Injury due to exposure to external cause|inpo|||exposures||||888|163|171
SE|00000000||tx|1|entity|C0914729|almotriptan|orch,phsu|||almotriptan||||1000|176|186
SE|00000000||tx|1|entity|C0914729|almotriptan|orch,phsu|||almotriptan||||1000|209|219
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||1000|254|264


SE|00000000||tx|1|text|Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|7|19
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high doses||||983|24|33
SE|00000000||tx|1|entity|C0235378|Hepatotoxicity|inpo|||hepatotoxicity||||1000|60|73
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|76|86
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|106|115
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|121|133
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|189|196


SE|00000000||tx|1|text|Antidiabetic Agents: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent.
SE|00000000||tx|1|entity|C0935929|Antidiabetics|phsu|||Antidiabetic Agents||||1000|1|19
SE|00000000||tx|1|entity|C2699787|Disturbance|qlco|||Disturbances||||966|22|33
SE|00000000||tx|1|entity|C0005802|Blood Glucose|carb|||blood glucose||||1000|38|50
SE|00000000||tx|1|entity|C0020456|Hyperglycemia|dsyn|||hyperglycemia||||1000|63|75
SE|00000000||tx|1|entity|C0020615|Hypoglycemia|dsyn|||hypoglycemia||||1000|81|92
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|117|124
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|153|162
SE|00000000||tx|1|entity|C0935929|Antidiabetics|phsu|||antidiabetic agent||||1000|171|188
SE|00000000||tx|1|relation|5|1|C0020615|Hypoglycemia|dsyn|dsyn|||hypoglycemia||||1000|81|92|PREP|PROCESS_OF||114|115|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|117|124


SE|00000000||tx|1|text|During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multiple||||851|26|33
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||851|35|38
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||851|40|44
SE|00000000||tx|1|entity|C0592158|Tambocor|orch,phsu|||TAMBOCOR||||1000|49|56
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy subjects||||1000|61|76
SE|00000000||tx|1|entity|C0024501|Maintenance|acty|||maintenance||||888|94|104
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|106|109
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|114|120
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||827|133|140
SE|00000000||tx|1|entity|C1276040|Plasma digoxin measurement|lbpr|||plasma digoxin levels||||983|145|165
SE|00000000||tx|1|entity|C0205452|Six|qnco|||six||||888|179|181
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||888|183|187


SE|00000000||tx|1|text|Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs.
SE|00000000||tx|1|entity|C0019116|Hemostatic function|ortf|||hemostasis||||1000|50|59
SE|00000000||tx|1|entity|C0022635|Ketoprofen|orch,phsu|||ketoprofen||||1000|65|74
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|83|88
SE|00000000||tx|1|entity|C1254881|Platelet function|celf|||platelet function||||1000|93|109
SE|00000000||tx|1|entity|C0205170|Good|qlco|||well||||802|114|117
SE|00000000||tx|1|entity|C0022635|Ketoprofen|orch,phsu|||ketoprofen||||1000|143|152
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|158|165
SE|00000000||tx|1|entity|C0587267|Closed|ftcn|||close||||694|176|180
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|196|203
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|213|217
SE|00000000||tx|1|relation|10|7|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||1000|158|165|NOM|AFFECTS||42|45|10|1|C0019116|Hemostatic function|ortf|ortf|||hemostasis||||1000|50|59
SE|00000000||tx|1|relation|7|3|C0022635|Ketoprofen|orch,phsu|orch|||ketoprofen||||1000|143|152|NOM|AFFECTS||83|88|7|1|C1254881|Platelet function|celf|celf|||platelet function||||1000|93|109


SE|00000000||tx|1|text|The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.
SE|00000000||tx|1|entity|C0205253|Immediate|tmco|||immediate||||888|5|13
SE|00000000||tx|1|entity|C0391871|Released (action)|ftcn|||release||||888|15|21
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|28|30
SE|00000000||tx|1|entity|C1522408|Coating (film)|qlco|||coat||||623|36|39
SE|00000000||tx|1|entity|C0444669|Core|spco|||core||||623|41|44
SE|00000000||tx|1|entity|C0028116|Nisoldipine|orch,phsu|||nisoldipine||||833|61|71
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||833|73|81
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||833|90|98
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma quinidine concentrations||||833|83|113


SE|00000000||tx|1|text|Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.
SE|00000000||tx|1|entity|C1511726|Data|idcn|||data||||1000|16|19
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||Vardenafil||||1000|22|31
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|40|42
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|55|62
SE|00000000||tx|1|entity|C0001641|Adrenergic alpha-Antagonists|phsu|||alpha-blocker||||901|67|79
SE|00000000||tx|1|relation|2|1|C0971579|vardenafil|orch,phsu|phsu|||Vardenafil||||1000|22|31|PREP|TREATS||52|53|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|55|62


SE|00000000||tx|1|text|Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||Diazepam||||1000|1|8
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||Fluvoxamine||||888|36|46
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||Tablets||||888|48|54
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|60|67
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||694|82|84


SE|00000000||tx|1|text|Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||888|1|12
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||888|14|20
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|36|45
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|50|61
SE|00000000||tx|1|entity|C0085149|Tacrolimus|orch,phsu|||tacrolimus||||1000|64|73
SE|00000000||tx|1|entity|C0025815|Methylprednisolone|horm,phsu,strd|||methylprednisolone||||1000|80|97
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||890|113|120
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|122|142
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||861|158|162
SE|00000000||tx|1|relation|1|1|C0039225|Tablet Dosage Form|bodm|bodm|||tablets||||888|14|20|VERB|INTERACTS_WITH||26|30|6|2|C0010592|Cyclosporine|aapp,gngm,phsu|aapp|||cyclosporine||||1000|50|61


SE|00000000||tx|1|text|Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL.
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||Hypotension||||888|1|11
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||888|15|22
SE|00000000||tx|1|entity|C0948575|diuretic therapy|topp|||Diuretic Therapy||||1000|27|42
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|45|52
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|57|65
SE|00000000||tx|1|entity|C0948575|diuretic therapy|topp|||diuretic therapy||||1000|97|112
SE|00000000||tx|1|entity|C0332185|Recent|tmco|||recently||||1000|118|125
SE|00000000||tx|1|entity|C0442802|Excessive|qlco|||excessive||||888|170|178
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||888|180|188
SE|00000000||tx|1|entity|C0005823|Blood Pressure|orgf|||blood pressure||||1000|193|206
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|214|223
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|228|234
SE|00000000||tx|1|entity|C0701176|Prinivil|aapp,phsu|||PRINIVIL||||1000|241|248
SE|00000000||tx|1|relation|4|4|C0701176|Prinivil|aapp,gngm,phsu|aapp|||PRINIVIL||||1000|241|248|NOM|DISRUPTS||180|188|4|1|C0005823|Blood Pressure|orgf|orgf|||blood pressure||||1000|193|206


SE|00000000||tx|1|text|In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||861|15|24
SE|00000000||tx|1|entity|C0015230|Exanthema|dsyn|||rash||||827|41|44
SE|00000000||tx|1|entity|C1514756|Receive|qlco|||receiving||||872|52|60
SE|00000000||tx|1|entity|C0674427|Sustiva|orch,phsu|||SUSTIVA||||872|62|68
SE|00000000||tx|1|entity|C0055856|Clarithromycin|antb,orch|||clarithromycin||||1000|74|87


SE|00000000||tx|1|text|Trecator has been found to temporarily raise serum concentrations of isoniazid.
SE|00000000||tx|1|entity|C0733402|Trecator|orch,phsu|||Trecator||||1000|1|8
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentrations||||983|46|65
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|70|78


SE|00000000||tx|1|text|Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients.
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||Beta-blockers||||1000|1|13
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|15|17
SE|00000000||tx|1|entity|C1527144|Therapeutic Effect|hlca|||therapeutic effects||||983|34|52
SE|00000000||tx|1|entity|C0243192|agonists|phsu|||agonists||||861|62|69
SE|00000000||tx|1|entity|C0006266|Bronchial Spasm|dsyn|||bronchospasm||||861|95|106
SE|00000000||tx|1|entity|||gngm|260431|COPD|COPD||||861|111|114
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|116|123
SE|00000000||tx|1|relation|3|1|C0243192|agonists|phsu|phsu|||agonists||||861|62|69|VERB|CAUSES||80|86|2|1|C0006266|Bronchial Spasm|dsyn|dsyn|||bronchospasm||||861|95|106
SE|00000000||tx|1|relation|4|1|C0006266|Bronchial Spasm|dsyn|dsyn|||bronchospasm||||861|95|106|PREP|PROCESS_OF||108|109|1|1|C0030705|Patients|podg,humn|humn|||patients||||861|116|123


SE|00000000||tx|1|text|These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.
SE|00000000||tx|1|entity|C1709520|Pharmacokinetic Effect|moft|||pharmacokinetic effects||||983|7|29
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||694|43|51
SE|00000000||tx|1|entity|C0205210|Clinical|qlco|||clinical||||890|94|101
SE|00000000||tx|1|entity|C0595938|EFFECT INCREASED|patf|||increased clinical effects||||890|84|109
SE|00000000||tx|1|entity|C0439590|Prolonged|tmco|||prolonged||||694|118|126
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||midazolam||||1000|145|153
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||triazolam||||1000|159|167


SE|00000000||tx|1|text|When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|6|12
SE|00000000||tx|1|entity|C0591189|Brevibloc|orch,phsu|||BREVIBLOC||||1000|18|26
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||888|77|82
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|84|93
SE|00000000||tx|1|entity|C0052080|antineoplaston A10|orch,phsu|||a 10||||824|106|109
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||824|115|122
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||901|135|139
SE|00000000||tx|1|entity|C0337449|Digoxin measurement|lbpr|||digoxin blood levels||||901|127|146
SE|00000000||tx|1|entity|C2348792|Timepoint|tmco|||time points||||966|156|166
SE|00000000||tx|1|relation|2|1|C0591189|Brevibloc|orch,phsu|orch|||BREVIBLOC||||1000|18|26|VERB|ADMINISTERED_TO||47|58|4|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|84|93
SE|00000000||tx|1|relation|2|1|C0012265|Digoxin|carb,phsu,strd|carb|||digoxin||||1000|6|12|VERB|ADMINISTERED_TO||47|58|4|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|84|93


SE|00000000||tx|1|text|Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.
SE|00000000||tx|1|entity|C0027361|Persons|popg|||individual||||888|14|23
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|25|32
SE|00000000||tx|1|entity|C1524062|Additional|ftcn|||additional||||694|46|55
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||888|76|87
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||888|89|94
SE|00000000||tx|1|entity|C0050940|lansoprazole|orch,phsu|||lansoprazole||||1000|101|112
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effective||||750|157|165
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||750|167|171
SE|00000000||tx|1|relation|0|0|C0030705|Patients|podg,humn|podg|||patients||||888|25|32|MOD/HEAD|ISA||14|32|0|0|C0027361|Persons|popg,humn|popg|||individual||||888|14|23


SE|00000000||tx|1|text|The action of colchicine is potentiated by alkalinizing agents.
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|5|10
SE|00000000||tx|1|entity|C0009262|Colchicine|orch,phsu|||colchicine||||1000|15|24
SE|00000000||tx|1|entity|C0304463|Alkalinizing agent|phsu|||alkalinizing agents||||1000|44|62
SE|00000000||tx|1|relation|1|1|C0304463|Alkalinizing agent|phsu|phsu|||alkalinizing agents||||1000|44|62|VERB|STIMULATES||29|39|2|1|C0009262|Colchicine|orch,phsu|orch|||colchicine||||1000|15|24


SE|00000000||tx|1|text|Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs.
SE|00000000||tx|1|entity|C0305353|Atrovent Inhalation Aerosol|clnd|||ATROVENT Inhalation Aerosol||||1000|57|83
SE|00000000||tx|1|entity|C2700400|Contain (action)|acty|||containing||||901|112|121
SE|00000000||tx|1|entity|C0242896|Anticholinergic Agents|phsu|||anticholinergic-containing drugs||||901|96|127


SE|00000000||tx|1|text|Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.
SE|00000000||tx|1|entity|C1831759|pharmacological studies|diap|||Pharmacologic studies||||950|1|21
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|50|57
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|59|65
SE|00000000||tx|1|entity|C0085614|First degree atrioventricular block|dsyn|||prolonging AV conduction||||988|70|93
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blockers||||1000|106|118
SE|00000000||tx|1|entity|C0723743|Tiazac|orch,phsu|||Tiazac||||1000|152|157
SE|00000000||tx|1|relation|2|2|C1831759|pharmacological studies|diap|diap|||Pharmacologic studies||||950|1|21|PREP|DIAGNOSES||67|68|4|1|C0085614|First degree atrioventricular block|dsyn|dsyn|||prolonging AV conduction||||988|70|93


SE|00000000||tx|1|text|The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|5|14
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|16|18
SE|00000000||tx|1|entity|C0242896|Anticholinergic Agents|phsu|||anticholinergics||||1000|23|38
SE|00000000||tx|1|entity|C0020264|Hydrocodone|orch,phsu|||hydrocodone||||1000|45|55
SE|00000000||tx|1|entity|C0030446|Paralytic Ileus|dsyn|||paralytic ileus||||1000|69|83
SE|00000000||tx|1|relation|3|1|C0020264|Hydrocodone|orch,phsu|orch|||hydrocodone||||1000|45|55|VERB|CAUSES||61|67|1|1|C0030446|Paralytic Ileus|dsyn|dsyn|||paralytic ileus||||1000|69|83


SE|00000000||tx|1|text|The beneficial effects on arterial thrombus formation from combined therapy with antiplatelet and anticoagulant medication must be weighed against an increased risk of inducing hemorrhage.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|16|22
SE|00000000||tx|1|entity|C0221464|Arterial|spco|||arterial||||851|27|34
SE|00000000||tx|1|entity|C0087086|Thrombus|patf|||thrombus||||851|36|43
SE|00000000||tx|1|entity|C1522492|Formation|ftcn|||formation||||851|45|53
SE|00000000||tx|1|entity|C0033972|Psychotherapy, Multiple|topp|||combined therapy||||1000|60|75
SE|00000000||tx|1|entity|C0848112|on anti-coagulants|topp|||anticoagulant||||901|99|111
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medication||||901|113|122
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|151|159
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|161|164
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||inducing||||888|169|176
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||hemorrhage||||888|178|187
SE|00000000||tx|1|relation|5|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medication||||901|113|122|NOM|PREDISPOSES||161|164|1|1|C0019080|Hemorrhage|patf|patf|||hemorrhage||||888|178|187
SE|00000000||tx|1|relation|5|1|C0033972|Psychotherapy, Multiple|topp|topp|||combined therapy||||1000|60|75|NOM|PREDISPOSES||161|164|1|1|C0019080|Hemorrhage|patf|patf|||hemorrhage||||888|178|187


SE|00000000||tx|1|text|However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.
SE|00000000||tx|1|entity|C0050559|Acitretin|orch,phsu|||acitretin||||1000|39|47
SE|00000000||tx|1|entity|C3179447|Contraceptive Effect|phsf|||contraceptive effect||||1000|69|88
SE|00000000||tx|1|entity|C0850358|minipill|topp|||minipill||||824|114|121
SE|00000000||tx|1|entity|C0033306|Progestins|horm,phsu,strd|||progestin minipill preparations||||824|104|134
SE|00000000||tx|1|relation|1|1|C0050559|Acitretin|orch,phsu|orch|||acitretin||||1000|39|47|VERB|DISRUPTS||49|58|2|1|C3179447|Contraceptive Effect|phsf|phsf|||contraceptive effect||||1000|69|88


SE|00000000||tx|1|text|Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||Tricyclic antidepressants||||1000|1|25
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||861|58|63
SE|00000000||tx|1|entity|C0018318|Guanethidine|orch,phsu|||guanethidine||||1000|68|79
SE|00000000||tx|1|entity|C0205198|Compound|qlco|||compounds||||793|102|110


SE|00000000||tx|1|text|or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.
SE|00000000||tx|1|entity|C0301532|Multivitamin preparation|orch,phsu,vita|||multivitamins||||1000|9|21
SE|00000000||tx|1|entity|C0043481|Zinc|bacs,elii,phsu|||zinc||||1000|34|37
SE|00000000||tx|1|entity|C0678745|drug absorption|phsf|||drug absorption||||1000|72|86
SE|00000000||tx|1|entity|C1274040|Result|ftcn|||result||||1000|92|97
SE|00000000||tx|1|entity|C0205412|Inadequate (qualifier)|qlco|||insufficient||||888|102|113
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||888|115|120
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolone||||790|133|141
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||790|143|156
SE|00000000||tx|1|relation|2|1|C0043481|Zinc|bacs,elii,phsu|bacs|||zinc||||1000|34|37|VERB|DISRUPTS||57|65|4|1|C0678745|drug absorption|phsf|phsf|||drug absorption||||1000|72|86


SE|00000000||tx|1|text|In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.
SE|00000000||tx|1|entity|C0687676|Post|tmco|||post-||||851|4|8
SE|00000000||tx|1|entity|C0024826|Marketing|ocac|||marketing||||851|9|17
SE|00000000||tx|1|entity|C0596545|Experience|menp|||experience||||851|19|28
SE|00000000||tx|1|entity|C0441471|Event|evnt|||events||||1000|40|45
SE|00000000||tx|1|entity|C1999167|Old age|fndg|||elderly||||1000|88|94
SE|00000000||tx|1|entity|C0439849|Relationships|qlco|||association||||1000|100|110
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||1000|117|125
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|130|145
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|150|157
SE|00000000||tx|1|entity|C0876768|Vioxx|orch,phsu|||VIOXX||||861|169|173
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|193|200
SE|00000000||tx|1|relation|6|4|C1999167|Old age|fndg|fndg|||elderly||||1000|88|94|PREP|PROCESS_OF||147|148|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|150|157
SE|00000000||tx|1|relation|2|1|C0876768|Vioxx|orch,phsu|orch|||VIOXX||||861|169|173|VERB|ADMINISTERED_TO||159|167|7|1|C0030705|Patients|podg,humn|humn|||patients||||1000|150|157


SE|00000000||tx|1|text|Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
SE|00000000||tx|1|entity|C0015827|Fenfluramine|orch,phsu|||Fenfluramine||||1000|1|12
SE|00000000||tx|1|entity|C0750482|Slightly|idcn|||slightly||||1000|27|34
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|40|45
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensive drugs||||1000|50|71
SE|00000000||tx|1|entity|C0018318|Guanethidine|orch,phsu|||guanethidine||||1000|80|91
SE|00000000||tx|1|entity|C0025741|Methyldopa|nsba,phsu|||methyldopa||||1000|94|103
SE|00000000||tx|1|entity|C0035179|Reserpine|orch,phsu|||reserpine||||1000|106|114
SE|00000000||tx|1|relation|4|2|C0018318|Guanethidine|orch,phsu|orch|||guanethidine||||1000|80|91|NOM|INTERACTS_WITH||40|45|4|1|C0003364|Antihypertensive Agents|phsu|phsu|||antihypertensive drugs||||1000|50|71


SE|00000000||tx|1|text|If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.
SE|00000000||tx|1|entity|C0038317|Steroids|strd|||steroid||||888|25|31
SE|00000000||tx|1|entity|C0021461|Inhaler|medd|||inhaler||||888|33|39
SE|00000000||tx|1|entity|C0053817|bitolterol|orch,phsu|||bitolterol||||888|47|56
SE|00000000||tx|1|entity|C1279901|Firstly|qlco|||first||||888|58|62
SE|00000000||tx|1|entity|C1883708|Then|tmco|||then||||1000|68|71
SE|00000000||tx|1|entity|C1442447|15 Minutes|tmco|||15 minutes||||1000|84|93
SE|00000000||tx|1|entity|C0038317|Steroids|strd|||steroid||||888|112|118
SE|00000000||tx|1|entity|C0021461|Inhaler|medd|||inhaler||||888|120|126


SE|00000000||tx|1|text|In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|4|11
SE|00000000||tx|1|entity|C0700739|Nalfon|orch,phsu|||Nalfon||||1000|23|28
SE|00000000||tx|1|entity|C0038317|Steroids|strd|||steroid||||861|36|42
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|63|71
SE|00000000||tx|1|entity|C0038317|Steroids|strd|||steroid||||888|76|82
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||888|84|89
SE|00000000||tx|1|entity|C0439833|Gradual|qlco|||gradual||||1000|101|107
SE|00000000||tx|1|entity|C1882348|Permutation|qlco|||order||||861|112|116
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||888|131|138
SE|00000000||tx|1|entity|C0009566|Complication|patf|||complications||||888|140|152
SE|00000000||tx|1|entity|C0038317|Steroids|strd|||steroid||||790|164|170
SE|00000000||tx|1|entity|C2349954|Withdraw (activity)|acty|||withdrawal||||790|172|181
SE|00000000||tx|1|relation|8|1|C0700739|Nalfon|orch,phsu|orch|||Nalfon||||1000|23|28|VERB|ADMINISTERED_TO||13|21|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|4|11
SE|00000000||tx|1|relation|3|1|C0038317|Steroids|strd|strd|||steroid||||861|36|42|NOM|INHIBITS||63|71|5|1|C0038317|Steroids|strd|strd|||steroid||||888|76|82


SE|00000000||tx|1|text|If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||1000|19|28
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||861|33|38
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||861|40|47
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|58|69
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|87|95
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|98|106
SE|00000000||tx|1|entity|C0286738|Saquinavir|orch,phsu|||saquinavir||||1000|109|118
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|121|132
SE|00000000||tx|1|entity|C1548556|etc.|idcn|||etc||||1000|135|137
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|155|163
SE|00000000||tx|1|entity|C0054201|Budesonide|phsu,strd|||budesonide||||888|172|181
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|183|186


SE|00000000||tx|1|text|Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.
SE|00000000||tx|1|entity|C0003232|Antibiotics|antb|||Antibiotics||||861|16|26
SE|00000000||tx|1|entity|C0008168|Chloramphenicol|antb,orch|||Chloramphenicol||||1000|29|43
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycins||||1000|46|58
SE|00000000||tx|1|entity|C0038760|Sulfonamides|orch,phsu|||sulfonamides||||1000|61|72
SE|00000000||tx|1|entity|C0039651|Tetracyclines|orch|||tetracyclines||||1000|78|90
SE|00000000||tx|1|entity|C0004635|Bactericide, NOS|antb|||bactericidal||||853|115|126
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||853|128|133
SE|00000000||tx|1|entity|C0030842|Penicillins|antb,orch|||penicillins||||1000|138|148
SE|00000000||tx|1|relation|5|1|C0039651|Tetracyclines|orch|orch|||tetracyclines||||1000|78|90|NOM|INTERACTS_WITH||128|133|5|0|C0004635|Bactericide, NOS|antb|antb|||bactericidal||||853|115|126
SE|00000000||tx|1|relation|5|1|C0038760|Sulfonamides|orch,phsu|orch|||sulfonamides||||1000|61|72|NOM|INTERACTS_WITH||128|133|5|0|C0004635|Bactericide, NOS|antb|antb|||bactericidal||||853|115|126
SE|00000000||tx|1|relation|5|1|C0014806|Erythromycin|antb,orch|orch|||erythromycins||||1000|46|58|NOM|INTERACTS_WITH||128|133|5|0|C0004635|Bactericide, NOS|antb|antb|||bactericidal||||853|115|126
SE|00000000||tx|1|relation|5|1|C0008168|Chloramphenicol|antb,orch|orch|||Chloramphenicol||||1000|29|43|NOM|INTERACTS_WITH||128|133|5|0|C0004635|Bactericide, NOS|antb|antb|||bactericidal||||853|115|126


SE|00000000||tx|1|text|Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|7|17
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|37|46
SE|00000000||tx|1|entity|C1514468|product|enty|||products||||1000|53|60
SE|00000000||tx|1|entity|C0302583|Iron|bacs,elii,phsu|||iron||||1000|73|76
SE|00000000||tx|1|entity|C0301532|Multivitamin preparation|orch,phsu,vita|||multivitamins||||1000|79|91
SE|00000000||tx|1|entity|C0043481|Zinc|bacs,elii,phsu|||zinc||||1000|104|107
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||Videx||||1000|113|117
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||1000|120|129
SE|00000000||tx|1|entity|C0006353|Buffers|irda,phsu|||buffered||||901|141|148
SE|00000000||tx|1|entity|C0304290|Chewable Tablet|bodm|||chewable/buffered tablets||||901|132|156
SE|00000000||tx|1|entity|C1521725|Pediatric|qlco|||pediatric||||694|165|173
SE|00000000||tx|1|entity|C0991536|Oral Solution|bodm|||oral solution||||1000|186|198
SE|00000000||tx|1|entity|C0205251|low|qlco|||low||||623|214|216
SE|00000000||tx|1|entity|C0042036|Urine|bdsu|||urine||||623|218|222
SE|00000000||tx|1|relation|0|0|C0592249|Videx|nnon,phsu|nnon|||Videx||||1000|113|117|SPEC|ISA||113|129|0|0|C0012133|Didanosine|nnon,phsu|nnon|||didanosine||||1000|120|129


SE|00000000||tx|1|text|Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.
SE|00000000||tx|1|entity|C0021853|Intestines|bpoc|||intestine||||1000|60|68
SE|00000000||tx|1|entity|C0040135|Thyroid Hormones|aapp,horm|||thyroid hormones||||1000|106|121


SE|00000000||tx|1|text|Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|16|22
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|27|35
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|40|52
SE|00000000||tx|1|entity|C0042291|Valproic Acid|orch,phsu|||valproic acid||||1000|55|67
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|80|85
SE|00000000||tx|1|entity|C0037567|Sodium Valproate|lipd,phsu|||sodium plasma valproate||||861|73|95
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||861|97|110
SE|00000000||tx|1|relation|5|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|27|35|NOM|INTERACTS_WITH||16|22|5|2|C0031412|Phenobarbital|orch,phsu|orch|||phenobarbital||||1000|40|52
SE|00000000||tx|1|relation|5|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|27|35|NOM|INTERACTS_WITH||16|22|5|2|C0037567|Sodium Valproate|lipd,phsu|lipd|||sodium plasma valproate||||861|73|95
SE|00000000||tx|1|relation|5|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|27|35|NOM|INTERACTS_WITH||16|22|5|2|C0042291|Valproic Acid|orch,phsu|orch|||valproic acid||||1000|55|67


SE|00000000||tx|1|text|Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||Interactions||||966|1|12
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combined||||888|32|39
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|41|43
SE|00000000||tx|1|entity|C0004609|Baclofen|aapp,phsu|||baclofen||||888|48|55
SE|00000000||tx|1|entity|C1533685|Injection procedure|topp|||injection||||888|57|65
SE|00000000||tx|1|entity|C0026549|Morphine|orch,phsu|||morphine||||861|80|87
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||1000|97|107
SE|00000000||tx|1|entity|C0013404|Dyspnea|sosy|||dyspnea||||1000|113|119
SE|00000000||tx|1|relation|0|0|C1533685|Injection procedure|topp|topp|||injection||||888|57|65|MOD/HEAD|USES||48|65|0|0|C0004609|Baclofen|aapp,gngm,phsu|phsu|||baclofen||||888|48|55


SE|00000000||tx|1|text|Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.
SE|00000000||tx|1|entity|C0023570|Levodopa|aapp,nsba,phsu|||Levodopa||||1000|1|8
SE|00000000||tx|1|entity|C0002403|Amantadine|orch,phsu|||Amantadine||||1000|14|23
SE|00000000||tx|1|entity|C1516606|Clinical Data|inpr|||clinical data||||901|34|46
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||872|58|63
SE|00000000||tx|1|entity|C0021149|Incidence|qnco|||incidence||||872|65|73
SE|00000000||tx|1|entity|C0877248|Adverse event|fndg|||adverse experiences||||983|78|96
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|101|108
SE|00000000||tx|1|entity|C0085208|Bupropion|orch,phsu|||bupropion||||861|120|128
SE|00000000||tx|1|entity|C0023570|Levodopa|aapp,nsba,phsu|||levodopa||||861|155|162
SE|00000000||tx|1|entity|C0002403|Amantadine|orch,phsu|||amantadine||||1000|167|176
SE|00000000||tx|1|relation|5|1|C0877248|Adverse event|fndg|fndg|||adverse experiences||||983|78|96|PREP|PROCESS_OF||98|99|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|101|108
SE|00000000||tx|1|relation|3|1|C0085208|Bupropion|orch,phsu|orch|||bupropion||||861|120|128|VERB|ADMINISTERED_TO||110|118|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|101|108


SE|00000000||tx|1|text|(Concurrent use with thiazide diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.)
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|2|11
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|13|15
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|22|39
SE|00000000||tx|1|entity|C0012254|Digitalis Toxicity|inpo|||digitalis toxicity||||1000|72|89
SE|00000000||tx|1|entity|C0020621|Hypokalemia|fndg|||hypokalemia||||1000|107|117


SE|00000000||tx|1|text|Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
SE|00000000||tx|1|entity|C0020517|Hypersensitivity|patf|||Hypersensitivity reactions||||1000|1|26
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|50|57
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||888|69|79
SE|00000000||tx|1|entity|C2945654|Regimen - CHV concept|inpr|||regimens||||888|81|88
SE|00000000||tx|1|entity|C1705294|Sequential|qlco|||sequential||||861|101|110
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high dose||||861|112|120
SE|00000000||tx|1|entity|C0701339|Proleukin|orch,phsu|||PROLEUKIN||||861|122|130
SE|00000000||tx|1|entity|C0003392|Antineoplastic Agents|orch,phsu|||antineoplastic agents||||1000|136|156
SE|00000000||tx|1|entity|C0010927|Dacarbazine|orch,phsu|||dacarbazine||||1000|173|183
SE|00000000||tx|1|entity|C0008838|Cisplatin|inch,phsu|||cis-platinum||||1000|186|197
SE|00000000||tx|1|entity|C0039286|Tamoxifen|orch,phsu|||tamoxifen||||1000|200|208
SE|00000000||tx|1|entity|C0002199|Interferon-alpha|aapp,imft,phsu|||interferon-alfa||||1000|214|228
SE|00000000||tx|1|relation|1|1|C0020517|Hypersensitivity|patf|patf|||Hypersensitivity reactions||||1000|1|26|PREP|PROCESS_OF||47|48|8|1|C0030705|Patients|podg,humn|humn|||patients||||1000|50|57


SE|00000000||tx|1|text|Therefore, the combination of ketoprofen and probenecid is not recommended.
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|16|26
SE|00000000||tx|1|entity|C0022635|Ketoprofen|orch,phsu|||ketoprofen||||1000|31|40
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|46|55
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|60|62


SE|00000000||tx|1|text|Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||Carbamazepine||||1000|1|13
SE|00000000||tx|1|entity|C0205250|High|qlco|||Elevated||||623|16|23
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||623|25|37
SE|00000000||tx|1|entity|C0596545|Experience|menp|||experience||||861|82|91
SE|00000000||tx|1|entity|C0678177|Suprax|antb,orch|||SUPRAX||||1000|98|103


SE|00000000||tx|1|text|Intravenous ranitidine was shown to double the bioavailability of oral alendronate.
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||Intravenous||||888|1|11
SE|00000000||tx|1|entity|C0034665|Ranitidine|orch,phsu|||ranitidine||||888|13|22
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||1000|48|62
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|67|70
SE|00000000||tx|1|entity|C0102118|Alendronate|opco,phsu|||alendronate||||888|72|82


SE|00000000||tx|1|text|Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|entity|C0002367|Aluminum|elii|||aluminum||||1000|11|18
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||magnesium||||1000|24|32
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|47|57
SE|00000000||tx|1|entity|C0060405|cefdinir|antb,orch|||cefdinir||||813|84|91
SE|00000000||tx|1|entity|C2347138|Milligram per Capsule|qnco|||mg cefdinir capsules||||813|81|100
SE|00000000||tx|1|entity|C0353791|Maalox TC Suspension|clnd|||Maalox TC suspension||||854|113|132
SE|00000000||tx|1|entity|C1521828|Rate|qnco|||rate||||1000|146|149
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|152|155
SE|00000000||tx|1|entity|C0439792|Extent|spco|||extent||||1000|162|167
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|170|172
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||888|192|204
SE|00000000||tx|1|entity|C0439509|/40|tmco|||40%||||888|206|208


SE|00000000||tx|1|text|Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin-like drugs simultaneously.
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|12|27
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|62|69
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||1000|81|92
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin||||1000|98|105
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|112|116
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneously||||888|118|131
SE|00000000||tx|1|relation|3|1|C0064113|Itraconazole|orch,phsu|orch|||Itraconazole||||1000|81|92|VERB|ADMINISTERED_TO||71|79|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|62|69
SE|00000000||tx|1|relation|3|1|C0010206|coumarin|orch,phsu|orch|||coumarin||||1000|98|105|VERB|ADMINISTERED_TO||71|79|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|62|69


SE|00000000||tx|1|text|Acetaminophen: May increase plasma concentration of synthetic estrogens, possibly by inhibiting conjugation.
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||Acetaminophen||||1000|1|13
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||1000|29|48
SE|00000000||tx|1|entity|C0014941|Estrogens, Synthetic|orch,phsu|||synthetic estrogens||||1000|53|71
SE|00000000||tx|1|entity|C2362652|Possible diagnosis|qlco|||possibly||||1000|74|81
SE|00000000||tx|1|entity|C0021469|Metabolic Inhibition|moft|||inhibiting||||888|86|95
SE|00000000||tx|1|entity|C1160466|conjugation|celf|||conjugation||||888|97|107
SE|00000000||tx|1|relation|2|2|C0000970|Acetaminophen|orch,phsu|orch|||Acetaminophen||||1000|1|13|VERB|STIMULATES||20|27|3|2|C0014941|Estrogens, Synthetic|orch,phsu|orch|||synthetic estrogens||||1000|53|71


SE|00000000||tx|1|text|High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||High-dose||||888|1|9
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporin A||||888|11|23
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||1000|38|51
SE|00000000||tx|1|entity|C0439275|Microgram per Liter|qnco|||ng/mL||||901|64|68
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|88|91
SE|00000000||tx|1|entity|C0015133|Etoposide|carb,phsu|||etoposide||||888|93|101
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|121|128
SE|00000000||tx|1|entity|C0015133|Etoposide|carb,phsu|||etoposide||||694|133|141
SE|00000000||tx|1|entity|C0450361|38|inpr|||38%||||888|159|161
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decrease||||888|163|170
SE|00000000||tx|1|entity|C0229960|Entire body as a whole|ffas|||total body||||901|175|184
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||901|186|194
SE|00000000||tx|1|entity|C0015133|Etoposide|carb,phsu|||etoposide||||1000|199|207
SE|00000000||tx|1|entity|C0015133|Etoposide|carb,phsu|||etoposide||||1000|221|229
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|231|235
SE|00000000||tx|1|relation|9|1|C0015133|Etoposide|carb,phsu|carb|||etoposide||||1000|199|207|VERB|compared_with||209|216|2|1|C0015133|Etoposide|carb,phsu|carb|||etoposide||||1000|221|229
SE|00000000||tx|1|relation|6|4|C0015133|Etoposide|carb,phsu|carb|||etoposide||||1000|199|207|NOM|STIMULATES||121|128|6|1|C0015133|Etoposide|carb,phsu|carb|||etoposide||||694|133|141
SE|00000000||tx|1|relation|6|4|C0015133|Etoposide|carb,phsu|carb|||etoposide||||1000|221|229|NOM|STIMULATES||121|128|6|1|C0015133|Etoposide|carb,phsu|carb|||etoposide||||694|133|141
SE|00000000||tx|1|relation|4|1|C0229960|Entire body as a whole|ffas|ffas|||total body||||901|175|184|PREP|LOCATION_OF||172|173|7|2|C0015133|Etoposide|carb,phsu|carb|||etoposide||||694|133|141


SE|00000000||tx|1|text|Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.
SE|00000000||tx|1|entity|C0392676|Hyperpyrexia|patf|||Hyperpyrexia||||1000|1|12
SE|00000000||tx|1|entity|C0700523|Amitriptyline Hydrochloride|orch,phsu|||amitriptyline HCl||||1000|37|53
SE|00000000||tx|1|entity|C0242896|Anticholinergic Agents|phsu|||anticholinergic agents||||1000|76|97
SE|00000000||tx|1|entity|C0040615|Antipsychotic Agents|phsu|||neuroleptic drugs||||1000|107|123
SE|00000000||tx|1|entity|C0337004|Hot weather|npop|||hot weather||||1000|146|156


SE|00000000||tx|1|text|Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||Non-steroidal Anti-inflammatory Drugs||||991|1|37
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|48|55
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||non-steroidal anti-inflammatory agent||||1000|82|118
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||888|135|142
SE|00000000||tx|1|entity|C0597421|saluretic|phsu|||natriuretic||||888|145|155
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|179|185
SE|00000000||tx|1|entity|C0445022|Loop|spco|||loop||||1000|190|193
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||694|196|204
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|218|235
SE|00000000||tx|1|relation|1|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||Non-steroidal Anti-inflammatory Drugs||||991|1|37|PREP|TREATS||40|41|8|1|C0030705|Patients|podg,humn|podg|||patients||||1000|48|55
SE|00000000||tx|1|relation|4|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||non-steroidal anti-inflammatory agent||||1000|82|118|VERB|INHIBITS||124|129|5|1|C0597421|saluretic|phsu|phsu|||natriuretic||||888|145|155


SE|00000000||tx|1|text|Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
SE|00000000||tx|1|entity|C0085208|Bupropion|orch,phsu|||bupropion||||1000|33|41
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|48|52
SE|00000000||tx|1|entity|C1332830|CYP2D6 gene|gngm|1565|CYP2D6|CYP2D6||||901|78|83
SE|00000000||tx|1|entity|C0022173|Isoenzymes|aapp,enzy|||isoenzyme||||901|85|93
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||888|105|111
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants||||888|113|127
SE|00000000||tx|1|entity|C0028420|Nortriptyline|orch,phsu|||nortriptyline||||1000|136|148
SE|00000000||tx|1|entity|C0020934|Imipramine|orch,phsu|||imipramine||||1000|151|160
SE|00000000||tx|1|entity|C0011685|Desipramine|orch,phsu|||desipramine||||1000|163|173
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||paroxetine||||1000|176|185
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|188|197
SE|00000000||tx|1|entity|C0074393|Sertraline|orch,phsu|||sertraline||||1000|200|209
SE|00000000||tx|1|entity|C0040615|Antipsychotic Agents|phsu|||antipsychotics||||1000|213|226
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||haloperidol||||1000|235|245
SE|00000000||tx|1|entity|C0073393|Risperidone|orch,phsu|||risperidone||||1000|248|258
SE|00000000||tx|1|entity|C0039943|Thioridazine|orch,phsu|||thioridazine||||1000|261|272
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blockers||||1000|276|288
SE|00000000||tx|1|entity|C0025859|Metoprolol|orch,phsu|||metoprolol||||1000|297|306
SE|00000000||tx|1|entity|||gngm|6445|SGCG|Type||||827|314|317
SE|00000000||tx|1|entity|C0003195|Anti-Arrhythmia Agents|phsu|||antiarrhythmics||||827|322|336
SE|00000000||tx|1|entity|C0033429|Propafenone|orch,phsu|||propafenone||||1000|345|355
SE|00000000||tx|1|entity|C0016229|Flecainide|orch,phsu|||flecainide||||1000|358|367
SE|00000000||tx|1|entity|C0444930|End|spco|||end||||861|442|444
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|453|456
SE|00000000||tx|1|entity|C1514721|Range|qnco|||range||||888|458|462
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|471|481
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medication||||888|483|492
SE|00000000||tx|1|relation|0|0|C0011685|Desipramine|orch,phsu|orch|||desipramine||||1000|163|173|SPEC|ISA||151|173|0|0|C0020934|Imipramine|orch,phsu|orch|||imipramine||||1000|151|160
SE|00000000||tx|1|relation|21|1|C1332830|CYP2D6 gene|gngm,aapp|gngm|1565|CYP2D6|CYP2D6||||901|78|83|VERB|INTERACTS_WITH||63|73|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|48|52


SE|00000000||tx|1|text|However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
SE|00000000||tx|1|entity|C1704324|Scientific Publication|inpr|||published||||888|16|24
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||888|26|32
SE|00000000||tx|1|entity|C0702240|Elevation|spco|||elevations||||861|50|59
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||1000|62|65
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two-||||888|72|75
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||888|76|79
SE|00000000||tx|1|entity|C0009079|Clozapine|orch,phsu|||clozapine||||1000|85|93
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||888|99|108
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|110|123
SE|00000000||tx|1|entity|C0009079|Clozapine|orch,phsu|||clozapine||||1000|130|138
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||paroxetine||||1000|155|164
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|167|176
SE|00000000||tx|1|entity|C0074393|Sertraline|orch,phsu|||sertraline||||1000|183|192


SE|00000000||tx|1|text|When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|6|14
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|22|30
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|32|35
SE|00000000||tx|1|entity|C1292429|8 Hours|tmco|||8 hours||||1000|52|58
SE|00000000||tx|1|entity|C0674427|Sustiva|orch,phsu|||SUSTIVA||||1000|76|82
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||763|97|101
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||888|109|117
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|119|121
SE|00000000||tx|1|entity|C2827771|Cmin|qnco|||Cmin||||1000|127|130
SE|00000000||tx|1|entity|C1510992|Average|qnco|||average||||1000|150|156
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|211|219
SE|00000000||tx|1|entity|C1292429|8 Hours|tmco|||8 hours||||1000|235|241
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|254|258
SE|00000000||tx|1|relation|8|1|C0674427|Sustiva|orch,phsu|orch|||SUSTIVA||||1000|76|82|VERB|COEXISTS_WITH||65|69|4|4|C0376637|Indinavir|orch,phsu|orch|||indinavir||||1000|6|14


SE|00000000||tx|1|text|Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||Plasma||||694|1|6
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|20|27
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||773|36|38
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||1000|90|99
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||840|108|110
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|120|123
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||694|132|137
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||1000|151|160
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||840|169|171
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|178|180
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|234|241
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||773|250|252
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|262|265


SE|00000000||tx|1|text|Caution should be exercised if tacrolimus and bosentan are used together.
SE|00000000||tx|1|entity|C0085149|Tacrolimus|orch,phsu|||tacrolimus||||888|32|41
SE|00000000||tx|1|entity|C0252643|bosentan|orch,phsu|||bosentan||||1000|47|54
SE|00000000||tx|1|entity|C1883357|Together|qlco|||together||||1000|65|72


SE|00000000||tx|1|text|Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.
SE|00000000||tx|1|entity|C1511726|Data|idcn|||Data||||1000|1|4
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|31|40
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||901|52|59
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interaction||||901|61|76
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|83|92
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||1000|102|110
SE|00000000||tx|1|entity|C0074393|Sertraline|orch,phsu|||sertraline||||1000|113|122
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||paroxetine||||1000|128|137


SE|00000000||tx|1|text|Agents Increasing Serum Potassium: PRINIVIL attenuates potassium loss caused by thiazide-type diuretics.
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||Agents||||966|1|6
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||Serum||||888|19|23
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||Potassium||||888|25|33
SE|00000000||tx|1|entity|C0701176|Prinivil|aapp,phsu|||PRINIVIL||||1000|36|43
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||888|56|64
SE|00000000||tx|1|entity|C1517945|Loss|qnco|||loss||||888|66|69
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide-type diuretics||||913|81|103
SE|00000000||tx|1|relation|3|1|C0701176|Prinivil|aapp,gngm,phsu|aapp|||PRINIVIL||||1000|36|43|VERB|INHIBITS||45|54|2|1|C0032821|Potassium|elii|elii|||potassium||||888|56|64


SE|00000000||tx|1|text|Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||Furosemide||||1000|1|10
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||Clinical studies||||1000|13|28
SE|00000000||tx|1|entity|C0687676|Post|tmco|||post||||851|42|45
SE|00000000||tx|1|entity|C0024826|Marketing|ocac|||marketing||||851|47|55
SE|00000000||tx|1|entity|C0700325|Patient observation|hlca|||observations||||851|57|68
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|87|92
SE|00000000||tx|1|entity|C3179308|Natriuretic Effect|phsf|||natriuretic effect||||1000|109|126
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|131|140
SE|00000000||tx|1|entity|C0541746|Thiazides|orch,phsu|||thiazides||||1000|146|154
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|164|171
SE|00000000||tx|1|relation|4|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||1000|87|92|VERB|DISRUPTS||98|103|4|1|C3179308|Natriuretic Effect|phsf|phsf|||natriuretic effect||||1000|109|126
SE|00000000||tx|1|relation|7|3|C3179308|Natriuretic Effect|phsf|phsf|||natriuretic effect||||1000|109|126|PREP|PROCESS_OF||156|157|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|164|171


SE|00000000||tx|1|text|Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)
SE|00000000||tx|1|entity|C0020273|Hydroflumethiazide|orch,phsu|||hydroflumethiazide||||1000|17|34
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory agents||||1000|40|76
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|106|112
SE|00000000||tx|1|entity|C0871633|desires|menp|||desired||||872|161|167
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||872|169|174
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|183|190
SE|00000000||tx|1|relation|4|3|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory agents||||1000|40|76|NOM|INTERACTS_WITH||169|174|1|1|C0012798|Diuretics|phsu|phsu|||diuretic||||1000|183|190
SE|00000000||tx|1|relation|4|3|C0020273|Hydroflumethiazide|orch,phsu|phsu|||hydroflumethiazide||||1000|17|34|NOM|INTERACTS_WITH||169|174|1|1|C0012798|Diuretics|phsu|phsu|||diuretic||||1000|183|190


SE|00000000||tx|1|text|ACE-inhibitors:Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE-inhibitors||||1000|1|14
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||Reports||||1000|16|22
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|37|42
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|78|83
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE-inhibitors||||1000|88|101


SE|00000000||tx|1|text|Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||888|11|17
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||888|19|29
SE|00000000||tx|1|entity|C0332148|Probable diagnosis|qlco|||likely||||1000|34|39
SE|00000000||tx|1|entity|C0525004|Viracept|orch,phsu|||VIRACEPT||||1000|42|49
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|63|65
SE|00000000||tx|1|entity|C0085170|Astemizole|orch,phsu|||astemizole||||1000|101|110


SE|00000000||tx|1|text|Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||clinical studies||||1000|10|25
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|32|34
SE|00000000||tx|1|entity|C0015127|Etiology aspects|ftcn|||cause||||1000|50|54
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|60|65
SE|00000000||tx|1|entity|C0439849|Relationships|qlco|||relationship||||888|67|78
SE|00000000||tx|1|entity|C0031831|Physicians|prog|||physicians||||1000|81|90
SE|00000000||tx|1|entity|C0004448|Awareness|menp|||aware||||1000|102|106
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|122|128
SE|00000000||tx|1|entity|C0005778|Blood coagulation|ortf|||blood coagulation||||1000|133|149
SE|00000000||tx|1|entity|C0442824|Very|qlco|||very||||888|170|173
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||rarely||||888|175|180
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|185|192
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulants||||1000|204|222
SE|00000000||tx|1|entity|C0008188|Chlordiazepoxide|orch,phsu|||chlordiazepoxide||||1000|228|243
SE|00000000||tx|1|relation|7|1|C0005778|Blood coagulation|ortf|ortf|||blood coagulation||||1000|133|149|PREP|PROCESS_OF||182|183|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|185|192
SE|00000000||tx|1|relation|2|1|C0354604|Anticoagulants, Oral|orch,phsu|orch|||oral anticoagulants||||1000|204|222|VERB|ADMINISTERED_TO||194|202|8|1|C0030705|Patients|podg,humn|humn|||patients||||1000|185|192
SE|00000000||tx|1|relation|2|1|C0008188|Chlordiazepoxide|orch,phsu|orch|||chlordiazepoxide||||1000|228|243|VERB|ADMINISTERED_TO||194|202|8|1|C0030705|Patients|podg,humn|humn|||patients||||1000|185|192


SE|00000000||tx|1|text|Concomitant administration of clarithromycin with pimozide is contraindicated.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0055856|Clarithromycin|antb,orch|||clarithromycin||||1000|31|44
SE|00000000||tx|1|entity|C0031935|Pimozide|orch,phsu|||pimozide||||1000|51|58


SE|00000000||tx|1|text|Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||nelfinavir||||1000|22|31
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||1000|36|47
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|56|61
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|63|66
SE|00000000||tx|1|entity|C0052796|Azithromycin|antb,orch|||azithromycin||||1000|71|82
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||762|96|102
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||852|116|124
SE|00000000||tx|1|entity|C0052796|Azithromycin|antb,orch|||azithromycin||||852|126|137
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentrations||||852|139|158
SE|00000000||tx|1|relation|6|2|C0052796|Azithromycin|antb,orch|antb|||azithromycin||||1000|71|82|PREP|COEXISTS_WITH||113|114|1|1|C0052796|Azithromycin|antb,orch|antb|||azithromycin||||852|126|137


SE|00000000||tx|1|text|Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of Lithium toxicity.
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||Lithium||||1000|1|7
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||Lithium||||1000|10|16
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|35|37
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|53|61
SE|00000000||tx|1|entity|C0006376|Bumetanide|orch,phsu|||bumetanide||||1000|72|81
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|108|112
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|114|122
SE|00000000||tx|1|entity|C0205250|High|qlco|||high||||888|134|137
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|139|142
SE|00000000||tx|1|entity|C0238242|LITHIUM TOXICITY|inpo|||Lithium toxicity||||1000|147|162
SE|00000000||tx|1|relation|5|1|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|53|61|VERB|COEXISTS_WITH||42|46|2|1|C0023870|Lithium|elii,phsu|elii|||Lithium||||1000|10|16
SE|00000000||tx|1|relation|4|4|C0023870|Lithium|elii,phsu|elii|||Lithium||||1000|1|7|VERB|DISRUPTS||97|102|3|1|C0022646|Kidney|bpoc|bpoc|||renal||||888|108|112


SE|00000000||tx|1|text|Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0041165|Troleandomycin|antb,orch|||troleandomycin||||1000|15|28
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|34|45
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|63|72
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|77|91
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|117|125
SE|00000000||tx|1|relation|0|0|C0041165|Troleandomycin|antb,orch|antb|||troleandomycin||||1000|15|28|SPEC|ISA||1|28|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|relation|0|0|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|34|45|SPEC|ISA||1|28|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|relation|3|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|34|45|VERB|INHIBITS||51|57|3|2|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroids||||1000|77|91
SE|00000000||tx|1|relation|3|1|C0041165|Troleandomycin|antb,orch|orch|||troleandomycin||||1000|15|28|VERB|INHIBITS||51|57|3|2|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroids||||1000|77|91


SE|00000000||tx|1|text|Digitalis: Thyroid preparations may potentiate the toxic effects of digitalis.
SE|00000000||tx|1|entity|C0279175|Thyroid preparation|aapp,horm,phsu|||Thyroid preparations||||983|12|31
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxic effects||||966|52|64
SE|00000000||tx|1|relation|2|1|C0279175|Thyroid preparation|aapp,gngm,horm,phsu|aapp|||Thyroid preparations||||983|12|31|VERB|AUGMENTS||37|46|2|1|C0600688|Toxic effect|inpo|inpo|||toxic effects||||966|52|64


SE|00000000||tx|1|text|There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.
SE|00000000||tx|1|entity|C0205374|Transitory|tmco|||transient||||888|12|20
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||888|22|30
SE|00000000||tx|1|entity|C0023884|Liver|bpoc|||liver||||872|35|39
SE|00000000||tx|1|entity|C0001899|Alanine Transaminase|aapp,enzy|||ALT||||872|41|43
SE|00000000||tx|1|entity|||gngm|26503|SLC17A5|AST||||1000|49|51
SE|00000000||tx|1|entity|C0935984|Cancidas|aapp,phsu|||CANCIDAS||||1000|58|65
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|71|82
SE|00000000||tx|1|relation|0|0|C0001899|Alanine Transaminase|aapp,gngm,enzy|aapp|||ALT||||872|41|43|MOD/HEAD|PART_OF||35|43|0|0|C0023884|Liver|bpoc|bpoc|||liver||||872|35|39


SE|00000000||tx|1|text|Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|31|40
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|46|58
SE|00000000||tx|1|entity|C0012984|Canis familiaris|mamm|||dogs||||1000|63|66
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|73|75
SE|00000000||tx|1|entity|C0034693|Rattus norvegicus|mamm|||rats||||1000|80|83
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||802|89|101
SE|00000000||tx|1|entity|C1632851|Times|qnco|||times||||802|105|109
SE|00000000||tx|1|entity|C0034866|Recommendation|idcn|||recommended||||822|115|125
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximum||||822|127|133
SE|00000000||tx|1|entity|C0086418|Homo sapiens|humn|||human||||822|135|139
SE|00000000||tx|1|entity|C0302350|Therapeutic|ftcn|||therapeutic||||822|141|151
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||822|153|156
SE|00000000||tx|1|entity|C0439400|mg/day/kg|qnco|||mg/kg/day||||923|176|184
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||888|189|198
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||888|200|212
SE|00000000||tx|1|entity|C0443228|Largest|qnco|||greater||||901|227|233
SE|00000000||tx|1|entity|C1142499|gastrointestinal toxicity|fndg|||gastrointestinal toxicity||||901|235|259
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||861|278|281
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|300|304
SE|00000000||tx|1|relation|3|1|C0000970|Acetaminophen|orch,phsu|phsu|||acetaminophen||||1000|46|58|PREP|TREATS||60|61|9|1|C0012984|Canis familiaris|mamm|mamm|||dogs||||1000|63|66
SE|00000000||tx|1|relation|3|1|C0012228|Diflunisal|orch,phsu|phsu|||diflunisal||||1000|31|40|PREP|TREATS||60|61|9|1|C0012984|Canis familiaris|mamm|mamm|||dogs||||1000|63|66


SE|00000000||tx|1|text|During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.
SE|00000000||tx|1|entity|C2587213|Control function|ftcn|||controlled||||851|8|17
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||851|19|29
SE|00000000||tx|1|entity|C0278134|Absence of sensation|sosy|||anesthesia||||851|31|40
SE|00000000||tx|1|entity|C0699440|Labetalol hydrochloride|orch,phsu|||labetalol HCl||||1000|48|60
SE|00000000||tx|1|entity|C0439849|Relationships|qlco|||association||||1000|65|75
SE|00000000||tx|1|entity|C0018549|Halothane|orch,phsu|||halothane||||1000|82|90
SE|00000000||tx|1|entity|C0205250|High|qlco|||high||||888|93|96
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|98|111
SE|00000000||tx|1|entity|C1282910|Upper|spco|||above||||1000|120|124
SE|00000000||tx|1|entity|C0018549|Halothane|orch,phsu|||halothane||||1000|130|138
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|147|149
SE|00000000||tx|1|entity|C0441889|Levels (qualifier value)|qlco|||degree||||1000|171|176
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||1000|181|191
SE|00000000||tx|1|entity|C0549177|Large|qnco|||large||||888|247|251
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||888|253|261
SE|00000000||tx|1|entity|C0007165|Cardiac Output|clna|||cardiac output||||1000|266|279
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|288|295
SE|00000000||tx|1|entity|C0428640|Central venous pressure|clna|||central venous pressure||||1000|300|322


SE|00000000||tx|1|text|In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).
SE|00000000||tx|1|entity|C0920321|Phase I Clinical Trials|resa|||Phase I trial||||1000|6|18
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||861|37|41
SE|00000000||tx|1|entity|C0678133|Taxol|orch,phsu|||TAXOL||||1000|46|50
SE|00000000||tx|1|entity|C1319266|mg/sq.m|qnco|||mg/m2||||861|61|65
SE|00000000||tx|1|entity|C0008838|Cisplatin|inch,phsu|||cisplatin||||1000|72|80
SE|00000000||tx|1|entity|C1319266|mg/sq.m|qnco|||mg/m2||||901|92|96
SE|00000000||tx|1|entity|C1705294|Sequential|qlco|||sequential||||888|108|117
SE|00000000||tx|1|entity|C0574032|Infusion procedures|topp|||infusions||||888|119|127
SE|00000000||tx|1|entity|C0854467|Myelosuppression|dsyn|||myelosuppression||||1000|130|145
SE|00000000||tx|1|entity|C0205172|More|ftcn|||more||||888|151|154
SE|00000000||tx|1|entity|C0439808|Profound|qlco|||profound||||888|156|163
SE|00000000||tx|1|entity|C0678133|Taxol|orch,phsu|||TAXOL||||1000|170|174
SE|00000000||tx|1|entity|C0008838|Cisplatin|inch,phsu|||cisplatin||||1000|192|200
SE|00000000||tx|1|entity|C0332270|Alternating|ftcn|||alternate||||888|216|224
SE|00000000||tx|1|entity|C1519249|Sequence|ftcn|||sequence||||888|226|233
SE|00000000||tx|1|entity|C0678133|Taxol|orch,phsu|||TAXOL||||888|240|244
SE|00000000||tx|1|entity|C0008838|Cisplatin|inch,phsu|||cisplatin||||1000|253|261


SE|00000000||tx|1|text|Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||Furosemide||||1000|1|10
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|19|21
SE|00000000||tx|1|entity|C0014963|Ethacrynic Acid|orch,phsu|||ethacrynic acid||||1000|50|64
SE|00000000||tx|1|entity|C0235280|Ototoxicity|inpo|||ototoxicity||||1000|96|106


SE|00000000||tx|1|text|Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||Carbamazepine||||1000|1|13
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy subjects||||1000|19|34
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|50|55
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|66|78
SE|00000000||tx|1|entity|C0585361|Twice a day|tmco|||twice daily||||824|91|101
SE|00000000||tx|1|entity|C1442459|3 Days|tmco|||3 days||||1000|107|112
SE|00000000||tx|1|entity|C0585361|Twice a day|tmco|||twice daily||||824|125|135
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||861|144|147
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||694|150|157
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|169|171
SE|00000000||tx|1|entity|C1506770|lapatinib|orch,phsu|||lapatinib||||1000|177|185
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|201|213
SE|00000000||tx|1|relation|2|2|C0006949|Carbamazepine|orch,phsu|orch|||Carbamazepine||||1000|1|13|NOM|STIMULATES||57|63|2|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|50|55


SE|00000000||tx|1|text|Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.
SE|00000000||tx|1|entity|C1881878|Moderation|qlco|||moderate||||802|9|16
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||802|18|23
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||802|25|34
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|43|51
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||851|66|69
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||851|71|78
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|83|103
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||aprepitant||||1000|108|117
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|120|130


SE|00000000||tx|1|text|Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||1000|1|12
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|35|46
SE|00000000||tx|1|entity|C0525004|Viracept|orch,phsu|||VIRACEPT||||1000|53|60
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|80|87
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||nelfinavir||||583|92|101
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||583|103|108


SE|00000000||tx|1|text|MAO inhibitors should be used with caution in patients receiving hydralazine.
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|1|14
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|47|54
SE|00000000||tx|1|entity|C0020223|Hydralazine|orch,phsu|||hydralazine||||1000|66|76
SE|00000000||tx|1|relation|2|2|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|phsu|||MAO inhibitors||||1000|1|14|PREP|TREATS||44|45|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|47|54
SE|00000000||tx|1|relation|1|1|C0020223|Hydralazine|orch,phsu|orch|||hydralazine||||1000|66|76|VERB|ADMINISTERED_TO||56|64|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|47|54


SE|00000000||tx|1|text|These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.
SE|00000000||tx|1|entity|C1274040|Result|ftcn|||results||||1000|7|13
SE|00000000||tx|1|entity|C0948482|analgesic effect|fndg|||analgesic effect||||1000|32|47
SE|00000000||tx|1|entity|C0038119|Stadol|orch,phsu|||STADOL NS||||1000|52|60
SE|00000000||tx|1|entity|C1253507|Sumatriptan Nasal Spray|clnd|||sumatriptan nasal spray||||1000|118|140
SE|00000000||tx|1|entity|C1442458|30 Minutes|tmco|||30 minutes||||1000|150|159
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|170|178
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|183|188
SE|00000000||tx|1|entity|C0547040|Minimal|qlco|||minimal||||1000|200|206


SE|00000000||tx|1|text|Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||Corticosteroids||||1000|1|15
SE|00000000||tx|1|entity|C1883725|Replicate|qlco|||replication||||1000|41|51
SE|00000000||tx|1|entity|C0029235|Organism|orgm|||organisms||||1000|61|69
SE|00000000||tx|1|entity|C0599946|Attenuation|acty|||attenuated||||901|89|98
SE|00000000||tx|1|entity|C0042211|Vaccines, Attenuated|imft,phsu|||live attenuated vaccines||||901|84|107
SE|00000000||tx|1|relation|1|1|C0042211|Vaccines, Attenuated|imft,phsu|imft|||live attenuated vaccines||||901|84|107|VERB|PART_OF||71|79|3|1|C0029235|Organism|orgm|orgm|||organisms||||1000|61|69


SE|00000000||tx|1|text|For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters
SE|00000000||tx|1|entity|C0392360|Indication of (contextual qualifier)|idcn|||reason||||1000|10|15
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|22|25
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulant||||1000|34|46
SE|00000000||tx|1|entity|C0439659|Beginning|tmco|||start||||1000|85|89
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|94|102
SE|00000000||tx|1|entity|C0591179|Bezalip|orch,phsu|||Bezalip||||1000|109|115
SE|00000000||tx|1|entity|C0591179|Bezalip|orch,phsu|||Bezalip||||1000|120|126
SE|00000000||tx|1|entity|C1883708|Then|tmco|||then||||1000|139|142
SE|00000000||tx|1|entity|C0005778|Blood coagulation|ortf|||blood clotting||||901|170|183
SE|00000000||tx|1|entity|C0449381|Observation parameter|fndg|||parameters||||901|185|194
SE|00000000||tx|1|relation|5|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||1000|94|102|PREP|USES||104|107|3|1|C0591179|Bezalip|orch,phsu|phsu|||Bezalip||||1000|109|115


SE|00000000||tx|1|text|Lithium: Nonsteroidal anti-inflammatory agents have been reported to increase steadystate plasma lithium levels.
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||Lithium||||1000|1|7
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||Nonsteroidal anti-inflammatory agents||||1000|10|46
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steadystate||||618|79|89
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||618|91|96
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||618|98|104
SE|00000000||tx|1|relation|2|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||Nonsteroidal anti-inflammatory agents||||1000|10|46|VERB|STIMULATES||70|77|1|1|C0023870|Lithium|elii,phsu|elii|||lithium||||618|98|104


SE|00000000||tx|1|text|Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|21|29
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|36|43
SE|00000000||tx|1|entity|C0205309|Known|qlco|||known||||660|52|56
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||660|58|63
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||1000|96|103
SE|00000000||tx|1|entity|C0002346|Alternative Medicine|bmod|||alternative therapy||||1000|110|128


SE|00000000||tx|1|text|When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||1000|6|17
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|43|51
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|54|61
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||890|90|95
SE|00000000||tx|1|entity|C0424099|Reduced concentration|fndg|||reduced plasma concentrations||||890|82|110
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|115|126


SE|00000000||tx|1|text|Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.
SE|00000000||tx|1|entity|C0031328|Pharmacokinetic aspects|ftcn|||pharmacokinetics||||901|7|22
SE|00000000||tx|1|entity|C0596723|human data|inpr,resa|||Human pharmacokinetics data||||901|1|27
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||790|43|46
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||790|48|59
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|83|92
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|97|105
SE|00000000||tx|1|entity|C0205454|Eight|qnco|||eight-||||851|123|128
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||851|129|132
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||851|134|141
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||861|155|157
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|162|170
SE|00000000||tx|1|relation|2|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||790|48|59|VERB|INHIBITS||70|77|5|2|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|97|105


SE|00000000||tx|1|text|However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
SE|00000000||tx|1|entity|C0150097|Cross-Over Studies|resa|||crossover study||||1000|12|26
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy subjects||||1000|31|46
SE|00000000||tx|1|entity|C0984914|Cimetidine 300 MG|clnd|||Tagamet 300 mg||||784|65|78
SE|00000000||tx|1|entity|C0152277|Incision and drainage|topp|||i.d||||784|82|84
SE|00000000||tx|1|entity|C0439421|mg/h|qnco|||mg h.s||||861|94|99
SE|00000000||tx|1|entity|C0439423|Milligram per 24 Hours|qnco|||mg b.i.d||||762|127|134
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||762|137|142
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|147|158
SE|00000000||tx|1|entity|C0700057|Theodur|orch,phsu|||Theo-Dur||||1000|161|168
SE|00000000||tx|1|entity|C0331845|Key Pharmaceuticals|hcro|||Key Pharmaceuticals||||1000|172|190
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||888|212|215
SE|00000000||tx|1|entity|C1515926|Alteration|idcn|||alteration||||888|217|226
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||832|231|242
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||832|244|255
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||832|262|266
SE|00000000||tx|1|entity|C0444505|Peak level|qnco|||peak serum levels||||832|257|273
SE|00000000||tx|1|entity|C0439421|mg/h|qnco|||mg h.s||||824|288|293
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||regimen||||824|296|302
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||966|321|328
SE|00000000||tx|1|entity|C0439234|year|tmco|||years||||861|338|342
SE|00000000||tx|1|entity|C0580836|Old|tmco|||older||||966|348|352
SE|00000000||tx|1|relation|0|0|C0700057|Theodur|orch,phsu|orch|||Theo-Dur||||1000|161|168|SPEC|ISA||147|168|0|0|C0039771|Theophylline|bacs,orch,phsu|bacs|||theophylline||||1000|147|158


SE|00000000||tx|1|text|In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneous||||888|4|15
SE|00000000||tx|1|entity|C0020923|Imidazole|orch,phsu|||imidazole||||888|32|40
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|42|46
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin||||888|52|59
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|61|65
SE|00000000||tx|1|entity|C0520996|Anticoagulant effect|ortf|||anticoagulant effect||||1000|72|91
SE|00000000||tx|1|relation|0|0|C0020923|Imidazole|orch,phsu|orch|||imidazole||||888|32|40|MOD/HEAD|ISA||32|46|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|42|46
SE|00000000||tx|1|relation|0|0|C0010206|coumarin|orch,phsu|orch|||coumarin||||888|52|59|MOD/HEAD|ISA||52|65|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|61|65


SE|00000000||tx|1|text|Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||Corticosteroids||||1000|1|15
SE|00000000||tx|1|entity|C0001655|Corticotropin|aapp,horm,nsba,phsu|||Corticotropin||||1000|21|33
SE|00000000||tx|1|entity|||gngm|5443|POMC|ACTH||||1000|36|39
SE|00000000||tx|1|entity|C0002679|Amphotericin B|antb,orch|||amphotericin B||||861|58|71
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induced||||861|74|80
SE|00000000||tx|1|entity|C0020621|Hypokalemia|fndg|||hypokalemia||||861|82|92
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|119|125
SE|00000000||tx|1|entity|C0018787|Heart|bpoc|||cardiac||||888|130|136
SE|00000000||tx|1|relation|3|2|C0001655|Corticotropin|aapp,gngm,horm,nsba,phsu|aapp|||Corticotropin||||1000|21|33|VERB|AUGMENTS||47|56|3|1|C0020621|Hypokalemia|fndg|fndg|||hypokalemia||||861|82|92
SE|00000000||tx|1|relation|3|2|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|phsu|||Corticosteroids||||1000|1|15|VERB|AUGMENTS||47|56|3|1|C0020621|Hypokalemia|fndg|fndg|||hypokalemia||||861|82|92


SE|00000000||tx|1|text|A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||Vardenafil||||833|8|17
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||833|19|22
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|31|33
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|60|70
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||740|89|93
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||740|95|106


SE|00000000||tx|1|text|Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.
SE|00000000||tx|1|entity|C1148284|Felbamate:Mass:Point in time:Dose med or substance:Quantitative|clna|||felbamate dose||||1000|16|29
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|39|44
SE|00000000||tx|1|entity|C0205452|Six|qnco|||six||||1000|49|51
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||966|62|69
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||861|85|96
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||861|98|106
SE|00000000||tx|1|entity|C2827771|Cmin|qnco|||Cmin||||861|108|111
SE|00000000||tx|1|entity|C0439268|Microgram per Milliliter|qnco|||micrograms/mL||||844|121|133


SE|00000000||tx|1|text|The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
SE|00000000||tx|1|entity|C0205393|Most|qnco|||most||||861|5|8
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interactions||||1000|29|45
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|67|71
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||890|98|106
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma phenytoin concentrations||||890|91|121
SE|00000000||tx|1|entity|C0205178|acute|tmco|||acute||||901|132|136
SE|00000000||tx|1|entity|C0001948|Alcohol consumption|inbe|||alcohol intake||||901|138|151
SE|00000000||tx|1|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||1000|154|163
SE|00000000||tx|1|entity|C0008188|Chlordiazepoxide|orch,phsu|||chlordiazepoxide||||1000|183|198
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|201|210
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|213|220
SE|00000000||tx|1|entity|C0005640|Dicumarol|orch,phsu|||dicumarol||||1000|223|231
SE|00000000||tx|1|entity|C0012772|Disulfiram|orch,phsu|||disulfiram||||1000|234|243
SE|00000000||tx|1|entity|C0014939|Estrogens|horm,phsu,strd|||estrogens||||1000|246|254
SE|00000000||tx|1|entity|C0015043|Ethosuximide|orch,phsu|||ethosuximide||||1000|257|268
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|271|280
SE|00000000||tx|1|entity|C0243076|antagonists|chvf|||antagonists||||888|286|296
SE|00000000||tx|1|entity|C0018549|Halothane|orch,phsu|||halothane||||1000|299|307
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|310|318
SE|00000000||tx|1|entity|C0025810|Methylphenidate|orch,phsu|||methylphenidate||||1000|321|335
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|338|351
SE|00000000||tx|1|entity|C0031463|Phenylbutazone|orch,phsu|||phenylbutazone||||1000|354|367
SE|00000000||tx|1|entity|C0036077|Salicylates|orch,phsu|||salicylates||||1000|370|380
SE|00000000||tx|1|entity|C0038623|Succinimides|orch,phsu|||succinimides||||1000|383|394
SE|00000000||tx|1|entity|C0038760|Sulfonamides|orch,phsu|||sulfonamides||||1000|397|408
SE|00000000||tx|1|entity|C0040374|Tolbutamide|orch,phsu|||tolbutamide||||1000|411|421
SE|00000000||tx|1|entity|C0040805|Trazodone|orch,phsu|||trazodone||||1000|424|432
SE|00000000||tx|1|relation|0|0|C0040374|Tolbutamide|orch,phsu|orch|||tolbutamide||||1000|411|421|SPEC|ISA||397|421|0|0|C0038760|Sulfonamides|orch,phsu|orch|||sulfonamides||||1000|397|408
SE|00000000||tx|1|relation|2|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|67|71|VERB|STIMULATES||82|89|23|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||890|98|106


SE|00000000||tx|1|text|Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.
SE|00000000||tx|1|entity|C1274040|Result|ftcn|||results||||1000|16|22
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|27|29
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|42|52
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||888|54|64
SE|00000000||tx|1|entity|C0146226|Toradol|orch,phsu|||TORADOL||||1000|74|80
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|86|93
SE|00000000||tx|1|entity|C0019134|Heparin|bacs,carb,phsu|||heparin||||1000|98|104
SE|00000000||tx|1|entity|C0146226|Toradol|orch,phsu|||TORADOL||||1000|129|135
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|140|147
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|156|169
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|212|219
SE|00000000||tx|1|relation|8|5|C0146226|Toradol|orch,phsu|orch|||TORADOL||||1000|129|135|NOM|INTERACTS_WITH||54|64|8|1|C0146226|Toradol|orch,phsu|orch|||TORADOL||||1000|74|80
SE|00000000||tx|1|relation|2|1|C0003280|Anticoagulants|phsu|phsu|||anticoagulants||||1000|156|169|VERB|ADMINISTERED_TO||149|154|8|1|C0030705|Patients|podg,humn|humn|||patients||||1000|140|147


SE|00000000||tx|1|text|Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.
SE|00000000||tx|1|entity|C0001443|Adenosine|nnon,nsba,phsu|||Adenosine||||1000|1|9
SE|00000000||tx|1|entity|C0012582|Dipyridamole|orch,phsu|||Dipyridamole||||1000|12|23
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|59|64
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|92|98
SE|00000000||tx|1|entity|C0001443|Adenosine|nnon,nsba,phsu|||adenosine||||1000|103|111


SE|00000000||tx|1|text|Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||Barbiturates||||1000|1|12
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|15|23
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|29|36
SE|00000000||tx|1|entity|C0311400|Metabolic|ftcn|||metabolic||||888|48|56
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|58|66
SE|00000000||tx|1|entity|C0616274|fluorocortisol acetate|horm,phsu,strd|||fludrocortisone acetate||||1000|71|93
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induction||||1000|110|118
SE|00000000||tx|1|entity|C0428321|Measurement of liver enzyme|lbpr|||hepatic enzymes||||983|123|137
SE|00000000||tx|1|relation|3|1|C0035608|Rifampin|antb,orch|antb|||rifampin||||1000|29|36|VERB|STIMULATES||38|46|4|2|C0616274|fluorocortisol acetate|horm,phsu,strd|horm|||fludrocortisone acetate||||1000|71|93
SE|00000000||tx|1|relation|3|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|15|23|VERB|STIMULATES||38|46|4|2|C0616274|fluorocortisol acetate|horm,phsu,strd|horm|||fludrocortisone acetate||||1000|71|93
SE|00000000||tx|1|relation|3|1|C0004745|Barbiturates|orch,phsu|orch|||Barbiturates||||1000|1|12|VERB|STIMULATES||38|46|4|2|C0616274|fluorocortisol acetate|horm,phsu,strd|horm|||fludrocortisone acetate||||1000|71|93


SE|00000000||tx|1|text|Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||Effects||||1000|1|7
SE|00000000||tx|1|entity|C0003299|Antiepileptic Agents|phsu|||Antiepileptic Drugs||||1000|18|36
SE|00000000||tx|1|entity|C0728742|Felbatol|orch,phsu|||Felbatol||||888|41|48
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||888|51|59
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||1000|62|70
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximate||||888|82|92
SE|00000000||tx|1|entity|C0205173|Duplicate|ftcn|||doubling||||888|94|101
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|110|118
SE|00000000||tx|1|entity|C0728742|Felbatol|orch,phsu|||Felbatol||||1000|123|130
SE|00000000||tx|1|entity|C0060135|felbamate|orch,phsu|||felbamate||||1000|134|142
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady state||||1000|148|159
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|181|188
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|193|201
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximate||||802|213|223
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decrease||||802|229|236
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||861|245|256
SE|00000000||tx|1|entity|C0444506|Trough|qnco|||trough||||861|258|263
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||861|265|278
SE|00000000||tx|1|entity|C0728742|Felbatol|orch,phsu|||Felbatol||||1000|283|290
SE|00000000||tx|1|entity|C0445247|Same|qlco|||same||||888|312|315
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|317|320
SE|00000000||tx|1|entity|C0728742|Felbatol|orch,phsu|||Felbatol||||1000|325|332
SE|00000000||tx|1|relation|0|0|C0728742|Felbatol|orch,phsu|orch|||Felbatol||||1000|123|130|SPEC|ISA||123|142|0|0|C0060135|felbamate|orch,phsu|orch|||felbamate||||1000|134|142
SE|00000000||tx|1|relation|16|1|C0003299|Antiepileptic Agents|phsu|phsu|||Antiepileptic Drugs||||1000|18|36|NOM|INTERACTS_WITH||1|7|16|2|C0031507|Phenytoin|orch,phsu|orch|||Phenytoin||||888|51|59


SE|00000000||tx|1|text|Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||Coumarin Anticoagulants||||983|1|23
SE|00000000||tx|1|entity|C0441509|Coagulation procedure|topp|||coagulation||||888|33|43
SE|00000000||tx|1|entity|C0449381|Observation parameter|fndg|||parameters||||888|45|54
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||1000|63|70
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|94|101
SE|00000000||tx|1|entity|C0671970|capecitabine|nnon,phsu|||capecitabine||||861|110|121
SE|00000000||tx|1|entity|C1527240|Derivative|ftcn|||derivative||||890|151|160
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin-derivative anticoagulants||||890|142|175
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|185|192
SE|00000000||tx|1|entity|C0031444|Phenprocoumon|orch,phsu|||phenprocoumon||||1000|198|210
SE|00000000||tx|1|relation|0|0|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||1000|185|192|SPEC|ISA||142|192|0|0|C0010206|coumarin|orch,phsu|orch|||coumarin-derivative anticoagulants||||890|142|175
SE|00000000||tx|1|relation|1|1|C0010206|coumarin|orch,phsu|phsu|||Coumarin Anticoagulants||||983|1|23|VERB|AFFECTS||25|31|7|1|C0449381|Observation parameter|fndg|fndg|||parameters||||888|45|54
SE|00000000||tx|1|relation|3|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|63|70|PREP|PROCESS_OF||91|92|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|94|101
SE|00000000||tx|1|relation|4|1|C0671970|capecitabine|nnon,phsu|phsu|||capecitabine||||861|110|121|VERB|ADMINISTERED_TO||103|108|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|94|101


SE|00000000||tx|1|text|Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||1000|1|12
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||1000|15|26
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|62|71
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||888|76|82
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||888|84|98
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||888|125|133
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||888|135|138
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroid||||901|143|156
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||901|158|169
SE|00000000||tx|1|relation|2|1|C0022625|Ketoconazole|orch,phsu|orch|||Ketoconazole||||1000|15|26|VERB|INHIBITS||49|56|4|2|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroids||||888|84|98


SE|00000000||tx|1|text|When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||842|12|17
SE|00000000||tx|1|entity|C0030551|parent|famg|||parental||||842|19|26
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensive drugs||||842|28|49
SE|00000000||tx|1|entity|C0012022|Diazoxide|orch,phsu|||diazoxide||||1000|60|68
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|83|93
SE|00000000||tx|1|entity|C0020223|Hydralazine|orch,phsu|||hydralazine||||1000|100|110
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|113|120
SE|00000000||tx|1|entity|C0443302|Several|qnco|||several||||888|158|164
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||888|166|170
SE|00000000||tx|1|entity|C0442802|Excessive|qlco|||excessive||||888|180|188
SE|00000000||tx|1|entity|C0238715|Autumn|tmco|||fall||||888|190|193
SE|00000000||tx|1|entity|C0005823|Blood Pressure|orgf|||blood pressure||||1000|198|211
SE|00000000||tx|1|relation|0|0|C0012022|Diazoxide|orch,phsu|orch|||diazoxide||||1000|60|68|SPEC|ISA||28|68|0|0|C0003364|Antihypertensive Agents|phsu|phsu|||antihypertensive drugs||||842|28|49


SE|00000000||tx|1|text|A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|3|6
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|8|15
SE|00000000||tx|1|entity|C0939237|lopinavir / Ritonavir|orch,phsu|||lopinavir/ritonavir||||1000|20|38
SE|00000000||tx|1|entity|C0585361|Twice a day|tmco|||twice daily||||785|54|64
SE|00000000||tx|1|entity|C0016452|Food|food|||food||||694|71|74
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|93|103
SE|00000000||tx|1|entity|C0132326|Nevirapine|nnon,phsu|||nevirapine||||1000|110|119
SE|00000000||tx|1|relation|5|5|C0132326|Nevirapine|nnon,phsu|phsu|||nevirapine||||1000|110|119|NOM|STIMULATES||8|15|5|1|C0939237|lopinavir / Ritonavir|orch,phsu|orch|||lopinavir/ritonavir||||1000|20|38


SE|00000000||tx|1|text|Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.
SE|00000000||tx|1|entity|C0055443|chloroprocaine|orch,phsu|||chloroprocaine||||1000|12|25
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|34|36
SE|00000000||tx|1|entity|C0348080|Condition|qlco|||condition||||1000|53|61
SE|00000000||tx|1|entity|C0038760|Sulfonamides|orch,phsu|||sulfonamide||||888|74|84
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||888|86|89
SE|00000000||tx|1|relation|0|0|C0038760|Sulfonamides|orch,phsu|orch|||sulfonamide||||888|74|84|MOD/HEAD|ISA||74|89|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||888|86|89


SE|00000000||tx|1|text|Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|22|31
SE|00000000||tx|1|entity|C0001367|Acyclovir|nnon,phsu|||acyclovir||||1000|38|46
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||901|84|92
SE|00000000||tx|1|entity|C0205146|Area|spco|||area||||1000|102|105
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||790|131|134
SE|00000000||tx|1|entity|C0205134|Curved|spco|||curve||||790|136|140


SE|00000000||tx|1|text|This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||888|6|9
SE|00000000||tx|1|entity|C1272706|Interval|tmco|||window||||888|11|16
SE|00000000||tx|1|entity|C1705242|Different|qlco|||different||||1000|21|29
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||694|46|49
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|67|79
SE|00000000||tx|1|entity|C1292425|2 Hours|tmco|||2 hours||||1000|113|119
SE|00000000||tx|1|entity|C1292428|6 Hours|tmco|||6 hours||||1000|131|137
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|145|152


SE|00000000||tx|1|text|The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
SE|00000000||tx|1|entity|C0039644|Tetracycline|antb,orch|||tetracycline||||1000|19|30
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|33|42
SE|00000000||tx|1|entity|C0030827|Penicillin G|antb,orch|||penicillin G||||1000|45|56
SE|00000000||tx|1|entity|C0020261|Hydrochlorothiazide|orch,phsu|||hydrochlorothiazide||||1000|59|77
SE|00000000||tx|1|entity|C0017245|Gemfibrozil|lipd,phsu|||gemfibrozil||||1000|84|94
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneously||||1000|135|148
SE|00000000||tx|1|entity|C0354648|Colestipol Hydrochloride|orch,phsu|||colestipol hydrochloride||||1000|155|178
SE|00000000||tx|1|relation|1|1|C0354648|Colestipol Hydrochloride|orch,phsu|orch|||colestipol hydrochloride||||1000|155|178|VERB|COEXISTS_WITH||129|133|6|1|C0017245|Gemfibrozil|lipd,phsu|lipd|||gemfibrozil||||1000|84|94
SE|00000000||tx|1|relation|1|1|C0354648|Colestipol Hydrochloride|orch,phsu|orch|||colestipol hydrochloride||||1000|155|178|VERB|COEXISTS_WITH||129|133|6|1|C0020261|Hydrochlorothiazide|orch,phsu|orch|||hydrochlorothiazide||||1000|59|77
SE|00000000||tx|1|relation|1|1|C0354648|Colestipol Hydrochloride|orch,phsu|orch|||colestipol hydrochloride||||1000|155|178|VERB|COEXISTS_WITH||129|133|6|1|C0030827|Penicillin G|antb,orch|antb|||penicillin G||||1000|45|56
SE|00000000||tx|1|relation|1|1|C0354648|Colestipol Hydrochloride|orch,phsu|orch|||colestipol hydrochloride||||1000|155|178|VERB|COEXISTS_WITH||129|133|6|1|C0016860|Furosemide|orch,phsu|orch|||furosemide||||1000|33|42
SE|00000000||tx|1|relation|1|1|C0354648|Colestipol Hydrochloride|orch,phsu|orch|||colestipol hydrochloride||||1000|155|178|VERB|COEXISTS_WITH||129|133|6|1|C0039644|Tetracycline|antb,orch|antb|||tetracycline||||1000|19|30


SE|00000000||tx|1|text|Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||Aspirin||||1000|1|7
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|10|20
SE|00000000||tx|1|entity|C0012091|Diclofenac|orch,phsu|||diclofenac||||1000|40|49
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|55|61
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|66|68
SE|00000000||tx|1|entity|C0012091|Diclofenac|orch,phsu|||diclofenac||||1000|90|99
SE|00000000||tx|1|entity|C0005456|Binding Sites|rcpt|||binding sites||||1000|123|135
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|148|158
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|178|184
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||884|206|226
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||890|234|239
SE|00000000||tx|1|entity|C0444505|Peak level|qnco|||peak plasma levels||||890|229|246
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|253|255
SE|00000000||tx|1|entity|C0042295|Values|qlco|||values||||888|257|262


SE|00000000||tx|1|text|Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||Erythromycin||||888|1|12
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|14|16
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|21|28
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high doses||||983|48|57
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|62|73
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|101|108
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||890|113|117
SE|00000000||tx|1|entity|C0039773|Theophylline Assay|lbpr|||theophylline levels||||890|119|137
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||901|143|151
SE|00000000||tx|1|entity|C0274770|Poisoning by theophylline|inpo|||theophylline toxicity||||901|153|173


SE|00000000||tx|1|text|It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|28|31
SE|00000000||tx|1|entity|C0140575|Rifabutin|antb,orch|||rifabutin||||1000|36|44
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|60|62
SE|00000000||tx|1|entity|C2825407|Half|qnco|||half||||888|64|67
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||861|79|82
SE|00000000||tx|1|entity|C0525004|Viracept|orch,phsu|||VIRACEPT||||1000|107|114


SE|00000000||tx|1|text|Beta-adrenergic receptor antagonists (beta-blockers) and BROVANA may interfere with the effect of each other when administered concurrently.
SE|00000000||tx|1|entity|C0242889|Adrenergic Antagonists|phsu|||adrenergic receptor antagonists||||923|6|36
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blockers||||1000|39|51
SE|00000000||tx|1|entity|C1815278|Brovana|orch,phsu|||BROVANA||||1000|58|64
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|89|94
SE|00000000||tx|1|relation|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-blockers||||1000|39|51|SPEC|ISA||6|51|0|0|C0242889|Adrenergic Antagonists|phsu|phsu|||adrenergic receptor antagonists||||923|6|36


SE|00000000||tx|1|text|Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||Quinolones||||1000|1|10
SE|00000000||tx|1|entity|C0028365|Norfloxacin|orch,phsu|||norfloxacin||||1000|23|33
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|52|58
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulants||||1000|63|81
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|94|101
SE|00000000||tx|1|entity|C0243072|derivatives|chvs|||derivatives||||1000|110|120
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||872|125|131
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||872|133|138
SE|00000000||tx|1|relation|2|1|C0028365|Norfloxacin|orch,phsu|orch|||norfloxacin||||1000|23|33|NOM|INTERACTS_WITH||52|58|4|1|C0354604|Anticoagulants, Oral|orch,phsu|orch|||oral anticoagulants||||1000|63|81


SE|00000000||tx|1|text|H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.
SE|00000000||tx|1|entity|C0019593|Histamine H2 Antagonists|phsu|||H2 Blockers||||1000|8|18
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|31|33
SE|00000000||tx|1|entity|C0019602|Histidine|aapp,bacs,phsu|||L-histidine||||1000|45|55
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|66|75
SE|00000000||tx|1|entity|C0019588|Histamine|nsba,orch|||histamine||||1000|80|88
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|110|117
SE|00000000||tx|1|entity|C0019593|Histamine H2 Antagonists|phsu|||H2 blockers||||1000|129|139


SE|00000000||tx|1|text|Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|21|28
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|35|43
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||890|57|65
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|67|87
SE|00000000||tx|1|relation|3|1|C0012373|Diltiazem|orch,phsu|orch|||diltiazem||||1000|35|43|VERB|INHIBITS||45|51|2|1|C0012373|Diltiazem|orch,phsu|orch|||diltiazem||||890|57|65


SE|00000000||tx|1|text|There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|26|32
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|37|44
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||1000|59|67
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin times||||1000|78|94
SE|00000000||tx|1|entity|C0086268|Etidronate|opco,phsu|||etidronate||||1000|101|110
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||888|125|132


SE|00000000||tx|1|text|Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.
SE|00000000||tx|1|entity|C0591129|Atromid|orch,phsu|||Atromid-S||||1000|1|9
SE|00000000||tx|1|entity|C0001128|Acids|chem|||acidic||||888|24|29
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|31|35
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|45|53
SE|00000000||tx|1|entity|C0040374|Tolbutamide|orch,phsu|||tolbutamide||||1000|58|68
SE|00000000||tx|1|entity|C0005456|Binding Sites|rcpt|||binding sites||||1000|81|93
SE|00000000||tx|1|relation|0|0|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|45|53|SPEC|ISA||31|53|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|31|35
SE|00000000||tx|1|relation|0|0|C0040374|Tolbutamide|orch,phsu|orch|||tolbutamide||||1000|58|68|SPEC|ISA||31|53|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|31|35


SE|00000000||tx|1|text|Caution should be used if ibuprofen is administered concomitantly with methotrexate.
SE|00000000||tx|1|entity|C0020740|Ibuprofen|orch,phsu|||ibuprofen||||888|27|35
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|72|83


SE|00000000||tx|1|text|International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.
SE|00000000||tx|1|entity|C0525032|International Normalized Ratio|lbpr|||International Normalized Ratio||||916|1|30
SE|00000000||tx|1|entity|C0702240|Elevation|spco|||elevations||||916|38|47
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||888|56|63
SE|00000000||tx|1|entity|C0441471|Event|evnt|||events||||888|65|70
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|99|106
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|115|122
SE|00000000||tx|1|entity|C0919281|Iressa|orch,phsu|||IRESSA||||888|133|138
SE|00000000||tx|1|relation|2|1|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||1000|115|122|VERB|ADMINISTERED_TO||108|113|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|99|106
SE|00000000||tx|1|relation|2|1|C0919281|Iressa|orch,phsu|orch|||IRESSA||||888|133|138|VERB|ADMINISTERED_TO||108|113|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|99|106


SE|00000000||tx|1|text|Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||Theophylline||||1000|1|12
SE|00000000||tx|1|entity|C0015011|Ethinyl Estradiol|horm,phsu,strd|||Ethinyl estradiol||||1000|15|31
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|49|58
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|63|74
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||890|88|96
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|98|118
SE|00000000||tx|1|relation|2|1|C0015011|Ethinyl Estradiol|horm,phsu,strd|horm|||Ethinyl estradiol||||1000|15|31|VERB|INHIBITS||37|43|3|2|C0039771|Theophylline|bacs,orch,phsu|bacs|||theophylline||||1000|63|74


SE|00000000||tx|1|text|In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|6|12
SE|00000000||tx|1|entity|C0040132|Thyroid Gland|bpoc|||thyroid gland||||901|36|48
SE|00000000||tx|1|entity|C0279033|Replacement therapy|topp|||replacement therapy||||901|75|93
SE|00000000||tx|1|entity|C1880497|Empty (qualifier)|qlco|||free||||888|96|99
SE|00000000||tx|1|entity|C0040165|Thyroxine|aapp,horm,phsu|||levothyroxine||||888|101|113
SE|00000000||tx|1|entity|C0014939|Estrogens|horm,phsu,strd|||estrogens||||1000|137|145
SE|00000000||tx|1|entity|C1514873|Requirement|ftcn|||requirements||||827|183|194
SE|00000000||tx|1|relation|5|1|C0040132|Thyroid Gland|bpoc|bpoc|||thyroid gland||||901|36|48|PREP|PART_OF||14|17|1|1|C0030705|Patients|podg,humn|humn|||patient||||1000|6|12
SE|00000000||tx|1|relation|4|1|C0279033|Replacement therapy|topp|topp|||replacement therapy||||901|75|93|VERB|ADMINISTERED_TO||57|65|2|2|C0030705|Patients|podg,humn|humn|||patient||||1000|6|12
SE|00000000||tx|1|relation|4|1|C0014939|Estrogens|horm,phsu,strd|horm|||estrogens||||1000|137|145|VERB|ADMINISTERED_TO||57|65|2|2|C0030705|Patients|podg,humn|humn|||patient||||1000|6|12
SE|00000000||tx|1|relation|4|1|C0040165|Thyroxine|aapp,gngm,horm,phsu|horm|||levothyroxine||||888|101|113|VERB|ADMINISTERED_TO||57|65|2|2|C0030705|Patients|podg,humn|humn|||patient||||1000|6|12


SE|00000000||tx|1|text|Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|21|29
SE|00000000||tx|1|entity|C0723503|Sular|orch,phsu|||SULAR||||833|42|46
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||833|48|54
SE|00000000||tx|1|entity|C0014544|Epilepsy|dsyn|||epileptic||||888|59|67
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|69|76
SE|00000000||tx|1|entity|C0028116|Nisoldipine|orch,phsu|||nisoldipine||||890|90|100
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|102|122
SE|00000000||tx|1|relation|0|0|C0014544|Epilepsy|dsyn|dsyn|||epileptic||||888|59|67|MOD/HEAD|PROCESS_OF||59|76|0|0|C0030705|Patients|podg,humn|humn|||patients||||888|69|76
SE|00000000||tx|1|relation|3|2|C0031507|Phenytoin|orch,phsu|phsu|||phenytoin||||1000|21|29|PREP|TREATS||56|57|3|1|C0030705|Patients|podg,humn|podg|||patients||||888|69|76
SE|00000000||tx|1|relation|0|0|C0031507|Phenytoin|orch,phsu|phsu|||phenytoin||||1000|21|29|INFER|TREATS(INFER)||56|57|0|0|C0014544|Epilepsy|dsyn|dsyn|||epileptic||||888|59|67


SE|00000000||tx|1|text|Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.
SE|00000000||tx|1|entity|C0014479|Ephedrine|orch,phsu|||Ephedrine||||1000|1|9
SE|00000000||tx|1|entity|C0014479|Ephedrine|orch,phsu|||Ephedrine||||1000|12|20
SE|00000000||tx|1|entity|C0311400|Metabolic|ftcn|||metabolic||||888|38|46
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|48|56
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|61|75
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decreased||||790|91|99
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||790|101|105
SE|00000000||tx|1|entity|C0205463|Physiological|ftcn|||physiologic||||790|127|137
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||790|139|146
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|167|174
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroid||||888|179|192
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||888|194|199
SE|00000000||tx|1|relation|2|1|C0014479|Ephedrine|orch,phsu|orch|||Ephedrine||||1000|12|20|VERB|STIMULATES||26|32|6|2|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroids||||1000|61|75
SE|00000000||tx|1|relation|4|4|C0014479|Ephedrine|orch,phsu|orch|||Ephedrine||||1000|1|9|ADJ|INHIBITS||91|99|3|3|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroid||||888|179|192


SE|00000000||tx|1|text|A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|3|6
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|8|15
SE|00000000||tx|1|entity|C0939237|lopinavir / Ritonavir|orch,phsu|||lopinavir/ritonavir||||1000|20|38
SE|00000000||tx|1|entity|C0006935|capsule (pharmacologic)|bodm|||capsules||||888|57|64
SE|00000000||tx|1|entity|C0442749|6/5|fndg|||6.5||||901|69|71
SE|00000000||tx|1|entity|C0585361|Twice a day|tmco|||twice daily||||1000|77|87
SE|00000000||tx|1|entity|C0016452|Food|food|||food||||1000|100|103
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|133|143
SE|00000000||tx|1|entity|C0674427|Sustiva|orch,phsu|||SUSTIVA||||1000|150|156


SE|00000000||tx|1|text|When Mefloquine is taken concurrently with oral live typhoid vaccines, attenuation of immunization cannot be excluded.
SE|00000000||tx|1|entity|C0025153|Mefloquine|orch,phsu|||Mefloquine||||1000|6|15
SE|00000000||tx|1|entity|C1548795|Live|qlco|||live||||861|49|52
SE|00000000||tx|1|entity|C0359940|Typhoid live oral vaccine|aapp,imft,phsu|||oral live typhoid||||861|44|60
SE|00000000||tx|1|entity|C0042210|Vaccines|imft,phsu|||vaccines||||861|62|69
SE|00000000||tx|1|entity|C0599946|Attenuation|acty|||attenuation||||1000|72|82
SE|00000000||tx|1|entity|C0020971|Immunization|topp|||immunization||||1000|87|98
SE|00000000||tx|1|relation|0|0|C0359940|Typhoid live oral vaccine|aapp,gngm,imft,phsu|aapp|||oral live typhoid||||861|44|60|MOD/HEAD|ISA||44|69|0|0|C0042210|Vaccines|imft,phsu|imft|||vaccines||||861|62|69


SE|00000000||tx|1|text|Imipramine hydrochloride may potentiate the effects of CNS depressant drugs.
SE|00000000||tx|1|entity|C0589978|Imipramine Hydrochloride|orch,phsu|||Imipramine hydrochloride||||1000|1|24
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|45|51
SE|00000000||tx|1|entity|C0007680|Central Nervous System Agents|phsu|||CNS depressant drugs||||913|56|75


SE|00000000||tx|1|text|Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.
SE|00000000||tx|1|entity|C0005640|Dicumarol|orch,phsu|||Dicumarol||||1000|1|9
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|38|48
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||1000|63|71
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulant||||1000|80|92
SE|00000000||tx|1|entity|C0005640|Dicumarol|orch,phsu|||dicumarol||||1000|95|103


SE|00000000||tx|1|text|Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulants||||1000|24|42
SE|00000000||tx|1|entity|C0279033|Replacement therapy|topp|||replacement therapy||||901|77|95
SE|00000000||tx|1|entity|C0442824|Very|qlco|||very||||861|115|118


SE|00000000||tx|1|text|Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.
SE|00000000||tx|1|entity|C0529793|sildenafil|orch,phsu|||Sildenafil||||888|1|10
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|12|15
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|24|26
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximum||||1000|37|43
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hour||||790|63|66
SE|00000000||tx|1|entity|C0439531|per period (qualifier value)|tmco|||period||||790|68|73
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|78|85
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||901|109|117
SE|00000000||tx|1|entity|C1707479|Concomitant Therapy|topp|||concomitant indinavir therapy||||901|97|125
SE|00000000||tx|1|relation|4|4|C0529793|sildenafil|orch,phsu|phsu|||Sildenafil||||888|1|10|PREP|TREATS||75|76|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|78|85
SE|00000000||tx|1|relation|1|1|C1707479|Concomitant Therapy|topp|topp|||concomitant indinavir therapy||||901|97|125|VERB|ADMINISTERED_TO||87|95|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|78|85
SE|00000000||tx|1|relation|0|0|C1707479|Concomitant Therapy|topp|topp|||concomitant indinavir therapy||||901|97|125|MOD/HEAD|USES||109|125|0|0|C0376637|Indinavir|orch,phsu|phsu|||indinavir||||901|109|117


SE|00000000||tx|1|text|ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitors||||1000|1|14
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||Reports||||1000|17|23
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|38|43
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|79|84
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||Angiotensin Converting Enzyme (ACE) inhibitors||||1000|89|134


SE|00000000||tx|1|text|Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||clinical study||||1000|15|28
SE|00000000||tx|1|entity|C0443211|Established|qlco|||established||||888|42|52
SE|00000000||tx|1|entity|C0036078|Sulfasalazine|orch,phsu|||sulfasalazine||||1000|67|79
SE|00000000||tx|1|entity|C0720193|Enbrel|aapp,phsu|||ENBREL||||1000|91|96
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|138|145
SE|00000000||tx|1|entity|C0027950|neutrophil|cell|||neutrophil||||861|155|164
SE|00000000||tx|1|entity|C0441833|Groups|idcn|||groups||||1000|190|195
SE|00000000||tx|1|entity|C0720193|Enbrel|aapp,phsu|||ENBREL||||660|217|222
SE|00000000||tx|1|entity|C0036078|Sulfasalazine|orch,phsu|||sulfasalazine||||1000|230|242
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|244|248
SE|00000000||tx|1|relation|5|1|C0027950|neutrophil|cell|cell|||neutrophil||||861|155|164|PREP|LOCATION_OF||147|148|6|2|C0720193|Enbrel|aapp,gngm,phsu|aapp|||ENBREL||||1000|91|96


SE|00000000||tx|1|text|in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|4|6
SE|00000000||tx|1|entity|C0024554|Male gender|fndg|||man||||888|8|10
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||C max||||1000|17|21
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||1000|26|36
SE|00000000||tx|1|entity|C0439275|Microgram per Liter|qnco|||ng/mL||||861|46|50
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||1000|57|67
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|69|73
SE|00000000||tx|1|entity|C0439275|Microgram per Liter|qnco|||ng/mL||||861|83|87
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||802|94|104
SE|00000000||tx|1|entity|C0058445|dirithromycin|antb,orch|||dirithromycin||||802|111|123


SE|00000000||tx|1|text|Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||Non-steroidal Anti-inflammatory Agents||||1000|1|38
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|49|56
SE|00000000||tx|1|entity|C2945640|compromise|fndg|||compromised||||865|63|73
SE|00000000||tx|1|entity|C0232804|Renal function|ortf|||renal function||||865|75|88
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory drugs||||1000|117|152
SE|00000000||tx|1|entity|C0014025|Enalapril|aapp,phsu|||enalapril||||1000|180|188
SE|00000000||tx|1|entity|C1517331|Further|spco|||further||||888|206|212
SE|00000000||tx|1|entity|C0868945|Deterioration|phpr|||deterioration||||888|214|226
SE|00000000||tx|1|entity|C0232804|Renal function|ortf|||renal function||||1000|231|244
SE|00000000||tx|1|relation|1|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||Non-steroidal Anti-inflammatory Agents||||1000|1|38|PREP|TREATS||41|42|7|1|C0030705|Patients|podg,humn|podg|||patients||||1000|49|56
SE|00000000||tx|1|relation|6|1|C0232804|Renal function|ortf|ortf|||renal function||||865|75|88|PREP|PROCESS_OF||58|61|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|49|56


SE|00000000||tx|1|text|Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||Caffeine||||861|1|8
SE|00000000||tx|1|entity|C0163712|Relate - vinyl resin|orch|||related||||861|10|16
SE|00000000||tx|1|entity|C0879626|Adverse effects|patf|||adverse effects||||861|18|32
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|51|58
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|70|77
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|88|94
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||enoxacin||||1000|101|108
SE|00000000||tx|1|relation|1|1|C0879626|Adverse effects|patf|patf|||adverse effects||||861|18|32|VERB|OCCURS_IN||39|46|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|51|58
SE|00000000||tx|1|relation|4|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||1000|88|94|PREP|USES||96|99|1|1|C0014310|Enoxacin|orch,phsu|phsu|||enoxacin||||1000|101|108


SE|00000000||tx|1|text|Of particular importance, sufficient time must elapse before initiating TCAtreatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
SE|00000000||tx|1|entity|C0205410|Sufficient|qlco|||sufficient||||888|27|36
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||888|38|41
SE|00000000||tx|1|entity|C0332152|Before|tmco|||before||||606|55|60
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiating||||606|62|71
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|91|97
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|120|129
SE|00000000||tx|1|entity|C0205166|Long|qlco|||long||||901|142|145
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||901|147|155
SE|00000000||tx|1|entity|C0030551|parent|famg|||parent||||1000|164|169
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||888|175|180
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||888|182|191
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|197|201
SE|00000000||tx|1|entity|C0439230|week|tmco|||weeks||||785|205|209


SE|00000000||tx|1|text|Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.
SE|00000000||tx|1|entity|C0150457|Anticoagulant therapy|topp|||Anticoagulant therapy||||1000|1|21
SE|00000000||tx|1|entity|C1279901|Firstly|qlco|||first||||802|68|72
SE|00000000||tx|1|entity|C0439230|week|tmco|||weeks||||802|78|82
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiating||||872|91|100
SE|00000000||tx|1|entity|C1101725|Bextra|orch,phsu|||BEXTRA||||1000|115|120
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|125|132
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|144|151
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||872|156|162
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||872|164|169
SE|00000000||tx|1|relation|3|3|C0150457|Anticoagulant therapy|topp|topp|||Anticoagulant therapy||||1000|1|21|PREP|USES||110|113|4|1|C1101725|Bextra|orch,phsu|phsu|||BEXTRA||||1000|115|120
SE|00000000||tx|1|relation|4|1|C1101725|Bextra|orch,phsu|phsu|||BEXTRA||||1000|115|120|PREP|TREATS||122|123|3|1|C0030705|Patients|podg,humn|podg|||patients||||1000|125|132
SE|00000000||tx|1|relation|2|1|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||1000|144|151|VERB|ADMINISTERED_TO||134|142|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|125|132
SE|00000000||tx|1|relation|2|1|C1254351|Pharmacologic Substance|phsu|phsu|||agents||||872|164|169|VERB|ADMINISTERED_TO||134|142|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|125|132


SE|00000000||tx|1|text|Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||Rifampicin||||1000|1|10
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|18|22
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|27|44
SE|00000000||tx|1|entity|C0205452|Six|qnco|||six||||851|49|51
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||851|53|55
SE|00000000||tx|1|entity|C0750729|Course|tmco|||course||||851|57|62
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampicin||||1000|67|76
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|85|90
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||775|106|111
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||775|118|121
SE|00000000||tx|1|entity|C0071304|Isradipine|orch,phsu|||isradipine||||1000|126|135
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|151|159
SE|00000000||tx|1|entity|C0071304|Isradipine|orch,phsu|||isradipine||||694|164|173
SE|00000000||tx|1|entity|C0439801|Limited (extensiveness)|ftcn|||limits||||861|202|207
SE|00000000||tx|1|relation|8|1|C0071304|Isradipine|orch,phsu|orch|||isradipine||||1000|126|135|NOM|INHIBITS||151|159|2|1|C0071304|Isradipine|orch,phsu|orch|||isradipine||||694|164|173


SE|00000000||tx|1|text|Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||Nonsteroidal Anti-Inflammatory Drugs||||1000|1|36
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|61|70
SE|00000000||tx|1|entity|C0205307|Normal|qlco|||normal||||888|75|80
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|82|91
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|103|114
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|130|134
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|136|144
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|178|183
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|195|206
SE|00000000||tx|1|relation|6|1|C0012228|Diflunisal|orch,phsu|orch|||diflunisal||||1000|61|70|NOM|ADMINISTERED_TO||43|56|6|2|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|82|91
SE|00000000||tx|1|relation|4|1|C0021246|Indomethacin|orch,phsu|orch|||indomethacin||||1000|103|114|VERB|ADMINISTERED_TO||93|101|4|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|82|91


SE|00000000||tx|1|text|Therefore, patients on propranolol should be observed when COLESTID Tablets are either added or deleted from a therapeutic regimen.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|12|19
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||1000|24|34
SE|00000000||tx|1|entity|C0591276|Colestid|orch,phsu|||COLESTID||||888|60|67
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||Tablets||||888|69|75
SE|00000000||tx|1|entity|C1276413|Therapeutic regimen|topp|||therapeutic regimen||||1000|112|130


SE|00000000||tx|1|text|Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||1000|21|32
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|38|49
SE|00000000||tx|1|entity|C0085149|Tacrolimus|orch,phsu|||tacrolimus||||1000|52|61
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|66|72
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||890|85|93
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|95|115
SE|00000000||tx|1|entity|C0205449|Three|qnco|||three||||790|131|135
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||790|137|141


SE|00000000||tx|1|text|Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||Probenecid||||1000|1|10
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|17|20
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||888|22|32
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|37|46
SE|00000000||tx|1|entity|C0021492|Intramuscular injection|ftcn|||intramuscular injection||||1000|55|77
SE|00000000||tx|1|entity|C0701912|Pipracil|antb,orch|||PIPRACIL||||1000|82|89
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|103|110
SE|00000000||tx|1|entity|C0031955|Piperacillin|antb,orch|||piperacillin||||861|115|126
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||861|133|137
SE|00000000||tx|1|entity|C0444505|Peak level|qnco|||peak serum level||||861|128|143
SE|00000000||tx|1|relation|5|3|C0701912|Pipracil|antb,orch|antb|||PIPRACIL||||1000|82|89|NOM|COEXISTS_WITH||22|32|5|1|C0033209|Probenecid|orch,phsu|orch|||probenecid||||1000|37|46


SE|00000000||tx|1|text|Valproate: Felbatol  causes an increase in steady-state valproate concentrations.
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||Valproate||||1000|1|9
SE|00000000||tx|1|entity|C0728742|Felbatol|orch,phsu|||Felbatol||||1000|12|19
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|32|39
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||861|44|55
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||valproate||||861|57|65
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||861|67|80
SE|00000000||tx|1|relation|3|2|C0728742|Felbatol|orch,phsu|orch|||Felbatol||||1000|12|19|PREP|COEXISTS_WITH||41|42|1|1|C0080356|Valproate|lipd,phsu|lipd|||valproate||||861|57|65


SE|00000000||tx|1|text|The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||1000|5|8
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximum||||888|22|28
SE|00000000||tx|1|entity|C0028778|Obstruction|patf|||block||||888|30|34
SE|00000000||tx|1|entity|C0530102|Nimbex|orch,phsu|||NIMBEX||||1000|46|51
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||802|56|68
SE|00000000||tx|1|entity|C0700321|Small|qnco|||minutes||||802|72|78
SE|00000000||tx|1|entity|C0456962|Fast|qlco|||faster||||966|80|85
SE|00000000||tx|1|entity|C0332152|Before|tmco|||prior||||888|92|96
SE|00000000||tx|1|entity|C0038627|Succinylcholine|orch,phsu|||succinylcholine||||1000|116|130


SE|00000000||tx|1|text|Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.
SE|00000000||tx|1|entity|C0038792|Sulindac|orch,phsu|||Sulindac||||1000|1|8
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|15|25
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|45|54
SE|00000000||tx|1|entity|C0038792|Sulindac|orch,phsu|||sulindac||||1000|60|67
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||888|72|77
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|79|88
SE|00000000||tx|1|entity|C0441994|Lower - spatial qualifier|spco|||lowering||||1000|102|109
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|118|123
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||916|139|144
SE|00000000||tx|1|entity|C0808113|Sulindac sulfide metabolite|orch,phsu|||sulindac sulfide metabolite||||916|146|172
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||851|177|189
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||851|191|193
SE|00000000||tx|1|entity|C0205437|Third|qnco|||third||||851|195|199
SE|00000000||tx|1|relation|4|1|C0038792|Sulindac|orch,phsu|phsu|||sulindac||||1000|60|67|PREP|TREATS||69|70|4|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|79|88
SE|00000000||tx|1|relation|4|1|C0038792|Sulindac|orch,phsu|phsu|||Sulindac||||1000|1|8|PREP|TREATS||69|70|4|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|79|88


SE|00000000||tx|1|text|In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.
SE|00000000||tx|1|entity|C0034693|Rattus norvegicus|mamm|||rats||||1000|4|7
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneous||||888|10|21
SE|00000000||tx|1|entity|C0232478|Ingestion|biof|||ingestion||||888|23|31
SE|00000000||tx|1|entity|C0012772|Disulfiram|orch,phsu|||disulfiram||||1000|36|45
SE|00000000||tx|1|entity|C1384115|Nitrite|inch|||nitrite||||1000|51|57
SE|00000000||tx|1|entity|C0012155|Diet|food|||diet||||1000|66|69
SE|00000000||tx|1|entity|C0439230|week|tmco|||weeks||||861|78|82
SE|00000000||tx|1|entity|C0027651|Neoplasms|neop|||tumors||||1000|111|116
SE|00000000||tx|1|entity|C0012772|Disulfiram|orch,phsu|||disulfiram||||1000|150|159
SE|00000000||tx|1|entity|C0028137|Nitrites|chvs|||nitrites||||1000|176|183
SE|00000000||tx|1|entity|C1882874|Rat Stomach|bpoc|||rat stomach||||901|192|202
SE|00000000||tx|1|entity|C0028197|Nitrosamines|hops,orch|||nitrosamine||||1000|214|224
SE|00000000||tx|1|entity|C1519697|Tumorigenicity|patf|||tumorigenic||||928|236|246
SE|00000000||tx|1|relation|6|2|C0012155|Diet|food|food|||diet||||1000|66|69|VERB|CAUSES||105|109|6|1|C0027651|Neoplasms|neop|neop|||tumors||||1000|111|116
SE|00000000||tx|1|relation|3|1|C1882874|Rat Stomach|bpoc|bpoc|||rat stomach||||901|192|202|PREP|LOCATION_OF||185|186|9|2|C0012772|Disulfiram|orch,phsu|orch|||disulfiram||||1000|150|159


SE|00000000||tx|1|text|Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
SE|00000000||tx|1|entity|C0000618|mercaptopurine|nnon,phsu|||Mercaptopurine||||888|1|14
SE|00000000||tx|1|entity|C0004482|Azathioprine|orch,phsu|||Azathioprine||||888|16|27
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||Allopurinol||||1000|30|40
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzymatic||||853|55|63
SE|00000000||tx|1|entity|C0030011|Oxidation|moft|||oxidation||||853|65|73
SE|00000000||tx|1|entity|C0000618|mercaptopurine|nnon,phsu|||mercaptopurine||||1000|78|91
SE|00000000||tx|1|entity|C0004482|Azathioprine|orch,phsu|||azathioprine||||1000|97|108
SE|00000000||tx|1|entity|C0049721|6-thiouric acid|orch|||6-thiouric acid||||1000|113|127
SE|00000000||tx|1|relation|2|1|C0002144|Allopurinol|orch,phsu|phsu|||Allopurinol||||1000|30|40|VERB|DISRUPTS||42|49|4|1|C0030011|Oxidation|moft|moft|||oxidation||||853|65|73


SE|00000000||tx|1|text|On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|22|25
SE|00000000||tx|1|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||888|27|36
SE|00000000||tx|1|entity|C0027552|Needs|qlco|||need||||1000|43|46
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||861|62|68
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|97|100
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|113|125
SE|00000000||tx|1|relation|2|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||861|62|68|PREP|USES||48|50|3|2|C0002598|Amiodarone|orch,phsu|phsu|||amiodarone||||888|27|36


SE|00000000||tx|1|text|Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
SE|00000000||tx|1|entity|C0808279|Toxicology studies|resa|||Toxicology studies||||1000|1|18
SE|00000000||tx|1|entity|C0011892|Heroin|hops,orch,phsu|||heroin||||851|23|28
SE|00000000||tx|1|entity|C0163712|Relate - vinyl resin|orch|||related||||851|30|36
SE|00000000||tx|1|entity|C1306577|Death (finding)|fndg|||deaths||||851|38|43
SE|00000000||tx|1|entity|C0332183|Frequent|tmco|||frequent||||694|52|59
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||central nervous system depressants||||1000|82|115
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|128|134
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|137|151
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|161|168
SE|00000000||tx|1|entity|C0699187|Valium|orch,phsu|||Valium||||1000|171|176
SE|00000000||tx|1|entity|C0035853|Rosa|plnt|||rising||||872|190|195
SE|00000000||tx|1|entity|C0441889|Levels (qualifier value)|qlco|||degree||||872|197|202
SE|00000000||tx|1|entity|C0025605|Methadone|orch,phsu|||methadone||||1000|205|213
SE|00000000||tx|1|relation|0|0|C0012010|Diazepam|orch,phsu|orch|||diazepam||||1000|161|168|SPEC|ISA||137|168|0|0|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|137|151
SE|00000000||tx|1|relation|0|0|C0699187|Valium|orch,phsu|orch|||Valium||||1000|171|176|SPEC|ISA||161|176|0|0|C0012010|Diazepam|orch,phsu|orch|||diazepam||||1000|161|168
SE|00000000||tx|1|relation|7|3|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|137|151|NOM|INTERACTS_WITH||61|71|7|1|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressants||||1000|82|115
SE|00000000||tx|1|relation|0|0|C0012010|Diazepam|orch,phsu|orch|||diazepam||||1000|161|168|INFER|INTERACTS_WITH(SPEC)||137|168|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||central nervous system depressants||||1000|82|115


SE|00000000||tx|1|text|The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|5|19
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|32|41
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||861|52|59
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressant||||861|61|74
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|76|82
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||861|129|139
SE|00000000||tx|1|entity|C0003286|Anticonvulsants|phsu|||anticonvulsants||||1000|142|156
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistaminics||||1000|159|173
SE|00000000||tx|1|entity|C0001962|Ethanol|orch|||ethanol||||1000|176|182
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|195|199
SE|00000000||tx|1|entity|C0151559|Central nervous system depression (disorder)|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|0|0|C0001962|Ethanol|orch|orch|||ethanol||||1000|176|182|SPEC|ISA||176|199|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|195|199
SE|00000000||tx|1|relation|0|0|C0001962|Ethanol|orch|orch|||ethanol||||1000|176|182|SPEC|ISA||176|199|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||861|129|139
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|195|199|SPEC|ISA||176|199|0|0|C0001962|Ethanol|orch|orch|||ethanol||||1000|176|182
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|195|199|SPEC|ISA||176|199|0|0|C0003360|Antihistamines|orch,phsu|phsu|||antihistaminics||||1000|159|173
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|195|199|SPEC|ISA||176|199|0|0|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsants||||1000|142|156
SE|00000000||tx|1|relation|0|0|C0003360|Antihistamines|orch,phsu|orch|||antihistaminics||||1000|159|173|SPEC|ISA||176|199|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|195|199
SE|00000000||tx|1|relation|0|0|C0003360|Antihistamines|orch,phsu|orch|||antihistaminics||||1000|159|173|SPEC|ISA||176|199|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||861|129|139
SE|00000000||tx|1|relation|0|0|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsants||||1000|142|156|SPEC|ISA||176|199|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|195|199
SE|00000000||tx|1|relation|0|0|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsants||||1000|142|156|SPEC|ISA||176|199|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||861|129|139
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||861|129|139|SPEC|ISA||176|199|0|0|C0001962|Ethanol|orch|orch|||ethanol||||1000|176|182
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||861|129|139|SPEC|ISA||176|199|0|0|C0003360|Antihistamines|orch,phsu|phsu|||antihistaminics||||1000|159|173
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||861|129|139|SPEC|ISA||176|199|0|0|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsants||||1000|142|156
SE|00000000||tx|1|relation|2|1|C0002333|Alprazolam|orch,phsu|orch|||alprazolam||||1000|32|41|NOM|INTERACTS_WITH||76|82|2|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressant||||861|61|74
SE|00000000||tx|1|relation|8|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|195|199|VERB|CAUSES||218|224|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|8|1|C0001962|Ethanol|orch|orch|||ethanol||||1000|176|182|VERB|CAUSES||218|224|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|8|1|C0003360|Antihistamines|orch,phsu|phsu|||antihistaminics||||1000|159|173|VERB|CAUSES||218|224|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|8|1|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsants||||1000|142|156|VERB|CAUSES||218|224|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|8|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||861|129|139|VERB|CAUSES||218|224|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|0|0|C0001962|Ethanol|orch|orch|||ethanol||||1000|176|182|INFER|CAUSES(SPEC)||176|199|0|0|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|0|0|C0001962|Ethanol|orch|orch|||ethanol||||1000|176|182|INFER|CAUSES(SPEC)||176|199|0|0|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|195|199|INFER|CAUSES(SPEC)||176|199|0|0|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|195|199|INFER|CAUSES(SPEC)||176|199|0|0|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|195|199|INFER|CAUSES(SPEC)||176|199|0|0|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|0|0|C0003360|Antihistamines|orch,phsu|orch|||antihistaminics||||1000|159|173|INFER|CAUSES(SPEC)||176|199|0|0|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|0|0|C0003360|Antihistamines|orch,phsu|orch|||antihistaminics||||1000|159|173|INFER|CAUSES(SPEC)||176|199|0|0|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|0|0|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsants||||1000|142|156|INFER|CAUSES(SPEC)||176|199|0|0|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|0|0|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsants||||1000|142|156|INFER|CAUSES(SPEC)||176|199|0|0|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||861|129|139|INFER|CAUSES(SPEC)||176|199|0|0|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||861|129|139|INFER|CAUSES(SPEC)||176|199|0|0|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||861|129|139|INFER|CAUSES(SPEC)||176|199|0|0|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|226|239


SE|00000000||tx|1|text|Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.
SE|00000000||tx|1|entity|C0010976|Dantrolene|orch,phsu|||dantrolene||||1000|19|28
SE|00000000||tx|1|entity|C0242531|Vecuronium|phsu,strd|||vecuronium||||861|45|54
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induced||||861|56|62
SE|00000000||tx|1|entity|C0235062|Induction of neuromuscular blockade|topp|||neuromuscular block||||861|64|82


SE|00000000||tx|1|text|The increase of phenobarbital level, however, is small (15%) when given with Trileptal.
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|5|12
SE|00000000||tx|1|entity|C0524238|Phenobarbital measurement|lbpr|||phenobarbital level||||1000|17|35
SE|00000000||tx|1|entity|C0700321|Small|qnco|||small||||1000|50|54
SE|00000000||tx|1|entity|C0876196|Trileptal|orch,phsu|||Trileptal||||1000|78|86
SE|00000000||tx|1|relation|3|2|C0524238|Phenobarbital measurement|lbpr|lbpr|||phenobarbital level||||1000|17|35|PREP|USES||73|76|1|1|C0876196|Trileptal|orch,phsu|phsu|||Trileptal||||1000|78|86


SE|00000000||tx|1|text|With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||simultaneous||||694|6|17
SE|00000000||tx|1|entity|C1176939|vardenafil 10 MG|clnd|||Vardenafil 10 mg||||1000|29|44
SE|00000000||tx|1|entity|C1123697|Terazosin 10 MG|clnd|||terazosin 10 mg||||1000|50|64
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||827|74|81
SE|00000000||tx|1|entity|C0488055|Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative|clna|||systolic blood pressure||||923|106|128
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||1000|133|136
SE|00000000||tx|1|entity|C0439475|mmHg|qnco|||mm Hg||||901|146|150


SE|00000000||tx|1|text|As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensive agents||||1000|15|37
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|61|66
SE|00000000||tx|1|entity|C0126174|Losartan|orch,phsu|||losartan||||1000|71|78
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||non-steroidal anti-inflammatory drug||||928|102|137
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||928|139|150
SE|00000000||tx|1|relation|0|0|C0021246|Indomethacin|orch,phsu|orch|||indomethacin||||928|139|150|MOD/HEAD|ISA||102|150|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||non-steroidal anti-inflammatory drug||||928|102|137
SE|00000000||tx|1|relation|1|1|C0003364|Antihypertensive Agents|phsu|phsu|||antihypertensive agents||||1000|15|37|NOM|INTERACTS_WITH||61|66|2|1|C0126174|Losartan|orch,phsu|orch|||losartan||||1000|71|78


SE|00000000||tx|1|text|Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||Cyclosporine||||1000|1|12
SE|00000000||tx|1|entity|C0003209|Anti-Inflammatory Agents|phsu|||anti-inflammatory drugs||||884|45|67
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|88|99
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|129|136
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||851|141|152
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induced||||851|154|160
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||851|162|169
SE|00000000||tx|1|entity|C2362652|Possible diagnosis|qlco|||possibly||||1000|172|179
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decreased||||888|188|196
SE|00000000||tx|1|entity|C0220781|Anabolism|biof|||synthesis||||888|198|206
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|211|215
SE|00000000||tx|1|entity|C0033567|Epoprostenol|bacs,eico,phsu|||prostacyclin||||888|217|228
SE|00000000||tx|1|relation|3|3|C0033567|Epoprostenol|bacs,eico,phsu|bacs|||prostacyclin||||888|217|228|NOM|AUGMENTS||129|136|3|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||851|162|169
SE|00000000||tx|1|relation|0|0|C0033567|Epoprostenol|bacs,eico,phsu|bacs|||prostacyclin||||888|217|228|MOD/HEAD|PART_OF||211|228|0|0|C0022646|Kidney|bpoc|bpoc|||renal||||888|211|215


SE|00000000||tx|1|text|Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||1000|21|31
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||1000|38|49
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||890|62|69
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|71|91
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||1000|96|106
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||rare||||872|122|125
SE|00000000||tx|1|entity|C1550608|Instance|idcn|||instances||||872|127|135
SE|00000000||tx|1|entity|C2826244|Life Threatening|fndg|||life- threatening||||888|140|156
SE|00000000||tx|1|entity|C0003811|Cardiac Arrhythmia|patf|||cardiac dysrhythmias||||888|158|177
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|183|185
SE|00000000||tx|1|entity|C0011065|Cessation of life|orgf|||death||||888|187|191


SE|00000000||tx|1|text|Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||Corticosteroids||||1000|1|15
SE|00000000||tx|1|entity|C0011777|Dexamethasone|phsu,strd|||Dexamethasone||||1000|18|30
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|33|42
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||regimen||||1000|61|67
SE|00000000||tx|1|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||1000|83|95
SE|00000000||tx|1|entity|C0442027|Oral|spco|||orally||||1000|112|117
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|131|133
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|142|151
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|170|175
SE|00000000||tx|1|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||1000|182|194
SE|00000000||tx|1|entity|C0442027|Oral|spco|||orally||||1000|211|216
SE|00000000||tx|1|entity|C0439228|day|tmco|||Days||||861|229|232
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|261|263
SE|00000000||tx|1|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||1000|268|280
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|285|290
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||802|309|312
SE|00000000||tx|1|entity|C0439228|day|tmco|||Days||||861|318|321
SE|00000000||tx|1|relation|5|2|C0040808|Treatment Protocols|topp|topp|||regimen||||1000|61|67|PREP|USES||78|81|10|1|C0011777|Dexamethasone|phsu,strd|phsu|||dexamethasone||||1000|83|95
SE|00000000||tx|1|relation|13|1|C0011777|Dexamethasone|phsu,strd|phsu|||dexamethasone||||1000|268|280|NOM|INTERACTS_WITH||292|300|13|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|285|290


SE|00000000||tx|1|text|Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.
SE|00000000||tx|1|entity|C0205250|High|qlco|||Elevated||||790|1|8
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|10|15
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|27|38
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|64|74
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|76|78
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|88|97


SE|00000000||tx|1|text|Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||Aminoglycosides||||1000|1|15
SE|00000000||tx|1|entity|C0205430|Mixed (qualifier value)|ftcn|||mixing||||1000|22|27
SE|00000000||tx|1|entity|C0031955|Piperacillin|antb,orch|||piperacillin||||1000|32|43
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycoside||||1000|53|66
SE|00000000||tx|1|entity|C0544461|Inactivation|comd|||inactivation||||861|103|114
SE|00000000||tx|1|entity|C0002556|Aminoglycosides|carb,phsu|||aminoglycoside||||1000|123|136
SE|00000000||tx|1|relation|5|2|C0002556|Aminoglycosides|carb,phsu|carb|||aminoglycoside||||1000|53|66|VERB|CAUSES||81|86|2|1|C0544461|Inactivation|comd|comd|||inactivation||||861|103|114
SE|00000000||tx|1|relation|5|3|C0031955|Piperacillin|antb,orch|antb|||piperacillin||||1000|32|43|NOM|INHIBITS||103|114|1|1|C0002556|Aminoglycosides|carb,phsu|carb|||aminoglycoside||||1000|123|136


SE|00000000||tx|1|text|(Thiazide drugs may increase the responsiveness to tubocurarine.)
SE|00000000||tx|1|entity|C0541746|Thiazides|orch,phsu|||Thiazide||||888|2|9
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|11|15
SE|00000000||tx|1|entity|C0205342|Responsive|ftcn|||responsiveness||||928|34|47
SE|00000000||tx|1|entity|C0041345|Tubocurarine|orch,phsu|||tubocurarine||||1000|52|63
SE|00000000||tx|1|relation|0|0|C0541746|Thiazides|orch,phsu|orch|||Thiazide||||888|2|9|MOD/HEAD|ISA||2|15|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|11|15


SE|00000000||tx|1|text|The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.
SE|00000000||tx|1|entity|C0237795|Pressors|phsu|||pressor||||888|5|11
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|13|19
SE|00000000||tx|1|entity|C0007412|Catecholamines|nsba,orch,phsu|||catecholamines||||1000|24|37
SE|00000000||tx|1|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine||||1000|47|54
SE|00000000||tx|1|entity|C0028351|Norepinephrine|nsba,orch,phsu|||norepinephrine||||1000|59|72
SE|00000000||tx|1|entity|C0006168|Bretylium Tosylate|orch,phsu|||Bretylium Tosylate||||1000|90|107
SE|00000000||tx|1|relation|0|0|C0013030|Dopamine|nsba,orch,phsu|nsba|||dopamine||||1000|47|54|SPEC|ISA||24|54|0|0|C0007412|Catecholamines|nsba,orch,phsu|nsba|||catecholamines||||1000|24|37
SE|00000000||tx|1|relation|0|0|C0028351|Norepinephrine|nsba,orch,phsu|nsba|||norepinephrine||||1000|59|72|SPEC|ISA||24|54|0|0|C0007412|Catecholamines|nsba,orch,phsu|nsba|||catecholamines||||1000|24|37
SE|00000000||tx|1|relation|1|1|C0006168|Bretylium Tosylate|orch,phsu|orch|||Bretylium Tosylate||||1000|90|107|VERB|STIMULATES||78|85|4|1|C0028351|Norepinephrine|nsba,orch,phsu|nsba|||norepinephrine||||1000|59|72
SE|00000000||tx|1|relation|1|1|C0006168|Bretylium Tosylate|orch,phsu|orch|||Bretylium Tosylate||||1000|90|107|VERB|STIMULATES||78|85|4|1|C0013030|Dopamine|nsba,orch,phsu|nsba|||dopamine||||1000|47|54


SE|00000000||tx|1|text|In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|9|16
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||non-steroidal anti-inflammatory agent||||1000|43|79
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||888|96|103
SE|00000000||tx|1|entity|C0597421|saluretic|phsu|||natriuretic||||888|106|116
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|140|146
SE|00000000||tx|1|entity|C0445022|Loop|spco|||loop||||1000|151|154
SE|00000000||tx|1|entity|C0032821|Potassium|elii|||potassium||||694|157|165
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|179|196
SE|00000000||tx|1|relation|3|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||non-steroidal anti-inflammatory agent||||1000|43|79|VERB|INHIBITS||85|90|5|1|C0597421|saluretic|phsu|phsu|||natriuretic||||888|106|116


SE|00000000||tx|1|text|Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||Warfarin||||1000|1|8
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||Quinolones||||1000|11|20
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|38|44
SE|00000000||tx|1|entity|C0354604|Anticoagulants, Oral|orch,phsu|||oral anticoagulant||||1000|53|70
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|73|80
SE|00000000||tx|1|entity|C0243072|derivatives|chvs|||derivatives||||1000|90|100


SE|00000000||tx|1|text|Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.
SE|00000000||tx|1|entity|C0030174|Package Inserts|mnob|||package insert||||1000|14|27
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||872|33|39
SE|00000000||tx|1|entity|C1521827|Preparation|ftcn|||preparations||||872|41|52
SE|00000000||tx|1|entity|C1521827|Preparation|ftcn|||preparations||||966|73|84
SE|00000000||tx|1|entity|C0020261|Hydrochlorothiazide|orch,phsu|||Hydrochlorothiazide||||1000|91|109


SE|00000000||tx|1|text|Theophylline: Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||Theophylline||||1000|1|12
SE|00000000||tx|1|entity|C0287721|grepafloxacin|orch,phsu|||Grepafloxacin||||1000|15|27
SE|00000000||tx|1|entity|C0679932|competition|socb|||competitive||||888|34|44
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||888|46|54
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|63|72
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|77|88
SE|00000000||tx|1|relation|2|1|C0287721|grepafloxacin|orch,phsu|orch|||Grepafloxacin||||1000|15|27|NOM|INHIBITS||46|54|2|2|C0039771|Theophylline|bacs,orch,phsu|bacs|||theophylline||||1000|77|88


SE|00000000||tx|1|text|Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||Cyclosporine||||1000|1|12
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|23|34
SE|00000000||tx|1|entity|C0599918|nephrotoxicity|inpo|||nephrotoxicity||||1000|48|61
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decreases||||1000|68|76
SE|00000000||tx|1|entity|C0812399|Creatinine clearance|fndg|||creatinine clearance||||1000|81|100
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||888|115|119
SE|00000000||tx|1|entity|C0010294|Creatinine|bacs,orch|||creatinine||||888|121|130
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||888|145|149
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|151|159
SE|00000000||tx|1|entity|C0013153|Drug Administration Routes|ftcn|||route||||851|188|192
SE|00000000||tx|1|entity|C1449704|Fibrates|orch,phsu|||fibrate||||872|197|203
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||872|205|209
SE|00000000||tx|1|entity|C0723893|Tricor|orch,phsu|||TRICOR||||1000|221|226
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|240|243
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|253|263
SE|00000000||tx|1|entity|C0868945|Deterioration|phpr|||deterioration||||1000|278|290
SE|00000000||tx|1|relation|0|0|C1449704|Fibrates|orch,phsu|orch|||fibrate||||872|197|203|MOD/HEAD|ISA||197|209|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||872|205|209
SE|00000000||tx|1|relation|2|1|C0010592|Cyclosporine|aapp,gngm,phsu|aapp|||cyclosporine||||1000|23|34|VERB|CAUSES||40|46|11|1|C0599918|nephrotoxicity|inpo|inpo|||nephrotoxicity||||1000|48|61
SE|00000000||tx|1|relation|2|1|C0010592|Cyclosporine|aapp,gngm,phsu|aapp|||Cyclosporine||||1000|1|12|VERB|CAUSES||40|46|11|1|C0599918|nephrotoxicity|inpo|inpo|||nephrotoxicity||||1000|48|61
SE|00000000||tx|1|relation|9|6|C0723893|Tricor|orch,phsu|phsu|||TRICOR||||1000|221|226|NOM|INHIBITS||68|76|9|1|C0812399|Creatinine clearance|fndg|fndg|||creatinine clearance||||1000|81|100


SE|00000000||tx|1|text|Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.
SE|00000000||tx|1|entity|C0674428|efavirenz|orch,phsu|||efavirenz||||1000|24|32
SE|00000000||tx|1|entity|C0016277|Fluconazole|orch,phsu|||fluconazole||||1000|37|47
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|62|67
SE|00000000||tx|1|entity|C0031327|Drug Kinetics|phsf|||pharmacokinetics||||1000|76|91
SE|00000000||tx|1|entity|C0052796|Azithromycin|antb,orch|||azithromycin||||1000|96|107
SE|00000000||tx|1|relation|2|2|C0052796|Azithromycin|antb,orch|antb|||azithromycin||||1000|96|107|NOM|AFFECTS||62|67|2|1|C0031327|Drug Kinetics|phsf|phsf|||pharmacokinetics||||1000|76|91


SE|00000000||tx|1|text|When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.
SE|00000000||tx|1|entity|C0085826|Antiplatelet Agents|phsu|||antiplatelet agents||||1000|12|30
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|35|48
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|87|95
SE|00000000||tx|1|entity|C0376357|Flolan|eico,phsu|||FLOLAN||||861|101|106
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|124|127
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||1000|132|139
SE|00000000||tx|1|relation|4|1|C0376357|Flolan|eico,phsu|eico|||FLOLAN||||861|101|106|NOM|PREDISPOSES||124|127|1|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|132|139


SE|00000000||tx|1|text|Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.
SE|00000000||tx|1|entity|C0027396|Naproxen|orch,phsu|||Naproxen||||1000|1|8
SE|00000000||tx|1|entity|C0546873|Naproxen sodium|orch,phsu|||naproxen sodium||||901|38|52
SE|00000000||tx|1|entity|C0006935|capsule (pharmacologic)|bodm|||capsules||||901|54|61
SE|00000000||tx|1|entity|C0678176|Neurontin|orch,phsu|||Neurontin||||1000|77|85
SE|00000000||tx|1|entity|C1265611|Quantity|qnco|||amount||||1000|120|125
SE|00000000||tx|1|entity|C0060926|gabapentin|orch,phsu|||gabapentin||||1000|130|139
SE|00000000||tx|1|relation|6|2|C0678176|Neurontin|orch,phsu|orch|||Neurontin||||1000|77|85|VERB|STIMULATES||107|114|2|2|C0060926|gabapentin|orch,phsu|orch|||gabapentin||||1000|130|139


SE|00000000||tx|1|text|Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||Anticoagulants||||1000|1|14
SE|00000000||tx|1|entity|C0016377|Flurbiprofen|orch,phsu|||Flurbiprofen||||1000|17|28
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory drugs||||1000|41|76
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||888|104|111
SE|00000000||tx|1|entity|C0449381|Observation parameter|fndg|||parameters||||888|113|122
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|127|134
SE|00000000||tx|1|entity|C0009117|Coagulants|phsu|||coagulants||||861|151|160
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||851|167|173
SE|00000000||tx|1|entity|C0205210|Clinical|qlco|||clinical||||851|175|182
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||851|184|191
SE|00000000||tx|1|relation|3|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory drugs||||1000|41|76|VERB|AFFECTS||97|102|4|1|C0449381|Observation parameter|fndg|fndg|||parameters||||888|113|122
SE|00000000||tx|1|relation|4|1|C0449381|Observation parameter|fndg|fndg|||parameters||||888|113|122|PREP|PROCESS_OF||124|125|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|127|134
SE|00000000||tx|1|relation|2|1|C0009117|Coagulants|phsu|phsu|||coagulants||||861|151|160|VERB|ADMINISTERED_TO||136|144|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|127|134


SE|00000000||tx|1|text|Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines
SE|00000000||tx|1|entity|C0039651|Tetracyclines|orch|||Tetracyclines||||1000|1|13
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|16|26
SE|00000000||tx|1|entity|C0699581|Accutane|orch,phsu|||Accutane||||1000|43|50
SE|00000000||tx|1|entity|C0039651|Tetracyclines|orch|||tetracyclines||||1000|56|68
SE|00000000||tx|1|entity|C0699581|Accutane|orch,phsu|||Accutane||||888|96|103
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|105|107
SE|00000000||tx|1|entity|C0237753|Numbers|qnco|||number||||1000|136|141
SE|00000000||tx|1|entity|C0868928|Case (situation)|ftcn|||cases||||1000|146|150
SE|00000000||tx|1|entity|C0033845|Pseudotumor Cerebri|dsyn|||pseudotumor cerebri||||1000|155|173
SE|00000000||tx|1|entity|C0033845|Pseudotumor Cerebri|dsyn|||benign intracranial hypertension||||1000|176|207
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|234|244
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|246|248
SE|00000000||tx|1|entity|C0039651|Tetracyclines|orch|||tetracyclines||||1000|253|265


SE|00000000||tx|1|text|Ketamine: Marked hypertension and tachycardia have been reported in association with concomitant administration of levothyroxine sodium and ketamine.
SE|00000000||tx|1|entity|C0022614|Ketamine|orch,phsu|||Ketamine||||1000|1|8
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||Marked||||888|11|16
SE|00000000||tx|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||888|18|29
SE|00000000||tx|1|entity|C0039231|Tachycardia|fndg|||tachycardia||||1000|35|45
SE|00000000||tx|1|entity|C0439849|Relationships|qlco|||association||||1000|69|79
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|86|96
SE|00000000||tx|1|entity|C0079691|Levothyroxine Sodium|aapp,horm,phsu|||levothyroxine sodium||||1000|116|135
SE|00000000||tx|1|entity|C0022614|Ketamine|orch,phsu|||ketamine||||1000|141|148
SE|00000000||tx|1|relation|3|3|C0022614|Ketamine|orch,phsu|orch|||Ketamine||||1000|1|8|NOM|COEXISTS_WITH||69|79|3|2|C0079691|Levothyroxine Sodium|aapp,gngm,horm,phsu|aapp|||levothyroxine sodium||||1000|116|135
SE|00000000||tx|1|relation|3|3|C0022614|Ketamine|orch,phsu|orch|||ketamine||||1000|141|148|NOM|COEXISTS_WITH||69|79|3|2|C0079691|Levothyroxine Sodium|aapp,gngm,horm,phsu|aapp|||levothyroxine sodium||||1000|116|135


SE|00000000||tx|1|text|In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.
SE|00000000||tx|1|entity|C0205454|Eight|qnco|||eight||||833|4|8
SE|00000000||tx|1|entity|C0019699|HIV Seropositivity|fndg|||HIV-||||833|10|13
SE|00000000||tx|1|entity|C0439663|Infected|ftcn|||infected||||833|14|21
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||833|23|30
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||901|37|48
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||901|50|52
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|57|69
SE|00000000||tx|1|entity|C1510992|Average|qnco|||average||||1000|88|94
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|128|140
SE|00000000||tx|1|entity|C1292425|2 Hours|tmco|||2 hours||||1000|159|165
SE|00000000||tx|1|entity|C1318228|Market|geoa|||marketed||||612|178|185
SE|00000000||tx|1|entity|C1273630|Tablet For Suspension Dosage Form|bodm|||dispersible tablet||||612|196|213
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||VIDEX||||1000|230|234


SE|00000000||tx|1|text|Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.
SE|00000000||tx|1|entity|C0443302|Several|qnco|||Several||||901|1|7
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||901|9|33
SE|00000000||tx|1|entity|C0728866|Drug effect|ftcn|||pharmacologic effects||||1000|67|87
SE|00000000||tx|1|entity|C0018318|Guanethidine|orch,phsu|||guanethidine||||1000|92|103
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||1000|106|114
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||872|120|126
SE|00000000||tx|1|entity|C1254351|Pharmacologic Substance|phsu|||agents||||872|128|133
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|148|153
SE|00000000||tx|1|entity|C0678594|Structure|spco|||structural||||888|198|207
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similarity||||888|209|218
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|229|253


SE|00000000||tx|1|text|Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0010762|Cytochrome P450|aapp,enzy|||Cytochrome P450 Enzymes||||983|22|44
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interaction||||901|50|65
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||901|67|71
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|88|93
SE|00000000||tx|1|entity|C0287721|grepafloxacin|orch,phsu|||grepafloxacin||||1000|98|110
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|115|126
SE|00000000||tx|1|entity|C0287721|grepafloxacin|orch,phsu|||grepafloxacin||||1000|143|155
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||888|166|177
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|179|188
SE|00000000||tx|1|entity|C1332826|CYP1A2 gene|gngm|1544|CYP1A2|CYP1A2||||1000|212|217
SE|00000000||tx|1|relation|8|1|C0010762|Cytochrome P450|aapp,gngm,enzy|aapp|||Cytochrome P450 Enzymes||||983|22|44|VERB|INTERACTS_WITH||7|17|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|relation|5|1|C0287721|grepafloxacin|orch,phsu|orch|||grepafloxacin||||1000|98|110|NOM|INTERACTS_WITH||88|93|5|2|C0039771|Theophylline|bacs,orch,phsu|bacs|||theophylline||||1000|115|126
SE|00000000||tx|1|relation|7|1|C0287721|grepafloxacin|orch,phsu|orch|||grepafloxacin||||1000|143|155|VERB|INHIBITS||157|164|2|1|C0039771|Theophylline|bacs,orch,phsu|bacs|||theophylline||||888|166|177
SE|00000000||tx|1|relation|1|1|C1332826|CYP1A2 gene|gngm,aapp|gngm|1544|CYP1A2|CYP1A2||||1000|212|217|VERB|INTERACTS_WITH||200|207|8|1|C0039771|Theophylline|bacs,orch,phsu|bacs|||theophylline||||888|166|177


SE|00000000||tx|1|text|Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|23|28
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|33|42
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||888|51|56
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|58|60
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|78|85
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|101|103
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||660|124|131
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|140|147
SE|00000000||tx|1|entity|||gngm|1559|CYP2C9|CYP2C9||||1000|152|157
SE|00000000||tx|1|entity|C0444506|Trough|qnco|||trough||||694|170|175
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||861|212|219
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|228|243
SE|00000000||tx|1|entity|C0525032|International Normalized Ratio|lbpr|||International Normalized Ratio||||1000|258|287
SE|00000000||tx|1|entity|C0525032|International Normalized Ratio|lbpr|||INR||||1000|292|294
SE|00000000||tx|1|entity|C1442466|5 Days|tmco|||5 days||||1000|297|302
SE|00000000||tx|1|entity|C0205197|Complete|qlco|||completion||||1000|310|319
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|336|345
SE|00000000||tx|1|relation|17|6|C0033707|Prothrombin time assay|lbpr|lbpr|||prothrombin time||||1000|228|243|PREP|USES||331|334|1|1|C1176306|aprepitant|orch,phsu|phsu|||Aprepitant||||1000|336|345


SE|00000000||tx|1|text|An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|4|11
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||901|22|28
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum lithium concentration||||901|16|42
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|69|79
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|99|105
SE|00000000||tx|1|entity|C0718711|Atacand|orch,phsu|||ATACAND||||1000|112|118
SE|00000000||tx|1|entity|C0236281|Serum lithium measurement|lbpr|||serum lithium levels||||988|146|165
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|189|199
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|201|203


SE|00000000||tx|1|text|On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|21|30
SE|00000000||tx|1|entity|C0765273|bexarotene|orch,phsu|||bexarotene||||1000|35|44
SE|00000000||tx|1|entity|C1142644|Cytochrome P450 3A4|aapp,enzy|||cytochrome P450 3A4||||1000|49|67
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|70|81
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|84|95
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|98|109
SE|00000000||tx|1|entity|C0017245|Gemfibrozil|lipd,phsu|||gemfibrozil||||1000|112|122
SE|00000000||tx|1|entity|C0452456|Grapefruit juice|food|||grapefruit juice||||1000|125|140
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||1000|153|162
SE|00000000||tx|1|entity|C1142644|Cytochrome P450 3A4|aapp,enzy|||cytochrome P450 3A4||||1000|167|185
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|219|226
SE|00000000||tx|1|entity|C0765273|bexarotene|orch,phsu|||bexarotene||||890|238|247
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma bexarotene concentrations||||890|231|262
SE|00000000||tx|1|relation|8|2|C0017245|Gemfibrozil|lipd,phsu|lipd|||gemfibrozil||||1000|112|122|NOM|INHIBITS||153|162|3|1|C1142644|Cytochrome P450 3A4|aapp,gngm,enzy|gngm|||cytochrome P450 3A4||||1000|167|185
SE|00000000||tx|1|relation|8|2|C0014806|Erythromycin|antb,orch|antb|||erythromycin||||1000|98|109|NOM|INHIBITS||153|162|3|1|C1142644|Cytochrome P450 3A4|aapp,gngm,enzy|gngm|||cytochrome P450 3A4||||1000|167|185
SE|00000000||tx|1|relation|8|2|C0064113|Itraconazole|orch,phsu|orch|||itraconazole||||1000|84|95|NOM|INHIBITS||153|162|3|1|C1142644|Cytochrome P450 3A4|aapp,gngm,enzy|gngm|||cytochrome P450 3A4||||1000|167|185
SE|00000000||tx|1|relation|8|2|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|70|81|NOM|INHIBITS||153|162|3|1|C1142644|Cytochrome P450 3A4|aapp,gngm,enzy|gngm|||cytochrome P450 3A4||||1000|167|185
SE|00000000||tx|1|relation|8|2|C1142644|Cytochrome P450 3A4|aapp,gngm,enzy|aapp|||cytochrome P450 3A4||||1000|49|67|NOM|INHIBITS||153|162|3|1|C1142644|Cytochrome P450 3A4|aapp,gngm,enzy|gngm|||cytochrome P450 3A4||||1000|167|185
SE|00000000||tx|1|relation|10|9|C0765273|bexarotene|orch,phsu|orch|||bexarotene||||1000|35|44|NOM|STIMULATES||219|226|1|1|C0765273|bexarotene|orch,phsu|orch|||bexarotene||||890|238|247


SE|00000000||tx|1|text|Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.
SE|00000000||tx|1|entity|C0025853|Metoclopramide|orch,phsu|||Metoclopramide||||1000|1|14
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||Bioavailability||||1000|17|31
SE|00000000||tx|1|entity|C0750532|MILDLY|idcn|||mildly||||1000|36|41
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|52|64
SE|00000000||tx|1|entity|C0012132|Zalcitabine|nnon,phsu|||zalcitabine||||1000|76|86
SE|00000000||tx|1|entity|C0025853|Metoclopramide|orch,phsu|||metoclopramide||||1000|92|105


SE|00000000||tx|1|text|Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|14|21
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|27|37
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|46|48


SE|00000000||tx|1|text|Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).
SE|00000000||tx|1|entity|C0001128|Acids|chem|||acid||||888|10|13
SE|00000000||tx|1|entity|C0342579|Electrolyte imbalance|patf|||electrolyte disturbances||||983|24|47
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|54|56
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||clinical trials||||1000|74|88
SE|00000000||tx|1|entity|C0165590|dorzolamide|orch,phsu|||dorzolamide||||1000|95|105
SE|00000000||tx|1|entity|C2699787|Disturbance|qlco|||disturbances||||966|114|125
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||916|151|154
SE|00000000||tx|1|entity|C0007036|Carbonic Anhydrase Inhibitors|phsu|||carbonic anhydrase inhibitors||||916|156|184
SE|00000000||tx|1|entity|C1550608|Instance|idcn|||instances||||966|204|212
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interactions||||1000|227|243
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|252|259
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high-dose||||861|277|285
SE|00000000||tx|1|entity|C0036075|salicylate|orch,phsu|||salicylate||||861|287|296


SE|00000000||tx|1|text|Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|||gngm|9360|PPIG|CYP||||827|26|28
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||Inhibitors||||827|33|42
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||Possible||||901|47|54
SE|00000000||tx|1|entity|C2826293|Clinical Significance|fndg|||Clinical Significance||||901|56|76
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||Clinical Studies||||1000|94|109
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||Alprazolam||||1000|121|130
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|185|194
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|218|227
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|234|243
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximum||||901|259|265
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||901|267|286
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|291|300
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||decreased||||888|310|318
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|320|328
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||901|338|346
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||901|348|356
SE|00000000||tx|1|entity|C0444706|Measured|qlco|||measured||||901|380|387
SE|00000000||tx|1|entity|C0033923|Psychomotor Performance|menp|||psychomotor performance||||901|389|411
SE|00000000||tx|1|relation|0|0|C0243077|inhibitors|chvf|chvf|||Inhibitors||||827|33|42|SPEC|ISA||1|42|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|relation|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|NOM|INHIBITS||33|42|14|1|C2826293|Clinical Significance|fndg|fndg|||Clinical Significance||||901|56|76
SE|00000000||tx|1|relation|11|1|C0002333|Alprazolam|orch,phsu|orch|||alprazolam||||1000|234|243|VERB|STIMULATES||245|253|5|2|C0002333|Alprazolam|orch,phsu|orch|||alprazolam||||1000|291|300
SE|00000000||tx|1|relation|0|0|C0243077|inhibitors|chvf|chvf|||Inhibitors||||827|33|42|INFER|INHIBITS(SPEC)||1|42|0|0|C2826293|Clinical Significance|fndg|fndg|||Clinical Significance||||901|56|76


SE|00000000||tx|1|text|Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|16|26
SE|00000000||tx|1|entity|C1101331|Tracleer|orch,phsu|||TRACLEER||||1000|46|53
SE|00000000||tx|1|entity|C0017628|Glyburide|orch,phsu|||glyburide||||1000|59|67
SE|00000000||tx|1|entity|C1523987|Alternative|cnce|||alternative||||901|93|103
SE|00000000||tx|1|entity|C0020616|Hypoglycemic Agents|phsu|||hypoglycemic agents||||901|105|123


SE|00000000||tx|1|text|Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.
SE|00000000||tx|1|entity|C0025041|Sodium Meclofenamate|orch,phsu|||meclofenamate sodium||||1000|17|36
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||840|52|58
SE|00000000||tx|1|entity|C1514756|Receive|qlco|||receiving||||840|60|68
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||840|70|77
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||1000|84|89
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|94|101
SE|00000000||tx|1|entity|C0442802|Excessive|qlco|||excessive||||694|132|140
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|162|177


SE|00000000||tx|1|text|Phenytoin: Isoniazid may increase serum levels of phenytoin.
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||1000|1|9
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||Isoniazid||||1000|12|20
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||861|35|39
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|51|59


SE|00000000||tx|1|text|Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.
SE|00000000||tx|1|entity|C0546852|2-Bromoergocryptine Mesylate|orch,phsu|||Bromocriptine mesylate||||1000|1|22
SE|00000000||tx|1|entity|C0242702|Dopamine Antagonists|nsba,phsu|||dopamine antagonists||||1000|42|61
SE|00000000||tx|1|entity|C0006525|Butyrophenones|orch,phsu|||butyrophenones||||1000|64|77
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||1000|84|90
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|98|103
SE|00000000||tx|1|relation|1|1|C0546852|2-Bromoergocryptine Mesylate|orch,phsu|orch|||Bromocriptine mesylate||||1000|1|22|VERB|INTERACTS_WITH||28|35|4|1|C0242702|Dopamine Antagonists|nsba,phsu|nsba|||dopamine antagonists||||1000|42|61
SE|00000000||tx|1|relation|1|1|C0546852|2-Bromoergocryptine Mesylate|orch,phsu|orch|||Bromocriptine mesylate||||1000|1|22|VERB|INTERACTS_WITH||28|35|4|1|C0006525|Butyrophenones|orch,phsu|orch|||butyrophenones||||1000|64|77


SE|00000000||tx|1|text|Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||Anticoagulants||||1000|1|14
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|36|38
SE|00000000||tx|1|entity|C0012091|Diclofenac|orch,phsu|||diclofenac||||861|46|55
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|74|87
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||694|96|103
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interactions||||966|159|170
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|198|203
SE|00000000||tx|1|relation|3|1|C0012091|Diclofenac|orch,phsu|orch|||diclofenac||||861|46|55|VERB|INTERACTS_WITH||60|67|5|1|C0003280|Anticoagulants|phsu|phsu|||anticoagulants||||1000|74|87


SE|00000000||tx|1|text|Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.
SE|00000000||tx|1|entity|C0031327|Drug Kinetics|phsf|||pharmacokinetics||||1000|11|26
SE|00000000||tx|1|entity|C0939273|Busulfex|orch,phsu|||BUSULFEX||||1000|31|38
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|56|63
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|78|86
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|93|101
SE|00000000||tx|1|entity|C0939273|Busulfex|orch,phsu|||BUSULFEX||||1000|106|113
SE|00000000||tx|1|entity|C0034866|Recommendation|idcn|||recommended||||888|122|132
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|134|137
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|166|168
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||966|171|176
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|181|188
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|190|192
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|207|215
SE|00000000||tx|1|relation|2|2|C0031327|Drug Kinetics|phsf|phsf|||pharmacokinetics||||1000|11|26|PREP|PROCESS_OF||53|54|11|1|C0030705|Patients|podg,humn|humn|||patients||||1000|56|63
SE|00000000||tx|1|relation|10|1|C0031507|Phenytoin|orch,phsu|phsu|||phenytoin||||1000|78|86|VERB|TREATS||65|71|3|1|C0030705|Patients|podg,humn|podg|||patients||||1000|56|63
SE|00000000||tx|1|relation|11|6|C0939273|Busulfex|orch,phsu|phsu|||BUSULFEX||||1000|106|113|PREP|TREATS||178|179|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|181|188


SE|00000000||tx|1|text|Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
SE|00000000||tx|1|entity|C0002932|Anesthetics|phsu|||Anesthetics||||852|1|11
SE|00000000||tx|1|entity|C0020592|Hypnotics and Sedatives|phsu|||Sedatives/Hypnotics||||852|13|31
SE|00000000||tx|1|entity|C0242402|Opioids|hops,orch,phsu|||Opioids||||852|33|39
SE|00000000||tx|1|entity|C0876757|Precedex|orch,phsu|||PRECEDEX||||1000|63|70
SE|00000000||tx|1|entity|C0002932|Anesthetics|phsu|||anesthetics||||1000|77|87
SE|00000000||tx|1|entity|C0036557|Sedatives|phsu|||sedatives||||1000|90|98
SE|00000000||tx|1|entity|C0020591|Hypnotics|phsu|||hypnotics||||1000|101|109
SE|00000000||tx|1|entity|C0242402|Opioids|hops,orch,phsu|||opioids||||1000|116|122
SE|00000000||tx|1|entity|C0332148|Probable diagnosis|qlco|||likely||||861|127|132
SE|00000000||tx|1|entity|C2349975|Enhance (action)|acty|||enhancement||||1000|148|158
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|163|169


SE|00000000||tx|1|text|Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||Plasma concentrations||||983|1|21
SE|00000000||tx|1|entity|C1882518|Quinolone Antibiotic|antb|||quinolone antibiotics||||983|26|46
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|85|92
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||magnesium||||1000|105|113
SE|00000000||tx|1|entity|C0006675|Calcium|bacs,elii,phsu|||calcium||||1000|116|122
SE|00000000||tx|1|entity|C0002367|Aluminum|elii|||aluminum||||1000|128|135


SE|00000000||tx|1|text|There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|17|23
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||861|28|39
SE|00000000||tx|1|entity|C0163712|Relate - vinyl resin|orch|||related||||861|41|47
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||861|49|60
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|65|72
SE|00000000||tx|1|entity|C1707479|Concomitant Therapy|topp|||concomitant therapy||||1000|77|95
SE|00000000||tx|1|entity|C0028365|Norfloxacin|orch,phsu|||norfloxacin||||1000|102|112
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|118|129
SE|00000000||tx|1|relation|4|1|C1707479|Concomitant Therapy|topp|topp|||concomitant therapy||||1000|77|95|PREP|USES||97|100|2|1|C0028365|Norfloxacin|orch,phsu|phsu|||norfloxacin||||1000|102|112
SE|00000000||tx|1|relation|4|1|C1707479|Concomitant Therapy|topp|topp|||concomitant therapy||||1000|77|95|PREP|USES||97|100|2|1|C0039771|Theophylline|bacs,orch,phsu|phsu|||theophylline||||1000|118|129


SE|00000000||tx|1|text|Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin.
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||Diuretics||||1000|1|9
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|12|19
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|24|32
SE|00000000||tx|1|entity|C0948575|diuretic therapy|topp|||diuretic therapy||||1000|60|75
SE|00000000||tx|1|entity|C0332185|Recent|tmco|||recently||||1000|81|88
SE|00000000||tx|1|entity|C0442802|Excessive|qlco|||excessive||||888|133|141
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||888|143|151
SE|00000000||tx|1|entity|C0005823|Blood Pressure|orgf|||blood pressure||||1000|156|169
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiation||||1000|177|186
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|191|197
SE|00000000||tx|1|entity|C0721436|Lotensin|orch,phsu|||Lotensin||||1000|204|211
SE|00000000||tx|1|relation|4|4|C0721436|Lotensin|orch,phsu|orch|||Lotensin||||1000|204|211|NOM|DISRUPTS||143|151|4|1|C0005823|Blood Pressure|orgf|orgf|||blood pressure||||1000|156|169


SE|00000000||tx|1|text|Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.
SE|00000000||tx|1|entity|C0050393|Acarbose|carb,phsu|||Acarbose||||1000|1|8
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||861|55|61
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||901|112|118
SE|00000000||tx|1|entity|C2826232|Dose Adjustment|hlca|||dose adjustment||||901|120|134
SE|00000000||tx|1|relation|0|0|C2826232|Dose Adjustment|hlca|hlca|||dose adjustment||||901|120|134|MOD/HEAD|USES||112|134|0|0|C0012265|Digoxin|carb,phsu,strd|phsu|||digoxin||||901|112|118


SE|00000000||tx|1|text|Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combining||||872|29|37
SE|00000000||tx|1|entity|C0008290|Chlorprothixene|orch,phsu|||chlorprothixene||||872|39|53
SE|00000000||tx|1|entity|C0242896|Anticholinergic Agents|phsu|||anticholinergic drugs||||1000|66|86
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|89|113
SE|00000000||tx|1|entity|C0003405|Antiparkinson Agents|phsu|||antiparkinsonian agents||||1000|119|141
SE|00000000||tx|1|entity|C1999167|Old age|fndg|||elderly||||1000|162|168
SE|00000000||tx|1|entity|C0011206|Delirium|mobd|||delirium||||1000|182|189
SE|00000000||tx|1|entity|C0205250|High|qlco|||high||||888|192|195
SE|00000000||tx|1|entity|C0015967|Fever|fndg|||fever||||888|197|201
SE|00000000||tx|1|entity|C0221152|Obstipation|dsyn|||obstipation||||861|211|221
SE|00000000||tx|1|entity|C1258215|Ileus|dsyn|||ileus||||861|229|233
SE|00000000||tx|1|entity|C0017601|Glaucoma|dsyn|||glaucoma||||1000|239|246


SE|00000000||tx|1|text|Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||Epinephrine||||861|1|11
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|55|59
SE|00000000||tx|1|entity|C0017977|Glycosides|carb|||glycosides||||1000|79|88
SE|00000000||tx|1|entity|C0027061|Myocardium|tisu|||myocardium||||1000|110|119
SE|00000000||tx|1|entity|C0441472|Clinical action|ftcn|||actions||||1000|128|134
SE|00000000||tx|1|entity|C0039052|Sympathomimetics|phsu|||sympathomimetic drugs||||1000|139|159
SE|00000000||tx|1|relation|4|3|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|55|59|VERB|AUGMENTS||96|104|3|1|C0027061|Myocardium|tisu|tisu|||myocardium||||1000|110|119


SE|00000000||tx|1|text|Aminoglutethimide diminishes the effect of coumarin and warfarin.
SE|00000000||tx|1|entity|C0002555|Aminoglutethimide|orch,phsu|||Aminoglutethimide||||1000|1|17
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|34|39
SE|00000000||tx|1|entity|C0010206|coumarin|orch,phsu|||coumarin||||1000|44|51
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|57|64


SE|00000000||tx|1|text|Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.
SE|00000000||tx|1|entity|C0913246|valdecoxib|orch,phsu|||valdecoxib||||623|23|32
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||623|34|42
SE|00000000||tx|1|entity|C0028978|Omeprazole|orch,phsu|||omeprazole||||1000|56|65
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|68|70


SE|00000000||tx|1|text|Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||1000|1|12
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||763|27|31
SE|00000000||tx|1|entity|C0052080|antineoplaston A10|orch,phsu|||a 10||||861|43|46
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||861|48|51
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|53|60
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||vardenafil||||888|65|74
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|76|78
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||851|88|91
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||851|93|100
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|105|108
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||Vardenafil||||1000|136|145
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|157|174


SE|00000000||tx|1|text|Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||Enoxacin||||1000|1|8
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|30|39
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|44|55
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose-||||775|83|87
SE|00000000||tx|1|entity|C0163712|Relate - vinyl resin|orch|||related||||775|88|94
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||775|96|103
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||888|108|119
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|121|129
SE|00000000||tx|1|entity|C0332282|Following|tmco|||subsequent||||861|137|146
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|161|168
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||890|173|177
SE|00000000||tx|1|entity|C0039773|Theophylline Assay|lbpr|||theophylline levels||||890|179|197
SE|00000000||tx|1|relation|1|1|C0014310|Enoxacin|orch,phsu|orch|||Enoxacin||||1000|1|8|VERB|DISRUPTS||10|19|6|1|C0025519|Metabolism|orgf|orgf|||metabolism||||1000|30|39
SE|00000000||tx|1|relation|3|0|C0163712|Relate - vinyl resin|orch|orch|||related||||775|88|94|NOM|INHIBITS||96|103|3|1|C0039771|Theophylline|bacs,orch,phsu|bacs|||theophylline||||888|108|119


SE|00000000||tx|1|text|Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or
SE|00000000||tx|1|entity|C0038710|Sulfapyridine|orch,phsu|||Sulfapyridine||||1000|1|13
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||1000|44|52
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||Acetaminophen||||1000|57|69
SE|00000000||tx|1|entity|C0699142|Tylenol|orch,phsu|||Tylenol||||1000|78|84
SE|00000000||tx|1|entity|C0443252|Long-term|tmco|||long-term||||857|93|101
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high-dose||||857|104|112
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||857|114|116


SE|00000000||tx|1|text|Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||Caffeine||||1000|1|8
SE|00000000||tx|1|entity|C0022635|Ketoprofen|orch,phsu|||ketoprofen||||1000|41|50
SE|00000000||tx|1|entity|C0042036|Urine|bdsu|||urine||||888|64|68
SE|00000000||tx|1|entity|C0449468|Volume|qnco|||volume||||888|70|75
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||890|82|99


SE|00000000||tx|1|text|Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.
SE|00000000||tx|1|entity|C0442801|Exaggerated|qlco|||Exaggerated||||802|1|11
SE|00000000||tx|1|entity|C0871261|Response process|orga|||responses||||802|26|34
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combined||||888|64|71
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|73|75
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic antagonists||||988|80|106
SE|00000000||tx|1|entity|C2003941|Alpha|inpr|||alpha-||||851|112|117
SE|00000000||tx|1|entity|C0599756|adrenergic|ftcn|||adrenergic||||851|118|127
SE|00000000||tx|1|entity|C0304402|Stimulant|phsu|||stimulants||||851|129|138
SE|00000000||tx|1|entity|C0991524|Nasal drops|bodm|||nasal drops||||901|217|227


SE|00000000||tx|1|text|Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.
SE|00000000||tx|1|entity|C1711239|Since|tmco|||Since||||879|1|5
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||higher doses||||879|7|18
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|23|34
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||790|44|48
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||872|65|70
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||872|72|80
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|85|88
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|94|96
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||762|101|106
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||762|115|118
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||Vardenafil||||1000|123|132
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|141|143
SE|00000000||tx|1|entity|C0439584|24 hour time frame|tmco|||24-hour||||890|162|168
SE|00000000||tx|1|entity|C0439531|per period (qualifier value)|tmco|||period||||890|170|175
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|190|200
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||775|207|218
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||775|227|231


SE|00000000||tx|1|text|Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.
SE|00000000||tx|1|entity|C1514468|product|enty|||Products||||1000|1|8
SE|00000000||tx|1|entity|C0006675|Calcium|bacs,elii,phsu|||calcium||||1000|21|27
SE|00000000||tx|1|entity|C0007447|Cations|chvs|||cations||||861|51|57
SE|00000000||tx|1|entity|C0002367|Aluminum|elii|||aluminum||||1000|68|75
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||magnesium||||1000|78|86
SE|00000000||tx|1|entity|C0302583|Iron|bacs,elii,phsu|||iron||||1000|89|92
SE|00000000||tx|1|entity|C0332148|Probable diagnosis|qlco|||likely||||861|99|104
SE|00000000||tx|1|entity|C0379199|Ibandronate|orch,phsu|||Ibandronate||||1000|138|148


SE|00000000||tx|1|text|Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.
SE|00000000||tx|1|entity|C0003299|Antiepileptic Agents|phsu|||Antiepileptic Drugs||||1000|31|49
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|56|63
SE|00000000||tx|1|entity|C0728742|Felbatol|orch,phsu|||Felbatol||||1000|68|75
SE|00000000||tx|1|entity|C0003299|Antiepileptic Agents|phsu|||antiepileptic drugs||||1000|81|99
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||877|120|131
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||877|133|153
SE|00000000||tx|1|entity|C0003299|Antiepileptic Agents|phsu|||AEDs||||1000|158|161
SE|00000000||tx|1|relation|5|1|C0003299|Antiepileptic Agents|phsu|phsu|||antiepileptic drugs||||1000|81|99|VERB|INTERACTS_WITH||108|114|2|2|C0003299|Antiepileptic Agents|phsu|phsu|||AEDs||||1000|158|161


SE|00000000||tx|1|text|Propranolol increases hydralazines serum concentrations.
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||Propranolol||||777|1|11
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increases||||777|13|21
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentrations||||777|36|55


SE|00000000||tx|1|text|The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|18|24
SE|00000000||tx|1|entity|C0017887|Nitroglycerin|orch,phsu|||nitroglycerin||||1000|29|41
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||1000|50|57
SE|00000000||tx|1|entity|C0042402|Vasodilator Agents|phsu|||vasodilators||||1000|79|90
SE|00000000||tx|1|relation|0|0|C0017887|Nitroglycerin|orch,phsu|orch|||nitroglycerin||||1000|29|41|SPEC|ISA||29|90|0|0|C0042402|Vasodilator Agents|phsu|phsu|||vasodilators||||1000|79|90


SE|00000000||tx|1|text|In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
SE|00000000||tx|1|entity|C0241863|DIABETIC|fndg|||diabetic||||888|4|11
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|13|20
SE|00000000||tx|1|entity|C2945675|metabolic effects|phsf|||metabolic effects||||1000|27|43
SE|00000000||tx|1|entity|C0002844|Androgens|horm,phsu|||androgens||||1000|48|56
SE|00000000||tx|1|entity|C0005802|Blood Glucose|carb|||blood glucose||||1000|71|83
SE|00000000||tx|1|entity|C0021641|Insulin|aapp,horm,phsu|||insulin||||872|100|106
SE|00000000||tx|1|entity|C1514873|Requirement|ftcn|||requirements||||872|108|119
SE|00000000||tx|1|relation|0|0|C0241863|DIABETIC|fndg|fndg|||diabetic||||888|4|11|MOD/HEAD|PROCESS_OF||4|20|0|0|C0030705|Patients|podg,humn|humn|||patients||||888|13|20
SE|00000000||tx|1|relation|3|1|C0002844|Androgens|horm,phsu|horm|||androgens||||1000|48|56|VERB|INHIBITS||62|69|2|1|C0005802|Blood Glucose|carb|carb|||blood glucose||||1000|71|83


SE|00000000||tx|1|text|Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.
SE|00000000||tx|1|entity|C0022885|Laboratory Procedures|lbpr|||Laboratory Tests||||1000|1|16
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|23|33
SE|00000000||tx|1|entity|C0754188|Amprenavir|orch,phsu|||Amprenavir||||1000|38|47
SE|00000000||tx|1|entity|C0445550|Low dose|qnco|||low-dose||||901|53|60
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||901|62|70
SE|00000000||tx|1|entity|C0702240|Elevation|spco|||elevations||||1000|97|106
SE|00000000||tx|1|entity|C0008377|Cholesterol|bacs,strd|||cholesterol||||1000|111|121
SE|00000000||tx|1|entity|C0041004|Triglycerides|bacs,lipd|||triglycerides||||1000|127|139
SE|00000000||tx|1|entity|C0201899|Aspartate aminotransferase assay|lbpr|||SGOT||||1000|142|145
SE|00000000||tx|1|entity|||gngm|26503|SLC17A5|AST||||1000|148|150
SE|00000000||tx|1|entity|C0001899|Alanine Transaminase|aapp,enzy|||ALT||||966|164|166
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|177|184
SE|00000000||tx|1|relation|11|8|C0292818|Ritonavir|orch,phsu|phsu|||ritonavir||||901|62|70|PREP|TREATS||169|170|1|1|C0030705|Patients|podg,humn|podg|||patients||||1000|177|184
SE|00000000||tx|1|relation|11|8|C0754188|Amprenavir|orch,phsu|phsu|||Amprenavir||||1000|38|47|PREP|TREATS||169|170|1|1|C0030705|Patients|podg,humn|podg|||patients||||1000|177|184


SE|00000000||tx|1|text|Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||Additive||||901|1|8
SE|00000000||tx|1|entity|C0151559|Central nervous system depression (disorder)|dsyn|||CNS depression||||901|10|23
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|40|53
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||1000|97|111
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|123|134
SE|00000000||tx|1|entity|C0040614|Tranquilizing Agents|phsu|||tranquilizers||||1000|137|149
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|156|162


SE|00000000||tx|1|text|Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral.
SE|00000000||tx|1|entity|C0037490|Sodium Cephalothin|antb,orch|||Sodium cephalothin||||1000|1|18
SE|00000000||tx|1|entity|C0599918|nephrotoxicity|inpo|||nephrotoxicity||||1000|36|49
SE|00000000||tx|1|entity|C0719445|Coly Mycin M|orch,phsu|||Coly-Mycin M||||1000|54|65
SE|00000000||tx|1|relation|1|1|C0037490|Sodium Cephalothin|antb,orch|antb|||Sodium cephalothin||||1000|1|18|VERB|AUGMENTS||24|30|3|1|C0599918|nephrotoxicity|inpo|inpo|||nephrotoxicity||||1000|36|49


SE|00000000||tx|1|text|Flurbiprofen did not affect the pharmacokinetic profile of either drug, and the mechanism under lying the interference with propranolols hypotensive effect is unknown.
SE|00000000||tx|1|entity|C0016377|Flurbiprofen|orch,phsu|||Flurbiprofen||||1000|1|12
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|18|20
SE|00000000||tx|1|entity|C2003903|Profiling (action)|ftcn|||profile||||861|49|55
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||861|67|70
SE|00000000||tx|1|entity|C0038846|Supine Position|spco|||lying||||1000|97|101
SE|00000000||tx|1|entity|C2346501|Interference|acty|||interference||||1000|107|118
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||790|138|148
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||790|150|155
SE|00000000||tx|1|entity|C0439673|Unknown|qlco|||unknown||||1000|160|166
SE|00000000||tx|1|relation|1|1|C0016377|Flurbiprofen|orch,phsu|orch|||Flurbiprofen||||1000|1|12|VERB|INTERACTS_WITH|negation|22|27|7|2|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||861|67|70


SE|00000000||tx|1|text|Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
SE|00000000||tx|1|entity|C0010463|Curare|hops,orch,phsu|||Curariform||||865|1|10
SE|00000000||tx|1|entity|C0358430|Muscle relaxants|phsu|||muscle relaxants||||865|12|27
SE|00000000||tx|1|entity|C0041345|Tubocurarine|orch,phsu|||tubocurarine||||1000|34|45
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|58|62
SE|00000000||tx|1|entity|C0014994|Ether, Ethyl|orch,phsu|||ether||||1000|75|79
SE|00000000||tx|1|entity|C0038627|Succinylcholine|orch,phsu|||succinylcholine||||1000|82|96
SE|00000000||tx|1|entity|C0016971|Gallamine|orch,phsu|||gallamine||||1000|99|107
SE|00000000||tx|1|entity|C0057231|decamethonium|orch,phsu|||decamethonium||||1000|110|122
SE|00000000||tx|1|entity|C0142825|sodium citrate|orch,phsu|||sodium citrate||||1000|128|141
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blocking||||901|173|180
SE|00000000||tx|1|entity|C3179228|Neuromuscular Effect|phsf|||neuromuscular blocking effect||||901|159|187
SE|00000000||tx|1|entity|C0205403|Extreme|qlco|||extreme||||694|213|219
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|232|239
SE|00000000||tx|1|entity|C0719445|Coly Mycin M|orch,phsu|||Coly-Mycin M||||1000|260|271
SE|00000000||tx|1|relation|9|1|C0142825|sodium citrate|orch,phsu|orch|||sodium citrate||||1000|128|141|VERB|AUGMENTS||144|153|5|1|C3179228|Neuromuscular Effect|phsf|phsf|||neuromuscular blocking effect||||901|159|187
SE|00000000||tx|1|relation|11|4|C0057231|decamethonium|orch,phsu|phsu|||decamethonium||||1000|110|122|PREP|TREATS||229|230|3|1|C0030705|Patients|podg,humn|podg|||patients||||1000|232|239


SE|00000000||tx|1|text|Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have The potential of binding thiazide diuretics and reducing diuretic absorption from The gastrointestinal tract
SE|00000000||tx|1|entity|C0009279|Colestipol|orch,phsu|||colestipol||||888|20|29
SE|00000000||tx|1|entity|C0035191|Resins, Plant|bodm|||resins||||888|31|36
SE|00000000||tx|1|entity|C0009279|Colestipol|orch,phsu|||colestipol||||888|58|67
SE|00000000||tx|1|entity|C0035191|Resins, Plant|bodm|||resins||||888|69|74
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|85|93
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||901|106|123
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reducing||||623|129|136
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||623|138|145
SE|00000000||tx|1|entity|C1281182|Entire gastrointestinal tract|bdsy|||gastrointestinal tract||||1000|167|188


SE|00000000||tx|1|text|In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|10|17
SE|00000000||tx|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||1000|25|36
SE|00000000||tx|1|entity|C0028066|Nifedipine|orch,phsu|||nifedipine||||1000|58|67
SE|00000000||tx|1|entity|C1176940|vardenafil 20 MG|clnd|||Vardenafil 20 mg||||1000|70|85
SE|00000000||tx|1|entity|C1524062|Additional|ftcn|||additional||||775|101|110
SE|00000000||tx|1|entity|C0039155|Systole|tmco|||systolic||||775|119|126
SE|00000000||tx|1|entity|C0012000|Diastole|clna|||diastolic||||775|128|136
SE|00000000||tx|1|entity|C0428886|Mean blood pressure|fndg|||mean additional supine systolic/diastolic blood pressure||||775|96|151
SE|00000000||tx|1|entity|C0441610|Reduction - action|topp|||reductions||||775|153|162
SE|00000000||tx|1|entity|C0442749|6/5|fndg|||6/5||||901|167|169
SE|00000000||tx|1|entity|C0439475|mmHg|qnco|||mm Hg||||901|171|175
SE|00000000||tx|1|entity|C1696465|placebo|bodm|||placebo||||1000|189|195
SE|00000000||tx|1|relation|5|1|C0028066|Nifedipine|orch,phsu|phsu|||nifedipine||||1000|58|67|VERB|TREATS||42|51|2|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||1000|25|36


SE|00000000||tx|1|text|The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|5|15
SE|00000000||tx|1|entity|C0332206|Blocking|ftcn|||blocking||||851|37|44
SE|00000000||tx|1|entity|C0205054|Hepatic|blor|||hepatic||||851|46|52
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||851|54|63
SE|00000000||tx|1|entity|C0971579|vardenafil|orch,phsu|||vardenafil||||1000|68|77
SE|00000000||tx|1|entity|C0292818|Ritonavir|orch,phsu|||ritonavir||||1000|82|90
SE|00000000||tx|1|entity|C0205250|High|qlco|||highly||||742|95|100
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||742|102|107
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||742|109|114
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||742|116|124
SE|00000000||tx|1|entity|||gngm|1559|CYP2C9|CYP2C9||||1000|147|152
SE|00000000||tx|1|relation|5|1|C0292818|Ritonavir|orch,phsu|orch|||ritonavir||||1000|82|90|NOM|INHIBITS||116|124|5|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||742|109|114
SE|00000000||tx|1|relation|6|2|C0292818|Ritonavir|orch,phsu|orch|||ritonavir||||1000|82|90|VERB|INHIBITS||138|145|1|1|||gngm,aapp|gngm|1559|CYP2C9|CYP2C9||||1000|147|152


SE|00000000||tx|1|text|Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.
SE|00000000||tx|1|entity|C0022860|Labetalol|orch,phsu|||labetalol||||888|25|33
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium antagonists||||966|62|80
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||694|89|97


SE|00000000||tx|1|text|This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|6|16
SE|00000000||tx|1|entity|C0518609|consideration|fndg|||consideration||||1000|34|46
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|51|58
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||861|67|72
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE-inhibitors||||1000|93|106
SE|00000000||tx|1|relation|2|1|C0518609|consideration|fndg|fndg|||consideration||||1000|34|46|PREP|PROCESS_OF||48|49|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|51|58
SE|00000000||tx|1|relation|2|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs||||861|67|72|VERB|ADMINISTERED_TO||60|65|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|51|58


SE|00000000||tx|1|text|Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.
SE|00000000||tx|1|entity|C1176306|aprepitant|orch,phsu|||Aprepitant||||1000|1|10
SE|00000000||tx|1|entity|C0040808|Treatment Protocols|topp|||regimen||||1000|29|35
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|50|52
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|63|68
SE|00000000||tx|1|entity|C0439228|day|tmco|||Days||||861|73|76
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|101|103
SE|00000000||tx|1|entity|C0025815|Methylprednisolone|horm,phsu,strd|||methylprednisolone||||1000|108|125
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|130|135
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||802|156|159
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|164|166
SE|00000000||tx|1|entity|C0450346|2/5|qnco|||2.5||||901|177|179
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||901|181|184
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|189|191
SE|00000000||tx|1|entity|C0025815|Methylprednisolone|horm,phsu,strd|||methylprednisolone||||1000|201|218
SE|00000000||tx|1|entity|C0439228|day|tmco|||Day||||861|266|268
SE|00000000||tx|1|entity|C0442027|Oral|spco|||orally||||1000|276|281
SE|00000000||tx|1|entity|C0439228|day|tmco|||Days||||861|295|298
SE|00000000||tx|1|relation|6|1|C0025815|Methylprednisolone|horm,phsu,strd|horm|||methylprednisolone||||1000|108|125|NOM|INTERACTS_WITH||137|145|6|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|130|135


SE|00000000||tx|1|text|Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0036572|Seizures|sosy|||Seizure||||888|18|24
SE|00000000||tx|1|entity|C0449864|Threshold|qlco|||Threshold||||888|26|34
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|37|46
SE|00000000||tx|1|entity|C0085934|Wellbutrin|orch,phsu|||WELLBUTRIN||||1000|66|75
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|81|86
SE|00000000||tx|1|entity|C0040615|Antipsychotic Agents|phsu|||antipsychotics||||1000|95|108
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants||||1000|117|131
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|134|145
SE|00000000||tx|1|entity|C2825233|Steroid, Systemic|strd|||systemic steroids||||983|148|164
SE|00000000||tx|1|entity|C1548556|etc.|idcn|||etc||||1000|167|169
SE|00000000||tx|1|entity|C0234976|Lowered convulsive threshold|fndg|||lower seizure threshold||||1000|178|200
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||only||||1000|223|226
SE|00000000||tx|1|entity|C0205403|Extreme|qlco|||extreme||||694|233|239


SE|00000000||tx|1|text|drugs with ototoxic potential: Especially In The presence of impaired renal function, The use of parenterally administered bumetanide In patients to whom aminoglycoside antibiotics are also being given should be avoided, except In life-threatening conditions.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|1|5
SE|00000000||tx|1|entity|C0235280|Ototoxicity|inpo|||ototoxic||||853|12|19
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||853|21|29
SE|00000000||tx|1|entity|C0341697|Renal impairment|dsyn|||impaired renal function||||1000|62|84
SE|00000000||tx|1|entity|C0006376|Bumetanide|orch,phsu|||bumetanide||||827|124|133
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|138|145
SE|00000000||tx|1|entity|C0003233|Antibiotics, Aminoglycoside|antb,carb|||aminoglycoside antibiotics||||1000|155|180
SE|00000000||tx|1|entity|C2826244|Life Threatening|fndg|||life-threatening||||850|232|247
SE|00000000||tx|1|entity|C0348080|Condition|qlco|||conditions||||850|249|258
SE|00000000||tx|1|relation|6|3|C0341697|Renal impairment|dsyn|dsyn|||impaired renal function||||1000|62|84|PREP|PROCESS_OF||135|136|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|138|145


SE|00000000||tx|1|text|Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.
SE|00000000||tx|1|entity|C0252643|bosentan|orch,phsu|||bosentan||||1000|22|29
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|45|65
SE|00000000||tx|1|entity|C0017628|Glyburide|orch,phsu|||glyburide||||1000|70|78
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||888|83|95
SE|00000000||tx|1|entity|C0439509|/40|tmco|||40%||||888|97|99
SE|00000000||tx|1|relation|2|1|C0252643|bosentan|orch,phsu|orch|||bosentan||||1000|22|29|VERB|INHIBITS||31|39|2|2|C0017628|Glyburide|orch,phsu|orch|||glyburide||||1000|70|78


SE|00000000||tx|1|text|In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|4|11
SE|00000000||tx|1|entity|C0009429|Combined Modality Therapy|topp|||concurrent therapy||||1000|23|40
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||1000|47|55
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|61|67
SE|00000000||tx|1|entity|C0724461|Zebeta|orch,phsu|||ZEBETA||||1000|113|118
SE|00000000||tx|1|entity|C0443302|Several|qnco|||several||||888|140|146
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||888|148|151
SE|00000000||tx|1|entity|C2349954|Withdraw (activity)|acty|||withdrawal||||1000|164|173
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||1000|178|186
SE|00000000||tx|1|relation|7|1|C0009429|Combined Modality Therapy|topp|topp|||concurrent therapy||||1000|23|40|VERB|ADMINISTERED_TO||13|21|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|4|11
SE|00000000||tx|1|relation|7|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||1000|61|67|VERB|ADMINISTERED_TO||13|21|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|4|11
SE|00000000||tx|1|relation|2|1|C0009429|Combined Modality Therapy|topp|topp|||concurrent therapy||||1000|23|40|PREP|USES||42|45|6|1|C0009014|Clonidine|orch,phsu|phsu|||clonidine||||1000|47|55
SE|00000000||tx|1|relation|2|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||1000|61|67|PREP|USES||42|45|6|1|C0009014|Clonidine|orch,phsu|phsu|||clonidine||||1000|47|55


SE|00000000||tx|1|text|Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||Furosemide||||1000|1|10
SE|00000000||tx|1|entity|C0008972|Clinical Research|resa|||Clinical studies||||1000|13|28
SE|00000000||tx|1|entity|C0439605|Random|qlco|||random||||888|42|47
SE|00000000||tx|1|entity|C0700325|Patient observation|hlca|||observations||||888|49|60
SE|00000000||tx|1|entity|C0020740|Ibuprofen|orch,phsu|||ibuprofen||||1000|79|87
SE|00000000||tx|1|entity|C3179308|Natriuretic Effect|phsf|||natriuretic effect||||1000|104|121
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|126|135
SE|00000000||tx|1|entity|C0541746|Thiazides|orch,phsu|||thiazides||||1000|141|149
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|159|166
SE|00000000||tx|1|relation|4|1|C0020740|Ibuprofen|orch,phsu|orch|||ibuprofen||||1000|79|87|VERB|DISRUPTS||93|98|4|1|C3179308|Natriuretic Effect|phsf|phsf|||natriuretic effect||||1000|104|121
SE|00000000||tx|1|relation|7|3|C3179308|Natriuretic Effect|phsf|phsf|||natriuretic effect||||1000|104|121|PREP|PROCESS_OF||151|152|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|159|166


SE|00000000||tx|1|text|Beta blockers may exacerbate the hypertensive response seen with clonidine withdrawl.
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||Beta blockers||||1000|1|13
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||694|66|74


SE|00000000||tx|1|text|Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine calcium channel blockers.
SE|00000000||tx|1|entity|C0013604|Edema|patf|||Edema||||1000|1|5
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|28|35
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||1000|61|72
SE|00000000||tx|1|entity|C0012315|Dihydropyridines|orch,phsu|||dihydropyridine||||916|78|92
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium channel blockers||||916|94|117
SE|00000000||tx|1|relation|1|1|C0013604|Edema|patf|patf|||Edema||||1000|1|5|PREP|PROCESS_OF||25|26|3|1|C0030705|Patients|podg,humn|humn|||patients||||861|28|35
SE|00000000||tx|1|relation|2|1|C0064113|Itraconazole|orch,phsu|orch|||Itraconazole||||1000|61|72|VERB|ADMINISTERED_TO||51|59|2|1|C0030705|Patients|podg,humn|humn|||patients||||861|28|35
SE|00000000||tx|1|relation|2|1|C0006684|Calcium Channel Blockers|phsu|phsu|||calcium channel blockers||||916|94|117|VERB|ADMINISTERED_TO||51|59|2|1|C0030705|Patients|podg,humn|humn|||patients||||861|28|35


SE|00000000||tx|1|text|Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics.
SE|00000000||tx|1|entity|C2826293|Clinical Significance|fndg|||clinical significance||||1000|14|34
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|45|51
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|56|58
SE|00000000||tx|1|entity|C0243192|agonists|phsu|||agonists||||861|119|126
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||non||||916|133|135
SE|00000000||tx|1|entity|C0304490|Potassium Sparing Diuretics|phsu|||potassium sparing diuretics||||916|137|163


SE|00000000||tx|1|text|Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|18|26
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|32|39
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|41|47
SE|00000000||tx|1|entity|C0428977|Bradycardia|patf|||bradycardia||||1000|57|67
SE|00000000||tx|1|entity|C0004245|Atrioventricular Block|dsyn|||AV block||||1000|73|80
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|107|114
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||1000|126|134
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|141|146
SE|00000000||tx|1|entity|C0428907|Sinus node function|lbtr|||sinus node function||||1000|164|182
SE|00000000||tx|1|entity|C0004247|Structure of atrioventricular node|bpoc|||AV nodal||||698|187|194
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium channel blockers||||1000|225|248
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blockers||||1000|255|267
SE|00000000||tx|1|relation|5|2|C0004245|Atrioventricular Block|dsyn|dsyn|||AV block||||1000|73|80|PREP|PROCESS_OF||104|105|8|1|C0030705|Patients|podg,humn|humn|||patients||||1000|107|114
SE|00000000||tx|1|relation|5|2|C0428977|Bradycardia|patf|patf|||bradycardia||||1000|57|67|PREP|PROCESS_OF||104|105|8|1|C0030705|Patients|podg,humn|humn|||patients||||1000|107|114
SE|00000000||tx|1|relation|7|1|C0009014|Clonidine|orch,phsu|orch|||clonidine||||1000|126|134|VERB|ADMINISTERED_TO||116|124|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|107|114


SE|00000000||tx|1|text|Oral contraceptives may be less effective while you are taking lymecycline.
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||Oral contraceptives||||1000|1|19
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||888|28|31
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effective||||888|33|41
SE|00000000||tx|1|entity|C1515187|Take|hlca|||taking||||872|57|62
SE|00000000||tx|1|entity|C0024200|Lymecycline|antb,orch|||lymecycline||||872|64|74


SE|00000000||tx|1|text|Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.
SE|00000000||tx|1|entity|C0010868|Cytotoxin|bacs,hops|||Cytotoxic Agents||||1000|1|16
SE|00000000||tx|1|entity|C2349975|Enhance (action)|acty|||Enhanced||||916|19|26
SE|00000000||tx|1|entity|C0280962|bone marrow suppression|inpo|||bone marrow suppression||||916|28|50
SE|00000000||tx|1|entity|C0010583|Cyclophosphamide|opco,phsu|||cyclophosphamide||||1000|55|70
SE|00000000||tx|1|entity|C0010868|Cytotoxin|bacs,hops|||cytotoxic agents||||1000|82|97
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|123|130
SE|00000000||tx|1|entity|C1882062|Neoplastic disease|neop|||neoplastic disease||||1000|137|154
SE|00000000||tx|1|entity|C0023418|leukemia|neop|||leukemia||||1000|164|171
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|193|203
SE|00000000||tx|1|relation|0|0|C0023418|leukemia|neop|neop|||leukemia||||1000|164|171|SPEC|ISA||137|171|0|0|C1882062|Neoplastic disease|neop|neop|||neoplastic disease||||1000|137|154
SE|00000000||tx|1|relation|4|3|C0280962|bone marrow suppression|inpo|inpo|||bone marrow suppression||||916|28|50|PREP|PROCESS_OF||117|121|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|123|130
SE|00000000||tx|1|relation|4|1|C1882062|Neoplastic disease|neop|neop|||neoplastic disease||||1000|137|154|PREP|PROCESS_OF||132|135|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|123|130
SE|00000000||tx|1|relation|7|7|C0010868|Cytotoxin|bacs,hops|bacs|||Cytotoxic Agents||||1000|1|16|NOM|COEXISTS_WITH||181|188|1|1|C0002144|Allopurinol|orch,phsu|orch|||allopurinol||||1000|193|203
SE|00000000||tx|1|relation|7|7|C0010868|Cytotoxin|bacs,hops|bacs|||cytotoxic agents||||1000|82|97|NOM|COEXISTS_WITH||181|188|1|1|C0002144|Allopurinol|orch,phsu|orch|||allopurinol||||1000|193|203
SE|00000000||tx|1|relation|0|0|C0023418|leukemia|neop|neop|||leukemia||||1000|164|171|INFER|PROCESS_OF(SPEC)||137|171|0|0|C0030705|Patients|podg,humn|humn|||patients||||1000|123|130


SE|00000000||tx|1|text|5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
SE|00000000||tx|1|entity|||gngm|3359|HTR3A|5HT3||||861|1|4
SE|00000000||tx|1|entity|C0243076|antagonists|chvf|||Antagonists||||861|6|16
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|28|34
SE|00000000||tx|1|entity|C0439808|Profound|qlco|||profound||||888|39|46
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||888|48|58
SE|00000000||tx|1|entity|C1517945|Loss|qnco|||loss||||1000|64|67
SE|00000000||tx|1|entity|C0234421|Conscious|menp|||consciousness||||1000|72|84
SE|00000000||tx|1|entity|C0003596|Apomorphine|orch,phsu|||apomorphine||||1000|91|101
SE|00000000||tx|1|entity|C0061851|Ondansetron|orch,phsu|||ondansetron||||1000|125|135
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|142|152
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|154|156
SE|00000000||tx|1|entity|C0003596|Apomorphine|orch,phsu|||apomorphine||||1000|161|171
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|178|182
SE|00000000||tx|1|entity|C2936526|Serotonin 5-HT3 Receptor Antagonists|phsu|||5HT3 antagonist||||916|191|205
SE|00000000||tx|1|entity|C0456387|Class|inpr|||class||||916|207|211
SE|00000000||tx|1|entity|C1707959|Example|cnce|||example||||1000|229|235
SE|00000000||tx|1|entity|C0061851|Ondansetron|orch,phsu|||ondansetron||||1000|238|248
SE|00000000||tx|1|entity|C0061863|Granisetron|orch,phsu|||granisetron||||1000|251|261
SE|00000000||tx|1|entity|C0209210|Dolasetron|orch,phsu|||dolasetron||||1000|264|273
SE|00000000||tx|1|entity|C0220578|palonosetron|orch,phsu|||palonosetron||||1000|276|287
SE|00000000||tx|1|entity|C0291772|alosetron|orch,phsu|||alosetron||||1000|294|302


SE|00000000||tx|1|text|Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||Antacids||||1000|1|8
SE|00000000||tx|1|entity|C0718690|aspirin enteric coated|orch,phsu|||Enteric Coated Aspirin||||1000|11|32
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|41|43
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|72|79
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|91|98
SE|00000000||tx|1|entity|C0038351|Stomach|bpoc|||stomach||||1000|117|123
SE|00000000||tx|1|entity|C1304890|Enteral|spco|||enteric||||861|140|146
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||1000|163|169
SE|00000000||tx|1|relation|6|1|C0003138|Antacids|phsu|phsu|||antacids||||1000|72|79|VERB|COEXISTS_WITH||48|52|2|1|C0718690|aspirin enteric coated|orch,phsu|orch|||Enteric Coated Aspirin||||1000|11|32


SE|00000000||tx|1|text|Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|10|12
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|31|35
SE|00000000||tx|1|entity|C0879626|Adverse effects|patf|||adverse effects||||1000|38|52
SE|00000000||tx|1|entity|C0007716|Cephalexin|antb,orch|||cephalexin||||1000|104|113
SE|00000000||tx|1|entity|C0025598|Metformin|orch,phsu|||metformin||||1000|119|127
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|132|141
SE|00000000||tx|1|entity|C0232819|Tubular secretion|ortf|||tubular secretion||||1000|146|162
SE|00000000||tx|1|entity|C1335132|Organic Cation Transporter|aapp,bacs|||organic cationic transporter||||890|168|195
SE|00000000||tx|1|entity|C0449913|System|ftcn|||systems||||890|197|203
SE|00000000||tx|1|relation|5|1|C0025598|Metformin|orch,phsu|orch|||metformin||||1000|119|127|NOM|INHIBITS||132|141|2|1|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|146|162
SE|00000000||tx|1|relation|5|1|C0007716|Cephalexin|antb,orch|orch|||cephalexin||||1000|104|113|NOM|INHIBITS||132|141|2|1|C0232819|Tubular secretion|ortf|ortf|||tubular secretion||||1000|146|162


SE|00000000||tx|1|text|However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||901|19|24
SE|00000000||tx|1|entity|C0444505|Peak level|qnco|||peak plasma level||||901|14|30
SE|00000000||tx|1|entity|C0025598|Metformin|orch,phsu|||metformin||||1000|35|43
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|60|72
SE|00000000||tx|1|entity|C1515187|Take|hlca|||taking||||872|83|88
SE|00000000||tx|1|entity|C0050393|Acarbose|carb,phsu|||Acarbose||||872|90|97
SE|00000000||tx|1|entity|C2945599|Mild (qualifier value)|qlco|||slight||||888|108|113
SE|00000000||tx|1|entity|C0205421|Deferred|tmco|||delay||||888|115|119
SE|00000000||tx|1|entity|C0025598|Metformin|orch,phsu|||metformin||||1000|142|150


SE|00000000||tx|1|text|Potential drug interactions for doxylamine include, increased sedation if doxylamine is combined with other CNS depressant drugs.
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||Potential||||901|1|9
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interactions||||901|11|27
SE|00000000||tx|1|entity|C0013092|Doxylamine|orch,phsu|||doxylamine||||1000|33|42
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||888|53|61
SE|00000000||tx|1|entity|C0600097|Sedation|sosy|||sedation||||888|63|70
SE|00000000||tx|1|entity|C0013092|Doxylamine|orch,phsu|||doxylamine||||1000|75|84
SE|00000000||tx|1|entity|C0007680|Central Nervous System Agents|phsu|||CNS depressant drugs||||913|109|128
SE|00000000||tx|1|relation|1|1|C0007680|Central Nervous System Agents|phsu|phsu|||CNS depressant drugs||||913|109|128|VERB|COEXISTS_WITH||89|96|4|1|C0013092|Doxylamine|orch,phsu|orch|||doxylamine||||1000|75|84


SE|00000000||tx|1|text|This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|6|16
SE|00000000||tx|1|entity|C0518609|consideration|fndg|||consideration||||1000|34|46
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|51|58
SE|00000000||tx|1|entity|C0719198|Celebrex|orch,phsu|||CELEBREX||||861|67|74
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE-inhibitors||||1000|95|108
SE|00000000||tx|1|relation|2|1|C0518609|consideration|fndg|fndg|||consideration||||1000|34|46|PREP|PROCESS_OF||48|49|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|51|58
SE|00000000||tx|1|relation|2|1|C0719198|Celebrex|orch,phsu|orch|||CELEBREX||||861|67|74|VERB|ADMINISTERED_TO||60|65|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|51|58


SE|00000000||tx|1|text|Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.
SE|00000000||tx|1|entity|C0209738|Lamivudine|nnon,phsu|||Lamivudine||||1000|1|10
SE|00000000||tx|1|entity|C0012132|Zalcitabine|nnon,phsu|||zalcitabine||||1000|16|26
SE|00000000||tx|1|entity|C0175996|Protoplasm|celc|||intracellular||||888|44|56
SE|00000000||tx|1|entity|C0031715|Phosphorylation|moft|||phosphorylation||||888|58|72
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||1000|77|79
SE|00000000||tx|1|relation|2|1|C0012132|Zalcitabine|nnon,phsu|phsu|||zalcitabine||||1000|16|26|VERB|DISRUPTS||32|38|2|1|C0031715|Phosphorylation|moft|moft|||phosphorylation||||888|58|72
SE|00000000||tx|1|relation|2|1|C0209738|Lamivudine|nnon,phsu|phsu|||Lamivudine||||1000|1|10|VERB|DISRUPTS||32|38|2|1|C0031715|Phosphorylation|moft|moft|||phosphorylation||||888|58|72


SE|00000000||tx|1|text|Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.
SE|00000000||tx|1|entity|C0042528|Veratrum Alkaloids|orch,phsu|||Veratrum alkaloids||||1000|1|18
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||Amphetamines||||1000|21|32
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|46|56
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|58|63
SE|00000000||tx|1|entity|C0042528|Veratrum Alkaloids|orch,phsu|||veratrum alkaloids||||1000|68|85
SE|00000000||tx|1|relation|1|1|C0042528|Veratrum Alkaloids|orch,phsu|orch|||veratrum alkaloids||||1000|68|85|NOM|AFFECTS||58|63|2|0|C0857353|Hypotensive|patf|patf|||hypotensive||||888|46|56


SE|00000000||tx|1|text|Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||Propranolol||||1000|1|11
SE|00000000||tx|1|entity|C0018810|heart rate|orga|||heart rate||||901|28|37
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||901|39|46
SE|00000000||tx|1|entity|C0205253|Immediate|tmco|||immediate||||851|76|84
SE|00000000||tx|1|entity|C0391871|Released (action)|ftcn|||release||||851|86|92
SE|00000000||tx|1|entity|C0028116|Nisoldipine|orch,phsu|||nisoldipine||||851|94|104


SE|00000000||tx|1|text|Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||Marked||||861|1|6
SE|00000000||tx|1|entity|C0231220|Symptomatic|ftcn|||symptomatic||||861|8|18
SE|00000000||tx|1|entity|C0020651|Hypotension, Orthostatic|fndg|||orthostatic hypotension||||861|20|42
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium channel blockers||||1000|67|90
SE|00000000||tx|1|entity|C0747055|Organic|qlco|||organic||||888|96|102
SE|00000000||tx|1|entity|C0028125|Nitrates|chvs|||nitrates||||888|104|111
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|126|136


SE|00000000||tx|1|text|Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high doses||||983|36|45
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|50|59
SE|00000000||tx|1|entity|C0585361|Twice a day|tmco|||twice daily||||824|69|79
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|96|99
SE|00000000||tx|1|entity|C0762662|rofecoxib|orch,phsu|||rofecoxib||||1000|104|112
SE|00000000||tx|1|entity|C0450348|23|qnco|||23%||||1000|140|142


SE|00000000||tx|1|text|A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|13|20
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|25|27
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||1000|33|36
SE|00000000||tx|1|entity|C0028116|Nisoldipine|orch,phsu|||nisoldipine||||1000|41|51
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|71|81
SE|00000000||tx|1|entity|C0984915|Cimetidine 400 MG|clnd|||cimetidine 400 mg||||893|101|117
SE|00000000||tx|1|entity|C0585361|Twice a day|tmco|||twice daily||||893|119|129


SE|00000000||tx|1|text|Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.
SE|00000000||tx|1|entity|C0040284|Tissue culture|lbpr|||Tissue culture||||1000|1|14
SE|00000000||tx|1|entity|C0683949|Animal Study|anim|||animal studies||||1000|20|33
SE|00000000||tx|1|entity|C0699262|Elspar|aapp,enzy,phsu|||ELSPAR||||1000|49|54
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|84|89
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||1000|94|105
SE|00000000||tx|1|entity|C2698007|Malignant Cell Count|lbpr|||malignant cells||||901|110|124
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|134|139
SE|00000000||tx|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate||||888|144|155
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||888|157|164
SE|00000000||tx|1|entity|C0205166|Long|qlco|||long||||1000|178|181
SE|00000000||tx|1|entity|C1271686|Plasma asparagine measurement|lbpr|||plasma asparagine levels||||988|186|209


SE|00000000||tx|1|text|Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.
SE|00000000||tx|1|entity|C0591189|Brevibloc|orch,phsu|||BREVIBLOC||||1000|57|65
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||1000|71|79
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|84|91
SE|00000000||tx|1|entity|C1522564|Myocardial|spco|||myocardial||||790|108|117
SE|00000000||tx|1|entity|C0031843|physiological aspects|phsf|||function||||790|119|126
SE|00000000||tx|1|relation|4|1|C0042523|Verapamil|orch,phsu|phsu|||verapamil||||1000|71|79|PREP|TREATS||81|82|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|84|91
SE|00000000||tx|1|relation|4|1|C0591189|Brevibloc|orch,phsu|phsu|||BREVIBLOC||||1000|57|65|PREP|TREATS||81|82|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|84|91


SE|00000000||tx|1|text|Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||Corticosteroids||||1000|1|15
SE|00000000||tx|1|entity|C0066447|methylxanthine|orch,phsu|||Methylxanthines||||1000|18|32
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||Diuretics||||1000|38|46
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|49|59
SE|00000000||tx|1|entity|C1718515|Xanthine derivatives|bacs,orch|||xanthine derivatives||||1000|76|95
SE|00000000||tx|1|entity|C0038317|Steroids|strd|||steroids||||1000|98|105
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|111|119
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||828|138|145
SE|00000000||tx|1|entity|C0020621|Hypokalemia|fndg|||hypokalemic||||828|147|157
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||828|159|164
SE|00000000||tx|1|entity|C1417683|NEUROD1 gene|gngm|4760|NEUROD1|beta2||||888|170|174
SE|00000000||tx|1|entity|C0243192|agonists|phsu|||agonists||||888|176|183
SE|00000000||tx|1|relation|7|2|C0038317|Steroids|strd|strd|||steroids||||1000|98|105|NOM|INTERACTS_WITH||159|164|1|1|C0243192|agonists|phsu|phsu|||agonists||||888|176|183


SE|00000000||tx|1|text|Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||Barbiturates||||1000|1|12
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|15|27
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|34|42
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||1000|57|65
SE|00000000||tx|1|entity|C0013090|Doxycycline|antb,orch|||doxycycline||||1000|70|80


SE|00000000||tx|1|text|ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.
SE|00000000||tx|1|entity|C0001962|Ethanol|orch|||ETHANOL||||825|1|7
SE|00000000||tx|1|entity|C0392209|Nutritional status|orga|||NUTRITION||||825|11|19
SE|00000000||tx|1|entity|C0019240|Herb|plnt|||HERB||||825|23|26
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||INTERACTIONS||||825|28|39
SE|00000000||tx|1|entity|C0016452|Food|food|||Food||||1000|42|45
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||861|52|58
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|63|70
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||833|91|101
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||833|103|110
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||833|112|125
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|154|161
SE|00000000||tx|1|relation|3|2|C0009871|Contraceptive Agents|phsu|phsu|||contraceptives||||833|112|125|NOM|INTERACTS_WITH||52|58|3|1|C0006644|Caffeine|orch,phsu|orch|||caffeine||||1000|63|70


SE|00000000||tx|1|text|Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||Thiazide Diuretics||||1000|1|18
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|25|31
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|42|52
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|54|56
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|61|71
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|77|94
SE|00000000||tx|1|entity|C2349975|Enhance (action)|acty|||enhancement||||1000|118|128
SE|00000000||tx|1|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||888|133|143
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||888|145|152
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|162|169
SE|00000000||tx|1|entity|C1516084|Attempt|evnt|||attempt||||861|196|202
SE|00000000||tx|1|entity|C0015127|Etiology aspects|ftcn|||cause||||1000|219|223
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|229|234
SE|00000000||tx|1|entity|C0439849|Relationships|qlco|||relationship||||888|236|247
SE|00000000||tx|1|entity|C1524003|Science of Etiology|cnce|||causation||||1000|268|276
SE|00000000||tx|1|relation|5|1|C0012802|Thiazide Diuretics|orch,phsu|orch|||thiazide diuretics||||1000|77|94|NOM|AUGMENTS||118|128|7|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||888|145|152
SE|00000000||tx|1|relation|5|1|C0012802|Thiazide Diuretics|orch,phsu|orch|||Thiazide Diuretics||||1000|1|18|NOM|AUGMENTS||118|128|7|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||888|145|152
SE|00000000||tx|1|relation|7|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||888|145|152|PREP|PROCESS_OF||154|155|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|162|169


SE|00000000||tx|1|text|In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase In The serum creatinine level) has been reported In organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate.
SE|00000000||tx|1|entity|C1853237|Isolated cases|fndg|||isolated cases||||1000|4|17
SE|00000000||tx|1|entity|C0205343|Reversible|ftcn|||reversible||||888|40|49
SE|00000000||tx|1|entity|C0232804|Renal function|ortf|||renal function||||1000|66|79
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|113|120
SE|00000000||tx|1|entity|C0600061|Serum creatinine level|lbtr|||serum creatinine level||||1000|129|150
SE|00000000||tx|1|entity|C0029216|Organ Transplantation|topp|||organ transplant||||901|174|189
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||901|191|198
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||therapy||||827|229|235
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|241|251
SE|00000000||tx|1|entity|C0005330|Bezafibrate|orch,phsu|||bezafibrate||||888|253|263
SE|00000000||tx|1|relation|6|3|C0232804|Renal function|ortf|ortf|||renal function||||1000|66|79|PREP|PROCESS_OF||171|172|3|1|C0030705|Patients|podg,humn|humn|||patients||||901|191|198
SE|00000000||tx|1|relation|2|1|C0087111|Therapeutic procedure|topp|topp|||therapy||||827|229|235|VERB|ADMINISTERED_TO||200|208|7|1|C0030705|Patients|podg,humn|humn|||patients||||901|191|198
SE|00000000||tx|1|relation|2|1|C0005330|Bezafibrate|orch,phsu|orch|||bezafibrate||||888|253|263|VERB|ADMINISTERED_TO||200|208|7|1|C0030705|Patients|podg,humn|humn|||patients||||901|191|198


SE|00000000||tx|1|text|Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|7|17
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||enoxacin||||1000|37|44
SE|00000000||tx|1|entity|C0053792|bismuth subsalicylate|orch,phsu|||bismuth subsalicylate||||1000|50|70


SE|00000000||tx|1|text|Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|32|34
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|74|78
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|111|116
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium channel blockers||||1000|123|146
SE|00000000||tx|1|entity|C0010980|Dapsone|orch,phsu|||dapsone||||1000|149|155
SE|00000000||tx|1|entity|C0012702|Disopyramide|orch,phsu|||disopyramide||||1000|158|169
SE|00000000||tx|1|entity|C0034417|Quinine|orch,phsu|||quinine||||1000|172|178
SE|00000000||tx|1|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||1000|181|190
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|193|201
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|204|211
SE|00000000||tx|1|entity|C0085149|Tacrolimus|orch,phsu|||tacrolimus||||1000|214|223
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|226|237
SE|00000000||tx|1|entity|C0870507|Ergot Derivative [EPC]|orch,phsu|||ergot derivatives||||1000|240|256
SE|00000000||tx|1|entity|C0031935|Pimozide|orch,phsu|||pimozide||||1000|259|266
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|269|281
SE|00000000||tx|1|entity|C0015846|Fentanyl|orch,phsu|||fentanyl||||1000|284|291
SE|00000000||tx|1|entity|C0002026|Alfentanil|orch,phsu|||alfentanyl||||1000|294|303
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|306|315
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||triazolam||||1000|322|330
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||890|342|349
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|351|371
SE|00000000||tx|1|entity|C0286738|Saquinavir|orch,phsu|||saquinavir||||1000|398|407
SE|00000000||tx|1|relation|20|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|111|116|VERB|INTERACTS_WITH||96|106|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|74|78


SE|00000000||tx|1|text|The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
SE|00000000||tx|1|entity|C0020616|Hypoglycemic Agents|phsu|||hypoglycemic||||888|5|16
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||888|18|23
SE|00000000||tx|1|entity|C0038766|Sulfonylurea Compounds|orch,phsu|||sulfonylureas||||1000|28|40
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||888|64|70
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|72|76
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory agents||||1000|88|124
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|136|140
SE|00000000||tx|1|entity|C0205250|High|qlco|||highly||||888|151|156
SE|00000000||tx|1|entity|C0033684|Proteins|aapp,bacs|||protein||||888|158|164
SE|00000000||tx|1|entity|C0036077|Salicylates|orch,phsu|||salicylates||||1000|173|183
SE|00000000||tx|1|entity|C0038760|Sulfonamides|orch,phsu|||sulfonamides||||1000|186|197
SE|00000000||tx|1|entity|C0008168|Chloramphenicol|antb,orch|||chloramphenicol||||1000|200|214
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|217|226
SE|00000000||tx|1|entity|C0010207|Coumarins|orch,phsu|||coumarins||||1000|229|237
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|240|267
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta adrenergic blocking agents||||1000|274|304
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory agents||||1000|88|124|SPEC|ISA||88|140|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|136|140
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory agents||||1000|88|124|SPEC|ISA||88|140|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|72|76
SE|00000000||tx|1|relation|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta adrenergic blocking agents||||1000|274|304|SPEC|ISA||88|140|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|136|140
SE|00000000||tx|1|relation|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta adrenergic blocking agents||||1000|274|304|SPEC|ISA||88|140|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|72|76
SE|00000000||tx|1|relation|0|0|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein||||888|158|164|SPEC|ISA||136|164|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|136|140
SE|00000000||tx|1|relation|0|0|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein||||888|158|164|SPEC|ISA||136|164|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|72|76
SE|00000000||tx|1|relation|11|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|72|76|VERB|STIMULATES||49|59|2|1|C0038766|Sulfonylurea Compounds|orch,phsu|orch|||sulfonylureas||||1000|28|40
SE|00000000||tx|1|relation|11|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|136|140|VERB|STIMULATES||49|59|2|1|C0038766|Sulfonylurea Compounds|orch,phsu|orch|||sulfonylureas||||1000|28|40
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory agents||||1000|88|124|INFER|STIMULATES(SPEC)||88|140|0|0|C0038766|Sulfonylurea Compounds|orch,phsu|orch|||sulfonylureas||||1000|28|40
SE|00000000||tx|1|relation|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory agents||||1000|88|124|INFER|STIMULATES(SPEC)||88|140|0|0|C0038766|Sulfonylurea Compounds|orch,phsu|orch|||sulfonylureas||||1000|28|40
SE|00000000||tx|1|relation|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta adrenergic blocking agents||||1000|274|304|INFER|STIMULATES(SPEC)||88|140|0|0|C0038766|Sulfonylurea Compounds|orch,phsu|orch|||sulfonylureas||||1000|28|40
SE|00000000||tx|1|relation|0|0|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta adrenergic blocking agents||||1000|274|304|INFER|STIMULATES(SPEC)||88|140|0|0|C0038766|Sulfonylurea Compounds|orch,phsu|orch|||sulfonylureas||||1000|28|40
SE|00000000||tx|1|relation|0|0|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein||||888|158|164|INFER|STIMULATES(SPEC)||136|164|0|0|C0038766|Sulfonylurea Compounds|orch,phsu|orch|||sulfonylureas||||1000|28|40
SE|00000000||tx|1|relation|0|0|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein||||888|158|164|INFER|STIMULATES(SPEC)||136|164|0|0|C0038766|Sulfonylurea Compounds|orch,phsu|orch|||sulfonylureas||||1000|28|40


SE|00000000||tx|1|text|The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|5|10
SE|00000000||tx|1|entity|C0038766|Sulfonylurea Compounds|orch,phsu|||sulphonylureas||||1000|15|28
SE|00000000||tx|1|entity|C0021641|Insulin|aapp,horm,phsu|||insulin||||1000|34|40
SE|00000000||tx|1|entity|C0591179|Bezalip|orch,phsu|||Bezalip||||1000|61|67
SE|00000000||tx|1|entity|C0591179|Bezalip|orch,phsu|||Bezalip||||1000|72|78
SE|00000000||tx|1|relation|2|1|C0591179|Bezalip|orch,phsu|orch|||Bezalip||||1000|61|67|VERB|STIMULATES||49|56|3|1|C0021641|Insulin|aapp,gngm,horm,phsu|gngm|||insulin||||1000|34|40
SE|00000000||tx|1|relation|2|1|C0591179|Bezalip|orch,phsu|orch|||Bezalip||||1000|61|67|VERB|STIMULATES||49|56|3|1|C0038766|Sulfonylurea Compounds|orch,phsu|orch|||sulphonylureas||||1000|15|28


SE|00000000||tx|1|text|Patients taking disopyramide phosphate and erythromycin concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0700534|Disopyramide Phosphate|orch,phsu|||disopyramide phosphate||||1000|17|38
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||861|44|55
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||890|83|91
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentrations||||890|93|112
SE|00000000||tx|1|entity|C0012702|Disopyramide|orch,phsu|||disopyramide||||1000|117|128
SE|00000000||tx|1|entity|C0442802|Excessive|qlco|||excessive||||888|143|151
SE|00000000||tx|1|entity|C0332464|Widening|spco|||widening||||888|153|160
SE|00000000||tx|1|entity|C0439855|Complex|qlco|||complex||||861|173|179
SE|00000000||tx|1|entity|C0429028|QT interval feature (observable entity)|clna|||Q-T interval||||1000|208|219
SE|00000000||tx|1|relation|8|1|C0700534|Disopyramide Phosphate|orch,phsu|orch|||disopyramide phosphate||||1000|17|38|VERB|ADMINISTERED_TO||10|15|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8


SE|00000000||tx|1|text|Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.
SE|00000000||tx|1|entity|C1533685|Injection procedure|topp|||Injection||||1000|1|9
SE|00000000||tx|1|entity|C2092263|lorazepam injection|clnd|||Lorazepam injection||||1000|12|30
SE|00000000||tx|1|entity|C1272883|Injection product|bodm|||injectable||||888|44|53
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||888|55|69
SE|00000000||tx|1|entity|C0344315|Depressed mood|fndg|||depression||||1000|81|90
SE|00000000||tx|1|entity|C0927232|Neuraxis|bdsy|||central nervous system||||1000|99|120
SE|00000000||tx|1|entity|C0001962|Ethanol|orch|||ethyl alcohol||||1000|145|157
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|160|173
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|176|187
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitors||||1000|190|203
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants||||1000|216|230
SE|00000000||tx|1|relation|0|0|C2092263|lorazepam injection|clnd|clnd|||Lorazepam injection||||1000|12|30|SPEC|ISA||12|69|0|0|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||888|55|69
SE|00000000||tx|1|relation|0|0|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||MAO inhibitors||||1000|190|203|SPEC|ISA||190|230|0|0|C0003289|Antidepressive Agents|phsu|phsu|||antidepressants||||1000|216|230
SE|00000000||tx|1|relation|0|0|C0003289|Antidepressive Agents|phsu|phsu|||antidepressants||||1000|216|230|SPEC|ISA||190|230|0|0|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|phsu|||MAO inhibitors||||1000|190|203
SE|00000000||tx|1|relation|3|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||888|55|69|VERB|CAUSES||72|79|7|1|C0344315|Depressed mood|fndg|fndg|||depression||||1000|81|90
SE|00000000||tx|1|relation|0|0|C2092263|lorazepam injection|clnd|clnd|||Lorazepam injection||||1000|12|30|INFER|CAUSES(SPEC)||12|69|0|0|C0344315|Depressed mood|fndg|fndg|||depression||||1000|81|90

SE|00000000||tx|2|text|When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
SE|00000000||tx|2|entity|C0036442|Scopolamine|orch,phsu|||scopolamine||||1000|6|16
SE|00000000||tx|2|entity|C1272883|Injection product|bodm|||injectable||||888|45|54
SE|00000000||tx|2|entity|C0024002|Lorazepam|orch,phsu|||lorazepam||||888|56|64
SE|00000000||tx|2|entity|C0442805|Increase|ftcn|||increased||||888|70|78
SE|00000000||tx|2|entity|C0021149|Incidence|qnco|||incidence||||888|80|88
SE|00000000||tx|2|entity|C0600097|Sedation|sosy|||sedation||||1000|93|100
SE|00000000||tx|2|entity|C0018524|Hallucinations|mobd|||hallucinations||||1000|103|116
SE|00000000||tx|2|entity|C0542058|IRRATIONAL|fndg|||irrational||||888|123|132
SE|00000000||tx|2|entity|C0004927|Behavior|inbe|||behavior||||888|134|141


SE|00000000||tx|1|text|Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||Carbamazepine||||1000|1|13
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||Isoniazid||||1000|16|24
SE|00000000||tx|1|entity|C0439834|Slow|qlco|||slow||||1000|38|41
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|47|56
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|61|73
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||597|92|96
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||Carbamazepine||||597|105|117
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|156|165
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|187|195
SE|00000000||tx|1|entity|C0311392|Physical findings|fndg|||signs||||1000|198|202
SE|00000000||tx|1|entity|C1457887|Symptoms|sosy|||symptoms||||1000|208|215
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||888|220|232
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||888|234|241
SE|00000000||tx|1|entity|C1548787|Appropriate|qlco|||appropriate||||623|276|286
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||623|288|293
SE|00000000||tx|1|entity|C0003286|Anticonvulsants|phsu|||anticonvulsant||||1000|313|326
SE|00000000||tx|1|relation|5|1|C0006949|Carbamazepine|orch,phsu|orch|||carbamazepine||||1000|61|73|VERB|STIMULATES||79|86|8|1|C0006949|Carbamazepine|orch,phsu|orch|||Carbamazepine||||597|105|117


SE|00000000||tx|1|text|and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||Videx||||1000|5|9
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||Didanosine||||1000|14|23
SE|00000000||tx|1|entity|C0006353|Buffers|irda,phsu|||buffered||||901|36|43
SE|00000000||tx|1|entity|C0304290|Chewable Tablet|bodm|||chewable/buffered tablets||||901|27|51
SE|00000000||tx|1|entity|C1521725|Pediatric|qlco|||pediatric||||694|60|68
SE|00000000||tx|1|entity|C0991536|Oral Solution|bodm|||oral solution||||1000|81|93
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolones||||1000|146|155
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||694|171|178
SE|00000000||tx|1|relation|0|0|C0592249|Videx|nnon,phsu|nnon|||Videx||||1000|5|9|SPEC|ISA||5|23|0|0|C0012133|Didanosine|nnon,phsu|nnon|||Didanosine||||1000|14|23


SE|00000000||tx|1|text|When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.
SE|00000000||tx|1|entity|C0245561|duloxetine|orch,phsu|||duloxetine||||1000|6|15
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||1000|40|43
SE|00000000||tx|1|entity|C0048106|4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate|orch,phsu|||BID||||773|54|56
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||775|81|86
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||775|94|97
SE|00000000||tx|1|entity|C0011685|Desipramine|orch,phsu|||desipramine||||1000|102|112
SE|00000000||tx|1|entity|C1332830|CYP2D6 gene|gngm|1565|CYP2D6|CYP2D6||||694|117|122
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|139|141
SE|00000000||tx|1|entity|C0011685|Desipramine|orch,phsu|||desipramine||||1000|146|156
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||861|170|173
SE|00000000||tx|1|relation|5|1|C0011685|Desipramine|orch,phsu|orch|||desipramine||||1000|102|112|NOM|INTERACTS_WITH||124|132|5|0|C1332830|CYP2D6 gene|gngm,aapp|gngm|1565|CYP2D6|CYP2D6||||694|117|122


SE|00000000||tx|1|text|It is suggested to monitor both ketoconazole and phenytoin.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|33|44
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|50|58


SE|00000000||tx|1|text|however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|24|29
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|32|42
SE|00000000||tx|1|entity|C0700001|Lodine|orch,phsu|||Lodine||||1000|62|67
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|73|79
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|84|86
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|125|133
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||901|138|146
SE|00000000||tx|1|entity|C0879626|Adverse effects|patf|||adverse effects||||901|148|162


SE|00000000||tx|1|text|Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
SE|00000000||tx|1|entity|C0592157|Tagamet|orch,phsu|||Tagamet||||1000|1|7
SE|00000000||tx|1|entity|C0750541|apparently|idcn|||apparently||||1000|10|19
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|32|37
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||844|42|48
SE|00000000||tx|1|entity|C0815014|microsomal enzymes|aapp,enzy|||microsomal enzyme||||844|50|66
SE|00000000||tx|1|entity|C0449913|System|ftcn|||systems||||844|68|74
SE|00000000||tx|1|entity|C0205054|Hepatic|blor|||hepatic||||888|109|115
SE|00000000||tx|1|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|117|126
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||802|131|138
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||802|145|158
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|161|169
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||1000|172|182
SE|00000000||tx|1|entity|C0028066|Nifedipine|orch,phsu|||nifedipine||||1000|185|194
SE|00000000||tx|1|entity|C0008188|Chlordiazepoxide|orch,phsu|||chlordiazepoxide||||1000|197|212
SE|00000000||tx|1|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|215|222
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||901|225|231
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||901|233|257
SE|00000000||tx|1|entity|C0023660|Lidocaine|orch,phsu|||lidocaine||||1000|260|268
SE|00000000||tx|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|271|282
SE|00000000||tx|1|entity|C0025872|Metronidazole|orch,phsu|||metronidazole||||1000|288|300
SE|00000000||tx|1|entity|C0442808|Increasing|ftcn|||increasing||||790|336|345
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||790|347|351
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|369|373
SE|00000000||tx|1|relation|15|4|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|161|169|NOM|INTERACTS_WITH||32|37|15|1|C0815014|microsomal enzymes|aapp,gngm,enzy|aapp|||microsomal enzyme||||844|50|66
SE|00000000||tx|1|relation|15|2|C0025872|Metronidazole|orch,phsu|orch|||metronidazole||||1000|288|300|ADJ|STIMULATES||336|345|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|369|373


SE|00000000||tx|1|text|The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.
SE|00000000||tx|1|entity|C0036043|Safety|hcpp|||safety||||1000|5|10
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|16|23
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|28|38
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|40|42
SE|00000000||tx|1|entity|C0591842|ReVia|orch,phsu|||REVIA||||1000|47|51
SE|00000000||tx|1|entity|C0012772|Disulfiram|orch,phsu|||disulfiram||||1000|57|66
SE|00000000||tx|1|entity|C0439673|Unknown|qlco|||unknown||||1000|71|77
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|88|98
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|100|102
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||751|107|109
SE|00000000||tx|1|entity|C0235378|Hepatotoxicity|inpo|||hepatotoxic||||751|123|133
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||751|135|145
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|150|152
SE|00000000||tx|1|entity|C0033204|Probability|qnco|||probable||||888|188|195
SE|00000000||tx|1|entity|C0814225|Benefits|qnco|||benefits||||888|197|204
SE|00000000||tx|1|entity|C0205309|Known|qlco|||known||||888|219|223
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risks||||888|225|229
SE|00000000||tx|1|relation|0|0|C0012772|Disulfiram|orch,phsu|orch|||disulfiram||||1000|57|66|SPEC|ISA||57|145|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||751|135|145
SE|00000000||tx|1|relation|0|0|C0591842|ReVia|orch,phsu|orch|||REVIA||||1000|47|51|SPEC|ISA||57|145|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||751|135|145


SE|00000000||tx|1|text|When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics.
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||888|37|45
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|47|51
SE|00000000||tx|1|entity|C0597357|receptor|aapp,rcpt|||receptor||||928|87|94
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic receptor blocking agents||||928|71|110
SE|00000000||tx|1|entity|C0002932|Anesthetics|phsu|||Anesthetics||||1000|113|123
SE|00000000||tx|1|entity|C0205246|Generalized|spco|||general||||1000|126|132
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||1000|155|165
SE|00000000||tx|1|entity|C0017302|General anesthetic drugs|phsu|||general anesthetics||||1000|178|196
SE|00000000||tx|1|relation|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|47|51|VERB|INTERACTS_WITH||57|64|6|1|C0001645|Adrenergic beta-Antagonists|phsu|phsu|||beta-adrenergic receptor blocking agents||||928|71|110
SE|00000000||tx|1|relation|1|1|C0017302|General anesthetic drugs|phsu|phsu|||general anesthetics||||1000|178|196|VERB|CAUSES||167|173|6|1|C0020649|Hypotension|fndg|fndg|||hypotension||||1000|155|165


SE|00000000||tx|1|text|Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.
SE|00000000||tx|1|entity|C0021853|Intestines|bpoc|||Intestinal||||888|1|10
SE|00000000||tx|1|entity|C0350056|Adsorbents|phsu|||adsorbents||||888|12|21
SE|00000000||tx|1|entity|C0007955|Charcoal|elii,phsu|||charcoal||||1000|31|38
SE|00000000||tx|1|entity|C0544420|Digestive Enzymes|aapp,enzy,phsu|||digestive enzyme preparations||||988|45|73
SE|00000000||tx|1|entity|C0007004|Carbohydrates|carb|||carbohydrate||||851|86|97
SE|00000000||tx|1|entity|C1881714|Medical Device Material Split|phpr|||splitting||||851|99|107
SE|00000000||tx|1|entity|C0014442|Enzymes|enzy,orch|||enzymes||||851|109|115
SE|00000000||tx|1|entity|C0002712|Amylases|aapp,enzy,phsu|||amylase||||1000|125|131
SE|00000000||tx|1|entity|C0030304|Pancreatin|aapp,enzy,phsu|||pancreatin||||1000|134|143
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|161|166
SE|00000000||tx|1|entity|C0050393|Acarbose|carb,phsu|||Acarbose||||1000|171|178
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|191|193
SE|00000000||tx|1|relation|8|1|C0030304|Pancreatin|aapp,gngm,enzy,phsu|aapp|||pancreatin||||1000|134|143|NOM|INTERACTS_WITH||161|166|1|1|C0050393|Acarbose|carb,phsu|carb|||Acarbose||||1000|171|178


SE|00000000||tx|1|text|Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.
SE|00000000||tx|1|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||HMG-CoA reductase inhibitor||||1000|35|61
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|98|102
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||1000|136|143
SE|00000000||tx|1|entity|C0205227|Endogenous|ftcn|||endogenous||||901|148|157
SE|00000000||tx|1|entity|C0301818|Steroid hormone|horm,strd|||steroid hormones||||901|159|174
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|185|196
SE|00000000||tx|1|entity|C0037982|Spironolactone|phsu,strd|||spironolactone||||1000|199|212
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|219|228


SE|00000000||tx|1|text|Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.
SE|00000000||tx|1|entity|C0031831|Physicians|prog|||Physicians||||1000|1|10
SE|00000000||tx|1|entity|C1533716|Information|idcn|||information||||861|30|40
SE|00000000||tx|1|entity|C0004448|Awareness|menp|||awareness||||1000|54|62
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|71|79
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||872|85|91
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interactions||||872|93|104
SE|00000000||tx|1|entity|C0008806|Cinoxacin|orch,phsu|||cinoxacin||||1000|111|119
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||916|125|131
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory agents||||916|133|169


SE|00000000||tx|1|text|The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
SE|00000000||tx|1|entity|C0441472|Clinical action|ftcn|||actions||||1000|5|11
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|20|34
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|58|69
SE|00000000||tx|1|entity|C0027415|Narcotics|hops,phsu|||narcotics||||1000|72|80
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|83|96
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|99|126
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants||||1000|137|151
SE|00000000||tx|1|relation|0|0|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||monoamine oxidase inhibitors||||1000|99|126|SPEC|ISA||99|151|0|0|C0003289|Antidepressive Agents|phsu|phsu|||antidepressants||||1000|137|151
SE|00000000||tx|1|relation|0|0|C0003289|Antidepressive Agents|phsu|phsu|||antidepressants||||1000|137|151|SPEC|ISA||99|151|0|0|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|phsu|||monoamine oxidase inhibitors||||1000|99|126
SE|00000000||tx|1|relation|5|1|C0004745|Barbiturates|orch,phsu|orch|||barbiturates||||1000|58|69|VERB|STIMULATES||43|53|2|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|20|34
SE|00000000||tx|1|relation|5|1|C0003289|Antidepressive Agents|phsu|phsu|||antidepressants||||1000|137|151|VERB|STIMULATES||43|53|2|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|20|34
SE|00000000||tx|1|relation|5|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||monoamine oxidase inhibitors||||1000|99|126|VERB|STIMULATES||43|53|2|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|20|34
SE|00000000||tx|1|relation|5|1|C0031436|Phenothiazines|orch,phsu|orch|||phenothiazines||||1000|83|96|VERB|STIMULATES||43|53|2|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|20|34
SE|00000000||tx|1|relation|5|1|C0027415|Narcotics|hops,phsu|hops|||narcotics||||1000|72|80|VERB|STIMULATES||43|53|2|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|20|34
SE|00000000||tx|1|relation|0|0|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||monoamine oxidase inhibitors||||1000|99|126|INFER|STIMULATES(SPEC)||99|151|0|0|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|20|34
SE|00000000||tx|1|relation|0|0|C0003289|Antidepressive Agents|phsu|phsu|||antidepressants||||1000|137|151|INFER|STIMULATES(SPEC)||99|151|0|0|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|20|34


SE|00000000||tx|1|text|Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine.
SE|00000000||tx|1|entity|C0040264|Tinnitus|fndg|||Tinnitus||||1000|1|8
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decreased||||888|14|22
SE|00000000||tx|1|entity|C0018767|Hearing|phsf|||hearing||||888|24|30
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|54|61
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||Itraconazole||||1000|87|98
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|104|112
SE|00000000||tx|1|relation|2|1|C0018767|Hearing|phsf|phsf|||hearing||||888|24|30|PREP|PROCESS_OF||51|52|3|1|C0030705|Patients|podg,humn|humn|||patients||||861|54|61
SE|00000000||tx|1|relation|2|1|C0040264|Tinnitus|fndg|fndg|||Tinnitus||||1000|1|8|PREP|PROCESS_OF||51|52|3|1|C0030705|Patients|podg,humn|humn|||patients||||861|54|61
SE|00000000||tx|1|relation|2|1|C0064113|Itraconazole|orch,phsu|orch|||Itraconazole||||1000|87|98|VERB|ADMINISTERED_TO||77|85|3|1|C0030705|Patients|podg,humn|humn|||patients||||861|54|61
SE|00000000||tx|1|relation|2|1|C0034414|Quinidine|orch,phsu|orch|||quinidine||||1000|104|112|VERB|ADMINISTERED_TO||77|85|3|1|C0030705|Patients|podg,humn|humn|||patients||||861|54|61


SE|00000000||tx|1|text|Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||Effects||||861|10|16
SE|00000000||tx|1|entity|C0728742|Felbatol|orch,phsu|||Felbatol||||1000|21|28
SE|00000000||tx|1|entity|C0003299|Antiepileptic Agents|phsu|||Antiepileptic Drugs||||901|40|58
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||901|60|68
SE|00000000||tx|1|entity|C0728742|Felbatol|orch,phsu|||Felbatol||||1000|71|78
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||1000|91|98
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady-state||||849|103|114
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||849|116|124
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||849|126|146
SE|00000000||tx|1|relation|5|1|C0728742|Felbatol|orch,phsu|orch|||Felbatol||||1000|21|28|NOM|INTERACTS_WITH||10|16|5|2|C0031507|Phenytoin|orch,phsu|orch|||Phenytoin||||901|60|68
SE|00000000||tx|1|relation|5|2|C0728742|Felbatol|orch,phsu|orch|||Felbatol||||1000|71|78|PREP|COEXISTS_WITH||100|101|1|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||849|116|124


SE|00000000||tx|1|text|Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.
SE|00000000||tx|1|entity|C0205421|Deferred|tmco|||Delayed||||901|1|7
SE|00000000||tx|1|entity|C0559546|Adverse reactions|fndg|||Adverse Reactions||||901|9|25
SE|00000000||tx|1|entity|C1960405|Iodinated contrast media|irda|||Iodinated Contrast Media||||1000|30|53
SE|00000000||tx|1|entity|C0023866|Literature|inpr|||literature||||1000|72|81
SE|00000000||tx|1|entity|C1514721|Range|qnco|||range||||827|104|108
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|125|132
SE|00000000||tx|1|entity|C0021756|Interleukin-2|aapp,imft|||interleukin-2||||798|155|167
SE|00000000||tx|1|entity|C2700400|Contain (action)|acty|||containing||||798|169|178
SE|00000000||tx|1|entity|C2945654|Regimen - CHV concept|inpr|||regimens||||798|180|187
SE|00000000||tx|1|entity|C0443076|Radiographic iodinated contrast medium|irda|||radiographic iodinated contrast media||||988|224|260
SE|00000000||tx|1|entity|C0205178|acute|tmco|||acute||||861|274|278
SE|00000000||tx|1|entity|C0205182|Atypical|qlco|||atypical||||861|281|288
SE|00000000||tx|1|entity|C0559546|Adverse reactions|fndg|||adverse reactions||||861|290|306
SE|00000000||tx|1|relation|1|1|C0559546|Adverse reactions|fndg|fndg|||adverse reactions||||861|290|306|VERB|PROCESS_OF||262|272|7|3|C0030705|Patients|podg,humn|humn|||patients||||861|125|132


SE|00000000||tx|1|text|Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN.
SE|00000000||tx|1|entity|C0302350|Therapeutic|ftcn|||therapeutic||||660|26|36
SE|00000000||tx|1|entity|C0003195|Anti-Arrhythmia Agents|phsu|||antiarrhythmics||||1000|82|96
SE|00000000||tx|1|entity|C0701105|Crixivan|orch,phsu|||CRIXIVAN||||1000|123|130


SE|00000000||tx|1|text|A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||861|19|29
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|39|47
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine||||1000|53|64
SE|00000000||tx|1|entity|C0022646|Kidney|bpoc|||renal||||1000|109|113
SE|00000000||tx|1|entity|C0018823|Heart Transplantation|topp|||cardiac transplant||||901|119|136
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||901|138|145
SE|00000000||tx|1|relation|4|2|C0010592|Cyclosporine|aapp,gngm,phsu|aapp|||cyclosporine||||1000|53|64|VERB|AFFECTS||99|107|2|1|C0022646|Kidney|bpoc|bpoc|||renal||||1000|109|113
SE|00000000||tx|1|relation|4|2|C0012373|Diltiazem|orch,phsu|orch|||diltiazem||||1000|39|47|VERB|AFFECTS||99|107|2|1|C0022646|Kidney|bpoc|bpoc|||renal||||1000|109|113


SE|00000000||tx|1|text|This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors.
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||1000|6|16
SE|00000000||tx|1|entity|C0518609|consideration|fndg|||consideration||||1000|34|46
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|51|58
SE|00000000||tx|1|entity|C1101725|Bextra|orch,phsu|||BEXTRA||||861|67|72
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE-inhibitors||||1000|93|106
SE|00000000||tx|1|relation|2|1|C0518609|consideration|fndg|fndg|||consideration||||1000|34|46|PREP|PROCESS_OF||48|49|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|51|58
SE|00000000||tx|1|relation|2|1|C1101725|Bextra|orch,phsu|orch|||BEXTRA||||861|67|72|VERB|ADMINISTERED_TO||60|65|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|51|58


SE|00000000||tx|1|text|Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||Cimetidine||||1000|1|10
SE|00000000||tx|1|entity|C0034665|Ranitidine|orch,phsu|||Ranitidine||||1000|13|22
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||888|28|33
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|35|44
SE|00000000||tx|1|entity|C1550147|Pretreatment|sbst|||pretreatment||||1000|53|64
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|71|80
SE|00000000||tx|1|entity|C0034665|Ranitidine|orch,phsu|||ranitidine||||1000|85|94
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|100|102
SE|00000000||tx|1|entity|C0016377|Flurbiprofen|orch,phsu|||flurbiprofen||||888|111|122
SE|00000000||tx|1|entity|C0031328|Pharmacokinetic aspects|ftcn|||pharmacokinetics||||888|124|139
SE|00000000||tx|1|entity|C0700321|Small|qnco|||small||||1000|155|159
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||statistically significant||||901|172|196
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||901|198|205
SE|00000000||tx|1|entity|C0205146|Area|spco|||area||||1000|214|217
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentration||||901|229|247
SE|00000000||tx|1|entity|C0205134|Curved|spco|||curve||||901|249|253
SE|00000000||tx|1|entity|C0016377|Flurbiprofen|orch,phsu|||flurbiprofen||||1000|258|269
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|285|294
SE|00000000||tx|1|relation|2|1|C0034665|Ranitidine|orch,phsu|phsu|||Ranitidine||||1000|13|22|PREP|TREATS||25|26|12|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|35|44
SE|00000000||tx|1|relation|2|1|C0034665|Ranitidine|orch,phsu|phsu|||ranitidine||||1000|85|94|PREP|TREATS||25|26|12|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|35|44
SE|00000000||tx|1|relation|7|2|C0008783|Cimetidine|orch,phsu|orch|||cimetidine||||1000|71|80|VERB|INTERACTS_WITH|negation|104|109|7|1|C0016377|Flurbiprofen|orch,phsu|orch|||flurbiprofen||||888|111|122


SE|00000000||tx|1|text|Co-administration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A4 substrate) by approximately 50%.
SE|00000000||tx|1|entity|C0252643|bosentan|orch,phsu|||bosentan||||1000|22|29
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|45|65
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine A||||1000|70|83
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|88|93
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|109|121
SE|00000000||tx|1|relation|2|1|C0252643|bosentan|orch,phsu|orch|||bosentan||||1000|22|29|VERB|INHIBITS||31|39|3|2|C0010592|Cyclosporine|aapp,gngm,phsu|gngm|||cyclosporine A||||1000|70|83


SE|00000000||tx|1|text|- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
SE|00000000||tx|1|entity|C0591179|Bezalip|orch,phsu|||Bezalip||||1000|8|14
SE|00000000||tx|1|entity|C0591179|Bezalip|orch,phsu|||Bezalip||||1000|19|25
SE|00000000||tx|1|entity|C0003072|Anion Exchange Resins|bodm,irda|||anion-exchange resins||||1000|60|80
SE|00000000||tx|1|entity|C1272706|Interval|tmco|||interval||||1000|109|116
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||785|124|128
SE|00000000||tx|1|entity|C0439227|Hour|tmco|||hours||||785|132|136
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||888|171|173
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medicines||||888|175|183
SE|00000000||tx|1|entity|C0591179|Bezalip|orch,phsu|||Bezalip||||1000|210|216
SE|00000000||tx|1|entity|C0591179|Bezalip|orch,phsu|||Bezalip||||1000|221|227


SE|00000000||tx|1|text|In vitro data suggest that itraconazole, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.
SE|00000000||tx|1|entity|C1511726|Data|idcn|||data||||861|10|13
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|28|39
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|59|70
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||802|79|82
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||802|95|100
SE|00000000||tx|1|entity|C0220798|biotransformational|ftcn|||biotransformation||||888|109|125
SE|00000000||tx|1|entity|C0449913|System|ftcn|||system||||888|127|132
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|154|163
SE|00000000||tx|1|entity|C0085170|Astemizole|orch,phsu|||astemizole||||1000|168|177
SE|00000000||tx|1|relation|2|1|C0064113|Itraconazole|orch,phsu|orch|||itraconazole||||1000|28|39|VERB|compared_with||47|54|6|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|59|70
SE|00000000||tx|1|relation|5|3|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|59|70|ADJ|AFFECTS||134|144|2|1|C0025519|Metabolism|orgf|orgf|||metabolism||||1000|154|163
SE|00000000||tx|1|relation|5|3|C0064113|Itraconazole|orch,phsu|orch|||itraconazole||||1000|28|39|ADJ|AFFECTS||134|144|2|1|C0025519|Metabolism|orgf|orgf|||metabolism||||1000|154|163


SE|00000000||tx|1|text|Aspirin: Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents, including ibuprofen, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||Aspirin||||1000|1|7
SE|00000000||tx|1|entity|C0683949|Animal Study|anim|||Animal studies||||734|10|23
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|36|42
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory agents||||1000|55|91
SE|00000000||tx|1|entity|C0020740|Ibuprofen|orch,phsu|||ibuprofen||||1000|104|112
SE|00000000||tx|1|entity|C1423506|SPINK5 gene|gngm|11005|SPINK5|net||||872|124|126
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decrease||||872|128|135
SE|00000000||tx|1|entity|C0333348|Inflammatory|ftcn|||inflammatory||||790|145|156
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||790|158|165
SE|00000000||tx|1|entity|C0441994|Lower - spatial qualifier|spco|||lowered||||790|172|178
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||790|180|184
SE|00000000||tx|1|entity|C0722138|Non-Aspirin|orch,phsu|||non-aspirin||||901|200|210
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||901|212|215
SE|00000000||tx|1|relation|0|0|C0722138|Non-Aspirin|orch,phsu|orch|||non-aspirin||||901|200|210|MOD/HEAD|ISA||200|215|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||901|212|215
SE|00000000||tx|1|relation|6|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||nonsteroidal anti-inflammatory agents||||1000|55|91|VERB|COEXISTS_WITH||44|48|3|1|C0004057|Aspirin|orch,phsu|orch|||aspirin||||1000|36|42
SE|00000000||tx|1|relation|5|1|C0020740|Ibuprofen|orch,phsu|orch|||ibuprofen||||1000|104|112|NOM|INHIBITS||128|135|5|0|C1423506|SPINK5 gene|gngm,aapp|gngm|11005|SPINK5|net||||872|124|126


SE|00000000||tx|1|text|Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).
SE|00000000||tx|1|entity|C1621583|Administer|ftcn|||administering||||773|40|52
SE|00000000||tx|1|entity|C0068788|nitazoxanide|orch,phsu|||nitazoxanide||||773|54|65
SE|00000000||tx|1|entity|C0205250|High|qlco|||highly||||849|91|96
SE|00000000||tx|1|entity|C0032120|Plasma Proteins|aapp,bacs|||plasma protein||||849|98|111
SE|00000000||tx|1|entity|C0678751|protein-bound drug fraction|qnco|||bound drugs||||849|113|123
SE|00000000||tx|1|entity|C0333164|Narrow|qnco|||narrow||||884|130|135
SE|00000000||tx|1|entity|C0678793|Therapeutic Index|qnco|||therapeutic indices||||884|137|155
SE|00000000||tx|1|entity|C0679932|competition|socb|||competition||||1000|161|171
SE|00000000||tx|1|entity|C0005456|Binding Sites|rcpt|||binding sites||||1000|177|189
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|208|215
SE|00000000||tx|1|relation|4|3|C0068788|nitazoxanide|orch,phsu|orch|||nitazoxanide||||773|54|65|NOM|INTERACTS_WITH||161|171|2|1|C0005456|Binding Sites|rcpt|rcpt|||binding sites||||1000|177|189


SE|00000000||tx|1|text|In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.
SE|00000000||tx|1|entity|C0936012|Analysis|resa|||analysis||||1000|7|14
SE|00000000||tx|1|entity|C0428974|Supraventricular arrhythmia|patf|||supraventricular arrhythmia||||1000|23|49
SE|00000000||tx|1|entity|C0057717|Diamond|elii|||DIAMOND||||851|55|61
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||851|63|69
SE|00000000||tx|1|entity|C0032659|geographic population|qnco|||populations||||851|71|81
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|88|98
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||1000|118|126
SE|00000000||tx|1|entity|C0114771|dofetilide|orch,phsu|||dofetilide||||1000|133|142
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||872|166|171
SE|00000000||tx|1|entity|C2745955|Occurrence|tmco|||occurrence||||872|173|182
SE|00000000||tx|1|entity|C0040479|Torsades de Pointes|dsyn|||torsade de pointes||||1000|187|204


SE|00000000||tx|1|text|Combination hormonal contraceptives may also decrease the plasma concentration of acetaminophen.
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||Combination||||851|1|11
SE|00000000||tx|1|entity|C0458083|Hormonal|qlco|||hormonal||||851|13|20
SE|00000000||tx|1|entity|C0009871|Contraceptive Agents|phsu|||contraceptives||||851|22|35
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||1000|59|78
SE|00000000||tx|1|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|83|95
SE|00000000||tx|1|relation|1|1|C0009871|Contraceptive Agents|phsu|phsu|||contraceptives||||851|22|35|VERB|INHIBITS||46|53|2|2|C0000970|Acetaminophen|orch,phsu|orch|||acetaminophen||||1000|83|95


SE|00000000||tx|1|text|however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1
SE|00000000||tx|1|entity|C0392760|Affecting|ftcn|||affected||||824|23|30
SE|00000000||tx|1|entity|C0237585|Response Duration|tmco|||response duration||||824|32|48
SE|00000000||tx|1|entity|C0034272|pyridoxine|orch,phsu,vita|||pyridoxine||||1000|66|75
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|84|86
SE|00000000||tx|1|entity|C0594753|Hexalen|orch,phsu|||HEXALEN||||1000|109|115
SE|00000000||tx|1|entity|C0008838|Cisplatin|inch,phsu|||cisplatin||||861|124|132


SE|00000000||tx|1|text|It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.
SE|00000000||tx|1|entity|C0441509|Coagulation procedure|topp|||coagulation||||888|26|36
SE|00000000||tx|1|entity|C0040223|Time|tmco|||time||||888|38|41
SE|00000000||tx|1|entity|C1279901|Firstly|qlco|||first||||802|54|58
SE|00000000||tx|1|entity|C0439228|day|tmco|||days||||802|64|67
SE|00000000||tx|1|entity|C0439659|Beginning|tmco|||start||||1000|79|83
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuation||||1000|89|103
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||888|108|116
SE|00000000||tx|1|entity|C1548787|Appropriate|qlco|||appropriate||||694|135|145
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulant||||901|165|177
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||901|179|182


SE|00000000||tx|1|text|Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN.
SE|00000000||tx|1|entity|C0205393|Most|qnco|||Most||||1000|1|4
SE|00000000||tx|1|entity|C1282910|Upper|spco|||above||||888|13|17
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|19|25
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|38|46
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||966|73|77
SE|00000000||tx|1|entity|C0449719|Part|spco|||part||||1000|82|85
SE|00000000||tx|1|entity|C0441712|Mechanism (attribute)|ftcn|||mechanisms||||1000|91|100
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|112|121
SE|00000000||tx|1|entity|C1157324|prostaglandin biosynthetic process|moft|||prostaglandin synthesis||||1000|126|148
SE|00000000||tx|1|entity|C0700798|Indocin|orch,phsu|||INDOCIN||||1000|153|159
SE|00000000||tx|1|relation|2|2|C0700798|Indocin|orch,phsu|phsu|||INDOCIN||||1000|153|159|NOM|DISRUPTS||112|121|2|1|C1157324|prostaglandin biosynthetic process|moft|moft|||prostaglandin synthesis||||1000|126|148


SE|00000000||tx|1|text|Nitrofurantoin interferes with the therapeutic action of nalidixic acid.
SE|00000000||tx|1|entity|C0028156|Nitrofurantoin|orch,phsu|||Nitrofurantoin||||1000|1|14
SE|00000000||tx|1|entity|C0302350|Therapeutic|ftcn|||therapeutic||||888|36|46
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||888|48|53
SE|00000000||tx|1|entity|C0027353|Nalidixic Acid|antb,orch|||nalidixic acid||||1000|58|71


SE|00000000||tx|1|text|There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.
SE|00000000||tx|1|entity|C0237753|Numbers|qnco|||number||||1000|19|24
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|29|35
SE|00000000||tx|1|entity|C0687676|Post|tmco|||post-||||851|44|48
SE|00000000||tx|1|entity|C0024826|Marketing|ocac|||marketing||||851|49|57
SE|00000000||tx|1|entity|C0596545|Experience|menp|||experience||||851|59|68
SE|00000000||tx|1|entity|C0009421|Comatose|dsyn|||coma||||1000|73|76
SE|00000000||tx|1|entity|C0011065|Cessation of life|orgf|||death||||1000|82|86
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||851|108|118
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||851|120|130
SE|00000000||tx|1|entity|C0549649|MISUSE|fndg|||misuse||||851|132|137
SE|00000000||tx|1|entity|C0006405|Buprenorphine|orch,phsu|||buprenorphine||||1000|142|154
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|160|174
SE|00000000||tx|1|entity|C0858354|addict|podg|||addicts||||1000|179|185
SE|00000000||tx|1|relation|4|1|C0549649|MISUSE|fndg|fndg|||misuse||||851|132|137|VERB|COEXISTS_WITH||88|97|5|2|C0009421|Comatose|dsyn|dsyn|||coma||||1000|73|76


SE|00000000||tx|1|text|Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||1000|1|12
SE|00000000||tx|1|entity|C1168564|bosentan 125 MG|clnd|||bosentan 125 mg||||822|36|50
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|63|74
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||752|79|84
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||752|86|91
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||752|93|101
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|118|138
SE|00000000||tx|1|entity|C0252643|bosentan|orch,phsu|||bosentan||||1000|143|150
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||802|155|167
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||802|171|174
SE|00000000||tx|1|relation|4|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|63|74|NOM|INHIBITS||93|101|4|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||752|86|91
SE|00000000||tx|1|relation|4|1|C0022625|Ketoconazole|orch,phsu|orch|||Ketoconazole||||1000|1|12|NOM|INHIBITS||93|101|4|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||752|86|91


SE|00000000||tx|1|text|As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
SE|00000000||tx|1|entity|C0040615|Antipsychotic Agents|phsu|||antipsychotic agents||||1000|15|34
SE|00000000||tx|1|entity|C0591585|Haldol|orch,phsu|||HALDOL||||1000|61|66
SE|00000000||tx|1|entity|C2698977|Capability|qlco|||capable||||928|75|81
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||901|99|113
SE|00000000||tx|1|entity|C0002932|Anesthetics|phsu|||anesthetics||||1000|123|133
SE|00000000||tx|1|entity|C0376196|Opiates|hops,phsu|||opiates||||1000|136|142
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|149|155
SE|00000000||tx|1|relation|0|0|C0591585|Haldol|orch,phsu|orch|||HALDOL||||1000|61|66|SPEC|ISA||61|113|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||901|99|113
SE|00000000||tx|1|relation|0|0|C0002932|Anesthetics|phsu|phsu|||anesthetics||||1000|123|133|SPEC|ISA||99|133|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||901|99|113
SE|00000000||tx|1|relation|0|0|C0001975|Alcohols|orch,phsu|phsu|||alcohol||||1000|149|155|SPEC|ISA||99|133|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||901|99|113
SE|00000000||tx|1|relation|0|0|C0376196|Opiates|hops,phsu|phsu|||opiates||||1000|136|142|SPEC|ISA||99|133|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||901|99|113


SE|00000000||tx|1|text|Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0876170|Sonata|orch,phsu|||Sonata||||1000|31|36
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|50|59
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|86|93
SE|00000000||tx|1|entity|C2347813|Cmax|qnco|||Cmax||||861|107|110
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|116|118
SE|00000000||tx|1|entity|C0251504|zaleplon|orch,phsu|||zaleplon||||1000|123|130


SE|00000000||tx|1|text|Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).
SE|00000000||tx|1|entity|C0935987|Gleevec|orch,phsu|||Gleevec||||1000|1|7
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||790|52|57
SE|00000000||tx|1|entity|C1524026|Metabolic Process, Cellular|celf|||metabolized||||790|59|69
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||790|71|75
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||861|93|107
SE|00000000||tx|1|entity|C0012315|Dihydropyridines|orch,phsu|||dihydropyridine||||916|110|124
SE|00000000||tx|1|entity|C0006684|Calcium Channel Blockers|phsu|||calcium channel blockers||||916|126|149
SE|00000000||tx|1|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||928|152|158
SE|00000000||tx|1|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||HMG-CoA reductase inhibitors||||928|160|187
SE|00000000||tx|1|entity|C1548556|etc.|idcn|||etc||||1000|190|192


SE|00000000||tx|1|text|Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
SE|00000000||tx|1|entity|C0004963|Diphenhydramine Hydrochloride|orch,phsu|||Diphenhydramine hydrochloride||||1000|1|29
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|35|42
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|44|50
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|57|63
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||1000|75|89
SE|00000000||tx|1|entity|C0020591|Hypnotics|phsu|||hypnotics||||1000|92|100
SE|00000000||tx|1|entity|C0036557|Sedatives|phsu|||sedatives||||1000|103|111
SE|00000000||tx|1|entity|C0040614|Tranquilizing Agents|phsu|||tranquilizers||||1000|114|126
SE|00000000||tx|1|entity|C1548556|etc.|idcn|||etc||||1000|129|131
SE|00000000||tx|1|relation|0|0|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|57|63|SPEC|ISA||57|89|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|75|89
SE|00000000||tx|1|relation|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|75|89|SPEC|ISA||57|89|0|0|C0001975|Alcohols|orch,phsu|phsu|||alcohol||||1000|57|63
SE|00000000||tx|1|relation|0|0|C0020591|Hypnotics|phsu|phsu|||hypnotics||||1000|92|100|SPEC|ISA||75|100|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|75|89


SE|00000000||tx|1|text|Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).
SE|00000000||tx|1|entity|C0010961|Danazol|horm,phsu,strd|||Danazol||||1000|1|7
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|14|17
SE|00000000||tx|1|entity|C0026848|Myopathy|dsyn|||myopathy||||888|22|29
SE|00000000||tx|1|entity|C0035410|Rhabdomyolysis|patf|||rhabdomyolysis||||888|31|44
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|62|72
SE|00000000||tx|1|entity|C0010961|Danazol|horm,phsu,strd|||danazol||||861|92|98
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||higher doses||||966|118|129
SE|00000000||tx|1|entity|C0024027|Lovastatin|orch,phsu|||lovastatin||||1000|134|143
SE|00000000||tx|1|entity|C0871599|Cautionary Warning|gora|||WARNINGS||||1000|150|157
SE|00000000||tx|1|entity|C0026848|Myopathy|dsyn|||Myopathy||||888|160|167
SE|00000000||tx|1|entity|C0035410|Rhabdomyolysis|patf|||Rhabdomyolysis||||888|169|182


SE|00000000||tx|1|text|Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0291772|alosetron|orch,phsu|||alosetron||||1000|31|39
SE|00000000||tx|1|entity|C1881878|Moderation|qlco|||moderate||||851|45|52
SE|00000000||tx|1|entity|C1332826|CYP1A2 gene|gngm|1544|CYP1A2|CYP1A2||||851|54|59
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||851|61|70
SE|00000000||tx|1|entity|C1882518|Quinolone Antibiotic|antb|||quinolone antibiotics||||983|83|103
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|109|118
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|125|127
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||861|206|212
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||861|214|222
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interactions||||861|224|240
SE|00000000||tx|1|relation|2|1|C0291772|alosetron|orch,phsu|orch|||alosetron||||1000|31|39|NOM|INHIBITS||61|70|2|0|C1332826|CYP1A2 gene|gngm,aapp|gngm|1544|CYP1A2|CYP1A2||||851|54|59


SE|00000000||tx|1|text|Narcotic analgesics may potentiate the hypotensive effects of clonidine.
SE|00000000||tx|1|entity|C0027409|Narcotic Analgesics|phsu|||Narcotic analgesics||||1000|1|19
SE|00000000||tx|1|entity|C0857353|Hypotensive|patf|||hypotensive||||888|40|50
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|52|58
SE|00000000||tx|1|entity|C0009014|Clonidine|orch,phsu|||clonidine||||1000|63|71


SE|00000000||tx|1|text|Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
SE|00000000||tx|1|entity|C0205253|Immediate|tmco|||Immediate||||851|12|20
SE|00000000||tx|1|entity|C0391871|Released (action)|ftcn|||Release||||851|22|28
SE|00000000||tx|1|entity|C0006935|capsule (pharmacologic)|bodm|||Capsules||||851|30|37
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|71|77
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|82|89
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||901|96|103
SE|00000000||tx|1|entity|C0337449|Digoxin measurement|lbpr|||digoxin levels||||901|105|118
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||888|136|143
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interaction||||888|145|155
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|165|171
SE|00000000||tx|1|entity|C0028066|Nifedipine|orch,phsu|||nifedipine||||1000|177|186
SE|00000000||tx|1|entity|C0337449|Digoxin measurement|lbpr|||digoxin levels||||1000|212|225
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiating||||966|245|254
SE|00000000||tx|1|entity|C1444662|Discontinued|fndg|||discontinuing||||773|272|284
SE|00000000||tx|1|entity|C0028066|Nifedipine|orch,phsu|||nifedipine||||773|286|295
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||861|306|313
SE|00000000||tx|1|entity|C2919279|Administration of digitalis|hlca|||digitalization||||1000|330|343
SE|00000000||tx|1|relation|5|4|C0006935|capsule (pharmacologic)|bodm|bodm|||Capsules||||851|30|37|NOM|INTERACTS_WITH||145|155|6|1|C0012265|Digoxin|carb,phsu,strd|carb|||digoxin||||1000|165|171
SE|00000000||tx|1|relation|5|4|C0006935|capsule (pharmacologic)|bodm|bodm|||Capsules||||851|30|37|NOM|INTERACTS_WITH||145|155|6|1|C0028066|Nifedipine|orch,phsu|orch|||nifedipine||||773|286|295
SE|00000000||tx|1|relation|5|4|C0006935|capsule (pharmacologic)|bodm|bodm|||Capsules||||851|30|37|NOM|INTERACTS_WITH||145|155|6|1|C0028066|Nifedipine|orch,phsu|orch|||nifedipine||||1000|177|186


SE|00000000||tx|1|text|aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||reports||||1000|11|17
SE|00000000||tx|1|entity|C0029104|Opioid withdrawal|mobd|||narcotic withdrawal||||901|22|40
SE|00000000||tx|1|entity|C0039082|Syndrome|dsyn|||syndrome||||901|42|49
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|54|61
SE|00000000||tx|1|entity|C0132326|Nevirapine|nnon,phsu|||nevirapine||||1000|76|85
SE|00000000||tx|1|entity|C0025605|Methadone|orch,phsu|||methadone||||861|91|99
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decreased||||890|131|139
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||890|141|161
SE|00000000||tx|1|entity|C0025605|Methadone|orch,phsu|||methadone||||1000|166|174
SE|00000000||tx|1|relation|0|0|C0029104|Opioid withdrawal|mobd|mobd|||narcotic withdrawal||||901|22|40|MOD/HEAD|ISA||22|49|0|0|C0039082|Syndrome|dsyn|dsyn|||syndrome||||901|42|49
SE|00000000||tx|1|relation|3|1|C0039082|Syndrome|dsyn|dsyn|||syndrome||||901|42|49|PREP|PROCESS_OF||51|52|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|54|61
SE|00000000||tx|1|relation|5|1|C0132326|Nevirapine|nnon,phsu|phsu|||nevirapine||||1000|76|85|VERB|TREATS||63|69|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|54|61
SE|00000000||tx|1|relation|5|1|C0025605|Methadone|orch,phsu|phsu|||methadone||||861|91|99|VERB|TREATS||63|69|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|54|61
SE|00000000||tx|1|relation|0|0|C0029104|Opioid withdrawal|mobd|mobd|||narcotic withdrawal||||901|22|40|INFER|PROCESS_OF(SPEC)||22|49|0|0|C0030705|Patients|podg,humn|humn|||patients||||1000|54|61
SE|00000000||tx|1|relation|0|0|C0132326|Nevirapine|nnon,phsu|phsu|||nevirapine||||1000|76|85|INFER|TREATS(INFER)||63|69|0|0|C0039082|Syndrome|dsyn|dsyn|||syndrome||||901|42|49
SE|00000000||tx|1|relation|0|0|C0025605|Methadone|orch,phsu|phsu|||methadone||||861|91|99|INFER|TREATS(INFER)||63|69|0|0|C0039082|Syndrome|dsyn|dsyn|||syndrome||||901|42|49


SE|00000000||tx|1|text|BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.
SE|00000000||tx|1|entity|C0591189|Brevibloc|orch,phsu|||BREVIBLOC||||888|1|9
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|11|24
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||827|43|48
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|66|73
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||790|88|90
SE|00000000||tx|1|entity|C0332148|Probable diagnosis|qlco|||likely||||790|92|97
SE|00000000||tx|1|relation|2|1|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||1000|66|73|VERB|COEXISTS_WITH||55|59|2|2|C0591189|Brevibloc|orch,phsu|orch|||BREVIBLOC||||888|1|9


SE|00000000||tx|1|text|In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.
SE|00000000||tx|1|entity|C1883712|Add - instruction imperative|ftcn|||addition||||1000|4|11
SE|00000000||tx|1|entity|C0282563|Macrolides|orch,phsu|||macrolides||||1000|19|28
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|53|60
SE|00000000||tx|1|entity|C0085173|Terfenadine|orch,phsu|||terfenadine||||888|72|82
SE|00000000||tx|1|entity|C2347662|Pre-existing|qlco|||pre-existing||||880|101|112
SE|00000000||tx|1|entity|C0018798|Congenital Heart Defects|cgab|||cardiac abnormalities||||880|114|134
SE|00000000||tx|1|entity|C0428977|Bradycardia|patf|||bradycardia||||1000|149|159
SE|00000000||tx|1|entity|C1272706|Interval|tmco|||interval||||597|167|174
SE|00000000||tx|1|entity|C0010054|Coronary Arteriosclerosis|dsyn|||ischemic heart disease||||1000|190|211
SE|00000000||tx|1|entity|C0018802|Congestive heart failure|dsyn|||congestive heart failure||||1000|214|237
SE|00000000||tx|1|entity|C1548556|etc.|idcn|||etc||||1000|240|242
SE|00000000||tx|1|entity|C0342579|Electrolyte imbalance|patf|||electrolyte disturbances||||983|249|272
SE|00000000||tx|1|relation|2|1|C0282563|Macrolides|orch,phsu|phsu|||macrolides||||1000|19|28|PREP|TREATS||50|51|10|1|C0030705|Patients|podg,humn|podg|||patients||||1000|53|60


SE|00000000||tx|1|text|Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
SE|00000000||tx|1|entity|C0039651|Tetracyclines|orch|||tetracyclines||||1000|15|27
SE|00000000||tx|1|entity|C0003138|Antacids|phsu|||antacids||||1000|44|51
SE|00000000||tx|1|entity|C0002367|Aluminum|elii|||aluminum||||1000|64|71
SE|00000000||tx|1|entity|C0006675|Calcium|bacs,elii,phsu|||calcium||||1000|74|80
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||magnesium||||1000|86|94
SE|00000000||tx|1|entity|C2700400|Contain (action)|acty|||containing||||901|106|115
SE|00000000||tx|1|entity|C0302583|Iron|bacs,elii,phsu|||iron-containing preparations||||901|101|128


SE|00000000||tx|1|text|The extent to which SSRI-TCAinteractions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
SE|00000000||tx|1|entity|C0439792|Extent|spco|||extent||||1000|5|10
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRI||||694|21|24
SE|00000000||tx|1|entity|C0205210|Clinical|qlco|||clinical||||694|51|58
SE|00000000||tx|1|entity|C0441889|Levels (qualifier value)|qlco|||degree||||1000|88|93
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|98|107
SE|00000000||tx|1|entity|C0031327|Drug Kinetics|phsf|||pharmacokinetics||||1000|117|132
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRI||||1000|141|144


SE|00000000||tx|1|text|Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.
SE|00000000||tx|1|entity|C2826232|Dose Adjustment|hlca|||dose adjustment||||1000|12|26
SE|00000000||tx|1|entity|C0052796|Azithromycin|antb,orch|||azithromycin||||1000|31|42
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|47|49
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|84|94
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||nelfinavir||||1000|101|110
SE|00000000||tx|1|entity|C0587267|Closed|ftcn|||close||||694|113|117
SE|00000000||tx|1|entity|C0205309|Known|qlco|||known||||901|134|138
SE|00000000||tx|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects||||901|140|151
SE|00000000||tx|1|entity|C0052796|Azithromycin|antb,orch|||azithromycin||||1000|156|167
SE|00000000||tx|1|entity|C0438237|Liver enzymes abnormal|fndg|||liver enzyme abnormalities||||961|178|203
SE|00000000||tx|1|entity|C1384666|hearing impairment|fndg|||hearing impairment||||1000|209|226
SE|00000000||tx|1|relation|3|3|C2826232|Dose Adjustment|hlca|hlca|||dose adjustment||||1000|12|26|PREP|USES||96|99|6|1|C0525005|Nelfinavir|orch,phsu|phsu|||nelfinavir||||1000|101|110


SE|00000000||tx|1|text|Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Drugs||||1000|1|5
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||851|18|28
SE|00000000||tx|1|entity|C0443318|Sustained|ftcn|||sustained||||851|30|38
SE|00000000||tx|1|entity|C0702240|Elevation|spco|||elevation||||851|40|48
SE|00000000||tx|1|entity|C1168023|Gastric pH|diap|||gastric pH (||||901|53|64
SE|00000000||tx|1|entity|C0019593|Histamine H2 Antagonists|phsu|||histamine H2-receptor antagonists||||901|65|97
SE|00000000||tx|1|entity|C0034665|Ranitidine|orch,phsu|||ranitidine||||1000|107|116
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|121|130
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||983|144|164
SE|00000000||tx|1|entity|C0919281|Iressa|orch,phsu|||IRESSA||||1000|169|174
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||efficacy||||1000|213|220
SE|00000000||tx|1|relation|0|0|C0034665|Ranitidine|orch,phsu|orch|||ranitidine||||1000|107|116|SPEC|ISA||65|116|0|0|C0019593|Histamine H2 Antagonists|phsu|phsu|||histamine H2-receptor antagonists||||901|65|97
SE|00000000||tx|1|relation|0|0|C0008783|Cimetidine|orch,phsu|orch|||cimetidine||||1000|121|130|SPEC|ISA||65|116|0|0|C0019593|Histamine H2 Antagonists|phsu|phsu|||histamine H2-receptor antagonists||||901|65|97
SE|00000000||tx|1|relation|2|2|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|PREP|COEXISTS_WITH||50|51|6|1|C0019593|Histamine H2 Antagonists|phsu|phsu|||histamine H2-receptor antagonists||||901|65|97
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|INFER|COEXISTS_WITH(SPEC)||65|116|0|0|C0034665|Ranitidine|orch,phsu|orch|||ranitidine||||1000|107|116
SE|00000000||tx|1|relation|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||Drugs||||1000|1|5|INFER|COEXISTS_WITH(SPEC)||65|116|0|0|C0008783|Cimetidine|orch,phsu|orch|||cimetidine||||1000|121|130


SE|00000000||tx|1|text|Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|20|33
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|65|74
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|76|78
SE|00000000||tx|1|entity|C0007680|Central Nervous System Agents|phsu|||CNS depressant drugs||||913|89|108
SE|00000000||tx|1|relation|3|1|C0003360|Antihistamines|orch,phsu|orch|||antihistamines||||1000|20|33|VERB|ADMINISTERED_TO||10|18|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8


SE|00000000||tx|1|text|Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||790|11|21
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||888|41|52
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||888|54|60
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|67|75


SE|00000000||tx|1|text|Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.
SE|00000000||tx|1|entity|C2936509|Serotonin 5-HT1B Receptor Agonists|phsu|||5-HT1B/1D Agonists||||846|7|24
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||846|26|36
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||846|38|40
SE|00000000||tx|1|entity|C2936509|Serotonin 5-HT1B Receptor Agonists|phsu|||5-HT1B/1D agonists||||908|51|68
SE|00000000||tx|1|entity|C1442770|24 Hours|tmco|||24 hours||||1000|77|84
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|89|97
SE|00000000||tx|1|entity|C0939679|Axert|orch,phsu|||AXERT||||1000|104|108
SE|00000000||tx|1|relation|4|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||1000|89|97|PREP|USES||99|102|1|1|C0939679|Axert|orch,phsu|phsu|||AXERT||||1000|104|108


SE|00000000||tx|1|text|Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0016377|Flurbiprofen|orch,phsu|||flurbiprofen||||1000|20|31
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|37|46
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|57|65
SE|00000000||tx|1|entity|C0871633|desires|menp|||desired||||872|114|120
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||872|122|127
SE|00000000||tx|1|relation|0|0|C0016860|Furosemide|orch,phsu|orch|||furosemide||||1000|37|46|SPEC|ISA||37|65|0|0|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|57|65
SE|00000000||tx|1|relation|5|1|C0016377|Flurbiprofen|orch,phsu|orch|||flurbiprofen||||1000|20|31|VERB|ADMINISTERED_TO||10|18|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8


SE|00000000||tx|1|text|Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
SE|00000000||tx|1|entity|C0026054|Midamor|orch,phsu|||MIDAMOR||||1000|17|23
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||non-steroidal anti-inflammatory agents||||1000|29|66
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|96|102
SE|00000000||tx|1|entity|C0871633|desires|menp|||desired||||872|151|157
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||872|159|164
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|173|180
SE|00000000||tx|1|relation|4|3|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||non-steroidal anti-inflammatory agents||||1000|29|66|NOM|INTERACTS_WITH||159|164|1|1|C0012798|Diuretics|phsu|phsu|||diuretic||||1000|173|180
SE|00000000||tx|1|relation|4|3|C0026054|Midamor|orch,phsu|phsu|||MIDAMOR||||1000|17|23|NOM|INTERACTS_WITH||159|164|1|1|C0012798|Diuretics|phsu|phsu|||diuretic||||1000|173|180


SE|00000000||tx|1|text|Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|25|36
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|42|51
SE|00000000||tx|1|entity|C0871633|desires|menp|||desired||||872|100|106
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||872|108|115
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|141|146
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|151|160
SE|00000000||tx|1|relation|6|1|C0021246|Indomethacin|orch,phsu|orch|||indomethacin||||1000|25|36|VERB|ADMINISTERED_TO||10|18|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8
SE|00000000||tx|1|relation|5|3|C0016860|Furosemide|orch,phsu|orch|||furosemide||||1000|42|51|NOM|INTERACTS_WITH||141|146|1|1|C0016860|Furosemide|orch,phsu|orch|||furosemide||||1000|151|160


SE|00000000||tx|1|text|Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.
SE|00000000||tx|1|entity|C0684224|Report (document)|inpr|||Reports||||1000|1|7
SE|00000000||tx|1|entity|C0023866|Literature|inpr|||literature||||1000|16|25
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|40|45
SE|00000000||tx|1|entity|C0013089|Doxorubicin|antb,orch|||doxorubicin||||1000|57|67
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||active||||851|78|83
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||851|85|94
SE|00000000||tx|1|entity|C0050885|adriamycinol|orch,phsu|||doxorubicinol||||851|96|108
SE|00000000||tx|1|entity|C0144576|Paclitaxel|orch,phsu|||paclitaxel||||1000|133|142
SE|00000000||tx|1|entity|C0013089|Doxorubicin|antb,orch|||doxorubicin||||1000|148|158
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|172|182


SE|00000000||tx|1|text|Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.
SE|00000000||tx|1|entity|C0003374|Antimalarials|phsu|||anti-malarial||||901|15|27
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||901|29|33
SE|00000000||tx|1|entity|C0008269|Chloroquine|orch,phsu|||chloroquine||||1000|44|54
SE|00000000||tx|1|entity|C0025153|Mefloquine|orch,phsu|||mefloquine||||1000|60|69
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||1000|91|98
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|103|115
SE|00000000||tx|1|relation|0|0|C0003374|Antimalarials|phsu|phsu|||anti-malarial||||901|15|27|MOD/HEAD|ISA||15|33|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||901|29|33


SE|00000000||tx|1|text|Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||Furosemide||||1000|1|10
SE|00000000||tx|1|entity|C0242692|Skeletal muscle structure|bpoc|||skeletal muscle||||861|45|59
SE|00000000||tx|1|entity|C0542193|Relaxed|qlco|||relaxing||||861|61|68
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|70|75
SE|00000000||tx|1|entity|C0041345|Tubocurarine|orch,phsu|||tubocurarine||||1000|80|91
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|116|121
SE|00000000||tx|1|entity|C0038627|Succinylcholine|orch,phsu|||succinylcholine||||1000|126|140
SE|00000000||tx|1|relation|2|2|C0016860|Furosemide|orch,phsu|orch|||Furosemide||||1000|1|10|NOM|INTERACTS_WITH||70|75|3|1|C0041345|Tubocurarine|orch,phsu|orch|||tubocurarine||||1000|80|91


SE|00000000||tx|1|text|Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.
SE|00000000||tx|1|entity|C0031328|Pharmacokinetic aspects|ftcn|||pharmacokinetics||||901|7|22
SE|00000000||tx|1|entity|C0596723|human data|inpr,resa|||Human pharmacokinetics data||||901|1|27
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||790|43|46
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||790|48|59
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|83|92
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|97|105
SE|00000000||tx|1|entity|C0205454|Eight|qnco|||eight-||||775|127|132
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||775|133|136
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||775|138|145
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|150|152
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|157|165
SE|00000000||tx|1|relation|2|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||790|48|59|VERB|INHIBITS||70|77|5|2|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|97|105


SE|00000000||tx|1|text|Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.
SE|00000000||tx|1|entity|C0449440|Clinical status|qlco|||clinical status||||1000|29|43
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|63|70
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||haloperidol||||851|107|117
SE|00000000||tx|1|entity|C1522326|Treating|ftcn|||treated||||851|119|125
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||851|127|134
SE|00000000||tx|1|relation|3|1|C0035608|Rifampin|antb,orch|antb|||rifampin||||1000|63|70|PREP|TREATS||104|105|1|1|C0030705|Patients|podg,humn|podg|||patients||||851|127|134


SE|00000000||tx|1|text|Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||Indinavir||||1000|1|9
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|32|40
SE|00000000||tx|1|entity|C0525004|Viracept|orch,phsu|||VIRACEPT||||1000|47|54
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|75|82
SE|00000000||tx|1|entity|C0525005|Nelfinavir|orch,phsu|||nelfinavir||||851|87|96
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||851|98|103
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||851|105|107
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|119|126
SE|00000000||tx|1|entity|C0376637|Indinavir|orch,phsu|||indinavir||||583|131|139
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||583|141|146


SE|00000000||tx|1|text|Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
SE|00000000||tx|1|entity|C0304461|Acidifying preparation|phsu|||Acidifying agents||||1000|1|17
SE|00000000||tx|1|entity|C0017173|Gastrointestinal Agents|phsu|||Gastrointestinal acidifying agents||||913|20|53
SE|00000000||tx|1|entity|C0018318|Guanethidine|orch,phsu|||guanethidine||||1000|56|67
SE|00000000||tx|1|entity|C0035179|Reserpine|orch,phsu|||reserpine||||1000|70|78
SE|00000000||tx|1|entity|C0061472|Glutamic Acid|aapp,bacs,phsu|||glutamic acid||||734|81|93
SE|00000000||tx|1|entity|C0003968|Ascorbic Acid|orch,phsu,vita|||ascorbic acid||||1000|100|112
SE|00000000||tx|1|entity|C0452453|Fruit juice|food|||fruit juices||||1000|115|126
SE|00000000||tx|1|entity|C1548556|etc.|idcn|||etc||||1000|129|131
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||amphetamines||||1000|155|166


SE|00000000||tx|1|text|Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|31|39
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|46|58
SE|00000000||tx|1|entity|C0205250|High|qlco|||elevated||||790|91|98
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||790|100|104
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|116|128
SE|00000000||tx|1|entity|C0439509|/40|tmco|||40%||||1000|131|133
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||861|142|149
SE|00000000||tx|1|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|166|173
SE|00000000||tx|1|entity|C0868928|Case (situation)|ftcn|||cases||||1000|183|187
SE|00000000||tx|1|relation|6|2|C0006949|Carbamazepine|orch,phsu|orch|||carbamazepine||||1000|116|128|VERB|CAUSES||153|161|2|1|C0600688|Toxic effect|inpo|inpo|||toxicity||||1000|166|173


SE|00000000||tx|1|text|It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|27|34
SE|00000000||tx|1|entity|C0003280|Anticoagulants|phsu|||anticoagulants||||1000|43|56
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|59|74
SE|00000000||tx|1|entity|C1272689|Started|qlco|||starting||||872|97|104
SE|00000000||tx|1|entity|C0024027|Lovastatin|orch,phsu|||lovastatin||||872|106|115
SE|00000000||tx|1|entity|C0332183|Frequent|tmco|||frequently||||694|121|130
SE|00000000||tx|1|entity|C3177188|Early Therapy|topp|||early therapy||||901|146|158
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|178|188
SE|00000000||tx|1|entity|C1515926|Alteration|idcn|||alteration||||888|190|199
SE|00000000||tx|1|entity|C0033707|Prothrombin time assay|lbpr|||prothrombin time||||1000|204|219
SE|00000000||tx|1|relation|7|1|C0003280|Anticoagulants|phsu|phsu|||anticoagulants||||1000|43|56|VERB|ADMINISTERED_TO||36|41|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|27|34


SE|00000000||tx|1|text|Patients who are applying Panretin gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0185125|Application procedure|hlca|||applying||||840|18|25
SE|00000000||tx|1|entity|C0722482|Panretin|orch,phsu|||Panretin||||840|27|34
SE|00000000||tx|1|entity|C0017243|Gel|bodm|||gel||||840|36|38
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|47|49
SE|00000000||tx|1|entity|C1514468|product|enty|||products||||1000|68|75
SE|00000000||tx|1|entity|C0011134|Deet|hops,orch,phsu|||DEET||||1000|90|93
SE|00000000||tx|1|entity|C0011134|Deet|hops,orch,phsu|||diethyl-m-toluamide||||875|101|119
SE|00000000||tx|1|entity|C1522138|shared attribute|ftcn|||common||||694|125|130
SE|00000000||tx|1|entity|C0021572|Insect Repellents|hops|||insect repellent||||901|145|160
SE|00000000||tx|1|entity|C1514468|product|enty|||products||||901|162|169


SE|00000000||tx|1|text|The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|5|10
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|19|33
SE|00000000||tx|1|entity|C0003286|Anticonvulsants|phsu|||anticonvulsants||||1000|57|71
SE|00000000||tx|1|entity|C0003360|Antihistamines|orch,phsu|||antihistamines||||1000|74|87
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|90|96
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|99|110
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|113|140
SE|00000000||tx|1|entity|C0027415|Narcotics|hops,phsu|||narcotics||||1000|143|151
SE|00000000||tx|1|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines||||1000|154|167
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||861|183|193
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|205|209
SE|00000000||tx|1|entity|C0151559|Central nervous system depression (disorder)|dsyn|||CNS depression||||1000|224|237
SE|00000000||tx|1|relation|10|1|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsants||||1000|57|71|VERB|STIMULATES||42|52|2|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|19|33
SE|00000000||tx|1|relation|10|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|205|209|VERB|STIMULATES||42|52|2|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|19|33
SE|00000000||tx|1|relation|10|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||861|183|193|VERB|STIMULATES||42|52|2|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|19|33
SE|00000000||tx|1|relation|10|1|C0031436|Phenothiazines|orch,phsu|phsu|||phenothiazines||||1000|154|167|VERB|STIMULATES||42|52|2|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|19|33
SE|00000000||tx|1|relation|10|1|C0027415|Narcotics|hops,phsu|phsu|||narcotics||||1000|143|151|VERB|STIMULATES||42|52|2|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|19|33
SE|00000000||tx|1|relation|10|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|phsu|||monoamine oxidase inhibitors||||1000|113|140|VERB|STIMULATES||42|52|2|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|19|33
SE|00000000||tx|1|relation|10|1|C0004745|Barbiturates|orch,phsu|phsu|||barbiturates||||1000|99|110|VERB|STIMULATES||42|52|2|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|19|33
SE|00000000||tx|1|relation|10|1|C0001975|Alcohols|orch,phsu|phsu|||alcohol||||1000|90|96|VERB|STIMULATES||42|52|2|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|19|33
SE|00000000||tx|1|relation|10|1|C0003360|Antihistamines|orch,phsu|phsu|||antihistamines||||1000|74|87|VERB|STIMULATES||42|52|2|1|C0005064|Benzodiazepines|orch,phsu|orch|||benzodiazepines||||1000|19|33
SE|00000000||tx|1|relation|11|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|205|209|VERB|CAUSES||216|222|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|224|237
SE|00000000||tx|1|relation|11|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||861|183|193|VERB|CAUSES||216|222|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|224|237
SE|00000000||tx|1|relation|11|1|C0031436|Phenothiazines|orch,phsu|phsu|||phenothiazines||||1000|154|167|VERB|CAUSES||216|222|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|224|237
SE|00000000||tx|1|relation|11|1|C0027415|Narcotics|hops,phsu|phsu|||narcotics||||1000|143|151|VERB|CAUSES||216|222|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|224|237
SE|00000000||tx|1|relation|11|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|phsu|||monoamine oxidase inhibitors||||1000|113|140|VERB|CAUSES||216|222|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|224|237
SE|00000000||tx|1|relation|11|1|C0004745|Barbiturates|orch,phsu|phsu|||barbiturates||||1000|99|110|VERB|CAUSES||216|222|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|224|237
SE|00000000||tx|1|relation|11|1|C0001975|Alcohols|orch,phsu|phsu|||alcohol||||1000|90|96|VERB|CAUSES||216|222|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|224|237
SE|00000000||tx|1|relation|11|1|C0003360|Antihistamines|orch,phsu|phsu|||antihistamines||||1000|74|87|VERB|CAUSES||216|222|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|224|237
SE|00000000||tx|1|relation|11|1|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsants||||1000|57|71|VERB|CAUSES||216|222|1|1|C0151559|Central nervous system depression (disorder)|dsyn|dsyn|||CNS depression||||1000|224|237


SE|00000000||tx|1|text|Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||1000|1|9
SE|00000000||tx|1|entity|C0050559|Acitretin|orch,phsu|||acitretin||||1000|15|23
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|52|60
SE|00000000||tx|1|entity|C0033618|Protein Binding|moft|||protein binding||||1000|67|81
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|86|94
SE|00000000||tx|1|relation|3|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|52|60|VERB|COEXISTS_WITH||28|32|2|1|C0050559|Acitretin|orch,phsu|orch|||acitretin||||1000|15|23
SE|00000000||tx|1|relation|3|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|52|60|VERB|COEXISTS_WITH||28|32|2|1|C0031507|Phenytoin|orch,phsu|orch|||Phenytoin||||1000|1|9


SE|00000000||tx|1|text|In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|6|10
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||827|32|39
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|56|59
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||haloperidol||||888|61|71
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|77|84
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||623|87|92
SE|00000000||tx|1|entity|C0018546|Haloperidol|orch,phsu|||haloperidol||||623|94|104
SE|00000000||tx|1|entity|C0449820|Score|qnco|||scores||||861|154|159
SE|00000000||tx|1|entity|C0029941|Brief Psychiatric Rating Scale|diap,inpr|||Brief Psychiatric Rating Scale||||1000|168|197
SE|00000000||tx|1|entity|C1442488|Baseline|qnco|||baseline||||1000|219|226


SE|00000000||tx|1|text|Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
SE|00000000||tx|1|entity|C0014695|Ergocalciferol|orch,phsu,vita|||Vitamin D||||901|12|20
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||901|22|27
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|61|68
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|81|89
SE|00000000||tx|1|entity|C0020437|Hypercalcemia|dsyn|||hypercalcemia||||1000|110|122
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|132|139
SE|00000000||tx|1|entity|C0003811|Cardiac Arrhythmia|patf|||cardiac arrhythmias||||1000|157|175
SE|00000000||tx|1|relation|3|2|C0014695|Ergocalciferol|orch,phsu,vita|phsu|||Vitamin D||||901|12|20|PREP|TREATS||58|59|6|1|C0030705|Patients|podg,humn|podg|||patients||||1000|61|68
SE|00000000||tx|1|relation|5|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||1000|81|89|VERB|TREATS||70|79|4|1|C0030705|Patients|podg,humn|podg|||patients||||1000|61|68
SE|00000000||tx|1|relation|7|1|C0020437|Hypercalcemia|dsyn|dsyn|||hypercalcemia||||1000|110|122|PREP|PROCESS_OF||124|125|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|132|139


SE|00000000||tx|1|text|Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||Erythromycin||||1000|1|12
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||1000|48|56
SE|00000000||tx|1|entity|C0040879|Triazolam|orch,phsu|||triazolam||||1000|61|69
SE|00000000||tx|1|entity|C0026056|Midazolam|orch,phsu|||midazolam||||1000|75|83
SE|00000000||tx|1|entity|C0728866|Drug effect|ftcn|||pharmacologic effect||||983|111|130
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepines||||1000|141|155
SE|00000000||tx|1|relation|1|1|C0014806|Erythromycin|antb,orch|antb|||Erythromycin||||1000|1|12|VERB|INHIBITS||35|42|5|2|C0040879|Triazolam|orch,phsu|orch|||triazolam||||1000|61|69


SE|00000000||tx|1|text|Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
SE|00000000||tx|1|entity|C0068333|nabilone|orch,phsu|||Nabilone||||1000|1|8
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|49|56
SE|00000000||tx|1|entity|C0033978|Psychotropic Drugs|phsu|||psychoactive drugs||||1000|79|96
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CNS depressants||||1000|101|115
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|128|134
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|137|148
SE|00000000||tx|1|entity|C0027409|Narcotic Analgesics|phsu|||narcotic analgesics||||1000|154|172
SE|00000000||tx|1|entity|C0332287|In addition to|qlco|||with||||888|187|190
SE|00000000||tx|1|entity|C0019665|Historical aspects qualifier|inpr|||history||||888|194|200
SE|00000000||tx|1|entity|C0004936|Mental disorders|mobd|||psychiatric disorder||||1000|205|224
SE|00000000||tx|1|entity|C0005586|Bipolar Disorder|mobd|||manic-depressive illness||||1000|237|260
SE|00000000||tx|1|entity|C0036341|Schizophrenia|mobd|||schizophrenia||||1000|266|278
SE|00000000||tx|1|relation|9|1|C0033978|Psychotropic Drugs|phsu|phsu|||psychoactive drugs||||1000|79|96|VERB|ADMINISTERED_TO||66|71|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|49|56
SE|00000000||tx|1|relation|9|1|C0007681|Central Nervous System Depressants|phsu|phsu|||CNS depressants||||1000|101|115|VERB|ADMINISTERED_TO||66|71|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|49|56


SE|00000000||tx|1|text|Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.
SE|00000000||tx|1|entity|C0596723|human data|inpr,resa|||Human pharmacokinetic data||||913|1|26
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||851|42|45
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||851|47|58
SE|00000000||tx|1|entity|C0522501|Massive|qlco|||markedly||||851|60|67
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|82|91
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|96|104
SE|00000000||tx|1|entity|C0205454|Eight|qnco|||eight-||||775|127|132
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||775|133|136
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||775|138|145
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|150|152
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|157|165
SE|00000000||tx|1|relation|2|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||851|47|58|VERB|INHIBITS||69|76|5|2|C0072916|Cisapride|orch,phsu|orch|||cisapride||||1000|96|104


SE|00000000||tx|1|text|Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||Aspirin||||1000|1|7
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroids||||1000|55|69
SE|00000000||tx|1|entity|C0020640|Inherited Factor II deficiency|dsyn|||hypoprothrombinemia||||1000|74|92
SE|00000000||tx|1|relation|2|1|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroids||||1000|55|69|PREP|ASSOCIATED_WITH||71|72|1|1|C0020640|Inherited Factor II deficiency|dsyn|dsyn|||hypoprothrombinemia||||1000|74|92


SE|00000000||tx|1|text|While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug-drug interaction||||854|18|38
SE|00000000||tx|1|entity|C0947630|Scientific Study|lbpr|||studies||||854|40|46
SE|00000000||tx|1|entity|C0014892|Estazolam|orch,phsu|||estazolam||||1000|71|79
SE|00000000||tx|1|entity|||gngm|1574|CYP3A|CYP3A||||1000|97|101
SE|00000000||tx|1|entity|C0205198|Compound|qlco|||compounds||||966|104|112
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||560|123|128
SE|00000000||tx|1|entity|||gngm|1574|CYP3A|CYP3A||||560|130|134
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|154|166
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|169|177
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|180|187
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||barbiturates||||1000|194|205
SE|00000000||tx|1|entity|C0014892|Estazolam|orch,phsu|||estazolam||||888|238|246
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|248|261
SE|00000000||tx|1|relation|5|2|||gngm,aapp|gngm|1574|CYP3A|CYP3A||||1000|97|101|NOM|STIMULATES||136|143|5|0|||gngm,aapp|gngm|1574|CYP3A|CYP3A||||560|130|134
SE|00000000||tx|1|relation|10|9|C0014892|Estazolam|orch,phsu|orch|||estazolam||||1000|71|79|VERB|INHIBITS||229|236|1|1|C0014892|Estazolam|orch,phsu|orch|||estazolam||||888|238|246


SE|00000000||tx|1|text|Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.
SE|00000000||tx|1|entity|C0242531|Vecuronium|phsu,strd|||Vecuronium||||1000|1|10
SE|00000000||tx|1|entity|C2712230|Perioperative Period|tmco|||perioperative period||||1000|30|49
SE|00000000||tx|1|entity|C0031955|Piperacillin|antb,orch|||piperacillin||||1000|52|63
SE|00000000||tx|1|entity|C0700323|Observation of Neuromuscular Block|dsyn|||neuromuscular blockade||||1000|112|133
SE|00000000||tx|1|entity|C0242531|Vecuronium|phsu,strd|||vecuronium||||1000|138|147


SE|00000000||tx|1|text|If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||851|4|14
SE|00000000||tx|1|entity|C0939679|Axert|orch,phsu|||AXERT||||1000|31|35
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRI||||1000|44|47
SE|00000000||tx|1|entity|C1548787|Appropriate|qlco|||appropriate||||888|74|84
SE|00000000||tx|1|entity|C1964257|Observation - diagnostic procedure|diap|||observation||||888|86|96
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|105|111


SE|00000000||tx|1|text|If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||861|4|11
SE|00000000||tx|1|entity|C0008425|Cholinesterase Inhibitors|orch,phsu|||anticholinesterase agents||||861|14|38
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||least||||890|63|67
SE|00000000||tx|1|entity|C0439584|24 hour time frame|tmco|||24 hours||||890|69|76
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiating||||890|85|94
SE|00000000||tx|1|entity|C0149783|Steroid therapy|topp|||corticosteroid therapy||||890|96|117


SE|00000000||tx|1|text|The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|5|8
SE|00000000||tx|1|entity|C1706947|Bioavailability Study|resa|||bioavailability||||888|10|24
SE|00000000||tx|1|entity|C0014310|Enoxacin|orch,phsu|||enoxacin||||1000|29|36
SE|00000000||tx|1|entity|C0034665|Ranitidine|orch,phsu|||ranitidine||||1000|81|90


SE|00000000||tx|1|text|Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.
SE|00000000||tx|1|entity|C0002403|Amantadine|orch,phsu|||Amantadine||||1000|1|10
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|13|37
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAOIs||||966|44|48
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|79|84
SE|00000000||tx|1|entity|C0055877|clidinium|orch,phsu|||clidinium||||1000|89|97
SE|00000000||tx|1|relation|3|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||MAOIs||||966|44|48|NOM|INTERACTS_WITH||79|84|1|1|C0055877|clidinium|orch,phsu|orch|||clidinium||||1000|89|97
SE|00000000||tx|1|relation|3|1|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|13|37|NOM|INTERACTS_WITH||79|84|1|1|C0055877|clidinium|orch,phsu|orch|||clidinium||||1000|89|97
SE|00000000||tx|1|relation|3|1|C0002403|Amantadine|orch,phsu|orch|||Amantadine||||1000|1|10|NOM|INTERACTS_WITH||79|84|1|1|C0055877|clidinium|orch,phsu|orch|||clidinium||||1000|89|97


SE|00000000||tx|1|text|Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.
SE|00000000||tx|1|entity|C0012802|Thiazide Diuretics|orch,phsu|||thiazide diuretics||||1000|19|36
SE|00000000||tx|1|entity|C0020626|Hypoparathyroidism|dsyn|||hypoparathyroid||||888|41|55
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|57|64
SE|00000000||tx|1|entity|C0014695|Ergocalciferol|orch,phsu,vita|||ergocalciferol||||1000|106|119
SE|00000000||tx|1|entity|C0020437|Hypercalcemia|dsyn|||hypercalcemia||||1000|131|143
SE|00000000||tx|1|relation|4|1|C0012802|Thiazide Diuretics|orch,phsu|orch|||thiazide diuretics||||1000|19|36|NOM|ADMINISTERED_TO||1|14|4|2|C0030705|Patients|podg,humn|humn|||patients||||888|57|64
SE|00000000||tx|1|relation|0|0|C0020626|Hypoparathyroidism|dsyn|dsyn|||hypoparathyroid||||888|41|55|MOD/HEAD|PROCESS_OF||41|64|0|0|C0030705|Patients|podg,humn|humn|||patients||||888|57|64
SE|00000000||tx|1|relation|2|1|C0014695|Ergocalciferol|orch,phsu,vita|phsu|||ergocalciferol||||1000|106|119|VERB|TREATS||93|99|3|1|C0030705|Patients|podg,humn|podg|||patients||||888|57|64
SE|00000000||tx|1|relation|0|0|C0014695|Ergocalciferol|orch,phsu,vita|phsu|||ergocalciferol||||1000|106|119|INFER|TREATS(INFER)||93|99|0|0|C0020626|Hypoparathyroidism|dsyn|dsyn|||hypoparathyroid||||888|41|55


SE|00000000||tx|1|text|THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.
SE|00000000||tx|1|entity|C3266814|Action|acty|||ACTION||||861|18|23
SE|00000000||tx|1|entity|C0020404|Hydroxyzine|orch,phsu|||HYDROXYZINE||||1000|28|38
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||DRUG||||1000|68|71
SE|00000000||tx|1|entity|C0007681|Central Nervous System Depressants|phsu|||CENTRAL NERVOUS SYSTEM DEPRESSANTS||||1000|101|134
SE|00000000||tx|1|entity|C0027415|Narcotics|hops,phsu|||NARCOTICS||||1000|144|152
SE|00000000||tx|1|entity|C0242937|Analgesics, Non-Narcotic|phsu|||NON-NARCOTIC ANALGESICS||||1000|155|177
SE|00000000||tx|1|entity|C0004745|Barbiturates|orch,phsu|||BARBITURATES||||1000|183|194
SE|00000000||tx|1|relation|0|0|C0027415|Narcotics|hops,phsu|hops|||NARCOTICS||||1000|144|152|SPEC|ISA||101|152|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CENTRAL NERVOUS SYSTEM DEPRESSANTS||||1000|101|134
SE|00000000||tx|1|relation|0|0|C0004745|Barbiturates|orch,phsu|orch|||BARBITURATES||||1000|183|194|SPEC|ISA||101|152|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CENTRAL NERVOUS SYSTEM DEPRESSANTS||||1000|101|134
SE|00000000||tx|1|relation|0|0|C0242937|Analgesics, Non-Narcotic|phsu|phsu|||NON-NARCOTIC ANALGESICS||||1000|155|177|SPEC|ISA||101|152|0|0|C0007681|Central Nervous System Depressants|phsu|phsu|||CENTRAL NERVOUS SYSTEM DEPRESSANTS||||1000|101|134


SE|00000000||tx|1|text|Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||888|31|42
SE|00000000||tx|1|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||888|44|50
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|57|65
SE|00000000||tx|1|entity|C0025519|Metabolism|orgf|||metabolism||||1000|81|90
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||1000|95|97
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|114|118
SE|00000000||tx|1|relation|3|1|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||1000|57|65|VERB|AFFECTS||71|75|3|1|C0025519|Metabolism|orgf|orgf|||metabolism||||1000|81|90


SE|00000000||tx|1|text|Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.
SE|00000000||tx|1|entity|C0701063|Cerubidine|orch,phsu|||Cerubidine||||1000|8|17
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|24|30
SE|00000000||tx|1|entity|C1514756|Receive|qlco|||received||||790|51|58
SE|00000000||tx|1|entity|C0013089|Doxorubicin|antb,orch|||doxorubicin||||790|60|70
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|86|89
SE|00000000||tx|1|entity|C0876994|cardiac toxicity|inpo|||cardiotoxicity||||1000|94|107
SE|00000000||tx|1|relation|2|1|C0701063|Cerubidine|orch,phsu|phsu|||Cerubidine||||1000|8|17|PREP|TREATS||19|20|4|1|C0030705|Patients|podg,humn|podg|||patient||||1000|24|30
SE|00000000||tx|1|relation|4|1|C0013089|Doxorubicin|antb,orch|antb|||doxorubicin||||790|60|70|NOM|PREDISPOSES||86|89|1|1|C0876994|cardiac toxicity|inpo|inpo|||cardiotoxicity||||1000|94|107


SE|00000000||tx|1|text|SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRIs||||1000|1|5
SE|00000000||tx|1|entity|C0004093|Asthenia|sosy|||Weakness||||888|8|15
SE|00000000||tx|1|entity|C0151889|Hyperreflexia|fndg|||hyperreflexia||||888|17|29
SE|00000000||tx|1|entity|C0520966|Abnormal coordination|sosy|||incoordination||||1000|36|49
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||rarely||||1000|70|75
SE|00000000||tx|1|entity|C0439084|>5|qnco|||5-HT1||||851|82|86
SE|00000000||tx|1|entity|C0450565|HT1|blor|||5-HT1||||851|82|86
SE|00000000||tx|1|entity|C0243192|agonists|phsu|||agonists||||851|88|95
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRIs||||1000|128|132


SE|00000000||tx|1|text|Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||Agents||||966|1|6
SE|00000000||tx|1|entity|C0035100|Chymosin|aapp,enzy,phsu|||Renin||||888|16|20
SE|00000000||tx|1|entity|C0391871|Released (action)|ftcn|||Release||||888|22|28
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|52|57
SE|00000000||tx|1|entity|C0014025|Enalapril|aapp,phsu|||enalapril||||1000|62|70
SE|00000000||tx|1|entity|C0014025|Enalapril|aapp,phsu|||enalapril||||694|76|84
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensive agents||||1000|105|127
SE|00000000||tx|1|entity|C0035100|Chymosin|aapp,enzy,phsu|||renin||||888|140|144
SE|00000000||tx|1|entity|C0391871|Released (action)|ftcn|||release||||888|146|152
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|161|169
SE|00000000||tx|1|relation|5|5|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|161|169|NOM|INTERACTS_WITH||52|57|5|1|C0014025|Enalapril|aapp,gngm,phsu|aapp|||enalapril||||1000|62|70
SE|00000000||tx|1|relation|5|5|C0012798|Diuretics|phsu|phsu|||diuretics||||1000|161|169|NOM|INTERACTS_WITH||52|57|5|1|C0014025|Enalapril|aapp,gngm,phsu|aapp|||enalapril||||694|76|84


SE|00000000||tx|1|text|Chlorprothixene may increase the plasma-level of concomitantly given lithium.
SE|00000000||tx|1|entity|C0008290|Chlorprothixene|orch,phsu|||Chlorprothixene||||1000|1|15
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma-||||888|34|40
SE|00000000||tx|1|entity|C2946261|Level|phsu|||level||||888|41|45
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||827|70|76
SE|00000000||tx|1|relation|1|1|C0008290|Chlorprothixene|orch,phsu|orch|||Chlorprothixene||||1000|1|15|VERB|STIMULATES||21|28|2|2|C0023870|Lithium|elii,phsu|elii|||lithium||||827|70|76


SE|00000000||tx|1|text|Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.
SE|00000000||tx|1|entity|C0003232|Antibiotics|antb|||Antibiotics||||1000|1|11
SE|00000000||tx|1|entity|C0003240|Macrolide Antibiotics|antb,orch|||Macrolide antibiotics||||1000|14|34
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|66|76
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decrease||||888|78|85
SE|00000000||tx|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroid||||888|90|103
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|105|113
SE|00000000||tx|1|relation|2|1|C0003240|Macrolide Antibiotics|antb,orch|antb|||Macrolide antibiotics||||1000|14|34|NOM|INHIBITS||78|85|1|1|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|horm|||corticosteroid||||888|90|103


SE|00000000||tx|1|text|Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
SE|00000000||tx|1|entity|C0001675|Adult|aggp|||adult||||888|10|14
SE|00000000||tx|1|entity|C3245479|data|medd|||data||||888|16|19
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||861|28|32
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|37|44
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|90|94
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||888|127|134
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|155|164
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|170|181
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||890|188|193
SE|00000000||tx|1|entity|C0366376|Caffeine:Mass:Point in time:Dose med or substance:Quantitative|clna|||caffeine doses||||890|195|208
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|254|258
SE|00000000||tx|1|entity|C0006644|Caffeine|orch,phsu|||caffeine||||888|274|281
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|302|314
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|320|328


SE|00000000||tx|1|text|The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|5|11
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medicinal products||||1000|16|33
SE|00000000||tx|1|entity|C2348205|Similarity|qlco|||similar||||888|40|46
SE|00000000||tx|1|entity|C1292721|Has property|ftcn|||properties||||888|48|57
SE|00000000||tx|1|entity|C0128513|Milrinone|orch,phsu|||milrinone||||861|77|85
SE|00000000||tx|1|entity|C0116190|Enoximone|orch,phsu|||enoximone||||1000|88|96
SE|00000000||tx|1|entity|C0002697|Inamrinone|orch,phsu|||amrinone||||1000|99|106
SE|00000000||tx|1|entity|C0637063|olprinone|orch,phsu|||olprinone||||1000|109|117
SE|00000000||tx|1|entity|C0055729|cilostazol|orch,phsu|||cilostazol||||1000|123|132
SE|00000000||tx|1|entity|C0051809|anagrelide|orch,phsu|||anagrelide||||1000|156|165
SE|00000000||tx|1|relation|8|4|C0116190|Enoximone|orch,phsu|orch|||enoximone||||1000|88|96|NOM|INTERACTS_WITH||5|11|8|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medicinal products||||1000|16|33
SE|00000000||tx|1|relation|8|4|C0055729|cilostazol|orch,phsu|orch|||cilostazol||||1000|123|132|NOM|INTERACTS_WITH||5|11|8|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medicinal products||||1000|16|33
SE|00000000||tx|1|relation|8|4|C0637063|olprinone|orch,phsu|orch|||olprinone||||1000|109|117|NOM|INTERACTS_WITH||5|11|8|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medicinal products||||1000|16|33
SE|00000000||tx|1|relation|8|4|C0002697|Inamrinone|orch,phsu|orch|||amrinone||||1000|99|106|NOM|INTERACTS_WITH||5|11|8|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medicinal products||||1000|16|33
SE|00000000||tx|1|relation|8|4|C0128513|Milrinone|orch,phsu|orch|||milrinone||||861|77|85|NOM|INTERACTS_WITH||5|11|8|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medicinal products||||1000|16|33


SE|00000000||tx|1|text|Concomitant use of HIVID with didanosine is not recommended.
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|1|11
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|13|15
SE|00000000||tx|1|entity|C0678123|Hivid|nnon,phsu|||HIVID||||1000|20|24
SE|00000000||tx|1|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||1000|31|40
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|45|47


SE|00000000||tx|1|text|Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.
SE|00000000||tx|1|entity|C0036579|Selegiline|orch,phsu|||Selegiline||||802|1|10
SE|00000000||tx|1|entity|C0031453|Phenylalanine|aapp,bacs,phsu|||phenylalanine||||802|16|28
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||MAO inhibitor||||824|48|60
SE|00000000||tx|1|entity|C0036579|Selegiline|orch,phsu|||selegiline||||824|62|71
SE|00000000||tx|1|entity|C2986495|Synergistic|qlco|||synergistic||||851|82|92
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressant||||851|94|107
SE|00000000||tx|1|entity|C0439167|Percent Activity|qnco|||activity||||851|109|116
SE|00000000||tx|1|relation|0|0|C0036579|Selegiline|orch,phsu|orch|||selegiline||||824|62|71|MOD/HEAD|ISA||48|71|0|0|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||MAO inhibitor||||824|48|60


SE|00000000||tx|1|text|Nevertheless, caution is indicated in the co-administration of T.A. with any of the SSRIs and also in switching from one class to the other.
SE|00000000||tx|1|entity|C0193959|Tonsillectomy and adenoidectomy|topp|||T.A||||1000|64|66
SE|00000000||tx|1|entity|C0360105|Selective serotonin re-uptake inhibitor|phsu|||SSRIs||||1000|85|89
SE|00000000||tx|1|entity|C0205447|One|qnco|||one||||888|118|120
SE|00000000||tx|1|entity|C0456387|Class|inpr|||class||||888|122|126


SE|00000000||tx|1|text|Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||Atorvastatin||||1000|1|12
SE|00000000||tx|1|entity|C0286651|atorvastatin|orch,phsu|||Atorvastatin||||1000|15|26
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|42|44
SE|00000000||tx|1|entity|C0028356|Norethindrone|horm,phsu,strd|||norethindrone||||1000|50|62
SE|00000000||tx|1|entity|C0015011|Ethinyl Estradiol|horm,phsu,strd|||ethinyl estradiol||||1000|68|84


SE|00000000||tx|1|text|Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||Digoxin||||1000|1|7
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||Digoxin||||888|10|16
SE|00000000||tx|1|entity|C0086045|Mental concentration|menp|||concentrations||||888|18|31
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|65|71
SE|00000000||tx|1|entity|C0054836|carvedilol|orch,phsu|||carvedilol||||1000|77|86


SE|00000000||tx|1|text|Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||Rifampin||||1000|1|8
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|21|31
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||single||||888|53|58
SE|00000000||tx|1|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||888|60|63
SE|00000000||tx|1|entity|C0718644|Arava|orch,phsu|||ARAVA||||1000|68|72
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||966|77|84
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multiple||||888|96|103
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|105|109
SE|00000000||tx|1|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|114|121
SE|00000000||tx|1|entity|C0444505|Peak level|qnco|||peak levels||||884|127|137
SE|00000000||tx|1|entity|C0439509|/40|tmco|||40%||||1000|156|158
SE|00000000||tx|1|entity|C0718644|Arava|orch,phsu|||ARAVA||||1000|182|186
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|198|202


SE|00000000||tx|1|text|Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||Phenytoin||||1000|1|9
SE|00000000||tx|1|entity|C0392747|Changing|ftcn|||Altered||||790|12|18
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||790|20|24
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|36|44
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||decreased||||1000|61|69
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|94|101
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|113|123
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||888|125|137
SE|00000000||tx|1|relation|4|2|C0031507|Phenytoin|orch,phsu|phsu|||phenytoin||||1000|36|44|PREP|TREATS||91|92|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|94|101
SE|00000000||tx|1|relation|1|1|C0008809|Ciprofloxacin|orch,phsu|orch|||ciprofloxacin||||888|125|137|VERB|ADMINISTERED_TO||103|111|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|94|101


SE|00000000||tx|1|text|Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary
SE|00000000||tx|1|entity|C0020402|hydroxyurea|orch,phsu|||hydroxyurea||||1000|7|17
SE|00000000||tx|1|entity|C0455272|Serum urate measurement|lbpr|||serum uric acid level||||1000|33|53
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||694|56|61
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medication||||861|88|97


SE|00000000||tx|1|text|Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a further deterioration of renal function.
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||Non-steroidal Anti-inflammatory Agents||||1000|1|38
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|49|56
SE|00000000||tx|1|entity|C2945640|compromise|fndg|||compromised||||865|63|73
SE|00000000||tx|1|entity|C0232804|Renal function|ortf|||renal function||||865|75|88
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||non-steroidal anti-inflammatory drugs||||991|117|153
SE|00000000||tx|1|entity|C0065374|Lisinopril|aapp,phsu|||lisinopril||||1000|181|190
SE|00000000||tx|1|entity|C1517331|Further|spco|||further||||888|208|214
SE|00000000||tx|1|entity|C0868945|Deterioration|phpr|||deterioration||||888|216|228
SE|00000000||tx|1|entity|C0232804|Renal function|ortf|||renal function||||1000|233|246
SE|00000000||tx|1|relation|1|1|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||Non-steroidal Anti-inflammatory Agents||||1000|1|38|PREP|TREATS||41|42|7|1|C0030705|Patients|podg,humn|podg|||patients||||1000|49|56
SE|00000000||tx|1|relation|6|1|C0232804|Renal function|ortf|ortf|||renal function||||865|75|88|PREP|PROCESS_OF||58|61|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|49|56


SE|00000000||tx|1|text|Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Medications||||861|18|28
SE|00000000||tx|1|entity|C0042402|Vasodilator Agents|phsu|||Vasodilators||||1000|34|45
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||901|52|60
SE|00000000||tx|1|entity|C0877248|Adverse event|fndg|||adverse events||||901|62|75
SE|00000000||tx|1|entity|C0205172|More|ftcn|||more||||861|94|97
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|111|118
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||802|130|140
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications||||802|159|169
SE|00000000||tx|1|entity|C0042402|Vasodilator Agents|phsu|||vasodilators||||1000|174|185
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|208|215
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|217|219
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|237|247
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|249|253
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||861|266|276
SE|00000000||tx|1|entity|C0027051|Myocardial Infarction|dsyn|||myocardial infarction||||901|289|309
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||790|321|327
SE|00000000||tx|1|entity|C0032285|Pneumonia|dsyn|||pneumonia||||790|329|337
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||790|349|355
SE|00000000||tx|1|entity|C0085639|Falls|fndg|||falls||||790|357|361
SE|00000000||tx|1|entity|C1266909|Entire bony skeleton|bdsy|||bone||||1000|377|380
SE|00000000||tx|1|entity|C0409497|Joint injury|inpo|||joint injuries||||884|386|399
SE|00000000||tx|1|relation|3|1|C0877248|Adverse event|fndg|fndg|||adverse events||||901|62|75|PREP|PROCESS_OF||108|109|6|1|C0030705|Patients|podg,humn|humn|||patients||||1000|111|118
SE|00000000||tx|1|relation|5|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medications||||802|159|169|VERB|ADMINISTERED_TO||120|128|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|111|118
SE|00000000||tx|1|relation|2|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|249|253|VERB|ADMINISTERED_TO|negation|221|229|7|1|C0030705|Patients|podg,humn|humn|||patients||||1000|208|215


SE|00000000||tx|1|text|Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||Phenobarbital||||1000|1|13
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|32|44
SE|00000000||tx|1|entity|C0060135|felbamate|orch,phsu|||felbamate||||890|64|72
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma felbamate concentrations||||890|57|87
SE|00000000||tx|1|relation|2|1|C0031412|Phenobarbital|orch,phsu|orch|||phenobarbital||||1000|32|44|VERB|INHIBITS||50|55|1|1|C0060135|felbamate|orch,phsu|orch|||felbamate||||890|64|72


SE|00000000||tx|1|text|Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.
SE|00000000||tx|1|entity|C0033493|Propoxyphene|orch,phsu|||propoxyphene||||1000|21|32
SE|00000000||tx|1|entity|C0806909|Maximum|qnco|||maximum||||901|48|54
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||901|56|75
SE|00000000||tx|1|entity|C0002333|Alprazolam|orch,phsu|||alprazolam||||1000|80|89
SE|00000000||tx|1|entity|C0205216|Decreased|qnco|||decreased||||888|98|106
SE|00000000||tx|1|entity|C0449297|Clearance|qlco|||clearance||||888|108|116
SE|00000000||tx|1|entity|C0450361|38|inpr|||38%||||1000|121|123
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||901|130|138
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||901|140|148
SE|00000000||tx|1|relation|2|1|C0033493|Propoxyphene|orch,phsu|orch|||propoxyphene||||1000|21|32|VERB|INHIBITS||34|42|4|2|C0002333|Alprazolam|orch,phsu|orch|||alprazolam||||1000|80|89


SE|00000000||tx|1|text|Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0013360|Dyphylline|orch,phsu|||dyphylline||||1000|30|39
SE|00000000||tx|1|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|45|54
SE|00000000||tx|1|entity|C0232819|Tubular secretion|ortf|||tubular secretion||||1000|76|92
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||901|126|131
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||901|133|141
SE|00000000||tx|1|entity|C0013360|Dyphylline|orch,phsu|||dyphylline||||1000|146|155


SE|00000000||tx|1|text|The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued.
SE|00000000||tx|1|entity|C2348767|Therapeutic Efficacy|qlco|||therapeutic efficacy||||1000|5|24
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|29|53
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|83|90
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|97|106
SE|00000000||tx|1|relation|2|1|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|29|53|PREP|TREATS||74|75|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|83|90


SE|00000000||tx|1|text|Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||Warfarin||||1000|1|8
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|15|21
SE|00000000||tx|1|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|26|33
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|39|44
SE|00000000||tx|1|entity|C0017181|Gastrointestinal Hemorrhage|patf|||GI bleeding||||1000|49|59
SE|00000000||tx|1|entity|C2986495|Synergistic|qlco|||synergistic||||1000|65|75
SE|00000000||tx|1|entity|C1706077|user - individual|humn|||users||||1000|88|92
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|102|106
SE|00000000||tx|1|entity|C1883357|Together|qlco|||together||||888|108|115
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|124|127
SE|00000000||tx|1|entity|C0205404|Serious|qlco|||serious||||901|132|138
SE|00000000||tx|1|entity|C0017181|Gastrointestinal Hemorrhage|patf|||GI bleeding||||901|140|150
SE|00000000||tx|1|entity|C0205250|High|qlco|||higher||||966|152|157
SE|00000000||tx|1|entity|C1706077|user - individual|humn|||users||||1000|164|168
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||861|180|183
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|185|189
SE|00000000||tx|1|relation|5|4|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||861|180|183|NOM|PREDISPOSES||124|127|5|1|C0017181|Gastrointestinal Hemorrhage|patf|patf|||GI bleeding||||901|140|150


SE|00000000||tx|1|text|Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||Indomethacin||||851|1|12
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||851|16|26
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||851|28|30
SE|00000000||tx|1|entity|C0017797|Glutamine|aapp,bacs,phsu|||L-glutamine||||1000|35|45
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|51|62
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||851|79|87
SE|00000000||tx|1|entity|C0021853|Intestines|bpoc|||intestinal||||851|89|98
SE|00000000||tx|1|entity|C0031164|Permeability|npop|||permeability||||851|100|111
SE|00000000||tx|1|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|123|134


SE|00000000||tx|1|text|However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.
SE|00000000||tx|1|entity|C1548787|Appropriate|qlco|||appropriate||||694|10|20
SE|00000000||tx|1|entity|C0005802|Blood Glucose|carb|||blood glucose||||1000|36|48
SE|00000000||tx|1|entity|C1704686|Initiation|ftcn|||initiating||||872|75|84
SE|00000000||tx|1|entity|C1174755|Extraneal|carb,phsu|||EXTRANEAL||||872|86|94
SE|00000000||tx|1|entity|C0241863|DIABETIC|fndg|||diabetic||||888|99|106
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|108|115
SE|00000000||tx|1|entity|C0021641|Insulin|aapp,horm,phsu|||insulin||||888|121|127
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||888|129|134
SE|00000000||tx|1|relation|0|0|C0241863|DIABETIC|fndg|fndg|||diabetic||||888|99|106|MOD/HEAD|PROCESS_OF||99|115|0|0|C0030705|Patients|podg,humn|humn|||patients||||888|108|115
SE|00000000||tx|1|relation|3|1|C1174755|Extraneal|carb,phsu|phsu|||EXTRANEAL||||872|86|94|PREP|TREATS||96|97|2|1|C0030705|Patients|podg,humn|podg|||patients||||888|108|115
SE|00000000||tx|1|relation|0|0|C1174755|Extraneal|carb,phsu|phsu|||EXTRANEAL||||872|86|94|INFER|TREATS(INFER)||96|97|0|0|C0241863|DIABETIC|fndg|fndg|||diabetic||||888|99|106


SE|00000000||tx|1|text|Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained
SE|00000000||tx|1|entity|C0008273|Chlorothiazide|orch,phsu|||chlorothiazide||||1000|17|30
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||non-steroidal anti-inflammatory agents||||1000|36|73
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patient||||1000|103|109
SE|00000000||tx|1|entity|C0871633|desires|menp|||desired||||872|158|164
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||872|166|171
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretic||||1000|180|187
SE|00000000||tx|1|relation|4|3|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||non-steroidal anti-inflammatory agents||||1000|36|73|NOM|INTERACTS_WITH||166|171|1|1|C0012798|Diuretics|phsu|phsu|||diuretic||||1000|180|187
SE|00000000||tx|1|relation|4|3|C0008273|Chlorothiazide|orch,phsu|phsu|||chlorothiazide||||1000|17|30|NOM|INTERACTS_WITH||166|171|1|1|C0012798|Diuretics|phsu|phsu|||diuretic||||1000|180|187


SE|00000000||tx|1|text|Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.
SE|00000000||tx|1|entity|C0086548|Leukocyte Transfusion|topp|||Leukocyte transfusions||||1000|1|22
SE|00000000||tx|1|entity|C0205178|acute|tmco|||acute||||901|25|29
SE|00000000||tx|1|entity|C0919924|pulmonary toxicity|patf|||pulmonary toxicity||||901|31|48
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|71|78
SE|00000000||tx|1|entity|C0348016|Intravenous|spco|||intravenous||||901|90|100
SE|00000000||tx|1|entity|C0002679|Amphotericin B|antb,orch|||amphotericin B||||901|102|115
SE|00000000||tx|1|entity|C0086548|Leukocyte Transfusion|topp|||leukocyte transfusions||||1000|121|142
SE|00000000||tx|1|relation|2|1|C0919924|pulmonary toxicity|patf|patf|||pulmonary toxicity||||901|31|48|PREP|PROCESS_OF||68|69|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|71|78
SE|00000000||tx|1|relation|2|1|C0002679|Amphotericin B|antb,orch|antb|||amphotericin B||||901|102|115|VERB|ADMINISTERED_TO||80|88|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|71|78


SE|00000000||tx|1|text|Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||Dose||||888|1|4
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||888|6|14
SE|00000000||tx|1|entity|C0701105|Crixivan|orch,phsu|||CRIXIVAN||||1000|19|26
SE|00000000||tx|1|entity|C1292429|8 Hours|tmco|||8 hours||||1000|44|50
SE|00000000||tx|1|entity|C1515187|Take|hlca|||taking||||744|78|83
SE|00000000||tx|1|entity|C0288165|Delavirdine|orch,phsu|||delavirdine||||744|85|95
SE|00000000||tx|1|entity|C0205449|Three|qnco|||three||||744|104|108
SE|00000000||tx|1|entity|C1632851|Times|qnco|||times||||744|110|114
SE|00000000||tx|1|entity|C0439228|day|tmco|||day||||1000|118|120


SE|00000000||tx|1|text|Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.
SE|00000000||tx|1|entity|C0009279|Colestipol|orch,phsu|||colestipol||||888|20|29
SE|00000000||tx|1|entity|C0035191|Resins, Plant|bodm|||resins||||888|31|36
SE|00000000||tx|1|entity|C0020261|Hydrochlorothiazide|orch,phsu|||hydrochlorothiazide||||1000|53|71
SE|00000000||tx|1|entity|C0003072|Anion Exchange Resins|bodm,irda|||anionic exchange resins||||976|104|126


SE|00000000||tx|1|text|Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.
SE|00000000||tx|1|entity|C0020517|Hypersensitivity|patf|||Hypersensitivity Reactions||||1000|1|26
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|29|36
SE|00000000||tx|1|entity|C0019665|Historical aspects qualifier|inpr|||history||||1000|45|51
SE|00000000||tx|1|entity|C0020517|Hypersensitivity|patf|||hypersensitivity reactions||||901|63|88
SE|00000000||tx|1|entity|C1514468|product|enty|||products||||1000|93|100
SE|00000000||tx|1|entity|C0056476|cremophor EL|carb,phsu|||Cremophor  EL||||1000|113|125
SE|00000000||tx|1|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporin||||1000|132|142
SE|00000000||tx|1|entity|C1272891|Injection concentrate|bodm|||injection concentrate||||1000|148|168
SE|00000000||tx|1|entity|C0039512|Teniposide|carb,phsu|||teniposide||||1000|174|183
SE|00000000||tx|1|entity|C1272891|Injection concentrate|bodm|||injection concentrate||||1000|189|209
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|219|221
SE|00000000||tx|1|entity|C0678133|Taxol|orch,phsu|||TAXOL||||1000|239|243
SE|00000000||tx|1|relation|1|1|C0678133|Taxol|orch,phsu|phsu|||TAXOL||||1000|239|243|VERB|TREATS||226|232|11|8|C0020517|Hypersensitivity|patf|patf|||hypersensitivity reactions||||901|63|88


SE|00000000||tx|1|text|Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.
SE|00000000||tx|1|entity|C0284968|Betaseron|aapp,phsu|||Betaseron||||901|1|9
SE|00000000||tx|1|entity|C0205449|Three|qnco|||three||||890|29|33
SE|00000000||tx|1|entity|C1516213|Cancer Patient|podg|||cancer patients||||890|35|49
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dose||||888|58|61
SE|00000000||tx|1|entity|C1514721|Range|qnco|||range||||888|63|67
SE|00000000||tx|1|entity|C1512045|Dose-dependent|qnco|||dose-dependent||||901|100|113
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||901|115|124
SE|00000000||tx|1|entity|C0003420|Antipyrine|orch,phsu|||antipyrine||||790|129|138
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|159|164
SE|00000000||tx|1|entity|C0558287|Alternate days|tmco|||alternate-day||||901|169|181
SE|00000000||tx|1|entity|C0284968|Betaseron|aapp,phsu|||Betaseron||||1000|212|220
SE|00000000||tx|1|entity|C0683140|Drug Metabolism|moft|||drug metabolism||||1000|225|239
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||861|247|254
SE|00000000||tx|1|entity|C0439673|Unknown|qlco|||unknown||||1000|259|265
SE|00000000||tx|1|relation|0|0|C0284968|Betaseron|aapp,gngm,phsu|phsu|||Betaseron||||901|1|9|NOM|ADMINISTERED_TO||11|24|12|1|C1516213|Cancer Patient|podg,humn|humn|||cancer patients||||890|35|49
SE|00000000||tx|1|relation|6|3|C0284968|Betaseron|aapp,gngm,phsu|aapp|||Betaseron||||1000|212|220|NOM|AFFECTS||159|164|6|4|C0683140|Drug Metabolism|moft|moft|||drug metabolism||||1000|225|239


SE|00000000||tx|1|text|Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.
SE|00000000||tx|1|entity|C0522498|Rare|qlco|||Rarely||||901|1|6
SE|00000000||tx|1|entity|C0161544|Poisoning by salicylate|inpo|||salicylate toxicity||||901|8|26
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|41|48
SE|00000000||tx|1|entity|C0038317|Steroids|strd|||steroids||||1000|66|73
SE|00000000||tx|1|entity|C0444956|High dose|qnco|||high-dose||||857|92|100
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||857|102|108
SE|00000000||tx|1|entity|C0009429|Combined Modality Therapy|topp|||concurrent high-dose aspirin therapy||||857|81|116
SE|00000000||tx|1|relation|1|1|C0161544|Poisoning by salicylate|inpo|inpo|||salicylate toxicity||||901|8|26|VERB|OCCURS_IN||32|36|3|1|C0030705|Patients|podg,humn|podg|||patients||||1000|41|48
SE|00000000||tx|1|relation|0|0|C0009429|Combined Modality Therapy|topp|topp|||concurrent high-dose aspirin therapy||||857|81|116|MOD/HEAD|USES||102|116|0|0|C0004057|Aspirin|orch,phsu|phsu|||aspirin||||857|102|108


SE|00000000||tx|1|text|Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
SE|00000000||tx|1|entity|C0022180|Isoflurane|orch,phsu|||Isoflurane||||1000|1|10
SE|00000000||tx|1|entity|C0014277|Enflurane|orch,phsu|||enflurane||||1000|15|23
SE|00000000||tx|1|entity|C0028215|Nitrous Oxide|bacs,inch,phsu|||nitrous oxide||||824|43|55
SE|00000000||tx|1|entity|C0030054|Oxygen|elii,phsu|||oxygen||||824|57|62
SE|00000000||tx|1|entity|C0599662|magnetic cell separation system|lbpr|||MAC [||||774|80|84
SE|00000000||tx|1|entity|C1440080|Alveolar|bpoc|||Alveolar||||774|93|100
SE|00000000||tx|1|entity|C2827771|Cmin|qnco|||Minimum Alveolar Concentration||||774|85|114
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effective||||790|144|152
SE|00000000||tx|1|entity|C2926735|Duration|phsu|||duration||||790|154|161
SE|00000000||tx|1|entity|C3266814|Action|acty|||action||||1000|166|171
SE|00000000||tx|1|entity|C1279901|Firstly|qlco|||initial||||1000|176|182
SE|00000000||tx|1|entity|C0024501|Maintenance|acty|||maintenance||||888|188|198
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|200|204
SE|00000000||tx|1|entity|C0530102|Nimbex|orch,phsu|||NIMBEX||||1000|209|214
SE|00000000||tx|1|entity|C1514873|Requirement|ftcn|||required||||901|233|240
SE|00000000||tx|1|entity|C2964135|Infusion Rate|tmco|||infusion rate||||901|242|254
SE|00000000||tx|1|entity|C0530102|Nimbex|orch,phsu|||NIMBEX||||1000|259|264


SE|00000000||tx|1|text|Although ROMAZICON exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.
SE|00000000||tx|1|entity|C0591091|Romazicon|orch,phsu|||ROMAZICON||||1000|10|18
SE|00000000||tx|1|entity|C2945599|Mild (qualifier value)|qlco|||slight||||833|29|34
SE|00000000||tx|1|entity|C0205102|Internal|spco|||intrinsic||||833|36|44
SE|00000000||tx|1|entity|C0003286|Anticonvulsants|phsu|||anticonvulsant||||833|46|59
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||833|61|66
SE|00000000||tx|1|entity|C0439181|% suppression|qnco|||suppression||||861|80|90
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||861|110|115
SE|00000000||tx|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepine||||888|122|135
SE|00000000||tx|1|entity|C2987634|Agonist|phsu|||agonist||||888|137|143
SE|00000000||tx|1|entity|C0009951|Convulsions|sosy|||convulsions||||1000|162|172
SE|00000000||tx|1|entity|C0014544|Epilepsy|dsyn|||epileptic||||888|177|185
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||888|187|194
SE|00000000||tx|1|relation|1|1|C0591091|Romazicon|orch,phsu|orch|||ROMAZICON||||1000|10|18|NOM|INTERACTS_WITH||61|66|1|0|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsant||||833|46|59
SE|00000000||tx|1|relation|0|0|C0014544|Epilepsy|dsyn|dsyn|||epileptic||||888|177|185|MOD/HEAD|PROCESS_OF||177|194|0|0|C0030705|Patients|podg,humn|humn|||patients||||888|187|194


SE|00000000||tx|1|text|Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
SE|00000000||tx|1|entity|C1521827|Preparation|ftcn|||preparations||||966|18|29
SE|00000000||tx|1|entity|C0282374|Decongestants|phsu|||decongestants||||1000|39|51
SE|00000000||tx|1|entity|C0002934|Local Anesthetics|phsu|||local anesthetics||||1000|57|73
SE|00000000||tx|1|entity|C0002509|Amines, Sympathomimetic|phsu|||sympathomimetic amine||||1000|93|113
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||epinephrine||||1000|122|132
SE|00000000||tx|1|entity|C0028351|Norepinephrine|nsba,orch,phsu|||norepinephrine||||1000|135|148
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|184|208
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|229|235
SE|00000000||tx|1|entity|C0007412|Catecholamines|nsba,orch,phsu|||catecholamines||||1000|240|253
SE|00000000||tx|1|relation|8|2|C0028351|Norepinephrine|nsba,orch,phsu|nsba|||norepinephrine||||1000|135|148|NOM|INTERACTS_WITH||229|235|1|1|C0007412|Catecholamines|nsba,orch,phsu|nsba|||catecholamines||||1000|240|253


SE|00000000||tx|1|text|Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
SE|00000000||tx|1|entity|C0442802|Excessive|qlco|||Excessive||||851|1|9
SE|00000000||tx|1|entity|C1979768|Neuromuscular|qlco|||neuromuscular||||851|11|23
SE|00000000||tx|1|entity|C0004093|Asthenia|sosy|||weakness||||851|25|32
SE|00000000||tx|1|entity|C0006055|Botulinum Toxins|aapp,hops,phsu|||botulinum toxin||||1000|82|96
SE|00000000||tx|1|entity|C2699488|Resolution|cnce|||resolution||||1000|111|120
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||1000|129|135
SE|00000000||tx|1|entity|C0006055|Botulinum Toxins|aapp,hops,phsu|||botulinum toxin||||861|166|180
SE|00000000||tx|1|relation|4|2|C0006055|Botulinum Toxins|aapp,gngm,hops,phsu|aapp|||botulinum toxin||||1000|82|96|NOM|INTERACTS_WITH||129|135|1|1|C0006055|Botulinum Toxins|aapp,gngm,hops,phsu|aapp|||botulinum toxin||||861|166|180


SE|00000000||tx|1|text|The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.
SE|00000000||tx|1|entity|C0700323|Observation of Neuromuscular Block|dsyn|||neuromuscular blockade||||1000|14|35
SE|00000000||tx|1|entity|C0038627|Succinylcholine|orch,phsu|||succinylcholine||||1000|40|54
SE|00000000||tx|1|entity|C2986417|Unaffected|cnce|||unaffected||||1000|60|69
SE|00000000||tx|1|entity|C0591189|Brevibloc|orch,phsu|||BREVIBLOC||||1000|74|82
SE|00000000||tx|1|entity|C2926735|Duration|phsu|||duration||||1000|93|100
SE|00000000||tx|1|entity|C0700323|Observation of Neuromuscular Block|dsyn|||neuromuscular blockade||||1000|105|126
SE|00000000||tx|1|entity|C1442468|5 Minutes|tmco|||5 minutes||||1000|147|155
SE|00000000||tx|1|entity|C0439232|Minute of time|tmco|||minutes||||861|162|168


SE|00000000||tx|1|text|In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||drug interaction||||901|12|27
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||study||||901|29|33
SE|00000000||tx|1|entity|C0442027|Oral|spco|||orally||||851|57|62
SE|00000000||tx|1|entity|C0004048|Inspiration function|orgf|||inhaled||||851|64|70
SE|00000000||tx|1|entity|C0907850|ciclesonide|bacs,phsu,strd|||ciclesonide||||851|72|82
SE|00000000||tx|1|entity|C0442027|Oral|spco|||oral||||888|88|91
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||888|93|104
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potent||||838|109|114
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||838|116|124
SE|00000000||tx|1|entity|C1142644|Cytochrome P450 3A4|aapp,enzy|1555|CYP2B6|cytochrome P450 3A4||||1000|129|147
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|174|176
SE|00000000||tx|1|entity|C0012203|Diethylstilbestrol|horm,orch,phsu|||des||||888|182|184
SE|00000000||tx|1|entity|C0907850|ciclesonide|bacs,phsu,strd|||ciclesonide||||888|186|196
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||791|201|213
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||791|219|222
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steady state||||1000|227|238
SE|00000000||tx|1|entity|C0907850|ciclesonide|bacs,phsu,strd|||ciclesonide||||1000|257|267
SE|00000000||tx|1|entity|C2346711|About The Same|qlco|||unchanged||||1000|278|286
SE|00000000||tx|1|relation|4|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||888|93|104|NOM|INHIBITS||116|124|9|1|C1142644|Cytochrome P450 3A4|aapp,gngm,enzy|gngm|1555|CYP2B6|cytochrome P450 3A4||||1000|129|147
SE|00000000||tx|1|relation|4|1|C0907850|ciclesonide|bacs,phsu,strd|bacs|||ciclesonide||||851|72|82|NOM|INHIBITS||116|124|9|1|C1142644|Cytochrome P450 3A4|aapp,gngm,enzy|gngm|1555|CYP2B6|cytochrome P450 3A4||||1000|129|147


SE|00000000||tx|1|text|Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
SE|00000000||tx|1|entity|C0020740|Ibuprofen|orch,phsu|||ibuprofen||||1000|12|20
SE|00000000||tx|1|entity|C0023870|Lithium|elii,phsu|||lithium||||1000|26|32
SE|00000000||tx|1|entity|C1550501|Subject -direct target|idcn|||subjects||||966|65|72
SE|00000000||tx|1|entity|C0311392|Physical findings|fndg|||signs||||1000|107|111
SE|00000000||tx|1|entity|C0238242|LITHIUM TOXICITY|inpo|||lithium toxicity||||1000|116|131
SE|00000000||tx|1|relation|3|2|C0023870|Lithium|elii,phsu|phsu|||lithium||||1000|26|32|PREP|TREATS||103|105|2|1|C0311392|Physical findings|fndg|fndg|||signs||||1000|107|111
SE|00000000||tx|1|relation|3|2|C0020740|Ibuprofen|orch,phsu|phsu|||ibuprofen||||1000|12|20|PREP|TREATS||103|105|2|1|C0311392|Physical findings|fndg|fndg|||signs||||1000|107|111


SE|00000000||tx|1|text|Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.
SE|00000000||tx|1|entity|C0026549|Morphine|orch,phsu|||Morphine||||1000|1|8
SE|00000000||tx|1|entity|C0023866|Literature|inpr|||literature||||888|13|22
SE|00000000||tx|1|entity|C1706852|Article|inpr|||article||||888|24|30
SE|00000000||tx|1|entity|C0868939|Controlled release|tmco|||controlled-release||||805|59|76
SE|00000000||tx|1|entity|C0026549|Morphine|orch,phsu|||morphine||||805|78|85
SE|00000000||tx|1|entity|C2347138|Milligram per Capsule|qnco|||mg controlled-release morphine capsule||||805|56|93
SE|00000000||tx|1|entity|C1292425|2 Hours|tmco|||2 hours||||1000|112|118
SE|00000000||tx|1|entity|C0678176|Neurontin|orch,phsu|||Neurontin||||824|138|146
SE|00000000||tx|1|entity|C2347138|Milligram per Capsule|qnco|||mg Neurontin  capsule||||824|135|155
SE|00000000||tx|1|entity|C0060926|gabapentin|orch,phsu|||gabapentin||||790|170|179
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||790|181|183
SE|00000000||tx|1|entity|C0060926|gabapentin|orch,phsu|||gabapentin||||1000|214|223
SE|00000000||tx|1|entity|C0026549|Morphine|orch,phsu|||morphine||||1000|246|253
SE|00000000||tx|1|relation|6|6|C0026549|Morphine|orch,phsu|orch|||Morphine||||1000|1|8|VERB|compared_with||202|209|2|1|C0060926|gabapentin|orch,phsu|orch|||gabapentin||||1000|214|223


SE|00000000||tx|1|text|Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.
SE|00000000||tx|1|entity|C0442027|Oral|spco|||Oral||||888|1|4
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|6|10
SE|00000000||tx|1|entity|C0604279|Antizol|orch,phsu|||Antizol||||1000|15|21
SE|00000000||tx|1|entity|C0439272|ug/g|qnco|||mg/kg||||861|30|34
SE|00000000||tx|1|entity|C0001942|Alcohol dehydrogenase|aapp,enzy|||alcohol dehydrogenase||||901|42|62
SE|00000000||tx|1|entity|C1628982|Percent inhibition|qnco|||inhibition||||901|64|73
SE|00000000||tx|1|entity|C1521828|Rate|qnco|||rate||||1000|102|105
SE|00000000||tx|1|entity|C0001962|Ethanol|orch|||ethanol||||1000|125|131
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||888|137|149
SE|00000000||tx|1|entity|C0439509|/40|tmco|||40%||||888|151|153
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|165|182
SE|00000000||tx|1|entity|C1881878|Moderation|qlco|||moderate||||888|187|194
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|196|200
SE|00000000||tx|1|relation|3|2|C0604279|Antizol|orch,phsu|orch|||Antizol||||1000|15|21|NOM|INHIBITS||64|73|3|0|C0001942|Alcohol dehydrogenase|aapp,gngm,enzy|gngm|||alcohol dehydrogenase||||901|42|62


SE|00000000||tx|1|text|Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
SE|00000000||tx|1|entity|C0007447|Cations|chvs|||Cation||||775|13|18
SE|00000000||tx|1|entity|C2700400|Contain (action)|acty|||Containing||||775|20|29
SE|00000000||tx|1|entity|C1514468|product|enty|||Products||||775|31|38
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|41|50
SE|00000000||tx|1|entity|C0034428|Quinolones|orch|||quinolone||||1000|72|80
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|93|105
SE|00000000||tx|1|entity|C0007447|Cations|chvs|||cation||||775|125|130
SE|00000000||tx|1|entity|C2700400|Contain (action)|acty|||containing||||775|132|141
SE|00000000||tx|1|entity|C1514468|product|enty|||products||||775|143|150
SE|00000000||tx|1|entity|C0024467|Magnesium|elii|||magnesium||||1000|160|168
SE|00000000||tx|1|entity|C0304540|Aluminum-based antacid|inch,phsu|||aluminum antacids||||1000|173|189
SE|00000000||tx|1|entity|C0038633|Sucralfate|carb,phsu|||sucralfate||||1000|192|201
SE|00000000||tx|1|entity|C0592249|Videx|nnon,phsu|||VIDEX||||861|204|208
SE|00000000||tx|1|entity|C0006353|Buffers|irda,phsu|||buffered||||861|219|226
SE|00000000||tx|1|entity|C0304290|Chewable Tablet|bodm|||chewable/buffered tablets||||861|210|234
SE|00000000||tx|1|entity|C1521725|Pediatric|qlco|||pediatric||||694|239|247
SE|00000000||tx|1|entity|C1514468|product|enty|||products||||1000|260|267
SE|00000000||tx|1|entity|C0006675|Calcium|bacs,elii,phsu|||calcium||||1000|280|286
SE|00000000||tx|1|entity|C0302583|Iron|bacs,elii,phsu|||iron||||1000|289|292
SE|00000000||tx|1|entity|C0043481|Zinc|bacs,elii,phsu|||zinc||||1000|298|301
SE|00000000||tx|1|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|348|360
SE|00000000||tx|1|entity|C0229671|Serum|bdsu|||serum||||1000|376|380
SE|00000000||tx|1|entity|C0042036|Urine|bdsu|||urine||||694|386|390


SE|00000000||tx|1|text|Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.
SE|00000000||tx|1|entity|C0700321|Small|qnco|||smaller||||888|7|13
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|15|19
SE|00000000||tx|1|entity|C0001443|Adenosine|nnon,nsba,phsu|||adenosine||||1000|24|32
SE|00000000||tx|1|entity|C1704419|Effective|qlco|||effective||||1000|41|49
SE|00000000||tx|1|entity|C0012582|Dipyridamole|orch,phsu|||dipyridamole||||1000|70|81
SE|00000000||tx|1|relation|3|2|C0001443|Adenosine|nnon,nsba,phsu|nsba|||adenosine||||1000|24|32|NOM|COEXISTS_WITH||58|65|1|1|C0012582|Dipyridamole|orch,phsu|orch|||dipyridamole||||1000|70|81


SE|00000000||tx|1|text|Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||Ketoconazole||||1000|1|12
SE|00000000||tx|1|entity|C1708335|Healthy Subject|qlco|||healthy subjects||||1000|18|33
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|45|56
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||861|61|66
SE|00000000||tx|1|entity|C1999216|Inhibitor|qlco|||inhibitor||||861|68|76
SE|00000000||tx|1|entity|C0585361|Twice a day|tmco|||twice daily||||824|89|99
SE|00000000||tx|1|entity|C1547085|7 days|tmco|||7 days||||1000|105|110
SE|00000000||tx|1|entity|C0205373|Systemic|ftcn|||systemic||||694|113|120
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|132|134
SE|00000000||tx|1|entity|C1506770|lapatinib|orch,phsu|||lapatinib||||1000|140|148
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||762|167|179
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||762|185|188
SE|00000000||tx|1|entity|C0018517|Half-Life|tmco|||half-life||||1000|205|213
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||802|232|235
SE|00000000||tx|1|relation|3|1|C0022625|Ketoconazole|orch,phsu|orch|||ketoconazole||||1000|45|56|NOM|INHIBITS||68|76|3|0|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||861|61|66


SE|00000000||tx|1|text|Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.
SE|00000000||tx|1|entity|C0596545|Experience|menp|||Experience||||1000|1|10
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||nonsteroidal anti-inflammatory drugs||||1000|17|52
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|76|84
SE|00000000||tx|1|entity|C1704675|Interaction|ftcn|||interactions||||966|90|101
SE|00000000||tx|1|entity|C0016860|Furosemide|orch,phsu|||furosemide||||1000|108|117
SE|00000000||tx|1|entity|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|||ACE inhibitors||||1000|123|136


SE|00000000||tx|1|text|Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||Urinary||||901|1|7
SE|00000000||tx|1|entity|C0304461|Acidifying preparation|phsu|||acidifying agents||||901|9|25
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||861|36|40
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||888|53|60
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|62|70
SE|00000000||tx|1|entity|C0002667|Amphetamines|nsba,orch,phsu|||amphetamines||||1000|75|86
SE|00000000||tx|1|relation|2|2|C0304461|Acidifying preparation|phsu|phsu|||acidifying agents||||901|9|25|NOM|STIMULATES||53|60|1|1|C0002667|Amphetamines|nsba,orch,phsu|nsba|||amphetamines||||1000|75|86


SE|00000000||tx|1|text|The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).
SE|00000000||tx|1|entity|C0439165|Percent (qualifier value)|qnco|||percentage||||790|10|19
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||790|21|28
SE|00000000||tx|1|entity|C0017642|Glipizide|orch,phsu|||glipizide||||888|37|45
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||888|47|49
SE|00000000||tx|1|entity|C0016277|Fluconazole|orch,phsu|||fluconazole||||888|57|67
SE|00000000||tx|1|entity|C1514721|Range|qnco|||range||||1000|95|99


SE|00000000||tx|1|text|Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.
SE|00000000||tx|1|entity|C0010711|Cytarabine|nnon,phsu|||Cytosine arabinoside||||1000|1|20
SE|00000000||tx|1|entity|C0010858|Cytostatic Agents|phsu|||cytostatic agent||||1000|25|40
SE|00000000||tx|1|entity|C0718566|Anti-Fungal|orch,phsu|||antifungal||||901|79|88
SE|00000000||tx|1|entity|C0205177|Active|ftcn|||activity||||901|90|97
SE|00000000||tx|1|entity|C0016278|Flucytosine|nnon,phsu|||flucytosine||||1000|102|112
SE|00000000||tx|1|entity|C0301626|Competitive inhibition|moft|||competitive inhibition||||1000|117|138
SE|00000000||tx|1|relation|2|1|C0010858|Cytostatic Agents|phsu|phsu|||cytostatic agent||||1000|25|40|VERB|INHIBITS||64|73|3|1|C0718566|Anti-Fungal|orch,phsu|orch|||antifungal||||901|79|88


SE|00000000||tx|1|text|Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||Inhibitors||||1000|1|10
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|15|20
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|27|38
SE|00000000||tx|1|entity|C1332830|CYP2D6 gene|gngm|1565|CYP2D6|CYP2D6||||1000|44|49
SE|00000000||tx|1|entity|C0034414|Quinidine|orch,phsu|||quinidine||||1000|56|64
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|67|76
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||paroxetine||||1000|82|91
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||888|106|117
SE|00000000||tx|1|entity|C0015127|Etiology aspects|ftcn|||cause||||775|135|139
SE|00000000||tx|1|entity|C0205217|Increased|qnco|||increased||||775|141|149
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||775|151|155


SE|00000000||tx|1|text|Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.
SE|00000000||tx|1|entity|C1524062|Additional|ftcn|||Additional||||888|1|10
SE|00000000||tx|1|entity|C0005823|Blood Pressure|orgf|||blood pressure||||1000|26|39
SE|00000000||tx|1|entity|C0376357|Flolan|eico,phsu|||FLOLAN||||1000|56|61
SE|00000000||tx|1|entity|C0012798|Diuretics|phsu|||diuretics||||1000|84|92
SE|00000000||tx|1|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensive agents||||1000|95|117
SE|00000000||tx|1|entity|C0042402|Vasodilator Agents|phsu|||vasodilators||||1000|129|140
SE|00000000||tx|1|relation|0|0|C0042402|Vasodilator Agents|phsu|phsu|||vasodilators||||1000|129|140|SPEC|ISA||95|140|0|0|C0003364|Antihypertensive Agents|phsu|phsu|||antihypertensive agents||||1000|95|117
SE|00000000||tx|1|relation|0|0|C0003364|Antihypertensive Agents|phsu|phsu|||antihypertensive agents||||1000|95|117|SPEC|ISA||95|140|0|0|C0042402|Vasodilator Agents|phsu|phsu|||vasodilators||||1000|129|140


SE|00000000||tx|1|text|(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.
SE|00000000||tx|1|entity|C0031332|Clinical pharmacology discipline|bmod|||CLINICAL PHARMACOLOGY||||1000|6|26
SE|00000000||tx|1|entity|C0701348|Femara|orch,phsu|||Femara||||1000|49|54
SE|00000000||tx|1|entity|C1126289|Tamoxifen 20 MG|clnd|||tamoxifen 20 mg||||916|60|74
SE|00000000||tx|1|entity|C0332173|Daily|tmco|||daily||||916|76|80
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||reduction||||1000|96|104
SE|00000000||tx|1|entity|C0246421|letrozole|orch,phsu|||letrozole||||790|109|117
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||790|119|124
SE|00000000||tx|1|entity|C0450361|38|inpr|||38%||||1000|136|138
SE|00000000||tx|1|entity|C1510992|Average|qnco|||average||||1000|143|149


SE|00000000||tx|1|text|When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.
SE|00000000||tx|1|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||1000|6|15
SE|00000000||tx|1|entity|C0016229|Flecainide|orch,phsu|||flecainide||||851|29|38
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||623|49|54
SE|00000000||tx|1|entity|C0016229|Flecainide|orch,phsu|||flecainide||||623|56|65
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two-||||888|87|90
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||888|91|94
SE|00000000||tx|1|entity|C0205172|More|ftcn|||more||||1000|99|102
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|112|119
SE|00000000||tx|1|entity|C0016229|Flecainide|orch,phsu|||flecainide||||888|125|134
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||dosage||||888|136|141
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|146|148
SE|00000000||tx|1|relation|4|2|C0016229|Flecainide|orch,phsu|phsu|||flecainide||||623|56|65|PREP|TREATS||104|105|2|1|C0030705|Patients|podg,humn|podg|||patients||||1000|112|119


SE|00000000||tx|1|text|Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||Patients||||1000|1|8
SE|00000000||tx|1|entity|C0284941|acamprosate|orch,phsu|||Acamprosate||||861|17|27
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants||||827|48|62
SE|00000000||tx|1|entity|C0043094|Weight Gain|fndg|||weight gain||||1000|92|102
SE|00000000||tx|1|entity|C0043096|Body Weight decreased|fndg|||weight loss||||1000|108|118
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|135|142
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medication||||861|158|167
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|169|173
SE|00000000||tx|1|relation|6|1|C0284941|acamprosate|orch,phsu|orch|||Acamprosate||||861|17|27|VERB|ADMINISTERED_TO||10|15|1|1|C0030705|Patients|podg,humn|humn|||Patients||||1000|1|8
SE|00000000||tx|1|relation|2|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medication||||861|158|167|VERB|ADMINISTERED_TO||144|149|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|135|142


SE|00000000||tx|1|text|The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
SE|00000000||tx|1|entity|C0002934|Local Anesthetics|phsu|||local anesthetic||||901|23|38
SE|00000000||tx|1|entity|C0037633|Solutions|sbst|||solutions||||901|40|48
SE|00000000||tx|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||epinephrine||||1000|61|71
SE|00000000||tx|1|entity|C0028351|Norepinephrine|nsba,orch,phsu|||norepinephrine||||1000|76|89
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|94|101
SE|00000000||tx|1|entity|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|||monoamine oxidase inhibitors||||1000|113|140
SE|00000000||tx|1|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|145|169
SE|00000000||tx|1|entity|C0439590|Prolonged|tmco|||prolonged||||790|191|199
SE|00000000||tx|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||790|201|212
SE|00000000||tx|1|relation|3|1|C0026457|Monoamine Oxidase Inhibitors|orch,phsu|orch|||monoamine oxidase inhibitors||||1000|113|140|VERB|ADMINISTERED_TO||103|111|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|94|101
SE|00000000||tx|1|relation|7|1|C0003290|Tricyclic Antidepressive Agents|phsu|phsu|||tricyclic antidepressants||||1000|145|169|VERB|CAUSES||175|181|1|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension||||790|201|212


SE|00000000||tx|1|text|Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||Drug-Drug Interactions||||988|1|22
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||802|46|52
SE|00000000||tx|1|entity|C0299792|aripiprazole|orch,phsu|||aripiprazole||||1000|57|68
SE|00000000||tx|1|entity|C1170019|Abilify|orch,phsu|||ABILIFY||||1000|99|105
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|119|129
SE|00000000||tx|1|entity|C0007680|Central Nervous System Agents|phsu|||centrally acting drugs||||1000|142|163
SE|00000000||tx|1|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|169|175


SE|00000000||tx|1|text|A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.
SE|00000000||tx|1|entity|C2603343|Study|resa|||study||||1000|3|7
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||790|15|20
SE|00000000||tx|1|entity|C1706429|Male, Self-Reported|orga|||male||||790|22|25
SE|00000000||tx|1|entity|C1705497|Female, Self-Report|qlco|||female||||888|31|36
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|38|47
SE|00000000||tx|1|entity|C0072916|Cisapride|orch,phsu|||cisapride||||1000|83|91
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|97|108
SE|00000000||tx|1|entity|C0429028|QT interval feature (observable entity)|clna|||QT interval||||1000|144|154
SE|00000000||tx|1|entity|C0013798|Electrocardiogram|fndg|||ECG||||966|163|165


SE|00000000||tx|1|text|In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.
SE|00000000||tx|1|entity|C0237401|Individual|humn|||individuals||||827|7|17
SE|00000000||tx|1|entity|C0070122|Paroxetine|orch,phsu|||paroxetine||||1000|32|41
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|46|55
SE|00000000||tx|1|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|62|64
SE|00000000||tx|1|entity|C0076823|atomoxetine|orch,phsu|||atomoxetine||||1000|69|79
SE|00000000||tx|1|entity|C0332232|Approximate|qlco|||approximately||||861|84|96
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||861|106|109
SE|00000000||tx|1|entity|C0265338|Coffin-Siris syndrome|cgab,dsyn|||Css||||1000|115|117
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||888|140|143
SE|00000000||tx|1|entity|C1704243|Greater|qnco|||greater||||1000|145|151
SE|00000000||tx|1|entity|C0076823|atomoxetine|orch,phsu|||atomoxetine||||1000|158|168
SE|00000000||tx|1|entity|C0205171|Singular|qnco|||alone||||1000|170|174
SE|00000000||tx|1|entity||<<greatness>>||||greater|||||145|151
SE|00000000||tx|1|relation|10|6|C0076823|atomoxetine|orch,phsu|orch|||atomoxetine||||1000|69|79|PREP|compared_with||153|156|2|1|C0076823|atomoxetine|orch,phsu|orch|||atomoxetine||||1000|158|168
SE|00000000||tx|1|relation|10|6|C0076823|atomoxetine|orch,phsu|orch|||atomoxetine||||1000|69|79|PREP|higher_than||153|156|2|1|C0076823|atomoxetine|orch,phsu|orch|||atomoxetine||||1000|158|168
SE|00000000||tx|1|relation|11|1|C0070122|Paroxetine|orch,phsu|phsu|||paroxetine||||1000|32|41|VERB|TREATS||19|25|1|1|C0237401|Individual|grup,humn|humn|||individuals||||827|7|17


SE|00000000||tx|1|text|Digoxin: Some calcium blockers may increase the concentration of digitalis preparations in the blood.
SE|00000000||tx|1|entity|C0012265|Digoxin|carb,phsu,strd|||Digoxin||||1000|1|7
SE|00000000||tx|1|entity|C0006675|Calcium|bacs,elii,phsu|||calcium||||861|15|21
SE|00000000||tx|1|entity|C0304520|Digitalis preparation|carb,phsu|||digitalis preparations||||1000|66|87
SE|00000000||tx|1|entity|C0005767|Blood|tisu|||blood||||1000|96|100
SE|00000000||tx|1|relation|2|2|C0012265|Digoxin|carb,phsu,strd|carb|||Digoxin||||1000|1|7|VERB|STIMULATES||36|43|3|2|C0304520|Digitalis preparation|carb,phsu|carb|||digitalis preparations||||1000|66|87
SE|00000000||tx|1|relation|1|1|C0005767|Blood|tisu|tisu|||blood||||1000|96|100|PREP|LOCATION_OF||89|90|4|1|C0304520|Digitalis preparation|carb,phsu|carb|||digitalis preparations||||1000|66|87


SE|00000000||tx|1|text|Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
SE|00000000||tx|1|entity|C0018787|Heart|bpoc|||Cardiac||||888|1|7
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effects||||888|9|15
SE|00000000||tx|1|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine||||1000|20|27
SE|00000000||tx|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic blocking agents||||1000|48|78
SE|00000000||tx|1|entity|C0033497|Propranolol|orch,phsu|||propranolol||||1000|89|99
SE|00000000||tx|1|entity|C0025859|Metoprolol|orch,phsu|||metoprolol||||1000|105|114
SE|00000000||tx|1|relation|4|1|C0013030|Dopamine|nsba,orch,phsu|nsba|||dopamine||||1000|20|27|NOM|AFFECTS||9|15|0|0|C0018787|Heart|bpoc|bpoc|||Cardiac||||888|1|7


SE|00000000||tx|1|text|In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|4|11
SE|00000000||tx|1|entity|C0003286|Anticonvulsants|phsu|||anticonvulsant||||1000|23|36
SE|00000000||tx|1|entity|C0042291|Valproic Acid|orch,phsu|||valproic acid||||1000|43|55
SE|00000000||tx|1|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|58|70
SE|00000000||tx|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|73|85
SE|00000000||tx|1|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|90|98
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|106|116
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|118|120
SE|00000000||tx|1|entity|C0025153|Mefloquine|orch,phsu|||Mefloquine||||1000|125|134
SE|00000000||tx|1|entity|C0036572|Seizures|sosy|||seizure||||861|147|153
SE|00000000||tx|1|entity|C0441994|Lower - spatial qualifier|spco|||lowering||||1000|166|173
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|179|184
SE|00000000||tx|1|entity|C0003286|Anticonvulsants|phsu|||anticonvulsant||||1000|200|213
SE|00000000||tx|1|relation|12|1|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsant||||1000|23|36|VERB|ADMINISTERED_TO||13|18|1|1|C0030705|Patients|podg,humn|humn|||patients||||1000|4|11
SE|00000000||tx|1|relation|3|3|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsant||||1000|200|213|NOM|TREATS||155|161|9|0|C0036572|Seizures|sosy|sosy|||seizure||||861|147|153


SE|00000000||tx|1|text|If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.
SE|00000000||tx|1|entity|C0023343|Leprosy|dsyn|||leprosy||||774|4|10
SE|00000000||tx|1|entity|C0021368|Inflammation|patf|||inflammatory reactions||||774|23|44
SE|00000000||tx|1|entity|C0030705|Patients|podg|||patients||||1000|57|64
SE|00000000||tx|1|entity|C0010980|Dapsone|orch,phsu|||dapsone||||1000|85|91
SE|00000000||tx|1|entity|C0008996|Clofazimine|irda,orch,phsu|||clofazimine||||1000|97|107
SE|00000000||tx|1|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|144|152
SE|00000000||tx|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||1000|164|168
SE|00000000||tx|1|relation|1|1|C0021368|Inflammation|patf|patf|||inflammatory reactions||||774|23|44|PREP|PROCESS_OF||54|55|5|1|C0030705|Patients|podg,humn|humn|||patients||||1000|57|64
SE|00000000||tx|1|relation|5|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||1000|144|152|PREP|USES||154|157|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||1000|164|168


SE|00000000||tx|1|text|Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).
SE|00000000||tx|1|entity|C0012132|Zalcitabine|nnon,phsu|||Zalcitabine||||861|1|11
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||888|25|35
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|37|42
SE|00000000||tx|1|entity|C0175996|Protoplasm|celc|||intracellular||||888|51|63
SE|00000000||tx|1|entity|C0031715|Phosphorylation|moft|||phosphorylation||||888|65|79
SE|00000000||tx|1|entity|C0043474|Zidovudine|nnon,phsu|||ZDV||||1000|84|86
SE|00000000||tx|1|entity|C1513475|Mononuclear|clna|||mononuclear||||905|127|137
SE|00000000||tx|1|entity|C0005773|Blood Cells|cell|||peripheral blood mononuclear cells||||905|110|143
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two||||1000|151|153
SE|00000000||tx|1|entity|C0007600|Cultured Cell Line|cell|||cell lines||||1000|161|170
SE|00000000||tx|1|entity|C1823394|TMEM132D gene|gngm|121256|TMEM132D|Molt||||861|182|185
SE|00000000||tx|1|relation|7|2|C0043474|Zidovudine|nnon,phsu|phsu|||ZDV||||1000|84|86|NOM|AFFECTS|negation|37|42|7|1|C0031715|Phosphorylation|moft|moft|||phosphorylation||||888|65|79


SE|00000000||tx|1|text|Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.
SE|00000000||tx|1|entity|C0016277|Fluconazole|orch,phsu|||Fluconazole||||1000|1|11
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||Concomitant||||888|14|24
SE|00000000||tx|1|entity|C0016277|Fluconazole|orch,phsu|||fluconazole||||1000|44|54
SE|00000000||tx|1|entity|C0205448|Two|qnco|||two-||||851|83|86
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||851|87|90
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increase||||851|92|99
SE|00000000||tx|1|entity|C0538927|celecoxib|orch,phsu|||celecoxib||||901|104|112
SE|00000000||tx|1|entity|C0683150|plasma drug concentration|qnco|||plasma concentration||||901|114|133
SE|00000000||tx|1|relation|4|2|C0016277|Fluconazole|orch,phsu|orch|||fluconazole||||1000|44|54|NOM|STIMULATES||92|99|1|1|C0538927|celecoxib|orch,phsu|orch|||celecoxib||||901|104|112


SE|00000000||tx|1|text|Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
SE|00000000||tx|1|entity|C0027396|Naproxen|orch,phsu|||Naproxen||||1000|1|8
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|15|25
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|45|54
SE|00000000||tx|1|entity|C0027396|Naproxen|orch,phsu|||naproxen||||1000|60|67
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||888|72|77
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|79|88
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||1000|97|102
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|111|116
SE|00000000||tx|1|entity|C0027396|Naproxen|orch,phsu|||naproxen||||1000|128|135
SE|00000000||tx|1|entity|C1524119|urinary|qlco|||urinary||||888|170|176
SE|00000000||tx|1|entity|C0221102|Excretory function|phsf|||excretion||||888|178|186
SE|00000000||tx|1|entity|C0027396|Naproxen|orch,phsu|||naproxen||||1000|191|198
SE|00000000||tx|1|entity|C0812407|Glucuronide|carb|||glucuronide||||888|208|218
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolite||||888|220|229
SE|00000000||tx|1|relation|4|1|C0027396|Naproxen|orch,phsu|phsu|||naproxen||||1000|60|67|PREP|TREATS||69|70|7|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|79|88
SE|00000000||tx|1|relation|4|1|C0027396|Naproxen|orch,phsu|phsu|||Naproxen||||1000|1|8|PREP|TREATS||69|70|7|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|79|88


SE|00000000||tx|1|text|Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||Agents||||966|1|6
SE|00000000||tx|1|entity|||gngm|1576|CYP3A4|CYP3A4||||861|17|22
SE|00000000||tx|1|entity|C0243077|inhibitors|chvf|||inhibitors||||861|24|33
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||861|86|91
SE|00000000||tx|1|entity|C0332282|Following|tmco|||following||||1000|121|129
SE|00000000||tx|1|entity|C0000981|Acetazolamide|orch,phsu|||Acetazolamide||||1000|132|144
SE|00000000||tx|1|entity|C0360363|Azole antifungal|orch,phsu|||azole antifungals||||1000|147|163
SE|00000000||tx|1|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|166|175
SE|00000000||tx|1|entity|C0055856|Clarithromycin|antb,orch|||clarithromycin||||1000|178|191
SE|00000000||tx|1|entity|C0756085|dalfopristin|aapp,antb|||dalfopristin||||1000|197|208
SE|00000000||tx|1|entity|C0010961|Danazol|horm,phsu,strd|||danazol||||1000|211|217
SE|00000000||tx|1|entity|C0288165|Delavirdine|orch,phsu|||delavirdine||||1000|220|230
SE|00000000||tx|1|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|233|241
SE|00000000||tx|1|entity|C0014806|Erythromycin|antb,orch|||erythromycin||||1000|244|255
SE|00000000||tx|1|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||1000|261|270
SE|00000000||tx|1|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|273|283
SE|00000000||tx|1|entity|C0452456|Grapefruit juice|food|||grapefruit juice||||1000|286|301
SE|00000000||tx|1|entity|C0022209|isoniazid|orch,phsu|||isoniazid||||1000|304|312
SE|00000000||tx|1|entity|C0064113|Itraconazole|orch,phsu|||itraconazole||||1000|315|326
SE|00000000||tx|1|entity|C0022625|Ketoconazole|orch,phsu|||ketoconazole||||1000|329|340
SE|00000000||tx|1|entity|C0065180|Loratadine|orch,phsu|||loratadine||||1000|343|352
SE|00000000||tx|1|entity|C0068485|nefazodone|orch,phsu|||nefazodone||||1000|355|364
SE|00000000||tx|1|entity|C0028027|Niacinamide|orch,phsu,vita|||niacinamide||||1000|367|377
SE|00000000||tx|1|entity|C0028027|Niacinamide|orch,phsu,vita|||nicotinamide||||1000|380|391
SE|00000000||tx|1|entity|C0033607|Protease Inhibitor|bacs,phsu|||protease inhibitors||||1000|394|412
SE|00000000||tx|1|entity|C0033493|Propoxyphene|orch,phsu|||propoxyphene||||1000|415|426
SE|00000000||tx|1|entity|C0034417|Quinine|orch,phsu|||quinine||||1000|429|435
SE|00000000||tx|1|entity|C0756081|quinupristin|aapp,antb|||quinupristin||||1000|438|449
SE|00000000||tx|1|entity|C0041165|Troleandomycin|antb,orch|||troleandomycin||||1000|452|465
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||valproate||||1000|468|476
SE|00000000||tx|1|entity|C0042523|Verapamil|orch,phsu|||verapamil||||1000|482|490
SE|00000000||tx|1|entity|C0081408|zileuton|orch,phsu|||zileuton||||1000|493|500
SE|00000000||tx|1|relation|0|0|C0243077|inhibitors|chvf|chvf|||inhibitors||||861|24|33|SPEC|ISA||1|33|0|0|C0450442|Agent|chvf|chvf|||Agents||||966|1|6


SE|00000000||tx|1|text|Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||Aspirin||||1000|1|7
SE|00000000||tx|1|entity|C0439166|Percent normal|qnco|||normal||||888|13|18
SE|00000000||tx|1|entity|C0042960|Voluntary Workers|prog|||volunteers||||888|20|29
SE|00000000||tx|1|entity|C0700321|Small|qnco|||small||||888|34|38
SE|00000000||tx|1|entity|C0547047|Decrease|qnco|||decrease||||888|40|47
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||694|52|61
SE|00000000||tx|1|entity|C0439064|Numerous|qnco|||multiple||||888|88|95
SE|00000000||tx|1|entity|C0178602|Dosage|qnco|||doses||||888|97|101
SE|00000000||tx|1|entity|C0012228|Diflunisal|orch,phsu|||diflunisal||||1000|106|115
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|121|127
SE|00000000||tx|1|relation|1|1|C0004057|Aspirin|orch,phsu|phsu|||Aspirin||||1000|1|7|PREP|TREATS||10|11|6|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers||||888|20|29
SE|00000000||tx|1|relation|4|4|C0004057|Aspirin|orch,phsu|orch|||aspirin||||1000|121|127|NOM|INHIBITS||40|47|4|1|C0012228|Diflunisal|orch,phsu|orch|||diflunisal||||694|52|61


SE|00000000||tx|1|text|Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|12|14
SE|00000000||tx|1|entity|C0039651|Tetracyclines|orch|||tetracyclines||||1000|19|31
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives||||1000|38|56
SE|00000000||tx|1|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives||||1000|69|87
SE|00000000||tx|1|entity|C0547044|Smaller|qlco|||less||||888|89|92
SE|00000000||tx|1|entity|C1280519|Effectiveness|qlco|||effective||||888|94|102


SE|00000000||tx|1|text|There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.
SE|00000000||tx|1|entity|C0521114|Infrequent|tmco|||rare||||888|17|20
SE|00000000||tx|1|entity|C0237881|Statistical Significance|qnco|||significant||||901|33|43
SE|00000000||tx|1|entity|C0235063|Respiratory Depression|patf|||respiratory depression||||901|45|66
SE|00000000||tx|1|entity|C0085628|Stupor|fndg|||stupor||||1000|69|74
SE|00000000||tx|1|entity|C0020649|Hypotension|fndg|||hypotension||||1000|83|93
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|104|114
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|116|118
SE|00000000||tx|1|entity|C0024056|Loxapine|orch,phsu|||loxapine||||1000|123|130
SE|00000000||tx|1|entity|C0024002|Lorazepam|orch,phsu|||lorazepam||||1000|136|144


SE|00000000||tx|1|text|Steroids enhance the renal toxicity of edetate calcium disodium in animals.
SE|00000000||tx|1|entity|C0038317|Steroids|strd|||Steroids||||1000|1|8
SE|00000000||tx|1|entity|C0595916|Toxic nephropathy|dsyn|||renal toxicity||||1000|22|35
SE|00000000||tx|1|entity|C0006692|edetate calcium disodium|irda,orch,phsu|||edetate calcium disodium||||1000|40|63
SE|00000000||tx|1|entity|C0003062|Animals|anim|||animals||||1000|68|74
SE|00000000||tx|1|relation|1|1|C0038317|Steroids|strd|strd|||Steroids||||1000|1|8|VERB|AUGMENTS||10|16|3|1|C0595916|Toxic nephropathy|dsyn|dsyn|||renal toxicity||||1000|22|35
SE|00000000||tx|1|relation|3|2|C0595916|Toxic nephropathy|dsyn|dsyn|||renal toxicity||||1000|22|35|PREP|PROCESS_OF||65|66|1|1|C0003062|Animals|anim|anim|||animals||||1000|68|74

SE|00000000||tx|2|text|7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc.
SE|00000000||tx|2|entity|C0006692|edetate calcium disodium|irda,orch,phsu|||Edetate calcium disodium||||923|3|26
SE|00000000||tx|2|entity|C3266814|Action|acty|||action||||1000|48|53
SE|00000000||tx|2|entity|C0043481|Zinc|bacs,elii,phsu|||zinc||||901|58|61
SE|00000000||tx|2|entity|C0021641|Insulin|aapp,horm,phsu|||insulin preparations||||901|63|82
SE|00000000||tx|2|entity|C0043481|Zinc|bacs,elii,phsu|||zinc||||1000|101|104

SE|00000000||tx|3|text|7


SE|00000000||tx|1|text|There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.
SE|00000000||tx|1|entity|C1704243|Greater|qnco|||greater||||1000|17|23
SE|00000000||tx|1|entity|C0332462|Folded structure|spco|||fold||||888|32|35
SE|00000000||tx|1|entity|C0032105|Plasma|bdsu|||plasma||||812|68|73
SE|00000000||tx|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants||||1000|91|105
SE|00000000||tx|1|entity|C0028420|Nortriptyline|orch,phsu|||nortriptyline||||1000|118|130
SE|00000000||tx|1|entity|C0733380|Fluoxetine Hydrochloride|orch,phsu|||fluoxetine hydrochloride||||1000|138|161
SE|00000000||tx|1|entity|C0205195|Combined|qlco|||combination||||1000|188|198
SE|00000000||tx|1|entity|C0450442|Agent|chvf|||agents||||966|211|216


SE|00000000||tx|1|text|Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.
SE|00000000||tx|1|entity|C1148284|Felbamate:Mass:Point in time:Dose med or substance:Quantitative|clna|||felbamate dose||||1000|16|29
SE|00000000||tx|1|entity|C0439422|milligram/day|qnco|||mg/day||||901|39|44
SE|00000000||tx|1|entity|C0678587|steady state|npop|||steadystate||||861|60|70
SE|00000000||tx|1|entity|C0080356|Valproate|lipd,phsu|||valproate||||861|72|80
SE|00000000||tx|1|entity|C2827771|Cmin|qnco|||Cmin||||861|82|85
SE|00000000||tx|1|entity|C0439268|Microgram per Milliliter|qnco|||micrograms/mL||||844|96|108


SE|00000000||tx|1|text|By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.
SE|00000000||tx|1|entity|C0442797|Decreasing|qlco|||decreasing||||1000|4|13
SE|00000000||tx|1|entity|C0021826|Intestinal Absorption|ortf|||gastrointestinal absorption||||1000|19|45
SE|00000000||tx|1|entity|C0033148|Primidone|orch,phsu|||primidone||||1000|50|58
SE|00000000||tx|1|entity|C0591362|Diamox|orch,phsu|||DIAMOX||||1000|61|66
SE|00000000||tx|1|entity|C0683149|serum drug concentration|qnco|||serum concentrations||||983|81|100
SE|00000000||tx|1|entity|C0033148|Primidone|orch,phsu|||primidone||||1000|105|113
SE|00000000||tx|1|entity|C0870883|Metabolite|bacs|||metabolites||||1000|123|133
SE|00000000||tx|1|entity|C0332149|Possible|qlco|||possible||||790|154|161
SE|00000000||tx|1|entity|C0392756|Reduced|qlco|||decrease||||790|163|170
SE|00000000||tx|1|entity|C0003286|Anticonvulsants|phsu|||anticonvulsant||||888|175|188
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|190|195
SE|00000000||tx|1|relation|4|1|C0591362|Diamox|orch,phsu|orch|||DIAMOX||||1000|61|66|VERB|INHIBITS||72|79|5|2|C0033148|Primidone|orch,phsu|orch|||primidone||||1000|105|113
SE|00000000||tx|1|relation|4|1|C0591362|Diamox|orch,phsu|orch|||DIAMOX||||1000|61|66|VERB|INHIBITS||72|79|5|2|C0870883|Metabolite|bacs|bacs|||metabolites||||1000|123|133
SE|00000000||tx|1|relation|8|2|C0870883|Metabolite|bacs|bacs|||metabolites||||1000|123|133|NOM|INTERACTS_WITH||190|195|8|0|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsant||||888|175|188
SE|00000000||tx|1|relation|8|2|C0033148|Primidone|orch,phsu|orch|||primidone||||1000|105|113|NOM|INTERACTS_WITH||190|195|8|0|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsant||||888|175|188


SE|00000000||tx|1|text|Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).
SE|00000000||tx|1|entity|C0205210|Clinical|qlco|||clinical||||1000|10|17
SE|00000000||tx|1|entity|C1274040|Result|ftcn|||results||||861|39|45
SE|00000000||tx|1|entity|||gngm|6375|XCL1|ATAC||||861|56|59
SE|00000000||tx|1|entity|C0008976|Clinical Trials|resa|||trial||||861|61|65
SE|00000000||tx|1|entity|C0039286|Tamoxifen|orch,phsu|||tamoxifen||||1000|68|76
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||1000|85|87
SE|00000000||tx|1|entity|C0290883|anastrozole|orch,phsu|||anastrozole||||1000|110|120
SE|00000000||tx|1|entity|C0031332|Clinical pharmacology discipline|bmod|||CLINICAL PHARMACOLOGY||||888|127|147
SE|00000000||tx|1|entity|C0687133|Drug Interactions|moft|||Drug Interactions||||888|151|167
SE|00000000||tx|1|entity|C1831759|pharmacological studies|diap|||PHARMACOLOGY - Clinical Studies||||772|182|212
SE|00000000||tx|1|entity|C0001551|Immunologic Adjuvants|imft,phsu|||Adjuvant||||772|216|223
SE|00000000||tx|1|entity|C1516635|Clinical Treatment|topp|||CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment||||772|173|233
SE|00000000||tx|1|entity|C0006142|Malignant neoplasm of breast|neop|||Breast Cancer||||1000|238|250
SE|00000000||tx|1|entity|C0043210|Woman|popg|||Women||||773|270|274
SE|00000000||tx|1|entity|C1552859|Subsection|idcn|||subsections||||773|276|286


SE|00000000||tx|1|text|Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.
SE|00000000||tx|1|entity|C0002783|Epidemiologic Studies|resa|||Epidemiological studies||||1000|1|23
SE|00000000||tx|1|entity|C0872128|case control|hlca|||case-control||||1000|32|43
SE|00000000||tx|1|entity|C0599755|Cohort|popg|||cohort||||1000|49|54
SE|00000000||tx|1|entity|C0439849|Relationships|qlco|||association||||1000|89|99
SE|00000000||tx|1|entity|C0033978|Psychotropic Drugs|phsu|||psychotropic drugs||||1000|116|133
SE|00000000||tx|1|entity|C0036751|Serotonin|nsba,orch|||serotonin||||888|155|163
SE|00000000||tx|1|entity|C0599702|reuptake|celf|||reuptake||||888|165|172
SE|00000000||tx|1|entity|C2745955|Occurrence|tmco|||occurrence||||1000|182|191
SE|00000000||tx|1|entity|C0041909|Upper gastrointestinal hemorrhage|patf|||upper gastrointestinal bleeding||||1000|196|226
SE|00000000||tx|1|entity|C0205420|Concurrent|tmco|||concurrent||||888|249|258
SE|00000000||tx|1|entity|C0042153|utilization qualifier|ftcn|||use||||888|260|262
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAID||||1000|270|274
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|279|285
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|303|306
SE|00000000||tx|1|entity|C0019080|Hemorrhage|patf|||bleeding||||1000|311|318
SE|00000000||tx|1|relation|6|1|C0033978|Psychotropic Drugs|phsu|phsu|||psychotropic drugs||||1000|116|133|VERB|DISRUPTS||140|148|8|1|C0599702|reuptake|celf|celf|||reuptake||||888|165|172
SE|00000000||tx|1|relation|12|7|C0033978|Psychotropic Drugs|phsu|phsu|||psychotropic drugs||||1000|116|133|NOM|PREDISPOSES||303|306|1|1|C0019080|Hemorrhage|patf|patf|||bleeding||||1000|311|318


SE|00000000||tx|1|text|Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.
SE|00000000||tx|1|entity|C0681873|study data|resa|||study data||||901|23|32
SE|00000000||tx|1|entity|C0600437|Nitric Oxide Donors|phsu|||nitric oxide donor||||905|63|80
SE|00000000||tx|1|entity|C0205198|Compound|qlco|||compounds||||905|82|90
SE|00000000||tx|1|entity|C0037533|Sodium Nitroprusside|orch,phsu|||sodium nitroprusside||||1000|103|122
SE|00000000||tx|1|entity|C0017887|Nitroglycerin|orch,phsu|||nitroglycerin||||1000|128|140
SE|00000000||tx|1|entity|C0442796|Additive|qlco|||additive||||888|155|162
SE|00000000||tx|1|entity|C1280500|Effect|qlco|||effect||||888|164|169
SE|00000000||tx|1|entity|C1330345|INOmax|inch,phsu|||INOmax||||1000|176|181
SE|00000000||tx|1|entity|C0035647|Risk|qlco|||risk||||1000|190|193
SE|00000000||tx|1|entity|C0025637|Methemoglobinemia|dsyn|||methemoglobinemia||||861|209|225
SE|00000000||tx|1|relation|7|1|C1330345|INOmax|inch,phsu|inch|||INOmax||||1000|176|181|NOM|PREDISPOSES||190|193|1|1|C0025637|Methemoglobinemia|dsyn|dsyn|||methemoglobinemia||||861|209|225


SE|00000000||tx|1|text|Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||Aspirin||||1000|1|7
SE|00000000||tx|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs||||1000|24|29
SE|00000000||tx|1|entity|C0521115|Simultaneous|tmco|||concomitant||||888|32|42
SE|00000000||tx|1|entity|C0699209|Ponstel|orch,phsu|||Ponstel||||1000|62|68
SE|00000000||tx|1|entity|C0004057|Aspirin|orch,phsu|||aspirin||||1000|74|80
SE|00000000||tx|1|entity|C1518422|Negation|ftcn|||not||||861|85|87
SE|00000000||tx|1|entity|C3245505|Potential|qlco|||potential||||1000|126|134
SE|00000000||tx|1|entity|C0442805|Increase|ftcn|||increased||||901|139|147
SE|00000000||tx|1|entity|C0879626|Adverse effects|patf|||adverse effects||||901|149|163

